PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	van der Horn, HJ; Spikman, JM; Jacobs, B; van der Naalt, J				van der Horn, Harm J.; Spikman, Jacoba M.; Jacobs, Bram; van der Naalt, Joukje			Postconcussive Complaints, Anxiety, and Depression Related to Vocational Outcome in Minor to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Depression; Rehabilitation; Sex; Traumatic brain injuries; Work	MILD HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; DSM-IV CRITERIA; PSYCHIATRIC-DISORDERS; RISK-FACTORS; MODERATE; EMPLOYMENT; ADULTS; RETURN; WORK	Objectives: To investigate the relation of postconcussive complaints, anxiety, and depression with vocational outcome in patients with traumatic brain injury (TBI) of various severities and to assess sex differences. Design: A prospective cross-sectional cohort study. Setting: Level I trauma center. Participants: Adults (N=242) with TBI of various severity. Interventions: Not applicable. Main Outcome Measures: Extended Glasgow Outcome Scale, return to work (RTW), Head Injury Symptom Checklist, and Hospital Anxiety and Depression Scale. Results: In 67% of the patients, complaints were present; 22% were anxious, and 18% were depressed. The frequency of complaints increased significantly with injury severity, in contrast to anxiety and depression. Frequencies of patients with anxiety and depression (9% and 5%) were lower with complete RTW than with incomplete RTW (42% and 37%; P<.001). Patients with minor TBI with complaints were more anxious (50% vs 27%; P<.05) and depressed (46% vs 23%; P<.05) compared with patients with other severity categories and patients with incomplete RTW (67% vs 36% and 60% vs 30%, respectively). A higher percentage of women with minor TBI were depressed (45% vs 13%; P=.01) and had incomplete RTW (50% vs 18%; P<.05) compared with men. Multiple regression analysis showed that injury severity, complaints, anxiety, and depression were all predictive of RTW (explained variance 45%). In all severity categories, anxiety and depression were predictive of RTW, complaints, and sex only for minor TBI. Conclusions: Anxiety and depression are related to vocational outcome after TBI, with a different profile in the minor TBI category, partly due to sex differences. Archives of Physical Medicine and Rehabilitation 2013;94:867-74 (C) 2013 by the American Congress of Rehabilitation Medicine	[van der Horn, Harm J.; Jacobs, Bram; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, NL-9700 RB Groningen, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Horn, Harm Jan/0000-0001-9923-0866			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Medley AR, 2010, NEUROPSYCHOL REHABIL, V20, P899, DOI 10.1080/09602011.2010.517688; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	69	69	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2013	94	5					867	874		10.1016/j.apmr.2012.11.039			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	134HX	WOS:000318202100011	23220341				2021-06-18	
J	Cooper, DJ; Myburgh, J; Heritier, S; Finfer, S; Bellomo, R; Billot, L; Murray, L; Vallance, S				Cooper, D. James; Myburgh, John; Heritier, Stephane; Finfer, Simon; Bellomo, Rinaldo; Billot, Laurent; Murray, Lynette; Vallance, Shirley		SAFE-TBI Investigators; Australian & New Zealand Intensive	Albumin Resuscitation for Traumatic Brain Injury: Is Intracranial Hypertension the Cause of Increased Mortality?	JOURNAL OF NEUROTRAUMA			English	Article						albumin; ICP; resuscitation; saline; TBI	QUALITY-OF-LIFE; SUBARACHNOID HEMORRHAGE; PROGRESSION; PRESSURE; MODELS	Mortality is higher in patients with traumatic brain injury (TBI) resuscitated with albumin compared with saline, but the mechanism for increased mortality is unknown. In patients from the Saline vs. Albumin Fluid Evaluation (SAFE) study with TBI who underwent intracranial pressure (ICP) monitoring, interventional data were collected from randomization to day 14 to determine changes in ICP (primary outcome) and in therapies used to treat increased ICP. Pattern mixture modelling, designed to address informative dropouts, was used to compare temporal changes between the albumin and saline groups, and 321 patients were identified, of whom 164 (51.1%) received albumin and 157 (48.9%) received saline. There was a significant linear increase in mean ICP and significantly more deaths in the albumin group compared with saline when ICP monitoring was discontinued during the first week (1.30 +/- 0.33 vs. -0.37 +/- 0.36, p = 0.0006; and 34.4% vs. 17.4%; p = 0.006 respectively), but not when monitoring ceased during the second week (-0.08 +/- 0.44 vs. -0.23 +/- 0.38, p = 0.79; and 18.6% vs. 12.1%; p = 0.36 respectively). There were statistically significant differences in the mean total daily doses of morphine (-0.42 +/- 0.07 vs. -0.66 +/- 0.0, p = 0.0009), propofol (-0.45 +/- 0.11 vs. -0.76 +/- 0.11; p = 0.034) and norepinephrine (-0.50 +/- 0.07 vs. -0.74 +/- 0.07) and in temperature (0.03 +/- 0.03 vs. 0.16 +/- 0.03; p = 0.0014) between the albumin and saline groups when ICP monitoring ceased during the first week. The use of albumin for resuscitation in patients with severe TBI is associated with increased ICP during the first week. This is the most likely mechanism of increased mortality in these patients.	[Cooper, D. James; Vallance, Shirley] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Cooper, D. James; Bellomo, Rinaldo; Murray, Lynette] Monash Univ, Australia & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Myburgh, John; Heritier, Stephane; Finfer, Simon; Billot, Laurent] George Inst Global Hlth, Sydney, NSW 2000, Australia; [Myburgh, John] Univ New S Wales, Fac Med, Sydney, NSW, Australia; [Myburgh, John] St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Heritier, Stephane; Finfer, Simon] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Finfer, Simon] Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Bellomo, Rinaldo] Austin Hosp, Dept Intens Care Med, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo] Univ Melbourne, Fac Med, Melbourne, Vic, Australia	Myburgh, J (corresponding author), George Inst Global Hlth, Div Crit Care & Trauma, Level 7,341 George St, Sydney, NSW 2000, Australia.	jmyburgh@georgeinstitute.org.au	Billot, Laurent/Y-1241-2019; Cooper, D. James/G-7961-2013	Billot, Laurent/0000-0002-4975-9793; Cooper, D. James/0000-0002-5872-9051; Finfer, Simon/0000-0002-2785-5864; Bellomo, Rinaldo/0000-0002-1650-8939	Victorian Neurotrauma Initiative, Australia [DP016]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [57281]; Division of Critical Care and Trauma of the George Institute for Global Health, Sydney, Australia; CSL Limited; George Institute for Global Health and the University of Sydney	This study was funded by a project grant (number DP016) from the Victorian Neurotrauma Initiative (grant number DP016), Australia. Associate Professor Heritier is supported by a program grant (number 57281) from the National Health and Medical Research Council of Australia. Statistical analysis was partially funded by the Division of Critical Care and Trauma of the George Institute for Global Health, Sydney, Australia. The Management Committee consisted of D James Cooper, (co-chair), John Myburgh, (co-chair), Michael Bailey, Rinaldo Bellomo, Laurent Billot, Simon Finfer, Parisa Glass, Stephane Heritier, Michael Fitzharris, Alisa Higgins, Daryl Jones, Siouxzy Morrison, Lynette Murray, Alistair Nichol, Gillian Syres, and Shirley Vallance. Associate Professor Michael Bailey assisted with the initial statistical analyses. Associate Professor Dinesh Varma, Alfred Hospital, Melbourne conducted the blind review of cranial CT scans. The Site investigators (Australia unless stated) were Alfred Hospital, Melbourne: D James Cooper, and Shirley Vallance; Austin Hospital, Melbourne: Rinaldo Bellomo, and Donna Goldsmith; Australian and New Zealand Research Centre, Melbourne: Michael Bailey, Rinaldo Bellomo, D James Cooper, Andrew Forbes, Alisa Higgins, Daryl Jones, Siouxzy Morrison, Lynette Murray, Alistair Nichol, and Gillian Syres; Royal Darwin Hospital: Diane Stephens, and Jane Thomas; Fremantle Hospital: David Blythe, and Anna Palermo; John Hunter Hospital, Newcastle: Peter Harrigan, Brett McFadyen, and Agness Tembo; George Institute for Global Health, Sydney: Laurent Billot, Simon Finfer, Michael Fitzharris, Parisa Glass, Stephane Heritier, Serigne Lo, Mathieu Rose, and John Myburgh; Middlemore Hospital, New Zealand: Judy Tai, and Anthony Williams; Nepean Hospital, Sydney: Louise Cole, Iveta Nalos, Ian Seppelt, and Leonie Weisbrodt; Princess Alexandra Hospital, Brisbane: Sally Gipps, Chris Joyce, Ben Mackie, and Bala Venkatesh; Royal Adelaide Hospital: Marianne Chapman, Stephanie O'Connor, and Justine Rivett; Royal Hobart Hospital: Anthony Bell, Kathryn Marsden, and Andrew Turner; Royal Melbourne Hospital: Deborah Barge, Jack Cade, Tania Caf, and Megan Robertson; Royal North Shore Hospital, Sydney: Simon Finfer, Anne O'Connor, Julie Potter, and Naresh Ramakrishnan; St George Hospital, Sydney: Vanessa Dhiacou, Alina Jovanovska, and John Myburgh.; Professor Cooper has no competing financial interests in relation to this study. Professor Myburgh has no competing financial interests exist in relation to this study. In relation to ongoing fluid resuscitation research, The George Institute for Global Health and the University of Sydney have received a speaker's fee, unrestricted research grant support, and refund of travel expenses incurred on Professor Myburgh's behalf from Fresenius Kabi. Associate Professor Heritier has no competing financial interests in relation to this study. Professor Finfer has no competing financial interests in relation to this study. The SAFE Study was partially funded by CSL Limited. CSL Limited paid travel expenses for Professor Finfer to present results of the SAFE Study at scientific and industry-sponsored meetings. In relation to ongoing fluid resuscitation research, The George Institute for Global Health and the University of Sydney have received unrestricted research grant support and refund of travel expenses incurred on Professor Finfer's behalf from Fresenius Kabi. Professor Bellomo has no competing financial interests in relation to this study. The SAFE Study was part funded by CSL Limited. CSL Limited paid travel expenses for Professor Bellomo to present results of the SAFE Study at scientific and industry-sponsored meetings. Laurent Billot has no competing financial interests in relation to this study. Lynette Murray has no competing financial interests in relation to this study. Shirley Vallance has no competing financial interests in relation to this study.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; BTF Guidelines The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, AGE J NEUROTRAUMA, V17, P573; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Jeffcote T, 2010, ANAESTH INTENS CARE, V38, P274, DOI 10.1177/0310057X1003800208; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Molenberghs G, 2004, BIOSTATISTICS, V5, P445, DOI 10.1093/biostatistics/kxh001; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Pauler DK, 2003, STAT MED, V22, P795, DOI 10.1002/sim.1397; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P563; van der Heijde D, 2007, ARTHRITIS RHEUM, V56, P3928, DOI 10.1002/art.23141; Vangeneugden T, 2004, CONTROL CLIN TRIALS, V25, P13, DOI 10.1016/j.cct.2003.08.009; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Weintraub WS, 2008, NEW ENGL J MED, V359, P677, DOI 10.1056/NEJMoa072771	17	69	73	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					512	518		10.1089/neu.2012.2573			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300002	23194432	Green Published			2021-06-18	
J	Ahmad, A; Crupi, R; Campolo, M; Genovese, T; Esposito, E; Cuzzocrea, S				Ahmad, Akbar; Crupi, Rosalia; Campolo, Michela; Genovese, Tiziana; Esposito, Emanuela; Cuzzocrea, Salvatore			Absence of TLR4 Reduces Neurovascular Unit and Secondary Inflammatory Process after Traumatic Brain Injury in Mice	PLOS ONE			English	Article							NITRIC-OXIDE-SYNTHASE; TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; NF-KAPPA-B; EXPRESSION; NEUROPROTECTION; ACTIVATION; SYSTEM; INHIBITION; RELEASE	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and behavioral impairment. Toll-like receptors (TLRs) are signaling receptors in the innate immune system, although emerging evidence indicates their role in brain injury. We have therefore investigated the role played by TLR4 signaling pathway in the development of mechanisms of secondary inflammatory process in traumatic brain injury (TBI) differ in mice that lack a functional TLR4 signaling pathway. Methods/Principal Findings: Controlled cortical impact injury was performed on TLR4 knockout (KO) mice (C57BL/10ScNJ) and wild-type (WT) mice (C57BL/10ScNJ). TBI outcome was evaluated by determination of infarct volume and assessment of neurological scores. Brains were collected at 24 h after TBI. When compared to WT mice, TLR4 KO mice had lower infarct volumes and better outcomes in neurological and behavioral tests (evaluated by EBST and rotarod test). Mice that lacked TLR4 had minor expression of TBI-induced GFAP, Chymase, Tryptase, IL-1 beta, iNOS, PARP and Nitrotyrosine mediators implicated in brain damage. The translocation of expression of p-JNK, I kappa B-alpha and NF-kappa B pathway were also lower in brains from TLR4 KO mice. When compared to WT mice, resulted in significant augmentation of all the above described parameters. In addition, apoptosis levels in TLR4 KO mice had minor expression of Bax while on the contrary with Bcl-2. Conclusions/Significance: Our results clearly demonstrated that absence of TLR4 reduces the development of neuroinflammation, tissues injury events associated with brain trauma and may play a neuroprotective role in TBI in mice.	[Ahmad, Akbar; Crupi, Rosalia; Campolo, Michela; Genovese, Tiziana; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Manchester, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	salvator@unime.it	Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019; AHMAD, AKBAR/D-6621-2013	AHMAD, AKBAR/0000-0003-4341-0352; Cuzzocrea, Salvatore/0000-0001-6131-3690; GENOVESE, Tiziana/0000-0002-3335-7327; Crupi, Rosalia/0000-0002-7629-3132; Ahmad, Akbar/0000-0003-1841-9670	Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, Messina, Italy	Funding provided by the Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, Messina, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; Barcia C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002977; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Cao GD, 2002, J NEUROSCI, V22, P5423; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Chvatal A, 2007, J NEUROSCI RES, V85, P260, DOI 10.1002/jnr.21113; Cuzzocrea S, 2001, SHOCK, V16, P51, DOI 10.1097/00024382-200116010-00010; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Jin JJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-23; Jou I, 2006, AM J PATHOL, V168, P1619, DOI 10.2353/ajpath.2006.050924; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kielian T, 2006, J NEUROSCI RES, V83, P711, DOI 10.1002/jnr.20767; KOWNATZKI E, 1982, MOL IMMUNOL, V19, P1297, DOI 10.1016/0161-5890(82)90296-6; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee JY, 2005, BIOCHEM PHARMACOL, V70, P1231, DOI 10.1016/j.bcp.2005.07.020; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mishra BB, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-53; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001; Owens T, 2005, BRAIN RES REV, V48, P178, DOI 10.1016/j.brainresrev.2004.12.007; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez JJ, 2009, CELL DEATH DIFFER, V16, P378, DOI 10.1038/cdd.2008.172; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Schomacher M, 2008, BRAIN RES, V1240, P213, DOI 10.1016/j.brainres.2008.09.019; SHEA TB, 1994, BIOTECHNIQUES, V16, P1126; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609; Vanzani MC, 2005, MEDICINA-BUENOS AIRE, V65, P213; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zerfaoui M, 2010, J IMMUNOL, V185, P1894, DOI 10.4049/jimmunol.1000646; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	57	69	76	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2013	8	3							e57208	10.1371/journal.pone.0057208			12	Multidisciplinary Sciences	Science & Technology - Other Topics	121RP	WOS:000317262200001	23555560	DOAJ Gold, Green Published			2021-06-18	
J	Lee, PC; Bordelon, Y; Bronstein, J; Ritz, B				Lee, Pei-Chen; Bordelon, Yvette; Bronstein, Jeff; Ritz, Beate			Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease	NEUROLOGY			English	Article							ENVIRONMENTAL RISK-FACTORS; ALPHA-SYNUCLEIN; HEAD-INJURY; INFLAMMATORY RESPONSE; PESTICIDE EXPOSURE; POPULATION; CALIFORNIA; ACCUMULATION; HISTORY	Objectives: Traumatic brain injury (TBI) increased risk of Parkinson disease (PD) in many but not all epidemiologic studies, giving rise to speculations about modifying factors. A recent animal study suggested that the combination of TBI with subthreshold paraquat exposure increases dopaminergic neurodegeneration. The objective of our study was to investigate PD risk due to both TBI and paraquat exposure in humans. Methods: From 2001 to 2011, we enrolled 357 incident idiopathic PD cases and 754 population controls in central California. Study participants were asked to report all head injuries with loss of consciousness for >5 minutes. Paraquat exposure was assessed via a validated geographic information system (GIS) based on records of pesticide applications to agricultural crops in California since 1974. This GIS tool assesses ambient pesticide exposure within 500 m of residences and workplaces. Results: In logistic regression analyses, we observed a 2-fold increase in risk of PD for subjects who reported a TBI (adjusted odds ratio [AOR] 2.00, 95% confidence interval [CI] 1.28-3.14) and a weaker association for paraquat exposures (AOR 1.36, 95% CI 1.02-1.81). However, the risk of developing PD was 3-fold higher (AOR 3.01, 95% CI 1.51-6.01) in study participants with a TBI and exposure to paraquat than those exposed to neither risk factor. Conclusions: While TBI and paraquat exposure each increase the risk of PD moderately, exposure to both factors almost tripled PD risk. These environmental factors seem to act together to increase PD risk in a more than additive manner. Neurology (R) 2012; 79: 2061-2066	[Lee, Pei-Chen; Ritz, Beate] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Bordelon, Yvette; Bronstein, Jeff; Ritz, Beate] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA	Lee, PC (corresponding author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.	pel27@ucla.edu	Ritz, Beate R/E-3043-2015	, Pei-Chen/0000-0001-7813-0823	National Institute of Environmental Health ScienceUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES010544, U54ES012078]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS038367]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30ES007048]; American Parkinson Disease Association; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [U54ES012078, P30ES007048, R01ES010544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS038367] Funding Source: NIH RePORTER	This work was supported by the National Institute of Environmental Health Science (grant numbers R01ES010544 and U54ES012078) and the National Institute of Neurological Disorders and Stroke (grant number P50NS038367); in addition, initial pilot funding was provided from NIH P30ES007048 and a pilot grant by the American Parkinson Disease Association.	Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dinis-Oliveira RJ, 2006, NEUROTOXICOLOGY, V27, P1110, DOI 10.1016/j.neuro.2006.05.012; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldberg DW, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-60; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Kang GA, 2005, MOVEMENT DISORD, V20, P1133, DOI 10.1002/mds.20513; Kay DM, 2008, AM J MED GENET B, V147B, P1222, DOI 10.1002/ajmg.b.30758; Kuter K, 2010, NEUROCHEM RES, V35, P1121, DOI 10.1007/s11064-010-0163-x; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manthripragada AD, 2010, EPIDEMIOLOGY, V21, P87, DOI 10.1097/EDE.0b013e3181c15ec6; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; McCann SJ, 1998, NEUROEPIDEMIOLOGY, V17, P310, DOI 10.1159/000026185; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Ritz B, 2006, ANN NY ACAD SCI, V1076, P378, DOI 10.1196/annals.1371.074; Ritz B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036199; Ritz BR, 2009, ENVIRON HEALTH PERSP, V117, P964, DOI 10.1289/ehp.0800277; ROTHMAN KJ, 2002, EPIDEMIOLOGY INTRO; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Rull RA, 2003, ENVIRON HEALTH PERSP, V111, P1582, DOI 10.1289/ehp.6118; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.3.CO;2-R; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang A, 2011, EUR J EPIDEMIOL, V26, P547, DOI 10.1007/s10654-011-9574-5	40	69	71	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	NOV	2012	79	20					2061	2066		10.1212/WNL.0b013e3182749f28			6	Clinical Neurology	Neurosciences & Neurology	036NC	WOS:000311032100013	23150532	Green Published			2021-06-18	
J	Bikson, M; Rahman, A; Datta, A; Fregni, F; Merabet, L				Bikson, Marom; Rahman, Asif; Datta, Abhishek; Fregni, Felipe; Merabet, Lotfi			High-Resolution Modeling Assisted Design of Customized and Individualized Transcranial Direct Current Stimulation Protocols	NEUROMODULATION			English	Article						Electrical stimulation; FEM; fMRI; head model; lesion; modeling; neuromodulation; skull defects; stroke; tDCS; TMS; traumatic brain injury	BRAIN; TOLERABILITY; POLARIZATION; EXCITABILITY; FIELD; TDCS; FEM	Objectives: Transcranial direct current stimulation (tDCS) is a neuromodulatory technique that delivers low-intensity currents facilitating or inhibiting spontaneous neuronal activity. tDCS is attractive since dose is readily adjustable by simply changing electrode number, position, size, shape, and current. In the recent past, computational models have been developed with increased precision with the goal to help customize tDCS dose. The aim of this review is to discuss the incorporation of high-resolution patient-specific computer modeling to guide and optimize tDCS. Methods: In this review, we discuss the following topics: 1) The clinical motivation and rationale for models of transcranial stimulation is considered pivotal in order to leverage the flexibility of neuromodulation; 2) the protocols and the workflow for developing high-resolution models; 3) the technical challenges and limitations of interpreting modeling predictions; and 4) real cases merging modeling and clinical data illustrating the impact of computational models on the rational design of rehabilitative electrotherapy. Conclusions: Though modeling for noninvasive brain stimulation is still in its development phase, it is predicted that with increased validation, dissemination, simplification, and democratization of modeling tools, computational forward models of neuromodulation will become useful tools to guide the optimization of clinical electrotherapy.	[Bikson, Marom; Rahman, Asif] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA; [Datta, Abhishek; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat, Boston, MA USA; [Merabet, Lotfi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Vis Rehabil Ctr,Dept Ophthalmol, Boston, MA USA	Bikson, M (corresponding author), 160 Convent Ave,Steinman Hall,Rm 403B, New York, NY 10031 USA.	bikson@ccny.cuny.edu	merabet, lotfi/AAU-8259-2020; Merabet, Lotfi B./V-2735-2017	merabet, lotfi/0000-0002-8094-9536; Merabet, Lotfi B./0000-0002-8094-9536; Fregni, Felipe/0000-0001-9359-8643	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S06 GM008168 NS054783, CRCNS 41771]; Andy Grove Foundation; Wallace H Coulter Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM008168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS054783] Funding Source: NIH RePORTER	Dr. Datta is cofounder of Soterix Medical. The City University of New York has patent applications in Dr. Datta's name on brain stimulation. Dr. Bikson is funded by the National Institutes of Health (nos. S06 GM008168 NS054783, CRCNS 41771), the Andy Grove Foundation, and the Wallace H Coulter Foundation. The City University of New York has patent applications in Dr. Bikson's name on brain stimulation. Dr. Bikson is cofounder of Soterix Medical.	Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Bikson M, 2004, J PHYSIOL-LONDON, V557, P175, DOI 10.1113/jphysiol.2003.055772; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; Borckardt JJ, 2012, J PAIN, V13, P112, DOI 10.1016/j.jpain.2011.07.001; Brunoni AR, 2011, BRAIN STIMU IN PRESS; DaSilva A, 2012, HEADACHE IN PRESS; Datta A, 2008, J NEURAL ENG, V5, P163, DOI 10.1088/1741-2560/5/2/007; Datta A, 2011, BRAIN STIMUL, V4, P169, DOI 10.1016/j.brs.2010.11.001; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; Datta A, 2009, IEEE ENG MED BIO, P670, DOI 10.1109/IEMBS.2009.5333673; Datta A, 2009, BRAIN STIMUL, V2, P201, DOI 10.1016/j.brs.2009.03.005; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Fregni F, 2006, EPILEPSIA, V47, P335, DOI 10.1111/j.1528-1167.2006.00426.x; Fridriksson J, 2011, J COMMUN DISORD, V44, P557, DOI 10.1016/j.jcomdis.2011.04.009; Halko MA, 2011, NEUROIMAGE, V57, P885, DOI 10.1016/j.neuroimage.2011.05.026; Holsheimer J, 1998, SPINAL CORD, V36, P531, DOI 10.1038/sj.sc.3100717; Joucla S, 2009, BIOPHYS J, V96, P3495, DOI 10.1016/j.bpj.2008.12.3961; Lindenberg R, 2012, NEUROREHABI IN PRESS; Mattai A, 2011, BRAIN STIMUL, V4, P275, DOI 10.1016/j.brs.2011.01.001; Mclntyre CC, 2007, EXPERT REV MED DEVIC, V4, P615, DOI 10.1586/17434440.4.5.615; Mendonca ME, 2011, J PAIN, V12, P610, DOI 10.1016/j.jpain.2010.12.015; Miranda PC, 2007, P ANN INT IEEE EMBS, P1715, DOI 10.1109/IEMBS.2007.4352640; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Miranda PC, 2009, CLIN NEUROPHYSIOL, V120, P1183, DOI 10.1016/j.clinph.2009.03.023; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Oostendorp TF, 2008, IEEE ENG MED BIO, P4226, DOI 10.1109/IEMBS.2008.4650142; Parazzini M, 2011, IEEE T BIO-MED ENG, V58, P1773, DOI 10.1109/TBME.2011.2116019; Peterchev A, 2011, BRAIN STIMU IN PRESS; RATTAY F, 1986, IEEE T BIO-MED ENG, V33, P974, DOI 10.1109/TBME.1986.325670; RUSH S, 1968, ANESTH ANAL CURR RES, V47, P717; Sadleir RJ, 2010, NEUROIMAGE, V51, P1310, DOI 10.1016/j.neuroimage.2010.03.052; Salvador R, 2010, C P IEEE ENG MED BIO, V2010, P2073; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Suh H.S., 2009, C P IEEE ENG MED BIO, P638; Turkeltaub PE, 2011, BRAIN STIMU IN PRESS; Varga ET, 2011, EPILEPSY RES, V97, P142, DOI 10.1016/j.eplepsyres.2011.07.016; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wolters CH, 2006, NEUROIMAGE, V30, P813, DOI 10.1016/j.neuroimage.2005.10.014; ZENTNER J, 1989, NEUROSURGERY, V24, P709, DOI 10.1227/00006123-198905000-00008	40	69	69	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					306	315		10.1111/j.1525-1403.2012.00481.x			10	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900006	22780230	Green Accepted			2021-06-18	
J	Archavlis, E; Nievas, MCY				Archavlis, E.; Carvi Y Nievas, Mario			The impact of timing of cranioplasty in patients with large cranial defects after decompressive hemicraniectomy	ACTA NEUROCHIRURGICA			English	Article						Cranioplasty; Decompressive craniectomy; Hemicraniectomy; Outcome; Timing	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; SINKING SKIN FLAP; BLOOD-FLOW; MALIGNANT INFARCTION; CRANIECTOMY; CT; MULTICENTER; METABOLISM; SURGERY	It is unclear how soon after a decompressive hemicraniectomy that cranioplasty be safely performed in a patient in whom the ICP has been normalized. Early surgery has been associated with infection, intracerebral hematoma, and complications due to persistent or recurrent brain edema. Delayed cranioplasty of large cranial defects exposes the patient to different conditions known in the literature as the syndrome of the sinking skin flap. The purpose of this study was to investigate the hypothesis that timing of cranioplasty after decompressive hemicraniectomy influences outcome and complications. We retrospectively examined outcome after cranioplasty performed at < 7 weeks, 7-12 weeks, and > 13 weeks after craniectomy in patients with large cranial defects after decompressive hemicraniectomy in our institution between 1997 and 2008. The time between craniectomy and cranioplasty ranged from 17 days to 4 months depending on several factors such as: the cause of decompression, infection before or after craniectomy, and skin flap concavity. The analysis of the registered postoperative complications revealed that there were no significant differences between the examined groups. The cranioplasty at < 7 weeks, in the form of reimplantation of the own skull flap, led to a GOS improvement of 78 %, at 7-12 weeks 46 % and at > 13 weeks12 %, respectively. Pairwise comparisons showed that the difference between cranioplasty at < 7 weeks versus 7-12 weeks or > 13 weeks cranioplasty groups was statistically significant ( = 0.05 and < 0.001, respectively). Our study suggests that many patients with large cranial defects after decompressive craniectomy can safely undergo cranioplasty in an early stage; direct answers to these questions of timing of cranioplasty are best addressed by prospective studies. Nevertheless, the present study provides a basis for decision-making in certain patients and for the design of future investigations.	[Archavlis, E.] Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Offenbach, Akad Lehrkrankenhaus, D-63069 Offenbach, Germany; [Carvi Y Nievas, Mario] Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Frankfurt Hoechst, Akad Lehrkrankenhaus, D-63069 Offenbach, Germany	Archavlis, E (corresponding author), Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Offenbach, Akad Lehrkrankenhaus, Starkenburgring 66, D-63069 Offenbach, Germany.	neurosurgery@t-online.de					Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Regel JP, 2004, NEUROCHIRURGIE, P231; RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schimidek H., 2000, OPERATIVE NEUROSURGI; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timmons RL, 1982, NEUROLOGICAL SURGERY, V4, P2228; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	32	69	72	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2012	154	6					1055	1062		10.1007/s00701-012-1333-1			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	943II	WOS:000304113800015	22527574				2021-06-18	
J	van Horn, JD; Irimia, A; Torgerson, CM; Chambers, MC; Kikinis, R; Toga, AW				van Horn, John Darrell; Irimia, Andrei; Torgerson, Carinna M.; Chambers, Micah C.; Kikinis, Ron; Toga, Arthur W.			Mapping Connectivity Damage in the Case of Phineas Gage	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; FUNCTIONAL CONNECTIVITY; FRONTOTEMPORAL DEMENTIA; EXECUTIVE DYSFUNCTION; UNCINATE FASCICULUS; PREFRONTAL CORTEX; NETWORK; LESIONS; GAGE,PHINEAS	White matter (WM) mapping of the human brain using neuroimaging techniques has gained considerable interest in the neuroscience community. Using diffusion weighted (DWI) and magnetic resonance imaging (MRI), WM fiber pathways between brain regions may be systematically assessed to make inferences concerning their role in normal brain function, influence on behavior, as well as concerning the consequences of network-level brain damage. In this paper, we investigate the detailed connectomics in a noted example of severe traumatic brain injury (TBI) which has proved important to and controversial in the history of neuroscience. We model the WM damage in the notable case of Phineas P. Gage, in whom a "tamping iron'' was accidentally shot through his skull and brain, resulting in profound behavioral changes. The specific effects of this injury on Mr. Gage's WM connectivity have not previously been considered in detail. Using computed tomography (CT) image data of the Gage skull in conjunction with modern anatomical MRI and diffusion imaging data obtained in contemporary right handed male subjects (aged 25-36), we computationally simulate the passage of the iron through the skull on the basis of reported and observed skull fiducial landmarks and assess the extent of cortical gray matter (GM) and WM damage. Specifically, we find that while considerable damage was, indeed, localized to the left frontal cortex, the impact on measures of network connectedness between directly affected and other brain areas was profound, widespread, and a probable contributor to both the reported acute as well as long-term behavioral changes. Yet, while significantly affecting several likely network hubs, damage to Mr. Gage's WM network may not have been more severe than expected from that of a similarly sized "average'' brain lesion. These results provide new insight into the remarkable brain injury experienced by this noteworthy patient.	[van Horn, John Darrell; Irimia, Andrei; Torgerson, Carinna M.; Chambers, Micah C.; Toga, Arthur W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA; [Kikinis, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Surg Planning Lab,Dept Radiol, Boston, MA 02115 USA	van Horn, JD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA.	jvanhorn@loni.ucla.edu	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Van Horn, John/0000-0003-1537-0816	NAMIC: Traumatic Brain Injury - Driving Biological Project [2U54EB005149-06]; Informatics Meta-Spaces for the Exploration of Human Neuroanatomy [1RC1MH088194]; Computational Anatomy and Multidimensional Modeling [P41RR013642]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088194] Funding Source: NIH RePORTER	This work was supported by 2U54EB005149-06 "NAMIC: Traumatic Brain Injury - Driving Biological Project" to JVH, 1RC1MH088194 "Informatics Meta-Spaces for the Exploration of Human Neuroanatomy" to JVH, and P41RR013642 "Computational Anatomy and Multidimensional Modeling" to AWT. This work was performed as part of the Human Connectome Project (HCP; www.humanconnectomeproject.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarabi B, 2000, Neurosurg Focus, V8, pe1; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Aly M, 2011, BEHAV BRAIN RES, V225, P297, DOI 10.1016/j.bbr.2011.07.043; Baird AA, 2005, J COGNITIVE NEUROSCI, V17, P687, DOI 10.1162/0898929053467569; Bigelow H. J., 1850, AM J MED SCI, V20, P13; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Chiang MC, 2011, NEUROIMAGE, V54, P2308, DOI 10.1016/j.neuroimage.2010.10.015; Clark L, 2004, NEUROCASE, V10, P398, DOI 10.1080/13554790490882799; Cobb S, 1940, ARCH INTERN MED, V66, P1341, DOI 10.1001/archinte.1940.00190180153011; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Damasio AR, DESCARTES ERROR; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damoiseaux JS, 2009, HUM BRAIN MAPP, V30, P1051, DOI 10.1002/hbm.20563; de Haan W, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-101; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dinov I, 2010, PLOS ONE IN PRESS; Dinov I, 2010, FRONT NEUROINFORM, V3, P1; Dinov I. D., 2009, FRONTIERS NEUROINFOR, V3; Dinov I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013070; Dunbar RIM, 2009, CORTEX, V45, P1119, DOI 10.1016/j.cortex.2009.05.005; Dupuy E, 1877, MED TIMES GAZ, Vii, P11; Falk D, 2005, SCIENCE, V308, P242, DOI 10.1126/science.1109727; Falk D, 2000, J HUM EVOL, V38, P695, DOI 10.1006/jhev.1999.0378; Ferrier D, 1878, Br Med J, V1, P443; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Hamilton LS, 2008, NEUROREPORT, V19, P1705, DOI 10.1097/WNR.0b013e3283174415; Harlow JM, 1993, HIST PSYCHIAT, V4; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Irimia A, 2012, FRONTIERS NEUROLOGY, V3; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Johnson CP, 2011, J INT NEUROPSYCH SOC, P1; Kaiser M, 2007, EUR J NEUROSCI, V25, P3185, DOI 10.1111/j.1460-9568.2007.05574.x; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Knake S, 2009, EPILEPTIC DISORD; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kubicki M, 2002, AM J PSYCHIAT, V159, P813, DOI 10.1176/appi.ajp.159.5.813; Lee DY, 2006, J NEUROPSYCH CLIN N, V18, P191, DOI 10.1176/appi.neuropsych.18.2.191; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; MacKenzie-Graham AJ, 2008, NEUROIMAGE, V42, P178, DOI 10.1016/j.neuroimage.2008.04.186; MACMILLAN M, 1992, BRAIN COGNITION, V19, P72, DOI 10.1016/0278-2626(92)90038-N; MACMILLAN M, 2000, ODD KIND FAME STORIE; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald CR, 2005, J CLIN EXP NEUROPSYC, V27, P485, DOI 10.1080/13803390490520454; Newman MEJ, 2007, P NATL ACAD SCI USA, V104, P9564, DOI 10.1073/pnas.0610537104; Nobe MY, 2010, OPHTHAL PLAST RECONS, V26, P475, DOI 10.1097/IOP.0b013e3181cff655; Ordia JI, 2009, CLIN NEUROL NEUROSUR, V111, P368, DOI 10.1016/j.clineuro.2008.10.016; Ostry DJ, 1997, J SPEECH LANG HEAR R, V40, P1341, DOI 10.1044/jslhr.4006.1341; Pal D, 2011, CLIN NEUROL NEUROSUR; Pascual JM, 2009, ACTA NEUROCHIR, V151, P689, DOI 10.1007/s00701-009-0222-8; Phillips OR, 2009, SCHIZOPHR RES, V107, P30, DOI 10.1016/j.schres.2008.10.019; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Pijnenburg YAL, 2008, CLIN NEUROPHYSIOL, V119, P1732, DOI 10.1016/j.clinph.2008.02.024; Ratiu P, 2004, J NEUROTRAUM, V21, P637, DOI 10.1089/089771504774129964; Ratiu PF, 2004, NEW ENGL J MED, V351, pE21, DOI 10.1056/NEJMicm031024; Rosen B, 2010, ORG HUM BRAIN MAPP A; Rothschild MA, 2000, INT J LEGAL MED, V113, P349; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schoenemann PT, 2007, AM J PHYS ANTHROPOL, V132, P183, DOI 10.1002/ajpa.20499; Selvanathan S, 2007, J CLIN NEUROSCI, V14, P678, DOI 10.1016/j.jocn.2006.02.017; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; Shields LBE, 1998, J FORENSIC SCI, V43, P1068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stepanyants A, 2009, P NATL ACAD SCI USA, V106, P3555, DOI 10.1073/pnas.0810390106; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Tononi G, 1999, P NATL ACAD SCI USA, V96, P3257, DOI 10.1073/pnas.96.6.3257; TUSA RJ, 1985, ANN NEUROL, V18, P583, DOI 10.1002/ana.410180512; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilgus J, 2009, J HIST NEUROSCI, V18, P340, DOI 10.1080/09647040903018402; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	90	69	70	0	83	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2012	7	5			1				e37454	10.1371/journal.pone.0037454			24	Multidisciplinary Sciences	Science & Technology - Other Topics	959UR	WOS:000305341300116	22616011	DOAJ Gold, Green Published			2021-06-18	
J	Diaz, AP; Schwarzbold, ML; Thais, ME; Hohl, A; Bertotti, MM; Schmoeller, R; Nunes, JC; Prediger, R; Linhares, MN; Guarnieri, R; Walz, R				Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Thais, Maria Emilia; Hohl, Alexandre; Bertotti, Melina More; Schmoeller, Roseli; Nunes, Jean Costa; Prediger, Rui; Linhares, Marcelo Neves; Guarnieri, Ricardo; Walz, Roger			Psychiatric Disorders and Health-Related Quality of Life after Severe Traumatic Brain Injury: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						major depressive disorder; personality changes; quality of life; severe traumatic brain injury	DEPRESSION; RELIABILITY; INTERVIEW; VALIDITY; IMPACT; APATHY	Traumatic brain injury (TBI) is a major cause of death and disability and impairs health-related quality of life (HRQOL). Psychiatric disorders have been recognized as major components of TBI morbidity, yet few studies have addressed the relationship between these outcomes. Sample size, selection bias, and retrospective design, are methodological limitations for TBI-related psychiatric studies. For this study, 33 patients with severe TBI were evaluated prospectively regarding demographic, clinical, radiological, neurosurgical, laboratory, and psychosocial characteristics, as well as psychiatric manifestations and HRQOL, 18 months after hospitalization. Psychiatric manifestations were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Hospital Anxiety and Depression Scale (HADS), the Brief Psychiatric Rating Scale (BPRS), and the Apathy Evaluation Scale (AES). HRQOL was determined using the Medical Outcomes Study's 36-item Short-Form Health Survey (SF-36). Following TBI, a significant increase in the prevalence of major depressive disorder (MDD) and generalized anxiety disorder (p = 0.02), and a significant decrease in the prevalence of alcohol and cannabinoid abuse (p = 0.001) were observed. The most frequent psychiatric disorders following severe TBI were found to be MDD (30.3%), and personality changes (33.3%). In comparison to patients without personality changes, patients with personality changes experienced a decline in general health and impairments in physical and social functioning. Patients with MDD showed impairment in all SF-36 domains compared to non-depressed patients. This prospective TBI-related psychiatric study is the first to demonstrate a significant association between MDD, personality changes, and HRQOL, following severe TBI in a well-defined sample of patients.	[Diaz, Alexandre Paim] Inst Psiquiatria Estado Santa Catarina IPQ, Sao Jose, SC, Brazil; [Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Thais, Maria Emilia; Hohl, Alexandre; Schmoeller, Roseli; Nunes, Jean Costa; Prediger, Rui; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas CeNAp, Univ Hosp, Florianopolis, SC, Brazil; [Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Guarnieri, Ricardo] Univ Fed Santa Catarina, Ambulatorio Transtornos Psiquiatr Resistentes Tra, Univ Hosp, Florianopolis, SC, Brazil; [Hohl, Alexandre; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, Univ Hosp, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Guarnieri, Ricardo] Univ Fed Santa Catarina, Dept Cirurgia, Univ Hosp, Florianopolis, SC, Brazil; [Prediger, Rui] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Ctr Ciencias Biol, Florianopolis, SC, Brazil; [Thais, Maria Emilia; Linhares, Marcelo Neves] Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil	Walz, R (corresponding author), Univ Fed Santa Trindade, Univ Hosp, Dept Clin Med, 3 Andar, BR-88040970 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Hohl, Alexandre/R-9269-2019; Walz, Roger/K-9096-2013; Diaz, Alexandre Paim/J-9042-2014; Neurociencia, Inct/I-1011-2013; Prediger, Rui Daniel/AAV-3419-2020; Prediger, Rui D/C-4036-2013; Schwarzbold, Marcelo Liborio/J-8960-2014; Diaz, Alexandre Paim/AAD-8323-2019	Hohl, Alexandre/0000-0002-8073-5837; Walz, Roger/0000-0002-9875-6687; Prediger, Rui Daniel/0000-0002-7547-6463; Prediger, Rui D/0000-0002-7547-6463; Diaz, Alexandre Paim/0000-0002-6591-6648	Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This research was supported by Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC) and CNPq (Dr. Walz). Dr. Schwarzbold is a post-graduate fellow from CNPq (Brazil).	Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Botega NJ, 1998, J BRAS PSIQUIAT, V47, P285; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Crippa JAS, 2001, ACTA PSYCHIAT SCAND, V103, P465, DOI 10.1034/j.1600-0447.2001.00185.x; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; First M.B., 1996, STRUCTURED CLIN INTE; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Gullo J.D., 2010, HOSP MORTALITY PATIE; Hawthorne G, 2011, J CLIN NEUROSCI, V18, P197, DOI 10.1016/j.jocn.2010.06.015; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARKLUND N, 2010, BR J PHARM; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rao V, 2008, J NEUROPSYCH CLIN N, V20, P118, DOI 10.1176/jnp.2008.20.1.118; RHOADES HM, 1988, PSYCHOPHARMACOL BULL, V24, P101; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strawbridge WJ, 1998, GROWTH HORM IGF RES, V8, P59, DOI 10.1016/S1096-6374(98)80011-7; Tavares M, 1996, ENTREVISTA CLIN ESTR; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	41	69	69	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1029	1037		10.1089/neu.2011.2089			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100001	22111890				2021-06-18	
J	Perel, P; Salman, RAS; Kawahara, T; Morris, Z; Prieto-Merino, D; Roberts, I; Sandercock, P; Shakur, H; Wardlaw, J				Perel, P.; Salman, R. Al-Shahi; Kawahara, T.; Morris, Z.; Prieto-Merino, D.; Roberts, I.; Sandercock, P.; Shakur, H.; Wardlaw, J.			CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury - a nested, randomised, placebo-controlled trial	HEALTH TECHNOLOGY ASSESSMENT			English	Article							HEMATOMAS; SCALE; CT	Background: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events. These findings raise the possibility that it might also be effective in traumatic brain injury (TBI). Objective: The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage Intracranial Bleeding Study (CRASH-2 IBS) was conducted to quantify the effect of an early short course of TXA on intracranial haemorrhage and new focal cerebral ischaemic lesions in patients with TBI. Design: CRASH-2 IBS was a prospective randomised controlled trial nested within the CRASH-2 trial. Randomisation was balanced by centre, with an allocation sequence based on a block size of eight. We used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs. Apart from the pack number, the treatment packs were identical. The pack number was recorded on the entry form, which was sent to the international trial co-ordinating centre in London, UK. Once the treatment pack number was recorded, the patient was included in the trial whether or not the treatment pack was opened or the allocated treatment started. All site investigators and trial co-ordinating centre staff were masked to treatment allocation. Setting: Ten hospitals: (India) Aditya Neuroscience Centre, Sanjivani Hospital, CARE Hospital, Christian Medical College, Medical Trust Hospital, Jeevan Jyoti Hospital and (Colombia) Hospital Universitario San Vicente de Paul, Hospital Pablo Tobon Uribe, Hospital Universitario San Jose de Popayan and Fundacion Valle del Lili. Participants: The trial was conducted in a subset of 270 CRASH-2 trial participants. Patients eligible for inclusion in the CRASH-2 IBS fulfilled the inclusion criteria for the CRASH-2 trial, and also had TBI [Glasgow Coma Scale score of <= 14 and a brain computerised tomography (CT) scan compatible with TBI]. Pregnant women and patients for whom a second brain CT scan was not possible were excluded. Interventions: Participants were randomly allocated to receive either a loading dose of 1g of TXA infused over 10 minutes followed by an intravenous infusion of 1g over 8 hours or matching placebo. Main outcome measure: The primary outcome was the increase in size of intracranial haemorrhage growth between a CT scan at hospital admission and a second scan 24-48 hours later. Results: One hundred and thirty-three patients were allocated to TXA and 137 to placebo, of whom information on the primary (imaging) outcome was available for 123 (92%) and 126 (92%) respectively. The analysis suggested that TXA was likely to be associated with a reduction in haemorrhage growth [adjusted difference -3.8 ml, 95% credibility interval (CrI) -11.5 ml to 3.9 ml], fewer focal ischaemic lesions [adjusted odds ratio (OR) 0.54, 95% CrI 0.20 to 1.46] and fewer deaths (adjusted OR 0.49, 95% CrI 0.22 to 1.06). Conclusions: This was the first randomised controlled study to evaluate the effect of TXA in TBI patients and it found that neither moderate benefits nor moderate harmful effects can be excluded. However, although uncertainty remains, our analyses suggest that TXA administration might improve outcome in TBI patients and provide grounds for evaluating this hypothesis in future research.	[Perel, P.; Kawahara, T.; Prieto-Merino, D.; Roberts, I.; Shakur, H.] London Sch Hyg & Trop Med, London WC1, England; [Salman, R. Al-Shahi; Morris, Z.; Sandercock, P.; Wardlaw, J.] Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Perel, P (corresponding author), London Sch Hyg & Trop Med, Keppel St, London WC1, England.	pablo.perel@lshtm.ac.uk		Al-Shahi Salman, Rustam/0000-0002-2108-9222; Prieto-Merino, David/0000-0001-5001-0061; Shakur-Still, Haleema/0000-0002-6511-109X	NIHRNational Institute for Health Research (NIHR)	This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 16, No. 13. See the HTA programme website for further project information.	Astrup Jens, 2006, Ugeskr Laeger, V168, P1107; Bayir A, 2006, NEUROL INDIA, V54, P363, DOI 10.4103/0028-3886.28106; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Edwards P, 2005, LANCET, V365, P1957; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; KWAK R, 1983, STROKE, V14, P493, DOI 10.1161/01.STR.14.4.493; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Osborn AG, 2004, DIAGNOSTIC IMAGING B, pI6; Pathak A, 2005, Neurol India, V53, P178; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Prentice C R, 1980, J Clin Pathol Suppl (R Coll Pathol), V14, P35; ROOS YB, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001245, 10.1002/14651858.CD001245]; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Stein SC, 2007, INDIAN J MED RES, V125, P186; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; WARDLAW JM, 1994, AM J NEURORADIOL, V15, P1933; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109	32	69	70	0	9	NIHR JOURNALS LIBRARY	SOUTHAMPTON	UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND	1366-5278	2046-4924		HEALTH TECHNOL ASSES	Health Technol. Assess.	MAR	2012	16	13					1	+		10.3310/hta16130			47	Health Care Sciences & Services	Health Care Sciences & Services	932HI	WOS:000303280900001	22417901	DOAJ Gold, Green Accepted			2021-06-18	
J	Yan, EB; Hellewell, SC; Bellander, BM; Agyapomaa, DA; Morganti-Kossmann, MC				Yan, Edwin B.; Hellewell, Sarah C.; Bellander, Bo-Michael; Agyapomaa, Doreen A.; Morganti-Kossmann, M. Cristina			Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; traumatic axonal injury; hypoxia; neurological deficit; cytokine; brain edema; ventricle; metabolism	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD-INJURY; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; FACTOR-ALPHA; VENTRICULAR ENLARGEMENT; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; SECONDARY INSULTS; OXIDATIVE STRESS	Background: The combination of diffuse brain injury with a hypoxic insult is associated with poor outcomes in patients with traumatic brain injury. In this study, we investigated the impact of post-traumatic hypoxia in amplifying secondary brain damage using a rat model of diffuse traumatic axonal injury (TAI). Rats were examined for behavioral and sensorimotor deficits, increased brain production of inflammatory cytokines, formation of cerebral edema, changes in brain metabolism and enlargement of the lateral ventricles. Methods: Adult male Sprague-Dawley rats were subjected to diffuse TAI using the Marmarou impact-acceleration model. Subsequently, rats underwent a 30-minute period of hypoxic (12% O-2/88% N-2) or normoxic (22% O-2/78% N-2) ventilation. Hypoxia-only and sham surgery groups (without TAI) received 30 minutes of hypoxic or normoxic ventilation, respectively. The parameters examined included: 1) behavioural and sensorimotor deficit using the Rotarod, beam walk and adhesive tape removal tests, and voluntary open field exploration behavior; 2) formation of cerebral edema by the wet-dry tissue weight ratio method; 3) enlargement of the lateral ventricles; 4) production of inflammatory cytokines; and 5) real-time brain metabolite changes as assessed by microdialysis technique. Results: TAI rats showed significant deficits in sensorimotor function, and developed substantial edema and ventricular enlargement when compared to shams. The additional hypoxic insult significantly exacerbated behavioural deficits and the cortical production of the pro-inflammatory cytokines IL-6, IL-1 beta and TNF but did not further enhance edema. TAI and particularly TAI+Hx rats experienced a substantial metabolic depression with respect to glucose, lactate, and glutamate levels. Conclusion: Altogether, aggravated behavioural deficits observed in rats with diffuse TAI combined with hypoxia may be induced by enhanced neuroinflammation, and a prolonged period of metabolic dysfunction.	[Yan, Edwin B.; Hellewell, Sarah C.; Agyapomaa, Doreen A.; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Yan, Edwin B.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Hellewell, Sarah C.; Agyapomaa, Doreen A.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Bellander, Bo-Michael] Karolinska Univ Hosp, Sect Neurosurg, Dept Clin Neurosci, S-17176 Stockholm, Sweden	Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu		Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Health and Medical Research Council AustraliaNational Health and Medical Research Council of Australia; Victorian Neurotrauma Initiative	This study was supported by the National Health and Medical Research Council Australia and the Victorian Neurotrauma Initiative.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDO Y, 1989, BRAIN RES, V477, P286, DOI 10.1016/0006-8993(89)91416-9; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabrielian L, 2011, J NEUROTRAUMA; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; Ghabriel M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P89; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sumbria RK, 2011, NEUROCHEM RES, V36, P109, DOI 10.1007/s11064-010-0276-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vespa PM, 2003, J CEREB BLOOD FLOW M, V23; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	115	69	73	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	OCT 28	2011	8								147	10.1186/1742-2094-8-147			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	849NK	WOS:000297132100001	22034986	DOAJ Gold, Green Published			2021-06-18	
J	Grujicic, M; Bell, WC; Pandurangan, B; Glomski, PS				Grujicic, M.; Bell, W. C.; Pandurangan, B.; Glomski, P. S.			Fluid/Structure Interaction Computational Investigation of Blast-Wave Mitigation Efficacy of the Advanced Combat Helmet	JOURNAL OF MATERIALS ENGINEERING AND PERFORMANCE			English	Article						advanced combat helmet; computational analysis; fluid-structure interaction; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POLYUREA; IMPACT; TBI	To combat the problem of traumatic brain injury (TBI), a signature injury of the current military conflicts, there is an urgent need to design head protection systems with superior blast/ballistic impact mitigation capabilities. Toward that end, the blast impact mitigation performance of an advanced combat helmet (ACH) head protection system equipped with polyurea suspension pads and subjected to two different blast peak pressure loadings has been investigated computationally. A fairly detailed (Lagrangian) finite-element model of a helmet/skull/brain assembly is first constructed and placed into an Eulerian air domain through which a single planar blast wave propagates. A combined Eulerian/Lagrangian transient nonlinear dynamics computational fluid/solid interaction analysis is next conducted in order to assess the extent of reduction in intra-cranial shock-wave ingress (responsible for TBI). This was done by comparing temporal evolutions of intra-cranial normal and shear stresses for the cases of an unprotected head and the helmet-protected head and by correlating these quantities with the three most common types of mild traumatic brain injury (mTBI), i.e., axonal damage, contusion, and subdural hemorrhage. The results obtained show that the ACH provides some level of protection against all investigated types of mTBI and that the level of protection increases somewhat with an increase in blast peak pressure. In order to rationalize the aforementioned findings, a shockwave propagation/reflection analysis is carried out for the unprotected head and helmet-protected head cases. The analysis qualitatively corroborated the results pertaining to the blast-mitigation efficacy of an ACH, but also suggested that there are additional shockwave energy dissipation phenomena which play an important role in the mechanical response of the unprotected/protected head to blast impact.	[Grujicic, M.; Bell, W. C.; Pandurangan, B.; Glomski, P. S.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA	Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, 241 Engn Innovat Bldg, Clemson, SC 29634 USA.	mica.grujicic@ces.clemson.edu			Office of Naval Research (ONR) through the Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]	The material presented in this article is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head," Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University. The authors are indebted to Dr. Roshdy Barsoum of ONR for continuing support and interest in the present work and to professors J. Runt, J. Tarter, G. Settles, G. Dillon, and M. Hargether for stimulating discussions and friendship.	Amini MR, 2010, INT J IMPACT ENG, V37, P90, DOI 10.1016/j.ijimpeng.2009.04.005; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; [Anonymous], HYP; *ANSYS INC, 2007, ANSYS AUT 2D 3D VERS; Bahei-El-Din YA, 2006, INT J SOLIDS STRUCT, V43, P7644, DOI 10.1016/j.ijsolstr.2006.03.021; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogoslovov RB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2745212; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI [10.1108/eb023876, DOI 10.1108/EB023876, DOI 10.1108/EB023876>]; Cullis I G, 2001, J R Army Med Corps, V147, P16; *DASS SYST, 2008, ABAQUS VERS 6 8 1 US; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2009, MATER DESIGN, V30, P4273, DOI 10.1016/j.matdes.2009.04.028; GRUJICIC M, 2009, MAT STRUCT, V6; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; KAMBOUCHEV N, 2007, COMPUT STRUCT, V23, P325; Moore DF, 2008, ANN NEUROL, V64, pS30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tham CY, 2008, INT J IMPACT ENG, V35, P304, DOI 10.1016/j.ijimpeng.2007.03.008; *USA CORPS ENG, CONWEP BLAST SIM SOF; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh SM, 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; PERSPECTIVES NETWORK	27	69	70	1	36	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1059-9495	1544-1024		J MATER ENG PERFORM	J. Mater. Eng. Perform.	AUG	2011	20	6					877	893		10.1007/s11665-010-9724-z			17	Materials Science, Multidisciplinary	Materials Science	792MN	WOS:000292749800005					2021-06-18	
J	Stein, DM; Hu, PF; Brenner, M; Sheth, KN; Liu, KH; Xiong, W; Aarabi, B; Scalea, TM				Stein, Deborah M.; Hu, Peter F.; Brenner, Megan; Sheth, Kevin N.; Liu, Keng-Hao; Xiong, Wei; Aarabi, Bizhan; Scalea, Thomas M.			Brief Episodes of Intracranial Hypertension and Cerebral Hypoperfusion Are Associated With Poor Functional Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	24th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 25-29, 2011	Naples, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; Secondary insults; Intracranial hypertension; Cerebral hypoperfusion	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; PERFUSION-PRESSURE; FIBEROPTIC BRONCHOSCOPY; AGGRESSIVE TREATMENT; INTENSIVE-CARE; MORTALITY; ICP; MANAGEMENT; CHILDREN	Background: Management strategies after severe traumatic brain injury (TBI) target prevention and treatment of intracranial hypertension (ICH) and cerebral hypoperfusion (CH). We have previously established that continuous automated recordings of vital signs (VS) are more highly correlated with outcome than manual end-hour recordings. One potential benefit of automated vital sign data capture is the ability to detect brief episodes of ICH and CH. The purpose of this study was to establish whether a relationship exists between brief episodes of ICH and CH and outcome after severe TBI. Materials: Patients at the R Adams Cowley Shock Trauma Center were prospectively enrolled over a 2-year period. Inclusion criteria were as follows: age > 14 years, admission within the first 6 hours after injury, Glasgow Coma Scale score < 9 on admission, and placement of a clinically indicated ICP monitor. From high-resolution automated VS data recording system, we calculated the 5-minute means of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and Brain Trauma Index (BTI = CPP/ICP). Patients were stratified by mortality and 6-month Extended Glasgow Outcome Score (GOSE). Results: Sixty subjects were enrolled with a mean admission Glasgow Coma Scale score of 6.4 +/- 3.1, a mean Head Abbreviated Injury Severity Scale score of 4.2 +/- 0.7, and a mean Marshall CT score of 2.5 +/- 0.9. Significant differences in the mean number of brief episodes of CPP < 50 and BTI < 2 in patients with a GOSE 1-4 versus GOSE 5-8 (9.4 vs. 4.7, p = 0.02 and 9.3 vs. 4.9, p = 0.03) were found. There were significantly more mean brief episodes per day of ICP > 30 (0.52 vs. 0.29, p = 0.02), CPP < 50 (0.65 vs. 0.28, p < 0.001), CPP < 60 (1.09 vs. 0.7, p = 0.03), BTI < 2 (0.66 vs. 0.31, p = 0.002), and BTI < 3 (1.1 vs. 0.64, p = 0.01) in those patients with GOSE 1-4. Number of brief episodes of CPP < 50, CPP < 60, BTI < 2, and BTI < 3 all demonstrated high predictive power for unfavorable functional outcome (area under the curve = 0.65-0.75, p < 0.05). Conclusions: This study demonstrates that the number of brief 5-minute episodes of ICH and CH is predictive of poor outcome after severe TBI. This finding has important implications for management paradigms which are currently targeted to treatment rather than prevention of ICH and CH. This study demonstrates that these brief episodes may play a significant role in outcome after severe TBI.	[Stein, Deborah M.; Brenner, Megan; Sheth, Kevin N.; Aarabi, Bizhan; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Stein, Deborah M.; Hu, Peter F.; Brenner, Megan; Sheth, Kevin N.; Liu, Keng-Hao; Xiong, Wei; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Med Ctr, Div Crit Care, Program Trauma R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Caruselli G, 1992, J Neurosurg Sci, V36, P219; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1983, INTRACRANIAL PRESSUR, V5, P501; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Harviel JD, 2000, J TRAUMA, V48, P882; Helbok R, 2009, NEUROCRIT CARE, V11, P133, DOI 10.1007/s12028-009-9262-4; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marmarou A, 2005, ACT NEUR S, V95, P277; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORDBY HK, 1985, ACTA NEUROCHIR, V74, P21, DOI 10.1007/BF01413271; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155	53	69	70	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					364	373		10.1097/TA.0b013e31822820da			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	806XH	WOS:000293850200032	21825940				2021-06-18	
J	Kalbermatten, DF; Schaakxs, D; Kingham, PJ; Wiberg, M				Kalbermatten, Daniel F.; Schaakxs, Dominique; Kingham, Paul J.; Wiberg, Mikael			Neurotrophic activity of human adipose stem cells isolated from deep and superficial layers of abdominal fat	CELL AND TISSUE RESEARCH			English	Article						Growth factor; Nerve; Regeneration; Stem cell; Tissue engineering	GROWTH-FACTOR; BONE-MARROW; IN-VITRO; DIFFERENTIATION; TISSUE; TRANSPLANTATION; PHENOTYPE; OUTGROWTH; DELIVERY	New approaches to the clinical treatment of traumatic nerve injuries may one day utilize stem cells to enhance nerve regeneration. Adipose-derived stem cells (ASC) are found in abundant quantities and can be harvested by minimally invasive procedures that should facilitate their use in such regenerative applications. We have analyzed the properties of human ASC isolated from the deep and superficial layers of abdominal fat tissue obtained during abdominoplasty procedures. Cells from the superficial layer proliferate significantly faster than those from the deep layer. In both the deep and superficial layers, ASC express the pluripotent stem cell markers oct4 and nanog and also the stro-1 cell surface antigen. Superficial layer ASC induce the significantly enhanced outgrowth of neurite-like processes from neuronal cell lines when compared with that of deep layer cells. However, analysis by reverse transcription with the polymerase chain reaction and by enzyme-linked immunosorbent assay has revealed that ASC isolated from both layers express similar levels of the following neurotrophic factors: nerve growth factor, brain-derived neurotrophic factor and glial-derived neurotrophic factor. Thus, human ASC show promising potential for the treatment of traumatic nerve injuries. In particular, superficial layer ASC warrant further analysis of their neurotrophic molecules.	[Kalbermatten, Daniel F.; Schaakxs, Dominique; Kingham, Paul J.; Wiberg, Mikael] Umea Univ, Dept Integrat Med Biol, Sect Anat, SE-90187 Umea, Sweden; [Wiberg, Mikael] Umea Univ, Dept Surg & Perioperat Sci, Sect Hand & Plast Surg, SE-90187 Umea, Sweden; [Kalbermatten, Daniel F.; Schaakxs, Dominique] Univ Lausanne Hosp, Div Plast Reconstruct & Aesthet Surg, CHUV, Lausanne, Switzerland; [Kalbermatten, Daniel F.] Univ Basel Hosp, Dept Plast Reconstruct & Aesthet Surg, CH-4031 Basel, Switzerland	Kingham, PJ (corresponding author), Umea Univ, Dept Integrat Med Biol, Sect Anat, SE-90187 Umea, Sweden.	paul.kingham@anatomy.umu.se		Kingham, Paul/0000-0003-2596-5936; Kalbermatten, Daniel Felix/0000-0002-6626-1233	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Umea University; County of Vasterbotten; Magn. Bergvalls Stiftelse; Clas Groschinskys Minnesfond; Ake Wibergs Stiftelse; Gunvor and Josef Aner Foundation; SwissLife Foundation; SUVA; University of Lausanne FBM	This study was supported by the Swedish Medical Research Council, Umea University, County of Vasterbotten, Magn. Bergvalls Stiftelse, Clas Groschinskys Minnesfond, Ake Wibergs Stiftelse, the Gunvor and Josef Aner Foundation, SwissLife Foundation, the SUVA and the University of Lausanne FBM.	Aksu AE, 2008, ANN PLAS SURG, V60, P306, DOI 10.1097/SAP.0b013e3180621ff0; Anghileri E, 2008, STEM CELLS DEV, V17, P909, DOI 10.1089/scd.2007.0197; Baglioni S, 2009, FASEB J, V23, P3494, DOI 10.1096/fj.08-126946; Barrilleaux B, 2006, TISSUE ENG, V12, P3007, DOI 10.1089/ten.2006.12.3007; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Carlson KB, 2011, GLIA, V59, P267, DOI 10.1002/glia.21099; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593; Choi RCY, 1997, NEUROSCI LETT, V236, P167, DOI 10.1016/S0304-3940(97)00789-1; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; di Summa PG, 2010, J PLAST RECONSTR AES, V63, P1544, DOI 10.1016/j.bjps.2009.09.012; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Lambert APF, 2009, DIFFERENTIATION, V77, P221, DOI 10.1016/j.diff.2008.10.016; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Jiang L, 2008, NEUROREPORT, V19, P1015, DOI 10.1097/WNR.0b013e3283040efc; Kim JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007166; Kim YJ, 2007, CELL PHYSIOL BIOCHEM, V20, P867, DOI 10.1159/000110447; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165; Oedayrajsingh-Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125; Padoin AV, 2008, PLAST RECONSTR SURG, V122, P614, DOI 10.1097/PRS.0b013e31817d5476; Pfister LA, 2007, J PERIPHER NERV SYST, V12, P65, DOI 10.1111/j.1529-8027.2007.00125.x; Quirici N, 2010, STEM CELLS DEV, V19, P915, DOI 10.1089/scd.2009.0408; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015-009-9094-9; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Santiago LY, 2009, CELL TRANSPLANT, V18, P145, DOI 10.3727/096368909788341289; Schipper BM, 2008, ANN PLAS SURG, V60, P538, DOI 10.1097/SAP.0b013e3181723bbe; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sterodimas A, 2010, J PLAST RECONSTR AES, V63, P1886, DOI 10.1016/j.bjps.2009.10.028; Terenghi G, 2009, INT REV NEUROBIOL, V87, P393, DOI 10.1016/S0074-7742(09)87021-9; Walsh S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E2; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21; Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210; Zimmerlin L, 2010, CYTOM PART A, V77A, P22, DOI 10.1002/cyto.a.20813	37	69	70	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAY	2011	344	2					251	260		10.1007/s00441-011-1142-5			10	Cell Biology	Cell Biology	758LZ	WOS:000290167600007	21400216				2021-06-18	
J	Gosselin, N; Bottari, C; Chen, JK; Petrides, M; Tinawi, S; de Guise, E; Ptito, A				Gosselin, Nadia; Bottari, Carolina; Chen, Jen-Kai; Petrides, Michael; Tinawi, Simon; de Guise, Elaine; Ptito, Alain			Electrophysiology and Functional MRI in Post-Acute Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram; neuropsychology; functional magnetic resonance imaging; mild traumatic brain injury	WORKING-MEMORY LOAD; SPORTS CONCUSSION; FRONTAL-CORTEX; AXONAL INJURY; HEAD-INJURY; SYMPTOMS; FMRI; ORGANIZATION; RECOVERY; ABNORMALITIES	Symptoms persisting beyond the acute phase (>2 months) after a mild traumatic brain injury (MTBI) are often reported, but their origin remains controversial. Some investigators evoke dysfunctional cerebral mechanisms, while others ascribe them to the psychological consequences of the injury. We address this controversy by exploring possible cerebral dysfunction with functional magnetic resonance imaging (fMRI) and event-related potentials (ERP) in a group of patients during the post-acute phase. Fourteen MTBI symptomatic patients (5.7 +/- 2.9 months post-injury) were tested with fMRI and ERP using a visual externally ordered working memory task, and were compared with 23 control subjects. Attenuated blood oxygen level dependent (BOLD) signal changes in the left and right mid-dorsolateral prefrontal cortex (mid-DLPFC), the putamen, the body of the caudate nucleus, and the right thalamus were found in the MTBI group compared with the control group. Moreover, symptom severity and BOLD signal changes were correlated: patients with more severe symptoms had lower BOLD signal changes in the right mid-DLPFC. For ERP, a group x task interaction was observed for N350 amplitude. A larger amplitude for the working memory task than for the control task was found in control subjects, but not in MTBI subjects, who had weak amplitudes for both tasks. This study confirms that persistent symptoms after MTBI cannot be uniquely explained by psychological factors, such as depression and/or malingering, and indicates that they can be associated with cerebral dysfunction. ERP reveals decreased amplitude of the N350 component, while fMRI demonstrates that the more severe the symptoms, the lower the BOLD signal changes in the mid-DLPFC.	[Gosselin, Nadia; Bottari, Carolina; Petrides, Michael; Ptito, Alain] Montreal Neurol Hosp & Inst, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Gosselin, Nadia; Bottari, Carolina; Petrides, Michael; de Guise, Elaine; Ptito, Alain] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Tinawi, Simon; de Guise, Elaine; Ptito, Alain] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; [Chen, Jen-Kai] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada	Ptito, A (corresponding author), Montreal Neurol Hosp & Inst, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds pour la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec	This study was supported by the Canadian Institutes of Health Research (grant to A. P. and M. P., and fellowships to N.G. and C. B.), and by the Fonds pour la Recherche en Sante du Quebec (fellowship to J.K.C.). The authors are grateful to Dr. Diane Diorio, Mitra Feyz, Isabel Roy, Dr. Gilles Lavigne, Kristina Martinu, Cindy Hovington, and Dr. Tomas Paus for their help to recruit subjects and/or for technical support. We would also like to thank the staff of the Magnetic Resonance Imaging Unit of the McConnell Brain Imaging Centre for their assistance.	ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GOSSELIN N, 2009, TENN C MONTR CAN; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Missonnier P, 2007, NEUROSCIENCE, V150, P346, DOI 10.1016/j.neuroscience.2007.09.009; Missonnier P, 2003, NEUROREPORT, V14, P1451, DOI 10.1097/00001756-200308060-00009; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1995, J NEUROSCI, V15, P359; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Ptito A, 2007, NEUROREHABILITATION, V22, P217; SMITS M, 2008, HUM BRAIN MAPP; Talairach J., 1988, COPLANAR STEREOTACTI; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; YETERIAN EH, 1991, J COMP NEUROL, V312, P43, DOI 10.1002/cne.903120105	42	69	70	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					329	341		10.1089/neu.2010.1493			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600001	21309680				2021-06-18	
J	Jin, KL; Xie, L; Mao, XO; Greenberg, MB; Moore, A; Peng, BT; Greenberg, RB; Greenberg, DA				Jin, Kunlin; Xie, Lin; Mao, XiaoOu; Greenberg, Maeve B.; Moore, Alexander; Peng, Botao; Greenberg, Rose B.; Greenberg, David A.			Effect of human neural precursor cell transplantation on endogenous neurogenesis after focal cerebral ischemia in the rat	BRAIN RESEARCH			English	Article						Ischemia; Stroke; Transplantation; Neurogenesis; Subventricular zone	TRAUMATIC BRAIN-INJURY; STEM-CELLS; SUBVENTRICULAR ZONE; FOREBRAIN NEUROGENESIS; PROMOTE PROLIFERATION; ADULT NEUROGENESIS; DENTATE GYRUS; AGED RATS; STROKE; MODEL	Little is known about the relationship between neuronal cell transplantation and endogenous neurogenesis after experimental stroke. We found previously that transplantation of neuronal precursors derived from BG01 human embryonic stem cells reduced infarct volume and improved behavioral outcome after distal middle cerebral artery occlusion (MCAO) in rats. In this study, transplantation was performed 14 days after distal MCAO and doublecortin (Dcx)-expressing cells in the subventricular zone (SVZ) and subgranular zone of dentate gyrus (SGZ) were counted 60 days post-transplant. Transplantation increased neurogenesis (Dcx expression) in ipsilateral SVZ, but not in contralateral SVZ or either SGZ, in both young adult (3-month-old) and aged (24-month-old) rats. These findings suggest that cell-based therapy for stroke may be associated with changes in endogenous adaptive processes, including neurogenesis. (C) 2010 Elsevier B.V. All rights reserved.	[Jin, Kunlin; Xie, Lin; Mao, XiaoOu; Greenberg, Maeve B.; Moore, Alexander; Peng, Botao; Greenberg, Rose B.; Greenberg, David A.] Buck Inst Age Res, Novato, CA 94945 USA	Greenberg, DA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dgreenberg@buckinstitute.org			USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NS44921, AG21980, NS057186]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044921, R01NS057186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021980] Funding Source: NIH RePORTER	Supported by USPHS grants NS44921 (to D.A.G) and AG21980 and NS057186 (to K.J.).	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Carbonaro DA, 2008, BLOOD, V111, P5745, DOI 10.1182/blood-2007-08-103663; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Esneault E, 2008, J CEREBR BLOOD F MET, V28, P1552, DOI 10.1038/jcbfm.2008.40; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Hattiangady B, 2007, STEM CELLS, V25, P2104, DOI 10.1634/stemcells.2006-0726; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Locatelli F, 2009, CELL MOL LIFE SCI, V66, P757, DOI 10.1007/s00018-008-8346-1; Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Park DH, 2010, STEM CELLS DEV, V19, P175, DOI 10.1089/scd.2009.0172; Shin SJ, 2006, STEM CELLS, V24, P125, DOI 10.1634/stemcells.2004-0150; Stroemer P, 2009, NEUROREHAB NEURAL RE, V23, P895, DOI 10.1177/1545968309335978; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Urban VS, 2008, STEM CELLS, V26, P244, DOI 10.1634/stemcells.2007-0267; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Won SJ, 2006, BRAIN RES, V1123, P237, DOI 10.1016/j.brainres.2006.09.055; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Yoshioka T, 2005, STEM CELLS, V23, P355, DOI 10.1634/stemcells.2004-0200; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	29	69	72	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 16	2011	1374						56	62		10.1016/j.brainres.2010.12.037			7	Neurosciences	Neurosciences & Neurology	725DA	WOS:000287624200007	21167824	Green Accepted, Green Published			2021-06-18	
J	Andrews, PJD; Sinclair, HL; Battison, CG; Polderman, KH; Citerio, G; Mascia, L; Harris, BA; Murray, GD; Stocchetti, N; Menon, DK; Shakur, H; De Backer, D				Andrews, Peter J. D.; Sinclair, Helen Louise; Battison, Claire G.; Polderman, Kees H.; Citerio, Giuseppe; Mascia, Luciana; Harris, Bridget A.; Murray, Gordon D.; Stocchetti, Nino; Menon, David K.; Shakur, Haleema; De Backer, Daniel			European society of intensive care medicine study of therapeutic hypothermia (32-35 degrees C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial)	TRIALS			English	Article							TERM MILD HYPOTHERMIA; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; GUIDELINES; EXPERIENCE; MANAGEMENT; INDUCTION	Background: Traumatic brain injury is a major cause of death and severe disability worldwide with 1,000,000 hospital admissions per annum throughout the European Union. Therapeutic hypothermia to reduce intracranial hypertension may improve patient outcome but key issues are length of hypothermia treatment and speed of re-warming. A recent meta-analysis showed improved outcome when hypothermia was continued for between 48 hours and 5 days and patients were re-warmed slowly (1 degrees C/4 hours). Previous experience with cooling also appears to be important if complications, which may outweigh the benefits of hypothermia, are to be avoided. Methods/design: This is a pragmatic, multi-centre randomised controlled trial examining the effects of hypothermia 32-35 degrees C, titrated to reduce intracranial pressure <20 mmHg, on morbidity and mortality 6 months after traumatic brain injury. The study aims to recruit 1800 patients over 41 months. Enrolment started in April 2010. Participants are randomised to either standard care or standard care with titrated therapeutic hypothermia. Hypothermia is initiated with 20-30 ml/kg of intravenous, refrigerated 0.9% saline and maintained using each centre's usual cooling technique. There is a guideline for detection and treatment of shivering in the intervention group. Hypothermia is maintained for at least 48 hours in the treatment group and continued for as long as is necessary to maintain intracranial pressure <20 mmHg. Intracranial hypertension is defined as an intracranial pressure >20 mmHg in accordance with the Brain Trauma Foundation Guidelines, 2007. Discussion: The Eurotherm3235Trial is the most important clinical trial in critical care ever conceived by European intensive care medicine, because it was launched and funded by the European Society of Intensive Care Medicine and will be the largest non-commercial randomised controlled trial due to the substantial number of centres required to deliver the target number of patients. It represents a new and fundamental step for intensive care medicine in Europe. Recruitment will continue until January 2013 and interested clinicians from intensive care units worldwide can still join this important collaboration by contacting the Trial Coordinating Team via the trial website http://www.eurotherm3235trial.eu.	[Andrews, Peter J. D.; Sinclair, Helen Louise; Battison, Claire G.; Harris, Bridget A.] Univ Edinburgh, Dept Anaesthesia, Crit Care & Pain Management, Edinburgh EH8 9YL, Midlothian, Scotland; [Polderman, Kees H.] Crit Care Med, Pittsburgh, PA 15261 USA; [Citerio, Giuseppe] Nuovo Osped S Gerardo, Dipartimento Anestesia & Rianimaz, I-20052 Monza, MI, Italy; [Mascia, Luciana] Univ Turin, Osped S Giovanni Battista, Dipartimento Anestesiol & Rianimaz, Turin, Italy; [Murray, Gordon D.] Univ Edinburgh, Sch Med, Publ Hlth Sci Sect, Div Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Stocchetti, Nino] Osped Maggiore, Policlin IRCCS, Terapia Intens Neurosci, I-3520122 Milan, Italy; [Menon, David K.] Univ Cambridge, Dept Anaesthesia, Div Anaesthesia, Cambridge CB2 1TN, England; [Shakur, Haleema] London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England; [De Backer, Daniel] Free Univ Brussels, Erasme Univ Hosp, B-1070 Brussels, Belgium	Andrews, PJD (corresponding author), Univ Edinburgh, Dept Anaesthesia, Crit Care & Pain Management, Edinburgh EH8 9YL, Midlothian, Scotland.	p.andrews@ed.ac.uk	Citerio, Giuseppe/B-1839-2015; Forbes, John F/L-2558-2013; De Backer, Daniel/AAF-4177-2020; mascia, Luciana/L-3039-2018; Polderman, Kees H/K-3623-2012; Stocchetti, Nino/O-7444-2017	Citerio, Giuseppe/0000-0002-5374-3161; Forbes, John F/0000-0002-8255-3762; De Backer, Daniel/0000-0001-9841-5762; Stocchetti, Nino/0000-0003-3250-6834; Shakur-Still, Haleema/0000-0002-6511-109X; Murray, Gordon/0000-0001-9866-4734	European Society of Intensive Care Medicine; University of Edinburgh; NHS Lothian; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237, G0800803] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Funded by: The European Society of Intensive Care Mediciner Sponsored by: The University of Edinburgh and NHS Lothian	Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; *BRAIN TRAUM FDN A, 2007, GUID MAN SEV TRAUM B, V3; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dixon SR, 2005, HEART, V91, pIII2, DOI 10.1136/hrt.2005.060251; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Grant A. M., 2005, ISSUES DATA MONITORI; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; National Patient Safety Agency, 2007, INF SHEETS CONS FORM; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Polderman KH, 2002, INTENS CARE MED, V28, pS103; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; POLDERMAN KH, 2003, INTENS CARE MED, V29, P1637; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yan Y, 2001, Chin J Traumatol, V4, P8; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	47	69	73	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JAN 12	2011	12								8	10.1186/1745-6215-12-8			12	Medicine, Research & Experimental	Research & Experimental Medicine	711KX	WOS:000286591500001	21226939	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Bigler, ED; Maxwell, WL				Bigler, Erin D.; Maxwell, William L.			Neuroimaging and neuropathology of TBI	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; DIFFUSION-TENSOR; WHITE-MATTER; THALAMIC NUCLEI; HEAD; MODERATE; INTEGRITY; CHILDREN; ATROPHY; MEMORY	Neuroimaging at all stages of a traumatic brain injury (TBI) provides information about gross brain pathology. In this review, post-mortem TBI cases are matched to neuroimaging findings from TBI survivors to demonstrate the close correlation between observable pathology with in vivo neuroimaging to the underlying neuropathology. An emphasis of this review focuses on neuroimaging identification of trauma induced cortical and white matter degeneration along with hydrocephalus ex vacuo expansion of the ventricular system as the injured brain exhibits atrophic changes. The role of hippocampal atrophy and thalamic injury along with the vulnerability of the corpus callosum in TBI are also reviewed. The aim of this review is to provide pathological confirmation of observable neuroimaging abnormalities that relate directly to trauma-induced effects of the injury.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Maxwell, William L.] Univ Glasgow, Dept Anat, Glasgow G12 8QQ, Lanark, Scotland	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1190D Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BRICKMAN AM, 2010, HIPPOCAMPUS; Budson AE, 2009, NEUROLOGIST, V15, P71, DOI 10.1097/NRL.0b013e318188040d; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Izhikevich EM, 2008, P NATL ACAD SCI USA, V105, P3593, DOI 10.1073/pnas.0712231105; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kesner RP, 2007, LEARN MEMORY, V14, P771, DOI 10.1101/lm.688207; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lajiness-O'Neill R, 2010, APPL NEUROPSYCHOL, V17, P83, DOI 10.1080/09084281003708837; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maruichi K, 2009, NEUROPATHOLOGY, V29, P132, DOI 10.1111/j.1440-1789.2008.00956.x; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wu TC, 2010, DEV NEUROSCI; Wu Y, 2010, J MAGN RESON IMAGING, V31, P980, DOI 10.1002/jmri.22120; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001	51	69	71	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	2					63	74		10.3233/NRE-2011-0633			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768MZ	WOS:000290940300001	21447905				2021-06-18	
J	Roozenbeek, B; Lingsma, HF; Perel, P; Edwards, P; Roberts, I; Murray, GD; Maas, AIR; Steyerberg, EW				Roozenbeek, Bob; Lingsma, Hester F.; Perel, Pablo; Edwards, Phil; Roberts, Ian; Murray, Gordon D.; Maas, Andrew I. R.; Steyerberg, Ewout W.		IMPACT Int Mission Prognosis Clin; CRASH Corticosteroid Randomisation	The added value of ordinal analysis in clinical trials: an example in traumatic brain injury	CRITICAL CARE			English	Article							RANDOMIZED CONTROLLED-TRIALS; NEUROPROTECTIVE AGENTS; OUTCOME SCALES; ACUTE STROKE; HEAD-INJURY; EFFICACY; DESIGN	Introduction: In clinical trials, ordinal outcome measures are often dichotomized into two categories. In traumatic brain injury (TBI) the 5-point Glasgow outcome scale (GOS) is collapsed into unfavourable versus favourable outcome. Simulation studies have shown that exploiting the ordinal nature of the GOS increases chances of detecting treatment effects. The objective of this study is to quantify the benefits of ordinal analysis in the real-life situation of a large TBI trial. Methods: We used data from the CRASH trial that investigated the efficacy of corticosteroids in TBI patients (n = 9,554). We applied two techniques for ordinal analysis: proportional odds analysis and the sliding dichotomy approach, where the GOS is dichotomized at different cut-offs according to baseline prognostic risk. These approaches were compared to dichotomous analysis. The information density in each analysis was indicated by a Wald statistic. All analyses were adjusted for baseline characteristics. Results: Dichotomous analysis of the six-month GOS showed a non-significant treatment effect (OR = 1.09, 95% CI 0.98 to 1.21, P = 0.096). Ordinal analysis with proportional odds regression or sliding dichotomy showed highly statistically significant treatment effects (OR 1.15, 95% CI 1.06 to 1.25, P = 0.0007 and 1.19, 95% CI 1.08 to 1.30, P = 0.0002), with 2.05-fold and 2.56-fold higher information density compared to the dichotomous approach respectively. Conclusions: Analysis of the CRASH trial data confirmed that ordinal analysis of outcome substantially increases statistical power. We expect these results to hold for other fields of critical care medicine that use ordinal outcome measures and recommend that future trials adopt ordinal analyses. This will permit detection of smaller treatment effects.	[Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Roozenbeek, Bob; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Edwards, Phil; Roberts, Ian] Univ London London Sch Hyg & Trop Med, Epidemiol & Populat Hlth Dept, London WC1E 7HT, England; [Murray, Gordon D.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland	Roozenbeek, B (corresponding author), Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	b.roozenbeek@erasmusmc.nl	Abdullah, J/C-2828-2011; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Abdullah, J/0000-0002-0258-7410; Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; /0000-0002-2342-301X; Edwards, Phil/0000-0003-4431-8822	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This study was performed as a part of the IMPACT Study in collaboration with the MRC CRASH Trial Collaborators. The IMPACT study was funded by the US National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691). The CRASH trial was funded by the UK Medical Research Council.	Aberegg Scott K, 2010, Crit Care, V14, pR77, DOI 10.1186/cc8990; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; den Hertog HM, 2009, LANCET NEUROL, V8, P434, DOI 10.1016/S1474-4422(09)70051-1; Edwards P, 2005, LANCET, V365, P1957; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MAHONEY F I, 1965, Md State Med J, V14, P61; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Mendelow AD, 2005, LANCET, V365, P387; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RANKIN J, 1957, Scott Med J, V2, P200; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Valenta Z, 2006, STAT MED, V25, P4227, DOI 10.1002/sim.2678	28	69	70	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2011	15	3							R127	10.1186/cc10240			7	Critical Care Medicine	General & Internal Medicine	832JB	WOS:000295799700009	21586148	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Rosenthal, G; Sanchez-Mejia, RO; Phan, N; Hemphill, JC; Martin, C; Manley, GT				Rosenthal, Guy; Sanchez-Mejia, Rene O.; Phan, Nicolas; Hemphill, J. Claude, III; Martin, Christine; Manley, Geoffrey T.			Incorporating a parenchymal thermal diffusion cerebral blood flow probe in bedside assessment of cerebral autoregulation and vasoreactivity in patients with severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral autoregulation; thermal diffusion probe; advanced neuromonitoring; MAP challenge; hyperventilation challenge	CARBON-DIOXIDE REACTIVITY; SEVERE HEAD-INJURY; PRESSURE AUTOREGULATION; INDUCED HYPERTENSION	Object. Cerebral autoregulation may be altered after traumatic brain injury (TBI). Recent evidence suggests that patients' autoregulatory status following severe TBI may influence cerebral perfusion pressure management. The authors evaluated the utility of incorporating a recently upgraded parenchymal thermal diffusion probe for the measurement of cerebral blood flow (CBF) in the neurointensive care unit for assessing cerebral autoregulation and vasoreactivity at bedside. Methods. The authors evaluated 20 patients with severe TBI admitted to San Francisco General Hospital who underwent advanced neuromonitoring. Patients had a parenchymal thermal diffusion probe placed for continuous bedside monitoring of local CBF (locCBF) in addition to the standard intracranial pressure and brain tissue oxygen tension (PbtO2) monitoring. The CBF probes were placed in the white matter using a separate cranial bolt. A pressure challenge, whereby mean arterial pressure (MAP) was increased by about 10 mm Hg, was performed in all patients to assess autoregulation. Cerebral CO2 vasoreactivity was assessed with a hyperventilation challenge. Local cerebral vascular resistance (locCVR) was calculated by dividing cerebral perfusion pressure by locCBF. Local cerebral vascular resistance normalized to baseline (locCVRnormalized) was also calculated for the MAP and hyperventilation challenges. Results. In all cases, bedside measurement of locCBF using a cranial bolt in patients with severe TBI resulted in correct placement in the white matter with a low rate of complications. Mean locCBF decreased substantially with hyperventilation challenge (-7 +/- 8 ml/100 g/min, p = 0.0002) and increased slightly with MAP challenge (1 +/- 7 ml/100 g/min, p = 0.17). Measurements of locCBF following MAP and hyperventilation challenges can be used to calculate locCVR. In 83% of cases locCVR increased during a hyperventilation challenge (mean change +3.5 +/- 3.8 mm Hg/ml/100 g/min, p = 0.0002), indicating preserved cerebral CO2 vasoreactivity. In contrast, we observed a more variable response of locCVR to MAP challenge, with increased locCVR in only 53% of cases during a MAP challenge (mean change -0.17 +/- 3.9 mm Hg/ml/100 g/min, p = 0.64) indicating that in many cases autoregulation was impaired following severe TBI. Conclusions. Use of the Hemedex thermal diffusion probe appears to be a safe and feasible method that enables continuous monitoring of CBF at the bedside. Cerebral autoregulation and CO, vasoreactivity can be assessed in patients with severe TBI using the CBF probe by calculating locCVR in response to MAP and hyperventilation challenges. Determining whether CVR increases or decreases with a MAP challenge (locCVRnormalized) may be a simple provocative test to determine patients' autoregulatory status following severe TBI and helping to optimize CPP management. (DOI: 10.3171/2010.6.JNS091360)	[Rosenthal, Guy; Sanchez-Mejia, Rene O.; Phan, Nicolas; Martin, Christine; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Rosenthal, Guy] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, Jerusalem, Israel	Manley, GT (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS050173]; University of California, San Francisco Brain and Spinal Cord Injury CenterUniversity of California System; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grant R01 NS050173 and the University of California, San Francisco Brain and Spinal Cord Injury Center.	ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma F, 2008, J NEUROTRAUM, V25, P276; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS26; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2007, NEUROSURGERY, V61, P249, DOI [10.1227/01.NEU.0000143029.42638.2c, 10.1227/01.neu.0000279220.30633.45]; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Soukup J, 2008, J NEUROSURG ANESTH, V20, P249, DOI 10.1097/ANA.0b013e31817ef487; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Thome C, 2001, J NEUROSURG, V95, P402, DOI 10.3171/jns.2001.95.3.0402; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	23	69	72	2	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					62	70		10.3171/2010.6.JNS091360			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500015	20707619				2021-06-18	
J	Vangel, SJ; Rapport, LJ; Hanks, RA				Vangel, Stephen J., Jr.; Rapport, Lisa J.; Hanks, Robin A.			Effects of Family and Caregiver Psychosocial Functioning on Outcomes in Persons With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; chronic; family factors; predictors	SOCIAL SUPPORT; ASSESSMENT DEVICE; COPING STYLE; HEAD-INJURY; DISTRESS; REHABILITATION; SATISFACTION; DEPRESSION; CHILDREN; VALIDITY	Objectives: To examine the predictive value of caregiver/family status to well-being of persons with brain injury and to examine whether perceived social support to caregivers moderates their well-being. Participants: One hundred nine pairs of adults, a caregiver, and an individual with TBI. Main Measures: Brief Symptom Inventory-18, Satisfaction With Life Scale; Disability Rating Scale; Social Provision Scale, Family Assessment Device, and Disability Rating Scale. Results: Canonical correlation indicated the presence of a relationship between well-being in TBI and caregiver participants. Two canonical variates accounted for 47.5% variance. Poor psychological well-being among persons with TBI was associated with poor caregiver perceived social support and poor familial behavioral control. Individuals with high disability also had caregivers with poorer psychological well-being. In post hoc multiple regressions, caregiver/family psychosocial characteristics added unique prediction of outcome for individuals with TBI. Hierarchical multiple regressions provided evidence that social support of caregivers moderates outcome status for individuals with TBI. Conclusions: Future research efforts should focus on understanding of the specific mechanisms of reciprocal effects, to help design future therapy.	[Vangel, Stephen J., Jr.; Hanks, Robin A.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI 48201 USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48201 USA	Vangel, SJ (corresponding author), Wayne State Univ, Dept Phys Med & Rehabil, Room 555,261 Mack Ave, Detroit, MI 48201 USA.	svangel@med.wayne.edu			National Institute on Disability and Rehabilitation Research [H133A080044]	This project was supported by the National Institute on Disability and Rehabilitation Research, grant H133A080044.	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BARAKAT LP, 1992, J PEDIATR PSYCHOL, V17, P725, DOI 10.1093/jpepsy/17.6.725; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Cutrona CE, 1987, ADV PERSONAL RELATIO, V1; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Derogatis L. R., 2001, BRIEF SYMPTOM INVENT; Derogatis LR, 1977, SCL 90 MANUAL 1 SCOR; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Heaton R. K, 1981, WISCONSIN CARD SORTI; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KAPLAN S, 1991, CLIN NEUROPSYCHOL, V5, P360, DOI DOI 10.1080/13854049108404103; KlOve H, 1963, MED CLIN N AM; Kosciulek J.F., 1998, J APPL REHABILITATIO, V29, P8; Kosciulek JF, 1996, J REHABIL, V62, P49; Kosciulek JF, 1999, BRAIN INJURY, V13, P245, DOI 10.1080/026990599121610; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, pR7; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Max JE, 1998, BRAIN INJURY, V12, P41; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ridenour TA, 1999, FAM PROCESS, V38, P497, DOI 10.1111/j.1545-5300.1999.00497.x; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SANDER AM, 1999, REHABILITATION THEAD; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Smith A., 1982, SYMBOL DIGIT MODALIT; STEWART D, 1968, PSYCHOL BULL, V70, P160, DOI 10.1037/h0026143; Tabachnick BG, 2007, USING MULTIVARIATE S; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	51	69	69	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					20	29		10.1097/HTR.0b013e318204a70d			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200003	21209560				2021-06-18	
J	Nelson, NW; Hoelzle, JB; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.			Evaluation Context Impacts Neuropsychological Performance of OEF/OIF Veterans with Reported Combat-Related Concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Forensic neuropsychology; Malingering; symptom validity testing	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; AMERICAN-ACADEMY; TEST-SCORES; MILD TBI; SOLDIERS; SEQUELAE; IRAQ	Although soldiers of Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF) encounter combat-related concussion at an unprecedented rate, relatively few studies have examined how evaluation context, insufficient effort, and concussion history impact neuropsychological performances in the years following injury. The current study explores these issues in a sample of 119 U.S. veterans (OEF/OIF forensic concussion, n = 24; non-OEF/OIF forensic concussion, n = 20; OEF/OIF research concussion, n = 38; OEF/OIF research without concussion, n = 37). The OEF/OIF forensic concussion group exhibited significantly higher rates of insufficient effort relative to the OEF/OIF research concussion group, but a comparable rate of insufficient effort relative to the non-OEF/OIF forensic concussion group. After controlling for effort, the research concussion and the research non-concussion groups demonstrated comparable neuropsychological performance. Results highlight the importance of effort assessment among OEF/OIF and other veterans with concussion history, particularly in forensic contexts.	[Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA	Nelson, NW (corresponding author), Minneapolis VA Med Ctr, 1 Vet Dr 116B, Minneapolis, MN 55417 USA.	nels5363@umn.edu	Sponheim, Scott/J-3857-2017	Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported in part by Grants funded by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to SRS and the Minnesota Veterans Research Institute (MVRI) to NWN.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; First M.B., 2007, STRUCTURED CLIN INTE; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden C., 1978, STROOP COLOR WORD TE; Green, 2004, GREENS MED SYMPTOM V; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1996, TEST MEMORY MALINGER; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; VANDERPLOEG RD, 2009, NEUROPSYCHOLOGY MALI; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	58	69	69	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2010	25	8					713	723		10.1093/arclin/acq075			11	Psychology, Clinical; Psychology	Psychology	679KE	WOS:000284159500002	20923860	Bronze, Green Published			2021-06-18	
J	Mazur, M; Miller, RH; Robinson, S				Mazur, Marcus; Miller, Robert H.; Robinson, Shenandoah			Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury Laboratory investigation	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cerebral palsy; epilepsy; oligodendrocyte; erythropoietin receptor; gamma-aminobutyric acid; preterm brain injury	TRAUMATIC BRAIN-INJURY; LOW-BIRTH-WEIGHT; DOSE RECOMBINANT ERYTHROPOIETIN; CEREBRAL-ISCHEMIA; PERIVENTRICULAR LEUKOMALACIA; MEDIATED NEUROPROTECTION; EXPRESSION PATTERNS; CEREBROSPINAL-FLUID; WHITE-MATTER; SPINAL-CORD	Object. Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival. Methods. Transient systemic hypoxia-ischemia (TSHI) on embryonic Day 18 in rats mimics human early-third-trimester placental insufficiency. This model was used to test the authors' hypothesis using a novel clinically relevant paradigm of prenatal injury on embryonic Day 18, neonatal systemic rhEPO administration initiated 4 days after injury on postnatal Day 1, and histological, biochemical, and functional analyses in neonatal, juvenile, and adult rats. Results. The results showed that prenatal TSHI upregulates brain EPO receptors, but not EPO ligand. Sustained EPO receptor upregulation was pronounced on oligodendroglial lineage cells and neurons, neural cell populations particularly prone to loss from CNS injury due to preterm birth. Postnatal rhEPO administration after prenatal TSHI minimized histological damage and rescued oligodendrocytes and gamma-aminobutyric acidergic interneurons. Myelin basic protein expression in adult rats after insult was reduced compared with sham controls, but could be restored to near normal levels by neonatal rhEPO treatment. Erythropoietin-treated TSHI rats performed significantly better than their saline-treated peers as adults in motor skills tests, and showed significant seizure threshold restoration using a pentylenetetrazole increasing-dose paradigm. Conclusions. These data demonstrate that neonatal rhEPO administration in a novel clinically relevant paradigm initiated 4 days after a global prenatal hypoxic-ischemic insult in rats rescues neural cells, and induces lasting histological and functional improvement in adult rats. (DOI: 10.3171/2010.5.PEDS1032)	[Mazur, Marcus; Robinson, Shenandoah] Rainbow Babies & Childrens Hosp, Dept Neurosurg, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, Cleveland, OH 44106 USA; [Miller, Robert H.] Rainbow Babies & Childrens Hosp, Dept Neurosci, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, Cleveland, OH 44106 USA	Robinson, S (corresponding author), Rainbow Babies & Childrens Hosp, Dept Neurosurg, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, B501,11100 Euclid Ave, Cleveland, OH 44106 USA.	shenandoah.robinson@UHhospitals.org			National Institute of Neurological Disorders and Stroke, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS46486, R01 NS060765]; Rainbow Babies and Children's Hospital Board of Trustees; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS046486, R01NS060765, R01NS030800] Funding Source: NIH RePORTER	This work was supported by grants to Dr. Robinson from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, No. K08 NS46486 and R01 NS060765, and from the Rainbow Babies and Children's Hospital Board of Trustees.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Arrieta O, 2005, EPILEPSIA, V46, P1599, DOI 10.1111/j.1528-1167.2005.00267.x; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Back SA, 2002, J NEUROPATH EXP NEUR, V61, P197, DOI 10.1093/jnen/61.2.197; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Daw MI, 2007, NAT NEUROSCI, V10, P453, DOI 10.1038/nn1866; Demers EJ, 2005, PEDIATR RES, V58, P297, DOI 10.1203/01.PDR.0000169971.64558.5A; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fauchere JC, 2008, PEDIATRICS, V122, P375, DOI 10.1542/peds.2007-2591; Golan H, 2006, DEVELOPMENTAL SCI, V9, P338, DOI 10.1111/j.1467-7687.2006.00498.x; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Iai M, 1999, NEUROPEDIATRICS, V30, P14, DOI 10.1055/s-2007-973450; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; McPherson RJ, 2008, INT J DEV NEUROSCI, V26, P103, DOI 10.1016/j.ijdevneu.2007.08.012; McPherson RJ, 2007, NEONATOLOGY, V91, P36, DOI 10.1159/000096969; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Minino Arialdi M, 2007, Natl Vital Stat Rep, V55, P1; Mizuno K, 2008, NEONATOLOGY, V94, P255, DOI 10.1159/000151644; Nakajima W, 2000, J NEUROSCI, V20, P7994; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petrou S, 2005, BJOG-INT J OBSTET GY, V112, P10, DOI 10.1111/j.1471-0528.2005.00577.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Robinson S, 2005, EPILEPSY BEHAV, V7, P345, DOI 10.1016/j.yebeh.2005.06.005; Robinson S, 2005, NEUROBIOL DIS, V18, P568, DOI 10.1016/j.nbd.2004.10.024; Robinson S, 2006, J NEUROSURG, V104, P396, DOI 10.3171/ped.2006.104.6.396; Ronen GM, 2007, NEUROLOGY, V69, P1816, DOI 10.1212/01.wnl.0000279335.85797.2c; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Sizonenko SV, 2005, PEDIATR RES, V57, P865, DOI 10.1203/01.PDR.0000157673.36848.67; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Trollmann R, 2008, AM J PHYSIOL-REG I, V295, pR1973, DOI 10.1152/ajpregu.00053.2008; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Uzum G, 2006, LIFE SCI, V78, P2571, DOI 10.1016/j.lfs.2005.10.027; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Volpe JJ, 2005, PEDIATRICS, V116, P221, DOI 10.1542/peds.2005-0191; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wen TC, 2004, NEUROSCI LETT, V355, P165, DOI 10.1016/j.neulet.2003.10.078; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Xenocostas A, 2005, EUR J CLIN PHARMACOL, V61, P189, DOI 10.1007/s00228-005-0896-7; Yu XB, 2002, DEVELOPMENT, V129, P505	62	69	75	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	SEP	2010	6	3					206	221		10.3171/2010.5.PEDS1032			16	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	641FT	WOS:000281110900003	20809703	Green Accepted			2021-06-18	
J	Inamasu, J; Miyatake, S; Suzuki, M; Nakatsukasa, M; Tomioka, H; Honda, M; Kase, K; Kobayashi, K				Inamasu, Joji; Miyatake, Satoru; Suzuki, Masaru; Nakatsukasa, Masashi; Tomioka, Hideto; Honda, Masanori; Kase, Kenichi; Kobayashi, Kenji			Early CT signs in out-of-hospital cardiac arrest survivors: Temporal profile and prognostic significance	RESUSCITATION			English	Article						Early CT sign; Loss of boundary; Out-of-hospital cardiac arrest; Return of spontaneous circulation; Sulcal effacement	VENTRICULAR-FIBRILLATION; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS; BRAIN-INJURY; CARDIOPULMONARY ARREST; COMPUTED-TOMOGRAPHY; PREDICTIVE-VALUE; WHITE-MATTER; RESUSCITATION; DEATH	Aim: Although computed tomography (CT) signs of ischaemia, including loss of boundary (LOB) between grey matter and white matter and cortical sulcal effacement, in cardiac arrest (CA) survivors are known, their temporal profile and prognostic significance remains unclear: their clarification is necessary. Methods: Brain CT scans were obtained immediately after resuscitation in 75 non-traumatic CA survivors in a prospective fashion. They were divided into two groups according to the CA-return of spontaneous circulation (ROSC) interval: <= 20 min vs. > 20 min. The incidence of the CT signs and predictability of these signs for outcome, assessed 6 months after CA, was evaluated and compared. Results: The incidence of the positive LOB sign was 24% in the <= 20-min group and 83% in the > 20-min group, and the difference was statistically significant (p < 0.001). The interval of 20 min seemed to be the time window for the LOB development. The incidence of the positive sulcal effacement sign was 0% in the <= 20 min group and 34% in the > 20-min group, and the difference was statistically significant (p = 0.004). A positive LOB sign was predictive of unfavourable outcome with an 81% sensitivity and 92% specificity. A positive sulcal effacement sign was predictive of unfavourable outcome with a 32% sensitivity and 100% specificity. Conclusion: A time window may exist for ischaemic CT signs in CA survivors. The LOB sign may develop when the CA-ROSC interval exceeds 20 min, whereas the sulcal effacement sign may develop later. However, their temporal profile and outcome predictability should be verified by multicentre studies. (c) 2010 Elsevier Ireland Ltd. All rights reserved.	[Inamasu, Joji; Miyatake, Satoru; Suzuki, Masaru; Tomioka, Hideto; Kase, Kenichi; Kobayashi, Kenji] Saiseikai Utsunomiya Hosp, Dept Emergency Med, Utsunomiya, Tochigi 3210974, Japan; [Inamasu, Joji; Nakatsukasa, Masashi] Saiseikai Utsunomiya Hosp, Dept Neurosurg, Utsunomiya, Tochigi 3210974, Japan; [Honda, Masanori] Saiseikai Utsunomiya Hosp, Dept Diagnost Radiol, Utsunomiya, Tochigi 3210974, Japan	Inamasu, J (corresponding author), Saiseikai Utsunomiya Hosp, Dept Emergency Med, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan.	ginamasu@aol.com	Inamasu, Joji/R-7314-2019				Arbelaez A, 1999, AM J NEURORADIOL, V20, P999; Barrett KM, 2007, MAYO CLIN PROC, V82, P828, DOI 10.4065/82.7.828; Belliard G, 2007, RESUSCITATION, V75, P252, DOI 10.1016/j.resuscitation.2007.04.014; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bottiger BW, 2008, NEW ENGL J MED, V359, P2651, DOI 10.1056/NEJMoa070570; Choi SP, 2008, EMERG MED J, V25, P666, DOI 10.1136/emj.2007.053306; European Resuscitation Council, 2005, RESUSCITATION, V67, P213; Holzer M, 2002, NEW ENGL J MED, V346, P549; Inamasu J, 2009, RESUSCITATION, V80, P977, DOI 10.1016/j.resuscitation.2009.05.010; Kandiah P, 2006, SEMIN NEUROL, V26, P413, DOI 10.1055/s-2006-948322; KJOS BO, 1983, AM J ROENTGENOL, V141, P1227, DOI 10.2214/ajr.141.6.1227; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Kucinski T, 1998, AM J NEURORADIOL, V19, P839; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Mysiak Andrzej, 2007, Cardiol J, V14, P24; Oddo M, 2008, CRIT CARE MED, V36, P2296, DOI 10.1097/CCM.0b013e3181802599; Oksanen T, 2009, RESUSCITATION, V80, P165, DOI 10.1016/j.resuscitation.2008.08.017; Pierce LC, 2008, AM J EMERG MED, V26, P1042, DOI 10.1016/j.ajem.2007.12.014; Torbey MT, 2000, STROKE, V31, P2163, DOI 10.1161/01.STR.31.9.2163; Virkkunen I, 2008, RESUSCITATION, V77, P207, DOI 10.1016/j.resuscitation.2007.12.006; Yanagawa Y, 2005, RESUSCITATION, V64, P97, DOI 10.1016/j.resuscitation.2004.06.015	23	69	73	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	MAY	2010	81	5					534	538		10.1016/j.resuscitation.2010.01.012			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	604MH	WOS:000278282600008	20189285				2021-06-18	
J	Sun, D; Bullock, MR; Altememi, N; Zhou, ZW; Hagood, S; Rolfe, A; McGinn, MJ; Hamm, R; Colello, RJ				Sun, Dong; Bullock, M. Ross; Altememi, Nabil; Zhou, Zhengwen; Hagood, Sarah; Rolfe, Andrew; McGinn, Melissa J.; Hamm, Robert; Colello, Raymond J.			The Effect of Epidermal Growth Factor in the Injured Brain after Trauma in Rats	JOURNAL OF NEUROTRAUMA			English	Article						epidermal growth factor; hippocampus; Morris water maze; neurogenesis; subventricular zone; traumatic brain injury	FACTOR RECEPTOR EXPRESSION; LONG-TERM POTENTIATION; DENTATE GYRUS; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; CELL-PROLIFERATION; COGNITIVE RECOVERY; STEM-CELLS; ADULT RATS; IN-VIVO	Epidermal growth factor (EGF) is a known mitogen for neural stem and progenitor cells (NS/NPCs) in the central nervous system (CNS). In vitro, EGF maintains NS/NPCs in the proliferative state, whereas in the normal rodent brain it promotes their proliferation and migration in the subventricular zone (SVZ). Additionally, EGF administration can augment neuronal replacement in the ischemic-injured adult striatum. Recently we found that the SVZ and the hippocampus display an injury-induced proliferative response following traumatic brain injury (TBI) that is linked to increased EGF expression. As adult neurogenesis is associated with cognitive function, we hypothesized that post-TBI administration of EGF could affect neurogenesis and cognitive recovery. Adult rats were intraventricularly infused with EGF or vehicle for 7 days following TBI. 5-Bromo-2-deoxyuridine (BrdU) was administered to label proliferating cells and the animals were sacrificed at 1 or 4 weeks post-injury. Using immunohistochemistry and stereology, we found that at 1 week post-injury, compared to vehicle-infused animals EGF-infused animals had significantly more BrdU-positive cells in the SVZ and hippocampus concomitant with enhanced EGF receptor expression. At 4 weeks post-injury, the number of BrdU-positive cells in the hippocampus was similar in both groups, suggesting that EGF does not support long-term survival of newly generated cells. Furthermore, we found that the EGF-induced proliferative population differentiated preferentially toward astroglial phenotype. Nevertheless, animals treated with EGF showed significant improvement in cognitive function, which was accompanied by reduced hippocampal neuronal cell loss. Collectively, the data from this study demonstrate that EGF exerts a neuroprotective rather than neurogenic effect in protecting the brain from injury.	[Sun, Dong; Bullock, M. Ross; Altememi, Nabil; Zhou, Zhengwen; Hagood, Sarah; Rolfe, Andrew] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa J.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Hamm, Robert] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA	Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631,Med Coll Virginia Campus, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086]; Virginia Commonwealth University Department of Anatomy; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health Grant no. NS055086 (to D. S.). The photomicrography for this study was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, which is supported in part by funding from NIH-NINDS center core grant 5P30NS047463.	ABE K, 1992, NEUROSCI RES, V14, P117, DOI 10.1016/0168-0102(92)90087-S; ABE K, 1992, BRAIN RES, V593, P335, DOI 10.1016/0006-8993(92)91332-9; Aberg MAI, 2000, J NEUROSCI, V20, P2896; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; CASPER D, 1995, J NEUROCHEM, V65, P1016; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Close JL, 2006, GLIA, V54, P94, DOI 10.1002/glia.20361; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gritti A, 1999, J NEUROSCI, V19, P3287; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; ISHIYAMA J, 1991, NEUROSCI RES, V12, P403, DOI 10.1016/0168-0102(91)90071-6; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuruba R, 2009, EPILEPSY BEHAV, V14, P65, DOI 10.1016/j.yebeh.2008.08.020; Laskowski A, 2005, BRAIN RES, V1037, P78, DOI 10.1016/j.brainres.2004.12.035; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Ninomiya M, 2006, NEUROSCI LETT, V403, P63, DOI 10.1016/j.neulet.2006.04.039; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; SEROOGY KB, 1995, BRAIN RES, V670, P157, DOI 10.1016/0006-8993(94)01300-7; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Trouche S, 2009, P NATL ACAD SCI USA, V106, P5919, DOI 10.1073/pnas.0811054106; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; Wong RWC, 2003, CELL MOL LIFE SCI, V60, P113, DOI 10.1007/s000180300007	44	69	72	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					923	938		10.1089/neu.2009.1209			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400014	20158379	Green Published			2021-06-18	
J	Poca, MA; Benejam, B; Sahuquillo, J; Riveiro, M; Frascheri, L; Merino, MA; Delgado, P; Alvarez-Sabin, J				Antonia Poca, Maria; Benejam, Bessy; Sahuquillo, Juan; Riveiro, Marilyn; Frascheri, Laura; Angels Merino, Maria; Delgado, Pilar; Alvarez-Sabin, Jose			Monitoring intracranial pressure in patients with malignant middle cerebral artery infarction: is it useful? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; middle cerebral artery; infarction; midline shift; pupillary abnormality; intracranial hypertension	SEVERE HEAD-INJURY; ACUTE HEMISPHERIC STROKE; MODERATE HYPOTHERMIA; DECOMPRESSIVE CRANIECTOMY; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; ISCHEMIC-STROKE; HEMICRANIECTOMY; BRAIN; SURGERY	Object. Intracranial pressure (ICP) monitoring is increasingly used in the treatment of patients with malignant middle cerebral artery (MCA) infarction. However, neurological deterioration may exist independent from intracranial hypertension. This study aimed to present the findings of continuous ICP monitoring in a cohort of patients with malignant MCA infarction and to correlate these findings with clinical and radiological features. Methods. The authors studied a prospective cohort of 25 patients with malignant MCA infarction consecutively admitted to the neurotrauma intensive care unit of the Vall d'Hebron University Hospital between March 2002 and September 2006. The patients were treated using a combined protocol of initial moderate hypothermia and hemicraniectomy. The latter was performed when patients showed a midline shift (MLS) >= 5 mm or ICP > 20 mm Hg. Six patients had an MLS >= 5 mm on the first CT scan and underwent surgery without prior ICP monitoring. This study focuses on the subgroup of 19 patients who underwent intraparenchymatous ICP monitoring before surgery. Results. Intracranial pressure readings were evaluated and correlated with pupillary abnormalities, MLS, and ischemic tissue volume. In 12 of the 19 patients, ICP values were always <= 20 mm Hg, despite a mean (+/- SD) MLS of 6.7 +/- 2 mm and a mean ischemic tissue volume of 241.3 +/- 83 cm(3). In 2 patients with anisocoria, ICP values were also normal. Conclusions. In patients with a malignant MCA infarction, pupillary abnormalities and severe brainstem compression may be present despite normal ICP values. Therefore, continuous ICP monitoring cannot substitute for close clinical and radiological follow-up in the management of these patients. (DOI: 10.3171/2009.7.JNS081677)	[Antonia Poca, Maria; Sahuquillo, Juan] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurosurg, E-08035 Barcelona, Spain; [Antonia Poca, Maria; Benejam, Bessy; Sahuquillo, Juan; Angels Merino, Maria] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurotraumatol Neurosurg Res Unit, E-08035 Barcelona, Spain; [Riveiro, Marilyn] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurotraumatol Intens Care Unit, E-08035 Barcelona, Spain; [Frascheri, Laura] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Inst Diagnost Imaging, E-08035 Barcelona, Spain; [Delgado, Pilar; Alvarez-Sabin, Jose] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurovasc Unit, E-08035 Barcelona, Spain; [Delgado, Pilar; Alvarez-Sabin, Jose] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurol, E-08035 Barcelona, Spain	Poca, MA (corresponding author), Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurosurg, Passeig Vall Hebron 119-129, E-08035 Barcelona, Spain.	pocama@neurotrauma.net	Riveiro, Marilyn/S-5242-2016; Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008	Riveiro, Marilyn/0000-0002-1645-3720; Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; Delgado Martinez, Maria Pilar/0000-0002-1628-4488; Alvarez-Sabin, Jose/0000-0002-8054-9209	Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS)Instituto de Salud Carlos III [05/1092, 07/0681]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [QLK1-CT-2002-02583]	This work was supported in part by Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS) grants received by Dr. J. Sahuquillo (No. 05/1092) and Dr. M. A. Poca ( No. 07/0681), and by the Fifth European Framework of the European Commission (SMILE project QLK1-CT-2002-02583). Dr. Sahuquillo is a consultant for Vasopharm Gmbh. The authors report no other conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.	BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Benejam B, 2008, NEUROLOGIA, V23, P40; Bennett JA, 2002, HEART LUNG, V31, P262, DOI 10.1067/mhl.2002.124554; Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625; Brandt T, 1996, BAILLIERE CLIN NEUR, V5, P515; Carhuapoma JR, 2002, J NEUROSURG ANESTH, V14, P299, DOI 10.1097/00008506-200210000-00005; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; Delgado-Lopez P, 2004, NEUROCIRUGIA, V15, P43; Desco M, 1999, INT CONGR SER, V1191, P218; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Keller E, 2000, CRIT CARE MED, V28, P511, DOI 10.1097/00003246-200002000-00037; Kraus JJ, 2002, NEUROL RES, V24, pS47; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 2005, Cerebrovasc Dis, V20 Suppl 2, P169, DOI 10.1159/000089371; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; Stolz E, 1999, STROKE, V30, P70, DOI 10.1161/01.STR.30.1.70; Su J, 2003, INT J DEV NEUROSCI, V21, P353, DOI 10.1016/S0736-5748(03)00070-4; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P583; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Yanamoto H, 2001, STROKE, V32, P232, DOI 10.1161/01.STR.32.1.232	38	69	78	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2010	112	3					648	657		10.3171/2009.7.JNS081677			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	562IQ	WOS:000275043900028	19663552				2021-06-18	
J	Ponsford, J; Schonberger, M				Ponsford, Jennie; Schoenberger, Michael			Family functioning and emotional state two and five years after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Family functioning; Relatives; Anxiety; Depression; Structural Equation Modelling	RANDOMIZED CONTROLLED-TRIAL; CAREGIVER BURDEN; PSYCHOLOGICAL DISTRESS; DEPRESSION SCALE; HOSPITAL ANXIETY; SOCIAL SUPPORT; ASSESSMENT DEVICE; HEAD-INJURY; FOLLOW-UP; REHABILITATION	Previous studies have documented poor family functioning. anxiety, and depression in relatives of individuals with traumatic brain injury (TBI). However, few studies have examined family functioning over extended periods after injury. The present study aimed to investigate family functioning and relatives' emotional state 2 and 5 years following TBI, predictive factors, and their interrelationships. Participants were individuals with TBI and their relatives, with 301 seen at 2 years and 266 at 5 years post-injury. Measures included a Structured Outcome Questionnaire, Family Assessment Device (FAD), Hospital Anxiety and Depression Scale, and the Craig Handicap Assessment and Reporting Technique. Results showed that while the group did not differ greatly in family functioning from a normative group, a significant proportion showed unhealthy functioning across most FAD subscales. Both TBI participants and their relatives showed elevated rates of anxiety and depression. There was little difference between family functioning or relatives' anxiety or depression levels at 2 and 5 years post-injury. Path analysis indicated that neurobehavioral changes in the injured individual have an impact on family functioning and distress in relatives even at 5 years post-injury. These findings indicate the need for long-term Support of families with a brain-injured member. (JINS, 2010, 16, 306-317.)	[Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	Jennie.Ponsford@med.monash.edu.au			Victorian Transport Accident Commission; Victorian Neurotrauma Initiative	Funding for this study came from the Victorian Transport Accident Commission and the Victorian Neurotrauma Initiative. The authors have no conflict of interest.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Chan J, 2007, INT J REHABIL RES, V30, P137, DOI 10.1097/MRR.0b013e32813a2f11; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI 10.1037/1082-989X.9.4.466; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hoofien D, 2001, BRAIN INJURY, V15, P189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PERLESZ A, 1989, RECOVERY BRAIN INJUR, P180; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; SCHONBERGER M, PSYCHIAT RE IN PRESS; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; SNAITH RP, 1983, HOSP ANXIETY DEPRESS; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001	55	69	69	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					306	317		10.1017/S1355617709991342			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900011	20128950				2021-06-18	
J	Kimberley, TJ; Samargia, S; Moore, LG; Shakya, JK; Lang, CE				Kimberley, Teresa Jacobson; Samargia, Sharyl; Moore, Lisa G.; Shakya, Josefin K.; Lang, Catherine E.			Comparison of amounts and types of practice during rehabilitation for traumatic brain injury and stroke	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cortical reorganization; CVA; neuroplasticity; observation; occupational therapy; physical therapy; rehabilitation; repetitions; stroke; TBI	INDUCED MOVEMENT THERAPY; ADULT SQUIRREL-MONKEYS; MOTOR CORTEX; CONTROLLED-TRIAL; FINGER TRACKING; RECOVERY; REPRESENTATIONS; REORGANIZATION; PLASTICITY; SESSIONS	Patients with acquired neurological deficits may capitalize on cortical reorganization to recover functional skills that have been lost. Research in neuroplasticity proposes that a high number of repetitions may lead to cortical reorganization. The purposes of this study were to quantify the number and type of activities performed by patients with traumatic brain injury (TBI) and stroke in physical and occupational therapy sessions to determine whether (1) the number of repetitions approaches the numbers in neuroplasticity research, (2) there were differences based on patient diagnosis, and (3) patient or therapist characteristics affected the type or amount of activities performed. Forty-eight patient and forty provider subjects participated. One hundred seven therapy sessions were observed. Data from therapy sessions were counted and categorized. Neither patient group approached the total number of repetitions neuroplasticity research suggests may be required for neuroplastic change. Repetitions per session did not differ between groups. Subjects with TBI performed more repetitions per minute in three categories (total upper-limb repetitions, gait steps, and transfers) than subjects with stroke. Therapists with <1 year or >15 years of neurological therapy experience instructed patients in fewer functional repetitions per minute than did therapists with 5 to 15 years of experience.	[Kimberley, Teresa Jacobson; Moore, Lisa G.; Shakya, Josefin K.] Univ Minnesota, Program Phys Therapy, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA; [Kimberley, Teresa Jacobson; Samargia, Sharyl] Univ Minnesota, Program Rehabil Sci, Minneapolis, MN 55455 USA; [Lang, Catherine E.] Washington Univ, Dept Neurol, Program Occupat Therapy, Program Phys Therapy, St Louis, MO USA	Kimberley, TJ (corresponding author), Univ Minnesota, Program Phys Therapy, Dept Phys Med & Rehabil, MMC 388,420 Church St SE, Minneapolis, MN 55455 USA.	tjk@umn.edu	Kimberley, Teresa/AAL-1893-2020	Kimberley, Teresa/0000-0001-6397-4054; Lang, Catherine/0000-0002-7120-0136	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD047669]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD047669] Funding Source: NIH RePORTER	This material was unfunded at the time of manuscript preparation. Salary support for Dr. Lang was provided by the National Institutes of Health (grant HD047669).	Birkenmeier RL, 2010, NEUROREHAB NEURAL RE, V24, P620, DOI 10.1177/1545968310361957; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Canning CG, 2003, CLIN REHABIL, V17, P355, DOI 10.1191/0269215503cr620oa; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Cha J, 2007, J NEUROTRAUM, V24, P1000, DOI 10.1089/neu.2006.0233; Chau C, 1998, J NEUROPHYSIOL, V79, P392; Classen J, 1998, J NEUROPHYSIOL, V79, P1117; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329; Elson T, 2009, INT J THER REHABIL, V16, P78, DOI 10.12968/ijtr.2009.16.2.38893; English CK, 2007, ARCH PHYS MED REHAB, V88, P955, DOI 10.1016/j.apmr.2007.04.010; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kimberley TJ, 2004, EXP BRAIN RES, V154, P450, DOI 10.1007/s00221-003-1695-y; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; LANG CE, 2006, TXB NEURAL REPAIR RE, V2; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, ACTA NEUROL SCAND, V101, P321, DOI 10.1034/j.1600-0404.2000.90337a.x; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P336, DOI 10.1177/1545968308321773; NATHAN PW, 1982, BRAIN, V105, P223, DOI 10.1093/brain/105.2.223; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; NUDO RJ, 1988, J COMP NEUROL, V277, P53, DOI 10.1002/cne.902770105; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shaw SE, 2005, J REHABIL RES DEV, V42, P769, DOI 10.1682/JRRD.2005.06.0094; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	34	69	70	0	30	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	9					851	861		10.1682/JRRD.2010.02.0019			11	Rehabilitation	Rehabilitation	707PX	WOS:000286299600006	21174250	Bronze			2021-06-18	
J	D'Ambrosio, R; Hakimian, S; Stewart, T; Verley, DR; Fender, JS; Eastman, CL; Sheerin, AH; Gupta, P; Diaz-Arrastia, R; Ojemann, J; Miller, JW				D'Ambrosio, Raimondo; Hakimian, Shahin; Stewart, Tessandra; Verley, Derek R.; Fender, Jason S.; Eastman, Clifford L.; Sheerin, Aaron H.; Gupta, Puneet; Diaz-Arrastia, Ramon; Ojemann, Jeffrey; Miller, John W.			Functional definition of seizure provides new insight into post-traumatic epileptogenesis	BRAIN			English	Article						traumatic brain injury; epileptogenesis; biomarkers; drug screening; prophylaxis	FLUID PERCUSSION INJURY; HIPPOCAMPAL SCLEROSIS; EPILEPTIC SEIZURES; ANIMAL-MODELS; THETA RHYTHM; OSCILLATIONS; PATHWAYS; RATS	Experimental animals' seizures are often defined arbitrarily based on duration, which may lead to misjudgement of the syndrome and failure to develop a cure. We employed a functional definition of seizures based on the clinical practice of observing epileptiform electrocorticography and simultaneous ictal behaviour, and examined post-traumatic epilepsy induced in rats by rostral parasagittal fluid percussion injury and epilepsy patients evaluated with invasive monitoring. We showed previously that rostral parasagittal fluid percussion injury induces different types of chronic recurrent spontaneous partial seizures that worsen in frequency and duration over the months post injury. However, a remarkable feature of rostral parasagittal fluid percussion injury is the occurrence, in the early months post injury, of brief (< 2 s) focal, recurrent and spontaneous epileptiform electrocorticography events (EEEs) that are never observed in sham-injured animals and have electrographic appearance similar to the onset of obvious chronic recurrent spontaneous partial seizures. Simultaneous epidural-electrocorticography and scalp-electroencephalography recordings in the rat demonstrated that these short EEEs are undetectable by scalp electrocorticography. Behavioural analysis performed blinded to the electrocorticography revealed that (i) brief EEEs lasting 0.8-2 s occur simultaneously with behavioural arrest; and (ii) while behavioural arrest is part of the rat's behavioural repertoire, the probability of behavioural arrest is greatly elevated during EEEs. Moreover, spectral analysis showed that EEEs lasting 0.8-2 s occurring during periods of active behaviour with dominant theta activity are immediately followed by loss of such theta activity. We thus conclude that EEEs lasting 0.8-2 s are ictal in the rat. We demonstrate that the assessment of the time course of fluid percussion injury-induced epileptogenesis is dramatically biased by the definition of seizure employed, with common duration-based arbitrary definitions resulting in artificially prolonged latencies for epileptogenesis. Finally, we present four human examples of electrocorticography capturing short (< 2 s), stereotyped, neocortically generated EEEs that occurred in the same ictal sites as obvious complex partial seizures, were electrographically similar to rat EEEs and were not noted during scalp electroencephalography. When occurring in the motor cortex, these short EEEs were accompanied by ictal behaviour detectable with simultaneous surface electromyography. These data demonstrate that short (< 2 s) focal recurrent spontaneous EEEs are seizures in both rats and humans, that they are undetectable by scalp electroencephalography, and that they are typically associated with subtle and easily missed behavioural correlates. These findings define the earliest identifiable markers of progressive post-traumatic epilepsy in the rat, with implications for mechanistic and prophylactic studies, and should prompt a re-evaluation of the concept of post-traumatic silent period in both animals and humans.	[D'Ambrosio, Raimondo; Stewart, Tessandra; Verley, Derek R.; Fender, Jason S.; Eastman, Clifford L.; Sheerin, Aaron H.; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Hakimian, Shahin; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Hakimian, Shahin; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Ojemann, Jeffrey] Univ Washington, Sch Med, Ctr Human Dev & Disabil, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Stewart, Tessandra] Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98104 USA; [Gupta, Puneet; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA	D'Ambrosio, R (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA.	raid@u.washington.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Ojemann, Jeffrey/0000-0001-7580-8934; Diaz-Arrastia, Ramon/0000-0001-6051-3594	CURE Epilepsy foundation [5154001.01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053928, T32NS07144]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007144, R01NS053928] Funding Source: NIH RePORTER	CURE Epilepsy foundation [ 5154001.01 to R. D.]; the National Institutes of Health [NS053928 to R. D. and T32NS07144].	Binnie CD., 2003, EEG PAEDIAT NEUROPHY, V2; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; Cukiert A, 2001, EPILEPSIA, V42, P889, DOI 10.1046/j.1528-1157.2001.00201.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2007, EPILEPSIA, V48, P294; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Holmes GL, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.9_suppl_5.S3; JUULJENSEN P, 1986, INTRACTABLE EPILEPSY, P5; Kay LM, 2005, P NATL ACAD SCI USA, V102, P3863, DOI 10.1073/pnas.0407920102; Magill PJ, 2005, NEUROSCIENCE, V132, P659, DOI 10.1016/j.neuroscience.2005.01.006; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Mattson RH, 1996, NEUROLOGY, V47, P68, DOI 10.1212/WNL.47.1.68; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Sloviter RS, 2008, EPILEPSIA, V49, P85, DOI 10.1111/j.1528-1167.2008.01931.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula TP, 2003, CURR OPIN NEUROL, V16, P189, DOI 10.1097/00019052-200304000-00012; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; Tatum WO, 2001, J CLIN NEUROPHYSIOL, V18, P14, DOI 10.1097/00004691-200101000-00004; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	27	69	69	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2009	132		10				2805	2821		10.1093/brain/awp217			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	505IG	WOS:000270685600027	19755519	Other Gold, Green Published			2021-06-18	
J	Figaji, AA; Zwane, E; Fieggen, AG; Slesjo, P; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Fieggen, A. Graham; Slesjo, Peter; Peter, Jonathan C.			Transcranial Doppler pulsatility index is not a reliable indicator of intracranial pressure in children with severe traumatic brain injury	SURGICAL NEUROLOGY			English	Article						Transcranial Doppler; Intracranial pressure; Cerebral perfusion pressure; Children; Traumatic brain injury; pulsatility index	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; VELOCITY; ULTRASONOGRAPHY; ULTRASOUND; SONOGRAPHY; AUTOREGULATION; HEMODYNAMICS; METABOLISM; SCORE	Background: The TCD-derived PI has been associated with ICP in adult studies but has not been well investigated in children. We examined the relationship between PI and ICP and CPP in children with severe TBI. Methods: Data were prospectively collected from consecutive TCD studies in children with severe TBI undergoing ICP monitoring. Ipsilateral ICP and CPP values were examined with Spearman correlation coefficient (mean values and raw observations), with a GEE, and as binary values (1 and 20 mm Hg, respectively). Results: Thirty-four children underwent 275 TCD studies. There was a weak relationship between mean values of ICP and PI (P = .04, r = 0.36), but not when raw observations (P = .54) or GEE (P = .23) were used. Pulsatility index was 0.76 when ICP was lower than 20 mm Hg and 0.86 when ICP was 20 mm Hg or higher. When PI was 1 or higher, ICP was lower than 20 mm Hg in 62.5% (25 of 40 studies), and when ICP was 20 mm Hg or higher, PI was lower than 1 in 75% (46 of 61 studies). The sensitivity and specificity of a PI threshold of 1 for examining the ICP threshold of 20 mm Hg were 25% and 88%, respectively. The relationship between CPP and PI was stronger (P = .001, r -0.41), but there were too few observations below 50 mm Hg to examine PI at this threshold. Conclusion: The absolute value of the PI is not a reliable noninvasive indicator of ICP in children with severe TBI. Further study is required to examine the relationship between PI and a CPP threshold of 50 mm Hg. (C) 2009 Elsevier Inc. All rights reserved.	[Figaji, Anthony A.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Neurosurg, ZA-7700 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Child & Adolescent Hlth, Infect Dis Epidemiol Unit Biostat, ZA-7700 Cape Town, South Africa; [Slesjo, Peter] Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Pediat Crit Care, ZA-7700 Cape Town, South Africa; [Slesjo, Peter] Lund Univ, Dept Neurosurg, Univ Lund Hosp, Lund, Sweden	Figaji, AA (corresponding author), Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Neurosurg, ZA-7700 Cape Town, South Africa.	anthony.figaji@uct.ac.za		Figaji, Anthony/0000-0002-3357-6490; Fieggen, Graham/0000-0001-6541-8377; Siesjo, Peter/0000-0002-5848-690X	Swedish-South African Links Programme [GUN 2072790]	This study was supported by a Swedish-South African Links Programme grant GUN 2072790, which supports a collaborative study investigating TBI in children between the University of Cape Town, Cape Town, South Africa, and Lund University, Lund, Sweden.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHIRON C, 1992, J NUCL MED, V33, P696; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Levis S, 1998, ACT NEUR S, V71, P174; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Meyer PG, 2005, CHILD NERV SYST, V21, P133, DOI 10.1007/s00381-004-1016-1; Minassian AT, 1998, J NEUROSURG, V88, P996, DOI 10.3171/jns.1998.88.6.0996; Moreno J A, 2000, Neurosurg Focus, V8, pe8; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NADVI SS, 1994, BRIT J NEUROSURG, V8, P573, DOI 10.3109/02688699409002950; Ng SCP, 2000, ACT NEUR S, V76, P479; POPLE IK, 1991, EUR J PEDIATR SURG, V1, P27, DOI 10.1055/s-2008-1042534; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; SANKER P, 1991, CHILD NERV SYST, V7, P391, DOI 10.1007/BF00304204; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Splavski B, 2006, BRIT J NEUROSURG, V20, P386, DOI 10.1080/02688690601048104; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; STEINMEIER R, 1993, NEUROSURGERY, V33, P10; STEINMEIER R, 1993, NEUROSURGERY, V33, P18; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	33	69	70	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2009	72	4					389	394		10.1016/j.surneu.2009.02.012			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	498YW	WOS:000270183900014	19608224				2021-06-18	
J	Kilinc, D; Gallo, G; Barbee, KA				Kilinc, Devrim; Gallo, Gianluca; Barbee, Kenneth A.			Mechanical membrane injury induces axonal beading through localized activation of calpain	EXPERIMENTAL NEUROLOGY			English	Article						Diffuse axonal injury; Mechanoporation; Axonal bead formation; Calcium; Calpain; Poloxamer 188; Mitochondria	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; HIPPOCAMPAL-NEURONS; SURFACTANT POLOXAMER-188; CALCIUM TRANSIENTS; CYTOSOLIC CALCIUM; STRETCH-INJURY; OPTIC-NERVE; CELL-DEATH; PROTEIN	Diffuse axonal injury (DAI), a major component of traumatic brain injury, is characterized by a sequence of neurochemical reactions initiated at the time of trauma and resulting in axonal degeneration and cell death. Calcium influx through mechanically induced axolemmal pores and subsequent activation of calpains are thought to be responsible for the cytoskeletal damage leading to impaired axonal transport. Focal disruption of cytoskeleton accompanied by the accumulation of transported membranous cargo leads to axonal beading which is the characteristic morphology of DAI. By applying fluid shear stress injury on cultured primary neurons, acute calcium (Ca2+) and calpain responses of axons to mechanical trauma were investigated. Intracellular Ca2+ concentration ([Ca2+](i)) shows a steady increase following injury that can be blocked by sealing membrane pores with Poloxamer 188 and by chelating intra- or extracellular Ca2+. Calpain activity increases in response to mechanical injury and this increase depends on Ca2+ availability and on axolemmal permeability. Both the [Ca2+](i) increase and calpain activity exhibit focal peaks along the axons which co-localize with mitochondria and predict future axonal bead locations. These findings suggest that mechanoporation may be the initiating mechanism resulting in ensuing calcium fluxes and subsequent calpain activity and that post-injury membrane repair may be a valid therapeutic approach for acute intervention in DAI. (C) 2009 Elsevier Inc. All rights reserved.	[Kilinc, Devrim; Barbee, Kenneth A.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Gallo, Gianluca] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA	Barbee, KA (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014; Kilinc, Devrim/E-8733-2011; Kilinc, Devrim/I-4180-2019	Kilinc, Devrim/0000-0003-3321-5203; Kilinc, Devrim/0000-0003-3321-5203	State of Pennsylvania Tobacco Settlement Fund; National Institutes HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048090]; Drexel University Neuroengineering Major Research Initiative; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048090, R56NS048090] Funding Source: NIH RePORTER	This research was supported in part by a grant from the State of Pennsylvania Tobacco Settlement Fund (K.A.B.); by the National Institutes Health (NS048090, G.G.); and by Drexel University Neuroengineering Major Research Initiative (K.A.B., D.K.). K.A. Barbee and G. Gallo share last authorship on this work.	Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Heidemann SR, 2003, METHOD CELL BIOL, V71, P51, DOI 10.1016/S0091-679X(03)01004-5; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, COMPUT METH PROG BIO, V95, P62, DOI 10.1016/j.cmpb.2009.01.002; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu J, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.123tr3; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2005, ANN NY ACAD SCI, V1066, P310, DOI 10.1196/annals.1363.018; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1996, LAB INVEST, V74, P315; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; OBrien ET, 1997, CELL MOTIL CYTOSKEL, V36, P125, DOI 10.1002/(SICI)1097-0169(1997)36:2<125::AID-CM3>3.0.CO;2-8; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; SHAPIRA Y, 1989, Neurological Research, V11, P169; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; STRICH SJ, 1961, LANCET, V2, P443; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Wang GJ, 2003, J NEUROCHEM, V87, P85, DOI 10.1046/j.1471-4159.2003.01970.x; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoo S, 2003, J NEUROSCI RES, V74, P541, DOI 10.1002/jnr.10771; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	66	69	75	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2009	219	2					553	561		10.1016/j.expneurol.2009.07.014			9	Neurosciences	Neurosciences & Neurology	498QN	WOS:000270157300021	19619536	Green Accepted			2021-06-18	
J	Saljo, A; Svensson, B; Mayorga, M; Hamberger, A; Bolouri, H				Saljo, Annette; Svensson, Berndt; Mayorga, Maria; Hamberger, Anders; Bolouri, Hayde			Low-Level Blasts Raise Intracranial Pressure and Impair Cognitive Function in Rats	JOURNAL OF NEUROTRAUMA			English	Article						blast overpressure; brain edema; cognitive function; impulse noise; intracranial pressure; mild traumatic brain injury; Morris water maze	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; LASTING IMPULSE NOISE; CLOSED-HEAD INJURY; CELL-DEATH; EXPOSURE; DEFICITS; EDEMA; OVERPRESSURE; INCREASE	Brain injury after high-level blast has been established both clinically and experimentally. Less is known about the effects on the brain of exposure to low to moderate blast levels, such as those encountered by military personnel during the firing of weapons. This study investigates if exposure to occupational levels of low-level blasts affect intracranial pressure and cognitive performance. Rats were exposed to blast overpressure in a shock tube at peak levels of 10, 30, and 60 kPa. Intracranial pressure (ICP) was measured after 0.5, 3, 6, and 10 h and 1, 2, 3, 5, and 7 days. We found two features of the response: a dose-dependent rise in ICP in rats exposed to blast, and an increasing time delay in elevation with decreasing intensity of exposure. The ICP increased in a dose-dependent fashion, up to 15.7mm Hg after exposure to a 60-kPa blast from a control level of 6 mm Hg. While the initial elevation took place within 30 min after exposure to 60 kPa, it did not appear until after 2 and 6 h for 30 and 10 kPa, respectively. In all cases, the ICP returned to control levels after 7 days. The cognitive function of the blast-exposed rats was assessed with the Morris water maze. After exposure to 10 or 30 kPa and re-testing 2 days later, the latency was increased by over 100%. The results show that exposure of rats to blast levels as low as 10 kPa affects both ICP and cognitive function. Though species differences do not allow direct extrapolation to humans, these findings do pose the question as to whether the thresholds for brain injury might be lower than those of other organs used to set training standards for blast exposure.	[Saljo, Annette; Svensson, Berndt; Mayorga, Maria; Hamberger, Anders; Bolouri, Hayde] Univ Gothenburg, Inst Biomed, Dept Med Chem & Cell Biol, Sahlgren Acad, SE-40530 Gothenburg, Sweden	Saljo, A (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Chem & Cell Biol, Sahlgren Acad, Box 440, SE-40530 Gothenburg, Sweden.	annette.saljo@gu.se			Swedish Armed Forces/FMV	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, for sharing with us his knowledge on pressure sensors and pressure recording. The study was supported by grants from the Swedish Armed Forces/FMV.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; *BOP HHA, 2004, BLAST OV ASS SOFTW; BOWEN IG, 1965, BIOL SCALING PRIMARY; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; CLEMEDSON C.-J., 1957, ACTA PATHOL ET MICROBIOL SCAND, V40, P89; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; *JAYC, 1996, J29972401158 JAYC; Jennische E, 2008, BRAIN RES, V1227, P189, DOI 10.1016/j.brainres.2008.05.083; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MAYORGA MA, 2008, SPANISH J NEUROPSYCH, V10, P109; MAYORGA MA, 2007, 4 ANN POL BLAST M TA; *MIL, 1997, MILSTD1474D; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott FW, 1917, BRIT MED J, V1917, P612; NEWMAN LA, 2003, ASHA LEADER      OCT, P10; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; PRUSACZYK WK, 2008, ANN BATTL HEALTHC C; RICHMOND DR, 1961, AEROSPACE MED, V32, P997; RICHMOND DR, 1991, SCAND AUDIOL, P49; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TANIELIAN T, 2008, MG720CCF RAND; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WHITE CS, 1971, AGARD C P, V88; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	58	69	69	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1345	1352		10.1089/neu.2008.0856			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900017	19317610				2021-06-18	
J	Cusimano, MD				Cusimano, Michael D.			Canadian Minor Hockey Participants' Knowledge about Concussion	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SCHOOL FOOTBALL PLAYERS; ICE HOCKEY; SPORTS; GUIDELINES; MANAGEMENT; COLLEGIATE; INJURY; RISK	Background and Objectives: In Canada and the USA, ice hockey is a cause of traumatic brain injury. Post-concussive symptoms are the most important feature of the diagnosis of concussion in sports and it is recommended that athletes not return to play while still symptomatic. Lack of knowledge of concussions could therefore be one of the main detriments to concussion prevention in hockey. The purpose of this research is to describe what minor league hockey players, coaches, parents and trainers know about concussion and its management. Methods: A questionnaire to assess concussion knowledge and return to play guidelines was developed and administered to players at different competitive levels (n = 267), coaches, trainers and parents (total adults n = 142) from the Greater Toronto Area. Results: Although a majority of adults and players could identify mechanisms responsible for concussion, about one-quarter of adults and about a quarter to a half of children could not recall any symptoms or recalled only one symptom of a concussion. A significant number of players and some adults did not know what it concussion was or how it occurred. Almost half of the players and a fifth of the adults incorrectly stated that concussion was treated with medication or physical therapy. Nearly one quarter of all players did not know if an athlete experiencing symptoms of concussion should continue playing. Conclusions: This study demonstrated that a significant number of people held misconceptions about concussion in hockey which could lead to serious health consequences and creates a need for better preventive and educational strategies.	St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, Toronto, ON M5B 1W8, Canada	Cusimano, MD (corresponding author), St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Akers R.L., 1998, SOCIAL LEARNING SOCI; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; COLLINS MW, 2002, NEUROSURGERY, V51, P1; FICK DS, 1995, POSTGRAD MED, V97, P53; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GOODWINGERBERIC.S, 1983, AM J PUBLIC HEALTH, V73, P1370; GRANT K, 2003, GLOBE MAIL; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, 2001, BRIT J SPORT MED, V35, P367; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; NASH JE, 1981, YOUTH SOC, V13, P229, DOI 10.1177/0044118X8101300202; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; 1997, MMWR WKLY REP, V46, P224	26	69	69	1	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2009	36	3					315	320		10.1017/S0317167100007046			6	Clinical Neurology	Neurosciences & Neurology	448HL	WOS:000266253600013	19534331	Bronze			2021-06-18	
J	Davis, GA; Iverson, GL; Guskiewicz, KM; Ptito, A; Johnston, KM				Davis, G. A.; Iverson, G. L.; Guskiewicz, K. M.; Ptito, A.; Johnston, K. M.			Contributions of neuroimaging, balance testing, electrophysiology and blood markers to the assessment of sport-related concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; NEURON-SPECIFIC ENOLASE; ERROR SCORING SYSTEM; SERUM-LEVELS; BIOCHEMICAL MARKERS; POSTURAL STABILITY; NEUROCOGNITIVE PERFORMANCE; STANDARDIZED ASSESSMENT; AGREEMENT STATEMENT	Objective: To review the diagnostic tests and investigations used in the management of sports concussion, in the adult and paediatric populations, to (a) monitor the severity of symptoms and deficits, (b) track recovery and (c) advance knowledge relating to the natural history and neurobiology of the injury. Design: Qualitative literature review of the neuroimaging, balance testing, electrophysiology, blood marker and concussion literature. Intervention: PubMed and Medline databases were reviewed for investigations used in the management of adult and paediatric concussion, including structural imaging (computerised tomography, magnetic resonance imaging, diffusion tensor imaging), functional imaging (single photon emission computerised tomography, positron emission tomography, functional magnetic resonance imaging), spectroscopy (magnetic resonance spectroscopy, near infrared spectroscopy), balance testing (Balance Error Scoring System, Sensory Organization Test, gait testing, virtual reality), electrophysiological tests (electroencephalography, evoked potentials, event related potentials, magnetoencephalography, heart rate variability), genetics (apolipoprotein E4, channelopathies) and blood markers (S100, neuron-specific enolase, cleaved Tau protein, glutamate). Results: For the adult and paediatric populations, each test has been classified as being: (1) clinically useful, (2) a research tool only or (3) not useful in sports-related concussion. Conclusions: The current status of the diagnostic tests and investigations is analysed, and potential directions for future research are provided. Currently, all tests and investigations, with the exception of clinical balance testing, remain experimental. There is accumulating research, however, that shows promise for the future clinical application of functional magnetic resonance imaging in sport concussion assessment and management.	[Davis, G. A.] Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, G. A.] Austin Hosp, Melbourne, Vic, Australia; [Iverson, G. L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, G. L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Guskiewicz, K. M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Ptito, A.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Ptito, A.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Johnston, K. M.] Univ Toronto, Dept Neurosurg, Toronto, ON, Canada; [Johnston, K. M.] Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada	Davis, GA (corresponding author), Cabrini Med Ctr, Suite 53 Neurosurg, Malvern, Vic 3144, Australia.	gadavis@netspace.net.au		Guskiewicz, Kevin/0000-0002-8682-2130; Iverson, Grant/0000-0001-7348-9570			Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Altrocchi PH, 1996, NEUROLOGY, V46, P278; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bergman DA, 1999, PEDIATRICS, V104, P1407; Bernard G, 2008, PEDIATR NEUROL, V38, P73, DOI 10.1016/j.pediatrneurol.2007.09.007; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; *CDCP, 2007, MORTALITY MORBIDITY, V0056; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cote C, 2005, MED SCI SPORT EXER, V37, pS469, DOI 10.1097/00005768-200505001-02448; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2007, NEUROIMAGE, V35, P166, DOI 10.1016/j.neuroimage.2006.10.040; Nioka Shoko, 2006, Dyn Med, V5, P5, DOI 10.1186/1476-5918-5-5; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; Ptito A, 2007, NEUROSCIENTIST, V13, P506, DOI 10.1177/1073858407300598; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Susco TM, 2004, J ATHL TRAINING, V39, P241; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WICKENS CD, 1983, HUM FACTORS, V25, P227; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; ZEMAITYTE D, 1984, PSYCHOPHYSIOLOGY, V21, P279, DOI 10.1111/j.1469-8986.1984.tb02935.x	117	69	70	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I36	I45		10.1136/bjsm.2009.058123			10	Sport Sciences	Sport Sciences	450YO	WOS:000266438100007	19433424				2021-06-18	
J	Dawson, DR; Gaya, A; Hunt, A; Levine, B; Lemsky, C; Polatajko, HJ				Dawson, Deirdre R.; Gaya, Arvinder; Hunt, Anne; Levine, Brian; Lemsky, Carolyn; Polatajko, Helene J.			Using the Cognitive Orientation to Occupational Performance (CO-OP) with adults with executive dysfunction following traumatic brain injury	CANADIAN JOURNAL OF OCCUPATIONAL THERAPY-REVUE CANADIENNE D ERGOTHERAPIE			English	Article						Executive dysfunction; Rehabilitation; Brain injury; Cognition; CO-OP; Problem solving	SELF-IDENTIFIED GOALS; QUALITY-OF-LIFE; REHABILITATION; ACHIEVEMENT; AWARENESS	Background. Meta-cognitive strategies have a positive effect on the rehabilitation of executive dysfunction. However, achieving generalization to daily life remains a challenge. We believe that providing rehabilitation in the person's own physical environment and using self-identified tasks will enhance the benefits of meta-cognitive training and promote generalization. Purpose. This pilot study tested the applicability of the Cognitive Orientation to Occupational Performance (CO-OP) approach for use with adults with executive dysfunction arising from traumatic brain injury (TB!). Methods. A single-case design was used with 3 adults, 5 to 20 years post-TBI and their self-identified significant others. Assessments included neuropsychological tests and the Canadian Occupational Performance Measure. The intervention entailed guiding participants to use a meta-cognitive problem-solving strategy to perform self-identified daily tasks that they needed and wanted to do and with which they were having difficulties. The intervention occurred over 20 one-hour sessions in participants' environments. Findings. Performance improved to criterion (2-point positive change) on 7 of 9 trained goals and on 4 of 7 untrained goals (self-report). Improvement was maintained at a 3-month follow-up assessment. Implications. The CO-OP approach has the potential to improve performance in daily functioning for adults with executive dysfunction following TBI.	[Dawson, Deirdre R.; Hunt, Anne] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Dawson, Deirdre R.; Polatajko, Helene J.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Dawson, Deirdre R.; Polatajko, Helene J.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Gaya, Arvinder] COTA Hlth, Toronto, ON M6A 3B4, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Baycrest, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; [Lemsky, Carolyn] Community Head Injury Resource Serv CHIRS, Toronto, ON M2N 7G1, Canada; [Dawson, Deirdre R.] Toronto Rehabil Inst, Toronto, ON, Canada	Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019; Dawson, Deirdre R/I-8882-2014	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121	Faculty of Medicine, University of TorontoUniversity of Toronto; Ontario Neurotrauma Foundation [2005-ABI-POP-363]	This research was supported by funding from the Dean's Fund, Faculty of Medicine, University of Toronto (to D. Dawson) and by funding from the Ontario Neurotrauma Foundation(2005-ABI-POP-363 to D. Dawson). Parts of these results were presented in poster format at the Annual Meeting of the International Neuropsychological Society in February 2007 and in pacer format at the Annual Meeting of the Canadian Association of Occupational Therapists in July 2007 and at the Annual Meeting of the American Congress of Rehabilitation Medicine in October 2007. We are appreciative of the assistance of the following people on this project: Adrienne Lo, Candace Ikeda-Douglas, Michelle Ryan, and Venus Sayed. Finally, we are especially thankful for the time and energy given to this project by our research participants and their significant others.	Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; *ADJ GEN OFF, 1944, MAN DIR SCOR; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Dawson D. R., 2005, J HEAD TRAUMA REHAB, V20, P436; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Feuerstein R., 1980, INSTRUMENTAL ENRICHM; Fleming Jennifer M, 2006, Can J Occup Ther, V73, P44; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Giles G. M., 1990, BRIT J OCCUPATIONAL, V53, P314; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton R. K., 1991, SUPPLEMENT WESCHLER; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Law M., 1994, CANADIAN OCCUPATIONA; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Luria AR, 1982, LANGUAGE COGNITION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Meichenbaum D., 1977, COGNITIVE BEHAV MODI; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Polatajko H. J., 2004, ENABLING OCCUPATION; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; TOGLIA JP, 2005, COGNITION OCCUPATION; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Turner GR, 2004, SCI PRACT NEUROPSYCH, P224; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Vygotsky L. S., 1978, MIND SOC DEV HIGHER; Wechsler D, 1985, WECHSLER ADULT INTEL; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI DOI 10.1080/110381299443771; Young DA, 2002, NEUROPSYCHOL REHABIL, V12, P257, DOI 10.1080/0960201044000066; Zasler N, 2000, NEUROPSYCHOLOGICAL M, P23	48	69	70	1	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0008-4174	1911-9828		CAN J OCCUP THER	Can. J. Occup. Ther.	APR	2009	76	2					115	127		10.1177/000841740907600209			13	Rehabilitation	Rehabilitation	V20TK	WOS:000208162100009	19456090				2021-06-18	
J	Tsaousides, T; Gordon, WA				Tsaousides, Theodore; Gordon, Wayne A.			Cognitive Rehabilitation Following Traumatic Brain Injury: Assessment to Treatment	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						attention; cognitive deficits; cognitive rehabilitation; comprehensive day treatment; executive function; memory; traumatic brain injury	CLOSED-HEAD-INJURY; EXECUTIVE DYSFUNCTION; CLINICAL-PRACTICE; GOAL MANAGEMENT; MEMORY; ATTENTION; DEFICITS; THERAPY; PROGRAM; RECOMMENDATIONS	Cognitive rehabilitation refers to a set of interventions that aim to improve a person's ability to perform cognitive tasks by retraining previously learned skills and teaching compensatory strategies. Cognitive rehabilitation begins with a thorough neuropsychological assessment to identify cognitive strengths and weaknesses and the degree of change in cognitive ability following a brain injury. The conclusion of the assessment are used to formulate appropriate treatment plans. Common interventions for improvements in attention, memory, and executive function, as well as the nature of comprehensive program, which combine treatment modalities, are reviewed. Cognitive rehabilitation is effective for mild-to-severe injuries and beneficial at any time post-injury. Sufficient evidence exists supporting the efficacy and effectiveness of cognitive rehabilitation, which has become the treatment of choice for cognitive impairments and leads to improvements in cognitive and psychosocial functioning. Mt Sinai J Med 76:173-181, 2009 (C) 2009 Mount Sinai School of Medicine	[Tsaousides, Theodore; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Tsaousides, T (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.	theodore.tsaousides@mssm.edu			US Department of Education National Institute of Rehabiliation ResearchUS Department of Education [H133B040033, H133A070033]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grants from the US Department of Education National Institute of Rehabiliation Research (H133B040033 and H133A070033) and from the Centers for Disease Control and Prevention (1R49CE001171-01)	Ashman TA, 2006, MT SINAI J MED, V73, P999; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gordon WA, 2005, TXB TRAUMATIC BRAIN, P655; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kennedy MRT, 2006, NEUROPSYCHOL REV, V16, P151, DOI 10.1007/s11065-006-9012-8; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Palmese CA, 2000, BRAIN INJURY, V14, P535; Parente R, 1999, NEUROREHABILITATION, V13, P157; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; TSAOUSIDES T, TRAUMATIC B IN PRESS; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854	46	69	70	0	35	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0027-2507			MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					173	181		10.1002/msj.20099			9	Medicine, General & Internal	General & Internal Medicine	427OE	WOS:000264787800010	19306374				2021-06-18	
J	Salim, A; Hadjizacharia, P; Dubose, J; Brown, C; Inaba, K; Chan, LS; Margulies, D				Salim, Ali; Hadjizacharia, Pantelis; Dubose, Joseph; Brown, Carlos; Inaba, Kenji; Chan, Linda S.; Margulies, Daniel			Persistent Hyperglycemia in Severe Traumatic Brain Injury: An Independent Predictor of Outcome	AMERICAN SURGEON			English	Article							ADMISSION HYPERGLYCEMIA; MORTALITY; IMPACT	In patients with severe traumatic brain injury (TBI), admission hyperglycemia is associated with poor outcome. The effect of persistent hyperglycemia (PH) on outcome in severe TBI, however, remains unknown. We performed a retrospective review of all blunt trauma patients with severe TBI (head Abbreviated Injury Score >= 3) admitted to the intensive care unit at a Level I trauma center from January 1998 through December 2005. Admission and daily intensive care unit blood glucose levels up to the end of the first week were measured. PH was defined as an average daily blood glucose >= 1.50 mg/dL on all days for the first week of the hospital stay. TBI patients with and without PH were compared with respect to baseline demographics, injury characteristics, and outcomes. Independent risk factors for mortality were identified using logistic regression analysis. One hundred and five (12.6%) out of 834 severe TBI patients had PH. Patients with PH were older, more severely injured, and had worse head injury compared with patients without PH. After adjusting for significant risk factors, PH was identified as an independent risk factor for mortality (odds ratio (OR): 4.91 [95% confidence interval (CI), 2.88-8.56, P < 0.0001]). PH is associated with significantly higher mortality rates in severe TBI patients.	[Salim, Ali; Margulies, Daniel] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; Dubose, Joseph; Inaba, Kenji; Chan, Linda S.] Univ So Calif, Med Ctr, Div Trauma & Crit Care Los Angeles Cty, Los Angeles, CA 90033 USA; [Brown, Carlos] Brackenridge Hosp, Austin, TX USA	Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215 North, Los Angeles, CA 90048 USA.	ali.salim@cshs.org					Biffl W, 2007, J TRAUMA, V62, P1375; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Gale SC, 2007, AM SURGEON, V73, P454; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	18	69	79	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JAN	2009	75	1					25	29					5	Surgery	Surgery	392WD	WOS:000262332000005	19213392				2021-06-18	
J	Sayer, NA; Cifu, DX; McNamee, S; Chiros, CE; Sigford, BJ; Scoff, S; Lew, HL				Sayer, Nina A.; Cifu, David X.; McNamee, Shane; Chiros, Christine E.; Sigford, Barbara J.; Scoff, Steve; Lew, Henry L.			Rehabilitation Needs of Combat-Injured Service Members Admitted to the VA Polytrauma Rehabilitation Centers: The Role of PM&R in the Care of Wounded Warriors	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; PHYSICAL MEDICINE; KRUSEN,FRANK; HISTORY; BLAST; DIARY	Objective: To describe the rehabilitation course of combat-injured service members who sustained polytraumatic injuries during the current wars in and around Iraq and Afghanistan. Design: Retrospective descriptive analysis. Setting: Department of Veterans Administration Polytrauma Rehabilitation Centers (PRCs). Participants: One hundred eighty-eight consecutive, acutely combat-injured service members suffering polytraumatic injuries requiring inpatient rehabilitation and being treated at PRCs between October 2001 and January 2006. Interventions: Not applicable. Main Outcome Measures: Medications prescribed, devices used, injuries and impairment information, and consultative services. Results: Ninety-three percent of the patients had sustained a traumatic brain injury (TBI) and more than half of these were incurred secondary to blast explosions. Over half of the patients had infections or surgeries prior to PRC admission that required continued medical attention during their stay. Pain and mental health issues were present in 100% and 39%, respectively, of all patients admitted and added complexity to the brain injury rehabilitation process. Common treatment needs included cognitive-behavioral interventions, pain care, assistive devices, mental health interventions for both patients and their families, and specialty consultations, in particular to ophthalmology, otolaryngology, and neurology. Conclusions: Combat-injured polytrauma patients have complex rehabilitation needs that require a high level of specialized training and skill. Physical medicine and rehabilitation specialists treating war injured service members need a high level of expertise in assessment and treatment of co-occurring pain, TBI, and stress disorders. Physiatrists are playing an important role in providing and coordinating the rehabilitation care for individuals with significant polytraumatic war injuries from the Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) conflicts.	[Lew, Henry L.] VA Boston Healthcare Syst, VA Med Ctr, Phys Med & Rehabil, Boston, MA 02130 USA; [Sayer, Nina A.; Chiros, Christine E.] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Cifu, David X.; McNamee, Shane] VA Med Ctr, Richmond, VA USA; [Scoff, Steve] VA Med Ctr, Tampa, FL USA	Lew, HL (corresponding author), VA Boston Healthcare Syst, VA Med Ctr, Phys Med & Rehabil, 150 S Huntington Ave, Boston, MA 02130 USA.	henry.lew@va.gov	Sayer, Nina/E-3249-2016	Cifu, David/0000-0003-1600-9387	VA Health Service Research & Development (HSRD) [RRP 06-150]	This research was supported by VA Health Service Research & Development (HSR&D) grant RRP 06-150.	American Academy of Physical Medicine & Rehabilitation, WHAT IS PHYS; Baruch Committee on Physical Medicine, 1944, NCEA ANN REP, p[1, 17]; Department of Veterans Affairs, 2005, VHA HDB, V1172.1; Farahmand JM, 2001, COMPREHENSIVE REHABI, P241; Folz TJ, 1997, ARCH PHYS MED REHAB, V78, P446, DOI 10.1016/S0003-9993(97)90241-0; Gaylord Kathryn M, 2006, Crit Care Nurs Clin North Am, V18, P349, DOI 10.1016/j.ccell.2006.05.010; Gelfman R, 1997, ARCH PHYS MED REHAB, V78, P556, DOI 10.1016/S0003-9993(97)90178-7; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Grieger T. A., 2006, PRIM PSYCHIAT, V13, P45; HUMAYUN F, 2006, CAPABILITIES COMMUN, V14, P8; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; MALKMUS D, 1980, REHABILITATION HEAD; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Opitz JL, 1997, ARCH PHYS MED REHAB, V78, P442, DOI 10.1016/S0003-9993(97)90240-9; Peters DJ, 1997, ARCH PHYS MED REHAB, V78, P562, DOI 10.1016/S0003-9993(97)90179-9; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025	22	69	70	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JAN	2009	1	1					23	28		10.1016/j.pmrj.2008.10.003			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LD	WOS:000208411000005	19627869				2021-06-18	
J	Vajtr, D; Benada, O; Kukacka, J; Prusa, R; Houstava, L; Toupalik, P; Kizek, R				Vajtr, D.; Benada, O.; Kukacka, J.; Prusa, R.; Houstava, L.; Toupalik, P.; Kizek, R.			Correlation of Ultrastructural Changes of Endothelial Cells and Astrocytes Occurring during Blood Brain Barrier Damage after Traumatic Brain Injury with Biochemical Markers of Blood Brain Barrier Leakage and Inflammatory Response	PHYSIOLOGICAL RESEARCH			English	Article						Blood brain barrier; Expansive contusion; Metalloproteinases; S-100B protein; Interleukin-6	NEURON-SPECIFIC-ENOLASE; S-100B PROTEIN; RELEASE	Focal cerebral contusion can be dynamic and expansive. It has been proved that subsequent expansive contusion is caused by brain parenchyma damage, especially BBB damage. We investigated a group of patients with traumatic brain injury. The patients (n=18) were divided into group I (n=7) of patients submitted to neurosurgery due to expansive contusion, and group II (n=11) of patients without surgery. Serum concentrations of NSE and S-100B protein were measured by electrochemiluminescence immunoassay, interleukin-6 (IL-6) was measured by chemiluminescent sequential immunometric assay and matrix metalloproteinases (MMP-9, MMP-2) were measured by immunoassays. Cortical biopsy specimens of brain were investigated by electron microscopy in patients with trauma brain injury submitted to neurosurgery. Biochemical investigation from first day up to third day after traumatic brain injury proved increased values of IL-6 (302.2 +/- 119.9 vs. 59.6 +/- 11.9 ng/l, p<0.02) and S-100B protein (3.064 +/- 1.064 vs. 0.649 +/- 0.182 mu g/l, p<0.05) in patients with expansive lesion compared to patients without expansive contusion. Significantly higher levels of MMP-9 (150.4 +/- 28.46 vs. 74.11 +/- 13.16 ng/l, p<0.05) and of MMP- 2 (814.5 +/- 126.3 vs. 523.1 +/- 25.28 ng/l, p<0.05) were found during first 3 days after admission in group I compared to group II. MMP- 9 has also elevated in group II from lower values after admission (74.11 +/- 13.16 ng/l) up to high levels on the 10th day of hospitalization (225.1 +/- 49.35 ng/l). Ultrastructural investigation of endothelial cells and surrounded tissue revealed perivascular hemorrhage, increased pinocytic activity of endothelial cells, and cytotoxic edema of astroglial cells. Multivesical bodies were disclosed inside the endothelial cells. Higher levels of serum protein S-100B and IL-6 correlated with ultrastructural changes of endothelial cells, and with inflammatory response following TBI, respectively.	[Vajtr, D.; Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic; [Vajtr, D.; Kukacka, J.; Prusa, R.] Univ Hosp Motol, Prague, Czech Republic; [Benada, O.] Acad Sci Czech Republ, Inst Microbiol, Prague, Czech Republic; [Vajtr, D.] Charles Univ Prague, Fac Med 1, Dept Forens Med & Toxicol, Prague 15006 5, Czech Republic; [Houstava, L.] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Prague 15006 5, Czech Republic; [Toupalik, P.] Charles Univ Prague, Fac Med 2, Dept Forens Med, Prague 15006 5, Czech Republic; [Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, Brno, Czech Republic	Vajtr, D (corresponding author), Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic.	vajtr.david.1LFUK@seznam.cz	Benada, Oldrich/H-2437-2014; Kizek, Rene/D-7748-2012; Kukacka, Jiri/C-4770-2013	Benada, Oldrich/0000-0002-4592-6216; Kizek, Rene/0000-0002-0467-6169	IGA CR [NR/8793-3/2006]; Institutional Scientific Project [AV0Z50200510]	We thank M. Elleder for expert assistance. Our work was supported by IGA CR, reg. no. NR/8793-3/2006 and Institutional Scientific Project AV0Z50200510.	Adelson PD, 1998, ACT NEUR S, V71, P104; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P263; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; Conti AC, 1998, J NEUROSCI, V18, P5663; Cucullo L, 2003, MOL CELL PROTEOMICS, V2, P234, DOI 10.1074/mcp.M200077-MCP200; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Sawaughi S, 2005, NEUROL SURG TOKYO, V33, P1073; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	21	69	73	0	10	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2009	58	2					263	268		10.33549/physiolres.931253			6	Physiology	Physiology	442PM	WOS:000265853100013	18380546	DOAJ Gold			2021-06-18	
J	Mueller, SC; Jackson, CPT; Skelton, RW				Mueller, Sven C.; Jackson, Carl P. T.; Skelton, Ron W.			Sex differences in a virtual water maze: An eye tracking and pupillometry study	BEHAVIOURAL BRAIN RESEARCH			English	Article						spatial navigation; eye tracking; pupillometry; sex differences; strategy; allocentric; egocentric; water maze	GENDER-RELATED DIFFERENCES; HUMAN SPATIAL NAVIGATION; TRAUMATIC BRAIN-INJURY; VISUAL-SEARCH; AGE-DIFFERENCES; WORKING-MEMORY; MOVEMENTS; ABILITY; TASK; ENVIRONMENT	Sex differences in human spatial navigation are well known. However, the exact strategies that males and females employ in order to navigate successfully around the environment are unclear. While some researchers propose that males prefer environment-centred (allocentric) and females prefer self-centred (egocentric) navigation, these findings have proved difficult to replicate. In the present study we examined eye movements and physiological measures of memory (pupillometry) in order to compare visual scanning of spatial orientation using a human virtual analogue of the Morris Water Maze task. Twelve women and twelve men (average age= 24 years) were trained on a visible platform and had to locate an invisible platform over a series of trials. On all but the first trial, participants' eye movements were recorded for 3 s and they were asked to orient themselves in the environment. While the behavioural data replicated previous findings of improved spatial performance for males relative to females, distinct sex differences in eye movements were found. Males tended to explore consistently more space early on while females demonstrated initially longer fixation durations and increases in pupil diameter usually associated with memory processing. The eye movement data provides novel insight into differences in navigational strategies between the sexes. Published by Elsevier B.V.	[Mueller, Sven C.; Jackson, Carl P. T.] Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England; [Jackson, Carl P. T.] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; [Skelton, Ron W.] Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada	Mueller, SC (corresponding author), NIMH, MAP, NIH, Bethesda, MD 20892 USA.	msven@mail.nih.gov	Skelton, Ronald/E-5605-2012	Mueller, Sven/0000-0003-1661-3840			Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Beatty J., 2000, HDB PSYCHOPHYSIOLOGY, P142; Blanch RJ, 2004, CEREB CORTEX, V14, P1207, DOI 10.1093/cercor/bhh081; Blokland A, 2006, BEHAV BRAIN RES, V171, P216, DOI 10.1016/j.bbr.2006.03.033; Brown LN, 1998, ENVIRON BEHAV, V30, P123, DOI 10.1177/0013916598302001; Chen X, 2006, VISION RES, V46, P4118, DOI 10.1016/j.visres.2006.08.008; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dabbs JM, 1998, EVOL HUM BEHAV, V19, P89, DOI 10.1016/S1090-5138(97)00107-4; DEIJEN JB, 1993, J AFFECT DISORDERS, V29, P33, DOI 10.1016/0165-0327(93)90116-2; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Galpin AJ, 2005, PERCEPT PSYCHOPHYS, V67, P1313, DOI 10.3758/BF03193637; Gitelman DR, 2002, BEHAV RES METH INS C, V34, P605, DOI 10.3758/BF03195488; Gron G, 2000, NAT NEUROSCI, V3, P404; Iachini T, 2005, BRAIN COGNITION, V59, P52, DOI 10.1016/j.bandc.2005.04.004; Jones CM, 2003, BEHAV NEUROSCI, V117, P403, DOI 10.1037/0735-7044.117.3.403; Jordan K, 2004, NEUROREPORT, V15, P135, DOI 10.1097/00001756-200401190-00026; Jordan K, 2002, NEUROPSYCHOLOGIA, V40, P2397, DOI 10.1016/S0028-3932(02)00076-3; KAHNEMAN D, 1966, SCIENCE, V154, P1583, DOI 10.1126/science.154.3756.1583; Karatekin C, 2007, PSYCHOPHYSIOLOGY, V44, P128, DOI 10.1111/j.1469-8986.2006.00477.x; Lawton CA, 1996, ENVIRON BEHAV, V28, P204, DOI 10.1177/0013916596282003; LINN MC, 1985, CHILD DEV, V56, P1479, DOI 10.1111/j.1467-8624.1985.tb00213.x; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Moffat SD, 2007, CEREB CORTEX, V17, P1274, DOI 10.1093/cercor/bhl036; Moffat SD, 1998, EVOL HUM BEHAV, V19, P73, DOI 10.1016/S1090-5138(97)00104-9; Moffat SD, 2001, NEUROBIOL AGING, V22, P787, DOI 10.1016/S0197-4580(01)00251-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUELLER SC, EARLY ANDROGEN UNPUB; New J, 2007, P ROY SOC B-BIOL SCI, V274, P2679, DOI 10.1098/rspb.2007.0826; Newhouse P, 2007, BEHAV BRAIN RES, V183, P1, DOI 10.1016/j.bbr.2007.05.011; Ohnishi T, 2006, NEUROSCI RES, V55, P361, DOI 10.1016/j.neures.2006.04.009; Osaka N, 2002, AM J PSYCHOL, V115, P501, DOI 10.2307/1423525; Porter G, 2007, Q J EXP PSYCHOL, V60, P211, DOI 10.1080/17470210600673818; Reingold EM, 2001, PSYCHOL SCI, V12, P48, DOI 10.1111/1467-9280.00309; ROOF RL, 1992, BRAIN RES, V572, P310, DOI 10.1016/0006-8993(92)90491-Q; Ross S. P., 2006, VIRTUAL REALITY, V10, P175, DOI DOI 10.1007/S10055-006-0041-7; Ryan JD, 2007, MEMORY, V15, P508, DOI 10.1080/09658210701391022; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; Sheinberg DL, 2001, J NEUROSCI, V21, P1340; Siegle GJ, 2003, NEUROIMAGE, V20, P114, DOI 10.1016/S1053-8119(03)00298-2; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Tatler BW, 2005, Q J EXP PSYCHOL-A, V58, P931, DOI 10.1080/02724980443000430; Underwood G, 2006, EUR J COGN PSYCHOL, V18, P321, DOI 10.1080/09541440500236661; Vogt S, 2007, PERCEPTION, V36, P91, DOI 10.1068/p5262; VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250	48	69	73	1	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	NOV 21	2008	193	2					209	215		10.1016/j.bbr.2008.05.017			7	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	350NP	WOS:000259359700008	18602173				2021-06-18	
J	Galloway, NR; Tong, KA; Ashwal, S; Oyoyo, U; Obenaus, A				Galloway, Nicholas R.; Tong, Karen A.; Ashwal, Stephen; Oyoyo, Udochukwu; Obenaus, Andre			Diffusion-Weighted Imaging Improves Outcome Prediction in Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		apparent diffusion coefficient; children; diffuse axonal injury; magnetic resonance imaging	AXONAL INJURY; HEAD-INJURY; CORPUS-CALLOSUM; INTENSIVE-CARE; CHILDREN; EDEMA; MRI; COEFFICIENT; ANISOTROPY; DISCHARGE	Diffusion-weighted imaging (DWI) and consequent apparent diffusion coefficient (ADC) maps have been used for lesion detection and as a predictor of outcome in adults with traumatic brain injury (TBI), but few studies have been reported in children. We evaluated the role of DWI and ADC for outcome prediction after pediatric TBI (n = 37 TBI; n = 10 controls). Fifteen regions of interest (ROIs) were manually drawn on ADC maps that were grouped for analysis into peripheral gray matter, peripheral white matter, deep gray and white matter, and posterior fossa. All ROIs excluded areas that appeared abnormal on T2-weighted images (T2WI). Acute injury severity was measured using the Glasgow Coma Scale (GCS) score, and 6-12-month outcomes were assessed using the Pediatric Cerebral Performance Category Scale (PCPCS) score. Patients were categorized into five groups: (1) controls; (2) all TBI patients; (3) mild/moderate TBI with good outcomes; (4) severe TBI with good outcomes; and (5) severe TBI with poor outcomes. ADC values in the peripheral white matter were significantly reduced in children with severe TBI with poor outcomes (72.8 +/- 14.4 X 10(-3) mm(2)/sec) compared to those with severe TBI and good outcomes (82.5 +/- 3.8 X 10(-3) mm(2)/sec; p < 0.05). We also found that the average total brain ADC value alone had the greatest ability to predict outcome and could correctly predict outcome in 84% of cases. Assessment of DWI and ADC values in pediatric TBI is useful in evaluating injury, particularly in brain regions that appear normal on conventional imaging. Early identification of children at high risk for poor outcome may assist in aggressive clinical management of pediatric TBI patients.	[Obenaus, Andre] Loma Linda Univ, Dept Radiat Med, Radiobiol Program, Loma Linda, CA 92354 USA; [Tong, Karen A.; Oyoyo, Udochukwu; Obenaus, Andre] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Ashwal, Stephen] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA	Obenaus, A (corresponding author), Loma Linda Univ, Dept Radiat Med, Radiobiol Program, CSP A1010, Loma Linda, CA 92354 USA.	aobenaus@dominion.llumc.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Castejon OJ, 2002, BRAIN INJURY, V16, P331, DOI 10.1080/02699050110088209; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GIZA C, 2006, PEDIAT NEUROLOGY PRI, P1401; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Jones RA, 2003, J MAGN RESON IMAGING, V18, P665, DOI 10.1002/jmri.10413; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KUROIWA T, 1994, ACTA NEUROCHIR, P158; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McGraw P, 2002, AM J ROENTGENOL, V179, P1515, DOI 10.2214/ajr.179.6.1791515; Okanishi T, 2007, J NEUROL SCI, V263, P218, DOI 10.1016/j.jns.2007.06.048; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Prayer D, 2003, EUR J RADIOL, V45, P235, DOI 10.1016/S0720-048X(02)00312-1; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	33	69	76	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1153	1162		10.1089/neu.2007.0494			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200003	18842104				2021-06-18	
J	Pagulayan, KF; Hoffman, JM; Temkin, NR; Machamer, JE; Dikmen, SS				Pagulayan, Kathleen Farrell; Hoffman, Jeanne M.; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.			Functional Limitations and Depression After Traumatic Brain Injury: Examination of the Temporal Relationship	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Longitudinal studies; Rehabilitation; Sickness Impact Profile	MAJOR DEPRESSION; CHRONIC PAIN; RELIABILITY; VALIDITY; SCALE; PREVALENCE; DISORDER; PANEL; INDIVIDUALS; VALIDATION	Objective: To examine the temporal relationship between self-reported injury-related functional limitations and depressive symptomatology after traumatic brain injury (TBI). Design: A longitudinal cohort study with 3 evaluation points. Setting: A level I trauma center. Participants: Adolescents and adults (N=135) with complicated mild to severe TBI (72% had complicated mild injuries) who were recruited within 24 hours of injury and then completed the measure at all 3 time points. Interventions: Not applicable. Main Outcome Measures: Sickness Impact Profile and Center for Epidemiological Studies-Depression Scale. Results: Individuals who reported more depressive symptomatology consistently endorsed more injury-related difficulties, showing the strong relationship between depression and perceived psychosocial functioning. Examination of these relationships over time revealed that increased depressive symptomatology follows higher levels of perceived injury-related changes but that reports of injury-related changes are not associated with earlier depression. These findings suggest a unidirectional temporal relationship between these variables. Conclusions: Perceived changes in daily functioning appear to influence emotional well-being over time after TBI. However, depressive symptoms do not appear to negatively impact individuals' perception of later functioning. These results further our understanding of the complicated relationship between these variables and may have important implications for treatment of depression after TBI.	[Pagulayan, Kathleen Farrell; Hoffman, Jeanne M.; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA	Pagulayan, KF (corresponding author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116 MHC, Seattle, WA 98108 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS19643, F32 HD048030]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	Supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health (grant no. RO1 NS19643) and the National Center for Medical Rehabilitation Research, National Institutes of Health (grant no. F32 HD048030).	ALLOY LB, 1979, J EXP PSYCHOL GEN, V108, P441, DOI 10.1037/0096-3445.108.4.441; ANDERSON TN, 1982, J ACCOUNT RES, V20, P403, DOI 10.2307/2490748; Beck A. T., 1979, COGNITIVE THERAPY DE; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Burns JW, 2003, J CONSULT CLIN PSYCH, V71, P81, DOI 10.1037/0022-006X.71.1.81; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finkel S, 1995, CAUSAL ANAL PANEL DA; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; Gotlib IH, 1988, COGNITION EMOTION, V2, P185, DOI 10.1080/02699938808410923; Gotlib IH, 2004, J ABNORM PSYCHOL, V113, P127, DOI 10.1037/0021-843X.113.1.121; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Judd LL, 2000, ARCH GEN PSYCHIAT, V57, P375, DOI 10.1001/archpsyc.57.4.375; Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6; KATZ R, 1995, BRIT J PSYCHIAT, V166, P100, DOI 10.1192/bjp.166.1.100; KENNY DA, 1975, PSYCHOL BULL, V82, P887, DOI 10.1037/0033-2909.82.6.887; Klinkman MS, 1997, ARCH FAM MED, V6, P567, DOI 10.1001/archfami.6.6.567; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MURRELL SA, 1983, AM J EPIDEMIOL, V117, P173, DOI 10.1093/oxfordjournals.aje.a113528; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; PARIKH RM, 1988, INT J PSYCHIAT MED, V18, P169, DOI 10.2190/BH75-EUYA-4FM1-J7QA; PELZ DC, 1964, AM SOCIOL REV, V29, P836, DOI 10.2307/2090866; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; Prigatano G. F., 2005, REHABILITATION TRAUM, P118; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBERTS RE, 1980, PSYCHIAT RES, V2, P125, DOI 10.1016/0165-1781(80)90069-4; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Rytsala HJ, 2006, J NERV MENT DIS, V194, P570, DOI 10.1097/01.nmd.0000230394.21345.c4; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 2004, FED REG, V64, P45744	56	69	69	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2008	89	10					1887	1892		10.1016/j.apmr.2008.03.019			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	366LY	WOS:000260484200006	18929017				2021-06-18	
J	Spaethling, JM; Klein, DM; Singh, P; Meaney, DF				Spaethling, Jennifer M.; Klein, Donna M.; Singh, Pallab; Meaney, David F.			Calcium-Permeable AMPA Receptors Appear in Cortical Neurons after Traumatic Mechanical Injury and Contribute to Neuronal Fate	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		calcium-permeable AMPA receptors; CaMKII; mechanical injury; trafficking; traumatic brain injury	LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; IN-VITRO; GLUTAMATE RECEPTORS; BRAIN-INJURY; SYNAPTIC PLASTICITY; SUBUNIT COMPOSITION; CULTURED NEURONS; NMDA RECEPTORS; RAT	Traumatic brain injury (TBI) is one of the most disabling injuries in the population, with 1.5 million Americans new cases each year and 5.3 million Americans overall requiring long-term daily care as a result of their injuries. One critical aspect in developing effective treatments for TBI is determining if new, specific receptor populations emerge in the early phase after injury that can subsequently be targeted to reduce neuronal death after injury. One specific glutamate receptor subtype, the calcium-permeable AMPA receptor (CP-AMPAR), is becoming increasingly recognized for its role in physiological and pathophysiological processes. Although present in relatively low levels in the mature brain, recent studies show that CP-AMPARs can appear following ischemic brain injury or status epilepticus, and the mechanisms that regulate the appearance of these receptors include alterations in transcription, RNA editing, and receptor trafficking. In this report, we use an in vitro model of TBI to show a gradual appearance of CP-AMPARs four hours following injury to cortical neurons. Moreover, the appearance of these receptors is mediated by the phosphorylation of CaMKII alpha following injury. Selectively blocking CP-AMPARs after mechanical injury leads to a significant reduction in the cell death that occurs 24 h following injury in untreated controls, and is similar in protection offered by broad-spectrum NMDA and AMPA receptor antagonists. These data point to a potentially new and more targeted therapeutic approach for treating TBI.	[Klein, Donna M.; Singh, Pallab; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Spaethling, Jennifer M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD41699] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035712, R01 NS035712-03, NS 35712] Funding Source: Medline		Adesnik H, 2007, J NEUROSCI, V27, P4598, DOI 10.1523/JNEUROSCI.0325-07.2007; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Calderone A, 2003, J NEUROSCI, V23, P2112; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Hall BJ, 2007, J NEUROSCI, V27, P13446, DOI 10.1523/JNEUROSCI.3793-07.2007; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang YF, 2002, J NEUROSCI, V22, P8422; Iino M, 1996, J PHYSIOL-LONDON, V496, P431, DOI 10.1113/jphysiol.1996.sp021696; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Jones TL, 2005, PAIN, V117, P259, DOI 10.1016/j.pain.2005.06.003; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Kakegawa W, 2002, J NEUROSCI, V22, P4312, DOI 10.1523/JNEUROSCI.22-11-04312.2002; Kato K, 2007, NEUROSCI LETT, V418, P4, DOI 10.1016/j.neulet.2007.02.058; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lee SH, 2004, NEURON, V43, P221, DOI 10.1016/j.neuron.2004.06.015; Lin YC, 2002, J NEUROSCI RES, V67, P484, DOI 10.1002/jnr.10077; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Liu SQJ, 2000, NATURE, V405, P454; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Noh KM, 2005, P NATL ACAD SCI USA, V102, P12230, DOI 10.1073/pnas.0505408102; Okada T, 2003, EUR J NEUROSCI, V17, P341, DOI 10.1046/j.1460-9568.2003.02458.x; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Plant K, 2006, NAT NEUROSCI, V9, P602, DOI 10.1038/nn1678; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Semyanov A, 2001, NEUROPHARMACOLOGY, V40, P203, DOI 10.1016/S0028-3908(00)00147-7; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sorkin LS, 1999, NEUROREPORT, V10, P3523, DOI 10.1097/00001756-199911260-00011; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian XJ, 2006, J BIOL CHEM, V281, P7578, DOI 10.1074/jbc.M512060200; Van Damme P, 2002, J NEUROPHYSIOL, V88, P1279, DOI 10.1152/jn.2002.88.3.1279; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	60	69	71	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1207	1216		10.1089/neu.2008.0532			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200009	18986222	Green Published, Green Accepted			2021-06-18	
J	Nylen, K; Ost, M; Csajbok, LZ; Nilsson, I; Hall, C; Blennow, K; Nellgard, B; Rosengren, L				Nylen, K.; Oest, M.; Csajbok, L. Z.; Nilsson, I.; Hall, C.; Blennow, K.; Nellgard, B.; Rosengren, L.			Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						S100B; S100A1B; S100BB; traumatic brain injury; outcome; biochemical brain damage markers	MARKER; PROTEIN	Objectives. S100B is an established marker of brain damage. Used in the context as a biochemical marker, S100B denotes a measurement of all S100 proteins, including at least one S100B monomer, i.e. the sum of the two dimers S100A1B and S100BB. Almost all published studies are based on this "sum concentration". However, the brain specificity of S100B has been questioned and increased serum levels have also been reported after trauma without head injury. Since the S100B monomer dominates in the brain, we hypothesised that the S100BB dimer should be better related to outcome after severe traumatic brain injury than S100A1B or the "sum concentration". Methods. Daily serum samples were collected from 59 patients with severe traumatic brain injury. Three different ELISA methods were used for measurements of S100B, S100A1B and S100BB respectively. Outcome was assessed after one year and categorised according to the Glasgow Outcome Scale. Results. Serum levels of S100B, S100A1B and S100BB followed the same temporal course, with early maximum and rapidly decreasing values over the first days after the trauma. Maximum serum concentrations of each of the parameters were increased in the patient group with an unfavourable outcome compared with those with a favourable outcome (p = 0.01, 0.006 and 0.004, respectively). Conclusion. Both S100A1B and S100BB were related to outcome after severe traumatic brain injury. Even though this study is small, it seems unlikely that separate analyses of the dimers are of any advantage compared with measuring S100B alone.	[Nylen, K.; Rosengren, L.] Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden; [Oest, M.; Csajbok, L. Z.; Nellgard, B.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Anaesthesia, Neurointens Care Unit, S-41345 Gothenburg, Sweden; [Nilsson, I.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neuroradiol, Gothenburg, Sweden; [Blennow, K.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Expt Neurosci, Gothenburg, Sweden; [Hall, C.] Fujirebio Diagnost AB, Gothenburg, Sweden	Nylen, K (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden.	karin.nylen@neuro.gu.se	Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896			Anderson RE, 2003, J CARDIOTHOR VASC AN, V17, P598, DOI 10.1016/S1053-0770(03)00203-9; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; ISOBE T, 1983, BIOCHEM INT, V6, P419; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, BRIT J NEUROSURG, V18, P277, DOI 10.1080/02688690410001732742; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	20	69	72	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2008	150	3					221	227		10.1007/s00701-007-1489-2			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	274AP	WOS:000253974500003	18193148				2021-06-18	
J	Bondanelli, M; Ambrosio, MR; Cavazzini, L; Bertocchi, A; Zatelli, MC; Carli, A; Valle, D; Basaglia, N; Uberti, ECD				Bondanelli, Marta; Ambrosio, Maria Rosaria; Cavazzini, Lorenza; Bertocchi, Amedeo; Zatelli, Maria Chiara; Carli, Anna; Valle, Domenico; Basaglia, Nino; Uberti, Ettore C. Degli			Anterior pituitary function may predict functional and cognitive outcome in patients with traumatic brain injury undergoing rehabilitation	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone; hypopituitarism; rehabilitation; TBI	DISABILITY RATING-SCALE; SEVERE HEAD TRAUMA; GROWTH-HORMONE; ADRENAL INSUFFICIENCY; HYPOPITUITARISM; COMA; IMPACT; ADULTS; REPLACEMENT; DIAGNOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. Growth hormone-insulin-like growth factor I (GH-IGF-I) system has an important role in the recovery of the central nervous system. The aim of the study was to evaluate the relationship between pituitary function (in particular, the GH-IGF-I axis) and outcome from TBI. We studied 72 patients (56 males; mean age 37.2 +/- 1.8 years) receiving rehabilitation after TBI. According to the Glasgow Coma Scale (GCS), 10 patients had moderate and 52 severe TBI. Ten patients had growth hormone GH deficiency (GHD), 10 LH-FSH, three TSH, and three ACTH deficiency. Overall pituitary dysfunction occurred in 22 (30.5%) patients, with anterior hypopituitarism in 19 (26.4%), isolated diabetes insipidus in one, and isolated hyperprolactinemia in two. GH response to GHRH+ARG ( arginine) positively correlated with Functional Independence Measure (FIMD; r = 0.267, p < 0.02) and Level of Cognitive Functioning Scale (LCFSD; r = 0.287, p < 0.01) at discharge, and negatively with Disability Rating Score at discharge (DRSD; r = -0.324, p < 0.005). Unfavorable outcome measures (FIMD, LCFSD, and DRSD) occurred in patients with hypopituitarism as compared with normal pituitary function p < 0.05). Multiple regression analysis identified both GCS (p < 0.005) and GH peak (p < 0.05) as strong independent predictors of outcome. In conclusion, recovery after TBI may be negatively influenced by concomitant pituitary dysfunction. The GH peak value is an independent predictor of outcome, indicating that recovery during an intensive rehabilitation program after TBI may be positively influenced by normal GH secretion.	Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, I-44100 Ferrara, Italy; Arcispedale St Anna, Dept Rehabil Med, Ferrara, Italy; Eli Lilly & Co, Florence, Italy	Bondanelli, M (corresponding author), Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, Via Savonarola 9, I-44100 Ferrara, Italy.		Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	Zatelli, Maria Chiara/0000-0001-8408-7796; degli Uberti, Ettore/0000-0002-9441-7223; ambrosio, maria rosaria/0000-0002-7911-9770; Bondanelli, Marta/0000-0001-8071-6559			Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Bondanelli M, 2006, J CLIN ENDOCR METAB, V91, P3928, DOI 10.1210/jc.2006-1040; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; HAGEN C, 1982, COGNITIVE REHABILITA, P131; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Schmidt IL, 2003, J CLIN ENDOCR METAB, V88, P4193, DOI 10.1210/jc.2002-021897; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Simpson H, 2002, GROWTH HORM IGF RES, V12, P1, DOI 10.1054/ghir.2001.0263; Sonntag WE, 2006, AM J PHYSIOL-ENDOC M, V291, pE604, DOI 10.1152/ajpendo.00012.2006; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Suliman AM, 2002, CLIN ENDOCRINOL, V56, P533, DOI 10.1046/j.1365-2265.2002.01509.x; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Toschlog EA, 2003, AM SURGEON, V69, P491; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Van der Heljde D, 2005, ANN RHEUM DIS, V64, P109; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Young TP, 2007, BRAIN INJURY, V21, P645, DOI 10.1080/02699050701210426	42	69	72	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1687	1697		10.1089/neu.2007.0343			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500002	18001199				2021-06-18	
J	Bowman, SM; Martin, DP; Sharar, SR; Zimmerman, FJ				Bowman, Stephen M.; Martin, Diane P.; Sharar, Sam R.; Zimmerman, Frederick J.			Racial disparities in outcomes of persons with moderate to severe traumatic brain injury	MEDICAL CARE			English	Article						traumatic brain injury; race; disparity; mortality; rehabilitation	EMERGENCY-DEPARTMENT	Background: Although racial differences in hospital outcomes are well known for medical conditions (eg, cardiovascular disease), it is unknown whether differences exist for patients with traumatic brain injury (TBI). Research Design: Using the National Trauma Data Bank, we examined racial and ethnic differences in hospital outcomes of 56,482 patients with moderate to severe TBI who were hospitalized in level I or 11 trauma-designated hospitals between 2000 and 2003. We examined racial and ethnic disparities in in-hospital mortality and the likelihood of survivors receiving postacute care at a rehabilitation center. Results: After multivariable adjustment, compared with whites, we observed increased in-hospital mortality for blacks (odds ratio [OR] = 1.19, P = 0.026) and Asians (OR = 1.41, P = 0.005). We observed a trend toward significance for Hispanics (OR = 1.41, P = 0.077), but not for other races. For survivors, compared with whites, blacks and Hispanics were less likely to be discharged to a rehabilitation center (OR = 0.68, P < 0.001, and OR = 0.67, P = 0.002, respectively). Conclusions: Racial and ethnic disparities exist both in mortality and in discharge to postacute rehabilitation centers among persons with TBI.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	Bowman, SM (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Peds CARE Slot 512-26,800 Marshall St, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Zimmerman, Frederick/C-7259-2008; Zimmerman, Frederick/AAM-5432-2020; Bowman, Stephen/AAF-2154-2019	Zimmerman, Frederick/0000-0002-4163-9893; Zimmerman, Frederick/0000-0002-4163-9893; 			American College of Surgeons, NAT TRAUM DAT BANK 2; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention, 2001, INJ FACT BOOK 2001 2; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; FELICIANO D, 1996, TRAUMA; *I MED, 2002, UN TREATM HEALTHC PR; *J HOPK U TRI AN I, 1997, ICDMAP 90 INJ SEV CO; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sacco WJ, 1999, J TRAUMA, V47, P441, DOI 10.1097/00005373-199909000-00001; Stephenson SCR, 2002, J TRAUMA, V53, P326, DOI 10.1097/00005373-200208000-00023; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DHHS, 2005, 2005 NAT HEALTHC DIS; *WASH STAT DEP HLT, 2006, WASH TRAUM REG; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	18	69	70	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	JUL	2007	45	7					686	690		10.1097/MLR.0b013e31803dcdf3			5	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	186OR	WOS:000247788500014	17571018				2021-06-18	
J	Robertson, CL; Saraswati, M; Fiskum, G				Robertson, Courtney L.; Saraswati, Manda; Fiskum, Gary			Mitochondrial dysfunction early after traumatic brain injury in immature rats	JOURNAL OF NEUROCHEMISTRY			English	Article						brain mitochondria; cerebral metabolism; cytochrome c; development; oxidative stress	PYRUVATE-DEHYDROGENASE COMPLEX; CYTOCHROME-C RELEASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; TERM FOREBRAIN ISCHEMIA; OXIDATIVE STRESS; CELL-DEATH; CEREBROSPINAL-FLUID; HYPOXIA-ISCHEMIA; LIPID-PEROXIDATION; CASPASE ACTIVATION	Mitochondria play central roles in acute brain injury; however, little is known about mitochondrial function following traumatic brain injury (TBI) to the immature brain. We hypothesized that TBI would cause mitochondrial dysfunction early (< 4 h) after injury. Immature rats underwent controlled cortical impact (CCI) or sham injury to the left cortex, and mitochondria were isolated from both hemispheres at 1 and 4 h after TBI. Rates of phosphorylating (State 3) and resting (State 4) respiration were measured with and without bovine serum albumin. The respiratory control ratio was calculated (State 3/State 4). Rates of mitochondrial H2O2 production, pyruvate dehydrogenase complex enzyme activity, and cytochrome c content were measured. Mitochondrial State 4 rates (ipsilateral/contralateral ratios) were higher after TBI at 1 h, which was reversed with bovine serum albumin. Four hours after TBI, pyruvate dehydrogenase complex activity and cytochrome c content (ipsilateral/contralateral ratios) were lower in TBI mitochondria. These data demonstrate abnormal mitochondrial function early (<= 4 h) after TBI in the developing brain. Future studies directed at reversing mitochondrial abnormalities could guide neuroprotective interventions after pediatric TBI.	Univ Maryland, Dept Pediat, Sch Med, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA	Robertson, CL (corresponding author), Univ Maryland, Dept Pediat, Sch Med, 22 S Greene St,N5E13, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS42805] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; ALLEN KL, 1995, J NEUROCHEM, V64, P2222; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; Buki A, 2000, J NEUROSCI, V20, P2825; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; CLARK JB, 1993, DEV NEUROSCI-BASEL, V15, P174, DOI 10.1159/000111333; CULLINGFORD TE, 1994, J NEUROCHEM, V62, P1682; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; ELNAGEH KM, 1988, J NEUROCHEM, V51, P1482, DOI 10.1111/j.1471-4159.1988.tb01115.x; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HILLERED L, 1988, J NEUROSCI RES, V20, P451, DOI 10.1002/jnr.490200407; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; JOPE R, 1975, BIOCHEM J, V150, P397, DOI 10.1042/bj1500397; Kagan VE, 2006, CHEM-BIOL INTERACT, V163, P15, DOI 10.1016/j.cbi.2006.04.019; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MALLOCH GDA, 1986, BIOCHEM J, V238, P729, DOI 10.1042/bj2380729; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Nakajima W, 2000, J NEUROSCI, V20, P7994; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schuh RA, 2005, TOXICOL SCI, V88, P495, DOI 10.1093/toxsci/kfi334; SEVANIAN A, 1988, BIOCHIM BIOPHYS ACTA, V961, P316, DOI 10.1016/0005-2760(88)90079-3; SHINOHARA Y, 1995, BBA-BIOENERGETICS, V1228, P229, DOI 10.1016/0005-2728(94)00179-9; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Starner TE, 2003, IEEE PERVAS COMPUT, V2, P86, DOI 10.1109/MPRV.2003.1251172; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Zaidan E, 1998, J NEUROCHEM, V70, P233; Zaidan E, 1997, BRAIN RES, V772, P23, DOI 10.1016/S0006-8993(97)00833-0; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	68	69	69	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2007	101	5					1248	1257		10.1111/j.1471-4159.2007.04489.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	166GF	WOS:000246365600010	17403141	Bronze			2021-06-18	
J	Levin, H; Hanten, G; Max, J; Li, XQ; Swank, P; Ewing-Cobbs, L; Dennis, M; Menefee, DS; Schachar, R				Levin, Harvey; Hanten, Gerri; Max, Jeffrey; Li, Xiaoqi; Swank, Paul; Ewing-Cobbs, Linda; Dennis, Maureen; Menefee, Deleene S.; Schachar, Russell			Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; attention-deficit/hyperactivity disorder; children	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; RESPONSE-INHIBITION; ADOLESCENTS; ADHD; RECOVERY; BEHAVIOR; TERM; SYMPTOMATOLOGY	Methods: We investigated changes in inattentive and hyperactive symptoms over 2 years following traumatic brain injury (TBI) in relation to preinjury attention-deficit/hyperactivity disorder (ADHD), injury, and socioeconomic status (SES) variables. Postinjury stimulant medication treatment was also documented. of 175 consecutive patients of ages 5 to 15 years with acute TBI, 148 consented, including 114 without preinjury ADHD (mean age, 10.0 years, SD = 2.76) and 34 with preinjury ADHD (mean age 10.36 years, SD = 2.75). The Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present and Lifetime Version, was administered at baseline and at 6, 12, and 24 months post-injury to assess the presence of nine core inattentive and nine hyperactive symptoms and associated impairment. The baseline assessment was performed within 1 month post- injury to establish preinjury diagnosis. Results: Nonlinear change in inattentive symptoms in patients without preinjury ADHD contrasted with higher and more stable symptom levels in children with preinjury diagnosis, including the cubic trend (chi(2)(1) = 6.23, p = .0126). There was also a significant interaction of group x gender effect (chi(2)(1), = 4.08, p = .0435) as males had higher numbers of inattentive symptoms than females in the preinjury ADHD group. Change in hyperactive symptoms over time also differed by group, including both linear (chi(2)(1) = 5.42, p = .0199) and cubic trends (chi(2)(1) = 8.91, p = .0029), refleding greater and more frequent fluctuations in children without preinjury ADHD. Socioeconomic level also contributed to change in hyperactive symptoms as reflected by the interaction of SES and linear time (chi(2)(1) = 6.91, p = .009), as well as quadratic time (chi(2)(1) = 4.90, p = .027). Occurrence of ADHD diagnosed post-injury ranged from 14.5% (12 months) to 18.3% (24 months) in the group without preinjury ADHD compared with a range from 86.4% (12 months) to 96.2% (6 months) in children with preinjury ADHD. In children without preinjury ADHD, SES was the only patient variable that predicted onset of ADHD, t(110) = -2.85, p = .0052. Treatment with stimulant medication post-injury was more frequently associated with preinjury ADHD (39% vs 7% of children without preinjury ADHD), p < .0001 (Fisher exact test). Children with preinjury ADHD who were treated pre-injury with stimulant medication had fewer total symptoms at 24 months post-injury relative to untreated patients with preinjury ADHD (F[1,14] = 3.93, p = 0.069, Cohen's d = 1.28). Conclusion: Change in ADHD symptoms after TBI varies with preinjury diagnosis, reflects injury severity in children without preinjury ADHD, and is treated with stimulant medication mainly in those patients with preinjury ADHD.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA; Univ Toronto, Dept Surg, Toronto, ON, Canada; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada	Levin, H (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	hlevin@bcm.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Barbaresi WJ, 2006, J DEV BEHAV PEDIATR, V27, P1, DOI 10.1097/00004703-200602000-00001; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI 10.1016/S0887-6185(97)00047-9; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Counts CA, 2005, J AM ACAD CHILD PSY, V44, P690, DOI 10.1097/01.chi.0000162582.87710.66; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Homer CJ, 2000, PEDIATRICS, V105, P1158; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Konrad KN, 2000, BRAIN INJURY, V14, P859; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; Murphy KR, 2002, J NERV MENT DIS, V190, P147, DOI 10.1097/00005053-200203000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutter M., 1987, RISK PROTECTIVE FACT, P181; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	48	69	70	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	APR	2007	28	2					108	118		10.1097/01.DBP.0000267559.26576.cd			11	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	158KG	WOS:000245789800005	17435461				2021-06-18	
J	Rees, L; Marshall, S; Hartridge, C; Mackie, D; Weiser, M				Rees, Laura; Marshall, Shawn; Hartridge, Cheryl; Mackie, David; Weiser, Margaret		ERABI Grp	Cognitive interventions post acquired brain injury	BRAIN INJURY			English	Article						attention; brain; brain injuries; craniocerebral trauma; cognition; cognition disorders; cognitive therapy; drug therapy; evidence-based medicine; memory; rehabilitation	CLOSED-HEAD-INJURY; METHYLPHENIDATE TREATMENT; POSTTRAUMATIC AMNESIA; MEMORY REMEDIATION; ATTENTION DEFICITS; TRAINING-PROGRAM; POCKET-COMPUTER; REHABILITATION; EFFICACY; PERFORMANCE	Objective: Cognitive rehabilitation represents a substantial portion of rehabilitative efforts put forth in increasing independence following an acquired brain injury. Main outcomes and results: This review examined four major areas of cognitive therapy including: attention/concentration, learning and memory, executive functioning, and general cognitive rehabilitation approaches. In total, 64 studies were evaluated throughout the four major areas, which provided the evidence-base for 18 conclusions. The majority of the conclusions were based on moderate and limited evidence, however three strong and one conflicting conclusions were made. Conclusions: Future research should explore functional outcome measures and long-term effects of treatment interventions through follow-up.	Univ Western Ontario, Ottawa Rehabil Ctr, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, St Josephs Hlth Care London, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, Div Phy Med, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, Div Rehabil, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada	Marshall, S (corresponding author), Ottawa Hosp, Rehabil Ctr, Ottawa, ON, Canada.	smarshall@ottawahospital.on.ca					Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Brett A W, 1998, Pediatr Rehabil, V2, P27; Burke DT, 2001, J HEAD TRAUMA REHAB, V16, P284, DOI 10.1097/00001199-200106000-00007; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; ESLINGER PJ, 2002, NEUROPSYCHOLOGICAL I; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Goldstein G, 1996, CLIN NEUROPSYCHOL, V10, P66, DOI 10.1080/13854049608406664; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Harrington D E, 1987, Brain Inj, V1, P65, DOI 10.3109/02699058709034447; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hux K, 2000, BRAIN INJURY, V14, P907; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MALEC EA, 1991, NEUROPSYCHOLOGY, V5, P29, DOI DOI 10.1037/0894-4105.5.1.29; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; MILDERS MV, 1995, NEUROPSYCHOL REHABIL, V5, P223, DOI 10.1080/09602019508401468; Miller MA, 2003, ARCH PHYS MED REHAB, V84, pS12, DOI 10.1053/apmr.2003.50053; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Parente R, 1999, NEUROREHABILITATION, V13, P13; Parente R, 1999, NEUROREHABILITATION, V13, P157; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Schneider WN, 1999, BRAIN INJURY, V13, P863; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Watanabe TK, 1998, BRAIN INJURY, V12, P81; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; 2005, DEFINITION ACQUIRED	72	69	69	1	21	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2007	21	2					161	200		10.1080/02699050701201813			40	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	162SQ	WOS:000246110200005	17364530				2021-06-18	
J	Silver, JM; Koumaras, B; Chen, M; Mirski, D; Potkin, SG; Reyes, P; Warden, D; Harvey, PD; Arciniegas, D; Katz, DI; Gunay, I				Silver, J. M.; Koumaras, B.; Chen, M.; Mirski, D.; Potkin, S. G.; Reyes, P.; Warden, D.; Harvey, P. D.; Arciniegas, D.; Katz, D. I.; Gunay, I.			Effects of rivastigmine on cognitive function in patients with traumatic brain injury	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; SENILE DEMENTIA; HEAD-INJURY; ACETYLCHOLINE; INVENTORY; DEPRESSION; VALIDATION; DEFICITS	Objective: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. Methods: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A' subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A' or HVLT. Results: The percentage of responders at week 12 on either the CANTAB RVIP A' or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. Conclusions: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.	Novartis Pharmacuet, E Hanover, NJ 07936 USA; NYU, Sch Med, New York, NY 10021 USA; Univ Calif Irvine, Med Ctr, Orange, CA USA; Creighton Univ, Sch Med, Omaha, NE USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Healths Braintree Rehabil Hosp, Braintree, MA USA	Gunay, I (corresponding author), Novartis Pharmacuet, 1 Hlth Pl, E Hanover, NJ 07936 USA.	ibrahim.gunay@novartis.com	Noble, James/AAA-4218-2020; Potkin, Steven G/A-2021-2013; Arciniegas, David/A-3792-2009	Noble, James/0000-0003-0648-6702; Potkin, Steven/0000-0003-1028-1013; Katz, Douglas/0000-0002-7502-8505			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Corey-Bloom J, 1998, INT J GERIATR PSYCHO, V1, P55; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; ESLINGER PJ, 1985, JAMA-J AM MED ASSOC, V253, P670, DOI 10.1001/jama.253.5.670; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; GUY W, 1976, PUBLICATION ADM USDA; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; PERRY EK, 1978, NEUROPATH APPL NEURO, V4, P273, DOI 10.1111/j.1365-2990.1978.tb00545.x; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Steer RA, 1999, J CLIN PSYCHOL, V55, P117, DOI 10.1002/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	25	69	73	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 12	2006	67	5					748	755		10.1212/01.wnl.0000234062.98062.e9			8	Clinical Neurology	Neurosciences & Neurology	083EC	WOS:000240437700005	16966534				2021-06-18	
J	Chappell, MH; Ulug, AM; Zhang, L; Heitger, MH; Jordan, BD; Zimmerman, RD; Watts, R				Chappell, Michael H.; Ulug, Aziz M.; Zhang, Lijuan; Heitger, Marcus H.; Jordan, Barry D.; Zimmerman, Robert D.; Watts, Richard			Distribution of microstructural damage in the brains of professional boxers: A diffusion MRI study	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						boxers; diffusion tensor imaging (DTI); apparent diffusion coefficient (ADC); fractional anisotropy (FA); traumatic brain injury (TBI); voxel-based analysis (VBA)	AXONAL INJURY; HEAD-INJURY; ACTIVATION; TENSOR; CONCUSSION	Purpose: To investigate and localize cerebral abnormalities in professional boxers with no history of moderate or severe head trauma. Materials and Methods: Diffusion tensor imaging (DTI) was used to determine the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in the brains of 81 professional male boxers and 12 male control subjects. Voxel-based analysis (VBA) of both the diffusion and anisotropy values was performed using statistical parametric mapping (SPM). From this objective analysis, regions of microstructural abnormalities in the brains of the boxers were located. Results: Increases in the ADC, and decreases in FA were identified in deep white matter (WM), while decreases in ADC were identified in cortical gray matter (GM). Regions of positive correlation between ADC and age were also found in both the boxer and control groups, although the regions and strength of the correlation were not the same in each group. Conclusion: Using VBA, we localized previously unreported abnormalities in the brains of professional boxers. These abnormalities are assumed to reflect cumulative (chronic) brain injury resulting from nonsevere head trauma.	Univ Canterbury, Dept Phys & Astron, Christchurch 8020, New Zealand; Cornell Univ, Dept Radiol, Weill Med Coll, New York, NY USA; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Burke Rehabil Hosp, New York, NY USA	Chappell, MH (corresponding author), Univ Canterbury, Dept Phys & Astron, Ilam Rd,Private Bag 4800, Christchurch 8020, New Zealand.	mhc15@student.canterbury.ac.nz	Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chun T, 2000, AM J NEURORADIOL, V21, P1078; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Pointinger H, 2002, BRAIN INJURY, V16, P799, DOI 10.1080/02699050210131911; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Witzel T, 2001, NEUROIMAGE, V13, pS286; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	26	69	73	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	SEP	2006	24	3					537	542		10.1002/jmri.20656			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	081EU	WOS:000240300800008	16878306	Green Published, Bronze			2021-06-18	
J	Trokel, M; Wadimmba, A; Griffith, J; Sege, R				Trokel, M; Wadimmba, A; Griffith, J; Sege, R			Variation in the diagnosis of child abuse in severely injured infants	PEDIATRICS			English	Article						medical error; hospital discharge data; child abuse; femur fracture; traumatic brain injury; medical error	YOUNG-CHILDREN; HEALTH-CARE; HEAD-INJURY; FRACTURES; PHYSICIAN	OBJECTIVE. Diagnosis of child abuse is difficult and may reflect patient, practitioner, and system factors. Previous studies have demonstrated potential lethal consequences if cases of abuse are missed and suggested a role for continuing medical education in improving the accuracy of diagnosis of suspected abuse. Although the majority of injured American children are treated at general hospitals, most published studies of severe injury resulting from child abuse have been conducted at children's hospitals. The objective of this study was to evaluate the role of hospital type in observed variations in the frequency of diagnosis of child physical abuse among children with high-risk injuries. METHODS. Hospital discharge data were evaluated, and adjusted rates of abuse diagnosis were reported according to hospital type. A regression model estimated the number of cases of abuse that would have been diagnosed if all hospitals identified abuse as frequently as observed at pediatric specialty hospitals. This study consisted of children who were < 1 year old and admitted to US hospitals in 1997 for treatment of traumatic brain injury or femur fracture, excluding penetrating trauma or motor-vehicle-related injury. A total of 2253 weighted cases were analyzed. RESULTS. The proportion of patients with a medical diagnosis of child abuse varied widely between hospital types: 29% of the cases were diagnosed as abuse at children's hospitals compared with 13% at general hospitals. An estimated 178 infants (39% of total) with these specific injuries would have been identified as abused had they been treated at children's rather than general hospitals. CONCLUSIONS. Hospital type was associated with large variations in the frequency of diagnosis of child abuse. This variation was not related to observed differences in the patients or their injuries and may result from systematic underdiagnosis in general hospitals. This result has implications for quality-improvement programs at general hospitals, where the majority of injured children in the United States receive emergent medical care.	Boston Univ, Dept Publ Hlth, Boston, MA 02215 USA; Boston Med Ctr, Dept Pediat, Boston, MA USA; Tufts Univ, New England Med Ctr, Floating Hosp Children, Biostat Res Ctr, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Floating Hosp Children, Pediat & Adolescent Hlth Res Ctr, Boston, MA 02111 USA	Sege, R (corresponding author), NEMC, Box 351,750 Washington St, Boston, MA 02111 USA.	rsege@tufts-nemc.org		Waddimba, Anthony/0000-0002-5377-0864; Sege, Robert/0000-0003-1260-4787	AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS000060] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW001083] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32 HS00060] Funding Source: Medline; FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW001083-04] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR1186-03] Funding Source: Medline		ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BADGER LW, 1989, SOUTHERN MED J, V82, P281, DOI 10.1097/00007611-198903000-00002; BEALS RK, 1983, J PEDIATR ORTHOPED, V3, P583, DOI 10.1097/01241398-198311000-00004; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CANIANO DA, 1986, ANN SURG, V203, P219, DOI 10.1097/00000658-198602000-00017; DALTON HJ, 1990, AM J DIS CHILD, V144, P875, DOI 10.1001/archpedi.1990.02150320039022; DIAMOND P, 1994, PEDIATR EMERG CARE, V10, P83, DOI 10.1097/00006565-199404000-00005; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Flaherty EG, 2002, AMBUL PEDIATR, V2, P120, DOI 10.1367/1539-4409(2002)002<0120:AOSOAI>2.0.CO;2; Flaherty EG, 2000, ARCH PEDIAT ADOL MED, V154, P489, DOI 10.1001/archpedi.154.5.489; GROSS RH, 1983, J PEDIATR ORTHOPED, V3, P341, DOI 10.1097/01241398-198307000-00012; *HEALTHC COST UT P, 1997, KIDS INP DAT; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; JACKSON G, 1972, BRIT MED J, V2, P756, DOI 10.1136/bmj.2.5816.756; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Lawrence LL, 2000, MIL MED, V165, P607; McCormick MC, 2000, PEDIATRICS, V105, P219; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; *US DEP HHS, 2003, CHILD MALTR 2001	22	69	69	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2006	117	3					722	728		10.1542/peds.2004-2731			7	Pediatrics	Pediatrics	017QV	WOS:000235709000043	16510652				2021-06-18	
J	Gowda, NK; Agrawal, D; Bal, C; Chandrashekar, N; Tripati, M; Bandopadhyaya, GP; Malhotra, A; Mahapatra, AK				Gowda, NK; Agrawal, D; Bal, C; Chandrashekar, N; Tripati, M; Bandopadhyaya, GP; Malhotra, A; Mahapatra, AK			Technetium Tc-99m ethyl cysteinate dimer brain single-photon emission CT in mild traumatic brain injury: A prospective study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; HMPAO SPECT; PERFUSION; MRI	PURPOSE: To explore the role of single-photon emission CT (SPECT) in initial diagnostic evaluation of patients with mild traumatic brain injury (MTBI) and to identify subgroups in which it may serve as a useful diagnostic tool. MATERIALS AND METHODS: Patients with MTBI seen during a 14-month period were prospectively included in this study. All patients had a CT of head within 12 hours of injury and SPECT by using technetium Tc99m ethyl cysteinate dimer (Tc99m-ECD) within 72 hours of injury. Both SPECT and CT findings were compared with clinical features such as posttraumatic amnesia (PTA), postconcussion syndrome (PCS), and loss of consciousness (LOC). RESULTS: Ninety-two patients with MTBI underwent SPECT in the study period. There were 28 children and 64 adults, with male-to-female ratio of 4.5 to 1. CT findings were abnormal in 31 (34%) and SPECT in 58 (63%). The most common abnormality was hypoperfusion in the frontal lobe(s) in adults and the temporal lobe in children. A significantly higher number of perfusion abnormalities were seen in patients with PTA (P = .03), LOC (P = .02), and PCS (P = .01) than in patients without these symptoms. Compared to CT, SPECT had a much higher sensitivity for detecting an organic basis in these subgroup, of patients (P < .05). CONCLUSION: Tc99m-ECD SPECT can be used as a complementary technique to CT in initial evaluation of patients with MTBI. It is particularly useful in patients having PCS, LOC, or PTA with normal CT scan.	All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India; All India Inst Med Sci, Dept Neurosurg, New Delhi, India; All India Inst Med Sci, Ctr Neurosci, New Delhi, India	Gowda, NK (corresponding author), All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India.			Agrawal, Deepak/0000-0002-5499-0746			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; AHMADI A, 1989, J NEUROPSYCHIATRY S, V1, P45; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Catafau AM, 2001, J NUCL MED, V42, P259; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAY BG, 1992, J NUCL MED, V33, P52; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; INGEBRIGSTEN T, 1998, ASPECTS MANAGEMENT M; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Jennett B, 1991, J NEUROTRAUM, V8, P81; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; LINDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; MAHAPATRA AK, 1999, TXB HEAD INJURY; Masdeu J C, 1994, J Neuroimaging, V4, P177; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWBERG AB, 2003, SEMIN NUCL MED, V33, P36; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROPER SN, 1991, J NUCL MED, V32, P1684; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; *WHO, 2003, ICD10 CLASS MENT BEH, P67; WHO, 1999, WORLD HLTH REP 1999; *WHO, 1999, INJ LEAD CAUS GLOB B; WILSON JTL, 1997, SPECT IMAGING BRAIN, P69	34	69	70	0	5	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2006	27	2					447	451					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	014GJ	WOS:000235467100054	16484427				2021-06-18	
J	Siren, AL; Radyushkin, K; Boretius, S; Kammer, D; Riechers, CC; Natt, O; Sargin, D; Watanabe, T; Sperling, S; Michaelis, T; Price, J; Meyer, B; Frahm, J; Ehrenreich, H				Siren, AL; Radyushkin, K; Boretius, S; Kammer, D; Riechers, CC; Natt, O; Sargin, D; Watanabe, T; Sperling, S; Michaelis, T; Price, J; Meyer, B; Frahm, J; Ehrenreich, H			Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin	BRAIN			English	Article						EPO; MRI; neuroprotection; neurodegeneration; neurotrauma; schizophrenia	DENTATE GYRUS; CEREBRAL-ISCHEMIA; HEAD-INJURY; ADULT; NEUROGENESIS; ONSET; NEUROPROTECTION; SCHIZOPHRENIA; EXPRESSION; DISORDER	In humans, neurotrauma is suspected to cause brain atrophy and accelerate slowly progressive neurodegenerative disorders, such as Alzheimer's disease or schizophrenia. However, a direct link between brain injury and subsequent delayed global neurodegeneration has remained elusive. Here we show that juvenile (4-week-old) mice that are given a discrete unilateral lesion of the parietal cortex, develop to adulthood without obvious clinical symptoms. However, when monitored 3 and 9 months after lesioning, using high-resolution three-dimensional MRI and behavioural testing, the same mice display global neurodegenerative changes. Surprisingly, erythropoietin, a haematopoietic growth factor with potent neuroprotective activity, prevents behavioural abnormalities, cognitive dysfunction and brain atrophy when given for 2 weeks after acute brain injury. This demonstrates that a localized brain lesion is a primary cause of delayed global neurodegeneration that can be efficiently counteracted by neuroprotection.	Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Biomed NMR Forsch GmbH, D-37077 Gottingen, Germany; Univ Wurzburg, Sect Expt Neurosurg, Dept Neurosurg, Wurzburg, Germany; Kings Coll London, Inst Psychiat, London WC2R 2LS, England	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Price, Jack/G-9510-2011; Meyer, Bernhard/Q-9413-2016; Meyer, Bernhard/AAH-3329-2019; Siren, Anna-Leena/AAE-1374-2019	Meyer, Bernhard/0000-0001-6486-7955; Siren, Anna-Leena/0000-0002-2217-0081; Watanabe, Takashi/0000-0002-4096-7908; Price, Jack/0000-0003-2235-9180; Ehrenreich, Hannelore/0000-0001-8371-5711; Boretius, Susann/0000-0003-2792-7423			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benedict RHB, 2004, J NEUROIMAGING, V14, p36S, DOI 10.1111/j.1552-6569.2004.tb00277.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; DELATOUR B, IN VIVO MRI HISTOLOG; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Ehrenreich H, 2004, SCIENCE, V305, P184, DOI 10.1126/science.1100891; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Magavi SS, 2000, NATURE, V405, P951; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McAllister TW, 1998, SEMIN CLIN NEUROPSYC, V3, P211; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; Resnick SM, 2003, J NEUROSCI, V23, P3295; Rusinek H, 2003, RADIOLOGY, V229, P691, DOI 10.1148/radiol.2293021299; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schott JM, 2005, NEUROLOGY, V65, P119, DOI 10.1212/01.wnl.0000167542.89697.0f; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Siren AL, 2000, NEUROCHEM RES, V25, P957, DOI 10.1023/A:1007552408463; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sirigu A, 2004, NAT NEUROSCI, V7, P80, DOI 10.1038/nn1160; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu XB, 2002, DEVELOPMENT, V129, P505	48	69	75	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2006	129		2				480	489		10.1093/brain/awh703			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	007JR	WOS:000234965500019	16339796				2021-06-18	
J	Busch, RM; McBride, A; Curtiss, G; Vanderploeg, RD				Busch, RM; McBride, A; Curtiss, G; Vanderploeg, RD			The components of executive functioning in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	111th Annual Convention of the American-Psychological-Association	AUG 07-10, 2003	Toronto, CANADA	Amer Psychol Assoc			FRONTAL-LOBE; RHESUS-MONKEY; PREFRONTAL CORTEX; INTERDIGITATION; PROJECTIONS; ATTENTION; BEHAVIOR; DAMAGE	Theorists have proposed models of executive functioning, and functional neuroimaging and factor analytic studies have attempted to examine the components of executive functioning. These studies have arrived at different conclusions and many empirical studies are wrought with methodological confounds. The purpose of this exploratory study was to investigate the subcomponents of executive abilities while addressing some of the limitations common in previous studies. Neuropsychological test data were obtained from a sample of individuals with a history of TBI seen at one-year follow-up (n = 104). Principal components factor analysis was conducted and yielded three factors that accounted for 52.7% of the variance. The first factor included higher-order executive functions with two components: self-generative behavior and cognitive flexibility/set shifting. The second factor appeared to represent mental control, particularly of ongoing working memory. The third factor consisted of memory errors, representing failure to inhibit reporting of inaccurate information. Although the results are not entirely consistent with any of the current theoretical models of executive function, they appear to be most consistent with the 1986 model of Stuss and Benson.	James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv, 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				AMASIO AR, 1983, NEUROPSYCHOLOGY HUMA, P85; ANDERSON SW, 1993, ACTA PSYCHOL, V82, P193, DOI 10.1016/0001-6918(93)90012-G; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Baddeley A. D., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; Benton A, 1989, MULTILINGUAL APHASIA; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Golden C., 1978, STROOP COLOR WORD TE; Goldman-Rakic P. S., 2002, PRINCIPLES FRONTAL L, P85, DOI DOI 10.1093/ACPR0F:0S0/9780195134971.003.0005; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gorsuch R. L., 1983, FACTOR ANAL; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R., 1993, WISCONSIN CARD SORTI; HEATON RK, 1993, WCST COMPUTER VERSIO; Kane MJ, 2002, PSYCHON B REV, V9, P637, DOI 10.3758/BF03196323; Lezak M.D., 1987, NEUROPSYCHOL REHABIL, P41; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M., 2002, PRINCIPLES FRONTAL L, P188, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0012; NORMAN DA, 1980, COGNITIVE SCI, V4, P1, DOI 10.1207/s15516709cog0401_1; Russell EW., 1993, HALSTEAD RUSSELL NEU; Sarazin M, 2003, J NEUROL, V250, P827, DOI 10.1007/s00415-003-1087-z; SELEMON LD, 1985, J NEUROSCI, V5, P776; SELEMON LD, 1988, J NEUROSCI, V8, P4049; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Shallice T., 2002, PRINCIPLES FRONTAL L, P261, DOI [10.1093/acprof:oso/9780195134971.003.0017, DOI 10.1093/ACPROF:OSO/9780195134971.003.0017]; *SPSS INC, 2002, SPSS STAT PROGR SOC; Strauss ME, 2000, NEUROPSYCHOLOGY, V14, P201, DOI [10.1037/0894-4105.14.2.201, 10.1037//0894-4105.14.2.201]; Stuss D. T., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Vanderploeg RD, 2000, CLIN GUIDE NEUROPSYC; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th	44	69	72	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	2005	27	8					1022	1032		10.1080/13803390490919263			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	977CJ	WOS:000232779700006	16207623				2021-06-18	
J	Cantor, JB; Ashman, TA; Schwartz, ME; Gordon, WA; Hibbard, MR; Brown, M; Spielmar, L; Charatz, HJ; Cheng, ZF				Cantor, JB; Ashman, TA; Schwartz, ME; Gordon, WA; Hibbard, MR; Brown, M; Spielmar, L; Charatz, HJ; Cheng, ZF			The role of self-discrepancy theory in understanding post-traumatic brain injury affective disorders - A pilot study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	82nd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 28-OCT 02, 2005	Chicago, IL	Amer Congress Rehabil Med		affect; anxiety; brain injury; depression; identity; self-discrepancy; TBI	QUALITY-OF-LIFE; SPINAL-CORD-INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; HEAD-INJURY; AXIS-I; PSYCHOSOCIAL ADJUSTMENT; COPING STRATEGIES; RESPONSE SHIFT; ANXIETY	This pilot study examined the utility of self-discrepancy theory (SDT) in explaining post-traumatic brain injury (TBI) depression and anxiety. The SDT model was expanded to include the discrepancy between the postinjury self and the preinjury self. Study participants were 21 individuals with mild to severe TBI residing in the community, who completed the Selves Interview, the Selves Adjective Checklist, the Beck Depression Inventory-II and the Beck Anxiety Inventory. Strong correlations were found between affective distress and setf-discrepancies, as measured by the checklist. Scores on the interview were not related to affective distress. The findings suggest that further research is merited to examine the utility of the SDT in addressing issues of post-TBI depression and anxiety.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Community Med, New York, NY 10029 USA; CUNY, Grad Sch, New York, NY USA; CUNY, Univ Ctr, New York, NY USA	Cantor, JB (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.	josbua.cantor@mssm.edu	Ashman, Teresa/B-1621-2013				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Beck A. T., 1996, BECK DEPRESSION INVE; Beck A.T., 1993; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1999, BRAIN INJURY, V13, P547; BRAY GP, 1978, J APPLIED REHABILITA, V9, P70; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carver CS, 2000, SOC SCI MED, V50, P1715, DOI 10.1016/S0277-9536(99)00412-8; Childers MK, 1998, BRAIN INJURY, V12, P613; Christensen B., 1994, ADV MED PSYCHOTHER, V7, P23; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEMBO T, 1975, REHABIL PSYCHOL, V22, P100; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dunne EA, 2001, J HEALTH PSYCHOL, V6, P679, DOI 10.1177/135910530100600606; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; ERIKSON E, 2003, CHILDHOOD SOC; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; GELSO CJ, 1992, J COUNS PSYCHOL, V39, P275, DOI 10.1037/0022-0167.39.3.275; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Granger C V, 1985, Int Rehabil Med, V7, P45; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hahn H, 1991, PSYCHOL SOCIAL IMPAC, P18; Hewson D, 1997, SOC SCI MED, V44, P1129, DOI 10.1016/S0277-9536(96)00244-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Higgins E. T., 1987, SELF IDENTITY PSYCHO, P173; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; HIGGINS ET, 1986, J PERS SOC PSYCHOL, V51, P5, DOI 10.1037/0022-3514.51.1.5; HIGGINS ET, 1985, SOC COGNITION, V3, P51, DOI 10.1521/soco.1985.3.1.51; Hill C. S. E., 2000, CLIN REHABIL, V14, P279; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hollingsworth Lisa, 2002, Issues Ment Health Nurs, V23, P135, DOI 10.1080/016128402753542776; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kendall E, 1998, J REHABIL, V64, P16; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; KISHI Y, 1994, J NEUROPSYCH CLIN N, V6, P237; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kubler-Ross E., 1969, DEATH DYING; Labbate L A, 2000, Curr Psychiatry Rep, V2, P268, DOI 10.1007/s11920-996-0021-3; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LIVNEH H, 1991, PSYCHOL SOCIAL IMPAC, P111; LIVNEH H, 1990, J APPL REHABIL COUNS, V34, P13; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PEPPER GA, 1977, AM J NURS, V77, P1330; PRIGATANO GP, 1997, DEPRESSION PHYS ILLN, P341; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Russo AA, 1996, ARCH CLIN NEUROPSYCH, V11, P443; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Strauman T. J., 1993, SELF EMOTIONAL DISTR, P3; STRAUMAN TJ, 1992, J ABNORM PSYCHOL, V101, P87, DOI 10.1037/0021-843X.101.1.87; STRAUMAN TJ, 1993, J PERS SOC PSYCHOL, V64, P1042, DOI 10.1037/0022-3514.64.6.1042; Strauman TJ, 1996, J PERS SOC PSYCHOL, V71, P1142, DOI 10.1037/0022-3514.71.6.1142; STRAUMAN TJ, 1989, J ABNORM PSYCHOL, V98, P14, DOI 10.1037/0021-843X.98.1.14; Strauman TJ, 2001, COGNITIVE THER RES, V25, P693, DOI 10.1023/A:1012915205800; STRAUMAN TJ, 1990, J PERS SOC PSYCHOL, V59, P869, DOI 10.1037/0022-3514.59.5.869; STRAUMAN TJ, 1991, J PERS SOC PSYCHOL, V61, P946, DOI 10.1037/0022-3514.61.6.946; STRAUMAN TJ, 2003, SELF SYSTEM THERAPY; Tangney JP, 1998, J PERS SOC PSYCHOL, V75, P256, DOI 10.1037/0022-3514.75.1.256; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Trieschmann R.B., 1988, SPINAL CORD INJURIES, V2nd edition; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wallace CA, 2000, BRAIN INJURY, V14, P549; Waters SJ, 2004, J PAIN SYMPTOM MANAG, V27, P251, DOI 10.1016/j.jpainsymman.2003.07.001; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; WRIGHT B, 1960, PHYS DISABILTIY PSYC; ZOLA IK, 1993, SOC SCI MED, V36, P167, DOI 10.1016/0277-9536(93)90208-L; 1995, ROGETS, V2	114	69	69	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					527	543		10.1097/00001199-200511000-00005			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900005	16304489				2021-06-18	
J	Wood, RL; Liossi, C; Wood, L				Wood, RL; Liossi, C; Wood, L			The impact of head injury neurobehavioural sequelae on personal relationships: Preliminary findings	BRAIN INJURY			English	Article						brain injury; personal relationships; neurobehavioural sequelae	TRAUMATIC BRAIN INJURY; ADJUSTMENT; CAREGIVERS; PATIENT	Background: Existing evidence suggests that neurobehavioural disability is a frequent legacy of serious head trauma and has a major impact on the psychological well-being of relatives and friends of people with brain injuries. Objective: To explore which neurobehavioural legacies of serious head trauma have the greatest impact on personal relationships and increase the risk of relationship breakdown. Method: Forty-eight partners of people who had suffered serious head trauma were asked to complete a 12-item measure to rate how different neurobehavioural characteristics had adversely affected their relationship with the brain injured person. Twenty-three couples who had divorced or separated from their injured partner in the years following injury comprised the 'separated' group, 25 still in the relationship at the time data were collected comprised the 'together' group. Results: Even though many neurobehavioural characteristics of brain injury were reported by partners of both the separated and the together group as placing a strain on the relationship only mood swings accounted for a significant between groups difference [t(40.13) = 3.33, p = 0.002]. The magnitude of the difference in the means was large (eta(2) = 0.19). Conclusions: Unpredictable patterns of behaviour, as perceived by partners of brain injured individuals, impose the greatest burden on personal relationships and may contribute to relationship breakdown.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales; HMP Leyhill, Gloucester, England	Wood, RL (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Liossi, Christina/0000-0003-0627-6377			Amato PR, 1997, J MARRIAGE FAM, V59, P612, DOI 10.2307/353949; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cohen, 1981, MODELS CLIN PSYCHOPA, P177, DOI DOI 10.1007/978-94-015-7129-6; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P508; HOLM S, 1979, SCAND J STAT, V6, P65; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; NOVACK TA, 1987, ARCH PHYS MED REHAB, V68, P729; Panting A., 1972, REHABILITATION, V38, P33; RODRIGUE JR, 1994, PSYCHO-ONCOLOGY, V3, P205, DOI 10.1002/pon.2960030307; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VELLEMAN PF, 1993, AM STAT, V47, P65, DOI 10.2307/2684788; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; Wolcott I., 1999, 20 AUSTR I FAM STUD; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	23	69	70	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2005	19	10					845	851		10.1080/02699050500058778			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800010	16175844				2021-06-18	
J	Floyd, CL; Gorin, FA; Lyeth, BG				Floyd, CL; Gorin, FA; Lyeth, BG			Mechanical strain injury increases intracellular sodium and reverses Na+/Ca2+ exchange in cortical astrocytes	GLIA			English	Article						traumatic brain injury; Fura-2; calcium; SBFI-AM; KB-R7943; TBOA; glutamate	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; STRETCH-INDUCED INJURY; THREO-BETA-BENZYLOXYASPARTATE; RAT HIPPOCAMPAL ASTROCYTES; EXTRACELLULAR ION SHIFTS; CULTURED ASTROCYTES; AXONAL INJURY; GLUTAMATE RELEASE; HYPOXIC/HYPOGLYCEMIC INJURY	Traditionally, astrocytes have been considered less susceptible to injury than neurons. Yet, we have recently shown that astrocyte death precedes neuronal death in a rat model of traumatic brain injury (TBI) (Zhao et al.: Glia 44:140152, 2003). A main mechanism hypothesized to contribute to cellular injury and death after TBI is elevated intracellular calcium ([Ca2+](i)). Since calcium regulation is also influenced by regulation of intracellular sodium ([Na+](i)), we used an in vitro model of strain-induced traumatic injury and live-cell fluorescent digital imaging to investigate alterations in [Na+](i) in cortical astrocytes after injury. Changes in [Na+](i), or [Ca2+](i) were monitored after mechanical injury or L-glutamate exposure by ratiometric imaging of sodium-binding benzofuran isophthalate (SBFI-AM), or Fura-2-AM, respectively. Mechanical strain injury or exogenous glutamate application produced increases in [Na+](i) that were dependent on the severity of injury or concentration. Injury-induced increases in [Na+](i) were significantly reduced, but not completely eliminated, by inhibition of glutamate uptake by DL-threo-beta-benzyloxyaspartate (TBOA). Blockade of sodium-dependent calcium influx through the odium-calcium exchanger with 2-[2-[4-(4-Nitrobenzyloxy)-)phenyl]ethyl]isothiourea mesylate (KB-R7943) reduced Ca2+](i) after injury. KB-R7943 also reduced astrocyte death after injury. These findings suggest that in astrocytes subjected to mechanical injury or glutamate excitotoxicity, in intracellular Na+ may be a critical component in the injury cascade and a therapeutic target for reduction A lasting deficits after traumatic brain injury. (C) 2005 Wiley-Liss, Inc.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Neurol, Ctr Neurosci, Davis, CA 95616 USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS043085, R01NS040489, R01NS045136, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS043085, NS 45136, R01 NS045136, R01 NS029995, R01 NS040489-03, NS 43085, R01 NS040489-01A1, NS 40489, R01 NS040489-02, NS 29995, R01 NS040489] Funding Source: Medline		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Anderson CM, 2000, GLIA, V32, P1; Arakawa N, 2000, BIOCHEM BIOPH RES CO, V279, P354, DOI 10.1006/bbrc.2000.3968; Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; ASCHNER M, 1991, NEUROTOXICOLOGY, V12, P505; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Blaustein MP, 1999, PHYSIOL REV, V79, P763; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Chatton JY, 2001, BRAIN RES, V893, P46, DOI 10.1016/S0006-8993(00)03286-8; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONDORELLI DF, 1993, J NEUROSCI RES, V36, P344, DOI 10.1002/jnr.490360312; Czyz A, 2002, J NEUROCHEM, V83, P1321, DOI 10.1046/j.1471-4159.2002.01227.x; Dong H, 2002, ANN NY ACAD SCI, V976, P159; Duan SM, 2003, J NEUROSCI, V23, P1320; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Fern R, 1997, CLIN NEUROSCI, V4, P246; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hansson E, 1997, ACT NEUR S, V70, P148; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hertz L, 1998, METHODS, V16, P293, DOI 10.1006/meth.1998.0686; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; Povlishock JT, 1999, ACT NEUR S, V73, P15; Rose CR, 1996, J NEUROSCI, V16, P5393; Rose CR, 1998, J NEUROSCI, V18, P3554; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scemes E, 2000, MOL NEUROBIOL, V22, P167, DOI 10.1385/MN:22:1-3:167; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shelton MK, 1999, GLIA, V26, P1, DOI 10.1002/(SICI)1098-1136(199903)26:1<1::AID-GLIA1>3.0.CO;2-Z; Shimamoto K, 1998, MOL PHARMACOL, V53, P195; Somjen George G., 1995, P319; Takahashi S, 2000, EUR J PHARMACOL, V408, P127, DOI 10.1016/S0014-2999(00)00790-1; Tomes Daniel J, 2002, Spine J, V2, P35, DOI 10.1016/S1529-9430(01)00151-6; Waagepetersen HS, 2001, NEUROCHEM RES, V26, P661, DOI 10.1023/A:1010939304104; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	84	69	76	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2005	51	1					35	46		10.1002/glia.20183			12	Neurosciences	Neurosciences & Neurology	934IZ	WOS:000229703800004	15779085	Green Accepted			2021-06-18	
J	Mailhan, L; Azouvi, P; Dazord, A				Mailhan, L; Azouvi, P; Dazord, A			Life satisfaction and disability after severe traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	3rd World Congress in Neurological Rehabilitation	APR 02-06, 2002	VENICE, ITALY				QUALITY-OF-LIFE; BLUNT HEAD-INJURY; RATING-SCALE; REHABILITATION; EMPLOYMENT; RELATIVES; OUTCOMES; PROFILE; SAMPLE; COMA	Objective: To assess the relationships between life satisfaction and disability after a severe traumatic brain injury (TBI). Design: Cross-sectional study, including 75 patients 2 years or more after a severe TBI. Methods: Life satisfaction was assessed with the Subjective Quality of Life Profile. Impairments, activities and participation were assessed with standardized tests. Results: The satisfaction profile was flat, i.e. the majority of items obtained mean satisfaction scores close to 0, suggesting that participants felt indifferent to these items or in other words that they were neither satisfied nor unsatisfied. Patients were on average slightly dissatisfied with their cognitive functions, physical abilities and self-esteem. A factor analysis revealed three underlying factors. The main finding was that the relationships between life satisfaction and disability were not linear: the lowest satisfaction scores were reported by participants with moderate disability rated by the Glasgow Outcome Scale, while individuals with severe disability did not significantly differ from the good recovery group. Conclusion: Life satisfaction is not linearly related to disability after severe TBI.	Univ Versailles, Hop Raymond Poincare, Dept Neurol Rehabil,Serv Reeduc Neurol, Format Rech Associee Claude Bernard, F-92380 Garches, France; Univ Versailles, Hop Raymond Poincare, Fac Med Paris Ile France Ouest, INSERM,U483, F-92380 Garches, France; Hop St Jean de Dieu, Script Inserm, Lyon, France	Azouvi, P (corresponding author), Univ Versailles, Hop Raymond Poincare, Dept Neurol Rehabil,Serv Reeduc Neurol, Format Rech Associee Claude Bernard, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr					Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; AZOUVI P, UNPUB LIFE SATISFACT; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Bonomi AE, 2000, J CLIN EPIDEMIOL, V53, P1, DOI 10.1016/S0895-4356(99)00123-7; Bonomi AE, 2000, J CLIN EPIDEMIOL, V53, P19, DOI 10.1016/S0895-4356(99)00121-3; Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dazord A, 1996, EUR PSYCHIAT, V11, P277, DOI 10.1016/S0924-9338(96)89895-6; Dazord A, 1998, EUR PSYCHIAT, V13, P235, DOI 10.1016/S0924-9338(98)80011-4; Dazord A, 1998, COMMUNITY MENT HLT J, V34, P525, DOI 10.1023/A:1018746614552; DAZORD A, 1994, QUALITY LIFE ASSESSM, P185; DAZORD A, 1997, QUALITY LIFE NEWSLET, V18, P7; Dehail P., 1998, Annales de Readaptation et de Medecine Physique, V41, P133, DOI 10.1016/S0168-6054(98)80011-1; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; GERIN P, 1992, FUNDAM CLIN PHARM, V6, P263, DOI 10.1111/j.1472-8206.1992.tb00120.x; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LORHANDICAP GDR, 2000, REV SCI HUMAINES SOC, V88, P1; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Morton RP, 2003, LARYNGOSCOPE, V113, P1091, DOI 10.1097/00005537-200307000-00001; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Riegel B, 2003, QUAL LIFE RES, V12, P689, DOI 10.1023/A:1025132623647; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Truelle J L, 1990, Brain Inj, V4, P305, DOI 10.3109/02699059009026181; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 2001, BRAIN DAM B, P3	56	69	71	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					227	238		10.1080/02699050410001720149			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400001	15832869				2021-06-18	
J	Germano, C; Kinsella, GJ				Germano, C; Kinsella, GJ			Working memory and learning in early Alzheimer's disease	NEUROPSYCHOLOGY REVIEW			English	Article						early Alzheimer's disease; working memory; learning; acquisition	TRAUMATIC BRAIN INJURY; MINI-MENTAL-STATE; FRONTOTEMPORAL DEMENTIA; NEUROPSYCHOLOGICAL MEASURES; EXECUTIVE FUNCTION; DIVIDED ATTENTION; RETRIEVAL; IMPAIRMENT; PATTERNS; DEFICITS	Cognitive deficits associated with early Alzheimer's disease (AD) have been recently operationalised in terms of an acquisition deficit and the research supporting this view is presented. However, there is still debate concerning the nature of this deficit and how underlying cognitive processes may be detrimentally affecting the ability to acquire new information in early AD. This review argues that the pattern of cognitive deficits contributing to the acquisition impairment in early AD patients may be readily interpreted within the context of a working memory model. Isolating the component processes of working memory that underlie the acquisition deficit in early AD patients will aid in the design of clinical applications that are focussed at enhancing the ability to acquire new information in everyday life.	La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia	Kinsella, GJ (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia.	g.kinsella@latrobe.edu.au	Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Backman L, 1998, PSYCHOL AGING, V13, P267; BADDELEY A, 1992, SCIENCE, V255, P556, DOI 10.1126/science.1736359; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Baddeley A, 2002, NEUROPSYCHOLOGIA, V40, P1737, DOI 10.1016/S0028-3932(01)00146-4; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; BADDELEY A, 1997, COGNITIVE MODELS MEM, P61; Baddeley A.D., 1999, MODELS WORKING MEMOR, P28, DOI DOI 10.1017/CBO9781139174909.005; Baddeley AD, 2000, J EXP PSYCHOL GEN, V129, P126, DOI 10.1037//0096-3445.129.1.126; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; Baddeley AD, 2000, J EXP CHILD PSYCHOL, V77, P128, DOI 10.1006/jecp.2000.2592; Baddeley AD., 1974, PSYCHOL LEARNING MOT; BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9; Belleville S, 1996, NEUROPSYCHOLOGIA, V34, P195, DOI 10.1016/0028-3932(95)00097-6; Bird M, 2001, NEUROPSYCHOL REHABIL, V11, P357, DOI 10.1080/09602010042000042; Brown S.C., 2000, OXFORD HDB MEMORY, P93, DOI DOI 10.1016/J.ADOLESCENCE.2017.05.018; Cahn D A, 1997, J Int Neuropsychol Soc, V3, P387; Cannata AP, 2002, DEMENT GERIATR COGN, V13, P101, DOI 10.1159/000048641; Carlesimo GA, 1998, J CLIN EXP NEUROPSYC, V20, P14, DOI 10.1076/jcen.20.1.14.1482; CHERRY KE, 1999, J CLIN GEROPSYCHOLOG, V5, P159, DOI DOI 10.1023/A:1022983131186; Collette F, 1999, NEUROPSYCHOLOGIA, V37, P905, DOI 10.1016/S0028-3932(98)00148-1; Collette F, 1999, CORTEX, V35, P57, DOI 10.1016/S0010-9452(08)70785-8; CRONINGOLOMB A, 1992, PSYCHOL AGING, V7, P359, DOI 10.1037/0882-7974.7.3.359; Crowell TA, 2002, AGING NEUROPSYCHOL C, V9, P288, DOI 10.1076/anec.9.4.288.8772; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Dorrego MF, 1999, J NEUROPSYCH CLIN N, V11, P490, DOI 10.1176/jnp.11.4.490; Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160; Fernandes MA, 2000, J EXP PSYCHOL GEN, V129, P155, DOI 10.1037/0096-3445.129.2.155; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox N C, 1999, Rev Neurol (Paris), V155 Suppl 4, pS33; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; Glosser G, 2002, NEUROPSYCHOLOGY, V16, P190, DOI 10.1037//0894-4105.16.2.190; GRANHOLM E, 1988, BRAIN COGNITION, V7, P335, DOI 10.1016/0278-2626(88)90007-3; Greene JDW, 1996, NEUROPSYCHOLOGIA, V34, P537, DOI 10.1016/0028-3932(95)00151-4; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P667, DOI 10.1080/01688639108401081; Grober E, 1997, PSYCHOL AGING, V12, P183, DOI 10.1037/0882-7974.12.1.183; GROBER E, 1985, BRAIN LANG, V26, P276, DOI 10.1016/0093-934X(85)90043-4; HAXBY JV, 1988, NEUROLOGY, V38, P1853, DOI 10.1212/WNL.38.12.1853; HILL RD, 2000, COGNITIVE REHABILITA, P23; Hodges JR, 2000, OXFORD HDB MEMORY, P441; Kellogg RT, 1996, AM J PSYCHOL, V109, P205, DOI 10.2307/1423273; KOPELMAN MD, 1985, NEUROPSYCHOLOGIA, V23, P623, DOI 10.1016/0028-3932(85)90064-8; LAFLECHE G, 1995, NEUROPSYCHOLOGY, V9, P313, DOI 10.1037/0894-4105.9.3.313; Lipinska B, 1997, BRAIN COGNITION, V34, P274, DOI 10.1006/brcg.1997.0916; LOGIE RH, 1996, WORKING MEMORY HUMAN, P31; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miyake A, 2001, J EXP PSYCHOL GEN, V130, P621, DOI 10.1037/0096-3445.130.4.621; MORRIS RG, 1984, COGNITIVE NEUROPSYCH, V1, P143, DOI 10.1080/02643298408252019; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; MOSCOVITCH M, 1991, PERSPECTIVES COGNITI, P229; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524, DOI DOI 10.1037/0894-4105.8.4.524; Naveh-Benjamin M, 2000, Q J EXP PSYCHOL-A, V53, P609, DOI 10.1080/027249800410454; O'Hara R, 2000, WESTERN J MED, V172, P115, DOI 10.1136/ewjm.172.2.115; PARASURAMAN R, 1992, BRAIN, V115, P711, DOI 10.1093/brain/115.3.711; PARKIN AJ, 1997, MEMORY AMNESIA INTRO, P124; Pasquier F, 2001, NEUROCASE, V7, P161, DOI 10.1093/neucas/7.2.161; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Perry RJ, 2000, NEUROLOGY, V54, P2277, DOI 10.1212/WNL.54.12.2277; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; Reid W, 1996, ARCH NEUROL-CHICAGO, V53, P1056, DOI 10.1001/archneur.1996.00550100142023; Rochon E, 2000, J SPEECH LANG HEAR R, V43, P395, DOI 10.1044/jslhr.4302.395; Rosen VM, 2002, NEUROPSYCHOLOGIA, V40, P2226, DOI 10.1016/S0028-3932(02)00132-X; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; SGARAMELLA TM, 2001, TENNET, V11, P264; SIMON E, 1994, J CLIN EXP NEUROPSYC, V16, P414, DOI 10.1080/01688639408402652; SPINNLER H, 1988, COGNITIVE NEUROPSYCH, V5, P193, DOI 10.1080/02643298808252933; Storey E, 2002, FRONT BIOSCI-LANDMRK, V7, pE155, DOI 10.2741/storey; Storey E, 2001, J ALZHEIMERS DIS, V3, P261, DOI 10.3233/JAD-2001-3302; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; WENGER JL, 1995, J EXP PSYCHOL HUMAN, V21, P170; WILSON RS, 1983, J CLIN NEUROPSYCHOL, V5, P337, DOI 10.1080/01688638308401181	82	69	72	0	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1040-7308	1573-6660		NEUROPSYCHOL REV	Neuropsychol. Rev.	MAR	2005	15	1					1	10		10.1007/s11065-005-3583-7			10	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	920EZ	WOS:000228673500001	15929495				2021-06-18	
J	Zhong, CL; Zhao, XR; Sarva, J; Kozikowski, A; Neale, JH; Lyeth, BG				Zhong, CL; Zhao, XR; Sarva, J; Kozikowski, A; Neale, JH; Lyeth, BG			NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetylaspartylglutamate (NAAG); fluid percussion; glutamate; hippocampus; metabotropic glutamate receptor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; METABOTROPIC GLUTAMATE-RECEPTOR; EXCITATORY AMINO-ACIDS; N-ACETYLASPARTYLGLUTAMATE; GROUP-II; CARBOXYPEPTIDASE-II; NEUROPROTECTIVE ACTIVITY; ARBITRARY PARTICLES; BEHAVIORAL DEFICITS; FLUORO-JADE	Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate associated with excitotoxicity and secondary brain pathology. The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) suppresses glutamate transmission through selective activation of presynaptic Group II metabotropic glutamate receptor subtype 3 (mGluR3). Thus, inhibition of NAAG peptidase activity and the prolong presence of synaptic NAAG were hypothesized to have significant potential for cellular protection following TBI. In the present study, a novel NAAG peptidase inhibitor, ZJ-43, was used in four different doses (0, 50, 100, or 150 mg/kg). Each dose was repeatedly administered i.p. (n = 5/group) by multiple injections at three times (0 time, 8 h, 16 h) after moderate lateral fluid percussion TBI in the rat. An additional group was co-administered ZJ-43 (150 mg/kg) and the Group II mGluR antagonist, LY341495 (1 mg/kg), which was predicted to abolish any protective effects of ZJ-43. Rats were euthanized at 24 h after TBI, and brains were processed with a selective marker for degenerating neurons (Fluoro-Jade B) and a marker for astrocytes (GFAP). Ipsilateral neuronal degeneration and bilateral astrocyte loss in the CA2/3 regions of the hippocampus were quantified using stereological techniques. Compared with vehicle, ZJ-43 significantly reduced the number of the ipsilateral degenerating neurons (p < 0.01) with the greatest neuroprotection at the 50 mg/kg dose. Moreover, LY341495 successfully abolished the protective effects of ZJ-43. 50 mg/kg of ZJ-43 also significantly reduced the ipsilateral astrocyte loss (p < 0.05). We conclude that the NAAG peptidase inhibitor ZJ-43 is a potential novel strategy to reduce both neuronal and astrocyte damage associated with the glutamate excitotoxicity after TBI.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA; Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA; Georgetown Univ, Dept Biol, Washington, DC USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Ct,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 42672, NS 45136] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS042672, R01NS045136] Funding Source: NIH RePORTER		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Bischofberger J, 1996, J NEUROPHYSIOL, V76, P2089; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hansson E, 1997, ACT NEUR S, V70, P148; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riba-Bosch A, 2004, NEUROSCIENCE, V125, P803, DOI 10.1016/j.neuroscience.2004.02.017; Rong SB, 2002, J MED CHEM, V45, P4140, DOI 10.1021/jm010561g; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Takahashi M, 1997, J EXP BIOL, V200, P401; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; Xi ZX, 2002, J PHARMACOL EXP THER, V300, P162, DOI 10.1124/jpet.300.1.162; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, BRAIN RES, V909, P138, DOI 10.1016/S0006-8993(01)02650-6; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zhang W, 2002, J NEUROL SCI, V194, P21, DOI 10.1016/S0022-510X(01)00670-0; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhao ZX, 2001, SOLID STATE SCI, V3, P339, DOI 10.1016/S1293-2558(00)01087-6; Zucchini S, 2002, NEUROREPORT, V13, P2071, DOI 10.1097/00001756-200211150-00016; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	46	69	71	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					266	276		10.1089/neu.2005.22.266			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400006	15716632				2021-06-18	
J	Anderson, AJ; Robert, S; Huang, WC; Young, W; Cotman, CW				Anderson, AJ; Robert, S; Huang, WC; Young, W; Cotman, CW			Activation of complement pathways after contusion-induced spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						complement cascade; demyelination; immune response; inflammation; neuron; neurodegeneration; oligodendrocyte	MEMBRANE ATTACK COMPLEX; TRAUMATIC BRAIN-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; NERVOUS-SYSTEM; ADULT-RAT; BLOOD-BRAIN; ALZHEIMERS-DISEASE	Previous studies have shown that a cellular inflammatory response is initiated, and inflammatory cytokines are synthesized, following experimental spinal cord injury (SCI). In the present study, we tested the hypothesis that the complement cascade, a major component of both the innate and adaptive immune response, is also activated following experimental SCI. We investigated the pathways, cellular localization, timecourse, and degree of complement activation in rat spinal cord following acute contusion-induced SCI using the New York University (NYU) weight drop impactor. Mild and severe injuries (12.5 and 50 mm drop heights) at 1, 7, and 42 days post injury time points were evaluated. Classical (C1q and C4), alternative (Factor B) and terminal (C5b-9) complement pathways were strongly activated within 1 day of SCI. Complement protein immunoreactivity was predominantly found in cell types vulnerable to degeneration, neurons and oligodendrocytes, and was not generally observed in inflammatory or astroglial cells. Surprisingly, immunoreactivity for complement proteins was also evident 6 weeks after injury, and complement activation was observed as far as 20 mm rostral to the site of injury. Axonal staining by C1q and Factor B was also observed, suggesting a potential role for the complement cascade in demyelination or axonal degeneration. These data support the hypothesis that complement activation plays a role in SCI.	Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Anat, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Neurobiol, Irvine, CA 92696 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA; State Univ New Jersey, Ctr Neurosci, Piscataway, NJ USA	Anderson, AJ (corresponding author), Univ Calif Irvine, Reeve Irvine Res Ctr, 1107 Gillespie Neurosci Facil, Irvine, CA 92696 USA.	aja@uci.edu	Anderson, Aileen J/H-5926-2012		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-043428-01A1] Funding Source: Medline		Agoropoulou C, 1996, NEUROREPORT, V7, P997, DOI 10.1097/00001756-199604100-00009; Agoropoulou C, 1998, NEUROREPORT, V9, P927, DOI 10.1097/00001756-199803300-00030; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bhat RV, 1996, GLIA, V17, P169; Birdsall HH, 1997, CIRCULATION, V95, P684, DOI 10.1161/01.CIR.95.3.684; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Bracken MB, 2000, J TRAUMA, V48, P558, DOI 10.1097/00005373-200003000-00036; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BRUCK W, 1990, ACTA NEUROPATHOL, V80, P415; BRUCK W, 1995, ACTA NEUROPATHOL, V90, P601; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Dailey AT, 1998, J NEUROSCI, V18, P6713; Dashiell SM, 1999, J NEUROCHEM, V73, P2321, DOI 10.1046/j.1471-4159.1999.0732321.x; Dashiell SM, 2000, GLIA, V30, P187, DOI 10.1002/(SICI)1098-1136(200004)30:2<187::AID-GLIA8>3.0.CO;2-7; Davoust N, 1999, J IMMUNOL, V163, P6551; DeJong BA, 1997, NEUROCHEM RES, V22, P491, DOI 10.1023/A:1027372129989; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Dyer JK, 1998, EXP NEUROL, V154, P12, DOI 10.1006/exnr.1998.6905; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Eikelenboom P, 1996, NEUROBIOL AGING, V17, P673; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Ferrari S, 1998, ACTA NEUROPATHOL, V96, P569, DOI 10.1007/s004010050937; GASQUE P, 1995, J IMMUNOL, V154, P4726; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI12837; Hauben E, 2001, P NATL ACAD SCI USA, V98, P15173, DOI 10.1073/pnas.011585298; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; ITAGAKI S, 1994, BRAIN RES, V645, P78, DOI 10.1016/0006-8993(94)91640-3; Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9; Johnson SA, 1996, EXP NEUROL, V138, P198, DOI 10.1006/exnr.1996.0058; Jung S, 1995, NEUROSCI LETT, V200, P167, DOI 10.1016/0304-3940(95)12115-K; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Keirstead HS, 1998, EXP NEUROL, V151, P303, DOI 10.1006/exnr.1998.6806; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Liu L, 1998, GLIA, V23, P221, DOI 10.1002/(SICI)1098-1136(199807)23:3<221::AID-GLIA5>3.0.CO;2-7; LIU L, 1995, NEUROSCIENCE, V68, P167, DOI 10.1016/0306-4522(95)00103-P; Makrides SC, 1998, PHARMACOL REV, V50, P59; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; MORGAN BP, 1989, BIOCHEM J, V264, P1; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; Mosley K, 1996, NEUROCHEM RES, V21, P481, DOI 10.1007/BF02527713; NASO WB, 1995, NEUROSCI LETT, V189, P176, DOI 10.1016/0304-3940(95)11473-A; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Olby NJ, 1996, EXP NEUROL, V138, P82, DOI 10.1006/exnr.1996.0049; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; Piddlesden SJ, 1996, J NEUROIMMUNOL, V71, P173, DOI 10.1016/S0165-5728(96)00144-0; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; ROZOVSKY I, 1994, NEUROSCIENCE, V62, P741, DOI 10.1016/0306-4522(94)90473-1; Rus HG, 1996, J IMMUNOL, V156, P4892; SAIJA A, 1995, LIFE SCI, V56, P775, DOI 10.1016/0024-3205(95)00008-T; Schwartz M, 2002, SCIENCE, V296, P1400; SCOLDING NJ, 1989, J NEUROL SCI, V89, P289, DOI 10.1016/0022-510X(89)90030-0; SCOLDING NJ, 1989, IMMUNOLOGY, V67, P441; SHEN Y, 1995, BRAIN RES, V671, P282, DOI 10.1016/0006-8993(94)01264-I; Shen Y, 1997, BRAIN RES PROTOC, V1, P186, DOI 10.1016/S1385-299X(96)00026-8; SHIRAZI Y, 1993, J IMMUNOL, V150, P4581; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Soane L, 1999, J IMMUNOL, V163, P6132; Soane L, 2001, J IMMUNOL, V167, P2305, DOI 10.4049/jimmunol.167.4.2305; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290; Vasthare US, 1998, BRAIN RES BULL, V45, P413, DOI 10.1016/S0361-9230(97)00408-5; Walsh MJ, 1998, J CLIN INVEST, V101, P1923, DOI 10.1172/JCI1983; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	99	69	73	0	2	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1831	1846		10.1089/0897715042664894			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400012	15684772				2021-06-18	
J	Longhi, L; Watson, DJ; Saatman, KE; Thompson, HJ; Zhang, C; Fujimoto, S; Royo, N; Castelbuono, D; Raghupathi, R; Trojanowski, JQ; Lee, VMY; Wolfe, JH; Stocchetti, N; McIntosh, TK				Longhi, L; Watson, DJ; Saatman, KE; Thompson, HJ; Zhang, C; Fujimoto, S; Royo, N; Castelbuono, D; Raghupathi, R; Trojanowski, JQ; Lee, VMY; Wolfe, JH; Stocchetti, N; McIntosh, TK			Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; gene therapy; nerve growth factor; neurotrophins	NERVE GROWTH-FACTOR; CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; VESICULAR ACETYLCHOLINE TRANSPORTER; CELL-LINE; CHOLINERGIC INNERVATION; NEURAL TRANSPLANTATION; FUNCTIONAL RECOVERY; TRANSGENIC MOUSE; MESSENGER-RNA	Infusion of nerve growth factor (NGF) has been shown to be neuroprotective following traumatic brain injury (TBI). In this study, we tested the hypothesis that NGF-expressing human NT2N neurons transplanted into the basal forebrain of brain-injured mice can attenuate long-term cognitive dysfunction associated with TBI. Undifferentiated NT2 cells were transduced in vitro with a lentiviral vector to release NGF, differentiated into NT2N neurons by exposure to retinoic acid and transplanted into the medial septum of mice 24 h following controlled cortical impact (CCI) brain injury or sham injury. Adult mice (n = 78) were randomly assigned to one of four groups: (1) sham-injured and vehicle (serum-free medium)-treated, (2) brain-injured and vehicle-treated, (3) brain-injured engrafted with untransduced NT2N neurons, and (4) brain-injured engrafted with transduced NGF-NT2N neurons. All groups were immunosuppressed daily with cyclosporin A (CsA) for 4 weeks. At 1 month post-transplantation, animals engrafted with NGF-expressing NT2N neurons showed significantly improved learning ability (evaluated with the Morris water maze) compared to brain-injured mice receiving either vehicle (p < 0.05) or untransduced NT2N neurons (p < 0.01). No effect of NGF-secreting NT2N cells on motor function deficits at 1-4 weeks post-transplantation was observed. These data suggest that NGF gene therapy using transduced NT2N neurons (as a source of delivery) may selectively improve cognitive function following TBI.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; IRCCS, Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Drexel Univ, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK42707] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38690, P50-NS08803, R01-NS40978, NS11024] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK042707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803, F32NS011024] Funding Source: NIH RePORTER		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; Blesch A, 1998, PROG BRAIN RES, V117, P473; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conte V., 2003, EUR J TRAUMA, V29, P335; Conti AC, 1998, J NEUROSCI, V18, P5663; COOK DG, 1994, METHOD CELL BIOL, V43, P289; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1997, J NEUROTRAUM, V14, P159; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; Galpern WR, 1996, NEUROREPORT, V7, P2639, DOI 10.1097/00001756-199611040-00046; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Hartley RS, 1999, J COMP NEUROL, V415, P404, DOI 10.1002/(SICI)1096-9861(19991220)415:3<404::AID-CNE6>3.0.CO;2-R; HIGGINS GA, 1989, NEURON, V3, P247, DOI 10.1016/0896-6273(89)90038-X; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Kawaja MD, 1998, EUR J NEUROSCI, V10, P2207, DOI 10.1046/j.1460-9568.1998.00228.x; Kimpinski K, 1999, NEUROSCIENCE, V93, P253, DOI 10.1016/S0306-4522(99)00156-6; KITT CA, 1994, J COMP NEUROL, V341, P117, DOI 10.1002/cne.903410110; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; NEFTI F, 1986, J NEUROSCI, V6, P2155; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; ROYO NC, 2002, J NEUROTRAUM, V19, P1362; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Saragovi HU, 2000, TRENDS PHARMACOL SCI, V21, P93, DOI 10.1016/S0165-6147(99)01444-3; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Tuszynski MH, 2000, CELL TRANSPLANT, V9, P629, DOI 10.1177/096368970000900508; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Watson Deborah J, 2003, Methods Mol Med, V76, P383; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	79	69	70	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1723	1736		10.1089/0897715042664876			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400004	15684764				2021-06-18	
J	Koh, SH; Park, Y; Song, CW; Kim, JG; Kim, K; Kim, J; Kim, MH; Lee, SR; Kim, DW; Yu, HJ; Chang, DI; Hwang, SJ; Kim, SH				Koh, SH; Park, Y; Song, CW; Kim, JG; Kim, K; Kim, J; Kim, MH; Lee, SR; Kim, DW; Yu, HJ; Chang, DI; Hwang, SJ; Kim, SH			The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						neuroinflammation; neuronal cell death; PARP; stroke; survival factors	TRAUMATIC BRAIN-INJURY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; INTERCELLULAR-ADHESION MOLECULE-1; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; RAT-BRAIN; SYNTHETASE ACTIVATION; ENDOTHELIAL-CELLS; ADP-RIBOSYLATION; DNA-DAMAGE	Poly(ADP-ribose) polymerase (PARP) plays an important role in ischaemic cell death, and 3-aminobenzamide (3-AB), one of the PARP inhibitors, has a protective effect on ischaemic stroke. We investigated the neuroprotective mechanisms of 3-AB in ischaemic stroke. The occlusion of middle cerebral artery (MCA) was made in 170 Sprague-Dawley rats, and reperfusion was performed 2 h after the occlusion. Another 10 Sprague-Dawley rats were used for sham operation. 3-AB was administered to 85 rats 10 min before the occlusion [3-AB group (n = 85) vs. control group without 3-AB (n = 85)]. Infarct volume and water content were measured, brain magnetic resonance imaging, terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick end-labelling (TUNEL) and Cresyl violet staining were performed, and immunoreactivities (IRs) of poly(ADP-ribose) polymer (PAR), cleaved caspase-3, CD11b, intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), phospho-Akt (pAkt) and phospho-glycogen synthase kinase-3 (pGSK-3) were compared in the peri-infarcted region of the 3-AB group and its corresponding ischaemic region of the control group at 2, 8, 24 and 72 h after the occlusion. In the 3-AB group, the infarct volume and the water content were decreased (about 45% and 3.6%, respectively, at 24 h), the number of TUNEL-positive cells was decreased (about 36% at 24 h), and the IRs of PAR, cleaved caspase-3, CD11b, ICAM-1 and COX-2 were significantly reduced, while the IRs of pAkt and pGSK-3 were increased. These results suggest that 3-AB treatment could reduce the infarct volume by reducing ischaemic cell death, its related inflammation and increasing survival signals. The inhibition of PARP could be another potential neuroprotective strategy in ischaemic stroke.	Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea; KFDA, Natl Inst Toxicol Res, Div Neurotoxicol, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Radiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Anaesthesiol, Seoul 133791, South Korea; Bundang Jesaeng Hosp, Dept Neurol, Gyeonggi Do, South Korea; Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Anat, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Inst Mental Hlth, Seoul 133791, South Korea	Kim, SH (corresponding author), Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea.	kimsh1@hanyang.ac.kr	Chang, Dae-il/AAJ-5290-2020; Park, Yongsoon/E-6968-2017; Kim, Seung Hyun/T-5133-2017	Park, Yongsoon/0000-0001-5110-5716; Kim, Seung Hyun/0000-0001-9644-9598			AALTO TK, 1993, PEDIATR RES, V34, P572, DOI 10.1203/00006450-199311000-00004; Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; BARNETT HJM, 1998, STROKE; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; Czapski GA, 2004, NEUROSCI LETT, V356, P45, DOI 10.1016/j.neulet.2003.11.022; Diez J, 1998, CURR OPIN CARDIOL, V13, P317, DOI 10.1097/00001573-199809000-00005; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; He JL, 2001, J PHARMACOL EXP THER, V298, P180; HIROMATSU Y, 1993, IMMUNOLOGY, V80, P330; IKAI K, 1980, J HISTOCHEM CYTOCHEM, V28, P670, DOI 10.1177/28.7.6993553; Kametsu Y, 2003, J CEREBR BLOOD F MET, V23, P416, DOI 10.1097/01.WCB.0000052281.23292.7C; Kim SH, 2004, NEUROLOGY, V62, P319, DOI 10.1212/01.WNL.0000103291.04985.DC; Kim SH, 2003, J NEUROPATH EXP NEUR, V62, P88, DOI 10.1093/jnen/62.1.88; Koh SH, 2003, MOL BRAIN RES, V118, P72, DOI 10.1016/j.molbrainres.2003.07.003; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Love S, 1999, NEUROPATH APPL NEURO, V25, P98; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mazzon E, 2002, BIOCHEM PHARMACOL, V64, P327, DOI 10.1016/S0006-2952(02)01075-4; OGURA T, 1990, BIOCHEM BIOPH RES CO, V172, P377, DOI 10.1016/0006-291X(90)90683-E; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Strosznajder RP, 2003, J MOL NEUROSCI, V20, P61, DOI 10.1385/JMN:20:1:61; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; Welch K. M. A., 1997, PRIMER CEREBROVASCUL; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	52	69	70	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	SEP	2004	20	6					1461	1472		10.1111/j.1460-9568.2004.03632.x			12	Neurosciences	Neurosciences & Neurology	852GV	WOS:000223744600004	15355313				2021-06-18	
J	Keenan, HT; Marshall, SW; Nocera, MA; Runyan, DK				Keenan, HT; Marshall, SW; Nocera, MA; Runyan, DK			Increased incidence of inflicted traumatic brain injury in children after a natural disaster	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							SEQUELAE; ABUSE	Background: The incidence of child abuse following natural disasters has not been Studied thoroughly. However, parental stress and decreased social support have been linked to increased reports of child maltreatment. We hypothesized that a large-scale natural disaster (North Carolina's Hurricane Floyd) would increase the incidence of inflicted traumatic brain injury (TBI) in young children. Methods: An ecologic Study design was used to compare regions affected to those regions unaffected by the disaster. Cases of inflicted TBI resulting in admission to an intensive care unit or death from September 1998 through December 2001 in North Carolina were ascertained. Poisson regression modeling was employed to calculate rate ratios of injury for each geographic area by time period. Results: Inflicted TBI in the most affected counties increased in the G months post disaster in comparison to the same region pre-disaster (rate ratio 5.1, 95% confidence interval [CI] = 1.3-20.4), as did non-inflicted TBI (rate ratio 10.7, 95% CI = 2.0-59.4). No corresponding increased incidence was observed in counties less affected or unaffected by the disaster. The rate of inflicted injuries returned to baseline in the severely affected counties 6 months post-hurricane; however, the rate Of non-inflicted injuries appeared to remain elevated for the entire post-hurricane study period. Conclusions: Families are Vulnerable to an elevated risk of inflicted and non-inflicted child TBI following a disaster. This information may be useful in future disaster planning.	Univ N Carolina, Sch Med, Dept Social Med, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	Keenan, HT (corresponding author), Univ N Carolina, Sch Med, Dept Social Med, Injury Prevent Res Ctr, Wing D,CB 7240, Chapel Hill, NC 27599 USA.	hkeenan@med.unc.elu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; Marshall, Stephen/0000-0002-2664-9233	ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BRAVO M, 1990, AM J COMMUN PSYCHOL, V18, P661, DOI 10.1007/BF00931236; Briere J, 2000, J TRAUMA STRESS, V13, P661, DOI 10.1023/A:1007814301369; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P369; Curtis T, 2000, CHILD ABUSE NEGLECT, V24, P1151, DOI 10.1016/S0145-2134(00)00176-9; Greenland S, 1998, MODERN EPIDEMIOLOGY, P459; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOTCH JB, 1995, CHILD ABUSE NEGLECT, V19, P1115, DOI 10.1016/0145-2134(95)00072-G; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; *NC DIV EM MAN, FLOYD BUYOUT PROGR; OLDS DL, 1992, AM J DIS CHILD, V146, P704, DOI 10.1001/archpedi.1992.02160180062018; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; SHORE JH, 1986, AM J PUBLIC HEALTH, V76, P76, DOI 10.2105/AJPH.76.Suppl.76; Warheit GJ, 1996, J CHILD PSYCHOL PSYC, V37, P435, DOI 10.1111/j.1469-7610.1996.tb01424.x	14	69	69	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2004	26	3					189	193		10.1016/j.amepre.2003.10.023			5	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	804SU	WOS:000220319200001	15026097				2021-06-18	
J	Salman, H; Ghosh, P; Kernie, SG				Salman, H; Ghosh, P; Kernie, SG			Subventricular zone neural stem cells remodel the brain following traumatic injury in adult mice	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical injury; DiO; neural stem cells; subventricular zone; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; ROSTRAL MIGRATORY STREAM; OLFACTORY-BULB; GENERATED NEURONS; PROGENITOR CELLS; BONE-MARROW; NEUROGENESIS; PROLIFERATION; HIPPOCAMPUS; FOREBRAIN	Neural stem cells have recently been shown to contribute to the cellular remodeling that occurs following traumatic brain injury (TBI). Potential sources for these stem cells from within the brain include the subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus. Using intraventricular injections of the fluorescent vital dye DiO in mice, we demonstrate that the subventricular zone population of stem cells can be reliably labeled and followed over time. By following these injections with a contralateral controlled cortical injury we demonstrate that cells from the subventricular zone migrate to the most proximally injured cortical areas. Using double-labeling immunohistochemistry with anti-nestin, anti-GFAP, and anti-NeuN antibodies we demonstrate that labeled cells from the subventricular zone contribute primarily to the astroglial scar following injury. We do not observe any contribution to deeper areas of injury including the hippocampus. These data demonstrate that the subventricular zone contributes to brain remodeling following TBI, though neural stem cell sources outside the subventricular zone appear to play reparative roles as well.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Kent Waldrep Fdn Ctr Basic Res Nerve Growth & Reg, Dallas, TX 75390 USA	Kernie, SG (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K08 HD01470-01, K08 HD001470] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD001470] Funding Source: NIH RePORTER		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brock SC, 1998, METHODS, V16, P268, DOI 10.1006/meth.1998.0684; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coskun V, 2002, J NEUROSCI RES, V69, P795, DOI 10.1002/jnr.10336; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Demeurisse G, 2000, ACTA NEUROL BELG, V100, P77; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; HINDS JW, 1968, J COMP NEUROL, V134, P305, DOI 10.1002/cne.901340305; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Jankovski A, 1996, J COMP NEUROL, V371, P376; Kakita A, 2003, J COMP NEUROL, V458, P381, DOI 10.1002/cne.10597; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1994, FASEB J, V8, P722; Markakis EA, 1999, J COMP NEUROL, V406, P449; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stewart RR, 2002, J NEUROBIOL, V50, P305, DOI 10.1002/neu.10038; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	46	69	72	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					283	292		10.1089/089771504322972077			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600006	15115603				2021-06-18	
J	Seel, RT; Kreutzer, JS				Seel, RT; Kreutzer, JS			Depression assessment after traumatic brain injury: An empirically based classification method	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; depression; outcome assessment (health care); rehabilitation	MINOR HEAD-INJURIES; PSYCHOMETRIC PROPERTIES; INVENTORY; DISORDERS; CONCORDANCE; OUTPATIENTS; PERSONALITY; VALIDATION; DISABILITY; RELATIVES	Objectives: To describe the patterns of depression in patients with traumatic brain injury (TBI), to evaluate the psychometric properties of the Neurobehavioral Functioning Inventory (NFI) Depression Scale, and to classify empirically NFI Depression Scale scores. Design: Depressive symptoms were characterized by using the NFI Depression Scale. the Beck Depression Inventory (BDI), and the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Depression Scale. Setting: An outpatient clinic within a Traumatic Brain Injury Model Systems center. Participants: A demographically diverse sample of 172 outpatients with TBI. evaluated between 1996 and 2000. Interventions: Not applicable. Main Outcome Measures: The NFI, BDI, and MMPI-2 Depression Scale. The Cronbach alpha, analysis of variance, Pearson correlations. and canonical discriminant function analysis were used to examine the psychometric properties of the NFI Depression Scale. Results: Patients with TBI most frequently reported problems with frustration (81%), restlessness (73%), rumination (69%), boredom (66%). and sadness (66%) with the NFI Depression Scale. The percentages of patients classified as depressed with the BDI and the NFI Depression Scale were 37% and 30%, respectively. The Cronbach alpha for the NFI Depression Scale was 93, indicating a high degree of internal consistency. As hypothesized. NFI Depression Scale scores correlated highly with BDI (r=.765) and MMPI-2 Depression Scale T scores (r=.752). The NFI Depression Scale did not correlate significantly with the MMPI-2 Hypomania Scale, thus showing discriminant validity. Normal and clinically depressed BDI scores were most likely to be accurately predicted by the NFI Depression Scale. with 81% and 87% of grouped cases, respectively, correctly classified. Normal and depressed MMPI-2 Depression Scale scores were accurately predicted by the NFI Depression Scale. with 75% and 83% of grouped cases correctly classified, respectively. Patients' NFI Depression Scale scores were mapped to the corresponding BDI categories, and 3 NFI score classifications emerged: minimally depressed (13-28), borderline depressed (29-42), and clinically depressed (43-65). Conclusions: Our study provided further evidence that screening for depression should be a standard component of TBI assessment protocols. Between 30% and 38% of patients with TBI were classified as depressed with the NFI Depression Scale and the BDI, respectively. Our findings also provided empirical evidence that the NFI Depression Scale is a useful tool for classifying postinjury depression.	McGuire Vetr Adm Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; Virginia Commonwealth Univ Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA USA	Seel, RT (corresponding author), VAMC, Def & Vet Brain Injury Ctr, Dept Phys Med & Rehabil, ATT, 117, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anastasi A., 1988, PSYCHOL TESTING; Arbisi PA, 1999, NEUROREHABILITATION, V13, P117; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Beck A. T., 1993, BECK DEPRESSION INVE; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BETZ NE, 1987, J COUNS PSYCHOL, V34, P393, DOI 10.1037/0022-0167.34.4.393; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; Butcher, 1989, MINNESOTA MULTIPHASI; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dawes R. V., 1987, J COUNS PSYCHOL, V34, P481; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; Graham JR, 1993, MMPI 2 ASSESSING PER; Green R.L., 1991, MMPI 2 MMPI INTERPRE; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Keppel, 1991, DESIGN ANAL RES HDB; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN BE, 1988, J NEUROL NEUROSUR PS, V51, P1401, DOI 10.1136/jnnp.51.11.1401; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lykouras L, 1998, PSYCHOPATHOLOGY, V31, P213, DOI 10.1159/000029042; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NG KC, 1995, ACTA PSYCHIAT SCAND, V92, P75, DOI 10.1111/j.1600-0447.1995.tb09546.x; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PATRICK J, 1988, J CLIN PSYCHOL, V44, P186, DOI 10.1002/1097-4679(198803)44:2<186::AID-JCLP2270440215>3.0.CO;2-0; PORTER JH, 1986, STAT APPL BEHAV SCI; REYNOLDS WM, 1981, J CONSULT CLIN PSYCH, V49, P306, DOI 10.1037/0022-006X.49.2.306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STEER RA, 1989, J PERS ASSESS, V53, P693, DOI 10.1207/s15327752jpa5304_6; Tabachnick B.G., 1989, USING MULTIVARIATE S; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7	52	69	72	0	21	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2003	84	11					1621	1628		10.1053/S0003-9993(03)00270-3			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	741PR	WOS:000186466900008	14639561				2021-06-18	
J	Rohling, ML; Meyers, JE; Millis, SR				Rohling, ML; Meyers, JE; Millis, SR			Neuropsychological impairment following traumatic brain injury: A dose-response analysis	CLINICAL NEUROPSYCHOLOGIST			English	Article							LINEAR-MODELS; MEMORY; VALIDATION; INDEX	Dikmen, Machamer, Winn, and Temkin (1995) administered the Halstead-Reitan Battery (HRB) to a sample of TBI patients. Similar patients were obtained from the second author (JEM) for two main purposes. First, we wished to determine if there is a dose-response relationship between TBI severity and residual cognitive deficit. Second, are Dikmen et al. results generalizable to other TBI samples? Analyses of the Meyers sample replicated the analyses of Dikmen sample. A significant dose-response relationship between loss of consciousness (LOC) and cognitive impairment was found using effect sizes for the Dikmen sample, as well as using regression-based normative T scores for the Meyers sample. The two methods were highly correlated with one another. Using mean scores for the six LOC-severity groups and the two samples resulted in a correlation coefficient r=.97, p<.0001. Results are presented for clinicians to use when assessing individual patients.	Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; Mercy Rehabil Ctr, Sioux City, IA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA	Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, 381 LSCB, Mobile, AL 36688 USA.	mrohling@usouthal.edu					BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; DAWES RM, 1974, PSYCHOL BULL, V81, P95, DOI 10.1037/h0037613; DAWES RM, 1979, AM PSYCHOL, V34, P571, DOI 10.1037/0003-066X.34.7.571; DEFILIPPIS NA, 1991, BOOKLET CATEGORY TES; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DYER FN, 1973, MEM COGNITION, V1, P106, DOI 10.3758/BF03198078; FAITH MS, 1996, DESIGN ANAL SINGLE C; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P201; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton RK, 2001, ARCH GEN PSYCHIAT, V58, P24, DOI 10.1001/archpsyc.58.1.24; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; KIERNAN RJ, 1976, J CONSULT CLIN PSYCH, V44, P951, DOI 10.1037/0022-006X.44.6.951; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Lundin KA, 1999, CLIN NEUROPSYCHOL, V13, P433, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT433; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILBERG WP, 1986, ASSESSMENT NEUROPSYC; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; MILLER LS, 1998, ARCH CLIN NEUR ABSTR, V12, P86; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reitan RM, 2001, ARCH CLIN NEUROPSYCH, V16, P215; REITAN RM, 1999, WORKSH ANN NAT AC NE; Rohling ML, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P171; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P821, DOI 10.1016/S0887-6177(00)80311-X; ROHLING ML, IN PRESS CLIN NEUROP; ROHLING ML, IN PRESS NEUROPSYCHO; ROHLING ML, 1998, J INT NEUROPSYCH SOC, V4, P26; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Spreen O., 1998, COMPENDIUM NEUROPSYC; SWEET J, 2000, CLIN NEUROPSYCHOL, V14, P38; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wedding D, 1989, Arch Clin Neuropsychol, V4, P233, DOI 10.1016/0887-6177(89)90016-4	41	69	69	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2003	17	3					289	302		10.1076/clin.17.3.289.18086			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	748DP	WOS:000186847100001	14704881				2021-06-18	
J	Kent, RD; Vorperian, HK; Kent, JF; Duffy, JR				Kent, RD; Vorperian, HK; Kent, JF; Duffy, JR			Voice dysfunction in dysarthria: application of the Multi-Dimensional Voice Program (TM)	JOURNAL OF COMMUNICATION DISORDERS			English	Article						dysarthria; voice disorder; MDVP; acoustic analysis	AMYOTROPHIC-LATERAL-SCLEROSIS; COMPUTERIZED SPEECH LAB; TRAUMATIC BRAIN INJURY; PARKINSONS-DISEASE; FUNDAMENTAL-FREQUENCY; ACOUSTIC ANALYSIS; TREATMENT LSVT(R); PHONATORY DYSFUNCTION; CIGARETTE-SMOKING; ANALYSIS SYSTEMS	Phonatory dysfunction is a frequent component of dysarthria and often is a primary feature noted in clinical assessment. But the vocal impairment can be difficult to assess because (a) the analysis of voice disorder of any kind can be challenging, and (b) the voice disorder in dysarthria often occurs along with other impairments affecting articulation, resonance, and respiration. A promising assessment tool is multi-parameter acoustic analysis, such as the Multi-Dimensional Voice Program(TM) (MDVP). Part 1 of this paper recommends procedures and standards for the acoustic analysis of voice, including (1) selection of the sample to be analyzed, (2) signal quality requirements, (3) availability of normative data for both genders and different ages of speakers, (4) reliability of analysis, and (5) correlation of acoustic results with results from other methods of analysis. In Part 2, acoustic data are reviewed for the dysarthria associated with Parkinson disease (PD), cerebellar disease, amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), unilateral hemispheric stroke, and essential tremor. Tentative profiles of voice disorder are described for these conditions. These profiles may serve as hypotheses for future research. Although several issues remain to be resolved in the acoustic analysis of voice disorder in dysarthria, steps can be taken now to promote the reliability, validity, and clinical utility of such analyses. Learning outcomes: (1) As a result of this activity, the participant will be able to describe ways in which an optimal multi-dimensional analysis of voice can be performed with modem acoustic analysis systems. (2) As a result of this activity, the participant will be able to apply multi-dimensional acoustic analysis of voice to individuals who have a dysarthria-related voice disorder. (3) As a result of this activity, the participant will be able to identify major sources of normative data on the Multi-Dimensional Voice Program. (C) 2003 Elsevier Science Inc. All rights reserved.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA	Kent, RD (corresponding author), Univ Wisconsin, Waisman Ctr, Rm 435,1500 Highland Ave, Madison, WI 53705 USA.	kent@waisman.wisc.edu	Kent, Raymond D/AAI-1928-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [5 R01 DC 00319] Funding Source: Medline		ADAMS SG, 1997, CLIN MANAGEMENT SENS, P261; ARONSON AE, 1994, BRAIN INJURY, V8, P663, DOI 10.3109/02699059409151019; ARONSON AE, 1992, ANN OTO RHINOL LARYN, V101, P511, DOI 10.1177/000348949210100612; Baumgartner CA, 2001, J VOICE, V15, P105, DOI 10.1016/S0892-1997(01)00010-8; Behrman A, 1998, J VOICE, V12, P249, DOI 10.1016/S0892-1997(98)80045-3; Bielamowicz S, 1996, J SPEECH HEAR RES, V39, P126, DOI 10.1044/jshr.3901.126; Buder E.H., 2000, VOICE QUALITY MEASUR, P119; Bunton K, 2001, CLIN LINGUIST PHONET, V15, P181; Callan DE, 1999, J SPEECH LANG HEAR R, V42, P355, DOI 10.1044/jslhr.4202.355; Campisi P, 2002, ARCH OTOLARYNGOL, V128, P156, DOI 10.1001/archotol.128.2.156; Campisi P, 2000, J OTOLARYNGOL, V29, P302; CARROW E, 1974, ARCH OTOLARYNGOL, V100, P212; Crevier-Buchman L, 1995, Ann Otolaryngol Chir Cervicofac, V112, P169; Damborenea Tajada J, 1999, Acta Otorrinolaringol Esp, V50, P448; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Dejonckere P H, 1998, Rev Laryngol Otol Rhinol (Bord), V119, P247; DELIYSKI D, 1998, 1998 ANN CONV AM SPE; Desai S., 1995, J MED SPEECH-LANG PA, V3, P41; DOHERTY ET, 1988, J SPEECH HEAR RES, V31, P485, DOI 10.1044/jshr.3103.485; Gamboa J, 1998, J VOICE, V12, P444, DOI 10.1016/S0892-1997(98)80053-2; GELFER MP, 1995, J VOICE, V9, P378, DOI 10.1016/S0892-1997(05)80199-7; GENTIL M, 1990, FOLIA PHONIATR, V42, P125, DOI 10.1159/000266056; GILMAN S, 1992, NEUROLOGIC DISORDERS, P279; Gonzalez J, 2002, Acta Otorrinolaringol Esp, V53, P256; GRIFFITHS C, 1989, Journal of Voice, V3, P148, DOI 10.1016/S0892-1997(89)80141-9; HERTRICH I, 1995, ANN OTO RHINOL LARYN, V104, P197, DOI 10.1177/000348949510400304; HERTRICH I, 1998, CLIN PHONETICS LINGU, P448; Holmes RJ, 2000, INT J LANG COMM DIS, V35, P407; Jaeger M, 2001, FOLIA PHONIATR LOGO, V53, P326, DOI 10.1159/000052686; JOANETTE Y, 1980, BRAIN LANG, V10, P39, DOI 10.1016/0093-934X(80)90036-X; KARNELL MP, 1995, J VOICE, V9, P383, DOI 10.1016/S0892-1997(05)80200-0; Kay Elemetrics, 1993, MULT VOIC PROGR MDVP; Kent R, 1998, J MED SPEECH-LANG PA, V6, P165; Kent R. D., 1994, J MED SPEECH-LANG PA, V2, P157; Kent R. D., 2000, VOICE QUALITY MEASUR; Kent RD, 1999, AM J SPEECH-LANG PAT, V8, P129, DOI 10.1044/1058-0360.0802.129; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; Kent RD, 1997, FOLIA PHONIATR LOGO, V49, P63, DOI 10.1159/000266440; KENT RD, 1998, PHONOSCOPE, V4, P237; KOIKE Y, 1977, ACTA OTO-LARYNGOL, V84, P105, DOI 10.3109/00016487709123948; Leeper H. A., 1996, J MED SPEECH-LANG PA, V4, P163; LOGEMANN JA, 1978, J SPEECH HEAR DISORD, V43, P47, DOI 10.1044/jshd.4301.47; MATHIESON L, 2000, VOICE QUALITY MEASUR, P3; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; Mendoza E, 1998, J VOICE, V12, P263, DOI 10.1016/S0892-1997(98)80017-9; Murdoch BE, 1997, CLIN LINGUIST PHONET, V11, P245, DOI 10.3109/02699209708985194; MURPHY CH, 1987, OTOLARYNG HEAD NECK, V97, P376, DOI 10.1177/019459988709700406; Niedzielska G, 2001, INT J PEDIATR OTORHI, V57, P189, DOI 10.1016/S0165-5876(00)00411-0; Parsa V, 2001, J SPEECH LANG HEAR R, V44, P327, DOI 10.1044/1092-4388(2001/027); Perry C. K., 1996, AM J SPEECH-LANG PAT, V5, P86; Putzer M, 2001, FOLIA PHONIATR LOGO, V53, P73, DOI 10.1159/000052657; RAMIG L, 1996, ORGANIC VOICE DISORD, P323; Ramig L. O., 1992, INTELLIGIBILITY SPEE, DOI [10.1075/sspcl.1.05ram, DOI 10.1075/SSPCL.1.05RAM]; Ramig LO, 2001, MOVEMENT DISORD, V16, P79, DOI 10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; Revis J, 1999, FOLIA PHONIATR LOGO, V51, P108, DOI 10.1159/000021485; Robert D, 1999, ACTA OTO-LARYNGOL, V119, P724; Rovirosa A, 2000, INT J RADIAT ONCOL, V47, P73, DOI 10.1016/S0360-3016(99)00524-6; Sanabria J, 2001, CLIN NEUROPHARMACOL, V24, P99, DOI 10.1097/00002826-200103000-00006; Silbergleit AK, 1997, J VOICE, V11, P222, DOI 10.1016/S0892-1997(97)80081-1; SORENSEN D, 1982, J COMMUN DISORD, V15, P135, DOI 10.1016/0021-9924(82)90027-2; Souaid JP, 1998, J OTOLARYNGOL, V27, P301; STEWART C, 1995, MOVEMENT DISORD, V10, P562, DOI 10.1002/mds.870100506; STRAND EA, 1994, J VOICE, V8, P327, DOI 10.1016/S0892-1997(05)80281-4; Theodoros DG, 1996, DISORDERS MOTOR SPEE, P205; TITZE IR, 1995, WORKSH AC VOICE ANAL; van As CJ, 1998, J VOICE, V12, P239, DOI 10.1016/S0892-1997(98)80044-1; Van Lierde K, 1996, Acta Otorhinolaryngol Belg, V50, P345; WHALEN DH, 1990, BEHAV RES METH INSTR, V22, P550, DOI 10.3758/BF03204440; Xue SA, 2000, PERCEPT MOTOR SKILL, V91, P951, DOI 10.2466/PMS.91.7.951-958; Xue SA, 2001, EDUC GERONTOL, V27, P159, DOI 10.1080/03601270151075561; Yiu E, 2000, CLIN LINGUIST PHONET, V14, P295; Ziegler W., 2000, VOICE QUALITY MEASUR, P397; ZWIRNER P, 1992, J SPEECH HEAR RES, V35, P761, DOI 10.1044/jshr.3504.761; ZWIRNER P, 1991, J COMMUN DISORD, V24, P287, DOI 10.1016/0021-9924(91)90004-3	77	69	73	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2003	36	4					281	306		10.1016/S0021-9924(03)00016-9			26	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	700GX	WOS:000184105200003	12837587				2021-06-18	
J	Fee, D; Crumbaugh, A; Jacques, T; Herdrich, B; Sewell, D; Auerbach, D; Piaskowski, S; Hart, MN; Sandor, M; Fabry, Z				Fee, D; Crumbaugh, A; Jacques, T; Herdrich, B; Sewell, D; Auerbach, D; Piaskowski, S; Hart, MN; Sandor, M; Fabry, Z			Activated/effector CD4(+) cells exacerbate acute damage in the central nervous system following traumatic injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						CD4(+) T cells; traumatic injury; aseptic cerebral injury	INFLAMMATORY-BOWEL-DISEASE; AUTOIMMUNE T-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MICROVESSEL ENDOTHELIAL-CELLS; EXPERIMENTAL BRAIN INJURY; NECROSIS-FACTOR-ALPHA; SPINAL-CORD INJURY; IN-VITRO; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES	CD4(+) helper T cells (Th) have been demonstrated to participate in the chronic phase of traumatic injury repair in the central nervous system (CNS). Here, we show that CD4(+) T cells can also contribute to the severity of the acute phase of CNS traumatic injury. We compared the area of tissue damage and the level of cellular apoptosis in aseptic cerebral injury (ACI) sites of C57BL/6 wild type and RAG1(-/-) immunodeficient mice. We demonstrate that ACI is attenuated in RAG1(-/-) mice compared to C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(low)CD44(high) activated/effector T cells 24 h prior to ACI into RAG1(-/-) mice resulted in a significantly enhanced acute ACI that was comparable to ACI in the C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(high)CD44(low) naive/non-activated T cells did not increase ACI in the brains of RAG1(-/-) mice. T cell inhibitory agents, cyclosporin A (CsA) and FK506, significantly decreased ACI-induced acute damage in C57BL/6 mice. These results suggest a previously undescribed role for activated/effector CD4(+) T cells in exacerbating ACI-induced acute damage in the CNS and raise a novel possibility for acute treatment of sterile traumatic brain injury. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA	Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave,6130 MSC, Madison, WI 53706 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Asensio VC, 1997, J VIROL, V71, P7832, DOI 10.1128/JVI.71.10.7832-7840.1997; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; Bregenholt S, 1998, EUR J IMMUNOL, V28, P379, DOI 10.1002/(SICI)1521-4141(199801)28:01<379::AID-IMMU379>3.0.CO;2-X; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1972, LAB INVEST, V26, P376; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; FABRY Z, 1993, J IMMUNOL, V151, P38; FABRY Z, 1990, J IMMUNOL, V145, P1099; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fukuzuka K, 2000, AM J PHYSIOL-REG I, V278, pR1005; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; HAWKINS CP, 1990, BRAIN, V113, P365, DOI 10.1093/brain/113.2.365; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Huber SA, 2000, CARDIOVASC RES, V45, P579, DOI 10.1016/S0008-6363(99)00267-9; Ikegami M, 2002, J NEUROIMMUNOL, V127, P134, DOI 10.1016/S0165-5728(02)00100-5; Knopf PM, 1998, J IMMUNOL, V161, P692; Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; Markovic-Plese S, 2001, Curr Neurol Neurosci Rep, V1, P257, DOI 10.1007/s11910-001-0028-4; Matyszak MK, 1998, PROG NEUROBIOL, V56, P19, DOI 10.1016/S0301-0082(98)00014-8; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrissey SP, 1996, BRAIN, V119, P239, DOI 10.1093/brain/119.1.239; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Ohminami H, 1999, BLOOD, V93, P925, DOI 10.1182/blood.V93.3.925.403k32_925_935; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Qing Z, 2000, J NEUROIMMUNOL, V105, P169, DOI 10.1016/S0165-5728(99)00265-9; Qing Z, 2001, J NEUROPATH EXP NEUR, V60, P798, DOI 10.1093/jnen/60.8.798; Raghupathi R, 1998, J NEUROTRAUM, V15, P555, DOI 10.1089/neu.1998.15.555; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reiss Y, 1999, INT IMMUNOL, V11, P1527, DOI 10.1093/intimm/11.9.1527; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Silver N, 1999, J NEUROL, V246, P728, DOI 10.1007/s004150050442; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werring DJ, 2000, BRAIN, V123, P1667, DOI 10.1093/brain/123.8.1667	57	69	71	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	2003	136	1-2					54	66		10.1016/S0165-5728(03)00008-0			13	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	660PC	WOS:000181840700007	12620643				2021-06-18	
J	de Turco, EBR; Belayev, L; Liu, YT; Busto, R; Parkins, N; Bazan, NG; Ginsberg, MD				de Turco, EBR; Belayev, L; Liu, YT; Busto, R; Parkins, N; Bazan, NG; Ginsberg, MD			Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin	JOURNAL OF NEUROCHEMISTRY			English	Article						arachidonic acid; brain ischemia; docosahexaenoic acid; human albumin; middle cerebral artery occlusion; neuroprotection	IMPROVES NEUROLOGICAL DEFICIT; REDUCES INFARCT VOLUME; TRAUMATIC BRAIN INJURY; D-ASPARTATE ANTAGONIST; DOCOSAHEXAENOIC ACID; ARTERY OCCLUSION; ARACHIDONIC-ACID; CELLULAR UPTAKE; RAT-BRAIN; ELECTROCONVULSIVE SHOCK	Human albumin therapy is highly neuroprotective in focal cerebral ischemia. Because albumin is the main carrier of free fatty acids (FFA) in plasma, we investigated the content and composition of plasma FFA in jugular vein (JV), femoral artery (FA) and femoral vein (FV) of rats given intravenous human albumin (1.25 g/kg) or saline vehicle (5 mL/kg) 1 h after a 2 h middle cerebral artery occlusion (MCAo) or sham surgery. Arachidonic acid was the only FFA significantly increased by MCAo in all plasma samples prior to albumin administration, remaining at the same level regardless of subsequent treatments. Albumin treatment induced in both MCAo- and sham-groups a 1.7-fold increase in total plasma FFA (mainly 16:0, 18:1, 18:2n-6) during 90-min reperfusion. MCAo selectively stimulated the albumin-mediated mobilization of n-3 polyunsaturated fatty acids (PUFA), with an early increase in 22:5n-3 and 22:6n-3 in the FA prior to detectable changes in the JV. In the MCAo-albumin group, the lower level of FFA in JV as compared with FA and FV suggests an albumin-mediated systemic mobilization and supply of FFA to the brain, which may favor the replenishment of PUFA lost from cellular membranes during ischemia and/or to serve as an alternative source of energy, thus contributing to albumin neuroprotection.	Univ Miami, Sch Med, Dept Neurol, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Neurosci Ctr Excellence, New Orleans, LA USA	Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820] Funding Source: Medline		Bazan N G, 1980, Adv Neurol, V28, P197; Bazan NG, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P173; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bazan NG, 1996, RETINAL DEGENERATION AND REGENERATION, P89; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1992, AM OIL CHEM SOC, P107; BAZAN NG, 1990, NUTR BRAIN, P1; BAZXAN NG, 2001, NEUROPROTECTION BASI, P196; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; deTurco EBR, 1997, J BIOL CHEM, V272, P10491; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ginsberg MD, 1999, ACTA NEUROCHIR SUPPL, V73, P45; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Liu YT, 2000, BRAIN RES, V862, P111, DOI 10.1016/S0006-8993(00)02078-3; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; MARTIN RE, 1994, J NUTR BIOCHEM, V5, P151, DOI 10.1016/0955-2863(94)90087-6; MOORE SA, 1990, J NEUROCHEM, V55, P391, DOI 10.1111/j.1471-4159.1990.tb04150.x; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MOORE SA, 1993, ADV EXP MED BIOL, V331, P229; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; Narita K, 2000, NEUROL RES, V22, P393, DOI 10.1080/01616412.2000.11740689; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; Rapoport SI, 2001, J LIPID RES, V42, P678; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; REDDY TS, 1984, EUR J BIOCHEM, V145, P21, DOI 10.1111/j.1432-1033.1984.tb08517.x; REDDY TS, 1985, J NEUROSCI RES, V13, P381, DOI 10.1002/jnr.490130305; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; ROSENTHAL MD, 1987, PROG LIPID RES, V26, P87, DOI 10.1016/0163-7827(87)90009-9; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; SPECTOR AA, 1975, J LIPID RES, V16, P165; TRIGATTI BL, 1995, BIOCHEM J, V308, P155, DOI 10.1042/bj3080155; YOSHIDA S, 1986, J NEUROCHEM, V47, P744; ZHANG JP, 1995, J NEUROCHEM, V64, P1688	54	69	69	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	2002	83	3					515	524		10.1046/j.1471-4159.2002.01121.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	605KJ	WOS:000178676800004	12390513	Bronze			2021-06-18	
J	Walhovd, KB; Fjell, AM				Walhovd, KB; Fjell, AM			One-year test-retest reliability of auditory ERPs in young and old adults	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						ERP; P3; reliability; life-span; aging; waveform-measures	EVENT-RELATED POTENTIALS; CLOSED-HEAD INJURY; REACTION-TIME; BRAIN POTENTIALS; ELDERLY SUBJECTS; P300; VARIABILITY; UTILITY; PERFORMANCE; COMPONENTS	The reliability of ERP measures was investigated in a sample covering the adult life span (n = 59, age 21-92). This sample was divided into a young and an old group. ERPs to an auditory two-stimuli oddball task were recorded in the sample at two occasions separated by 12-14 months (T1 and T2). The recordings of T1 were split in half, to assess within session reliability. Correlations were calculated for N1, P2 and P3 peak latency and amplitude, for average amplitude during 50 ms epochs within the defined P3-window 250-550, and for average amplitude in successive 15 ms epochs from I to 705 ms. The results show that amplitude measures were more reliable than the latency measures at all electrodes. Time window/epoch amplitude measures yielded reliabilities in the same range as peak amplitude. Reliabilities peaked around the conventionally studied N1, P2 and P3, and this is seen as a validation of the components. In general, the old group exhibited weaker P3 peak latency reliabilities than the young group. However, many of these differences did not reach statistical significance. Implications of the findings are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Oslo, Inst Psychol, N-0317 Oslo, Norway; Ulleval Univ Hosp, Dept Neuropsychol, N-0407 Oslo, Norway	Walhovd, KB (corresponding author), Univ Oslo, Inst Psychol, POB 1094, N-0317 Oslo, Norway.						Anderer P, 1996, ELECTROEN CLIN NEURO, V99, P458, DOI 10.1016/S0013-4694(96)96518-9; Anstey KJ, 1999, AGING NEUROPSYCHOL C, V6, P84, DOI 10.1076/anec.6.2.84.786; Clark-Carter D., 1997, DOING QUANTITATIVE P; Fabiani M., 1987, ADV PSYCHOPHYSIOL, V2, P1; Fjell AM, 2001, BRAIN TOPOGR, V14, P25, DOI 10.1023/A:1012563605837; GEISLER MW, 1992, PSYCHOPHYSIOLOGY, V29, P86, DOI 10.1111/j.1469-8986.1992.tb02019.x; GOODIN DS, 1978, ELECTROEN CLIN NEURO, V44, P447, DOI 10.1016/0013-4694(78)90029-9; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; IRAGUI VJ, 1993, PSYCHOPHYSIOLOGY, V30, P10, DOI 10.1111/j.1469-8986.1993.tb03200.x; Kinoshita S, 1996, PHYSIOL BEHAV, V60, P1087, DOI 10.1016/0031-9384(96)00130-8; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Maeda H, 1995, PSYCHIAT CLIN NEUROS, V49, P281, DOI 10.1111/j.1440-1819.1995.tb01902.x; PAPALIA DE, 1996, ADULT DEV AGING; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; POLICH J, 1990, ELECTROEN CLIN NEURO, V77, P179, DOI 10.1016/0168-5597(90)90036-D; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; Polich J, 1986, ELECTROEN CLIN NEURO, V65, P665; Pratt H, 2000, CLIN NEUROPHYSIOL, V111, P1425, DOI 10.1016/S1388-2457(00)00344-8; Sandman CA, 2000, CLIN NEUROPHYSIOL, V111, P1427, DOI 10.1016/S1388-2457(00)00320-5; SEGALOWITZ SJ, 1993, PSYCHOPHYSIOLOGY, V30, P451, DOI 10.1111/j.1469-8986.1993.tb02068.x; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Shammi P, 1998, AGING NEUROPSYCHOL C, V5, P1, DOI 10.1076/anec.5.1.1.23; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; VESCO KK, 1993, ELECTROEN CLIN NEURO, V88, P302, DOI 10.1016/0168-5597(93)90054-S; Walhovd KB, 2001, NEUROREPORT, V12, P3149, DOI 10.1097/00001756-200110080-00033; Wechsler D., 2011, WECHLSER ABBREVIATED; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	31	69	71	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760			INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2002	46	1					29	40	PII S0167-8760(02)00039-9	10.1016/S0167-8760(02)00039-9			12	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	601WP	WOS:000178472000003	12374644				2021-06-18	
J	Cushman, JG; Agarwal, N; Fabian, TC; Garcia, V; Nagy, KK; Pasquale, MD; Salotto, AG				Cushman, JG; Agarwal, N; Fabian, TC; Garcia, V; Nagy, KK; Pasquale, MD; Salotto, AG			Practice management guidelines for the management of mild traumatic brain injury: The EAST Practice Management Guidelines Work Group	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MINOR HEAD-INJURY; INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; SKULL RADIOGRAPHY; CT SCANS; RISK; CLASSIFICATION; SEQUELAE; RECOVERY; TALK		Lehigh Valley Hosp, Div Trauma Surg Crit Care, Dept Surg, Allentown, PA 18105 USA; Wyntrebrooke SA, York, PA USA; Univ Tennessee, Memphis, TN USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Cook Cty Hosp, Chicago, IL 60612 USA; Rush Univ, Chicago, IL 60612 USA	Pasquale, MD (corresponding author), Lehigh Valley Hosp, Div Trauma Surg Crit Care, Dept Surg, POB 689,Cedar Crest & I-78, Allentown, PA 18105 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Bailes JE, 1999, SPORTS-RELATED CONCUSSION, P115; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Camins M B, 1996, Bull Am Coll Surg, V81, P16; Camins MB, 1996, B AM COLL SURG, V81, P47; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1978, Practitioner, V221, P77; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kelly JP, 1997, NEUROLOGY, V48, P581; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin HS, 1996, NEUROTRAUMA, P749; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MURSHID WR, 1994, ACTA NEUROCHIR, V129, P11, DOI 10.1007/BF01400866; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; REILLY PL, 1975, LANCET, V2, P375; REIMER W, 1995, BRAIN INJURY, V9, P55, DOI 10.3109/02699059509004572; Rhodes M, 1993, J TRAUMA, V35, P979; RHODES M, 1996, NEUROTRAUMA, P991; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1996, NEUROTRAUMA, P755; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Veltman R H, 1993, J Neurosci Nurs, V25, P367; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wilberger J E Jr, 1997, Bull Am Coll Surg, V82, P29; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WISNER DH, 1993, ADV TRAUMA CRIT CARE, V8, P183	73	69	71	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2001	51	5					1016	1026		10.1097/00005373-200111000-00034			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	495QJ	WOS:000172351600041	11706358				2021-06-18	
J	Becker, KJ				Becker, KJ			Targeting the central nervous system inflammatory response in ischemic stroke	CURRENT OPINION IN NEUROLOGY			English	Article							FOCAL CEREBRAL-ISCHEMIA; C-REACTIVE PROTEIN; TRAUMATIC BRAIN INJURY; NF-KAPPA-B; MATRIX METALLOPROTEINASES; TRANSGENIC MICE; PROINFLAMMATORY CYTOKINES; CARDIOVASCULAR-DISEASE; MODERATE HYPOTHERMIA; IL-6 EXPRESSION	In experimental models of stroke, inflammation appears to contribute to cerebral ischemic injury. Clinical trials that are aimed at limiting the postischemic inflammatory response, however, have thus far had disappointing results. These clinical failures probably reflect the fact that there has been insufficient preclinical data and inadequate trial design, rather than provide evidence against a role for inflammation in ischemic brain injury. Curr Opin Neurol 14:349-353. (C) 2001 Lippincott Williams & Wilkins.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Seattle, WA 98104 USA	Becker, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Box 359775,325 9th Ave, Seattle, WA 98104 USA.		Becker, Kyra/L-1420-2019	Becker, Kyra/0000-0002-8310-4846	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002160] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO2 NS02160-01 NST] Funding Source: Medline		Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Albertsson P, 2000, IN VIVO, V14, P269; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2000, J CEREBR BLOOD F MET, V20, P1409, DOI 10.1097/00004647-200010000-00002; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Becker K, 2001, STROKE, V32, P206, DOI 10.1161/01.STR.32.1.206; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Block F, 2000, NEUROREPORT, V11, P963, DOI 10.1097/00001756-200004070-00013; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bordet R, 2000, J CEREBR BLOOD F MET, V20, P1190, DOI 10.1097/00004647-200008000-00004; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Carlson NG, 1999, J IMMUNOL, V163, P3963; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark WM, 1999, NEUROL RES, V21, P287, DOI 10.1080/01616412.1999.11740933; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; Fassbender K, 1999, STROKE, V30, P1647, DOI 10.1161/01.STR.30.8.1647; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Ford ES, 2000, ARTERIOSCL THROM VAS, V20, P1052, DOI 10.1161/01.ATV.20.4.1052; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; Furuya K, 2000, STROKE, V31, P277; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; Johansson A, 2000, J INTERN MED, V247, P179, DOI 10.1046/j.1365-2796.2000.00600.x; Kano T, 2000, BRAIN RES, V854, P245, DOI 10.1016/S0006-8993(99)02276-3; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kim MH, 2000, J IMMUNOL, V164, P5883, DOI 10.4049/jimmunol.164.11.5883; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Letterio JJ, 2000, CYTOKINE GROWTH F R, V11, P81, DOI 10.1016/S1359-6101(99)00031-3; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Relton JK, 2001, STROKE, V32, P199, DOI 10.1161/01.STR.32.1.199; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Savitz SI, 2000, J CEREBR BLOOD F MET, V20, P1197, DOI 10.1097/00004647-200008000-00005; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; Toyoda T, 2000, J NEUROSURG, V92, P435, DOI 10.3171/jns.2000.92.3.0435; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vila N, 2000, J INTERF CYTOK RES, V20, P325, DOI 10.1089/107999000312478; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Vos CMP, 2000, J NEUROIMMUNOL, V109, P221, DOI 10.1016/S0165-5728(00)00308-8; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X	67	69	73	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2001	14	3					349	353		10.1097/00019052-200106000-00014			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	439NM	WOS:000169123400014	11371759				2021-06-18	
J	Bain, AC; Raghupathi, R; Meaney, DF				Bain, AC; Raghupathi, R; Meaney, DF			Dynamic stretch correlates to both morphological abnormalities and electrophysiological impairment in a model of traumatic axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomechanics; injury tolerance; stretch injury; head injury	VISUAL EVOKED-POTENTIALS; RAT OPTIC-NERVE; HEAD-INJURY; NEUROFILAMENT SUBUNITS; BRAIN; HUMANS; DAMAGE; RESPONSES; CRUSH; APP	In this investigation, the relationships between stretch and both morphological and electrophysiological signs of axonal injury were examined in the guinea pig optic nerve stretch model. Additionally, the relationship between axonal morphology and electrophysiological impairment was assessed. Axonal injury was produced in vivo by elongating the guinea pig optic nerve between 0 and 8 mm (N-total = 70). Morphological damage was detected using neurofilament immunohistochemistry (SMI 32). Electrophysiological impairment was determined using changes in visual evoked potentials (VEPs) measured prior to injury, every 5 min for 40 min following injury, and at sacrifice (72 h). All nerves subjected to ocular displacements greater than 6 mm demonstrated axonal swellings and retraction bulbs, while nerves subjected to displacements below 4 mm did not show any signs of morphological injury. Planned comparisons of latency shifts of the N-35 peak in the VEPs showed that ocular displacements greater than 5 mm produced electrophysiological impairment that was significantly different from sham animals. Logit analysis demonstrated that less stretch was required to elicit electrophysiological changes (5.5 mm) than morphological signs of damage (6.8 mm). Moreover, Student t tests indicated that the mean latency shift measured in animals exhibiting morphological injury was significantly greater than that calculated from animals lacking morphological injury (p < 0.01). These data show that distinct mechanical thresholds exist for both morphological and electrophysiological damage to the white matter. In a larger context, the distinct injury thresholds presented in the report will aid in the biomechanical assessment of animate models of head injury, as well as assist in extending these findings to predict the conditions that cause white matter injury in humans.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.			Meaney, David/0000-0002-0954-4122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS09903, NS35712] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER		Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altman D, 1991, PRACTICAL STAT MED R; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CONNELL FA, 1985, AM J EPIDEMIOL, V121, P744; CREEL DJ, 1972, EXP NEUROL, V36, P411, DOI 10.1016/0014-4886(72)90002-7; CREEL DJ, 1973, EXP NEUROL, V40, P351, DOI 10.1016/0014-4886(73)90079-4; DUCATI A, 1988, ELECTROEN CLIN NEURO, V71, P89, DOI 10.1016/0168-5597(88)90010-X; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Einstein AJ, 1997, ARCH PATHOL LAB MED, V121, P110; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HARDING GFA, 1984, OPHTHAL PHYSL OPT, V4, P293; Heshner D., 1981, APPL DISCRETE CHOICE; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; KAWARABAYASHI T, 1993, NEUROSCI LETT, V153, P73, DOI 10.1016/0304-3940(93)90080-5; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; MAHAPATRA AK, 1989, SURG NEUROL, V31, P339, DOI 10.1016/0090-3019(89)90064-5; MASLIAH E, 1993, AM J PATHOL, V142, P871; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRICE DL, 1990, PROG BRAIN RES, V86, P297; ROSENE DL, 1978, J HISTOCHEM CYTOCHEM, V26, P28, DOI 10.1177/26.1.413864; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SABEL BA, 1993, NEUROPSYCHOBIOLOGY, V28, P62, DOI 10.1159/000119001; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOKOL S, 1976, Survey of Ophthalmology, V21, P18, DOI 10.1016/0039-6257(76)90046-1; Steinberg D., 1991, LOGIT SUPPLEMENTARY; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SUGIOKA M, 1995, EXP NEUROL, V132, P262, DOI 10.1016/0014-4886(95)90031-4; SUZUKI M, 1991, J VET MED SCI, V53, P301, DOI 10.1292/jvms.53.301; SUZUKI M, 1991, J VET MED SCI, V53, P911, DOI 10.1292/jvms.53.911; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; TROJANOWSKI JQ, 1983, BRAIN RES, V267, P365, DOI 10.1016/0006-8993(83)90891-0; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; WALSH C, 1986, J NEUROSCI, V6, P1635; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	50	69	71	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					499	511		10.1089/089771501300227305			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000003	11393253				2021-06-18	
J	Rancan, M; Otto, VI; Hans, VHJ; Gerlach, I; Jork, R; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Rancan, M; Otto, VI; Hans, VHJ; Gerlach, I; Jork, R; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Upregulation of ICAM-1 and MCP-1 but not of MIP-2 and sensorimotor deficit in response to traumatic axonal injury in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; axonal injury; impact acceleration model; inflammation; sensorimotor deficit	CONTROLLED CORTICAL IMPACT; ADHESION MOLECULE-1 ICAM-1; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DIFFUSE BRAIN INJURY; CLOSED-HEAD INJURY; ENDOTHELIAL-CELLS; NEUTROPHIL ACCUMULATION; CEREBROSPINAL-FLUID; COGNITIVE DEFICITS	The pathophysiology of traumatic axonal injury (TAI) is only partially understood. In this study, we investigated the inflammatory response as well as the extent of neurological deficit in a rat model of traumatic brain injury (TBI). Forty-two adult rats were subjected to moderate impact-acceleration brain injury and their brains were analyzed immunohistochemically for ICAM-1 expression and neutrophil infiltration from 1 hr up to 14 days after trauma. In addition, the chemotactic factors MIP-2 and MCP-1 were measured in brain homogenates by ELISA. For evaluating the neurological deficit, three sensorimotor tests were applied for the first time in this model. In the first 24 hr after trauma, the number of ICAM-1 positive vessels increased up to 4-fold in cortical and subcortical regions compared with sham operated controls (P < 0.05). Maximal ICAM-1 expression (up to 8-fold increase) was detected after 4 days (P < 0.001 vs, 24 hr), returning to control levels in all brain regions by 7 days after trauma. MCP-1 was elevated between 4 hr and 16 hr post-injury as compared with controls. In contrast, neither neutrophil infiltration nor elevation of MIP-2, both events relevant in focal brain injury, could be detected. In all neurological tests, a significant deficit was observed in traumatized rats as compared with sham operated animals from Day 1 post-injury (grasping reflex of the hindpaws: P < 0.001, vibrissae-evoked forelimb placing: P = 0.002, lateral stepping: P = 0.037). In conclusion, after moderate impact acceleration brain injury ICAM-1 upregulation has been demonstrated in the absence of neutrophil infiltration and is paralleled by a selective induction of chemokines, pointing out that individual and distinct inflammatory events occur after diffuse vs, focal TBI. (C) 2001 Wiley-Liss, Inc.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany; Bayer AG, CNS Res, Pharma Res Ctr, Wuppertal, Germany	Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Ramistr 100, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eijkenboom M, 2000, NEUROPHARMACOLOGY, V39, P817, DOI 10.1016/S0028-3908(00)00002-2; Etienne S, 1998, J IMMUNOL, V161, P5755; Flecknell PA, 1999, LAB ANIM, V33, P169, DOI 10.1258/002367799780578381; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GERLACH I, 1998, J NEUROTRAUM, V15, P870; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hayes JH, 1999, LAB ANIM-UK, V33, P16, DOI 10.1258/002367799780578534; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KRAUS JF, 1996, NEUROTRAUMA, P13; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 2000, CURR OPIN CRIT CARE, V6, P98; OLSSON M, 1995, J NEUROSCI, V15, P3863; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Povlishock JT, 1999, ACT NEUR S, V73, P15; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Sano H, 1998, BIOCHEM BIOPH RES CO, V250, P694, DOI 10.1006/bbrc.1998.9385; Schmal H, 1998, J IMMUNOL, V161, P3685; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shrikant P, 1996, J IMMUNOL, V157, P1819; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROSCI, V15, P8223; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; STOCKER R, 1995, INTEGRATED APPROACH, P196; vanderStaay FJ, 1996, BRAIN RES, V735, P271; Whalen MJ, 1997, ACT NEUR S, V70, P260	57	69	77	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 1	2001	63	5					438	446		10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P			9	Neurosciences	Neurosciences & Neurology	405LV	WOS:000167161900009	11223919				2021-06-18	
J	Veinbergs, I; Mallory, M; Sagara, Y; Masliah, E				Veinbergs, I; Mallory, M; Sagara, Y; Masliah, E			Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						ageing; Alzheimer's disease; antioxidants; gene knock-out; neurodegeneration	LIPOPROTEIN LIPID-PEROXIDATION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; E KNOCKOUT MICE; ALZHEIMERS-DISEASE; CHOLINERGIC IMPAIRMENTS; IN-VIVO; APOE; NEURODEGENERATION; ATHEROSCLEROSIS	Recent studies have suggested that altered function of apolipoprotein E might lead to Alzheimer's disease via oxidative stress. In this context, the objective of this study was to determine if antioxidative treatment with vitamin E was neuroprotective in apolipoprotein E-deficient mice. For this purpose, 1-month-old control and apolipoprotein E-deficient mice received dietary vitamin E for 12 months. We showed that, compared to apolipoprotein E-deficient mice who received a regular diet, mice treated with vitamin E displayed a significantly improved behavioural performance in the Morris water maze. This improved performance was associated with preservation of the dendritic structure in vitamin E-treated apolipoprotein E-deficient mice. In addition, whilst untreated apolipoprotein E-deficient mice displayed increased levels of lipid peroxidation and glutathione, vitamin E-treated mice showed near normal levels of both lipid peroxidation and glutathione. These results support the contention that vitamin E prevents the age-related neurodegenerative alterations in apolipoprotein E-deficient mice.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R29AG010869] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG5131, AG10869] Funding Source: Medline		Buttini M, 1999, J NEUROSCI, V19, P4867; delaTorre JC, 1996, VIROLOGY, V220, P508, DOI 10.1006/viro.1996.0340; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Fisher A, 1998, J NEUROCHEM, V70, P1991; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; Gozes I, 1997, J NEUROBIOL, V33, P329, DOI 10.1002/(SICI)1097-4695(199709)33:3<329::AID-NEU10>3.0.CO;2-A; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hayek T, 1998, J CARDIOVASC PHARM, V31, P540, DOI 10.1097/00005344-199804000-00011; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; Letters JM, 1999, J LIPID RES, V40, P1104; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Masliah E, 1996, PROG NEUROBIOL, V50, P493, DOI 10.1016/S0301-0082(96)00038-X; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; MASLIAH E, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P405; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MASLIAH E, 1995, APOLIPOPROTEIN E ALZ, P59; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moghadasian MH, 1999, CIRCULATION, V99, P1733, DOI 10.1161/01.CIR.99.13.1733; Montine TJ, 1996, J NEUROPATH EXP NEUR, V55, P202, DOI 10.1097/00005072-199602000-00009; Montine TJ, 1999, EXP NEUROL, V158, P234, DOI 10.1006/exnr.1999.7067; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Oitzl MS, 1997, BRAIN RES, V752, P189, DOI 10.1016/S0006-8993(96)01448-5; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; Sagara Y, 1998, J NEUROCHEM, V71, P1002, DOI 10.1046/j.1471-4159.1998.71031002.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shaish A, 1999, ARTERIOSCL THROM VAS, V19, P1470, DOI 10.1161/01.ATV.19.6.1470; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsimikas S, 2000, ARTERIOSCL THROM VAS, V20, P689, DOI 10.1161/01.ATV.20.3.689; Veinbergs I, 1998, NEUROSCI LETT, V249, P71, DOI 10.1016/S0304-3940(98)00399-1; WEST HL, 1994, NEUROSCI LETT, V175, P460; Witting PK, 1999, FASEB J, V13, P667	44	69	72	0	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2000	12	12					4541	4546		10.1111/j.1460-9568.2000.01308.x			6	Neurosciences	Neurosciences & Neurology	387FV	WOS:000166113000038	11122365				2021-06-18	
J	Combes, P; Fauvage, B; Oleyer, C				Combes, P; Fauvage, B; Oleyer, C			Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system	INTENSIVE CARE MEDICINE			English	Article						nosocomial pneumopathy; mechanical ventilation; Cox model; closed suctioning device; ICU	INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; RISK-FACTORS; HEAD-INJURY; BRONCHOALVEOLAR LAVAGE; CONTROLLED TRIAL; MORTALITY; ADULTS; BRONCHOSCOPY; COLONIZATION	Objective: To compare the ventilator-associated pneumonia (VAP) incidence rates in mechanically ventilated patients according to the type of endotracheal suctioning (closed versus open). Setting: The Neurosurgery Intensive Care Unit of the Grenoble University Hospital, France. Design: A prospective randomised study performed after a 6-month period of nursing personnel training. Patients: One hundred four consecutive patients needing mechanical ventilation for more than 48 h were randomised into two groups. To be eligible, patients had to have no active infection or respiratory affection in their passes. In the Stericath group (S + n = 54), patients were not; disconnected from the ventilator during suctioning. The others were routinely managed (S-, n = 50). In both groups patterns of frequency and duration of suctioning were performed according to a standardised protocol. Measurements: The non-adjusted incidence rate of VAP was lower for S + than for S- (7.32 versus15.89 per 1000 patient-days, p = 0.07). Multivariate analysis performed using the Cox model showed an adjusted risk of VAP 3.5 times higher in S- (95 % Cl: 11.00-12.33). The risk being 4.3 higher in patients receiving gastric acid secretion inhibitors (1.08-16.82). In non-censored cases (n = 76) length of ICU stay increased by an average of 16.8 days when VAP was present (p = 0.0008). No adverse effect due to Stericath use was noted and volume of tracheal aspirate was similar between groups (p = 0.178). Conclusion: The use of Stericath reduced the incidence rate of VAP without demonstrating any adverse effect.	CHU Grenoble, F-38043 Grenoble 9, France; Ctr Hosp Roanne, Dept Informat Med & Sante Publ, F-42300 Roanne, France	Fauvage, B (corresponding author), CHU Grenoble, BP 217, F-38043 Grenoble 9, France.						BROWN SE, 1983, CHEST, V83, P621, DOI 10.1378/chest.83.4.621; Brucia J, 1996, HEART LUNG, V25, P295, DOI 10.1016/S0147-9563(96)80065-3; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; CARLON GC, 1987, CRIT CARE MED, V15, P522, DOI 10.1097/00003246-198705000-00015; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CLARK AP, 1990, HEART LUNG, V19, P552; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CROCE MA, 1994, J TRAUMA, V37, P721, DOI 10.1097/00005373-199411000-00005; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; DEPPE SA, 1990, CRIT CARE MED, V18, P1389, DOI 10.1097/00003246-199012000-00016; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JENNETT B, 1975, LANCET, V1, P480; JOHNSON KL, 1994, CRIT CARE MED, V22, P658, DOI 10.1097/00003246-199404000-00023; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MAYHALL CG, 1988, INFECT CONT HOSP EP, V9, P125; MONTRAVERS P, 1993, CHEST, V104, P1541, DOI 10.1378/chest.104.5.1541; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PAPAZIAN L, 1993, CHEST, V104, P1548, DOI 10.1378/chest.104.5.1548; PEERLESS JR, 1995, CHEST, V108, P962, DOI 10.1378/chest.108.4.962; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; RUDY EB, 1991, HEART LUNG, V20, P667; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; TEASDALE G, 1974, LANCET, V2, P81; Timsit JF, 1996, AM J RESP CRIT CARE, V154, P116, DOI 10.1164/ajrccm.154.1.8680666; TORRES A, 1990, AM REV RESPIR DIS, V142, P521; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; WEINSTEIN R, 1991, AM J MED S3B, V91, P180; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349; WUNDERINK RG, 1992, CHEST, V102, P580	40	69	80	0	11	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2000	26	7					878	882		10.1007/s001340051276			5	Critical Care Medicine	General & Internal Medicine	342AR	WOS:000088623500008	10990101				2021-06-18	
J	Nakagawa, Y; Reed, L; Nakamura, M; McIntosh, TK; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Lee, VMY; Trojanowski, JQ				Nakagawa, Y; Reed, L; Nakamura, M; McIntosh, TK; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Lee, VMY; Trojanowski, JQ			Brain trauma in aged transgenic mice induces regression of established A beta deposits	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease; amyloid plaques; brain injury; head trauma; PDAPP mice	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; HEAD-INJURY; SENILE PLAQUES; CELL-DEATH; MEMORY DEFICITS; NERVOUS-SYSTEM; NEURON DEATH; MOUSE MODEL	Traumatic brain injury (TBI) increases susceptibility to Alzheimer's disease (AD), but it is not known if TBI affects the progression of AD. To address this question, we studied the neuropathological consequences of TBI in transgenic (TG) mice with a mutant human A beta precursor protein (APP) mini-gene driven by a platelet-derived (PD) growth factor promoter resulting in overexpression of mutant APP (V717F), elevated brain A beta levels, and AD-like amyloidosis. Since brain A beta deposits first appear in 6-month-old TG (PDAPP) mice and accumulate with age, 2-year-old PDAPP and wild-type (WT) mice were subjected to controlled cortical impact (CCI) TBI or sham treatment. At 1, 9, and 16 weeks after TBI, neuron loss, gliosis, and atrophy were most prominent near the CCI site in PDAPP and WT mice. However, there also was a remarkable regression in the A beta amyloid plaque burden in the hippocampus ipsilateral to TBI compared to the contralateral hippocampus of the PDAPP mice by 16 weeks postinjury. Thus, these data suggest that previously accumulated A beta plaques resulting from progressive amyloidosis in the AD brain also may be reversible. (C) 2000 Academic Press.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anatom Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan; Eli Lilly Inc, Indianapolis, IN USA	Nakagawa, Y (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anatom Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09215, AG11542] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542, P01AG009215] Funding Source: NIH RePORTER		ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; Arnold SE, 1998, ARCH GEN PSYCHIAT, V55, P225, DOI 10.1001/archpsyc.55.3.225; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Chen KS, 1998, PROG BRAIN RES, V117, P327; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; CURZ L, 1997, P NATL ACAD SCI USA, V94, P7612; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frautschy SA, 1998, AM J PATHOL, V152, P307; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; GOEDERT M, 1997, MOL GENETIC BASIS NE, P613; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; Masliah E, 1996, J NEUROSCI, V16, P5795; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REAUME AG, 1996, J BIOL CHEM, V271, P2338; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROCKENSTEIN E, 1995, J BIOL CHEM, V47, P28257; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P1; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schmidt ML, 1998, ACTA NEUROPATHOL, V95, P117, DOI 10.1007/s004010050774; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shin RW, 1997, J NEUROSCI, V17, P8187; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Su Y, 1998, J NEUROSCI RES, V53, P177, DOI 10.1002/(SICI)1097-4547(19980715)53:2<177::AID-JNR6>3.0.CO;2-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281	76	69	69	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2000	163	1					244	252		10.1006/exnr.2000.7375			9	Neurosciences	Neurosciences & Neurology	313NV	WOS:000087006500027	10785464				2021-06-18	
J	Satz, P; Alfano, MS; Light, R; Morgenstern, H; Zaucha, K; Asarnow, RF; Newton, S				Satz, P; Alfano, MS; Light, R; Morgenstern, H; Zaucha, K; Asarnow, RF; Newton, S			Persistent post-concussive syndrome: A proposed methodology and literature review to determine the effects, if any, of mild head and other bodily injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; CHRONIC PAIN; BASE RATES; SYMPTOMS; CHILDREN; ATTENTION; SEQUELAE; SEVERITY	Following mild head injury, a subgroup of individuals exhibit a constellation of chronic symptoms, a condition Alexander(1995) labeled Persistent Post-Concussive Syndrome (PPCS). He implicated neurological factors in the initial phase of the syndrome but psychological factors in the maintenance of symptoms. However, it is unclear as to whether an initial mild head injury is necessary or sufficient to cause the symptoms of PPCS. We first outline a study design comparing a mild closed-head injury group to both a normal and an other injury control group to answer this question. Next, we review the literature since 1960 to determine the findings of any studies using this design. The results of the literature review indicate that few such studies exist. To date, those that have been done suggest that there is no strong evidence for a specific effect for mild head injury on cognitive functioning. We discuss directions for future research given these findings.	Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Daniel Freeman Mem Hosp, Inglewood, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Child Psychiat, Los Angeles, CA 90024 USA; Fuller Theol Seminary, Grad Sch Psychol, Pasadena, CA 91101 USA	Satz, P (corresponding author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, NPI Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.	psatz@med.net.ucla.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alexander MP, 1996, NEUROLOGY, V46, P1488, DOI 10.1212/WNL.46.5.1488-a; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BARRY C, 1997, P INT NEUR SOC C ORL; BIJUR PE, 1990, PEDIATRICS, V86, P337; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KURTZKE JF, 1997, CLIN NEUROLOGY, V66, P1; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; WEISSMAN HN, 1991, FORENSIC REPORTS, V4, P417; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	36	69	70	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1999	21	5					620	628		10.1076/jcen.21.5.620.870			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	264XG	WOS:000084207900003	10572282				2021-06-18	
J	Cormio, M; Valadka, AB; Robertson, CS				Cormio, M; Valadka, AB; Robertson, CS			Elevated jugular venous oxygen saturation after severe head injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral metabolic rate of oxygen; cerebral perfusion pressure; dysoxia; head injury; ischemia; jugular venous oxygen saturation	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; METABOLISM; CONSUMPTION; HYPEREMIA; BULB; COMA	Object. The aim of this study was to investigate the incidence of elevated (greater than or equal to 75%) jugular venous oxygen saturation (SjvO(2),) and its relationship to-cerebral hemodynamic and metabolic parameters and to outcome after severe head injury. Methods. Data from 450 severely head injured patients admitted to the Neurosurgical Intensive Care Unit of Ben Taub General Hospital were analyzed retrospectively. The SjvO(2), was measured in blood obtained from indwelling jugular bulb catheters. Patients were classified into the following categories: high (Group I), normal (Group II), or low SjvO(2), (Group III) if their mean SjvO(2), over the duration of monitoring was 75% or higher, 74 to 56%, or 55% or lower, respectively. A high SjvO(2), occurred in 19.1% of patients. There was no consistent relationship between SjvO(2), and simultaneous cerebral blood flow (CBF) or cerebral perfusion pressure measurements. Compared with Groups II and III, the patients in Group I had a significantly higher CBF and lower cerebral metabolic rate of oxygen (CMRO2. In Group I, the outcomes were death or persistent vegetative state in 48.8% of patients and severe disability in 25.6%. These outcomes were significantly worse than for patients in Group II. Within Group I, the patients with a poor neurological outcome were older and more likely to have suffered a focal head injury; they demonstrated a lower CMRO2, and a greater rate of cerebral lactate production than the patients who attained a favorable outcome. Conclusions. Posttraumatic elevation of SjvO(2) is common but cannot be automatically equated with hyperemia. Instead, elevated SjvO(2), is a heterogeneous condition that is associated with poor outcome after head injury and may carry important implications for the management of comatose patients.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; New Hosp San Gerardo, Dept Anesthesia & Crit Care, Milan, Italy	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bmc.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		Andrews PJD, 1996, J NEUROSURG ANESTH, V8, P220, DOI 10.1097/00008506-199607000-00006; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; Cold GE, 1992, INTENSIVE CARE WORLD, V9, P172; CONNETT RJ, 1990, J APPL PHYSIOL, V68, P833; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Marion D W, 1995, New Horiz, V3, P439; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Matta BF, 1997, ANESTHESIOLOGY, V86, P806, DOI 10.1097/00000542-199704000-00010; MATTHEWS DSF, 1995, J NEUROL NEUROSUR PS, V59, P359, DOI 10.1136/jnnp.59.4.359; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROBIN ED, 1977, ARCH INTERN MED, V137, P905, DOI 10.1001/archinte.137.7.905; ROQUEFEUIL B, 1907, NEUROCHIRURGIA, V23, P401; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; YUKOTA H, 1994, NEUROCHEMICAL MONITO, P98	30	69	76	1	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	1999	90	1					9	15		10.3171/jns.1999.90.1.0009			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168TH	WOS:000078708400002	10413150				2021-06-18	
J	Kreuter, M; Dahllof, AG; Gudjonsson, G; Sullivan, M; Siosteen, A				Kreuter, M; Dahllof, AG; Gudjonsson, G; Sullivan, M; Siosteen, A			Sexual adjustment and its predictors after traumatic brain injury	BRAIN INJURY			English	Article							GLASGOW OUTCOME SCALE; CLOSED HEAD-INJURY; SOCIAL RECOVERY; ATTITUDES; HEALTH	The aim of this study was to investigate the impact of traumatic brain injury (TBI) on sexual ability, activity and satisfaction and to relate the findings to neurological status, functioning and well-being. A total of 92 TBI persons (65 men, 27 women) participated. Their ages ranged from 20-70 years (median 40 years); the median age at injury was 32 years, ranging from 16-56 years. The elapsed time since injury ranged from 1-20 years (median 9 years). The participants were examined according to a procedure including neurological examination, self-assessment of general health status and functioning and mooed, and collection of data on social conditions. A structured study-specific questionnaire was developed to assess various aspects of sexuality before and after the injury. Fifty-three of the participants had a stable partner relationship at the time of the investigation. This study showed that a TBI commonly alters sexual functioning as well as desire. Many of the respondents reported decreased ability to achieve an erection, decreased ability to experience orgasm, decreased sexual desire and diminished frequency of intercourse. A high degree of physical independence and maintained sexual ability were the most important predictors for sexual adjustment. Considering that many TBI persons in this study reported physiological sexual disturbances and decreased sexual ability, it is important to inform. patients about possibilities of optimizing their sexual ability. Organized programmes of sexuality education should be an integral component of TBI rehabilitation.	Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Rehabil Med, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Hlth Care Res Unit, S-41345 Gothenburg, Sweden	Kreuter, M (corresponding author), Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden.						AHLMEN EM, 1990, SCAND J RHEUMATOL, V19, P413, DOI 10.3109/03009749009097630; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BANCROFT J, 1991, ARCH SEX BEHAV, V20, P105, DOI 10.1007/BF01541938; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLACKBURN BK, 1989, STEREOCHEMISTRY ORGA, V3, P143; Bradley JV, 1968, DISTRIBUTION FREE ST; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Cole TM, 1990, KRUSENS HDB PHYSICAL, P988; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; ELASS L, 1987, PSYCHOL MED, V17, P67; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON BB, 1987, ARCH PHYS MED REHAB, V68, P583; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEITH RA, 1987, ADV CLIN REHABILITAT, P10; KENNETT B, 1975, LANCET, V1, P480; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LEVIN HS, 1987, HEAD INJURY; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141, DOI 10.1192/bjp.153.2.141; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Medlar T. M., 1993, SEX DISABIL, V11, P57, DOI DOI 10.1007/BF01102309; MEYER JE, 1971, J NEUROVIS REL S10, P519; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1987, BNI Q, V3, P2; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SILVERBAGE GC, 1986, THESIS U GOTEBORG GO; SIOSTEEN A, 1990, PARAPLEGIA, V28, P285; SULLIVAN M, 1988, J DRUGTHER RES, V13, P167; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WOLF AL, 1989, EMERGENCY MED SERVIC, V18, P35; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	69	69	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	1998	12	5					349	368		10.1080/026990598122494			20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZL444	WOS:000073433500001	9591141				2021-06-18	
J	Goss, JR; Taffe, KM; Kochanek, PM; DeKosky, ST				Goss, JR; Taffe, KM; Kochanek, PM; DeKosky, ST			The antioxidant enzymes glutathione peroxidase and catalase increase following traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; DELAYED NEURONAL DEATH; ISCHEMIA-REPERFUSION; SYSTEM TRAUMA; HEAD-INJURY; TOXICITY	The inflammatory response following mechanical brain injury is characterized by an increase in the cytokine interleukin-1 beta (IL-1 beta) followed by a large elevation in the neurotrophin, nerve growth factor (NGF). The substantial upregulation in NGF observed in our previous studies suggests that it may have functions in addition to that of a target-derived neuronal support mechanism. We hypothesize that NGF is a mediator of oxidative homeostasis, by inducing the production of oxygen-free radical scavengers in brain tissue following injury. We tested this hypothesis by measuring the activity of the antioxidant enzymes, glutathione peroxidase (GSH-Px), and catalase in cortical brain tissue following experimentally induced cortical contusion. We observed a twofold increase in GSH-Px and a threefold increase in catalase activities in a time course which reflected the temporal increase in NGF observed following the same cortical contusion model. These findings support the hypothesis and illuminate an important reparative role for NGF following trauma. (C) 1997 Academic Press.	UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT NEUROBIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT ANESTHESIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT NEUROL, PITTSBURGH, PA 15260 USA; SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA USA	Goss, JR (corresponding author), UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758			AEBI H, 1984, METHOD ENZYMOL, V105, P121; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GUIDOT DM, 1994, INFLAMMATION, V18, P537, DOI 10.1007/BF01560700; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; JACKSON GR, 1994, BRAIN RES, V634, P69, DOI 10.1016/0006-8993(94)90259-3; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MATTSON MP, 1993, EXP NEUROL, V124, P89, DOI 10.1006/exnr.1993.1178; MATTSON MP, 1993, STROKE, V24, pI136; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NISTICO G, 1991, NEUROSCI LETT, V130, P117, DOI 10.1016/0304-3940(91)90241-K; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PASINETTI GM, 1991, ADV EXP MED BIOL, V296, P249; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SINET PM, 1980, J NEUROCHEM, V34, P1421, DOI 10.1111/j.1471-4159.1980.tb11222.x; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; TSAN MF, 1991, J APPL PHYSIOL, V71, P688; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAMOTO S, 1992, NEUROSCI LETT, V141, P161, DOI 10.1016/0304-3940(92)90885-B	32	69	71	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	1997	146	1					291	294		10.1006/exnr.1997.6515			4	Neurosciences	Neurosciences & Neurology	XJ922	WOS:A1997XJ92200033	9225764				2021-06-18	
J	Moseley, AM				Moseley, AM			The effect of casting combined with stretching on passive ankle dorsiflexion in adults with traumatic head injuries	PHYSICAL THERAPY			English	Article						ankle; contracture; head injuries; physical therapy; rehabilitation	IMMOBILIZED MUSCLE; CONNECTIVE-TISSUE; SOLEUS MUSCLE; CONTRACTURE; STIFFNESS; LENGTH; RABBIT	Background and Purpose. Ankle plantar-flexion contractures are a common problem following traumatic head injury. Although serial. casting is used to correct and prevent ankle plantar-flexion contractures, treatment efficacy has not been evaluated using an experimental design, The aim of this research was to establish the effect of a regimen of casting combined with stretching on passive ankle dorsiflexion motion. Subjects. Nine people who had sustained traumatic closed head injuries and had limited dorsiflexion motion participated in the study. Methods. A crossover design was used in the study. Subjects were assigned to both experimental and control groups. Torque-controlled measurements of passive ankle dorsiflexion motion were obtained for all subjects before and after 1 week of casting combined with stretching, as well as before and after a 1-week control period. The order of the experimental and control conditions was randomized. Results. Passive ankle dorsiflexion increased by a mean of 13.5 degrees (SD = 9.3) during the experimental condition, as compared with a mean decrease of 1.9 degrees (SD = 10.2) during the control condition. The difference between the experimental and control conditions was statistically significant. Conclusion and Discussion. These findings suggest that casting combined with stretching is an effective method Of correcting ankle plantar-flexion contractures in patients with traumatic head injuries.		Moseley, AM (corresponding author), LIVERPOOL HLTH SERV, BRAIN INJURY REHABIL UNIT, ELIZABETH ST, LIVERPOOL, NSW 2170, AUSTRALIA.						Ada L, 1980, Aust J Physiother, V26, P57, DOI 10.1016/S0004-9514(14)60801-1; AKESON WH, 1974, CONNECT TISSUE RES, V2, P315, DOI 10.3109/03008207409152261; BOOTH BJ, 1983, PHYS THER, V63, P1960, DOI 10.1093/ptj/63.12.1960; Carr J, 1987, MOTOR RELEARNING PRO; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CHESWORTH BM, 1995, PHYS THER, V75, P253, DOI 10.1093/ptj/75.4.253; CONINE TA, 1990, ARCH PHYS MED REHAB, V71, P310; Cook T.D., 1979, QUASIEXPERIMENTATION; Grieve DW, 1978, BIOMECHANICS A, P405; HERBERT RD, 1993, J ORTHOPAED RES, V11, P358, DOI 10.1002/jor.1100110307; HERBERT RD, 1995, 15 C INT SOC BIOM, P380; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; IMIE PC, 1986, PHYS THER, V66, P748; JONES A, 1990, Physiotherapy Canada, V42, P15; KENT H, 1990, Physiotherapy Canada, V42, P189; Moore S, 1993, Aust J Physiother, V39, P271, DOI 10.1016/S0004-9514(14)60487-6; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Moseley A, 1993, Aust J Physiother, V39, P259, DOI 10.1016/S0004-9514(14)60486-4; Moseley Anne M., 1993, Physiotherapy Theory and Practice, V9, P215, DOI 10.3109/09593989309036493; Narici MV, 1996, J PHYSIOL-LONDON, V496, P287, DOI 10.1113/jphysiol.1996.sp021685; SIEGLER S, 1984, J BIOMECH, V17, P647, DOI 10.1016/0021-9290(84)90118-0; SULLIVAN T, 1988, Physiotherapy Canada, V40, P346; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; TARDIEU C, 1989, PHYS THER, V69, P656, DOI 10.1093/ptj/69.8.656; WILLIAMS PE, 1988, ANN RHEUM DIS, V47, P1014, DOI 10.1136/ard.47.12.1014; WILLIAMS PE, 1978, J ANAT, V127, P459; WILLIAMS PE, 1984, J ANAT, V138, P343; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; ZACHAZEWSKI JE, 1982, PHYS THER, V62, P453, DOI 10.1093/ptj/62.4.453	29	69	69	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	MAR	1997	77	3					240	247		10.1093/ptj/77.3.240			8	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	WL837	WOS:A1997WL83700002	9062567	Bronze			2021-06-18	
J	McIntosh, TK; Smith, DH; Voddi, M; Perri, BR; Stutzmann, JM				McIntosh, TK; Smith, DH; Voddi, M; Perri, BR; Stutzmann, JM			Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; edema; excitotoxicity; glutamate; neuroprotection; rat	CONTROLLED CORTICAL IMPACT; AMINO-ACID NEUROTRANSMISSION; GLUTAMATE RELEASE INHIBITOR; REGIONAL CEREBRAL EDEMA; FLUID-PERCUSSION MODEL; SODIUM-CHANNEL BLOCKER; D-ASPARTATE RECEPTORS; MODERATE HYPOTHERMIA; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; NEUROCHEMICAL SEQUELAE	Several potential mechanisms are involved in mediating the pathophysiology of traumatic brain injury (TBI), including inflammatory processes and excitotoxicity. In the present study, we evaluated the ability of the use-dependent sodium channel inhibitor Riluzole to attenuate cognitive and neurologic motor deficits and reduce regional cerebral edema and histologic cell damage following lateral fluid-percussion (FP) brain injury in rats (n = 109). In study 1, 58 anesthetized male Sprague-Dawley rats (350-400 g) were subjected to FP brain injury of moderate severity (2.3-2.5 atm). Fifteen minutes following brain injury, animals randomly received an i.v. bolus of either Riluzole (4 mg/kg, n = 11), Riluzole (8 mg/kg, n = 11), or glycol vehicle (n = 20), followed by 6 h and 24 h s.c. injections (identical dose). Surgically prepared but uninjured animals received vehicle (n = 16) and served as controls. Animals were evaluated for cognitive deficits at 48 h postinjury and killed for assessment of regional brain edema. Administration of vehicle or Riluzole (4 mg/kg x 3) had no significant effect on memory or edema, whereas Riluzole (8 mg/kg x 3) significantly attenuated posttraumatic cognitive dysfunction (p < 0.05). In study 2, a second group of animals (n = 25) was injured, treated with Riluzole (8 mg/kg x 3 doses, n = 13) or vehicle (n = 12), and evaluated for neurologic motor function over 2 weeks. Animals treated with Riluzole demonstrated significantly improved motor scores beginning 1 week postinjury (p < 0.05). In study 3, brain-injured animals were treated with Riluzole (8 mg/kg x 3 doses, n = 10) or vehicle (n = 10), and posttraumatic Iesion volume was assessed at 48 h postinjury using 2,3,5-triphenyltetrazolium chloride (TTC) staining. Treatment with Riluzole had no significant effect on posttraumatic lesion volume. The present study demonstrates that use-dependent sodium channel inhibitors, such as Riluzole, can attenuate both cognitive and neuromotor dysfunction associated with brain trauma.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT NEUROL DIS,VITRY SUR SEINE,FRANCE	McIntosh, TK (corresponding author), UNIV PENN,DIV NEUROSURG,105 HAYDEN HALL,3320 SMITH WALK,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818, P50NS008803, R55NS026818] Funding Source: NIH RePORTER		ALAOUI F, 1995, EUR J PHARMACOL, V276, P55, DOI 10.1016/0014-2999(95)00006-7; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CLINESCHMIDT BV, 1982, DRUG DEVELOP RES, V2, P123, DOI 10.1002/ddr.430020203; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOBLE A, 1989, NEUROCHEM INT, V15, P1, DOI 10.1016/0197-0186(89)90069-7; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DOBLE A, 1996, IN PRESS NEUROLOGY; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P789; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYWARD NJ, 1993, EUR J PHARMACOL, V236, P247, DOI 10.1016/0014-2999(93)90595-9; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HYLTON C, 1995, J NEUROTRAUM, V12, P124; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAUS JF, 1995, 1 WORLD C BRAIN INJ, P5; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; Perri Brain, 1995, Journal of Neurotrauma, V12, P481; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHOHAMI E, 1995, BRAIN RES, V674, P44; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SE, 1989, NEUROREPORT, V32, P1339; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STUTZMANN JM, 1991, EUR J PHARMACOL, V193, P223, DOI 10.1016/0014-2999(91)90040-W; STUTZMANN JM, 1995, NEURODEGENERATIVE DI, P205; STUTZMANN JM, 1996, IN PRESS NEUROREPORT; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TORREGROSA G, 1994, J VASC RES, V31, P221, DOI 10.1159/000159047; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VODDI MD, 1995, J NEUROTRAUM, V12, P146; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	86	69	69	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1996	13	12					767	780		10.1089/neu.1996.13.767			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WC105	WOS:A1996WC10500004	9002062				2021-06-18	
J	Baldwin, SA; Scheff, SW				Baldwin, SA; Scheff, SW			Intermediate filament change in astrocytes following mild cortical contusion	GLIA			English	Article						glial fibrillary acidic protein; vimentin; proliferation	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; MESSENGER-RNA; DENTATE GYRUS; BRAIN INJURY; ADULT-RATS; CEREBRAL-CORTEX; GLIAL REACTION; VISUAL-CORTEX; EXPRESSION	Astrocytes are known to become reactive as a result of various types of lesions. They upregulate astrocytic-specific intermediate filament glial fibrillary acidic protein (GFAP) and show a positive signal for the intermediate filament vimentin, a protein primarily found in developing astrocytes. An animal model for cortical contusions has been developed that manifests many of the neuropathologies seen in human closed head injury. The model involves an electronic controlled pneumatic impact device (ECPI), which can deliver precise and controlled cortical contusions to an animal. This model can be used to study astrocyte response to injury, leading to a better understanding of glial reaction to head trauma in humans. Young adult male Fisher 344 rats were subjected to a mild dorsal lateral cortical impact. The astrocytic intermediate filaments GFAP and vimentin were upregulated in a time-dependent manner 2 days after injury. By 30 days following contusion these intermediate filaments returned to near preinjury levels. Using the same injury model bromodeoxyuridine (BrdU) was injected in additional animals on the day of sacrifice, 1, 2, 4, and 10 days after injury, to label cells synthesizing new DNA. Double labeling utilizing fluorescence immunocytochemistry indicated that on postinjury day 2 very few GFAP-positive cells were double labeled with BrdU. No double-labeled cells were seen at the other time points. These data suggest that astrocyte proliferation may not be a major response to mild cortical contusion and that vimentin expression may not necessarily be associated with astrocytic proliferation in response to injury. (C) 1996 Wiley-Liss, Inc.	UNIV KENTUCKY, SANDERS BROWN CTR AGING 311, LEXINGTON, KY 40536 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		AGHAJANIAN G. K., 1967, BRAIN RES, V6, P716, DOI 10.1016/0006-8993(67)90128-X; BARRES BA, 1991, J NEUROSCI, V11, P3685; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BRAND S, 1984, ANAT EMBRYOL, V169, P21, DOI 10.1007/BF00300583; CALEY DW, 1968, J COMP NEUROL, V133, P45, DOI 10.1002/cne.901330104; CIESIELSKITRESKA J, 1982, NEUROSCIENCE, V7, P509, DOI 10.1016/0306-4522(82)90284-6; CIESIELSKITRESKA J, 1982, NEUROCHEM RES, V7, P275, DOI 10.1007/BF00965640; CORTEZ S, 1982, BRAIN RES, V482, P271; Cotman C. W., 1985, SYNAPTIC PLASTICITY, P13; COTMAN CW, 1978, NEURONAL PLASTICITY, P227; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duffy PE, 1983, ASTROCYTES NORMAL RE; DYSON SE, 1976, BRAIN RES, V114, P365, DOI 10.1016/0006-8993(76)90960-4; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; FEDOROFF S, 1985, MOL BASES NEURAL DEV, P91; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GILMORE SA, 1990, GLIA, V3, P342, DOI 10.1002/glia.440030505; GLEZER II, 1990, BRAIN RES BULL, V24, P401, DOI 10.1016/0361-9230(90)90096-I; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; LANGAN TJ, 1992, BRAIN RES, V577, P200, DOI 10.1016/0006-8993(92)90275-E; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MIKUCKI SA, 1991, METAB BRAIN DIS, V6, P33, DOI 10.1007/BF01000383; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; OBLINGER MM, 1993, INT J DEV NEUROSCI, V11, P149, DOI 10.1016/0736-5748(93)90075-O; OPPENHEIM RW, 1975, J COMP NEUROL, V161, P383, DOI 10.1002/cne.901610308; PALAY SL, 1962, J CELL BIOL, V12, P385, DOI 10.1083/jcb.12.2.385; PETITO CK, 1992, PROG BRAIN RES, V94, P381; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; PRIVAT A, 1988, ASTROCYTES CELL BIOL, P105; SCHEFF SW, 1989, NEURAL REGENERATION, P137; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; SINGH DNP, 1989, ACTA ANAT, V134, P156; STEWARD O, 1990, J NEUROSCI, V10, P2373; STEWARD O, 1974, EXP BRAIN RES, V20, P45; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; SUZUKI M, 1991, ACTA NEUROPATHOL, V82, P93, DOI 10.1007/BF00293950; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	53	69	70	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	1996	16	3					266	275					10	Neurosciences	Neurosciences & Neurology	TY427	WOS:A1996TY42700009	8833197				2021-06-18	
J	FINSET, A; DYRNES, S; KROGSTAD, JM; BERSTAD, J				FINSET, A; DYRNES, S; KROGSTAD, JM; BERSTAD, J			SELF-REPORTED SOCIAL NETWORKS AND INTERPERSONAL SUPPORT 2 YEARS AFTER SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; REHABILITATION; ADJUSTMENT; RECOVERY	Fifty-four patients with traumatic brain injury (TBI) consecutively admitted to a rehabilitation hospital were examined 2 years post-injury. Social interaction and support, subjective complaints, and functional status were assessed. A large variability in social interaction and support patterns was found. Most patients had more interaction and received more support from family members than from friends and neighbours. Thirty-one patients (57.4%) reported that their social networks had markedly declined subsequent to injury. Relatively short duration of coma (<1 week) and severe sequelae in terms of low functional status and poor emotional adjustment at follow-up, especially in terms of deficits in initiating behaviour, were found to be related to little interaction and support. The importance of both provider and patient initiative in order to establish and preserve a social support network is suggested, and clinical implications briefly discussed.	BERG GARD,CENT INST HABIL,OSLO,NORWAY; SUNNASS REHABIL HOSP,NESODDTANGEN,NORWAY	FINSET, A (corresponding author), UNIV OSLO,DEPT BEHAV SCI MED,POB 1111 BLINDERN,N-0317 OSLO,NORWAY.						Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FINSET A, UNPUB FUNKSJONSBEDRI; FINSET A, 1993, 12TH WORLD C PSYCH M; FINSET A, 1993, FORSCHRITTE NEUROTRA, V1, P153; FINSET A, 1990, COGNITIVE REHABILITA, P99; FYRAND L, 1994, SOSIALE NETTVERK TEO; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Holosko M, 1989, CANADIAN J REHABILIT, V2, P145; KAPLAN SP, 1990, REHABILITATION COUNS, V34, P17; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Stuss D.T., 1986, FRONTAL LOBES; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VARDEBERG K, 1991, WORLD FEDERATION OCC, V24, P30; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	28	69	69	0	9	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					141	150		10.3109/02699059509008187			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800003	7787834				2021-06-18	
J	VILKKI, J; AHOLA, K; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O				VILKKI, J; AHOLA, K; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O			PREDICTION OF PSYCHOSOCIAL RECOVERY AFTER HEAD-INJURY WITH COGNITIVE TESTS AND NEUROBEHAVIORAL RATINGS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; NEUROPSYCHOLOGICAL DEFICITS; BRAIN INJURY; PERSEVERATION; QUALITY; SCALE; LIFE; COMA	A series of 53 patients was studied using a battery of tests and a neurobehavioral rating scale on average 4 months after closed-head injury (CHI). Social outcome was assessed 1 year after injury by interviewing a family member. The results supported the hypothesis that tests of flexibility and programming rather than tests of cognitive skills predict psychosocial recovery after CHI. Spatial Learning with Self-Set Coals and Sorting were measures of flexibility and programming. Contrary to expectation, word fluency performance was unrelated to these measures, but was associated with conventional intelligence tests, which did not predict psychosocial recovery. Cognition/energy deficit on the Neurobehavioral Rating Scale and increased age were useful predictors of poor psychosocial outcome, whereas computed tomography findings or the Glasgow Coma Score were weakly related to the outcome indices. Evidently, cognitive flexibility and mental programming are very important psychological prerequisites of social recovery after CHI.		VILKKI, J (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.			Ohman, Juha/0000-0002-6592-1367			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Baddeley A. D., 1986, WORKING MEMORY; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BENTON AL, 1963, REVISED VISUAL RETEN; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Fuster J, 1989, PREFRONTAL CORTEX; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDSTEIN FC, 1987, NEUROBEHAVIORAL RECO, P217; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GROSS Y, 1989, CLIN NEUROPSYCHOLOGY, P179; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUZER JS, 1990, VOCATIONAL REHABILIT, P35; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luria A. R, 1973, WORKING BRAIN; Mayes A., 1988, HUMAN ORGANIC MEMORY; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Milner B, 1964, FRONTAL GRANULAR COR, P313; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; SANDSON J, 1984, NEUROPSYCHOLOGIA, V22, P715, DOI 10.1016/0028-3932(84)90098-8; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1990, J CLIN EXP NEUROPSYC, V12, P34; STUSS DT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P157; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P1101, DOI 10.1016/0028-3932(89)90189-9; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P971, DOI 10.1016/0028-3932(89)90072-9; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wechsler D., 2008, WECHSLER ADULT INTEL	49	69	71	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					325	338		10.1080/01688639408402643			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400001	7929700				2021-06-18	
J	ROSS, DT; GRAHAM, DI; ADAMS, JH				ROSS, DT; GRAHAM, DI; ADAMS, JH			SELECTIVE LOSS OF NEURONS FROM THE THALAMIC RETICULAR NUCLEUS FOLLOWING SEVERE HUMAN HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article							FOREBRAIN ISCHEMIA; BRAIN INJURY; RAT; DAMAGE; COLLATERALS; COMPLEX; DEATH; MODEL; CAT	The GABAergic neurons of the thalamic reticular nucleus, or nucleus reticularis thalami (RT), have been implicated as important components in attentional processing systems. Neurons in the RT are exquisitely sensitive to degeneration following kainic and domoic acid toxicity, experimental global ischemia, human cardiac arrest, and experimental closed head injury in nonhuman primates. The present study was performed to establish whether the selective loss of human RT neurons occurred following severe head injury. Brains from 37 human nonsurvivors of head injury were examined for evidence of RT neuronal loss. RT lesions in were found in 36 of 37 cases, representing 65 of 73 (89%) of the reticular nuclei examined. The incidence of RT lesions was similar in all age groups: 13 of 14 cases (92.9%) in the pediatric (less-than-or-equal-to 16 years) group, 33 of 37 (89.2%) in the young adult (18-45 years) group, and 19 of 22 (86.4%) in the older adult (>45 years) group. RT lesions were characterized by loss of one fourth to three fourths of the neurons from the region of the nucleus associated with the frontal cortex and thalamic mediodorsal (MD) and ventrolateral (VL) nuclei. Sparing of RT neurons correlated highly with the presence of extensive frontal cortical lesions, suggesting that an intact corticothalamic projection was necessary for RT degeneration following head injury. A pathologic cascade with a prominent excitotoxic component is proposed. The loss of these inhibitory thalamic reticular neurons and the resultant thalamic and neocortical neuronal dysfunctions may underlie some forms of attentional deficits that persist following head injury.	SO GEN HOSP,INST NEUROSCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND	ROSS, DT (corresponding author), UNIV PENN,CTR HEAD INJURY,DIV NEUROSURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS028852, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS NS-28852-02, NINDS NS-08803-22] Funding Source: Medline		Adams J. H., 1982, HEAD INJURY BASIC CL, P141; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BRIERLEY JB, 1971, BRAIN RES, V25, P483, DOI 10.1016/0006-8993(71)90456-2; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; CARMAN JB, 1964, J ANAT, V98, P587; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOW KL, 1952, J COMP NEUROL, V97, P37, DOI 10.1002/cne.900970105; COOK J, 1990, REHABILITATION ADULT, P493; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; DECURTIS M, 1989, NEUROSCIENCE, V33, P275, DOI 10.1016/0306-4522(89)90207-8; DESCHENES M, 1990, EUR J NEUROSCI, V2, P140, DOI 10.1111/j.1460-9568.1990.tb00406.x; FRIEDBERG EB, 1993, IN PRESS NEUROSCI LE; Fuster J, 1989, PREFRONTAL CORTEX; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GENNARELLI TA, 1980, INTRACRANIAL PRESSUR, V4, P28; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Gronwall D, 1989, MILD HEAD INJURY, P153; Grunthal E, 1942, MON PSYCHIATR NEUROL, V106, P114; HARRINGTON DE, 1990, REHABILITATION ADULT, P493; HARRIS RM, 1987, J COMP NEUROL, V258, P397, DOI 10.1002/cne.902580308; Hayes RL, 1989, MILD HEAD INJURY, P54; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HOUSER CR, 1980, BRAIN RES, V200, P341, DOI 10.1016/0006-8993(80)90925-7; Jasper H.H., 1954, BRAIN MECHANISMS CON, P374; Jones E.G., 1985, THALAMUS; JONES EG, 1975, J COMP NEUROL, V162, P285, DOI 10.1002/cne.901620302; JORGENSEN MB, 1987, ACTA NEUROPATHOL, V73, P189, DOI 10.1007/BF00693788; KAWAI K, 1991, J CEREB BLOOD FLO S2, V11, pS532; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MARTIN JJ, 1975, HDB CLIN NEUROLOGY, V21, P469; MARTIN JJ, 1969, HDB CLIN NEUROLOGY, V2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OHARA PT, 1985, J NEUROCYTOL, V14, P365, DOI 10.1007/BF01217752; ONODERA H, 1986, NEUROSCI LETT, V68, P169, DOI 10.1016/0304-3940(86)90136-9; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RINVIK E, 1988, CELLULAR THALAMIC ME, P321; ROSS D T, 1987, Society for Neuroscience Abstracts, V13, P762; ROSS DT, 1989, BRAIN RES, V501, P129, DOI 10.1016/0006-8993(89)91034-2; ROSS DT, 1993, IN PRESS J CEREB BLO; ROSS DT, 1990, SOC NEUR ABSTR, V20, P476; ROSS DT, 1993, UNPUB J NEUROSCI; ROSS DT, 1992, J NEUROTRAUM, V9, P399; SCHEIBEL MADGE E., 1966, BRAIN RES, V1, P43, DOI 10.1016/0006-8993(66)90104-1; SCHEIBEL ME, 1967, NEUROSCIENCES STUDY, P577; SHOSAKU A, 1986, J NEUROPHYSIOL, V55, P1030; SKINNER JE, 1976, ELECTROEN CLIN NEURO, V40, P288, DOI 10.1016/0013-4694(76)90152-8; SKINNER JF, 1977, PROGR CLIN NEUROPHYS, P30; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; STERIADE M, 1986, DYNAMIC ASPECTS NEOC, P107; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TOURTELLOTTE WG, 1990, BRAIN RES, V515, P227, DOI 10.1016/0006-8993(90)90600-G; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VONHARTMANMONAK.N, 1972, SCHWEIZ ARCH NEUROL, V110, P13; YEN CT, 1983, BRAIN RES, V280, P148, DOI 10.1016/0006-8993(83)91183-6; YINGLING CD, 1976, ELECTROEN CLIN NEURO, V41, P476, DOI 10.1016/0013-4694(76)90059-6; YOON M S, 1989, Anatomical Record, V223, p125A	61	69	69	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					151	165		10.1089/neu.1993.10.151			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600006	8411218				2021-06-18	
J	SCHWAB, K; GRAFMAN, J; SALAZAR, AM; KRAFT, J				SCHWAB, K; GRAFMAN, J; SALAZAR, AM; KRAFT, J			RESIDUAL IMPAIRMENTS AND WORK STATUS 15 YEARS AFTER PENETRATING HEAD-INJURY - REPORT FROM THE VIETNAM HEAD-INJURY STUDY	NEUROLOGY			English	Article							FOLLOW-UP; NEUROLOGY; EPILEPSY; LESIONS	We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam. Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85). Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls. Seven systematically defined impairments proved to be most correlated with work status. These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior. These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work. We suggest that a simple summed score of the number of these seven disabilities can yield a residual ''disability score'' which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and perhaps in other brain-injured populations. These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work.	UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, HEAD INJURY UNIT, BETHESDA, MD 20814 USA; NINCDS, COGNIT NEUROSCI SECT, BETHESDA, MD 20892 USA				Grafman, Jordan H./0000-0001-8645-4457			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECK SJ, 1960, RORSCHACHS TEST BASI, V2, P75; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; COHANY SR, 1990, MONTHLY LABOR RE APR, P22; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Eysenck H. J, 1975, MANUAL EYSENCK PERSO; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRAFMAN J, 1990, CORTEX, V26, P361, DOI 10.1016/S0010-9452(13)80086-X; GRAFMAN J, 1985, ARCH NEUROL-CHICAGO, V42, P1162, DOI 10.1001/archneur.1985.04060110044014; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Grafman J., 1987, NEUROBEHAVIORAL RECO, P43; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1988, HEAD TRAUMA RES PROJ; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; KJONAS B, 1987, P SECTION SURVEY RES; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KRAFT J, IN PRESS ARCH PHYS M; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LUDLOW CL, 1986, BRAIN, V109, P55, DOI 10.1093/brain/109.1.55; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OVERALL JE, 1962, PSYCHOL REP, V10, P799; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; SALAZAR AM, 1987, DV  EPILEPTOLOGY, V16, P753; SALAZAR AM, 1987, ADV EPILEPTOL, V16, P627; SMUTOK M A, 1985, Neurology, V35, P83; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1987, Brain Inj, V1, P113; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; 1982, B US DEP LABOR, V2096	45	69	70	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN	1993	43	1					95	103		10.1212/WNL.43.1_Part_1.95			9	Clinical Neurology	Neurosciences & Neurology	KJ189	WOS:A1993KJ18900017	8423917				2021-06-18	
J	HAMM, RJ; WHITEGBADEBO, DM; LYETH, BG; JENKINS, LW; HAYES, RL				HAMM, RJ; WHITEGBADEBO, DM; LYETH, BG; JENKINS, LW; HAYES, RL			THE EFFECT OF AGE ON MOTOR AND COGNITIVE DEFICITS AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSURGERY			English	Article						AGE; BRAIN INJURY; CONCUSSION; FLUID PERCUSSION MODEL; HEAD INJURY	SEVERE HEAD-INJURY; PROGNOSIS; CONCUSSION; RECEPTORS; GLUTAMATE; DISEASE; ADULT; COMA	AGE IS ONE of the most important predictors of outcome after human traumatic brain injury. This study used fluid percussion brain injury to investigate the effects of aging on outcome after brain injury in rats. Three-month-old (n = 8) and 20-month-old (n = 11) rats were injured at a low level (1.7-1.8 atm) of fluid percussion brain injury or received a sham injury (n = 6 for both age groups). Body weight and motor function (beam balance and beam walking) were assessed before injury and for the first 5 days after injury. Cognitive outcome was assessed with the Morris water maze on Days 11 to 15 after injury. Injury did not produce significant weight loss in either age group. At the low level of brain injury used in this study, the 3-month-old rats did not demonstrate any significant motor deficits on the beam-balance or beam-walking tasks. However, the 20-month-old rats displayed significant beam-balance deficits on each of the 5 postinjury test days and significant beam-walking deficits for the first 3 postinjury days. Although Morris water maze performance was impaired in both age groups, the magnitude of impairment was greater in the aged animals. These data demonstrate that traumatic brain injury in the aged animal is marked by increased motor and cognitive deficits, in the absence of pronounced compromise of the animal's general health. Because the rat model of fluid percussion brain injury reproduces the age-related increase in chronic morbidity observed in cases of human brain injury, the fluid percussion model should be useful for studying mechanisms responsible for the age-related increase in vulnerability to brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298	HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,VCU BOX 2018,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, NS19950, NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS019950, P01NS012587, P50NS012587] Funding Source: NIH RePORTER		ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHIO SC, 1983, J NEUROSURG, V59, P294; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; COTMAN CW, 1989, DRUG DEVELOP RES, V17, P331, DOI 10.1002/ddr.430170408; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINGER S, 1978, RECOVERY BRAIN DAMAG; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HAMM RJ, 1991, J NEUROSURG, V85, P915; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KENNARD MA, 1940, AM J PHYSIOL, V115, P138; KENNARD MA, 1942, ARCH NEUROL PSYCHIAT, V48, P228; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAKIYAMA Y, IN PRESS ACTA NEUROP; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; OVERGAARD J, 1973, LANCET, V2, P631; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHWARCZ R, 1984, LIFE SCI, V35, P19, DOI 10.1016/0024-3205(84)90148-6; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILSON JA, 1988, BRAIN INJURY, V1, P183	41	69	70	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1992	31	6					1072	1078		10.1227/00006123-199212000-00013			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KD087	WOS:A1992KD08700013	1335138				2021-06-18	
J	WEHMAN, PH; KREUTZER, JS; WEST, MD; SHERRON, PD; ZASLER, ND; GROAH, CH; STONNINGTON, HH; BURNS, CT; SALE, PR				WEHMAN, PH; KREUTZER, JS; WEST, MD; SHERRON, PD; ZASLER, ND; GROAH, CH; STONNINGTON, HH; BURNS, CT; SALE, PR			RETURN TO WORK FOR PERSONS WITH TRAUMATIC BRAIN INJURY - A SUPPORTED EMPLOYMENT APPROACH	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article										WEHMAN, PH (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,RICHMOND,VA 23298, USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Dahlstrom W. G., 1972, MMPI HDB, V1; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; FRASER RT, 1988, REHABILITATION ED, V2, P179; GRANGER CV, 1982, KRUSENS HDB PHYSICAL, P253; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; KREUTZER JS, 1989, REHABIL PSYCHOL, V34, P117; KREUTZER JS, 1988, VOCATIONAL REHABILIT, P291; KREUTZER JS, 1987, REHABILITATION RES T; MANK D, 1986, PATHWAYS EMPLOYMENT, P139; MCMORDLE W, 1989, BRAIN INJURY, V4, P57; MOON MS, 1988, VOCATIONAL REHABILIT, P17; PECK G, 1984, ANN M INT NEUROPSYCH; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; REITAN RM, 1979, HALSTEAD REITAN NEUR; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109; WEHMAN P, 1988, REHABIL COUNS BULL, V31, P298; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; Wehman P, 1985, J ASSOC PERS SEVERE, V10, P3; WEHMAN P, 1990, VOCATIONAL REHABILIT; WIEDERHOLT FL, 1986, GRAY ORAL READING TE; ZASLER ND, 1990, VOCATIONAL REHABILIT, P71; ZUNG BJ, 1975, J STUD ALCOHOL, V36, P127, DOI 10.15288/jsa.1975.36.127; ZUNG BJ, 1979, J STUD ALCOHOL, V40, P845, DOI 10.15288/jsa.1979.40.845; 1984, WIDE RANGE ACHIEVEME; 1985, STATISTICAL ANAL SYS	35	69	69	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1990	71	13					1047	1052					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EN093	WOS:A1990EN09300002	2256804				2021-06-18	
J	FADEN, AI				FADEN, AI			TRH ANALOG YM-14673 IMPROVES OUTCOME FOLLOWING TRAUMATIC BRAIN AND SPINAL-CORD INJURY IN RATS - DOSE-RESPONSE STUDIES	BRAIN RESEARCH			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	FADEN, AI (corresponding author), VET ADM MED CTR,NEUROL SERV 127,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		BASSIRI RM, 1973, J CLIN INVEST, V52, P1616, DOI 10.1172/JCI107339; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; DEMEDIUK P, IN PRESS J NEUROTRAU; FADEN AI, 1985, NEUROLOGY, V35, P1331, DOI 10.1212/WNL.35.9.1331; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, PEPTIDES, V4, P631, DOI 10.1016/0196-9781(83)90009-8; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1982, NEUROLOGY, V32, P1083, DOI 10.1212/WNL.32.10.1083; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1987, PHYSL BASIS FUNCTION, V47, P531; FEUERSTEIN G, 1984, NEUROPEPTIDES, V4, P303, DOI 10.1016/0143-4179(84)90004-0; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HANNAN CJ, 1982, NEUROSCI LETT, V33, P299, DOI 10.1016/0304-3940(82)90389-5; HOLADAY JW, 1982, LIFE SCI, V31, P385, DOI 10.1016/0024-3205(82)90419-2; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KOSKINEN LOD, IN PRESS ANN NY ACAD; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; LUX WE, 1983, CIRC SHOCK, V10, P262; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, IN PRESS NEUROSCIENC; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; OSHAUGHNESSY CT, IN PRESS J PHYSL LON; PRANGE A J JR, 1979, P75; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; YAMAKAMI I, IN PRESS J CEREB BLO; YAMAMOTO M, IN PRESS ANN NY ACAD; YARBROUGH GG, 1979, PROG NEUROBIOL, V12, P291, DOI 10.1016/0301-0082(79)90012-1; Young W, 1985, Cent Nerv Syst Trauma, V2, P109	36	69	72	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 8	1989	486	2					228	235		10.1016/0006-8993(89)90509-X			8	Neurosciences	Neurosciences & Neurology	U6056	WOS:A1989U605600004	2499400				2021-06-18	
J	EVANS, RW; GUALTIERI, CT; PATTERSON, D				EVANS, RW; GUALTIERI, CT; PATTERSON, D			TREATMENT OF CHRONIC CLOSED HEAD-INJURY WITH PSYCHOSTIMULANT DRUGS - A CONTROLLED CASE-STUDY AND AN APPROPRIATE EVALUATION PROCEDURE	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article									UNIV N CAROLINA,SCH MED,DEPT PSYCHIAT,CHAPEL HILL,NC 27514	EVANS, RW (corresponding author), UNIV N CAROLINA,SCH MED,BIOL SCI RES CTR,220-H,CHAPEL HILL,NC 27514, USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 07201] Funding Source: Medline		EVANS RW, 1986, CLIN NEUROPHARMACOL, V9, P264, DOI 10.1097/00002826-198606000-00005; EVANS RW, 1986, 14TH ANN M INT NEUR; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; GUALTIERI CT, 1982, J AM ACAD CHILD PSY, V21, P19, DOI 10.1097/00004583-198201000-00005; GUALTIERI CT, 1984, PSYCHOPHARMACOLOGY, V83, P44, DOI 10.1007/BF00427420; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; WEINGARTNER H, 1982, PSYCHIAT RES, V6, P21, DOI 10.1016/0165-1781(82)90034-8; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; WENDER PH, 1985, AM J PSYCHIAT, V142, P547; WERRY JS, 1978, PEDIATRIC PSYCHOPHAR	17	69	69	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	1987	175	2					106	110		10.1097/00005053-198702000-00007			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	G0548	WOS:A1987G054800007	3543216				2021-06-18	
J	HADLEY, MN; GRAHM, TW; HARRINGTON, T; SCHILLER, WR; MCDERMOTT, MK; POSILLICO, DB				HADLEY, MN; GRAHM, TW; HARRINGTON, T; SCHILLER, WR; MCDERMOTT, MK; POSILLICO, DB			NUTRITIONAL SUPPORT AND NEUROTRAUMA - A CRITICAL-REVIEW OF EARLY NUTRITION IN 45 ACUTE HEAD-INJURY PATIENTS	NEUROSURGERY			English	Article									ST JOSEPHS HOSP & MED CTR, TRAUMA SERV, PHOENIX, AZ 85013 USA	HADLEY, MN (corresponding author), ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, DIV NEUROL SURG, PHOENIX, AZ 85013 USA.						ASKANAZI J, 1980, ANN SURG, V191, P40, DOI 10.1097/00000658-198001000-00008; BLACKETT RL, 1978, BRIT J SURG, V65, P393, DOI 10.1002/bjs.1800650607; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; BOZZETTI F, 1982, SURGERY, V91, P383; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DOMINIONI L, 1985, JPEN-PARENTER ENTER, V9, P269, DOI 10.1177/0148607185009003269; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; Garden O J, 1983, Clin Nutr, V2, P51, DOI 10.1016/0261-5614(83)90031-6; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; KEOHANE PP, 1983, LANCET, V2, P1388; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MULLEN JL, 1980, ANN SURG, V192, P604, DOI 10.1097/00000658-198019250-00004; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SCHILLER WR, 1979, SURG GYNECOL OBSTET, V149, P561; SITGESSERRA A, 1985, JPEN-PARENTER ENTER, V9, P322, DOI 10.1177/0148607185009003322; SOROFF HS, 1961, SURG GYNECOL OBSTET, V112, P159	24	69	73	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1986	19	3					367	373		10.1227/00006123-198609000-00006			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	D9560	WOS:A1986D956000006	3093915				2021-06-18	
J	LINDGREN, S; RINDER, L				LINDGREN, S; RINDER, L			EXPERIMENTAL STUDIES IN HEAD INJURY .2. PRESSURE PROPAGATION IN PERCUSSION CONCUSSION	BIOPHYSIK			English	Article																Clark S. L., 1943, SURG GYNECOL OBSTET, V77, P403; CLEMEDSON C, 1961, ACTA PHYSIOL SCAND, V51, P47, DOI 10.1111/j.1748-1716.1961.tb02112.x; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HAMBERGER A, 1966, J NEUROPATH EXP NEUR, V25, P68, DOI 10.1097/00005072-196601000-00004; LINDGREN SO, 1964, LANCET, V1, P1251; LINDGREN SO, 1966, ACTA CHIR SCAND S360; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LUNDBECK H, 1963, BIOTECHNOL BIOENG, V5, P167, DOI 10.1002/bit.260050302; TREVENA DH, 1964, NATURE, V203, P1158, DOI 10.1038/2031158c0	11	69	69	0	0				0006-3517			BIOPHYSIK			1966	3	2					174	&		10.1007/BF01191611			0	Biophysics	Biophysics	82478	WOS:A19668247800009	5982794				2021-06-18	
J	Ahmedani, BK; Peterson, EL; Hu, Y; Rossom, RC; Lynch, F; Lu, CY; Waitzfelder, BE; Owen-Smith, AA; Hubley, S; Prabhakar, D; Williams, LK; Zeld, N; Mutter, E; Beck, A; Tolsma, D; Simon, GE				Ahmedani, Brian K.; Peterson, Edward L.; Hu, Yong; Rossom, Rebecca C.; Lynch, Frances; Lu, Christine Y.; Waitzfelder, Beth E.; Owen-Smith, Ashli A.; Hubley, Samuel; Prabhakar, Deepak; Williams, L. Keoki; Zeld, Nicole; Mutter, Elizabeth; Beck, Arne; Tolsma, Dennis; Simon, Gregory E.			Major Physical Health Conditions and Risk of Suicide	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE PATIENTS; PREVENTION; MANAGEMENT; SYMPTOMS; VETERANS; PAIN	Introduction: Most individuals make healthcare visits before suicide, but many do not have a diagnosed mental health condition. This study seeks to investigate suicide risk among patients with a range of physical health conditions in a U.S. general population sample and whether risk persists after adjustment for mental health and substance use diagnoses. Methods: This study included 2,674 individuals who died by suicide between 2000 and 2013 along with 267,400 controls matched on year and location in a case-control study conducted in 2016 across eight Mental Health Research Network healthcare systems. A total of 19 physical health conditions were identified using diagnostic codes within the healthcare systems' Virtual Data Warehouse, including electronic health record and insurance claims data, during the year before index date. Results: Seventeen physical health conditions were associated with increased suicide risk after adjustment for age and sex (p < 0.001); nine associations persisted after additional adjustment for mental health and substance use diagnoses. Three conditions had a more than twofold increased suicide risk: traumatic brain injury (AOR = 8.80, p < 0.001); sleep disorders; and HIV/AIDS. Multimorbidity was present in 38% of cases versus 15.5% of controls, and represented nearly a twofold increased risk for suicide. Conclusions: Although several individual conditions, for example, traumatic brain injury, were associated with high risk of suicide, nearly all physical health conditions increased suicide risk, even after adjustment for potential confounders. In addition, having multiple physical health conditions increased suicide risk substantially. These data support suicide prevention based on the overall burden of physical health. (C) 2017 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.	[Ahmedani, Brian K.; Hu, Yong; Williams, L. Keoki; Zeld, Nicole; Mutter, Elizabeth] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI 48202 USA; [Ahmedani, Brian K.; Prabhakar, Deepak] Henry Ford Hlth Syst, Behav Hlth Serv, Detroit, MI 48202 USA; [Peterson, Edward L.; Hu, Yong] Henry Ford Hlth Syst, Publ Hlth Sci, Detroit, MI 48202 USA; [Rossom, Rebecca C.] HealthPartners Inst, Bloomington, MN USA; [Lynch, Frances] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA; [Lu, Christine Y.] Harvard Med Sch, Dept Populat Med, Boston, MA USA; [Lu, Christine Y.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Waitzfelder, Beth E.] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA; [Owen-Smith, Ashli A.] Georgia State Univ, Sch Publ Hlth, Atlanta, GA 30303 USA; [Owen-Smith, Ashli A.; Tolsma, Dennis] Kaiser Permanente Georgia, Ctr Clin & Outcomes Res, Atlanta, GA USA; [Hubley, Samuel] Univ Colorado, Dept Family Med, Denver, CO 80202 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; [Beck, Arne] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA; [Simon, Gregory E.] Kaiser Permanente Washington, Seattle, WA USA	Ahmedani, BK (corresponding author), Henry Ford Hlth Syst, LMSW, 1 Ford Pl,3A, Detroit, MI 48202 USA.	bahmeda1@hfhs.org	Rossom, Rebecca/R-7103-2019	Hubley, Samuel/0000-0001-7188-6003; Prabhakar, Deepak/0000-0003-4237-162X; Rossom, Rebecca/0000-0002-9531-914X; Mutter, Elizabeth/0000-0003-1779-6300	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH103539, U19MH092201]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U19MH092201, R01MH103539] Funding Source: NIH RePORTER	This project was supported by Award Numbers R01MH103539 and U19MH092201 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. All authors have contributed to and have approved the final submitted manuscript.	Ahmedani BK, 2015, MED CARE, V53, P430, DOI 10.1097/MLR.0000000000000335; Ahmedani BK, 2014, AM J PREV MED, V47, pS222, DOI 10.1016/j.amepre.2014.05.038; Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; Bernert RA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0554-4; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Cavanagh JTO, 2003, PSYCHOL MED, V33, P395, DOI 10.1017/S0033291702006943; CDC, 2014, CDC NAT HLTH REP HIG; Curtin SC., 2016, INCREASE SUICIDE US; Go AS, 2008, CIRC-CARDIOVASC QUAL, V1, P138, DOI 10.1161/CIRCOUTCOMES.108.801654; Gunnell D, 2012, BRIT J PSYCHIAT, V201, P233, DOI 10.1192/bjp.bp.111.104422; Hogan MF, 2016, HEALTH AFFAIR, V35, P1084, DOI 10.1377/hlthaff.2015.1672; HORNBROOK MC, 2005, J NATL CANC I MONOGR, V35, P12, DOI DOI 10.1093/JNCIMONOGRAPHS/LGI033; Howe CQ, 2015, PHYS MED REH CLIN N, V26, P283, DOI 10.1016/j.pmr.2014.12.003; Ilgen MA, 2013, JAMA PSYCHIAT, V70, P692, DOI 10.1001/jamapsychiatry.2013.908; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179; Kuo CJ, 2010, AM J PSYCHIAT, V167, P1092, DOI 10.1176/appi.ajp.2010.09101455; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; McCarthy JF, 2015, AM J PUBLIC HEALTH, V105, P1935, DOI 10.2105/AJPH.2015.302737; McDowell AK, 2011, MAYO CLIN PROC, V86, P792, DOI 10.4065/mcp.2011.0076; National Action Alliance for Suicide Prevention, 2014, PRIOR RES AG SUIC PR; National Center for Health Statistics, 2010, INT CLASS DIS; O'Connor E, 2013, ANN INTERN MED, V158, P741, DOI 10.7326/0003-4819-158-10-201305210-00642; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Organization WH, 2012, INT CLASS DIS 10 REV; Robson A, 2010, PSYCHO-ONCOLOGY, V19, P1250, DOI 10.1002/pon.1717; Rossom RC, 2016, PSYCHIAT SERV, V67, P830, DOI 10.1176/appi.ps.201600068; St Sauver JL, 2013, MAYO CLIN PROC, V88, P56, DOI 10.1016/j.mayocp.2012.08.020; Swanson JW, 2015, JAMA-J AM MED ASSOC, V314, P2229, DOI 10.1001/jama.2015.15566; The Joint Commission, 2016, SENT EV AL 56 DET TR; Tinetti ME, 2012, JAMA-J AM MED ASSOC, V307, P2493, DOI 10.1001/jama.2012.5265; Tran T, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471-244X-14-76; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; US Department of Health and Human Services (DHHS) - Office of the Surgeon General and National Action Alliance for Suicide Prevention, 2012, 2012 NAT STRAT SUIC; Webb RT, 2012, ARCH GEN PSYCHIAT, V69, P256, DOI 10.1001/archgenpsychiatry.2011.1561; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1	38	68	69	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	SEP	2017	53	3					308	315		10.1016/j.amepre.2017.04.001			8	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	FE0QI	WOS:000407924400013	28619532	Green Accepted	Y	N	2021-06-18	
J	Galetta, KM; Morganroth, J; Moehringer, N; Mueller, B; Hasanaj, L; Webb, N; Civitano, C; Cardone, DA; Silverio, A; Galetta, SL; Balcer, LJ				Galetta, Kristin M.; Morganroth, Jennifer; Moehringer, Nicholas; Mueller, Bridget; Hasanaj, Lisena; Webb, Nikki; Civitano, Courtney; Cardone, Dennis A.; Silverio, Arlene; Galetta, Steven L.; Balcer, Laura J.			Adding Vision to Concussion Testing: A Prospective Study of Sideline Testing in Youth and Collegiate Athletes	JOURNAL OF NEURO-OPHTHALMOLOGY			English	Article							VISUAL SCREENING TOOL; KING-DEVICK TEST; STANDARDIZED ASSESSMENT; RECURRENT CONCUSSION; EYE-MOVEMENTS; FOOTBALL; DEPRESSION; KNOWLEDGE; SPORT	Background:Sports-related concussion commonly affects the visual pathways. Current sideline protocols test cognition and balance but do not include assessments of visual performance. We investigated how adding a vision-based test of rapid number naming could increase our ability to identify concussed athletes on the sideline at youth and collegiate levels.Methods:Participants in this prospective study included members of a youth ice hockey and lacrosse league and collegiate athletes from New York University and Long Island University. Athletes underwent preseason baseline assessments using: 1) the King-Devick (K-D) test, a <2-minute visual performance measure of rapid number naming, 2) the Standardized Assessment of Concussion (SAC), a test of cognition, and 3) a timed tandem gait test of balance. The SAC and timed tandem gait are components of the currently used Sport Concussion Assessment Tool, 3rd Edition (SCAT3 and Child-SCAT3). In the event of a concussion during the athletic season, injured athletes were retested on the sideline/rink-side. Nonconcussed athletes were also assessed as control participants under the same testing conditions.Results:Among 243 youth (mean age 11 3 years, range 5-17) and 89 collegiate athletes (age 20 +/- 1 years, range 18-23), baseline time scores for the K-D test were lower (better) with increasing participant age (P < 0.001, linear regression models). Among 12 athletes who sustained concussions during their athletic season, K-D scores worsened from baseline by an average of 5.2 seconds; improvement by 6.4 seconds was noted for the nonconcussed controls (n = 14). The vision-based K-D test showed the greatest capacity to distinguish concussed vs control athletes based on changes from preseason baseline to postinjury (receiver operating characteristic [ROC] curve areas from logistic regression models, accounting for age = 0.92 for K-D, 0.87 for timed tandem gait, and 0.68 for SAC; P = 0.0004 for comparison of ROC curve areas).Conclusions:Adding a vision-based performance measure to cognitive and balance testing enhances the detection capabilities of current sideline concussion assessment. This observation in patients with mild traumatic brain injury reflects the common involvement and widespread distribution of brain pathways dedicated to vision.	[Morganroth, Jennifer; Moehringer, Nicholas; Mueller, Bridget; Hasanaj, Lisena; Galetta, Steven L.; Balcer, Laura J.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA; [Galetta, Steven L.; Balcer, Laura J.] NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA; [Cardone, Dennis A.] NYU, Sch Med, Dept Sports Med Orthopaed Surg, New York, NY 10016 USA; [Webb, Nikki] NYU, Dept Athlet, New York, NY 10016 USA; [Civitano, Courtney] Long Isl Univ, Dept Athlet, Brooklyn, NY USA; [Silverio, Arlene] Hofstra North Shore LIJ Sch Med, Cohen Childrens Med Ctr New York, Dept Emergency Med, Philadelphia, PA USA; [Silverio, Arlene] Hofstra North Shore LIJ Sch Med, Cohen Childrens Med Ctr New York, Dept Pediat, Philadelphia, PA USA; [Galetta, Kristin M.; Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Balcer, Laura J.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA	Balcer, LJ (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA.	laura.balcer@nyumc.org	Meijer, Anna/K-5118-2016				DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fukushima K, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00004; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Jeon ST, 2010, J EXP CHILD PSYCHOL, V107, P423, DOI 10.1016/j.jecp.2010.05.009; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Luna B, 2008, BRAIN COGNITION, V68, P293, DOI 10.1016/j.bandc.2008.08.019; Marinides Z, NEUROL CLIN IN PRESS; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Pierrot-Deseilligny C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5	31	68	68	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1070-8022	1536-5166		J NEURO-OPHTHALMOL	J. Neuro-Ophthal.	SEP	2015	35	3					235	241		10.1097/WNO.0000000000000226			7	Clinical Neurology; Ophthalmology	Neurosciences & Neurology; Ophthalmology	CQ4DC	WOS:000360553500002	25742059				2021-06-18	
J	Genet, F; Kulina, I; Vaquette, C; Torossian, F; Millard, S; Pettit, AR; Sims, NA; Anginot, A; Guerton, B; Winkler, IG; Barbier, V; Lataillade, JJ; Le Bousse-Kerdiles, MC; Hutmacher, DW; Levesque, JP				Genet, Francois; Kulina, Irina; Vaquette, Cedryck; Torossian, Frederic; Millard, Susan; Pettit, Allison R.; Sims, Natalie A.; Anginot, Adrienne; Guerton, Bernadette; Winkler, Ingrid G.; Barbier, Valerie; Lataillade, Jean-Jacques; Le Bousse-Kerdiles, Marie-Caroline; Hutmacher, Dietmar W.; Levesque, Jean-Pierre			Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle	JOURNAL OF PATHOLOGY			English	Article						heterotopic ossification; spinal cord injury; macrophage; inflammation	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; SATELLITE CELLS; STEM-CELLS; PROGRESSIVA; MOUSE; PREVALENCE; DEPLETION; IMPACT; SERUM	Neurological heterotopic ossification (NHO) is the abnormal formation of bone in soft tissues as a consequence of spinal cord or traumatic brain injury. NHO causes pain, ankyloses, vascular and nerve compression and delays rehabilitation in this high-morbidity patient group. The pathological mechanisms leading to NHO remain unknown and consequently there are no therapeutic options to prevent or reduce NHO. Genetically modified mouse models of rare genetic forms of heterotopic ossification (HO) exist, but their relevance to NHO is questionable. Consequently, we developed the first model of spinal cord injury (SCI)-induced NHO in genetically unmodified mice. Formation of NHO, measured by micro-computed tomography, required the combination of both SCI and localized muscular inflammation. Our NHO model faithfully reproduced many clinical features of NHO in SCI patients and both human and mouse NHO tissues contained macrophages. Muscle-derived mesenchymal progenitors underwent osteoblast differentiation in vitro in response to serum from NHO mice without additional exogenous osteogenic stimuli. Substance P was identified as a candidate NHO systemic neuropeptide, as it was significantly elevated in the serum of NHO patients. However, antagonism of substance P receptor in our NHO model only modestly reduced the volume of NHO. In contrast, ablation of phagocytic macrophages with clodronate-loaded liposomes reduced the size of NHO by 90%, supporting the conclusion that NHO is highly dependent on inflammation and phagocytic macrophages in soft tissues. Overall, we have developed the first clinically relevant model of NHO and demonstrated that a combined insult of neurological injury and soft tissue inflammation drives NHO pathophysiology. Copyright (c) 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.	[Genet, Francois; Kulina, Irina; Millard, Susan; Pettit, Allison R.; Winkler, Ingrid G.; Barbier, Valerie; Hutmacher, Dietmar W.; Levesque, Jean-Pierre] Univ Queensland, Mater Res Inst, Blood & Bone Dis Programme, Woolloongabba, Qld 4102, Australia; [Genet, Francois] Hop Raymond Poincare, APHP, Dept Phys Med & Rehabil, CIC IT 1429, Garches, France; [Genet, Francois] Univ Versailles St Quentin Yvelines, END ICAP INSERM U1179, Montigny Le Bretonneux, France; [Kulina, Irina; Levesque, Jean-Pierre] Univ Queensland, Sch Med, Herston, Qld, Australia; [Vaquette, Cedryck] Queensland Univ Technol, Inst Hlth Biomed Innovat, Kelvin Grove, Australia; [Torossian, Frederic; Anginot, Adrienne; Guerton, Bernadette; Lataillade, Jean-Jacques; Le Bousse-Kerdiles, Marie-Caroline] INSERM, U972, Villejuif, France; [Torossian, Frederic; Anginot, Adrienne; Guerton, Bernadette; Le Bousse-Kerdiles, Marie-Caroline] Univ Paris 11, Inst Andre Lwoff, Paris, France; [Sims, Natalie A.] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Lataillade, Jean-Jacques] Ctr Transfus Sanguine Armees, Clamart, France	Levesque, JP (corresponding author), Univ Queensland, Mater Res Inst, Translat Res Inst, Blood & Bone Dis Programme, 37 Kent St, Woolloongabba, Qld 4102, Australia.	jp.levesque@mater.uq.edu.au	Sims, Natalie A/A-7192-2012; Anginot, Adrienne/N-9299-2017; Levesque, Jean-Pierre/C-5426-2011; Winkler, Ingrid G/F-3263-2011; Millard, Susan/C-8115-2011; Pettit, Allison/O-4462-2019; Le Bousse-Kerdiles, Marie-Caroline/Q-4029-2018	Sims, Natalie A/0000-0003-1421-8468; Levesque, Jean-Pierre/0000-0002-7299-6025; Winkler, Ingrid G/0000-0001-6026-3572; Millard, Susan/0000-0003-1738-3362; Pettit, Allison/0000-0003-4707-7892; Hutmacher, Dietmar Werner/0000-0001-5678-2134; Vaquette, Cedryck/0000-0001-7937-4432; Le Bousse-Kerdiles, Marie-Caroline/0000-0003-0863-5222	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia [1033736, 1044091]; Mater Foundation; NHMRC Project GrantNational Health and Medical Research Council of Australia; Fondation BNP-Paribas; Assistance Publique - Hopitaux de Paris; Universite de Versailles Saint Quentin; Institut National de la Sante et de la Recherche MedicaleInstitut National de la Sante et de la Recherche Medicale (Inserm); Service de Sante des Armees; Forum for European-Australian Science and Technology Cooperation; IPSENIpsen; MERZ; ALLERGANAbbVieAllergan	IGW and JPL are supported by a Career Development Fellowship (No. 1033736) and a Research Fellowship (No. 1044091), respectively, from the National Health and Medical Research Council (NHMRC) of Australia. This study was supported in part by the Mater Foundation (to JPL), a NHMRC Project Grant (to NAS), Fondation BNP-Paribas (to FG), Assistance Publique - Hopitaux de Paris (to FG), Universite de Versailles Saint Quentin (to FG), Institut National de la Sante et de la Recherche Medicale (to MCLBK), Service de Sante des Armees (to JJL) and travel fellowships from the Forum for European-Australian Science and Technology Cooperation, IPSEN, MERZ and ALLERGAN (to FG).	Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Aubut JAL, 2011, NEUROREHABILITATION, V28, P151, DOI 10.3233/NRE-2011-0643; Banovac K, 2000, J Spinal Cord Med, V23, P40; BRADLEIGH LH, 1992, ARCH PHYS MED REHAB, V73, P293; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; Chakkalakal SA, 2012, J BONE MINER RES, V27, P1746, DOI 10.1002/jbmr.1637; Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232; Dizdar D, 2013, BRAIN INJURY, V27, P807, DOI 10.3109/02699052.2013.775490; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Genet F, 2009, J BONE JOINT SURG BR, V91B, P1493, DOI 10.1302/0301-620X.91B11.22305; Genet F, 2012, J HEAD TRAUMA REHAB, V27, P443, DOI 10.1097/HTR.0b013e31822b54ba; Genet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016632; Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040; HARAN M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003321.PUB3; Hruska KA, 2011, ADV CHRONIC KIDNEY D, V18, P98, DOI 10.1053/j.ackd.2011.01.001; Jacobsen RN, 2014, EXP HEMATOL, V42, P547, DOI 10.1016/j.exphem.2014.03.009; Jaovisidha S, 1998, SPINAL CORD, V36, P647, DOI 10.1038/sj.sc.3100701; Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Mitchell EJ, 2010, J ORTHOP TRAUMA, V24, P530, DOI 10.1097/BOT.0b013e3181ed147b; Mitchell KJ, 2010, NAT CELL BIOL, V12, P257, DOI 10.1038/ncb2025; Montarras D, 2005, SCIENCE, V309, P2064, DOI 10.1126/science.1114758; Muller PA, 2014, CELL, V158, P300, DOI 10.1016/j.cell.2014.04.050; Oishi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056641; Pirraco RP, 2013, J TISSUE ENG REGEN M, V7, P392, DOI 10.1002/term.535; Raggatt LJ, 2014, AM J PATHOL, V184, P3192, DOI 10.1016/j.ajpath.2014.08.017; Reznik JE, 2014, J MUSCULOSKEL NEURON, V14, P19; RODRIGUEZ GP, 1989, ARCH PHYS MED REHAB, V70, P442, DOI 10.1016/0003-9993(89)90003-8; Salga M, 2015, SKELETAL RADIOL, V44, P233, DOI 10.1007/s00256-014-2003-6; Salisbury E, 2011, J CELL BIOCHEM, V112, P2748, DOI 10.1002/jcb.23225; Schurch B, 1998, SPINAL CORD, V36, P78, DOI 10.1038/sj.sc.3100561; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; van Rooijen N, 2010, METHODS MOL BIOL, V605, P189, DOI 10.1007/978-1-60327-360-2_13; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wick L, 2005, EUR RADIOL, V15, P1867, DOI 10.1007/s00330-005-2769-y; Winkler IG, 2010, BLOOD, V116, P4815, DOI 10.1182/blood-2009-11-253534	43	68	73	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3417	1096-9896		J PATHOL	J. Pathol.	JUN	2015	236	2					229	240		10.1002/path.4519			12	Oncology; Pathology	Oncology; Pathology	CH8YA	WOS:000354321400011	25712044				2021-06-18	
J	Daneshvar, DH; Goldstein, LE; Kiernan, PT; Stein, TD; McKee, AC				Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.			Post-traumatic neurodegeneration and chronic traumatic encephalopathy	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Chronic traumatic encephalopathy; Axonal injury; Brain trauma; Posttraumatic neurodegeneration; Motor neuron disease; Tau protein; Concussion; Blast and impact neurotrauma	AMYOTROPHIC-LATERAL-SCLEROSIS; REPETITIVE HEAD-INJURY; BRAIN-INJURY; ALZHEIMERS-DISEASE; AMYLOID-BETA; SUBDURAL-HEMATOMA; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; DEPRESSIVE SYMPTOMS	Traumatic brain injury (TBI) is a leading cause of mortality and morbidity around the world. Concussive and subconcussive forms of closed-head injury due to impact or blast neurotrauma represent the most common types of TBI in civilian and military settings. It is becoming increasingly evident that TBI can lead to persistent, long-term debilitating effects, and in some cases, progressive neurodegeneration and chronic traumatic encephalopathy (CTE). The epidemiological literature suggests that a single moderate-to-severe TBI may be associated with accelerated neurodegeneration and increased risk of Alzheimer's disease, Parkinson's disease, or motor neuron disease. However, the pathologic phenotype of these post-traumatic neurodegenerations is largely unknown and there may be pathobiological differences between post-traumatic disease and the corresponding sporadic disorder. By contrast, the pathology of CTE is increasingly well known and is characterized by a distinctive pattern of progressive brain atrophy and accumulation of hyperphosphorylated tau neurofibrillary and glial tangles, dystrophic neurites, 43 kDa TAR DNA-binding protein (TDP-43) neuronal and glial aggregates, microvasculopathy, myelinated axonopathy, neuroinflammation, and white matter degeneration. Clinically, CTE is associated with behavioral changes, executive dysfunction, memory deficits, and cognitive impairments that begin insidiously and most often progress slowly over decades. Although research on the long-term effects of TBI is advancing quickly, the incidence and prevalence of post-traumatic neurodegeneration and CTE are unknown. Critical knowledge gaps include elucidation of pathogenic mechanisms, identification of genetic risk factors, and clarification of relevant variables-including age at exposure to trauma, history of prior and subsequent head trauma, substance use, gender, stress, and comorbidities-all of which may contribute to risk profiles and the development of post-traumatic neurodegeneration and CTE. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. Published by Elsevier Inc.	[Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Goldstein, Lee E.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Photon Ctr, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Mech Engn, Boston, MA 02115 USA; [Stein, Thor D.; McKee, Ann C.] VA Boston Healthcare Syst, Jamaica Plain, MA 02130 USA	McKee, AC (corresponding author), Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.			Daneshvar, Daniel/0000-0003-3691-9513; Stein, Thor/0000-0001-6954-4477	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [R01 [AG1649]]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; National Football League; Andlinger Foundation; WWE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	We gratefully acknowledge the use of resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA). We also gratefully acknowledge the help of all members of the Boston University and the Boston VA, and the individuals and families whose participation and contributions made this work possible. This work was supported by the Department of Veterans Affairs; Veterans Affairs Biorepository (CSP 501); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); National Institute of Neurological Diseases and Stroke 1U01NS086659-01, National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846; supplement 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study R01 [AG1649]; Sports Legacy Institute; and National Operating Committee on Standards for Athletic Equipment. This work was also supported by an unrestricted gift from the National Football League, the Andlinger Foundation and the WWE.	Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P228, DOI 10.1177/0891988710383572; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Binazzi A, 2009, AMYOTROPH LATERAL SC, V10, P361, DOI 10.3109/17482960802382313; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Centers for Disease Control and Prevention Department of Defense VA Leadership Panel, 2013, C TRAUM BRAIN INJ US; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Czell D, 2013, NEURODEGENER DIS, V12, P150, DOI 10.1159/000345835; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daneshvar DH, 2013, ALZHEIMERS DEMENT, V9, P438, DOI DOI 10.1016/JJALZ.2013.05.868; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Di Maria E, 2000, ANN NEUROL, V47, P374, DOI 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; Gasparini L, 2007, NEURODEGENER DIS, V4, P236, DOI 10.1159/000101848; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GORELL JM, 1994, NEUROLOGY, V44, P1865, DOI 10.1212/WNL.44.10.1865; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Institute of Medicine (US) Committee on Gulf War and Health, 2008, GULF WAR AND HLTH, V7; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jicha GA, 2010, J ALZHEIMERS DIS, V19, P253, DOI 10.3233/JAD-2010-1237; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kenney K., 2014, ALZHEIMERS DEMENT, V10, pP843; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lee SE, 2013, ALZ DIS ASSOC DIS, V27, P302, DOI 10.1097/WAD.0b013e31828cc357; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Logan SM, 2001, J ATHL TRAINING, V36, P433; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morales R, 2009, CNS NEUROL DISORD-DR, V8, P363, DOI 10.2174/187152709789541998; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mott F. N., 1919, WAR NEUROSES SHELL S; Mott FW, 1916, LANCET, V1, P331; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Rosenbohm A, 2014, J NEUROL, V261, P283, DOI 10.1007/s00415-013-7185-7; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Sephton C.F., 2012, TDP 43 CENTRAL NERVO; Sephton CF, 2011, J BIOL CHEM, V286, P1204, DOI 10.1074/jbc.M110.190884; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Strickland D, 1996, ACTA NEUROL SCAND, V94, P45, DOI 10.1111/j.1600-0404.1996.tb00038.x; Strong MJ, 2011, J MOL NEUROSCI, V45, P648, DOI 10.1007/s12031-011-9609-0; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S., 2014, BRAIN, V236; Uryu K, 2006, AM J PATHOL, V168, P947, DOI 10.2353/ajpath.2006.050770; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vandrovcova J, 2010, CURR ALZHEIMER RES, V7, P726, DOI 10.2174/156720510793611619; Waite LM, 1997, MED J AUSTRALIA, V167, P429, DOI 10.5694/j.1326-5377.1997.tb126655.x; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029	120	68	68	0	71	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		81	90		10.1016/j.mcn.2015.03.007			10	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900003	25758552				2021-06-18	
J	Kumar, RG; Diamond, ML; Boles, JA; Berger, RP; Tisherman, SA; Kochanek, PM; Wagner, AK				Kumar, R. G.; Diamond, M. L.; Boles, J. A.; Berger, R. P.; Tisherman, S. A.; Kochanek, P. M.; Wagner, A. K.			Acute CSF interleukin-6 trajectories after TBI: Associations with neuroinflammation, polytrauma, and outcome	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Cytokines; Interleukin-6; Rehabilomics	TRAUMATIC BRAIN-INJURY; TRANSLATIONAL REHABILITATION RESEARCH; CEREBROSPINAL-FLUID; TRANSGENIC MICE; ANTIINFLAMMATORY MEDIATORS; INFLAMMATORY RESPONSE; PROGNOSTIC BIOMARKER; RHEUMATOID-ARTHRITIS; MULTIPLE INJURIES; HORMONE-LEVELS	Traumatic brain injury (TBI) results in a significant inflammatory burden that perpetuates the production of inflammatory mediators and biomarkers. Interleukin-6 (IL-6) is a pro-inflammatory cytokine known to be elevated after trauma, and a major contributor to the inflammatory response following TBI. Previous studies have investigated associations between IL-6 and outcome following TBI, but to date, studies have been inconsistent in their conclusions. We hypothesized that cohort heterogeneity, temporal inflammatory profiles, and concurrent inflammatory marker associations are critical to characterize when targeting subpopulations for anti-inflammatory therapies. Toward this objective, we used serial cerebrospinal fluid (CSF) samples to generate temporal acute IL-6 trajectory (TRAJ) profiles in a prospective cohort of adults with severe TBI (n = 114). We examined the impact of injury type on IL-6 profiles, and how IL-6 profiles impact sub-acute (2 weeks-3 months) serum inflammatory marker load and long-term global outcome 6-12 months post-injury. There were two distinct acute CSF IL-6 profiles, a high and low TRAJ group. Individuals in the high TRAJ had increased odds of unfavorable Glasgow Outcome Scale (GOS) scores at 6 months (adjusted OR = 3.436, 95% CI: 1.259, 9.380). Individuals in the high TRAJ also had higher mean acute CSF inflammatory load compared to individuals in the low TRAJ (p <= 0.05). The two groups did not differ with respect acute serum profiles; however, individuals in the high CSF IL-6 TRAJ also had higher mean sub-acute serum IL-beta and IL-6 levels compared with the low TRAJ group (p <= 0.05). Lastly, injury type (isolated TBI vs. TBI + polytrauma) was associated with IL-6 TRAJ group (chi(2) = 5.31, p = 0.02). Specifically, there was 70% concordance between those with TBI + polytrauma and the low TRAJ; in contrast, isolated TBI was similarly distributed between TRAJ groups. These data provide evidence that sustained, elevated levels of CSF IL-6 are associated with an increased inflammatory load, and these increases are associated with increased odds for unfavorable global outcomes in the first year following TBI. Future studies should explore additional factors contributing to IL-6 elevations, and therapies to mitigate its detrimental effects on outcome. (C) 2014 Elsevier Inc. All rights reserved.	[Kumar, R. G.; Diamond, M. L.; Boles, J. A.; Wagner, A. K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, A. K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Berger, R. P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Berger, R. P.; Kochanek, P. M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Tisherman, S. A.] Univ Maryland, Med Ctr, Ctr Shock Trauma, Baltimore, MD 21201 USA; [Kochanek, P. M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	Wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729	University of Pittsburgh Women's Studies Faculty Research Fund [CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR: H133A120087]	This work was supported in part by: CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR: H133A120087, University of Pittsburgh Women's Studies Faculty Research Fund.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brand RE, 2011, CLIN CANCER RES, V17, P805, DOI 10.1158/1078-0432.CCR-10-0248; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; DROST AC, 1993, J TRAUMA, V35, P335, DOI 10.1097/00005373-199309000-00001; Failla M.D., 2014, NEUROREHABIL NEURAL; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kesinger M.R., 2014, J TRAUMA IN PRESS; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kumar R., 2014, J HEAD TRAUMA REHABI; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Long J. S., 1997, REGRESSION MODELS CA; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; NIJSTEN MWN, 1991, SURGERY, V109, P761; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Pavelko KD, 2003, J NEUROSCI, V23, P481; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Qi HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037858; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2014, J SPINAL CORD MED, V37, P493, DOI 10.1179/2045772314Y.0000000248; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2012, BRAIN INJURY, V26, P1658, DOI 10.3109/02699052.2012.700089; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Weaver S.M., 2012, BRAIN IMAGING BEHAV; Weckbach S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/890816; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	73	68	70	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2015	45						253	262		10.1016/j.bbi.2014.12.021			10	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	CC7BX	WOS:000350523800026	25555531				2021-06-18	
J	Kochanek, PM; Jackson, TC; Ferguson, NM; Carlson, SW; Simon, DW; Brockman, EC; Ji, J; Bayir, H; Poloyac, SM; Wagner, AK; Kline, AE; Empey, PE; Clark, RSB; Jackson, EK; Dixon, CE				Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Carlson, Shaun W.; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Poloyac, Samuel M.; Wagner, Amy K.; Kline, Anthony E.; Empey, Philip E.; Clark, Robert S. B.; Jackson, Edwin K.; Dixon, C. Edward			Emerging Therapies in Traumatic Brain Injury	SEMINARS IN NEUROLOGY			English	Article						head injury; concussion; neurocritical care; treatment; drugs; excitotoxicity; inflammation; oxidative stress; regeneration; rehabilitation; secondary injury	CONTROLLED CORTICAL IMPACT; MARROW STROMAL CELLS; CEREBRAL-BLOOD-FLOW; MITOCHONDRIAL PERMEABILITY TRANSITION; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CHRONIC METHYLPHENIDATE TREATMENT; RANDOMIZED CLINICAL-TRIAL; RAT HIPPOCAMPAL-NEURONS; WATER MAZE PERFORMANCE; DIFFUSE AXONAL INJURY	Despite decades of basic and clinical research, treatments to improve outcomes after traumatic brain injury (TBI) are limited. However, based on the recent recognition of the prevalence of mild TBI, and its potential link to neurodegenerative disease, many new and exciting secondary injury mechanisms have been identified and several new therapies are being evaluated targeting both classic and novel paradigms. This includes a robust increase in both preclinical and clinical investigations. Using a mechanism-based approach the authors define the targets and emerging therapies for TBI. They address putative new therapies for TBI across both the spectrum of injury severity and the continuum of care, from the field to rehabilitation. They discuss TBI therapy using 11 categories, namely, (1) excitotoxicity and neuronal death, (2) brain edema, (3) mitochondria and oxidative stress, (4) axonal injury, (5) inflammation, (6) ischemia and cerebral blood flow dysregulation, (7) cognitive enhancement, (8) augmentation of endogenous neuroprotection, (9) cellular therapies, (10) combination therapy, and (11) TBI resuscitation. The current golden age of TBI research represents a special opportunity for the development of breakthroughs in the field.	[Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Carlson, Shaun W.; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Poloyac, Samuel M.; Wagner, Amy K.; Kline, Anthony E.; Empey, Philip E.; Clark, Robert S. B.; Jackson, Edwin K.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Carlson, Shaun W.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wagner, Amy K.; Kline, Anthony E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Ferguson, Nikki Miller; Simon, Dennis W.; Brockman, Erik C.; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Bayir, Huelya] Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Empey, Philip/L-9604-2019; Ferguson, Nikki Miller/AAA-4548-2020	Kochanek, Patrick M/0000-0002-2627-913X; Empey, Philip/0000-0001-7474-2339; Jackson, Edwin/0000-0002-8101-6009; Carlson, Shaun/0000-0002-1413-5075	U.S. ArmyUnited States Department of Defense [W81XWH-10-1-0623, W81XWH-14-2-0018]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS088145, NS087978, T32HD040686]; NCATS as part of the Multidisciplinary Clinical Research Scholars Program [KL2-TR000146]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088145, R01NS087978] Funding Source: NIH RePORTER	Supported by U.S. Army grants W81XWH-10-1-0623 (PMK) and W81XWH-14-2-0018 (PMK), NIH grants NS088145 (TJ), NS087978 (PMK, EKJ), and T32HD040686 (NF, EB, SC); and KL2-TR000146 from the NCATS as part of the Multidisciplinary Clinical Research Scholars Program (PE).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Armstead WM, 2010, BRAIN RES, V1330, P142, DOI 10.1016/j.brainres.2010.03.024; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bales James W, 2010, Open Drug Discov J, V2, P119; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baroncelli L, 2010, CELL DEATH DIFFER, V17, P1092, DOI 10.1038/cdd.2009.193; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Baumgartner HK, 2009, J BIOL CHEM, V284, P20796, DOI 10.1074/jbc.M109.025353; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benge JF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00195; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brands J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077252; BRANNAN T, 1993, J NEURAL TRANSM-PARK, V6, P81, DOI 10.1007/BF02261001; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Brockman EC, 2013, J CEREBR BLOOD F MET, V33, P1457, DOI 10.1038/jcbfm.2013.104; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chip S, 2011, NEUROBIOL DIS, V43, P388, DOI 10.1016/j.nbd.2011.04.010; Cho J, 2007, CORONARY ARTERY DIS, V18, P215, DOI 10.1097/01.mca.0000236285.71683.b6; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; CHOI DW, 1987, J NEUROSCI, V7, P369; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Conti AC, 1998, J NEUROSCI, V18, P5663; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davies DJ, 2012, BIOORG MED CHEM LETT, V22, P2620, DOI 10.1016/j.bmcl.2012.01.108; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dezfulian C, 2009, CIRCULATION, V120, P897, DOI 10.1161/CIRCULATIONAHA.109.853267; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2015, BRAIN NEURO IN PRESS; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; Elkind MSV, 2008, INT J STROKE, V3, P210, DOI 10.1111/j.1747-4949.2008.00200.x; Empey PE, 2012, J NEUROTRAUM, V29, P229; FAN L, 1995, MOL BRAIN RES, V30, P125; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Fordsmann JC, 2013, J NEUROSCI, V33, P2562, DOI 10.1523/JNEUROSCI.2308-12.2013; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giannopoulos S, 2012, J CEREBR BLOOD F MET, V32, P1973, DOI 10.1038/jcbfm.2012.122; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Giunti D, 2014, IMMUNOLOGY, V141, P328, DOI 10.1111/imm.12177; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; GRELAK RP, 1970, SCIENCE, V169, P203, DOI 10.1126/science.169.3941.203; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Harun R, 2013, UNDERSTANDING TRAUMA, P255; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jackson TC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.187; Jansen JO, 2013, CRIT CARE, V17, DOI 10.1186/cc12499; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jungner M, 2010, ANESTHESIOLOGY, V112, P1194, DOI 10.1097/ALN.0b013e3181d94d6e; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kagan VE, 2009, ADV DRUG DELIVER REV, V61, P1375, DOI 10.1016/j.addr.2009.06.008; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Karpova A, 2013, CELL, V152, P1119, DOI 10.1016/j.cell.2013.02.002; Kaufman AM, 2012, J NEUROSCI, V32, P3992, DOI 10.1523/JNEUROSCI.4129-11.2012; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099950; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kochanek P. M., 2012, ADENOSINE KEY LINK M, P307; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee CY, 2009, BRIT J PHARMACOL, V158, P1753, DOI 10.1111/j.1476-5381.2009.00463.x; Li YL, 2008, NEUROSCI LETT, V447, P120, DOI 10.1016/j.neulet.2008.08.037; Liu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.69; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Macias CA, 2004, SHOCK, V22, P151, DOI 10.1097/01.shk.0000131489.83194.1a; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pacella JJ, 2012, MICROCIRCULATION, V19, P580, DOI 10.1111/j.1549-8719.2012.00190.x; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Poloyac SM, 2006, J CEREBR BLOOD F MET, V26, P1551, DOI 10.1038/sj.jcbfm.9600309; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rammes G, 2008, CURR NEUROPHARMACOL, V6, P55, DOI 10.2174/157015908783769671; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rao VLR, 2001, BRAIN RES, V911, P96; Rassaf T, 2014, CIRC RES, V114, P1601, DOI 10.1161/CIRCRESAHA.114.303822; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Schwarzschild MA, 2014, JAMA NEUROL, V71, P141, DOI 10.1001/jamaneurol.2013.5528; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shaik JSB, 2013, AM J PHYSIOL-HEART C, V305, pH1605, DOI 10.1152/ajpheart.00471.2013; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sies H., 1985, OXIDATIVE STRESS, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; Sikoglu EM, 2014, BEHAV BRAIN RES, V259, P354, DOI 10.1016/j.bbr.2013.11.008; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein DM, J TRAUMA, P373; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Su X, 2011, MEDIAT INFLAMM, V2011, P807; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Tas PWL, 2003, NEUROSCI LETT, V338, P229, DOI 10.1016/S0304-3940(02)01420-9; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Thiels E, 2000, J NEUROSCI, V20, P7631; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tu WH, 2010, CELL, V140, P222, DOI 10.1016/j.cell.2009.12.055; Tyurina YY, 2014, NAT CHEM, V6, P542, DOI [10.1038/nchem.1924, 10.1038/NCHEM.1924]; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wakita M, 2014, J PHARMACOL EXP THER, V348, P246, DOI 10.1124/jpet.113.208751; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhou ZL, 2012, BRAIN RES, V1481, P79, DOI 10.1016/j.brainres.2012.08.051; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	232	68	69	0	37	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	FEB	2015	35	1					83	100		10.1055/s-0035-1544237			18	Clinical Neurology	Neurosciences & Neurology	CC4AP	WOS:000350293300011	25714870	Green Accepted, Bronze			2021-06-18	
J	Mac Donald, CL; Johnson, AM; Wierzechowski, L; Kassner, E; Stewart, T; Nelson, EC; Werner, NJ; Zonies, D; Oh, J; Fang, R; Brody, DL				Mac Donald, Christine L.; Johnson, Ann M.; Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Nelson, Elliot C.; Werner, Nicole J.; Zonies, David; Oh, John; Fang, Raymond; Brody, David L.			Prospectively Assessed Clinical Outcomes in Concussive Blast vs Nonblast Traumatic Brain Injury Among Evacuated US Military Personnel	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; NEUROBEHAVIORAL RATING-SCALE; ADMINISTERED PTSD SCALE; HEAD-INJURY; MENTAL-HEALTH; NOS-TBI; STRUCTURED INTERVIEWS; OEF/OIF VETERANS; SERVICE MEMBERS	IMPORTANCE Blast injury has been identified as the signature injury in the conflicts in Iraq and Afghanistan. However it remains to be determined whether fundamental differences may exist between blast-related traumatic brain injury (TBI) and TBI due to other mechanisms. OBJECTIVES To determine similarities and differences between clinical outcomes in US military personnel with blast-related vs. non-blast-related concussive TBI and to identify the specific domains of impairment that best correlate with overall disability. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study involving active duty US Military personnel evacuated from Iraq or Afghanistan to Landstuhl Regional Medical Center, in Landstuhl, Germany. Four groups of participants were enrolled from 2010 to 2013: (1) blast plus impact complex TBI (n = 53), (2) non-blast related TBI with injury due to other mechanisms (n = 29), (3) blast-exposed controls evacuated for other medical reasons (n = 27) (4) non-blastexposed controls evacuated for other medical reasons (n = 69). All patients with TBI met Department of Defense criteria for concussive (mild) TBI. The study participants were evaluated 6-12 months after injury at Washington University in St Louis. In total, 255 subjects were enrolled in the study, and 183 participated in follow-up evaluations, 5 of whom were disqualified. MAIN OUTCOMES AND MEASURES In-person clinical examinations included evaluation for overall disability, a standardized neurological exam, headache questionnaires, neuropsychological test battery, combat exposure and alcohol use surveys, and structured interview evaluations for post-traumatic stress disorder (PTSD) and depression. RESULTS Global outcomes, headache severity, neuropsychological performance, and surprisingly even PTSD severity and depression were indistinguishable between the two TBI groups, independent of mechanism of injury. Both TBI groups had higher rates of moderate to severe overall disability than the respective control groups: 41/53 (77%) of blast plus impact TBI and 23/29 (79%) of nonblast TBI vs. 16/27 (59%) of blast-exposed controls and 28/69 (41%) of non-blast-exposed controls. In addition, blast-exposed controls had worse headaches and more severe PTSD than non-blast-exposed controls. Self-reported combat exposure intensity was higher in the blast plus impact TBI group than in nonblast TBI group and was higher in blast-exposed controls than in non-blast-exposed controls. However, combat exposure intensity did not correlate with PTSD severity in the TBI groups, but a modest positive correlation was observed in the controls. Overall outcomes were most strongly correlated with depression, headache severity, and number of abnormalities on neuropsychological testing. However a substantial fraction of the variance in overall outcome was not explained by any of the assessed measures. CONCLUSIONS AND RELEVANCE One potential interpretation of these results is that TBI itself, independent of injury mechanism and combat exposure intensity, is a primary driver of adverse outcomes. Many other important factors may be as yet unmeasured, and adverse outcomes following war-time injuries are difficult to fully explain.	[Mac Donald, Christine L.; Johnson, Ann M.; Werner, Nicole J.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Zonies, David; Oh, John; Fang, Raymond] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Nelson, Elliot C.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Oh, John] Walter Reed Natl Mil Med Ctr, Dept Trauma Crit Care & Acute Care Surg, Baltimore, MD USA; [Fang, Raymond] Univ Maryland, R Adams Cowley Shock Trauma Ctr, US Air Force Ctr Sustainment Trauma & Readiness S, Baltimore, MD 21201 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,POB 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Zonies, David/B-6497-2011; Oh, John/AAS-9557-2020	Oh, John/0000-0001-9010-0627	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT090444]	The study was funded by grant PT090444 from the Congressionally Directed Medical Research Program (Dr Brody, principal investigator).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Defense and Veterans Brain Injury Center, 2013, DOD NUMB TRAUM BRAIN; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Maguen S, 2012, J TRAUMA STRESS, V25, P3, DOI 10.1002/jts.21669; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Myers KM, 2007, MOL PSYCHIATR, V12, P120, DOI 10.1038/sj.mp.4001939; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Taniellian T, 2008, INVISIBLE WOUNDS WAR; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	54	68	69	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	AUG	2014	71	8					994	1002		10.1001/jamaneurol.2014.1114			9	Clinical Neurology	Neurosciences & Neurology	AN3IW	WOS:000340481800009	24934200	Bronze			2021-06-18	
J	Tate, R; Kennedy, M; Ponsford, J; Douglas, J; Velikonja, D; Bayley, M; Stergiou-Kita, M				Tate, Robyn; Kennedy, Mary; Ponsford, Jennie; Douglas, Jacinta; Velikonja, Diana; Bayley, Mark; Stergiou-Kita, Mary			INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part III: Executive Function and Self-Awareness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; executive function; guidelines; knowledge translation; neuropsychology; rehabilitation; self-awareness; traumatic brain injury	PROBLEM-SOLVING PROGRAM; OF-THE-LITERATURE; POSTACUTE REHABILITATION; METHODOLOGICAL QUALITY; CONTROLLED-TRIAL; N-OF-1 TRIALS; PEOPLE; DEFICITS; SKILLS; INTERVENTIONS	Introduction: Traumatic brain injury (TBI) results in complex cognitive (and other) sequelae. Impairments in executive function and self-awareness are among the most characteristic neuropsychological sequelae and can exert a profound effect on resuming previous life roles. An international group of researchers and clinicians (known as INCOG) convened to develop recommendations for interventions to improve impairments in executive functioning and self-awareness after TBI. Methods: The team reviewed the available literature and ensured the recommendations were current. To promote implementation, the team developed decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials. The team then prioritized the recommendations for implementation and developed audit criteria to evaluate the adherence to the best practice recommendations. Results: Intervention programs incorporating metacognitive strategy instruction for planning, problem-solving, and other cognitive-executive impairments have a solid evidence base. New evidence supports the use of strategies to specifically improve reasoning skills. Substantial support exists for use of direct corrective feedback to improve self-awareness. Conclusions: An increasing number of scientifically well-designed studies are available that demonstrate the effectiveness of a variety of interventions for the remediation of impairments in executive function and self-awareness after TBI.	[Tate, Robyn] Univ Sydney, Kolling Inst, Sydney Med Sch Northern, Rehabil Res Ctr, St Leonards, NSW 2065, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Kennedy, Mary] Chapman Univ Orange, Dept Commun Sci & Disorders, Orange, CA USA; [Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Douglas, Jacinta] La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia; [Douglas, Jacinta] Summer Fdn, Melbourne, Vic, Australia; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Bayley, Mark] Univ Toronto, UHN Toronto Rehabil Inst, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Dept Med, Div Physiatry, Toronto, ON, Canada; [Stergiou-Kita, Mary] Univ Toronto, Toronto, ON, Canada; [Stergiou-Kita, Mary] Toronto Rehabil Inst, Toronto, ON, Canada	Tate, R (corresponding author), Univ Sydney, Kolling Inst Med Res, Sydney Med Sch Northern, Rehabil Studies Unit,Royal North Shore Hosp, Level 9, St Leonards, NSW 2065, Australia.	rtate@med.usyd.edu.au		Bayley, Mark/0000-0001-7860-9463; Douglas, Jacinta/0000-0003-0940-6624	Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University; Ontario Neurotrauma Foundation	We gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University and the Ontario Neurotrauma Foundation for their support of this project.	Appraisal of Guidelines Research and Evaluation, AGREE ADV SCI PRACT; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Boelen DHE, 2011, J NEUROPSYCHOL, V5, P73, DOI 10.1348/174866410X516434; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chandrashekar R, 2007, J REHABIL, V73, P50; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Chittum WR, 1996, BRAIN INJURY, V10, P763; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cicerone KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Constantinidou F, 2005, J HEAD TRAUMA REHAB, V20, P143, DOI 10.1097/00001199-200503000-00003; Constantinidou F, 2008, J HEAD TRAUMA REHAB, V23, P312, DOI 10.1097/01.HTR.0000336844.99079.2c; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Delazer M, 1998, NEUROPSYCHOL REHABIL, V8, P401; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Eakin Paul J., 1991, DUAL CITY RESTRUCTUR, P3, DOI DOI 10.4095/134069; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming Jennifer M, 2006, Can J Occup Ther, V73, P44; Fong KNK, 2009, AM J OCCUP THER, V63, P525, DOI 10.5014/ajot.63.5.525; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Grimshaw Jeremy, 2004, J Contin Educ Health Prof, V24 Suppl 1, pS31, DOI 10.1002/chp.1340240506; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Howick J, 2011 OXFORD CEBM EVI; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Lane-Brown AT, 2009, NEUROPSYCHOL REHABIL, V19, P481, DOI 10.1080/09602010902949207; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lucas SE, 2005, AUST OCCUP THER J, V52, P160, DOI DOI 10.1111/J.1440-1630.2005.00485.X; Lundqvist A, 2010, BRAIN INJURY, V24, P823, DOI 10.3109/02699051003724986; Luria, 1973, WORKING BRAIN INTRO; Luria A. R., 1966, HIGHER CORTICAL FUNC; Maher C., 2000, BRAIN IMPAIR, V1, P130; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Man DWK, 2006, NEUROREHABILITATION, V21, P205; Man DWK, 2006, BRAIN INJURY, V20, P981, DOI 10.1080/13561820600909852; Marshall RC, 2004, APHASIOLOGY, V18, P659, DOI 10.1080/02687030444000237; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Papathanasiou I, 2011, APHASIA RELATED DISO, P365; PERDICES M, 2006, BRAIN IMPAIR, V7, P119, DOI DOI 10.1375/BRIM.7.2.119; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P321, DOI 10.1097/HTR.0000000000000072; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Sackett D. L., 2000, EVIDENCE BASED MED P, V2nd; Satish U, 2008, DISABIL REHABIL, V30, P468, DOI 10.1080/09638280701625401; Schmidt J, 2013, NEUROREHAB NEURAL RE, V27, P316, DOI 10.1177/1545968312469838; Schmidt J, 2011, J REHABIL MED, V43, P673, DOI 10.2340/16501977-0846; Soong W, 2005, INT J REHABIL RES, V28, P341, DOI 10.1097/00004356-200512000-00006; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tate RL, 2014, NEUROPSYCHOL REHABIL, V24, P315, DOI 10.1080/09602011.2013.875043; Tate RL, 2013, NEUROPSYCHOL REHABIL, V23, P619, DOI 10.1080/09602011.2013.824383; Tate RL, 2011, BRAIN IMPAIR, V12, P1, DOI 10.1375/brim.12.1.1; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Turkstra LS, 2002, J COMMUN DISORD, V35, P467, DOI 10.1016/S0021-9924(02)00118-1; van Heugten C, 2012, NEUROPSYCHOL REHABIL, V22, P653, DOI 10.1080/09602011.2012.680891; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007; Zoccolotti P, 2011, EUR J PHYS REHAB MED, V47, P123	105	68	69	0	51	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					338	352		10.1097/HTR.0000000000000068			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300010	24984096				2021-06-18	
J	Lazaridis, C; DeSantis, SM; Smielewski, P; Menon, DK; Hutchinson, P; Pickard, JD; Czosnyka, M				Lazaridis, Christos; DeSantis, Stacia M.; Smielewski, Peter; Menon, David K.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek			Patient-specific thresholds of intracranial pressure in severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; cerebrovascular pressure reactivity; neuromonitoring; clinical outcome; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; NEUROCRITICAL CARE; REACTIVITY; HYPERTENSION; MORTALITY; INSULTS; IMPACT	Object. Based on continuous monitoring of the pressure reactivity index (PRx), the authors defined individualized intracranial pressure (ICP) thresholds by graphing the relationship between ICP and PRx. These investigators hypothesized that an "ICP dose" based on individually assessed ICP thresholds would correlate more closely with the 6-month outcome when compared with ICP doses derived by the recommended universal thresholds of 20 and 25 mm Hg. Methods. This study was a retrospective analysis of prospectively collected data from 327 patients with severe traumatic brain injury. Results. Individualized thresholds were visually identified from graphs of PRx versus ICP; PRx > 0.2 was the cutoff. Intracranial pressure doses were then computed as the cumulative area under the curve above the defined thresholds in graphing ICP versus time. The term "Dose 20" (D20) was used to refer to an ICP threshold of 20 mm Hg; the markers D25 and DPRx were calculated similarly. Separate logistic regression models were fit with death as the outcome and each dose as the predictor, both alone and adjusted for covariates. The discriminative ability of each dose for mortality was assessed by receiver operating characteristic AUC analysis in which 5-fold cross-validation was used. A clearly identifiable PRx-based threshold was possible in 224 patients (68%). The DPRx (AUC 0.81, 95% CI 0.74-0.87) was found to have the highest area under the curve (AUC) over both D20 (0.75, 95% CI 0.68-0.81) and D25 (0.77, 95% CI 0.70-0.83); in the cross-validation model, DPRx remained the best discriminator of mortality (DPRx: AUC 0.77 [95% CI 0.68-0.89]; D20: 0.72 [95% CI 0.66-0.81]; and D25: 0.65 [95% CI 0.56-0.73]). Conclusions. The authors explored the importance of different ICP thresholds for outcome by calculating patient-specific ICP doses based on the continuous monitoring of cerebrovascular pressure reactivity. They found that these individualized doses of intracranial hypertension were stronger predictors of death than doses derived from the universal thresholds of 20 and 25 mm Hg. The PRx could offer a method that can be directed toward individualizing the ICP threshold.	[Lazaridis, Christos; Smielewski, Peter; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Lazaridis, Christos] Baylor Coll Med, Dept Neurol, Div Neurocrit Care, Houston, TX 77030 USA; [Lazaridis, Christos] Baylor Coll Med, Dept Neurol, Div Vasc Neurol, Houston, TX 77030 USA; [DeSantis, Stacia M.] Univ Texas Houston, Sch Publ Hlth Houston, Div Biostat, Houston, TX USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England	Lazaridis, C (corresponding author), Baylor Coll Med, Dept Neurol, Div Neurocrit Care, 6501 Fannin St,Mail Slot NB320, Houston, TX 77030 USA.	lazaridi@bcm.edu		Smielewski, Peter/0000-0001-5096-3938	Academy of Medical SciencesAcademy of Medical Sciences (AMS); Health Foundation Senior Scientist Fellowship; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NIHR Cambridge Biomedical Centre; NIHR Biomedical Research Centre (Cambridge University Hospital Foundation Trust); MRC "Acute Brain Injury Programme"; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0601025, G1000183B, G9439390, G0001354B, G0001354, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NF-SI-0512-10090, NIHR-RP-R3-12-013, NF-SI-0508-10327] Funding Source: researchfish	The software for brain monitoring ICM+ (http://www.neuro surg.cam.ac.uk/icmplus) is licensed by the University of Cambridge (Cambridge Enterprise Ltd.). Mr. Czosnyka and Mr. Smielewski have a financial interest in a part of the licensing fee. Mr. Hutchinson is supported by an Academy of Medical Sciences/Health Foundation Senior Scientist Fellowship and grants from the Medical Research Council (MRC)/National Institute for Health Research (NIHR). He has also received a lecture honorarium from Codman and is a patent holder in Technicam. Mr. Menon is supported by funding from the MRC, the NIHR Cambridge Biomedical Centre, and an NIHR Senior Investigator award. Mr. Pickard is an NIHR senior investigator awardee and a principal investigator within the NIHR Biomedical Research Centre (Cambridge University Hospital Foundation Trust) and lead principal investigator for the MRC "Acute Brain Injury Programme" grant. The remaining authors have not disclosed any potential conflict of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Biousse V, 2012, J NEUROL NEUROSUR PS, V83, P488, DOI 10.1136/jnnp-2011-302029; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; JENNETT B, 1975, LANCET, V1, P480; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Romero CM, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	31	68	75	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					893	900		10.3171/2014.1.JNS131292			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800014	24506248				2021-06-18	
J	Tosun, C; Kurland, DB; Mehta, R; Castellani, RJ; deJong, JL; Kwon, MS; Woo, SK; Gerzanich, V; Simard, JM				Tosun, Cigdem; Kurland, David B.; Mehta, Rupal; Castellani, Rudy J.; deJong, Joyce L.; Kwon, Min Seong; Woo, Seung Kyoon; Gerzanich, Volodymyr; Simard, J. Marc			Inhibition of the Sur1-Trpm4 Channel Reduces Neuroinflammation and Cognitive Impairment in Subarachnoid Hemorrhage	STROKE			English	Article						cognition; memory; subarachnoid hemorrhage; sulfonylurea receptor; transient receptor potential melastatin 4	SULFONYLUREA RECEPTOR 1; TRAUMATIC BRAIN-INJURY; POTENTIAL MELASTATIN 4; LEARNING-DEFICITS; EDEMA; EXPRESSION; CELLS; MODEL; RATS	Background and Purpose Subarachnoid hemorrhage (SAH) can leave patients with memory impairments that may not recover fully. Molecular mechanisms are poorly understood, and no treatment is available. The sulfonylurea receptor 1-transient receptor potential melastatin 4 (Sur1-Trpm4) channel plays an important role in acute central nervous system injury. We evaluated upregulation of Sur1-Trpm4 in humans with SAH and, in rat models of SAH, we examined Sur1-Trpm4 upregulation, its role in barrier dysfunction and neuroinflammation, and its consequences on spatial learning. Methods We used Forster resonance energy transfer to detect coassociated Sur1 and Trpm4 in human autopsy brains with SAH. We studied rat models of SAH involving filament puncture of the internal carotid artery or injection of blood into the subarachnoid space of the entorhinal cortex. In rats, we used Forster resonance energy transfer and coimmunoprecipitation to detect coassociated Sur1 and Trpm4, we measured immunoglobulin G extravasation and tumor necrosis overexpression as measures of barrier dysfunction and neuroinflammation, and we assessed spatial learning and memory on days 7 to 19. Results Sur1-Trpm4 channels were upregulated in humans and rats with SAH. In rats, inhibiting Sur1 using antisense or the selective Sur1 inhibitor glibenclamide reduced SAH-induced immunoglobulin G extravasation and tumor necrosis overexpression. In models with entorhinal SAH, rats treated with glibenclamide for 7 days after SAH exhibited better platform search strategies and better performance on incremental and rapid spatial learning than vehicle-treated controls. Conclusions Sur1-Trpm4 channels are upregulated in humans and rats with SAH. Channel inhibition with glibenclamide may reduce neuroinflammation and the severity of cognitive deficits after SAH.	[Tosun, Cigdem; Kurland, David B.; Kwon, Min Seong; Woo, Seung Kyoon; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Mehta, Rupal; Castellani, Rudy J.; Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [deJong, Joyce L.] Western Michigan Univ, Sch Med, Dept Pathol, Kalamazoo, MI 49008 USA	Simard, JM (corresponding author), Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020	deJong, Joyce/0000-0002-8222-3587	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072501, R01NS061808] Funding Source: NIH RePORTER	This work was supported by grants to Dr Simard from the National Heart, Lung, and Blood Institute (HL082517) and the National Institute of Neurological Disorders and Stroke (NS061808).	Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Chen G, 2013, NEUROSCIENCE, V231, P136, DOI 10.1016/j.neuroscience.2012.11.024; Guiot Y, 2007, DIABETOLOGIA, V50, P1889, DOI 10.1007/s00125-007-0731-z; Hanel RA, 2002, NEUROL RES, V24, pS58; Hollenstein K, 2007, CURR OPIN STRUC BIOL, V17, P412, DOI 10.1016/j.sbi.2007.07.003; Jeon H, 2010, NEUROSCIENCE, V169, P1805, DOI 10.1016/j.neuroscience.2010.06.039; Ma JP, 2012, CRIT CARE, V16, DOI 10.1186/cc11686; Mehta RI, 2013, J NEUROPATH EXP NEUR, V72, P871, DOI 10.1097/NEN.0b013e3182a32e40; Niikawa S, 1998, NEUROL MED-CHIR, V38, P844, DOI 10.2176/nmc.38.844; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Quigley MR, 2008, SURG NEUROL, V69, P261, DOI 10.1016/j.surneu.2007.02.013; Shi NQ, 2005, J MOL CELL CARDIOL, V39, P51, DOI 10.1016/j.yjmcc.2004.11.024; Silasi G, 2009, BEHAV BRAIN RES, V198, P380, DOI 10.1016/j.bbr.2008.11.019; Simard JM, 2012, PFLUG ARCH EUR J PHY, V464, P573, DOI 10.1007/s00424-012-1166-z; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2012, TRANSL STROKE RES, V3, pS155, DOI 10.1007/s12975-012-0166-9; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Teruyama R, 2011, J NEUROENDOCRINOL, V23, P1204, DOI 10.1111/j.1365-2826.2011.02211.x; Wagner KR, 2005, CURR NEUROVASC RES, V2, P149, DOI 10.2174/1567202053586785; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xavier GF, 2009, PROG NEURO-PSYCHOPH, V33, P762, DOI 10.1016/j.pnpbp.2009.03.036	26	68	73	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2013	44	12					3522	3528		10.1161/STROKEAHA.113.002904			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	257LR	WOS:000327386300327	24114458	Green Accepted, Bronze			2021-06-18	
J	Bender, A; Heulin, S; Rohrer, S; Mehrkens, JH; Heidecke, V; Straube, A; Pfefferkorn, T				Bender, Andreas; Heulin, Sandrine; Roehrer, Stefan; Mehrkens, Jan-Hinnerk; Heidecke, Volkmar; Straube, Andreas; Pfefferkorn, Thomas			Early cranioplasty may improve outcome in neurological patients with decompressive craniectomy	BRAIN INJURY			English	Article						Cranioplasty; decompressive craniectomy; neurorehabilitation; outcome; stroke; traumatic brain injury	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; MALIGNANT INFARCTION; CASE SERIES; HEMICRANIECTOMY; MULTICENTER; SURGERY; RECOVERY; INFECTION; TRIAL	Primary objective: Decompressive craniectomy is an effective therapy to relieve intractable intracranial hypertension following acute brain injury. However, little is known about the optimal timing for cranioplasties in the sub-acute phase. The objective of the present study was to analyse the effect of cranioplasty timing on neurological outcomes. Research design: Single-centre observational study. Methods and procedures: One hundred and forty-seven consecutive patients with decompressive craniectomy and cranioplasty during the course of inpatient neurorehabilitation were identified by means of a retrospective hospital database search. This database contains the following prospectively-entered weekly scores: Barthel-Index (BI), Functional Independence Measure (FIM) and Coma Remission Scale (CRS). Additional clinical data were taken retrospectively from patient charts. Regression analysis was used to identify factors that influenced the end-of-rehabilitation outcome. Main outcomes and results: Patients with shorter delays to cranioplasty (<86 days) had a better functional outcome than patients with longer delays of >85 days (60 +/- 29.5 versus 25 +/- 24.1 BI points; p<0.01, respectively). Age, pre-operative BI and CRS scores were additional independent outcome factors. Complication rates were not different between early and late cranioplasty groups. Conclusions: Patients with decompressive craniectomy for management of intracranial hypertension may benefit from early cranioplasty.	[Bender, Andreas; Heulin, Sandrine; Straube, Andreas; Pfefferkorn, Thomas] Univ Munich, Dept Neurol, D-81377 Munich, Germany; [Bender, Andreas; Heulin, Sandrine] Therapiezentrum Burgau, Dept Neurol, D-89331 Burgau, Germany; [Roehrer, Stefan] Univ Ulm, Dept Neurosurg, D-89069 Ulm, Germany; [Roehrer, Stefan] Bezirkskrankenhaus Gunzburg, Dept Neurosurg, Gunzburg, Germany; [Mehrkens, Jan-Hinnerk] Univ Munich, Dept Neurosurg, D-81377 Munich, Germany; [Heidecke, Volkmar] Zent Klinikum, Dept Neurosurg, Augsburg, Germany	Bender, A (corresponding author), Therapiezentrum Burgau, Dept Neurol, Kapuzinerstr 34, D-89331 Burgau, Germany.	anbender@med.uni-muenchen.de		Bender, Andreas/0000-0002-6328-7104			Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; MAHONEY F I, 1965, Md State Med J, V14, P61; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Voss A, 1993, SPECTRUM NEUROREHABI, P112; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43	36	68	73	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1073	1079		10.3109/02699052.2013.794972			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100012	23662672				2021-06-18	
J	Kageyama, H; Toyooka, T; Tsuzuki, N; Oka, K				Kageyama, Hiroshi; Toyooka, Terushige; Tsuzuki, Nobusuke; Oka, Kazunari			Nonsurgical treatment of chronic subdural hematoma with tranexamic acid Clinical article	JOURNAL OF NEUROSURGERY			English	Article						chronic subdural hematoma; tranexamic acid; fibrinolysis; kallikrein system; traumatic brain injury	LOCAL HYPERFIBRINOLYSIS; SPONTANEOUS RESOLUTION; FIBRINOLYSIS	Object. Chronic subdural hematoma (CSDH) is a common condition after head trauma. It can often be successfully treated surgically by inserting a bur hole and draining the liquefied hematoma. However, to the best of the authors' knowledge, for nonemergency cases not requiring surgery, no reports have indicated the best approach for preventing hematoma enlargement or resolving it completely. The authors hypothesized that hyperfibrinolysis plays a major role in liquefaction of the hematoma. Therefore, they evaluated the ability of an antifibrinolytic drug, tranexamic acid, to completely resolve CSDH compared with bur hole surgery alone. Methods. From 2007 to 2011, a total of 21 patients with CSDH seen consecutively at Kuki General Hospital, Japan, were given 750 mg of tranexamic acid orally every day. Patients were identified by a retrospective records review, which collected data on the volume of the hematoma (based on radiographic measurements) and any complications. Follow-up for each patient consisted of CT or MRI every 21 days from diagnosis to resolution of the CSDH. Results. Of the 21 patients, 3 with early stages of CSDH were treated by bur hole surgery before receiving medical therapy. The median duration of clinical and radiographic follow-up was 58 days (range 28-137 days). Before tranexamic acid therapy was initiated, the median hematoma volume for the 21 patients was 58.5 ml (range 7.5-223.2 ml); for the 18 patients who had not undergone surgery, the median hematoma volume was 55.6 ml (range 7.5-140.5 ml). After therapy, the median volume for all 21 patients was 3.7 ml (range 0-22.1 ml). No hematomas recurred or progressed. Conclusions. Chronic subdural hematoma can be treated with tranexamic acid without concomitant surgery. Tranexamic acid might simultaneously inhibit the fibrinolytic and inflammatory (kinin-kallikrein) systems, which might consequently resolve CSDH. This medical therapy could prevent the early stages of CSDH that can occur after head trauma and the recurrence of CSDH after surgery.	[Kageyama, Hiroshi; Toyooka, Terushige; Tsuzuki, Nobusuke; Oka, Kazunari] Kuki Gen Hosp, Dept Neurosurg, Kuki, Saitama 3460021, Japan; [Kageyama, Hiroshi] Juntendo Univ, Dept Neurosurg, Tokyo, Japan	Kageyama, H (corresponding author), Kuki Gen Hosp, Kamihayami 418-1, Kuki, Saitama 3460021, Japan.	kageyamahiroshi29@gmail.com					[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Ducloy-Bouthors AS, 2011, CRIT CARE, V15, DOI 10.1186/cc10143; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; FUJISAWA H, 1995, J NEUROL NEUROSUR PS, V59, P388, DOI 10.1136/jnnp.59.4.388; Goksu E, 2009, ULUS TRAVMA ACIL CER, V15, P95; Harada K, 1989, Neurol Med Chir (Tokyo), V29, P113, DOI 10.2176/nmc.29.113; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; ITO H, 1976, J NEUROSURG, V45, P26, DOI 10.3171/jns.1976.45.1.0026; KASSELL NF, 1984, J NEUROSURG, V61, P225, DOI 10.3171/jns.1984.61.2.0225; KAWAKAMI Y, 1989, NEUROSURGERY, V25, P25, DOI 10.1227/00006123-198907000-00005; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; NOMURA S, 1994, J NEUROSURG, V81, P910, DOI 10.3171/jns.1994.81.6.0910; Oh HJ, 2010, J KOREAN NEUROSURG S, V48, P518, DOI 10.3340/jkns.2010.48.6.518; SAITO K, 1989, J NEUROSURG, V70, P68, DOI 10.3171/jns.1989.70.1.0068; Suzuki M, 1998, ACTA NEUROCHIR, V140, P261, DOI 10.1007/s007010050093; YAMASHIMA T, 1983, J NEUROSURG, V59, P298, DOI 10.3171/jns.1983.59.2.0298	16	68	74	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					332	337		10.3171/2013.3.JNS122162			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400012	23641825				2021-06-18	
J	Kochanek, PM; Dixon, CE; Shellington, DK; Shin, SS; Bayir, H; Jackson, EK; Kagan, VE; Yan, HQ; Swauger, PV; Parks, SA; Ritzel, DV; Bauman, R; Clark, RSB; Garman, RH; Bandak, F; Ling, G; Jenkins, LW				Kochanek, Patrick M.; Dixon, C. Edward; Shellington, David K.; Shin, Samuel S.; Bayir, Huelya; Jackson, Edwin K.; Kagan, Valerian E.; Yan, Hong Q.; Swauger, Peter V.; Parks, Steven A.; Ritzel, David V.; Bauman, Richard; Clark, Robert S. B.; Garman, Robert H.; Bandak, Faris; Ling, Geoffrey; Jenkins, Larry W.			Screening of Biochemical and Molecular Mechanisms of Secondary Injury and Repair in the Brain after Experimental Blast-Induced Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						adenosine; antioxidant; ascorbate; ATP; axonal injury; chemokine; combat casualty care; cyclic AMP; cytokine; gene array; glutathione; improvised explosive device; lipid peroxidation; multiplex; post-traumatic stress disorder; purine	POSTTRAUMATIC-STRESS-DISORDER; HUMAN CEREBROSPINAL-FLUID; OXIDATIVE STRESS; GENE-EXPRESSION; CELLS; MODEL; INTERLEUKIN-6; ACTIVATION; MIP-1-ALPHA; CHEMOKINE	Explosive blast-induced traumatic brain injury (TBI) is the signature insult in modern combat casualty care and has been linked to post-traumatic stress disorder, memory loss, and chronic traumatic encephalopathy. In this article we report on blast-induced mild TBI (mTBI) characterized by fiber-tract degeneration and axonal injury revealed by cupric silver staining in adult male rats after head-only exposure to 35 psi in a helium-driven shock tube with head restraint. We now explore pathways of secondary injury and repair using biochemical/molecular strategies. Injury produced similar to 25% mortality from apnea. Shams received identical anesthesia exposure. Rats were sacrificed at 2 or 24 h, and brain was sampled in the hippocampus and prefrontal cortex. Hippocampal samples were used to assess gene array (RatRef-12 Expression BeadChip; Illumina, Inc., San Diego, CA) and oxidative stress (OS; ascorbate, glutathione, low-molecular-weight thiols [LMWT], protein thiols, and 4-hydroxynonenal [HNE]). Cortical samples were used to assess neuroinflammation (cytokines, chemokines, and growth factors; Luminex Corporation, Austin, TX) and purines (adenosine triphosphate [ATP], adenosine diphosphate, adenosine, inosine, 2'-AMP [adenosine monophosphate], and 5'-AMP). Gene array revealed marked increases in astrocyte and neuroinflammatory markers at 24 h (glial fibrillary acidic protein, vimentin, and complement component 1) with expression patterns bioinformatically consistent with those noted in Alzheimer's disease and long-term potentiation. Ascorbate, LMWT, and protein thiols were reduced at 2 and 24 h; by 24 h, HNE was increased. At 2 h, multiple cytokines and chemokines (interleukin [IL]-1 alpha, IL-6, IL-10, and macrophage inflammatory protein 1 alpha [MIP-1 alpha]) were increased; by 24 h, only MIP-1 alpha remained elevated. ATP was not depleted, and adenosine correlated with 2'-cyclic AMP (cAMP), and not 5'-cAMP. Our data reveal (1) gene-array alterations similar to disorders of memory processing and a marked astrocyte response, (2) OS, (3) neuroinflammation with a sustained chemokine response, and (4) adenosine production despite lack of energy failure-possibly resulting from metabolism of 2'-3'-cAMP. A robust biochemical/molecular response occurs after blast-induced mTBI, with the body protected from blast and the head constrained to limit motion.	[Kochanek, Patrick M.; Dixon, C. Edward; Shin, Samuel S.; Bayir, Huelya; Yan, Hong Q.; Clark, Robert S. B.; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Dixon, C. Edward; Shin, Samuel S.; Yan, Hong Q.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Med Pharmacol, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Sch Med, Pittsburgh Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Shellington, David K.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Swauger, Peter V.; Parks, Steven A.] ORA Inc, Fredericksburg, VA USA; [Bauman, Richard] Walter Reed Army Inst Res, Silver Spring, MD USA; [Ritzel, David V.] Dyn FX Consulting Ltd, Amherstburg, ON, Canada; [Bandak, Faris; Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Tiwari, Prafulla/I-1320-2014	Kochanek, Patrick M/0000-0002-2627-913X; Tiwari, Prafulla/0000-0001-7913-5386; Kagan, Valerian E./0000-0002-7245-1885; Shellington, David/0000-0001-6708-6978; Jackson, Edwin/0000-0002-8101-6009	DARPA PREVENT [N660001-10C2124]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM113746] Funding Source: NIH RePORTER	This work was supported by DARPA PREVENT (N660001-10C2124). The authors thank Keri Janesko-Feldman and Jeremy Henchir for their technical support. The authors thank Marci Provins and Fran Mistrick for their help with manuscript preparation. Microarray data were generated by the Genomics Core Laboratory, University of Pittsburgh, and statistical analyses were performed by the GPCL-Bioinformatics Analysis Core (GPCL-BAC), University of Pittsburgh. The authors thank Dr. James Lyons-Weiler for his valuable assistance. The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies either expressed or implied of DARPA or the DoD. This work has been approved for public release, distribution unlimited.	Andre R, 2005, NEUROREPORT, V16, P153, DOI 10.1097/00001756-200502080-00017; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belikova NA, 2011, J NEUROSCI METH, V201, P185, DOI 10.1016/j.jneumeth.2011.08.001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Clahsen T, 2008, J LEUKOCYTE BIOL, V84, P1521, DOI 10.1189/jlb.0308178; Cohen I, 2010, P NATL ACAD SCI USA, V107, P2574, DOI 10.1073/pnas.0915018107; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hulse RE, 2004, J NEUROSCI METH, V136, P87, DOI 10.1016/j.jneumeth.2003.12.023; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Jordan BR, 2004, BIOESSAYS, V26, P1236, DOI 10.1002/bies.20128; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lemke R, 1999, GLIA, V27, P75, DOI 10.1002/(SICI)1098-1136(199907)27:1<75::AID-GLIA8>3.3.CO;2-A; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Morey R.A., 2012, HUM BRAIN MAPP, DOI [10.1002/hbm.22117, DOI 10.1002/HBM.22117.[]; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Zalewska T, 1996, ACTA NEUROBIOL EXP, V56, P41; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	63	68	69	1	33	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					920	937		10.1089/neu.2013.2862			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300003	23496248	Green Published			2021-06-18	
J	Beauchamp, MH; Beare, R; Ditchfield, M; Coleman, L; Babl, FE; Kean, M; Crossley, L; Catroppa, C; Yeates, KO; Anderson, V				Beauchamp, Miriam H.; Beare, Richard; Ditchfield, Michael; Coleman, Lee; Babl, Franz E.; Kean, Michael; Crossley, Louise; Catroppa, Cathy; Yeates, Keith O.; Anderson, Vicki			Susceptibility weighted imaging and its relationship to outcome after pediatric traumatic brain injury	CORTEX			English	Article						Traumatic brain injury; Children; Intellectual function; Magnetic resonance imaging; Susceptibility weighted imaging	DIFFUSE AXONAL INJURY; CHILDHOOD HEAD-INJURY; CHILDREN; PREDICTORS; LESIONS; PERFORMANCE; RECOVERY; MRI; SWI	Introduction: Traumatic brain injury (TBI) sustained during childhood can cause difficulties in a wide range of physical, neurological, cognitive, social and functional domains. However, the ability of health professionals and researchers to accurately predict the outcome of pediatric TBI remains limited. The advent of advanced neuroimaging techniques shows some promise in improving outcome prediction, as they contribute to greater sensitivity in characterizing intracranial lesions underlying many cognitive and functional deficits. In this study, the relationship between lesions identified on susceptibility weighted imaging (SWI) and cognitive and functional outcomes was investigated following childhood TBI. Method: Participants between 5 and 14 years of age with varying levels of TBI severity (mild, mild complicated, moderate, severe, n = 106) underwent susceptibility weighted scanning on average 1-month post-injury and completed an assessment of intellectual functioning, processing speed, and behavioral and adaptive skills 6-month post-injury. Results: More severe TBI was generally associated with poorer intellectual functioning, greater behavioral problems and lower adaptive functioning. Number and volume of SWI lesions were significantly correlated with clinical outcome variables including Glasgow Coma Score (GCS), surgical intervention, length of hospital stay and length of intubation, as well as with intellectual functioning. Together, SWI and GCS accounted for a significant, though small, proportion of the variance in intellectual quotient (IQ). Conclusions: SWI is a sensitive technique for detecting brain lesions at all TBI severity levels and shows promise in contributing to prediction of cognitive outcomes in the initial stages post-injury. (C) 2012 Elsevier Ltd. All rights reserved.	[Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Beare, Richard; Coleman, Lee; Babl, Franz E.; Kean, Michael; Crossley, Louise; Catroppa, Cathy; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Australia; [Ditchfield, Michael] Monash Med Ctr, Melbourne, Australia; [Coleman, Lee; Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	Anderson, V (corresponding author), Murdoch Childrens Res Inst, 4th Floor West,Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Beare, Richard/0000-0002-7530-5664	Victoria Neurotrauma Initiative, Australia; Victorian Government Operational Infrastructure Support Program; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This work was supported by a grant from the Victoria Neurotrauma Initiative, Australia; the Victorian Government Operational Infrastructure Support Program; and a fellowship from the Canadian Institutes of Health Research to MB. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, HDB CLIN PE IN PRESS; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Coffey C., 1991, Psychopathology and the Brain, V3, P243; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 2011, J MAGN RESON, V32, P516; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 2003, MANUAL WECHSLER INTE; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	36	68	71	0	14	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2013	49	2			SI		591	598		10.1016/j.cortex.2012.08.015			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	117BJ	WOS:000316926800022	23062584				2021-06-18	
J	Tweedie, D; Rachmany, L; Rubovitch, V; Lehrmann, E; Zhang, YQ; Becker, KG; Perez, E; Miller, J; Hoffer, BJ; Greig, NH; Pick, CG				Tweedie, David; Rachmany, Lital; Rubovitch, Vardit; Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Miller, Jonathan; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury (mTBI); Glucagon-like peptide-1; Exendin-4; Gene expression; Novel object recognition; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; NECROSIS-FACTOR-ALPHA; CELL-CYCLE; ALZHEIMERS-DISEASE; AMYLOID-BETA; MOUSE MODEL; A-BETA; COGNITIVE DEFICITS; BINDING-SITES	Traumatic brain injury (TBI) is a global problem reaching near epidemic numbers that manifests clinically with cognitive problems that decades later may result in dementias like Alzheimer's disease (AD). Presently, little can be done to prevent ensuing neurological dysfunctions by pharmacological means. Recently, it has become apparent that several CNS diseases share common terminal features of neuronal cell death. The effects of exendin-4 (Ex-4), a neuroprotective agent delivered via a subcutaneous micro-osmotic pump, were examined in the setting of mild TBI (mTBI). Utilizing a model of mTBI, where cognitive disturbances occur over time, animals were subjected to four treatments: sham; Ex-4; mTBI and Ex-4/mTBI. mTBI mice displayed deficits in novel object recognition, while Ex-4/mTBI mice performed similar to sham. Hippocampal gene expression, assessed by gene array methods, showed significant differences with little overlap in co-regulated genes between groups. Importantly, changes in gene expression induced by mTBI, including genes associated with AD were largely prevented by Ex-4. These data suggest a strong beneficial action of Ex-4 in managing secondary events induced by a traumatic brain injury. (c) 2012 Elsevier Inc. All rights reserved.	[Tweedie, David] NIA, Translat Gerontol Branch, Intramural Res Program, Drug Design & Dev Sect,Lab Neurosci,NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.] NIA, Gene Express & Genom Unit, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Expt Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA	Tweedie, D (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, Drug Design & Dev Sect,Lab Neurosci,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov; litalrac@post.tau.ac.il; rubovitc@post.tau.ac.il; elehrman@mail.nih.gov; zhangyon@grc.nia.nih.gov; BeckerK@grc.nia.nih.gov; perezev@grc.nia.nih.gov; Jonathan.Miller@UHhospitals.org; bjh82@case.edu; greign@grc.nia.nih.gov; pickc@post.tau.ac.il		Lehrmann, Elin/0000-0002-9869-9475; Miller, Jonathan/0000-0001-5441-1751; Becker, Kevin/0000-0002-6794-6656	Sackler School of Medicine, Tel-Aviv University; Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Intramural Research Program of the National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZICAG000616, ZIAAG000333, ZIAAG000311] Funding Source: NIH RePORTER	This research was supported in part by the Sackler School of Medicine, Tel-Aviv University, and the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health.	Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Bak AM, 2011, EXPERT OPIN THER TAR, V15, P1153, DOI 10.1517/14728222.2011.600691; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Belsham DD, 2009, FASEB J, V23, P4256, DOI 10.1096/fj.09-133454; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chung LTK, 2009, BIOCHEM BIOPH RES CO, V390, P613, DOI 10.1016/j.bbrc.2009.10.015; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Currais A, 2009, AGING-US, V1, P363, DOI 10.18632/aging.100045; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drucker DJ, 2008, LANCET, V372, P1240, DOI 10.1016/S0140-6736(08)61206-4; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernando RN, 2011, P NATL ACAD SCI USA, V108, P5837, DOI 10.1073/pnas.1014993108; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; GOKE R, 1995, NEUROENDOCRINOLOGY, V62, P130, DOI 10.1159/000126997; GOKE R, 1995, EUR J NEUROSCI, V7, P2294, DOI 10.1111/j.1460-9568.1995.tb00650.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Griffioen KJ, 2011, CARDIOVASC RES, V89, P72, DOI 10.1093/cvr/cvq271; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Hamilton A, 2011, J NEUROSCI RES, V89, P481, DOI 10.1002/jnr.22565; Hayes MR, 2008, ENDOCRINOLOGY, V149, P4059, DOI 10.1210/en.2007-1743; Holscher C, 2010, VITAM HORM, V84, P331, DOI [10.1016/S0083-6729(10)84005-1, 10.1016/B978-0-12-381517-0.00013-8]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan-Sciutto Kelly L., 1999, J Alzheimers Dis, V1, P409; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Lahiri DK, 2004, NEUROBIOL AGING, V25, P651, DOI 10.1016/j.neurobiolaging.2003.12.024; Li H, 2010, NEUROSCI LETT, V486, P38, DOI 10.1016/j.neulet.2010.09.040; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu XX, 2005, NAT NEUROSCI, V8, P1179, DOI 10.1038/nn1522; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morita N, 1996, J NEUROSCI, V16, P5961; OShea D, 1996, NEUROREPORT, V7, P830, DOI 10.1097/00001756-199602290-00035; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Rachmany L., 2012, AGE DORDR; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Russo I, 2011, CELL CYCLE, V10, P2568, DOI 10.4161/cc.10.15.15946; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Zhong N, 2009, CURR ALZHEIMER RES, V6, P415, DOI 10.2174/156720509789207921; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	84	68	69	0	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2013	239						170	182		10.1016/j.expneurol.2012.10.001			13	Neurosciences	Neurosciences & Neurology	073TH	WOS:000313765000021	23059457	Green Accepted			2021-06-18	
J	Helmy, A; Antoniades, CA; Guilfoyle, MR; Carpenter, KLH; Hutchinson, PJ				Helmy, Adel; Antoniades, Chrystalina A.; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Hutchinson, Peter J.			Principal Component Analysis of the Cytokine and Chemokine Response to Human Traumatic Brain Injury	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; INTENSIVE-CARE PATIENTS; HUMAN VENTRICULAR CSF; CLOSED-HEAD INJURY; PROGNOSTIC VALUE; INTRACEREBRAL MICRODIALYSIS; INNATE IMMUNITY; DUAL ROLE; INTERLEUKIN-6; IMPACT	There is a growing realisation that neuro-inflammation plays a fundamental role in the pathology of Traumatic Brain Injury (TBI). This has led to the search for biomarkers that reflect these underlying inflammatory processes using techniques such as cerebral microdialysis. The interpretation of such biomarker data has been limited by the statistical methods used. When analysing data of this sort the multiple putative interactions between mediators need to be considered as well as the timing of production and high degree of statistical co-variance in levels of these mediators. Here we present a cytokine and chemokine dataset from human brain following human traumatic brain injury and use principal component analysis and partial least squares discriminant analysis to demonstrate the pattern of production following TBI, distinct phases of the humoral inflammatory response and the differing patterns of response in brain and in peripheral blood. This technique has the added advantage of making no assumptions about the Relative Recovery (RR) of microdialysis derived parameters. Taken together these techniques can be used in complex microdialysis datasets to summarise the data succinctly and generate hypotheses for future study.	[Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Antoniades, Chrystalina A.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Dept Clin Neurol, Oxford OX1 2JD, England; [Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England	Helmy, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England.	adelhelmy@cantab.net	Viani, Rafael/V-1196-2018; Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Antoniades, Chrystalina/0000-0002-1192-3834; Carpenter, Keri/0000-0001-8236-7727	Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Raymond and Beverly Sackler Fellowship; Royal College of Surgeons of England; National Institute of Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research Council (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, ID 65883, G0600986, ID 79068]; National Institute of Health Research (NIHR) Oxford Biomedical Research CentreNational Institute for Health Research (NIHR); Thames Valley Dementia and Neurodegenerative Disease Research Network (DeNDRoN); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0802251, G1002277] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004] Funding Source: researchfish	AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship and a Raymond and Beverly Sackler Fellowship. MRG is supported by the Royal College of Surgeons of England and a Raymond and Beverly Sackler Fellowship. KLHC is supported by the National Institute of Health Research Biomedical Research Centre, Cambridge and by the Medical Research Council (Acute Brain Injury Programme Grant). PJAH is supported by the Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. Study support was provided by the Medical Research Council (Grant numbers G9439390 ID 65883 and G0600986 ID 79068). CAA is funded by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre and by the Thames Valley Dementia and Neurodegenerative Disease Research Network (DeNDRoN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre R, 2005, NEUROREPORT, V16, P153, DOI 10.1097/00001756-200502080-00017; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Boulesteix AL, 2007, BRIEF BIOINFORM, V8, P32, DOI 10.1093/bib/bb1016; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Eriksson L., 2001, MULTI MEGAVARIATE DA; Eriksson L., 2006, MULTI MEGAVARIATE DA; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gasteiger J, 2006, ANAL BIOANAL CHEM, V384, P57, DOI 10.1007/s00216-005-0065-y; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2011, PROG NEUROBIOL; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2010, ACTA NEUROCHIR, V152, P953, DOI 10.1007/s00701-009-0584-y; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marcus HJ, 2010, J NEURO-ONCOL, V97, P11, DOI 10.1007/s11060-009-9990-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Ramon J, 2007, ADV ENG INFORM, V21, P243, DOI 10.1016/j.aei.2006.12.002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stenken JA, 2010, AAPS J, V12, P73, DOI 10.1208/s12248-009-9163-7; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Yao HH, 2010, J NEUROIMMUNE PHARM, V5, P489, DOI 10.1007/s11481-010-9211-1	61	68	68	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39677	10.1371/journal.pone.0039677			14	Multidisciplinary Sciences	Science & Technology - Other Topics	964XV	WOS:000305730900097	22745809	DOAJ Gold, Green Published			2021-06-18	
J	Shively, SB; Perl, DP				Shively, Sharon B.; Perl, Daniel P.			Traumatic Brain Injury, Shell Shock, and Posttraumatic Stress Disorder in the Military-Past, Present, and Future	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic traumatic encephalopathy; improvised explosive device; military; neurodegeneration; neurofibrillary tangle; neuropathology; posttraumatic stress disorder; shell shock; tau; traumatic brain injury	REPETITIVE HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; HIGH EXPLOSIVES; ENCEPHALOPATHY; AFTERMATH	With preferential use of high explosives in modern warfare, traumatic brain injury (TBI) has become a common injury for troops. Most TBIs are classified as "mild," although military personnel with these injuries can have persistent symptoms such as headache, memory impairment, and behavioral changes. DuringWorld War I, soldiers in the trenches, undergoing unrelenting artillery bombardment, suffered from similar symptoms, designated at the time as "shell shock." Dr Frederick Mott proposed studying the brains of deceased soldiers to elucidate the neuropathology of this clinical entity. Subsequent to a British government enquiry after World War I, the term "shell shock" was banned and further investigation into a possible organic cause for these symptoms was discontinued. Nevertheless, similar clinical entities, such as combat or battle fatigue and posttraumatic stress disorder, continue to be encountered by combatants in subsequent military conflicts. To this day, there exists a paucity of neuropathology studies investigating the effects of high explosives on the human brain. By analogy, studies have recently revealed that athletes with repeated head trauma can develop a neurodegenerative disease, chronic traumatic encephalopathy, who present with similar clinical features. Given current circumstance, we propose completing the work envisioned by Dr Mott almost 100 years ago.	[Shively, Sharon B.; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Shively, Sharon B.; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, Neuropathol Core, Bethesda, MD USA; [Shively, Sharon B.] Henry M Jackson Fdn Advancement Mil Med, Bethesda, MD USA	Shively, SB (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	sharon.shively.ctr@usuhs.edu			Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Uniformed Services University of the Health Sciences; United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	The authors thank the Center for Neuroscience and Regenerative Medicine for their ongoing support by, the Uniformed Services University of the Health Sciences, and the United States Army Medical Research and Materiel Command for their ongoing support. They also thank the following individuals for their invaluable discussions: Drs Ramon Diaz-Arrastia, Ann McKee, and Stanley Prusiner. Dr McKee has generously allowed one of the authors (D.P.P.) to evaluate many cases of athletes with chronic traumatic encephalopathy in her neuropathology laboratory. They also acknowledge Professor Edgar Jones's scholarship in delineating the history of World War I, shell shock, and the connection to PTSD.	CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones E, 2010, J HIST MED ALL SCI, V65, P368, DOI 10.1093/jhmas/jrq006; JONES EDGAR, 2005, SHELL SHOCK PTSD MIL; Martland H, 1922, JAMA-J AM MED ASSOC, V91, P1103; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott F. N., 1919, WAR NEUROSES SHELL S; Mott Frederick, 1926, BR MED J, P1106; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Southborough Lord, 1922, REPORT WAR OFFICE CO	19	68	69	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					234	239		10.1097/HTR.0b013e318250e9dd			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500013	22573042				2021-06-18	
J	Benz-Woerner, J; Delodder, F; Benz, R; Cueni-Villoz, N; Feihl, F; Rossetti, AO; Liaudet, L; Oddo, M				Benz-Woerner, Jakobea; Delodder, Frederik; Benz, Romedi; Cueni-Villoz, Nadine; Feihl, Francois; Rossetti, Andrea O.; Liaudet, Lucas; Oddo, Mauro			Body temperature regulation and outcome after cardiac arrest and therapeutic hypothermia	RESUSCITATION			English	Article						Body temperature; Thermoregulation; Cardiac arrest; Therapeutic hypothermia; Hypothermia; Rewarming; Post-resuscitation disease; Outcome	EMERGENCY CARDIOVASCULAR CARE; TRAUMATIC BRAIN-INJURY; COMATOSE SURVIVORS; RESUSCITATION; CARDIOPULMONARY; THERMOREGULATION; PROGNOSTICATION; GUIDELINES; ADMISSION; COUNCIL	Objective: Therapeutic temperature modulation is recommended after cardiac arrest (CA). However, body temperature (BT) regulation has not been extensively studied in this setting. We investigated BT variation in CA patients treated with therapeutic hypothermia (TH) and analyzed its impact on outcome. Methods: A prospective cohort of comatose CA patients treated with TH (32-34 degrees C, 24 h) at the medical/surgical intensive care unit of the Lausanne University Hospital was studied. Spontaneous BT was recorded on hospital admission. The following variables were measured during and after TH: time to target temperature (TTT = time from hospital admission to induced BT target <34 degrees C), cooling rate (spontaneous BT - induced BT target/TTT) and time of passive rewarming to normothermia. Associations of spontaneous and induced BT with in-hospital mortality were examined. Results: A total of 177 patients (median age 61 years; median time to ROSC 25 min) were studied. Non-survivors (N = 90, 51%) had lower spontaneous admission BT than survivors (median 34.5 [interquartile range 33.7-35.9]degrees C vs. 35.1 [34.4-35.8]degrees C, p = 0.04). Accordingly, time to target temperature was shorter among non-survivors (200 [25-363] min vs. 270 [158-375] min, p = 0.03); however, when adjusting for admission BT, cooling rates were comparable between the two outcome groups (0.4 [0.2-0.5]degrees C/h vs. 0.3 [0.2-0.4]degrees C/h, p = 0.65). Longer duration of passive rewarming (600 [464-744] min vs. 479 [360-600] min, p < 0.001) was associated with mortality. Conclusions: Lower spontaneous admission BT and longer time of passive rewarming were associated with in-hospital mortality after CA and TH. Impaired thermoregulation may be an important physiologic determinant of post-resuscitation disease and CA prognosis. When assessing the benefit of early cooling on outcome, future trials should adjust for patient admission temperature and use the cooling rate rather than the time to target temperature. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Benz-Woerner, Jakobea; Delodder, Frederik; Cueni-Villoz, Nadine; Liaudet, Lucas; Oddo, Mauro] Univ Lausanne Hosp, CHUV, Dept Intens Care Med, CH-1011 Lausanne, Switzerland; [Benz-Woerner, Jakobea; Delodder, Frederik; Cueni-Villoz, Nadine; Feihl, Francois; Rossetti, Andrea O.; Liaudet, Lucas; Oddo, Mauro] Fac Biol & Med, CH-1011 Lausanne, Switzerland; [Benz, Romedi] Luzerner Kantonsspital, Dept Anesthesiol, CH-6000 Luzern, Switzerland; [Feihl, Francois] Univ Lausanne Hosp, CHUV, Div Clin Pathophysiol, CH-1011 Lausanne, Switzerland; [Rossetti, Andrea O.] Univ Lausanne Hosp, CHUV, Dept Clin Neurosci, CH-1011 Lausanne, Switzerland	Oddo, M (corresponding author), Univ Lausanne Hosp, CHUV, Dept Intens Care Med, Rue Bugnon 46,BH 08-623, CH-1011 Lausanne, Switzerland.	mauro.oddo@chuv.ch	Rossetti, Andrea O./A-6712-2008; Oddo, Mauro/R-3370-2016; Liaudet, Lucas/E-1322-2017	Rossetti, Andrea O./0000-0002-7878-172X; Oddo, Mauro/0000-0002-6155-2525; Liaudet, Lucas/0000-0003-2670-4930	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [320030_138191]; European Society of Intensive Care Medicine (ECCRN)	Mauro Oddo is supported by a Grant from the Swiss National Science Foundation (Grant 320030_138191) and the European Society of Intensive Care Medicine (ECCRN Clinical Research Award 2010).	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; CHANEY RH, 1994, BRAIN INJURY, V8, P475, DOI 10.3109/02699059409150999; Childs C, 2008, BRIT J NEUROSURG, V22, P486, DOI 10.1080/02688690802245541; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; den Hartog AW, 2010, CRIT CARE, V14, DOI 10.1186/cc9077; Felies M, 2004, J PHYSIOL-LONDON, V561, P245, DOI 10.1113/jphysiol.2004.073635; Gordan ML, 2010, PERFUSION-UK, V25, P349, DOI 10.1177/0267659110377946; Grigore AM, 2009, ANESTH ANALG, V109, P1741, DOI 10.1213/ANE.0b013e3181c04fea; Haugk M, 2011, CRIT CARE, V15, DOI 10.1186/cc10116; Holzer M, 2002, NEW ENGL J MED, V346, P549; Howes D, 2010, RESUSCITATION, V81, P388, DOI 10.1016/j.resuscitation.2009.12.025; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; Lyon RM, 2010, RESUSCITATION, V81, P867, DOI 10.1016/j.resuscitation.2010.03.017; Morrison SF, 2011, FRONT BIOSCI-LANDMRK, V16, P74, DOI 10.2741/3677; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Noguchi K, 2011, RESUSCITATION, V82, P481, DOI 10.1016/j.resuscitation.2010.09.477; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Oddo M, 2008, CRIT CARE MED, V36, P2296, DOI 10.1097/CCM.0b013e3181802599; Oliveira-Pelegrin GR, 2009, NEUROIMMUNOMODULAT, V16, P45, DOI 10.1159/000179666; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; ROTHWELL NJ, 1994, CRIT REV NEUROBIOL, V8, P1; Sacho RH, 2008, BRIT J NEUROSURG, V22, P497, DOI 10.1080/02688690802245558; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; Shafi S, 2005, J TRAUMA, V59, P1081, DOI 10.1097/01.ta.0000188647.03665.fd; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Suffoletto B, 2009, RESUSCITATION, V80, P1365, DOI 10.1016/j.resuscitation.2009.08.020; TOBIN J, 1994, J PAEDIATR CHILD H, V30, P176, DOI 10.1111/j.1440-1754.1994.tb00606.x; Wang HE, 2005, CRIT CARE MED, V33, P1296, DOI 10.1097/01.CCM.0000165965.31895.80	31	68	70	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	MAR	2012	83	3					338	342		10.1016/j.resuscitation.2011.10.026			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	910NF	WOS:000301645700030	22079947				2021-06-18	
J	Brittain, JM; Chen, L; Wilson, SM; Brustovetsky, T; Gao, X; Ashpole, NM; Molosh, AI; You, HT; Hudmon, A; Shekhar, A; White, FA; Zamponi, GW; Brustovetsky, N; Chen, JH; Khanna, R				Brittain, Joel M.; Chen, Liang; Wilson, Sarah M.; Brustovetsky, Tatiana; Gao, Xiang; Ashpole, Nicole M.; Molosh, Andrei I.; You, Haitao; Hudmon, Andy; Shekhar, Anantha; White, Fletcher A.; Zamponi, Gerald W.; Brustovetsky, Nickolay; Chen, Jinhui; Khanna, Rajesh			Neuroprotection against Traumatic Brain Injury by a Peptide Derived from the Collapsin Response Mediator Protein 2 (CRMP2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; CONTROLLED CORTICAL IMPACT; NEURONAL DEATH; MITOCHONDRIAL DYSFUNCTION; POSTSYNAPTIC DENSITY-95; CALPAIN CLEAVAGE; CLINICAL-TRIALS; NMDA-RECEPTORS; NR2B SUBUNIT; IN-VITRO	Background: CRMP2 is an axonal guidance protein that has been linked to NMDA receptor-mediated excitotoxicity. Results: A CRMP2 peptide protects against NMDA receptor-mediated excitotoxicity in vitro and in vivo following a traumatic brain injury. Conclusion: CRMP2 is a novel target for neuroprotection. Significance: Targeting CRMP2 could lead to development of neurotherapeutics against traumatic brain injury as well as other neuronal insults.	[Brittain, Joel M.; Wilson, Sarah M.; Ashpole, Nicole M.; Hudmon, Andy; White, Fletcher A.; Brustovetsky, Nickolay; Chen, Jinhui; Khanna, Rajesh] Indiana Univ, Sch Med, Program Med Neurosci, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Chen, Liang; Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Brustovetsky, Tatiana; Brustovetsky, Nickolay] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Ashpole, Nicole M.; Hudmon, Andy] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Molosh, Andrei I.; Shekhar, Anantha] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [White, Fletcher A.] Indiana Univ, Sch Med, Dept Anesthesia, Indianapolis, IN 46202 USA; [Shekhar, Anantha] Indiana Univ, Sch Med, Indiana Clin & Translat Sci Inst, Indianapolis, IN 46202 USA; [White, Fletcher A.; Chen, Jinhui; Khanna, Rajesh] Indiana Univ, Sch Med, Indiana Spinal Cord & Brain Injury Grp, Indianapolis, IN 46202 USA; [You, Haitao; Zamponi, Gerald W.] Univ Calgary, Dept Physiol & Pharmacol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	Khanna, R (corresponding author), 950 W Walnut St,R2 Rm 478, Indianapolis, IN 46202 USA.	khanna5@iupui.edu	White, Fletcher A/F-2895-2012; White, Fletcher/F-3203-2015	White, Fletcher/0000-0002-8408-9262; Zamponi, Gerald/0000-0002-0644-9066; Molosh, Andrei/0000-0001-6451-7912; Khanna, Rajesh/0000-0002-9066-2969	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS050131]; Alberta Heritage Foundation for Medical Research (AHFMR)Alberta Heritage Foundation for Medical Research; American Heart AssociationAmerican Heart Association [SDG5280023]; Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761]; Ralph W. and Grace M. Showalter foundation [A70-0-079212, A70-9-079138]; Elwert Award in Medicine; Larry Kays Medical Neuroscience Fellowship; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075733, R21NS072631, R01NS049136, R01NS050131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA026040] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant R01 NS050131 (to N. B.). This work was also supported by a fellowship from the Alberta Heritage Foundation for Medical Research (AHFMR) (to H. Y.), American Heart Association National Scientist Development Grant SDG5280023 (to R. K.), a grant from the Indiana Clinical and Translational Sciences Institute funded, in part by a Project Development Team Grant Number RR025761 from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award (Indiana State Department of Health, Indiana Spinal Cord and Brain Injury Research Fund, Grants A70-0-079212 (to N. B.) and A70-9-079138 (to R. K.)), grants from the Ralph W. and Grace M. Showalter foundation (to A. H., N. B., and R. K.), and the Elwert Award in Medicine (to R. K.).; Recipient of a Larry Kays Medical Neuroscience Fellowship.; An AHFMR Scientist and a Canada Research Chair, supported by the Canadian Institutes of Health Research.	Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Chen A, 2007, NEUROCHEM INT, V50, P1078, DOI 10.1016/j.neuint.2006.11.008; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; Clapp P, 2010, J PHARMACOL EXP THER, V332, P720, DOI 10.1124/jpet.109.158741; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; CRUNELLI V, 1983, J PHYSIOL-LONDON, V341, P627, DOI 10.1113/jphysiol.1983.sp014829; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; Hou ST, 2009, J NEUROCHEM, V111, P870, DOI 10.1111/j.1471-4159.2009.06375.x; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Khosravani H, 2008, J CELL BIOL, V181, P551, DOI 10.1083/jcb.200711002; Kopec CD, 2006, J NEUROSCI, V26, P2000, DOI 10.1523/JNEUROSCI.3918-05.2006; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kowara R, 2005, J NEUROCHEM, V95, P466, DOI 10.1111/j.1471-4159.2005.03383.x; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liu W, 2009, PROTEOMICS, V9, P3712, DOI 10.1002/pmic.200800979; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Molosh AI, 2010, NEUROPSYCHOPHARMACOL, V35, P1333, DOI 10.1038/npp.2010.2; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Muir KW, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001244; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pickel VM, 2006, NEUROSCIENCE, V142, P671, DOI 10.1016/j.neuroscience.2006.06.059; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005; Stanika RI, 2009, P NATL ACAD SCI USA, V106, P9854, DOI 10.1073/pnas.0903546106; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Touma E, 2007, EUR J NEUROSCI, V26, P3368, DOI 10.1111/j.1460-9568.2007.05943.x; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Volbracht C, 2006, EUR J NEUROSCI, V23, P2611, DOI 10.1111/j.1460-9568.2006.04787.x; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang Yuying, 2010, Commun Integr Biol, V3, P172; Wilson S. M., 2011, CHANNELS AU IN PRESS; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Yuen EY, 2008, MOL PHARMACOL, V74, P360, DOI 10.1124/mol.108.046813; Zhang S, 2008, J NEUROSCI, V28, P415, DOI 10.1523/JNEUROSCI.1900-07.2008; Zhang Z, 2009, CELL MOL LIFE SCI, V66, P526, DOI 10.1007/s00018-008-8362-1; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	72	68	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2011	286	43					37778	37792		10.1074/jbc.M111.255455			15	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	841VD	WOS:000296542400073	21832084	Green Published, Other Gold			2021-06-18	
J	Wang, JQ; Hamm, RJ; Povlishock, JT				Wang, Jiaqiong; Hamm, Robert J.; Povlishock, John T.			Traumatic Axonal Injury in the Optic Nerve: Evidence for Axonal Swelling, Disconnection, Dieback, and Reorganization	JOURNAL OF NEUROTRAUMA			English	Article						anterograde and retrograde axonal change; amyloid precursor protein; axonal dieback; brain edema; traumatic brain injury; YFP mice	AMYLOID PRECURSOR PROTEIN; EXPERIMENTAL BRAIN-INJURY; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; WALLERIAN DEGENERATION; RETROGRADE CONVERSION; TRANSPORTED VESICLES; STRETCH-INJURY; CYCLOSPORINE-A; SPINAL-CORD	Traumatic axonal injury (TAI) is a major feature of traumatic brain injury (TBI) and is associated with much of its morbidity. To date, significant insight has been gained into the initiating pathogenesis of TAI. However, the nature of TAI within the injured brain precludes the consistent evaluation of its specific anterograde and retrograde sequelae. To overcome this limitation, we used the relatively organized optic nerve in a central fluid percussion injury (cFPI) model. To improve the visualization of TAI, we utilized mice expressing yellow fluorescent protein (YFP) in their visual pathways. Through this approach, we consistently generated TAI in the optic nerve and qualitatively and quantitatively evaluated its progression over a 48-h period in YFP axons via confocal microscopy and electron microscopy. In this model, delayed axonal swelling with subsequent disconnection were the norm, together with the fact that once disconnected, both the proximal and distal axonal segments revealed significant dieback, with the proximal swellings showing regression and reorganization, while the distal swellings persisted, although showing signs of impending degeneration. When antibodies targeting the C-terminus of amyloid precursor protein (APP), a routine marker of TAI were employed, they mapped exclusively to the proximal axonal segments without distal targeting, regardless of the survival time. Concomitant with this evolving axonal pathology, focal YFP fluorescence quenching occurred and mapped precisely to immunoreactive loci positive for Texas-Red-conjugated-IgG, indicating that blood-brain barrier disruption and its attendant edema contributed to this phenomenon. This was confirmed through the use of antibodies targeting endogenous YFP, which demonstrated the retention of intact immunoreactive axons despite YFP fluorescence quenching. Collectively, the results of this study within the injured optic nerve provide unprecedented insight into the evolving pathobiology associated with TAI.	[Wang, Jiaqiong; Hamm, Robert J.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			 [HD055813];  [5P30NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	This research is supported by grants HD055813 and 5P30NS047463. We thank Raymond Colello, Scott Henderson, Susan A. Walker, Lynn Carol Davis, Sharon Toussaint, and Jesse A. Sims for their technical assistance and guidance in various aspects of this study.	Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 2000, J NEUROSCI, V20, P2825; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; EBBESEN TW, 1989, J PHYS CHEM-US, V93, P7139, DOI 10.1021/j100357a023; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hellman AN, 2010, LAB CHIP, V10, P2083, DOI 10.1039/b927153h; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; KILINC D, 2007, C P IEEE ENG MED BIO, P5395; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; ODA Y, 2010, J CEREB BLOOD F 1215; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Oshima J, 2006, CHEM PHYS LETT, V423, P306, DOI 10.1016/j.cplett.2006.03.073; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAATMAN KE, 2009, HDB NEUROCHEMISTRY M, P343; SADKOWSKI PJ, 1980, CHEM PHYS, V54, P79, DOI 10.1016/0301-0104(80)80037-1; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SELISKAR CJ, 1971, J AM CHEM SOC, V93, P5405, DOI 10.1021/ja00750a016; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Sprecher SG, 2008, NATURE, V454, P533, DOI 10.1038/nature07062; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULAIMAN A, 2010, J NEUROTRAUMA; Tobita S, 2001, RES CHEM INTERMEDIAT, V27, P205, DOI 10.1163/156856701745087; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619	64	68	72	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1185	1198		10.1089/neu.2011.1756			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600007	21506725	Green Published			2021-06-18	
J	Li, BY; Lingsma, HF; Steyerberg, EW; Lesaffre, E				Li, Baoyue; Lingsma, Hester F.; Steyerberg, Ewout W.; Lesaffre, Emmanuel			Logistic random effects regression models: a comparison of statistical packages for binary and ordinal outcomes	BMC MEDICAL RESEARCH METHODOLOGY			English	Article							LINEAR MIXED MODELS; TRAUMATIC BRAIN-INJURY; IMPACT DATABASE; DESIGN	Background: Logistic random effects models are a popular tool to analyze multilevel also called hierarchical data with a binary or ordinal outcome. Here, we aim to compare different statistical software implementations of these models. Methods: We used individual patient data from 8509 patients in 231 centers with moderate and severe Traumatic Brain Injury (TBI) enrolled in eight Randomized Controlled Trials (RCTs) and three observational studies. We fitted logistic random effects regression models with the 5-point Glasgow Outcome Scale (GOS) as outcome, both dichotomized as well as ordinal, with center and/or trial as random effects, and as covariates age, motor score, pupil reactivity or trial. We then compared the implementations of frequentist and Bayesian methods to estimate the fixed and random effects. Frequentist approaches included R (lme4), Stata (GLLAMM), SAS (GLIMMIX and NLMIXED), MLwiN (p[R]IGLS) and MIXOR, Bayesian approaches included WinBUGS, MLwiN (MCMC), R package MCMCglmm and SAS experimental procedure MCMC. Three data sets (the full data set and two sub-datasets) were analysed using basically two logistic random effects models with either one random effect for the center or two random effects for center and trial. For the ordinal outcome in the full data set also a proportional odds model with a random center effect was fitted. Results: The packages gave similar parameter estimates for both the fixed and random effects and for the binary (and ordinal) models for the main study and when based on a relatively large number of level-1 (patient level) data compared to the number of level-2 (hospital level) data. However, when based on relatively sparse data set, i.e. when the numbers of level-1 and level-2 data units were about the same, the frequentist and Bayesian approaches showed somewhat different results. The software implementations differ considerably in flexibility, computation time, and usability. There are also differences in the availability of additional tools for model evaluation, such as diagnostic plots. The experimental SAS (version 9.2) procedure MCMC appeared to be inefficient. Conclusions: On relatively large data sets, the different software implementations of logistic random effects regression models produced similar results. Thus, for a large data set there seems to be no explicit preference (of course if there is no preference from a philosophical point of view) for either a frequentist or Bayesian approach (if based on vague priors). The choice for a particular implementation may largely depend on the desired flexibility, and the usability of the package. For small data sets the random effects variances are difficult to estimate. In the frequentist approaches the MLE of this variance was often estimated zero with a standard error that is either zero or could not be determined, while for Bayesian methods the estimates could depend on the chosen "noninformative" prior of the variance parameter. The starting value for the variance parameter may be also critical for the convergence of the Markov chain.	[Li, Baoyue; Lesaffre, Emmanuel] Erasmus MC, Dept Biostat, Rotterdam, Netherlands; [Li, Baoyue; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Lesaffre, Emmanuel] Katholieke Univ Leuven, L Biostat, Leuven, Belgium	Lesaffre, E (corresponding author), Erasmus MC, Dept Biostat, Dr Molewaterpl 50, Rotterdam, Netherlands.	e.lesaffre@erasmusmc.nl	Steyerberg, Ewout/C-1509-2018	Steyerberg, Ewout/0000-0002-7787-0122			Austin PC, 2003, AM HEART J, V145, P27, DOI 10.1067/mhj.2003.23; Bates D, 2009, PACKAGE IME4; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Browne W., 2009, MCMC ESTIMATION MLWI; Browne WJ, 2006, BAYESIAN ANAL, V1, P473, DOI 10.1214/06-BA117; DONALD H, 1996, COMPUTER METHODS PRO, V49, P157; Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A; GOLDSTEIN H, 1989, BIOMETRIKA, V76, P622; Goldstein H, 1995, MULTILEVEL STAT MODE; Guo G, 2000, ANNU REV SOCIOL, V26, P441, DOI 10.1146/annurev.soc.26.1.441; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Lesaffre E, 2001, J ROY STAT SOC C-APP, V50, P325, DOI 10.1111/1467-9876.00237; Lin XH, 1996, J AM STAT ASSOC, V91, P1007, DOI 10.2307/2291720; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Molenberghs G., 2005, MODELS DISCRETE LONG; Ng ESW, 2006, STAT MODEL, V6, P23, DOI 10.1191/1471082X06st106oa; Pendergast JF, 1996, INT STAT REV, V64, P89, DOI 10.2307/1403425; Rabe-Hesketh S., 2004, GLLAMM MANUAL; Rasbash J., WHAT ARE MULTILEVEL; Rasbash JF, 2004, USERS GUIDE MLWIN VE; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Rodriguez G, 2003, STATA J, V3, P32, DOI 10.1177/1536867X0300300102; Rubin D.B., 2003, BAYESIAN DATA ANAL; Snijders T.A.B., 1999, MULTILEVEL ANAL INTR; Spiegelhalter D.J., 2007, WINBUGS USER MANUAL; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Zhou XH, 1999, AM STAT, V53, P282, DOI 10.2307/2686112; COMP TIMINGS; 2009, NLMIXED PROCEDURE SA; CALLING WINBUGS 1 4; 2009, MCMC PROCEDURE SAS S; 2009, GLIMMIX PROCEDURE SA	35	68	69	1	53	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	MAY 23	2011	11								77	10.1186/1471-2288-11-77			11	Health Care Sciences & Services	Health Care Sciences & Services	776JZ	WOS:000291531900001	21605357	DOAJ Gold, Green Published			2021-06-18	
J	Chibbaro, S; Di Rocco, F; Mirone, G; Fricia, M; Makiese, O; Di Emidio, P; Romano, A; Vicaut, E; Menichelli, A; Reiss, A; Mateo, J; Payen, D; Guichard, JP; George, B; Bresson, D				Chibbaro, Salvatore; Di Rocco, Fedreico; Mirone, Giuseppe; Fricia, Marco; Makiese, Orphee; Di Emidio, Paolo; Romano, Antonio; Vicaut, Eric; Menichelli, Alina; Reiss, Alisha; Mateo, Joaquim; Payen, Didier; Guichard, Jean Pierre; George, Bernard; Bresson, Damien			Decompressive Craniectomy and Early Cranioplasty for the Management of Severe Head Injury: A Prospective Multicenter Study on 147 Patients	WORLD NEUROSURGERY			English	Article						Decompressive craniectomy; Early cranioplasty; Head injury	TRAUMATIC BRAIN-INJURY; SINKING SKIN-FLAP; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL HYPERTENSION; EXPERIENCE; DAMAGE; PROTECTION; PROTOCOL; THERAPY; IMPACT	OBJECTIVE: In emergency care of patients with severe blunt head injury, uncontrollable high intracranial pressure is one of major causes of morbidity and mortality. The purpose of this study was to evaluate the efficacy of aggressive surgical treatment in managing uncontrollable elevated intracranial pressure coupled with early skull reconstruction. METHODS: This was a prospective study on a series of 147 consecutive patients, managed according to the same protocol by five different neurosurgical units, for severe head injuries (Glasgow coma scale score <= 8/15 and high intracranial pressure >25 mm Hg) during a five-year period. All patients received a wide decompressive craniectomy and duroplasty in the acute phase, and a cranioplasty was also performed within 12 weeks (median 6 weeks, range 4-12 weeks). RESULTS: The emergency decompressive surgery was performed within 28 hours (median 16 hours, range 6-28 hours) after sustaining the head injury. The median preoperative Glasgow coma scale score was 6/15 (range 3-8/15). At a mean follow-up of 26 months (range 14-74 months) 14 patients were lost to long-term follow-up, leaving only 133 patients available for the study. The outcome was favorable in 89 (67%, Glasgow outcome score 4 or 5), it was not favorable in 25 (19%, Glasgow outcome score 2 and 3), and 19 patients (14%) died. A younger age (<50 years) and earlier operation (within 9 hours from trauma) had a significant effect on positive outcomes (P < 0.0001 and P < 0.03, respectively). CONCLUSIONS: A prompt aggressive surgery, including a wide decompressive craniectomy coupled with early cranioplasty, could be an effective treatment method to improve the outcome after a severe closed head injury reducing, perhaps, many of the complications related to decompressive craniectomy.	[Chibbaro, Salvatore; Makiese, Orphee; Di Emidio, Paolo; George, Bernard; Bresson, Damien] Lariboisiere Univ Hosp, Dept Neurosurg, Paris, France; [Di Rocco, Fedreico] Necker Univ Hosp, Dept Neurosurg, Paris, France; [Mirone, Giuseppe] Naples Univ Hosp, Dept Neurosurg, Naples, Italy; [Fricia, Marco] Cannizzaro Univ Hosp, Dept Neurosurg, Catania, Italy; [Romano, Antonio] Parma Univ Hosp, Dept Neurosurg, Parma, Italy; [Vicaut, Eric] Hop Univ Lariboisiere Fernand Widal, Unite Rech Clin, Paris, France; [Menichelli, Alina] Trieste Univ Hosp, Rehabil Unit, Trieste, Italy; [Reiss, Alisha] Columbus Ohio State Univ Med Ctr, Dept Neurosurg, Columbus, OH USA; [Mateo, Joaquim; Payen, Didier] Lariboisiere Univ Hosp, Neuro ITU, Paris, France; [Guichard, Jean Pierre] Lariboisiere Univ Hosp, Dept Neuroradiol, Paris, France	Chibbaro, S (corresponding author), Lariboisiere Univ Hosp, Dept Neurosurg, Paris, France.	schibbaro@hotmail.com	Chibbaro, Salvatore/AAI-6368-2020; DI ROCCO, Federico/C-6343-2015	chibbaro, salvatore/0000-0003-1318-1245			Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DeWitt D S, 1995, New Horiz, V3, P376; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1990, ACT NEUR S, V51, P326; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; Hodozuka A, 2000, NEUROL SURG TOKYO, V28, P245; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maekawa M, 1999, NEUROL SURG TOKYO, V27, P717; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1992, GREENFIELDS NEUROPAT, P69; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Safar P, 2001, NEW ENGL J MED, V345, P66; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; STULA D, 1982, J MAXILLOFAC SURG, V10, P142, DOI 10.1016/S0301-0503(82)80030-1; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yamaura A, 1977, No Shinkei Geka, V5, P345; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	47	68	76	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR-APR	2011	75	3-4					558	562		10.1016/j.wneu.2010.10.020			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	793KK	WOS:000292820400055	21600512				2021-06-18	
J	Skaper, SD				Skaper, Stephen D.			Ion Channels on Microglia: Therapeutic Targets for Neuroprotection	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Microglia; neuroinflammation; neurotoxicity; ATP; purinergic receptors; chloride channels; potassium channels; amyloid; Alzheimer's disease	CA2+-ACTIVATED K+ CHANNEL; ACTIVATED POTASSIUM CHANNEL; P2X(7) RECEPTOR EXPRESSION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER CHANGES; HUMAN T-LYMPHOCYTES; INTERMEDIATE-CONDUCTANCE; ALZHEIMERS-DISEASE	Under pathological conditions microglia (resident CNS immune cells) become activated, and produce reactive oxygen and nitrogen species and pro-inflammatory cytokines: molecules that can contribute to axon demyelination and neuron death. Because some microglia functions can exacerbate CNS disorders, including stroke, traumatic brain injury, progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, and several retinal diseases, controlling their activation might ameliorate immune-mediated CNS disorders. A growing body of evidence now points to ion channels on microglia as contributing to the above neuropathologies. For example, the ATP-gated P2X(7) purinergic receptor cation channel is up-regulated around amyloid beta-peptide plaques in transgenic mouse models of Alzheimer's disease and co-localizes to microglia and astrocytes. Up-regulation of the P2X(7) receptor subtype on microglia occurs also following spinal cord injury and after ischemia in the cerebral cortex of rats, while P2X(7) receptor-like immunoreactivity is increased in activated microglial cells of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. Utilizing neuron/microglia co-cultures as an in vitro model for neuroinflammation, P2X(7) receptor activation on microglia appears necessary for microglial cell-mediated injury of neurons. A second example can be found in the chloride intracellular channel 1 (CLIC1), whose expression is related to macrophage activation, undergoes translocation from the cytosol to the plasma membrane (activation) of microglia exposed to amyloid beta-peptide, and participates in amyloid beta-peptide-induced neurotoxicity through the generation of reactive oxygen species. A final example is the small-conductance Ca2+/calmodulin-activated K+ channel KCNN4/KCa3.1/SK4/IK1, which is highly expressed in rat microglia. Lipopolysaccharide-activated microglia are capable of killing adjacent neurons in co-culture, and show markedly reduced toxicity when treated with an inhibitor of KCa3.1 channels. Moreover, blocking KCa3.1 channels mitigated the neurotoxicity of amyloid beta-peptide-stimulated microglia. Excessive microglial cell activation and production of potentially neurotoxic molecules, mediated by ion channels, may thus constitute viable targets for the discovery and development of neurodegenerative disease therapeutics. This chapter will review recent data that reflect the prevailing approaches targeting neuroinflammation as a pathophysiological process contributing to the onset or progression of neurodegenerative diseases, with a focus on microglial ion channels and their neuroprotective potential.	Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy	Skaper, SD (corresponding author), Univ Padua, Dept Pharmacol & Anesthesiol, Largo E Meneghetti 2, I-35131 Padua, Italy.	Stephen.skaper@unipd.it					Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Agresti C, 2005, GLIA, V50, P132, DOI 10.1002/glia.20160; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bartzokis G, 2003, ARCH NEUROL-CHICAGO, V60, P393, DOI 10.1001/archneur.60.3.393; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267; Bernardino L, 2008, J NEUROCHEM, V106, P271, DOI 10.1111/j.1471-4159.2008.05387.x; BIANCA VD, 1999, J BIOL CHEM, V274, P15493; Blank T, 2004, CNS NEUROL DISORD-DR, V3, P161, DOI 10.2174/1568007043337472; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bond CT, 2005, CURR OPIN NEUROBIOL, V15, P305, DOI 10.1016/j.conb.2005.05.001; Braak H, 2000, ANN NY ACAD SCI, V924, P53; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Chakfe Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Craft JM, 2005, EXPERT OPIN THER TAR, V9, P887, DOI 10.1517/14728222.9.5.887; Culbert AA, 2006, J BIOL CHEM, V281, P23658, DOI 10.1074/jbc.M513646200; D'Ambrosi N, 2009, J IMMUNOL, V183, P4648, DOI 10.4049/jimmunol.0901212; D'Aversa TG, 2004, J NEUROVIROL, V10, P86, DOI 10.1080/13550280490279807; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Diemel LT, 1998, NEUROCHEM RES, V23, P341, DOI 10.1023/A:1022405516630; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Domercq M, 2010, GLIA, V58, P730, DOI 10.1002/glia.20958; Duan SM, 2003, J NEUROSCI, V23, P1320; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577; Ducharme G, 2007, EUR J NEUROSCI, V26, P2119, DOI 10.1111/j.1460-9568.2007.05802.x; Eder C, 1997, N-S ARCH PHARMACOL, V356, P233, DOI 10.1007/PL00005046; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Farber K, 2006, GLIA, V54, P656, DOI 10.1002/glia.20412; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Felts PA, 1997, J NEUROSCI, V17, P7267; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Furber M, 2007, J MED CHEM, V50, P5882, DOI 10.1021/jm700949w; Ge YL, 2002, AM J NEURORADIOL, V23, P1334; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Grgic I, 2005, ARTERIOSCL THROM VAS, V25, P704, DOI 10.1161/01.ATV.0000156399.12787.5c; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Heneka MT, 2010, P NATL ACAD SCI USA, V107, P6058, DOI 10.1073/pnas.0909586107; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Inoue K, 1998, BRIT J PHARMACOL, V123, P1304, DOI 10.1038/sj.bjp.0701732; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Jensen B S, 2002, Expert Opin Ther Targets, V6, P623, DOI 10.1517/14728222.6.6.623; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kohler R, 2003, CIRCULATION, V108, P1119, DOI 10.1161/01.CIR.0000086464.04719.DD; Kohler R, 2010, EXPERT OPIN THER TAR, V14, P143, DOI 10.1517/14728220903540257; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langford D, 2001, BRAIN PATHOL, V11, P306; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; McGeer PL, 2001, ARCH NEUROL-CHICAGO, V58, P1790, DOI 10.1001/archneur.58.11.1790; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3; McNeish AJ, 2006, STROKE, V37, P1277, DOI 10.1161/01.STR.0000217307.71231.43; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Milton RH, 2008, J NEUROSCI, V28, P11488, DOI 10.1523/JNEUROSCI.2431-08.2008; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Moreland JG, 2006, J BIOL CHEM, V281, P12277, DOI 10.1074/jbc.M511030200; Narcisse L, 2005, GLIA, V49, P245, DOI 10.1002/glia.20110; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Nelson DW, 2008, J MED CHEM, V51, P3030, DOI 10.1021/jm701516f; Nieber K, 1999, PROG BRAIN RES, V120, P287; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novarino G, 2004, J NEUROSCI, V24, P5322, DOI 10.1523/JNEUROSCI.1170-04.2004; O'Sullivan M, 2001, NEUROLOGY, V57, P632, DOI 10.1212/WNL.57.4.632; Parachikova A, 2007, NEUROBIOL AGING, V28, P1821, DOI 10.1016/j.neurobiolaging.2006.08.014; Paradisi S, 2008, J NEUROSCI RES, V86, P2488, DOI 10.1002/jnr.21693; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pedarzani P, 2008, CELL MOL LIFE SCI, V65, P3196, DOI 10.1007/s00018-008-8216-x; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615; Perry VH, 2002, CURR OPIN NEUROL, V15, P349, DOI 10.1097/00019052-200206000-00020; Peters A, 2000, J COMP NEUROL, V419, P364, DOI 10.1002/(SICI)1096-9861(20000410)419:3<364::AID-CNE8>3.0.CO;2-R; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Reich EP, 2005, EUR J IMMUNOL, V35, P1027, DOI 10.1002/eji.200425954; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Sanz JM, 2009, J IMMUNOL, V182, P4378, DOI 10.4049/jimmunol.0803612; SCHLICHTER LC, 2002, ROLES ION CHANNELS P; Schlichter LC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-4; Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Sikora A, 1999, J IMMUNOL, V163, P558; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379; Skaper Stephen D, 2009, Cardiovasc Psychiatry Neurol, V2009, P545263, DOI 10.1155/2009/545263; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Stadelmann C, 2002, BRAIN, V125, P75, DOI 10.1093/brain/awf015; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Stocker M, 2004, NAT REV NEUROSCI, V5, P758, DOI 10.1038/nrn1516; Stokes L, 2010, FASEB J, V24, P2916, DOI 10.1096/fj.09-150862; Sultana R, 2010, J ALZHEIMERS DIS, V19, P341, DOI 10.3233/JAD-2010-1222; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takata K, 2007, FEBS LETT, V581, P475, DOI 10.1016/j.febslet.2007.01.009; Tang Y, 1997, NEUROBIOL AGING, V18, P609, DOI 10.1016/S0197-4580(97)00155-3; Teismann P, 2004, CELL TISSUE RES, V318, P149, DOI 10.1007/s00441-004-0944-0; Tharp DL, 2006, AM J PHYSIOL-HEART C, V291, pH2493, DOI 10.1152/ajpheart.01254.2005; Tharp D. L., 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P1; Tonini R, 2000, FASEB J, V14, P1171; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Vasilevko V, 2007, J NEUROSCI, V27, P13376, DOI 10.1523/JNEUROSCI.2788-07.2007; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WAXMAN SG, 1977, PROG NEUROBIOL, V8, P297, DOI 10.1016/0301-0082(77)90009-0; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xia XM, 1998, NATURE, V395, P503; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12; Yu Y, 2008, BRAIN RES, V1194, P45, DOI 10.1016/j.brainres.2007.11.064	178	68	77	1	22	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2011	10	1					44	56					13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	715HE	WOS:000286872800005	21143139				2021-06-18	
J	Sullivan, PG; Sebastian, AH; Hall, ED				Sullivan, Patrick G.; Sebastian, Andrea H.; Hall, Edward D.			Therapeutic Window Analysis of the Neuroprotective Effects of Cyclosporine A after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cortical contusion; cyclosporine; cyclosporine A; mitochondrial permeability transition; neuroprotection	NERVOUS-SYSTEM TOXICITY; ALPHA-II-SPECTRIN; MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; CEREBROSPINAL-FLUID; CELL-DEATH; NEUROLOGIC COMPLICATIONS; BREAKDOWN PRODUCTS; OXIDATIVE DAMAGE; FREE-RADICALS	Mitochondrial dysfunction plays a pivotal role in secondary cell death mechanisms following traumatic brain injury (TBI). Several reports have demonstrated that inhibition of the mitochondrial permeability transition pore with the immunosuppressant drug cyclosporine A (CsA) is efficacious. Accordingly, CsA is being moved forward into late-stage clinical trials for the treatment of moderate and severe TBI. However, several unknowns exist concerning the optimal therapeutic window for administering CsA at the proposed dosages to be used in human studies. The present study utilized a moderate (1.75 mm) unilateral controlled cortical impact model of TBI to determine the most efficacious therapeutic window for initiating CsA therapy. Rats were administered an IP dose of CsA (20 mg/kg) or vehicle at 1, 3, 4, 5, 6, and 8 h post-injury. Immediately following the initial IP dose, osmotic mini-pumps were implanted at these time points to deliver 10 mg/kg/d of CsA or vehicle. Seventy-two hours following the initiation of treatment the pumps were removed to stop CsA administration. Quantitative analysis of cortical tissue sparing 7 days post-injury revealed that CsA treatment initiated at any of the post-injury initiation times out to 8 h resulted in significantly less cortical damage compared to animals receiving vehicle treatment. However, earlier treatment begun in the first 3 h was significantly more protective than that begun at 4 and 8 h. Treatment initiated at 1 h post-injury (similar to 68% decrease) was not significantly different than that seen at 3 h (similar to 46% decrease), but resulted in significantly greater cortical tissue sparing compared to CsA treatment initiated at least 4 h post-injury (28% decrease). Together these results illustrate the importance of initiating therapeutic interventions such as CsA as soon as possible following TBI, preferably within 4 h post-injury, to achieve the best possible neuroprotective effect. However, the drug appears to retain some protective efficacy even when initiated as late as 8 h post-injury.	[Sullivan, Patrick G.; Sebastian, Andrea H.; Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Sullivan, Patrick G.; Hall, Edward D.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 475 BBSRB, Lexington, KY 40536 USA.	patsullivan@uky.edu	Hall, Edward D/F-8930-2013		National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, P30NS051220, R01NS062993] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, U.S. Public Health Service grants R01 NS48191 and R01 NS062993 (to P.G.S.), and P30 NS051220 (to E.D.H.), and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BERDEN JHM, 1985, LANCET, V1, P219; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CHOI DW, 1987, J NEUROSCI, V7, P357; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jordan J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	68	68	69	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					311	318		10.1089/neu.2010.1646			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700014	21142667	Green Published			2021-06-18	
J	Acosta-Escribano, J; Fernandez-Vivas, M; Carmona, TG; Caturla-Such, J; Garcia-Martinez, M; Menendez-Mainer, A; Solera-Suarez, M; Sanchez-Paya, J				Acosta-Escribano, Jose; Fernandez-Vivas, Miguel; Grau Carmona, Teodoro; Caturla-Such, Juan; Garcia-Martinez, Miguel; Menendez-Mainer, Ainhoa; Solera-Suarez, Manuel; Sanchez-Paya, Jose			Gastric versus transpyloric feeding in severe traumatic brain injury: a prospective, randomized trial	INTENSIVE CARE MEDICINE			English	Article						Nutrition; Neurotrauma; Mechanical ventilation; Complications	CRITICALLY-ILL PATIENTS; VENTILATOR-ASSOCIATED PNEUMONIA; ENTERAL NUTRITION; GASTROINTESTINAL COMPLICATIONS; CARE; HYPERGLYCEMIA; DEFINITIONS; GUIDELINES; MORTALITY; INFECTION	To evaluate the efficacy of transpyloric feeding (TPF) compared with gastric feeding (GF) with regard to the incidence of ventilator-associated pneumonia in severe traumatic brain injury patients (TBI). Prospective, open-label, randomized study in an intensive care unit of a university hospital. One hundred and four CHI adult patients admitted for TBI between April 2007 and December 2008. Patients were included within the first 24 h after ICU admission and were followed until discharge or 30 days after admission. Patients were randomized to TPF or GF groups. They received the same diet, with 25 kcal kg(-1) day(-1) of calculated energy requirements and a nitrogen intake of 0.2 g N kg(-1) day(-1). Primary outcome was the incidence of early and ventilatory-associated pneumonia. Secondary outcomes were enteral nutrition-related gastrointestinal complications (GIC), days on mechanical ventilation, length of ICU stay and hospital stay, and sequential organ failure assessment score (SOFA). The TPF group had a lower incidence of pneumonia, OR 0.3 (95% CI 0.1-0.7, P = 0.01). There were no significant differences in other nosocomial infections. The TPF group received higher amounts of diet compared to the GF group (92 vs. 84%, P < 0.01) and had lesser incidence of increased gastric residuals, OR 0.2 (95% CI 0.04-0.6, P = 0.003). Enteral nutrition delivered through the transpyloric route reduces the incidence of overall and late pneumonia and improves nutritional efficacy in severe TBI patients.	[Acosta-Escribano, Jose; Caturla-Such, Juan; Garcia-Martinez, Miguel; Menendez-Mainer, Ainhoa; Solera-Suarez, Manuel] Hosp Gen Univ Alicante, Intens Care Unit, Alicante 03010, Spain; [Fernandez-Vivas, Miguel] Hosp Univ Virgen Arrixaca, Intens Care Unit, Murcia, Spain; [Grau Carmona, Teodoro] Hosp Univ Doce Octubre, Intens Care Unit, Madrid, Spain; [Sanchez-Paya, Jose] Hosp Gen Univ Alicante, Epidemiol Unit, Alicante 03010, Spain	Acosta-Escribano, J (corresponding author), Hosp Gen Univ Alicante, Intens Care Unit, Pintor Baeza 12, Alicante 03010, Spain.	acosta_jos@telefonica.net	Grau, Teodoro/J-5127-2019	Grau, Teodoro/0000-0002-6243-6323			ACOSTA JA, 2001, NUTR HOSP, V6, P262; *AM THOR SOC, 1995, AM J RESP CRIT CARE, V153, P1711; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; APELGREN KN, 1982, CRIT CARE MED, V10, P305, DOI 10.1097/00003246-198205000-00003; BLOM M, 1975, CLIN CHEM, V21, P195; Bochicchio GV, 2006, JPEN-PARENTER ENTER, V30, P503, DOI 10.1177/0148607106030006503; BRATTON S, 2005, J NEUROTRAUM, V24, pS1; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; CHANDRA RK, 1983, LANCET, V1, P688; DeMeo Mark T., 2002, Journal of Parenteral and Enteral Nutrition, V26, pS9, DOI 10.1177/014860710202600603; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Grau T., 2005, Nutr. Hosp., V20, P278; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Heyland DK, 2001, CRIT CARE MED, V29, P1495, DOI 10.1097/00003246-200108000-00001; HEYLAND DK, 2003, JPEN, V27, P255; Ho KM, 2006, INTENS CARE MED, V32, P639, DOI 10.1007/s00134-006-0128-3; Hubmayr R D, 2002, Intensive Care Med, V28, P1521; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Marik PE, 2003, CRIT CARE, V7, pR46, DOI 10.1186/cc2190; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Montejo JC, 2010, INTENS CARE MED, V36, P1386, DOI 10.1007/s00134-010-1856-y; Montejo JC, 1999, CRIT CARE MED, V27, P1447, DOI 10.1097/00003246-199908000-00006; Montejo JC, 2002, CRIT CARE MED, V30, P796, DOI 10.1097/00003246-200204000-00013; MOYLAN JA, 1976, J TRAUMA, V16, P517, DOI 10.1097/00005373-197607000-00001; Nguyen NQ, 2008, INTENS CARE MED, V34, P454, DOI 10.1007/s00134-007-0942-2; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Ravasco Paula, 2003, Nutr Clin Pract, V18, P427, DOI 10.1177/0115426503018005427; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Tarling MM, 1997, INTENS CARE MED, V23, P256, DOI 10.1007/s001340050325; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Valles J, 2007, INTENS CARE MED, V33, P1363, DOI 10.1007/s00134-007-0721-0; Vincent JL, 2000, CRIT CARE CLIN, V16, P353, DOI 10.1016/S0749-0704(05)70114-7; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025	40	68	87	0	15	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2010	36	9					1532	1539		10.1007/s00134-010-1908-3			8	Critical Care Medicine	General & Internal Medicine	638PV	WOS:000280908000012	20495781				2021-06-18	
J	Venkatesan, C; Chrzaszcz, M; Choi, N; Wainwright, MS				Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.			Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury	JOURNAL OF NEUROINFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; AUTONOMIC DYSREFLEXIA; HEAD-INJURY; CELL-DEATH; OLIGODENDROCYTES; NEUROPROTECTION; PHAGOCYTOSIS; REGENERATION; INVOLVEMENT; RECEPTORS	Background: Diffuse axonal injury in patients with traumatic brain injury (TBI) can be associated with morbidity ranging from cognitive difficulties to coma. Magnetic resonance imaging scans now allow early detection of axonal injury following TBI, and have linked cognitive disability in these patients to white matter signal changes. However, little is known about the pathophysiology of this white matter injury, and the role of microglial activation in this process. It is increasingly recognized that microglia constitute a heterogeneous population with diverse roles following injury. In the present studies, we tested the hypothesis that following diffuse axonal injury involving the corpus callosum, there is upregulation of a subpopulation of microglia that express the lectin galectin-3/Mac-2 and are involved in myelin phagocytosis. Methods: Adult mice were subject to midline closed skull injury or sham operation and were sacrificed 1, 8, 14 or 28 days later. Immunohistochemistry and immunofluorescence techniques were used to analyze patterns of labelling within the corpus callosum qualitatively and quantitatively. Results: Activated microglia immunoreactive for galectin-3/Mac-2 were most abundant 1 day following injury. Their levels were attenuated at later time points after TBI but still were significantly elevated compared to sham animals. Furthermore, the majority of galectin-3/Mac-2+ microglia were immunoreactive for nerve growth factor in both sham and injured animals. Conclusions: Our results suggest that galectin-3/Mac-2+ microglia play an important role in the pathogenesis of diffuse axonal injury both acutely and chronically and that they mediate their effects, at least in part by releasing nerve growth factor.	[Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Div Neurol, Dept Pediat, Chicago, IL 60614 USA; [Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60614 USA	Venkatesan, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Neurol, Dept Pediat, Chicago, IL 60614 USA.	cvenkatesan@childrensmemorial.org	venkatesan, charu/ABE-7369-2020; Venkatesan, Charu/D-5944-2016		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD052902, KO8 NS044998]; Medical Research Junior Board Foundation; Lyndsey Whittingham Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS044998] Funding Source: NIH RePORTER	This work was supported by NIH grants K12 HD052902 (CV) and KO8 NS044998 (MSW), the Medical Research Junior Board Foundation (MSW), and the Lyndsey Whittingham Foundation (MSW).	ALTHAUS HH, 1992, NEUROSCI LETT, V135, P219, DOI 10.1016/0304-3940(92)90440-I; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Frade JM, 1996, NATURE, V383, P166; Frielingsdorf H, 2007, NEUROBIOL DIS, V26, P47, DOI 10.1016/j.nbd.2006.11.015; GONZALEZSCARANO F, 1999, ANNU REV NEUROSCI, V219, P40; HO MK, 1982, J IMMUNOL, V128, P1221; HOOFIEN D, 2001, BRAIN INJURY, V189, P10; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Krenz NR, 1999, J NEUROSCI, V19, P7405, DOI 10.1523/JNEUROSCI.19-17-07405.1999; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lynch G, 2005, AM NETW, V109, P16; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marsh DR, 2002, J NEUROTRAUM, V19, P1531, DOI 10.1089/089771502762300201; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REICHERT F, 1994, J NEUROSCI, V14, P3231; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; Rotshenker S, 2008, GLIA, V56, P1607, DOI 10.1002/glia.20713; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sugama S, 2007, NEUROSCIENCE, V146, P1388, DOI 10.1016/j.neuroscience.2007.02.043; Thored P, 2009, GLIA, V57, P835, DOI 10.1002/glia.20810; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Yoon SO, 1998, J NEUROSCI, V18, P3273; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	52	68	69	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAY 27	2010	7								32	10.1186/1742-2094-7-32			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	616YS	WOS:000279248400001	20507613	DOAJ Gold, Green Published			2021-06-18	
J	Dijkers, MP; Harrison-Felix, C; Marwitz, JH				Dijkers, Marcel P.; Harrison-Felix, Cynthia; Marwitz, Jennifer H.			The Traumatic Brain Injury Model Systems: History and Contributions to Clinical Service and Research	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						care systems; government support; history; traumatic brain injuries; rehabilitation; research	GLASGOW OUTCOME SCALE; DISABILITY RATING-SCALE; HEAD-INJURY; COMA	The model systems (MSs) of care for traumatic brain injury (TBI) is a demonstration program started by the National Institute on Disability and Rehabilitation Research in 1987 to improve care and outcomes for individuals with TBI, from emergency services through life-long follow-up. Over the next 20 years, the program increased in size, and the emphasis shifted from demonstration to research. The focal point of that research is the National Data Base, a longitudinal database including nearly 9000 individuals who were admitted for inpatient acute TBI rehabilitation. In addition to preinjury, injury, acute care, and rehabilitation information, the database includes reports of outcomes at 1, 2, 5, 10, 15, etc, years postinjury. The National Data Base criteria, main contents, and mechanisms used to improve data quantity and quality are described. The MSs' other research is described: local (site-specific), module, and collaborative, with illustrative glimpses of the content. The impact of the TBI MSs program, through dissemination, knowledge translation, training of clinicians and researchers, as well as consulting with policy makers, administrators, clinicians, and researchers is discussed.	[Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Harrison-Felix, Cynthia] Craig Hosp, Englewood, CO USA; [Harrison-Felix, Cynthia] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA	Dijkers, MP (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 5 E 98th St, New York, NY 10029 USA.	marcel.dijkers@mssm.edu		Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036, H133A070033, H133A070022, H133A060038]	This study was supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grants H133A070036, H133A070033, H133A070022, and H133A060038).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; *CESSI, 2006, DESCR TRAUM BRAIN IN; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 2009, ARCH PHYS MED REHAB, V90, pe39, DOI DOI 10.1016/j.apmr.2009.08.123; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sanchez Gonzalo Moreno, 2007, Neurosurg Focus, V23, pE5; TEASDALE G, 1974, LANCET, V2, P81; THOMAS RL, 1988, TOXIC CONTAMINATION, V3, P1; *TRAUM BRAIN INJ M, STAND OP PROC A, V101; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; 2002, FED REG, V67, P39571; 1987, FED REG, V52, P15448; 2003, FED REG, V68, P44752; 1999, J HEAD TRAUMA REHABI, V14, P189; 1998, FED REG, V62, P25759; 2008, FED REG, V73, P6132; 2007, FED REG, V72, P7287; 1999, FED REG, V63, P40155	26	68	68	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					81	91		10.1097/HTR.0b013e3181cd3528			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000003	20134334				2021-06-18	
J	Taepavarapruk, P; Song, C				Taepavarapruk, Pornnarin; Song, Cai			Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1 beta administrations: effects of omega-3 fatty acid EPA treatment	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylcholine; eicosapentaenoate; interleukin-1beta; memory impairment; microdialysis; nerve growth factor	TRAUMATIC BRAIN-INJURY; EICOSAPENTAENOIC ACID; FATTY-ACIDS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; INFLAMMATORY RESPONSE; DOCOSAHEXAENOIC ACID; HIPPOCAMPAL ATROPHY; DOWNS-SYNDROME; ETHYL-ESTERS	Interleukin (IL)-1 beta may play an important role in Alzheimer's disease. However, the relationships between glucocorticoids and acetylcholine (ACh), and between neurotrophins and ACh in IL-1-induced memory deficits are unknown. While ethyleicosapentaenoate (E-EPA) has recently been reported to reduce inflammation and improve memory, cholinergic and neurotrophic mechanisms by which E-EPA improves memory is unclear. This study evaluated: (i) the correlation between ACh release and memory impairment; (ii) the effect of glucocorticoids on ACh release; (iii) the relationship between nerve growth factor (NGF) and inflammation; and (iv) the effects of E-EPA treatment on IL-1 beta-induced changes. Intracerebroventricular IL-1 beta administrations produced a significant reduction in hippocampal ACh release in rats fed control diet, which was partially attenuated by mifepristone (RU 486) and completely blocked by IL-1 receptor antagonist. In eight-arm radial maze, significantly less ACh release was correlated with the memory deficits after IL-1 beta administrations. mRNA expression of hippocampal NGF was lower, whereas IL-1 beta was higher when compared with controls. E-EPA treatment significantly improved the memory, which was correlated with normalizing ACh release, and expressions of NGF and IL-1 beta. This study revealed important mechanisms by which IL-1 beta impairs, while E-EPA improves memory through IL-1-glucocorticoid-ACh release and IL-1-NGF-ACh release pathways.	[Taepavarapruk, Pornnarin; Song, Cai] Univ Prince Edward Isl, Dept Biomed Sci, AVC, Charlottetown, PE C1A 4P3, Canada; [Taepavarapruk, Pornnarin] Naresuan Univ, Dept Physiol, Fac Med Sci, Phitsanulok 65000, Thailand	Song, C (corresponding author), Univ Prince Edward Isl, Dept Biomed Sci, AVC, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.	cai.song@nrc.gc.ca			Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Amarin Neurosciences Ltd.; Atlantic Innovation Foundation	This work was supported by the Canadian Institutes for Health Research (CIHR) grant to Cai Song. We thank Amarin Neurosciences Ltd. and Atlantic Innovation Foundation for their financial supports.	Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; BECKERMANN B, 1990, ARZNEIMITTEL-FORSCH, V40-1, P700; Brunton S, 2007, CURR MED RES OPIN, V23, P1139, DOI 10.1185/030079907X188017; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Cattaneo A, 2008, J ALZHEIMERS DIS, V15, P255; Chiu CC, 2008, PROG NEURO-PSYCHOPH, V32, P1538, DOI 10.1016/j.pnpbp.2008.05.015; Ferrari CC, 2006, NEUROBIOL DIS, V24, P183, DOI 10.1016/j.nbd.2006.06.013; Colangelo AM, 2004, MOL BRAIN RES, V124, P97, DOI 10.1016/j.molbrainres.2004.01.011; Counts SE, 2005, J NEUROPATH EXP NEUR, V64, P263, DOI 10.1093/jnen/64.4.263; Crochemore C, 2005, MOL PSYCHIATR, V10, P790, DOI 10.1038/sj.mp.4001679; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; DeToledo-Morrell L, 2007, PROG BRAIN RES, V163, P741, DOI 10.1016/S0079-6123(07)63040-4; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749-6632.2000.tb05426.x; Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hashimoto M, 2009, J NUTR BIOCHEM, V20, P965, DOI 10.1016/j.jnutbio.2008.08.009; Isacson O, 2002, TRENDS NEUROSCI, V25, P79, DOI 10.1016/S0166-2236(02)02037-4; Johnson VJ, 2003, NEUROTOXICOLOGY, V24, P261, DOI 10.1016/S0161-813X(02)00194-8; Kornman KS, 2006, AM J CLIN NUTR, V83, p475S; Kou W, 2008, EUR J NUTR, V47, P104, DOI 10.1007/s00394-008-0703-1; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; LAWSON LD, 1988, BIOCHEM BIOPH RES CO, V152, P328, DOI 10.1016/S0006-291X(88)80718-6; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Lynch AM, 2007, NEUROBIOL AGING, V28, P845, DOI 10.1016/j.neurobiolaging.2006.04.006; Masuda J, 2005, NEUROSCIENCE, V132, P537, DOI 10.1016/j.neuroscience.2005.01.010; McLay RN, 1997, NEUROSCI BIOBEHAV R, V21, P615, DOI 10.1016/S0149-7634(96)00046-2; Mitsushima D, 2003, NEUROENDOCRINOLOGY, V78, P234, DOI 10.1159/000073707; Mizuno T, 1997, NEUROSCI LETT, V222, P49, DOI 10.1016/S0304-3940(97)13340-7; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Murray CA, 1998, J NEUROSCI, V18, P2974; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nichols NR, 2005, BRAIN RES REV, V48, P287, DOI 10.1016/j.brainresrev.2004.12.019; Nichols NR, 2001, BRAIN RES REV, V37, P273, DOI 10.1016/S0165-0173(01)00131-X; Otsuka M, 2000, Nihon Ronen Igakkai Zasshi, V37, P970; Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x; Phillips AG, 2004, J NEUROSCI, V24, P547, DOI 10.1523/JNEUROSCI.4653-03.2004; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101; Puskas Laszlo G., 2006, Nutrition and Health (Bicester), V18, P227; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; Salehi A, 2006, NEURON, V51, P29, DOI 10.1016/j.neuron.2006.05.022; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Singer P, 2008, INTENS CARE MED, V34, P1580, DOI 10.1007/s00134-008-1142-4; Song C, 2004, MOL PSYCHIATR, V9, P630, DOI 10.1038/sj.mp.4001462; Song C, 2003, J LIPID RES, V44, P1984, DOI 10.1194/jlr.M300217-JLR200; SONG C, 2008, BRAIN BEHAV IMMUN, V22, pS41; Song C, 2009, J NEUROSCI, V29, P14, DOI 10.1523/JNEUROSCI.3569-08.2009; Srikumar BN, 2006, NEUROSCIENCE, V143, P679, DOI 10.1016/j.neuroscience.2006.08.041; Su KP, 2009, NEUROSIGNALS, V17, P144, DOI 10.1159/000198167; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Wu K, 2004, MOL THER, V9, P262, DOI 10.1016/j.ymthe.2003.11.010; YAU JLW, 1992, BRAIN RES, V577, P155, DOI 10.1016/0006-8993(92)90550-S	57	68	70	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2010	112	4					1054	1064		10.1111/j.1471-4159.2009.06524.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	546PH	WOS:000273822200019	19968753	Bronze			2021-06-18	
S	Roy, MJ; Francis, J; Friedlander, J; Banks-Williams, L; Lande, RG; Taylor, P; Blair, J; McLellan, J; Law, W; Tarpley, V; Patt, I; Yu, H; Mallinger, A; Difede, J; Rizzo, A; Rothbaum, B		Barchas, JD; Difede, J		Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Blair, James; McLellan, Jennifer; Law, Wendy; Tarpley, Vanita; Patt, Ivy; Yu, Henry; Mallinger, Alan; Difede, Joann; Rizzo, Albert; Rothbaum, Barbara			Improvement in cerebral function with treatment of posttraumatic stress disorder	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	posttraumatic stress disorder; traumatic brain injury; combat stress; functional magnetic resonance imaging; virtual reality; exposure therapy	DEPRESSION INVENTORY-II; REALITY EXPOSURE THERAPY; ADMINISTERED PTSD SCALE; TRAUMATIC BRAIN-INJURY; BECK DEPRESSION; NEURAL RESPONSES; PHYSICAL HEALTH; FEARFUL FACES; PRIMARY-CARE; IRAQ	Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) are signature illnesses of the Iraq and Afghanistan wars, but current diagnostic and therapeutic measures for these conditions are suboptimal. In our study, functional magnetic resonance imaging (fMRI) is used to try to differentiate military service members with: PTSD and mTBI, PTSD alone, mTBI alone, and neither PTSD nor mTBI. Those with PTSD are then randomized to virtual reality exposure therapy or imaginal exposure. fMRI is repeated after treatment and along with the Clinician-Administered PTSD Scale (CAPS) and Clinical Global Impression (CGI) scores to compare with baseline. Twenty subjects have completed baseline fMRI scans, including four controls and one mTBI only; of 15 treated for PTSD, eight completed posttreatment scans. Most subjects have been male (93%) and Caucasian (83%), with a mean age of 34. Significant improvements are evident on fMRI scans, and corroborated by CGI scores, but CAPS scores improvements are modest. In conclusion, CGI scores and fMRI scans indicate significant improvement in PTSD in both treatment arms, though CAPS score improvements are less robust.	[Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Law, Wendy; Tarpley, Vanita; Patt, Ivy] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Law, Wendy; Tarpley, Vanita; Patt, Ivy] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Blair, James; McLellan, Jennifer; Yu, Henry; Mallinger, Alan] NIMH, NIH, Bethesda, MD 20892 USA; [Difede, Joann] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Rizzo, Albert] Univ So Calif, Inst Creat Technol, Los Angeles, CA USA; [Rothbaum, Barbara] Emory Univ, Sch Med, Atlanta, GA USA	Roy, MJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, Room A3062,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	mroy@usuhs.mil	Blair, Robert James/ABH-7982-2020	Lande, R Gregory/0000-0002-0072-3538; Yu, Henry/0000-0003-3789-5250			Berg A. O, 2008, TREATMENT POSTTRAUMA; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Chisolm Theresa H, 2005, Trends Amplif, V9, P111, DOI 10.1177/108471380500900303; Cole JC, 2003, PSYCHOL REP, V93, P1115, DOI 10.2466/PR0.93.7.1115-1129; Contreras S, 2004, HISPANIC J BEHAV SCI, V26, P446, DOI 10.1177/0739986304269164; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DEROGATIS LR, 2004, USE PSYCHOL TESTING, V3, P59; Difede J, 2007, J CLIN PSYCHIAT, V68, P1639, DOI 10.4088/JCP.v68n1102; Dozois D.J., 2004, COMPREHENSIVE HDB PS, V2, P50; Dutton GR, 2004, GEN HOSP PSYCHIAT, V26, P437, DOI 10.1016/j.genhosppsych.2004.06.002; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; Guy, 1976, ECDEU ASSESSMENT MAN; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; Longwell BT, 2005, BEHAV THER, V36, P265, DOI 10.1016/S0005-7894(05)80075-9; Nakic M, 2006, NEUROIMAGE, V31, P1752, DOI 10.1016/j.neuroimage.2006.02.022; PINE DS, 2010, NEUROIMAGE IN PRESS; Rizzo AA, 2008, STUD HEALTH TECHNOL, V132, P420; Rothbaum BO, 2001, J CLIN PSYCHIAT, V62, P617, DOI 10.4088/JCP.v62n0808; Roy MJ, 1998, PSYCHOSOM MED, V60, P663, DOI 10.1097/00006842-199811000-00001; Schwab KA, 2006, NEUROLOGY, V66, pA235; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Stein MB, 1997, AM J PSYCHIAT, V154, P1120; Thomas KM, 2001, ARCH GEN PSYCHIAT, V58, P1057, DOI 10.1001/archpsyc.58.11.1057; Ullman SE, 1996, J TRAUMA STRESS, V9, P703, DOI 10.1007/BF02104098; van Tubergen A, 2003, ANN RHEUM DIS, V62, P140, DOI 10.1136/ard.62.2.140; Wagner AW, 2000, J TRAUMA STRESS, V13, P41, DOI 10.1023/A:1007716813407; Walker EA, 2003, ARCH GEN PSYCHIAT, V60, P369, DOI 10.1001/archpsyc.60.4.369; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Zarahn E, 2000, COGNITIVE BRAIN RES, V9, P1, DOI 10.1016/S0926-6410(99)00033-6; Zarahn E, 2000, NEUROIMAGE, V11, P783, DOI 10.1006/nimg.2000.0560	38	68	68	1	19	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						142	149		10.1111/j.1749-6632.2010.05689.x			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000018	20955336				2021-06-18	
J	Dawson, DR; Anderson, ND; Burgess, P; Cooper, E; Krpan, KM; Stuss, DT				Dawson, Deirdre R.; Anderson, Nicole D.; Burgess, Paul; Cooper, Erin; Krpan, Katherine M.; Stuss, Donald T.			Further Development of the Multiple Errands Test: Standardized Scoring, Reliability, and Ecological Validity for the Baycrest Version	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Rehabilitation; Stroke	EXECUTIVE FUNCTIONS; BRAIN-INJURY; PERFORMANCE; SEVERITY; DEFICITS; MOTOR; AGE	Dawson DR, Anderson ND, Burgess P, Cooper E, Krpan KM, Stuss DT. Further development of the Multiple Errands Test: standardized scoring, reliability, and ecological validity for the Baycrest version. Arch Phys Med Rehabil 2009;90(11 Suppl 1):S41-51. Objectives: (1) To determine the summary scores on the Baycrest Multiple Errands Test (BMET) that best discriminate between community dwelling people with traumatic brain injury or stroke and matched controls; (2) to determine interrater reliability; (3) to evaluate further the ecological validity. Design: Case-control. Setting: Large, university-affiliated health care center and participants' homes. Participants: People with acquired brain injury (n=27) and healthy matched controls (n=25). Interventions: Not applicable. Main Outcome Measures: (1) BMET; (2) performance-based measure of instrumental activities of daily living: the Assessment of Motor and Process Skills; (3) self-report and significant other report of daily life function, the Dysexecutive Questionnaire, the Sickness Impact Profile, and the Mayo-Portland Adaptability Inventory. Results: Performance on the BMET was significantly different between people with acquired brain injury and controls (P<.05); good to strong correlations (>.50) were found in more than one third of the correlations between the BMET and measures of IADL and everyday function. Interclass correlation coefficients (ICCs) on BMET summary scores were high (ICC=.71-.88), illustrating very good interrater reliability. Conclusions: This study extends the psychometric findings of the Multiple Errands Test, thus further confirming its value for clinical and research purposes. It is a reliable and ecologically valid assessment that provides a standard way of categorizing executive performance errors in a naturalistic environment.	[Dawson, Deirdre R.; Anderson, Nicole D.; Cooper, Erin; Krpan, Katherine M.] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.; Stuss, Donald T.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Anderson, Nicole D.; Stuss, Donald T.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Anderson, Nicole D.; Krpan, Katherine M.; Stuss, Donald T.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Stuss, Donald T.] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Burgess, Paul] Inst Cognit Neurosci, London, England	Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Burgess, Paul W/A-1811-2010; Dawson, Deirdre R/I-8882-2014; Anderson, Nicole D/E-9101-2011	Dawson, Deirdre R/0000-0001-7517-6121; Anderson, Nicole D/0000-0002-5979-2220	McDonnell Foundation 21st Century Collaborative Activity Award; Heart and Stroke Foundation of Ontario Center for Stroke RecoveryHeart & Stroke Foundation of Ontario	Supported by the McDonnell Foundation 21st Century Collaborative Activity Award and the Heart and Stroke Foundation of Ontario Center for Stroke Recovery.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Army Individual Test Battery, 1944, MAN DIR SCOR; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cicerone KD, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P246; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Delis DC, 1987, CALIFORNIA VERBAL LE; Duran LJ, 1996, ARCH PHYS MED REHAB, V77, P1019, DOI 10.1016/S0003-9993(96)90062-3; Fisher AG, 2006, ASSESSMENT MOTOR PRO, V1; Fisher AG, 2001, ASSESSMENT MOTOR PRO, VI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, V2; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R., 1993, WISCONSIN CARD SORTI; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Kongs SK, 2000, WISCONSIN CARD SORTI; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; McDowell I., 1996, MEASURING HLTH, V2nd ed.; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAND D, 2008, NEUROPSYCHOL REHABIL, V1; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, V3rd ed., P367; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stauffer LM, 2000, AM J OCCUP THER, V54, P607, DOI 10.5014/ajot.54.6.607; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; Wechsler D, 1985, WECHSLER ADULT INTEL; Wilson BA, 1996, BEHAV ASSESSMENT DYS; World Health Organization, 2001, INT CLASS FUNCT DIS	46	68	68	0	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2009	90	11		1			S41	S51		10.1016/j.apmr.2009.07.012			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	520XE	WOS:000271882100007	19892074				2021-06-18	
J	Bombardier, CH; Bell, KR; Temkin, NR; Fann, JR; Hoffman, J; Dikmen, S				Bombardier, Charles H.; Bell, Kathleen R.; Temkin, Nancy R.; Fann, Jesse R.; Hoffman, Jeanne; Dikmen, Sureyya			The Efficacy of a Scheduled Telephone Intervention for Ameliorating Depressive Symptoms During the First Year After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; motivational interviewing; problem solving; telephone intervention	RANDOMIZED CONTROLLED-TRIAL; HEAD-INJURY; PSYCHIATRIC-DISORDERS; BEHAVIORAL TREATMENT; CARE MANAGEMENT; MILD; MODERATE; PSYCHOTHERAPY; INDIVIDUALS; IMPAIRMENT	Objective: To determine whether an designed to improve functioning after traumatic brain injury (TBI) also ameliorates depressive symptoms. Design: Single-blinded, randomized controlled trial comparing a scheduled telephone intervention to usual care. Participants: One hundred seventy-one persons with TBI discharged from an inpatient rehabilitation unit. Methods: The treatment group received up to 7 scheduled telephone sessions over 9 months designed to elicit current concerns, provide information, and facilitate problem solving in domains relevant to TBI recovery. Outcome Measures: Brief Symptom Inventory-Depression (BSI-D) subscale, Neurobehavioral Functioning Inventory-Depression subscale, and Mental Health Index-5 from the Short-Form-36 Health Survey. Results: Baseline BSI-D subscale and outcome data were available on 126 (74%) participants. Randomization was effective except for greater severity of depressive symptoms in the usual care (control) group at baseline. Outcome analyses were adjusted for these differences. Overall, control participants developed greater depressive symptom severity from baseline to 1 year than did the treatment group. The treated group reported significantly lower depression symptom severity on all outcome measures. For those more depressed at baseline, the treated group demonstrated greater improvement in symptoms than did the controls. Conclusions: Telephone-based interventions using problem-solving and behavioral activation approaches may be effective in ameliorating depressive symptoms following TBI. Proactive telephone calls, motivational interviewing, and including significant others in the intervention may have contributed to its effectiveness.	[Bombardier, Charles H.] Univ Washington, Sch Med, Dept Rehabil Med, Harborview Med Ctr, Seattle, WA 98104 USA; [Temkin, Nancy R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98104 USA; [Fann, Jesse R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA	Bombardier, CH (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Harborview Med Ctr, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research [H133A020508]	This research was supported by the National Institute on Disability and Rehabilitation Research, grant number H133A020508, Traumatic Brain Injuly Model Systems. The authors express their gratitude to Jason Barber, MS, for his assistance with data analysis and to the Issue Editor Dr Tessa Hartfor her expert guidance.	Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569; Cuijpers P, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-36; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jakupcak M, 2006, J TRAUMA STRESS, V19, P387, DOI 10.1002/jts.20125; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Miller WR, 1991, MOTIVATIONAL INTERVI; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; Mohr DC, 2000, J CONSULT CLIN PSYCH, V68, P356, DOI 10.1037//0022-006X.68.2.356; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; NEZU AM, 1986, J CONSULT CLIN PSYCH, V54, P196, DOI 10.1037/0022-006X.54.2.196; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Strong V, 2008, LANCET, V372, P40, DOI 10.1016/S0140-6736(08)60991-5; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836	48	68	68	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					230	238		10.1097/HTR.0b013e3181ad65f0			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000002	19625862				2021-06-18	
J	Kilbride, RD; Costello, DJ; Chiappa, KH				Kilbride, Ronan D.; Costello, Daniel J.; Chiappa, Keith H.			How Seizure Detection by Continuous Electroencephalographic Monitoring Affects the Prescribing of Antiepileptic Medications	ARCHIVES OF NEUROLOGY			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; INTRACEREBRAL HEMORRHAGE; ELECTROGRAPHIC SEIZURES; MORTALITY; DAMAGE	Objectives: To assess the effect of continuous electroencephalographic monitoring on the decision to treat seizures in the inpatient setting, particularly in the intensive care unit. Design: Retrospective cohort study. Setting: Medical and neuroscience intensive care units and neurological wards. Patients: Three hundred consecutive nonelective continuous electroencephalographic monitoring studies, performed on 287 individual inpatients over a 27-month period. Main Outcome Measures: Epileptiform electroencephalographic abnormalities and changes in antiepileptic drug (AED) therapy based on the electroencephalographic findings. Results: The findings from the continuous electroencephalographic monitoring led to a change in AED prescribing in 52% of all studies with initiation of an AED therapy in 14%, modification of AED therapy in 33%, and discontinuation of AED therapy in 5% of all studies. Specifically, the detection of electrographic seizures led to a change in AED therapy in 28% of all studies. Conclusions: The findings of continuous electroencephalographic monitoring resulted in a change in AED prescribing during or after half of the studies performed. Most AED changes were made as a result of the detection of electrographic seizures. Arch Neurol. 2009;66(6):723-728	[Kilbride, Ronan D.] Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Clin Neurophysiol Serv, Boston, MA 02114 USA	Kilbride, RD (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, ACC 7,15 Parkman St, Boston, MA 02114 USA.	rkilbride@partners.org					Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Drislane FW, 1999, J CLIN NEUROPHYSIOL, V16, P323, DOI 10.1097/00004691-199907000-00004; Fountain NB, 2007, NEUROLOGY, V69, P1312, DOI 10.1212/01.wnl.0000285495.12791.62; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Jordan KG, 2006, EPILEPSIA, V47, P2211; Knake S, 2006, EPILEPSIA, V47, P2020, DOI 10.1111/j.1528-1167.2006.00845.x; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0; Sutula TP, 2003, CURR OPIN NEUROL, V16, P189, DOI 10.1097/00019052-200304000-00012; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Wittman JJ, 2005, NEUROCRIT CARE, V2, P330, DOI 10.1385/NCC:2:3:330; Young GB, 1996, NEUROLOGY, V47, P83	21	68	70	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JUN	2009	66	6					723	728		10.1001/archneurol.2009.100			6	Clinical Neurology	Neurosciences & Neurology	455OQ	WOS:000266772200005	19506131	Bronze			2021-06-18	
J	Ding, JY; Kreipke, CW; Speirs, SL; Schafer, P; Schafer, S; Rafols, JA				Ding, Jamie Y.; Kreipke, Christian W.; Speirs, Susan L.; Schafer, Patrick; Schafer, Steven; Rafols, Jose A.			Hypoxia-inducible factor-1 alpha signaling in aquaporin upregulation after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Close head injury; Brain edema; MnSOD; Hypoxia; 2ME2	FOCAL CEREBRAL-ISCHEMIA; ENDOTHELIAL GROWTH-FACTOR; RAT-BRAIN; ARTERY OCCLUSION; WATER TRANSPORT; MESSENGER-RNA; EXPRESSION; EDEMA; MODEL; VEGF	Previous studies have demonstrated that traumatic brain injury (TBI) causes brain edema via aquaporins (AQPs), the water-transporting proteins. In the present study, we determined the role of hypoxia inducible factor-1 alpha (HIF-1 alpha), which is a transcription factor in response to physiological hypoxia, in regulating expression of AQP4 and AQP9. Adult male Sprague-Dawley rats (400-425 g) received a closed head injury using the Marmarou weight drop model with a 450 g weight and survived for 1, 4, 24 and 48 h. Some animals were administered 30 min after injury with 2-methoxyestradiol (2ME2), a naturally occurring metabolite of estradiol which is known to post-transcriptionally down-regulate HIF-1 alpha expression, and sacrificed 4h after injury. Real-time PCR and Western blot were used, respectively, to detect gene and protein expressions of manganese superoxide dismutase (MnSOD, showing hypoxic stress), HIF-1 alpha, AQP4, and AQP9. ANOVA analysis demonstrated a significant (p < 0.05) increase in gene expression of MnSOD, HIF-1 alpha, AQP4, and AQP9, starting at I h after injury through 48 h. Western blot analysis further indicated a significant (p < 0.05) increase in protein expression of these molecules at the same time points. Pharmacological inhibition of HIF-1 alpha by 2ME2 reduced the up-regulated levels of AQP4 and AQP9 after TBI. The present study suggests that hypoxic conditions determined by MnSOD expression after closed head injury contribute to HIF-1 alpha expression. HIF-1 alpha, in turn, up-regulates expression of AQP4 and AQP9. These results characterize the pathophysiological mechanisms, and suggest possible therapeutic targets for TBI patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Ding, Jamie Y.; Kreipke, Christian W.; Speirs, Susan L.; Schafer, Patrick; Schafer, Steven; Rafols, Jose A.] Wayne State Univ, Sch Med, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, 9312 Scott Hall,540 E Canfield St, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39860, R01 NS039860-08, R01 NS039860] Funding Source: Medline		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Agre P, 2004, NEUROSCIENCE, V129, P849, DOI 10.1016/j.neuroscience.2004.10.001; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Badaut J, 2004, NEUROSCIENCE, V129, P971, DOI 10.1016/j.neuroscience.2004.06.035; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bemeur C, 2004, NEUROCHEM INT, V45, P1167, DOI 10.1016/j.neuint.2004.06.010; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Danielisova V, 2007, J NEUROL SCI, V253, P61, DOI 10.1016/j.jns.2006.12.001; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Gerard HC, 2002, J RHEUMATOL, V29, P1827; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Li LH, 2008, ACTA NEUROPATHOL, V115, P297, DOI 10.1007/s00401-008-0339-5; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Nemethova M, 2008, CELL BIOL INT, V32, P128, DOI 10.1016/j.cellbi.2007.08.023; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rite I, 2008, NEUROCHEM INT, V52, P897, DOI 10.1016/j.neuint.2007.10.004; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1	42	68	76	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 27	2009	453	1					68	72		10.1016/j.neulet.2009.01.077			5	Neurosciences	Neurosciences & Neurology	426HM	WOS:000264698600016	19429018	Green Accepted			2021-06-18	
J	Green, P; Flaro, L; Courtney, J				Green, P.; Flaro, L.; Courtney, J.			Examining false positives on the Word Memory Test in adults with mild traumatic brain injury	BRAIN INJURY			English	Article							SYMPTOM VALIDITY TESTS; CLAIMANTS; CHILDREN; SAMPLE	Primary objective: Many adults with mild traumatic brain injury (MTBI) fail effort tests, indicating poor effort and invalid test results. However, two studies have suggested a high rate of false positives on the Word Memory Test (WMT) in adults with MTBI. This study examines the question of false positives in adults with MTBI who failed the effort subtests of the WMT. Research design: A modified and shortened version of the WMT, the Medical Symptom Validity Test (MSVT) was given to adults with MTBI, some of whom failed the WMT. It was also given to samples of schoolchildren in grades two and above, to several hundred children with developmental disabilities and to healthy adults. Outcomes and results: Failures on the MSVT were far more frequent in adults with MTBI than in second grade children or in children with developmental disabilities. Adults with MTBI who failed the WMT scored much lower on the MSVT effort subtests than children with a mean FSIQ of 63 and much lower than children with impaired memory. Conclusions: Comparison with developmentally disabled children on the MSVT suggests that the adults with MTBI who failed the WMT were not making an effort to do well on either the WMT or the MSVT. Their results were invalid. False positives on the WMT in adults with mild TBI are very rare.	[Courtney, J.] Childrens Hosp New Orleans, Dept Psychol, New Orleans, LA USA	Green, P (corresponding author), Suite 210,17010 103 Ave, Edmonton, AB T5S 1K7, Canada.	paulgreen@shaw.ca					Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; BROCKHAUS R, 2008, ANN C GES NEUR TUEB; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Gill David, 2007, Med Leg J, V75, P64; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2008, MANUAL NONVERBAL MED; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; GREVE K, 2007, CLIN NEUROPSYCHOL, V22, P1; Howe L. S, 2008, CLIN NEUROPSYCHOL, V28, P1; IVERSON G, 2005, CURRENT OPINION PSYC, P18301; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Montijo J, 2008, ARCH CLIN NEUROPSYCH, V23, P633; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; ROHLING M, CLIN NEUROP IN PRESS; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Talley, 1993, CHILDRENS AUDITORY V; Tombaugh T, 1997, TEST MEMORY MALINGER	22	68	68	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	9					741	750	PII 913456043	10.1080/02699050903133962			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600005	19636999				2021-06-18	
J	Ng, K; Mikulis, DJ; Glazer, J; Kabani, N; Till, C; Greenberg, G; Thompson, A; Lazinski, D; Agid, R; Colella, B; Green, RE				Ng, Kevin; Mikulis, David J.; Glazer, Joanna; Kabani, Noor; Till, Christine; Greenberg, Gahl; Thompson, Andrew; Lazinski, Dorothy; Agid, Ronit; Colella, Brenda; Green, Robin E.			Magnetic Resonance Imaging Evidence of Progression of Subacute Brain Atrophy in Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Atrophy; Brain injuries; Magnetic resonance imaging; Follow-up studies; Rehabilitation	CLOSED-HEAD-INJURY; CORTICAL ATROPHY; RECOVERY; MEMORY; MILD; MRI; VOLUME; PERFORMANCE; TOMOGRAPHY; MORPHOLOGY	Objective: To demonstrate subacute progression of brain atrophy (from 4.5-29mo postinjury) in moderate to severe traumatic brain injury (TBI) using structural magnetic resonance imaging (MRI). Design: Within-subjects, repeated-measures design. Setting: Inpatient neurorehabilitation program and teaching hospital (MRI department). Participants: Adults (N=14) with moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: Neuroradiologist readings and volumetric measurements (total brain cerebrospinal fluid and hippocampus) at 4.5 months and 2.5 years postinjury. Results: Ten of 14 patients showed visible atrophy progression. Significant increase in cerebrospinal fluid (CSF) volume (t(13)=-4.073, P<.001) and decrease in right and left hippocampal volumes (t(13) =4.221, P<.001 and t(13)=3.078, P<.005, respectively) were observed from 4.5 months to 2.5 years. Compared with published normative data, patients with TBI showed significantly more pathologic percent annual volume change for the hippocampi (t(26)=-3.864, P<.001, right; and t(26)=-2.737, P<.01, left), and a trend for CSF (t(26)=1.655, P=.059). Conclusions: This study provides strong MRI evidence for subacute progression of atrophy, as distinct from early, acute neurologic changes observed.	[Ng, Kevin; Mikulis, David J.; Greenberg, Gahl; Thompson, Andrew; Lazinski, Dorothy; Agid, Ronit] Univ Toronto, Univ Hlth Network, Dept Med Imaging, Div Neuroradiol, Toronto, ON M5S 1A1, Canada; [Glazer, Joanna; Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Till, Christine; Colella, Brenda; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Kabani, Noor] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	Green, RE (corresponding author), 550 Univ Ave,Room 11004, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca	Mikulis, David J/H-5167-2019	Till, Christine/0000-0001-5030-3155; Mikulis, David/0000-0003-3956-0892; Green, Robin/0000-0001-9451-3963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Inc [MOP-67072, 05-50]; Toronto Rehabilitation InstituteUniversity of Toronto; Ministry of Health and Long-Term Care in Ontario.Ministry of Health and Long-Term Care, Ontario	Supported by the Canadian Institutes of Health Research and the Physicians' Services Inc (grant nos. MOP-67072, 05-50) and the Toronto Rehabilitation Institute, which receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario.	ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; BASSO A, 1989, COGNITIVE APPROACHES; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brooks D N, 1979, Int Rehabil Med, V1, P166; Bruns J. Jr., 2003, EPILEPSIA, V10, P2, DOI DOI 10.1046/J.1528-1157.44.S10.3.X; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; COOK RJ, 1998, ENCY BIOSTATISTICS, P2166; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farne A, 2004, J NEUROL NEUROSUR PS, V75, P1401, DOI 10.1136/jnnp.2002.003095; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GUGGENMOOSHOLZMANN I, 1993, STAT MED, V12, P2191, DOI 10.1002/sim.4780122305; HAYASHI N, 2004, HYPOTHERMIA ACUTE BR; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; Koch GG, 1982, INTRACLASS CORRELATI; Levin H. S., 1979, GALVESTON ORIENTATIO; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MACDONALD JD, 1996, MNI DISPLAY PROGRAM; MACKENZIE JD, 2002, AM J NEURORADIOL, V23, P1442; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; *MCCONN BRAIN IM C, BRAIN IM SOFTW TOOLB; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Novack TA, 2000, BRAIN INJURY, V14, P987; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Talairach J., 1988, COPLANAR STEREOTAXIC; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VALLAR G, 1988, J NEUROL NEUROSUR PS, V51, P1269, DOI 10.1136/jnnp.51.10.1269; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; WHYTE J, 1999, P NIH CONS DEV C REH, P23; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zijdenbos A, 1998, LECT NOTES COMPUT SC, V1496, P439; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	74	68	69	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S35	S44		10.1016/j.apmr.2008.07.006			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	388DB	WOS:000261999400005	19081440				2021-06-18	
J	Wijdicks, EFM; Rabinstein, AA; Manno, EM; Atkinson, JD				Wijdicks, Eelco F. M.; Rabinstein, Alejandro A.; Manno, Edward M.; Atkinson, John D.			Pronouncing brain death - Contemporary practice and safety of the apnea test	NEUROLOGY			English	Article							ORGAN; IDENTIFICATION; COMA	Background: Little is known of hospital practice in brain death determination, specialty involvement, and followed procedures, including the apnea test. Methods: We reviewed 228 patients pronounced brain dead at Mayo Clinic from 1996 to 2007. We performed a detailed review of clinical determination of brain death, intensive care support, apnea test procedure, and complications. Results: There were 228 patients who were pronounced brain dead, mostly after traumatic brain injury, cerebral hematoma, or aneurysmal subarachnoid hemorrhage. Brain death was declared within 24 hours of ictus in 30% of the patients and within 3 days in 62%. All patients were using one or more vasopressors, and 61% of the patients received vasopressin for diabetes insipidus. An apnea test could not be performed in 7% of the patients because of hemodynamic instability or poor oxygenation at baseline. In 3% of the patients, the apnea test procedure was aborted because of hypoxemia or hypotension. No major complications (cardiac arrest or pneumothorax) occurred during the apnea test. Polytrauma resulting in brain death was significantly more common in patients with aborted or not attempted apnea tests than in patients with completed apnea tests (p = 0.0004). During the study epoch, we found a shift toward determination of the tests by neurointensivists, pediatric neurologists, and neurosurgeons. Conclusions: Brain death declaration is frequent within the first 3 days of admission. It is usually performed in hemodynamically unstable patients requiring vasopressors and vasopressin. If preconditions are met, apnea testing using an oxygen-diffusion technique is safe. However, in 1 of 10 patients, an apnea test could not be completed and confirmatory tests were needed.	[Wijdicks, Eelco F. M.] Mayo Clin, Coll Med, Dept Neurol, Div Crit Care Neurol, Rochester, MN 55905 USA; [Atkinson, John D.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA	Wijdicks, EFM (corresponding author), Mayo Clin, Coll Med, Dept Neurol, Div Crit Care Neurol, 200 1st St SW, Rochester, MN 55905 USA.	wijde@mayo.edu					[Anonymous], 1995, Neurology, V45, P1012; Bustos JL, 2006, TRANSPLANT P, V38, P3697, DOI 10.1016/j.transproceed.2006.10.046; de Freitas GR, 2005, J NEUROL, V252, P106, DOI 10.1007/s00415-005-0605-6; Goudreau JL, 2000, NEUROLOGY, V55, P1045, DOI 10.1212/WNL.55.7.1045; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Helms AK, 2004, NEUROLOGY, V63, P1955, DOI 10.1212/01.WNL.0000144197.06562.24; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; Rodrigue JR, 2006, AM J TRANSPLANT, V6, P190, DOI 10.1111/j.1600-6143.2005.01130.x; Ruiz-Garcia M, 2000, CHILD NERV SYST, V16, P40, DOI 10.1007/s003810050010; SASPOSNIK G, 2005, AM J MED, V118, P311; Senouci K, 2004, INTENS CARE MED, V30, P38, DOI 10.1007/s00134-003-1923-8; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20	13	68	75	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 14	2008	71	16					1240	1244		10.1212/01.wnl.0000327612.69106.4c			5	Clinical Neurology	Neurosciences & Neurology	359KT	WOS:000259986300006	18852438				2021-06-18	
J	Yune, TY; Park, HG; Lee, JY; Oh, TH				Yune, Tae Y.; Park, Hong G.; Lee, Jee Y.; Oh, Tae H.			Estrogen-Induced Bcl-2 Expression after Spinal Cord Injury Is Mediated through Phosphoinositide-3-Kinase/Akt-Dependent CREB Activation	JOURNAL OF NEUROTRAUMA			English	Article						Akt; Bcl-2; CREB; estradiol; spinal cord injury	SIGNAL-REGULATED KINASE; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; IMPROVES FUNCTIONAL RECOVERY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; DEATH-PROMOTING EVENTS; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-I; GLOBAL-ISCHEMIA	Our previous study showed that, after spinal cord injury (SCI) in rats, estrogen provides neuroprotection through expression of Bcl-2. However, molecular targets that mediate estrogen-induced expression of Bcl-2 are not fully understood. Here, we investigated whether, after SCI, the phosphatidylinositol-3 kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) pathways are involved in estrogen-induced expression of Bcl-2. Both Akt and ERK were activated and peaked at 8 h after SCI. Treatment with estrogen significantly increased the level of phosphorylated Akt (pAkt) and ERK (pERK) after injury. Cyclic-AMP response element binding protein (CREB) transcription factor was also activated and peaked at 8 h after SCI. Treatment with estrogen significantly increased the level of phosphorylated CREB (pCREB) after injury. Administration of LY294002, an inhibitor of PI3K/Akt, decreased the level of pCREB after SCI, whereas PD98059, an inhibitor of ERK, showed no significant effect. Also, treatment with LY294002 significantly inhibited expression of Bcl-2, but PD98059 showed no significant effect. Furthermore, treatment with estrogen inhibited apoptotic cell death, whereas treatment with LY294002 or PD98059 increased apoptotic cell death after SCI. Together, these data indicate that estrogen's neuroprotection is mediated in part by induction of Bcl-2 through PI3K/Akt-dependent CREB activation.	[Yune, Tae Y.; Park, Hong G.; Lee, Jee Y.; Oh, Tae H.] Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Lee, Jee Y.] Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul, South Korea	Yune, TY (corresponding author), Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Med Bldg 10th Floor,Hoegi Dong 1, Seoul 130701, South Korea.	tyune@khu.ac.kr			Korea Science and Engineering Foundation (KOSEF)Korea Science and Engineering Foundation; Korea Government (MOST)Ministry of Science and Technology (MOST) KoreaKorean Government [R01-2007-000-20617-0, M1041200011-07N1200-01110]; Seoul R BD ProgramSeoul RBD program [10524]; BK21 ProgramMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea	We wish to thank Dr. George Markelonis at the University of Maryland School of Medicine for his editorial assistance. This study was supported in part by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea Government (MOST) (no. R01-2007-000-20617-0, M1041200011-07N1200-01110), Seoul R & BD Program (no. 10524), and Post BK21 Program.	Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Bagetta G, 2004, NEUROSCI LETT, V368, P87, DOI 10.1016/j.neulet.2004.06.062; Cardona-Gomez GP, 2002, MOL BRAIN RES, V107, P80, DOI 10.1016/S0169-328X(02)00449-7; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; Furlan JC, 2005, J NEUROTRAUM, V22, P368, DOI 10.1089/neu.2005.22.368; Henderson VW, 1996, PSYCHONEUROENDOCRINO, V21, P421, DOI 10.1016/0306-4530(95)00060-7; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mannella P, 2006, J NEUROSCI, V26, P9439, DOI 10.1523/JNEUROSCI.1443-06.2006; Neary JT, 2004, NEUROCHEM RES, V29, P2037, DOI 10.1007/s11064-004-6876-y; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Platania P, 2003, NEUROENDOCRINOLOGY, V77, P334, DOI 10.1159/000070899; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sakurai M, 2003, J THORAC CARDIOV SUR, V125, P370, DOI 10.1067/mtc.2003.112; Sakurai M, 2001, NEUROSCI LETT, V302, P17, DOI 10.1016/S0304-3940(01)01609-3; Singer CA, 1999, J NEUROSCI, V19, P2455; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wilson ME, 2002, MOL BRAIN RES, V102, P48, DOI 10.1016/S0169-328X(02)00181-X; Wu TW, 2005, NEUROSCIENCE, V135, P59, DOI 10.1016/j.neuroscience.2004.12.027; Xiang H, 2006, MOL CELL BIOL, V26, P8599, DOI 10.1128/MCB.01062-06; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yu CG, 2005, MOL BRAIN RES, V138, P244, DOI 10.1016/j.molbrainres.2005.04.013; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	55	68	74	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1121	1131		10.1089/neu.2008.0544			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900008	18785877				2021-06-18	
J	Vilalta, A; Sahuquillo, J; Rosell, A; Poca, MA; Riveiro, M; Montaner, J				Vilalta, Anna; Sahuquillo, Juan; Rosell, Anna; Poca, Maria A.; Riveiro, Marilyn; Montaner, Joan			Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	8th International Neurotrauma Symposium	MAY 21-25, 2006	Rotterdam, NETHERLANDS			blood-brain barrier; brain extracellular fluid; matrix metalloproteinases; gelatinases; microdialysis; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; MESSENGER-RNA; HEAD-INJURY; MATRIX-METALLOPROTEINASE-9; EXPRESSION; BLOOD; BARRIER; EDEMA	Objective: Recent experimental evidence suggests that matrix metalloproteinases (MMPs) are implicated in the pathophysiology of traumatic brain injury (TBI) by increasing blood-brain barrier permeability and exacerbating posttraumatic edema. We examined the acute profile ofMMP- 2 and MMP-9 in the plasma of patients with moderate or severe TBI and in the brain extracellular fluid (ECF). Design: Prospective observational study. Setting: Neurotraumatology intensive care unit of a tertiary university hospital. Patients: Twenty patients with moderate or severe TBI were included and three groups were used as controls: 20 patients with a mild head injury and normal CT scan, 15 moderate polytrauma patients without TBI, and 20 healthy volunteers. Interventions: Plasma samples were collected within the first 12 h and at 24 h post-injury. Simultaneous brain microdialysate and plasma samples were obtained in four moderate-severe TBI patients at additional timepoints: 48, 72, and 96 h post-TBI. Measurements and main results: Gelatinases (MMP-2 and MMP-9) were measured by gelatin zymography. A significant increase in plasma gelatinases was observed at baseline when compared with healthy volunteers in the study group. This early increase was followed by a significant decrease at 24 h post-injury. Brain microdialysis samples presented a similar time profile as plasma samples for both gelatinases. Conclusions: High levels of gelatinases were found in plasma and brain ECF in the early phase of TBI, indicating that both local and systemic trauma-induced upregulation of gelatinases in the acute phase might play an important role in the pathophysiology of TBI and could be a future therapeutic target.	[Sahuquillo, Juan; Poca, Maria A.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona 08035, Spain; [Vilalta, Anna] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, UNINN, Barcelona 08035, Spain; [Rosell, Anna; Montaner, Joan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Res Lab, Barcelona 08035, Spain; [Rosell, Anna; Montaner, Joan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Unit, Barcelona 08035, Spain; [Riveiro, Marilyn] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurotraumatol Intens Care Unit, Barcelona 08035, Spain	Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Neurosurg, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sahuquillo@neurotrauma.net	Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008; Montaner, Joan/D-3063-2015; Riveiro, Marilyn/S-5242-2016	Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; Montaner, Joan/0000-0003-4845-2279; Riveiro, Marilyn/0000-0002-1645-3720; Rosell Novel, Anna/0000-0003-1082-3599; Vilalta, Anna/0000-0002-2183-072X			Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Fatar M, 2005, CEREBROVASC DIS, V20, P141, DOI 10.1159/000087197; Gasche Y, 2006, FRONT BIOSCI-LANDMRK, V11, P1289, DOI 10.2741/1883; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ning M, 2006, NEUROLOGY, V66, P1550, DOI 10.1212/01.wnl.0000216133.98416.b4; Parks WC, 1998, BIOL EXTRAC, P263; Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sellebjerg F, 2003, BRAIN RES BULL, V61, P347, DOI 10.1016/S0361-9230(03)00097-2; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; TEASDALE G, 1974, LANCET, V2, P81; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vilalta A, 2006, J NEUROTRAUM, V23, P772; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375	38	68	70	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1384	1392		10.1007/s00134-008-1056-1			9	Critical Care Medicine	General & Internal Medicine	330IH	WOS:000257933700006	18350273				2021-06-18	
J	Kristman, VL; Tator, CH; Kreiger, N; Richards, D; Mainwaring, L; Jaglal, S; Tomlinson, G; Comper, P				Kristman, Vicki L.; Tator, Charles H.; Kreiger, Nancy; Richards, Doug; Mainwaring, Lynda; Jaglal, Susan; Tomlinson, George; Comper, Paul			Does the apolipoprotein epsilon 4 allele predispose varsity athletes to concussion? A prospective cohort study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article; Proceedings Paper	25th Annual National-Neurotrauma-Society Symposium	JUL 29-AUG 01, 2007	Kansas City, MO	Natl Neurotrauma Soc		cohort studies; collegiate athletes; concussion; genetics; risk factor	TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; E-DEFICIENT MICE; E POLYMORPHISM; FOOTBALL; PROTEIN; EPIDEMIOLOGY; ASSOCIATION; E-EPSILON-4; GENOTYPE	Objective: To determine the association between the apolipoprotein epsilon 4 allele and concussion. We hypothesized that apolipoprotein epsilon 4 carriers may be more likely to sustain a concussion. Design: Prospective cohort study. Setting: University of Toronto varsity athletics. Participants: Included 318 of 822 collegiate student athletes who participated in University of Toronto varsity sports from September 2002 to April 2006. Assessment of Risk Factors: The presence of apolipoprotein EA was described dichotomously after genotyping blood samples collected from participants. Main Outcome Measurements: Concussions were identified by sport-medicine professionals present on the sidelines using on-field assessment forms. All concussion diagnoses were verified by a sports medicine physician. Survival analysis was used to determine the association between apolipoprotein epsilon 4 and first concussion. Results: The unadjusted hazard ratio for concussion in the apolipoprotein FA carriers was 1.18 (95% CI: 0.52, 2.69) compared to noncarriers. Adjustment for sex, weight, height, and team type resulted in a hazard ratio of 1.06 (95% Cl: 0.41, 2.72), indicating little effect from confounding factors. Conclusions: There is no important association between carrying the apolipoprotein epsilon 4 allele and sustaining a concussion. At this time, we do not recommend preseason genetic testing for varsity. athletes as a mechanism for targeting prevention strategies.	[Kristman, Vicki L.] Toronto Western Hosp, Univ Hlth Network, CREIDO, Toronto, ON M5T 2S8, Canada; [Kristman, Vicki L.; Kreiger, Nancy; Jaglal, Susan; Tomlinson, George] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Kristman, Vicki L.; Tator, Charles H.] Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Richards, Doug; Mainwaring, Lynda; Comper, Paul] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON, Canada; [Richards, Doug; Comper, Paul] Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada; [Jaglal, Susan] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Tomlinson, George] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada	Kristman, VL (corresponding author), Toronto Western Hosp, Univ Hlth Network, CREIDO, Fell Pavilion 4-132,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	vicki.kristman@uhnresearch.ca	Tomlinson, George A/L-5432-2016	Tomlinson, George A/0000-0002-9328-6399; Kristman, Vicki/0000-0001-5508-0552; Jaglal, Susan/0000-0002-2930-1443			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boland LL, 2006, ANN EPIDEMIOL, V16, P763, DOI 10.1016/j.annepidem.2006.04.005; Buttini M, 1999, J NEUROSCI, V19, P4867; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; COMPER PN, 2003, BRAIN INJ S1, V17, P85; de Barros EMKP, 2000, J PEDIATR ORTHOPED, V20, P786; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; Meeuwisse WH, 2000, AM J SPORT MED, V28, P516, DOI 10.1177/03635465000280041201; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; *SAS I INC, 2002, SAS COMP MICR WIND E; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SIEST G, 1995, CLIN CHEM, V41, P1068; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	68	69	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2008	18	4					322	328		10.1097/JSM.0b013e31817e6f3e			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	325DK	WOS:000257568300003	18614883				2021-06-18	
J	Tanriverdi, F; Unluhizarci, K; Kocyigit, I; Tuna, IS; Karaca, Z; Durak, AC; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Kocyigit, Ismail; Tuna, Ibrahim S.; Karaca, Zuleyha; Durak, Ahmet C.; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Brief communication: Pituitary volume and function in competing and retired male boxers	ANNALS OF INTERNAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; HYPOPITUITARISM; SPORT	Background: Pituitary consequences of chronic head trauma in boxing have not been investigated in detail. Objective: To investigate the pituitary function in retired or active amateur boxers. Design: Cross-sectional, observational study. Setting: Turkey. Participants: 61 actively competing (n = 44) or retired (n = 17) male boxers of the Turkish National Boxing Team. Measurements: Body composition variables, pituitary volume (in 38 of 61 boxers), and pituitary function. Results: 9 of 61 boxers (15%) had growth hormone (GH) deficiency and 5 of 61 boxers (8%) had adrenocorticotropic hormone deficiency. All boxers with GH deficiency except 1 were retired from boxing. Of 17 retired boxers, 8 (47%) had GH deficiency. Retired boxers with GH deficiency had significantly lower pituitary volume than retired boxers with normal GH. Limitation: Pituitary volume was measured in only 38 of 61 boxers, and the study had no comparison group. Conclusion: This study suggests that retired boxers have a high rate of pituitary dysfunction. Therefore, investigation of pituitary function in boxers, particularly retired ones, is recommended.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Inst Salud Carlos III, Santiago De Compostela, Spain	Tanriverdi, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fatihtan@erciyes.edu.tr		KOCYIGIT, ISMAIL/0000-0002-6654-4727; Tuna, Ibrahim/0000-0003-4170-6483			Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI20401; Orme SM, 1996, CLIN ENDOCRINOL, V45, P135, DOI 10.1046/j.1365-2265.1996.d01-1562.x; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; Takano K, 1999, AM J NEURORADIOL, V20, P312; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	17	68	68	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					827	U35		10.7326/0003-4819-148-11-200806030-00005			6	Medicine, General & Internal	General & Internal Medicine	308CG	WOS:000256365300004	18519929				2021-06-18	
J	Rao, V; Spiro, J; Vaishnavi, S; Rastogi, P; Mielke, M; Noll, K; Cornwell, E; Schretlen, D; Makley, M				Rao, Vani; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Mielke, Michelle; Noll, Kathy; Cornwell, Edward; Schretlen, David; Makley, Michael			Prevalence and types of sleep disturbances acutely after traumatic brain injury	BRAIN INJURY			English	Article						trauma; mood disorder; sleep	HEAD-INJURY; GENDER-DIFFERENCES; INSOMNIA; COMPLAINTS; DISORDERS; SYMPTOMS; PATTERNS; PAIN; SEX	Primary objective: To assess the prevalence of and risk factors for sleep disturbances in the acute post-traumatic brain injury (TBI) period. Research design: Longitudinal, observational study. Methods and procedures: Fifty-four first time closed-head injury patients were recruited and evaluated within 3 months after injury. Pre-injury and post-injury sleep disturbances were compared on the Medical Outcome Scale for Sleep. The subjects were also assessed on anxiety, depression, medical comorbidity and severity of TBI. Main outcomes and results: Subjects were worse on most sleep measures after TBI compared to before TBI. Anxiety disorder secondary to TBI was the most consistent significant risk factor to be associated with worsening sleep status. Conclusions: Anxiety is associated with sleep disturbances after TBI. Further studies need to be done to evaluate if this is a causal relationship.	[Rao, Vani; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Mielke, Michelle] Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Baltimore, MD USA; [Noll, Kathy; Cornwell, Edward] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Schretlen, David] Johns Hopkins Sch Med, Dept Psychiat, Div Med Psychol, Baltimore, MD USA; [Makley, Michael] Univ Maryland, Kernan Hosp, Baltimore, MD 21201 USA	Rao, V (corresponding author), 550 N Broadway, Baltimore, MD 21205 USA.	vrao@jhmi.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Mielke, Michelle/0000-0001-7177-1185	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH066894, K23 MH 066894, K23 MH066894-03] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER		BARTLETT DJ, 2007, SLEEP MED       1031; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; First MB., 1997, STRUCTURED CLIN INTE; Foley DJ, 1999, SLEEP, V22, pS366; GIILBAY BE, 2007, RESPIRATION     0627; Hays RD, 2005, SLEEP MED, V6, P41, DOI 10.1016/j.sleep.2004.07.006; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kapur VK, 2002, SLEEP, V25, P289; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Kroenke K, 1998, PSYCHOSOM MED, V60, P150, DOI 10.1097/00006842-199803000-00006; Lyketsos CG, 1999, J AM GERIATR SOC, V47, P487, DOI 10.1111/j.1532-5415.1999.tb07245.x; Neau JP, 2002, SLEEP MED REV, V6, P457, DOI 10.1053/smrv.2002.0207; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Resta O, 2001, INT J OBESITY, V25, P669, DOI 10.1038/sj.ijo.0801603; RICHTER KJ, 1995, J HEAD TRAUMA REHAB, V10, P7, DOI 10.1097/00001199-199512000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; VanWijk CMTG, 1997, SOC SCI MED, V45, P231, DOI 10.1016/S0277-9536(96)00340-1; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WOOL CA, 1994, PSYCHOSOMATICS, V35, P445, DOI 10.1016/S0033-3182(94)71738-2; YJINK ME, 1992, ARCH INTERN MED, V152, P1634	30	68	71	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2008	22	5					381	386		10.1080/02699050801935260			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500003	18415718	Green Accepted			2021-06-18	
J	Rapport, LJ; Bryer, RC; Hanks, RA				Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.			Driving and community integration after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						automobile driving; brain injuries; rehabilitation	SELF-REPORT; OUTCOMES; PREDICTORS; NEUROREHABILITATION; PARTICIPATION; CLIENTS; PEOPLE; ADULTS; DAMAGE	Objective: To examine resumption of driving after traumatic brain injury (TBI) and its relation to community integration. Design: Cross-sectional cohort study; Survey and cognitive data. Settings: Inpatient rehabilitation hospital of the Traumatic Brain Injury Model Systems and community. Participants: Persons (N=261) ranging from 3 months to 15 years postinjury. Interventions: Not applicable. Main Outcome Measures: Barriers to Driving Questionnaire, Driver Survey, community Integration Measure, and Craig Hospital Assessment and Reporting Technique. Results: Forty-four percent of survivors had resumed driving; of nondrivers. 48% reported a strong desire to resume driving. Nondriver survivors who Sought to resume driving generally rated themselves as currently fit to drive, viewed themselves as having physical and cognitive profiles like those of survivor drivers, and reported their greatest barriers to driving as social and resource related. However, cognitive functioning was similar to nondriver survivors who did not seek to resume driving and significantly worse than Survivors who were Currently driving. Nondrivers showed poorer community integration than did drivers, even after accounting for injury severity. social support. negative affectivity, and use of alternative transportation. Use of alternative transportation was common among nondrivers. but it was unrelated to community integration Outcomes. Cognitive functioning moderated risk of adverse incident: among survivors with low cognitive functioning, and high self-estimates of driving ability, which is indicative Of unawareness of deficit. adverse incidents showed positive relation to amount of driving and inverse relation to cognitive functioning. Conclusions: Driving status has unique and independent association with post-TBI community integration. Additional research is needed to evaluate transportation barriers that undermine full engagement in community living after TBI and to determine which barriers to driving, reflect valid risk to Survivors and the public.	[Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.] Wayne State Univ, Dept Phys Med & Rehabil, Sch Med, Detroit, MI 48202 USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave,7th Fl, Detroit, MI 48202 USA.	rapport@wayne.edu			National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	Anderson CJ, 2002, ARCH PHYS MED REHAB, V83, P791, DOI 10.1053/apmr.2002.32742; Arthur W, 2001, HUM FACTORS, V43, P1, DOI 10.1518/001872001775992507; Barkley RA, 2002, J INT NEUROPSYCH SOC, V8, P655, DOI 10.1017/S1355617702801345; Benton A. L., 1994, CONTRIBUTIONS NEUROP; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Coleman BR., 2005, DRIVER REHABILITATIO, P165; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DELIS DC, 2000, CVLT 2 CALIFORNIA LE; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Glasgow Nina, 2000, SOCIAL INTEGRATION 2, P108; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Golden C., 1978, STROOP COLOR WORD TE; Groeger JA, 1996, BRIT J PSYCHOL, V87, P61, DOI 10.1111/j.2044-8295.1996.tb02577.x; GROEGER JA, 1989, ACCIDENT ANAL PREV, V21, P155, DOI 10.1016/0001-4575(89)90083-3; Halstead WC, 1985, HALSTEAD REITAN NEUR; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnson J E, 1999, J Gerontol Nurs, V25, P12; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kiyono Y, 2001, ARCH PHYS MED REHAB, V82, P1389, DOI 10.1053/apmr.2001.26089; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lewis R.F., 1995, DIGIT VIGILANCE TEST; Liddle J., 2003, BRIT J OCCUP THER, V66, DOI [https://doi.org/10.1177/030802260306600307, DOI 10.1177/030802260306600307]; Lister R., 1999, BRIT J OCCUPATIONAL, V62, P514; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; Marcotte TD, 2000, J INT NEUROPSYCH SOC, V6, P233; Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McKenna FP, 2006, HEALTH PSYCHOL, V25, P163, DOI 10.1037/0278-6133.25.2.163; MCKENNA FP, 1991, ACCIDENT ANAL PREV, V23, P45, DOI 10.1016/0001-4575(91)90034-3; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; RAPPORT LJ, 2004, P M INT NEUR SOC JUL; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SCOTT CA, 2007, J INT NEUROPSYCHO S1, V13, P58; Smith A., 1982, SYMBOL DIGIT MODALIT; SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6; Tabachnick B., 2001, USING MULTIVARIATE S; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WHITENECK G, 1997, ASSESSING MED REHABI; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001	58	68	71	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					922	930		10.1016/j.apmr.2008.01.009			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900019	18452742				2021-06-18	
J	Ellingson, KD; Leventhal, JM; Weiss, HB				Ellingson, Katherine D.; Leventhal, John M.; Weiss, Harold B.			Using hospital discharge data to track inflicted traumatic brain injury	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							INFANTS; SHAKE; BABY	Background: Inflicted traumatic brain injury (inflicted TBI) in infants has been the subject of recent preventive interventions, yet the burden of this problem is poorly defined. This article estimates the national incidence of hospitalizations due to inflicted TBI in infants aged <1 year using hospital discharge databases (HDDs) over 3 years, compares findings to previous infant inflicted TBI studies, and assesses differences in case composition and coding over time. Methods: The Kids' Inpatient Databases (KIDs) for 1997, 2000, and 2003 were used to estimate the incidence of inflicted TBI hospitalizations in infants. Cases were identified by the presence of ICD-9-CM codes indicating both TBI and abuse. Incidence estimates were generated by dividing the weighted number of inflicted TBI cases identified by the year-specific infant population. Changes over time were evaluated using Cochran-Armitage and ANOVA statistical tests. Results: The 1997, 2000, and 2003 KIDs yielded infant inflicted TBI incidence estimates of 27.5 (95% CI=20.8-34.0), 27.5 (95% 6=22.6-32.3), and 32.2 (95% CI=26.9-37.4) cases per 100,000 infants per year, respectively. KIDs estimates were within the range of previous inflicted TBI incidence studies that used active surveillance. Over time, the proportion of cases covered by Medicaid increased (p<0.0001). Conclusions: The KIDs call be used to generate incidence estimates of infant inflicted TBI hospitalizations that are consistent with previously published active surveillance estimates. HDDs call be used to assess the scope of infant inflicted TBI as well as trends in case composition and coding practices. Such assessments may be useful for the evaluation of prevention programs.	[Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Ellingson, Katherine D.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Weiss, Harold B.] Univ Pittsburgh, Ctr Injury Prevent & Control, Pittsburgh, PA USA	Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu	Weiss, Hank/D-1052-2010		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR323155] Funding Source: Medline		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; *COUNC STAT TERR I, 2005, STAT COLL US CAUS IN; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; *HCUP, KID DAT DOC; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Langlois JA, 2006, TRAUMATIC BRAIN INJU; *NAT CTR HLTH STAT, INT CLASS DIS 9 REV; SHOWERS J, 1992, CHILD ABUSE NEGLECT, V16, P11, DOI 10.1016/0145-2134(92)90004-B; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Thurman DJ., 1995, GUIDELINES SURVEILLA; *USDHHS, ICD9CM OFF GUID COD; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	18	68	68	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S157	S162		10.1016/j.amepre.2007.12.021			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300012	18374268				2021-06-18	
J	Yan, W; Wang, HD; Hu, ZG; Wang, QF; Yin, HX				Yan, Wei; Wang, Han-Dong; Hu, Zhi-Gang; Wang, Qing-Feng; Yin, Hong-Xia			Activation of Nrf2-ARE pathway in brain after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						nuclear factor E2-related factor 2; antioxidant response element; heme oxygenase-1; quinone oxidoreductase-1; traumatic brain injury	HEME OXYGENASE-1 HO-1; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; IN-VIVO; EXPRESSION; INDUCTION; PROTECTS; NEURONS; RAT; REDUCTASE	Secondary brain injury plays a pivotal role in the outcome of patients suffering from traumatic brain injury (TBI). The mechanisms underlying secondary brain injury are complex and interrelated. Previous studies focused on one of these mechanisms have been proved to be ineffective in clinical practice. Therefore, a target, which can interrupt multi-mechanisms underlying TBI, is desirable. Nrf2-ARE pathway has been proved to be the key regulator in reducing oxidative stress, inflammatory damage and accumulation of toxic metabolites, which are all involved in TBI. However, whether Nrf2-ARE pathway is activated after TBI has not been studied. In the present study, the nuclear Nrf2 protein level was detected by Western blot, and the mRNA levels of heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase-1 (NQO1), two Nrf2-regulated gene products, were determined using reverse-transcriptase polymerase chain reaction (RT-PCR) 24 It after TBI. Furthermore, we also localized the expression of Nrf2 and HO-I using immunohistochemical study. After TBI, the nuclear Nrf2 protein level was significantly increased, and the mRNA levels of both HO-1 and NQO1 were also up regulated. Moreover, both Nrf2 and HO-1 were localized in the same types of cells. According to these results, it could be postulated that Nrf2-ARE pathway was activated in brain after TBI. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Yan, Wei; Wang, Han-Dong; Hu, Zhi-Gang; Wang, Qing-Feng; Yin, Hong-Xia] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Jiangsu 210002, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Jiangsu 210002, Peoples R China.	hdwang-nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835			Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Ku BM, 2006, NEUROSCI LETT, V405, P168, DOI 10.1016/j.neulet.2006.06.052; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Le W, 1999, J NEUROSCI RES, V56, P652; Moreira TJTP, 2007, J CEREBR BLOOD F MET, V27, P1710, DOI 10.1038/sj.jcbfm.9600479; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018; van Muiswinkel FL, 2004, NEUROBIOL AGING, V25, P1253, DOI 10.1016/j.neurobiolaging.2003.12.010; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	28	68	71	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 31	2008	431	2					150	154		10.1016/j.neulet.2007.11.060			5	Neurosciences	Neurosciences & Neurology	266MK	WOS:000253439800011	18162315				2021-06-18	
J	Huijgen, BCH; Volienbroek-Hutten, MMR; Zampolini, M; Opisso, E; Bernabeu, M; Van Nieuwenhoven, J; Ilsbrouk, S; Magni, R; Giacomozzi, C; Marcellari, V; Marchese, SS; Hermens, HJ				Huijgen, Barbara C. H.; Volienbroek-Hutten, Miriam M. R.; Zampolini, Mauro; Opisso, Eloy; Bernabeu, Montse; Van Nieuwenhoven, Johan; Ilsbrouk, Stephan; Magni, Riccardo; Giacomozzi, Claudia; Marcellari, Velio; Marchese, Sandro Scattareggia; Hermens, Hermie J.			Feasibility of a home-based telerehabilitation system compared to usual care: arm/hand function in patients with stroke, traumatic brain injury and multiple sclerosis	JOURNAL OF TELEMEDICINE AND TELECARE			English	Article							RANDOMIZED CLINICAL-TRIAL; UPPER EXTREMITY; REHABILITATION; RECOVERY; ARM; PARESIS; PEOPLE	We conducted a randomized controlled multicentre trial to investigate the feasibility of a telerehabilitation intervention for arm/hand function (the Home Care Activity Desk [HCAD] training) in a home setting. Usual care was compared to HCAD training. The hypothesis was that the clinical outcomes of the HCAD intervention would be at least the same as those measured after a period of usual care for patients with stroke, traumatic brain injury (TBI) and multiple sclerosis (MS) with respect to their arm/hand function. Eighty-one patients with affected arm/hand function resulting from either stroke, MS or TBI were recruited in Italy, Spain and Belgium; 11 were lost during follow-up (14%). The outcome measures were the Action Research Arm Test (ARAT) and the Nine Hole Peg Test (NHPT). There were no significant differences between the two groups on the outcome measures (ARAT and NHPT); in both groups, patients maintained or even improved their arm/hand function. The HCAD training was found to be as feasible as usual care in terms of clinical outcomes, and both therapists and patients were satisfied with the HCAD intervention. A telerehabilitation intervention using HCAD may increase the efficiency of care.	[Huijgen, Barbara C. H.; Volienbroek-Hutten, Miriam M. R.; Hermens, Hermie J.] Roessingh Res & Dev BV, Enschede, Netherlands; [Zampolini, Mauro] Unita Organ Riabilitaz Intens Neuromotoria, ASL Umbria 3, Trevi, Italy; [Opisso, Eloy; Bernabeu, Montse] Inst Univ Neurorehabil, Inst Guttman, Badalona, Spain; [Van Nieuwenhoven, Johan; Ilsbrouk, Stephan] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium; [Magni, Riccardo] Pragma Engn, Perugia, Italy; [Giacomozzi, Claudia; Marcellari, Velio] Inst Super Sanita, Rome, Italy; [Marchese, Sandro Scattareggia] Signo Motus Srl Messina, Messina, Italy; [Hermens, Hermie J.] Univ Twente, Fac Elect Engn Math & Comp Sci, Enschede, Netherlands	Volienbroek-Hutten, MMR (corresponding author), Roessingh Res & Dev, Roessinghbleekweg 33B, NL-7522 AH Enschede, Netherlands.	m.vollenbroek@rrd.nl	Giacomozzi, Claudia/AAH-1640-2021; Zampolini, Mauro/B-7749-2009; Giacomozzi, Claudia/G-5018-2016	Giacomozzi, Claudia/0000-0001-6950-4934; Giacomozzi, Claudia/0000-0001-6950-4934; Vollenbroek-Hutten, Miriam/0000-0001-8730-1487	HELLODOC; European UnionEuropean Commission; UORIN; FPING; HCAD; Pragma Engineering	The work was part of the project 'HELLODOC' health service linking telerehabilitation to disabled people and clinicians supported by the European Union. We are grateful for the scientific contribution of MF Schifini and MF Spitali (UORIN) and S Tasies and E Prats (FPING) and the technical work on the HCAD apparatus from F Magnino (Pragma Engineering)	Broens THF, 2007, J TELEMED TELECARE, V13, P303, DOI 10.1258/135763307781644951; BRONFORT G, 1997, THESIS AMSTERDAM; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DeChant H K, 1996, Telemed J, V2, P303, DOI 10.1089/tmj.1.1996.2.303; DENNIS M, 1994, BMJ-BRIT MED J, V309, P1273, DOI 10.1136/bmj.309.6964.1273; Egner A, 2003, NEUROREHABILITATION, V18, P125; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Heinzelmann PJ, 2005, TELEMED J E-HEALTH, V11, P329, DOI 10.1089/tmj.2005.11.329; in't Veld MHAH, 2006, J TELEMED TELECARE, V12, P289, DOI 10.1258/135763306778558178; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kuttuva M, 2006, CYBERPSYCHOL BEHAV, V9, P148, DOI 10.1089/cpb.2006.9.148; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Legg L, 2007, BMJ-BRIT MED J, V335, P922, DOI 10.1136/bmj.39343.466863.55; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; Man DWK, 2006, NEUROREHABILITATION, V21, P205; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; Parker V M, 1986, Int Rehabil Med, V8, P69; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Scattareggia MS, 2004, INT J REHABIL RES, V27, P110; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Wade D T, 1989, Int Disabil Stud, V11, P89; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WAGENAAR RC, 1990, SCAND J REHABIL MED, V22, P1	24	68	70	0	25	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1357-633X	1758-1109		J TELEMED TELECARE	J. Telemed. Telecare		2008	14	5					249	256		10.1258/jtt.2008.080104			8	Health Care Sciences & Services	Health Care Sciences & Services	337TO	WOS:000258458600008	18633000				2021-06-18	
J	McCrea, M; Pliskin, N; Barth, J; Cox, D; Fink, J; French, L; Hammeke, T; Hess, D; Hopewell, A; Orme, D; Powell, M; Ruff, R; Schrock, B; Terryberryspohr, L; Vanderploeg, R; Yoash-Gantz, R				McCrea, Michael; Pliskin, Neil; Barth, Jeffrey; Cox, David; Fink, Joseph; French, Louis; Hammeke, Thomas; Hess, David; Hopewell, Alan; Orme, Daniel; Powell, Matthew; Ruff, Ron; Schrock, Barbara; Terryberryspohr, Lori; Vanderploeg, Rodney; Yoash-Gantz, Ruth			Official position of the military TBI task force on the role of neuropsychology and rehabilitation psychology in the evaluation, management, and research of military veterans with traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							MENTAL-HEALTH PROBLEMS; FOOTBALL PLAYERS; CONCUSSION; IRAQ; AFGHANISTAN; NEUROTRAUMA; RECOVERY	This Position Statement is a summary of the literature and learning regarding current issues raised by the occurrence, treatment, and study of traumatic brain injury in military service members and veterans. The Report has been approved by the American Academy of Clinical Neuropsychology (AACN), Divisions 40 (Neuropsychology) and 22 (Rehabilitation Psychology) of the American psychological Association (APA), and the National Academy of Neuropsychology (NAN), with the goal of providing information of relevance on an important public policy matter within their respective areas of expertise. The Report is not intended to establish guidelines or standards for the professional practice of psychology, nor has it been adopted as official policy by the American Psychological Association or any other division or subunit of APA.	[McCrea, Michael; Pliskin, Neil; Barth, Jeffrey; Cox, David; Fink, Joseph; French, Louis; Hammeke, Thomas; Hess, David; Hopewell, Alan; Orme, Daniel; Powell, Matthew; Ruff, Ron; Schrock, Barbara; Terryberryspohr, Lori; Vanderploeg, Rodney; Yoash-Gantz, Ruth] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.	Michael.mccrea@phci.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Barr WB, 2001, J ATHL TRAINING, V36, P297; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; *DVBIC, 2006, DEF VET BRAIN INJ CT; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Jennett B, 1981, MANAGEMENT HEAD INJU; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEADHAM CS, 1993, MIL MED, V158, P508; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea MA, 2007, MILD TRAUMATIC BRAIN; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; *NAT INJ PREV CONT, 2003, REP C MILD TRAUM BAR; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Randolph C, 2005, J ATHL TRAINING, V40, P139; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; World Health Organization, 1992, ICD 10 INT STAT CLAS; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZOROYA G, 2006, US TODAY        0808	34	68	69	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN	2008	22	1					10	26		10.1080/13854040701760981			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	258TF	WOS:000252891700002	18247218				2021-06-18	
J	Schlenk, F; Graetz, D; Nagel, A; Schmidt, M; Sarrafzadeh, AS				Schlenk, Florian; Graetz, Daniela; Nagel, Alexandra; Schmidt, Maren; Sarrafzadeh, Asita S.			Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage	CRITICAL CARE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; SUBSTRATE DELIVERY; HEAD-INJURY; BLOOD-FLOW; HYPERGLYCEMIA; METABOLISM; ISCHEMIA; THERAPY	Introduction Hyperglycaemia following aneurysmal subarachnoid hemorrhage ( SAH) is associated with complications and impaired neurological recovery. The aim of this study was to determine the effect of insulin treatment for glucose control on cerebral metabolism in SAH patients. Methods This prospective, nonrandomized study was conducted in 31 SAH patients in an intensive care unit ( age 52 +/- 10 years, World Federation of Neurological Surgeons grade 2.9 +/- 1.6). A microdialysis catheter was inserted into the vascular territory of the aneurysm after clipping. Blood glucose levels above 140 mg/ dl were treated with intravenous insulin and the microdialysates were analyzed hourly for the first 12 hours of infusion. Results No hypoglycaemia occurred. Twenty-four patients were treated with insulin for glucose control. Higher age and World Federation of Neurological Surgeons score were risk factors for need for insulin treatment ( P < 0.05). Although blood glucose remained stable after initiation of insulin infusion, insulin induced a significant decrease in cerebral glucose at 3 hours after onset of the infusion until the end of the observation period ( P < 0.05), reflecting high glucose utilization. The lactate: pyruvate ratio and glutamate did not increase, excluding ischaemia as possible cause of the decrease in glucose. Glycerol tended toward higher values at the end of the observation period ( 9 to 12 hours), reflecting either tissue damage after SAH or the beginning of cellular distress after insulin infusion. Conclusion Higher SAH grade was among the risk factors for need for insulin. Intensive glycaemic control using insulin induced a decrease of cerebral glucose and a slight increase in glycerol, though blood glucose remained normal. Future studies might detect relevant metabolic derangements when insulin treatment starts at low cerebral glucose levels, and may allow us to design a strategy for avoidance of insulin-induced metabolic crisis in SAH patients.	[Schlenk, Florian; Graetz, Daniela; Nagel, Alexandra; Sarrafzadeh, Asita S.] Charite Campus Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany; [Schmidt, Maren] Charite Campus Virchow Med Ctr, Dept Anaesthesiol & Intens Care Med, D-13353 Berlin, Germany	Sarrafzadeh, AS (corresponding author), Charite Campus Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de		Schmidt, Maren/0000-0002-7821-9577			Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Cranston I, 1998, J CEREBR BLOOD F MET, V18, P130, DOI 10.1097/00004647-199802000-00002; DRAKE CG, 1988, J NEUROSURG, V68, P985; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; SCHLENK F, 2008, IN PRESS INTENSIVE C; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	21	68	69	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	1							R9	10.1186/cc6776			7	Critical Care Medicine	General & Internal Medicine	285YQ	WOS:000254812500049	18218076	DOAJ Gold, Green Published			2021-06-18	
J	Fitzpatrick, W; Lowry, N				Fitzpatrick, W.; Lowry, N.			PLEDS: Clinical correlates	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							LATERALIZED EPILEPTIFORM DISCHARGES; CRITICALLY-ILL; METABOLIC ABNORMALITIES; NONCONVULSIVE SEIZURES; STRUCTURAL LESIONS; EEG PATTERNS; CHILDREN; ASSOCIATION; EVOLUTION; ETIOLOGY	Objective: We reviewed our experience in 96 consecutive patients exhibiting periodic lateralized epileptiform discharges (PLEDs) on EEG. Methods: EEG reports from January 1, 1999 to September 30, 2006 were screened for the term 'PLEDs' and its variants. A retrospective chart review, including examination of neuroimaging and other investigations, was conducted on each patient identified. Results: Acute stroke, tumor and central nervous system infection were the most common etiologies, accounting for 26%, 12% and 12% of cases respectively. Acute hemorrhage and traumatic brain injury combined accounted for another 12%. Previously unreported etiologies included posterior reversible encephalopathy syndrome (PRES), familial hemiplegic migraine and cerebral amyloiclosis. There were 9 cases of chronic PLEDs attributable to underlying cortical dysplasia or severe remote cerebral injury, all with an accompanying partial seizure disorder. A prominent role for alcohol withdrawal was noted, and in 6 cases was the sole etiological factor. Fever was present as a potential contributing factor in 40% of cases, and significant metabolic abnormalities in 35%. Seizure activity occurred in 85% of patients overall., but in 100% of patients with PLEDs Plus and BiPLEDs Plus. The overall mortality rate was 27%. Mortality among patients with BiPLEDs however was almost twice that, at 52%. Conclusions: This case series demonstrates the wide variety of potential PLED etiologies. It also emphasizes that despite advances in neurocritical care, the morbidity and mortality associated with PLEDs has changed little since their recognition four decades ago.	Univ Saskatchewan, Dept Med, Div Neurol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Pediat Neurol, Saskatoon, SK, Canada	Fitzpatrick, W (corresponding author), 106 Brookdale Crescent, Saskatoon, SK S7V 1K5, Canada.						Assal F, 2001, SEIZURE-EUR J EPILEP, V10, P260, DOI 10.1053/seiz.2000.0506; Baykan B, 2000, SEIZURE-EUR J EPILEP, V9, P402, DOI 10.1053/seiz.2000.0435; Beaumanoir A, 1996, ELECTROEN CLIN NEURO, V99, P287; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V17, P177, DOI 10.1016/0013-4694(64)90149-X; Chen KS, 2003, PEDIATR NEUROL, V28, P100, DOI 10.1016/S0887-8994(02)00493-9; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; CHU NS, 1980, ARCH NEUROL-CHICAGO, V37, P551, DOI 10.1001/archneur.1980.00500580047006; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DAUBEN RD, 1977, CLIN ELECTROENCEPHAL, V8, P116, DOI 10.1177/155005947700800302; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; DRURY I, 1985, NEUROLOGY, V35, P911, DOI 10.1212/WNL.35.6.911; Ebersole J, 2003, CURRENT PRACTICE CLI, P506; Garcia-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009; GARG BP, 1995, PEDIATR NEUROL, V12, P225, DOI 10.1016/0887-8994(95)00020-G; Gross DW, 1999, CLIN NEUROPHYSIOL, V110, P1516, DOI 10.1016/S1388-2457(99)00119-4; Gurer G, 2004, CLIN EEG NEUROSCI, V35, P88, DOI 10.1177/155005940403500207; HAMANO K, 1994, PEDIATR NEUROL, V11, P28, DOI 10.1016/0887-8994(94)90086-8; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; KUROIWA Y, 1980, ARCH NEUROL-CHICAGO, V37, P15, DOI 10.1001/archneur.1980.00500500045005; Lawn ND, 2000, CLIN NEUROPHYSIOL, V111, P2125, DOI 10.1016/S1388-2457(00)00466-1; LESSER RP, 1985, EPILEPSIA, V26, P622, DOI 10.1111/j.1528-1157.1985.tb05702.x; MARKAND ON, 1971, NEUROLOGY, V21, P975, DOI 10.1212/WNL.21.10.975; Neufeld MY, 1997, ELECTROEN CLIN NEURO, V102, P295, DOI 10.1016/S0013-4694(96)95726-0; PEBENITO R, 1979, ANN NEUROL, V6, P47, DOI 10.1002/ana.410060111; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; RAROQUE HG, 1993, EPILEPSIA, V34, P279, DOI 10.1111/j.1528-1157.1993.tb02411.x; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; SCHRAEDER PL, 1980, EPILEPSIA, V21, P647, DOI 10.1111/j.1528-1157.1980.tb04318.x; SCHWARTZ MS, 1973, BRAIN, V96, P613, DOI 10.1093/brain/96.3.613; SINGH BM, 1980, ANN NEUROL, V8, P155, DOI 10.1002/ana.410080205; SNODGRASS SM, 1989, J CLIN NEUROPHYSIOL, V6, P159, DOI 10.1097/00004691-198904000-00003; Striano S, 1986, Acta Neurol (Napoli), V8, P1; TERZANO MG, 1986, EPILEPSIA, V27, P446, DOI 10.1111/j.1528-1157.1986.tb03566.x; WALSH JM, 1987, EPILEPSIA, V28, P533, DOI 10.1111/j.1528-1157.1987.tb03684.x; WESTMORELAND BF, 1986, ARCH NEUROL-CHICAGO, V43, P494, DOI 10.1001/archneur.1986.00520050066024; Young G, 1988, AM J EEG TECHNOL, V28, P1; Young GB, 1996, NEUROLOGY, V47, P83	38	68	72	0	4	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	NOV	2007	34	4					443	450		10.1017/S0317167100007332			8	Clinical Neurology	Neurosciences & Neurology	233YO	WOS:000251126400009	18062453	Bronze			2021-06-18	
J	Fazekas, G; Horvath, M; Troznai, T; Toth, A				Fazekas, Gabor; Horvath, Monika; Troznai, Tibor; Toth, Andras			Robot-mediated upper limb physiotherapy for patients with spastic hemiparesis: A preliminary study	JOURNAL OF REHABILITATION MEDICINE			English	Article						spasticity; hemiparesis; robotics; stroke; traumatic brain injury	THERAPY	Objective: To investigate the clinical usefulness of the REHAROB Therapeutic System, which provides passive robot-mediated physiotherapy for patients with spastic hemiparesis. Design: Controlled, randomized, preliminary study. Patients and methods: Thirty patients with hemiparesis as a consequence of upper motor neurone lesion were divided randomly into 2 groups: robotic and control. Subjects from both groups received 30 minutes of Bobath therapy sessions on 20 consecutive work days. Members of the robotic group received an additional 30 minutes of robot-mediated therapy on the same days. The clinical status of each patient was assessed before the first session and at the end of the programme. The difference in the scores was statistically evaluated by t-test for dependent variables in case of parametric data and Friedman's test in case of non-parametric data. Results: The majority of the parameters measured improved in both groups, but modified Ashworth score of shoulder adductors and elbow flexors showed a statistically significant change only in the robotic group. Conclusion: The results suggest that it could be useful to supplement traditional physiotherapy with this form of robotmediated therapy. Clinical investigation of a higher number of patients is planned in the near future.	Natl Inst Med Rehabil, H-1528 Budapest, Hungary; Budapest Univ Technol & Econ, Natl Inst Med Rehabil, Budapest, Hungary; Budapest Univ Technol & Econ, Szent Janos Hosp, Budapest, Hungary	Fazekas, G (corresponding author), Natl Inst Med Rehabil, Szanatorium Str 19th, H-1528 Budapest, Hungary.	fazekas123@t-online.hu					BOBATH B, 1990, ADULT HEMIPLEGIA EVA, P13; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; COOTE S, 2003, TECHNOL DISABIL, P27; Fasoli SE, 2004, ARCH PHYS MED REHAB, V85, P1106, DOI 10.1016/j.apmr.2003.11.028; Fazekas G, 2006, INT J REHABIL RES, V29, P251, DOI 10.1097/01.mrr.0000230050.16604.d9; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; FUGLMEYER AR, 1980, SCAND J REHABIL MED, P85; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hidler Joseph, 2005, Top Stroke Rehabil, V12, P22, DOI 10.1310/RYT5-62N4-CTVX-8JTE; Lum Peter, 2002, Top Stroke Rehabil, V8, P40; Lum PS, 2002, ARCH PHYS MED REHAB, V83, P952, DOI 10.1053/apmr.2001.33101; Toth A, 2005, INT C REHAB ROBOT, P127; Toth A, 2004, LECT NOTES CONTR INF, V306, P391	13	68	68	4	17	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2007	39	7					580	582		10.2340/16501977-0087			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	213IS	WOS:000249660700012	17724559	DOAJ Gold			2021-06-18	
J	Ichord, RN; Naim, M; Pollock, AN; Nance, ML; Margulies, SS; Christian, CW				Ichord, Rebecca N.; Naim, Maryam; Pollock, Avrum N.; Nance, Michael L.; Margulies, Susan S.; Christian, Cindy W.			Hypoxic-ischemic injury complicates inflicted and accidental traumatic brain injury in young children: The role of diffusion-weighted imaging	JOURNAL OF NEUROTRAUMA			English	Article						infants; inflicted trauma; MRI; traumatic brain injury	HEAD-INJURY; APNEA; NEUROPATHOLOGY; ASSOCIATION; MECHANISMS; PATTERNS; INFANTS	We evaluated the relationship between clinical features and hypoxic-ischemic injury (HII) shown by diffusion-weighted MRI (DWI) in young children with head trauma, comparing inflicted trauma (IT) to accidental trauma (AT). This single-center consecutive cohort study included children age birth to 36 months admitted for head injury July 2001 to December 2004 with brain magnetic resonance imaging (MRI) obtained :5 1 week, identified from prospectively maintained registries of children with trauma. Clinical and radiological data during the hospital stay were extracted from medical records. MRIs were analyzed by study examiners blinded to clinical status and scored by type, severity and location of lesions attributable to traumatic, hypoxic-ischemic, or mixed injury patterns. 30 IT patients and 22 AT patients met inclusion criteria. IT cases were younger than AT, 3.0 versus 8.5 months. Mean time to MRI in IT (2.1 days) was similar to AT (1.9 days). HII was more common in IT (11 of 30) than AT (2/22, p = 0.03). Children with HII more commonly had seizures, needed intubation at presentation, and needed neurosurgical intervention compared to those without HII. Most patients with HII (10/14) required in-patient rehabilitation compared to those without HII (4/38). Our study is the first to characterize HII using diffusion-weighted MRI in young children, comparing IT and AT. The higher rate of HII on DWI-MRI in IT than in AT is likely multifactorial, involving respiratory insufficiency, seizures, and intracranial mass-occupying lesions requiring neurosurgical intervention. HII predicted need for in-patient rehabilitation in a large majority of children.	Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Ichord, RN (corresponding author), Childrens Hosp Philadelphia, Dept Neurol, Wood 6th Fl,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ichord@email.chop.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39679] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KAUFMANN CR, 1990, JAMA-J AM MED ASSOC, V263, P69, DOI 10.1001/jama.263.1.69; KELLAWAY P, 1990, NEONATAL SEIZURES, P1; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Miller SP, 2002, NEUROLOGY, V58, P542, DOI 10.1212/WNL.58.4.542; Phillips MD, 1999, NEUROIMAG CLIN N AM, V9, P41; Shannon P, 2001, LANCET, V358, P686, DOI 10.1016/S0140-6736(01)05849-4; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011	28	68	70	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					106	118		10.1089/neu.2006.0087			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100010	17263674				2021-06-18	
J	Isele, NB; Lee, HS; Landshamer, S; Straube, A; Padovan, CS; Plesnila, N; Culmsee, C				Isele, Nicola B.; Lee, Hea-Sook; Landshamer, Stefan; Straube, Andreas; Padovan, Claudio S.; Plesnila, Nikolaus; Culmsee, Carsten			Bone marrow stromal cells mediate protection through stimulation of PI3-K/Akt and MAPK signaling in neurons	NEUROCHEMISTRY INTERNATIONAL			English	Article						apoptosis; neuroprotection; conditioned medium; staurosporine; amyloid-beta; growth factors	GROWTH-FACTOR PRODUCTION; TRAUMATIC BRAIN-INJURY; FACTOR-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL RECOVERY; REGULATED KINASE; PROTEIN-KINASE; SPINAL-CORD; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION	Application of adult bone marrow stromal cells (BMSC) improves functional outcome in animal models of cerebral ischemia, traumatic brain injury, and spinal cord injury. Accumulating evidence suggests that such functional recovery after BMSC treatment is mediated by enhanced trophic support of the injured neurons and improved neuronal plasticity rather than tissue replacement by bone marrow-derived stem cells. Therefore, the aim of the present study was to explore the potential of non-hematopoietic BMSC to stimulate signaling pathways in neurons that mediate trophic effects and neuroprotection. In primary embryonic rat neurons, BMSC conditioned medium (CM) attenuated staurosporine (STS) or amyloid-beta peptide-induced apoptosis in a concentration-dependent manner. The neuroprotective effect of CM required several hours of pretreatment and was abolished by heating over 90 degrees C. Immunoblot analyses revealed that CM enhanced Erk1/2 and Akt phosphorylation in neurons, and the specific MEK1 inhibitor PD98059 or the phosphomositide-3 kinase (PI3-K) inhibitor Ly294002 abolished the neuroprotective effect of CM. Further, double-conditioned medium (DCM) obtained from BMSC previously stimulated by medium from STS-challenged neurons showed a more potent anti-apoptotic effect compared to the single-conditioned medium. Overall, these findings demonstrate that BMSC trigger endogenous survival signaling pathways in neurons that mediate protection against apoptotic insults. Moreover, the interaction between stressed neurons and BMSC further amplifies the observed neuroprotective effect. (c) 2006 Elsevier Ltd. All rights reserved.	Dept Pharm, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany; Univ Munich, Med Ctr, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Inst Surg Res, D-81377 Munich, Germany	Culmsee, C (corresponding author), Dept Pharm, D-81377 Munich, Germany.	carsten.culmsee@cup.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019	Culmsee, Carsten/0000-0002-5121-5015			Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson CNG, 1999, J NEUROSCI, V19, P664; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Culmsee C, 2005, MOL PHARMACOL, V68, P1006, DOI 10.1124/mol.105.013086; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.t01-1-00220.x; Culmsee C., 2005, DRUG DISCOV TODAY, V2, P463, DOI DOI 10.1016/J.DDMEC.2005.11.006; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; TOCCI A, 2003, HEMATOL J, V2, P92; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002	42	68	100	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	JAN	2007	50	1					243	250		10.1016/j.neuint.2006.08.007			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	128GA	WOS:000243645000028	17050038				2021-06-18	
J	Iverson, G				Iverson, Grant			Predicting slow recovery from sport-related concussion: The new simple-complex distinction	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild traumatic brain injury; neuropsychological testing; classification	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TESTING USEFUL; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; CONSTRUCT-VALIDITY; MANAGEMENT; IMPACT; PERFORMANCE; STATEMENT	Objective: Following the Second International Conference on Concussion in Sport in 2005, a summary agreement statement was published that introduced new terminology for sport-related concussions. This new classification system is binary (ie, "simple" versus "complex" concussions). Athletes who are slow to recover (ie, >10 days) are classified as having complex concussions. The purpose of this study was to determine if high school football players, retrospectively classified as having a simple or a complex concussion, could be differentiated in the first 48 after injury on the basis of symptom reporting or neuropsychological testing. Design: Case-control study. Setting: Pennsylvania high school football programs. Participants: The total sample consisted of 114 concussed high school football players who were identified through a 3 year prospective cohort study. Interventions: All completed a computerized neuropsychological screening evaluation within 72 hours of injury. They were followed clinically until they recovered and were cleared to return to play. They were classified retrospectively as having a simple (n = 55) or complex (n = 59) concussion based on their recovery times. Main Outcome Measurements: Neurocognitive test performance and symptom ratings. Results: Within 72 hours after injury, athletes with complex concussions performed more poorly on neuropsychological testing and reported more symptoms than those with simple concussions. Athletes with complex concussions who were slow to recover were 18 times more likely to have 3 unusually low neuropsychological test scores than those with simple concussions (95% CI = 2.3-144.9). Athletes with previous concussions did not recover more slowly. Conclusions: This study provides evidence that supports and refutes the clinical usefulness of the new simple-complex concussion classification system.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada	Iverson, G (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins M. W., 2007, BRAIN INJURY MED PRI, P407; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; IVERSON GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Janusz A, 2004, BRIT J SPORT MED, V38, P659; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2006, IN PRESS APPL NEUROP; Macciocchi SN, 2005, J ATHL TRAINING, V40, P152; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2006, J ATHL TRAINING, V41, P138; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	60	68	69	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2007	17	1					31	37					7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	128QL	WOS:000243673000006	17304003				2021-06-18	
J	Ownsworth, T; Fleming, J; Strong, J; Radel, M; Chan, W; Clare, L				Ownsworth, Tamara; Fleming, Jenny; Strong, Jenny; Radel, Michael; Chan, Wilbur; Clare, Linda			Awareness typologies, long-term emotional adjustment and psychosocial outcomes following acquired brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD INJURY; SELF-AWARENESS; IMPAIRED AWARENESS; EXECUTIVE FUNCTION; DEFICITS; REHABILITATION; ANOSOGNOSIA; UNAWARENESS; SCALE; QUESTIONNAIRE	Previous research suggests considerable heterogeneity within groups of individuals identified as having low self-awareness or good self-awareness following acquired brain injury (ABI). The present study aimed to identify typologies of individuals according to neuropsychological and psychological factors related to awareness deficits and compare emotional adjustment and psychosocial outcomes at the initial assessment and 12-month follow-up. Eighty-four participants with ABI (mean time since injury 3.9 years) were assessed on the Self-Awareness of Deficits Interview, Awareness Questionnaire, Symptom Expectancy Checklist, Marlowe-Crowne Social Desirability Scale, Hospital Anxiety Depression Scale, Sydney Psychosocial Reintegration Scale, and an error self-regulation index. A 12-month follow-up assessment of emotional adjustment and psychosocial outcomes was conducted. A hierarchical cluster analysis distinguished four awareness typologies, namely, "poor self-awareness" (n = 12), "high defensiveness" (n = 13), "high symptom reporting" (n = 15), and "good self-awareness" (n = 44). An overall comparison of outcomes indicated that the poor self-awareness and high symptom reporting typologies experienced poorer outcomes than the high defensiveness and good self-awareness typologies. The findings confirm that there are different awareness typologies and highlight the need to tailor interventions according to the nature of awareness deficits.	Univ Queensland, Div Occupat Therapy, Brisbane, Qld, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; Prince Charles Hosp, Rehabil Day Hosp, Div Geriatr & Rehabil Med, Brisbane, Qld 4032, Australia; Univ Wales, Sch Psychol, Bangor, Gwynedd, Wales	Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Strong, Jenny/0000-0002-9367-8755; Ownsworth, Tamara/0000-0003-1835-7094; Clare, Linda/0000-0003-3989-5318			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GAINOTTI G, 1993, EUROPSYCHOLOGICAL RE, V3, P259; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HAIR JF, 1992, MULTIVARIATE DATA AN; Hartman-Maeir A, 2002, J REHABIL MED, V34, P158, DOI 10.1080/16501970213236; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Katz Noomi, 2002, Can J Occup Ther, V69, P281; KEPPEL G, 1991, DESIGN ANAL; Kolb B., 1990, FUNDAMENTALS HUMAN N; LANE RD, 1990, AM J PSYCHIAT, V147, P573; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loeb P. A., 1996, INDEPENDENT LIVING S; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; OWNSWORTH TL, IN PRESS NEUROPSYCHO; OWNSWORTH TL, IN PRESS REHABILITAT; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tabachnick B., 2001, USING MULTIVARIATE S; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; TUPPER DE, 1989, ANN M NOV NAT AC NEU; Vuilleumier P, 2004, CORTEX, V40, P9, DOI 10.1016/S0010-9452(08)70918-3; Wilson BA, 1996, BEHAV ASSESSMENT DYS	56	68	68	0	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	2					129	150		10.1080/09602010600615506			22	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IP	WOS:000246298400001	17454690				2021-06-18	
J	Bailey, CM; Echemendia, RJ; Arnett, PA				Bailey, Christopher M.; Echemendia, Ruben J.; Arnett, Peter A.			The impact of motivation on neuropsychological performance in sports-related mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; closed head injury; athletics; psychological tests; psychometrics; incentive	CONCUSSION	The current project examined the impact of differential motivation on baseline versus post-mild traumatic brain injury (MTBI) neuropsychological measures in athletes. Collegiate athletes were administered a neuropsychological battery prior to and post-MTBI. High Motivation at Baseline (HMB) and Suspect Motivation at Baseline (SMB) groups were established for each measure based on whether baseline performance fell +/- one or more standard deviations from the mean of the given measure. Greater improvement was expected in the SMB group than the HMB group given hypothesized differences in baseline motivation. In repeated measures analysis of covariance (ANCOVA) that removed achievement performance, the SMB groups demonstrated greater improvement than the HMB groups for the Trail Making Test A & B (TMT-A & B), Digit Span, and Stroop-Color Word (Stroop-CW) tests. Also, the percentage of participants who improved according to reliable change indices was greater for the SMB groups on the TMT-A & B, Stroop-CW, and the Vigil. These findings are likely due to lower motivation in the SMB group for each test. However, results also suggest that some tests may be relatively unaffected by motivation. These data may have clinical implications and point to the need for better methods of identifying athletes with suspect motivation at baseline.	Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; Psychol & Neurobehav Associates, State Coll, PA USA	Bailey, CM (corresponding author), Penn State Univ, Dept Psychol, 314 Moore Bldg, University Pk, PA 16802 USA.	cmb373@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anastasi A, 1997, PSYCHOL TESTING, V7th; Barth JT., 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER RL, 1991, AM J PSYCHIAT, V148, P1073; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Levine AJ, 2004, CLIN NEUROPSYCHOL, V18, P373, DOI 10.1080/1385404049052420; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SCHUNK DH, 1995, J APPL SPORT PSYCHOL, V7, P112, DOI 10.1080/10413209508406961; Smith A., 1982, SYMBOL DIGIT MODALIT; SPEER DC, 1995, J CONSULT CLIN PSYCH, V63, P1044, DOI 10.1037/0022-006X.63.6.1044; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Spreen O., 1991, COMPENDIUM NEUROPSYC; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wechsler D, 1997, WAIS 3 ADM SCORING M	36	68	68	1	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2006	12	4					475	484		10.1017/S1355617706060619			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	063DU	WOS:000238997300004	16981599				2021-06-18	
J	Liu-Snyder, P; McNally, H; Shi, R; Ben Borgens, R				Liu-Snyder, Peishan; McNally, Helen; Shi, Riyi; Ben Borgens, Richard			Acrolein-mediated mechanisms of neuronal death	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acrolein; endogenous toxin; secondary injury; neurotrauma; lipid peroxidation	SPINAL-CORD-INJURY; AXONAL MEMBRANE DISRUPTION; CONTROLLED TRIAL; CONDUCTION LOSS; METHYLPREDNISOLONE; CHEMISTRY; NALOXONE	It is well known that traumatic injury in the central nervous system can be viewed as a primary injury and a secondary injury. Increases in oxidative stress lead to breakdown of membrane lipids (lipid peroxidation) during secondary injury. Acrolein, an alpha, beta-unsaturated aldehyde, together with other aldehydes, increases as a result of self-propagating lipid peroxidation. Historically, most research on the pathology of secondary injury has focused on reactive oxygen species (ROS) rather than lipid peroxidation products. Little is known about the toxicology and cell death mediated by these aldehydes. In this study, we investigated and characterized certain features of cell death induced by acrolein on PC12 cells as well as cells from dorsal root ganglion (DRG) and sympathetic ganglion in vitro. In the companion paper, we evaluated a possible means to interfere with this toxicity by application of a compound that can bind to and inactivate acrolein. Here we use both light and atomic force microscopy to study cell morphology after exposure to acrolein. Administration of 100 M acrolein caused a dramatic change in cell morphology as early as 4 hr. Cytoskeletal structures significantly deteriorated after exposure to 100 mu M acrolein as demonstrated by fluorescence microscopy, whereas calpain activity increased significantly at this concentration. Cell viability assays indicated significant cell death with 100 mu M acrolein by 4 hr. Caspase 3 activity and DNA fragmentation assays were performed and supported the notion that 100 mu M acrolein induced PC12 cell death by the mechanism of necrosis, not apoptosis. (c) 2006 Wiley-Liss, Inc.	Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, Sch Vet Med, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Ben Borgens, R (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, Sch Vet Med, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					BORGENS RB, 2003, ADV ANATOMY EMBRYOLO; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRONK SF, 1993, AM J PHYSIOL, V264, P744; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; HALLED, 1993, ADV NEUROL, V59, P241; Higgins D., 1998, CULTURING NERVE CELL, P37; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; SMITH CL, 1998, CULTURING NERVE CELL, P261	21	68	69	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2006	84	1					209	218		10.1002/jnr.20863			10	Neurosciences	Neurosciences & Neurology	061UD	WOS:000238897400019	16619238				2021-06-18	
J	Ronne-Engstrom, E; Winkler, T				Ronne-Engstrom, E.; Winkler, T.			Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity	ACTA NEUROLOGICA SCANDINAVICA			English	Article						EEG; neurointensive care; seizures; traumatic brain injury	SEIZURES	Background - EEG is the only available method for real time monitoring of the brain and is therefore of great interest in the neurointensive care. The present study describes our experiences from implying continuous EEG monitoring as a routine method. We also present EEG patterns observed on patients with traumatic brain injury (TBI). Methods - Seventy TBI patients requiring neurointensive care were included. Digital EEG was recorded continuously. Five minutes every hour were analysed off-line. Results - Twenty-three patients (33%) developed seizures, 74 +/- 47 h after trauma. The seizures were brief, responding to phenytoin, or persistent, requiring propofol or barbiturate sedation. Six out of eight patients with persistent seizures had intracerebral contusions. Eighteen patients (26%) displayed focal high frequency activity that proceeded to seizures in eight cases. Twelve patients (17%) developed recurrent paroxysmal delta activity. The patients in the seizure group were significantly older (62 +/- 12 vs. 28 +/- 17 years) and more often exposed to low energy trauma (87% vs 22%) compared to the paroxysmal delta pattern group. Conclusion - TBI implies high risk for development of epileptiform activity, with a time lag between trauma and seizure onset. TBI patients also displayed other EEG pattern that should be investigated further in order to obtain a better understanding of posttraumatic mechanisms.	Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Neurophysiol, Div Neurosci, S-75185 Uppsala, Sweden	Ronne-Engstrom, E (corresponding author), Univ Uppsala Hosp, Dept Neurosurg & Neurosci, S-75185 Uppsala, Sweden.	elisabeth.ronne.engstrom@akademiska.se					Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Beaumanoir A, 1996, ELECTROEN CLIN NEURO, V99, P287; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TRIGGS WJ, 1990, NEUROSCI LETT, V180, P84; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Westmoreland BF, 2001, J CLIN NEUROPHYSIOL, V18, P20, DOI 10.1097/00004691-200101000-00005; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408	12	68	72	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	2006	114	1					47	53		10.1111/j.1600-0404.2006.00652.x			7	Clinical Neurology	Neurosciences & Neurology	050DC	WOS:000238066700009	16774627				2021-06-18	
J	Stalnacke, BM; Ohlsson, A; Tegner, Y; Sojka, P				Stalnacke, BM; Ohlsson, A; Tegner, Y; Sojka, P			Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROTEIN FAMILY; S100B PROTEIN; INJURY; CONCUSSIONS; EXERCISE; HISTORY; LEAD	Background: It is a matter of debate whether or not ordinary heading of the ball in soccer causes injury to brain tissue. Objective: To analyse concentrations of the biochemical markers of brain tissue damage S-100B and neurone specific enolase (NSE) in serum of female elite soccer players in association with a competitive game. Methods: Venous blood samples were obtained from 44 female soccer players before and after a competitive game for analysis. The number of headers and trauma events (falls, collisions, etc) was assessed from videotape recordings for each player. Results: Concentrations of both brain damage markers were increased after the game (S-100B, 0.18 (0.11) v 0.11 (0.05) mg/l (p = 0.000); NSE, 10.14 (1.74) v 9.05 (1.59) mg/l (p = 0.001)). There was a significant correlation between changes in S-100B concentrations and both the number of headers (r = 0.430, p = 0.004) and the number of other trauma events (r = 0.517, p < 0.001). Conclusion: The concentrations of both S-100B and NSE were increased by game associated activities and events. The increases in S-100B concentration were significantly related to the number of headers and other trauma events, which indicates that both these factors may have contributed to these increases.	Umea Univ, Dept Community Med & Rehabil Med, S-90185 Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci Sports Med, S-90185 Umea, Sweden; Lulea Tech Univ, Dept Hlth Sci, Baden, Sweden	Stalnacke, BM (corresponding author), Umea Univ, Dept Community Med & Rehabil Med, S-90185 Umea, Sweden.	brittmarie.stalhacke@rehabmed.umu.se		Tegner, Yelverton/0000-0003-3628-0705			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Covassin T, 2003, J ATHL TRAINING, V38, P238; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Ekstrand J, 1990, Br J Sports Med, V24, P117; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Mandelbaum BR, 1999, SCI SPORT, V14, P254, DOI 10.1016/S0765-1597(00)88245-3; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mussack T, 2003, EUR J MED RES, V8, P457; *NAT COLL ATHL ASS, 2000, INJ SURV SYST AC YEA; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Scaccianoce S, 2004, BRAIN RES, V1004, P208, DOI 10.1016/j.brainres.2004.01.028; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	33	68	69	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2006	40	4					313	316		10.1136/bjsm.2005.021584			4	Sport Sciences	Sport Sciences	024VI	WOS:000236224000007	16556784	Green Published			2021-06-18	
J	Hill, AJ; Theodoros, DG; Russell, TG; Cahill, LM; Ward, EC; Clark, KM				Hill, AJ; Theodoros, DG; Russell, TG; Cahill, LM; Ward, EC; Clark, KM			An Internet-based telerehabilitation system for the assessment of motor speech disorders: A pilot study	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						telepractice; rehabilitation; assessment; speech disorders	CLOSED-HEAD-INJURY; RELIABILITY; TELEHEALTH; HYPERNASALITY; AGREEMENT; RATINGS	Purpose: This pilot study explored the feasibility and effectiveness of an Internet-based telerehabilitation application for the assessment of motor speech disorders in adults with acquired neurological impairment. Method: Using a counterbalanced, repeated measures research design, 2 speech-language pathologists assessed 19 speakers with dysarthria on a battery of perceptual assessments. The assessments included a 19-item version of the Frenchay Dysarthria Assessment (FDA; P. Enderby, 1983), the Assessment of Intelligibility of Dysarthric Speech (K. M. Yorkston & D. R. Beukelman, 1981), perceptual analysis of a speech sample, and an overall rating of severity of the dysarthria. One assessment was conducted in the traditional face-to-face manner, whereas the other assessment was conducted using an online, custom-built telerehabilitation application. This application enabled real-time videoconferencing at 128 kb/s and the transfer of store-and-forward audio and video data between the speaker and speech-language pathologist sites. The assessment methods were compared using the J.M.Bland and D.G.Altman (1986, 1999) limits-of-agreement method and percentage level of agreement between the 2 methods. Results: Measurements of severity of dysarthria, percentage intelligibility in sentences, and most perceptual ratings made in the telerehabilitation environment were found to fall within the clinically acceptable criteria. However, several ratings on the FDA were not comparable between the environments, and explanations for these results were explored. Conclusions: The online assessment of motor speech disorders using an Internet-based telerehabilitation system is feasible. This study suggests that with additional refinement of the technology and assessment protocols, reliable assessment of motor speech disorders over the Internet is possible. Future research methods are outlined.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Hill, AJ (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	a.hill@shrs.uq.edu.au	Russell, Trevor/AAS-2590-2020; Theodoros, Deborah/F-1362-2010; Russell, Trevor/F-6888-2010; Hill, Anne/F-4106-2010; Ward, Elizabeth/F-9652-2010; Cahill, Louise/C-7919-2012	Russell, Trevor/0000-0002-9732-6167; Russell, Trevor/0000-0002-9732-6167; Hill, Anne/0000-0003-3907-8369; Ward, Elizabeth/0000-0002-2680-8978; Cahill, Louise/0000-0003-3662-896X			*AUSTR BUR STAT, 2004, MEAS KNOWL BAS EC SO; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Chenery H., 1998, DYSARTHRIA PHYSL APP, P36; Darley F., 1975, MOTOR SPEECH DISORDE; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Duffy JR, 2019, MOTOR SPEECH DISORDE; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; Farrell A, 2005, J SPEECH LANG HEAR R, V48, P5, DOI 10.1044/1092-4388(2005/002); HAYES JM, 2003, MICROSOFT NETMEETING; Hill A, 2002, J TELEMED TELECARE, V8, P187, DOI 10.1258/135763302320272158; KARNELL MP, 1995, CLEFT PALATE-CRAN J, V32, P145, DOI 10.1597/1545-1569(1995)032<0145:NDOHAT>2.3.CO;2; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KREIMAN J, 1993, J SPEECH HEAR RES, V36, P21, DOI 10.1044/jshr.3601.21; LLOYD R, 2004, AUSTR ONLINE AUSTR A; Loh PK, 2004, INTERN MED J, V34, P239, DOI 10.1111/j.1444-0903.2004.00531.x; Ludlow C. L., 1983, DYSARTHRIAS PHYSL AC, P163; Mashima PA, 2003, AM J SPEECH-LANG PAT, V12, P432, DOI 10.1044/1058-0360(2003/089); McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rosen MJ, 2004, TELEMED J E-HEALTH, V10, P115, DOI 10.1089/tmj.2004.10.115; Russell TG, 2003, MANUAL THER, V8, P242, DOI 10.1016/S1356-689X(03)00016-X; Russell TG, 2002, J TELEMED TELECARE, V8, P50, DOI 10.1258/13576330260440853; SHEARD C, 1991, J SPEECH HEAR RES, V34, P285, DOI 10.1044/jshr.3402.285; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; Torsney K, 2003, NEUROREHABILITATION, V18, P183; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA	33	68	68	2	23	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	FEB	2006	15	1					45	56		10.1044/1058-0360(2006/006)			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	027PZ	WOS:000236428800006	16533092				2021-06-18	
J	Shyu, WC; Lee, YJ; Liu, DD; Lin, SZ; Li, H				Shyu, WC; Lee, YJ; Liu, DD; Lin, SZ; Li, H			Homing genes, cell therapy and stroke	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						neuronal plasticity; stem cells; homing; SDF-1; CXCR4; stroke; review	MARROW STROMAL CELLS; COLONY-STIMULATING FACTOR; ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; NEURAL STEM-CELLS; ADULT BONE-MARROW; TRAUMATIC BRAIN INJURY; HUMAN CD34(+) CELLS; PROGENITOR CELLS; NEUROTROPHIC FACTOR	Stem cell therapies, such as bone marrow transplantation, are a promising strategy for the treatment of stroke. Bone marrow-derived stem cells (BMSCs) including both hematopoietic and mesenchymal stem cells (HSCs and MSCs) can exhibit tremendous cellular differentiation in numerous organs. BMSCs may also promote structural and functional repair in several organs such as the heart, liver, brain, and skeletal muscle via stem cell plasticity. Interestingly, ischemia is known to induce mobilization of BMSCs in both animal models and humans. The tissue injury is "sensed" by the stem cells and they migrate to the site of damage and undergo differentiation. The plasticity, differentiation, and migratory functions of BMSCs in a given tissue are dependent on the specific signals present in the local micro-environment of the damaged tissue. Therefore, the ischemic micro-environment has critical patho-biological functions that are essential for the seeding, expansion, survival, renewal, growth and differentiation of BMSCs in damaged brain remodeling. Recent studies have identified the specific molecular signals, such as SDF-1/CXCR4, required for the interaction of BMSCs and damaged host tissues. Understanding the exact molecular basis of stem cell plasticity in relation to local ischemic signals could offer new insights to permit better management of stroke and other ischemic disorders. The aim of this review is to summarize recent studies into how BMSCs reach, recognize, and function in cerebral ischemic tissues, with particular regard to phenotypical reprogramming of stem cells, or "stem cell plasticity".	Acad Sinica, Inst Mol Biol, Taipei, Taiwan; Tzu Chi Univ, Buddhist Gen Hosp, Neuro Med Sci Ctr, Hualien, Taiwan; Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan	Li, H (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.	hungli@ccvax.sinica.edu.tw	Lin, Shinn-Zong/AAX-2379-2020				Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Askari A, 2004, J AM COLL CARDIOL, V43, P1908, DOI 10.1016/j.jacc.2003.12.045; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Bernal GM, 2004, AGING CELL, V3, P345, DOI 10.1111/j.1474-9728.2004.00132.x; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Busch HJ, 2003, J CEREBR BLOOD F MET, V23, P621, DOI 10.1097/01.WCB.0000057741.00152.E4; Buschmann IR, 2005, CIRCULATION, V111, pE297, DOI 10.1161/01.CIR.0000165120.35950.C7; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chavakis E, 2005, J EXP MED, V201, P63, DOI 10.1084/jem.20041402; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; DEMETRI GD, 1991, BLOOD, V78, P2791; GAROFALO L, 1992, P NATL ACAD SCI USA, V89, P2639, DOI 10.1073/pnas.89.7.2639; Gritti A, 2002, J PHYSIOL-PARIS, V96, P81, DOI 10.1016/S0928-4257(01)00083-3; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Haas S, 2005, CURR OPIN NEUROL, V18, P59, DOI 10.1097/00019052-200502000-00012; HANABUSA K, 2005, STROKE; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; HEFTI F, 1986, J NEUROSCI, V6, P2155; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hiasa K, 2004, CIRCULATION, V109, P2454, DOI 10.1161/01.CIR.0000128213.96779.61; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Kollet O, 2001, BLOOD, V97, P3283, DOI 10.1182/blood.V97.10.3283; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LACHMUND A, 1994, NEUROSCIENCE, V62, P361, DOI 10.1016/0306-4522(94)90371-9; Lataillade JJ, 2000, BLOOD, V95, P756, DOI 10.1182/blood.V95.3.756; Law Ping, 2002, Cancer Treat Res, V110, P51; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Limatola C, 2000, EUR J NEUROSCI, V12, P2497, DOI 10.1046/j.1460-9568.2000.00139.x; Lindholm D, 1997, ADV NEUROL, V73, P1; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mariani M, 2003, J IMMUNOL METHODS, V273, P103, DOI 10.1016/S0022-1759(02)00503-3; Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rodgers KE, 2000, STEM CELLS, V18, P287, DOI 10.1634/stemcells.18-4-287; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; SAWA H, 1994, MOL CELL BIOCHEM, V132, P15, DOI 10.1007/BF00925670; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Stumm RK, 2002, J NEUROSCI, V22, P5865; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; VANGIJN J, 1998, LANCET S3, V352, P23; Wang Y, 1997, J NEUROSCI, V17, P4341; Wechsler Lawrence R, 2004, Cleve Clin J Med, V71 Suppl 1, pS40; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Wong SF, 2005, PHARMACOTHERAPY, V25, P372; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; YAMAGISHI H, 1993, J MOL CELL CARDIOL, V25, P1369, DOI 10.1006/jmcc.1993.1149; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	91	68	86	1	18	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN 1	2006	11						899	907		10.2741/1846			9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	973MX	WOS:000232528000072	16146779				2021-06-18	
J	Horner, MD; Ferguson, PL; Selassie, AW; Labbate, LA; Kniele, K; Corrigan, JD				Horner, MD; Ferguson, PL; Selassie, AW; Labbate, LA; Kniele, K; Corrigan, JD			Patterns of alcohol use 1 year after traumatic brain injury: A population-based, epidemiological study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						alcohol abuse; alcohol drinking; alcoholism; epidemiological studies; follow-up studies; substance abuse; traumatic brain injury	NATIONAL PROBABILITY SAMPLE; AMERICAN DRINKING PRACTICES; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; DRUG-USE; AXIS-I; EXTENT	This study delineated patterns of alcohol use 1 year after traumatic brain injury (TBI) in a large, population-based, epidemiological, nonclinical sample, and identified predictors of heavy alcohol use in these individuals. Participants were 1,606 adults identified by review of a South Carolina statewide hospital discharge data set, on the basis of satisfying the Centers for Disease Control case definition of TBI, and were interviewed by telephone 1 year after TBI-related discharge. Alcohol use in the month prior to interview was classified according to categories from the Quantity-Frequency-Variability Index; heavy drinking was defined as nearly daily use with >= 5 drinks at least occasionally, or at least three occasions with >= 5 drinks. A polychotomous logistic regression with 3 response levels (heavy, moderate, and abstinent/infrequent/light drinking) was used to identify predictors of heavy drinking. Heavy drinking in the month prior to interview was reported by 15.4% of participants, while 14.3% reported moderate drinking and 70.3% reported abstinence or light/infrequent drinking. Risk factors for heavy drinking included male gender, younger age, history of substance abuse prior to TBI, diagnosis of depression since TBI, fair/moderate mental health, and better physical functioning. There was no association between drinking patterns and TBI severity.	Ralph H Johnson Dept VA Med Ctr, Mental Hlth Serv, Charleston, SC USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH USA	Horner, MD (corresponding author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 109 Bee St, Charleston, SC 29401 USA.	hornermd@musc.edu	Cusco, Xavier Garcia/S-7576-2019	Cusco, Xavier Garcia/0000-0001-7199-6931			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Burnett DM, 2000, BRAIN INJURY, V14, P713; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; *CDC, 2003, BEH RISK FACT SURV S; Corrigan J. D., 1999, REHABILITATION ADULT; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; *CTR INJ RES POL J, 1997, ICMAP90 SOFTW; Darlington GA, 1998, ENCY BIOSTATISTICS, P788; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; ELLERD DA, 1992, J APPL REHABILITATIO, V23, P48; Findler RB, 2001, ACM SIGPLAN NOTICES, V36, P1, DOI 10.1145/504311.504283; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MASSAGLI TL, 1996, ARCH PHYS MED REHAB, V77, P25; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; *SAS I, 2001, STAT AN SOFTW VERS 8; Sherer M, 1999, BRAIN INJURY, V13, P973; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; STOKES MS, 1995, CATEGORICAL DATA ANA, P217; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Ware JE, 1993, SF36 HLTH SURVEY MAN	38	68	68	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2005	11	3					322	330		10.1017/S135561770505037X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	924UL	WOS:000229005900011	15892908				2021-06-18	
J	Selassie, AW; McCarthy, ML; Ferguson, PL; Tian, JM; Langlois, JA				Selassie, AW; McCarthy, ML; Ferguson, PL; Tian, JM; Langlois, JA			Risk of posthospitalization mortality among persons with traumatic brain injury, South Carolina 1999-2001	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							LONG-TERM SURVIVAL; PREEXISTING CONDITIONS; LIFE EXPECTANCY; DEATH; SEVERITY; EPIDEMIOLOGY; DISCHARGE; SYSTEMS; TRENDS	Traumatic brain injury (TBI) negatively impacts long-term survival. However, little is known about the likelihood of death within the first year following hospital discharge. This study examined mortality among a representative sample of 3679 persons within 1 year of being discharged from any of 62 acute care hospitals in South Carolina following TBI and identified the factors associated with early death using a multivariable Cox proportional hazards model. The mortality experience of the cohort was also compared with that of the general population by using standardized mortality ratios for selected causes of death by age, adjusted for race and sex.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA; S Carolina Dept Hlth & Environm Control, Div Biostat & Hlth GIS,Publ Hlth Stat & Informat, Charleston, SC USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Selassie, AW (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, 135 Cannon St,POB 250835, Charleston, SC 29425 USA.	selassie@musc.edu			ODCDC CDC HHS [U17/CCU421926] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Allison PD, 1995, ESTIMATING COMPARING, V29-59; Anderson PM, 2002, LEUKEMIA, V16, P406; Anderson Robert N, 2003, Natl Vital Stat Rep, V52, P1; Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1; Baguley I, 2000, BRAIN INJURY, V14, P505; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Butler J, 2001, CENTRAL NERVOUS SYST; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FAHY TJ, 1967, LANCET, V2, P475; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; KLEINBAUM DG, 1996, EVALUATING PROPORTIO, P133; Kraus J F, 2000, Neurosurg Focus, V8, pe5; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Olson CJ, 2003, J TRAUMA, V55, P45, DOI 10.1097/01.TA.0000071291.17287.57; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Sacco WJ, 1999, J TRAUMA, V47, P441, DOI 10.1097/00005373-199909000-00001; SACCO WJ, 1993, J TRAUMA, V35, P538, DOI 10.1097/00005373-199310000-00007; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US CENS BUR, 2001, UNP US POP AG SEX RA; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WHO, 2004, INT STAT CLASS DIS R; WOODWARD M, 1999, COX PROPORTIONAL HAZ, P534; 1982, INT CLASSIFICATION D	52	68	68	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					257	269		10.1097/00001199-200505000-00008			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500008	15908825				2021-06-18	
J	Gill, M; Windemuth, R; Steele, R; Green, SM				Gill, M; Windemuth, R; Steele, R; Green, SM			A comparison of the Glasgow coma scale score to simplified alternative scores for the prediction of traumatic brain injury outcomes	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Research Forum of the American-College-of-Emergency-Physicians	OCT 12-13, 2003	Boston, MA	Amer Coll Emergency Phys			RULE; CRITERIA; TRIAGE; SPINE	Study objective: The 15-point Glasgow Coma Scale (GCS) is extensively used in the initial evaluation of traumatic brain injury in emergency department (ED) settings. We hypothesized that the GCS might be unnecessarily complex and that a simpler scoring system might demonstrate similar accuracy in the prediction of traumatic brain injury outcomes. Methods: We analyzed a prospectively maintained trauma registry of patients evaluated at our Level 1 trauma center from 1990 to 2002. We calculated the test performance of ED GCS scores relative to 4 clinically relevant traumatic brain injury outcomes (emergency intubation, neurosurgical intervention, brain injury, and mortality) using areas under their receiver operating characteristic (ROC) curves. We performed similar analyses for each of the 3 GCS components and for 2 simplified 3-point scores (simplified verbal score: oriented=2, confused conversation=1, inappropriate words or less=0; simplified motor score: obeys commands=2, localizes pain=1, withdrawal to pain or less=0). We then compared the test performance of each of these 5 to the total GCS score using a priori thresholds for clinically important differences. Results: Each of the 3 GCS components alone and the 2 simplified 3-point scores demonstrated ROC areas within 9% of that of the GCS score for the 4 outcomes, with a median difference of 3.0% (interquartile range 1.6% to 4.5%). These differences were all below our a priori definitions of clinical importance. Conclusion: The 3 individual GCS components alone and two 3-point simplified scores demonstrated test performance similar to the total GCS score for the prediction of 4 clinically relevant traumatic brain injury outcomes. Despite the widespread use of the GCS for the initial evaluation of traumatic brain injury, this score may be unnecessarily complex for this indication.	Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, Loma Linda, CA 92354 USA	Gill, M (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, 11234 Anderson St,POB 2000,Room A-108, Loma Linda, CA 92354 USA.	mgill@ahs.llumc.edu					American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP M; Andersson RE, 1999, WORLD J SURG, V23, P133, DOI 10.1007/PL00013174; [Anonymous], 1999, RES OPT CAR INJ PAT; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; CAMPBELL JE, 1999, BASIC TRAUMA LIFE SU; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; CUMMINS RO, 2002, TXB ADV CARDIAC LIFE; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Hamani C, 2003, ARQ NEURO-PSIQUIAT, V61, P376, DOI 10.1590/S0004-282X2003000300010; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TEASDALE G, 1974, LANCET, V2, P81; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; World Health Organization, 1977, INT CLASS DIS; 2000, J NEUROTRAUMA, V17, P479	34	68	69	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2005	45	1					37	42		10.1016/j.annemergmed.2004.07.429			6	Emergency Medicine	Emergency Medicine	886SY	WOS:000226250100009	15635308				2021-06-18	
J	Pizzi, M; Sarnico, I; Boroni, F; Benarese, M; Dreano, M; Garotta, G; Valerio, A; Spano, PF				Pizzi, M; Sarnico, I; Boroni, F; Benarese, M; Dreano, M; Garotta, G; Valerio, A; Spano, PF			Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							SOLUBLE CYTOKINE RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; MYELIN GENE-EXPRESSION; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NORMAL HUMAN-URINE; MULTIPLE-SCLEROSIS; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; TRANSGENIC MICE	We investigated the effects of IL-6 and a chimeric derivative of IL-6 and soluble IL-6 receptor (IL6RIL6 chimera) on excitotoxic injury in rat organotypic hippocampal slices. Brief application of N-methyl-D-aspartate (NMDA) induced astrocyte reactivity, neuron cell death, and oligodendrocyte degeneration, the latter caused by secondary activation of AMPA/kainate receptors. Both these cytokines rescued neurons and oligodendrocytes, albeit the chimeric compound was much more potent and efficient than IL-6. No change was produced on reactive astrocytosis. The cytokines preserved myelin basic protein (MBP) production in slices exposed to excitotoxic insult, and when applied singularly for a week, they also enhanced both MBP and proteolipid protein expression. These effects occurred through activating the signal transducer gp130 and were associated with stimulation of transcription factors STAT1 and STAT3. Our results suggest that IL-6 and IL6RIL6 may prove to be valuable in treating neurodegenerative and demyelinating diseases. (C) 2003 Elsevier Inc. All rights reserved.	Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, I-25123 Brescia, Italy; Serono Int SA, CH-1228 Geneva, Switzerland	Pizzi, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, Viale Europa 11, I-25123 Brescia, Italy.	pizzi@med.unibs.it	Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/C-1452-2011; Valerio, Alessandra/B-3413-2009; Spano, Pier Franco F/J-9944-2016; Pizzi, Marina/K-2064-2016	Valerio, Alessandra/0000-0001-5844-2256; Spano, Pier Franco F/0000-0002-9906-0964; Pizzi, Marina/0000-0002-4857-5204			Aberg MAI, 2001, MOL CELL NEUROSCI, V17, P426, DOI 10.1006/mcne.2000.0947; Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; BARRES BA, 1993, DEVELOPMENT, V118, P283; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; Bensadoun JC, 2001, EUR J NEUROSCI, V14, P1753, DOI 10.1046/j.0953-816x.2001.01802.x; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Brooks PJ, 1996, J NEUROSCI, V16, P939; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Dell'Albani P, 1998, J NEUROSCI RES, V54, P191, DOI 10.1002/(SICI)1097-4547(19981015)54:2<191::AID-JNR7>3.0.CO;2-9; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; Elson GCA, 2000, NAT NEUROSCI, V3, P867; Eskes C, 2002, GLIA, V37, P43, DOI 10.1002/glia.10019; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; FREI K, 1991, J NEUROIMMUNOL, V31, P147; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; Haggiag S, 1999, FEBS LETT, V457, P200, DOI 10.1016/S0014-5793(99)01040-6; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; Hautecoeur P, 1997, ACTA NEUROL BELG, V97, P240; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inomata Y, 2003, BIOCHEM BIOPH RES CO, V302, P226, DOI 10.1016/S0006-291X(03)00127-X; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kristensen BW, 2001, BRAIN RES, V896, P1, DOI 10.1016/S0006-8993(00)03304-7; KUSHIMA Y, 1992, NEUROSCI LETT, V143, P110, DOI 10.1016/0304-3940(92)90244-2; Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200; Li S, 1999, J Neurosci, V19, pRC16; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Maimone D, 1997, J NEUROL SCI, V146, P59, DOI 10.1016/S0022-510X(96)00283-3; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; Pavelko KD, 2003, J NEUROSCI, V23, P481; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Stankoff B, 2002, J NEUROSCI, V22, P9221; Starkey GD, 2001, NEUROREPORT, V12, P4081, DOI 10.1097/00001756-200112210-00044; Sun Y, 2002, BIOCHEM BIOPH RES CO, V295, P532, DOI 10.1016/S0006-291X(02)00706-4; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Tsigos C, 1999, J INTERF CYTOK RES, V19, P1271, DOI 10.1089/107999099312948; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; VALERIO A, 1994, NEUROBIOL AGING, V15, P713, DOI 10.1016/0197-4580(94)90053-1; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X	76	68	77	1	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	FEB	2004	25	2					301	311		10.1016/j.mcn.2003.10.022			11	Neurosciences	Neurosciences & Neurology	804YF	WOS:000220333300010	15019946				2021-06-18	
J	Letenneur, L				Letenneur, L			Risk of dementia and alcohol and wine consumption: A review of recent results	BIOLOGICAL RESEARCH			English	Article; Proceedings Paper	Vinsalud Chile 2002 Wine and Health International Congress	OCT, 2002	Santiago, CHILE			Alcohol; Alzheimer's disease; dementia; wine	ALZHEIMERS-DISEASE; COMMUNITY	The term dementia refers to a clinical syndrome of acquired intellectual disturbances produced by brain dysfunction. Dementia may result from a wide variety of disorders, including degenerative (e.g. Alzheimer's disease, AD), vascular (e.g. multi-infarct dementia), and traumatic (e.g. head injury). Long-term abuse of alcohol is related to the development of the Wernicke-Korsakoff's syndrome or alcohol dementia. However. light to moderate alcohol intake might also reduce the risk of dementia and AD. In Bordeaux (France), a population-based prospective study found that subjects drinking 3 to 4 standard glasses of wine per day (>250 and up to 500 ml), categorized as moderate drinkers, the Crude odds ratio (OR) was 0.18 for incident dementia (p<0.01) and 0.25 for Alzheimer's disease (p<0.03), as compared to the non-drinkers. After adjusting for age, sex, education, occupation, baseline cognitive performances and other possible confounders, the ORs were respectively 0.19 (p<0.01) and 0.28 (p<0.05). In the 922 mild drinkers (<1 to 2 classes per day) there was a negative association only with AD, after adjustment (OR = 0.55 p<0.05). The inverse relationship between moderate wine drinking and incident dementia was explained neither by known predictors of dementia nor by medical, psychological or socio-familial factors. These results were confirmed from data of the Rotterdam study. Light-to-moderate drinking (one to three drinks per day) was significantly associated with a lower risk of any dementia (hazard ratio 0.58 [95% CI 0.38-0.90]) and vascular dementia (hazard ratio 0.29 [0.09-0.93]). No evidence that the relation between alcohol and dementia varied by type of alcoholic beverage was found. Stroke constitutes one of the most common causes of serious functional impairment in developed countries. Ischaemic strokes represent about 80% of all strokes, Several Studies have been published and the overall conclusion is that heavy drinking is a risk factor for most stroke subtypes. Regular light to moderate drinking seemed to be associated with a decreased risk for ischaemic stroke.	Univ Victor Segalen Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France	Letenneur, L (corresponding author), Univ Victor Segalen Bordeaux 2, INSERM, U593, Case 11,146 Rue Leo Saignat, F-33076 Bordeaux, France.	luc.letenneur@isped.u.bordeaux2.fr	LETENNEUR, Luc/T-4424-2019	LETENNEUR, Luc/0000-0002-3274-937X			Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Lemeshow S, 1998, AM J EPIDEMIOL, V148, P298; Letenneur L, 1999, J NEUROL NEUROSUR PS, V66, P177, DOI 10.1136/jnnp.66.2.177; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lobo A, 2000, NEUROLOGY, V54, pS4; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; Truelsen T, 2002, NEUROLOGY, V59, P1313, DOI 10.1212/01.WNL.0000031421.50369.E7	10	68	73	0	15	SOC BIOLGIA CHILE	SANTIAGO	CASILLA 16164, SANTIAGO 9, CHILE	0716-9760	0717-6287		BIOL RES	Biol. Res.		2004	37	2					189	193					5	Biology	Life Sciences & Biomedicine - Other Topics	857JJ	WOS:000224112200003	15455646	Other Gold			2021-06-18	
J	Gianinazzi, C; Grandgirard, D; Imboden, H; Egger, L; Meli, DN; Bifrare, YD; Joss, PC; Tauber, MG; Borner, C; Leib, SL				Gianinazzi, C; Grandgirard, D; Imboden, H; Egger, L; Meli, DN; Bifrare, YD; Joss, PC; Tauber, MG; Borner, C; Leib, SL			Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis	ACTA NEUROPATHOLOGICA			English	Article						apoptosis; caspase-3; dentate gyrus; bacterial meningitis	TRAUMATIC BRAIN INJURY; DELAYED NEURONAL DEATH; BACTERIAL-MENINGITIS; CELL-DEATH; NERVOUS-SYSTEM; MATRIX METALLOPROTEINASES; DNA FRAGMENTATION; PRECURSOR PROTEIN; LEARNING-DEFICITS; INHIBITION	Bacterial meningitis causes neuronal apoptosis in the hippocampal dentate gyrus, which is associated with learning and memory impairments after cured disease. The execution of the apoptotic program involves pathways that converge on activation of caspase-3, which is required for morphological changes associated with apoptosis. Here, the time course and the role of caspase-3 in neuronal apoptosis was assessed in an infant rat model of pneumococcal meningitis. During clinically asymptotic meningitis (0-12 h after infection), only minor apoptotic damage to the dentate gyrus was observed, while the acute phase (18-24 h) was characterized by a massive increase of apoptotic cells, which peaked at 36 h. In the subacute phase of the disease (36-72 h), the number of apoptotic cells decreased to control levels. Enzymatic caspase-3 activity was significantly increased in hippocampal tissue of infected animals compared to controls at 22 h. The activated enzyme was localized to immature cells of the dentate gyrus, and in vivo activity was evidenced by cleavage of the amyloid-beta precursor protein. Intracisternal administration of the caspase-3-specific inhibitor Ac-DEVDCHO significantly reduced apoptosis in the hippocampal dentate gyrus. In contrast to a study where the decrease of hippocampal apoptosis after administration of a pan-caspase inhibitor was due to downmodulation of the inflammatory response, our data demonstrate that specific inhibition of caspase-3 did not affect inflammation assessed by TNF-alpha and IL-1beta concentrations in the cerebrospinal fluid space. Taken together, the present results identify caspase-3 as a key effector of neuronal apoptosis in pneumococcal meningitis.	Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Univ Bern, Dept Neurobiol, Bern, Switzerland	Leib, SL (corresponding author), Univ Bern, Inst Infect Dis, Friedbuhlstr 51, CH-3010 Bern, Switzerland.	stephen.leib@ifik.unibe.ch	Grandgirard, Denis/AAB-8786-2020; Leib, Stephen L/A-7866-2011; Leib, Stephen/M-3786-2019	Grandgirard, Denis/0000-0002-4151-5196; Leib, Stephen L/0000-0002-1106-6123; Egger, Charlotte/0000-0001-6501-5703	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035902] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35902] Funding Source: Medline		Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BIFRARE YD, 2002, SWISS MED WEEKL S130, V132, P9; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Braun JS, 2002, J CLIN INVEST, V109, P19; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Chen J, 1998, J NEUROSCI, V18, P4914; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; De Bilbao F, 1999, J COMP NEUROL, V409, P339, DOI 10.1002/(SICI)1096-9861(19990705)409:3<339::AID-CNE1>3.0.CO;2-Q; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Enari M, 1998, NATURE, V391, P43; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerber J, 2001, BRAIN PATHOL, V11, P422, DOI 10.1111/j.1750-3639.2001.tb00410.x; Gerber J, 2001, ACTA NEUROPATHOL, V101, P499; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; Han BH, 2000, NEUROBIOL DIS, V7, P38; IMBODEN H, 1995, IMMUNOCYTOCHEMISTRY, P236; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Koedel U, 2002, ANN NEUROL, V51, P319, DOI 10.1002/ana.10103; Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000; Leib SL, 2001, BRAIN, V124, P1734, DOI 10.1093/brain/124.9.1734; Leib SL, 1996, J INFECT DIS, V173, P166, DOI 10.1093/infdis/173.1.166; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; LEIB SL, 2001, 41 INT C ANT AG CHEM; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffler JM, 2001, J INFECT DIS, V183, P247, DOI 10.1086/317921; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nau R, 1999, J NEUROPATH EXP NEUR, V58, P265, DOI 10.1097/00005072-199903000-00006; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NITATORI T, 1995, J NEUROSCI, V15, P1001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.3.CO;2-I; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schluter D, 1996, J NEUROPATH EXP NEUR, V55, P14, DOI 10.1097/00005072-199601000-00002; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; von Mering M, 2001, BRAIN PATHOL, V11, P282; Wellmer A, 2000, NEUROSCI LETT, V296, P137, DOI 10.1016/S0304-3940(00)01645-1; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	53	68	69	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2003	105	5					499	507		10.1007/s00401-003-0672-7			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	675NX	WOS:000182702400012	12677451				2021-06-18	
J	Ponsford, J				Ponsford, J			Sexual changes associated with traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; FOLLOW-UP; REHABILITATION	Findings from numerous outcome studies have suggested that people with traumatic brain injuries (TBI) experience relationship difficulties and changes in sexuality. However, there have been few investigations of these problems. This paper reports the results of a study of sexuality following TBI, which aimed to identify changes in sexual behaviour, affect, self-esteem, and relationship quality, and their inter-relationships. Two hundred and eight participants with moderate-to-severe TBI (69% males) completed a questionnaire 1-5 years post-injury. Their responses were compared with those of 150 controls, matched for age, gender, and education. Of TBI participants 36-54% reported: (1) A decrease in the importance of sexuality, opportunities, and frequency of engaging in sexual activities; (2) reduced sex drive; (3) a decline in their ability to give their partner sexual satisfaction and to engage in sexual intercourse; and (4) decreased enjoyment of sexual activity and ability to stay aroused and to climax. The frequencies of such negative changes were significantly higher than those reported by controls and far outweighed the frequency of increases on these dimensions. A significant proportion of TBI participants also reported decreased self-confidence, sex appeal, higher levels of depression, and decreased communication levels and relationship quality with their sexual partner. Factors associated with sexual problems in the TBI group are explored and implications of all findings discussed.	Monash Univ, Melbourne, Vic 3004, Australia; Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 30 Erin St, Richmond, Vic 3121, Australia.						ANDERSON DW, 1980, J NEUROSURGERY S, V53; Blackerby WF, 1990, J HEAD TRAUMA REHAB, V5, P73; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DUCHARME S, 1990, J HEAD TRAUMA REHAB, V5, P38, DOI DOI 10.1097/00001199-199005020-00007; Fryer J, 1989, TRAUMATIC BRAIN INJU, P255; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; *HLTH DEP VICT, 1991, REP HEAD INJ IMP STU; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; MILLER L, 1994, J COGNITIVE REHABILI, V12, P12; *NHIF, 1984, SIL EP; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SIMPSON GK, 1999, YOU ME ED PROGR SEX; SNAITH RP, 1994, HOSPITAL ANXIETY DEP; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P117; THORNGRAY BE, 1983, REHABIL LIT, V44, P138; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	31	68	68	0	9	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		275	289		10.1080/09602010244000363			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500015	21854338				2021-06-18	
J	Hart, T; Hawkey, K; Whyte, J				Hart, T; Hawkey, K; Whyte, J			Use of a portable voice organizer to remember therapy goals in traumatic brain injury rehabilitation: A within-subjects trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; cognitive remediation; traumatic brain injury	MEMORY-IMPAIRED PATIENTS; EVERYDAY MEMORY; AID; ACQUISITION; RETENTION; DEFICITS	Objective: To test the efficacy of a portable voice organizer in helping people with traumatic brain injury (TBI) to recall therapy goals and plans discussed with their clinical case managers. Design: Prospective within-subjects trial, in which individualized therapy goals were randomly assigned to intervention or no intervention. Setting: Comprehensive postacute TBI rehabilitation program. Participants: Ten people with moderate to severe Till enrolled from 3 months to 18 years after injury. Outcome measure: Memory for therapy goals. Clinicians generated statements describing six current therapy goals, half of which were randomly assigned to be recorded on a voice organizer during the next case management session. Participants selected three times per day to listen to the recorded goals, prompted by an alarm. One-week recall was tested using both free- and cued-recall formats. Results: Recorded goals were recalled better than unrecorded goals and appeared to be associated with better awareness or follow-through with therapy objectives. Conclusion: Portable electronic devices have the potential to assist with treatment areas beyond tasks involving prospective memory.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Dept Rehabil Med, Philadelphia, PA 19141 USA; MossRehab, Drucker Brain Injury Ctr, Moss Rehabil Res Inst, Philadelphia, PA USA	Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Dept Rehabil Med, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689	23	68	69	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					556	570		10.1097/00001199-200212000-00007			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900007	12802246				2021-06-18	
J	Teng, AL; Pinzur, MS; Lomasney, L; Mahoney, L; Havey, R				Teng, AL; Pinzur, MS; Lomasney, L; Mahoney, L; Havey, R			Functional outcome following anatomic restoration of tarsal-metatarsal fracture dislocation	FOOT & ANKLE INTERNATIONAL			English	Article							MIDFOOT	Anatomic restoration of displaced fracture-dislocation of the tarsometatarsal junction of the foot is essential, as even "minor" disruptions of this joint complex leads to poor clinical results. In order to determine a "key" element associated with good or poor functional outcomes, 11 patients with excellent radiographic results following surgical treatment of unilateral closed Lisfranc fracture dislocation of the tarsometatarsal joint of the foot were evaluated at an average of 41.2 (range, 14 to 53) months following their injury and surgery. Their average age was 40.6 (range, 21 to 58) years. AOFAS midfoot scores averaged 71.0 (range, 30 to 95). Radiographic analysis at follow-up revealed anatomic reduction in 10 of 11. Eight of 11 had evidence of arthritis of the tarsometatarsal joints. Clinical alignment was normal in all subjects, with nine of 11 clinically exhibiting decreased relative range of motion. Gait analysis was performed with the F-Scan (Tekscan, Boston, MA) in-shoe pressure-monitoring system. Vertical ground reaction force was recorded under the hallux, first metatarsal head, lateral metatarsals, and heel. Stance phase duration, rate of loading, rate of unloading, peak loading, and total loading were recorded at each of the named regions. There was no statistical difference in the parameters measured between the injured and normal control feet.	Loyola Univ, Ctr Med, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA; Loyola Univ, Ctr Med, Dept Radiol, Maywood, IL 60153 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Pinzur, MS (corresponding author), Loyola Univ, Ctr Med, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA.						Ahroni JH, 1998, FOOT ANKLE INT, V19, P668, DOI 10.1177/107110079801901004; AITKEN AP, 1963, J BONE JOINT SURG AM, V45, P246, DOI 10.2106/00004623-196345020-00003; ARNTZ CT, 1988, J BONE JOINT SURG AM, V70A, P173, DOI 10.2106/00004623-198870020-00003; BRUNET JA, 1987, J BONE JOINT SURG BR, V69, P437; Coester LM, 2001, J BONE JOINT SURG AM, V83A, P219, DOI 10.2106/00004623-200102000-00009; Corbett M L, 1993, Foot Ankle, V14, P520; GOOSSENS, 1982, CLIN ORTHOP, V176, P154; GRANBERRY WM, 1962, SURG GYNECOL OBSTET, V114, P467; KELLGREN JH, 1952, BRIT MED J, V1, P181, DOI 10.1136/bmj.1.4751.181; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701; Kuo RS, 2000, J BONE JOINT SURG AM, V82A, P1609, DOI 10.2106/00004623-200011000-00015; Lakin RC, 2001, J BONE JOINT SURG AM, V83A, P520, DOI 10.2106/00004623-200104000-00006; MYERSON MS, 1986, FOOT ANKLE, V6, P225, DOI 10.1177/107110078600600504; Pinzur MS, 1997, FOOT ANKLE INT, V18, P635, DOI 10.1177/107110079701801006	14	68	74	0	3	AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC	SEATTLE	2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA	1071-1007			FOOT ANKLE INT	Foot Ankle Int.	OCT	2002	23	10					922	926		10.1177/107110070202301006			5	Orthopedics	Orthopedics	603PH	WOS:000178568000006	12398144				2021-06-18	
J	Kolakowsky-Hayner, S; Gourley, EV; Kreutzer, JS; Marwitz, JH; Meade, MA; Cifu, DX				Kolakowsky-Hayner, S; Gourley, EV; Kreutzer, JS; Marwitz, JH; Meade, MA; Cifu, DX			Post-injury substance abuse among persons with brain injury and persons with spinal cord injury	BRAIN INJURY			English	Article							ALCOHOL-USE; HEAD-INJURY	Primary objective: To identify the patient population at greatest risk for post-injury adjustment problems, the present study independently examines and compares alcohol and drug use rates in patients with traumatic brain injury (TBI) and patients with spinal cord injury. Research design: The two samples were matched with regard to age, gender and mechanism of injury. The study provides a description of post-injury use rates for each population, and describes similarities and differences between the two groups. Methods and procedures: Participants included 30 consecutive Model Systems spinal cord injury (SCI) patients seen for follow-up neuropsychological testing between October 1996-June 1999. An equivalent number of Model Systems TBI patients were matched from a larger sample comprised of 440 consecutive hospital admissions, that returned for a 1-year follow-up neuropsychological evaluation between February 1989-December 1998. All participants were treated in an urban Level I trauma centre and associated inpatient rehabilitation programmes. Information regarding patient demographics, as well as pre- and post-injury psychiatric, employment, academic, criminal, and medical history was obtained via the General Health and History Questionnaire. Main outcomes and results: With regard to post-injury alcohol use rates, persons with spinal cord injury were more likely to drink on a daily basis. Although not statistically significant, pre- injury drinking rates differed from post-injury rates for both groups. With regard to illicit drug use, persons with TBI differed significantly from persons with SCI. A significant difference was also noted between pre- injury drug use and post-injury drug use for both groups. Conclusions: Persons who drink post-injury are unlikely to be 'light' or social drinkers. Either people choose to abstain completely or appear to use alcohol frequently.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kolakowsky-Hayner, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, 1200 E Broad St,Room 3-102,POB 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387			Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Drubach D A, 1993, Md Med J, V42, P989; EDNA T, 1984, ACTA CHIR SCAND, V148, P209; FISHBURNE PM, 1979, NATL SURVEY DRUG ABU; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Go Bette K., 1995, P21; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Krause J, 1992, NEUROREHABILITATION, V2, P45; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; ODONNELL JP, 1981, ALCOHOL HEALTH RES W, V148, P209; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rimel RW, 1990, REHABILITATION ADULT, P8; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Smith J, 1993, SPINAL NETWORK, P375; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; WILKINSON DA, 1987, NEUROPSYCHOLOGY ALCO, P76; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	39	68	69	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2002	16	7					583	592		10.1080/02699050110119475			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	569RN	WOS:000176616100003	12119077				2021-06-18	
J	Hesdorffer, DC; Ghajar, J; Iacono, L				Hesdorffer, DC; Ghajar, J; Iacono, L			Predictors of compliance with the evidence-based guidelines for traumatic brain injury care: A survey of United States trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	5th International Neurotrauma Symposium	OCT 01-05, 2000	GARMISCH-PARTENKIRCHEN, GERMANY			traumatic brain injury; guideline compliance; survey	HEAD-INJURY; CLINICAL-PRACTICE; MAJOR TRAUMA; IMPACT; MANAGEMENT; MORTALITY; OUTCOMES; SYSTEM	Background. In 1995, evidence-based guidelines for the management of severe traumatic brain injury (TBI) were published and disseminated. Information regarding their implementation is limited. Methods: During 1999 to 2000, we contacted all designated U.S. trauma centers caring for adults with severe TBI to determine the degree of guideline compliance and to identify predictors. Results: Of 924 centers identified, 828 participated (90%). Four hundred thirty-three with intensive care units caring for severe TBI were surveyed. Three hundred ninety-five centers transferring patients were excluded. Full guideline compliance was rare (n = 68 [16%]). In multivariate analyses, treatment protocols (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.9-6.6), neurosurgery residency program (OR, 5.0; 95% CI, 2.6-9.8), and state (OR, 2.7; 95% CI, 0.62-12) or American College of Surgeons (OR, 5.1; 95% CI, 1.1-23) designation increased the likelihood of full compliance versus noncompliance. Conclusion: Although evidence-based guidelines were published and disseminated in 1995, implementation is infrequent. Focus must turn to changing physician practice and transport decisions to provide guideline-compliant care and improve patient outcome.	Brain Trauma Fdn, New York, NY 10021 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Neurosurg, New York, NY USA	Hesdorffer, DC (corresponding author), Brain Trauma Fdn, 523 E 72nd St, New York, NY 10021 USA.	dch5@columbia.edu					*AM MED ASS OFF QU, 1990, HLTH CAR ORG ATTR GU; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM, P67; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; EAST TD, 1992, CHEST, V101, P697, DOI 10.1378/chest.101.3.697; GAAB MR, 1994, AENTRALBL NEUROCHIR, V55, P133; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRACEY DR, 1992, MAYO CLIN PROC, V67, P131, DOI 10.1016/S0025-6196(12)61313-5; Handley M R, 1994, HMO Pract, V8, P75; Hosmer D. W., 1989, APPL LOGISTIC REGRES, P216; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; KAGAN RJ, 1994, AM SURGEON, V60, P394; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NIH, 1994, REP TASK FORC TRAUM; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; TRASK AL, 1998, J TRAUMA, V45, P1109; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Young JS, 1998, AM SURGEON, V64, P88	33	68	68	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2002	52	6					1202	1209		10.1097/00005373-200206000-00031			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	562KJ	WOS:000176195700040	12045655				2021-06-18	
J	Fann, JR; Leonetti, A; Jaffe, K; Katon, WJ; Cummings, P; Thompson, RS				Fann, JR; Leonetti, A; Jaffe, K; Katon, WJ; Cummings, P; Thompson, RS			Psychiatric illness and subsequent traumatic brain injury: a case control study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEALTH MAINTENANCE ORGANIZATION; COGNITIVE DYSFUNCTION; BENZODIAZEPINE USE; DEPRESSED-PATIENTS; TRAFFIC ACCIDENTS; POPULATION; IMPAIRMENT; DISORDERS; SYMPTOMS; RISK	Objective: To determine whether psychiatric illness is a risk factor for subsequent traumatic brain injury (TBI). Methods: Case control study in a large staff model health maintenance organisation in western Washington State. Patients with TBI, determined by International classification of diseases, 9th revision, clinical modification (ICD-9-CM) diagnoses, were 1440 health plan members who had TBI diagnosed in 1993 and who had been enrolled in the previous year, during which no TBI was ascertained. Three health plan members were randomly selected as control subjects, matched by age, sex, and reference date. Psychiatric illness in the year before the TBI reference date was determined by using computerised records of ICD-9-CM diagnoses, psychiatric medication prescriptions, and utilisation of a psychiatric service. Results: For those with a psychiatric diagnosis in the year before the reference date, the adjusted relative risk for TBI was 1.7 (95% confidence interval (Cl) 1.4 to 2.0) compared with those without a psychiatric diagnosis. Patients who had filled a psychiatric medication prescription had an adjusted relative risk for TBI of 1.6 (95% Cl 1.2 to 2.1) compared with those who had not filled a psychiatric medication prescription. Patients who had utilised psychiatric services had an adjusted relative risk for TBI of 1.3 (95% Cl 1.0 to 1.6) compared with those who had not utilised psychiatric services. The adjusted relative risk for TBI for patients with psychiatric illness determined by any of the three psychiatric indicators was 1.6 (95% Cl 1.4 to 1.9) compared with those without any psychiatric indicator. Conclusion: Psychiatric illness appears to be associated with an increased risk for TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Harborview Injury Prevent & Res Ctr, Seattle, WA USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barbone F, 1998, LANCET, V352, P1331, DOI 10.1016/S0140-6736(98)04087-2; BEITMAN BD, 1982, J FAM PRACTICE, V15, P1119; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P192; BRODY EM, 1984, J AM GERIATR SOC, V32, P877, DOI 10.1111/j.1532-5415.1984.tb00886.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cornblatt B, 1997, PSYCHIAT QUART, V68, P343, DOI 10.1023/A:1025495030997; CORNELL DG, 1984, J ABNORM PSYCHOL, V93, P150; CRANCER A, 1969, AM J PSYCHIAT, V126, P807, DOI 10.1176/ajp.126.6.807; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; DICKER BG, 1992, J HEAD TRAUMA REHAB, V7, P83; EELKEMA RC, 1970, AM J PUBLIC HEALTH N, V60, P459, DOI 10.2105/AJPH.60.3.459; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; Fann JR, 1997, J PSYCHOSOM RES, V43, P335, DOI 10.1016/S0022-3999(97)00130-X; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FOY A, 1995, J GERONTOL A-BIOL, V50, pM99, DOI 10.1093/gerona/50A.2.M99; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOLINKOFF M, 1989, J AFFECT DISORDERS, V17, P105, DOI 10.1016/0165-0327(89)90032-3; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KATON W, 1981, J FAM PRACTICE, V13, P47; KATON W, 1990, GEN HOSP PSYCHIAT, V12, P355, DOI 10.1016/0163-8343(90)90002-T; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUNY S, 1995, PSYCHOPATHOLOGY, V28, P190, DOI 10.1159/000284922; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LEWIN I, 1982, ERGONOMICS, V25, P917, DOI 10.1080/00140138208925051; MacKenzie E J, 1989, Md Med J, V38, P725; Manheimer D I, 1997, Inj Prev, V3, P135, DOI 10.1136/ip.3.2.135; *NAT CTR HLTH STAT, 1991, DHHS PUBL; Oxman TE, 1996, J CLIN PSYCHIAT, V57, P38; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Schatz J, 1998, SCHIZOPHR RES, V30, P41, DOI 10.1016/S0920-9964(97)00125-4; SELZER ML, 1967, Q J STUD ALCOHOL, V28, P505; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Stergachis AS, 1991, PHARMACOPEIDEMIOLOGY, P222; SULLIVAN M, 1993, APS J, V2, P141, DOI 10.1016/S1058-9139(05)80078-6; Teasdale TW, 1997, BRIT MED J, V315, P569; Thurman DJ, 1996, WESTERN J MED, V165, P192; THURMAN DJ, 1996, P ANN M AM PUBL HLTH; Thurman DJ., 1995, GUIDELINES SURVEILLA; Trzepacz PT, 1996, PSYCHIAT CLIN N AM, V19, P429, DOI 10.1016/S0193-953X(05)70299-9; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; van den Bosch RJ, 1998, J NERV MENT DIS, V186, P364, DOI 10.1097/00005053-199806000-00007; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; Weinberger DR, 1997, INT CLIN PSYCHOPHARM, V12, pS29, DOI 10.1097/00004850-199709004-00006; Weiner DK, 1998, GERONTOLOGY, V44, P217, DOI 10.1159/000022013; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 2000, PHYSICIANS DESK REFE; 1998, J HOPKINS U ACG CASE	60	68	68	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2002	72	5					615	620		10.1136/jnnp.72.5.615			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	547QX	WOS:000175344200016	11971048	Green Published, Bronze			2021-06-18	
J	Paniak, C; Reynolds, S; Phillips, K; Toller-Lobe, G; Melnyk, A; Nagy, J				Paniak, C; Reynolds, S; Phillips, K; Toller-Lobe, G; Melnyk, A; Nagy, J			Patient complaints within 1 month of mild traumatic brain injury: A controlled study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RANDOMIZED-TRIAL; LONG	Symptom complaints of 118 patients with mild traumatic brain injury (MTBI), within I month postinjury, were compared with those of 118 control participants without a MTBI. The MTBI and control subjects were group-matched on age, gender, socioeconomic status (SES), and education status. Differences in symptom endorsements and severity ratings were found between the groups, with 16 of the 43 queried symptoms endorsed significantly more often (Bonferroni-corrected P < .00116) by MTBI patients than by controls. A total of 23 of the 43 symptoms were endorsed at a significantly higher severity by MTBI patients. The MTBI sample showed significantly higher within-group variability, with severity ranging from minimal to high. Perhaps because of this high variability, a logistic regression used to discriminate MTBI patients from controls was only moderately successful. This indicates that subjective complaints probably cannot be used, even soon after injury, to decisively distinguish individual MTBI patients from uninjured persons. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Glenrose Rehabil Hosp, Dept Psychol, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, Dept Psychol, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.	cpaniak@cha.ab.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUAS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; YOUNG RP, 1995, STUD AM POLIT DEV, V9, P1, DOI 10.1017/S0898588X00001164	37	68	68	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2002	17	4					319	334	PII S0887-6177(01)00115-9	10.1016/S0887-6177(01)00115-9			16	Psychology, Clinical; Psychology	Psychology	556DW	WOS:000175834900002	14589717	Bronze			2021-06-18	
J	Luis, CA; Mittenberg, W				Luis, CA; Mittenberg, W			Mood and anxiety disorders following pediatric traumatic brain injury: A prospective study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PSYCHIATRIC-DISORDERS; CHILDREN; ADOLESCENTS; SEQUELAE; INTERVIEWS	Studies utilizing standardized instruments for assessing mood and/or anxiety disorders following pediatric traumatic brain injury have seldom been reported in the literature. Previous reports have largely focused on cognitive impairment, behavioral dysfunction, or adaptive functioning, and have typically relied on parental informants. In this study, children hospitalized for mild (N = 42) and moderate/severe (N = 19) brain injury were assessed 6-months postinjury using the Anxiety disorders Module A and the Mood disorders Module C of the Diagnostic Interview Schedule for Children - IV Revision (DISC-IV). The data collected for the brain injury groups were compared to an orthopedic control group (N = 35). The relationship between a new onset mood and/or anxiety disorder (NOD) and injury severity indices was examined. Sequential logistical regression was also utilized to examine the impact of a brain injury, demographic variables, preinjury psychiatric disturbance, development disorders, litigation status and postinjury environmental stress on emotional outcome. Results indicated a relationship between brain injury and NOD. Multivariate analysis demonstrated that postinjury level of stress and severity of brain injury were the most robust predictors of NOD, accounting for 23% of the variance in the model. These results support the premise that the development of a mood and/or anxiety disorder following pediatric head injury is mediated by multiple determinants. The findings suggest that early psychosocial assessment and interventions aimed at increasing a child's coping may attenuate the emotional consequences of pediatric brain injury.	Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA	Luis, CA (corresponding author), 13251 SW 16th Ct, Davie, FL 33325 USA.						Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARRY C, 1997, 25 ANN M INT NEUR SO; Binder LM, 1997, AM J PSYCHIAT, V154, P135; Black P, 1981, BRAIN DYSFUNCTION CH, P171; BLOOM D, 1999, J INT NEUROPSYCH SOC, V5, P127; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CODDINGTON RD, 1972, J PSYCHOSOM RES, V16, P7, DOI 10.1016/0022-3999(72)90018-9; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FALLON T, 1994, J CHILD PSYCHOL PSYC, V35, P1391, DOI 10.1111/j.1469-7610.1994.tb01282.x; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HODGES K, 1993, J CHILD PSYCHOL PSYC, V34, P49, DOI 10.1111/j.1469-7610.1993.tb00967.x; Kaplan HI, 1994, SYNOPSIS PSYCHIAT; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; Lund R., 1985, Journal of Vertebrate Paleontology, V5, P1; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P106; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; PATRICK PD, 1998, BRAIN INJURY SOURCE, V2, P26; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; ZAHNER GEP, 1991, J AM ACAD CHILD PSY, V30, P659, DOI 10.1097/00004583-199107000-00020	40	68	70	0	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	3					270	279		10.1076/jcen.24.3.270.982			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	549MR	WOS:000175448400002	11992209				2021-06-18	
J	Arand, M; Melzner, H; Kinzl, L; Bruckner, UB; Gebhard, F				Arand, M; Melzner, H; Kinzl, L; Bruckner, UB; Gebhard, F			Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans	LANGENBECKS ARCHIVES OF SURGERY			English	Article						traumatic brain injury; inflammatory response; interleukin-6; interleukin-12; malone dialdehyde	ACUTE-PHASE RESPONSE; HEAD-INJURY; CEREBROSPINAL-FLUID; ADHESION MOLECULES; INTERLEUKIN-6; PLASMA; EPIDEMIOLOGY; HYPOTHERMIA; CYTOKINES; SEVERITY	The inflammatory response following isolated traumatic brain injury (TBI) is characterised by the release of pro- and anti-inflammatory mediators. In order to determine the important mediators regarding survival and outcome of patients with severe traumatic isolated head injuries, we performed this prospective preclinical and clinical study starting upon arrival at the site of the accident. After approval by the local ethics board committee, 94 multiple-injury patients were. enrolled. Of these, 72 patients suffered from major injuries; the other 22 patients had a severe isolated brain injury and were allotted to subsets of survival or nonsurvival. Of the pro- and antiinflammatory mediators (cytokines, arachidonic acid metabolites and soluble adhesion molecules), interleukin-6 (IL-6), IL-12 and malone dialdehyde (MDA) appeared to be of specific importance; maximum IL-6 plasma levels were eightfold higher in cases of nonsurvival than in those of survival. Patients that did not survive TBI were the only ones to express an IL-12 increase, whereas survivors and patients with other major trauma did not show any increase within the first 24 h. An early distinct decrease of MDA showed in patients who did not survive TBI, in contrast to survivor patients who exposed almost constant levels during the first 24 h.	Univ Ulm, Dept Trauma Surg Hand & Reconstruct Surg, D-89075 Ulm, Germany	Gebhard, F (corresponding author), Univ Ulm, Dept Trauma Surg Hand & Reconstruct Surg, Steinhovelstr 9, D-89075 Ulm, Germany.						BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bell MJ, 1997, ACT NEUR S, V70, P96; Bitsch A, 1998, STROKE, V29, P2129, DOI 10.1161/01.STR.29.10.2129; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hans VHJ, 1999, NEUROREPORT, V10, P409; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KOCHANEK P, 1997, TRAUMATIC BRAIN INJU, V6, P2; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KOSSMANN T, 1996, SHOCK SEPSIS ORGAN F, P263; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MORGANTIKOSSMAN.MC, 1997, IMMUNE RESPONSES NER, P159; MOVAT HZ, 1987, J LAB CLIN MED, V110, P668; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; POBER JS, 1990, PHYSIOL REV, V70, P427; Povlishock JT, 1999, ACT NEUR S, V73, P15; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	31	68	79	1	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	1435-2443			LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	JUL	2001	386	4					241	248		10.1007/s004230100204			8	Surgery	Surgery	461AA	WOS:000170341700001	11466564				2021-06-18	
J	Exner, GU				Exner, GU			Missed chronic anterior Monteggia lesion - Closed reduction by gradual lengthening and angulation of the ulna	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							RADIAL HEAD; CHILDREN; DISLOCATION; MANAGEMENT	Two consecutive cases of chronic dislocation of the head of the radius after missed Bado type-I Monteggia lesions are presented. Reduction was successfully achieved in both patients after ulnar corticotomy, gradual lengthening and angulation of the ulna using an external fixator. Open reduction or reconstruction of the radio-ulnar capitellar joint was not undertaken. The age at injury was seven years in the older and two years in the younger patient, The time from injury to treatment was five years in the older and three months in the younger child. At follow-up, nine years after completion of treatment in the older and eight months in the younger patient, both show satisfactory movement, function of the forearm and reduction of the head of the radius. This technique may be considered in missed Monteggia lesions before open procedures on the radio-ulnar capitellar joint are undertaken.	Univ Zurich, Orthopad Klin, Zurich, Switzerland	Exner, GU (corresponding author), Univ Klin Zurich, Sect Paediat & Tumour Orthopaed, Forchstr 340, CH-3008 Zurich, Switzerland.						Bado J L, 1967, Clin Orthop Relat Res, V50, P71; Bell Tawse AJ, 1965, J BONE JOINT SURG BR, V47, P718; HIRAYAMA T, 1987, J BONE JOINT SURG BR, V69, P639; Inoue G, 1998, ACTA ORTHOP SCAND, V69, P73, DOI 10.3109/17453679809002361; JUDET R, 1962, PRESSE MED, V70, P689; KALAMCHI A, 1986, J BONE JOINT SURG AM, V68A, P615, DOI 10.2106/00004623-198668040-00022; LAMMENS J, 1991, J BONE JOINT SURG BR, V73, P412; LLOYDROBERTS GC, 1977, J BONE JOINT SURG BR, V59, P402; Rodgers WB, 1996, J BONE JOINT SURG AM, V78A, P1322, DOI 10.2106/00004623-199609000-00005; Seel MJ, 1999, J PEDIATR ORTHOPED, V19, P306, DOI 10.1097/00004694-199905000-00006	10	68	73	0	2	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X	2044-5377		J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	MAY	2001	83B	4					547	550		10.1302/0301-620X.83B4.11103			4	Orthopedics; Surgery	Orthopedics; Surgery	434WW	WOS:000168839700018	11380129				2021-06-18	
J	Kline, AE; Yu, J; Horvath, E; Marion, DW; Dixon, CE				Kline, AE; Yu, J; Horvath, E; Marion, DW; Dixon, CE			The selective 5-HT1a receptor agonist repinotan HCL attenuates histopathology and spatial learning deficits following traumatic brain injury in rats	NEUROSCIENCE			English	Article						trauma; neuroprotection; recovery; learning; controlled cortical impact injury	CONTROLLED CORTICAL IMPACT; ACUTE SUBDURAL-HEMATOMA; TRANSIENT FOREBRAIN ISCHEMIA; GLOBAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; REDUCED EVOKED RELEASE; CENTRAL-NERVOUS-SYSTEM; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEUROTROPHIC FACTOR	The selective 5-HT1A receptor agonist Repinotan HCl (BAY x3702) has been reported to attenuate cortical damage and improve functional performance in experimental models of cerebral ischemia and acute subdural hematoma. Using a clinically relevant contusion model of traumatic brain injury, we tested the hypothesis that a 4-h continuous infusion of Repinotan HCl (10 mug/kg/h i.v.) commencing 5 min post-injury would ameliorate functional outcome and attenuate histopathology. Forty isoflurane-anesthetized male adult rats were randomly assigned to receive either a controlled cortical impact (2.7 mm tissue deformation, 4 m/s) or sham injury (Injury/Vehicle = 10, Injury/MK-801 = 10, Injury/Repinotan HCl = 10, Sham/Vehicle = 10), then tested for vestibulomotor function on post-operative days 1-5 and for spatial learning on days 14-18. Neither Repinotan HCI nor the non-competitive N-methyl-D-aspartate receptor antagonist MK-801, which served as a positive control. improved vestibulomotor function on beam balance and beam walk tasks relative to the Injury/Vehicle group, but both did significantly attenuate spatial learning and memory deficits on a water maze task. Repinotan HCI also reduced hippocampal CAI and CA,,, neuronal loss, as welt as cortical tissue damage, compared to the Injury/Vehicle group at 4 weeks post-trauma. No significant difference in histological outcome was revealed between the Repinotan HCl- and MK-801-treated groups. These findings extend the therapeutic efficacy of Repinotan HCI to a contusion model of experimental brain injury and demonstrate for the first time that 5-HT1A receptor agonists confer neuroprotection and attenuate spatial learning deficits following controlled cortical impact injury. This treatment strategy may be beneficial in a clinical context where memory impairments are common following human traumatic brain injury. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Bayer AG, CNR Res, D-42096 Wuppertal, Germany; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), 3430 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS30318, NS40125] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R01NS040125, R01NS033150, P50NS030318, P01NS030318] Funding Source: NIH RePORTER		Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cryan JF, 1999, J PSYCHOPHARMACOL, V13, P278, DOI 10.1177/026988119901300310; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Galter D, 2000, MOL CELL NEUROSCI, V15, P446, DOI 10.1006/mcne.2000.0841; GERLACH I, 1998, J NEUROTRAUM, V15, P870; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; HJORTH S, 1985, J NEURAL TRANSM, V61, P131, DOI 10.1007/BF01253058; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1997, J NEUROTRAUMA ABSTR, V14, P170; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, HEAD TRAUMA, P65; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; MILLAN MJ, 1993, J PHARMACOL EXP THER, V264, P1364; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; RINK A, 1995, AM J PATHOL, V147, P1575; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yan Q, 1997, J COMP NEUROL, V378, P135; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	87	68	75	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	106	3					547	555		10.1016/S0306-4522(01)00300-1			9	Neurosciences	Neurosciences & Neurology	483NH	WOS:000171640800006	11591455				2021-06-18	
J	Nayak, S; Wheeler, BL; Shiflett, SC; Agostinelli, S				Nayak, S; Wheeler, BL; Shiflett, SC; Agostinelli, S			Effect of music therapy on mood and social interaction among individuals with acute traumatic brain injury and stroke	REHABILITATION PSYCHOLOGY			English	Article							SICKNESS IMPACT PROFILE	Objective: To investigate the efficacy of music therapy techniques as an aid in improving mood and social interaction after traumatic brain injury or stroke. Design: Eighteen individuals with traumatic brain injury or stroke were assigned either standard rehabilitation alone or standard rehabilitation along with music therapy (3 treatments per week for up to 10 treatments). Measures: Pretreatment and posttreatment assessments of participant self-rating of mood, family ratings of mood and social interaction, and therapist rating of mood and participation in therapy. Results: There was a significant improvement in family members' assessment of participants' social interaction in the music therapy group relative to the control group. The staff rated participants in the music therapy group as more actively involved and cooperative in therapy than those in the control group. There was a trend suggesting that self-ratings and family ratings of mood showed greater improvement in the music group than in the control group. Conclusions: Results lend preliminary support to the efficacy of music therapy as a complementary therapy for social functioning and participation in rehabilitation with a trend toward improvement in mood during acute rehabilitation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07107 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Montclair State Univ, Dept Mus, Upper Montclair, NJ 07043 USA	Nayak, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, ADMC 1404,30 Bergen St, Newark, NJ 07107 USA.						Behrens G. A., 1988, MUSIC THERAPY PERSPE, V5, P16; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CASSITY MD, 1976, J MUSIC THER, V13, P66, DOI 10.1093/jmt/13.2.66; Clair AA, 1997, J MUSIC THER, V34, P148, DOI 10.1093/jmt/34.3.148; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; ESLINGER P, 1993, MUSIC THERAPY BRAIN; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hanser SB, 1998, J GERONTOL, V49, P265, DOI 10.1093/geronj/49.6.P265; Hodges D. A., 1980, HDB MUSIC PSYCHOL; MACRAE A, 1992, AM J OCCUP THER, V46, P275, DOI 10.5014/ajot.46.3.275; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P267, DOI 10.1001/jama.275.4.267; McDowell I., 1996, MEASURING HLTH GUIDE, P194; MCKINNEY CH, 1990, J MUSIC THER, V27, P34, DOI 10.1093/jmt/27.1.34; POLLACK NJ, 1992, J MUSIC THER, V29, P54, DOI 10.1093/jmt/29.1.54; STANDLEY JM, 1994, RES MUSIC THERAPY TR; Steckler M A, 1998, J Long Term Home Health Care, V17, P42; THAUT MH, 1989, J MUSIC THER, V26, P155, DOI 10.1093/jmt/26.3.155	17	68	70	2	49	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2000	45	3					274	283		10.1037/0090-5550.45.3.274			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	338BZ	WOS:000088399400004					2021-06-18	
J	O'Dell, DM; Raghupathi, R; Crino, PB; Eberwine, JH; McIntosh, TK				O'Dell, DM; Raghupathi, R; Crino, PB; Eberwine, JH; McIntosh, TK			Traumatic brain injury alters the molecular fingerprint of TUNEL-positive cortical neurons in vivo: A single-cell analysis	JOURNAL OF NEUROSCIENCE			English	Article						TUNEL; brain injury; gene expression; cell death; caspase; aRNA amplification	SPATIAL MEMORY DEFICITS; BINDING PROTEIN CREB; MESSENGER-RNA; NEUROTROPHIC FACTOR; DNA FRAGMENTATION; GENE-EXPRESSION; GLOBAL-ISCHEMIA; IMPACT INJURY; RAT-BRAIN; APOPTOTIC NEURONS	The cerebral cortex is selectively vulnerable to cell death after traumatic brain injury (TBI). We hypothesized that the ratio of mRNAs encoding proteins important for cell survival and/or cell death is altered in individual damaged neurons after injury that may contribute to the cell's fate. To investigate this possibility, we used amplified antisense mRNA (aRNA) amplification to examine the relative abundance of 31 selected candidate mRNAs in individual cortical neurons with fragmented DNA at 12 or 24 hr after lateral fluid percussion brain injury in anesthetized rats. Only pyramidal neurons characterized by nuclear terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUNEL) reactivity with little cytoplasmic staining were analyzed. For controls, non-TUNEL-positive neurons from the cortex of sham-injured animals were obtained and subjected to aRNA amplification. At 12 hr after injury, injured neurons exhibited a decrease in the relative abundance of specific mRNAs including those encoding for endogenous neuroprotective proteins. By 24 hr after injury, many of the mRNAs altered at 12 hr after injury had returned to baseline (sham-injured) levels except for increases in caspase-2 and bax mRNAs. These data suggest that TBI induces a temporal and selective alteration in the gene expression profiles or "molecular fingerprints" of TUNEL-positive neurons in the cerebral cortex. These patterns of gene expression may provide information about the molecular basis of cell death in this region after TBI and may suggest multiple avenues for therapeutic intervention.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,Room 105-C,Hayden Hall, Philadelphia, PA 19104 USA.		Eberwine, James/B-2247-2010		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG009900, R01-AG9900] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, P50 NS008803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG009900] Funding Source: NIH RePORTER		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BLAHA GR, 2000, IN PRESS NEUROSCIENC; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brandoli C, 1998, J NEUROSCI, V18, P7953; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DASH PK, 1995, J NEUROSCI, V15, P2030; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; EBERWINE J, 1995, NEUROSCIENTIST, V1, P200; Ferrand-Drake M, 1999, NEUROSCIENCE, V93, P537, DOI 10.1016/S0306-4522(99)00181-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorter JA, 1997, J NEUROSCI, V17, P6179; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kume T, 1997, BRAIN RES, V756, P200, DOI 10.1016/S0006-8993(97)00195-9; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELCHER T, 1996, NATURE, V379, P464; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morikawa E, 1998, J NEUROSCI, V18, P9727; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nibuya M, 1996, J NEUROSCI, V16, P2365; O'Dell DM, 1998, BIOTECHNIQUES, V25, P566, DOI 10.2144/98254bm04; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RINK A, 1995, AM J PATHOL, V147, P1575; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Rump A, 1996, J CEREBR BLOOD F MET, V16, P1362, DOI 10.1097/00004647-199611000-00034; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tuunanen J, 1999, NEUROSCIENCE, V94, P473, DOI 10.1016/S0306-4522(99)00251-1; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	65	68	71	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 1	2000	20	13					4821	4828					8	Neurosciences	Neurosciences & Neurology	327WC	WOS:000087816300008	10864939				2021-06-18	
J	Kelly, DF; Kozlowski, DA; Haddad, E; Echiverri, A; Hovda, DA; Lee, SM				Kelly, DF; Kozlowski, DA; Haddad, E; Echiverri, A; Hovda, DA; Lee, SM			Ethanol reduces metabolic uncoupling following experimental head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; ethanol; excitotoxicity; glucose metabolism; NMDA receptor; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; CORTICAL IMPACT MODEL; EXTRACELLULAR LEVELS; ALCOHOL INGESTION; CONTUSION TRAUMA; RAT; INTOXICATION; ACETATE; EXCITOTOXICITY	Previous investigations have shown that ethanol is neuroprotective following experimental traumatic brain injury (TBI). This study sought to determine if the neuroprotective effects of ethanol in a controlled cortical impact (CCI) injury model are related to its effects on cerebral glucose metabolism and blood flow. Adult rats were given ethanol (1.0 g/kg) or saline by intraperitoneal injection followed 40 min later by injury. Regional cerebral blood flow (CBF) and cerebral metabolic rates of glucose (CMRglc) were determined immediately, and at 3, 6, 12, 24, and 72 h postinjury using quantitative autoradiography. Immediately after injury, CMRglc in the contusion core and penumbra was reduced in the ethanol group compared to the saline group: (core CMRglc: 52.2 +/- 16.0 versus 94.2 +/- 14.1 mu mol/100 g/min, respectively, p < 0.001; penumbral CMRglc: 58.2 +/- 12.8 versus 82.8 +/- 19.7 mu mol/100 g/min, respectively; p < 0.05) However, at 24 and 72 h postinjury, penumbral CMRglc in the ethanol group was increased compared to the saline group (p < 0.05 and p < 0.001, respectively). Regarding CBF, contusion core values in the ethanol group were elevated compared to the saline group immediately postinjury, (70.4 +/- 17.1 versus 31.5 +/- 27.8 mL/100 g/min, respectively (p < .05), and at 6, 12, and 24 h postinjury (p < 0.05). Penumbral CBF was also higher at 6 and 72 h in the ethanol group compared to the saline group (p < 0.05). These results indicate that low-dose ethanol is associated with a marked attenuation of immediate postinjury hyperglycolysis and with more normal glucose metabolism in the injury penumbra over the ensuing 3 days. Simultaneously, the reduction in CBF typically seen within the contusion core and penumbra after CCI is less severe when ethanol is present. The net effect of these changes is a decreased degree of uncoupling between glucose metabolism and CBF that otherwise occurs in the absence of ethanol. These changes may likely explain the neuroprotective effect of ethanol.	Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Kelly, DF (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Room 18-218A NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27544, NS 30308, NS37363] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS037363, R01NS027544] Funding Source: NIH RePORTER		ABEL EL, 1979, PHYSIOL PSYCHOL, V7, P391; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALTURA BM, 1982, FED PROC, V41, P2447; BARBOUR RL, 1993, ALCOHOL CLIN EXP RES, V17, P1319, DOI 10.1111/j.1530-0277.1993.tb05248.x; BENGMARK S, 1980, THROMB HAEMOSTASIS, V43, P203; BLOOM F, 1982, BRIT J PHARMACOL, V75, P251, DOI 10.1111/j.1476-5381.1982.tb08780.x; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BRUNO R, 1983, FORENSIC SCI INT, V21, P215, DOI 10.1016/0379-0738(83)90125-1; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; BUTCHER T, 1951, KLIN WOCHENSCHR, V20, P615; CARMICHAEL FJ, 1991, J PHARMACOL EXP THER, V259, P403; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; DEWIT H, 1990, ALCOHOL CLIN EXP RES, V14, P482; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ECKARDT MJ, 1988, BRAIN RES, V444, P53, DOI 10.1016/0006-8993(88)90912-2; ELMER O, 1984, HAEMOSTASIS, V14, P223; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GERSHMAN H, 1991, Journal of Emergency Medicine, V9, P307, DOI 10.1016/0736-4679(91)90371-L; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; GULYA K, 1991, BRAIN RES, V547, P129; HALT PS, 1992, ARCH NEUROL-CHICAGO, V49, P1178, DOI 10.1001/archneur.1992.00530350096025; HANNAK D, 1985, BIOL CHEM H-S, V366, P749, DOI 10.1515/bchm3.1985.366.2.749; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KELLY DF, 1995, CRIT CARE MED, V23, pA245; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; MATHEW RJ, 1991, AM J PSYCHIAT, V148, P292; MATHEW RJ, 1986, STROKE, V17, P1156, DOI 10.1161/01.STR.17.6.1156; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; NEWLIN DB, 1982, INT J NEUROSCI, V17, P145, DOI 10.3109/00207458208985916; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OTT JF, 1985, ALCOHOL CLIN EXP RES, V9, P59, DOI 10.1111/j.1530-0277.1985.tb05051.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SANO M, 1993, J STUD ALCOHOL, V54, P369, DOI 10.15288/jsa.1993.54.369; SCHWARTZ JA, 1993, ALCOHOL CLIN EXP RES, V17, P1119, DOI 10.1111/j.1530-0277.1993.tb05217.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VOLKOW ND, 1990, PSYCHIAT RES-NEUROIM, V35, P39, DOI 10.1016/S0165-1781(06)80006-5; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WENDT PE, 1994, J CEREBR BLOOD F MET, V14, P963, DOI 10.1038/jcbfm.1994.129; WHITE G, 1990, BRAIN RES, V507, P332, DOI 10.1016/0006-8993(90)90292-J; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	72	68	68	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					261	272		10.1089/neu.2000.17.261			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500001	10776911				2021-06-18	
J	Bagley, LJ; McGowan, JC; Grossman, RI; Sinson, G; Kotapka, M; Lexa, FJ; Berlin, JA; McIntosh, TK				Bagley, LJ; McGowan, JC; Grossman, RI; Sinson, G; Kotapka, M; Lexa, FJ; Berlin, JA; McIntosh, TK			Magnetization transfer imaging of traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article; Proceedings Paper	5th Annual Meeting of ISMRM	APR, 1997	VANCOUVER, CANADA	Int Soc Magnet Resonance Med		magnetization transfer (MT); magnetic resonance (MR); brain injuries	DIFFUSE AXONAL INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; HISTOPATHOLOGIC CORRELATION; MICROSCOPIC DISEASE; TRANSFER CONTRAST; MILD; MR; TOMOGRAPHY; DAMAGE	Magnetization transfer imaging (MTI) has been shown to be sensitive for the detection of white matter abnormalities in entities such as multiple sclerosis, progressive multifocal leukencephalopathy, and wallerian degeneration. Our hypothesis was that MTI would detect traumatic white matter abnormalities (TWMA) and provide information additional to that obtainable with routine spin- and gradient-echo imaging, We hypothesized that the presence of TWMA defined by MTI would correlate with outcome following TBI. Twenty-eight victims of head trauma and 15 normal controls underwent magnetic resonance imaging including MTI. Magnetization transfer ratios (MTR) were calculated for areas of shearing injury and for normal-appearing white matter (NAWM) in locations frequently subject to diffuse axonal injury. Abnormal MTRs were detected in NAWM in eight patients. All eight had persistent neurologic deficits, including cognitive deficits, aphasia, and extremity weakness. Seven of the 28 patients had no abnormal findings on neurologic exam at discharge, transfer, or follow-up. None of these patients had an abnormal MTR in NAWM, In the remaining 13 patients, who had persistent neurologic deficits, no regions of abnormal MTR were detected in NAWM, MTI is a sensitive method for the detection of TWMA, Detection of abnormal MTR in NAWM that is prone to axonal injury may predict a poor patient outcome, The presence of normal MTR in NAWM in these areas does not necessarily confer a good outcome, however. (C) 2000 Wiley-Liss, Inc.	Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA	Bagley, LJ (corresponding author), Univ Penn, Med Ctr, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.	bagley@oasis.rad.upenn.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R55NS034353, R29NS034353, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS34353] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FARBER M, 1994, SPORTS ILLUSTRATED, V81, P39; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1993, HEAD INJURY, P137; GROSSMAN RI, 1988, RSNA 74 SCI ASS ANN; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MITTL RL, 1993, AM J NEURORADIOL, V14, P881; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SINSON G, 1996, J NEUROSURG, V84, P113; STRICH SJ, 1961, LANCET, V2, P443; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; VANBUCHEM MA, 1996, AJNR, V18, P1287; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	37	68	74	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JAN	2000	11	1					1	8		10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	323NT	WOS:000087572400001	10676614	Bronze			2021-06-18	
J	Zarkovic, N; Zarkovic, K; Schaur, RJ; Stolc, S; Schlag, G; Redl, H; Waeg, G; Borovic, S; Loncaric, I; Juric, G; Hlavka, V				Zarkovic, N; Zarkovic, K; Schaur, RJ; Stolc, S; Schlag, G; Redl, H; Waeg, G; Borovic, S; Loncaric, I; Juric, G; Hlavka, V			4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor	LIFE SCIENCES			English	Article; Proceedings Paper	International Symposium on Drug Action on Reactive Oxygen Species	SEP 29-30, 1997	CASTLE SMOLENICE, SLOVAKIA	Slovak Acad Sci, Inst Exptl Pharmacol, Centaur Pharmaceut Inc, Slovak Pharmacol Soc, Slovak Soc Biochem & Molec Biol, Free Radical Sect		oxidative stress; lipid peroxidation; 4-hydroxynonenal; brain; c-fos; immunohistochemistry; cell growth; free radicals; reactive oxygen species	CELL	Immunohistochemical analysis of the distribution of the lipid peroxidation product 4-hydroxynonenal (HNE) in the brain of baboons exposed to experimental hemorrhagic traumatic shock or sepsis showed that systemic oxidative stress and the thereby generated HNE affect the blood:brain barrier and the regulation of cerebral blood now determing secondary brain damage. Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain. After reperfusion, HNE disappeared from the blood vessels but remained in neurones and in glial cells. Since HNE modulates cell proliferation and differentiation (including proto-oncogene expression), it is postulated that HNE might have prominent local and systemic effects that are not only harmful but beneficial too, determing the outcome of various pathophysiologcial conditions based on oxidative stress.	Rudjer Boskovic Inst, Zagreb, Croatia; KBC Rebro, Inst Neuropathol, Fac Med, Zagreb, Croatia; Inst Biochem, Graz, Austria; Slovak Acad Sci, Inst Expt Pharmacol, Bratislava 84216, Slovakia; Ludwig Boltzmann Inst Traumatol, Vienna, Austria	Zarkovic, N (corresponding author), Rudjer Boskovic Inst, Pob 1016, Zagreb, Croatia.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ESTERBAU.H, 1967, MONATSH CHEM, V98, P1884, DOI 10.1007/BF01167149; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; HORAKOVA L, 1990, PHYSIOL BOHEMOSLOV, V39, P513; Kreuzer T, 1997, CANCER BIOTHER RADIO, V12, P131, DOI 10.1089/cbr.1997.12.131; Schlag G, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P3; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Zarkovic K, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P146; ZARKOVIC N, 1993, CELL BIOCHEM FUNCT, V11, P279, DOI 10.1002/cbf.290110409; ZARKOVIC N, 1994, FREE RADICAL BIO MED, V16, P877, DOI 10.1016/0891-5849(94)90208-9	9	68	69	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	OCT 1	1999	65	18-19					1901	1904		10.1016/S0024-3205(99)00444-0			4	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	245GX	WOS:000083099100008	10576434				2021-06-18	
J	Belayev, L; Alonso, OF; Huh, PW; Zhao, WZ; Busto, R; Ginsberg, MD				Belayev, L; Alonso, OF; Huh, PW; Zhao, WZ; Busto, R; Ginsberg, MD			Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						albumin; histopathology; neuroprotection; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; COLLOID ONCOTIC PRESSURE; HUMAN EXTRACELLULAR FLUIDS; SERUM-ALBUMIN; MODERATE HYPOTHERMIA; BARRIER DISRUPTION; HYPOCHLOROUS ACID; CRYOGENIC INJURY; DRUG-THERAPY; HEAD-INJURY	We have recently shown that high-dose human serum albumin (HSA) therapy confers marked histological protection in experimental middle cerebral artery occlusion. Thus, the purpose of this study was to determine whether treatment with high-dose HSA would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, the fluid percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and 30% oxygen and received right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). Cranial and rectal temperatures were monitored throughout the experiment and held at normothermic levels (36.5-37.5 degrees C) by a warming lamp above the animal's head. The agent (25% human serum albumin, HSA) or vehicle (sodium chloride 0.9%) was administered i.v. (1% of body weight) 15 min after trauma. Behavioral function was evaluated in all rats before and after TBI (at 2 h, 24 h, 48 h, 72 h, and 7 days). Neurological function was graded on a scale of 0-12 (normal score 0; maximal score = 12). Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas in the superficial, middle and deep layers of cortex and in the underlying fimbria were measured. HSA significantly improved the neurological score compared to saline at 24 h, 72 h, and 7 days after TBI (6.0 +/- 0.6 [albumin] versus 8.4 +/- 0.5 [saline]; 3.6 +/- 0.7 versus 6.8 +/- 1.0; and 2.6 +/- 0.6 versus 5.7 +/- 0.8, respectively; p < 0.05). HSA therapy also significantly reduced total contusion area (0.89 +/- 0.2 versus 1.82 +/- 0.3 mm(2); p = 0.02). Our findings document that high-concentration albumin therapy instituted 15 min after trauma significantly improves the neurological score and reduces histological damage. We believe that this pharmacological agent may have promising potential for the clinical treatment of brain injury.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol, Neurotrauma Res Ctr, Miami, FL 33101 USA	Belayev, L (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.	lbelayev@stroke.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS005820, P50NS030291, P01NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291, NS 05820] Funding Source: Medline		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Ginsberg MD, 1995, NEUROSCIENTIST, V1, P95; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HU ML, 1993, J LAB CLIN MED, V121, P257; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KOCHWESER J, 1976, NEW ENGL J MED, V294, P311, DOI 10.1056/NEJM197602052940605; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUI T, 1993, NEUROSURGERY, V32, P79, DOI 10.1227/00006123-199301000-00012; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; SMITH C, 1992, FOOD CHEM TOXICOL, V30, P483, DOI 10.1016/0278-6915(92)90099-7; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; TOMITA H, 1994, ACTA NEUROCHIR, P547; TRIGATTI BL, 1995, BIOCHEM J, V308, P155, DOI 10.1042/bj3080155; TULLIS JL, 1977, JAMA-J AM MED ASSOC, V237, P355; TULLIS JL, 1977, JAMA-J AM MED ASSOC, V237, P460, DOI 10.1001/jama.237.5.460; WASIL M, 1987, BIOCHEM J, V243, P219, DOI 10.1042/bj2430219; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005	42	68	70	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					445	453		10.1089/neu.1999.16.445			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800002	10391362				2021-06-18	
J	Gleckman, AM; Bell, MD; Evans, RJ; Smith, TW				Gleckman, AM; Bell, MD; Evans, RJ; Smith, TW			Diffuse axonal injury in infants with nonaccidental craniocerebral trauma - Enhanced detection by beta-amyloid precursor protein immunohistochemical staining	ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE			English	Article							PERMANENT BRAIN-DAMAGE; HEAD-INJURY; MENTAL-RETARDATION; SHAKING; MARKER; APP	Objective.-Accurate identification of diffuse axonal injury is important in the forensic investigation of infants who have died from traumatic brain injury. beta-Amyloid precursor protein (beta-APP) immunohistochemical staining is highly sensitive in identifying diffuse axonal injury. However the effectiveness of this method in brain-injured infants has not been well established. The present study was undertaken to assess the utility of beta-APP immunohistochemistry in detecting diffuse axonal injury in infants with either shaken baby syndrome or blunt head trauma. Materials and Methods.-Archival formalin-fixed, paraffin-embedded blocks from infants (<1 year old) with shaken baby syndrome (7 cases) and blunt head trauma (3) and blocks from 7 control cases that included nontraumatic cerebral edema (1), acute hypoxic-ischemic encephalopathy (1), and normal brain (5) were immunostained for beta-APP. A semiquantitative assessment of the severity of axonal staining was made. Corresponding hematoxylin-eosin-stained sections were examined for the presence of axonal swellings. Results.-Immunostaining for beta-APP identified diffuse axonal injury in 5 of 7 infants with shaken baby syndrome and 2 of 3 infants with blunt head trauma. Immunoreactive axons were easily identified and were present in the majority of the sections examined. By contrast, hematoxylineosin staining revealed axonal swellings in only 3 of 7 infants with shaken baby syndrome and 1 of 3 infants with blunt head trauma. Most of these sections had few if any visible axonal swellings, which were often overlooked on initial review of the slides. No beta-APP immunoreactivity was observed in any of the 7 control cases. Conclusions.-Immunostaining for beta-APP can easily and reliably identify diffuse axonal injury in infants younger than 1 year and is considerably more sensitive than routine hematoxylin-eosin staining. We recommend its use in the forensic evaluation of infants with fatal craniocerebral trauma.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; Med Examiner Dept, Miami, FL USA; Off Chief Med Examiner, Boston, MA USA	Smith, TW (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol Neuropathol, 55 Lake Ave N, Worcester, MA 01655 USA.						BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Di Maio DJ, 1993, FORENSIC PATHOLOGY; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, V1, P85; LEESTMA JE, 1995, PEDIAT NEUROPATHOLOG, P243; MAXWELL WI, 1997, J NEUROTRAUM, V15, P419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MERTEN DF, 1983, PEDIATR ANN, V12, P882, DOI 10.3928/0090-4481-19831201-06; NAOUMENKO J, 1967, J NEUROPATH EXP NEUR, V26, P669, DOI 10.1097/00005072-196710000-00012; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHERRIFF FE, 1993, ACTA NEUROPATHOL, V87, P57; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4	24	68	68	0	3	COLLEGE AMER PATHOLOGISTS	NORTHFIELD	C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA	0003-9985			ARCH PATHOL LAB MED	Arch. Pathol. Lab. Med.	FEB	1999	123	2					146	151					6	Medical Laboratory Technology; Medicine, Research & Experimental; Pathology	Medical Laboratory Technology; Research & Experimental Medicine; Pathology	166PM	WOS:000078586000013	10050789				2021-06-18	
J	Roberts, WO; Brust, JD; Leonard, B				Roberts, WO; Brust, JD; Leonard, B			Youth ice hockey tournament injuries: rates and patterns compared to season play	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; injury severity; injury mechanism	SPINAL-INJURIES; FACE MASKS; HEAD; NECK	Objective: To prospectively document the incidence of game injury rates in youth ice hockey tournaments to compare with season-long game injury rates and to analyze the injuries occurring at tournaments by mechanism, type, body location, severity, player position, and period of play. Design: A prospective injury report form completed for injured players by the tournament athletic trainer. Setting: Four boys' tournaments and one girls' tournament during the 1993-94 season. Participants: 807 boys and girls, ages 9-19. Measurements/Main Results: 60 injuries occurred in boys and 4 occurred in girls. There were 26 boys with significant injuries and no girls with significant injuries. The significant game injury rates per 1000 player hours were 50.9 for boys combined, 57.9 for boys' Peewee A, 42.7 for boys' Bantam A, 64.8 for boys' varsity high school, 44.8 for boys' Junior Gold, and 0 for girls' Peewee A and B. Cerebral concussion comprised 15% of boys' injuries. Conclusions: The significant injury rate for boys' tournament game play was 4-6 times higher than the season game injury rates in two previous season-long studies. in boys' games, 65% of "all" injuries and 77% of "significant" injuries were related to collisions. The girls' rules of play do not allow body checking, and there were no significant injuries in girls' games. The boys had high rates of cerebral concussion injury at all age levels. Minimizing the frequency and intensity of collisions in the boys' game may decrease the injury rates, especially in the tournament setting.	MinnHealth SportsCare, White Bear Lake, MN 55110 USA; Univ Minnesota, Sch Med, Dept Family Practice & Community Hlth, Minneapolis, MN 55455 USA; Allina Fdn, Minnetonka, MN USA; Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA	Roberts, WO (corresponding author), MinnHealth SportsCare, 4786 Banning Ave, White Bear Lake, MN 55110 USA.	rober037@maroon.tc.umn.edu		Roberts, William O/0000-0003-4517-4330			BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CASTALDI C R, 1991, Dental Clinics of North America, V35, P647; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; Kelly JP, 1997, NEUROLOGY, V48, P581; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; MURRAY TM, 1995, PEDIATRICS, V95, P419; PARAYRE R, 1989, ASTM STP, V1050, P37; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; RISSER WL, 1994, PEDIATRICS, V94, P757; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1991, CAN J SURG, V34, P63; Tegner Y, 1991, Br J Sports Med, V25, P87; *US HOCK ANN GUID, 1997, PUBL US, P75; Watson RC, 1997, CLIN J SPORT MED, V7, P192, DOI 10.1097/00042752-199707000-00007	26	68	69	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	1999	31	1					46	51		10.1097/00005768-199901000-00009			6	Sport Sciences	Sport Sciences	155ZF	WOS:000077976400008	9927009				2021-06-18	
J	Inman, TH; Vickery, CD; Berry, DTR; Lamb, DG; Edwards, CL; Smith, GT				Inman, TH; Vickery, CD; Berry, DTR; Lamb, DG; Edwards, CL; Smith, GT			Development and initial validation of a new procedure for evaluating adequacy of effort given during neuropsychological testing: The letter memory test	PSYCHOLOGICAL ASSESSMENT			English	Article							FORCED-CHOICE METHOD; TRAUMATIC BRAIN-INJURY; DIGIT RECOGNITION TEST; MILD HEAD TRAUMA; REY 15-ITEM TEST; IMPAIRMENT; DEFICITS; VALIDITY; PERFORMANCE; INCENTIVES	The authors report on results from a new procedure for evaluating adequacy of effort given during neuropsychological testing. The letter memory test (LMT) is a computer-administered, 45-item, forced-choice recognition task that uses consonant letters as stimuli and manipulates face difficulty level along 2 dimensions: number of letters to be remembered and number of choices amongst which the target stimulus must be identified. In 3 studies that included either analogue or known groups designs, the LMT discriminated poorly motivated from well-motivated groups at a moderately high level of accuracy, which was comparable to that of the Digit Memory Test and superior to that of the 21-Item Test. The internal consistency reliability of the LMT was also high.	Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; Duke Univ, Med Ctr, Dept Endocrinol & Psychiat, Durham, NC 27706 USA	Berry, DTR (corresponding author), Univ Kentucky, Dept Psychol, 125 Kastle Hall, Lexington, KY 40506 USA.						ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Beck A. T., 1993, BECK DEPRESSION INVE; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERRY D, 1996, 104 ANN CONV AM PSYC; BIGLER ED, 1990, J CONSULT CLIN PSYCH, V58, P244, DOI 10.1037/0022-006X.58.2.244; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON R, 1978, AM J PSYCHIAT, V153, P7; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; LARRABEE GJ, 1992, FORENSIC REPORTS, V5, P257; Lee G.P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI [10.1037/1040-3590.4.1.43, DOI 10.1037/1040-3590.4.1.43]; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; Prigatano GP, 1997, ARCH CLIN NEUROPSYCH, V12, P609, DOI 10.1016/S0887-6177(97)00020-6; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; PRITCHARD D, 1992, FORENSIC REPORTS, V5, P287; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROGERS R, 1988, CLIN ASSESSMENT MALI; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Rosenthal R., 1991, META ANAL PROCEDURES, V1st; SCHMIDT JP, 1989, PROF PSYCHOL-RES PR, V20, P140, DOI 10.1037/h0092792; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Trueblood W, 1997, ARCH CLIN NEUROPSYCH, V12, P13, DOI 10.1016/S0887-6177(96)00027-3; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; WIDIGER TA, 1984, ARCH GEN PSYCHIAT, V41, P1005, DOI 10.1001/archpsyc.1984.01790210087011; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Youngjohn J.R., 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	52	68	68	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	1998	10	2					128	139		10.1037/1040-3590.10.2.128			12	Psychology, Clinical	Psychology	ZW310	WOS:000074397400006					2021-06-18	
J	Salame, P; Danion, JM; Peretti, S; Cuervo, C				Salame, P; Danion, JM; Peretti, S; Cuervo, C			The state of functioning of working memory in schizophrenia	SCHIZOPHRENIA RESEARCH			English	Article; Proceedings Paper	2nd European Neuroscience Meeting	SEP 24-28, 1996	STRASBOURG, FRANCE			schizophrenia; working memory; phonological loop; visuo-spatial; central executive; slowness	SHORT-TERM-MEMORY; CLOSED-HEAD INJURY; PARKINSONS-DISEASE; PHONOLOGICAL LOOP; PERFORMANCE; DYSFUNCTION; HALLUCINATIONS; HETEROGENEITY; GENERATION; IMPAIRMENT	The functioning of working memory in schizophrenic patients according to Baddeley's model was examined in two complementary experiments. Experiment 1 comprised 27 patients and their controls, matched in age and level of education. Of this pool, 20 pairs participated also in Experiment 2. Digit span, reading rate, and immediate serial recall assessed the functioning of the phonological loop. Corsi and pattern span tasks assessed the capacity of visuospatial memory. The central executive's ability to monitor two concurrent tasks was evaluated in a dual task paradigm, and its capacity to control action in a random generation task. A preliminary jet of analyses showed that the patients' performances were reduced in all tasks explored, except in digit span. This initial pattern changed consistently after controlling for reading rate. While slow and fast reading patients were comparable in demographic and clinical criteria, slow reading patients showed impaired performance in all tasks, whereas fast reading patients exhibited reduced performance in visuo-spatial tasks and in the random generation task only. The state of functioning of working memory in schizophrenia appears, therefore, to vary consistently among the components of the model and is markedly impaired in slow reading patients. The implication of slowness are discussed. (C) 1998 Elsevier Science B.V.	Hop Civil, Dept Psychiat, INSERM, U405, F-67091 Strasbourg, France	Salame, P (corresponding author), Hop Civil, Dept Psychiat, INSERM, U405, F-67091 Strasbourg, France.	salame@alsace.u-strasbg.fr		DANION, Jean-Marie/0000-0002-1980-1006			American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th ed., P273; ANDREASEN NC, 1987, PSYCHIAT PSYCHOBIOL, V6, P1; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BADDELEY AD, 1975, J VERB LEARN VERB BE, V14, P575, DOI 10.1016/S0022-5371(75)80045-4; BADDELEY AD, 1993, CURR BIOL, V3, P563, DOI 10.1016/0960-9822(93)90059-W; BADDELEY AD, 1994, MEMORY SYSTEMS, V11, P351; Beats BC, 1996, PSYCHOL MED, V26, P591, DOI 10.1017/S0033291700035662; Bentall R. P., 1993, J MENTAL HLTH, V2, P223, DOI [10.3109/09638239309003768, DOI 10.3109/09638239309003768]; Brebion G, 1997, PSYCHOL MED, V27, P383, DOI 10.1017/S0033291796004448; CARDNO AG, 1995, SCHIZOPHR RES, V17, P153, DOI 10.1016/0920-9964(95)95686-4; CLARE L, 1993, NEUROPSYCHOLOGIA, V31, P1225, DOI 10.1016/0028-3932(93)90070-G; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; COLLE HA, 1976, J VERB LEARN VERB BE, V15, P17, DOI 10.1016/S0022-5371(76)90003-7; CONRAD R, 1964, BRIT J PSYCHOL, V55, P75, DOI 10.1111/j.2044-8295.1964.tb00899.x; CROW TJ, 1995, SCHIZOPHR RES, V17, P135, DOI 10.1016/0920-9964(95)00059-U; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DAVID AS, 1993, BRIT J CLIN PSYCHOL, V32, P431, DOI 10.1111/j.2044-8260.1993.tb01077.x; Della Sala S., 1997, VISUAL PATTERNS TEST; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; FLEMING K, 1995, PSYCHIAT RES, V56, P155, DOI 10.1016/0165-1781(95)02589-3; Fournet N, 1996, J NEUROL NEUROSUR PS, V60, P313, DOI 10.1136/jnnp.60.3.313; Gathercole S. E., 1993, WORKING MEMORY LANGU; GOLDBERG TE, 1995, SCHIZOPHR RES, V17, P147, DOI 10.1016/0920-9964(95)00060-Y; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; Haddock G, 1996, PERS INDIV DIFFER, V20, P753, DOI 10.1016/0191-8869(96)00006-2; JOYCE EM, 1991, NEUROPSYCHOLOGIA, V29, P709, DOI 10.1016/0028-3932(91)90067-I; KOLB B, 1983, J NERV MENT DIS, V171, P435, DOI 10.1097/00005053-198307000-00008; Kryter K.D., 1970, EFFECTS NOISE MAN, V1st; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; LEVY BA, 1971, J VERB LEARN VERB BE, V10, P123, DOI 10.1016/S0022-5371(71)80003-8; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOGIE RH, 1993, MEMORY EVERYDAY LIFE, P173; MCKENNA PJ, 1990, PSYCHOL MED, V20, P967, DOI 10.1017/S0033291700036667; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MORRIS RG, 1986, COGNITIVE NEUROPSYCH, V3, P77, DOI 10.1080/02643298608252670; NELSON HE, 1990, PSYCHOL MED, V20, P357, DOI 10.1017/S0033291700017670; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; Rizzo L, 1996, NEUROPSYCHOLOGY, V10, P376, DOI 10.1037/0894-4105.10.3.376; SALAME P, 1989, Q J EXP PSYCHOL-A, V41, P107, DOI 10.1080/14640748908402355; SALAME P, 1982, J VERB LEARN VERB BE, V21, P150, DOI 10.1016/S0022-5371(82)90521-7; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SALWAY AFS, 1995, BRIT J PSYCHOL, V86, P253, DOI 10.1111/j.2044-8295.1995.tb02560.x; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TAMLYN D, 1992, PSYCHOL MED, V22, P101, DOI 10.1017/S0033291700032773; TSUANG MT, 1995, SCHIZOPHR RES, V17, P161, DOI 10.1016/0920-9964(95)00057-S; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VERDOUX H, 1995, SCHIZOPHR RES, V14, P133, DOI 10.1016/0920-9964(94)00018-4	55	68	68	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	FEB 27	1998	30	1					11	29		10.1016/S0920-9964(97)00107-2			19	Psychiatry	Psychiatry	YZ142	WOS:000072224500002	9542785				2021-06-18	
J	Hillier, SL; Hiller, JE; Metzer, J				Hillier, SL; Hiller, JE; Metzer, J			Epidemiology of traumatic brain injury in south Australia	BRAIN INJURY			English	Article							HEAD TRAUMA; SEVERITY	Reviews of statewide hospital separations' summaries and medical record data from a major teaching hospital, were conducted to describe the epidemiology of traumatic brain injury (TBI) in South Australia (SA), and to document the demographics of the population affected and the nature of their injuries. The groups most at risk were defined for targeting preventive programmes, and predictions were made regarding their ongoing service needs, for more appropriate provision of care. The results indicate that SA experiences a high incidence of TBI. At 322 per 100 000 head of population annually, it exceeds studies (with comparable methodologies) in communities in the United States and Europe. The causes, nature and severity of the injuries were similar to those found in the international literature, as were the profiles of the population most at risk. Specifically, young males living in the country and working in manual trades showed the highest incidence, and were most likely to have sustained their TBI whilst driving a motor vehicle. When a formula to predict service needs was adapted using the SA data, it was apparent that hospitals in this state care for more than 4000 new cases of TBI each year and that, on discharge, over 1000 of these will have some degree of residual impairment and will therefore require some form of post-injury services.	UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA,AUSTRALIA; UNIV S AUSTRALIA,SCH PSYCHOL,ADELAIDE,SA 5001,AUSTRALIA			Hillier, Susan/D-4590-2009; Hiller, Janet E./A-5633-2008; Hillier, Susan/Q-7713-2019	Hillier, Susan/0000-0002-6071-6137; Hiller, Janet E./0000-0002-8532-4033; Hillier, Susan/0000-0002-6071-6137			*AD TRAUM REG, 1991, AD TRAUM REG REP; *AUSTR BUR STAT, 1992, 43084 AUSTR BUR STAT; *AUSTR BUR STAT, 1993, 27304 AUSTR BUR STAT; *AUSTR BUR STAT, 1993, 27224 AUSTR BUR STAT; BADCOCK KM, 1987, HEAD INJURY STUDY FL; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BRENNAN MA, 1981, IRISH MED J, V74, P5; CARLSSON GS, 1986, ACTA NEUROCHIR, V36, P13; Caveness W F, 1979, Adv Neurol, V22, P1; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; *INP SEP INF SYST, 1991, UNPUB; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; MacKenzie E J, 1989, Md Med J, V38, P725; PRIGATANO GP, 1991, AWARENESS DEFICIT BR, P3; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; SELECKI BR, 1981, INJURIES HEAD SPINE; Servadei F, 1985, J Neurosurg Sci, V29, P297; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; World Health Organization, 1978, INT CLASS DIS	25	68	68	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					649	659					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600004	9376833				2021-06-18	
J	Mukhin, AG; Ivanova, SA; Knoblach, SM; Faden, AI				Mukhin, AG; Ivanova, SA; Knoblach, SM; Faden, AI			New in vitro model of traumatic neuronal injury evaluation of secondary injury and glutamate receptor-mediated neurotoxicity	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; cell culture; glutamate antagonists; in vitro model; neuronal death	SPINAL-CORD INJURY; BRAIN INJURY; IN-VITRO; DEATH; NMDA; DEPRIVATION; CULTURE; ANTAGONISTS; BLOCKADE; GLUCOSE	The multiplicity and complexity of secondary injury processes following brain trauma in vivo make it difficult to elucidate the roles of specific injury mechanisms, As with other areas of CNS injury, such as ischemia, this has led to the development of in vitro models, Here we describe a new trauma model, in which standardized trauma is delivered to neuronal/glial cultures using a special mechanical device that produces concentric circular cuts in the cell layer. Changes in the number of circles (from 1 to 6) allows variation of injury severity, Comparison studies of cell death induced by such trauma in glial and neuronal/glial cultures demonstrated that glial cells are relatively resistant to this injury, and that the cell death after trauma to neuronal/glial cultures reflects primarily neuronal death, Consistent with other in vivo and in vitro studies, glutamate receptor antagonists MK 801 and MCPG were neuroprotective, Thus, this model appears useful for studying glutamatergic mechanisms involved in secondary injury, and may prove useful for evaluating certain pharmacological strategies for CNS trauma.	GEORGETOWN UNIV,MED CTR,GEORGETOWN INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007					PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR 306634-06] Funding Source: Medline		AMADOR E, 1963, CLIN CHEM, V9, P391; BIRRELL GJ, 1993, BRAIN RES, V607, P337, DOI 10.1016/0006-8993(93)91527-Y; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; CHENG B, 1995, J NEUROSCI, V15, P7095; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Flavin MP, 1996, EXP NEUROL, V139, P34, DOI 10.1006/exnr.1996.0078; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KEILHOFF G, 1993, NEUROREPORT, V5, P129, DOI 10.1097/00001756-199311180-00008; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; LUCAS JH, 1985, CNS TRAUMA, V2, P321; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, RECENT ADV EXCITATOR, P653; Mukhin A, 1996, J NEUROSCI, V16, P6012; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Regan R. F., 1994, Society for Neuroscience Abstracts, V20, P192; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; SHARPIRA Y, 1990, J NEUROTRAUM, V7, P131; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	32	68	71	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1997	14	9					651	663		10.1089/neu.1997.14.651			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XZ489	WOS:A1997XZ48900006	9337127				2021-06-18	
J	Gervasio, AH; Kreutzer, JS				Gervasio, AH; Kreutzer, JS			Kinship and family members' psychological distress after traumatic brain injury: A large sample study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; RELATIVES; PATIENT	Objective: To describe the level and type of psychological distress experienced by live-in relatives of people with traumatic brain injury (TBI) and to compare the distress of spouses with that of other relatives. Design: A 2 x 3 x 4 cross-sectional design was used, with two levels of kinship (parent/spouse); three categories of duration of coma (no coma, coma <1 week, coma >1 week); and three categories of time since injury (10-24 months; 25-48 months; >48 months), Multivariate analysis of variance ascertained differences in psychological distress among spouses and relatives. Regression analysis identified the psychiatric symptoms that accounted for ratings of perceived stress. Setting and Participants: Family members (N = 116) of a sample of outpatients with TBI, drawn from a database at a large urban medical center. Main Outcome Measures: The Brief Symptom inventory (BSI) and a perceived stress measure. Results: Over 40% of the relatives had clinically elevated scores on the BSI. The Obsessive Compulsive, Psychoticism, Paranoid Ideation and Hostility subscales were the most elevated. The BSI's Global Severity Index (GSI) correlated moderately with perceived stress. Spouses reported significantly more distress than other relatives (who were mostly parents) on all but three subscales. Male caregivers of female relatives with TBI displayed mote distress on the GSI than other gender combinations. Time since injury and patients' days In coma did not affect relatives' levels of distress. Conclusions: Standardized measures of psychological distress confirm the clinical impression that family caregivers of people with TBI feel alienated, isolated, overwhelmed, and mentally preoccupied. Spouses experience more distress, which suggests that earlier marital intervention may be useful. Further research should address the needs of male caregivers and ''cross-gender'' caregiving.		Gervasio, AH (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, POB 9809661, RICHMOND, VA 23298 USA.						BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUCHANAN K, 1992, COGN REH COMM INT SC; CAMPLAIR P, 1990, COMMUNITY INTEGRATIO; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; COHEN P, 1977, SOC CASEWORK-JCSW, V58, P223; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; DiMatteo M. R., 1982, ACHIEVING PATIENT CO; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST, V109; Gatz M., 1990, HDB PSYCHOL AGING; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GRIFFITH ER, 1992, SEXUALITY PERSON TRA; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HOROWITZ A, 1985, ANN REV GERONTOLOGY, V5, P195; KAY T, 1991, HEAD INJURY FAMILY M; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LITMAN TJ, 1974, SOC SCI MED, V8, P495, DOI 10.1016/0037-7856(74)90072-9; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199303000-00010, 10.1097/00001199-199303000-00010]; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SANDER AM, 1995, RELATIONSHIP COPING; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLIAMS J, 1991, HEAD INJURY FAMILY M; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009	38	68	69	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					14	26		10.1097/00001199-199706000-00003			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900003					2021-06-18	
J	Kelly, MP; Johnson, CT; Knoller, N; Drubach, DA; Winslow, MM				Kelly, MP; Johnson, CT; Knoller, N; Drubach, DA; Winslow, MM			Substance abuse, traumatic brain injury and neuropsychological outcome	BRAIN INJURY			English	Article							ACUTE ALCOHOL-INTOXICATION; CHRONIC COCAINE ABUSERS; SEVERE HEAD-INJURY; NERVOUS-SYSTEM; PREVALENCE; IMPAIRMENT; DEFICITS	The neuropsychological performance of 119 patients with severe closed traumatic brain injury (TBI) who had received toxicology screens at the time of trauma centre admission was examined. Three groups were created: normal screen, positive alcohol screen, or positive abused drugs screen (with or without the presence of alcohol). The admitting Glasgow Coma Scale (GCS) score was significantly lower in the positive alcohol screen group than the normal screen group, while the three groups did not differ in length of post-traumatic amnesia (PTA) or years of education. Neuropsychological assessment was conducted during inpatient rehabilitation: following resolution of PTA. Normal screen patients obtained significantly better scores than the abused-drugs patients on the Full Scale IQ (FIQ) and Verbal IQ (VIQ) indices of the Wechsler Adult Intelligence Scale--Revised and the Verbal Memory, General Memory, Attention-Concentration, and Delayed Recall indices of the Wechsler Memory Scale--Revised. Normal screen patients also scored significantly higher than positive alcohol screen patients on FIQ and VIQ indices and all five indices from the Wechsler Memory Scale-Revised. These data suggest the existence of an additive effect of substance abuse on neuropsychological outcome in TBI. Findings have potential implications for both acute management and rehabilitation of TBI.	TOWSON STATE UNIV, BALTIMORE, MD 21204 USA; TEL HASHOMER HOSP, KIRYAT ONO, ISRAEL	Kelly, MP (corresponding author), UNIV MARYLAND, MED SYST, SCH MED, R ADAMS COWLEY SHOCK TRAUMA CTR, 22 S GREENE ST, BALTIMORE, MD 21201 USA.						ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; BENOWITZ NL, 1992, CIBA F SYMP, V166, P125; BERRY J, 1993, DRUG ALCOHOL DEPEN, V32, P231, DOI 10.1016/0376-8716(93)90087-7; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BROOKS N, 1984, CLOSED HEAD INJURY, P41; BROWN E, 1992, AM J ROENTGENOL, V159, P137, DOI 10.2214/ajr.159.1.1609688; Carroll KM, 1995, PSYCHOL ASSESSMENT, V7, P349, DOI 10.1037/1040-3590.7.3.349; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DICRESCITO V, 1974, SURG FORUM, V25, P438; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Drubach D A, 1993, Md Med J, V42, P989; DRUBACH DA, 1994, CRIT CARE CLIN, V10, P635; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; ELMER O, 1984, HAEMOSTASIS, V14, P223; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; ELMER O, 1983, EUR SURG RES, V15, P268, DOI 10.1159/000128367; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Heaton R.K., 1991, COMPREHENSIVE NORMS; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSON WD, 1969, YALE J BIOL MED, V42, P71; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; LOBERG T, 1986, NEUROPSYCHOLOGICAL A, P415; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; MARR JJ, 1975, J LAB CLIN MED, V86, P253; McQueen J D, 1975, Surg Neurol, V4, P375; MILNER G, 1977, MED J AUSTRALIA, V1, P208, DOI 10.5694/j.1326-5377.1977.tb130632.x; MITTENBERG W, 1993, ARCH CLIN NEUROPSYCH, V8, P477, DOI 10.1016/0887-6177(93)90048-6; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; MUIR JK, 1995, AM J PHYSIOL-HEART C, V268, pH68; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; PFENNINGER E, 1987, RESUSCITATION, V15, P125, DOI 10.1016/0300-9572(87)90023-2; PRAKASH A, 1993, INT J CLIN PHARM TH, V31, P575; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Rosselli M, 1996, J CLIN EXP NEUROPSYC, V18, P122, DOI 10.1080/01688639608408268; ROUNSAVILLE BJ, 1982, J NERV MENT DIS, V170, P209, DOI 10.1097/00005053-198204000-00005; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SPRADEO FR, 1989, J HEAD TRAUMA REHAB, V4, P75; STRATTON R, 1981, ALCOHOL CLIN EXP RES, V5, P56; TURNETH SS, 1990, RADIOLOGY, V176, P821; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOOLF PD, ALCOHOLISM CLIN EXPT, V14, P205	54	68	69	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1997	11	6					391	402		10.1080/026990597123386			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600001	9171925				2021-06-18	
J	Sander, AM; Seel, RT; Kreutzer, JS; Hall, KM; High, WM; Rosenthal, M				Sander, AM; Seel, RT; Kreutzer, JS; Hall, KM; High, WM; Rosenthal, M			Agreement between persons with traumatic brain injury and their relatives regarding psychosocial outcome using the community integration questionnaire	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RECOVERY	Objective: To extend psychometric research on the Community Integration Questionnaire (CIQ) by comparing patients' reports with those of family members. Design: Reports on community integration were obtained from family members and patients 1 year after brain injury. Kappa reliability coefficients were used to examine agreement for individual items on the questionnaire. Total scores for the three CIQ scales were compared between groups using independent samples t tests. Setting: Outpatient clinics affiliated with the four NIDRR traumatic brain injury Model System rehabilitation centers. Participants: CIQ data were obtained for 259 adult patients with traumatic brain injury. For 122 cases, patients and family members provided corresponding data. In 101 cases, only self-reported data were available. In 36 cases, information was provided solely by family members. All patients received inpatient rehabilitation and were at least 16 years of age. The full range of brain injury severity was represented. Main Outcome Measure: The 15-item CIQ, comprised of three scales, Home Integration, Productive Activity, and Social Integration. Results: Analysis of kappa values found ''moderate'' to ''almost perfect'' agreement levels for all 15 items. Almost-perfect ratings were found for three of the four items on the Productive Activity Scale. Comparisons were made between scale scores derived from patients and families. The Home Integration scale showed differences, with patient scores higher than those reported by family members (t=3.51, p<.01). However, the difference in scores was attributable to small discrepancies on two items and was not considered clinically meaningful. The Total CIQ score also showed a difference, with patients reporting significantly higher levels of integration relative to family members (t=2.30, p<.05). This difference was also attributable to discrepancies on two items of the Home Integration Scale. Conclusions: The results have important implications for researchers who may be limited to one source of data. The hypothesis that patients and family members have very different perspectives of patients' community activities was not supported. Rather, similar ratings of individual activities were given with two exceptions, meal preparation and housekeeping. More research is needed to delineate relationships between agreement ratings and outcome categories. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, RICHMOND, VA 23298 USA; SANTA CLARA VALLEY MED CTR, DEPT PHYS MED & REHABIL, SAN JOSE, CA 95128 USA; BAYLOR COLL MED, INST REHABIL & RES, DEPT PHYS MED & REHABIL, HOUSTON, TX USA; WAYNE STATE UNIV, REHABIL INST MICHIGAN, DEPT PHYS MED & REHABIL, DETROIT, MI 48202 USA							BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; *COMM ACCR REH FAC, 1996, 1996 STAND MED REH; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; SHEIKH K, 1986, ARCH PHYS MED REHAB, V67, P245; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	20	68	68	1	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1997	78	4					353	357		10.1016/S0003-9993(97)90225-2			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WT595	WOS:A1997WT59500005	9111453				2021-06-18	
J	Hamm, RJ; Temple, MD; Pike, BR; ODell, DM; Buck, DL; Lyeth, BG				Hamm, RJ; Temple, MD; Pike, BR; ODell, DM; Buck, DL; Lyeth, BG			Working memory deficits following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						spatial working memory; traumatic brain injury, Morris water maze; rats	CLOSED HEAD-INJURY; CELL-DEATH; WATER-MAZE; IMPAIRMENT; HIPPOCAMPAL; DISRUPTION	This study was designed to examine working memory following fluid-percussion traumatic brain injury (TBI) using the Morris water maze (MWM). Rats were injured (n = 9) at a moderate level of central fluid percussion injury (2.1 atm) or were prepared for injury but did not receive a fluid pulse (sham injury) (n = 10). On days 11-15 postinjury, working memory was assessed using the MWM, Each animal received 8 pairs of trials per day, For each pair of trials, animals were randomly assigned to one of four possible starting points and one of four possible escape platform positions, On the first trial of each pair, rats were placed in the maze facing the wall and were given 120 sec to locate the hidden escape platform, After remaining on the goal platform for 10 sec, they were placed back into the maze for the second trial of the pair, The platform position and the start position remained unchanged on this trial, After the second trial, the animal was given a 4 min intertrial rest. Between pairs of trials, both the start position and the goal location were changed, Analyses of the latency to reach the goal platform indicated that sham-injured animals performed significantly better on the second trial than on the first trial of each pair, However, injured animals did not significantly differ between first and second trial goal latencies on any day, These results indicate that injured animals have a profound and enduring deficit in spatial working memory function on days 11-15 after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23284	Hamm, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,POB 842018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		BOISSARD CG, 1992, NEUROSCIENCE, V48, P807, DOI 10.1016/0306-4522(92)90268-7; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; ROFF RL, 1993, BEHAV BRAIN RES, V57, P47; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Seifert W, 1983, NEUROBIOLOGY HIPPOCA, P405; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WILKINS RH, 1985, NEUROSURGERY	22	68	70	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					317	323		10.1089/neu.1996.13.317			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200004	8835799				2021-06-18	
J	Marion, DW; White, MJ				Marion, DW; White, MJ			Treatment of experimental brain injury with moderate hypothermia and 21-aminosteroids	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; 21-aminosteroids; traumatic brain injury; secondary brain injury; axonal injury	EXPERIMENTAL HEAD-INJURY; RADICAL FORMATION; RAT-BRAIN; U74006F; DAMAGE; EDEMA; INHIBITION; MODEL	Studies of experimental traumatic brain injury have found that histologic injury is significantly reduced and behavioral outcome improved in animals treated with moderate hypothermia (32-33 degrees C) or a 21-aminosteroid. Because these treatments are thought to work through different neurochemical mechanisms, their combined use might be expected to be more efficacious than either treatment alone. To test this hypothesis, we studied each treatment separately and in combination in a rodent model of controlled cortical contusion. Treatment with moderate hypothermia (32 degrees C for 4 h), a 21-aminosteroid (U-74389G, Upjohn, 10 mg/kg intravenously, repeated 3 h after the first dose), or both, was initiated 10, 25, or 40 min after injury. The brains were perfused 24 h after injury, and sagittal sections were stained for the 68-kDa ''core'' neurofilament subunit, a marker of axonal injury. The total number of positively stained axons in the ipsilateral internal capsule were counted under light microscopy. Compared with the control group (injury but no treatment), treatment with each therapy alone or combined, initiated 10 min after injury, caused significant reductions in the number of stained axons (21-aminosteroid alone-35% reduction; hypothermia alone-55% reduction; combination-48% reduction). The number of positively stained axons was significantly reduced in the aminosteroid and combination therapy groups at all three postinjury times (p = 0.01) and in the hypothermia groups treated at 10 or 25 min (p = 0.01) but not at 40 min after injury. We concluded that combination therapy with hypothermia and 21-aminosteroids was no more efficacious than either therapy alone, and that 21-aminosteroid therapy was more efficacious than hypothermia when treatment was initiated 40 min after injury.		Marion, DW (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT NEUROL SURG,SUITE B400,200 LOTHROP ST,PITTSBURGH,PA 15213, USA.		Marion, Donald/AAR-5749-2021				ARAKI N, 1991, J CEREB BLOOD FLO S2, V11, pS843; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Dietrich W, 1991, J CEREB BLOOD FLO S2, V11, pS846; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GINSBERG MD, 1989, J CEREB BLOOD FLO S1, V9, P380; HALL ED, 1988, BRAIN RES, V451, P350, DOI 10.1016/0006-8993(88)90782-2; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Jennett W B, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P172; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1993, MOL CHEM NEUROPATHOL, V18, P247; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LEWIS DA, 1970, J PHARM PHARMACOL, V22, P902, DOI 10.1111/j.2042-7158.1970.tb08471.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	36	68	71	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1996	13	3					139	147		10.1089/neu.1996.13.139			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UD469	WOS:A1996UD46900003	8965323				2021-06-18	
J	Tavalin, SJ; Ellis, EF; Satin, LS				Tavalin, SJ; Ellis, EF; Satin, LS			Mechanical perturbation of cultured cortical neurons reveals a stretch-induced delayed depolarization	JOURNAL OF NEUROPHYSIOLOGY			English	Article							CONCUSSIVE BRAIN INJURY; GLUTAMATE NEUROTOXICITY; CELL-CULTURE; EXTRACELLULAR POTASSIUM; RAT; NMDA; ELECTROPHYSIOLOGY; ANTAGONISTS; RECEPTOR; CALCIUM	1. An in vitro cellular model of injury was used to elucidate mechanisms contributing to traumatic brain injury (TBI). Neonatal rat cortical neurons cultured on a flexible silastic membrane were stretched rapidly and reversibly by a 50-ms pulse of pressurized air. 2. Sublethal cell stretch depolarized neuronal resting membrane potential by similar to 10 mV but only if cells were incubated for 1 h after injury. Stretch-induced delayed depolarization (or SIDD) returned to baseline values within 24 h. 3. SIDD was dependent on the degree of cell stretch and required neuronal firing, calcium entry, and N-methyl-D-aspartate receptor activation for its induction but not its maintainance. 4. Similarities between SIDD and TBI suggest that SIDD may play a role in brain injury.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL, RICHMOND, VA 23298 USA					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07027] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		BIRCH PJ, 1988, EUR J PHARMACOL, V156, P177, DOI 10.1016/0014-2999(88)90163-X; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Nilsson P, 1990, J CEREB BLOOD FLOW M, V10, P331; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1	27	68	69	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	DEC	1995	74	6					2767	2773					7	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	TM559	WOS:A1995TM55900051	8747234				2021-06-18	
J	DIETRICH, WD; ALONSO, O; BUSTO, R; GINSBERG, MD				DIETRICH, WD; ALONSO, O; BUSTO, R; GINSBERG, MD			WIDESPREAD METABOLIC DEPRESSION AND REDUCED SOMATOSENSORY CIRCUIT ACTIVATION FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article								The effects of fluid percussion brain injury on the basal metabolic state and responsiveness of a somatosensory circuit to physiologic activation were investigated with [C-14]2-deoxyglucose autoradiography. Under controlled physiologic conditions and normothermic brain temperature (37 degrees C), rats were injured with a moderate fluid percussion pulse ranging from 1.7 to 2.1 atm. At 4 or 24 h after traumatic brain injury (TBI), unilateral vibrissae stimulation was carried out, resulting in the metabolic activation of the whisker-barrel circuit. In sham-operated control animals, whisker stimulation resulted in the metabolic activation of the ipsilateral trigeminal medullary complex (177% of control), contralateral ventrobasal thalamus (143% control), and primary somatosensory cortex (153% control). At 4 h after injury, local cerebral metabolic rates of glucose (ICMRglu) were significantly depressed throughout the traumatized hemisphere. Although depressed ICMRglu was most pronounced in cortical regions adjacent to the evolving contusion (53% of control), significant decreases were also seen in more remote areas, including the frontal cortex (75% of control), hippocampus (79% control), and lateral thalamus (68% of control). At 24 h following TBI, ICMRglu remained significantly reduced at the impact site, within the ipsilateral somatosensory cortex and lateral thalamus. Stimulus-evoked increases in ICMRglu were depressed within all three relay stations of the vibrissae-barrel-field circuit at 4 and 24 h after TBI. These results demonstrate both focal and diffuse metabolic depression after moderate TBI. Although the most severe and longer lasting metabolic consequences occurred in cortical and thalamic regions destined to exhibit histopathologic damage, milder abnormalities, most prominent in the early posttraumatic period, were also seen in noninjured areas. The inability to activate the somatosensory circuit metabolically indicates that circuit dysfunction is an acute consequence of TBI. Widespread circuit or synaptic dysfunction would be expected to participate in the functional and behavioral consequences of TBI.		DIETRICH, WD (corresponding author), UNIV MIAMI, SCH MED, DEPT NEUROL D4-5, NEUROTRAUMA CLIN RES CTR, POB 016960, MIAMI, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27127, NS-30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P50NS030291] Funding Source: NIH RePORTER		BECKER DP, 1987, PHYSL BASIS MODERN S, P763; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1989, J CEREB BLOOD FLO S1, V9, pS93; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIAZAKI S, 1989, INTRACRANIAL PRESSUR, V7, P651; MITCHELL DE, 1973, LANCET, V2, P215; NAPPER C H, 1989, Society for Neuroscience Abstracts, V15, P134; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; Paxinos G., 1982, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; WARD AA, 1966, HEAD INJURY C P; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOSHINO A, J CEREB BLOOD FLOW M, V12, P996	52	68	68	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					629	640		10.1089/neu.1994.11.629			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500001	7723063				2021-06-18	
J	BUDENZ, DL; FARBER, MG; MIRCHANDANI, HG; PARK, H; RORKE, LB				BUDENZ, DL; FARBER, MG; MIRCHANDANI, HG; PARK, H; RORKE, LB			OCULAR AND OPTIC-NERVE HEMORRHAGES IN ABUSED INFANTS WITH INTRACRANIAL INJURIES	OPHTHALMOLOGY			English	Article							SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; RETINAL HEMORRHAGE; CHILD-ABUSE; CARDIOPULMONARY RESUSCITATION; COMPUTED-TOMOGRAPHY; MENTAL-RETARDATION; AUTOPSY FINDINGS; YOUNG-CHILDREN; HEAD-INJURY	Purpose: To ascertain whether the pathology of the eye and optic nerve might be useful in determining the manner of death in infants who died after sustaining apparent nonaccidental intracranial injury. Methods: Complete autopsies were performed on 13 infants who died of acute intracranial injuries after nonaccidental trauma. The infants were divided into two groups: nine with physical evidence of blunt trauma to the head, and four without detectable scalp or skull injury whose intracranial injuries were attributed to violent shaking (shaken baby syndrome). Six infants with no intracranial injuries who died suddenly from unidentifiable causes (the so-called sudden infant death syndrome) served as controls. Results: Optic nerve sheath hemorrhage, most prominent in the subdural space, was present in all 13 infants with nonaccidental intracranial injury. Multilayered retinal hemorrhage was present in at least one eye of 11 of these 13 infants. The location and quantity of the intraocular and optic nerve sheath hemorrhages did not differ in those with external head trauma and those without scalp or skull lesions. A single control infant had a few erythrocytes in the nerve fiber layer of the anterior optic nerve of one eye. The remainder of the control infants did not have evidence of hemorrhage in the eye or optic nerve sheath. Conclusion: Histopathologic analysis of optic nerve sheath and intraocular hemorrhages may be helpful in distinguishing traumatic from non-traumatic causes of death in infants.	CHILDRENS HOSP PHILADELPHIA,DEPT PATHOL,PHILADELPHIA,PA 19104; OFF MED EXAMINER,PHILADELPHIA,PA	BUDENZ, DL (corresponding author), UNIV PENN,SCHEIE EYE INST,WILLIAM C FRAYER LAB EYE PATHOL,51 N 39TH ST,PHILADELPHIA,PA 19104, USA.						AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CARR RE, 1963, AM J OPHTHALMOL, V56, P23, DOI 10.1016/0002-9394(63)91296-0; CRISOSTOMO EA, 1986, DEV MED CHILD NEUROL, V28, P68; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; FRIENDLY D S, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P318; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; GILES CL, 1960, AM J OPHTHALMOL, V49, P1005, DOI 10.1016/0002-9394(60)91824-9; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1991, ARCH OPHTHALMOL-CHIC, V109, P321; GOETTING MG, 1990, PEDIATRICS, V85, P585; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; GUYER DR, 1989, OPHTHALMOLOGY, V96, P860; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HARLEY RD, 1980, J PEDIAT OPHTH STRAB, V17, P5; HOLT JM, 1969, BRIT J OPHTHALMOL, V53, P145, DOI 10.1136/bjo.53.3.145; JAIN IS, 1980, J PEDIAT OPHTH STRAB, V17, P14; Jensen AD, 1971, J PEDIATR OPHTHALMOL, V8, P270; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; KINCAID MC, 1983, SURV OPHTHALMOL, V27, P211, DOI 10.1016/0039-6257(83)90123-6; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MCCURTY K, 1993, 1992 ANN 50 STAT SUR; MCLELLAN NJ, 1986, ARCH DIS CHILD, V61, P1130, DOI 10.1136/adc.61.11.1130; MERIN S, 1968, AM J OPHTHALMOL, V66, P1102, DOI 10.1016/0002-9394(68)90818-0; MITCHEL L, 1987, CHILD ABUSE NEGLECT; MULLER PJ, 1974, J NEUROSURG, V41, P160, DOI 10.3171/jns.1974.41.2.0160; MUSHIN A, 1971, BRIT J OPHTHALMOL, V55, P343, DOI 10.1136/bjo.55.5.343; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; NISHIO A, 1991, SURG NEUROL, V35, P224, DOI 10.1016/0090-3019(91)90075-K; OBER RR, 1980, J PEDIAT OPHTH STRAB, V17, P17; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; RIVARA FP, 1988, PEDIATRICS, V81, P93; Robb R M, 1978, Trans Am Ophthalmol Soc, V76, P90; RUBENSTE.RA, 1968, AM J OPHTHALMOL, V65, P435, DOI 10.1016/0002-9394(68)93098-5; SEZEN F, 1970, BR J OPHTHALMOL, V55, P248; TILL K, 1968, BRIT MED J, V3, P400, DOI 10.1136/bmj.3.5615.400; VAPALAHT.PM, 1969, J NEUROSURG, V30, P169, DOI 10.3171/jns.1969.30.2.0169; WALSH FB, 1951, AM J OPHTHALMOL, V34, P509, DOI 10.1016/0002-9394(51)90294-2; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; 1988, CALIFORNIAS RECORDS	53	68	69	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0161-6420			OPHTHALMOLOGY	Ophthalmology	MAR	1994	101	3					559	565					7	Ophthalmology	Ophthalmology	NB220	WOS:A1994NB22000031	8127577				2021-06-18	
J	KOFLER, M; KRONENBERG, MF; RIFICI, C; SALTUARI, L; BAUER, G				KOFLER, M; KRONENBERG, MF; RIFICI, C; SALTUARI, L; BAUER, G			EPILEPTIC SEIZURES ASSOCIATED WITH INTRATHECAL BACLOFEN APPLICATION	NEUROLOGY			English	Article							SPASTICITY; OVERDOSE; EVENTS	We report the clinical and EEG findings in three patients presenting with seizures associated with intrathecal baclofen application for treatment of spasticity. All patients had a history of traumatic brain injury, while one patient also suffered a spinal cord injury. Two patients experienced their first seizure following intrathecal baclofen test bolus injection. Another patient had convulsions on two occasions: following postoperative baclofen dose adjustment, and after sleep deprivation. Structural brain disease seems prerequisite for baclofen to exert epileptogenic activity, since seizures have not occurred in patients receiving intrathecal baclofen for spasticity of solely spinal origin. Antiepileptic medication permitted the continuation of intrathecal baclofen treatment in the three patients.	BAYLOR COLL MED, DIV RESTORAT NEUROL & HUMAN NEUROBIOL, HOUSTON, TX USA; UNIV MESSINA, CTR NEUROLESI, MESSINA, ITALY	KOFLER, M (corresponding author), UNIV INNSBRUCK, DEPT NEUROL, ANICHSTR 35, A-6020 INNSBRUCK, AUSTRIA.		Kofler, Markus/P-5585-2019; Rifici, Carmela/ABH-4398-2020	Kofler, Markus/0000-0002-2962-0903			ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; DELHAAS EM, 1991, INT J CLIN PHARM TH, V29, P274; DRALLE D, 1989, LANCET, V2, P916; FAIGLE JW, 1972, POSTGRAD MED J, V48, P9; JONES RSG, 1989, EXP NEUROL, V104, P155, DOI 10.1016/S0014-4886(89)80009-3; MOTT DD, 1989, J PHARMACOL EXP THER, V249, P721; MULLER H, 1987, J NEUROL, V234, P348, DOI 10.1007/BF00314294; MULLERSCHWEFE G, 1989, J NEUROSURG, V71, P273, DOI 10.3171/jns.1989.71.2.0273; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROMIJN JA, 1986, LANCET, V2, P696; Saltuari L, 1992, Acta Neurol (Napoli), V14, P195; SALTUARI L, 1992, LANCET, V339, P373, DOI 10.1016/0140-6736(92)91697-7; Takahashi T., 1987, ELECTROENCEPHALOGRAP, V2nd ed., P209	13	68	69	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN	1994	44	1					25	27		10.1212/WNL.44.1.25			3	Clinical Neurology	Neurosciences & Neurology	MR371	WOS:A1994MR37100007	8290085				2021-06-18	
J	SCHALEN, W; MESSETER, K; NORDSTROM, CH				SCHALEN, W; MESSETER, K; NORDSTROM, CH			CEREBRAL VASOREACTIVITY AND THE PREDICTION OF OUTCOME IN SEVERE TRAUMATIC BRAIN-LESIONS	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						CEREBRAL BLOOD FLOW; CEREBRAL METABOLISM; HEAD INJURY; OUTCOME; VASOREACTIVITY	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; MULTIMODALITY EVOKED-POTENTIALS; LEVEL SCALE RLS85; BLOOD-FLOW; INTRAVENTRICULAR PRESSURE; XENON-133 INHALATION; COMATOSE PATIENTS; ACUTE PHASE; METABOLISM	Mean hemispheric blood flow (CBF) was studied in 38 comatose, severely brain-injured patients following intravenous administration of xenon-133. Repeated measurements were performed in order to evaluate cerebral vasoreactivity following a decrease in Paco2. Simultaneously, arterial-venous oxygen differences (AVDo2) and intracranial pressure (ICP) were measured. An impaired CBF response to hyperventilation (DELTA-CBF/DELTA-Paco2 < 1.0) was obtained in 22 patients. Three of 16 patients with preserved CO2-reactivity died because of their brain injuries and 12 patients reached good recovery/moderate disability. In the group of patients with impaired vasoreactivity 11 of 22 patients died and only three patients reached good recovery/moderate disability. The study documents that in patients with severe traumatic brain lesions measurements of cerebral vasoreactivity to hyperventilation give prognostic information that is not obtained by clinical observations or CT-scanning.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT ANESTHESIOL, S-22185 LUND, SWEDEN							ALEXANDER SC, 1965, ANESTHESIOLOGY, V26, P624, DOI 10.1097/00000542-196509000-00007; ALEXANDER SC, 1968, J APPL PHYSIOL, V24, P66; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P249, DOI 10.1111/j.1399-6576.1978.tb01299.x; ENEVOLDSEN EM, 1977, J NEUROSURG, V47, P699, DOI 10.3171/jns.1977.47.5.0699; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOTTSTEIN U, 1963, KLIN WOCHENSCHR, V41, P943, DOI 10.1007/BF01478536; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JENNETT B, 1976, LANCET, V1, P1031; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1975, STROKE, V6, P245, DOI 10.1161/01.STR.6.3.245; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1985, CEREBRAL BLOOD FLOW, P30; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; TEASDALE G, 1974, LANCET, V2, P81	45	68	68	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	1991	35	2					113	122		10.1111/j.1399-6576.1991.tb03258.x			10	Anesthesiology	Anesthesiology	EY354	WOS:A1991EY35400005	1902616				2021-06-18	
J	Vink, R; Head, VA; Rogers, PJ; McIntosh, TK; Faden, AI				Vink, Robert; Head, Valerie A.; Rogers, Peter J.; McIntosh, Tracy K.; Faden, Alan I.			Mitochondrial Metabolism Following Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-BLOOD-FLOW; OXIDATIVE-PHOSPHORYLATION; MG-2+	Although a number of studies of traumatic brain injury have implicated mitochondrial dysfunction as a cause of altered posttraumatic energy metabolism, no studies to date have isolated mitochondria and measured their respiratory capacity following trauma. The present study sought to determine whether mitochondrial capacity for oxidative phosphorylation is adversely affected by fluid-percussion-induced traumatic brain injury in rats. Prior to brain injury, the mitochondrial respiratory control ratio was 4.3 +/- 0.2 and the ratio of nmoles of ADP phosphorylated per natom oxygen consumed (ADP/O ratio) was 2.66 +/- 0.09. After injury (2.8 atm; t = 4 h), there were slight but not significant alterations in ADP/O ratio (2.41 +/- 0.07) and state 3 respiratory rate (ADP stimulated); however, there were no changes in the respiratory control ratio. These data suggest that traumatic brain injury, unlike ischemia, does not cause uncoupling of ATP synthesis from respiration, and that brain mitochondria are quite resistant to trauma-induced injury.	[Vink, Robert] James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia; [Head, Valerie A.; Faden, Alan I.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Head, Valerie A.; Faden, Alan I.] Vet Adm Med Ctr, Ctr Neural Injury, San Francisco, CA 94121 USA; [Rogers, Peter J.] Griffith Univ, Sch Sci, Brisbane, Qld 4111, Australia; [McIntosh, Tracy K.] Univ Connecticut, Ctr Hlth, Dept Surg, Farmington, CT USA	Vink, R (corresponding author), James Cook Univ N Queensland, Dept Chem & Biochem, Townsville, Qld 4811, Australia.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [902269]; Veterans Administration Merit ReviewUS Department of Veterans Affairs; Queen Elizabeth II Fellowship; Australian National Research Fellowships Advisory Committee	This work was supported in part by Centers for Disease Control Grant 902269 to A.I.F., and a Veterans Administration Merit Review Grant to T.K.M.R. Vink is a recipient of a Queen Elizabeth II Fellowship and is supported by the Australian National Research Fellowships Advisory Committee.	ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; Estabrook R., 1967, METHOD ENZYMOL, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FAGIAN MM, 1986, BIOCHIM BIOPHYS ACTA, V852, P262, DOI 10.1016/0005-2728(86)90231-8; GINSBERG MD, 1977, ANN NEUROL, V1, P519, DOI 10.1002/ana.410010603; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P438, DOI 10.1038/jcbfm.1984.63; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; KLINGENBERG M, 1977, STRUCTURE FUNCTION E, P275; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V855, P201, DOI 10.1016/0005-2736(86)90166-5; Lai J C, 1979, Methods Enzymol, V55, P51; LEE NM, 1970, BIOCHEM BIOPH RES CO, V40, P1058, DOI 10.1016/0006-291X(70)90901-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASINI A, 1983, J BIOENERG BIOMEMBR, V15, P217, DOI 10.1007/BF00743942; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; OZAWA K, 1967, J BIOCHEM-TOKYO, V61, P512, DOI 10.1093/oxfordjournals.jbchem.a128576; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WILSON EJ, 1987, NEUROCHEM RES, V12, P831; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	31	68	68	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SPR	1990	7	1					21	27		10.1089/neu.1990.7.21			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V21VN	WOS:000208235200003	2342116				2021-06-18	
J	ISHIGE, N; PITTS, LH; POGLIANI, L; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM; JAMES, TL				ISHIGE, N; PITTS, LH; POGLIANI, L; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM; JAMES, TL			EFFECT OF HYPOXIA ON TRAUMATIC BRAIN INJURY IN RATS .2. CHANGES IN HIGH-ENERGY PHOSPHATE-METABOLISM	NEUROSURGERY			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,EDITORIAL OFF,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143							ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; BOTTOMLEY P A, 1982, Magnetic Resonance Imaging, V1, P81, DOI 10.1016/0730-725X(82)90223-5; BROWN WJ, 1972, AM J PATHOL, V67, P41; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; DELPY DT, 1982, PEDIATRICS, V70, P310; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GERMAN WJ, 1974, T AM NEUROL ASS, V72, P86; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GORDON E, 1971, ACTA ANAESTH SCAND, V15, P209, DOI 10.1111/j.1399-6576.1971.tb05462.x; HASS WK, 1977, ACTA NEUROL SCAND, V56, P240; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; JAMES TL, 1984, NMR CT INTERVENTIONA, P235; Lewis H P, 1968, Surg Forum, V19, P433; LINDQUIST JL, 1942, SURG GYNECOL OBSTET, V75, P28; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Naruse S, 1984, Neurol Res, V6, P169; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; Nelson S, 1966, HEAD INJURY, P444; NG TC, 1982, ANESTHESIOLOGY, V57, pA126; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; PRICHARD JW, 1983, P NATL ACAD SCI-BIOL, V80, P2748, DOI 10.1073/pnas.80.9.2748; ROSENTHAL M, 1982, HEAD INJURY BASIC CL, P69; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SEITZ HD, 1977, ACTA NEUROCHIR, V38, P211, DOI 10.1007/BF01401092; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	34	68	68	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1987	20	6					854	858		10.1227/00006123-198706000-00006			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	H8835	WOS:A1987H883500005	3614564				2021-06-18	
J	VANZOMEREN, AH; DEELMAN, BG				VANZOMEREN, AH; DEELMAN, BG			DIFFERENTIAL EFFECTS OF SIMPLE AND CHOICE REACTION AFTER CLOSED HEAD-INJURY	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article									STATE UNIV GRONINGEN,DEPT NEUROL,GRONINGEN,NETHERLANDS							BENTON AL, 1957, J ABNORM SOC PSYCH, V54, P109, DOI 10.1037/h0047176; BLACKBURN H L, 1955, Confin Neurol, V15, P327; Bruhn P, 1971, Cortex, V7, P278; Carson DH, 1968, CORTEX, V4, P92; COSTA LD, 1962, PERCEPT MOTOR SKILL, V14, P391; DEE HL, 1972, T AM NEUROLOGICAL AS, V97; DERENZI E, 1965, CORTEX, V1, P410; Donders F. C., 1868, ONDERZOEKINGEN GEDAA, V2, P92; KARP E, 1971, CORTEX, V7, P419; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; Miller E, 1970, Cortex, V6, P121; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; Russell W Ritchie, 1934, Edinb Med J, V41, P129; Siegel S., 1956, NONPARAMETRIC STAT B; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STRICH SJ, 1961, LANCET, V2, P443; VECHT CJ, 1975, LIFE SCI, V16, P1179, DOI 10.1016/0024-3205(75)90201-5; WELFORD AT, 1962, LANCET, V1, P335	18	68	68	0	3	VAN GORCUM CO BV	ASSEN	PO BOX 43, 9400 AA ASSEN, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.		1976	79	2					81	90		10.1016/0303-8467(76)90001-9			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DH716	WOS:A1976DH71600001	1029638				2021-06-18	
J	Di Pietro, V; Ragusa, M; Davies, D; Su, ZJ; Hazeldine, J; Lazzarino, G; Hill, LJ; Crombie, N; Foster, M; Purrello, M; Logan, A; Belli, A				Di Pietro, Valentina; Ragusa, Marco; Davies, David; Su, Zhangjie; Hazeldine, Jon; Lazzarino, Giacomo; Hill, Lisa J.; Crombie, Nicholas; Foster, Mark; Purrello, Michele; Logan, Ann; Belli, Antonio			MicroRNAs as Novel Biomarkers for the Diagnosis and Prognosis of Mild and Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; concussion; diagnosis; microRNAs; prognosis; traumatic brain injury	IN-VITRO MODEL; TEMPORAL WINDOW; MESSENGER-RNAS; VULNERABILITY; EXPRESSION; REGULATORS; CONCUSSIONS; TARGETS; CELLS	Traumatic brain injury (TBI) is the leading cause of death and disability in people younger than 45 in Western countries. Despite many studies, no reliable biomarkers have been found to assess TBI severity and predict recovery. MicroRNA (miRNA) profiling has become widely used to identify biomarkers and therapeutic targets. Through use of the TaqMan Array Human MicroRNA A+B Cards, the expression of 754 miRNAs was analyzed in serum of five mild TBI (mTBI) patients with extra-cranial injury (EC), five severe TBI (sTBI) patients with EC, and five healthy volunteers (HV) at 1 day and 15 days post-injury. The aim was to find candidate biomarkers able to discriminate between mTBI and sTBI. Following this, it was possible to select 10 miRNAs for further study in an enlarged validation cohort of 120 patients by using single TaqMan assays at the following time-points: T0-1 h, T4-12 h, T48-72 h, and 15 days from the injury. Analysis revealed two miRNAs (miR-425-5p and miR-502) that were significantly downregulated (p < 0.05) in mTBI at early time-points and are ideal candidates for diagnosis of mTBI, and two miRNAs (miR-21 and miR-335) that were significantly upregulated (p < 0.01) and are valid biomarkers for the diagnosis of sTBI. In addition, miR-425-5p was a strong predictor of 6-month outcome at T0-1 h and T4-12 h, while miR-21 was predictive of the outcome at T4-12 h. The panel of selected miRNAs shows promise as biomarkers to discriminate mTBI from sTBI. In addition, the selected miRNAs represent new potential therapeutic targets.	[Di Pietro, Valentina; Hazeldine, Jon; Hill, Lisa J.; Logan, Ann; Belli, Antonio] Univ Birmingham, Inst Inflammat & Aging, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England; [Di Pietro, Valentina; Davies, David; Su, Zhangjie; Hazeldine, Jon; Hill, Lisa J.; Crombie, Nicholas; Logan, Ann; Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Ragusa, Marco; Purrello, Michele] Univ Catania, Dept Biomed Sci & Biotechnol, Catania, Italy; [Lazzarino, Giacomo] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Crombie, Nicholas] West Midlands Air Ambulance Trust, Stourbridge, W Midlands, England; [Foster, Mark] Acad Dept Mil Surg & Trauma, Royal Ctr Def Med, Inst Res & Dev, Birmingham, W Midlands, England	Di Pietro, V (corresponding author), Univ Birmingham, Sch Clin & Expt Med, Neurotrauma & Ophtalmol Res Grp, Birmingham B15 2TT, W Midlands, England.	v.dipietro@bham.ac.uk	Ragusa, Marco/D-7691-2010; Hazeldine, Jon/T-5725-2019; Hill, Lisa J/AAO-1560-2021; Belli, Antonio/I-3799-2015; Foster, Mark Anthony/AAS-9284-2020	Ragusa, Marco/0000-0002-4282-920X; Hill, Lisa J/0000-0001-8431-7029; Belli, Antonio/0000-0002-3211-9933; Lazzarino, Giacomo/0000-0003-1639-0966; Logan, Ann/0000-0003-3215-5042	National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); Midlands Neuroscience Training and Research Fund; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [G18986] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/N019016/1] Funding Source: researchfish	This study was funded by the National Institute for Health Research (NIHR) and by the Midlands Neuroscience Training and Research Fund. The views expressed are those of the authors and not necessarily those of the National Heath Service, the NIHR or the Department of Health.	Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Bracko O, 2014, J CEREBR BLOOD F MET, V34, P1522, DOI 10.1038/jcbfm.2014.112; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gauthier BR, 2006, NAT MED, V12, P36, DOI 10.1038/nm0106-36; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370; Ragusa M, 2013, MOL VIS, V19, P430; Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Sariaslan A., 2016, PLOS MED, V23, P13; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Signoretti S., 2001, PM R S2, V3, pS359; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Szafranskil K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00087; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Toman E, 2016, J ROY ARMY MED CORPS, V162, P103, DOI 10.1136/jramc-2015-000517; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Yokota M, 1999, J CLIN LAB ANAL, V13, P133, DOI 10.1002/(SICI)1098-2825(1999)13:3<133::AID-JCLA8>3.0.CO;2-0; Zafari S., 2015, GERONTOLOGY, V25	33	67	68	1	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1948	1956		10.1089/neu.2016.4857			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500005	28279125				2021-06-18	
J	Schain, AJ; Melo-Carrillo, A; Strassman, AM; Burstein, R				Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami			Cortical Spreading Depression Closes Paravascular Space and Impairs Glymphatic Flow: Implications for Migraine Headache	JOURNAL OF NEUROSCIENCE			English	Article						aura; glymph; interstitial fluid; lymph; neurodegeneration; trigeminovascular	BRAIN INTERSTITIAL FLUID; GENE-RELATED PEPTIDE; SENSORY NEURONS; RISK-FACTORS; SLEEP; AURA; ACTIVATION; CORTEX; INJURY; SENSITIZATION	Functioning of the glymphatic system, a network of paravascular tunnels through which cortical interstitial solutes are cleared from the brain, has recently been linked to sleep and traumatic brain injury, both of which can affect the progression of migraine. This led us to investigate the connection between migraine and the glymphatic system. Taking advantage of a novel in vivo method we developed using two- photon microscopy to visualize the paravascular space (PVS) in naive uninjected mice, we show that a single wave of cortical spreading depression (CSD), an animal model of migraine aura, induces a rapid and nearly complete closure of the PVS around surface as well as penetrating cortical arteries and veins lasting several minutes, and gradually recovering over 30 min. A temporal mismatch between the constriction or dilation of the blood vessel lumen and the closure of the PVS suggests that this closure is not likely to result from changes in vessel diameter. We also show that CSD impairs glymphatic flow, as indicated by the reduced rate at which intraparenchymally injected dye was cleared from the cortex to the PVS. This is the first observation of aPVSclosure in connection with an abnormal cortical event that underlies a neurological disorder. More specifically, the findings demonstrate a link between the glymphatic system and migraine, and suggest a novel mechanism for regulation of glymphatic flow.	[Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA; [Schain, Aaron J.; Melo-Carrillo, Agustin; Strassman, Andrew M.; Burstein, Rami] Harvard Med Sch, Boston, MA 02215 USA	Burstein, R (corresponding author), CLS 649, 3 Blackfan Circle, Boston, MA 02215 USA.	rburstei@bidmc.harvard.edu		Burstein, Rami/0000-0003-3763-8916	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 NS079678, RO1 NS069847]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069847, R01NS094198, R37NS079678] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants R37 NS079678 and RO1 NS069847 (R.B.), and by a grant from R. Chemers Neustein (A.J.S.). We thank Dr. Rony Nir for assistance with statistical analyses.	Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Anderson K, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/693925; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Aurora SK, 1998, NEUROLOGY, V50, P1111, DOI 10.1212/WNL.50.4.1111; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P1172, DOI 10.1097/01.WCB.0000137057.92786.F3; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Bakker ENTP, 2016, CELL MOL NEUROBIOL, V36, P181, DOI 10.1007/s10571-015-0273-8; BLAU JN, 1992, LANCET, V340, P355, DOI 10.1016/0140-6736(92)91415-5; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Cairns BE, 2002, NEUROSCIENCE, V109, P389, DOI 10.1016/S0306-4522(01)00489-4; Carare RO, 2008, NEUROPATH APPL NEURO, V34, P131, DOI 10.1111/j.1365-2990.2007.00926.x; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; Cook SP, 2002, PAIN, V95, P41, DOI 10.1016/S0304-3959(01)00372-4; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; DaSilva AFM, 2007, NEUROLOGY, V69, P1990, DOI 10.1212/01.wnl.0000291618.32247.2d; Dodick DW, 2003, HEADACHE, V43, P282, DOI 10.1046/j.1526-4610.2003.03055.x; Du JH, 2001, PAIN, V89, P187, DOI 10.1016/S0304-3959(00)00362-6; Dussor G, 2008, J NEUROPHYSIOL, V99, P1581, DOI 10.1152/jn.01396.2007; EDVINSSON L, 1981, CEPHALALGIA, V1, P175, DOI 10.1046/j.1468-2982.1981.0104175.x; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FABRICIUS M, 1993, BRAIN RES, V602, P350, DOI 10.1016/0006-8993(93)90701-N; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Granziera C, 2006, PLOS MED, V3, P1915, DOI 10.1371/journal.pmed.0030402; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Gudmundsson LS, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3966; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hamming AM, 2016, J CEREBR BLOOD F MET, V36, P1224, DOI 10.1177/0271678X15619189; Hansen JM, 2012, NEUROLOGY, V79, P2044, DOI 10.1212/WNL.0b013e3182749eed; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jennum P, 2002, SLEEP MED REV, V6, P471, DOI 10.1053/smrv.2001.0223; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Ju YES, 2014, NAT REV NEUROL, V10, P115, DOI 10.1038/nrneurol.2013.269; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kelman L, 2005, HEADACHE, V45, P904, DOI 10.1111/j.1526-4610.2005.05159.x; Kosaras B, 2009, J COMP NEUROL, V515, P331, DOI 10.1002/cne.22049; KRAIG RP, 1991, J NEUROSCI, V11, P2187; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Kruit MC, 2010, CEPHALALGIA, V30, P129, DOI 10.1111/j.1468-2982.2009.01904.x; Kruit MC, 2006, STROKE, V37, P1109, DOI 10.1161/01.STR.0000206446.26702.e9; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3659; Lateef T, 2011, CEPHALALGIA, V31, P648, DOI 10.1177/0333102410390395; Lauritzen M, 2016, J CEREB BLOOD FLOW M; Leao A A, 1986, Funct Neurol, V1, P363; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Liman TG, 2012, CEPHALALGIA, V32, P459, DOI 10.1177/0333102412444014; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Liveing E., 1873, MEGRIM SICK HEADACHE; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; MACIVER MB, 1993, J NEUROSCI, V13, P4511; Maleki N, 2013, BRAIN STRUCT FUNCT, V218, P903, DOI 10.1007/s00429-012-0437-y; Maleki N, 2012, CEPHALALGIA, V32, P607, DOI 10.1177/0333102412445622; Maleki N, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-71; Molchanova S, 2004, NEUROCHEM RES, V29, P1519, DOI 10.1023/B:NERE.0000029564.98905.5c; Molliver DC, 2002, EUR J NEUROSCI, V16, P1850, DOI 10.1046/j.1460-9568.2002.02253.x; Montagna P, 2003, LANCET NEUROL, V2, P167, DOI 10.1016/S1474-4422(03)00323-5; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; OCONNOR TP, 1986, J NEUROSCI, V6, P2200; Ostergaard L, 2015, STROKE, V46, P1392, DOI 10.1161/STROKEAHA.114.008077; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Rains JC, 2006, HEADACHE, V46, P1344, DOI 10.1111/j.1526-4610.2006.00578.x; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Scher AI, 2005, NEUROLOGY, V64, P614, DOI 10.1212/01.WNL.0000151857.43225.49; Schock SC, 2007, BRAIN RES, V1168, P129, DOI 10.1016/j.brainres.2007.06.070; Schurks M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3914; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Strassman AM, 1996, NATURE, V384, P560, DOI 10.1038/384560a0; Sukhotinsky I, 2011, CEPHALALGIA, V31, P1601, DOI 10.1177/0333102411425865; SUZUKI N, 1989, NEUROSCIENCE, V31, P427, DOI 10.1016/0306-4522(89)90385-0; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Tietjen GE, 2001, NEUROLOGY, V57, P334, DOI 10.1212/WNL.57.2.334; Tietjen GE, 2009, STROKE, V40, P2977, DOI 10.1161/STROKEAHA.109.547901; Tomita M, 2011, NEUROIMAGE, V56, P1001, DOI 10.1016/j.neuroimage.2011.02.078; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Toth P, 2016, AM J PHYSIOL-HEART C, V311, pH1118, DOI 10.1152/ajpheart.00267.2016; Unekawa M, 2015, J CEREBR BLOOD F MET, V35, P689, DOI 10.1038/jcbfm.2014.250; Vanmolkot FH, 2007, NEUROLOGY, V68, P1563, DOI 10.1212/01.wnl.0000260964.28393.ed; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xue JH, 2009, STROKE, V40, pE606, DOI 10.1161/STROKEAHA.109.560334; Yang G, 2010, NAT PROTOC, V5, P201, DOI 10.1038/nprot.2009.222; Zhang XC, 2011, ANN NEUROL, V69, P855, DOI 10.1002/ana.22329; Zhang XC, 2010, J NEUROSCI, V30, P8807, DOI 10.1523/JNEUROSCI.0511-10.2010; Zhao J, 2015, J NEUROPHYSIOL, V113, P2778, DOI 10.1152/jn.00991.2014	93	67	70	1	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 11	2017	37	11					2904	2915		10.1523/JNEUROSCI.3390-16.2017			12	Neurosciences	Neurosciences & Neurology	EQ1CX	WOS:000397808000011	28193695	Bronze, Green Published			2021-06-18	
J	Press, JN; Rowson, S				Press, Jaclyn N.; Rowson, Steven			Quantifying Head Impact Exposure in Collegiate Women's Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; gender; frequency; sensor; acceleration; football	ACCELERATION MEASUREMENT; NECK INJURIES; BRAIN-INJURY; FOOTBALL; CONCUSSION; BALL; PLAYERS; HOCKEY; RISK	Objective:The aim of this study was to quantify head impact exposure for a collegiate women's soccer team over the course of the 2014 season.Design:Observational and prospective study.Setting:Virginia Tech women's soccer games and practices.Participants:Twenty-six collegiate level women's soccer players with a mean player age of 19 1.Interventions:Participating players were instrumented with head impact sensors for biomechanical analysis. Video recordings of each event were used to manually verify each impact sustained.Main Outcome Measures:Head impact counts by player position and impact situation.Results:The sensors collected data from a total of 17865 accelerative events, 8999 of which were classified as head impacts. Of these, a total of 1703 impacts were positively identified (19% of total real impacts recorded by sensor), 90% of which were associated with heading the ball. The average number of impacts per player per practice or game was 1.86 +/- 1.42. Exposure to head impact varied by player position.Conclusions:Head impact exposure was quantified through 2 different methods, which illustrated the challenges associated with autonomously collecting acceleration data with head impact sensors. Users of head impact data must exercise caution when interpreting on-field head impact sensor data.	[Press, Jaclyn N.; Rowson, Steven] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA USA	Rowson, S (corresponding author), 343 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	rowson@vt.edu	Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596			Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daniel RW, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027872; Delany JS, 2002, CLIN J SPORT MED, V12, P8; Duma SM, 2014, CONCUSSIONS ATHLETIC, P115; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kunz M, 2007, FIFA MAGAZINE, P6; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Rowson S, 2014, J NEUROSURG, V120, P919, DOI 10.3171/2014.1.JNS13916; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Young TJ, 2014, CLIN J SPORT MED, V24, P416, DOI 10.1097/JSM.0000000000000055	27	67	67	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2017	27	2					104	110		10.1097/JSM.0000000000000313			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	EM8PJ	WOS:000395573100003	26978008				2021-06-18	
J	Slobounov, SM; Walter, A; Breiter, HC; Zhu, DC; Bai, XX; Bream, T; Seidenberg, P; Mao, XL; Johnson, B; Talavage, TM				Slobounov, Semyon M.; Walter, Alexa; Breiter, Hans C.; Zhu, David C.; Bai, Xiaoxiao; Bream, Tim; Seidenberg, Peter; Mao, Xianglun; Johnson, Brian; Talavage, Thomas M.			The effect of repetitive subconcussive collisions on brain integrity in collegiate football players over a single football season: A multi-modal neuroimaging study	NEUROIMAGE-CLINICAL			English	Article						Subconcussive; Repetitive impacts; Football; MRI; Accelerometers	HIGH-SCHOOL FOOTBALL; DEFAULT-MODE NETWORK; CHRONIC TRAUMATIC ENCEPHALOPATHY; PHYSICAL STRESS TEST; RESTING-STATE FMRI; FUNCTIONAL CONNECTIVITY; PROFESSIONAL FOOTBALL; HEAD IMPACTS; CONCUSSED INDIVIDUALS; SOCCER PLAYERS	The cumulative effect of repetitive subconcussive collisions on the structural and functional integrity of the brain remains largely unknown. Athletes in collision sports, like football, experience a large number of impacts across a single season of play. The majority of these impacts, however, are generally overlooked, and their long-term consequences remain poorly understood. This study sought to examine the effects of repetitive collisions across a single competitive season in NCAA Football Bowl Subdivision athletes using advanced neuroimaging approaches. Players were evaluated before and after the season using multiple MRI sequences, including T1 weighted imaging, diffusion tensor imaging (DTI), arterial spin labeling (ASL), resting-state functional MRI (rsfMRI), and susceptibility weighted imaging (SWI). While no significant differences were found between pre- and post-season for DTI metrics or cortical volumes, seed-based analysis of rs-fMRI revealed significant (p < 0.05) changes in functional connections to right isthmus of the cingulate cortex (ICC), left ICC, and left hippocampus. ASL data revealed significant (p < 0.05) increases in global cerebral blood flow (CBF), with a specific regional increase in right postcentral gyrus. SWI data revealed that 44% of the players exhibited outlier rates (p < 0.05) of regional decreases in SWI signal. Of key interest, athletes in whom changes in rs-fMRI, CBF and SWI were observed were more likely to have experienced high G impacts on a daily basis. These findings are indicative of potential pathophysiological changes in brain integrity arising from only a single season of participation in the NCAA Football Bowl Subdivision, even in the absence of clinical symptoms or a diagnosis of concussion. Whether these changes reflect compensatory adaptation to cumulative head impacts or more lasting alteration of brain integrity remains to be further explored.	[Slobounov, Semyon M.] Penn State Univ, Dept Kinesiol, Concuss Neuroimaging Consortium, University Pk, PA 16802 USA; [Walter, Alexa; Johnson, Brian] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Breiter, Hans C.] Northwestern Univ, Dept Psychiat & Behav Sci, Concuss Neuroimaging Consortium, Evanston, IL 60208 USA; [Zhu, David C.] Michigan State Univ, Dept Radiol & Psychol, Concuss Neuroimaging Consortium, E Lansing, MI 48824 USA; [Bai, Xiaoxiao] Penn State Univ, Social Life & Engn Sci Imaging Ctr, University Pk, PA 16802 USA; [Bream, Tim; Seidenberg, Peter] Penn State Univ, Athlet Dept, University Pk, PA 16802 USA; [Mao, Xianglun] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, Concuss Neuroimaging Consortium, W Lafayette, IN 47907 USA	Walter, A (corresponding author), 25 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu; aow5128@psu.edu; h-breiter@northwestern.edu; David.Zhu@radiology.msu.edu; xxb4@psu.edu; htb2@psu.edu; pseidenberg@hmc.psu.edu; mao48@purdue.edu; bdj5039@psu.edu; tmt@purdue.edu			Dr. Slobounov's lab	This project was entirely internally funded by Dr. Slobounov's lab. We would like to express special thanks to Dr. Josef Pfeuffer, Siemens Healthcare, Erlangen for providing us with the advanced 3D ASL WIP package. We would like to thank Penn State football players for their time and efforts participating in this study. We also would like to thank Katie Finelli for recruitment and logistics and Madeleine Scaramuzzo for collecting the accelerometer data.	Abbas K., 2015, BIOM ENG SOC 2015 AN; Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abbas K, 2015, DEV NEUROPSYCHOL, V40, P51, DOI 10.1080/87565641.2014.990455; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Cummiskey B., 2016, THESIS, P2015; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Giza Christopher C, 2014, Continuum (Minneap Minn), V20, P1545, DOI 10.1212/01.CON.0000458975.78766.11; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; Hobbs JG, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15617; Houck Z, 2016, AM J SPORT MED, V44, P2269, DOI 10.1177/0363546516645070; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lehman EJ, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt188; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2015, J NEUROTRAUM, V32, P1759, DOI 10.1089/neu.2014.3833; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meier TB, 2016, J NEUROTRAUM, V33, P330, DOI 10.1089/neu.2015.3919; Merchant-Borna K, 2016, ANN BIOMED ENG, V44, P3679, DOI 10.1007/s10439-016-1680-9; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Narayana PA, 2015, NEUROIMAGE-CLIN, V7, P87, DOI 10.1016/j.nicl.2014.07.010; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Obler LK, 2010, BRAIN LANG, V113, P113, DOI [10.1016/j.band1.2010.03.001, 10.1016/j.bandl.2010.03.001]; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Poole VN, 2015, DEV NEUROPSYCHOL, V40, P12, DOI 10.1080/87565641.2014.984810; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Svaldi D. O, 2016, BRAIN IMAGING BEHAV, P1; Svaldi DO, 2015, DEV NEUROPSYCHOL, V40, P80, DOI 10.1080/87565641.2014.973959; Talavage TM, 2016, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00273; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Velarde F, 1992, J NEUROTRAUMA, V9; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Ward B., 2000, SIMULTANEOUS INFEREN; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	70	67	67	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						708	718		10.1016/j.nicl.2017.03.006			11	Neuroimaging	Neurosciences & Neurology	FB2OY	WOS:000405984300076	28393012	DOAJ Gold, Green Published			2021-06-18	
J	Kim, CC; Nakamura, MC; Hsieh, CL				Kim, Charles C.; Nakamura, Mary C.; Hsieh, Christine L.			Brain trauma elicits non-canonical macrophage activation states	JOURNAL OF NEUROINFLAMMATION			English	Article						Innate immunity; Macrophage; Monocyte; Traumatic brain injury; Single-cell RNA sequencing; Neuroinflammation; RNA flow cytometry; Polarization; Neurotrauma; Myeloid cells	ALTERNATIVE ACTIVATION; INJURY; INFLAMMATION; CCR2; POLARIZATION; HETEROGENEITY; MICROGLIA; DIVERSITY; RESPONSES; PATHWAYS	Background: Macrophage polarization programs, commonly referred to as "classical" and "alternative" activation, are widely considered as distinct states that are exclusive of one another and are associated with different functions such as inflammation and wound healing, respectively. In a number of disease contexts, such as traumatic brain injury (TBI), macrophage polarization influences the extent of pathogenesis, and efforts are underway to eliminate pathogenic subsets. However, previous studies have not distinguished whether the simultaneous presence of both classical and alternative activation signatures represents the admixture of differentially polarized macrophages or if they have adopted a unique state characterized by components of both classical and alternative activation. Methods: We analyzed the gene expression profiles of individual monocyte-derived brain macrophages responding to TBI using single-cell RNA sequencing. RNA flow cytometry was used as another single-cell analysis technique to validate the single-cell RNA sequencing results. Results: The analysis of signature polarization genes by single-cell RNA sequencing revealed the presence of diverse activation states, including M(IL4), M(IL10), and M(LPS, IFN gamma). However, the expression of a given polarization marker was no more likely than at random to predict simultaneous expression or repression of markers of another polarization program within the same cell, suggesting a lack of exclusivity in macrophage polarization states in vivo in TBI. Also unexpectedly, individual TBI macrophages simultaneously expressed high levels of signature polarization genes across two or three different polarization states and in several distinct and seemingly incompatible combinations. Conclusions: Single-cell gene expression profiling demonstrated that monocytic macrophages in TBI are not comprised of distinctly polarized subsets but are uniquely and broadly activated. TBI macrophage activation in vivo is deeply complex, with individual cells concurrently adopting both inflammatory and reparative features with a lack of exclusivity. These data provide physiologically relevant evidence that the early macrophage response to TBI is comprised of novel activation states that are discordant with the current paradigm of macrophage polarization-a key consideration for therapeutic modulation.	[Nakamura, Mary C.; Hsieh, Christine L.] Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA; [Nakamura, Mary C.; Hsieh, Christine L.] San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA; [Kim, Charles C.] Univ Calif San Francisco, Dept Med, Div Expt Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94143 USA; [Kim, Charles C.] Verily, Mountain View, CA 94043 USA	Hsieh, CL (corresponding author), Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA.; Hsieh, CL (corresponding author), San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA.	Christine.hsieh@ucsf.edu	Nakamura, Mary/ABI-2887-2020	Nakamura, Mary C./0000-0001-8127-9426; Kim, Charles/0000-0001-6474-8227	NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30 AI027763]; NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK063720]; United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program [I01 BX002690]; NIH R01 grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG046282]; Rheumatology Research Foundation; Russell/Engleman Rheumatology Research Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK063720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046282] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002690] Funding Source: NIH RePORTER	CCK was supported by NIAID P30 AI027763 and NIDDK P30 DK063720. CLH and this work was supported by a Career Development Award-2 and a Merit Review Award #I01 BX002690 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program to CLH. MCN is supported by NIH R01 grant AG046282, the Rheumatology Research Foundation, and the Russell/Engleman Rheumatology Research Center.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Darmanis S, 2015, P NATL ACAD SCI USA, V112, P7285, DOI 10.1073/pnas.1507125112; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Pollen AA, 2014, NAT BIOTECHNOL, V32, P1053, DOI 10.1038/nbt.2967; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Treutlein B, 2014, NATURE, V509, P371, DOI 10.1038/nature13173; Van Dyken SJ, 2013, ANNU REV IMMUNOL, V31, P317, DOI 10.1146/annurev-immunol-032712-095906; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	31	67	68	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 24	2016	13								117	10.1186/s12974-016-0581-z			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DN7UW	WOS:000377286500002	27220367	DOAJ Gold, Green Published			2021-06-18	
J	Nelson, LD; Tarima, S; LaRoche, AA; Hammeke, TA; Barr, WB; Guskiewicz, K; Randolph, C; McCrea, MA				Nelson, Lindsay D.; Tarima, Sergey; LaRoche, Ashley A.; Hammeke, Thomas A.; Barr, William B.; Guskiewicz, Kevin; Randolph, Christopher; McCrea, Michael A.			Preinjury somatization symptoms contribute to clinical recovery after sport-related concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; PROLONGED RECOVERY; MENTAL-DISORDERS; HIGH-SCHOOL; PREDICTORS; SEVERITY	Objective:To determine the degree to which preinjury and acute postinjury psychosocial and injury-related variables predict symptom duration following sport-related concussion.Methods:A total of 2,055 high school and collegiate athletes completed preseason evaluations. Concussed athletes (n = 127) repeated assessments serially (<24 hours and days 8, 15, and 45) postinjury. Cox proportional hazard modeling was used to predict concussive symptom duration (in days). Predictors considered included demographic and history variables; baseline psychological, neurocognitive, and balance functioning; acute injury characteristics; and postinjury clinical measures.Results:Preinjury somatic symptom score (Brief Symptom Inventory-18 somatization scale) was the strongest premorbid predictor of symptom duration. Acute (24-hour) postconcussive symptom burden (Sport Concussion Assessment Tool-3 symptom severity) was the best injury-related predictor of recovery. These 2 predictors were moderately correlated (r = 0.51). Path analyses indicated that the relationship between preinjury somatization symptoms and symptom recovery was mediated by postinjury concussive symptoms.Conclusions:Preinjury somatization symptoms contribute to reported postconcussive symptom recovery via their influence on acute postconcussive symptoms. The findings highlight the relevance of premorbid psychological factors in postconcussive recovery, even in a healthy athlete sample relatively free of psychopathology or medical comorbidities. Future research should elucidate the neurobiopsychosocial mechanisms that explain the role of this individual difference variable in outcome following concussive injury.	[Nelson, Lindsay D.; LaRoche, Ashley A.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Tarima, Sergey] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA; [Hammeke, Thomas A.] Med Coll Wisconsin, Dept Psychiat & Behav Med, Milwaukee, WI 53226 USA; [Barr, William B.] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, 2160 S 1st Ave, Maywood, IL 60153 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.	linelson@mcw.edu		Barr, William/0000-0001-7711-7758	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 [-01]]; NIH National Center for Advancing Translational Sciences [8UL1TR000055]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Supported by the US Army Medical Research and Materiel Command (award W81XWH-12-1-0004), the Clinical and Translational Science Institute (grant 1UL1-RR031973 [-01]), and the NIH National Center for Advancing Translational Sciences (grant 8UL1TR000055). Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army. The manuscript's contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	[Anonymous], 2003, GREENS MED SYMPT VAL; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Browning M, 2011, PSYCHOSOM MED, V73, P173, DOI 10.1097/PSY.0b013e31820824f6; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dimsdale JE, 2013, J PSYCHOSOM RES, V75, P223, DOI 10.1016/j.jpsychores.2013.06.033; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Helmick K, 2006, DEFENSE VETERANS BRA, P1; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iacobucci D, 2012, J CONSUM PSYCHOL, V22, P582, DOI 10.1016/j.jcps.2012.03.006; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Krueger RF, 1999, ARCH GEN PSYCHIAT, V56, P921, DOI 10.1001/archpsyc.56.10.921; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2015, AM J SPORT MED, V43, P2018, DOI 10.1177/0363546515587714; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Tsao JW, 2014, NEUROLOGY, V83, P2196, DOI 10.1212/WNL.0000000000001086; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Wechsler D., 2001, WECHSLER TEST ADULT; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Widiger TA, 2005, J ABNORM PSYCHOL, V114, P494, DOI 10.1037/0021-843X.114.4.494; Wood RL, 2011, BRAIN INJURY, V25, P1296, DOI 10.3109/02699052.2011.624569; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491	39	67	67	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 17	2016	86	20					1856	1863		10.1212/WNL.0000000000002679			8	Clinical Neurology	Neurosciences & Neurology	DN0US	WOS:000376782000006	27164666	Green Published			2021-06-18	
J	Miller, JH; Gill, C; Kuhn, EN; Rocque, BG; Menendez, JY; O'Neill, JA; Agee, BS; Brown, ST; Crowther, M; Davis, RD; Ferguson, D; Johnston, JM				Miller, Joseph H.; Gill, Clarence; Kuhn, Elizabeth N.; Rocque, Brandon G.; Menendez, Joshua Y.; O'Neill, Jilian A.; Agee, Bonita S.; Brown, Steven T.; Crowther, Marshall; Davis, R. Drew; Ferguson, Drew; Johnston, James M.			Predictors of delayed recovery following pediatric sports-related concussion: a case-control study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; SCAT2 score; pediatric; trauma; recovery; head injury	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; NCAA CONCUSSION; MANAGEMENT; AGE	OBJECTIVE Pediatric sports-related concussions are a growing public health concern. The factors that determine injury severity and time to recovery following these concussions are poorly understood. Previous studies suggest that initial symptom severity and diagnosis of attention deficit hyperactivity disorder (ADHD) are predictors of prolonged recovery (> 28 days) after pediatric sports-related concussions. Further analysis of baseline patient characteristics may allow for a more accurate prediction of which patients are at risk for delayed recovery after a sports-related concussion. METHODS The authors performed a single-center retrospective case-control study involving patients cared for at the multidisciplinary Concussion Clinic at Children's of Alabama between August 2011 and January 2013. Patient demographic data, medical history, sport concussion assessment tool 2 (SCAT2) and symptom severity scores, injury characteristics, and patient balance assessments were analyzed for each outcome group. The control group consisted of patients whose symptoms resolved within 28 days. The case group included patients whose symptoms persisted for more than 28 days. The presence or absence of the SCAT2 assessment had a modifying effect on the risk for delayed recovery; therefore, stratum-specific analyses were conducted for patients with recorded SCAT2 scores and for patients without SCAT2 scores. Unadjusted ORs and adjusted ORs (aORs) for an association of delayed recovery outcome with specific risk factors were calculated with logistic regression analysis. RESULTS A total of 294 patients met the inclusion criteria of the study. The case and control groups did not statistically significantly differ in age (p = 0.7). For the patients who had received SCAT2 assessments, a previous history of concussion (aOR 3.67, 95% CI 1.51-8.95), presenting SCAT2 score < 80 (aOR 5.58, 95% CI 2.61-11.93), and female sex (aOR 3.48, 95% CI 1.43-8.49) were all associated with a higher risk for postconcussive symptoms lasting more than 28 days. For patients without SCAT2 scores, female sex and reporting a history of ADHD significantly increased the odds of prolonged recovery (aOR 4.41, 95% CI 1.93-10.07 and aOR 3.87, 95% C11.13-13.24, respectively). Concussions resulting from playing a nonhelmet sport were also associated with a higher risk for prolonged symptoms in patients with and without SCAT2 scores (OR 2.59, 95% CI 1.28-5.26 and OR 2.17, 95% CI 0.99-7.73, respectively). Amnesia, balance abnormalities, and a history of migraines were not associated with symptoms lasting longer than 28 days. CONCLUSIONS This case-control study suggests candidate risk factors for predicting prolonged recovery following sports-related concussion. Large prospective cohort studies of youth athletes examined and treated with standardized protocols will be needed to definitively establish these associations and confirm which children are at highest risk for delayed recovery.	[Miller, Joseph H.; Gill, Clarence; Kuhn, Elizabeth N.; Rocque, Brandon G.; Menendez, Joshua Y.; O'Neill, Jilian A.; Agee, Bonita S.; Brown, Steven T.; Johnston, James M.] Univ Alabama Birmingham, Dept Neurosurg, FOT 1030,1720 2nd Ave S, Birmingham, AL 35294 USA; [Crowther, Marshall; Davis, R. Drew; Ferguson, Drew; Johnston, James M.] Univ Alabama Birmingham, Dept Sports Med, Birmingham, AL USA	Johnston, JM (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, FOT 1030,1720 2nd Ave S, Birmingham, AL 35294 USA.	james.johnston@childrensa1.org	Alford, Elizabeth/W-1666-2019	Alford, Elizabeth/0000-0003-1779-089X; Johnston, James/0000-0001-8564-1808; Rocque, Brandon/0000-0002-7333-4808	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001417, KL2TR001419] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001419, UL1 TR001417] Funding Source: Medline		Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91	19	67	67	1	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2016	17	4					491	496		10.3171/2015.8.PEDS14332			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	DH3EF	WOS:000372669600017	26684762	Green Accepted, Bronze			2021-06-18	
J	Iraji, A; Benson, RR; Welch, RD; O'Neil, BJ; Woodard, JL; Ayaz, SI; Kulek, A; Mika, V; Medado, P; Soltanian-Zadeh, H; Liu, TM; Haacke, EM; Kou, ZF				Iraji, Armin; Benson, Randall R.; Welch, Robert D.; O'Neil, Brian J.; Woodard, John L.; Ayaz, Syed Imran; Kulek, Andrew; Mika, Valerie; Medado, Patrick; Soltanian-Zadeh, Hamid; Liu, Tianming; Haacke, E. Mark; Kou, Zhifeng			Resting State Functional Connectivity in Mild Traumatic Brain Injury at the Acute Stage: Independent Component and Seed-Based Analyses	JOURNAL OF NEUROTRAUMA			English	Article						functional connectivity; fMRI; functional MRI; mTBI; mild traumatic brain injury; resting state fMRI	DIFFUSE AXONAL INJURY; POSTERIOR CINGULATE CORTEX; WHITE-MATTER INJURY; HUMAN AMYGDALA; PREFRONTAL CORTEX; RHESUS-MONKEY; EMERGENCY-DEPARTMENT; FOOTBALL PLAYERS; DEFAULT NETWORK; WORKING-MEMORY	Mild traumatic brain injury (mTBI) accounts for more than 1 million emergency visits each year. Most of the injured stay in the emergency department for a few hours and are discharged home without a specific follow-up plan because of their negative clinical structural imaging. Advanced magnetic resonance imaging (MRI), particularly functional MRI (fMRI), has been reported as being sensitive to functional disturbances after brain injury. In this study, a cohort of 12 patients with mTBI were prospectively recruited from the emergency department of our local Level-1 trauma center for an advanced MRI scan at the acute stage. Sixteen age- and sex-matched controls were also recruited for comparison. Both group-based and individual-based independent component analysis of resting-state fMRI (rsfMRI) demonstrated reduced functional connectivity in both posterior cingulate cortex (PCC) and precuneus regions in comparison with controls, which is part of the default mode network (DMN). Further seed-based analysis confirmed reduced functional connectivity in these two regions and also demonstrated increased connectivity between these regions and other regions of the brain in mTBI. Seed-based analysis using the thalamus, hippocampus, and amygdala regions further demonstrated increased functional connectivity between these regions and other regions of the brain, particularly in the frontal lobe, in mTBI. Our data demonstrate alterations of multiple brain networks at the resting state, particularly increased functional connectivity in the frontal lobe, in response to brain concussion at the acute stage. Resting-state functional connectivity of the DMN could serve as a potential biomarker for improved detection of mTBI in the acute setting.	[Iraji, Armin; Mika, Valerie; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Benson, Randall R.] Ctr Neurol Studies, Novi, MI USA; [Welch, Robert D.; O'Neil, Brian J.; Ayaz, Syed Imran; Kulek, Andrew; Mika, Valerie; Medado, Patrick] Wayne State Univ, Dept Emergency Med, Detroit, MI USA; [Woodard, John L.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Soltanian-Zadeh, Hamid] Henry Ford Hosp, Dept Radiol, Detroit, MI 48202 USA; [Liu, Tianming] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Radiol, Detroit, MI USA	Kou, ZF (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA.	Zhifeng_kou@wayne.edu	Soltanian-Zadeh, Hamid/K-2903-2016; Mika, Valerie H./AAO-2816-2020	Soltanian-Zadeh, Hamid/0000-0002-7302-6856; Woodard, John/0000-0001-9196-3336	International Society for Magnetic Resonance in Medicine (ISMRM) seed grant; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]	This study was supported by the International Society for Magnetic Resonance in Medicine (ISMRM) seed grant and the Department of Defense (grant contract number: W81XWH-11-1-0493). The authors also thank Ms. Natalie Wiseman, MD, PhD candidate, for proofreading.	Adolphs R, 2008, CURR OPIN NEUROBIOL, V18, P166, DOI 10.1016/j.conb.2008.06.006; Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5; [Anonymous], 1999, JAMA, V282, P974; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2003, BRAIN, V126, P713, DOI 10.1093/brain/awg067; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Beckmann C. F., 2009, NEUROIMAGE, V47, pS148, DOI [10.1016/S1053-8119(09)71511-3, DOI 10.1016/S1053-8119(09)71511-3]; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Binder JR, 2011, TRENDS COGN SCI, V15, P527, DOI 10.1016/j.tics.2011.10.001; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bzdok D, 2013, HUM BRAIN MAPP, V34, P3247, DOI 10.1002/hbm.22138; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; CDC, 2003, REP C MILD TRAUM BRA; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Dettwiler A., 2014, J NEUROTRAUM, V31, P180; Gilbert SJ, 2007, SCIENCE, V317, P43, DOI 10.1126/science.1140801; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI 10.1016/j.tics.2007.04.005; Kou Z., CLIN MR NEUROIMAGING; Kou Z., 2007, P JOINT ANN M ISMRM; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Kou ZF, 2012, RSC DRUG DISCOV, V24, P19, DOI 10.1039/9781849734745-00019; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Lin QH, 2010, HUM BRAIN MAPP, V31, P1076, DOI 10.1002/hbm.20919; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maddock RJ, 2003, HUM BRAIN MAPP, V18, P30, DOI 10.1002/hbm.10075; Maratos EJ, 2001, NEUROPSYCHOLOGIA, V39, P910, DOI 10.1016/S0028-3932(01)00025-2; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M., 2000, STANDARDIZED ASSESSM; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris R, 1999, J COMP NEUROL, V407, P183, DOI 10.1002/(SICI)1096-9861(19990503)407:2<183::AID-CNE3>3.0.CO;2-N; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; PANDYA DN, 1981, EXP BRAIN RES, V42, P319, DOI 10.1007/BF00237497; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pearson JM, 2011, TRENDS COGN SCI, V15, P143, DOI 10.1016/j.tics.2011.02.002; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Steriade M, 2005, TRENDS NEUROSCI, V28, P317, DOI 10.1016/j.tins.2005.03.007; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Swanson LW, 1998, TRENDS NEUROSCI, V21, P323, DOI 10.1016/S0166-2236(98)01265-X; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tian LX, 2006, NEUROSCI LETT, V400, P39, DOI 10.1016/j.neulet.2006.02.022; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou Y, 2007, SCHIZOPHR RES, V97, P194, DOI 10.1016/j.schres.2007.05.029	76	67	71	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1031	1045		10.1089/neu.2014.3610			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000001	25285363	Green Published			2021-06-18	
J	Cairelli, MJ; Fiszman, M; Zhang, H; Rindflesch, TC				Cairelli, Michael J.; Fiszman, Marcelo; Zhang, Han; Rindflesch, Thomas C.			Networks of neuroinjury semantic predications to identify biomarkers for mild traumatic brain injury	JOURNAL OF BIOMEDICAL SEMANTICS			English	Article						Semantic predications; Semantic networks; Natural language processing; Degree centrality; Traumatic brain injury	LITERATURE-BASED DISCOVERY; LANGUAGE SYSTEM UMLS; CEREBROSPINAL-FLUID; CONCUSSION; CENTRALITY; KNOWLEDGE; PATTERNS; BIOLOGY	Objective: Mild traumatic brain injury (mTBI) has high prevalence in the military, among athletes, and in the general population worldwide (largely due to falls). Consequences can include a range of neuropsychological disorders. Unfortunately, such neural injury often goes undiagnosed due to the difficulty in identifying symptoms, so the discovery of an effective biomarker would greatly assist diagnosis; however, no single biomarker has been identified. We identify several body substances as potential components of a panel of biomarkers to support the diagnosis of mild traumatic brain injury. Methods: Our approach to diagnostic biomarker discovery combines ideas and techniques from systems medicine, natural language processing, and graph theory. We create a molecular interaction network that represents neural injury and is composed of relationships automatically extracted from the literature. We retrieve citations related to neurological injury and extract relationships (semantic predications) that contain potential biomarkers. After linking all relationships together to create a network representing neural injury, we filter the network by relationship frequency and concept connectivity to reduce the set to a manageable size of higher interest substances. Results: 99,437 relevant citations yielded 26,441 unique relations. 18,085 of these contained a potential biomarker as subject or object with a total of 6246 unique concepts. After filtering by graph metrics, the set was reduced to 1021 relationships with 49 unique concepts, including 17 potential biomarkers. Conclusion: We created a network of relationships containing substances derived from 99,437 citations and filtered using graph metrics to provide a set of 17 potential biomarkers. We discuss the interaction of several of these (glutamate, glucose, and lactate) as the basis for more effective diagnosis than is currently possible. This method provides an opportunity to focus the effort of wet bench research on those substances with the highest potential as biomarkers for mTBI.	[Cairelli, Michael J.; Fiszman, Marcelo; Rindflesch, Thomas C.] NIH, Natl Lib Med, Bethesda, MD 20892 USA; [Zhang, Han] China Med Univ, Dept Med Informat, Shenyang 110001, Liaoning, Peoples R China	Cairelli, MJ (corresponding author), NIH, Natl Lib Med, 38A 9N912A,8600 Rockville Pike, Bethesda, MD 20892 USA.	mike.cairelli@nih.gov	Zhang, Han/N-5849-2018		National Library of Medicine Research Participation Program; Intramural Research Program of the National Institutes of Health, National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)	This research was supported in part by an appointment to the National Library of Medicine Research Participation Program administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the US Department of Energy and the National Library of Medicine. This study was supported in part by the Intramural Research Program of the National Institutes of Health, National Library of Medicine.	Ahlers Caroline B, 2007, AMIA Annu Symp Proc, P6; Andronis C, 2011, BRIEF BIOINFORM, V12, P357, DOI 10.1093/bib/bbr005; Aronson AR, 2010, J AM MED INFORM ASSN, V17, P229, DOI 10.1136/jamia.2009.002733; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061; Bray Bruce E, 2008, AMIA Annu Symp Proc, P887; Cairelli Michael J, 2013, AMIA Annu Symp Proc, V2013, P164; Cameron D, 2013, J BIOMED INFORM, V46, P238, DOI 10.1016/j.jbi.2012.09.004; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen GC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003666; Cohen T, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.37; Cohen T, 2012, J BIOMED INFORM, V45, P1049, DOI 10.1016/j.jbi.2012.07.003; Cohen Trevor, 2009, AMIA Annu Symp Proc, V2009, P114; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dong WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100436; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fiszman Marcelo, 2008, AMIA Annu Symp Proc, P187; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gabetta M, 2013, STUD HEALTH TECHNOL, V192, P412, DOI 10.3233/978-1-61499-289-9-412; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Goodwin JC, 2012, IEEE INT C BIO BIO W; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; He Ying, 2008, AMIA Annu Symp Proc, P293; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Hristovski D, 2005, INT J MED INFORM, V74, P289, DOI 10.1016/j.ijmedinf.2004.04.024; Hristovski Dimitar, 2006, AMIA Annu Symp Proc, P349; Hristovski Dimitar, 2009, AMIA Annu Symp Proc, V2009, P255; Hristovski Dimitar, 2007, AMIA Annu Symp Proc, P979; Hristovski Dimitar, 2013, Cardiovascular & Hematological Agents in Medicinal Chemistry, V11, P14; Hur J, 2012, J BIOMED SEMANT, V3, DOI 10.1186/2041-1480-3-18; Hur J, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-49; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jonnalagadda SR, 2013, J AM MED INFORM ASSN, V20, P995, DOI 10.1136/amiajnl-2012-001347; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan Rick, 2014, J Clin Bioinforma, V4, P13, DOI 10.1186/2043-9113-4-13; Kastrin Andrej, 2008, AMIA Annu Symp Proc, P358; Kilicoglu H, 2012, BIOINFORMATICS, V28, P3158, DOI 10.1093/bioinformatics/bts591; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Levy ML, 2012, WORLD NEUROSURG, V78, P535, DOI 10.1016/j.wneu.2011.10.032; Li C, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat030; Liang R, 2013, CHINESE MED J-PEKING, V126, P2472, DOI 10.3760/cma.j.issn.0366-6999.20122846; Liu Ying, 2012, AMIA Annu Symp Proc, V2012, P587; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Maver A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/848952; Miller CM, 2012, SLEEP, V35, P279, DOI 10.5665/sleep.1640; Nadkarni PM, 2011, J AM MED INFORM ASSN, V18, P544, DOI 10.1136/amiajnl-2011-000464; Ozgur A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/426479; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Rindflesch TC, 2003, J BIOMED INFORM, V36, P462, DOI 10.1016/j.jbi.2003.11.003; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shang N, 2014, J BIOMED INFORM, V52, P293, DOI 10.1016/j.jbi.2014.07.011; Shang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023862; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Timmons SD, 2012, J NEUROSURG SCI, V56, P191; Trugenberger CA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-51; van Haagen HHHBM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078665; Vos R, 2014, J AM MED INFORM ASSN, V21, P139, DOI 10.1136/amiajnl-2012-001448; Wang K, 2010, DIS MARKERS, V28, P199, DOI [10.3233/DMA-2010-0697, 10.1155/2010/130861]; Weeber M, 2005, BRIEF BIOINFORM, V6, P277, DOI 10.1093/bib/6.3.277; West TD, 2007, REBUILDING TRUST REP; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zeng Qing T, 2012, AMIA Annu Symp Proc, V2012, P1050; Zhang H, 2011, J BIOMED INFORM, V44, P830, DOI 10.1016/j.jbi.2011.05.001; Zhang R, 2014, J BIOMED INFORM, V49, P134, DOI 10.1016/j.jbi.2014.01.004; Zhang X., 2007, P 16 INT C WORLD WID, P707, DOI DOI 10.1145/1242572.1242668	76	67	70	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1480			J BIOMED SEMANT	J. Biomed. Semant.	MAY 18	2015	6								25	10.1186/s13326-015-0022-4			14	Mathematical & Computational Biology	Mathematical & Computational Biology	CI7DH	WOS:000354922600001	25992264	DOAJ Gold, Green Published			2021-06-18	
J	Koerte, IK; Lin, AP; Willems, A; Muehlmann, M; Hufschmidt, J; Coleman, MJ; Green, I; Liao, HJ; Tate, DF; Wilde, EA; Pasternak, O; Bouix, S; Rathi, Y; Bigler, ED; Stern, RA; Shenton, ME				Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Liao, Huijun; Tate, David F.; Wilde, Elisabeth A.; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Bigler, Erin D.; Stern, Robert A.; Shenton, Martha E.			A Review of Neuroimaging Findings in Repetitive Brain Trauma	BRAIN PATHOLOGY			English	Article						neuroimaging; repetitive head injury	MILD COGNITIVE IMPAIRMENT; CEREBRAL GLUCOSE-METABOLISM; WHITE-MATTER INTEGRITY; RETIRED NFL PLAYERS; PROFESSIONAL BOXERS; CORTICAL THICKNESS; FOOTBALL PLAYERS; IMAGING FINDINGS; AMATEUR BOXERS; AXONAL INJURY	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease confirmed at postmortem. Those at highest risk are professional athletes who participate in contact sports and military personnel who are exposed to repetitive blast events. All neuropathologically confirmed CTE cases, to date, have had a history of repetitive head impacts. This suggests that repetitive head impacts may be necessary for the initiation of the pathogenetic cascade that, in some cases, leads to CTE. Importantly, while all CTE appears to result from repetitive brain trauma, not all repetitive brain trauma results in CTE. Magnetic resonance imaging has great potential for understanding better the underlying mechanisms of repetitive brain trauma. In this review, we provide an overview of advanced imaging techniques currently used to investigate brain anomalies. We also provide an overview of neuroimaging findings in those exposed to repetitive head impacts in the acute/subacute and chronic phase of injury and in more neurodegenerative phases of injury, as well as in military personnel exposed to repetitive head impacts. Finally, we discuss future directions for research that will likely lead to a better understanding of the underlying mechanisms separating those who recover from repetitive brain trauma vs. those who go on to develop CTE.	[Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Shenton, Martha E.] Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Lin, Alexander P.; Liao, Huijun] Brigham & Womens Hosp, Dept Radiol, Ctr Clin Spect, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA; [Koerte, Inga K.; Willems, Anna; Muehlmann, Marc] Univ Munich, Dr von Hauner Childrens Hosp, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Hufschmidt, Jakob] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Tate, David F.] San Antonio Mil Med Ctr, Def Ctr, San Antonio, TX USA; [Tate, David F.] San Antonio Mil Med Ctr, Vet Brain Injury Ctr, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, San Antonio, TX USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, San Antonio, TX USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Koerte, IK (corresponding author), Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Tate, David F/I-3963-2013; Shenton, Martha/V-8780-2019; , Bob/ABA-8507-2020	Tate, David F/0000-0003-0213-1920; Stern, Robert/0000-0002-5008-077X	Else Kroner-Fresenius-Stiftung, Germany; Department of DefenseUnited States Department of Defense [W81XWH-10-1-0835, X81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337, U01-NS086659]; VA Merit AwardUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659, R01NS078337] Funding Source: NIH RePORTER	This study was supported by the Else Kroner-Fresenius-Stiftung, Germany (IK, MM). This work was also partially funded by grants from the Department of Defense (W81XWH-10-1-0835: APL; X81XWH-07-CC-CSDoD; MES, RAS), the National Institutes of Health (R01-NS078337: APL, MES, RAS; U01-NS086659: RAS) and a VA Merit Award (MES).	Abbas K, 2014, BRAIN CONNECT; Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agel J, 2010, CAN J SURG, V53, P319; Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Attardo G, 2014, EUR J NUCL MED MOL I, V41, pS427; Aviv RI, 2010, CAN ASSOC RADIOL J, V61, P29, DOI 10.1016/j.carj.2009.09.002; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Bowman KM, 1940, INJURIES SKULL BRAIN, P309; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chang YL, 2010, CEREB CORTEX, V20, P1305, DOI 10.1093/cercor/bhp192; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corps K. N., 2015, JAMA NEUROL; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, NEUROCHIRURG HOMMAGE, P131; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; Dickerson BC, 2012, NEUROLOGY, V78, P84, DOI 10.1212/WNL.0b013e31823efc6c; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Hahnel S, 2008, AM J NEURORADIOL, V29, P388, DOI 10.3174/ajnr.A0799; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Ibarretxe-Bilbao N, 2012, MOVEMENT DISORD, V27, P1746, DOI 10.1002/mds.25240; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jubault T, 2011, NEUROIMAGE, V55, P462, DOI 10.1016/j.neuroimage.2010.12.043; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kaufman MS, 2014, PHYS MED REH CLIN N, V25, P707, DOI 10.1016/j.pmr.2014.06.002; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Khan AR, 2008, NEUROIMAGE, V41, P735, DOI 10.1016/j.neuroimage.2008.03.024; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Little DM, 2014, ALZHEIMERS DEMENT, V10, pS188, DOI 10.1016/j.jalz.2014.04.002; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malcolm JG, 2010, MED IMAGE ANAL, V14, P58, DOI 10.1016/j.media.2009.10.003; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; McAllister T, 2014, TASK RELATED CEREBRA; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ozarslan E, 2013, NEUROIMAGE, V78, P16, DOI 10.1016/j.neuroimage.2013.04.016; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Park H, 2013, NEUROSCI LETT, V550, P17, DOI 10.1016/j.neulet.2013.06.042; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rathi Y, 2013, LECT NOTES COMPUT SC, V8151, P510, DOI 10.1007/978-3-642-40760-4_64; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seo SW, 2010, J NEUROIMAGING, V20, P37, DOI 10.1111/j.1552-6569.2008.00293.x; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shah M, 2014, J NUCL MED, V55, P871, DOI 10.2967/jnumed.113.136069; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Shoup TM, 2013, J LABELLED COMPD RAD, V56, P736, DOI 10.1002/jlcr.3098; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Singh V, 2006, BRAIN, V129, P2885, DOI 10.1093/brain/awl256; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stamm JM, 2015, NEUROLOGY; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stone JR, 2013, J NEUROTRAUM, V30, pA120; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Villemagne VL, 2014, ALZHEIMERS DEMENT, V10, pS254, DOI 10.1016/j.jalz.2014.04.013; Villemagne VL, 2012, FUTUR NEUROL, V7, P409, DOI 10.2217/FNL.12.34; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Xu L, 2014, EXP NEUROL; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	173	67	67	2	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2015	25	3					318	349		10.1111/bpa.12249			32	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CG6CX	WOS:000353384200009	25904047	Green Accepted			2021-06-18	
J	Ge, XT; Han, ZL; Chen, FL; Wang, HC; Zhang, BL; Jiang, RC; Lei, P; Zhang, JN				Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Wang, Haichen; Zhang, Baoliang; Jiang, Rongcai; Lei, Ping; Zhang, Jianning			miR-21 alleviates secondary blood-brain barrier damage after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Traumatic brain injury; miR-21; Gene therapy; Blood-brain barrier; Secondary brain damage	ENDOTHELIAL GROWTH-FACTOR; VASCULAR STABILIZATION; EXPRESSION; ANGIOGENESIS; STROKE; MODEL; IMPROVES; ANGIOPOIETIN1/TIE2; MORPHOGENESIS; HIPPOCAMPUS	Our recent studies have identified increased expression of miR-21 in brain following traumatic brain injury (TBI), which alleviated brain edema that related to the blood-brain barrier (BBB) leakage. To analyze the potential effect of miR-21 on secondary BBB damage after TBI, we employed the fluid percussion injury rat model and manipulated the expression level of miR-21 in brain. We found that miR-21 level in brain microvascular endothelial cells (BMVECs) in lesioned cerebral cortex can be upregulated or downregulated by intracerebroventricular infusion of miR-21 agomir or antagomir. Upregulated miR-21 level conferred a better neurological outcome of TBI, and alleviated TBI-induced secondary BBB damage and loss of tight junction proteins. To explore the molecular mechanism underlying this protective effect, we detected the impact of miR-21 on the expression of Angiopoietin-1(Ang-1) and Tie-2, which can promote the expression of tight junction proteins and amplify BBB stabilization. We found that miR-21 exerts the protective effect on BBB by activating the Ang-1/Tie-2 axis in BMVECs. Thus, miR-21 could be a potential therapeutic target for interventions of secondary BBB damage after TBI. (C) 2015 Elsevier B.V. All rights reserved.	[Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin 300052, Peoples R China; [Ge, Xintong; Zhang, Baoliang; Jiang, Rongcai; Lei, Ping; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Wang, Haichen] Duke Univ, Sch Med, Dept Neurol, Durham, NC 27710 USA	Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	leiping1974@163.com; jianningzhang@hotmail.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81471252, 81271361]; Tianjin Municipal Science and Technology Commission natural fund project [13JCYBJC23700]; National Clinical Key Subject Construction Project of NHFPC Fund	This research was supported by grants from the National Natural Science Foundation of China (grant nos. 81330029, 81471252 and 81271361), Tianjin Municipal Science and Technology Commission natural fund project (grant no. 13JCYBJC23700) and National Clinical Key Subject Construction Project of NHFPC Fund. We express special acknowledgement to the senior professor Chunsheng Kang who contributes greatly on this research. The authors also appreciate Li Liu, Weiyun Cui, Ying Li, Lei Zhou, Zhifan Jia, and Guangxiu Wang from Tianjin Neurological Institute for their technical support.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Cui X, 2012, NEUROSCIENCE, V227, P223, DOI 10.1016/j.neuroscience.2012.09.066; Davis B, 2010, INT J DEV NEUROSCI, V28, P423, DOI 10.1016/j.ijdevneu.2010.06.010; Edwards P, 2005, LANCET, V365, P1957; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Qian XM, 2014, BIOMATERIALS, V35, P2322, DOI 10.1016/j.biomaterials.2013.11.039; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Senger DR, 2010, MOL BIOL CELL, V21, P377, DOI 10.1091/mbc.E09-07-0591; Sethi G, 2009, ADV EXP MED BIOL, V647, P207, DOI 10.1007/978-0-387-89520-8_15; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027; Zheng M., 2014, J MOL NEUROSCI; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126; Zhu Y, 2006, ACTA NEUROCHIR SUPPL, V96, P438; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	67	70	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 7	2015	1603						150	157		10.1016/j.brainres.2015.01.009			8	Neurosciences	Neurosciences & Neurology	CG2CL	WOS:000353082400015	25598202				2021-06-18	
J	Ji, SB; Zhao, W; Ford, JC; Beckwith, JG; Bolander, RP; Greenwald, RM; Flashman, LA; Paulsen, KD; McAllister, TW				Ji, Songbai; Zhao, Wei; Ford, James C.; Beckwith, Jonathan G.; Bolander, Richard P.; Greenwald, Richard M.; Flashman, Laura A.; Paulsen, Keith D.; McAllister, Thomas W.			Group-Wise Evaluation and Comparison of White Matter Fiber Strain and Maximum Principal Strain in Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; models of injury; axonal injury; finite element method; traumatic brain injury	HEAD ACCELERATION; AXONAL DAMAGE; BRAIN-TISSUE; IN-VIVO; IMPACT; FOOTBALL; MODELS; SYSTEM; IMPAIRMENT; GENERATION	Sports-related concussion is a major public health problem in the United States and yet its biomechanical mechanisms remain unclear. In vitro studies demonstrate axonal elongation as a potential injury mechanism; however, current response-based injury predictors (e.g., maximum principal strain, [GRAPHICS] ) typically do not incorporate axonal orientations. We investigated the significance of white matter (WM) fiber orientation in strain estimation and compared fiber strain ( [GRAPHICS] ) with [GRAPHICS] for 11 athletes with a clinical diagnosis of concussion. Geometrically accurate subject-specific head models with high mesh quality were created based on the Dartmouth Head Injury Model (DHIM), which was successfully validated (performance categorized as "good" to "excellent"). For WM regions estimated to be exposed to high strains using a range of injury thresholds (0.09-0.28), substantial differences existed between [GRAPHICS] and [GRAPHICS] in both distribution (Dice coefficient of 0.13-0.33) and extent (similar to 5-10-fold differences), especially at higher threshold levels and higher rotational acceleration magnitudes. For example, an average of 3.2% vs. 29.8% of WM was predicted above an optimal threshold of 0.18 established from an in vivo animal study using [GRAPHICS] and [GRAPHICS] , respectively, with an average Dice coefficient of 0.14. The distribution of WM regions with high [GRAPHICS] was consistent with typical heterogeneous patterns of WM disruptions in diffuse axonal injury, and the group-wise extent at the optimal threshold matched well with the percentage of WM voxels experiencing significant longitudinal changes of fractional anisotropy and mean diffusivity (3.2% and 3.44%, respectively) found from a separate independent study. These results suggest the significance of incorporating WM microstructural anisotropy in future brain injury studies.	[Ji, Songbai; Zhao, Wei; Greenwald, Richard M.; Paulsen, Keith D.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg & Orthoped Surg, Lebanon, NH USA; [Ford, James C.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Beckwith, Jonathan G.; Bolander, Richard P.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA	Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	Songbai.Ji@Dartmouth.edu	Ford, James/AAF-7039-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS078607, R01NS055020, R01HD048638]; National Operating Committee on Standards for Athletic Equipment [NOCSAE 04-07, SAC-1]; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; NOCSAE [SAC-1, 04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078607, R01NS055020] Funding Source: NIH RePORTER	This work was sponsored, in part, by the NIH grant R21 NS078607 and the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07 & SAC-1). Funding for the head impact biomechanical data collection and neuroimaging that supported this work included the NIH grants R01NS055020, R01HD048638, CDC R01/CE001254, and NOCSAE grant 04-07 & SAC-1, and are acknowledged. The authors would also like to thank Dr. Robert M. Roth in the Brain Imaging Laboratory at the Geisel School of Medicine at Dartmouth College for assistance with image segmentation in MRI, and Drs. Philip V. Bayly and Yuan Feng at Washington University in St. Louis for providing data needed for DHIM validation.	ARUN KS, 1987, IEEE T PATTERN ANAL, V9, P699, DOI 10.1109/TPAMI.1987.4767965; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; de Lange Ronald, 2005, Stapp Car Crash J, V49, P457; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Funk J. R., 2006, INJ BIOM RES 34 INT, P1; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gwin J., 2006, J BIOMECH, V39, pS153; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hayek L. C., 1994, MEASURING MONITORING; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McElhaney J. H., 1973, PERSPECTIVES BIOMEDI; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shugar TA, 1977, HS2893550 DOT, VI; Sigal IA, 2010, J BIOMECH, V43, P254, DOI 10.1016/j.jbiomech.2009.08.036; Slaughter W. S., 2002, LINEARIZED THEOR ELA; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2013, J NEUROTRAUM, V30, P1; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang JK, 2011, COMPUTATIONAL BIOMECHANICS FOR MEDICINE: SOFT TISSUES AND THE MUSCULOSKELETAL SYSTEM, P5, DOI 10.1007/978-1-4419-9619-0_2; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2012, INT J VEH SAF, V6, P91	63	67	67	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					441	454		10.1089/neu.2013.3268			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400004	24735430	Green Published			2021-06-18	
J	Ham, TE; Bonnelle, V; Hellyer, P; Jilka, S; Robertson, IH; Leech, R; Sharp, DJ				Ham, Timothy E.; Bonnelle, Valerie; Hellyer, Peter; Jilka, Sagar; Robertson, Ian H.; Leech, Robert; Sharp, David J.			The neural basis of impaired self-awareness after traumatic brain injury	BRAIN			English	Article						traumatic brain injury; fronto-parietal control network; salience network; self-awareness; functional connectivity	ANTERIOR CINGULATE CORTEX; RESPONSE-INHIBITION; FINANCIAL CAPACITY; SALIENCE NETWORK; SPATIAL NEGLECT; FRONTAL SYSTEMS; ERROR-DETECTION; CONNECTIVITY; PERFORMANCE; ATTENTION	Self-awareness is commonly impaired after traumatic brain injury. This is an important clinical issue as awareness affects long-term outcome and limits attempts at rehabilitation. It can be investigated by studying how patients respond to their errors and monitor their performance on tasks. As awareness is thought to be an emergent property of network activity, we tested the hypothesis that impaired self-awareness is associated with abnormal brain network function. We investigated a group of subjects with traumatic brain injury (n = 63) split into low and high performance-monitoring groups based on their ability to recognize and correct their own errors. Brain network function was assessed using resting-state and event-related functional magnetic resonance imaging. This allowed us to investigate baseline network function, as well as the evoked response of networks to specific events including errors. The low performance-monitoring group underestimated their disability and showed broad attentional deficits. Neural activity within what has been termed the fronto-parietal control network was abnormal in patients with impaired self-awareness. The dorsal anterior cingulate cortex is a key part of this network that is involved in performance-monitoring. This region showed reduced functional connectivity to the rest of the fronto-parietal control network at 'rest'. In addition, the anterior insulae, which are normally tightly linked to the dorsal anterior cingulate cortex, showed increased activity following errors in the impaired group. Interestingly, the traumatic brain injury patient group with normal performance-monitoring showed abnormally high activation of the right middle frontal gyrus, putamen and caudate in response to errors. The impairment of self-awareness was not explained either by the location of focal brain injury, or the amount of traumatic axonal injury as demonstrated by diffusion tensor imaging. The results suggest that impairments of self-awareness after traumatic brain injury result from breakdown of functional interactions between nodes within the fronto-parietal control network.	[Ham, Timothy E.; Hellyer, Peter; Jilka, Sagar; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, C3NL, Ctr Restorat Neurosci, Div Brain Sci,Dept Med, London W12 0NN, England; [Ham, Timothy E.] Univ Cambridge, Neurol Unit, Cambridge CB2 0SZ, England; [Bonnelle, Valerie] UCL, Inst Cognit Neurosci, London WC1N 3AR, England; [Jilka, Sagar] Univ London, Dept Psychol, London SE14 6NW, England; [Robertson, Ian H.] Trinity Coll Dublin, Trinity Coll, Inst Neurosci, Dublin 2, Ireland	Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Expt Med, Burlington Danes Bldg,Hammersmith Hosp Campus, London W12 0NN, England.	david.sharp@csc.mrc.ac.uk	Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013; Hellyer, Peter/F-7112-2013	Leech, Robert/0000-0002-5801-6318; Hellyer, Peter/0000-0002-5139-3401; Robertson, Ian H/0000-0001-8637-561X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; National Institute of Health ResearchNational Institute for Health Research (NIHR); Imperial College Healthcare Charity; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783, G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	This work was supported by grants from the Medical Research Council, the National Institute of Health Research and the Imperial College Healthcare Charity (to D.J.S).	BALTES PB, 1993, GERONTOLOGIST, V33, P580, DOI 10.1093/geront/33.5.580; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bekker EM, 2005, PSYCHOL MED, V35, P807, DOI 10.1017/S0033291704003459; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Dreer LE, 2012, REHABIL PSYCHOL, V57, P5, DOI 10.1037/a0025818; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fox MD, 2006, NAT NEUROSCI, V9, P23, DOI 10.1038/nn1616; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Ham T, 2013, J NEUROSCI, V33, P7091, DOI 10.1523/JNEUROSCI.4692-12.2013; Ham TE, 2013, CEREB CORTEX, V23, P703, DOI 10.1093/cercor/bhs056; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; He BJ, 2007, NEURON, V53, P905, DOI 10.1016/j.neuron.2007.02.013; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hesselmann G, 2008, P NATL ACAD SCI USA, V105, P10984, DOI 10.1073/pnas.0712043105; Husain M, 1997, NATURE, V385, P154, DOI 10.1038/385154a0; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Li CSR, 2008, J COGNITIVE NEUROSCI, V20, P1021, DOI 10.1162/jocn.2008.20071; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin RC, 2012, J HEAD TRAUMA REHAB, V27, pE81, DOI 10.1097/HTR.0b013e318273de49; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Modirrousta M, 2008, J NEUROSCI, V28, P14000, DOI 10.1523/JNEUROSCI.4450-08.2008; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Oakes TR, 2007, NEUROIMAGE, V34, P500, DOI 10.1016/j.neuroimage.2006.10.007; Oliveira FTP, 2007, J COGNITIVE NEUROSCI, V19, P1994, DOI 10.1162/jocn.2007.19.12.1994; Ornstein TJ, 2009, J CHILD PSYCHOL PSYC, V50, P506, DOI 10.1111/j.1469-7610.2008.01997.x; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2006, CEREB CORTEX, V16, P1739, DOI 10.1093/cercor/bhj109; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Soto D, 2009, P NATL ACAD SCI USA, V106, P6011, DOI 10.1073/pnas.0811681106; Spreng RN, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00145; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Taylor JG, 1997, NEURAL NETWORKS, V10, P1207, DOI 10.1016/S0893-6080(97)00064-6; Thompson E, 2001, TRENDS COGN SCI, V5, P418, DOI 10.1016/S1364-6613(00)01750-2; Triebel KL, 2012, NEUROLOGY, V78, P1472, DOI 10.1212/WNL.0b013e3182553c38; Ullsperger M, 2004, CORTEX, V40, P593, DOI 10.1016/S0010-9452(08)70155-2; Ullsperger M, 2010, BRAIN STRUCT FUNCT, V214, P629, DOI 10.1007/s00429-010-0261-1; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Verbruggen F, 2008, Q J EXP PSYCHOL, V61, P1151, DOI 10.1080/17470210801994971; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	75	67	68	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2014	137		2				586	597		10.1093/brain/awt350			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AA7QB	WOS:000331290900024	24371217	Green Published, Bronze			2021-06-18	
J	Farzan, F; Barr, MS; Hoppenbrouwers, SS; Fitzgerald, PB; Chen, R; Pascual-Leone, A; Daskalakis, ZJ				Farzan, Faranak; Barr, Mera S.; Hoppenbrouwers, Sylco S.; Fitzgerald, Paul B.; Chen, Robert; Pascual-Leone, Alvaro; Daskalakis, Zafiris J.			The EEG correlates of the TMS-induced EMG silent period in humans	NEUROIMAGE			English	Article						Cortical inhibition; Motor cortex; Transcranial magnetic stimulation; Electroencephalography; Electromyography; GABA; Cortical oscillations	TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY MOTOR CORTEX; DORSOLATERAL PREFRONTAL CORTEX; INTERVAL CORTICAL INHIBITION; MASS UNIVARIATE ANALYSIS; INTRACORTICAL INHIBITION; PARKINSONS-DISEASE; BRAIN-STIMULATION; SPORTS CONCUSSION; EXCITABILITY	Application of magnetic or electrical stimulation to the motor cortex can result in a period of electromyography (EMG) silence in a tonically active peripheral muscle. This period of EMG silence is referred to as the silent period (SP). The duration of SP shows intersubject variability and reflects the integrity of cortical and corticospinal pathways. A non-invasive technique for assessing the duration of SP is the combination of Transcranial Magnetic Stimulation (TMS) with EMG. Utilizing TMS-EMG, several studies have reported on the shortening or lengthening of SP in neuropsychiatric disorders such as schizophrenia, bipolar disorder, depression, obsessive compulsive disorder, epilepsy, Parkinson's disease, and stroke. However, cortical, corticospinal and peripheral components are difficult to disentangle from EMG alone. Here, we use the multimodal neuroimaging technique of TMS-EMG combined with concurrent electroencephalography (EEG) recording to further examine the cortical origin of SP and the cortical oscillatory activity that underlies SP genesis. We demonstrate that the duration of SP is related to the temporal characteristics of the cortical reactivity and the power of delta to alpha oscillations in both local and remote areas ipsilateral and contalateral to the stimulation site, and beta oscillations locally. We illustrate that, compared to EMG, the EEG indices of the SP provide additional information about the brain dynamics and propose that the EEG measures of SP may be used in future clinical and research investigations to more precisely delineate the mechanisms underlying inhibitory impairments. (C) 2013 Elsevier Inc. All rights reserved.	[Farzan, Faranak; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Dept Neurol,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Barr, Mera S.; Daskalakis, Zafiris J.] Univ Toronto, Temerty Ctr Therapeut Brain Intervent, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Hoppenbrouwers, Sylco S.] Univ Utrecht, Dept Expt Psychol, Helmholtz Inst, NL-3508 TC Utrecht, Netherlands; [Fitzgerald, Paul B.] The Alfred, Monash Alfred Psychiat Res Ctr, Clayton, Vic, Australia; [Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch, Clayton, Vic 3800, Australia; [Chen, Robert] Univ Toronto, Div Neurol, Toronto Western Res Inst, Toronto, ON, Canada; [Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Inst Univ Neurorehabil Guttmann, Badalona, Spain	Farzan, F (corresponding author), Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Kirstein Bldg KS 423, Boston, MA 02215 USA.	ffarzan@bidmc.harvard.edu; Jeff.Daskalakis@camh.ca	Fitzgerald, Paul B/A-1225-2008; Pascual-Leone, Alvaro/AAC-5101-2019; Chen, Robert/B-3899-2009	Fitzgerald, Paul B/0000-0003-4217-8096; Pascual-Leone, Alvaro/0000-0001-8975-0382; Chen, Robert/0000-0002-8371-8629; Barr, Mera/0000-0002-1103-1887; Farzan, Faranak/0000-0001-9249-2994	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [201102MFE-246635-181538]; Harvard-Thomdike Clinical Research Center at Beth Israel Deaconess Medical Center integrated in the Harvard Clinical and Translational Science Center [M01-RR01066, UL1 RR025758]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR001066, UL1RR025758] Funding Source: NIH RePORTER	FF was supported by the Canadian Institute of Health Research (CIHR) fellowship award (201102MFE-246635-181538). This study was supported in part by the Harvard-Thomdike Clinical Research Center at Beth Israel Deaconess Medical Center integrated in the Harvard Clinical and Translational Science Center (grants M01-RR01066 and UL1 RR025758 from the National Center for Research Resources, National Institutes of Health). PBF is supported by an NHMRC Practitioner Fellowship. This work was also supported in part by the Ontario Mental Health Foundation (OMHF), the Brain and Behavior Research Foundation and the Temerty and Grant Family through the Centre for Addiction and Mental Health (CAMH) Foundation.	Adrian ED, 1939, J PHYSIOL-LONDON, V97, P153, DOI 10.1113/jphysiol.1939.sp003798; Alagona G, 2001, NEUROSCI LETT, V314, P57, DOI 10.1016/S0304-3940(01)02288-1; Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036; Bajbouj MK, 2006, J PSYCHIAT RES, V40, P322, DOI 10.1016/j.jpsychires.2005.07.002; BARKER AT, 1985, LANCET, V1, P1106; Barnow S, 2009, BIOL PSYCHIAT, V65, P313, DOI 10.1016/j.biopsych.2008.08.016; Battaglia F, 2006, CLIN NEUROPHYSIOL, V117, P1009, DOI 10.1016/j.clinph.2006.01.008; Bender S, 2005, ANN NEUROL, V58, P58, DOI 10.1002/ana.20521; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Bonnard M, 2009, EUR J NEUROSCI, V30, P913, DOI 10.1111/j.1460-9568.2009.06864.x; BRAUNE HJ, 1995, STROKE, V26, P550, DOI 10.1161/01.STR.26.4.550; Brignani D, 2008, HUM BRAIN MAPP, V29, P603, DOI 10.1002/hbm.20423; Bruckmann S, 2012, BRAIN, V135, P2215, DOI 10.1093/brain/aws071; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Cincotta M, 2000, CLIN NEUROPHYSIOL, V111, P1340, DOI 10.1016/S1388-2457(00)00330-8; Cincotta M, 2002, CLIN NEUROPHYSIOL, V113, P597, DOI 10.1016/S1388-2457(02)00021-4; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; Daskalakis ZJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2860, DOI 10.1038/npp.2008.22; Daskalakis ZJ, 2008, J PSYCHOPHARMACOL, V22, P203, DOI 10.1177/0269881107084002; Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Deisz RA, 1999, NEUROPHARMACOLOGY, V38, P1755, DOI 10.1016/S0028-3908(99)00136-7; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Di Lazzaro V, 2002, CLIN NEUROPHYSIOL, V113, P1673, DOI 10.1016/S1388-2457(02)00264-X; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Farzan F., 2011, EMG METHODS EVALUATI; Farzan F, 2010, J NEUROPHYSIOL, V104, P1339, DOI 10.1152/jn.00279.2010; Farzan F, 2010, BRAIN, V133, P1505, DOI 10.1093/brain/awq046; Farzan F, 2009, NEUROPSYCHOPHARMACOL, V34, P1543, DOI 10.1038/npp.2008.211; Fecteau S, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-21; Ferreri F, 2011, NEUROIMAGE, V54, P90, DOI 10.1016/j.neuroimage.2010.07.056; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Fitzgerald PB, 2004, SCHIZOPHR RES, V71, P17, DOI 10.1016/j.schres.2004.01.018; Fitzgerald PB, 2002, PSYCHIAT RES-NEUROIM, V114, P11, DOI 10.1016/S0925-4927(02)00002-1; Fries P, 2007, TRENDS NEUROSCI, V30, P309, DOI 10.1016/j.tins.2007.05.005; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; Furukawa Toshiaki, 2010, Tokai J Exp Clin Med, V35, P29; Gjini K, 2012, J PSYCHIATR RES, V46, P248, DOI 10.1016/j.jpsychires.2011.10.006; Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1726, DOI 10.1111/j.1469-8986.2011.01272.x; Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1711, DOI 10.1111/j.1469-8986.2011.01273.x; Ilmoniemi RJ, 2010, BRAIN TOPOGR, V22, P233, DOI 10.1007/s10548-009-0123-4; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Inghilleri M, 1996, EXP BRAIN RES, V109, P467; Ives JR, 2006, CLIN NEUROPHYSIOL, V117, P1870, DOI 10.1016/j.clinph.2006.04.010; Julkunen P, 2008, CLIN NEUROPHYSIOL, V119, P475, DOI 10.1016/j.clinph.2007.09.139; Kapogiannis Dimitrios, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P234; Kicic D, 2008, NEUROSCIENCE, V152, P1119, DOI 10.1016/j.neuroscience.2008.01.043; Kimiskidis VK, 2005, EXP BRAIN RES, V163, P21, DOI 10.1007/s00221-004-2134-4; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; Komssi S, 2006, BRAIN RES REV, V52, P183, DOI 10.1016/j.brainresrev.2006.01.008; Korhonen RJ, 2011, MED BIOL ENG COMPUT, V49, P397, DOI 10.1007/s11517-011-0748-9; KRNJEVIC K, 1966, J PHYSIOL-LONDON, V184, P16, DOI 10.1113/jphysiol.1966.sp007902; KRNJEVIC K, 1964, NATURE, V201, P1294, DOI 10.1038/2011294a0; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Lefaucheur JP, 2005, CLIN NEUROPHYSIOL, V116, P244, DOI 10.1016/j.clinph.2004.11.017; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Levinson AJ, 2007, J CLIN PSYCHOPHARM, V27, P493, DOI 10.1097/jcp.0b013e31814ce524; Levinson AJ, 2010, BIOL PSYCHIAT, V67, P458, DOI 10.1016/j.biopsych.2009.09.025; Macdonell RAL, 2001, NEUROLOGY, V57, P706, DOI 10.1212/WNL.57.4.706; Maki H, 2011, NEUROIMAGE, V54, P2706, DOI 10.1016/j.neuroimage.2010.11.041; Maki H, 2010, NEUROSCI LETT, V478, P24, DOI 10.1016/j.neulet.2010.04.059; Marsden C D, 1983, Adv Neurol, V39, P387; Mathewson KE, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00099; MCCORMICK DA, 1989, J NEUROPHYSIOL, V62, P1018; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Murase N, 2005, BRAIN, V128, P104, DOI 10.1093/brain/awh315; Mutanen T, 2013, BRAIN STIMUL, V6, P371, DOI 10.1016/j.brs.2012.07.005; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; NAKASHIMA K, 1995, J NEUROL SCI, V130, P209, DOI 10.1016/0022-510X(95)00029-2; Nikulin VV, 2003, EUR J NEUROSCI, V18, P1206, DOI 10.1046/j.1460-9568.2003.02858.x; Oechsner M, 1999, J NEUROL SCI, V168, P107, DOI 10.1016/S0022-510X(99)00164-1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Paus T, 2001, J NEUROPHYSIOL, V86, P1983; PRIORI A, 1994, MOVEMENT DISORD, V9, P178, DOI 10.1002/mds.870090209; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; Radhu N, 2012, BRAIN STIMUL, V5, P44, DOI 10.1016/j.brs.2011.01.006; Richter MA, 2012, NEUROPSYCHOPHARMACOL, V37, P1144, DOI 10.1038/npp.2011.300; Rollnik JD, 2000, MUSCLE NERVE, V23, P112, DOI 10.1002/(SICI)1097-4598(200001)23:1<112::AID-MUS15>3.3.CO;2-2; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Saisanen L, 2008, J NEUROSCI METH, V169, P231, DOI 10.1016/j.jneumeth.2007.12.005; Salerno A, 2000, CLIN NEUROPHYSIOL, V111, P994, DOI 10.1016/S1388-2457(00)00267-4; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Sarfeld AS, 2012, HUM BRAIN MAPP, V33, P1107, DOI 10.1002/hbm.21272; Sekiguchi H, 2011, CLIN NEUROPHYSIOL, V122, P984, DOI 10.1016/j.clinph.2010.09.004; Siebner HR, 2000, NEUROSCI LETT, V284, P147, DOI 10.1016/S0304-3940(00)00990-3; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Stetkarova I, 2013, CLIN NEUROPHYSIOL, V124, P339, DOI 10.1016/j.clinph.2012.07.005; Tamburin S, 2004, CLIN NEUROPHYSIOL, V115, P348, DOI 10.1016/S1388-2457(03)00357-2; Tazoe T, 2007, EXP BRAIN RES, V177, P419, DOI 10.1007/s00221-006-0686-1; Teo JTH, 2008, MOVEMENT DISORD, V23, P378, DOI 10.1002/mds.21847; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; VALLSSOLE J, 1992, ELECTROEN CLIN NEURO, V85, P355, DOI 10.1016/0168-5597(92)90048-G; Veniero D, 2009, CLIN NEUROPHYSIOL, V120, P1392, DOI 10.1016/j.clinph.2009.04.023; WASSERMANN EM, 1991, NEUROLOGY, V41, P1795, DOI 10.1212/WNL.41.11.1795; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Ziemann U, 2000, J CLIN NEUROPHYSIOL, V17, P397, DOI 10.1097/00004691-200007000-00005	104	67	69	1	41	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	DEC	2013	83						120	134		10.1016/j.neuroimage.2013.06.059			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	251TN	WOS:000326953700013	23800790	Green Accepted			2021-06-18	
J	Fukuda, AM; Adami, A; Pop, V; Bellone, JA; Coats, JS; Hartman, RE; Ashwal, S; Obenaus, A; Badaut, J				Fukuda, Andrew M.; Adami, Arash; Pop, Viorela; Bellone, John A.; Coats, Jacqueline S.; Hartman, Richard E.; Ashwal, Stephen; Obenaus, Andre; Badaut, Jerome			Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aquaporin; astrocyte; juvenile traumatic brain injury; pediatric neurology; siRNA	TRAUMATIC BRAIN-INJURY; PROTECTIVE ROLE; INHIBITION; EXPRESSION; CHANNELS; ASTROCYTES; MICROGLIA; IMMATURE; ROLES; BETA	Traumatic brain injury (TBI) is common in young children and adolescents and is associated with long-term disability and mortality. The neuropathologic sequelae that result from juvenile TBI are a complex cascade of events that include edema formation and brain swelling. Brain aquaporin-4 (AQP4) has a key role in edema formation. Thus, development of novel treatments targeting AQP4 to reduce edema could lessen the neuropathologic sequelae. We hypothesized that inhibiting AQP4 expression by injection of small-interfering RNA (siRNA) targeting AQP4 (siAQP4) after juvenile TBI would decrease edema formation, neuroinflammation, neuronal cell death, and improve neurologic outcomes. The siAQP4 or a RNA-induced silencing complex (RISC)-free control siRNA (siGLO) was injected lateral to the trauma site after controlled cortical impact in postnatal day 17 rats. Magnetic resonance imaging, neurologic testing, and immunohistochemistry were performed to assess outcomes. Pups treated with siAQP4 showed acute (3 days after injury) improvements in motor function and in spatial memory at long term (60 days after injury) compared with siGLO-treated animals. These improvements were associated with decreased edema formation, increased microglial activation, decreased blood-brain barrier disruption, reduced astrogliosis and neuronal cell death. The effectiveness of our treatment paradigm was associated with a 30% decrease in AQP4 expression at the injection site.	[Fukuda, Andrew M.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Fukuda, Andrew M.; Pop, Viorela; Coats, Jacqueline S.; Obenaus, Andre; Badaut, Jerome] Loma Linda Univ, Med Ctr, Dept Pediat, Loma Linda, CA 92354 USA; [Adami, Arash; Ashwal, Stephen; Obenaus, Andre] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA; [Bellone, John A.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu		Fukuda, Andrew/0000-0002-7927-6602	National Institute of child disorders (NICHD) [R01HD061946]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	This study was supported by a grant from the National Institute of child disorders (NICHD) R01HD061946 and The Swiss National Science Foundation (Jerome Badaut). A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core (LLUSM AIM) that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Sean M Wilson) and the Loma Linda University School of Medicine.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Badaut J, 2007, METAB BRAIN DIS, V22, P251, DOI 10.1007/s11011-007-9057-2; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Berezowski Vincent, 2012, Int J Cell Biol, V2012, P176287, DOI 10.1155/2012/176287; Brower V, 2010, J NATL CANCER I, V102, P1459, DOI 10.1093/jnci/djq405; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Eder C, 1998, J NEUROSCI, V18, P7127; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038; Igarashi H, 2011, NEUROL SCI, V32, P113, DOI 10.1007/s10072-010-0431-1; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; Li LH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-94; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lu DC, 2011, J NEUROTRAUMA; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Migliati E, 2009, MOL PHARMACOL, V76, P105, DOI 10.1124/mol.108.053744; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Shi WZ, 2012, NEUROSCI BULL, V28, P61, DOI 10.1007/s12264-012-1063-7; Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Thorne RG, 2008, NEUROSCIENCE, V152, P785, DOI 10.1016/j.neuroscience.2008.01.013; Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018	40	67	73	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2013	33	10					1621	1632		10.1038/jcbfm.2013.118			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	228PV	WOS:000325199600017	23899928	Green Published, Bronze			2021-06-18	
J	Bobinski, L; Koskinen, LOD; Lindvall, P				Bobinski, Lukas; Koskinen, Lars-Owe D.; Lindvall, Peter			Complications following cranioplasty using autologous bone or polymethylmethacrylate-Retrospective experience from a single center	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Decompressive hemicraniectomy; Cranioplasty; Autologous bone; Polymethylmethacrylate; Complications	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; SURGICAL DECOMPRESSION; DELAYED CRANIOPLASTY; GRAFT INFECTION; PRESERVATION; INFARCTION; CHILDREN; SURGERY	Objective: A decompressive hemicraniectomy is a potentially life-saving intervention following head trauma. Once performed patients are obliged to undergo a second procedure with cranioplasty. Two of the most commonly used materials are autologous bone and polymethylmethacrylate (PMMA). We have now evaluated complications following a cranioplasty using these materials. Materials and methods: During a 7-year period (2002-2008) 49 patients were operated with a decompressive craniectomy following head trauma. Patients received a cranioplasty consisting of autologous bone (30 patients, 61.2%) or PMMA (19 patients, 38.8%) and were followed at least 24 months. Patient data were collected retrospectively. Results: Twenty patients (20/49, 40.8%) experienced a complication that prompted a re-operation. There was a significantly higher rate of complications leading to a re-operation (53.3% vs. 21.1%, p = 0.03) and a shorter survival time of the cranioplasty (mean 48.1 +/- 7.8 vs. 79.5 +/- 9.0 months, p = 0.035) in patients with autologous bone compared to PMMA. Bone resorption and the presence of postoperative hematomas were significantly more common in patients with autologous bone. The material used for cranioplasty was the only variable that significantly correlated to the rate of complications. Conclusions: In our series we had a high percentage of patients needing re-operation due to complications following a cranioplasty. Though generally considered a straightforward procedure, complications and associated morbidity in patients undergoing cranioplasty should not be underestimated. (C) 2013 Elsevier B.V. All rights reserved.	[Bobinski, Lukas; Koskinen, Lars-Owe D.; Lindvall, Peter] Univ Umea Hosp, Dept Pharmacol & Clin Neurosci, Div Neurosurg, S-90185 Umea, Sweden	Lindvall, P (corresponding author), Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden.	peter_lindvall_nkk@hotmail.com	Koskinen, Lars-Owe/AAQ-8957-2020; Lindvall, Peter/AAK-1225-2020	Lindvall, Peter/0000-0002-9552-2957; Koskinen, Lars-Owe/0000-0003-3528-8502			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Munch E, 2000, NEUROSURGERY, V47, P315; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	27	67	70	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2013	115	9					1788	1791		10.1016/j.clineuro.2013.04.013			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	223EQ	WOS:000324787900039	23725651				2021-06-18	
J	Register-Mihalik, JK; Guskiewicz, KM; Mihalik, JP; Schmidt, JD; Kerr, ZY; McCrea, MA				Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Schmidt, Julianne D.; Kerr, Zachary Y.; McCrea, Michael A.			Reliable Change, Sensitivity, and Specificity of a Multidimensional Concussion Assessment Battery: Implications for Caution in Clinical Practice	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						balance; cognition; mild traumatic brain injury; sensitivity; serial assessment; specificity	SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; MILD HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; IMPACT; MANAGEMENT; STATEMENT; RECOVERY; DEFICITS	Objective: To provide reliable change confidence intervals for common clinical concussion measures using a healthy sample of collegiate athletes and to apply these reliable change parameters to a sample of concussed collegiate athletes. Methods: Two independent samples were included in the study and evaluated on common clinical measures of concussion. The healthy sample included male, collegiate football student-athletes (n = 38) assessed at 2 time points. The concussed sample included college-aged student-athletes (n = 132) evaluated before and after a concussion. Outcome measures included symptom severity scores, Automated Neuropsychological Assessment Metrics throughput scores, and Sensory Organization Test composite scores. Results: Application of the reliable change parameters suggests that a small percentage of concussed participants were impaired on each measure. We identified a low sensitivity of the entire battery (all measures combined) of 50% but high specificity of 96%. Conclusions: Clinicians should be trained in understanding clinical concussion measures and should be aware of evidence suggesting the multifaceted battery is more sensitive than any single measure. Clinicians should be cautioned that sensitivity to balance and neurocognitive impairments was low for each individual measure. Applying the confidence intervals to our injured sample suggests that these measures do not adequately identify postconcussion impairments when used in isolation.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC 27610 USA; [Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Schmidt, Julianne D.; Kerr, Zachary Y.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	Register-Mihalik, JK (corresponding author), WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, 3024 New Bern Ave,Ste G01, Raleigh, NC 27610 USA.	jmihalik@wakemed.org		Register-Mihalik, Johna/0000-0002-4229-4743; Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322			Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Roebuck-Spencer T, 2007, ARCH CLIN NEUROPSYCH, V22, pS79, DOI 10.1016/j.acn.2006.10.011; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	67	67	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					274	283		10.1097/HTR.0b013e3182585d37			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900005	22691965				2021-06-18	
J	Edlow, BL; Haynes, RL; Takahashi, E; Klein, JP; Cummings, P; Benner, T; Greer, DM; Greenberg, SM; Wu, O; Kinney, HC; Folkerth, RD				Edlow, Brian L.; Haynes, Robin L.; Takahashi, Emi; Klein, Joshua P.; Cummings, Peter; Benner, Thomas; Greer, David M.; Greenberg, Steven M.; Wu, Ona; Kinney, Hannah C.; Folkerth, Rebecca D.			Disconnection of the Ascending Arousal System in Traumatic Coma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						ARAS; Ascending reticular activating system; Coma; Consciousness; HARDI; High angular resolution diffusion imaging; TAI; TBI; Tractography; Traumatic axonal injury; Traumatic brain injury	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; PERSISTENT VEGETATIVE STATE; SEVERE HEAD-INJURY; BRAIN-INJURY; RETICULAR-FORMATION; WATER RELAXATION; NERVOUS-TISSUE; LATE RECOVERY; CONSCIOUSNESS	Traumatic coma is associated with disruption of axonal pathways throughout the brain, but the specific pathways involved in humans are incompletely understood. In this study, we used high angular resolution diffusion imaging to map the connectivity of axonal pathways that mediate the 2 critical components of consciousness-arousal and awareness-in the postmortem brain of a 62-year-old woman with acute traumatic coma and in 2 control brains. High angular resolution diffusion imaging tractography guided tissue sampling in the neuropathologic analysis. High angular resolution diffusion imaging tractography demonstrated complete disruption of white matter pathways connecting brainstem arousal nuclei to the basal forebrain and thalamic intralaminar and reticular nuclei. In contrast, hemispheric arousal pathways connecting the thalamus and basal forebrain to the cerebral cortex were only partially disrupted, as were the cortical "awareness pathways." Neuropathologic examination, which used beta-amyloid precursor protein and fractin immunomarkers, revealed axonal injury in the white matter of the brainstem and cerebral hemispheres that corresponded to sites of high angular resolution diffusion imaging tract disruption. Axonal injury was also present within the gray matter of the hypothalamus, thalamus, basal forebrain, and cerebral cortex. We propose that traumatic coma may be a subcortical disconnection syndrome related to the disconnection of specific brainstem arousal nuclei from the thalamus and basal forebrain.	[Edlow, Brian L.; Klein, Joshua P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Klein, Joshua P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Edlow, Brian L.; Takahashi, Emi; Benner, Thomas; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Edlow, Brian L.; Greer, David M.; Greenberg, Steven M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,J Philip Kistler Stroke Re, Boston, MA 02115 USA; [Takahashi, Emi] Harvard Univ, Sch Med, Div Newborn Med, Boston Childrens Hosp, Boston, MA USA; [Takahashi, Emi] Harvard Univ, Sch Med, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston Childrens Hosp, Boston, MA USA; [Cummings, Peter] Off Chief Med Examiner, Boston, MA USA; [Wu, Ona] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Greer, David M.] Yale Univ, Sch Med, Dept Neurol, Yale New Haven Hosp, New Haven, CT 06510 USA; [Haynes, Robin L.; Kinney, Hannah C.; Folkerth, Rebecca D.] Harvard Univ, Sch Med, Dept Pathol, Boston Childrens Hosp, Boston, MA 02115 USA	Edlow, BL (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St Lunder 650, Boston, MA 02114 USA.	bedlow@partners.org	Demchuk, Andrew M/E-1103-2012; Haynes, Robin L/M-4401-2016	Demchuk, Andrew M/0000-0002-4930-7789; Haynes, Robin L/0000-0003-4909-9585; Wu, Ona/0000-0002-5509-9461; Greer, David/0000-0002-2026-8333	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, R01HD20991, R21HD069001, P41EB015896]; Center for Integration of Medicine & Innovative Technology; Neuropathology Division, Department of Pathology; Department of Neurology, Brigham; Women's Hospital, Boston, Mass; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1S10RR016811-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD020991, R21HD069001] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075, S10RR016811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (R25NS065743 to Brian Edlow, R01HD20991 to Hannah Kinney, R21HD069001 to Emi Takahashi, and P41EB015896 to the Athinoula A. Martinos Center for Biomedical Imaging) and the Center for Integration of Medicine & Innovative Technology (to Brian Edlow). This work was also supported by the Neuropathology Division, Department of Pathology, and the Department of Neurology, Brigham and Women's Hospital, Boston, Mass. This work involved the use of instrumentation supported by the National Center for Research Resources (1S10RR016811-01 to the Athinoula A. Martinos Center for Biomedical Imaging).	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Armstrong RA, 2010, FOLIA NEUROPATHOL, V48, P67; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Benarroch EE, 2007, NEUROLOGY, V69, P1293, DOI 10.1212/01.wnl.0000275537.71623.8e; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; CLINTON J, 1993, NEUROPATH APPL NEURO, V19, P277, DOI 10.1111/j.1365-2990.1993.tb00438.x; Coote JH, 1995, BIOL SIGNAL, V4, P142; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; D'Arceuil H, 2007, NEUROIMAGE, V36, P64, DOI 10.1016/j.neuroimage.2007.02.039; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; El-Khodor BF, 2002, J COMP NEUROL, V452, P65, DOI 10.1002/cne.10367; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAVOROV OV, 1990, J COMP NEUROL, V298, P97, DOI 10.1002/cne.902980108; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hansen B, 2011, NEUROIMAGE, V57, P1458, DOI 10.1016/j.neuroimage.2011.04.052; Haynes RL, 2008, PEDIATR RES, V63, P656, DOI 10.1203/PDR.0b013e31816c825c; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; JENNETT B, 1972, LANCET, V1, P734; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, P124; LECLERC SS, 1993, SOMATOSENS MOT RES, V10, P133, DOI 10.3109/08990229309028829; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Makris N, 2006, NEUROIMAGE, V33, P139, DOI 10.1016/j.neuroimage.2006.04.220; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNab JA, 2013, NEUROIMAGE, V69, P87, DOI 10.1016/j.neuroimage.2012.11.065; Mcnab JA, 2009, NEUROIMAGE, V46, P775, DOI 10.1016/j.neuroimage.2009.01.008; Miller KL, 2011, NEUROIMAGE, V57, P167, DOI 10.1016/j.neuroimage.2011.03.070; Moll CKE, 2009, PROG BRAIN RES, V177, P125, DOI 10.1016/S0079-6123(09)17710-5; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Paxinos G., 1995, ATLAS HUMAN BRAINSTE; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reese TG, 2009, J MAGN RESON IMAGING, V29, P517, DOI 10.1002/jmri.21497; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Shepherd TM, 2009, MAGN RESON MED, V62, P26, DOI 10.1002/mrm.21977; Shepherd TM, 2009, NEUROIMAGE, V44, P820, DOI 10.1016/j.neuroimage.2008.09.054; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sisodiya SM, 2000, NEUROREPORT, V11, P2601, DOI 10.1097/00001756-200008030-00050; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STRICH SJ, 1961, LANCET, V2, P443; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zoroya G, 2010, TROOPS BRAIN TRAUMA	87	67	70	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2013	72	6					505	523		10.1097/NEN.0b013e3182945bf6			19	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	151IR	WOS:000319454400006	23656993	Green Accepted, Bronze			2021-06-18	
J	DeWitt, DS; Perez-Polo, R; Hulsebosch, CE; Dash, PK; Robertson, CS				DeWitt, Douglas S.; Perez-Polo, Regino; Hulsebosch, Claire E.; Dash, Pramod K.; Robertson, Claudia S.			Challenges in the Development of Rodent Models of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal models; brain injury; head injury; mild traumatic brain injury; traumatic brain injury	MINOR HEAD-INJURY; LATERAL FLUID PERCUSSION; CONTROLLED CORTICAL IMPACT; FOOTBALL-LEAGUE PLAYER; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RETROGRADE-AMNESIA; HIPPOCAMPAL-LESIONS; RIGHTING REFLEX; RAT MODEL	Approximately 75% of traumatic brain injuries (TBI) are classified mild (mTBI). Despite the high frequency of mTBI, it is the least well studied. The prevalence of mTBI among service personnel returning from Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF) and the recent reports of an association between repeated mTBI and the early onset of Alzheimer's and other types of dementias in retired athletes has focused much attention on mTBI. The study of mTBI requires the development and validation of experimental models and one of the most basic requirements for an experimental model is that it replicates important features of the injury or disease in humans. mTBI in humans is associated with acute symptoms such as loss of consciousness and pre-and/or posttraumatic amnesia. In addition, many mTBI patients experience long-term effects of mTBI, including deficits in speed of information processing, attention and concentration, memory acquisition, retention and retrieval, and reasoning and decision-making. Although methods for the diagnosis and evaluation of the acute and chronic effects of mTBI in humans are well established, the same is not the case for rodents, the most widely used animal for TBI studies. Despite the magnitude of the difficulties associated with adapting these methods for experimental mTBI research, they must be surmounted. The identification and testing of treatments for mTBI depends of the development, characterization and validation of reproducible, clinically relevant models of mTBI.	[DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Perez-Polo, Regino] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Hulsebosch, Claire E.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Dash, Pramod K.] Univ Texas Hlth Sci Ctr, Dept Neurosci, Houston, TX USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	DeWitt, DS (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	ddewitt@utmb.edu		Dash, Pramod/0000-0001-6746-1002	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0132]	This work was supported by the U.S. Army Medical Research and Materiel Command award number W81XWH-08-2-0132. The authors are grateful to Emmy Miller, RN, PhD, for her coordination of the research of the Mission Connect Mild Traumatic Brain Injury Translational Research Consortium.	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bay Esther, 2007, J Neurosci Nurs, V39, P43; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIGNALL KE, 1974, EXP NEUROL, V42, P566, DOI 10.1016/0014-4886(74)90079-X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RC, 2002, ANESTHESIOLOGY, V96, P1223, DOI 10.1097/00000542-200205000-00027; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Epstein D, 2010, SPORTS ILLUSTRATED, V113, P42; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gaskin S, 2003, HIPPOCAMPUS, V13, P962, DOI 10.1002/hipo.10154; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Golding EM, 2001, J NEUROTRAUM, V18, P691, DOI 10.1089/089771501750357636; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; [Group M.o.C.M.T.W. Affairs/Defense V], 2009, CLIN PRACT GUID MAN, P1; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haijima A, 2008, LEARN MEMORY, V15, P477, DOI 10.1101/lm.862308; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jacobs A, 1996, J NUCL MED, V37, P1605; Jacobs A, 1994, J NUCL MED, V35; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jonasson Z, 2004, HIPPOCAMPUS, V14, P28, DOI 10.1002/hipo.10146; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; King P., 2010, SPORTS ILLUSTRATED, P34; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mumby DG, 2000, BEHAV BRAIN RES, V114, P119, DOI 10.1016/S0166-4328(00)00217-5; Navarro JC, 2012, J NEUROTRAUM, V29, P1; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Parsley M, 2007, J NEUROTRAUM, V24, P1277; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwarz A, 2007, NY TIMES; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Sukhotinsky I, 2007, EUR J NEUROSCI, V25, P1417, DOI 10.1111/j.1460-9568.2007.05399.x; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, P1; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Whiting MD, 2008, BRAIN RES, V1213, P69, DOI 10.1016/j.brainres.2008.01.107; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winocur G, 1999, J NEUROSCI, V19, P9611; Winocur G, 2001, HIPPOCAMPUS, V11, P18, DOI 10.1002/1098-1063(2001)11:1<18::AID-HIPO1016>3.0.CO;2-5; Young JW, 2009, PHARMACOL THERAPEUT, V122, P150, DOI 10.1016/j.pharmthera.2009.02.004; ZHOU YL, 1995, PHYSIOL BEHAV, V57, P1107, DOI 10.1016/0031-9384(95)00019-F	136	67	67	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		688	701		10.1089/neu.2012.2349			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600002	23286417				2021-06-18	
J	McCrory, P; Meeuwisse, W; Aubry, M; Cantu, B; Dvorak, J; Echemendia, R; Engebretsen, L; Johnston, K; Kutcher, J; Raftery, M; Sills, A; Benson, B; Davis, G; Ellenbogen, R; Guskiewicz, K; Herring, SA; Iverson, G; Jordan, B; Kissick, J; McCrea, M; McIntosh, A; Maddocks, D; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, C; Turner, M				McCrory, Paul; Meeuwisse, Willem; Aubry, Mark; Cantu, Bob; Dvorak, Jiri; Echemendia, Ruben; Engebretsen, Lars; Johnston, Karen; Kutcher, Jeff; Raftery, Martin; Sills, Allen; Benson, Brian; Davis, Gavin; Ellenbogen, Richard; Guskiewicz, Kevin; Herring, Stanley A.; Iverson, Grant; Jordan, Barry; Kissick, James; McCrea, Michael; McIntosh, Andrew; Maddocks, David; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles; Turner, Michael			Consensus statement on Concussion in Sport-The 4th International Conference on Concussion in Sport held in Zurich, November 2012	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article; Proceedings Paper	4th International Conference on Concussion in Sport	NOV, 2012	Zurich, SWITZERLAND				CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; POSTURAL CONTROL; HEAD-INJURIES; LONG-TERM; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; AUSTRALIAN RULES; BRAIN-INJURY		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Bob] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, CH-8006 Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zurich, Zurich, Switzerland; [Dvorak, Jiri] F MARC FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben] Univ Missouri, Kansas City, MO USA; [Engebretsen, Lars] Univ Oslo, Oslo Univ Hosp, Dept Orthopaed Surg, N-0316 Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] IOC, Lausanne, Switzerland; [Johnston, Karen] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Johnston, Karen] Concuss Management Program Athlet Edge Sports Med, Toronto, ON, Canada; [Kutcher, Jeff] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian] Univ Calgary, Dept Family Med, Fac Kinesiol, Calgary, AB, Canada; [Benson, Brian] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Melbourne, Vic 3084, Australia; [Davis, Gavin] Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, Gavin] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogen, Richard] Univ Washington Seattle, Dept Neurol Surg, Seattle, WA USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Seahawks, Seattle Sports Concuss Program, Seattle, WA USA; [Herring, Stanley A.] Seattle Mariners, Seattle, WA USA; [Iverson, Grant] Univ British Columbia, Neuropsychol Outcome Assessment Lab, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Jordan, Barry] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI USA; [McIntosh, Andrew] Monash Univ, Monash Injury Res Inst, Australian Ctr Res Injury Sports & Its Prevent, Clayton, Vic 3800, Australia; [McIntosh, Andrew] Univ New S Wales, Fac Sci, Sydney, NSW 2052, Australia; [McIntosh, Andrew] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Turner, Michael] British Horseracing Author, London, England; [Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Tator, Charles] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles] Krembil Neurosci Ctr, Toronto, ON, Canada	McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.	paulmccr@bigpond.net.au		Guskiewicz, Kevin/0000-0002-8682-2130; Iverson, Grant/0000-0001-7348-9570; Schneider, Kathryn/0000-0002-5951-5899; McCrory, Paul/0000-0003-4850-0568			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Broshek DK, 2005, CLIN SPORTS MED, V24, px; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney JS, 2008, BRIT J SPORT MED, V42, P51; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P4; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2004, CLIN SPORTS MED, V23, pix; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P., 2011, CLIN SPORTS MED, V30, pxi; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	162	67	68	1	44	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2013	16	3					178	189		10.1016/j.jsams.2013.02.009			12	Sport Sciences	Sport Sciences	142WH	WOS:000318827800002	23541595	Green Accepted, Other Gold			2021-06-18	
J	Turgeon, AF; Lauzier, F; Burns, KEA; Meade, MO; Scales, DC; Zarychanski, R; Moore, L; Zygun, DA; McIntyre, LA; Kanji, S; Hebert, PC; Murat, V; Pagliarello, G; Fergusson, DA				Turgeon, Alexis F.; Lauzier, Francois; Burns, Karen E. A.; Meade, Maureen O.; Scales, Damon C.; Zarychanski, Ryan; Moore, Lynne; Zygun, David A.; McIntyre, Lauralyn A.; Kanji, Salmaan; Hebert, Paul C.; Murat, Valerie; Pagliarello, Giuseppe; Fergusson, Dean A.		Canadian Critical Care Trials Grp	Determination of Neurologic Prognosis and Clinical Decision Making in Adult Patients With Severe Traumatic Brain Injury: A Survey of Canadian Intensivists, Neurosurgeons, and Neurologists	CRITICAL CARE MEDICINE			English	Article						critical care medicine; healthcare survey; traumatic brain injury; neurologic prognosis; withdrawal of life-sustaining therapies	OF-LIFE CARE; END; WITHDRAWAL; MORTALITY; CULTURE; SUPPORT; UNIT	Objectives: Accurate prognostic information in patients with severe traumatic brain injury remains limited, but mortality following the withdrawal of life-sustaining therapies is high and variable across centers. We designed a survey to understand attitudes of physicians caring for patients with severe traumatic brain injury toward the determination of prognosis and clinical decision making on the level of care. Design, Setting, and Participants: We conducted a cross-sectional study of intensivists, neurosurgeons, and neurologists that participate in the care of patients with severe traumatic brain injury at all Canadian level 1 and level 2 trauma centers. Intervention: None. Measurements: The main outcome measure was physicians' perceptions of prognosis and recommendations on the level of care. Main Results: Our response rate was 64% (455/712). Most respondents (65%) reported that an accurate prediction of prognosis would be most helpful during the first 7 days. Most respondents (>80%) identified bedside monitoring, clinical exam, and imaging to be useful for evaluating prognosis, whereas fewer considered electrophysiology tests (<60%) and biomarkers (<15%). In a case-based scenario, approximately one-third of respondents agreed, one-third were neutral, and one-third disagreed that the patient prognosis would be unfavorable at one year. About 10% were comfortable recommending withdrawal of life-sustaining therapies. Conclusions: A significant variation in perceptions of neurologic prognosis and in clinical decision making on the level of care was found among Canadian intensivists, neurosurgeons, and neurologists. Improved understanding of the factors that can accurately predict prognosis for patients with traumatic brain injury is urgently needed. (Crit Care Med 2013; 41:1087-1093)	[Turgeon, Alexis F.; Lauzier, Francois; Moore, Lynne; Murat, Valerie] Univ Laval, Trauma Emergency Crit Care Med Unit, Enfant Jesus Hosp, CHU Quebec,Res Ctr,Ctr Rech FRQ S, Quebec City, PQ, Canada; [Turgeon, Alexis F.; Lauzier, Francois] Univ Laval, Dept Anesthesiol, Div Crit Care Med, Quebec City, PQ, Canada; [Lauzier, Francois] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Burns, Karen E. A.; Scales, Damon C.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Meade, Maureen O.] McMaster Univ, Dept Crit Care Med, Hamilton, ON, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Crit Care Med, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Hematol, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Med Oncol, Winnipeg, MB, Canada; [Moore, Lynne] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Zygun, David A.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [McIntyre, Lauralyn A.; Kanji, Salmaan; Hebert, Paul C.; Fergusson, Dean A.] Univ Ottawa, Clin Epidemiol Program, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [McIntyre, Lauralyn A.; Hebert, Paul C.; Pagliarello, Giuseppe; Fergusson, Dean A.] Univ Ottawa, Dept Med, Div Crit Care Med, Ottawa, ON, Canada	Turgeon, AF (corresponding author), Univ Laval, Trauma Emergency Crit Care Med Unit, Enfant Jesus Hosp, CHU Quebec,Res Ctr,Ctr Rech FRQ S, Quebec City, PQ, Canada.	alexis.turgeon@fmed.ulaval.ca	Lauzier, Francois/B-9237-2015; McIntyre, Lauralyn/AAR-7710-2021	Lauzier, Francois/0000-0002-6530-5513; McIntyre, Lauralyn/0000-0001-7421-1407; Zarychanski, Ryan/0000-0001-9455-6138; Fergusson, Dean/0000-0002-3389-2485	Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation); Fonds de recherche du Quebec-Sante (FRQ-S); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHRCanadian Institutes of Health Research (CIHR); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Supported, in part, by the Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation) and by the Fonds de recherche du Quebec-Sante (FRQ-S) who had no role in any part of conduct of the study or preparation of the manuscript. Dr. Turgeon and Dr. Lauzier are recipients of a research career award from the Fonds de recherche du Quebec-Sante (FRQ-S). Dr. Fergusson, McIntyre, Moore, and Scales are recipients of New Investigator Awards from the Canadian Institutes of Health Research (CIHR). Dr Zarychanski is supported by a Randomized Controlled Trial Mentoring Award from the CIHR.; Dr. Scales received grant support from Canadian Institutes of Health Research and the New Investigator Award. The remaining authors have not disclosed any potential conflicts of interest	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ball CG, 2010, J TRAUMA, V69, P1323, DOI 10.1097/TA.0b013e3181f66878; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Cohen J, 2008, J MED ETHICS, V34, P247, DOI 10.1136/jme.2006.020297; Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC; Fergusson DA, 2007, AM J RESP CRIT CARE, V175, pA218; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Jacobs LM, 2010, J TRAUMA, V69, P1567, DOI 10.1097/TA.0b013e3181f65921; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lamontagne F, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2011.01.005; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Mosenthal AC, 2008, J TRAUMA, V64, P1587, DOI 10.1097/TA.0b013e318174f112; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; National Scientific Advisory Committee, 2004, LIST DIR INJ FIN REP; Nelson JE, 2006, CRIT CARE MED, V34, P2547, DOI 10.1097/01.CCM.0000239233.63425.1D; OCALLAHAN JG, 1995, CRIT CARE MED, V23, P1567, DOI 10.1097/00003246-199509000-00018; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Ramondetta L, 2011, INT J GYNECOL CANCER, V21, P573, DOI 10.1097/IGC.0b013e31820ba507; Randolph AG, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e46; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Scales DC, 2009, J CRIT CARE, V24, P176, DOI 10.1016/j.jcrc.2009.03.010; Schaller C, 2006, J MED ETHICS, V32, P65, DOI 10.1136/jme.2005.011767; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; The American Association of Public Opinion Research, 2011, STAND DEF FIN DISP C; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Turgeon AF, 2006, CAN J ANAESTH, V53, P344, DOI 10.1007/BF03022497; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	32	67	67	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2013	41	4					1086	1093		10.1097/CCM.0b013e318275d046			8	Critical Care Medicine	General & Internal Medicine	114HN	WOS:000316731800027	23385104				2021-06-18	
J	Inaba, K; Menaker, J; Branco, BC; Gooch, J; Okoye, OT; Herrold, J; Scalea, TM; DuBose, J; Demetriades, D				Inaba, Kenji; Menaker, Jay; Branco, Bernardino C.; Gooch, Jonathan; Okoye, Obi T.; Herrold, Joe; Scalea, Thomas M.; DuBose, Joseph; Demetriades, Demetrios			A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	PROMMTT Symposium held at the 71st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 12-15, 2012	HI	Amer Assoc Surg Trauma		Traumatic brain injury; seizure prophylaxis; phenytoin; levetiracetam; outcomes	BRAIN-INJURY; PREVENTION; TRIAL	BACKGROUND: Brain Trauma Foundation guidelines recommend seizure prophylaxis for preventing early posttraumatic seizure (PTS). Phenytoin (PHE) is commonly used. Despite a paucity of data in traumatic brain injury, levetiracetam (LEV) has been introduced as a potential replacement, which is more costly but does not require serum monitoring. The purpose of this study was to compare the efficacy of PHE with that of LEV for preventing early PTS. METHODS: Consecutive blunt traumatic brain injury patients undergoing seizure prophylaxis were prospectively enrolled at two Level 1 trauma centers during a 33-month period. Seizure prophylaxis was administered according to local protocol. Patients were monitored prospectively throughout their hospital stay for clinical evidence of seizure activity. PHE was compared with LEV with clinical early PTS as the primary outcome measure, defined as a seizure diagnosed clinically, occurring within 7 days of admission. RESULTS: Atotal of 1,191 patients were screened for enrollment, after excluding 378 (31.7%) who did notmeet inclusioncriteria; 813(68.3%) were analyzed (406 LEV and 407 PHE). There were no significant differences between LEV and PHE in age (51.7 [21.3] vs. 53.6 [22.5], p = 0.205), male (73.9% vs. 68.8%, p = 0.108), Injury Severity Score (ISS) (20.0 [10.0] vs. 21.0 [10.6], p = 0.175), Marshall score of 3 or greater (18.5% vs. 14.7%, p = 0.153), or craniectomy (8.4% vs. 11.8%, p = 0.106). There was no difference in seizure rate (1.5% vs. 1.5%, p = 0.997), adverse drug reactions (7.9% vs. 10.3%, p = 0.227), or mortality (5.4% vs. 3.7%, p = 0.236). CONCLUSION: In this prospective evaluation of early PTS prophylaxis, LEV did not outperform PHE. Cost and need for serum monitoring should be considered in guiding the choice of prophylactic agent. (J Trauma Acute Care Surg. 2013; 74: 766-773. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Inaba, Kenji; Branco, Bernardino C.; Okoye, Obi T.; Herrold, Joe] Univ So Calif, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA; [Menaker, Jay; Gooch, Jonathan; Scalea, Thomas M.; DuBose, Joseph] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Trauma & Surg Crit Care, Baltimore, MD 21201 USA	Inaba, K (corresponding author), Univ So Calif, Div Trauma & Surg Crit Care, 2051 Marengo St,Room C5L100, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu		Okoye, Obi/0000-0003-4794-4335			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; COHEN J, 1977, STAT POWER ANAL BEHA, P183; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Klein P, 2012, ARCH NEUROL-CHICAGO, P1; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steinbaugh LA, 2012, EPILEPSY BEHAV, V23, P280, DOI 10.1016/j.yebeh.2011.12.005; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	18	67	69	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2013	74	3					766	771		10.1097/TA.0b013e3182826e84			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UO	WOS:000316321900014	23425733				2021-06-18	
J	Furtado, MD; Rossetti, F; Chanda, S; Yourick, D				Furtado, Marcio de Araujo; Rossetti, Franco; Chanda, Soma; Yourick, Debra			Exposure to nerve agents: From status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy	NEUROTOXICOLOGY			English	Article						Nerve agents; Status epilepticus; Spontaneous recurrent seizures; Epileptogenesis; Neurogenesis	SOMAN-INDUCED SEIZURES; SPONTANEOUS RECURRENT SEIZURES; CONVULSIVE STATUS EPILEPTICUS; SARIN-INDUCED SEIZURES; CYCLOOXYGENASE-2 INHIBITOR; KAINIC ACID; HIPPOCAMPAL NEUROGENESIS; PILOCARPINE MODEL; INDUCED NEUROPATHOLOGY; ADULT NEUROGENESIS	Epilepsy is a common neurological disorder characterized by an initial injury due to stroke, traumatic brain injury, brain infection, or febrile seizures causing status epilepticus (SE). This phenomenon precedes recurrent (secondary) seizures, the latent period (period without seizures) and downstream appearance of spontaneous recurrent seizures (SRS). Epilepsy inducers include the organophosphorous (OP) compounds modified as chemical warfare nerve agents, such as soman. SE induced by soman is a result of cholinergic system hyperactivity caused by the irreversible inhibition of acetylcholinesterase, and the subsequent increase in the amount of the neurotransmitter acetylcholine at central and peripheral sites. SE leads to profound, permanent, complex and widespread brain damage and associated cognitive and behavioral deficits, accompanied by impaired neurogenesis. Several anticonvulsant and neuroprotective strategies have been studied in order to avoid the epileptogenesis which occurs after SE caused by soman exposure. In recent studies, we showed that SRS occur post-soman exposure and neuropathology can be reduced with diazepam (DZP) and valproic acid (VPA) when administered in combination treatment. These effects are accompanied by neurogenesis seen 15 days post-exposure in the hippocampal dentate gyrus (DG). This review discusses several findings about epilepsy induced by soman exposure such as behavioral changes, EEG anomalies, neuropathology, neuroinflammation, neurogenesis, possible circuitry changes and current strategies for treatment. The soman seizure model is an important model of temporal lobe epilepsy (TLE) and comparable in certain respects with well studied models in the literature such as pilocarpine and kainic acid. All these models together allow for a greater understanding of the different mechanisms of seizure induction, propagation and options for treatment. These studies are very necessary for current military and civilian treatment regimens, against OP nerve agent exposure, which fail to prevent SE resulting in severe neuropathology and epilepsy. Published by Elsevier Inc.	[Yourick, Debra] Walter Reed Army Inst Res, US Army Garrison Forest Glen, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA	Yourick, D (corresponding author), Walter Reed Army Inst Res, US Army Garrison Forest Glen, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, 2460 Linden Lane,Bldg 503, Silver Spring, MD 20910 USA.	debra.yourick@us.army.mil	Yourick, Debra/A-2121-2011		National Research Council; Defense Threat Reduction AgencyUnited States Department of DefenseDefense Threat Reduction Agency [I.E0042-08-WR-C]	Dr. Marcio de Araujo Furtado is currently employed by Clinical RM, Inc., and under contract to the Walter Reed Army Institute of Research. Dr. Franco Rossetti is supported administratively by a National Research Council fellowship. The present study was supported financially by the Defense Threat Reduction Agency (Grant I.E0042-08-WR-C, Principal Investigator: Dr. Debra Yourick).	Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Albuquerquet EX, 2006, P NATL ACAD SCI USA, V103, P13220, DOI 10.1073/pnas.0605370103; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Angoa-Perez M, 2010, NEUROTOXICOLOGY, V31, P738, DOI 10.1016/j.neuro.2010.06.007; Apland JP, 2009, NEUROSCIENCE, V159, P380, DOI 10.1016/j.neuroscience.2008.11.053; Apland JP, 2010, NEUROTOXICOLOGY, V31, P485, DOI 10.1016/j.neuro.2010.05.014; ASHANI Y, 1981, BIOCHEM PHARMACOL, V30, P2593, DOI 10.1016/0006-2952(81)90587-6; Auta J, 2004, NEUROPHARMACOLOGY, V46, P397, DOI 10.1016/j.neuropharm.2003.09.010; Avoli M., 2012, JASPERS BASIC MECH E; Awni W M, 1995, Clin Pharmacokinet, V29 Suppl 2, P112; BABB TL, 1992, EPILEPSY RES, P193; Baille V, 2005, TOXICOLOGY, V215, P1, DOI 10.1016/j.tox.2005.05.028; BailleLeCrom V, 1995, NEUROREPORT, V7, P365; Barelli A, 2011, MINERVA ANESTESIOL, V77, P1197; BENARI Y, 1979, BRAIN RES, V163, P176, DOI 10.1016/0006-8993(79)90163-X; Berger C, 2008, EXP NEUROL, V210, P543, DOI 10.1016/j.expneurol.2007.12.002; Bhagat YA, 2005, NEUROTOXICOLOGY, V26, P1001, DOI 10.1016/j.neuro.2005.04.006; Bradman A, 2007, J EXPO SCI ENV EPID, V17, P331, DOI 10.1038/sj.jes.7500507; Britt JO, 2000, COMPARATIVE MED, V50, P133; Candelario-Jalil E, 2008, PHARMACOL RES, V57, P266, DOI 10.1016/j.phrs.2008.03.003; Candelario-Jalil E, 2007, J NEUROCHEM, V100, P1108, DOI 10.1111/j.1471-4159.2006.04280.x; CAPACIO BR, 1991, EPILEPSIA, V32, P604, DOI 10.1111/j.1528-1157.1991.tb04699.x; CARPENTIER P, 1990, NEUROTOXICOLOGY, V11, P493; CARPENTIER P, 1991, BRAIN RES, V541, P293, DOI 10.1016/0006-8993(91)91030-5; Carpentier P, 2001, NEUROTOXICOLOGY, V22, P299, DOI 10.1016/S0161-813X(01)00019-5; CARPENTIER P, 1994, NEUROTOXICOLOGY, V15, P837; Castro OW, 2011, BRAIN RES, V1374, P43, DOI 10.1016/j.brainres.2010.12.012; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Chapman S, 2006, NEUROTOXICOLOGY, V27, P277, DOI 10.1016/j.neuro.2005.11.009; CHEN J, 1995, NEUROREPORT, V6, P245; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Choi EK, 2004, EUR J PHARMACOL, V505, P83, DOI 10.1016/j.ejphar.2004.10.034; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; Collombet JM, 2006, NEUROTOXICOLOGY, V27, P201, DOI 10.1016/j.neuro.2005.10.002; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Curtin BF, 2005, J CELL BIOCHEM, V96, P839, DOI 10.1002/jcb.20591; Dabisch PA, 2010, NEUROCHEMICAL CONSEQ, P185; Dabisch PA, 2007, TOXICOL SCI, V100, P281, DOI 10.1093/toxsci/kfm213; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; Demar JC, 2010, CHEM-BIOL INTERACT, V187, P191, DOI 10.1016/j.cbi.2010.02.015; Despain KE, 2007, TOXICOL MECH METHOD, V17, P255, DOI 10.1080/15376510600972733; Dhir A., 2008, Inflammopharmacology, V16, P83, DOI 10.1007/s10787-007-7007-6; Dhote F, 2012, TOXICOL APPL PHARM, V259, P195, DOI 10.1016/j.taap.2011.12.024; Dillman JF, 2009, CHEM RES TOXICOL, V22, P633, DOI 10.1021/tx800466v; Ding GD, 2012, ENVIRON SCI TECHNOL, V46, P2911, DOI 10.1021/es202583d; Doctor BP, 2005, CHEM-BIOL INTERACT, V157, P167, DOI 10.1016/j.cbi.2005.10.024; Dorandeu F, 2005, BRAIN RES, V1051, P164, DOI 10.1016/j.brainres.2005.06.013; Dorandeu F, 2007, TOXICOLOGY, V234, P185, DOI 10.1016/j.tox.2007.02.012; Doretto MC, 1998, NEUROREPORT, V9, P2415, DOI 10.1097/00001756-199807130-00048; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; DUDEK FE, 1994, HIPPOCAMPUS, V4, P259, DOI 10.1002/hipo.450040306; Duman RS, 2001, NEUROPSYCHOPHARMACOL, V25, P836, DOI 10.1016/S0893-133X(01)00358-X; Elmer E, 1997, NEUROREPORT, V8, P1193, DOI 10.1097/00001756-199703240-00027; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409, DOI 10.1289/ehp.99107s3409; Eskenazi B, 2008, BASIC CLIN PHARMACOL, V102, P228, DOI 10.1111/j.1742-7843.2007.00171.x; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Filliat P, 2007, NEUROTOXICOLOGY, V28, P508, DOI 10.1016/j.neuro.2006.11.004; Furtado M, 2008, TOXICOLOGIST S, V102, P469; Furtado M, 2011, MODERN TELEMETRY, P199; Furtado MA, 2011, EPILEPSY BEHAV, V20, P257, DOI 10.1016/j.yebeh.2010.11.024; Furtado MA, 2002, EPILEPSIA, V43, P37; Furtado MD, 2010, EPILEPSIA, V51, P1503, DOI 10.1111/j.1528-1167.2009.02478.x; Furtado MD, 2009, J NEUROSCI METH, V184, P176, DOI 10.1016/j.jneumeth.2009.07.020; GALE K, 1980, SCIENCE, V208, P288, DOI 10.1126/science.6768130; Gannon RL, 2011, BEHAV BRAIN RES, V218, P8, DOI 10.1016/j.bbr.2010.11.029; GAUSE EM, 1985, PHARMACOL BIOCHEM BE, V23, P1003, DOI 10.1016/0091-3057(85)90107-8; Gilat E, 2005, TOXICOL APPL PHARM, V209, P74, DOI 10.1016/j.taap.2005.03.007; Gobbo OL, 2004, NEUROSCIENCE, V125, P317, DOI 10.1016/j.neuroscience.2004.01.045; Goodkin HP, 2007, EPILEPSIA, V48, P14, DOI 10.1111/j.1528-1167.2007.01337.x; HAGGERTY GC, 1986, NEUROTOXICOL TERATOL, V8, P695; HARRIS LW, 1994, DRUG CHEM TOXICOL, V17, P35, DOI 10.3109/01480549409064045; HARRIS LW, 1984, DRUG CHEM TOXICOL, V7, P605, DOI 10.3109/01480548409042823; Haug KH, 2007, TOXICOL APPL PHARM, V220, P156, DOI 10.1016/j.taap.2006.12.023; HAYES SG, 1989, J CLIN PSYCHIAT, V50, P35; Hellier JL, 1999, EPILEPSY RES, V35, P47, DOI 10.1016/S0920-1211(98)00127-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jacobsson SOP, 1997, NEUROSCI LETT, V231, P155; Jakubs K, 2006, NEURON, V52, P1047, DOI 10.1016/j.neuron.2006.11.004; Jett DA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000752; Jiang JX, 2012, P NATL ACAD SCI USA, V109, P3149, DOI 10.1073/pnas.1120195109; JOHNSON DD, 1974, EUR J PHARMACOL, V28, P245, DOI 10.1016/0014-2999(74)90276-3; Joosen MJA, 2011, TOXICOL LETT, V206, P67, DOI 10.1016/j.toxlet.2011.05.231; Joosen MJA, 2009, NEUROTOXICOLOGY, V30, P72, DOI 10.1016/j.neuro.2008.11.010; JOPE RS, 1986, EXP NEUROL, V93, P404, DOI 10.1016/0014-4886(86)90200-1; JOPE RS, 1986, EXP NEUROL, V91, P471, DOI 10.1016/0014-4886(86)90045-2; Jung KH, 2006, NEUROBIOL DIS, V23, P237, DOI 10.1016/j.nbd.2006.02.016; Jung KH, 2004, EUR J NEUROSCI, V19, P3219, DOI 10.1111/j.0953-816X.2004.03412.x; Jutila L, 2002, ADV TECH STAND NEUR, V27, P3; Kalviainen R, 1998, NEUROLOGY, V50, P1377, DOI 10.1212/WNL.50.5.1377; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Klegeris A, 2002, NEUROBIOL AGING, V23, P787, DOI 10.1016/S0197-4580(02)00021-0; Koplovitz I, 1998, EPILEPSY RES, V30, P159, DOI 10.1016/S0920-1211(97)00100-9; Kozhemyakin M, 2010, J NEUROPHYSIOL, V103, P1748, DOI 10.1152/jn.00949.2009; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Laeng P, 2004, J NEUROCHEM, V91, P238, DOI 10.1111/j.1471-4159.2004.02725.x; LALLEMENT G, 1994, NEUROREPORT, V5, P2265, DOI 10.1097/00001756-199411000-00015; LALLEMENT G, 1991, BRAIN RES, V563, P234, DOI 10.1016/0006-8993(91)91539-D; Lallement G, 1998, ARCH TOXICOL, V72, P84; Lallement G, 1998, J PHYSIOLOGY-PARIS, V92, P369, DOI 10.1016/S0928-4257(99)80007-2; LANDAUER MR, 1984, NEUROBEH TOXICOL TER, V6, P239; LEITE JP, 1990, NEUROSCI BIOBEHAV R, V14, P511, DOI 10.1016/S0149-7634(05)80076-4; Liu H, 2003, EXP NEUROL, V184, P196, DOI 10.1016/S0014-4886(03)00207-3; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; LOTHMAN EW, 1989, EPILEPSY RES, V3, P107, DOI 10.1016/0920-1211(89)90038-7; Marrs Timothy C, 2006, Toxicol Rev, V25, P297, DOI 10.2165/00139709-200625040-00009; Marrs Timothy C, 2004, Toxicol Rev, V23, P145, DOI 10.2165/00139709-200423030-00002; Mathern GW, 1996, NEUROREPORT, V7, P1029, DOI 10.1097/00001756-199604100-00015; MAXWELL DM, 1988, J PHARMACOL EXP THER, V246, P986; Mazarati AM, 1998, BRAIN RES, V801, P251, DOI 10.1016/S0006-8993(98)00606-4; McDonnall D, 2009, IEEE ENG MED BIO, P5291, DOI 10.1109/IEMBS.2009.5333515; McDonough JH, 1998, NEUROTOXICOLOGY, V19, P381; MCDONOUGH JH, 1989, FUND APPL TOXICOL, V13, P256, DOI 10.1016/0272-0590(89)90262-5; MCDONOUGH JH, 1995, NEUROTOXICOLOGY, V16, P123; MCDONOUGH JH, 1986, NEUROBEH TOXICOL TER, V8, P179; McDonough JH, 1997, NEUROSCI BIOBEHAV R, V21, P559, DOI 10.1016/S0149-7634(96)00050-4; McDonough JH, 1999, ARCH TOXICOL, V73, P473, DOI 10.1007/s002040050637; MCDONOUGH JH, 1993, NEUROSCI BIOBEHAV R, V17, P203, DOI 10.1016/S0149-7634(05)80151-4; McDonough JH, 2000, EPILEPSY RES, V38, P1; McDonough JH, 2009, BASIC CLIN PHARMACOL, V104, P27, DOI 10.1111/j.1742-7843.2008.00326.x; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P1; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mirsattari SM, 2011, CAN J NEUROL SCI, V38, P487, DOI 10.1017/S0317167100011914; Moffett MC, 2011, PHARMACOL BIOCHEM BE, V98, P120, DOI 10.1016/j.pbb.2010.11.022; MOLLACE V, 1995, BIOCHEM BIOPH RES CO, V215, P793, DOI 10.1006/bbrc.1995.2533; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Murata K, 1997, J NEUROL, V244, P601, DOI 10.1007/s004150050153; Murphy BL, 2011, J NEUROSCI, V31, P105, DOI 10.1523/JNEUROSCI.2728-10.2011; Myhrer T, 2003, NEUROTOXICOLOGY, V24, P357, DOI 10.1016/S0161-813X(03)00040-8; Myhrer T, 2011, NEUROTOXICOLOGY; Myhrer T, 2007, TOXICOLOGY, V239, P1, DOI 10.1016/j.tox.2007.06.099; Nguyen N, 2007, NEUROTOXICOLOGY, V28, P13, DOI 10.1016/j.neuro.2006.09.007; Nielsen SS, 2010, ENVIRON HEALTH PERSP, V118, P144, DOI 10.1289/ehp.0901226; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; O'Donnell JC, 2011, ARCH TOXICOL, V85, P1607, DOI 10.1007/s00204-011-0724-z; Parent JM, 2007, PROG BRAIN RES, V163, P529, DOI 10.1016/S0079-6123(07)63028-3; Parent JM, 2006, HIPPOCAMPUS, V16, P321, DOI 10.1002/hipo.20166; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, EPILEPSY RES, V50, P179, DOI 10.1016/S0920-1211(02)00078-5; Park EM, 2005, NEUROSCIENCE, V132, P625, DOI 10.1016/j.neuroscience.2005.01.021; Pazdernik TL, 2001, J APPL TOXICOL, V21, pS87, DOI 10.1002/jat.818; Pereira EFR, 2010, J MOL NEUROSCI, V40, P196, DOI 10.1007/s12031-009-9234-3; Pernot F, 2009, NEUROSCIENCE, V162, P1351, DOI 10.1016/j.neuroscience.2009.05.068; Persinger MA, 2004, EPILEPSY BEHAV, V5, P440, DOI 10.1016/j.yebeh.2004.03.007; Peterson SL, 2005, NEUROTOXICOLOGY, V26, P969, DOI 10.1016/j.neuro.2005.04.002; PETRAS JM, 1994, J EXP ANAL BEHAV, V61, P319, DOI 10.1901/jeab.1994.61-319; PHILIPPENS IHCHM, 1992, PHARMACOL BIOCHEM BE, V42, P711, DOI 10.1016/0091-3057(92)90019-C; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pierre SC, 2007, BRIT J PHARMACOL, V151, P494, DOI 10.1038/sj.bjp.0707239; PISA M, 1980, BRAIN RES, V200, P481, DOI 10.1016/0006-8993(80)90938-5; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pizarro JM, 2012, TOXICOL SCI, V126, P497, DOI 10.1093/toxsci/kfr353; RAFFAELE K, 1987, PHARMACOL BIOCHEM BE, V27, P407, DOI 10.1016/0091-3057(87)90341-8; Rauh VA, 2006, PEDIATRICS, V118, pE1845, DOI 10.1542/peds.2006-0338; Romano J, 2001, CHEM WARFARE AGENT T; Rossetti F, 2012, NEUROTOXICOLOGY; Rotenberg JS, 2003, PEDIATRICS, V112, P648, DOI 10.1542/peds.112.3.648; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SAMSON FE, 1984, FUND APPL TOXICOL, V4, pS173, DOI 10.1016/0272-0590(84)90150-7; Saxena A, 2011, BIOCHEM PHARMACOL, V82, P1984, DOI 10.1016/j.bcp.2011.09.019; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scharfman HE, 2001, NEUROSCIENCE, V104, P741, DOI 10.1016/S0306-4522(01)00132-4; Schlichtiger J, 2010, BRIT J PHARMACOL, V160, P1062, DOI 10.1111/j.1476-5381.2010.00765.x; Schultz MK, 2012, TOXICOL APPL PHARM, V259, P376, DOI 10.1016/j.taap.2012.01.017; Scremin OU, 1998, BRAIN RES BULL, V45, P167, DOI 10.1016/S0361-9230(97)00334-1; Sekijima Y, 1995, Rinsho Shinkeigaku, V35, P1241; SHIH TM, 1990, EPILEPSY RES, V7, P105, DOI 10.1016/0920-1211(90)90095-D; Shih TM, 1997, J APPL TOXICOL, V17, P255, DOI 10.1002/(SICI)1099-1263(199707)17:4<255::AID-JAT441>3.0.CO;2-D; Shih TM, 1999, PHARMACOL BIOCHEM BE, V64, P147, DOI 10.1016/S0091-3057(99)00114-8; Shih TM, 2003, TOXICOL APPL PHARM, V188, P69, DOI 10.1016/S0041-008X(03)00019-X; Shih TM, 2011, TOXICOL MECH METHOD, V21, P53, DOI 10.3109/15376516.2010.529190; Shih TM, 2010, J MOL NEUROSCI, V40, P63, DOI 10.1007/s12031-009-9259-7; Shorvon SD, 2000, HDB EPILEPSY TREATME; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; Silbergleit R, 2012, NEW ENGL J MED, V366, P591, DOI 10.1056/NEJMoa1107494; Sit RK, 2011, J BIOL CHEM, V286, P19422, DOI 10.1074/jbc.M111.230656; Skovira JW, 2012, NEUROTOXICOLOGY, V33, P463, DOI 10.1016/j.neuro.2012.03.006; Skovira JW, 2010, J MOL NEUROSCI, V40, P56, DOI 10.1007/s12031-009-9253-0; Sloviter RS, 1999, EPILEPSIA, V40, pS34, DOI 10.1111/j.1528-1157.1999.tb00876.x; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SPARENBORG S, 1993, EPILEPSY RES, V14, P95, DOI 10.1016/0920-1211(93)90014-X; Spradling KD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-83; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Testylier G, 1999, ACTA BIOTHEOR, V47, P191, DOI 10.1023/A:1002626318172; Tetz LM, 2006, TOXICOL IND HEALTH, V22, P255, DOI 10.1191/0748233706th268oa; TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Tonduli LS, 2001, NEUROTOXICOLOGY, V22, P29, DOI 10.1016/S0161-813X(00)00015-2; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; TRYPHONAS L, 1995, TOXICOL PATHOL, V23, P393, DOI 10.1177/019262339502300316; Tryphonas L, 1996, TOXICOL PATHOL, V24, P190, DOI 10.1177/019262339602400207; Tu XK, 2009, NEUROL RES, V31, P848, DOI 10.1179/174313209X403913; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Vartiainen N, 2001, J NEUROCHEM, V76, P480, DOI 10.1046/j.1471-4159.2001.00065.x; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; VIOLAN JS, 1985, MED CLIN-BARCELONA, V85, P217; Voutsinos-Porche B, 2004, NEUROBIOL DIS, V17, P385, DOI 10.1016/j.nbd.2004.07.023; Wang Y, 2007, CURR NEUROVASC RES, V4, P176; Wang Yan-Ling, 2004, Zhonghua Er Ke Za Zhi, V42, P621; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; Wasterlain G, 2009, J NEUROSCI, V50, P16; White HS, 2011, ESILEPSIA; Williams PA, 2002, J NEUROPHYSIOL, V88, P2075, DOI 10.1152/jn.2002.88.4.2075; Williams PA, 2007, EPILEPSIA, V48, P157, DOI 10.1111/j.1528-1167.2007.01304.x; Wiltrout C, 2007, NEUROCHEM INT, V50, P1028, DOI 10.1016/j.neuint.2007.04.011; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x; Yamada A, 2009, NUCL MED BIOL, V36, P949, DOI 10.1016/j.nucmedbio.2009.06.008; Young JG, 2005, NEUROTOXICOLOGY, V26, P199, DOI 10.1016/j.neuro.2004.10.004; Yourick DL, 2007, RTOMPHFM149; Zandieh A, 2010, ACTA NEUROBIOL EXP, V70, P390; Zhang HJ, 2008, J ZHEJIANG UNIV-SC B, V9, P903, DOI 10.1631/jzus.B0820018; Zheng Z, 2007, BRAIN RES, V1186, P275, DOI 10.1016/j.brainres.2007.10.029; Zimmer LA, 1998, J NEUROSCI, V18, P3897	219	67	71	0	119	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	DEC	2012	33	6			SI		1476	1490		10.1016/j.neuro.2012.09.001			15	Neurosciences; Pharmacology & Pharmacy; Toxicology	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	063UI	WOS:000313027100011	23000013				2021-06-18	
J	Villapol, S; Yaszemski, AK; Logan, TT; Sanchez-Lemus, E; Saavedra, JM; Symes, AJ				Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Sanchez-Lemus, Enrique; Saavedra, Juan M.; Symes, Aviva J.			Candesartan, an Angiotensin II AT(1)-Receptor Blocker and PPAR-gamma Agonist, Reduces Lesion Volume and Improves Motor and Memory Function After Traumatic Brain Injury in Mice	NEUROPSYCHOPHARMACOLOGY			English	Article						traumatic brain injury; candesartan; TGF beta; inflammation; neuroprotection; PPAR gamma	ACTIVATED-RECEPTOR-GAMMA; CEREBRAL-BLOOD-FLOW; TRANSFORMING GROWTH FACTOR-BETA(1); INNATE IMMUNE-RESPONSE; TYPE-1 RECEPTOR; MICROGLIAL ACTIVATION; VASCULAR INFLAMMATION; HYPERTENSIVE-RATS; OXIDATIVE STRESS; EPITHELIAL-CELLS	Traumatic brain injury (TBI) results in complex pathological reactions, the initial lesion worsened by secondary inflammation and edema. Angiotensin II (Ang II) is produced in the brain and Ang II receptor type 1 (AT(1)R) overstimulation produces vasoconstriction and inflammation. Ang II receptor blockers (ARBs) are neuroprotective in models of stroke but little is known of their effect when administered in TBI models. We therefore performed controlled cortical impact (CCI) injury on mice to investigate whether the ARB candesartan would mitigate any effects of TBI. We administered candesartan or vehicle to mice 5 h before CCI injury. Candesartan treatment reduced the lesion volume after CCI injury by approximately 50%, decreased the number of dying neurons, lessened the number of activated microglial cells, protected cerebral blood flow (CBF), and reduced the expression of the cytokine TGF beta 1 while increasing expression of TGF beta 3. Candesartan-treated mice also showed better motor skills on the rotarod 3 days after injury, and improved performance in the Morris water maze 4 weeks after injury. These results indicate that candesartan is neuroprotective, reducing neuronal injury, decreasing lesion volume and microglial activation, protecting CBF and improving functional behavior in a mouse model of TBI. Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPAR gamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPAR gamma activation may contribute to part or to all of the neuroprotective effect of candesartan. Overall, our data suggest that ARBs with dual AT(1)R-blocking and PPAR gamma activation properties may have therapeutic value in treating TBI. Neuropsychopharmacology (2012) 37, 2817-2829; doi: 10.1038/npp.2012.152; published online 15 August 2012	[Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Symes, Aviva J.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Sanchez-Lemus, Enrique; Saavedra, Juan M.] NIMH, Pharmacol Sect, Div Intramural Res Programs, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Saavedra, Juan/AAO-7149-2020; Villapol, Sonia/D-1949-2014; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense; CNRM postdoctoral fellowship; Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002762] Funding Source: NIH RePORTER	This study was supported by a pilot award from the Center for Neuroscience and Regenerative Medicine (CNRM) grant (AJS). SV is supported by a CNRM postdoctoral fellowship. JMS and ESL are supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health. We thank Laura Tucker, Oz Malkesman, and Amanda Fu from the CNRM pre-clinical core facility for expert advice, Dr Tim ONeil for his assistance with blood pressure measurements. We are grateful to members of the Symes and Saavedra laboratories for their helpful comments and suggestions. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense.	An JB, 2010, HYPERTENS RES, V33, P831, DOI 10.1038/hr.2010.79; Ando H, 2004, ANN NY ACAD SCI, V1018, P345, DOI 10.1196/annals.1296.043; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Awad AS, 2011, J STROKE CEREBROVASC, V20, P541, DOI 10.1016/j.jstrokecerebrovasdis.2010.03.008; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bernardo A, 2006, CURR PHARM DESIGN, V12, P93, DOI 10.2174/138161206780574579; BURSON JM, 1994, AM J PHYSIOL, V267, pE260; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; Davisson RL, 2000, J CLIN INVEST, V106, P103, DOI 10.1172/JCI10022; dos Santos CC, 2005, CRIT CARE, V9, P280, DOI 10.1186/cc3022; Engelhorn T, 2004, J CEREBR BLOOD F MET, V24, P467, DOI 10.1097/00004647-200404000-00012; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Fogari R, 2004, DRUG AGING, V21, P377, DOI 10.2165/00002512-200421060-00003; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Guan WH, 2011, TRANSL STROKE RES, V2, P179, DOI 10.1007/s12975-010-0061-1; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hansson L, 1999, BLOOD PRESSURE, V8, P177; Harasawa S, 2010, J PHARM PHARMACOL, V62, P1740, DOI 10.1111/j.2042-7158.2010.01164.x; Igase M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/320648; Ito T, 2001, J RENIN-ANGIO-ALDO S, V2, P174, DOI 10.3317/jraas.2001.024; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Ji YY, 2009, LAB INVEST, V89, P887, DOI 10.1038/labinvest.2009.45; Jiao B, 2011, BIOSCI TRENDS, V5, P173, DOI 10.5582/bst.2011.v5.4.173; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Lanz TV, 2010, J CLIN INVEST, V120, P2782, DOI 10.1172/JCI41709; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Li JM, 2008, STROKE, V39, P2029, DOI 10.1161/STROKEAHA.107.503458; Liu H, 2008, J HYPERTENS, V26, P1435, DOI 10.1097/HJH.0b013e3283013b6e; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maeda A, 2009, INT IMMUNOPHARMACOL, V9, P1183, DOI 10.1016/j.intimp.2009.06.006; Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Meredith PA, 2004, J RENIN-ANGIO-ALDO S, V5, P59, DOI 10.3317/jraas.2004.011; Nishimura Y, 2000, BRAIN RES, V871, P29, DOI 10.1016/S0006-8993(00)02377-5; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Occleston NL, 2008, J BIOMAT SCI-POLYM E, V19, P1047, DOI 10.1163/156856208784909345; Omura-Matsuoka E, 2009, HYPERTENS RES, V32, P548, DOI 10.1038/hr.2009.69; Ozacmak VH, 2007, NEUROCHEM RES, V32, P1314, DOI 10.1007/s11064-007-9305-1; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Poon IO, 2008, PHARMACOTHERAPY, V28, P366, DOI 10.1592/phco.28.3.366; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Robbins ME, 2010, CURR DRUG TARGETS, V11, P1413; Rodriguez-Pallares J, 2008, NEUROBIOL DIS, V31, P58, DOI 10.1016/j.nbd.2008.03.003; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Stenman E, 2004, STROKE, V35, P970, DOI 10.1161/01.STR.0000121642.53822.58; Sugawara A, 2011, CURR MOL PHARM; Sugawara T, 2005, NEUROREPORT, V16, P325, DOI 10.1097/00001756-200503150-00004; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Thone-Reineke C, 2006, J HYPERTENS, V24, pS115; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209; Van Mieghem W, 2010, ACTA CLIN BELG, V65, P107, DOI 10.1179/acb.2010.022; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; Vivien D, 2006, CYTOKINE GROWTH F R, V17, P121, DOI 10.1016/j.cytogfr.2005.09.011; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Xiao J, 2009, CLIN IMMUNOL, V132, P266, DOI 10.1016/j.clim.2009.04.004; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yu CM, 2001, J AM COLL CARDIOL, V38, P1207, DOI 10.1016/S0735-1097(01)01518-2; Zanchetti A, 2006, BLOOD PRESSURE, V15, P71, DOI 10.1080/08037050600771583; Zhao SM, 2008, CHINESE J PHYSIOL, V51, P357; Zhou J, 2006, STROKE, V37, P1271, DOI 10.1161/01.STR.0000217404.64352.d7; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	82	67	69	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	DEC	2012	37	13					2817	2829		10.1038/npp.2012.152			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	037GT	WOS:000311090900009	22892395	Green Published, Bronze			2021-06-18	
J	Dickerson, RN; Pitts, SL; Maish, GO; Schroeppel, TJ; Magnotti, LJ; Croce, MA; Minard, G; Brown, RO				Dickerson, Roland N.; Pitts, Stefanie L.; Maish, George O.; Schroeppel, Thomas J.; Magnotti, Louis J.; Croce, Martin A.; Minard, Gayle; Brown, Rex O.			A reappraisal of nitrogen requirements for patients with critical illness and trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Enteral nutrition; parenteral nutrition; protein requirements; nitrogen balance; traumatic brain injury	SEVERE HEAD-INJURY; TOTAL PARENTERAL-NUTRITION; EARLY ENTERAL NUTRITION; METABOLIC-RESPONSE; INTENSIVE-CARE; ENERGY-EXPENDITURE; PROTEIN-METABOLISM; SUPPORT; EXCRETION; FAT	BACKGROUND: Studies regarding protein requirements for patients with critical illness are inconclusive owing to small sample size and population heterogeneity. The primary objectives of this study were to determine the amount of protein required to achieve nitrogen equilibrium or a positive nitrogen balance (NB, -4 g/d or better) and ascertain whether patients with traumatic brain injury (TBI) exhibit greater protein catabolism than those without TBI. METHODS: Adult patients admitted to the trauma center, given specialized nutrition support, and had an NB determination within 5 days to 14 days after injury were evaluated. Patients with obesity, incomplete urine collection, kidney disease, corticosteroid or pentobarbital therapy, or an oral diet were excluded. RESULTS: A total of 300 NB determinations from 249 patients were evaluated. Increasing the protein dosage generally resulted in improved NB; however, the data were highly variable. Of the patients who received a protein intake of 2 g/kg per day or greater, 54% achieved nitrogen equilibrium or positive NB (-4 g/d or better) in contrast to 38% and 29% of patients who received 1.5 g/kg per day to 1.99 g/kg per day and 1 g/kg per day to 1.49 g/kg per day, respectively (p < 0.001). There was no significant difference in NB between patients with and without TBI at similar protein intakes. CONCLUSION: A higher protein intake was generally associated with an improved NB; yet, many patients remained having a negative NB. A protein dosage of 2 g/kg per day or greater was more successful in achieving nitrogen equilibrium than were lower-dosage intakes. Patients with TBI do not exhibit significantly greater protein catabolism than do patients without TBI. (J Trauma Acute Care Surg. 2012;73: 549-557. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Dickerson, Roland N.; Pitts, Stefanie L.; Brown, Rex O.] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA; [Maish, George O.; Schroeppel, Thomas J.; Magnotti, Louis J.; Croce, Martin A.; Minard, Gayle] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA	Dickerson, RN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, 881 Madison Ave,Suite 345, Memphis, TN 38163 USA.	rdickerson@uthsc.edu		Dickerson, Roland/0000-0002-2086-6317	Haemonetics; Golden Helix; Expression Analysis; Illumina; Lineagan	Ernest E. Moore, MD, Editor, received research support from Haemonetics. David B. Hoyt, MD, Associate Editor/CME Editor, Ronald Maier, MD, Associate Editor, and Steven Shackford, MD, Associate Editor have nothing to disclose. Jennifer Crebs, Managing Editor, received consulting fees from Golden Helix, Expression Analysis, Illumina, and Lineagan. Jo Fields, Editorial Assistant, and Angela Sauaia, MD, Biostatistician, have nothing to disclose.	Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIRKHAHN RH, 1981, AM J PHYSIOL, V241, pE64; BLACK PR, 1982, ANN SURG, V196, P420, DOI 10.1097/00000658-198210000-00005; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; Dickerson RN, 2005, NUTRITION, V21, P332, DOI 10.1016/j.nut.2004.07.005; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Doig GS, 2011, INJURY, V42, P50, DOI 10.1016/j.injury.2010.06.008; Frankenfield DC, 1997, JPEN-PARENTER ENTER, V21, P324, DOI 10.1177/0148607197021006324; FRIED RC, 1989, J TRAUMA, V29, P1558, DOI 10.1097/00005373-198911000-00017; Garlick PJ, 2004, J NUTR, V134, p1633S, DOI 10.1093/jn/134.6.1633S; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hart DW, 2002, ANN SURG, V235, P152, DOI 10.1097/00000658-200201000-00020; Ishibashi N, 1998, CRIT CARE MED, V26, P1529, DOI 10.1097/00003246-199809000-00020; JEEVANANDAM M, 1990, CRIT CARE MED, V18, P467, DOI 10.1097/00003246-199005000-00001; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; LARSSON J, 1990, BRIT J SURG, V77, P413, DOI 10.1002/bjs.1800770418; Manatt M. W., 1992, Modern methods in protein nutrition and metabolism., P9; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; MORITZ F, 1993, BRIT J ANAESTH, V70, P451, DOI 10.1093/bja/70.4.451; Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; SHAW JHF, 1989, ANN SURG, V209, P63, DOI 10.1097/00000658-198901000-00010; SHAW JHF, 1987, ANN SURG, V205, P288, DOI 10.1097/00000658-198703000-00012; SHAWDELANTY SN, 1987, CLIN NUTR, V6, P257, DOI 10.1016/0261-5614(87)90041-0; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; WOLFE RR, 1983, ANN SURG, V197, P163, DOI 10.1097/00000658-198302000-00007; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	34	67	73	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					549	557		10.1097/TA.0b013e318256de1b			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	009TK	WOS:000309047900003	23007014				2021-06-18	
J	Crisco, JJ; Wilcox, BJ; Machan, JT; McAllister, TW; Duhaime, AC; Duma, SM; Rowson, S; Beckwith, JG; Chu, JJ; Greenwald, RM				Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.; McAllister, Thomas W.; Duhaime, Ann-Christine; Duma, Stefan M.; Rowson, Steven; Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.			Magnitude of Head Impact Exposures in Individual Collegiate Football Players	JOURNAL OF APPLIED BIOMECHANICS			English	Article						football; biomechanics; impacts; magnitude; acceleration	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; UNITED-STATES; EPIDEMIOLOGY; ACCELERATION; CONCUSSION; SPORTS; LOCATION	The purpose of this study was to quantify the severity of head impacts sustained by individual collegiate football players and to investigate differences between impacts sustained during practice and game sessions, as well as by player position and impact location. Head impacts (N = 184,358) were analyzed for 254 collegiate players at three collegiate institutions. In practice, the 50th and 95th percentile values for individual players were 20.0 g and 49.5 g for peak linear acceleration, 1187 rad/s(2) and 3147 rad/s(2) for peak rotational acceleration, and 13.4 and 29.9 for HITsp, respectively. Only the 95th percentile HITsp increased significantly in games compared with practices (8.4%, p = .0002). Player position and impact location were the largest factors associated with differences in head impacts. Running backs consistently sustained the greatest impact magnitudes. Peak linear accelerations were greatest for impacts to the top of the helmet, whereas rotational accelerations were greatest for impacts to the front and back. The findings of this study provide essential data for future investigations that aim to establish the correlations between head impact exposure, acute brain injury, and long-term cognitive deficits.	[Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA; [Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.] Rhode Isl Hosp, Providence, RI USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Duma, Stefan M.; Rowson, Steven] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [McAllister, Thomas W.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA	Crisco, JJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA.		Machan, Jason T/D-3897-2013; Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Machan, Jason T/0000-0003-2048-4914; Rowson, Steven/0000-0002-3227-0596; 	National Center for Medical Rehabilitation Research at the National Institute of Child Health [R01HD048638]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1NS055020]; NOCSAE [04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD040743, R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 from the National Center for Medical Rehabilitation Research at the National Institute of Child Health and 1RO1NS055020 from the National Institute of Neurological Disorders and Stroke, and NOCSAE 04-07. HIT System technology was developed in part under NIH R44HD40743 and research and development support from Riddell, Inc. (Chicago, IL). We appreciate and acknowledge the researchers and institutions from which the data were collected: Mike Goforth and Dave Dieter, Virginia Tech Sports Medicine; Jeff Frechette and Scott Roy, Dartmouth College Sports Medicine; Mary Hynes, Dartmouth Medical School; and Russell Fiore, David J. Murray, and Kevin R. Francis, Brown University. We acknowledge Lindley Brainard from Simbex for coordination of all data collection.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2009, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gerbeding J.L., 2003, COSTS INTIMATE PARTN, P1; Greenwald R.M., 2008, J NEUROSURG, V62, P798, DOI [10.1227/01.neu.0000318162.67472.ad, DOI 10.1227/01.NEU.0000318162.67472.AD]; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan 3rd W.P., 2010, AM J SPORTS MED; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik J.P., 2007, J NEUROSURG, V61, P1235, DOI [10.1227/01.neu.0000306101.83882.c8, DOI 10.1227/01.NEU.0000306101.83882.C8]; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D.W., 1971, SCANDINAVIAN J MED S, V3, P44; Pellman E.J., 2003, J NEUROSURG, V53, P812; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Schnebel B., 2007, J NEUROSURG, V60, P495; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	31	67	67	1	17	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	MAY	2012	28	2					174	183		10.1123/jab.28.2.174			10	Engineering, Biomedical; Sport Sciences	Engineering; Sport Sciences	970WS	WOS:000306163600008	21911854	Green Accepted			2021-06-18	
J	Garber, ST; Sivakumar, W; Schmidt, RH				Garber, Sarah T.; Sivakumar, Walavan; Schmidt, Richard H.			Neurosurgical complications of direct thrombin inhibitors catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran	JOURNAL OF NEUROSURGERY			English	Article						dabigatran; intracerebral hemorrhage; anticoagulation; thrombin; traumatic brain injury; neurosurgical complication	ATRIAL-FIBRILLATION; ANTITHROMBOTIC THERAPY; PREVENT STROKE; METAANALYSIS; WARFARIN; RISK	Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. Large randomized clinical trials have shown higher doses of dabigatran (150 mg taken twice daily) to be superior to warfarin in terms of stroke and systemic embolism rates in patients with nonvalvular atrial fibrillation. As a result, in 2010 the US FDA approved the use of dabigatran for the prevention of stroke and systemic embolism in patients with atrial Dabigatran is especially attractive in the outpatient setting because patients do not require routine monitoring with prothrombin times or international normalized ratios. To date, no effective reversal agent for dabigatran in the event of catastrophic hemorrhage has been identified. The authors report a case of an elderly patient, being treated with dabigatran for atrial fibrillation, who presented with a rapidly expanding intracranial hemorrhage after a ground-level fall. This case highlights an impending neurosurgical quandary of complications secondary to this new anticoagulation agent and suggests potential options for management. (http://thejns.org/doi/abs/10.3171/2012.2.JNS112132)	[Garber, Sarah T.; Sivakumar, Walavan; Schmidt, Richard H.] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA	Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 175 N Med Dr E, Salt Lake City, UT 84132 USA.	neuropub@hsc.utah.edu					Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Ganetsky M, 2011, J MED TOXICOL, V7, P281, DOI 10.1007/s13181-011-0178-y; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Medi C, 2010, STROKE, V41, P2705, DOI 10.1161/STROKEAHA.110.589218; Stangier J, 2008, CLIN PHARMACOKINET, V47, P47, DOI 10.2165/00003088-200847010-00005; TEASDALE G, 1974, LANCET, V2, P81; Zhou W, 2011, STROKE, V42, P3594, DOI 10.1161/STROKEAHA.111.624650	10	67	69	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1093	1096		10.3171/2012.2.JNS112132			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800025	22394293				2021-06-18	
J	Masliah, E; Diez-Tejedor, E				Masliah, E.; Diez-Tejedor, E.			THE PHARMACOLOGY OF NEUROTROPHIC TREATMENT WITH CEREBROLYSIN: BRAIN PROTECTION AND REPAIR TO COUNTERACT PATHOLOGIES OF ACUTE AND CHRONIC NEUROLOGICAL DISORDERS	DRUGS OF TODAY			English	Article							PEPTIDERGIC DRUG CEREBROLYSIN; MODERATE FOREBRAIN ISCHEMIA; FIBROBLAST-GROWTH-FACTOR; TRANSGENIC MODEL; ALZHEIMERS-DISEASE; CELL-DEATH; FIMBRIA-FORNIX; SPATIAL MEMORY; SHORT-TERM; NEUROGENESIS	Neurotrophic factors are considered as part of the therapeutic strategy for neurological disorders like dementia, stroke and traumatic brain injury. Cerebrolysin is a neuropeptide preparation which mimics the action of endogenous neurotrophic factors on brain protection and repair In dementia models, Cerebrolysin decreases beta-amyloid deposition and microtubule-associated protein tau phosphorylation by regulating glycogen synthase kinase-3 beta thus supporting the brain's self-repair after stroke. Both, traumatic brain and spinal cord injury conditions stimulate the expression of natural neurotrophic factors to promote repair and regeneration processes-axonal regeneration, neuronal plasticity and neurogenesis-that is considered to be crucial for the future recovery. Neuroprotective effects of Cerebrolysin on experimentally induced traumatic spinal cord injury have shown that Cerebrolysin prevents apoptosis of lesioned motoneurons and promotes functional recovery. This section summarizes the most relevant data on the pharmacology of Cerebrolysin obtained from in vitro assays (biochemical and cell cultures) and in vivo animal models of acute and chronic neurological disorders.	[Masliah, E.] Univ Calif La Jolla, Dept Neurosci, La Jolla, CA 92093 USA; [Diez-Tejedor, E.] Univ Autonoma Madrid, La Paz Univ Hosp, Dept Neurol, Health Res Inst,IdiPAZ,Neurosci Res Lab, Madrid, Spain; [Diez-Tejedor, E.] Univ Autonoma Madrid, La Paz Univ Hosp, Stroke Ctr, Health Res Inst,IdiPAZ,Neurosci Res Lab, Madrid, Spain	Masliah, E (corresponding author), Univ Calif La Jolla, Neurosci & Pathol Dept, 9500 Gilman Dr, La Jolla, CA 92093 USA.	emasliah@ucsd.edu			EVER Neuro Pharma	The production of this supplement of Drugs of Today was sponsored by EVER Neuro Pharma, the manufacturer of Cerebrolysin. The authors have not received any payments for the writing of this article.	Abdelaziz O., 2007, PAN ARAB J NEUROSURG, V11, P51; AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; Allegri RF, 2012, DRUG TODAY, V48, P25, DOI 10.1358/dot.2012.48(Suppl.A).1739721; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Bowes M., 2000, NEUROLOGYREVIEWS, V8; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Conte V., 2003, EUR J TRAUMA, V29, P335; CUMMINGS BJ, 1993, EXP NEUROL, V124, P315, DOI 10.1006/exnr.1993.1202; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; EVER Neuro Pharma GmbH, 2009, SUMM PROD CHAR; FrancisTurner L, 1996, NEUROSCI LETT, V202, P193, DOI 10.1016/0304-3940(95)12240-0; GOLD PE, 1986, BEHAV NEURAL BIOL, V46, P87, DOI 10.1016/S0163-1047(86)90927-1; Gonzalez ME, 1998, J NEURAL TRANSM-SUPP, P333; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gschanes A, 1998, J NEURAL TRANSM-SUPP, P313; Gschanes A, 1999, BEHAV BRAIN RES, V100, P161, DOI 10.1016/S0166-4328(98)00127-2; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Haninec P, 2004, EXP BRAIN RES, V159, P425, DOI 10.1007/s00221-004-1969-z; Haninec P, 2003, ANN ANAT, V185, P233, DOI 10.1016/S0940-9602(03)80030-4; Hanson LR, 2009, AM J NEUROPROTEC NEU, V1, P60, DOI [DOI 10.1166/AJNN.2009.1010, 10.1166/ajnn.2009.1010]; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P363; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P351; HutterPaier B, 1996, ARZNEIMITTELFORSCH, V46, P237; Lombardi VRM, 1999, METHOD FIND EXP CLIN, V21, P331, DOI 10.1358/mf.1999.21.5.541910; Magavi SS, 2000, NATURE, V405, P951; Mallory M, 1999, ACTA NEUROPATHOL, V97, P437, DOI 10.1007/s004010051012; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Masliah E, 2000, J NEURAL TRANSM-SUPP, P175; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; Masliah E., 1997, CONNECTIONS COGNITIO, P121; Mattson MP, 2000, BRAIN PATHOL, V10, P300, DOI 10.1111/j.1750-3639.2000.tb00264.x; Merino J.J., 2009, CEPHALALGIA S, V29, P60; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Revesz T, 2002, BRAIN PATHOL, V12, P343; Riley C, 2006, J NEURAL TRANSM, V113, P103, DOI 10.1007/s00702-005-0302-8; Rockenstein E, 2005, J NEURAL TRANSM, V112, P269, DOI 10.1007/s00702-004-0181-4; Rockenstein E, 2003, J NEURAL TRANSM, V110, P1313, DOI 10.1007/s00702-003-0025-7; Rockenstein E, 2002, J NEURAL TRANSM-SUPP, P327; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Rockenstein E, 2011, J NEUROSCI RES, V89, P1812, DOI 10.1002/jnr.22712; Sacchetti B, 2001, NEUROBIOL LEARN MEM, V76, P1, DOI 10.1006/nlme.2001.4014; Satou T, 2000, J NEURAL TRANSM, V107, P1253, DOI 10.1007/s007020070015; Schauer E, 2006, J NEURAL TRANSM, V113, P855, DOI 10.1007/s00702-005-0384-3; Schwab M, 1996, J NEURAL TRANSM-SUPP, P279; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Schwab M, 1997, EXP TOXICOL PATHOL, V49, P29; Schwab M, 1997, EXP TOXICOL PATHOL, V49, P105; STOPA EG, 1990, BIOCHEM BIOPH RES CO, V171, P690, DOI 10.1016/0006-291X(90)91201-3; Sugita Y, 1993, No To Shinkei, V45, P325; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Thome J, 2012, DRUG TODAY, V48, P63, DOI 10.1358/dot.2012.48(Suppl.A).1739724; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Valouskova V, 1999, NEUROBIOL LEARN MEM, V71, P132, DOI 10.1006/nlme.1998.3877; Valouskova V, 1998, J NEURAL TRANSM-SUPP, P343; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; VANTINI G, 1992, PSYCHONEUROENDOCRINO, V17, P401, DOI 10.1016/0306-4530(92)90045-9; Veinbergs I, 2000, J NEURAL TRANSM-SUPP, P273; WALLACE JE, 1980, J GERONTOL, V35, P355, DOI 10.1093/geronj/35.3.355; Wen Y, 2007, BBA-MOL BASIS DIS, V1772, P473, DOI 10.1016/j.bbadis.2006.10.011; Windholz E, 2000, HISTOCHEM J, V32, P79, DOI 10.1023/A:1004053809591; Wolf H.J., 2001, 5 INT C PROG ALZH PA; Wronski R, 2000, J NEURAL TRANSM, V107, P145, DOI 10.1007/s007020050013; Yuen EC, 1996, BRAIN DEV-JPN, V18, P362, DOI 10.1016/0387-7604(96)00051-4; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495	70	67	77	0	23	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	APR	2012	48			A			3	24		10.1358/dot.2012.48(Suppl.A).1739716			22	Pharmacology & Pharmacy	Pharmacology & Pharmacy	959GW	WOS:000305301900002	22514792				2021-06-18	
J	Migliore, A; Timmons, J; Butterworth, J; Lugas, J				Migliore, Alberto; Timmons, Jaimie; Butterworth, John; Lugas, Jaime			Predictors of Employment and Postsecondary Education of Youth With Autism	REHABILITATION COUNSELING BULLETIN			English	Article						employment; vocational rehabilitation; postsecondary education; transition; autism; RSA911	TRAUMATIC BRAIN-INJURY; DEVELOPMENTAL-DISABILITIES; SPECTRUM DISORDERS; OUTCOMES; SERVICES; ADULTS; CONSUMERS; PEOPLE	Using logistic and multiple regressions, the authors investigated predictors of employment and postsecondary education outcomes of youth with autism in the Vocational Rehabilitation Program. Data were obtained from the RSA911 data set, fiscal year 2008. Findings showed that the odds of gaining employment were greater for youth who received job placement services, yet only 48% of youth received this service. In addition, postsecondary education was among the strongest predictors of better earnings, yet only 10% of youth received college services. The authors recommended providing job placement services and college services to more youth with autism. At the same time, due to the relatively moderate effect sizes of these regression models, they recommend investigating additional variables currently not included in the RSA911 data set.	[Migliore, Alberto] Univ Massachusetts, Inst Community Inclus, Boston, MA 02116 USA	Migliore, A (corresponding author), Univ Massachusetts, Inst Community Inclus, 20 Pk Plaza,Suite 1300, Boston, MA 02116 USA.	amiglior@gmail.com	Butterworth, John/J-8278-2016				Alan, 2007, I REHABILITATION ISS, V32; Barnhill G.P., 2007, FOCUS AUTISM DEV DIS, V22, P116, DOI DOI 10.1177/10883576070220020301; Boeltzig H, 2008, INT J REHABIL RES, V31, P217, DOI 10.1097/MRR.0b013e3282fb7ce5; Bolton BF, 2000, REHABIL COUNS BULL, V44, P10, DOI 10.1177/003435520004400103; Butterworth J., 2011, STATEDATA NATL REPOR; Camarena PM, 2009, FOCUS AUTISM DEV DIS, V24, P115, DOI 10.1177/1088357609332675; Cimera RE, 2009, AUTISM, V13, P285, DOI 10.1177/1362361309103791; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Field A. P, 2009, DISCOVERING STAT USI; Gamble D, 2003, J REHABIL, V69, P31; Grigal M., 2010, THINK COLL POSTSECON; Hayward B. J., 2003, LONGITUDINAL STUDY V; Hendricks D, 2010, J VOCAT REHABIL, V32, P125, DOI 10.3233/JVR-2010-0502; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Jung Y, 2010, REHABIL COUNS BULL, V53, P175, DOI 10.1177/0034355209356596; Lawer L, 2009, J AUTISM DEV DISORD, V39, P487, DOI 10.1007/s10803-008-0649-4; Luecking R. G., 2004, WORKING RELATIONSHIP; Migliore A, 2008, REHABIL COUNS BULL, V52, P35, DOI 10.1177/0034355208320075; MOORE C, 2002, J REHABIL, V68, P6; Newman L, 2009, POSTHIGH SCH OUTCOME; Schaller J, 2005, REHABIL COUNS BULL, V49, P4, DOI 10.1177/00343552050490010201; Schonbrun SL, 2007, J REHABIL, V73, P26; Stevens J., 1996, APPL MULTIVARIATE ST; Stodden RA, 2010, FOCUS AUTISM DEV DIS, V25, P131, DOI 10.1177/1088357610371637; Tabachnick B., 2001, USING MULTIVARIATE S; Taylor JL, 2011, J AUTISM DEV DISORD, V41, P566, DOI 10.1007/s10803-010-1070-3; Test DW, 2009, CAREER DEV TRANSIT E, V32, P160, DOI 10.1177/0885728809346960; United States Government Accountability Office, 2005, GAO05865	28	67	67	1	35	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	APR	2012	55	3					176	184		10.1177/0034355212438943			9	Rehabilitation	Rehabilitation	913HB	WOS:000301866600005					2021-06-18	
J	Corral, L; Javierre, CF; Ventura, JL; Marcos, P; Herrero, JI; Manez, R				Corral, Luisa; Javierre, Casimiro F.; Ventura, Josep L.; Marcos, Pilar; Herrero, Jose I.; Manez, Rafael			Impact of non-neurological complications in severe traumatic brain injury outcome	CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; ACUTE KIDNEY INJURY; ACUTE LUNG INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; GOSE SCORES 6; ORGAN DYSFUNCTION; EXTRACRANIAL COMPLICATIONS; INTRACRANIAL HYPERTENSION; MANAGEMENT; FAILURE	Introduction: Non-neurological complications in patients with severe traumatic brain injury (TBI) are frequent, worsening the prognosis, but the pathophysiology of systemic complications after TBI is unclear. The purpose of this study was to analyze non-neurological complications in patients with severe TBI admitted to the ICU, the impact of these complications on mortality, and their possible correlation with TBI severity. Methods: An observational retrospective cohort study was conducted in one multidisciplinary ICU of a university hospital (35 beds); 224 consecutive adult patients with severe TBI (initial Glasgow Coma Scale (GCS) < 9) admitted to the ICU were included. Neurological and non-neurological variables were recorded. Results: Sepsis occurred in 75% of patients, respiratory infections in 68%, hypotension in 44%, severe respiratory failure (arterial oxygen pressure/oxygen inspired fraction ratio (PaO2/FiO(2)) < 200) in 41% and acute kidney injury (AKI) in 8%. The multivariate analysis showed that Glasgow Outcome Score (GOS) at one year was independently associated with age, initial GCS 3 to 5, worst Traumatic Coma Data Bank (TCDB) first computed tomography (CT) scan and the presence of intracranial hypertension but not AKI. Hospital mortality was independently associated with initial GSC 3 to 5, worst TCDB first CT scan, the presence of intracranial hypertension and AKI. The presence of AKI regardless of GCS multiplied risk of death 6.17 times (95% confidence interval (CI): 1.37 to 27.78) (P < 0.02), while ICU hypotension increased the risk of death in patients with initial scores of 3 to 5 on the GCS 4.28 times (95% CI: 1.22 to15.07) (P < 0.05). Conclusions: Low initial GCS, worst first CT scan, intracranial hypertension and AKI determined hospital mortality in severe TBI patients. Besides the direct effect of low GCS on mortality, this neurological condition also is associated with ICU hypotension which increases hospital mortality among patients with severe TBI. These findings add to previous studies that showed that non-neurological complications increase the length of stay and morbidity in the ICU but do not increase mortality, with the exception of AKI and hypotension in low GCS (3 to 5).	[Corral, Luisa; Ventura, Josep L.; Herrero, Jose I.; Manez, Rafael] Hosp Univ Bellvitge, Intens Care Unit, Barcelona 08907, Spain; [Corral, Luisa; Javierre, Casimiro F.] Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona 08907, Spain; [Marcos, Pilar] Hosp Badalona Germans Trias & Pujol, Intens Care Unit, Barcelona 08916, Spain; [Manez, Rafael] Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08907, Spain	Corral, L (corresponding author), Hosp Univ Bellvitge, Intens Care Unit, Feixa Llarga S-N, Barcelona 08907, Spain.	lcorral@bellvitgehospital.cat		Manez, Rafael/0000-0002-0884-5564; Corral, Luisa/0000-0002-2888-7833			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; Davenport A, 2010, HEMODIAL INT, V14, pS27, DOI 10.1111/j.1542-4758.2010.00487.x; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Kemp CD, 2008, AM SURGEON, V74, P866; Koutsoukou A, 2006, INTENS CARE MED, V32, P1947, DOI 10.1007/s00134-006-0406-0; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Miller JD, 1983, INTRACRANIAL PRESSUR, P44; Moore EM, 2010, RENAL FAILURE, V32, P1060, DOI 10.3109/0886022X.2010.510234; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rello J, 2011, J CRIT CARE, V26, P3, DOI 10.1016/j.jcrc.2010.04.001; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zygun D, 2005, CURR OPIN CRIT CARE, V11, P139, DOI 10.1097/01.ccx.0000155356.86241.c0; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	41	67	72	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2012	16	2							R44	10.1186/cc11243			7	Critical Care Medicine	General & Internal Medicine	066CF	WOS:000313196800010	22410278	DOAJ Gold, Green Published			2021-06-18	
J	van Heugten, C; Gregorio, GW; Wade, D				van Heugten, Caroline; Gregorio, Gisela Wolters; Wade, Derick			Evidence-based cognitive rehabilitation after acquired brain injury: A systematic review of content of treatment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injuries; Stroke; Cognition disorders; Rehabilitation; Randomised controlled trial	RANDOMIZED CONTROLLED-TRIAL; TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; HEMISPHERE STROKE PATIENTS; OF-THE-LITERATURE; SPEECH-THERAPY; UNILATERAL NEGLECT; CHRONIC APHASIA; VISUAL NEGLECT; LANGUAGE REHABILITATION	We reviewed all randomised trials on cognitive rehabilitation in order to determine the effective elements in terms of patients' and treatment characteristics, treatment goals and outcome. A total of 95 random controlled trials were included from January 1980 until August 2010 studying 4068 patients in total. Most studies had been conducted on language (n = 25), visuospatial functioning (n = 24), and memory (n = 14). Stroke patients were the commonest subjects (57%; overall mean age 52.2, SD = 15.0 years). Of the interventions 39% were offered more than 12 months after onset and 23% were offered within two months of onset. The mean (SD) number of hours of treatment actually delivered was 4.1 (3.6) per week; treatment was mostly offered individually. No papers gave specific information on the expertise or competences of the staff involved. With 95 RCTs there is a large body of evidence to support the efficacy of cognitive rehabilitation, and the current study can serve as a database for clinicians and researchers. But most studies have given little information about the actual content of the treatment which makes it difficult to use the studies when making treatment decisions in daily clinical practice. We suggest developing an international checklist to make standardised description of non-pharmacological complex interventions possible.	[van Heugten, Caroline] Maastricht Univ, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands; [Wade, Derick] Maastricht Univ, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [Wade, Derick] Oxford Ctr Enablement, Oxford, England	van Heugten, C (corresponding author), Maastricht Univ, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@maastrichtuniversity.nl		Wade, Derick/0000-0002-1188-8442			[Anonymous], 2005, CLIN REHABIL, V19, P811, DOI 10.1191/0269215505cr923ed; ANTONUCCI G, 1995, J CLIN EXP NEUROPSYC, V17, P383, DOI 10.1080/01688639508405131; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Barker-Collo SL, 2009, STROKE, V40, P3293, DOI 10.1161/STROKEAHA.109.558239; Berg I. J., 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI [DOI 10.1080/09602019108401384, 10.1080/09602019108401384]; Boutron I, 2005, J CLIN EPIDEMIOL, V58, P1233, DOI 10.1016/j.jclinepi.2005.05.004; CARTER LT, 1983, AM J OCCUP THER, V37, P320, DOI 10.5014/ajot.37.5.320; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cherney Leora R, 2003, Top Stroke Rehabil, V9, P22; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; Denes G, 1996, APHASIOLOGY, V10, P385, DOI 10.1080/02687039608248418; DICARLO LM, 1980, ARCH PHYS MED REHAB, V61, P41; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Doesborgh S, 2004, APHASIOLOGY, V18, P213, DOI 10.1080/02687030344000580; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Donkervoort M, 2001, NEUROPSYCHOL REHABIL, V11, P549, DOI 10.1080/09602010143000093; Doornhein K, 1998, NEUROPSYCHOL REHABIL, V8, P393, DOI 10.1080/713755579; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; DRUMMOND SS, 1981, J COMMUN DISORD, V14, P287, DOI 10.1016/0021-9924(81)90013-7; Edmans JA, 2000, CLIN REHABIL, V14, P230, DOI 10.1191/026921500673333145; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; FANTHOME Y, 1995, DISABIL REHABIL, V17, P413, DOI 10.3109/09638289509166654; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Geurtsen GJ, 2010, J REHABIL MED, V42, P97, DOI 10.2340/16501977-0508; Glasziou P, 2008, BMJ-BRIT MED J, V336, P1472, DOI 10.1136/bmj.39590.732037.47; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Gray J. M., 1992, NEUROPSYCHOL REHABIL, V2, P97; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hildebrandt H, 2006, J NEUROL, V253, P512, DOI 10.1007/s00415-006-0013-6; Hinckley JJ, 2001, APHASIOLOGY, V15, P463, DOI 10.1080/02687040042000340; Jacquin-Courtois S, 2010, BRAIN, V133, P895, DOI 10.1093/brain/awp327; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kang SH, 2009, CLIN REHABIL, V23, P434, DOI 10.1177/0269215508101732; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; Katz N, 2005, DISABIL REHABIL, V27, P1235, DOI 10.1080/09638280500076079; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kerner M, 1985, COGNIT REHABIL, V11, P26; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lincoln N B, 1985, Int Rehabil Med, V7, P99; LINCOLN NB, 1984, LANCET, V1, P1197; LINCOLN NB, 1984, BEHAV PSYCHOTHER, V12, P237, DOI 10.1017/S0141347300010806; LINCOLN NB, 1982, BEHAV PSYCHOTHER, V10, P162, DOI 10.1017/S0141347300007023; Luukkainen-Markkula R, 2009, RESTOR NEUROL NEUROS, V27, P663, DOI 10.3233/RNN-2009-0520; Lyon JG, 1997, APHASIOLOGY, V11, P693, DOI 10.1080/02687039708249416; MacKay S, 1988, Geriatr Nurs, V9, P177; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Man DWK, 2006, NEUROREHABILITATION, V21, P205; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; MEIKLE M, 1979, BRIT MED J, V2, P87, DOI 10.1136/bmj.2.6182.87; Meinzer M, 2007, J INT NEUROPSYCH SOC, V13, P846, DOI 10.1017/S1355617707071111; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Perera R, 2007, BRIT MED J, V334, P127, DOI 10.1136/bmj.39045.396817.68; Poggel DA, 2004, NEUROLOGY, V63, P2069, DOI 10.1212/01.WNL.0000145773.26378.E5; PRINS RS, 1989, APPL PSYCHOLINGUIST, V10, P85, DOI 10.1017/S0142716400008432; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Robertson IH, 2002, NEUROPSYCHOL REHABIL, V12, P439, DOI 10.1080/09602010244000228; Rochon E, 2005, NEUROPSYCHOL REHABIL, V15, P1, DOI 10.1080/09602010343000327; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rose FD, 1999, DISABIL REHABIL, V21, P548; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Rusconi ML, 2002, EURA MEDICOPHYS, V38, P159; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SHEWAN CM, 1984, BRAIN LANG, V23, P272, DOI 10.1016/0093-934X(84)90068-3; Smania N, 2000, ARCH PHYS MED REHAB, V81, P379, DOI 10.1053/mr.2000.6921; Smania N, 2006, NEUROLOGY, V67, P2050, DOI 10.1212/01.wnl.0000247279.63483.1f; SODERBACK I, 1988, SCAND J REHABIL MED, V20, P47; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Soong W, 2005, INT J REHABIL RES, V28, P341, DOI 10.1097/00004356-200512000-00006; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; TAYLOR M M, 1971, Archives of Physical Medicine and Rehabilitation, V52, P163; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; Thomas-Stonell N, 1994, J HEAD TRAUMA REHAB, V9, P25, DOI DOI 10.1097/00001199-199412000-00005; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tsang MHM, 2009, DISABIL REHABIL, V31, P630, DOI 10.1080/09638280802240621; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; van Hout MSE, 2008, PSYCHOTHER PSYCHOSOM, V77, P289, DOI 10.1159/000140088; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Watanabe TK, 1998, BRAIN INJURY, V12, P81; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; WEINBERG J, 1977, ARCH PHYS MED REHAB, V58, P479; WEINBERG J, 1982, Journal of Clinical Neuropsychology, V4, P59, DOI 10.1080/01688638208401117; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wiart L, 1997, ARCH PHYS MED REHAB, V78, P424, DOI 10.1016/S0003-9993(97)90236-7; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Worrall L, 2000, APHASIOLOGY, V14, P911, DOI 10.1080/02687030050127711; Zeloni G, 2002, J NEUROL NEUROSUR PS, V73, P195, DOI 10.1136/jnnp.73.2.195	107	67	67	2	59	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	5					653	673		10.1080/09602011.2012.680891			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	010UZ	WOS:000309121200001	22537117				2021-06-18	
J	Pavlov, I; Huusko, N; Drexel, M; Kirchmair, E; Sperk, G; Pitkanen, A; Walker, MC				Pavlov, I.; Huusko, N.; Drexel, M.; Kirchmair, E.; Sperk, G.; Pitkanen, A.; Walker, M. C.			PROGRESSIVE LOSS OF PHASIC, BUT NOT TONIC, GABA(A) RECEPTOR-MEDIATED INHIBITION IN DENTATE GRANULE CELLS IN A MODEL OF POST-TRAUMATIC EPILEPSY IN RATS	NEUROSCIENCE			English	Article						dentate gyrus; GAB(A) receptors; interneurons; parvalbumin; tonic inhibition; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; STATUS EPILEPTICUS; MOUSE MODEL; ALTERED EXPRESSION; HEAD TRAUMA; HIPPOCAMPUS; NEURONS; SUBUNITS; INTERNEURONS	Traumatic brain injury (TBI) is a risk factor for the development of epilepsy, which can occur months to years after the insult. The hippocampus is particularly vulnerable to the pathophysiological effects of TBI. Here, we determined whether there are long-term changes in inhibition in the dentate gyrus that could contribute to the progressive susceptibility to seizures after TBI. We used severe lateral-fluid percussion brain injury to induce TBI in rats. In this model, spontaneous seizure activity, which involves the hippocampus, appears after a long latent period, resembling the human condition. We demonstrate that synaptic GAB(A), receptor-mediated inhibition is profoundly reduced in ipsilateral dentate granule cells 1 month after TBI. Moreover, synaptic inhibition decreases over time, and by 6 months after TBI, it is also significantly decreased contralaterally. Progressive loss of synaptic inhibition is paralleled by a decline in the number of parvalbumin-positive interneurons, but, in contrast to status epilepticus models, GABA(A) receptor subunit expression is largely unaltered. At both time points, the magnitude of tonic GABA(A) receptor-mediated currents after TBI is maintained, indicating a preservation of the inhibitory constraint of granule cells through tonic inhibition. Our results extend the time window during which strategies to target epileptogenesis may be effective. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Pavlov, I.; Walker, M. C.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Huusko, N.; Pitkanen, A.] Univ Eastern Finland, Epilepsy Res Lab, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Drexel, M.; Kirchmair, E.; Sperk, G.] Med Univ Innsbruck, Dept Pharmacol, Innsbruck, Austria; [Pitkanen, A.] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland	Pavlov, I (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.	i.pavlov@ucl.ac.uk; skaamcw@ucl.ac.uk	Walker, Matthew C/C-1577-2008; Pavlov, Ivan/B-5939-2008	Walker, Matthew C/0000-0002-0812-0352; Pavlov, Ivan/0000-0002-9559-4600; Drexel, Meinrad/0000-0002-2705-9673; Pavlov, Ivan/0000-0003-1266-6988	European Integrated Project "EPICURE" [EFP6-037315]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Epilepsy Research UK [A0832]; Epilepsy Research UK [F0905] Funding Source: researchfish	We would like to thank Dr. Jari Nissinen and Mr. Jarmo Hartikainen for help with the experiments. This work was supported by the European Integrated Project "EPICURE" (EFP6-037315); the Academy of Finland to A.P.; the Sigrid Juselius Foundation to A.P. and Epilepsy Research UK Fellowship (A0832) to I.P.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brandon NJ, 2000, J BIOL CHEM, V275, P38856, DOI 10.1074/jbc.M004910200; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Cavelier P, 2005, PROG BIOPHYS MOL BIO, V87, P3, DOI 10.1016/j.pbiomolbio.2004.06.001; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; COLLINS RC, 1983, BRAIN RES, V280, P25, DOI 10.1016/0006-8993(83)91170-8; Cope DW, 2009, NAT MED, V15, P1392, DOI 10.1038/nm.2058; Coulter DA, 2007, PROG BRAIN RES, V163, P235, DOI 10.1016/S0079-6123(07)63014-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fritschy JM, 1999, NEUROCHEM INT, V34, P435, DOI 10.1016/S0197-0186(99)00040-6; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; HARTIG W, 1992, NEUROREPORT, V3, P869; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Huusko N, 2010, SOC NEUR SCI ANN M S; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kobayashi M, 2003, J NEUROSCI, V23, P2440; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lucas EK, 2010, J NEUROSCI, V30, P7227, DOI 10.1523/JNEUROSCI.0698-10.2010; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; Mann EO, 2010, NAT NEUROSCI, V13, P205, DOI 10.1038/nn.2464; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILNER TA, 1989, J COMP NEUROL, V290, P544, DOI 10.1002/cne.902900409; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; Nishimura T, 2005, NEUROSCIENCE, V134, P691, DOI 10.1016/j.neuroscience.2005.04.013; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; Pavlov I, 2009, J NEUROSCI, V29, P15341, DOI 10.1523/JNEUROSCI.2747-09.2009; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Rajasekaran K, 2010, NEUROBIOL DIS, V40, P490, DOI 10.1016/j.nbd.2010.07.016; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Scimemi A, 2005, J NEUROSCI, V25, P10016, DOI 10.1523/JNEUROSCI.2520-05.2005; Scimemi A, 2006, EUR J NEUROSCI, V24, P1157, DOI 10.1111/j.1460-9568.2006.04989.x; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhan RZ, 2009, J NEUROPHYSIOL; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	56	67	70	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 27	2011	194						208	219		10.1016/j.neuroscience.2011.07.074			12	Neurosciences	Neurosciences & Neurology	829IN	WOS:000295571900020	21840377				2021-06-18	
J	Bolander, R; Mathie, B; Bir, C; Ritzel, D; Vandevord, P				Bolander, Richard; Mathie, Blake; Bir, Cynthia; Ritzel, David; Vandevord, Pamela			Skull Flexure as a Contributing Factor in the Mechanism of Injury in the Rat when Exposed to a Shock Wave	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Blast; Injury; Mechanism; Explosion	TRAUMATIC BRAIN-INJURY; BLAST; MODEL	The manner in which energy from an explosion is transmitted into the brain is currently a highly debated topic within the blast injury community. This study was conducted to investigate the injury biomechanics causing blast-related neurotrauma in the rat. Biomechanical responses of the rat head under shock wave loading were measured using strain gauges on the skull surface and a fiber optic pressure sensor placed within the cortex. MicroCT imaging techniques were applied to quantify skull bone thickness. The strain gauge results indicated that the response of the rat skull is dependent on the intensity of the incident shock wave; greater intensity shock waves cause greater deflections of the skull. The intracranial pressure (ICP) sensors indicated that the peak pressure developed within the brain was greater than the peak side-on external pressure and correlated with surface strain. The bone plates between the lambda, bregma, and midline sutures are probable regions for the greatest flexure to occur. The data provides evidence that skull flexure is a likely candidate for the development of ICP gradients within the rat brain. This dependency of transmitted stress on particular skull dynamics for a given species should be considered by those investigating blast-related neurotrauma using animal models.	[Bolander, Richard; Mathie, Blake; Bir, Cynthia; Vandevord, Pamela] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Ritzel, David] Dyn FX Consulting Ltd, Amherstburg, ON N9V 2T5, Canada; [Vandevord, Pamela] John D Dingell VAMC, Detroit, MI 48201 USA	Vandevord, P (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	dt8583@wayne.edu; blakemathie@gmail.com; cbir@wayne.edu; dritz@dyn-fx.com; pvord@wayne.edu	VandeVord, Pamela/B-4606-2012	Bir, Cynthia/0000-0002-0777-0951	DODUnited States Department of Defense [W81XWH-08-2-0207]; Thomas J. Rumble Fellowship	We would like to thank the WSU Bioengineering Center staff and students for assisting with this project. We would also like thank Dr. Amanda Esquivel for obtaining the CT images. This project was partially funded by DOD Award Number W81XWH-08-2-0207 and the Thomas J. Rumble Fellowship.	Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON CJ, 1955, AM J PHYSIOL, V181, P471; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Henshall B, 1954, J ROYAL AERONAUT SOC, V58, P541; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Lechner R, 2010, UNFALLCHIRURG, V113, P106, DOI 10.1007/s00113-009-1732-9; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Luks FI, 2010, ACTA CHIR BELG, V110, P517, DOI 10.1080/00015458.2010.11680667; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott FW, 1916, LANCET, V1, P331; Risling Marten, 2010, Front Neurol, V1, P1, DOI 10.3389/fneur.2010.00001; Romba J., 1961, US ARMY ORDINANCE HU, P17; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765	22	67	68	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2011	39	10					2550	2559		10.1007/s10439-011-0343-0			10	Engineering, Biomedical	Engineering	841JE	WOS:000296507800008	21735320				2021-06-18	
J	Broglio, SP; Eckner, JT; Surma, T; Kutcher, JS				Broglio, Steven P.; Eckner, James T.; Surma, Tyler; Kutcher, Jeffrey S.			Post-Concussion Cognitive Declines and Symptomatology Are Not Related to Concussion Biomechanics in High School Football Players	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; concussion; cognitive decline	TRAUMATIC BRAIN-INJURY; HEAD IMPACTS; RECOVERY; ACCELERATION; SENSITIVITY; SYMPTOMS; LOCATION	Concussion is a major public health concern with nearly 4 million injuries occurring each year in the United States. In the acute post-injury stage, concussed individuals demonstrate cognitive function and motor control declines as well as reporting increased symptoms. Researchers have hypothesized that the severity of these impairments is related to impact magnitude. Using the Head Impact Telemetry System (HITS) to record head impact biomechanics, we sought to correlate pre- and post-concussive impact characteristics with declines in cognitive performance and increases in concussion-related symptoms. Over four seasons, 19 high school football athletes wearing instrumented helmets sustained 20 diagnosed concussions. Each athlete completed a baseline computer-based symptom and cognitive assessment during the pre-season and a post-injury assessment within 24 h of injury. Correlational analyses identified no significant relationships between symptoms and cognitive performance change scores and impact biomechanics (i.e., time from session start until injury, time from the previous impact, peak linear acceleration, peak rotational acceleration, and HIT severity profile [HITsp]). Nor were there any significant relationships between change scores and the number of impacts, cumulative linear acceleration, cumulative rotational acceleration, or cumulative HITsp values associated with all impacts prior to or following the injury. This investigation is the first to examine the relationship between concussion impact characteristics, including cumulative impact profiles, and post-morbid outcomes in high school athletes. There appears to be no association between head impact biomechanics and post-concussive outcomes. As such, the use of biomechanical variables to predict injury severity does not appear feasible at this time.	[Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, Ann Arbor, MI 48109 USA; [Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, 1402 Washington Hts, Ann Arbor, MI 48109 USA.	broglio@umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001097] Funding Source: Medline		Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Broglio S.P., 2011, J NEUROTRAU IN PRESS; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner J.T., 2011, J NEUROTRAU IN PRESS; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Iverson G.L., 2003, RELIABILITY VALIDITY; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell M.R, 2007, IMPACT 2007 6 0 SOFT; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	33	67	67	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2061	2068		10.1089/neu.2011.1905			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500007	21644811	Green Published			2021-06-18	
J	Windmiller, JR; Valdes-Ramirez, G; Zhou, N; Zhou, M; Miller, PR; Jin, CM; Brozik, SM; Polsky, R; Katz, E; Narayan, R; Wang, J				Windmiller, Joshua Ray; Valdes-Ramirez, Gabriela; Zhou, Nandi; Zhou, Ming; Miller, Philip R.; Jin, Chunming; Brozik, Susan M.; Polsky, Ronen; Katz, Evgeny; Narayan, Roger; Wang, Joseph			Bicomponent Microneedle Array Biosensor for Minimally-Invasive Glutamate Monitoring	ELECTROANALYSIS			English	Article						Amperometry; Biosensors; Glutamate; Microneedle; Poly(o-phenylenediamine)	TRAUMATIC BRAIN-INJURY; MODIFIED POLY(PHENYLENEDIAMINE)-COATED ELECTRODES; O-PHENYLENEDIAMINE FILM; EXCITATORY AMINO-ACIDS; GLUCOSE-OXIDASE; LACTATE BIOSENSOR; IN-VITRO; BLOOD; INTERFERENCE; EXTRACTION	This article describes the design of a new and attractive minimally-invasive bicomponent microneedle sensing device for the electrochemical monitoring of the excitatory neurotransmitter glutamate and glucose. The new device architecture relies on the close integration of solid and hollow microneedles into a single biosensor array device containing multiple microcavities. Such microcavities facilitate the electropolymeric entrapment of the recognition enzyme within each microrecess. The resulting microneedle biosensor array can be employed as a minimally-invasive on-body transdermal patch, obviating the extraction/sampling of the biological fluid, thereby simplifying device requirements. The new concept is demonstrated for the electropolymeric entrapment of glutamate oxidase and glucose oxidase within a poly(o-phenylenediamine) (PPD) thin film. The PPD-based enzyme entrapment methodology enables the effective rejection of coexisting electroactive interferents without compromising the sensitivity or response time of the device. The resulting microneedle-based glutamate and glucose biosensors thus exhibit high selectivity, sensitivity, speed, and stability in both buffer and undiluted human serum. High-fidelity glutamate measurements down to the 10 mu M level are obtained in serum. The attractive recess design also serves to protect the enzyme layer upon insertion into the skin. This simple, yet robust microneedle design is well-suited for diverse biosensing applications in which real-time metabolite monitoring is a core requirement.	[Miller, Philip R.; Jin, Chunming; Narayan, Roger] Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27695 USA; [Windmiller, Joshua Ray; Valdes-Ramirez, Gabriela; Zhou, Nandi; Zhou, Ming; Wang, Joseph] Univ Calif San Diego, Dept Nano Engn, La Jolla, CA 92093 USA; [Brozik, Susan M.; Polsky, Ronen] Sandia Natl Labs, Dept Biosensors & Nanomat, Albuquerque, NM 87185 USA; [Katz, Evgeny] Clarkson Univ, Dept Chem, Potsdam, NY 13699 USA	Narayan, R (corresponding author), Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27695 USA.	roger_narayan@unc.edu; josephwang@ucsd.edu	Wang, Joseph/C-6175-2011; Zhou, Ming/B-7451-2009; Zhou, Nandi/C-5111-2011; Valdes-Ramirez, Gabriela/D-2053-2012	Zhou, Ming/0000-0003-2239-9342; Zhou, Nandi/0000-0002-2906-7781; Valdes Ramirez, Gabriela/0000-0002-9566-930X	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]; National Science FoundationNational Science Foundation (NSF) [0547491]; Sandia National LaboratoriesUnited States Department of Energy (DOE); United States Department of Energy's National Nuclear Security AdministrationNational Nuclear Security Administration [DE-SC0004937, DE-AC04-94AL85000]; Mexican government; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [20805020]; Chinese Ministry of EducationMinistry of Education, China [109079]	This work was supported by the Office of Naval Research (Award No. N00014-08-1-1202), the National Science Foundation (Award No. 0547491), the Laboratory Directed Research and Development program at Sandia National Laboratories, and the United States Department of Energy's National Nuclear Security Administration (Grant Number DE-SC0004937) under Contract DE-AC04-94AL85000. G. V. R. acknowledges a CONACyT post-doctoral fellowship from the Mexican government. N. Z. acknowledges support from the National Natural Science Foundation of China (Award No. 20805020) and the Key Project of the Chinese Ministry of Education (Award No. 109079).	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BERNERS MOM, 1994, ANAL CHEM, V66, P2017, DOI 10.1021/ac00085a016; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Cosnier S, 2003, ANAL BIOANAL CHEM, V377, P507, DOI 10.1007/s00216-003-2131-7; DeBenedetto GE, 1996, BIOSENS BIOELECTRON, V11, P1001, DOI 10.1016/0956-5663(96)87659-7; DEMPSEY E, 1993, TALANTA, V40, P445, DOI 10.1016/0039-9140(93)80257-R; Gittard Shaun D., 2009, Biotechnology Journal, V4, P129, DOI 10.1002/biot.200800233; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GRIFFITHS T, 1984, J NEUROTRAUM, V15, P253; Henry C, 1998, ANAL CHEM, V70, p594A; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; LEUCHTNER RE, 1992, SURF COAT TECH, V51, P476, DOI 10.1016/0257-8972(92)90285-I; LOWRY JP, 1994, ELECTROANAL, V6, P369, DOI 10.1002/elan.1140060504; LOWRY JP, 1994, ANAL CHEM, V66, P1754, DOI 10.1021/ac00082a025; MALITESTA C, 1990, ANAL CHEM, V62, P2735, DOI 10.1021/ac00223a016; McAteer K, 1996, ANALYST, V121, P773, DOI 10.1039/an9962100773; McMahon CP, 2006, ANAL CHEM, V78, P2352, DOI 10.1021/ac0518194; Miller PR, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3569945; Mukerjee E, 2004, SENSOR ACTUAT A-PHYS, V114, P267, DOI 10.1016/j.sna.2003.11.008; Opitz T, 1994, NEUROPSYCHOPHARMACOL, V11, P278; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMISANO F, 1994, BIOSENS BIOELECTRON, V9, P471, DOI 10.1016/0956-5663(94)90009-4; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Ryan MR, 1997, ANALYST, V122, P1419, DOI 10.1039/a704508e; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; Tsuchiya K, 2005, BIOMED MICRODEVICES, V7, P347, DOI 10.1007/s10544-005-6077-8; Valencia E, 2002, NUTRITION, V18, P367, DOI 10.1016/S0899-9007(02)00774-8; Wang J, 2008, CHEM REV, V108, P814, DOI 10.1021/cr068123a; Windmiller JR, 2011, ANALYST, V136, P1846, DOI 10.1039/c1an00012h; Yang QL, 1999, BIOSENS BIOELECTRON, V14, P203, DOI 10.1016/S0956-5663(98)00109-2; ZILKHA E, 1995, J NEUROSCI METH, V40, P1	35	67	68	4	98	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1040-0397			ELECTROANAL	Electroanalysis	OCT	2011	23	10					2302	2309		10.1002/elan.201100361			8	Chemistry, Analytical; Electrochemistry	Chemistry; Electrochemistry	839WC	WOS:000296399200007					2021-06-18	
J	Chen, HI; Stiefel, MF; Oddo, M; Milby, AH; Maloney-Wilensky, E; Frangos, S; Levine, JM; Kofke, WA; LeRoux, PD				Chen, H. Isaac; Stiefel, Michael F.; Oddo, Mauro; Milby, Andrew H.; Maloney-Wilensky, Eileen; Frangos, Suzanne; Levine, Joshua M.; Kofke, W. Andrew; LeRoux, Peter D.			Detection of Cerebral Compromise With Multimodality Monitoring in Patients With Subarachnoid Hemorrhage	NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral metabolism; Cerebral microdialysis; Lactate/pyruvate ratio; Multimodality monitoring; Subarachnoid hemorrhage	BRAIN-TISSUE OXYGEN; RESPIRATORY-DISTRESS-SYNDROME; LACTATE-PYRUVATE RATIO; BLOOD-FLOW; INTRACRANIAL-PRESSURE; LACTATE/PYRUVATE RATIO; BEDSIDE MICRODIALYSIS; NEUROLOGICAL DEFICITS; NEUROCRITICAL CARE; PERFUSION-PRESSURE	BACKGROUND: Studies in traumatic brain injury suggest that monitoring techniques such as brain tissue oxygen (PBTO2) and cerebral microdialysis may complement conventional intracranial pressure (ICP) and cerebral perfusion pressure (CPP) measurements. OBJECTIVE: In this study of poor-grade (Hunt and Hess grade IV and V) subarachnoid hemorrhage (SAH) patients, we examined the prevalence of brain hypoxia and brain energy dysfunction in the presence of normal and abnormal ICP and CPP. METHODS: SAH patients who underwent multimodal neuromonitoring and cerebral microdialysis were studied. We examined the frequency of brain hypoxia and energy dysfunction in different ICP and CPP ranges and the relationship between PBTO2 and the lactate/pyruvate ratio (LPR). RESULTS: A total of 2394 samples from 19 patients were analyzed. There were 149 samples with severe brain hypoxia (PBTO2 <= 10 mm Hg) and 347 samples with brain energy dysfunction (LPR > 40). The sensitivities of abnormal ICP or CPP for elevated LPR and reduced PBTO2 were poor (21.2% at best), and the LPR or PBTO2 was abnormal in many instances when ICP or CPP was normal. Severe brain hypoxia was often associated with an LPR greater than 40 (86% of samples). In contrast, mild brain hypoxia (<= 20 mm Hg) and severe brain hypoxia were observed in only 53% and 36% of samples with brain energy dysfunction, respectively. CONCLUSION: Our data demonstrate that ICP and CPP monitoring may not always detect episodes of cerebral compromise in SAH patients. Our data suggest that several complementary monitors may be needed to optimize the care of poor-grade SAH patients.	[Chen, H. Isaac; Stiefel, Michael F.; Oddo, Mauro; Maloney-Wilensky, Eileen; Frangos, Suzanne; Levine, Joshua M.; Kofke, W. Andrew; LeRoux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kofke, W. Andrew] Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Milby, Andrew H.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	LeRoux, PD (corresponding author), Penn Hosp, Dept Neurosurg, Washington Sq W Bldg,235 S 8th St, Philadelphia, PA 19106 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	SICPA Foundation, Switzerland; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This research was supported in part by research grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adamides AA, 2009, J AM COLL SURGEONS, V209, P531, DOI 10.1016/j.jamcollsurg.2009.05.028; Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Barth M, 2010, NEUROCRIT CARE, V12, P234, DOI 10.1007/s12028-009-9287-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bjerring PN, 2008, NEUROCRIT CARE, V9, P3, DOI 10.1007/s12028-008-9060-4; Carles M, 2008, BRIT J ANAESTH, V100, P29, DOI 10.1093/bja/aem321; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dai YL, 2010, CARDIOVASC TOXICOL, V10, P130, DOI 10.1007/s12012-010-9071-1; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jahromi BS, 2004, MANAGEMENT CEREBRAL, P455; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Khaldi A, 2001, NEUROSURGERY, V49, P33; KOGURE K, 1975, AM J PHYSIOL, V228, P1862; Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Levy B, 1997, INTENS CARE MED, V23, P282, DOI 10.1007/s001340050329; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Maloney-Wilensky E, 2010, CHILD NERV SYST, V26, P419, DOI 10.1007/s00381-009-1037-x; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MICHENFELDER JD, 1975, AM J PHYSIOL, V229, P1050; MICHENFELDER JD, 1977, ANESTHESIOLOGY, V46, P196, DOI 10.1097/00000542-197703000-00007; Mileski WJ, 2004, J TRAUMA, V56, P472; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Nakasaki H, 1997, NUTRITION, V13, P110, DOI 10.1016/S0899-9007(96)00384-X; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Raabe A, 2005, J NEUROSURG, V103, P974, DOI 10.3171/jns.2005.103.6.0974; Ramakrishna R, 2008, J NEUROSURG, V109, P1075, DOI 10.3171/JNS.2008.109.12.1075; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stein Sherman C, 2006, Neurosurg Focus, V21, pE2; Stiefel MF, 2004, J NEUROSURG, V101, P594, DOI 10.3171/jns.2004.101.4.0594; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tinsa Faten, 2009, Tunis Med, V87, P159; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307; Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Winn HR., 2004, MANAGEMENT CEREBRAL, P303	80	67	68	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2011	69	1					53	63		10.1227/NEU.0b013e3182191451			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	773XK	WOS:000291344700033	21796073				2021-06-18	
J	Iverson, KM; Hendricks, AM; Kimerling, R; Krengel, M; Meterko, M; Stolzmann, KL; Baker, E; Pogoda, TK; Vasterling, JJ; Lew, HL				Iverson, Katherine M.; Hendricks, Ann M.; Kimerling, Rachel; Krengel, Maxine; Meterko, Mark; Stolzmann, Kelly L.; Baker, Errol; Pogoda, Terri K.; Vasterling, Jennifer J.; Lew, Henry L.			Psychiatric Diagnoses and Neurobehavioral Symptom Severity among OEF/OIF VA Patients with Deployment-Related Traumatic Brain Injury: A Gender Comparison	WOMENS HEALTH ISSUES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; HEALTH-CARE; VETERANS; IRAQ; AFGHANISTAN; WAR; WOMEN; ORGANIZATION; DEPRESSION; OUTCOMES	Background: Traumatic brain injury (TBI) has substantial negative implications for the post-deployment adjustment of veterans who served in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF); however, most research on veterans has focused on males. This study investigated gender differences in psychiatric diagnoses and neurobehavioral symptom severity among OEF/OIF veterans with deployment-related TBI. Methods: This population-based study examined psychiatric diagnoses and self-reported neurobehavioral symptom severity from administrative records for 12,605 United States OEF/OIF veterans evaluated as having deployment-related TBI. Men (n = 11,951) and women (n = 654) who were evaluated to have deployment-related TBI during a standardized comprehensive TBI evaluation in Department of Veterans Affairs facilities were compared on the presence of psychiatric diagnoses and severity of neurobehavioral symptoms. Findings: Posttraumatic stress disorder (PTSD) was the most common psychiatric condition for both genders, although women were less likely than men to have a PTSD diagnosis. In contrast, relative to men, women were 2 times more likely to have a depression diagnosis, 1.3 times more likely to have a non-PTSD anxiety disorder, and 1.5 times more likely to have PTSD with comorbid depression. Multivariate analyses indicated that blast exposure during deployment may account for some of these differences. Additionally, women reported significantly more severe symptoms across a range of neurobehavioral domains. Conclusion: Although PTSD was the most common condition for both men and women, it is also critical for providers to identify and treat other conditions, especially depression and neurobehavioral symptoms, among women veterans with deployment-related TBI. Published by Elsevier Inc.	[Iverson, Katherine M.; Vasterling, Jennifer J.] VA Boston Healthcare Syst, Psychol Serv, WHSD NCPTSD 116B 3, Boston, MA 02130 USA; [Iverson, Katherine M.] Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA; [Iverson, Katherine M.; Meterko, Mark; Stolzmann, Kelly L.; Baker, Errol; Pogoda, Terri K.] Ctr Org Leadership & Management Res, Boston, MA USA; [Iverson, Katherine M.; Krengel, Maxine; Vasterling, Jennifer J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Hendricks, Ann M.; Meterko, Mark; Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA; [Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Univ Richmond, Sch Med, Dept PM&R, Richmond, VA 23173 USA	Iverson, KM (corresponding author), VA Boston Healthcare Syst, Psychol Serv, WHSD NCPTSD 116B 3, 150 S Huntington Ave, Boston, MA 02130 USA.	Katherine.lverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780; Krengel, Maxine/0000-0001-7632-590X; Kimerling, Rachel/0000-0003-0996-4212	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836, T32 MH019836-14, T32 MH019836] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: NIH RePORTER		Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CHARD KM, J TRAUMATIC IN PRESS; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Department of Veterans Affairs Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FARACE E, 2000, NEUROSURG FOCUS, V8, P1, DOI DOI 10.3171/F0C.2000.8.1.152; French LM, 2011, CLIN MANUAL MANAGEME, P383; HENDRICKS A, 2011, NAT HSR D C WASH DC; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Iverson K. M, 2011, CLIN MANUAL MANAGEME, P157; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kimerling R., 2007, HDB PTSD, P207; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Marino SE, 2009, EPILEPSY BEHAV, V14, P459, DOI 10.1016/j.yebeh.2008.12.007; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; METERKO M, 2011, PSYCHOMETRIC A UNPUB; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murdoch M, 2006, J GEN INTERN MED, V21, pS5, DOI 10.1111/j.1525-1497.2006.00368.x; National Center for Mental Health Statistics and the Centers for Medicare & Medicaid Services, 2008, INT CLASS DIS 9 REV; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Resick PA, 2010, COGNITIVE PROCESSING; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Yano EM, 2010, J GEN INTERN MED, V25, P56, DOI 10.1007/s11606-009-1116-4; Yano EM, 2003, WOMEN HEALTH ISS, V13, P55, DOI 10.1016/S1049-3867(02)00198-6	35	67	67	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1049-3867			WOMEN HEALTH ISS	Womens Health Iss.	JUL-AUG	2011	21	4		S	SI		S210	S217		10.1016/j.whi.2011.04.019			8	Public, Environmental & Occupational Health; Women's Studies	Public, Environmental & Occupational Health; Women's Studies	792YA	WOS:000292785100022	21724143	Green Accepted			2021-06-18	
J	Wang, YG; Neumann, M; Hansen, K; Hong, SM; Kim, S; Noble-Haeusslein, LJ; Liu, JL				Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Noble-Haeusslein, Linda J.; Liu, Jialing			Fluoxetine Increases Hippocampal Neurogenesis and Induces Epigenetic Factors But Does Not Improve Functional Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; histone acetylation; memory; methyl-CpG binding domain 1; selective serotonin reuptake inhibitor	HISTONE H3 ACETYLATION; SYNAPTIC PLASTICITY; COGNITIVE DEFICITS; GENE-EXPRESSION; MOTOR RECOVERY; ANIMAL-MODEL; TERM-MEMORY; ADULT; 5-HT1A; IMPAIRMENT	The selective serotonin reuptake inhibitor fluoxetine induces hippocampal neurogenesis, stimulates maturation and synaptic plasticity of adult hippocampal neurons, and reduces motor/sensory and memory impairments in several CNS disorders. In the setting of traumatic brain injury (TBI), its effects on neuroplasticity and function have yet to be thoroughly investigated. Here we examined the efficacy of fluoxetine after a moderate to severe TBI, produced by a controlled cortical impact. Three days after TBI or sham surgery, mice were treated with fluoxetine (10 mg/kg/d) or vehicle for 4 weeks. To evaluate the effects of fluoxetine on neuroplasticity, hippocampal neurogenesis and epigenetic modification were studied. Stereologic analysis of the dentate gyrus revealed a significant increase in doublecortin-positive cells in brain-injured animals treated with fluoxetine relative to controls, a finding consistent with enhanced hippocampal neurogenesis. Epigenetic modifications, including an increase in histone 3 acetylation and induction of methyl-CpG-binding protein, a transcription factor involved in DNA methylation, were likewise seen by immunohistochemistry and quantitative Western immunoblots, respectively, in brain-injured animals treated with fluoxetine. To determine if fluoxetine improves neurological outcomes after TBI, gait function and spatial learning and memory were assessed by the CatWalk-assisted gait test and Barnes maze test, respectively. No differences in these parameters were seen between fluoxetine- and vehicle-treated animals. Thus while fluoxetine enhanced neuroplasticity in the hippocampus after TBI, its chronic administration did not restore locomotor function or ameliorate memory deficits.	[Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Noble-Haeusslein, Linda J.; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94121 USA; [Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA; [Wang, Yonggang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol Surg, Beijing, Peoples R China; [Neumann, Melanie] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	VA Merit awardUS Department of Veterans Affairs; Department of Defense collaborative in Neuroscience Center of ExcellenceUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This work was supported by a VA Merit award (to J.L.), and a Department of Defense collaborative in Neuroscience Center of Excellence (to J.L.).	Beauquis J, 2009, ANN NY ACAD SCI, V1153, P203, DOI 10.1111/j.1749-6632.2008.03983.x; Berends HI, 2009, CLIN NEUROPHARMACOL, V32, P1, DOI 10.1097/wnf.0b013e3181633482; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Boast C, 1999, NEUROBIOL LEARN MEM, V71, P259, DOI 10.1006/nlme.1998.3886; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Carli M, 1997, BRAIN RES, V774, P167, DOI 10.1016/S0006-8993(97)81700-3; CARLI M, 1992, BRAIN RES, V595, P50, DOI 10.1016/0006-8993(92)91451-J; CARLI M, 1992, BRIT J PHARMACOL, V105, P720, DOI 10.1111/j.1476-5381.1992.tb09045.x; Cassel S, 2006, MOL PHARMACOL, V70, P487, DOI 10.1124/mol.106.022301; CHEN Y, 1995, BRAIN RES BULL, V38, P153, DOI 10.1016/0361-9230(95)00082-P; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017; Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Holick KA, 2008, NEUROPSYCHOPHARMACOL, V33, P406, DOI 10.1038/sj.npp.1301399; Jin Y, 2009, BRAIN RES, V1281, P108, DOI 10.1016/j.brainres.2009.04.053; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kennard LE, 2005, BRIT J PHARMACOL, V144, P821, DOI 10.1038/sj.bjp.0706068; Kong EKC, 2002, NEUROCHEM RES, V27, P113, DOI 10.1023/A:1014862808126; Levenson JM, 2006, CELL MOL LIFE SCI, V63, P1009, DOI 10.1007/s00018-006-6026-6; Li WL, 2009, J NEUROSCI RES, V87, P112, DOI 10.1002/jnr.21829; Liang KC, 1998, CHINESE J PHYSIOL, V41, P33; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; Meneses A, 2002, CELL MOL NEUROBIOL, V22, P675, DOI 10.1023/A:1021800822997; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Miller CA, 2010, NAT NEUROSCI, V13, P664, DOI 10.1038/nn.2560; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mostert JP, 2008, CNS NEUROSCI THER, V14, P153, DOI 10.1111/j.1527-3458.2008.00040.x; Mowla A, 2007, J CLIN PSYCHOPHARM, V27, P67, DOI 10.1097/jcp.0b013e31802e0002; Nahon E, 2005, FEBS LETT, V579, P5105, DOI 10.1016/j.febslet.2005.08.020; Narushima K, 2007, BRIT J PSYCHIAT, V190, P260, DOI 10.1192/bjp.bp.106.025064; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Ouardouz M, 2005, NEUROPHARMACOLOGY, V48, P566, DOI 10.1016/j.neuropharm.2004.12.007; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Patterson DE, 1997, BRAIN INJURY, V11, P287, DOI 10.1080/026990597123593; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Richardson-Jones JW, 2010, NEURON, V65, P40, DOI 10.1016/j.neuron.2009.12.003; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Svenningsson P, 2005, AAPS J, V7, DOI 10.1208/aapsj070235; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wilson MA, 2002, FUEL, V81, P5, DOI 10.1016/S0016-2361(00)00192-7; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; ZHANG XH, 1993, NEUROREPORT, V4, P1235, DOI 10.1097/00001756-199309000-00006	57	67	68	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					259	268		10.1089/neu.2010.1648			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700009	21175261	Green Published			2021-06-18	
J	Lester, P; Mogil, C; Saltzman, W; Woodward, K; Nash, W; Leskin, G; Bursch, B; Green, S; Pynoos, R; Beardslee, W				Lester, Patricia; Mogil, Catherine; Saltzman, William; Woodward, Kirsten; Nash, William; Leskin, Gregoty; Bursch, Brenda; Green, Sara; Pynoos, Robert; Beardslee, William			Families Overcoming Under Stress: Implementing Family-Centered Prevention for Military Families Facing Wartime Deployments and Combat Operational Stress	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CHILD MALTREATMENT; MENTAL-HEALTH; LOW-INCOME; PARENTS; INTERVENTION; VETERANS; RISK; WAR; ADOLESCENTS	The toll of multiple and prolonged deployments on families has become clearer in recent years as military families have seen an increase in childhood anxiety, parental psychological distress, and marital discord. Families overcoming under stress (FOCUS), a family-centered evidence-informed resiliency training program developed at University of California, Los Angeles and Harvard Medical School, is being implemented at military installations through an initiative from Navy Bureau of Medicine and Surgery. The research foundation for FOCUS includes evidence-based preventive interventions that were adapted to meet the specific needs of military families facing combat operational stress associated with wartime deployments. Using a family narrative approach, FOCUS includes a customized approach utilizing core intervention components, including psychoeducation, emotional regulation skills, goal setting and problem solving skills, traumatic stress reminder management techniques, and family communication skills. The purpose of this study is to describe the development and implementation of FOCUS for military families. A case example is also presented.	[Lester, Patricia; Mogil, Catherine; Saltzman, William; Leskin, Gregoty; Bursch, Brenda; Green, Sara; Pynoos, Robert] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA; [Woodward, Kirsten] US Bur Navy Med & Surg, Washington, DC 20372 USA; [Nash, William] UCSD, VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Beardslee, William] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02215 USA	Lester, P (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room A8-159, Los Angeles, CA 90024 USA.				Unites States Department of Navy Bureau Medicine and Surgery (BUMED) [N00189-09-C-Z057]; Frederick R. Weisman Philanthropic Foundation and Discretionary Trust	FOCUS has been supported by resources from the Unites States Department of Navy Bureau Medicine and Surgery (BUMED; contract no. N00189-09-C-Z057) and the Frederick R. Weisman Philanthropic Foundation and Discretionary Trust.	Baker DG, 2009, MIL MED, V174, P773; Beardslee WR, 2007, J FAM PSYCHOL, V21, P703, DOI 10.1037/0893-3200.21.4.703; Beardslee WR, 2003, PEDIATRICS, V112, pE119, DOI 10.1542/peds.112.2.e119; Beardslee WR, 2009, ZERO 3, V29, P34; Chandra A., 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Compas BE, 1989, PRIMARY PREVENTION P, P60; D'Angelo EJ, 2009, FAM PROCESS, V48, P269, DOI 10.1111/j.1545-5300.2009.01281.x; Department of Defense Task Force on Mental Health, 2007, ARCH VIS REP DEP DEF; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Faber AJ, 2008, J FAM PSYCHOL, V22, P222, DOI 10.1037/0893-3200.22.2.222; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Hoge CQ, 2004, NEW ENGL J MED, V351, P2471; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; Jensen PS, 1996, J AM ACAD CHILD PSY, V35, P433, DOI 10.1097/00004583-199604000-00009; Layne CM, 2008, J AM ACAD CHILD PSY, V47, P1048, DOI 10.1097/CHI.0b013e31817eecae; Lester P., 2008, EVIDENCE BASED TREAT, P170; Lester P, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P149, DOI 10.1007/978-1-4419-7064-0_8; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lincoln A, 2008, J CLIN PSYCHOL, V64, P984, DOI 10.1002/jclp.20520; Luthar S, 2006, DEV PSYCHOPATHOL, V3, P740; McCarroll JE, 2008, CHILD ABUSE REV, V17, P108, DOI 10.1002/car.986; Mrazek PJ, 1994, RED RISKS MENT DIS F; Nash WP, 2011, PSYCHOSOC STRES, P33; Nash WP, OPERATIONAL IN PRESS; O'Connell M.E., 2009, PREV MENT EM BEH DIS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Palmer C, 2008, MIL PSYCHOL, V20, P205, DOI 10.1080/08995600802118858; PATTERSON JM, 1987, J ADOLESCENCE, V10, P163, DOI 10.1016/S0140-1971(87)80086-6; Podorefsky DL, 2001, J AM ACAD CHILD PSY, V40, P879, DOI 10.1097/00004583-200108000-00008; Reger GM, 2009, TELEMED J E-HEALTH, V15, P101, DOI 10.1089/tmj.2008.0050; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Rotheram-Borus MJ, 2004, ARCH PEDIAT ADOL MED, V158, P742, DOI 10.1001/archpedi.158.8.742; Rotheram-Borus MJ, 2001, J CONSULT CLIN PSYCH, V69, P763, DOI 10.1037//0022-006X.69.5.763; Rotherarn-Borus MJ, 2003, AIDS, V17, P1217, DOI 10.1097/01.aids.0000060337.12269.1d; Saltzman WR, 2009, FOCUS MILITARY UNPUB; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Solantaus T., 2009, INT J MENT HEALTH PR, V11, P15, DOI [10.1080/14623730.2009.9721796, DOI 10.1080/14623730.2009.9721796]; Waldrep DA, 2004, IRAQ WAR CLIN GUIDE, P83	44	67	67	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JAN	2011	176	1					19	25		10.7205/MILMED-D-10-00122			7	Medicine, General & Internal	General & Internal Medicine	703XS	WOS:000286015800005	21305955	Bronze			2021-06-18	
J	Feng, Y; Abney, TM; Okamoto, RJ; Pless, RB; Genin, GM; Bayly, PV				Feng, Y.; Abney, T. M.; Okamoto, R. J.; Pless, R. B.; Genin, G. M.; Bayly, P. V.			Relative brain displacement and deformation during constrained mild frontal head impact	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						traumatic brain injury; displacement; deformation; magnetic resonance imaging; image registration	MOTION; CALVARIUM; INJURY	This study describes the measurement of fields of relative displacement between the brain and the skull in vivo by tagged magnetic resonance imaging and digital image analysis. Motion of the brain relative to the skull occurs during normal activity, but if the head undergoes high accelerations, the resulting large and rapid deformation of neuronal and axonal tissue can lead to long-term disability or death. Mathematical modelling and computer simulation of acceleration-induced traumatic brain injury promise to illuminate the mechanisms of axonal and neuronal pathology, but numerical studies require knowledge of boundary conditions at the brain-skull interface, material properties and experimental data for validation. The current study provides a dense set of displacement measurements in the human brain during mild frontal skull impact constrained to the sagittal plane. Although head motion is dominated by translation, these data show that the brain rotates relative to the skull. For these mild events, characterized by linear decelerations near 1.5g (g = 9.81 m s(-2)) and angular accelerations of 120-140 rad s(-2), relative brain-skull displacements of 2-3 mm are typical; regions of smaller displacements reflect the tethering effects of brain-skull connections. Strain fields exhibit significant areas with maximal principal strains of 5 per cent or greater. These displacement and strain fields illuminate the skull-brain boundary conditions, and can be used to validate simulations of brain biomechanics.	[Feng, Y.; Abney, T. M.; Okamoto, R. J.; Genin, G. M.; Bayly, P. V.] Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA; [Bayly, P. V.] Dept Biomed Engn, St Louis, MO 63130 USA; [Pless, R. B.] Dept Comp Sci & Engn, St Louis, MO 63130 USA	Bayly, PV (corresponding author), Dept Mech Aerosp & Struct Engn, St Louis 1 Brookings Dr,Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu	Feng, Yuan/C-7417-2011; Pless, Robert B/I-4698-2013	Feng, Yuan/0000-0003-1902-3408; Okamoto, Ruth/0000-0002-3085-3878; Bayly, Philip/0000-0003-4303-0704	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055951, HL079165]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K25HL079165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS055951, R01NS055951] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance of Richard Nagel in acquisition of tagged MR images. Funding for the study was provided by the National Institutes of Health grants NS055951 and HL079165.	AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; GOSCH H H, 1969, Surgical Forum (Chicago), V20, P425; Hardy W N, 2001, Stapp Car Crash J, V45, P337; HODGSON VR, 1966, J NEUROSURG, V25, P549, DOI 10.3171/jns.1966.25.5.0549; Ivancevic VG, 2009, COGN NEURODYNAMICS, V3, P281, DOI 10.1007/s11571-008-9070-0; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; SHATSKY SA, 1974, P 18 STAPP CAR CRASH, P351; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STALNAKER RL, 1977, P 21 STAPP CAR CRASH, P305; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	23	67	69	0	16	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	DEC 6	2010	7	53					1677	1688		10.1098/rsif.2010.0210			12	Multidisciplinary Sciences	Science & Technology - Other Topics	673KT	WOS:000283660900003	20504801	Green Published			2021-06-18	
J	Haseler, CM; Carmont, MR; England, M				Haseler, Christine M.; Carmont, Michael R.; England, Michael			The epidemiology of injuries in English youth community rugby union	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TACKLE INJURIES; FOOTBALL; SCHOOL; PLAYERS	Introduction Recent studies report the incidence and epidemiology of injury in professional rugby union; however, there is limited research in amateur and youth rugby. Injuries in youth rugby may have consequences for sports participation and physical development. The authors performed a prospective cohort study of injuries during youth community rugby. Methods An injury surveillance programme was established for the 2008-2009 season (9 months, 1636 player-hours) of an English community rugby club. The study included 210 players, all males, in Under 9 to Under 17 (U9-U17) age groups. These were categorised into mini, junior, pubertal and school participation age groupings. Injuries were defined according to the International Rugby Board consensus statements. Results There were 39 injuries reported (overall injury rate 24/1000 player-hours). Injury rates ranged from 0 to 49.3/1000 player-hours. More injuries occurred in junior (34.2/1000 player-hours) than in minis (11.9/1000 player-hours) (p<0.025). Higher numbers of moderate (20.6/1000 player-hours, p<0.005) and severe (9.5/1000 player-hours, p<0.05) injuries occurred in the U16-U17 age groups compared with younger age groups (U9-U10) where only minor injuries were reported. Most injuries occurred in the tackle (59%). The knee (4.9/1000 player-hours), shoulder (4.9/1000 player-hours) and head (4.3/1000 player-hours) were the most commonly affected areas. Concussion (1.8/1000 player-hours) affected half of the head injuries. Conclusions Injuries in youth rugby occur infrequently and are lower than in adult series. The risk of injury and severity of injury increases with age. This study highlights the need for further research into injury risk factors around puberty and the need for first aid provision.	[Haseler, Christine M.] Univ Bath, Ctr Hlth & Exercise Sci, Bath BA2 7AY, Avon, England; [Carmont, Michael R.] Princess Royal Hosp, Telford TF6 6TF, Shrops, England; [England, Michael] Rugby Football Union, Twickenham, England	Haseler, CM (corresponding author), Springbank, Springbank Surg, Cheltenham GL51 0LG, Glos, England.	christinehas@doctors.org.uk					Abernethy L, 2003, BRIT J SPORT MED, V37, P354, DOI 10.1136/bjsm.37.4.354; Adams DG, 2001, SPORTS MED SPECIFIC, P95, DOI DOI 10.1136/BJSM.2006.033282; Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Boreham C., 2001, SPORTS MED SPECIFIC, P65, DOI DOI 10.1136/BJSM.2008.050864; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; BROOKS JH, 2006, AM J SPORT MED, V38, pS351, DOI DOI 10.1177/0363546508316768; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; DALLEY DR, 1982, NZ J SPORTS MED, V10, P5; Damore DT, 2003, PEDIATR EMERG CARE, V19, P65, DOI 10.1097/00006565-200304000-00001; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Emery CA, 2010, BRIT J SPORT MED, V44, P64, DOI 10.1136/bjsm.2009.068353; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Price RJ, 2004, BRIT J SPORT MED, V38, P466, DOI 10.1136/bjsm.2003.005165; Pringle RG, 1998, BRIT J SPORT MED, V32, P49, DOI 10.1136/bjsm.32.1.49; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; ROUX CE, 1987, S AFR MED J, V71, P307; SCARAMELLA TJ, 1978, PSYCHOSOM MED, V40, P262, DOI 10.1097/00006842-197805000-00007; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; Sparks J P, 1985, Br J Sports Med, V19, P71; Sparks J P, 1981, Br J Sports Med, V15, P30; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	34	67	69	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2010	44	15					1093	1099		10.1136/bjsm.2010.074021			7	Sport Sciences	Sport Sciences	696CW	WOS:000285420500005	20961921				2021-06-18	
J	Li, W; Lopez, L; Osher, J; Howard, JD; Parrish, TB; Gottfried, JA				Li, Wen; Lopez, Leonardo; Osher, Jason; Howard, James D.; Parrish, Todd B.; Gottfried, Jay A.			Right Orbitofrontal Cortex Mediates Conscious Olfactory Perception	PSYCHOLOGICAL SCIENCE			English	Article						olfactory perception; consciousness; orbitofrontal cortex; lesion	PREFRONTAL CORTEX; POSTTRAUMATIC ANOSMIA; TEMPORAL LOBECTOMY; HUMAN PIRIFORM; DISCRIMINATION; BRAIN; IDENTIFICATION; HUMANS; SMELL; ORGANIZATION	Understanding how the human brain translates sensory impressions into conscious percepts is a key challenge of neuroscience research. Work in this area has overwhelmingly centered on the conscious experience of vision at the exclusion of the other senses-in particular, smell. We hypothesized that the orbitofrontal cortex (OFC) is a central substrate for olfactory conscious experience because of its privileged physiological role in odor processing. Combining functional magnetic resonance imaging, peripheral autonomic recordings, and olfactory psychophysics, we studied a case of complete anosmia (smell loss) in a patient with circumscribed traumatic brain injury to the right OFC. Despite a complete absence of conscious olfaction, the patient exhibited robust "blind smell," as indexed by reliable odor-evoked neural activity in the left OFC and normal autonomic responses to odor hedonics during presentation of stimuli to the left nostril. These data highlight the right OFC's critical role in subserving human olfactory consciousness.	[Li, Wen] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA; [Li, Wen] Univ Wisconsin, Waisman Inst, Madison, WI 53706 USA; [Lopez, Leonardo; Osher, Jason; Parrish, Todd B.; Gottfried, Jay A.] Northwestern Univ, Cognit Neurol & Alzheimers Dis Ctr, Evanston, IL 60208 USA; [Howard, James D.; Gottfried, Jay A.] Northwestern Univ, Dept Neurol, Evanston, IL 60208 USA; [Parrish, Todd B.] Northwestern Univ, Dept Radiol, Evanston, IL 60208 USA; [Gottfried, Jay A.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA	Li, W (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	wenli@psych.wisc.edu	Li, Wen/AAU-8505-2020	Lopez, Leonardo/0000-0001-9769-7737; Parrish, Todd/0000-0002-1184-1572	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010014, K08DC007653] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K08 DC007653, R01 DC010014] Funding Source: Medline		ABRAHAM A, 1983, NEUROPSYCHOLOGIA, V21, P277, DOI 10.1016/0028-3932(83)90045-3; Allen WF, 1940, AM J PHYSIOL, V128, P0754; Anderson AK, 2003, NAT NEUROSCI, V6, P196, DOI 10.1038/nn1001; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P403, DOI 10.1002/cne.903460306; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Eftekhari M, 2006, AM J RHINOL, V20, P577, DOI 10.2500/ajr.2006.20.2906; Flykt A, 2007, BIOL PSYCHOL, V74, P328, DOI 10.1016/j.biopsycho.2006.08.004; Functional Imaging Laboratory, 2003, STAT PAR MAPP VERS 2; FUSTER JM, 1997, PREFRONTAL CORTEX AN; Gottfried JA, 2006, NEURON, V49, P467, DOI 10.1016/j.neuron.2006.01.007; Gottfried JA, 2005, BRAIN RES REV, V50, P287, DOI 10.1016/j.brainresrev.2005.08.004; Gottfried JA, 2002, J NEUROSCI, V22, P10829; Gottfried JA, 2007, ANN NY ACAD SCI, V1121, P102, DOI 10.1196/annals.1401.018; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; JONESGOTMAN M, 1993, BRAIN COGNITION, V22, P182, DOI 10.1006/brcg.1993.1033; Li W, 2008, J COGNITIVE NEUROSCI, V20, P95; Li W, 2006, NEURON, V52, P1097, DOI 10.1016/j.neuron.2006.10.026; Lundqvist D., 1998, KAROLINSKA DIRECTED; Mai J. K., 1997, ATLAS HUMAN BRAIN; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; Phelps EA, 2006, ANNU REV PSYCHOL, V57, P27, DOI 10.1146/annurev.psych.56.091103.070234; Plailly J, 2008, J NEUROSCI, V28, P5257, DOI 10.1523/JNEUROSCI.5607-07.2008; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; Price JL, 2007, ANN NY ACAD SCI, V1121, P54, DOI 10.1196/annals.1401.008; RAUSCH R, 1977, CORTEX, V13, P445, DOI 10.1016/S0010-9452(77)80024-5; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P751; Shepherd GM, 2007, ANN NY ACAD SCI, V1121, P87, DOI 10.1196/annals.1401.032; Shipley MT, 1996, J NEUROBIOL, V30, P123; Sobel N, 1999, BRAIN, V122, P209, DOI 10.1093/brain/122.2.209; Tait DS, 2007, ANN NY ACAD SCI, V1121, P407, DOI 10.1196/annals.1401.010; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71; Zeki S, 1998, BRAIN, V121, P25, DOI 10.1093/brain/121.1.25; Zelano C, 2005, NAT NEUROSCI, V8, P114, DOI 10.1038/nn1368	40	67	67	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0956-7976	1467-9280		PSYCHOL SCI	Psychol. Sci.	OCT	2010	21	10					1454	1463		10.1177/0956797610382121			10	Psychology, Multidisciplinary	Psychology	696QD	WOS:000285455600017	20817780	Green Accepted			2021-06-18	
J	Luo, CL; Chen, XP; Yang, R; Sun, YX; Li, QQ; Bao, HJ; Cao, QQ; Ni, H; Qin, ZH; Tao, LY				Luo, Cheng-Liang; Chen, Xi-Ping; Yang, Rui; Sun, Yu-Xia; Li, Qian-Qian; Bao, Hai-Jun; Cao, Qiang-Qiang; Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang			Cathepsin B Contributes to Traumatic Brain Injury-Induced Cell Death Through a Mitochondria-Mediated Apoptotic Pathway	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; cathepsin B; tBid; caspase-3; apoptosis	HIPPOCAMPAL NEURONAL DEATH; CONTROLLED CORTICAL IMPACT; PERMEABILITY; INHIBITION; LYSOSOMES; PRIMATES; NECROSIS; BCL-2	It has been reported that lysosomal proteases play important roles in ischemic and excitotoxic neuronal cell death. We have previously reported that cathepsin B expression increased remarkably after traumatic brain injury (TBI). The present study sought to investigate the effects of a selective cathepsin B inhibitor (CBI) [N-L-3-trans-prolcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline] on cell death and behavioral deficits in our model. We examined the levels of cathepsin B enzymatic activity and its expression by double labelling damaged cells in the brain slice with propidium iodide (PI) and anticathepsin B. The results showed an elevated enzymatic activity associated with TBI-induced increase in a mature form of cathepsin B, suggesting that cathepsin B may play a role in TBI-induced cell injury. PI was found to label cells positive for the neuronal-specific nuclear marker NeuN, whereas fewer GFAP-positive cells were labelled by PI, suggesting that neurons are more sensitive to cell death induced by TBI. Additionally, we found that pretreatment with CBI remarkably attenuated TBI-induced cell death, lesion volume, and motor and cognitive dysfunction. To analyze the mechanism of action of cathepsin B in the cell death signaling pathway, we assessed DNA fragmentation by electrophoresis, BcI-2/Bax protein expression levels, Bid cleavage, cytochrome c release, and caspase-3 activation. The results imply that cathepsin B contributes to TBI-induced cell death through the present programmed cell necrosis and mitochondria-mediated apoptotic pathways. (C) 2010 Wiley-Liss, Inc.	[Luo, Cheng-Liang; Chen, Xi-Ping; Yang, Rui; Sun, Yu-Xia; Li, Qian-Qian; Bao, Hai-Jun; Cao, Qiang-Qiang; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang] Soochow Univ, Dept Pharmacol, Suzhou 215123, Peoples R China; [Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang] Soochow Univ, Lab Aging & Nerves Dis, Suzhou 215123, Peoples R China; [Tao, Lu-Yang] Forens Key Lab Shanghai, Shanghai, Peoples R China	Tao, LY (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571909, 30872666, 30870808]; Shanghai Forensic Key Lab Foundation [KF0904]	Contract grant sponsor: the National Science Foundation of China; Contract grant number: 30571909; Contract grant number: 30872666; Contract grant number: 30870808; Contract grant sponsor: Shanghai Forensic Key Lab Foundation; Contract grant number: KF0904.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Arnoult D, 2007, TRENDS CELL BIOL, V17, P6, DOI 10.1016/j.tcb.2006.11.001; Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ellis RC, 2005, EXP NEUROL, V193, P19, DOI 10.1016/j.expneurol.2004.11.034; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029; JIANG X, 2000, J BIOL CHEM, V275, P159; Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lin KH, 2009, CARDIOVASC RES, V83, P575, DOI 10.1093/cvr/cvp139; MAMMIS A, 2009, REV SURG NEUROL, V74, P527; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Tao LY, 2003, J FORENSIC MED, V19, P4; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; Tsukada T, 2001, J NEUROCHEM, V79, P1196, DOI 10.1046/j.1471-4159.2001.00679.x; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao Zhi-guo, 2009, Zhonghua Pifuke Zazhi, V42, P49, DOI 10.3760/cma.j.issn.0412-4030.2009.01.019	32	67	70	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2010	88	13					2847	2858		10.1002/jnr.22453			12	Neurosciences	Neurosciences & Neurology	642OK	WOS:000281225100008	20653046				2021-06-18	
J	Grady, MF				Grady, Matthew F.			Concussion in the Adolescent Athlete	CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE			English	Article							TRAUMATIC BRAIN-INJURY; NATIONAL-FOOTBALL-LEAGUE; SPORTS-RELATED CONCUSSION; FLUID PERCUSSION INJURY; TEST-RETEST RELIABILITY; ICE HOCKEY INJURIES; CEREBRAL-BLOOD-FLOW; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES	Concussion in the adolescent athlete is a common sports and recreation injury. Traditional management of concussion in this age group has focused on sport return-to-play decisions. However, new research on mild traumatic brain injury has dramatically changed the management of concussion. During the acute healing phase, physical and cognitive rest are crucial for healing. In the school-aged athlete, new concepts, such as complete brain rest, have made school management decisions as important as sport return-to-play decisions. Despite tremendous improvements in the understanding of concussion, most of the research has been done in young adults. The lack of prospective studies in early adolescent student athletes limits definitive management recommendations. This article reviews the current understanding of the epidemiology, pathophysiology, and clinical presentation of concussion and discusses the unique factors involved in clinical management of concussion in the adolescent student-athlete. Curr Probl Pediatr Adolesc Health Care 2010;40:154-169	Childrens Hosp Philadelphia, Sports Med & Performance Ctr, King Of Prussia, PA USA	Grady, MF (corresponding author), Childrens Hosp Philadelphia, Sports Med & Performance Ctr, King Of Prussia, PA USA.						Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; [Anonymous], 2007, MMWR-MORBID MORTAL W, V56, P733; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bergschneider M, 2003, J NEUROSURG, V86, P241; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P624, DOI 10.1080/13803390490918589; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donat CK, 2010, INT J DEV NEUROSCI, V28, P31, DOI 10.1016/j.ijdevneu.2009.10.001; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gladwell M, 2009, NEW YORKER, V85, P50; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, CLIN J SPORT MED, V17, P31; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langham J, 2003, COCHRANE DB SYST REV, V4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lee Michael A, 2009, Conn Med, V73, P171; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pickering A, 2008, ANN EMERG MED, V51, P471, DOI 10.1016/j.annemergmed.2008.01.271; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tang-Schomer MD, 2009, FASEB J; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman, 1999, TRAUMATIC BRAIN INJU; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viccellio P, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e20; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zornow M H, 1996, New Horiz, V4, P107	124	67	67	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1538-5442	1538-3199		CURR PROB PEDIATR AD	Curr. Probl. Pediatr. Adolesc. Health Care	AUG	2010	40	7					154	169		10.1016/j.cppeds.2010.06.002			16	Pediatrics	Pediatrics	V26OH	WOS:000208554400002	20705248				2021-06-18	
J	Ahmed, OH; Sullivan, SJ; Schneiders, AG; McCrory, P				Ahmed, Osman Hassan; Sullivan, S. John; Schneiders, Anthony G.; McCrory, Paul			iSupport: do social networking sites have a role to play in concussion awareness?	DISABILITY AND REHABILITATION			English	Article						Social networking sites; internet; brain injury; concussion; self-help groups	TRAUMATIC BRAIN-INJURY; PATIENT SUPPORT GROUPS; HEALTH INFORMATION; ONLINE; TELEREHABILITATION; INTERNET; EMPOWERMENT; TECHNOLOGY; CYBERSPACE; COMMUNITY	Purpose. The Facebook web site is an exceptionally fast-growing social networking site (SNS) containing membership groups with discussion boards on a wide variety of issues. This study uses content analysis to scrutinise postings on Facebook groups related to concussion and examine the purpose of these postings. Method. 472 Facebook groups related to concussion were screened by three researchers using a specifically developed coding scheme to examine demographic information and the purpose of the posting. In those cases where agreement was not obtained, post-analysis discussion allowed consensus to be reached. Results. From the 17 Facebook groups which met the inclusion criteria, 145 postings were included for analysis. The predominant demographic group which posted on the Facebook discussion boards were North American males. In the main part, individuals utilised the Facebook group to relate personal experiences of concussion (65%), although it was also used to seek (8%) or offer advice (2%). Supporting quotes were extracted. Conclusions. This study highlights the evolving nature of healthcare support in the twenty-first century and the rich information present relating to concussion on SNSs such as Facebook. Although the information being shared on these sites is important, the peer-to-peer interaction may be the key aspect of this health education medium.	[Ahmed, Osman Hassan; Sullivan, S. John; Schneiders, Anthony G.] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin, New Zealand; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia	Ahmed, OH (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin, New Zealand.	osman.ahmed@otago.ac.nz	McCrory, Paul/Q-8688-2019; Ahmed, Mohamed/AAG-9664-2019; Schneiders, Anthony/F-4212-2015	Schneiders, Anthony/0000-0002-1583-3879; McCrory, Paul/0000-0003-4850-0568			[Anonymous], SOCIAL LIFE HLTH INF; Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Bernstam EV, 2005, INT J MED INFORM, V74, P13, DOI 10.1016/j.ijmedinf.2004.10.001; Cain J, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj720477; *CDCP, HEADS UPTAB COACH TO; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Coulson NS, 2007, PATIENT EDUC COUNS, V68, P173, DOI 10.1016/j.pec.2007.06.002; *FAC, FAC BRAINL ORG TRAUM; *FAC, FAC WHO HAV EV ATT C; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giansanti D, 2008, TELEMED J E-HEALTH, V14, P76, DOI 10.1089/tmj.2007.0019; Hadert A, 2008, MUSCULOSKELET CARE, V6, P181, DOI 10.1002/msc.131; Hansen DL, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e25; HARRIS JR, 1994, J COGNITIVE REHABILI, V12, P4; *HEADW BRAIN INJ A, INT; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Idriss SZ, 2009, ARCH DERMATOL, V145, P46, DOI 10.1001/archdermatol.2008.529; *INT WORLD STATS, INT; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Krippendorff K., 2009, CONTENT ANAL READER; McMillan SJ, 2006, NEW MEDIA SOC, V8, P73, DOI 10.1177/1461444806059871; Piron L, 2004, MED INFORM INTERNET, V29, P119, DOI 10.1080/14639230410001723428; Preece J, 2004, COMPUT HUM BEHAV, V20, P201, DOI 10.1016/j.chb.2003.10.015; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Ricker JH, 2003, NEUROREHABILITATION, V18, P179; Shuyler KS, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e24; Skinner H, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e32; *SPORTS CONC, SPORTS CONC S AFR IN; Steinfield C, 2008, J APPL DEV PSYCHOL, V29, P434, DOI 10.1016/j.appdev.2008.07.002; Subrahmanyam K, 2008, J APPL DEV PSYCHOL, V29, P420, DOI 10.1016/j.appdev.2008.07.003; Suzuki LK, 2004, J APPL DEV PSYCHOL, V25, P685, DOI 10.1016/j.appdev.2004.09.002; van Uden-Kraan CF, 2009, PATIENT EDUC COUNS, V74, P61, DOI 10.1016/j.pec.2008.07.044; van Uden-Kraan CF, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.992; FACEBOOK STAT INTERN	36	67	67	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32	22					1877	1883		10.3109/09638281003734409			7	Rehabilitation	Rehabilitation	671TA	WOS:000283532300010	20367328				2021-06-18	
J	Fish, J; Wilson, BA; Manly, T				Fish, Jessica; Wilson, Barbara A.; Manly, Tom			The assessment and rehabilitation of prospective memory problems in people with neurological disorders: A review	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injury; Assessment; Rehabilitaion; Everyday memory	TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; EVERYDAY MEMORY; GOAL MANAGEMENT; PAGING SYSTEM; EVENT; PERFORMANCE; INTENTIONS; TIME; ADULTS	People with neurological disorders often report difficulty with prospective memory (PM), that is, remembering to do things they had intended to do. This paper briefly reviews the literature regarding the neuropsychology of PM function, concluding that from the clinical perspective, PM is best considered in terms of its separable but interacting mnemonic and executive components. Next, the strengths and limitations in the current clinical assessment of PM, including the assessment of component processes, desktop analogues of PM tasks, and naturalistic PM tasks, are outlined. The evidence base for the rehabilitation of PM is then considered, focusing on retraining PM, using retrospective memory strategies, problem-solving training, and finally, electronic memory aids. It is proposed that further research should focus on establishing the predictive validity of PM assessment, and refining promising rehabilitation techniques.	[Fish, Jessica; Wilson, Barbara A.; Manly, Tom] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England; [Wilson, Barbara A.] Princess Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Wales	Fish, J (corresponding author), MRC, Cognit & Brain Sci Unit, 15 Chaucer Rd, Cambridge CB2 7EF, England.	jessica.fish@mrc-cbu.cam.ac.uk		Fish, Jessica/0000-0002-9337-1489	UK Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [U.1055.01.003.00001.01]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: researchfish	We gratefully acknowledge the financial support of the UK Medical Research Council (MRC U.1055.01.003.00001.01), and thank the two reviewers of this manuscript for their insightful comments.	BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baddeley A., 1997, HUMAN MEMORY THEORY; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Burgess PW, 2007, PHILOS T R SOC B, V362, P887, DOI 10.1098/rstb.2007.2095; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Camp C. J., 1996, PROSPECTIVE MEMORY T; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; Christoff K, 2003, BEHAV NEUROSCI, V117, P1161, DOI 10.1037/0735-7044.117.6.1161; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; den Ouden HEM, 2005, NEUROIMAGE, V28, P787, DOI 10.1016/j.neuroimage.2005.05.001; Einstein GO, 2005, J EXP PSYCHOL GEN, V134, P327, DOI 10.1037/0096-3445.134.3.327; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J., 1996, PROSPECTIVE MEMORY T; ELLIS J, 1988, PRACTICAL ASPECTS ME, V1; Elvevag B, 2003, BMC PSYCHIATRY, V3, DOI 10.1186/1471-244X-3-9; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Freeman JE, 2003, J EXP PSYCHOL LEARN, V29, P976, DOI 10.1037/0278-7393.29.5.976; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GOSCHKE T, 1993, J EXP PSYCHOL LEARN, V19, P1211, DOI 10.1037/0278-7393.19.5.1211; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Katai S, 2003, J NEUROL NEUROSUR PS, V74, P704, DOI 10.1136/jnnp.74.6.704; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kime SK, 1996, BRAIN INJURY, V10, P17; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kinsella GJ, 2007, NEUROPSYCHOL REHABIL, V17, P688, DOI 10.1080/09602010600892824; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kondel TK, 2002, BRAIN COGNITION, V48, P405, DOI 10.1006/brcg.2001.1387; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEVINE B, 2009, GOAL MANAGEMEN UNPUB; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P350, DOI 10.1037/0278-7393.24.2.350; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; McDaniel M.A., 1996, PROSPECTIVE MEMORY T; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; MOSCOVITCH M, 1982, AGING COGNITIVE PROC, V3; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Sellen AJ, 1997, MEMORY, V5, P483, DOI 10.1080/741941433; Shum D, 2004, SCHIZOPHRENIA BULL, V30, P693, DOI 10.1093/oxfordjournals.schbul.a007123; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2007, J EXP PSYCHOL LEARN, V33, P734, DOI 10.1037/0278-7393.33.4.734; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Szymkowiak A, 2005, PERS UBIQUIT COMPUT, V9, P1, DOI 10.1007/s00779-004-0259-x; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	80	67	70	0	33	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	2					161	179	PII 919148239	10.1080/09602010903126029			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	564ER	WOS:000275196600001	20146135	Green Published			2021-06-18	
J	Chamoun, RB; Robertson, CS; Gopinath, SP				Chamoun, Roukoz B.; Robertson, Claudia S.; Gopinath, Shankar P.			Outcome in patients with blunt head trauma and a Glasgow Coma Scale score of 3 at presentation Clinical article	JOURNAL OF NEUROSURGERY			English	Article						blunt head injury; Glasgow Coma Scale; outcome	BRAIN-INJURY; ADMISSION; PREDICTION; VARIABLES; SURVIVAL; CHANCE; PUPIL	Object. A Glasgow Coma Scale (GCS) score of 3 on presentation in patients with severe traumatic brain injury due to blunt trauma has been recognized as a bad prognostic factor. The reported mortality rate in these patients is very high, even approaching 100% in the presence of fixed and dilated pupils in some series. Consequently, there is often a tendency to treat these patients less aggressively because of the low expectations for a good recovery. In this paper, the authors' purpose is to report their experience in the management of this patient population, analyzing the mortality rate, prognostic factors, and functional outcome of survivors. Methods. The authors performed a retrospective review of patients who presented between 1997 and 2007 with blunt head trauma and a GCS score of 3. Demographics, mechanism of injury, examination, blood alcohol level, associated injury, intracranial pressure (ICP), surgical procedures, and outcome were all recorded. Results. A total of 189 patients met the inclusion criteria and were included in this study. The overall mortality rate was 49.2%. At the 6-month follow-up, 13.2% of the entire series achieved a good functional outcome (Glasgow Outcome Scale [GOS] score of 1 or 2). The patient population was then divided into 2 groups: Group 1 (patients who survived [96]) and Group 2 (patients who died [93]). Patients in Group 1 were younger (mean 33.3 +/- 12.8 vs 40.3 +/- 16.97 years; p = 0.002) and had lower ICP on admission (mean 16.3 +/- 11.1 vs 25.7 +/- 12.7 mm Hg; p < 0.001) than those in Group 2. The difference between the 2 groups regarding sex, mechanism of injury, hypotension on admission, alcohol, surgery, and associated injuries was not statistically significant. The presence of bilateral fixed, dilated pupils was found to be associated with the highest mortality rate (79.7%). Although not statistically significant because of the sample size, pupil status was also a good predictor of the functional outcome at the 6-month follow-up; a good functional outcome (GOS Score 1 or 2) was achieved in 25.5% of patients presenting with bilateral reactive pupils, and 27.6% of patients presenting with a unilateral fixed, dilated pupil, compared with 7.5% for those presenting with bilateral fixed, nondilated pupils, and 1.4% for patients with bilateral fixed, dilated pupils. Conclusions. Overall, 50.8% of patients survived their injury and 13.2% achieved a good functional outcome afterat 6 months of follow-up (GOS Score 1 or 2). Age, ICP on admission, and pupil status were found to be significant predictive factors of outcome. In particular, pupil size and reactivity appeared to be the most important prognostic factor since the mortality rate was 23.5% in the presence of bilateral reactive pupils and 79.7% in the case of bilateral fixed, dilated pupils. The authors believe that patients having suffered traumatic brain injury and present with a GCS score of 3 should still be treated aggressively initially since a good functional outcome can be obtained in some cases. (DOI: 10.3171/2009.2.JNS08817)	[Chamoun, Roukoz B.; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study is supported by an NIH Grant No. P01-NS38660. The authors report no other conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; VALADKA AB, 2000, TRAUMA, P377; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	15	67	69	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					683	687		10.3171/2009.2.JNS08817			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000009	19326973	Green Accepted			2021-06-18	
J	Shehata, N; Wiley, JP; Richea, S; Benson, BW; Duits, L; Meeuwisse, WH				Shehata, N.; Wiley, J. P.; Richea, S.; Benson, B. W.; Duits, L.; Meeuwisse, W. H.			Sport concussion assessment tool: baseline values for varsity collision sport athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							EPIDEMIOLOGY; SYMPTOMS; INJURIES	Objective: To determine baseline symptom and neurocognitive norms for non-concussed and previously concussed varsity athletes using the sport concussion assessment tool (SCAT). Study Design: Descriptive cohort study. Setting: University of Calgary. Subjects: 260 male and female university football, ice hockey and wrestling athletes over three seasons (2005-7). Methods: A baseline SCAT was completed during preseason medical evaluation. Subjects were grouped as follows: all participants, men, women, never concussed (NC) and previously concussed (PC). Main Results: The mean age of participants was 20.5 years (range 17-32). In total, 41.2% of all athletes had a total post-concussion symptom scale (PCSS) score of 0. The mean baseline PCSS scores were as follows: all participants 4.29; men 3.52; women 6.39; NC 3.75 and PC 5.25. The five most frequently reported symptoms for all athletes were fatigue/low energy (37% of subjects), drowsiness (23%), neck pain (20%), difficulty concentrating (18%) and difficulty remembering (18%). The median immediate recall score was 5/5 for all groups. Women scored a median of 5/5 on delayed recall, whereas all remaining groups scored a median of 4/5. Months in reverse order were successfully completed by 91.6% of subjects. All participants, women and PC scored a median of 6 on reverse digits, whereas men and NC scored a median of 5. Conclusions: The mean SCAT baseline PCSS score was approximately 5, although just under half of the athletes scored 0. Female athletes scored better on tests of neurocognitive function. PC athletes scored better than NC athletes on all neurocognitive tests except delayed five-word recall.	[Wiley, J. P.] Univ Calgary, Sport Med Ctr, Calgary, AB T2N 1N4, Canada; [Duits, L.] Univ Amsterdam, Amsterdam, Netherlands	Wiley, JP (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	wiley@ucalgary.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Bruce JM, 2004, NEUROLOGY, V63, P1516; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; GRINDEL S, CLIN J SPORT MED, V11, P134; GUSKIEWICZ KM, 2004, AM J MED SPORTS, V6, P13; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moeller James L, 2004, Curr Sports Med Rep, V3, P304; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; *U CALG, DIN AC CRIT	13	67	67	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2009	43	10					730	734		10.1136/bjsm.2009.059832			5	Sport Sciences	Sport Sciences	503FY	WOS:000270520100003	19460765				2021-06-18	
J	Harting, MT; Sloan, LE; Jimenez, F; Baumgartner, J; Cox, CS				Harting, Matthew T.; Sloan, LeeAnn E.; Jimenez, Fernando; Baumgartner, James; Cox, Charles S., Jr.			Subacute Neural Stem Cell Therapy for Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; neural stem cells; cellular therapy	COGNITIVE FUNCTION; TRANSPLANTATION; SURVIVAL; RATS; DIFFERENTIATION; MIGRATION; CYTOKINES; RECOVERY; MEMORY; MOTOR	Introduction. Traumatic brain injury (TBI) frequently results in devastating and prolonged morbidity. Cellular therapy is a burgeoning field of experimental treatment that has shown promise in the management of many diseases, including TBI. Previous work suggests that certain stem and progenitor cell populations migrate to sites of inflammation and improve functional outcome in rodents after neural injury. Unfortunately, recent study has revealed potential limitations of acute and intravenous stem cell therapy. We studied subacute, direct intracerebral neural stem and progenitor cell (NSC) therapy for TBI. Materials and methods. The NSCs were characterized by flow cytometry and placed (400,000 cells in 50 mu L 1 x phosphate-buffered saline) into and around the direct injury area, using stereotactic guidance, of female Sprague Dawley rats 1 wk after undergoing a controlled cortical impact injury. Immunohistochemistry was used to identify cells located in the brain at 48 h and 2 wk after administration. Motor function was assessed using the neurological severity score, foot fault, rotarod, and beam balance. Cognitive function was assessed using the Morris water maze learning paradigm. Repeated measures analysis of variance with post-hoc analysis were used to determine significance at P < 0.05. Results. Immunohistochemistry analysis revealed that 1.4-1.9% of infused cells remained in the neural tissue at 48 h and 2 wk post placement. Nearly all cells were located along injection tracks at 48 h. At 2 wk some cell dispersion was apparent. Rotarod motor testing revealed significant increases in maximal speed among NSC-treated rats compared with saline controls at d 4 (36.4 versus 27.1 rpm, P < 0.05) and 5 (35.8 versus 28.9 rpm, P < 0.05). All other motor and cognitive evaluations were not significantly different compared to controls. Conclusions. Placement of NSCs led to the cells incorporating and remaining in the tissues 2 wk after placement. Motor function tests revealed improvements in the ability to run on a rotating rod; however, other motor and cognitive functions were not significantly improved by NSC therapy. Further examination of a dose response and optimization of placement strategy may improve long-term cell survival and maximize functional recovery. (C) 2009 Elsevier Inc. All rights reserved.	[Harting, Matthew T.; Sloan, LeeAnn E.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Baumgartner, James; Cox, Charles S., Jr.] Childrens Mem Hermann Hosp, Houston, TX USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Hospital Foundation; Texas Higher Education Coordinating Board;  [T32 GM008792-06];  [MO1 RR 02558];  [R21 HD 04 2659-01Al]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by Grants T32 GM008792-06 (M.T.H.), MO1 RR 02558, R21 HD 04 2659-01Al, and the Children's Memorial Hermann Hospital Foundation and Texas Higher Education Coordinating Board.	Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HARTING MT, 2008, J SURG RES, V144, P425; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	26	67	75	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 15	2009	153	2					188	194		10.1016/j.jss.2008.03.037			7	Surgery	Surgery	438VX	WOS:000265585100002	18694578	Green Accepted			2021-06-18	
J	Willmott, C; Ponsford, J				Willmott, C.; Ponsford, J.			Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; DEFICITS; PERFORMANCE	Objectives: Most previous studies evaluating the use of methylphenidate following traumatic brain injury (TBI) have been conducted many years post-injury. This study evaluated the efficacy of methylphenidate in facilitating cognitive function in the inpatient rehabilitation phase. Methods: 40 participants with moderate-severe TBI (mean 68 days post-injury) were recruited into a randomised, crossover, double blind, placebo controlled trial. Methylphenidate was administered at a dose of 0.3 mg/kg twice daily and lactose in identical capsules served as placebo. Methylphenidate and placebo administration was randomised in a crossover design across six sessions over a 2 week period. Primary efficacy outcomes were neuropsychological tests of attention. Results: No participants were withdrawn because of side effects or adverse events. Methylphenidate significantly increased speed of information processing on the Symbol Digit Modalities Test (95% CI 0.30 to 2.95, Cohen's d = 0.39, p = 0.02), Ruff 2 and 7 Test-Automatic Condition (95% CI 1.38 to 6.12, Cohen's d = 0.51, p = 0.003), Simple Selective Attention Task (95% CI -58.35 to -17.43, Cohen's d = 0.59, p = 0.001) and Dissimilar Compatible (95% CI -70.13 to -15.38, Cohen's d = 0.51, p = 0.003) and Similar Compatible (95% CI -74.82 to -19.06, Cohen's d = 0.55, p = 0.002) conditions of the Four Choice Reaction Time Task. Those with more severe injuries and slower baseline information processing speed demonstrated a greater drug response. Conclusions: Methylphenidate enhances information processing speed in the inpatient rehabilitation phase following TBI. This trial is registered with the Australian New Zealand Clinical Trials Registry (12607000503426).	[Willmott, C.; Ponsford, J.] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia; [Willmott, C.; Ponsford, J.] Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia	Willmott, C (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia.	catherine.willmott@med.monash.edu.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035	Victorian Neurotrauma Initiative; Wenkart Foundation	This study was supported by the Victorian Neurotrauma Initiative and the Wenkart Foundation, neither of which had any involvement in study design, analysis and interpretation of data, writing of the report or the decision to submit the article for publication. Drugs were purchased for the trial on a commercial basis, and the company that manufactures Ritalin made no contribution to the study.	Al-Adawi S., 2005, Journal of Applied Research, V5, P61; ARNSTEN AF, 2005, BEHAV BRAIN FUNCT, V1, DOI DOI 10.1186/744-9081-1-2; Arnsten AFT, 2002, PRINCIPLES FRONTAL L, P51, DOI [DOI 10.1093/ACPROF:OSO/9780195134971.003.0004, 10.1093/acprof:oso/9780195134971.003.0004]; DANIEL A, 1983, POWER PRIVILEDGE PRE; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri CT, 2002, BRAIN INJURY MENTAL; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUFF R, 1995, RUFF 2 7 SELECTIVE A; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith A., 1991, SYMBOL DIGIT MODALIT; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WILLMOTT C, NEUROPSYCHO IN PRESS; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	30	67	67	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2009	80	5					552	557		10.1136/jnnp.2008.159632			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	433ZN	WOS:000265244900020	19060022				2021-06-18	
J	Ding, Y; Yan, Q; Ruan, JW; Zhang, YQ; Li, WJ; Zhang, YJ; Li, Y; Dong, HX; Zeng, YS				Ding, Ying; Yan, Qing; Ruan, Jing-Wen; Zhang, Yan-Qing; Li, Wen-Jie; Zhang, Yu-Jiao; Li, Yan; Dong, Hongxin; Zeng, Yuan-Shan			Electro-acupuncture promotes survival, differentiation of the bone marrow mesenchymal stem cells as well as functional recovery in the spinal cord-transected rats	BMC NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; NEURONS IN-VITRO; STROMAL CELLS; ADULT-RAT; AXONAL REGENERATION; NEUROTROPHIC FACTOR; SCHWANN-CELLS; NERVOUS-SYSTEM; DELAYED TRANSPLANTATION; ELECTRIC-FIELDS	Background: Bone marrow mesenchymal stem cells (MSCs) are one of the potential tools for treatment of the spinal cord injury; however, the survival and differentiation of MSCs in an injured spinal cord still need to be improved. In the present study, we investigated whether Governor Vessel electro-acupuncture (EA) could efficiently promote bone marrow mesenchymal stem cells (MSCs) survival and differentiation, axonal regeneration and finally, functional recovery in the transected spinal cord. Results: The spinal cords of adult Sprague-Dawley (SD) rats were completely transected at T10, five experimental groups were performed: 1. sham operated control (Sham-control); 2. operated control (Op-control); 3. electro-acupuncture treatment (EA); 4. MSCs transplantation (MSCs); and 5. MSCs transplantation combined with electro-acupuncture (MSCs+EA). After 2-8 weeks of MSCs transplantation plus EA treatment, we found that the neurotrophin-3 (NT-3), cAMP level, the differentiation of MSCs, the 5-HT positive and CGRP positive nerve fibers in the lesion site and nearby tissue of injured spinal cord were significantly increased in the MSCs+EA group as compared to the group of the MSCs transplantation or the EA treated alone. Furthermore, behavioral test and spinal cord evoked potentials detection demonstrated a significantly functional recovery in the MSCs+EA group. Conclusion: These results suggest that EA treatment may promote grafted MSCs survival and differentiation; MSCs transplantation combined with EA treatment could promote axonal regeneration and partial locomotor functional recovery in the transected spinal cord in rats and indicate a promising avenue of treatment of spinal cord injury.	[Ding, Ying; Yan, Qing; Zhang, Yan-Qing; Li, Wen-Jie; Zhang, Yu-Jiao; Li, Yan; Zeng, Yuan-Shan] Dept Histol & Embryol, Div Neurosci, Guangzhou, Guangdong, Peoples R China; [Zeng, Yuan-Shan] Ctr Stem Cell Biol & Tissue Engn, Guangzhou, Guangdong, Peoples R China; [Zeng, Yuan-Shan] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Spinal Cord Injury, Guangzhou 510275, Guangdong, Peoples R China; [Ruan, Jing-Wen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Acupuncture, Guangzhou 510275, Guangdong, Peoples R China; [Dong, Hongxin] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA	Zeng, YS (corresponding author), Dept Histol & Embryol, Div Neurosci, 74 Zhongshan 2nd Rd, Guangzhou, Guangdong, Peoples R China.	dingying@mail.sysu.edu.cn; yanqing312@yahoo.com.cn; ruanjw@163.com; xiaomaozhang2002@yahoo.com.cn; wenjie1124@sohu.com; gzjj520@yahoo.com; liyan@mail.sysu.edu.cn; h-dong@northwestern.edu; zengysh@mail.sysu.edu.cn			Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30472132]; Administrative Bureau of Chinese Traditional Medicine of Guangdong [1050167, 2007109]	We thank Keely Murphy at Northwestern University for editing this manuscript. This research was supported by a grant from the Chinese National Natural Science Foundation (No. 30472132) and a Research Grant of the Administrative Bureau of Chinese Traditional Medicine of Guangdong Province (No. 1050167; 2007109) to Y. S. Zeng.	Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; Cao L, 2004, BRAIN, V127, P535, DOI 10.1093/brain/awh072; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen YY, 2008, ACUPUNCTURE ELECTRO, V33, P19, DOI 10.3727/036012908803861212; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Crain BJ, 2005, J NEUROL SCI, V233, P121, DOI 10.1016/j.jns.2005.03.017; Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070; Dolbeare D, 2003, J NEUROTRAUM, V20, P1251, DOI 10.1089/089771503770802916; Dong ZQ, 2005, NEUROSCI LETT, V376, P143, DOI 10.1016/j.neulet.2004.11.044; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Han HS, 2005, MO CL BI CC, V4, P25; Hansen MR, 2001, J NEUROSCI, V21, P2256; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Hu Y, 2001, J NEUROL NEUROSUR PS, V71, P732, DOI 10.1136/jnnp.71.6.732; Iannotti C, 2003, EXP NEUROL, V183, P379, DOI 10.1016/S0014-4886(03)00188-2; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jean I, 2003, BRAIN RES, V972, P110, DOI 10.1016/S0006-8993(03)02510-1; Johnson JR, 2000, J NEUROCHEM, V74, P1409, DOI 10.1046/j.1471-4159.2000.0741409.x; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Kawaguchi S, 2004, PROG BRAIN RES, V143, P155, DOI 10.1016/S0079-6123(03)43015-X; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Li Xiao-bin, 2006, Jiepou Xuebao, V37, P622; [李晓滨 Li Xiaobin], 2004, [解剖学报, Acta Anatomica Sinica], V35, P582; Liu Y, 1999, J NEUROSCI, V19, P4370; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 1998, J NEUROSCI, V18, P5354; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; PAINO CL, 1991, EXP NEUROL, V114, P254, DOI 10.1016/0014-4886(91)90043-C; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; PATEL N, 1982, J NEUROSCI, V2, P483; PATEL NB, 1984, J NEUROSCI, V4, P2939; Patist CM, 2004, BIOMATERIALS, V25, P1569, DOI 10.1016/S0142-9612(03)00503-9; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Saini HS, 2004, J NEUROCHEM, V89, P951, DOI 10.1111/j.1471-4159.2004.02365.x; Shumsky JS, 2003, EXP NEUROL, V184, P114, DOI 10.1016/S0014-4886(03)00398-4; Song S, 2004, EXP NEUROL, V185, P191, DOI 10.1016/j.expneurol.2003.09.003; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Steward O, 2006, EXP NEUROL, V198, P483, DOI 10.1016/j.expneurol.2005.12.034; Suon S, 2006, BRAIN RES, V1106, P46, DOI 10.1016/j.brainres.2006.05.109; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wakabayashi Y, 2001, SPINE, V26, P1215, DOI 10.1097/00007632-200106010-00009; Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9; Wong AMK, 2003, AM J PHYS MED REHAB, V82, P21, DOI 10.1097/00002060-200301000-00004; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xie Jie, 2006, J Tradit Chin Med, V26, P148; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; Yang Cheng, 2005, Zhongguo Zhen Jiu, V25, P569; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zeng YS, 2005, DEV NEUROSCI-BASEL, V27, P20, DOI 10.1159/000084529; Zhang W, 2006, NEUROSCI LETT, V408, P98, DOI 10.1016/j.neulet.2006.08.079; Zhang XB, 2007, J NEUROTRAUM, V24, P1863, DOI 10.1089/neu.2007.0334	74	67	79	1	20	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	APR 20	2009	10								35	10.1186/1471-2202-10-35			13	Neurosciences	Neurosciences & Neurology	470OL	WOS:000267984900001	19374777	DOAJ Gold, Green Published			2021-06-18	
J	Yard, EE; Comstock, RD				Yard, Ellen E.; Comstock, R. Dawn			Compliance with return to play guidelines following concussion in US high school athletes, 2005-2008	BRAIN INJURY			English	Article						concussion; traumatic brain injury; sports; recovery; time loss	SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; FOOTBALL PLAYERS; COLLEGIATE; ASSOCIATION; MANAGEMENT; RECOVERY; STATEMENT	Primary objective: To determine whether US concussed high school athletes complied with recommended return-to-play guidelines during the 2005-2008 school years. Research design: Prospective cohort study in 100 nationally-representative US high schools. Methods and procedures: Certified athletic trainers submitted injury reports for concussed athletes in five boys' (football, soccer, basketball, wrestling, baseball) and four girls' (soccer, basketball, volleyball, softball) sports via High School RIO (Reporting Information Online). Concussions were retrospectively graded and it was determined whether athletes followed American Academy of Neurology (AAN) or Prague return-to-play guidelines. Main outcomes and results: There were 1308 concussions reported during 5 627 921 athlete-exposures (23.2 concussions per 100 000 athlete-exposures), reflecting an estimated 395 274 concussions sustained nationally. At least 40.5% and 15.0% of concussed athletes returned to play prematurely under AAN and Prague return-to-play guidelines, respectively. In football, 15.8% of athletes sustaining a concussion that resulted in loss-of-consciousness returned to play in 1 day. Males (12.6%) were more likely than females (5.9%) to return 1-2 days after sustaining an initial grade II concussion. Conclusions: Too many adolescent athletes are failing to comply with recommended return-to-play guidelines. Sports medicine professionals, parents, coaches and sports administrators must work together to ensure athletes follow recommended guidelines.	[Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA	Comstock, RD (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	dawn.comstock@nationwidechildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; DonJoy Orthotics; National Federation of State High School Associations; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC) grant #R49/CE000674-01. The content of this report is solely the responsibility of the authors and does not necessarily reflect the official view of the CDC. We would also like to acknowledge the generous research funding contributions of DonJoy Orthotics, the National Federation of State High School Associations, and EyeBlack.	[Anonymous], CAS HIGH SCH ACT; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; *NAT FED STAT HIGH, 2007, 2006 07 HIGH SCH ATH; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; United States Census Bureau, CENS REG US; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	32	67	69	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					888	898	PII 915243307	10.1080/02699050903283171			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300005	20100125				2021-06-18	
J	Qu, CS; Mahmood, A; Lu, DY; Goussev, A; Xiong, Y; Chopp, M				Qu, Changsheng; Mahmood, Asim; Lu, Dunyue; Goussev, Anton; Xiong, Ye; Chopp, Michael			Treatment of traumatic brain injury in mice with marrow stromal cells	BRAIN RESEARCH			English	Article						traumatic brain injury (TBI); marrow stromal cell (MSC); mice	STEM-CELLS; TRANSPLANTATION; RATS; PROMOTES; MOUSE	This study was designed to investigate the potential beneficial effects of bone marrow stromal cell (MSC) treatment of traumatic brain injury (TBI) in mice. Twelve female C57BL/6J mice (weight, 21-26 g) were injured with controlled cortical impact and divided into 2 groups (n = 6 each). The experimental group was injected with MSCs (0.3 x 10(6)) intravenously one day after TBI, whereas the control group was injected with saline. MSCs were harvested from male mice, and male to female transplantation was performed to identify male donor cells within female recipient animals. This was achieved by localizing Y chromosomes within the female mice. Neurological function was assessed using the Morris water maze and foot fault tests. All mice were sacrificed 35 days after TBI. Brain sections were stained using in situ hybridization and immunohistochemistry to identify MSCs as well as to analyze vascular density following MSC treatment. Both modalities of testing demonstrated significant improvement in neurological function in the MSC-treated group compared to the saline-treated control group (p < 0.05). Histologically, Y chromosome labeled MSCs were easily identified in the injured brain, localized primarily around the lesion boundary zone. There was also a significant increase in vascular density in the lesion boundary zone and hippocampus of MSC-treated mice compared to control mice. This is the first study to show beneficial effects of MSC treatment after TBI in mice. (C) 2008 Published by Elsevier B.V.	[Qu, Changsheng; Mahmood, Asim; Goussev, Anton; Xiong, Ye; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Qu, Changsheng; Mahmood, Asim; Goussev, Anton; Xiong, Ye; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042259, R01NS42259] Funding Source: Medline		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BERNSTEIN DC, 1988, ANN NY ACAD SCI, V532, P207, DOI 10.1111/j.1749-6632.1988.tb36339.x; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; HLATKY R, 2003, FOCUS, V14, P104; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	22	67	73	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 7	2008	1208						234	239		10.1016/j.brainres.2008.02.042			6	Neurosciences	Neurosciences & Neurology	316GP	WOS:000256937800026	18384759	Green Accepted			2021-06-18	
J	Oliveira, MS; Furian, AF; Royes, LF; Fighera, MR; Fiorenza, NG; Castelli, M; Machado, P; Bohrer, D; Veiga, M; Ferreira, J; Cavalheiro, EA; Mello, CF				Oliveira, Mauro Schneider; Furian, Ana Flavia; Freire Royes, Luiz Fernando; Fighera, Michele Rechia; Fiorenza, Natalia Gindri; Castelli, Marcelo; Machado, Pablo; Bohrer, Denise; Veiga, Marlei; Ferreira, Juliano; Cavalheiro, Esper Abraao; Mello, Carlos Fernando			Cyclooxygenase-2/PGE(2) pathway facilitates pentylenetetrazol-induced seizures	EPILEPSY RESEARCH			English	Article						COX-2; celecoxib; epilepsy; PGE(2); EEG; PTZ	TRAUMATIC BRAIN-INJURY; NEURONAL CYCLOOXYGENASE-2; SYNAPTIC-TRANSMISSION; MICE; RAT; HIPPOCAMPUS; INHIBITION; EXPRESSION; EXCITABILITY; PLASTICITY	Cyclooxygenases (CCXs) are rate-limiting enzymes in the metabolic pathways in which arachidonic acid is converted to prostaglandins. COX-2 is the isoform induced at injury/inflammation sites and expressed constitutively in a few tissues, such as the central nervous system, and plays a rote in neurodegenerative diseases associated with increased excitatory activity. However, the role of COX-2 and its main product, prostaglandin E-2 (PGE(2)), in the convulsive states is not fully established. In this study we showed that the selective COX-2 inhibitor, celecoxib (at the dose of 2mg/kg, but not at the doses of 0.2 or 20mg/kg, p.o.), protects against the seizures induced by pentylenetetrazol (PTZ, 60 mg/kg, i.p.). The role of PGE2 in the convulsions induced by PTZ was further investigated by administering anti-PGE(2) antibodies (4 mu g/2 mu l, i.c.v.), and assessing electroencephatographic changes induced by PTZ (PTZ, 60 mg/kg, i.p.). Anti-PGE(2) antibodies attenuated PTZ-induced seizures in rats. In addition, combining PGE(2) (100 ng/2 mu l, i.c.v.) with a subconvulsant dose of PTZ (20 mg/kg, i.p.) caused seizures, further supporting a role for this prostaglandin in the convulsions induced by PTZ. Finally, we showed that the anticonvulsant action of celecoxib (2 mg/kg, p.o.) was reversed by the intracerebroventricular administration of PGE(2) (10 ng/2 mu l, i.c.v.). These data constitute strong converging pharmacological evidence supporting a facilitatory role for the COX-2/PGE2 pathway in the seizures induced by PTZ. However, whether selective COX-2 inhibitors are safer anti-inflammatory drugs for epileptic patients than nonspecific inhibitors remains to be determined. (c) 2008 Elsevier B.V. All rights reserved.	[Oliveira, Mauro Schneider; Furian, Ana Flavia; Freire Royes, Luiz Fernando; Fighera, Michele Rechia; Fiorenza, Natalia Gindri; Castelli, Marcelo; Mello, Carlos Fernando] Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Fisiol & Farmacol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Programa Posgrad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil; [Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Ctr Educ Fis & Desportos, Dept Metodos & Tecn Desportivas, BR-97119900 Santa Maria, RS, Brazil; [Machado, Pablo; Bohrer, Denise; Veiga, Marlei; Ferreira, Juliano] Univ Fed Santa Maria, Ctr Ciencias Nat & Exatas, Dept Quim, BR-97119900 Santa Maria, RS, Brazil; [Cavalheiro, Esper Abraao] Univ Fed Sao Paulo, Lab Neurol Expt, Sao Paulo, Brazil	Mello, CF (corresponding author), Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Fisiol & Farmacol, BR-97105900 Santa Maria, RS, Brazil.	cf.mello@smail.ufsm.br	Fighera, Michele R/J-9576-2014; Mello, Carlos/C-7188-2013; Oliveira, Mauro Schneider/G-3437-2012; Ferreira, Juliano/A-9803-2013; royes, luiz/T-3581-2019; Cavalheiro, Esper A/F-4325-2014; Cavalheiro, Esper/N-3985-2019; Machado, Pablo/M-4356-2013; Cavalheiro, Esper A/I-3084-2016	Mello, Carlos/0000-0002-1326-1045; Oliveira, Mauro Schneider/0000-0002-5381-1208; Ferreira, Juliano/0000-0002-9562-0602; Cavalheiro, Esper A/0000-0002-0854-3582; Cavalheiro, Esper/0000-0002-0854-3582; Machado, Pablo/0000-0001-5616-9583; Cavalheiro, Esper A/0000-0002-0854-3582; royes, luiz/0000-0003-4045-4827			Akarsu ES, 2006, EPILEPSY RES, V71, P181, DOI 10.1016/j.eplepsyres.2006.06.009; Andre V, 1998, EUR J NEUROSCI, V10, P2094, DOI 10.1046/j.1460-9568.1998.00223.x; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Bezzi P, 1998, NATURE, V391, P281; CAVALHEIRO EA, 1992, EPILEPSY RES, P239; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Ciceri P, 2002, J PHARMACOL EXP THER, V302, P846, DOI 10.1124/jpet.302.3.846; Desjardins P, 2003, NEUROCHEM INT, V42, P299, DOI 10.1016/S0197-0186(02)00101-8; DHIR A, 2006, BIOL PSYCHIAT; Ferraro TN, 1999, J NEUROSCI, V19, P6733, DOI 10.1523/JNEUROSCI.19-16-06733.1999; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kim J, 2004, NAT NEUROSCI, V7, P697, DOI 10.1038/nn1262; Marklund N, 2005, RESTOR NEUROL NEUROS, V23, P31; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; Melnikova T, 2006, NEUROSCIENCE, V141, P1149, DOI 10.1016/j.neuroscience.2006.05.001; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Okada K, 2001, BRAIN RES, V894, P332, DOI 10.1016/S0006-8993(01)02019-4; Paulson SK, 2000, DRUG METAB DISPOS, V28, P514; Sang N, 2005, J NEUROSCI, V25, P9858, DOI 10.1523/JNEUROSCI.2392-05.2005; Sang N, 2006, NEUROSCIENTIST, V12, P425, DOI 10.1177/1073858406290794; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Slanina KA, 2005, NEUROPHARMACOLOGY, V49, P653, DOI 10.1016/j.neuropharm.2005.04.019; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tu B, 2003, EXP NEUROL, V179, P167, DOI 10.1016/S0014-4886(02)00019-5; Ueno N, 2005, BIOCHEM BIOPH RES CO, V338, P70, DOI 10.1016/j.bbrc.2005.08.152; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vidensky S, 2003, NEUROMOL MED, V3, P15, DOI 10.1385/NMM:3:1:15; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	35	67	68	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	MAR	2008	79	1					14	21		10.1016/j.eplepsyres.2007.12.008			8	Clinical Neurology	Neurosciences & Neurology	295CZ	WOS:000255453900003	18255268				2021-06-18	
J	Li, W; Dai, S; An, J; Li, P; Chen, X; Xiong, R; Liu, P; Wang, H; Zhao, Y; Zhu, M; Liu, X; Zhu, P; Chen, JF; Zhou, Y				Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Chen, J. -F.; Zhou, Y.			Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model	NEUROSCIENCE			English	Article						adenosine receptor; caffeine; TBI; glutamate; inflammatory cytokine; neuroprotection	A(2A) ADENOSINE RECEPTORS; INDUCED EXCITOTOXICITY; REPERFUSION INJURY; GLUTAMATE RELEASE; ACTIVATION; PROTECTION; ISCHEMIA; A(1); NEUROPROTECTION; INFLAMMATION	Caffeine, the most consumed psychoactive drug and non-specific adenosine receptor antagonist, has recently been shown to exert a neuroprotective effect against brain injury in animal models of Parkinson's disease (PD) and stroke. However, the effects of caffeine on traumatic brain injury (TBI) are not known. In this study, we investigated the effects of acute and chronic caffeine treatment on brain injury in a cortical-impact model of TBI in mice. Following TBI, neurological deficits, cerebral edema, as well as inflammatory cell infiltration were all significantly attenuated in mice pretreated chronically (for 3 weeks) with caffeine in drinking water compared with the mice pretreated with saline. Furthermore, we found that chronic caffeine treatment attenuated glutamate release and inflammatory cytokine production, effects that were correlated with an upregulation of brain A, receptor mRNA. By contrast, acute treatment with caffeine (i.p. injection, 30 min before TBI) was not effective in protecting against TBI-induced brain injury. These results suggest that chronic (but not acute) caffeine treatment attenuates brain injury, possibly by A, receptor-mediated suppression of glutamate release and inhibition of excessive inflammatory cytokine production. These results highlight the potential benefit of chronic caffeine intake for preventing TBI and provide a rationale for the epidemiological investigation of the potential association between TBI and human caffeine intake. (c) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Chen, J. -F.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Zhou, Y.] Third Mil Med Univ, Ctr Mol Biol, Inst Surg Res, Chongqing 400042, Peoples R China; [Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Zhou, Y.] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China	Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St, Boston, MA 02118 USA.	chenjf@bu.edu; ygzhou@cta.cq.cn	Li, ping/J-6507-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41083] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041083] Funding Source: NIH RePORTER		ADEN U, 1994, MOL BRAIN RES, V23, P354, DOI 10.1016/0169-328X(94)90247-X; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; BEGLEY DJ, 1994, J CHROMATOGR B, V657, P185, DOI 10.1016/0378-4347(94)80085-5; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; BONA E, 1995, PEDIATR RES, V38, P312, DOI 10.1203/00006450-199509000-00007; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Cheng JS, 2001, J RECEPT SIGNAL TR R, V21, P1, DOI 10.1081/RRS-100107138; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006; Dall'lgna OP, 2003, BRIT J PHARMACOL, V138, P1207, DOI 10.1038/sj.bjp.0705185; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Deleu D, 2006, NEUROLOGY, V67, P897, DOI 10.1212/01.wnl.0000233916.57415.9d; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; ENGLER RL, 1991, CIRCULATION, V84, P951, DOI 10.1161/01.CIR.84.2.951; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fredholm BB, 2001, PHARMACOL REV, V53, P527; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002; Hartley TR, 2004, AM J CARDIOL, V93, P1022, DOI 10.1016/j.amjcard.2003.12.057; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Johansson B, 1997, BRAIN RES, V762, P153, DOI 10.1016/S0006-8993(97)00378-8; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu HT, 2006, GLIA, V54, P343, DOI 10.1002/glia.20400; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okusa MD, 1999, AM J PHYSIOL-RENAL, V277, pF404; Peirce SM, 2001, AM J PHYSIOL-HEART C, V281, pH67; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; Rachima-Maoz C, 1998, AM J HYPERTENS, V11, P1426, DOI 10.1016/S0895-7061(98)00172-1; Reinert M, 2000, Neurosurg Focus, V8, pe10; Riksen NP, 2006, J AM COLL CARDIOL, V48, P700, DOI 10.1016/j.jacc.2006.04.083; Ross SC, 1999, J HEART LUNG TRANSPL, V18, P994, DOI 10.1016/S1053-2498(99)00066-2; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; SACHSE KT, 2004, ANESTHESIOLOGY, V101, pA354; Sands WA, 2005, IMMUNOL LETT, V101, P1, DOI 10.1016/j.imlet.2005.04.005; SMITH AP, 1993, J PSYCHOPHARMACOL, V7, P203, DOI 10.1177/026988119300700209; SMITH PF, 2000, REPORT EXPERT WORKIN, V20, P30; Sullivan GW, 1999, J INFECT DIS, V180, P1550, DOI 10.1086/315084; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Varani K, 2005, CELL MOL LIFE SCI, V62, P2350, DOI 10.1007/s00018-005-5312-z; Varani K, 2000, CIRCULATION, V102, P285; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V253, P95, DOI 10.1016/0014-2999(94)90762-5; Washington CB, 2005, J NEUROTRAUM, V22, P1256; Xu K, 2005, PHARMACOL THERAPEUT, V105, P267, DOI 10.1016/j.pharmthera.2004.10.007; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	62	67	74	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 19	2008	151	4					1198	1207		10.1016/j.neuroscience.2007.11.020			10	Neurosciences	Neurosciences & Neurology	264PS	WOS:000253301500025	18207647				2021-06-18	
J	Ehlhardt, LA; Sohlberg, MM; Kennedy, M; Coelho, C; Ylvisaker, M; Turkstra, L; Yorkston, K				Ehlhardt, Laurie A.; Sohlberg, Mckay Moore; Kennedy, Mary; Coelho, Carl; Ylvisaker, Mark; Turkstra, Lyn; Yorkston, Kathryn			Evidence-based practice guidelines for instructing individuals with neurogenic memory impairments: What have we learned in the past 20 years?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						evidence based practice guidelines; memory impairment; cognitive rehabilitation; instruction; errorless learning	FACE-NAME ASSOCIATIONS; TRAUMATIC BRAIN-INJURY; IMPAIRED PATIENTS; VANISHING CUES; COGNITIVE REHABILITATION; INTERVENTION RESEARCH; ORGANIC AMNESIA; ERRORLESS; ACQUISITION; IMPLICIT	This article examines the instructional research literature pertinent to teaching procedures or information to individuals with acquired memory impairments due to brain injury or related conditions. The purpose is to evaluate the available evidence in order to generate practice guidelines for clinicians working in the field of cognitive rehabilitation. A systematic review of the instructional literature from 1986 to 2006 revealed 51 studies meeting search criteria. Studies were analysed and coded within the following four key domains: Population Sample, Intervention, Study Design, and Treatment Outcomes. Coding included 17 characteristics of the population sample; seven intervention parameters; five study design features; and five treatment outcome parameters. Interventions that were evaluated included systematic instructional techniques such as method of vanishing cues and errorless learning. The majority of the studies reported positive outcomes in favour of systematic instruction. However, issues related to the design and execution of effective instruction lack clarity and require further study. The interaction between the target learning objective and the individual learner profile is not well understood. The evidence review concludes with clinical recommendations based on the instructional literature and a call to clinicians to incorporate these methods into their practice to maximise patient outcomes.	[Ehlhardt, Laurie A.] Western Oregon Univ, Teaching Res Inst Eugene, Monmouth, OR USA; [Sohlberg, Mckay Moore] Univ Oregon, Eugene, OR 97403 USA; [Kennedy, Mary] Univ Minnesota, Minneapolis, MN USA; [Coelho, Carl] Univ Connecticut, Storrs, CT USA; [Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [Turkstra, Lyn] Univ Wisconsin, Madison, WI 53706 USA; [Yorkston, Kathryn] Univ Washington, Seattle, WA 98195 USA	Sohlberg, MM (corresponding author), 5285 Univ Oregon Eugene, Eugene, OR 97403 USA.	mckay@uoregon.edu					Adams G. L., 1996, RES DIRECT INSTRUCTI; Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BRADLEY VA, 2003, EFFECTIVENESS REHABI, P115; BUTTERS MA, 1993, J CLIN EXP NEUROPSYC, V15, P219, DOI 10.1080/01688639308402559; Clare L, 2002, NEUROPSYCHOLOGY, V16, P538, DOI 10.1037//0894-4105.16.4.538; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; Donovan JJ, 1999, J APPL PSYCHOL, V84, P795, DOI 10.1037/0021-9010.84.5.795; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Ducharme JM, 2001, BRAIN INJURY, V15, P333, DOI 10.1080/02699050010005869; Dunn J, 2007, NEUROPSYCHOL REHABIL, V17, P735, DOI 10.1080/09602010701218317; Edlund W, 2004, CLIN PRACTICE GUIDEL; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GONZALEZROTHI L, 2006, FED INT C TBI MARCH; Graham S., 2003, HDB LEARNING DISABIL, P323; Haslam C, 2006, NEUROPSYCHOL REHABIL, V16, P505, DOI 10.1080/09602010500231867; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hopper T, 2005, J MED SPEECH-LANG PA, V13, pXXVII; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kavale KA, 2000, J LEARN DISABIL-US, V33, P239, DOI 10.1177/002221940003300303; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; Kern RS, 2002, AM J PSYCHIAT, V159, P1921, DOI 10.1176/appi.ajp.159.11.1921; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 1996, J PSYCHIATR RES, V30, P283, DOI 10.1016/0022-3956(96)00028-3; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kim AH, 2004, J LEARN DISABIL-US, V37, P105, DOI 10.1177/00222194040370020201; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Landis J, 2006, ARCH PHYS MED REHAB, V87, P799, DOI 10.1016/j.apmr.2006.02.017; LEMONCELLO R, 2005, ANN CONV AM SPEECH L; LENG NRC, 1991, BEHAV PSYCHOTHER, V19, P173, DOI 10.1017/S0141347300012209; MASTROPIERI MA, 1996, ADV LEARNING BEHAV D, P277; MCKENNA P, 1995, HDB MEMORY DISORDERS; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Metzler-Baddeley C, 2005, J CLIN EXP NEUROPSYC, V27, P1070, DOI 10.1080/13803390490919164; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; O'Carroll RE, 1999, PSYCHOL MED, V29, P105, DOI 10.1017/S0033291798007673; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Page M, 2006, NEUROPSYCHOLOGIA, V44, P90, DOI 10.1016/j.neuropsychologia.2005.04.004; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; Pope JW, 2006, J CLIN EXP NEUROPSYC, V28, P101, DOI 10.1080/13803390490918138; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Riley GA, 2000, NEUROPSYCHOL REHABIL, V10, P133, DOI 10.1080/096020100389219; Rothi LJG, 2001, J MED SPEECH-LANG PA, V9, P117; Ruis C, 2005, AGING CLIN EXP RES, V17, P514, DOI 10.1007/BF03327420; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SOHLBERG M, 2007, J MED SPEECH PATHOLO, V15; Sohlberg M. M., 2006, REV NEUROPSICOLOGIA, V1, P14; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stark C, 2005, NEUROPSYCHOLOGY, V19, P139, DOI 10.1037/0894-4105.19.2.139; Swanson H. L., 1999, LEARNING DISABILITIE, V14, P129, DOI [DOI 10.1207/SLDRP1403_1, DOI 10.1207/SLDRP1403_]; Swanson HL, 2001, FOCUS EXCEPT CHILD, V34, P1; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.2307/1170599; Swanson HL, 1996, SCHOOL PSYCHOL REV, V25, P370; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra LS, 2005, J MED SPEECH-LANG PA, V13, P205; VANDERLINDEN M, 1994, CORTEX, V30, P305, DOI 10.1016/S0010-9452(13)80201-8; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson FC, 2003, NEUROPSYCHOL REHABIL, V13, P537, DOI 10.1080/09602010343000200; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M., 2003, ASHA SUPPLEMENT, V23, P59, DOI [10.1044/policy.TR2003-00146, DOI 10.1044/POLICY.TR2003-00146]; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Young B, 2002, AQUAT CONSERV, V12, P3, DOI 10.1002/aqc.470	84	67	69	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	3					300	342		10.1080/09602010701733190			43	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	318CB	WOS:000257068100002	18569746				2021-06-18	
J	Fujiwara, E; Schwartz, ML; Gao, FQ; Black, SE; Levine, B				Fujiwara, Esther; Schwartz, Michael L.; Gao, Fuqiang; Black, Sandra E.; Levine, Brian			Ventral frontal cortex functions and quantified MRI in traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						head injury; diffuse axonal injury; focal lesions; neuropsychology; orbitofrontal cortex; partial least squares analysis	CLOSED-HEAD-INJURY; HUMAN ORBITOFRONTAL CORTEX; PARTIAL LEAST-SQUARES; PREFRONTAL CORTEX; OBJECT ALTERNATION; DECISION-MAKING; TEMPORAL-LOBE; NEUROPSYCHOLOGICAL DEFICITS; OLFACTORY DISCRIMINATION; ALZHEIMERS-DISEASE	Ventral frontal cortex is commonly involved in traumatic brain injury (TBI). The smell identification test (SIT), object alternation (OA), and the Iowa gambling task (IGT) are associated with this brain region in experimental and neuropsychological research. We examined the relationship of performance on these tests to residual structural brain integrity quantified from MRI in 58 TBI patients, including 18 patients with focal cortical contusions and 40 patients with diffuse injury only. Image analysis yielded regional volumetric measures of gray matter, white matter and cerebrospinal fluid. Multivariate analyses identified distributed patterns of regional volume loss associated with test performance across all three behavioral measures. The tasks were sensitive to effects of TBI. In multivariate analyses, performance in all three tasks was related to gray matter loss including ventral frontal cortex, but the SIT was most sensitive to ventral frontal cortex damage, even in patients without focal lesions. The SIT was further related to temporal lobe and posterior cingulate/retrosplenial volumes. OA and the IGT were associated with superior medial frontal volumes. Complex tasks, such as OA and the IGT, do not consistently localize to a single cortical region. The SIT is associated with the integrity of ventral frontal regions, but it is also affected by distributed damage, although the contribution of undetected olfactory tract or bulb damage could not be ruled out. This study illustrates the scope and limitations of functional localization in human ventral frontal cortex. (C) 2007 Elsevier Ltd. All rights reserved.	[Fujiwara, Esther; Black, Sandra E.; Levine, Brian] Rotman Res Inst Baycrest, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Schwartz, Michael L.] Sunnybrook Hlth Sci Ctr, Dept Surg Neurosurg, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Cognit Neurol, Toronto, ON M4N 3M5, Canada; [Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada; [Schwartz, Michael L.] Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; [Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada	Levine, B (corresponding author), Rotman Res Inst Baycrest, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.moronto.ca	Fujiwara, Esther/F-8233-2011; Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Fujiwara, Esther/0000-0003-4154-0145; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042385-05, R01 HD042385, HD42385-01] Funding Source: Medline		ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Beauchamp MS, 2005, CURR OPIN NEUROBIOL, V15, P145, DOI 10.1016/j.conb.2005.03.011; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bocti C, 2006, DEMENT GERIATR COGN, V21, P364, DOI 10.1159/000091838; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Buchel C, 1998, NATURE, V394, P274, DOI 10.1038/28389; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Carone DA, 2006, NEUROIMAGE, V29, P505, DOI 10.1016/j.neuroimage.2005.07.053; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; Dade LA, 2002, BRAIN, V125, P86, DOI 10.1093/brain/awf003; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; De Wit S, 2006, J NEUROSCI, V26, P5224, DOI 10.1523/JNEUROSCI.5175-05.2006; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; Edgington E. S., 1980, RANDOMIZATION TESTS; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Faw B, 2003, CONSCIOUS COGN, V12, P83, DOI 10.1016/S1053-8100(02)00030-2; Feinstein A, 2004, NEUROLOGY, V62, P586, DOI 10.1212/01.WNL.0000110316.12086.0C; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; GAINOTTI G, 1995, MEMORY, V3, P247, DOI 10.1080/09658219508253153; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Gold JM, 1996, NEUROPSYCHOLOGY, V10, P3; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 1996, WORD MEMORY TEST; Holbourn AHS, 1943, LANCET, V2, P438; Hornak J, 2004, J COGNITIVE NEUROSCI, V16, P463, DOI 10.1162/089892904322926791; Humphreys GW, 2001, BEHAV BRAIN SCI, V24, P453, DOI 10.1017/S0140525X01004150; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; JonesGotman M, 1997, BRAIN, V120, P1845, DOI 10.1093/brain/120.10.1845; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEVINE B, UNPUB QUANTIFIED MRI; LEVINE B, IN PRESS NEUROLOGY; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MISHKIN M, 1969, NEUROPSYCHOLOGIA, V7, P357, DOI 10.1016/0028-3932(69)90060-8; O'Doherty J, 2001, NAT NEUROSCI, V4, P95; PANDYA DN, 1987, FRONTAL LOBES REVIST; Pol HEH, 2002, NEUROPSYCHOLOGIA, V40, P888, DOI 10.1016/S0028-3932(01)00167-1; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; PRIBRAM KH, 1956, J COMP PHYSIOL PSYCH, V49, P41, DOI 10.1037/h0046248; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Talairach J., 1988, COPLANAR STEREOTACTI; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Turner GR, 2006, NEUROSCIENCE, V139, P327, DOI 10.1016/j.neuroscience.2005.08.067; Verger K, 2001, BRAIN INJURY, V15, P211; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wang J, 2005, J GERONTOL A-BIOL, V60, P510, DOI 10.1093/gerona/60.4.510; WASSERMAN S, 1989, PSYCHOPHYSIOLOGY, V26, P208, DOI 10.1111/j.1469-8986.1989.tb03159.x; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zachary R., 1986, SHIPLEY I LIVING SCA; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zald DH, 2005, NEUROPSYCHOLOGY, V19, P97, DOI 10.1037/0894-4105.19.1.97; Zald DH, 2002, NEUROPSYCHOLOGY, V16, P182, DOI 10.1037//0894-4105.16.2.182; ZATORRE RJ, 1991, BRAIN, V114, P71	91	67	67	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2008	46	2					461	474		10.1016/j.neuropsychologia.2007.08.027			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	272FK	WOS:000253845100009	17976665	Green Accepted			2021-06-18	
J	Magnus, T; Coksaygan, T; Korn, T; Xue, HP; Arumugam, TV; Mughal, MR; Eckley, DM; Tang, SC; DeTolla, L; Rao, MS; Cassiani-Ingoni, R; Mattson, MP				Magnus, Tim; Coksaygan, Turhan; Korn, Thomas; Xue, Haipeng; Arumugam, Thiruma V.; Mughal, Mohamed R.; Eckley, D. Mark; Tang, Sung-Chun; DeTolla, Louis; Rao, Mahendra S.; Cassiani-Ingoni, Riccardo; Mattson, Mark P.			Evidence that nucleocytoplasmic Olig2 translocation mediates brain-injury-induced differentiation of glial precursors to astrocytes	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						glial progenitors; Olig2; astrocytes; NG2; stabwound	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT SPINAL-CORD; SUBVENTRICULAR ZONE; PROGENITOR-CELL; RESTRICTED PRECURSORS; GENE-FUNCTION; RAT-BRAIN; EXPRESSION; NEUROGENESIS	The mechanisms by which neural and glial progenitor cells in the adult brain respond to tissue injury are unknown. We studied the responses of these cells to stab wound injury in rats and in two transgenic mouse models in which Y/GFP is driven either by Sox2 (a neural stem cell marker) or by T alpha-1 (which marks newly born neurons). The response of neural progenitors was low in all nonneurogenic regions, and no neurogenesis occurred at the injury site. Glial progenitors expressing Olig2 and NG2 showed the greatest response. The appearance of these progenitors preceded the appearance of reactive astrocytes. Surprisingly, we found evidence of the translocation of the transcription factor Olig2 into cytoplasm in the first week after injury, a mechanism that is known to mediate the differentiation of astrocytes during brain development. Translocation of Olig2, down-regulation of NG2, and increased glial fibrillary acidic protein expression were recapitulated in vitro after exposure of glial progenitors to serum components or bone morphogentic protein by up-regulation of Notch-1. The glial differentiation and Olig2 translocation could be blocked by inhibition of Notch-1 with the gamma-secretase inhibitor DAPT. Together, these data indicate that the prompt maturation of numerous Olig2(+) glial progenitors to astrocytes underlies the repair process after a traumatic injury. In contrast, neural stem cells and neuronal progenitor cells appear to play only a minor role in the injured adult CNS. (c) 2007 Wiley-Liss, Inc.	NIA, GRC, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA; Univ Maryland, Sch Med, Comparat Med Program, Baltimore, MD 21201 USA; Harvard Univ, Inst Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; NIA, Lab Genet, NIH, Baltimore, MD 21224 USA; Natl Taiwan Univ Hosp, Dept Neuol, Stroke Ctr, Taipei, Taiwan; Natl Inst Neurol Disorders & Stroke, Neuroimmunol Branch, NIH, Bethesda, MD USA	Magnus, T (corresponding author), NIA, GRC, Lab Neurosci, Intramural Res Program,NIH, 5600 Nathan Shock Dr,Room 406A, Baltimore, MD 21224 USA.	magnust@mail.nih.gov	Arumugam, Thiruma/AAG-6958-2019; Eckley, David Mark/I-9245-2019; Eckley, Mark/M-3526-2014; Arumugam, Thiruma Valavan/B-4898-2011; Korn, Thomas/AAE-6960-2019; Arumugam, Thiruma/C-7969-2009; Mattson, Mark P/F-6038-2012	Eckley, Mark/0000-0003-2296-5164; Korn, Thomas/0000-0002-3633-0955; Arumugam, Thiruma/0000-0002-3377-0939; Tang, Sung-Chun/0000-0003-3731-5973			Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; ARUMUGAM TV, 2006, IN PRESS NAT MED; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Cai JL, 2004, J NEUROCHEM, V88, P212, DOI 10.1046/j.1471-4159.2003.02184.x; Coksaygan T, 2006, EXP NEUROL, V197, P475, DOI 10.1016/j.expneurol.2005.10.030; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fukuda S, 2004, CELL DEATH DIFFER, V11, P196, DOI 10.1038/sj.cdd.4401332; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Hall AK, 2004, J NEUROSCI RES, V76, P1, DOI 10.1002/jnr.20019; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Ligon KL, 2006, P NATL ACAD SCI USA, V103, P7853, DOI 10.1073/pnas.0511001103; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Magavi SS, 2000, NATURE, V405, P951; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Mekki-Dauriac S, 2002, DEVELOPMENT, V129, P5117; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rao M, 2004, J NEUROTRAUM, V21, P415, DOI 10.1089/089771504323004566; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Setoguchi T, 2004, J CELL BIOL, V166, P963, DOI 10.1083/jcb.200404104; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; WOLSWIJK G, 1991, ANN NY ACAD SCI, V633, P502; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; Wu YY, 2002, GLIA, V38, P65, DOI 10.1002/glia.10049; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	55	67	68	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2126	2137		10.1002/jnr.21368			12	Neurosciences	Neurosciences & Neurology	196XO	WOS:000248516700007	17510983				2021-06-18	
J	Pompucci, A; De Bonis, P; Pettorini, B; Petrella, G; Di Chirico, A; Anile, C				Pompucci, Angelo; De Bonis, Pasquale; Pettorini, Benedetta; Petrella, Gianpaolo; Di Chirico, Alessandro; Anile, Carmelo			Decompressive craniectomy for traumatic brain injury: Patient age and outcome	JOURNAL OF NEUROTRAUMA			English	Article						age; decompressive craniectomy; head trauma; intracranial pressure; outcome	SEVERE HEAD-INJURIES; INTRACRANIAL HYPERTENSION; MANAGEMENT; CHILDREN; SURGERY	The overall degree by which different patients may benefit from decompressive craniectomy ( DC) remains controversial. In particular, the prognostic value of age has been investigated by very few studies. Many authors state there is no significant benefit in performing a DC in severe head injury after a certain age limit, with most placing the limit at 30-50 years of age. Between 1994 and 2004, 55 patients underwent DC at our institution. Advanced age did not constitute a contraindication to surgery for both ethical and cultural reasons. Thus, the data obtained were not biased by a selection of patients based on age. We analyzed potential predictors of outcome after DC, including sex, age, Glasgow Coma Scale (GCS), and presence of mass lesion. Chi-square test was used to compare categorical variables. The independent contribution of predictive factors to outcome was studied using logistic regression analysis. Initial GCS score was found to be an independent predictor of outcome (p = 0.001). No difference in the outcome was observed between patients with GCS 6-8 and GCS 9-15. These two groups have a better prognosis than patients with GCS 3-5. Logistic regression analysis showed age as an independent predictive factor to outcome (p = 0.005). A difference in outcome exists among patients over 65 and patients aged <= 65, while groups aged < 40 and 40-65 showed no difference in outcome. Based on these findings, we believe that the age limit for performing DC should be revised.	Univ Cattolica Sacro Cuore, Sch Med, Inst Neurosurg, I-00168 Rome, Italy	De Bonis, P (corresponding author), Univ Cattolica Sacro Cuore, Sch Med, Inst Neurosurg, I-00168 Rome, Italy.	debonisvox@gmail.com	de bonis, pasquale/K-8200-2016	de bonis, pasquale/0000-0002-9879-8940			*AANS, 1996, J NEUROTRAUM, V13, P639; Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ANILE C, 1993, INTRACRANIAL PRESSUR, V8, P682; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kocher T, 1901, HIRNERSCHUTTERUNG HI, P262; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311	21	67	74	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1182	1188		10.1089/neu.2006.0244			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200009	17610357				2021-06-18	
J	Jing, RF; Wilhelmsson, U; Goodwill, W; Li, LZ; Pan, YH; Pekny, M; Skalli, O				Jing, Runfeng; Wilhelmsson, Ulrika; Goodwill, William; Li, Lizhen; Pan, Yihang; Pekny, Milos; Skalli, Omar			Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks	JOURNAL OF CELL SCIENCE			English	Article						astrocytes; intermediate filament; GFAP; vimentin	FIBRILLARY ACIDIC PROTEIN; MICE LACKING; CELLS EXPRESS; IN-VITRO; ABSENCE; SYSTEM; IDENTIFICATION; HETEROPOLYMERS; PARANEMIN; NESTIN	Immature astrocytes and astrocytoma cells contain synemin and three other intermediate filament (IF) proteins: glial fibrillary acidic protein (GFAP), vimentin and nestin. Here, we show that, after neurotrauma, reactive astrocytes produce synemin and thus propose synemin as a new marker of reactive astrocytes. Comparison of synemin mRNA and protein levels in brain tissues and astrocyte cultures from wild-type, Vim(-/-) and Gfap(-/-) Vim(-/-) mice showed that in the absence of vimentin, synemin protein was undetectable although synemin mRNA was present at wild-type levels. By contrast, in Gfap(-/-) astrocytes, synemin protein and mRNA levels, as well as synemin incorporation into vimentin IFs, were unaltered. Biochemical assays with purified proteins suggested that synemin interacts with GFAP IFs like an IF-associated protein rather than like a polymerization partner, whereas the opposite was true for synemin interaction with vimentin. In transfection experiments, synemin did not incorporate into normal, filamentous GFAP networks, but integrated into vimentin and GFAP heteropolymeric networks. Thus, alongside GFAP, vimentin and nestin, reactive astrocytes contain synemin, whose accumulation is suppressed post-transcriptionally in the absence of a polymerization partner. In astrocytes, this partner is vimentin and not GFAP, which implies a functional difference between these two type III IF proteins.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Gothenburg Univ, Sahlgrensak Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, S-41390 Gothenburg, Sweden	Skalli, O (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA.	oskall@lsuhsc.edu	Skalli, Omar/D-4980-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035317, R01NS035317] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35317] Funding Source: Medline		Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bhosle RC, 2006, BIOCHEM BIOPH RES CO, V346, P768, DOI 10.1016/j.bbrc.2006.05.192; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; CALVO JL, 1990, BRAIN RES, V532, P355, DOI 10.1016/0006-8993(90)91784-E; Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; CHEN WJ, 1994, J CELL SCI, V107, P2299; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; DAHL D, 1981, EXP NEUROL, V73, P496, DOI 10.1016/0014-4886(81)90283-1; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; Izmiryan A, 2006, GLIA, V54, P204, DOI 10.1002/glia.20378; Jacomy H, 1999, J NEUROCHEM, V73, P972, DOI 10.1046/j.1471-4159.1999.0730972.x; Jing RF, 2005, GLIA, V50, P107, DOI 10.1002/glia.20158; KOOIJMAN M, 1995, FEBS LETT, V358, P185, DOI 10.1016/0014-5793(94)01419-2; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; Lane EB, 2004, METHOD CELL BIOL, V78, P229; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Marvin NJ, 1998, J CELL SCI, V111, P1951; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; MOON RT, 1983, P NATL ACAD SCI-BIOL, V80, P5495, DOI 10.1073/pnas.80.18.5495; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Pekny Milos, 2006, P10; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; QUINLAN RA, 1983, EUR J BIOCHEM, V132, P477, DOI 10.1111/j.1432-1033.1983.tb07386.x; RALTON JE, 1994, J CELL SCI, V107, P1935; Reichelt J, 1997, J CELL SCI, V110, P2175; Rogers SD, 1997, EXP NEUROL, V145, P180, DOI 10.1006/exnr.1997.6468; Russell MA, 2006, ARCH BIOCHEM BIOPHYS, V456, P204, DOI 10.1016/j.abb.2006.06.010; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; Schweitzer SC, 2001, J CELL SCI, V114, P1079; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; Stone DJ, 1998, J NEUROSCI, V18, P3180; Sultana S, 1998, AM J PATHOL, V153, P1157, DOI 10.1016/S0002-9440(10)65660-X; Sultana S, 2000, GLIA, V30, P143, DOI 10.1002/(SICI)1098-1136(200004)30:2<143::AID-GLIA4>3.0.CO;2-Z; Tao GZ, 2003, J CELL SCI, V116, P4629, DOI 10.1242/jcs.00782; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; TRAUB P, 1983, J CELL SCI, V63, P43; Uyama N, 2006, GUT, V55, P1276, DOI 10.1136/gut.2005.078865; WANG E, 1984, P NATL ACAD SCI-BIOL, V81, P2102, DOI 10.1073/pnas.81.7.2102; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Xue ZG, 2004, EXP CELL RES, V298, P431, DOI 10.1016/j.yexcr.2004.04.023; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200	62	67	72	0	1	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0021-9533	1477-9137		J CELL SCI	J. Cell Sci.	APR 1	2007	120	7					1267	1277		10.1242/jcs.03423			11	Cell Biology	Cell Biology	148VE	WOS:000245103900016	17356066	Other Gold			2021-06-18	
J	Yang, CC; Tu, YK; Hua, MS; Huang, SJ				Yang, Chi-Cheng; Tu, Yong-Kwang; Hua, Mau-Sun; Huang, Sheng-Jean			The association between the postconcussion symptoms and clinical outcomes for patients with mild traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; postconcussion symptoms; outcomes; Glasgow Outcome Scale-Extended	SEVERE HEAD-INJURY; COMA-SCALE SCORE; DISABILITY; MANAGEMENT; SEQUELAE; GUIDELINES; ADULTS; CLASSIFICATION; CONSEQUENCES; DEPRESSION	Background. Postconcussion symptoms (PCS) (such as dizziness, headache, irritability, fatigue, and impaired memory) are common in patients who sustain a mild traumatic brain injury (mTBI). However, few studies have systematically investigated the association between PCS and clinical outcomes in mTBI patients. Therefore, the present study attempted to examine PCS during the disease course and to determine whether PCS adversely affect outcome. Methods. This was a prospective, cohort and controlled study of 115 mTBI patients. The PCS checklist was used to identify PCS and the Glasgow Outcome Scale and the Glasgow Outcome Scale-Extended were used to investigate clinical outcomes. All patients were evaluated four times: at 1 week, 2 weeks, 4 weeks, and 8 weeks after the injury. Results. Physical symptoms such as dizziness and headache were prominent in the early after injury stage (1 and 2 weeks). On the other hand, the psychosocial symptoms, such as depression and irritability, were significant at the late after injury stage (4 and 8 weeks). Dizziness adversely affected clinical outcome at both the early and late stages of the disease, whereas the impact of intracranial lesions and depression on outcome was greatest early and late, respectively. Conclusions. The results show that PCS during the disease course and the relationship between PCS and clinical outcome can be systematically evaluated. In fact, different postconcussion symptom domains should be monitored while the disease is progressing.	Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Psychol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan	Huang, SJ (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, 7 Chung San S Rd, Taipei, Taiwan.	sjhuang@med.mc.ntu.edu.tw		Tu, Yong-kwang/0000-0003-2113-1176			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chi H. T., 2005, CLASSIFICATION MED R; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Department of Health, 2005, HLTH NAT HLTH INS AN; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HSIANG JN, 2005, LONG TERM EFFECTS ME, V15, P153; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1996, NEUROTRAUMA, P13; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute of Health Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury, 1998, JAMA-J AM MED ASSOC, V282, P974; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 1992, ICD 10 CLASS MENT BE	52	67	68	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2007	62	3					657	663		10.1097/01.ta.0000203577.68764.b8			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	145PP	WOS:000244877300022	17414343				2021-06-18	
J	Bushnik, T; Englander, J; Katznelson, L				Bushnik, Tamara; Englander, Jeffrey; Katznelson, Laurence			Fatigue after TBI: Association with neuroendocrine abnormalities	BRAIN INJURY			English	Article						traumatic brain injury; hypopituitarism; fatigue; growth hormone; rehabilitation	TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE DEFICIENCY; MINOR HEAD-INJURY; LONG-TERM; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; SLEEP DISTURBANCE; SEVERITY SCALE; HYPOPITUITARISM; DEPRESSION	Objective: Evaluate the association between neuroendocrine findings and fatigue after traumatic brain injury (TBI) Research design: Prospective, observational. Methods and procedures: Sixty- four individuals at least 1 year post-TBI underwent neuroendocrine testing including thyroid, adrenal, gonadal axes and growth hormone (GH) after glucagon stimulation with assessment of fatigue using the Global Fatigue Index ( GFI) and the Fatigue Severity Scale (FSS). Main outcomes and results: GFI and FSS scores were significantly higher within this sample compared to published control data. At least one pituitary axis was abnormal in 90% of participants. Higher GH levels were significantly associated with higher FSS scores. There was a noted trend between lower basal cortisol and higher scores on both the FSS and GFI. Conclusions: The association between higher GH levels and greater fatigue contradicted the prevailing hypothesis that postacute TBI fatigue is associated with GH deficiency. The association between lower basal cortisol and greater fatigue was in the expected direction. While no other trends were noted, the fatigue derived from neuroendocrine abnormalities alone may be masked by fatigue induced by other factors commonly experienced following TBI. Given the high prevalence of pituitary abnormalities, screening for hypopituitarism after TBI is a reasonable recommendation. The contribution of GH deficiency to diminished quality of life post- TBI remains unclear.	Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, PM&R, San Jose, CA 95128 USA; Stanford Univ, Med Ctr, Dept Neurosurg, Pituitary Ctr, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA	Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@tbi-sci.org		Bushnik, Tamara/0000-0003-3328-257X			Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BELZA BL, 1995, J RHEUMATOL, V22, P639; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Rijk AE, 1999, J PSYCHOSOM RES, V47, P509, DOI 10.1016/S0022-3999(99)00049-5; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FINKELMAN JM, 1994, HUM FACTORS, V36, P232; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hillier SL, 1997, BRAIN INJURY, V11, P661; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Michael Kathleen, 2002, Rehabil Nurs, V27, P89; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PACKER TL, 1994, ARCH PHYS MED REHAB, V75, P1122, DOI 10.1016/0003-9993(94)90088-4; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ravdin LD, 1996, J CLIN PSYCHIAT, V57, P282; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHARAR E, 1990, J FAM PRACTICE, V31, P257; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Wambach K A, 1998, J Hum Lact, V14, P219, DOI 10.1177/089033449801400311; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	65	67	69	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					559	566		10.1080/02699050701426915			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100002	17577706				2021-06-18	
J	Hoane, MR; Kaplan, SA; Ellis, AL				Hoane, Michael R.; Kaplan, Shelby A.; Ellis, Amy L.			The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury	BRAIN RESEARCH			English	Article						TBI; neuronal death; neuroprotection; treatment; vitamin B3; nicotinamide; rat	FOCAL CEREBRAL-ISCHEMIA; POLY(ADP-RIBOSE) POLYMERASE; INFARCTION	Nicotinamide has been shown to protect against many of the pathophysiological factors associated with both ischemic and traumatic brain injuries. The present study evaluated the neuroprotective effect of nicotinamide on the breakdown of the blood-brain barrier (BBB) and apoptosis expression following traumatic brain injury (TBI). Animals were prepared with a unilateral cortical contusion injury (CCI). Fifteen minutes following injury the animals received either nicotinamide (500 mg/kg, ip) or 0.9% saline. The animals were perfused at 5, 24, and 72 h post-injury. BBB integrity was assessed by endogenous rat IgG immunoreactivity. Recent studies have shown that IgG immunoreactivity is a reliable measure of BBB integrity. The results indicated that IgG immunoreactivity was greatest at 5 h and declined at 24 h after injury. Nicotinamide significantly reduced IgG expression at every time point following injury. Apoptosis was examined using the TUNEL method. The results indicated that TUNEL immunoreactivity peaked at 24 h. TUNEL+ cells were classified morphologically as nonapoptotic (Type I) or apoptotic (Type II) to verify that the neuroprotective effects of nicotinamide occur by inhibiting apoptosis or necrosis. Administration of nicotinamide significantly reduced the expression of all TUNEL+ cells in the tissue surrounding the lesion cavity. Specifically there was a significant reduction in the number of Type I, Type II and Total TUNEL+ cells in the nicotinamide-treated animals. in addition, nicotinamide reduced lesion cavity expansion 72 h following CCI. These findings suggest that nicotinamide reduces BBB breach and neuronal cell loss acutely following injury and that these reductions may account for the beneficial behavioral effects seen in previous studies. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Restorat Neurosci Lab, Brain & Cognit Sci Program, Dept Psychol,Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA	Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Brain & Cognit Sci Program, Dept Psychol,Ctr Integrat Res Cognit & Neural Sci, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-03] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R15] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Brewer KL, 2004, ACAD EMERG MED, V11, P125, DOI 10.1197/j.aem.2003.09.010; CALINGASAN NY, 1995, EXP NEUROL, V134, P64, DOI 10.1006/exnr.1995.1037; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Conti AC, 1998, J NEUROSCI, V18, P5663; Hartl R, 1997, ACT NEUR S, V70, P240; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; KAUFMANN WK, 1993, FASEB J, V7, P1188; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liaudet L, 2003, CORONARY ARTERY DIS, V14, P115, DOI 10.1097/00019501-200304000-00004; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	32	67	69	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 13	2006	1125						185	193		10.1016/j.brainres.2006.10.019			9	Neurosciences	Neurosciences & Neurology	122TZ	WOS:000243251200022	17109832				2021-06-18	
J	Collie, A; McCrory, P; Makdissi, M				Collie, A.; McCrory, P.; Makdissi, M.			Does history of concussion affect current cognitive status?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; SPORT-RELATED CONCUSSION; AGREEMENT STATEMENT; BRAIN-INJURY; IMPAIRMENT; FOOTBALL; SCIENCE	The association between self reported history of concussion and current neurocognitive status is controversial. Some football studies suggest that athletes with a history of concussion display cognitive impairment relative to athletes with no history of concussion, but other studies have not been able to reproduce such findings. This study shows that there is no relation between the number of previous self reported episodes of concussion and current cognitive state, directly contradicting the findings of previous research.	Univ Melbourne, Melbourne, Vic, Australia; CogState Ltd, London, England	Collie, A (corresponding author), Level 7,21 Victoria St, Melbourne, Vic 3000, Australia.	acollie@cogstate.com	McCrory, Paul/Q-8688-2019	Collie, Alex/0000-0003-2617-9339			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497	22	67	68	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2006	40	6					550	551		10.1136/bjsm.2005.019802			2	Sport Sciences	Sport Sciences	045LG	WOS:000237743000015	16720889	Green Published			2021-06-18	
J	Devitt, R; Colantonio, A; Dawson, D; Teare, G; Ratcliff, G; Chase, S				Devitt, R.; Colantonio, A.; Dawson, D.; Teare, G.; Ratcliff, G.; Chase, S.			Prediction of long-term occupational performance outcomes for adults after moderate to severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; ageing; occupational performance; long-term outcomes; prediction	COMMUNITY INTEGRATION QUESTIONNAIRE; SPINAL-CORD-INJURY; HEALTH SURVEY QUESTIONNAIRE; BLUNT HEAD-INJURY; DISABILITY; REHABILITATION; RELIABILITY; SF-36; IMPAIRMENT; EMPLOYMENT	Purpose. To examine predictors of long-term occupational performance outcomes for adults after moderate to severe traumatic brain injury (TBI). Method. This study involved analysis of data from a retrospective cohort of adults (N = 306) with moderate to severe TBI discharged from a Pennsylvania rehabilitation treatment facility. Extensive pre-injury sociodemographic, injury-severity, post-injury personal (cognitive, physical, affective), post-injury environmental (social, institutional, physical), and post-injury occupational performance (participation in self-care, productivity, leisure activities) data were gathered from hospital records and using in-person interviews. Interviews occurred at a mean time of 14 (range, 7-24) years post-injury. Hierarchical multiple regression analysis was used to investigate determinants of long-term occupational performance outcomes. Results. Pre-injury behavioural problems, male gender, post-injury cognitive and physical deficits, and lack of access to transportation were significant independent predictors of worse occupational performance outcomes. Conclusions. The study supports the use of a comprehensive model for long-term outcomes after TBI where pre-injury characteristics and post-injury cognitive and physical characteristics account for the greatest proportion of explained variance.	Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; Arthritis Community Res & Evaluat Unit, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; HeathSouth Harmarville Rehabil Ctr, Pittsburgh, PA USA; Working Order, Pittsburgh, PA USA	Colantonio, A (corresponding author), Univ Toronto, Fac Med, Grad Dept Rehabil Sci, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			Ashley M. J., 1997, J REHABILITATION OUT, V1, P40; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *CAN ASS OCC THER, 1997, EN OCC OCC THER PERS; Charlifue SW, 1999, ARCH PHYS MED REHAB, V80, P1429, DOI 10.1016/S0003-9993(99)90254-X; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; COOPER B, 2001, MEASURING OCCUPATION, P229; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; *COUNC CLIN CLASS, 1980, INT CLASS DIS, P11; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fleming J, 1999, BRAIN INJURY, V13, P417; Fougeyrollas P., 1997, ICIDH ENV FACTORS IN, V9, P6; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Greenspan A I, 1989, Md Med J, V38, P239; Harwood RH, 1995, MANUAL LONDON HANDIC; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KIM JA, 1997, OCCUPATIONAL THERAPY, V4, P178; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Law M., 2001, MEASURING OCCUPATION; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MENTER RR, 1995, SPINAL CORD INJURY C; MOSQUEDA L, 2004, AGING DISABILITY WHA, P35; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ocampo S, 1997, OCCUP THER INT, V4, P161; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Possl O, 2001, BRAIN INJURY, V15, P15; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan RM., 1985, HALSTEAD REITAN NEUR; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Spreen O., 1988, COMPENDIUM NEUROPSYC; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stewart AL, 1992, MEASURING FUNCTIONIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Weitzenkamp DA, 2001, SPINAL CORD, V39, P301, DOI 10.1038/sj.sc.3101146; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	69	67	67	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAY	2006	28	9					547	559		10.1080/00222930500219258			13	Rehabilitation	Rehabilitation	041QN	WOS:000237470900002	16690584				2021-06-18	
J	Ownsworth, T; Fleming, J; Desbois, J; Strong, J; Kuipers, P				Ownsworth, T; Fleming, J; Desbois, J; Strong, J; Kuipers, P			A metacognitive contextual intervention to enhance error awareness and functional outcome following traumatic brain injury: A single-case experimental design	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						self-awareness; errors; behavior; executive function; observation; rehabilitation; traumatic brain injury; real-life setting; case study	SELF-AWARENESS; PSYCHOSOCIAL ADJUSTMENT; ANOSOGNOSIA; DEFICITS; REHABILITATION; DAMAGE	Very few empirically validated interventions for improving metacognitive skills (i.e., self-awareness and self-regulation) and functional outcomes have been reported. This single-case experimental study presents JM, a 36-year-old man with a very severe traumatic brain injury (TBI) who demonstrated long-term awareness deficits. Treatment at four years post-injury involved a metacognitive contextual intervention based on a conceptualization of neuro-cognitive, psychological, and socio-environmental factors contributing to his awareness deficits. The 16-week intervention targeted error awareness and self-correction in two real life settings: (a) cooking at home: and (b) volunteer work. Outcome measures included behavioral observation of error behavior and standardized awareness measures. Relative to baseline performance in the cooking setting, JM demonstrated a 44% reduction in error frequency and increased self-correction. Although no spontaneous generalization was evident in the volunteer work setting, specific training in this environment led to a 39% decrease in errors. JM later gained paid employment and received brief metacognitive training in his work environment. JM's global self-knowledge of deficits assessed by self-report was unchanged after the program. Overall, the study provides preliminary support for a metacognitive contextual approach to improve error awareness and functional Outcome in real life settings.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld 4102, Australia; Univ Queensland, CONROD, St Lucia, Qld, Australia	Ownsworth, T (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Therapies Bldg 84A, Brisbane, Qld 4072, Australia.	t.ownsworth@shrs.uq.edu.au	Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Strong, Jenny/0000-0002-9367-8755; Ownsworth, Tamara/0000-0003-1835-7094; Kuipers, Pim/0000-0003-0340-2286			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone K. D., 1986, CLIN NEUROPSYCHOLOGY, P59; CICERONE KD, 1991, NEUROPSYCHOLOGY EVER, P271; Cocchini G, 2002, NEUROPSYCHOLOGIA, V40, P2030, DOI 10.1016/S0028-3932(02)00054-4; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; DOMHOLDTZ E, 2005, REHABILITATION RES P; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMING JM, 2006, IN PRESS NEUROPSYCHO, V16; GLYNN T, 1979, REMEDIAL READING HOM; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hersen M., 1990, INT HDB BEHAV MODIFI, P175, DOI DOI 10.1007/978-1-4613-0523-1_9; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Loeb P. A., 1996, INDEPENDENT LIVING S; Marcel AJ, 2004, CORTEX, V40, P19, DOI 10.1016/S0010-9452(08)70919-5; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCNAUGHTON SS, 1987, PAUSE PROMPT PRAISE; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morris RG., 2004, COGN NEUROPSYCHOL, P275; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; OWNSWORTH TL, 2005, NEUR REH C JUL 11 12; OWNSWORTH TL, 2006, IN PRESS NEUROPSYCHO, V10; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SNITH RP, 1994, HOSP ANXIETY DEPRESS; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss D. T., 2001, FRONTAL LOBES NEUROP, P101; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Toglia JP, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P5; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; Wilson BA, 1996, BEHAV ASSESSMENT DYS; YLIVISAKER M, 1998, TRAUMATIC BRAIN INJU, P221	50	67	68	1	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					54	63		10.1017/S135561770606005X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800007	16433944	Green Published			2021-06-18	
J	Ucar, T; Akyuz, M; Kazan, S; Tuncer, R				Ucar, T; Akyuz, M; Kazan, S; Tuncer, R			Role of decompressive surgery in the management of severe head injuries: Prognostic factors and patient selection	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; intracranial hypertension; severe head injury	TRAUMATIC BRAIN-INJURY; CEREBRAL HEMISPHERIC STROKE; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; CRANIECTOMY; CHILDREN; SUPPORT; EDEMA	Decompress(ve surgery or craniectomy (DC) is a treatment option, which should be considered when the intracranial pressure (ICP) cannot be treated by conservative methods. The purpose of this study was to evaluate the benefits of decompressive craniectomy in patients with intractable posttraumatic intracranial. hypertension and to evaluate the patient selection criteria for this management protocol. In this study, 100 patients with severe head injuries were involved. All patients were treated according to the European Brain Injury Consortium (EBIC) guidelines for severe head injuries and were assessed based on individual initial Glasgow Coma Scores (GCS), age, Glasgow Outcome Score (GOS), presence of systemic injury, changes in ICP, presence of mass lesion and the right timing for DC. All patients presented with a GCS of 8 or below. Based on their initial GCS, the patients were divided in two groups of 60 (group I with GCS 4-5) and 40 (group II with GCS 6-8) in each, respectively. Prognosis was evaluated according to the (GOS). After treatment with DC, 84 of the patients (84%) showed unfavorable and 16 (16%) showed favorable outcomes. In group 1, 58 patients (96.6%) showed unfavorable and two (3.4%) showed favorable outcomes. In group 11, 26 (65%) patients showed unfavorable and 14 (25%) showed favorable outcomes. The importance of initial GCS and age in patient outcomes were statistically significant. The presence of systemic injuries or mass lesions in outcomes were not statistically significant. Based on our findings, we conclude that patients with Glasgow Coma Scores of 6-8 are the best candidates for DC treatment.	Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey	Ucar, T (corresponding author), Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey.	tucar@akdeniz.edu.tr	Kazan, Saim/G-1782-2016; tuncer, mehmet recai/C-6969-2016				Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Engelhorn T, 1999, STROKE, V30, P1456, DOI 10.1161/01.STR.30.7.1456; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; Kunze E, 1998, ACT NEUR S, V71, P16; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCKINLEY BA, 1995, J TRAUMA, V43, P583; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315; Nievas MNCY, 1999, NEUROL RES, V21, P649, DOI 10.1080/01616412.1999.11740991; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACT NEUR S, V51, P394; Schneider GH, 2002, ACT NEUR S, V81, P77; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wick J, 1999, AORN J, V69, P517, DOI 10.1016/S0001-2092(06)62463-0; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	25	67	75	2	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1311	1318		10.1089/neu.2005.22.1311			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000005	16305319				2021-06-18	
J	Van Putten, HP; Bouwhuis, MG; Muizelaar, JP; Lyeth, BG; Berman, RF				Van Putten, HP; Bouwhuis, MG; Muizelaar, JP; Lyeth, BG; Berman, RF			Diffusion-weighted imaging of edema following traumatic brain injury in rats: Effects of secondary hypoxia	JOURNAL OF NEUROTRAUMA			English	Article						cortex; cytotoxic edema; diffusion weighted-imaging; hippocampus; histology; hypoxia; lateral fluid percussion; midline shift; MRI; rats; traumatic brain injury; vasogenic edema	CONTROLLED CORTICAL IMPACT; LATERAL FLUID-PERCUSSION; CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; TIME-COURSE; CELLULAR EDEMA; CONTUSION; MRI; ISOFLURANE; PERFUSION	Hypoxia and edema are frequent and serious complications of traumatic brain injury (TBI). Therefore, we examined the effects of hypoxia on edema formation after moderate lateral fluid percussion (LFP) injury using NMR diffusion-weighted imaging (DWI). Adult Sprague-Dawley rats were separated into four groups: sham uninjured (S), hypoxia alone (H), trauma alone (T), and trauma and hypoxia (TH). Animals in Groups T and TH received LFP brain injury, with Groups H and TH undergoing 30 min of moderately severe hypoxia (FiO(2) = 0.11) immediately after surgery or TBI (respectively). DWIs were obtained at 2, 4, and 24 h and at I week post injury, and apparent diffusion coefficient (ADC) maps were constructed. Animals in Groups T and TH showed an early decrease (p < 0.001) in ADC values in the cortex ipsilateral to TBI 4 hr post injury, followed by elevated ADCs I week later (p < 0.05). No significant differences in ADC values were seen between T and TH groups in the ipsilateral cortex. In contrast, the ipsilateral hippocampus for Group TH showed only increasing ADC values. This hyperintensity in the ADC map began at 2 h after TBI, was significant by 24 h (p < 0.05), and reached a maximum at I week. This hyperintensity was not observed in Group T. Histopathology seen in TBI animals corresponded well with the pathology observed with MRI. Midline shifts reflecting edema were only observed in TBI animals with little difference between normoxic (T) and hypoxic animals (TH). In sum, this study demonstrates that the development and extent of brain edema following TBI can be examined in vivo in rats using DWI technology. TBI resulted in an early decrease in ADC values indicating cytotoxic edema in the cortex that was followed at I week by an increase in the ADC that was associated with decreased tissue cellularity. Histopathology corresponded well to the regions of brain injury and edema visualized by T2 and DWI procedures. Overall, the addition of hypoxia to brain injury resulted in a small increase in the magnitude of edema in hippocampus and cortex over that seen with trauma alone.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 94515 USA; Univ Utrecht, Dept Neurol Surg, Utrecht, Netherlands	Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 94515 USA.	rfberman@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090, R01NS045136, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45136, NS29995, NS39090] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P119; BAUGHMAN VL, 1990, ANESTHESIOLOGY, V72, P85, DOI 10.1097/00000542-199001000-00016; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Creutzfeldt O.D., 1995, CORTEX CEREBRI PERFO; Dijkhuizen RM, 1998, STROKE, V29, P695, DOI 10.1161/01.STR.29.3.695; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KUROIWA T, 1994, PATHOL INT, V44, P171, DOI 10.1111/j.1440-1827.1994.tb02590.x; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Paczynski RP, 2000, STROKE, V31, P1702, DOI 10.1161/01.STR.31.7.1702; Portella G, 2000, ACT NEUR S, V76, P273; Rowley HA, 1999, NEUROIMAG CLIN N AM, V9, P343; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stroop R, 1998, ACT NEUR S, V71, P303; SWANSON LW, 1998, BRAIN MAPS STRUCTURE; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	53	67	67	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					857	872					16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900002	16083353				2021-06-18	
J	Satchell, MA; Lai, YC; Kochanek, PM; Wisniewski, SR; Fink, EL; Siedberg, NA; Berger, RP; DeKosky, ST; Adelson, PD; Clark, RSB				Satchell, MA; Lai, YC; Kochanek, PM; Wisniewski, SR; Fink, EL; Siedberg, NA; Berger, RP; DeKosky, ST; Adelson, PD; Clark, RSB			Cytochrome c, a biomarker of apoptosis, is increased in cerebrospinal fluid from infants with inflicted brain injury from child abuse	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						battered child syndrome; caspase; child abuse; programmed cell death; shaken baby syndrome	PROGRAMMED CELL-DEATH; HEAD-INJURY; NEURONAL APOPTOSIS; CASPASE-3; ACTIVATION; RELEASE; CONTRIBUTES; ISCHEMIA; HUMANS; BCL-2	Previous studies suggest that delayed neuronal death occurs in patients with inflicted traumatic brain injury (TBI) from child abuse. It is unknown whether the mode of this delayed neuronal death represents apoptosis or necrosis, a distinction that carries therapeutic ramifications. Cytochrome c, an electron transport chain component, can be released from mitochondria under conditions of cellular stress, whereupon it can initiate and serve as a biomarker of apoptosis. To resolve this issue, cytochrome c concentration was determined in 167 ventricular cerebrospinal fluid (CSF) samples from 67 infants and children with TBI (including 15 patients diagnosed with child abuse) by ELISA. Controls included lumbar CSF from 19 infants and children without trauma or meningitis. A multivariate model adjusted for multiple within-subject observations was used to identify clinical variables associated with CSF cytochrome c. Other apoptosis-related proteins were also examined in a subset of TBI patients. Increased CSF cytochrome c was independently associated with inflicted TBI (P=0.0001) and female gender (P=0.04), but not age, Glasgow coma scale score, or survival. Other apoptosis-related proteins including Fas and caspase-1 were increased in CSF after TBI, but did not independently discriminate between accidental and inflicted TBI. These data suggest that apoptosis, as detected by the presence of cytochrome c in CSF, is uniquely prominent among the subset of TBI patients diagnosed with child abuse. The degree of apoptosis after TBI also appears to be gender-dependent. Development of strategies targeting apoptosis after TBI, particularly in victims of child abuse and in girls, appears justified.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol & Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15213 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Sch Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Fink, Ericka/0000-0002-3683-4571; Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758; Lai, Yi-Chen/0000-0002-9450-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620] Funding Source: Medline		Ahlemeyer B, 2002, BRAIN RES, V934, P107, DOI 10.1016/S0006-8993(02)02365-X; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Qiu JH, 2002, J NEUROSCI, V22, P3504; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Tatsuta T, 2000, J BIOL CHEM, V275, P14248, DOI 10.1074/jbc.275.19.14248; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	32	67	71	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2005	25	7					919	927		10.1038/sj.jcbfm.9600088			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	940CW	WOS:000230122300014	15744250	Bronze			2021-06-18	
J	Cicerone, KD				Cicerone, KD			Participation as an outcome of traumatic brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; outcomes; rehabilitation	QUALITY-OF-LIFE; COMMUNITY INTEGRATION; SATISFACTION; INDIVIDUALS	Objectives: Participation in meaningful life situations is an important aspect of functioning after traumatic brain injury (TBI). However, to date, few studies have included measures of social participation or community integration as outcome measures after TBI rehabilitation. This paper is a selective review of the literature that examines the effects of TBI rehabilitation on measures of participation or community integration. It also addresses the related questions of clinically significant improvements in community integration, variability in patterns of community functioning, and the relationship of participation and quality of life after TBI. Design: Literature review. Conclusions: A small number of studies suggest that postacute TBI rehabilitation can produce improvements in participation and community integration. However, a considerable amount of variability in rehabilitation outcomes may be apparent. Analysis of clinically significant changes in individual's functioning suggests that rehabilitation may exert its benefits not only by facilitating improvements, but also by preventing declines in community functioning. Subjective well-being and quality of life have generally been ignored as TBI rehabilitation outcomes. There is considerable evidence that participation and subjective well-being represent distinct and dissociable outcomes after TBI which may reflect the importance of patients' preferences and values in evaluating the effectiveness of rehabilitation.	JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ USA	Cicerone, KD (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org					ACOUVI P, 2001, 4 WORLD C BRAIN INJ; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; EVANS C, 2003, J INT NEUROPSYCH SOC, V9, P253; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	25	67	67	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					494	501		10.1097/00001199-200411000-00006			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100006	15602311				2021-06-18	
J	Baguley, IJ; Cameron, ID; Green, AM; Slewa-Younan, S; Marosszeky, JE; Gurka, JA				Baguley, IJ; Cameron, ID; Green, AM; Slewa-Younan, S; Marosszeky, JE; Gurka, JA			Pharmacological management of Dysautonomia following traumatic brain injury	BRAIN INJURY			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; HEAD-INJURY; INTRATHECAL BACLOFEN; AUTONOMIC DYSFUNCTION; DIENCEPHALIC SEIZURES; ACUTE HYDROCEPHALUS; BROMOCRIPTINE; HYPERTENSION; HYPERTHERMIA; WITHDRAWAL	Primary objective : To document and critically evaluate the likely effectiveness of pharmacological treatments used in a sample of patients with Dysautonomia and to link these findings to previously published literature. Research design : Retrospective case control chart review. Methods and procedures : Data were collected on age, sex and GCS matched subjects with and without Dysautonomia (35 cases and 35 controls). Data included demographic and injury details, physiological parameters, medication usage, clinical progress and rehabilitation outcome. Descriptive analyses were undertaken to characterize the timing and frequency of CNS active medications. Main outcomes and results : Dysautonomic patients were significantly more likely to receive neurologically active medications. A wide variety of drugs were utilised with the most frequent being morphine/midazolam and chlorpromazine. Cessation of morphine/midazolam produced significant increases in heart rate and respiratory rate but not temperature. Chlorpromazine may have modified respiratory rate responses, but not temperature or heart rate. Conclusions : The features of Dysautonomia are similar to a number of conditions treated as medical emergencies. Despite this, no definitive treatment paradigm exists. The best available evidence is for morphine (especially intravenously), benzodiazepines, propanolol, bromocriptine and possibly intrathecal baclofen. Barriers to improving management include the lack of a standardized nomenclature, formal definition or accepted diagnostic test. Future research needs to be conducted to improve understanding of Dysautonomia with a view to minimizing disability.	Westmead Hosp, Brain Injury Rehabil Serv, Wentwothville, NSW 2145, Australia; Univ Sydney, Dept Rehabil Med, Sydney, NSW, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Westmead Hosp, Dept Rehabil Med, Wentwothville, NSW 2145, Australia	Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentwothville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; FIGATALAMANCA L, 1985, NEUROLOGY, V35, P258, DOI 10.1212/WNL.35.2.258; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Gurrera RJ, 1999, AM J PSYCHIAT, V156, P169; LU CS, 1991, MOVEMENT DISORD, V6, P381, DOI 10.1002/mds.870060424; MANDAC BR, 1993, ARCH PHYS MED REHAB, V74, P96; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; PerezVela JL, 1996, INTENS CARE MED, V22, P593, DOI 10.1007/s001340050138; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROPPER AH, 1992, CLIN DISORDERS AUTON, P747; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; SNEED RC, 1995, ARCH PHYS MED REHAB, V76, P101, DOI 10.1016/S0003-9993(95)80051-4; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Trasmonte J, 1999, CLIN PEDIATR, V38, P611, DOI 10.1177/000992289903801008; VINCENT FM, 1986, NEUROSURGERY, V18, P190, DOI 10.1227/00006123-198602000-00013; Wilkinson R, 1999, BRAIN INJURY, V13, P1025	33	67	70	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					409	417		10.1080/02699050310001645775			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600001	15195790				2021-06-18	
J	Collie, A; Maruff, P; McStephen, M; Darby, DG				Collie, A; Maruff, P; McStephen, M; Darby, DG			Psychometric issues associated with computerised neuropsychological assessment of concussed athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							REACTION-TIME; COGNITIVE ASSESSMENT; PERFORMANCE; CONSISTENCY; INJURY; LONG	Psychometric issues associated with computerised neuropsychological assessment in sports concussion are put forward. Issues critical to ensuring test reliability and sensitivity are discussed, with particular reference to how inappropriate test design can affect clinical decision making.	CogState Ltd, Carlton, Vic 3053, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; La Trobe Univ, Dept Psychol, Melbourne, Vic, Australia	Collie, A (corresponding author), CogState Ltd, 51 Leicester St, Carlton, Vic 3053, Australia.		Maruff, Paul/AAD-2454-2021; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; Collie, Alex/0000-0003-2617-9339			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCaffrey R.J., 2000, PRACTITIONERS GUIDE; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	18	67	67	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC 1	2003	37	6					556	559		10.1136/bjsm.37.6.556			4	Sport Sciences	Sport Sciences	751YN	WOS:000187118300025	14665603	Green Published, Bronze			2021-06-18	
J	Sherer, M; Nick, TG; Sander, AM; Hart, T; Hanks, R; Rosenthal, M; High, WM; Yablon, SA				Sherer, M; Nick, TG; Sander, AM; Hart, T; Hanks, R; Rosenthal, M; High, WM; Yablon, SA			Race and productivity outcome after traumatic brain injury - Influence of confounding factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; outcome; productivity; race; traumatic brain injury	DISABILITY RATING-SCALE; HEAD-INJURY; HEALTH BELIEFS; RECOVERY; REHABILITATION; COMMUNITY; VIOLENCE; CARE	Objective: Investigate the impact of race on productivity outcome after traumatic brain injury (TBI) and evaluate the influence of confounding factors on this relationship. Design: Inception cohort of 1083 adults with TBI for whom 1-year productivity follow-up data were available. Results: Univariable logistic regression indicated that race was a significant predictor of productivity outcome after TBI. African Americans were 2.76 times more likely to be nonproductive than whites and other racial minorities were 1.92 times more likely to be nonproductive than whites. Multivariable logistic regression analyses revealed that the effect of race on employability was influenced by confounds with preinjury productivity, education level, and cause of injury. After adjustment for other predictors, African Americans were 2.00 times more likely to be nonproductive than whites and other racial minorities were 2.08 times more likely to be nonproductive than whites. The multivariable logistic regression model with all predictors except race accounted for 39% of the variability in productivity outcome (R-2-Nagelkerke = 0.39), whereas the full logistic regression model including race accounted for 41% of the variability in productivity outcome (R-2-Nagelkerke = 0.41); a difference of only 2%. Conclusion: Any effect of race on productivity is significantly influenced by confounding with preinjury productivity, education level, and cause of injury.	Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Brain Injury Res Ctr, Inst Rehabil & Res, Houston, TX USA; Thomas Jefferson Univ, Moss Rehabil Res Inst, Jefferson Med Coll, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Rehabil Med, Jefferson Med Coll, Philadelphia, PA 19107 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; UMDNJ, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						ALZOLA C, 2001, INTRO S PLUS HMISC D; BELIN TR, 2000, HLTH SERV OUTCOMES R, V1, P7; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Chamberlain K, 1998, PSYCHOL HEALTH, V13, P1105, DOI 10.1080/08870449808407453; Christensen AJ, 1999, HEALTH PSYCHOL, V18, P169, DOI 10.1037/0278-6133.18.2.169; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NORMAN P, 2001, UNDERSTANDING CHANGI; Pourat N, 2000, J AGING HEALTH, V12, P112, DOI 10.1177/089826430001200106; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	29	67	67	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2003	18	5					408	424		10.1097/00001199-200309000-00003			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725BF	WOS:000185522200003	12973271				2021-06-18	
J	Griesbach, GS; Hovda, DA; Molteni, R; Gomez-Pinilla, F				Griesbach, GS; Hovda, DA; Molteni, R; Gomez-Pinilla, F			Alterations in BDNF and synapsin I within the occipital cortex and hippocampus after mild traumatic brain injury in the developing rat: Reflections of injury-induced neuroplasticity	JOURNAL OF NEUROTRAUMA			English	Article						development; fluid-percussion injury; neurotrophins; plasticity; trkB	FACTOR MESSENGER-RNA; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; ADULT-RAT; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; FLUID PERCUSSION; HEAD-INJURY; ANTEROGRADE TRANSPORT; RETROGRADE TRANSPORT	Brain-derived neurotrophic factor (BDNF), its signal transduction receptor trkB, and its downstream effector, synapsin I, were measured in the hippocampus and occipital cortex of young animals after fluid-percussion brain injury (FPI). Isofluorane anaesthetized postnatal day 19 rats were subjected to a mild lateral FPI or sham injury. Rats were sacrificed at 24 h, 7 days, or 14 days after injury in order to determine mRNA expression. Additional animals were sacrificed at 7 and 14 days after injury for protein analysis. Only FPI animals exhibited hemispheric differences in BDNF levels. These animals exhibited a contralateral increase, ranging from 40% to 75%, in BDNF mRNA within both the hippocampus and occipital cortex at 24 h and 7 days after injury. The increase in message within the occipital cortex was accompanied by an increase in BDNF protein at 7 and 14 days after injury. However, hippocampal BDNF protein increased in both hemispheres at postinjury day 7 and was restricted to the ipsilateral hippocampus at postinjury day 14. At postinjury day 7, both trkB and synapsin I mRNA expression increased ipsilaterally and decreased contralaterally in the occipital cortex. In addition, synapsin I phosphorylation was increased by 20% in the ipsilateral cortex and by 30% in the hippocampus on this day. These results indicate that the developing brain responds to a mild injury by modifying factors related to synaptic plasticity and suggest that regions remote from the site of injury express neurotrophic signals potentially needed for compensatory responses.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Brain Injury Res Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol Sci, Los Angeles, CA 90024 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA.		Molteni, Raffaella/Q-5011-2017	Molteni, Raffaella/0000-0002-5481-7572	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308, NS38978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544, R01NS038978] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Cabelli RJ, 1996, J NEUROSCI, V16, P7965; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CATSICAS S, 1987, P NATL ACAD SCI USA, V84, P8165, DOI 10.1073/pnas.84.22.8165; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Climent E, 2000, NEUROSCI LETT, V288, P53, DOI 10.1016/S0304-3940(00)01207-6; Conner JM, 1998, REV NEUROSCIENCE, V9, P91; Conner JM, 1997, J NEUROSCI, V17, P2295; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; GIZA CC, 2001, J NEUROTRAUMA, V18; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Gottschalk WA, 1999, LEARN MEMORY, V6, P243; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Lein ES, 2000, J NEUROSCI, V20, P1470; Lein ES, 2000, J COMP NEUROL, V420, P1, DOI 10.1002/(SICI)1096-9861(20000424)420:1<1::AID-CNE1>3.0.CO;2-H; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; MILLER MW, 1988, J COMP NEUROL, V274, P387, DOI 10.1002/cne.902740308; Mufson EJ, 1996, NEUROSCIENCE, V71, P179, DOI 10.1016/0306-4522(95)00431-9; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; ROZENWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429; SCHOUPS AA, 1995, DEV BRAIN RES, V86, P326, DOI 10.1016/0165-3806(95)00043-D; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH A, 1984, EARLY BRAIN DAMAGE, P299; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Takei N, 1997, J NEUROCHEM, V68, P370; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; VOLKMAR FR, 1972, SCIENCE, V176, P1447; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; Zhou JW, 1996, DEV BRAIN RES, V97, P297, DOI 10.1016/S0165-3806(96)00159-9	67	67	72	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					803	814		10.1089/08977150260190401			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700001	12184851				2021-06-18	
J	Callahan, CD; Hinkebein, JH				Callahan, CD; Hinkebein, JH			Assessment of anosmia after traumatic brain injury: Performance characteristics of the university of Pennsylvania Smell Identification Test	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Annual Convention of the American-Psychological-Association	AUG, 2000	WASHINGTON, D.C.	Amer Psychol Assoc		anosmia; performance characteristics; traumatic brain injury; University of Pennsylvania Smell Identification; Test	HEAD TRAUMA	Objective: To examine the performance characteristics of two forms of the University of Pennsylvania Smell Identification Test (UPSIT) in a sample of persons with traumatic brain injury (TBI). Design: Analysis of consecutive admissions into a brain injury rehabilitation program. Setting: Midwestern medical center. Participants: One hundred twenty-two adults diagnosed with TBI (49% severe TBI, 16% moderate TBI, 35% mild TBI). Main Outcome Measures: University of Pennsylvania Smell Identification Test (UPSIT; Sand 40-item versions). Results: Fifty-six percent of sample exhibited impaired olfaction on the full UPSIT; 40% of these patients were unaware of their deficits. Contrary to expectation, TBI patients detected dangerous odors (natural gas, gasoline, smoke) with high accuracy. Usefulness of a 3-item screening measure was examined: Missing even one item related to a 2:1 likelihood of being anosmic. Conclusions: These findings support past investigations indicating that anosmia, and unawareness of olfactory dysfunction, are common in persons with TBI and related to injury severity. The use of the 3-item screening measure as a gross indicator was supported, although caution is advised, because nearly 20% of patients performing perfectly on the 3-item screen scored in the anosmic range on the full UPSIT.	Mem Med Ctr, ABPP, Ctr Neuromuscular Sci, Springfield, IL 62781 USA; Univ Missouri, Sch Med, Dept Hlth Psychol, Columbia, MO USA	Callahan, CD (corresponding author), Mem Med Ctr, ABPP, Ctr Neuromuscular Sci, 701 N 1st St, Springfield, IL 62781 USA.						Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; CONSTANZO RM, 1992, J HEAD TRAUMA REHAB, V7, P15; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Zasler ND, 1992, J HEAD TRAUMA REHAB, V7, P66	10	67	69	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					251	256		10.1097/00001199-200206000-00006			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400006	12086578				2021-06-18	
J	Chatzipanteli, K; Garcia, R; Marcillo, AE; Loor, KE; Kraydieh, S; Dietrich, WD				Chatzipanteli, K; Garcia, R; Marcillo, AE; Loor, KE; Kraydieh, S; Dietrich, WD			Temporal and segmental distribution of constitutive and inducible nitric oxide synthases after traumatic spinal cord injury: Effect of aminoguanidine treatment	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; nitric oxide; nitric oxide synthase; 3-nitrotyrosine	FOCAL CEREBRAL-ISCHEMIA; ACUTE INFLAMMATORY RESPONSE; BRAIN INJURY; NADPH DIAPHORASE; L-ARGININE; POSTTRAUMATIC HYPOTHERMIA; NERVOUS-SYSTEM; NEURONAL DEATH; MESSENGER-RNA; SMOOTH-MUSCLE	Nitric oxide (NO) has been shown to play an important role in the pathophysiology of traumatic brain injury (TBI) and cerebral ischemia. However, its contribution to the pathogenesis of traumatic spinal cord injury (SCI) remains to be clarified. This study determined the time course of constitutive and inducible nitric oxide synthases (cNOS and iNOS, respectively) after SCI. Rats underwent moderate SCI at T10 using the NYU impactor device and were allowed to survive for 3, 6, or 24 h and 3 days after SCI (n = 5 in each group). For the determination of enzymatic activities, spinal cords were dissected into five segments, including levels rostral and caudal (remote) to the injury site. Other rats were perfusion fixed for the immunohistochemical localization of iNOS protein levels. cNOS activity was significantly decreased at 3 and 6 h within the traumatized T10 segment and at 3, 6, and 24 h at the rostral. (T9) level (p < 0.05). Rostral (T8) and caudal (T11, T12) to the injury site cNOS activity was also decreased at 3 h after injury (p < 0.05). However, cNOS activity returned to control levels within 6 h at T8, T11 and T12 and at one day at T10 and T9 segments. iNOS enzymatic activity was elevated at all time points tested (p < 0.05), with the most robust increase observed at 24 h. Immunostaining for iNOS at 24 h revealed that a significant cellular source of iNOS protein appeared to be invading polymorphonuclear leukocytes (PMNLs). To assess the functional consequences of iNOS inhibition, aminoguanidine treatment was initiated 5 min after SCI and rats tested using the BBB open field locomotor score. Treated rats demonstrated significantly improved hindlimb function up to 7 weeks after SCI. Histopathological analysis of contusion volume showed that aminoguanidine treatment decreased lesion volume by 37% (P < 0.05). In conclusion, these results indicate that (1) cNOS and iNOS activities are regionally and temporally affected after moderate SCI, (2) the early accumulation of PMNLs are a potentially significant source of NO-induced cytotoxic products, and (3) acute aminoguanidine treatment significantly improves functional and histopathological outcome after SCI.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33101 USA	Chatzipanteli, K (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, POB 016960, Miami, FL 33101 USA.	kchatzip@miamiproject.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1P01 NS38665-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665] Funding Source: NIH RePORTER		ANDERSON R, 1995, S AFR MED J, V85, P1024; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Baumgartner WA, 1999, ANN THORAC SURG, V67, P1871, DOI 10.1016/S0003-4975(99)00445-2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BECKMAN JS, 1996, CELL PHYSL, V40, pC1424; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLOT S, 1994, STROKE, V25, P1666, DOI 10.1161/01.STR.25.8.1666; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRITIGAN BE, 1988, NEW ENGL J MED, V318, P858; BRUHWYLER J, 1993, NEUROSCI BIOBEHAV R, V17, P373, DOI 10.1016/S0149-7634(05)80114-9; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Callsen-Cencic P, 1999, CELL TISSUE RES, V295, P183, DOI 10.1007/s004410051224; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; Dalkara T, 1997, INT REV NEUROBIOL, V40, P319; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; FLEMING I, 1991, EUR J PHARMACOL, V200, P375, DOI 10.1016/0014-2999(91)90602-M; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guizar-Sahagun G, 1998, NEUROREPORT, V9, P2899, DOI 10.1097/00001756-199808240-00040; HALL ED, 1986, J NEUROTRAUM, V3, P626; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hara H, 1997, J CEREBR BLOOD F MET, V17, P515, DOI 10.1097/00004647-199705000-00005; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hirabayashi H, 2000, BRAIN RES, V852, P319, DOI 10.1016/S0006-8993(99)02117-4; HOYT KR, 1992, BRAIN RES, V592, P310, DOI 10.1016/0006-8993(92)91690-G; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; Hu WH, 1998, EUR J PHARMACOL, V342, P325, DOI 10.1016/S0014-2999(97)01492-1; Hu WH, 2000, J CHEM NEUROANAT, V17, P183, DOI 10.1016/S0891-0618(99)00039-3; Hu WH, 1999, J NEUROTRAUM, V16, P85, DOI 10.1089/neu.1999.16.85; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Ishida A, 2001, EXP NEUROL, V168, P323, DOI 10.1006/exnr.2000.7606; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LAMAS S, 1992, J CLIN INVEST, V90, P879, DOI 10.1172/JCI115963; Lin SZ, 1996, STROKE, V27, P747, DOI 10.1161/01.STR.27.4.747; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAVAGOMI S, 1999, EUR J NEUROSCI, V11, P2160; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RAVICHANDRAN LV, 1995, AM J PHYSIOL-HEART C, V268, pH2216; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SHAPPELL SB, 1994, HDB IMMUNOPHARMACOLO, P29; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131; Vizzard MA, 1997, J AUTONOM NERV SYST, V64, P128, DOI 10.1016/S0165-1838(97)00025-8; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Xu M, 1998, BRAIN RES, V808, P23, DOI 10.1016/S0006-8993(98)00787-2; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; Zhao WG, 1996, J NEUROIMMUNOL, V64, P123, DOI 10.1016/0165-5728(95)00158-1	98	67	71	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					639	651		10.1089/089771502753754109			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900008	12042098				2021-06-18	
J	Linstedt, U; Meyer, O; Kropp, P; Berkau, A; Tapp, E; Zenz, M				Linstedt, U; Meyer, O; Kropp, P; Berkau, A; Tapp, E; Zenz, M			Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						postoperative cognitive deficit; serum markers; S-100; NSE	NEURON-SPECIFIC ENOLASE; CORONARY-ARTERY BYPASS; FEMORAL-NECK FRACTURES; TRAUMATIC BRAIN INJURY; NEUROBIOCHEMICAL MARKERS; CEREBRAL-ISCHEMIA; ELDERLY PATIENTS; CARDIAC-SURGERY; DAMAGE; BLOOD	Background: S-100 protein serum concentration (S-100) serves as a marker of cerebral ischemia in cardiac surgery head injury and stroke. In these circumstances S-100 corresponds well with the results of neuropsychological tests. The aim of the present study was to investigate the value of S-100 and neuron specific enolase (NSE) in reflecting postoperative cognitive deficit (POCD) after general surgical procedures. Methods: One hundred and twenty patients undergoing vascular, trauma, urological or abdominal surgery were investigated. Serum values of S-100 and NSE were determined preoperatively and 0.5, 4, 18 and 36 h postoperatively. Neuropsychological tests for detecting POCD were performed preoperatively and on day 1, 3, and 6 after the operation. A decline of more than 10% in neuropsychological test results was regarded as POCD. Furthermore, we retrospectively compared the S-100 in patients with and without POCD in different types of surgery. Results: According to our definition, forty-eight patients had POCD (95% confidence interval: 37.5-58.5). These patients showed higher serum concentrations of S-100 (median 024ng/ml; range 0.01-3.3ng/ml) compared with those without POCD (n=69; median 0.14ng/ml; range 0-1.34ng/ml) 30 min post-operatively (P=0.01). Neuron specific enolase was unchanged during the course of the study. Differences of S-100 in patients with and without POCD were found in abdominal and vascular surgery but not in urological surgery. Conclusion: When all patients are pooled, S-100 appears to be suitable in the assessment of incidence, course and outcome of cognitive deficits. We suspect that in some surgical procedures, such as urological surgery, S-100 appears to be of limited value in detecting POCD. Neuron specific enolase did not reflect neuropsychological dysfunction after noncardiac surgery. (C) Acta Anaesthesiologica Scandinavica 46 (2002).	Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Anesthesiol Intens Care Med & Pain Therpay, D-4630 Bochum, Germany; Univ Kiel, Inst Med Psychol, Kiel, Germany; Univ Kiel, Dept Anesthesiol & Intens Care Med, Kiel, Germany	Linstedt, U (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Klin Anaesthesiol Intensiv Med & Schmerztherapie, Schornau 23-25, D-44892 Bochum, Germany.		Kropp, Peter/B-8132-2012				Anderson RE, 1999, ANN THORAC SURG, V67, P1721, DOI 10.1016/S0003-4975(99)00318-5; BERGGREN D, 1987, ANESTH ANALG, V66, P497; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; Brickenkamp R., 1994, TEST D2 AUFMERKSAMKE, V8th ed.; GODET G, 2001, PROTEIN LEVELS CORRE, V15, P25; Grocott HP, 1998, ANN THORAC SURG, V65, P1645, DOI 10.1016/S0003-4975(98)00276-8; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; Hauschild A, 1999, ONCOLOGY-BASEL, V56, P338, DOI 10.1159/000011989; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Linstedt U, 2000, ANAESTHESIST, V49, P887, DOI 10.1007/s001010070042; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; NEWMAN S, 1987, CURR PSYCHOL RES REV, V6, P115, DOI 10.1007/BF02686616; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Oswald W. D., 1997, ZAHLEN VERBINDUNGS T; Rasmussen LS, 2000, J CARDIOTHOR VASC AN, V14, P166, DOI 10.1016/S1053-0770(00)90012-0; Rasmussen LS, 1999, ACTA ANAESTH SCAND, V43, P495, DOI 10.1034/j.1399-6576.1999.430502.x; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Spreen O, 1998, COMPENDIUM NEUROPSYC, P232; URDAL P, 1983, CLIN CHEM, V29, P310; Wechsler D, 1981, ADULT INTELLIGENCE S; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	29	67	85	1	7	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2002	46	4					384	389		10.1034/j.1399-6576.2002.460409.x			6	Anesthesiology	Anesthesiology	548AV	WOS:000175366500009	11952437				2021-06-18	
J	Hoofien, D; Vakil, E; Gilboa, A; Donovick, PJ; Barak, OHR				Hoofien, D; Vakil, E; Gilboa, A; Donovick, PJ; Barak, OHR			Comparison of the predictive power of socioeconomic variables, severity of injury and age on long-term outcome of traumatic brain injury: sample-specific variables versus factors as predictors	BRAIN INJURY			English	Article							COMMUNITY INTEGRATION; HEAD-INJURY; REHABILITATION; RECOVERY; ABILITY	The primary objective of this study was to measure the predictive power of pre-injury socio-economic status (SES), severity of injury and age variables on the very long-term outcomes of traumatic brain injury (TBI). By applying a within-subjects retroactive Follow-up design and a factor analysis, the study also compared the relative power of sample-specific predictors to that of more commonly used variables and conceptually based factors. Seventy-six participants with severe TBI were evaluated at an average of 14 years post-injury with in extensive neuropsychological battery. The results show that pre-injury SES variables predict long-term cognitive, psychiatric, vocational, and social/familial functioning. Measures of severity of injury Predict daily functioning, while age at injury fails to predict any of these variables. Sample-specific predictors were more powerful than more commonly used predictors. Implications regarding long-term clinically based and conceptually based prediction, and those regarding comparisons of predictors across samples are further discussed.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Bar Ilan Univ, Ramat Gan, Israel; SUNY Binghamton, Binghamton, NY USA	Hoofien, D (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.	mshoofi@mscc.huji.ac.il					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BROSCH I, 2000, MEGAMOT, V40, P198; Chamberlain M. A., 1995, TRAUMATIC BRAIN INJU, P3; Derogatis LR., 1977, SCL 90 MANUAL SCORIN; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; GAL R, 1986, PORTRAIT ISRAELI SOL, P81; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Haslam E., 1992, PHENOLIC COMPOUNDS F, P8, DOI 10.1021/bk-1992-0506.ch002.; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOOFIEN D, 1994, FINAL REPORT COMPREH; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Melamed S, 1999, SCAND J REHABIL MED, V31, P23; MELAMED S, 1985, SCAND J REHABIL MED, P129; Millis S R, 1994, Int J Neurosci, V79, P165; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Roe A., 1956, PSYCHOL OCCUPATIONS, P76; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sherer M, 1999, BRAIN INJURY, V13, P973; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SOLOMON Z, 1988, BEHAV MED, V14, P171, DOI 10.1080/08964289.1988.9935142; SOLOMON Z, 1992, BRIT J CLIN PSYCHOL, V31, P21, DOI 10.1111/j.2044-8260.1992.tb00965.x; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	39	67	67	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2002	16	1					9	27		10.1080/02699050110088227			19	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600002	11796096				2021-06-18	
J	Kishi, Y; Robinson, RG; Kosier, JT				Kishi, Y; Robinson, RG; Kosier, JT			Suicidal ideation among patients with acute life-threatening physical illness - Patients with stroke, traumatic brain injury, myocardial infarction, and spinal cord injury	PSYCHOSOMATICS			English	Article							PRIMARY-CARE; DEPRESSION; SYMPTOMS; OUTPATIENTS; FREQUENCY; EPILEPSY; DEATH; PLANS; MOOD	Suicide is one of the leading causes of death in the community. The risk of suicide is greater among patients with physical illnesses than among the general population. This study was undertaken to evaluate the clinical characteristics and correlates of suicidal ideation in patients with acute life-threatening physical illnesses and to assess the duration of suicidal ideation. The study included a consecutive series of patients admitted with stroke, traumatic brain injury myocardial infarction, or spinal cord injury (n = 496). Study participants were administered a semistructured psychiatric interview as well as a series of standardized quantitative scales of mood, cognitive function, physical impairment, social ties, and social functioning. Follow-up evaluations of up to 24 months were also carried out. This study found that 36 (7.3%) patients with acute medical illness had clinically, significant suicidal ideation. The suicidal ideation occurred mostly among patients with major depression and sometimes in those with minor depression. About 25% of patients with major depression and acute physical illnesses developed suicidal ideation. After the improvement of depressive disorders, suicidal ideations were ameliorated. These findings suggest that the detection and treatment of depressive disorders is the most important factor in preventing suicide among this patient population.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Chiba Hokusoh Hosp, Nippon Med Sch, Dept Psychiat, Chiba, Japan	Robinson, RG (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021; Kishi, Yasuhiro/T-4047-2019		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53592, MH52879] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH052879] Funding Source: NIH RePORTER		ACHTE KA, 1971, ACTA PSYCHIATR SCA S, V225, P3; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ASNIS GM, 1993, AM J PSYCHIAT, V150, P108; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; DEVIVO MJ, 1991, PARAPLEGIA, V29, P620, DOI 10.1038/sc.1991.91; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAWTON K, 1980, J NEUROL NEUROSUR PS, V43, P168, DOI 10.1136/jnnp.43.2.168; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kishi Y, 1999, PSYCHOSOMATICS, V40, P345, DOI 10.1016/S0033-3182(99)71230-2; Kishi Y, 1996, J NERV MENT DIS, V184, P274, DOI 10.1097/00005053-199605000-00002; Kishi Y, 1996, J NEUROPSYCH CLIN N, V8, P442; Kishi Y, 1996, Int Psychogeriatr, V8, P623, DOI 10.1017/S1041610296002931; LIEBENLUFT E, 1988, PSYCHOSOMATICS, V29, P379; Lish JD, 1996, PSYCHOSOMATICS, V37, P413, DOI 10.1016/S0033-3182(96)71528-1; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MAYOU R, 1988, J PSYCHOSOM RES, V32, P541, DOI 10.1016/0022-3999(88)90038-4; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MURPHY GE, 1983, ARCH GEN PSYCHIAT, V40, P342; Olfson M, 1996, J GEN INTERN MED, V11, P447, DOI 10.1007/BF02599038; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; Rost K, 1998, GEN HOSP PSYCHIAT, V20, P12, DOI 10.1016/S0163-8343(97)00095-9; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; Sartorius N, 1974, MEASUREMENT CLASSIFI; Starr L B, 1982, Soc Work Res Abstr, V18, P28; WELLS KB, 1994, PSYCHOSOMATICS, V35, P279, DOI 10.1016/S0033-3182(94)71776-X; WHITE SJ, 1979, LANCET, V2, P458; ZIMMERMAN M, 1995, J GEN INTERN MED, V10, P573, DOI 10.1007/BF02640368; Zisook S, 1994, Ann Clin Psychiatry, V6, P27, DOI 10.3109/10401239409148836	38	67	68	0	3	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	SEP-OCT	2001	42	5					382	390		10.1176/appi.psy.42.5.382			9	Psychiatry; Psychology	Psychiatry; Psychology	487PU	WOS:000171885100002	11739904				2021-06-18	
J	Marklund, N; Clausen, F; McIntosh, TK; Hillered, L				Marklund, N; Clausen, F; McIntosh, TK; Hillered, L			Free radical scavenger posttreatment improves functional and morphological outcome after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; Morris Water Maze; neuroprotection; nitrone scavengers; rat; reactive oxygen species; traumatic brain injury (TBI)	TRAUMATIC BRAIN INJURY; BUTYL-NITRONE PBN; SPATIAL MEMORY PERFORMANCE; CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; CLOSED-HEAD-INJURY; ALPHA-PHENYLNITRONE; MITOCHONDRIAL DYSFUNCTION; DELAYED TREATMENT	Reactive oxygen species (ROS) are thought to contribute to the secondary injury process after traumatic brain injury (TBI). ROS scavenging compounds have shown neuroprotective properties in various models of experimental brain injury, including TBI. Administration of nitrone radical scavengers has emerged as a promising pharmacological concept in focal experimental ischemia due to their low toxicity and neuroprotective properties, with a time window of several hours. The aim of this study was to test the neuroprotective efficacy of two nitrones, the readily blood-brain barrier (BBB) penetrating alpha -phenyl-N-tert-butyl nitrone (PBN) and the poorly BBB penetrating sulfo-derivative, 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) after moderate (2.20-2.45 atm) lateral fluid percussion injury (FPI) in rats. Twenty-six rats received a 24-h intravenous infusion (30 mg/kg/h) of saline, PBN, or an equimolar dose of S-PBN beginning 30 min after FPI. Eight sham-operated animals were used as controls. Cognitive function was assessed using the Morris Water Maze at day 11-15 after TBI, neurological status at day 1, 4, and 8 and morphological outcome at day 15. PBN and S-PBN treatment significantly reduced the loss of ipsilateral hemispheric tissue whereas only S-PBN tended to reduce the cortical lesion volume. PBN treatment caused a significant improvement in the neurological score as compared to saline-treated animals, while S-PBN alone attenuated the cognitive deficit. Our results suggest that nitrone radical scavengers are neuroprotective when administered 30 min after FPI in rats. Differences in pharmacokinetics may account for the observed individual neuroprotective profiles of the two nitrones.	Univ Hosp, Dept Neurol & Neurosurg, Uppsala, Sweden; Univ Hosp, Dept Med Sci & Clin Chem, Uppsala, Sweden; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Marklund, N (corresponding author), Univ Hosp, Dept Neurol & Neurosurg, Uppsala, Sweden.			Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			Atlante A, 1998, NEUROSCI LETT, V245, P127, DOI 10.1016/S0304-3940(98)00195-5; AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Butterfield DA, 1998, ANN NY ACAD SCI, V854, P448, DOI 10.1111/j.1749-6632.1998.tb09924.x; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FLOYD RA, 1992, ANN NEUROL, V32, P22; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hartl R, 1997, ACT NEUR S, V70, P240; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kumar M, 1996, BIOCHEM BIOPH RES CO, V219, P497, DOI 10.1006/bbrc.1996.0262; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MALIS CD, 1986, J BIOL CHEM, V261, P14201; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pahlmark K, 1996, ACTA PHYSIOL SCAND, V157, P41, DOI 10.1046/j.1365-201X.1996.440167000.x; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stewart CA, 1999, ARCH BIOCHEM BIOPHYS, V365, P71, DOI 10.1006/abbi.1999.1159; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	62	67	71	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					821	832		10.1089/089771501316919184			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600008	11526988				2021-06-18	
J	Geddes, DM; Cargill, RS				Geddes, DM; Cargill, RS			An in vitro model of neural trauma: Devise characterization and calcium response to mechanical stretch	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							IN-VITRO; NG108-15 CELLS; BRAIN INJURY; STRAIN; TISSUE; FLUORESCENCE; DEFORMATION; ASTROCYTES; CULTURE; NEURONS	An in vitro model for neural trauma was characterized and validated. The model is based on a novel device that is capable of applying high strain rate, homogeneous, and equibiaxial deformation to neural cells in culture. The deformation waveform is fully arbitrary and controlled via closed-loop feedback. Intracellular calcium ([Ca2+](i)) alterations were recorded in real time throughout the imposed strain with an epifluorescent microscopy system. Peak change in [Ca2+](i), recovery of [Ca2+](i), and percent responding NG108-15 cells were shown to be dependent on strain rate (1(-1) to 10(-1)) and magnitude (0.1 to 0.3 Green's Strain). These measures were also shown to depend significantly on the interaction between strain rate and magnitude. This model for neural trauma is a robust system that can be used to investigate the cellular tolerance and response to traumatic brain injury.	Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Mech Engn, Atlanta, GA 30332 USA	Geddes, DM (corresponding author), Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA.						Adams J. H., 1982, HEAD INJURY BASIC CL, P141; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDC, 1998, TRAUM BRAIN INJ US R; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG CT, 1994, J BIOMECH, V27, P227, DOI 10.1016/0021-9290(94)90212-7; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Linares-Hernandez L, 1998, BBA-BIOMEMBRANES, V1372, P1, DOI 10.1016/S0005-2736(98)00035-2; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NORONHABLOB L, 1988, J NEUROCHEM, V50, P1381, DOI 10.1111/j.1471-4159.1988.tb03020.x; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Sotoudeh M, 1998, ANN BIOMED ENG, V26, P181, DOI 10.1114/1.88; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THIBAULT LE, 1983, J BIOMECH ENG-T ASME, V105, P31, DOI 10.1115/1.3138381; Tymianski M, 1996, NEUROSURGERY, V38, P1176; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; ZAUNER A, 1995, J NEUROTRAUM, V12, P457	28	67	68	1	5	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JUN	2001	123	3					247	255		10.1115/1.1374201			9	Biophysics; Engineering, Biomedical	Biophysics; Engineering	452UU	WOS:000169878700007	11476368				2021-06-18	
J	Clarke, WE; Berry, M; Smith, C; Kent, A; Logan, A				Clarke, WE; Berry, M; Smith, C; Kent, A; Logan, A			Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							MOLECULAR-WEIGHT FORMS; FACTOR-LIKE IMMUNOREACTIVITY; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; FACTOR BFGF; ENDOTHELIAL-CELLS; CYTOPLASMIC LOCALIZATION; FOREBRAIN ISCHEMIA; BRAIN-INJURY; IN-VITRO	Traumatic injury to the adult central nervous system initiates a cascade of cellular and trophic events, culminating in the formation of a reactive gliotic scar through which transected axons fail to regenerate. Levels of fibroblast growth factor-2 (FGF-2), a potent gliogenic and neurotrophic factor, together with its full-length receptor, FGF receptor 1 (FGFR1) are coordinately and significantly increased postinjury in both nuclear and cytoplasmic fractions of extracted cerebral cortex biopsies after a penetrant injury. FGFR1 is colocalized with FGF-2 in the nuclei of reactive astrocytes, and here FGF-2 is associated with nuclear euchromatin. This study unequivocally demonstrates coordinate up-regulation and trafficking of FGF-2 and full-length FGFR1 to the nucleus of reactive astrocytes in an in vivo model of brain injury, thereby implicating a role in nuclear activity for these molecules. However, the precise contribution of nuclear FGF-2/FGFR1 to the pathophysiological response of astrocytes after injury is undetermined.	Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England; GKT, Ctr Neurosci Neural Damage & Repair, London SE1 1UL, England	Clarke, WE (corresponding author), Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England.			Logan, Ann/0000-0003-3215-5042			AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bailly K, 2000, FASEB J, V14, P333; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Ballabriga J, 1997, BRAIN RES, V752, P315, DOI 10.1016/S0006-8993(96)01308-X; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CUEVAS P, 1993, SURG NEUROL, V39, P380, DOI 10.1016/0090-3019(93)90205-F; DUVERGER E, 1995, J CELL SCI, V108, P1325; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; ENGELE J, 1991, J NEUROSCI, V11, P3070; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1991, ANN NY ACAD SCI, V638, P109, DOI 10.1111/j.1749-6632.1991.tb49022.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GomezPinilla F, 1997, NEUROSCIENCE, V76, P137; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; GROTHE C, 1999, CNS INJURIES CELLULA, P201; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; HANNEKEN A, 1994, P NATL ACAD SCI USA, V91, P9170, DOI 10.1073/pnas.91.19.9170; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525; Henderson JE, 1997, MOL CELL ENDOCRINOL, V129, P1, DOI 10.1016/S0303-7207(97)04021-5; Hill C, 2000, ENDOCRINOLOGY, V141, P1196, DOI 10.1210/en.141.3.1196; KAN M, 1993, SCIENCE, V259, P1919; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; Klein S, 1996, GROWTH FACTORS, V13, P219, DOI 10.3109/08977199609003223; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Lippoldt A, 1996, BRAIN RES, V730, P1; LOGAN A, 1990, J ENDOCRINOL, V125, P339, DOI 10.1677/joe.0.1250339; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1990, BRIT J HOSP MED, V43, P428; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Masumura M, 1996, NEUROSCI LETT, V213, P119, DOI 10.1016/0304-3940(96)12841-X; MATSUDA S, 1992, BRAIN RES, V577, P92, DOI 10.1016/0006-8993(92)90541-G; MENON VK, 1994, EXP NEUROL, V129, P142, DOI 10.1006/exnr.1994.1155; OKUMURA N, 1989, J BIOCHEM-TOKYO, V106, P904, DOI 10.1093/oxfordjournals.jbchem.a122950; Patry V, 1997, BIOCHEM J, V326, P259, DOI 10.1042/bj3260259; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; Seidman KJN, 1997, BRAIN RES, V753, P18, DOI 10.1016/S0006-8993(96)01481-3; Speliotes EK, 1996, MOL BRAIN RES, V39, P31, DOI 10.1016/0169-328X(95)00351-R; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; TAKAMI K, 1993, EXP BRAIN RES, V97, P185; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WALICKE PA, 1991, J NEUROSCI, V11, P2249; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WEIBEL M, 1985, INT J DEV NEUROSCI, V3, P617, DOI 10.1016/0736-5748(85)90052-8; WOLBURG H, 1996, NEUROSCI LETT, V72, P25; WOODWARD WR, 1992, J NEUROSCI, V12, P142; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	74	67	67	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JAN	2001	17	1					17	30		10.1006/mcne.2000.0920			14	Neurosciences	Neurosciences & Neurology	397GA	WOS:000166683900002	11161466				2021-06-18	
J	Novack, TA; Alderson, AL; Bush, BA; Meythaler, JM; Canupp, K				Novack, TA; Alderson, AL; Bush, BA; Meythaler, JM; Canupp, K			Cognitive and functional recovery at 6 and 12 months post-TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; COMA-DATA-BANK; PREDICTORS; 1-YEAR	Outcome studies examining recovery from traumatic brain injury (TBI) often fail to provide a clear understanding of the time course of cognitive, emotional, and behavioural recovery. The present study represents an effort to prospectively study individuals with TBI at fixed intervals, specifically 6 and 12 months post-injury with a window of +/-1 month. Seventy-two individuals with new-onset TBI underwent neuropsychological evaluation and clinical interview at 6 and 12 months post-injury. Results revealed significant improvements in cognitive abilities, including memory, processing speed, language abilities, and constructional skills. There were significant gains in community integration and involvement in productive activities, but limitations in driving activities remained. Although individuals with mild-moderate TBI performed better than individuals with severe TBI, both groups demonstrated equivalent rates of recovery across domains. The results of this study provide important information regarding the time course of TBI recovery.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA	Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 619-19th St S,SRC 530, Birmingham, AL 35249 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [403641] Funding Source: Medline		CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GORDON WA, 1984, EVOLUTION DEFICITS A; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOU JS, 1995, ARCH NEUROL-CHICAGO, V52, P982, DOI 10.1001/archneur.1995.00540340074015; MASS AIR, 1983, J NEUROSURG, V58, P321; MATTHEWS CG, 1964, INSTRUCTION MANUAL A; MEYALER JM, 1999, ARCH PHYSICAL MED RE, V80, P1132; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; VENTON AL, 1983, MULTILINGUAL APHASIA; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009	24	67	70	0	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2000	14	11					987	996					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	373UC	WOS:000165306800004	11104138				2021-06-18	
J	Baguley, I; Slewa-Younan, S; Lazarus, R; Green, A				Baguley, I; Slewa-Younan, S; Lazarus, R; Green, A			Long-term mortality trends in patients with traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; APOLIPOPROTEIN-E; SURVIVAL; MEN	Comparison of long-term mortality rates between patients with traumatic brain injury (TBI) and the general population has not been adequately investigated. This project aimed to obtain information on the long-term mortality rate of patients with TBI. Using a rehabilitation database of a major teaching hospital, the search identified 476 patients, of whom 27 were deceased. This mortality rate (5.7%) was compared with the expected mortality rate for an equivalent population without TBI (1.5%) using Australian Life Table data. It was found chat patients with TBI had a significantly higher mortality rate than the general population (chi(2) = 12.2, p < 0.001). Possible reasons for this finding are discussed.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Fac Med, Camperdown, NSW, Australia	Baguley, I (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705; lazarus, ross/0000-0003-3939-1961			*AUSTR BUR STAT, 1997, 33020 ABS; FELMINGHAM KL, UNPUB ARCH PHYSICAL; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1997, BRAIN PATHOL, V7, P1285; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Hartig W, 1997, BRAIN RES PROTOC, V2, P35, DOI 10.1016/S1385-299X(97)00026-3; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; *SPSS BAS 9 0, 1999, US GUID; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1968, HEAD INJURED MEN 15; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124	20	67	69	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2000	14	6					505	512					8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600002	10887885				2021-06-18	
J	Swaab-Barneveld, H; de Sonneville, L; Cohen-Kettenis, P; Gielen, A; Buitelaar, J; van Engeland, H				Swaab-Barneveld, H; de Sonneville, L; Cohen-Kettenis, P; Gielen, A; Buitelaar, J; van Engeland, H			Visual sustained attention in a child psychiatric population	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						sustained attention; vigilance; continuous performance; attention-deficit hyperactivity disorder	CONTINUOUS PERFORMANCE TASK; CLOSED-HEAD INJURY; VIGILANCE PERFORMANCE; HYPERACTIVITY; DEFICIT; METHYLPHENIDATE; DISORDER; ADHD; TIME; INTELLIGENCE	Objective: To increase knowledge of the diversity and specificity of sustained attention deficits in children with attention-deficit hyperactivity disorder (ADHD), with special reference to the issue of distinguishing between children with ADHD and children with other psychiatric diagnoses. Method: A Visual sustained attention task was used to compare 52 boys with ADHD with 55 normal controls, 29 boys with oppositional defiant disorder or conduct disorder (ODD/CD), 29 boys with anxiety or dysthymia (ANX/DYS), 43 boys with pervasive developmental disorder, 24 boys with ADHD plus ODD/CD, and 14 boys with ADHD plus ANX/DYS. Results: Compared with normal controls, children with ADHD were slower, were more inaccurate, were more impulsive, were less responsive to feedback, and showed less perceptual sensitivity and stability of performance, resulting in a marked decrease in vigilance over time. Unresponsiveness to feedback and the extent of the decrease in Vigilance during time on task were found to be the only factors that distinguished children with ADHD from children with other diagnoses. Conclusion: Although only children with ADHD are characterized primarily by "attention deficit" sustained attention deficit is common to a certain extent to all children with psychiatric disorders.	Univ Utrecht Hosp, Dept Child & Adolescent Psychiat, NL-3508 GA Utrecht, Netherlands; Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; Free Univ Amsterdam Hosp, Div Pediat Neurol, Amsterdam, Netherlands	Swaab-Barneveld, H (corresponding author), Univ Utrecht Hosp, Dept Child & Adolescent Psychiat, POB 85500, NL-3508 GA Utrecht, Netherlands.	H.Swaab@Psych.azu.nl	Buitelaar, Jan K/E-4584-2012	Buitelaar, Jan K/0000-0001-8288-7757; de Sonneville, Leo/0000-0003-0133-4953			Achenbach TM., 1991, INTEGRATIVE GUIDE 19; Althaus M, 1996, CHILD NEUROPSYCHOL, V2, P30, DOI 10.1080/09297049608401348; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; AYLWARD GP, 1990, J PSYCHOEDUC ASSESS, V8, P497, DOI 10.1177/073428299000800405; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BERCH DB, 1984, SUSTAINED ATTENTION, P143; CAMPBELL JW, 1991, J SCHOOL PSYCHOL, V29, P143; CHEE P, 1989, J ABNORM CHILD PSYCH, V17, P371, DOI 10.1007/BF00915033; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; DESONNEVILLE LMJ, 1994, J CLIN EXP NEUROPSYC, V16, P877, DOI 10.1080/01688639408402700; HOCHHAUS L, 1972, PSYCHOL BULL, V77, P375, DOI 10.1037/h0032459; KAUFMAN AS, 1975, J CONSULT CLIN PSYCH, V43, P135, DOI 10.1037/h0076502; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KOELEGA HS, 1992, BIOL PSYCHOL, V34, P59, DOI 10.1016/0301-0511(92)90024-O; Koelega HS, 1995, J CHILD PSYCHOL PSYC, V36, P1477, DOI 10.1111/j.1469-7610.1995.tb01677.x; KOPP MS, 1989, PSYCHOTHER PSYCHOSOM, V52, P74, DOI 10.1159/000288302; LAM CM, 1991, REM SPEC EDUC, V12, P40, DOI 10.1177/074193259101200208; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; LUEGER RJ, 1990, J CLIN PSYCHOL, V46, P696; MACKWORTH JF, 1970, VIGILANCE ATTENTION; MICHAEL RL, 1981, PSYCHOPHYSIOLOGY, V18, P665, DOI 10.1111/j.1469-8986.1981.tb01841.x; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R., 1984, VARIETIES ATTENTION; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RUND BR, 1992, ACTA PSYCHIAT SCAND, V86, P207, DOI 10.1111/j.1600-0447.1992.tb03253.x; RUTSCHMANN J, 1986, J ABNORM CHILD PSYCH, V14, P365, DOI 10.1007/BF00915432; SCHACHAR R, 1988, J ABNORM CHILD PSYCH, V16, P361, DOI 10.1007/BF00914169; SERGEANT JA, 1985, J CHILD PSYCHOL PSYC, V26, P97, DOI 10.1111/j.1469-7610.1985.tb01631.x; SWANSON HL, 1989, J SCHOOL PSYCHOL, V27, P141, DOI 10.1016/0022-4405(89)90002-2; SWANSON L, 1981, J CHILD PSYCHOL PSYC, V22, P393, DOI 10.1111/j.1469-7610.1981.tb00563.x; SYKES DH, 1971, J CHILD PSYCHOL PSYC, V12, P129, DOI 10.1111/j.1469-7610.1971.tb01056.x; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P641, DOI 10.1007/BF00913475; VanderSteene G., 1986, WECHSLER INTELLIGENC; WERRY JS, 1987, J ABNORM CHILD PSYCH, V15, P409, DOI 10.1007/BF00916458	37	67	71	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2000	39	5					651	659		10.1097/00004583-200005000-00020			9	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	308DC	WOS:000086694400020	10802984				2021-06-18	
J	Kolakowsky-Hayner, SA; Gourley, EV; Kreutzer, JS; Marwitz, JH; Cifu, DX; McKinley, WO				Kolakowsky-Hayner, SA; Gourley, EV; Kreutzer, JS; Marwitz, JH; Cifu, DX; McKinley, WO			Pre-injury substance abuse among persons with brain injury and persons with spinal cord injury	BRAIN INJURY			English	Article							ALCOHOL-USE; HEAD-INJURY; TRAUMA PATIENTS; MARIJUANA; PATTERNS	Alcohol and drug use at the time of injury have been strongly implicated as causal factors of spinal cord injury (SCI) and traumatic brain injury (TBI). Researchers have only begun their efforts to investigate the pre-injury incidence of substance abuse in an effort to identify persons at risk for traumatic injury. No studies have compared brain and spinal cord injury populations. This investigation was based in an urban, level one trauma center federally designated as a model system of comprehensive rehabilitative services for persons with TBI and persons with SCI. Pre-injury patterns of alcohol and illicit drug use were compared among patients with SCI and patients with TBI, matched for age, gender, race, and mechanism of injury (n = 52). In accordance with previous research, participants were primarily young, unmarried, males with at least a high school education. Eighty-one percent of patients with TBI and 96% of patients with SCI reported pre-injury alcohol use. The rate of pre-injury heavy drinking for both groups was alarmingly high. Fifty-seven percent of persons with SCI and 42% of persons with TBI were heavy drinkers. Implications for risk identification, treatment, and future research are discussed.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133N50015, H133A980026] Funding Source: Medline		Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EDNA T, 1984, ACTA CHIR SCAND, V148, P209; FISHBURNE PM, 1979, NATL SURVEY DRUG ABU; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GO BK, 1995, SPINAL CORD INJURY C; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawkins DA, 1998, REHABIL PSYCHOL, V43, P219, DOI 10.1037/0090-5550.43.3.219; HEINEMANN A, 1991, ARCH PHYSICAL MED RE, V73, P482; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; ODONNELL JP, 1981, ALCOHOL HEALTH RES W, V148, P209; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1983, REHABILITATION HEAD; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SMITH J, 1990, SPINAL NETWORK; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	40	67	68	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1999	13	8					571	581					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200002	10901686				2021-06-18	
J	Allen, JW; Ivanova, SA; Fan, L; Espey, MG; Basile, AS; Faden, AI				Allen, JW; Ivanova, SA; Fan, L; Espey, MG; Basile, AS; Faden, AI			Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL SLICES; CYCLIC-AMP FORMATION; NMDA-RECEPTORS; SPINAL-CORD; PHARMACOLOGICAL CHARACTERIZATION; SYNERGISTIC INTERACTION; MGLUR AGONIST; DCG-IV; DEATH	We examined the effects of modulating group II metabotropic glutamate receptors (mGluRs) on traumatic neuronal injury using both in vitro and in vivo models. Treatment with various selective group II mGluR agonists significantly decreased lactate dehydrogenase release, a marker of cell death, after traumatic injury to rat neuronal-glial cultures; injury-induced increases in cyclic AMP and glutamate levels were also significantly reduced by a group Il agonist. The neuroprotective effects of group II agonists were markedly attenuated by co-administration of a group II antagonist or a membrane-permeable cyclic AMP analog and were additive to those provided by an N-methyl-D-aspartate receptor antagonist or a selective group I mGluR antagonist. Administration of a group II mGluR agonist 30 min after lateral fluid percussion-induced brain injury in rats significantly improved subsequent behavioral recovery as compared with vehicle-treated controls. Together these studies indicate that group II mGluR agonists protect against traumatic neuronal injury by attenuating glutamate release and cAMP levels and suggest a potential role for these agents in the treatment of clinical neurotrauma.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA	Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [Z01DK032200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 1997, J NEUROSCI, V17, P1891; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bushell TJ, 1996, BRIT J PHARMACOL, V117, P1457, DOI 10.1111/j.1476-5381.1996.tb15306.x; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; ESPEY MG, 1997, CURRENT PROTOCOLS NE; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HEI YJ, 1991, MOL PHARMACOL, V39, P233; ISHIDA M, 1993, BRIT J PHARMACOL, V109, P1169, DOI 10.1111/j.1476-5381.1993.tb13745.x; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; Jane DE, 1996, NEUROPHARMACOLOGY, V35, P1029, DOI 10.1016/S0028-3908(96)00048-2; KEMP M, 1994, EUR J PHARM-MOLEC PH, V266, P187, DOI 10.1016/0922-4106(94)90109-0; KNOPFEL T, 1995, NEUROPHARMACOLOGY, V34, P1099, DOI 10.1016/0028-3908(95)00111-I; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1990, NEUROPHARMACOLOGY, V34, P1; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; ROMANI A, 1991, J BIOL CHEM, V266, P24376; Schoepp DD, 1996, J NEUROCHEM, V66, P1981; SCHOEPP DD, 1995, NEUROPHARMACOLOGY, V34, P843, DOI 10.1016/0028-3908(95)00061-A; Schoepp DD, 1996, NEUROPHARMACOLOGY, V35, P1661, DOI 10.1016/S0028-3908(96)00121-9; Sekiyama N, 1996, BRIT J PHARMACOL, V117, P1493, DOI 10.1111/j.1476-5381.1996.tb15312.x; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUYAMA K, 1995, J CEREBR BLOOD F MET, V15, P877, DOI 10.1038/jcbfm.1995.109; VINK R, 1988, J BIOL CHEM, V263, P757; WHITTINGHAM TS, 1984, J NEUROSCI, V4, P798; WILSCH VW, 1994, EUR J PHARMACOL, V262, P287, DOI 10.1016/0014-2999(94)90743-9	41	67	68	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	1999	290	1					112	120					9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	209GM	WOS:000081039900015	10381766				2021-06-18	
J	Packard, RC				Packard, RC			Epidemiology and pathogenesis of posttraumatic headache	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						epidemiology; mild head injury; pathophysiology; posttraumatic headache	TRAUMATIC BRAIN INJURY; MINOR HEAD; MIGRAINE; MILD; PATHOPHYSIOLOGY; GLUTAMATE; MAGNESIUM; MYTH	This article presents an overview of the epidemiology and pathophysiology of posttraumatic headache. It reviews definitions of mild head injury (MHI), mild traumatic brain injury (MTBI), and concussion, and discusses the confusion that often occurs with these terms. Headache types and their pathophysiology are examined in detail. Just as the exact pathophysiology is unknown for migraine and other types of headache, the exact pathophysiology of headache after trauma is also still unknown in many cases. Possible connections between head or neck injuries and headache are reviewed, as well as hypothesized neurochemical changes that may occur in both migraine and traumatic brain injury (TBI). Psychological and legal factors are also considered.	Univ W Florida, Dept Psychol, Pensacola, FL 32503 USA	Packard, RC (corresponding author), Univ W Florida, Dept Psychol, Pensacola, FL 32503 USA.						ADLER CS, 1987, PSYCHIAT ASPECTS HEA; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Balla J, 1987, Clin Exp Neurol, V23, P179; BARCELLOS S, 1996, HEAD INJURY POSTCONC; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BROWN DSO, 1991, SOC SCI MED, V33, P283, DOI 10.1016/0277-9536(91)90362-G; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CANTU RC, 1988, CLIN SPORT MED, V7, P459; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; DANDREA G, 1991, CEPHALALGIA, V11, P197, DOI 10.1046/j.1468-2982.1991.1104197.x; DENNYBRO.D, 1973, BRAIN, V96, P783, DOI 10.1093/brain/96.4.783; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Duckro PN, 1997, HEADACHE Q-CURR TREA, V8, P228; DUCKRO PN, 1992, HEADACHE Q-CURR TREA, V3, P295; EDVINSSON L, 1985, TRENDS NEUROSCI, V8, P126, DOI 10.1016/0166-2236(85)90050-5; ERICHSEN JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1992, NEUROL CLIN, V10, P975; EVANS RW, 1992, NEUROL CLIN, V10, P815; EVANS RW, 1996, NEUROLOGY TRAUMA; FERRARI MD, 1990, NEUROLOGY, V40, P1582, DOI 10.1212/WNL.40.10.1582; FOREMAN SM, 1995, WHIPLASH INJURIES CE; FOREMAN SM, 1995, WHIPLASH INJURIES AC; Gean A, 1994, IMAGING HEAD TRAUMA; GENARELLI T, 1993, HEAD INJURY; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Holbourn AHS, 1943, LANCET, V2, P438; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KELLY R, 1981, J ROY SOC MED, V74, P275; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LARSSON LI, 1976, BRAIN RES, V113, P400, DOI 10.1016/0006-8993(76)90951-3; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MEDINA JL, 1992, HEADACHE, V32, P180, DOI 10.1111/j.1526-4610.1992.hed3204180.x; MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16; OMAYA AK, 1979, BRAIN, V97, P644; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1979, HEADACHE, V19, P370, DOI 10.1111/j.1526-4610.1979.hed1907370.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P40, DOI 10.1055/s-2008-1041057; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; Packard RC, 1996, HEADACHE Q-CURR TREA, V7, P139; PAGE H, 1885, INJURIES SPINE SPINA; PERNOW B, 1983, PHARMACOL REV, V35, P85; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, NEUROTRAUMA; POVLISHOK JT, 1989, MILD HEAD INJURY; RAMADAN NM, 1989, HEADACHE, V29, P590, DOI 10.1111/j.1526-4610.1989.hed2909590.x; RASKIN NH, 1991, NEW ENGL J MED, V325, P353, DOI 10.1056/NEJM199108013250509; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZZO M, 1996, HEAD INJURY POSTCONC; RUTHERFORD WH, 1989, MILD HEAD INJURY; Salzman SK, 1994, NEUROBIOLOGY CENTRAL; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STRAUSS I, 1904, ARCH NEUROL PSYCHIAT, V31, P893; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; TAYLOR AR, 1966, LANCET, V2, P178; TEASDALE G, 1974, LANCET, V2, P81; Trimble MR, 1981, POSTTRAUMATIC NEUROS; VIJAYAN N, 1977, HEADACHE, V17, P19, DOI 10.1111/j.1526-4610.1977.hed1701019.x; VINK R, 1988, J BIOL CHEM, V263, P757; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Wolff HG., 1963, HEADACHE OTHER HEAD; YAGAMUCHI M, 1992, HEADACHE, V32, P427; YOUNG WB, 1997, HEADACHE; 1993, J HEAT TRAUMA REHABI, V6, P86	78	67	68	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					9	21		10.1097/00001199-199902000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100004	9949243				2021-06-18	
S	Merchant, RE; Bullock, MR; Carmack, CA; Shah, AK; Wilner, KD; Ko, G; Williams, SA		Trembly, B; Slikker, W		Merchant, RE; Bullock, MR; Carmack, CA; Shah, AK; Wilner, KD; Ko, G; Williams, SA			A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			REGIONAL CEREBRAL EDEMA; ANTAGONIST; CP101,606; RAT; NEUROPROTECTANT; CP-98,113; POTENT; DAMAGE	CP-101,606 is a postsynaptic antagonist of the glutamate-mediated NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor. When administered intravenously (i.v.) at the time of injury, CP-101,606 Is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia, Minimal adverse effects have been observed in normal human volunteers given i.v. doses of up to 3 mg/kg/hr for 72 hours. The objective of the present clinical trial was to assess the safety, pharmacokinetics, and tolerability of CP-101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9-14) or hemorrhagic stroke, Patients began receiving treatment within 12 hours of brain injury, ii total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double-blind fashion to receive CP-101,606 or placebo (4 drug:1 placebo). Drug/placebo was administered by i.v. infusion (0.75 mg/kg/hr) for 2 hours and then stopped (n = 25) or continued for 22 hours (n = 4) or 70 hours (n = 24) at a rate of 0.37 mg/kg/hr, Mean plasma drug concentrations were well above the predicted therapeutic concentration of 200 ng/ml within two hours of initiating treatment and were sustained as long as drug was infused. All the patients tolerated their drug/placebo treatment, and there were no clinically significant cardiovascular or hematological abnormalities in either group. A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo. Modified Kurtzke Scoring also showed a similar pattern of improvement irrespective of type of head injury or drug/placebo treatment. This study suggests that CP-101,606, infused for up to 72 hours has no psychotropic effects and is well-tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.	Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Richmond, VA 23298 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA	Merchant, RE (corresponding author), Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Box 980631, Richmond, VA 23298 USA.						Brimecombe JC, 1998, J PHARMACOL EXP THER, V286, P627; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; KURTZKE JF, 1955, NEUROLOGY, V5, P580, DOI 10.1212/WNL.5.8.580; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; MENNITI FS, 1998, UNPUB EUR J PHARM; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409	11	67	67	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						42	50		10.1111/j.1749-6632.1999.tb07979.x			9	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700004	10668412				2021-06-18	
J	Muthuswamy, J; Sherman, DL; Thakor, NV				Muthuswamy, J; Sherman, DL; Thakor, NV			Higher-order spectral analysis of burst patterns in EEG	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						burst-suppression; EEG; nonlinearity and self-coupling; polyspectrum	NEONATAL ELECTROENCEPHALOGRAPHY; BISPECTRAL ANALYSIS; PROGNOSTIC VALUE	Burst suppression patterns in electroencephalograms (EEG's) have been observed in a variety of situations including recovery of a subject from a traumatic brain injury. They are associated with grave prognostic outcomes in neonates, We study power spectral parameters and bispectral parameters of the EEG at baseline, during early recovery from an asphyxic arrest (EEG burst patterns) and during late recovery after EEG evolves into a more continuous activity, The bicoherence indexes, which indicate the degree of phase coupling between two frequency components of a signal, are significantly higher within the delta-theta band of the EEG bursts than in the baseline of late recovery waveforms, The bispectral parameters show a more detectable trend than the power spectral parameters. In the second part of the study, we looked into the possibility of higher (>2) -order nonlinearities in the EEG bursts using the diagonal slices of the polyspectrum. The diagonal elements of the polyspectrum reveal the presence of self-frequency and self-phase coupling of orders higher than two in majority of the EEG bursts studied. The bicoherence indexes and the diagonal elements of the polyspectrum strongly indicate the presence of nonlinearities of order two and in many cases higher, in the EEG generator during episodes of bursting. This indication of nonlinearity in EEG signals provides a novel quantitative measure of brain's response to injury.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA	Thakor, NV (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 720 Rutland Ave, Baltimore, MD 21205 USA.		Thakor, Nitish V/A-5878-2008; Thakor, Nitish/G-9110-2015	Thakor, Nitish/0000-0002-9981-9395; Muthuswamy, Jit/0000-0003-3924-9869	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024282] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24282] Funding Source: Medline		ASO K, 1989, J CLIN NEUROPHYSIOL, V6, P103, DOI 10.1097/00004691-198904000-00001; BARNETT TP, 1971, SCIENCE, V172, P401, DOI 10.1126/science.172.3981.401; Brillinger D. R., 1980, Journal of Time Series Analysis, V1, P95, DOI 10.1111/j.1467-9892.1980.tb00303.x; DUMERMUTH G, 1971, ELECTROEN CLIN NEURO, V31, P137, DOI 10.1016/0013-4694(71)90183-0; DUMERMUTH G, 1970, IEEE T ACOUST SPEECH, VAU18, P404, DOI 10.1109/TAU.1970.1162144; Goel V, 1996, IEEE T BIO-MED ENG, V43, P1083, DOI 10.1109/10.541250; GRIGGDAMBERGER MM, 1989, PEDIATR NEUROL, V5, P84, DOI 10.1016/0887-8994(89)90032-5; Hinich M J, 1982, J TIME A, V3, P169, DOI DOI 10.1111/J.1467-9892.1982.TB00339.X; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; HOLMES GL, 1993, J CLIN NEUROPHYSIOL, V10, P323, DOI 10.1097/00004691-199307000-00008; HUBER PJ, 1971, IEEE T ACOUST SPEECH, VAU19, P78, DOI 10.1109/TAU.1971.1162163; LANGMOEN IA, 1983, J NEUROPHYSIOL, V50, P1320; MUTHUSWAMY J, 1995, THESIS RENSSELAER PO; NING T, 1993, IEEE T BIO-MED ENG, V40, P870, DOI 10.1109/10.245607; NING TK, 1989, IEEE T BIO-MED ENG, V36, P497, DOI 10.1109/10.18759; Patel J.K., 1982, HDB NORMAL DISTRIBUT; PEZZANI C, 1986, NEUROPEDIATRICS, V17, P11, DOI 10.1055/s-2008-1052492; RAGHUVEER MR, 1990, IEEE T AUTOMAT CONTR, V35, P48, DOI 10.1109/9.45142; SEBERT G, 1989, P WORKSH HIGHER ORDE, P223; SHERMAN DL, 1994, IEEE T SIGNAL PROCES, V42, P332, DOI 10.1109/78.275606; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; ZHOU GT, 1995, IEEE T SIGNAL PROCES, V43, P1173, DOI 10.1109/78.382402	22	67	68	0	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	NEW YORK	345 E 47TH ST, NEW YORK, NY 10017-2394 USA	0018-9294			IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	JAN	1999	46	1					92	99		10.1109/10.736762			8	Engineering, Biomedical	Engineering	152NA	WOS:000077782600011	9919830				2021-06-18	
J	Anderson, V; Fenwick, T; Manly, T; Robertson, I				Anderson, V; Fenwick, T; Manly, T; Robertson, I			Attentional skills following traumatic brain injury in childhood: a componential analysis	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; CONDUCT DISORDER; CHILDREN; DEFICITS; SURVIVORS; BEHAVIOR; AGE	Recent research has documented residual deficits in attention following traumatic brain injury in childhood. The present study aimed to investigate whether such deficits are global, or affect specific components of attention differentially. Four attentional domains were examined using a newly developed test of attention, the Test of Everyday Attention for Children: sustained attention, focussed attention, divided attention, and response inhibition. Eighteen children with a history of traumatic brain injury, aged between 8 and 14 years, and 18 non-injured matched controls participated in the study. Results indicated that attentional skills may be differentially impaired after TBI, with children who have sustained moderate-to-severe TBI exhibiting significant deficits for sustained and divided attention, and response inhibition, but relatively intact focussed attention.	MRC, Cognit & Brain Sci Unit, Cambridge, England	Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.			Robertson, Ian H/0000-0001-8637-561X			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, NEUROPSYCHOLOGICAL R, P319; ANDERSON V, NEUROPSYCHOLOGICAL R, P283; Anderson V., 1988, BRAIN IMPAIRMENT, P223; AUGUST GJ, 1990, J ABNORM CHILD PSYCH, V18, P29, DOI 10.1007/BF00919454; BAKKER K, 1996, J INT NEUROPSYCHOLOG, V2, P205; Barkley R. A., 1988, ASSESSMENT ISSUES CH, P145; Barkley R.A., 1994, DISRUPTIVE BEHAV DIS, P11, DOI [10.1007/978-1-4899-1501-6_2, DOI 10.1007/978-1-4899-1501-6_2]; Barkley RA, 1990, ATTENTION DEFICIT HY; BEGALI V, 1992, HEAD INJURY CHILDREN; BERK LE, 1991, J ABNORM CHILD PSYCH, V19, P357, DOI 10.1007/BF00911237; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; CATROPPA C, J INT NEUROPSYCHOLOG; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FENWICK T, UNPUB IMPAIRMENTS AT; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; GRIMWOOD K, 1995, PEDIATRICS, V95, P646; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; MANLY T, IN PRESS TEST EVERYD; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P178, DOI 10.1037/0021-843X.93.2.178; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner M.I., 1994, IMAGES MIND; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROURKE BP, 1987, CLIN NEUROPSYCHOL, V1, P209, DOI DOI 10.1080/13854048708520056; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; ROWE KS, 1993, RBRI USERS MANUAL PA; Sattler JM, 1988, ASSESSMENT CHILDREN; SCHAUGHENCY EA, 1989, LEARN INDIVID DIFFER, V1, P423, DOI DOI 10.1016/1041-6080(89)90022-8; SHAPIRO SK, 1986, J AM ACAD CHILD PSY, V25, P809, DOI 10.1016/S0002-7138(09)60200-4; SHAYWITZ BA, 1991, J CHILD NEUROL, V6, pS13, DOI 10.1177/0883073891006001S03; SHAYWITZ SE, 1987, PEDIATR NEUROL, V3, P129, DOI 10.1016/0887-8994(87)90077-4; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SZATMARI P, 1989, J AM ACAD CHILD PSY, V28, P865, DOI 10.1097/00004583-198911000-00010; TAYLOR HG, 1997, J INT NEUROPSYCHOLOG, V3, P557; TEASDALE G, 1974, LANCET, V2, P81; TIMMERMAN S, 1991, COGNITIVE REHABILITA, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VILLELLA S, UNPUB SUSTAINED SELE; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D., 1991, WECHSLER INTELLIGENC; YLIVASAKER M, 1985, HEAD INJURY REHABILI	56	67	67	1	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1998	12	11					937	949		10.1080/026990598121990			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300003	9839027				2021-06-18	
J	Kelly, JP; Rosenberg, JH				Kelly, JP; Rosenberg, JH			The development of guidelines for the management of concussion in sports	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; evidence-based guidelines; sports; traumatic brain injury	CEREBRAL CONCUSSION; HEAD-INJURIES; CONTACT-SPORTS; IMPACT; TRAUMA; MILD	Concussion in sports has caught the attention of the news media in recent years, primarily due to the high profile of certain athletes who have sustained traumatic brain injuries. Even though the management of concussion remains somewhat controversial, certain principles of neuroscience regarding mental status alterations and other symptoms resulting from concussion are well accepted by medical experts. Several authors have previously published management strategies for sports-related concussion based on their own experiences, but this article will describe the formal process of developing guidelines for the diagnosis and management of concussion in sports. The processes of literature review, evidence-based analysis, and consensus building are described. This article includes the grading scale, sideline evaluation, and management strategy adopted as a practice parameter by the American Academy of Neurology. Emphasis is placed on the need to detect mild forms of concussion through detailed observation and examination of athletes.	Rehabil Inst Chicago, Brain Injury Program, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; So Calif Kaiser Permanente, San Diego, CA USA; Amer Acad Neurol, Disseminat Implementat & Outcomes Comm, Minneapolis, MN 55414 USA	Kelly, JP (corresponding author), Rehabil Inst Chicago, Brain Injury Program, 345 E Super St, Chicago, IL 60611 USA.						[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barth JT, 1989, MILD HEAD INJURY; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *CO MED SOC, 1991, REP SPORTS MED COMM; Cooper PR, 1993, HEAD INJURY; DICK RW, 1994, HEAD NECK INJURIES S; Farber M, 1994, SPORTS ILLUSTRATED, p[38, 39, 46]; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENKINS A, 1986, LANCET, V2, P445; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JUGER EC, 1997, J NEUROSURG, V86, P425; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KELLY JP, 1995, BRAIN INJURY ASS TBI, V3, P3; KELLY JP, 1996, S SAFETY AM FOOTBALL; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P707; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1971, P 11  STAP CAR CRASH; PLUM F, 1986, DIAGNOSIS STUPOR COM; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SKULTETY F, 1981, SEMIN NEUROL, V1, P275; STONE JL, 1993, HEAD INJURY ITS COMP; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TORG JS, 1995, CURRENT THERAPY SPOR; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1970, LANCET, V1, P863; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 1997, MMWR, V46, P224; 1966, CLIN NEUROSURG, V12, P386	48	67	67	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1998	13	2					53	65		10.1097/00001199-199804000-00008			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF451	WOS:000072898800008	9575257				2021-06-18	
J	Faden, AI; Ivanova, SA; Yakovlev, AG; Mukhin, AG				Faden, AI; Ivanova, SA; Yakovlev, AG; Mukhin, AG			Neuroprotective effects of group III mGluR in traumatic neuronal injury	JOURNAL OF NEUROTRAUMA			English	Article						adenylyl cyclase; mRNA; neurons; NMDA receptor; RT-PCR; tissue culture	METABOTROPIC GLUTAMATE-RECEPTOR; SPINAL-CORD INJURY; AMINO-ACIDS; BRAIN INJURY; ACTIVATION; ANTAGONISTS; NMDA; NEUROTOXICITY; SELECTIVITY; DERIVATIVES	We have used an in vitro trauma model to examine the effects of modulation of group III metabotropic glutamate receptors (mGluR) on post-traumatic neuronal cell death, Rat cortical neuronal/glial cultures were subjected to standardized mechanical injury using a punch that delivers 28 parallel cuts to 96-well culture plates, resulting in approximately 50% neuronal cell loss in untreated cultures, RT-PCR demonstrated expression of mRNA for mGluR4, mGluR6, mGluR7, and mGluR8 in uninjured cultures as well as in adult rat brain, Treatment with the group III agonists L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) or L-serine-O-phosphate (L-SOP) resulted in dose-dependent neuroprotection, In contrast, treatment with the group III antagonists alpha-methyl-AP4 (MAP4) or (RS)-alpha-methylserine-O-phosphate (MSOP) caused dose-dependent exacerbation of injury, which was significantly attenuated by L-AP4 or L-SOP, The neuroprotective actions of L-AP4 or L-SOP were markedly reduced by the cyclic AMP analog 8-CPT-cAMP (500 mu m), which by itself had no effects at this concentration, Moreover, treatment with L-AP4 or L-SOP reduced basal cyclic AMP levels, Treatment with the NMDA antagonist MK 801 decreased post-traumatic cell death by 45% at optimal concentrations; combined treatment with MK 801 and group III agonists showed a significant enhancement of neuroprotection as compared to treatment with the NMDA antagonist alone, Our findings indicate a clear neuroprotective action for group III agonists in this model and suggest that group III mGluR are endogenously activated in response to trauma. The neuroprotective effects of group III agonists appear to result in part from modulation of adenylyl cyclase activity and are additive to those of an NMDA receptor antagonist.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Room EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		AMADOR E, 1963, CLIN CHEM, V9, P391; Bruno V, 1996, EUR J PHARMACOL, V310, P61, DOI 10.1016/0014-2999(96)00358-5; Bruno V, 1997, J NEUROSCI, V17, P1891; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, EUR J PHARMACOL, V256, P109; BUSHELL TJ, 1995, NEUROPHARMACOLOGY, V34, P239, DOI 10.1016/0028-3908(95)00012-U; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY BJ, 1992, BIOCHEM PHARMACOL, V44, P2303, DOI 10.1016/0006-2952(92)90673-7; COPANI A, 1995, MOL PHARMACOL, V47, P890; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P98; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, NEUROSCI LETT, V203, P211; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IVERSEN L, 1994, J NEUROCHEM, V63, P625; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; Johansen P.A., 1995, EUR J PHARMACOL, pR1; KNOPFEL T, 1995, NEUROPHARMACOLOGY, V34, P1099, DOI 10.1016/0028-3908(95)00111-I; KRISTENSEN P, 1993, NEUROSCI LETT, V155, P159, DOI 10.1016/0304-3940(93)90697-J; LEVESQUE A, 1995, J IMMUNOL METHODS, V178, P71, DOI 10.1016/0022-1759(94)00243-P; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maiese K, 1996, J NEUROCHEM, V66, P2419; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PANTER SS, 1994, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SHEILLS RA, 1990, P ROYAL SOC B, V242, P91; Thomas NK, 1996, NEUROPHARMACOLOGY, V35, P637; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Wroblewski J. T., 1996, Society for Neuroscience Abstracts, V22, P808; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	44	67	69	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1997	14	12					885	895		10.1089/neu.1997.14.885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	YU127	WOS:000071685000001	9475370				2021-06-18	
J	Koizumi, H; Fujisawa, H; Ito, H; Maekawa, T; Di, X; Bullock, R				Koizumi, H; Fujisawa, H; Ito, H; Maekawa, T; Di, X; Bullock, R			Effects of mild hypothermia on cerebral blood flow-independent changes in cortical extracellular levels of amino acids following contusion trauma in the rat	BRAIN RESEARCH			English	Article						cerebral contusion; excitatory amino acid; microdialysis; cerebral blood flow; extravasation; autoradiography; rat	CONCUSSIVE BRAIN INJURY; FREE FATTY-ACIDS; HEAD-INJURY; MODERATE HYPOTHERMIA; ISCHEMIA; GLUTAMATE; BARRIER; RELEASE; MICRODIALYSIS; DAMAGE	The mechanism of hypothermic cerebroprotection after traumatic brain injury (TBI) is unknown. The present study was conducted to investigate the effects of mild hypothermia on the changes in cortical extracellular amino acids and cerebral blood flow (CBF) caused by cerebral contusion created in the rat parietal cortex by a weight-drop method. CBF in both normothermia (37 degrees C) and hypothermia (32 degrees C) groups, which was monitored using the hydrogen clearance technique, decreased significantly after contusion, but never fell below the threshold for ischemia. Cortical levels of glutamate, aspartate, glycine and taurine, which were measured by intracerebral microdialysis, were significantly increased after contusion in each group. However, these increases were greater in the herpothermic than in the normothermic rats. Normal plasma amino acid levels were high, and autoradiography following intravenous injection of C-14-labeled glutamate revealed marked extravasation of [C-14]glutamate at the site of cortical impact. These results suggest that the post-traumatic increase in extracellular amino acids occurs independently of CBF reduction, and that extravasation of amino acids from the vascular compartment partly contributes to this increase. Hypothermic cerebroprotection in TBI is thus likely to occur through a mechanism other than reduction in interstitial excitatory amino acids. In TBI, it is postulated that the postsynaptic effects of hypothermia may be more important than the presynaptic effects, when CBF is kept above the ischemic threshold.	YAMAGUCHI UNIV,SCH MED,DEPT NEUROSURG,UBE,YAMAGUCHI 755,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT CRIT CARE & EMERGENCY MED,UBE,YAMAGUCHI 755,JAPAN; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,MCV STN,RICHMOND,VA 23298							BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHOI DW, 1987, J NEUROSCI, V7, P369; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1992, BRAIN RES, V590, P6, DOI 10.1016/0006-8993(92)91075-P; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	51	67	67	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 7	1997	747	2					304	312		10.1016/S0006-8993(96)01240-1			9	Neurosciences	Neurosciences & Neurology	WJ069	WOS:A1997WJ06900015	9046006				2021-06-18	
J	Armstead, WM				Armstead, WM			Role of endothelin in pial artery vasoconstriction and altered responses to vasopressin after brain injury	JOURNAL OF NEUROSURGERY			English	Article						fluid-percussion injury; neonate model; cerebral blood flow; vasopressin; pig	CEREBRAL BLOOD-FLOW; CANINE BASILAR ARTERY; PROTEIN-KINASE-C; NEWBORN PIGS; HEMODYNAMIC-RESPONSES; ETA RECEPTOR; SPINAL-CORD; HEAD-INJURY; RAT; VASOSPASM	Pial artery constriction following fluid-percussion injury to the brain is associated with elevated cerebrospinal fluid (CSF) vasopressin concentration in newborn pigs. It has also been observed the fluid-percussion injury reverse the function of vasopressin from that of a dilator to a constrictor. Endothelin-1 (ET-1), a purported mediator of cerebral vasospasm, can be released by several stimuli, including vasopressin. The present study was designed to investigate the role of ET-1 in pial artery constriction and in the reversal of vasopressin from a dilator to a constrictor, which is observed after fluid-percussion injury. Brain injury of moderate severity (1.9-2.3 atm) was produced in anesthetized newborn pigs that had been equipped with a closed cranial window. Endothelin-1 elicited pial dilation at low concentrations and vasoconstriction at higher concentrations. Fluid-percussion injury reversed the process of dilation to that of constriction at the low ET-1 concentration and potentiated this constriction at high ET-1 concentrations (10% +/- 1%, -8% +/- 1%, and -15% +/- 1% vs. -6% +/- 1%, -17% +/- 1%, and -26% +/- 2% for 10(-12), 10(-10), 10(-8) M ET-1 before and after fluid-percussion injury, respectively). Vasopressin modestly increased CSF ET-1 concentration before fluid-percussion injury. Fluid-percussion injury markedly increased CSF ET-1 concentration and the ability of vasopressin to release ET-1 (20 +/- 2, 26 +/- 3, and 40 +/- 4 pg/ml vs. 93 +/- 6, 141 +/- 9, and 247 +/- 31 pg/ml for control, 40 pg/ml vasopressin, and 400 pg/ml vasopressin before and after fluid-percussion injury, respectively). An ET-1 antagonist, BQ 123 (10(-6) M) blunted pial artery constriction following fluid-percussion injury (146 +/- 5 mu m-127 +/- 6 mu m vs. 144 +/- 5 mu m-136 +/- 4 mu m). The BQ 123 also blocked the reversal of vasopressin's function from that of a dilator to a constrictor after fluid-percussion injury (8% +/- 1%, 21% +/- 3%, and -5% +/- 1%, -14% +/- 2% vs. 8% +/- 1%, 21% +/- 2% and 4% +/- 1%, 2% +/- 1% for 40 and 4000 pg/ml vasopressin before and after fluid-percussion injury in the absence and presence of BQ 123, respectively). The BQ 123 blocked the constrictor component to ET-1, whereas it had no effect on the dilator component. These data show that ET-1 contributes to the reversal of vasopressin from a dilator to a constrictor following fluid-percussion injury. Furthermore, these data indicate the elevated CSF vasopressin and ET-1 interact in a positive feedback manner to promote pial artery constriction following fluid-percussion injury.	UNIV PENN, DEPT ANESTHESIA & PHARMACOL, PHILADELPHIA, PA 19104 USA	Armstead, WM (corresponding author), CHILDRENS HOSP, DEPT ANESTHESIA, 34TH ST & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.						Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1995, BRAIN RES, V689, P183, DOI 10.1016/0006-8993(95)00533-V; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; ARMSTEAD WM, 1989, AM J PHYSIOL, V257, pH707; ARMSTEAD WM, 1990, AM J PHYSIOL, V258, pH408; ARMSTEAD WM, 1989, CIRC RES, V64, P136, DOI 10.1161/01.RES.64.1.136; ARMSTEAD WM, 1992, J PHARMACOL EXP THER, V260, P1107; ARMSTEAD WM, 1992, AM J PHYSIOL, V262, pH862; ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4; BROOKS DP, 1994, J PHARMACOL EXP THER, V268, P1091; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; DOUGLAS SA, 1992, EUR J PHARMACOL, V221, P315, DOI 10.1016/0014-2999(92)90718-J; EKELUND L, 1974, NEURORADIOLOGY, V7, P209, DOI 10.1007/BF00342700; FIESCHI C, 1972, EUR NEUROL, V8, P192, DOI 10.1159/000114577; GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HANKO J, 1981, CEREBRAL MICROCIRCUL, P157; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V142, P1; HINO A, 1995, J NEUROSURG, V83, P503, DOI 10.3171/jns.1995.83.3.0503; HOSLI E, 1991, NEUROSCI LETT, V129, P55, DOI 10.1016/0304-3940(91)90719-A; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITAKURA T, 1988, J CEREBR BLOOD F MET, V8, P606, DOI 10.1038/jcbfm.1988.102; KATUSIC ZS, 1984, CIRC RES, V55, P575, DOI 10.1161/01.RES.55.5.575; LASSOFF S, 1980, BRAIN RES, V196, P266, DOI 10.1016/0006-8993(80)90736-2; LLUCH S, 1984, J PHARMACOL EXP THER, V228, P749; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MURRAY MA, 1992, AM J PHYSIOL, V263, pH1643; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; SHARE L, 1988, PHYSIOL REV, V68, P1248; SIMON JS, 1992, AM J PHYSIOL, V262, pH799; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; TOMOBE Y, 1993, BIOCHEM BIOPH RES CO, V191, P654, DOI 10.1006/bbrc.1993.1267; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WILLETTE RN, 1990, AM J PHYSIOL, V259, pH1688; YAMAURA I, 1992, J NEUROSURG, V76, P99, DOI 10.3171/jns.1992.76.1.0099; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	42	67	68	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					901	907		10.3171/jns.1996.85.5.0901			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900022	8893730				2021-06-18	
J	Rao, SM				Rao, SM			White matter disease and dementia	BRAIN AND COGNITION			English	Article; Proceedings Paper	Annual Conference on the Dementias - Diagnosis and Implications for Management	MAR, 1994	TORONTO, CANADA	Baycrest Ctr Geriatr Care, Rotman Res Inst, Univ Calif Los Angeles, Alzheimers Res Ctr			PROGRESSIVE MULTIPLE-SCLEROSIS; SORTING TEST-PERFORMANCE; CLINICALLY ISOLATED LESIONS; EVENT-RELATED POTENTIALS; FRONTAL-LOBE LESIONS; MAGNETIC-RESONANCE; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL PERFORMANCE; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT	Dementia is a common occurrence in patients with disorders affecting cerebral hemispheric white matter. Relatively little is known, however, about the specific pattern of neurobehavioral changes associated with abnormal white matter function. This review examines in detail the neurobehavioral features of a common white matter disease, multiple sclerosis (MS). The neuropsychological characteristics of MS-related dementia are compared and contrasted with those observed in three other white matter disorders (acquired immune deficiency syndrome, Binswanger's disease, and closed head injury) to determine if ''white matter dementia'' should be recognized as a unique diagnostic entity distinct from other dementing conditions. Finally, possible mechanisms by which white matter disease affects behavior are proposed. (C) 1996 Academic Press, Inc.		Rao, SM (corresponding author), MED COLL WISCONSIN, SECT NEUROPSYCHOL, DEPT NEUROL, 9200 W WISCONSIN AVE, MILWAUKEE, WI 53226 USA.		Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K04 NS01055, R01 NS22128] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K04NS001055, R01NS022128] Funding Source: NIH RePORTER		Albert M., 1978, ALZHEIMERS DISEASE S, P173; ANZOLA GP, 1990, J NEUROL NEUROSUR PS, V53, P142, DOI 10.1136/jnnp.53.2.142; ARNETT PA, 1994, NEUROLOGY, V44, P420, DOI 10.1212/WNL.44.3_Part_1.420; ARNETT PA, UNPUB TEMPORAL ORDER; Baddeley A. D., 1986, WORKING MEMORY; BARNARD RO, 1974, J NEUROL NEUROSUR PS, V37, P1259, DOI 10.1136/jnnp.37.11.1259; BEATTY PA, 1977, J NERV MENT DIS, V164, P42, DOI 10.1097/00005053-197701000-00008; Beatty W W, 1989, J Geriatr Psychiatry Neurol, V2, P145, DOI 10.1177/089198878900200305; Beatty W W, 1989, J Geriatr Psychiatry Neurol, V2, P153, DOI 10.1177/089198878900200306; BEATTY WW, 1989, ARCH NEUROL-CHICAGO, V46, P1113, DOI 10.1001/archneur.1989.00520460103020; BEATTY WW, 1989, BRAIN COGNITION, V11, P73, DOI 10.1016/0278-2626(89)90006-7; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; BEATTY WW, 1994, J CLIN EXP NEUROPSYC, V16, P165, DOI 10.1080/01688639408402627; BEATTY WW, 1990, INT J CLIN NEUROPSYC, V12, P166; BEATTY WW, 1990, B PSYCHONOMIC SOC, V28, P397; BERGIN JD, 1957, J NEUROL NEUROSUR PS, V20, P285, DOI 10.1136/jnnp.20.4.285; BERNARD BA, 1990, J CLIN EXP NEUROPSYC, V12, P22; Bernard Bryan A, 1992, Clin Neuropsychol, V6, P230, DOI 10.1080/13854049208401857; BERNARDIN LJ, 1993, J CLIN EXP NEUROPSYC, V15, P17; BERRIOS GE, 1990, BRIT J PSYCHIAT, V156, P10, DOI 10.1192/bjp.156.1.10; Bertrando P, 1983, Acta Psychiatr Belg, V83, P13; BORNSTEIN RA, 1991, ARCH NEUROL-CHICAGO, V48, P704, DOI 10.1001/archneur.1991.00530190050015; BRADLEY WG, 1984, NONINVASIVE MED IMAG, V1, P35; BRAININ M, 1988, J NEUROL, V235, P362, DOI 10.1007/BF00314234; BROOKS DJ, 1984, J NEUROL NEUROSUR PS, V47, P1182, DOI 10.1136/jnnp.47.11.1182; BROWN S, 1992, ARCH NEUROLOGY PSYCH, V7, P629; BROWNELL B, 1962, J NEUROL NEUROSUR PS, V25, P315, DOI 10.1136/jnnp.25.4.315; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; CALLANAN MM, 1989, BRAIN, V112, P361, DOI 10.1093/brain/112.2.361; Canter AH, 1951, J GEN PSYCHOL, V44, P3, DOI 10.1080/00221309.1951.9711235; CARROLL M, 1984, NEUROPSYCHOLOGIA, V22, P297, DOI 10.1016/0028-3932(84)90076-9; CLARK CM, 1992, CAN J NEUROL SCI, V19, P352, DOI 10.1017/S0317167100041986; COMI G, 1993, J NEUROL SCI, V115, pS66, DOI 10.1016/0022-510X(93)90212-H; CUMMINGS JL, 1984, ARCH NEUROL-CHICAGO, V41, P874, DOI 10.1001/archneur.1984.04050190080019; CUMMINGS JL, 1990, SUBCORTICAL DEMENTIA; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DESMEDT L, 1984, IMMUNOLOGICAL CLIN A, P342; DEVINS GM, 1987, PSYCHOL BULL, V101, P363, DOI 10.1037/0033-2909.101.3.363; DUNBAR N, 1992, AIDS, V6, P691, DOI 10.1097/00002030-199207000-00012; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; FEINSTEIN A, 1992, J NEUROL NEUROSUR PS, V55, P869, DOI 10.1136/jnnp.55.10.869; Filley CM, 1988, NEUROPSY NEUROPSY BE, V1, P239; FILLEY CM, 1996, NEUROPSYCHIATRY, P913; FINK STEPHEN L., 1966, ARCH PHYS MED REHABIL, V47, P56; FISCHER G, 1994, J ADHES SCI TECHNOL, V8, P151, DOI 10.1163/156856194X00122; Fisher J., 1988, CLIN NEUROPSYCHOL, V2; FRANKLIN GM, 1988, NEUROLOGY, V38, P1826, DOI 10.1212/WNL.38.12.1826; FRANZBLAU A, 1991, ARCH NEUROL-CHICAGO, V48, P263, DOI 10.1001/archneur.1991.00530150031013; FRIEDMAN JH, 1983, ANN NEUROL, V13, P222, DOI 10.1002/ana.410130234; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GEORGE AE, 1986, AM J NEURORADIOL, V7, P567; GERARD G, 1986, NEUROLOGY, V36, P998, DOI 10.1212/WNL.36.7.998; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GIESSER BS, 1992, ELECTROEN CLIN NEURO, V82, P320, DOI 10.1016/0013-4694(92)90002-Y; GOLDSTEIN FC, 1992, ARCH NEUROL-CHICAGO, V49, P1060, DOI 10.1001/archneur.1992.00530340080021; GRAFMAN J, 1991, ARCH NEUROL-CHICAGO, V48, P1072, DOI 10.1001/archneur.1991.00530220094025; Grafman J, 1990, NEUROBEHAVIORAL ASPE, P102; GRANT I, 1990, J CONSULT CLIN PSYCH, V58, P22, DOI 10.1037/0022-006X.58.1.22; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; GRIGSBY J, 1994, PERCEPT MOTOR SKILL, V78, P883, DOI 10.2466/pms.1994.78.3.883; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; HEINDEL WC, 1988, BEHAV NEUROSCI, V102, P141, DOI 10.1037/0735-7044.102.1.141; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HOTOPF MH, 1994, PSYCHOL MED, V24, P525, DOI 10.1017/S0033291700027483; HUBER SJ, 1987, ARCH NEUROL-CHICAGO, V44, P732, DOI 10.1001/archneur.1987.00520190040015; HUBER SJ, 1992, J NEUROPSYCH CLIN N, V4, P152; INZITARI D, 1987, ARCH NEUROL-CHICAGO, V44, P42, DOI 10.1001/archneur.1987.00520130034014; IVNIK RJ, 1978, J CLIN PSYCHIAT, V39, P304; IVNIK RJ, 1978, J CONSULT CLIN PSYCH, V46, P913, DOI 10.1037/0022-006X.46.5.913; JACOBSON JT, 1983, EAR HEARING, V4, P311, DOI 10.1097/00003446-198311000-00009; JAMBOR KL, 1969, BRIT J PSYCHIAT, V115, P765, DOI 10.1192/bjp.115.524.765; JENNEKENSSCHINKEL A, 1990, J NEUROL SCI, V99, P229, DOI 10.1016/0022-510X(90)90158-J; JERNIGAN TL, 1990, ARCH NEUROL-CHICAGO, V47, P27, DOI 10.1001/archneur.1990.00530010035015; JOFFE RT, 1987, ARCH NEUROL-CHICAGO, V44, P376, DOI 10.1001/archneur.1987.00520160018007; JONES RD, 1991, J CLIN EXP NEUROPSYC, V13, P74; KAEMINGK KL, 1989, CLIN NEUROPSYCHOL, V3, P309; KINKEL WR, 1985, ARCH NEUROL-CHICAGO, V42, P951, DOI 10.1001/archneur.1985.04060090033010; Krikorian R, 1990, J Neuropsychiatry Clin Neurosci, V2, P256; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P607, DOI 10.1001/archneur.1988.00520300025012; Lumsden CE, 1970, HDB CLIN NEUROLOGY, V9, P217; LYONCAEN O, 1986, ARCH NEUROL-CHICAGO, V43, P1138, DOI 10.1001/archneur.1986.00520110034010; MARSH GG, 1980, J NERV MENT DIS, V168, P758, DOI 10.1097/00005053-198012000-00009; MATEER EJ, 1993, NEUROPSYCHOLOGY ALZH, P416; MAURELLI M, 1992, ACTA NEUROL SCAND, V86, P124, DOI 10.1111/j.1600-0404.1992.tb05052.x; MCALLISTER RH, 1992, J NEUROL NEUROSUR PS, V55, P143, DOI 10.1136/jnnp.55.2.143; MCINTOSHMICHAELIS SA, 1991, BRIT J CLIN PSYCHOL, V30, P333, DOI 10.1111/j.2044-8260.1991.tb00954.x; MCKEGNEY FP, 1990, AIDS, V4, P565, DOI 10.1097/00002030-199006000-00011; MEDAER R, 1987, J NEUROL, V235, P86, DOI 10.1007/BF00718015; MILLER AKH, 1980, NEUROPATH APPL NEURO, V6, P119, DOI 10.1111/j.1365-2990.1980.tb00283.x; MINDEN SL, 1990, J CLIN EXP NEUROPSYC, V12, P566, DOI 10.1080/01688639008401002; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MINDEN SL, 1987, GEN HOSP PSYCHIAT, V9, P426, DOI 10.1016/0163-8343(87)90052-1; MOLLER A, 1994, ACTA PSYCHIAT SCAND, V89, P117, DOI 10.1111/j.1600-0447.1994.tb01497.x; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NEWTON MR, 1989, BRAIN, V112, P1637, DOI 10.1093/brain/112.6.1637; OLMOSLAU N, 1977, NEUROLOGY, V27, P623, DOI 10.1212/WNL.27.7.623; PARSONS OA, 1957, J NERV MENT DIS, V125, P221, DOI 10.1097/00005053-195704000-00006; PERDICES M, 1990, J ACQ IMMUN DEF SYND, V3, P555; PEYSER JM, 1980, ARCH NEUROL-CHICAGO, V37, P577, DOI 10.1001/archneur.1980.00500580073013; POUTIAINEN E, 1993, ACTA NEUROL SCAND, V87, P88; POZZILLI C, 1991, J NEUROL NEUROSUR PS, V54, P110, DOI 10.1136/jnnp.54.2.110; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUGNETTI L, 1993, J NEUROL SCI, V115, pS59, DOI 10.1016/0022-510X(93)90211-G; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; RAO SM, 1990, J CLIN EXP NEUROPSYC, V12, P74; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P40, DOI 10.1001/archneur.1989.00520370042017; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; RAO SM, 1992, J CONSULT CLIN PSYCH, V60, P369, DOI 10.1037/0022-006X.60.3.369; RAO SM, 1987, J CONSULT CLIN PSYCH, V55, P263, DOI 10.1037/0022-006X.55.2.263; RAO SM, 1984, BRAIN COGNITION, V3, P94, DOI 10.1016/0278-2626(84)90010-1; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P918, DOI 10.1001/archneur.1989.00520440114028; RAO SM, 1990, SUBCORTICAL DEMENTIA, P164; RAO VA, 1987, INT J SYST BACTERIOL, V37, P181; REISCHIES FM, 1988, ARCH NEUROL-CHICAGO, V45, P1114, DOI 10.1001/archneur.1988.00520340068014; REITAN RM, 1971, J NERV MENT DIS, V153, P218, DOI 10.1097/00005053-197109000-00006; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; RON MA, 1986, J PSYCHOSOM RES, V30, P3, DOI 10.1016/0022-3999(86)90060-7; RUBENS AB, 1985, ANN NEUROL, V18, P459, DOI 10.1002/ana.410180408; SALMON DP, 1988, J CLIN EXP NEUROPSYC, V10, P477, DOI 10.1080/01688638808408254; SCHIFFER RB, 1984, ARCH NEUROL-CHICAGO, V41, P1067, DOI 10.1001/archneur.1984.04050210065016; SCHIFFER RB, 1987, ARCH NEUROL-CHICAGO, V44, P596, DOI 10.1001/archneur.1987.00520180020009; STAPLES D, 1979, RHEUMATOL REHABIL, V18, P153, DOI 10.1093/rheumatology/18.3.153; STERN Y, 1991, ARCH GEN PSYCHIAT, V48, P131; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; VANDENBURG W, 1987, ARCH NEUROL-CHICAGO, V44, P494, DOI 10.1001/archneur.1987.00520170024017; VANDIJK JG, 1992, J NEUROL SCI, V109, P18, DOI 10.1016/0022-510X(92)90088-3; VANGORP WG, 1993, NEUROPSYCHOLOGY ALZH, P153; VOWELS LM, 1979, BRAIN IMPAIR, P10; WHITLOCK FA, 1980, J NEUROL NEUROSUR PS, V43, P861, DOI 10.1136/jnnp.43.10.861; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; YOUNG AC, 1976, J NEUROL NEUROSUR PS, V39, P1008, DOI 10.1136/jnnp.39.10.1008	144	67	69	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	JUL	1996	31	2					250	268		10.1006/brcg.1996.0044			19	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	UX223	WOS:A1996UX22300010	8812003				2021-06-18	
J	Long, DA; Ghosh, K; Moore, AN; Dixon, CE; Dash, PK				Long, DA; Ghosh, K; Moore, AN; Dixon, CE; Dash, PK			Deferoxamine improves spatial memory performance following experimental brain injury in rats	BRAIN RESEARCH			English	Article						spatial memory; free radical; deferoxamine; brain injury	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE; SUPEROXIDE; MODEL; EDEMA; PEROXYNITRITE; IMPAIRMENT; MICE	Traumatic brain injury (TBI) causes impairments of both motor and spatial memory performances. Research is only beginning to reveal the biochemical mechanism(s) underlying these deficits. It has been postulated that reactive oxygen species such as the superoxide and hydroxyl radicals, as well as the peroxynitrite anion,are generated by injury and may play a critical role in the observed memory deficits. The highly reactive hydroxyl radical, which is thought to contribute to neuronal toxicity, can be generated by an iron-catalyzed reaction. The source of this iron (or iron-bound proteins) could be a compromise of the blood-brain barrier, which can occur following TBI. In this report, we investigate the ability of deferoxamine, a scavenger of free iron, the hydroxyl radical and the peroxynitrite anion, to facilitate behavioral recovery following a controlled cortical impact of rats. Intraperitoneal administration of this drug prior to the injury did not affect the rate of recovery from motor deficits in comparison to vehicle (saline)-injected animals. However, deferoxamine-treated animals showed significant improvement in spatial memory performance in a Morris water maze task. Volumetric analysis of cortical tissue loss showed no significant differences between vehicle- and drug-injected animals. Similarly, histological examination of the hippocampus did not reveal any gross differences between the two groups. These results indicate that deferoxamine improves spatial memory performance, possibly through protection from neuronal dysfunction.	UNIV TEXAS,HLTH SCI CTR,DEPT ANAT & NEUROBIOL,HOUSTON,TX 77225; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77225					NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ARONOWSKI J, 1994, STROKE, V25, P2235, DOI 10.1161/01.STR.25.11.2235; ARONOWSKI J, IN PRESS J CEREB BLO; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRYAN RM, 1993, 1993 NEUR SOC M; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DASH PK, 1995, J NEUROSCI, V15, P2030; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, IN PRESS PHARM BIOCH; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALLIWELL B, 1989, FREE RADICAL BIO MED, P1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOE S, 1982, CHEM-BIOL INTERACT, V41, P75, DOI 10.1016/0009-2797(82)90018-7; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; IYENGAR J, 1990, J VASC SURG, V12, P545, DOI 10.1067/mva.1990.24155; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; OURY TD, 1993, J BIOL CHEM, V268, P15394; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393	37	67	68	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 22	1996	717	1-2					109	117		10.1016/0006-8993(95)01500-0			9	Neurosciences	Neurosciences & Neurology	UM505	WOS:A1996UM50500014	8738260				2021-06-18	
J	Mesenge, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M				Mesenge, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M			Reduction of the neurological deficit in mice with traumatic brain injury by nitric oxide synthase inhibitors	JOURNAL OF NEUROTRAUMA			English	Article						head injury; L-NAME; nitric oxide, 7-nitroindazole; mice	FOCAL CEREBRAL-ISCHEMIA	This study investigates the effect of the NO synthase inhibitors, N-G-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI), on the neurological deficit 24 h after a moderate closed head injury in mice, Low doses of L-NAME or 7-NI given soon after the injury significantly reduced the neurological deficit compared to the vehicle-treated group, L-Arginine (300 mg/kg) did not alter the neurological deficit, but reversed the protective effects of both L-NAME and 7-NI when given at the same time, Both L-NAME and 7-NI had dose-related effects, The neuroprotective effects of L-NAME and 7-NI occurred when the drugs were given 5, 30, or 60 min after brain injury, but not when treatment was begun 2 h after brain injury, suggesting a short therapeutic window for both drugs, These results suggest that NO synthesis by neuronal NO synthase plays an important role in the early neurotoxic cascade leading to neurological deficit following traumatic brain injury.		Mesenge, C (corresponding author), UNIV PARIS 05,PHARMACOL LAB,4 AVE OBSERV,F-75270 PARIS 06,FRANCE.		MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; CARREAU A, 1994, EUR J PHARMACOL, V256, P241, DOI 10.1016/0014-2999(94)90549-5; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENWOOD J, 1991, NEURORADIOLOGY, V33, P95, DOI 10.1007/BF00588242; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1995, IN PRESS CENTRAL NER; HUANG ZH, 1994, SCIENCE, V265, P1833; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG FY, 1995, J CEREBR BLOOD F MET, V15, P595, DOI 10.1038/jcbfm.1995.73	22	67	67	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1996	13	4					209	214		10.1089/neu.1996.13.209			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	UK144	WOS:A1996UK14400004	8860201				2021-06-18	
J	Allison, SC; Abraham, LD; Petersen, CL				Allison, SC; Abraham, LD; Petersen, CL			Reliability of the Modified Ashworth Scale in the assessment of plantar flexor muscle spasticity in patients with traumatic brain injury	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						spasticity measurement; ankle; reliability	STROKE PATIENTS; HEMIPARESIS; VARIABLES; GAIT	Although the Modified Ashworth Scale (MAS) is commonly used to assess the severity of muscle spasticity for ankle plantarflexors, its reliability has only been established for elbow muscles. Interrater reliability, intrarater reliability and temporal (between-days) reliability were examined in this study. Also, interrater reliability for use of the scale with plantarflexors was compared with reported results from the measurement of elbow flexors. Thirty adult volunteers with traumatic brain injuries participated. There were 20 men and 10 women; the mean age was 28.3 years (SD = 10.8). Two physical therapists used the MAS to score the subjects independently Measurements were repeated to yield multiple scores for intrarater reliability assessment. Twenty-one of the subjects returned individually on separate days to be measured again, so that temporal reliability could be assessed. Spearman's correlation coefficients were 0.73 for interrater reliability 0.74 and 0.55 for intrarater reliability, and 0.82 for temporal reliability. Overall, reliability of the MAS for assessing plantarflexor spasticity in patients with traumatic brain injury was found to be minimally adequate to support its continued use. However, interrater reliability was less than that which has been reported for elbow flexors, and intrarater reliability findings were mixed.	UNIV TEXAS,DEPT KINESIOL & HLTH EDUC,AUSTIN,TX 78712; HEALTHCARE REHABIL CTR,AUSTIN,TX	Allison, SC (corresponding author), AMEDD CTR & SCH,PHYS THERAPY BRANCH,FT SAM HOUSTON,TX 78234, USA.						ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bobath B, 1978, ADULT HEMIPLEGIA EVA; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOHANNON RW, 1987, PHYS THER, V67, P1218, DOI 10.1093/ptj/67.8.1218; BOHANNON RW, 1991, ARCH PHYS MED REHAB, V72, P682; FISHER RA, 1958, STATISTICAL METHODS; GONELLA C, 1982, PHYS THER, V62, P436; HUGENHOLTZ H, 1992, CAN J NEUROL SCI, V19, P188, DOI 10.1017/S0317167100042244; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; Lee K.-C., 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; LEVIN MF, 1993, J NEUROL, V240, P63, DOI 10.1007/BF00858718; PEACOCK WJ, 1991, J NEUROSURG, V74, P380, DOI 10.3171/jns.1991.74.3.0380; POTTER NA, 1985, PHYS THER, V65, P1671, DOI 10.1093/ptj/65.11.1671; ROSE SA, 1991, PHYS THER, V71, P961, DOI 10.1093/ptj/71.12.961; ROTHSTEIN JM, 1993, PRIMER MEASUREMENT I; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009	18	67	72	0	5	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	1996	19	1					67	78		10.1097/00004356-199603000-00007			12	Rehabilitation	Rehabilitation	UE742	WOS:A1996UE74200007	8730545				2021-06-18	
J	Dowd, MD; Krug, S				Dowd, MD; Krug, S			Pediatric blunt cardiac injury: Epidemiology, clinical features, and diagnosis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MYOCARDIAL CONTUSION; CHEST TRAUMA; THORACIC TRAUMA; CHILDREN	Aim: The goal of this study was to describe the epidemiology, clinical presentation, diagnostic methods, and outcome in a large series of children with blunt cardiac injury (BCI). Methods: A multicenter retrospective review of all individuals less than 18 years of age diagnosed with a BCI from 1983 to 1993 was conducted. Cases included all those with a discharge diagnosis of myocardial contusion, concussion, ventricular disruption, or unspecified BCI. Results: A total of 184 cases of BCI were identified in 16 participating centers. The median age was 7.4 years, and 73% were male. Myocardial contusions accounted for 95% of the diagnoses. The leading mechanisms were motor vehicle crashes involving a pedestrian (39.7%) or passenger (31.0%). The majority (87%) had multiple system trauma, with a mean Injury Severity Score of 27.2 (SD +/- 14.4). Pulmonary contusions were present in 50.5% and rib fractures in 23.0%. The most common diagnostic test performed was a 12-lead electrocardiogram (EKG) (82%), followed by a MB band of creatine phosphokinase (CPK-MB) (69%) and echocardiogram (65%). All three tests were performed in 50%. In these patients, agreement among various diagnostic test pairs was fair (echocardiogram vs. EKG, kappa = 0.27) to poor (echocardiogram vs, CPK-MB, kappa = -0.07 and EKG vs. CPK-MB, kappa = 0.08). No hemodynamically stable patient who presented with a normal sinus rhythm subsequently developed a cardiac arrhythmia or cardiac failure. There were 25 deaths (13.6%), 3 of which were caused by acute pump failure secondary to massive cardiac injury. The remainder died of head or abdominal injuries. Of the 159 (86.4%) patients surviving, 8 (5% of survivors) had significant cardiac sequela, most commonly mitral or tricuspid insufficiency or ventricular septal defect. Conclusions: Pediatric BCI is usually diagnosed in the context of severe multiple system trauma and is less commonly an isolated event. Because of the lack of a standard, various diagnostic tests are used in the diagnosis of BCI, and these tests rarely agree. In hospitalized pediatric patients with BCI, unanticipated complications are rare. Significant sequela, although uncommon, do occur and follow-up of children with BCI should be ensured.	CHILDRENS MEM HOSP,DIV GEN & EMERGENCY MED,CHICAGO,IL 60614	Dowd, MD (corresponding author), CHILDRENS HOSP,MED CTR,DIV EMERGENCY MED,3333 BURNET AVE,CINCINNATI,OH 45229, USA.				BHP HRSA HHS [T32 PE10002] Funding Source: Medline		[Anonymous], 1990, ABBREVIATED INJURY S; BAXER BT, 1989, AM J SURG, V158, P557; BODIN L, 1988, CHEST, V94, P72, DOI 10.1378/chest.94.1.72; COOPER A, 1992, PEDIAT EMERGENCY MED, P261; DEMUTH WE, 1967, J TRAUM, V7, P443, DOI 10.1097/00005373-196705000-00009; EICHELBERGER MR, 1988, J TRAUMA, V28, P1109, DOI 10.1097/00005373-198808000-00002; FABIAN TC, 1988, J TRAUMA, V28, P50, DOI 10.1097/00005373-198801000-00007; GOLLADAY ES, 1979, J TRAUMA, V19, P526, DOI 10.1097/00005373-197919070-00008; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HELLING TS, 1989, J TRAUMA, V29, P961, DOI 10.1097/00005373-198907000-00009; HOSSACK KF, 1988, AM J CARDIOL, V6, P1391; ILDSTAD ST, 1990, J PEDIATR SURG, V25, P287, DOI 10.1016/0022-3468(90)90066-I; KISSANE RW, 1952, CIRCULATION, V6, P421, DOI 10.1161/01.CIR.6.3.421; Krasna M J, 1992, Semin Thorac Cardiovasc Surg, V4, P195; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LANGER JC, 1989, J PEDIATR SURG, V24, P1091, DOI 10.1016/S0022-3468(89)80225-8; LAU VK, 1981, J TRAUMA, V21, P39, DOI 10.1097/00005373-198101000-00007; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377; LIEDTKE AJ, 1973, AM HEART J, V86, P687, DOI 10.1016/0002-8703(73)90349-9; MACDONALD RC, 1981, INTENS CARE MED, V7, P265, DOI 10.1007/BF01709720; MARVIN RF, 1973, AM J CARDIOL, V32, P723, DOI 10.1016/S0002-9149(73)80069-4; MCLEAN RF, 1992, J TRAUMA, V33, P240, DOI 10.1097/00005373-199208000-00013; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; NORTON MJ, 1990, AM J SURG, V160, P577, DOI 10.1016/S0002-9610(05)80749-4; PECLET MH, 1990, J PEDIATR SURG, V25, P961, DOI 10.1016/0022-3468(90)90238-5; RHEUBAN KS, 1981, J TRAUMA, V21, P170, DOI 10.1097/00005373-198102000-00015; ROUX P, 1992, J PEDIATR SURG, V27, P551, DOI 10.1016/0022-3468(92)90443-B; SABBAH HN, 1989, J TRAUMA, V29, P175, DOI 10.1097/00005373-198902000-00005; SCHROEDER JS, 1972, BRIT HEART J, V34, P645; SMYTH ST, 1979, J PEDIATR SURG, V14, P1441; TELLEZ DW, 1987, J PEDIATR SURG, V22, P1123, DOI 10.1016/S0022-3468(87)80721-2; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; WAXMAN K, 1986, ARCH SURG-CHICAGO, V121, P689; WISNER DH, 1990, ANN SURG, V212, P82, DOI 10.1097/00000658-199007000-00011; 1990, TXB PEDIATRIC ADV LI; 1994, INT CLASSIFICATION D	36	67	69	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1996	40	1					61	67		10.1097/00005373-199601000-00012			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	TU074	WOS:A1996TU07400013	8577001				2021-06-18	
J	FOX, DD; LEESHALEY, PR; EARNEST, K; DOLEZALWOOD, S				FOX, DD; LEESHALEY, PR; EARNEST, K; DOLEZALWOOD, S			BASE RATES OF POSTCONCUSSIVE SYMPTOMS IN HEALTH MAINTENANCE ORGANIZATION PATIENTS AND CONTROLS	NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; IMPAIRMENT	This study was intended to provide a normative comparison for determining the base rates of postconcussive syndrome (PCS) symptoms in patients from 4 medical departments of a health maintenance organization (HMO) and in people without acute medical or psychological complaints (controls). Recent research suggests that both neurologic and psychosocial factors influence these symptoms. Participants were 1,116 individuals who were surveyed regarding various symptoms, including those reported to be common in the PCS. Endorsement rates are presented for each PCS symptom for controls, each medical sample, and those people with a recent history of being knocked unconscious (2.3%), bumping their heads without losing consciousness (7.4%), and lawsuit involvement (6.8%), which were independently related to most PCS symptoms. The data indicate that neurologic, psychological, and environmental variables are related to having PCS complaints, and such factors should be considered before PCS complaints are used as evidence for brain damage.	LEES HALEY PSYCHOL CORP,ENCINO,CA; SO CALIF KAISER PERMANENTE,PANORAMA CITY,CA							American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GFELLER JD, 1993, 13TH ANN M NAT AC NE; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACKAY R P, 1960, Ind Med Surg, V29, P200; MELENDEZ F, 1994, ADULT NEUROPSYCHOLOG; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; NEWMAN B, 1992, NEW YORK U MED CTR R, V4, P3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; OHARA C, 1994, COGNITIVE SYMPTOMS C; *PSYCH ASS RES, 1994, SPRING 1994 CATALOG; Rattan G, 1987, Arch Clin Neuropsychol, V2, P257, DOI 10.1016/0887-6177(87)90013-8; REITAN R, 1992, AUG ANN M AM PSYCH A; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHINKA JA, 1994, NEUROPSYCHOLOGICAL S; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; SINGER RM, 1990, NEUROTOXICITY GUIDEB; WONG JM, 1993, 13TH ANN M NAT AC NE	29	67	68	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	OCT	1995	9	4					606	611		10.1037/0894-4105.9.4.606			6	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	TA644	WOS:A1995TA64400019					2021-06-18	
J	PRASAD, MR; RAMAIAH, C; MCINTOSH, TK; DEMPSEY, RJ; HIPKENS, S; YUREK, D				PRASAD, MR; RAMAIAH, C; MCINTOSH, TK; DEMPSEY, RJ; HIPKENS, S; YUREK, D			REGIONAL LEVELS OF LACTATE AND NOREPINEPHRINE AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROCHEMISTRY			English	Article						ATP; BRAIN INJURY; CORTICAL IMPACT; CATECHOLAMINES; NOREPINEPHRINE; LACTATE; PHOSPHOCREATINE	INCREASED PROSTAGLANDIN SYNTHESIS; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; TRANSIENT ISCHEMIA; FOREBRAIN ISCHEMIA; CEREBRAL-CORTEX; RAT-BRAIN; MAGNETIC-RESONANCE; LACTIC-ACIDOSIS; AMINO-ACIDS	The recently developed controlled cortical impact model of brain injury in rats may be an excellent tool by which to attempt to understand the neurochemical mechanisms mediating the pathophysiology of traumatic brain injury. In this study, rats were subjected to lateral controlled cortical impact brain injury of low grade severity; their brains were frozen in situ at various times after injury to measure regional levels of lactate, high energy phosphates, and norepinephrine. Tissue lactate concentration in the injury site left cortex was increased in injured animals by sixfold at 30 min and twofold at 2.5 h and 24 h after injury (p < 0.05). At all postinjury times, lactate concentration was also increased in injured animals by about twofold in the cortex and hippocampus adjacent to the injury site (p < 0.05). No significant changes occurred in the levels of ATP and phosphocreatine in most of the brain regions of injured animals. However, in the primary site of injury (left cortex), phosphocreatine concentration was decreased by 40% in injured animals at 30 min after injury (p < 0.05). The norepinephrine concentration was decreased in the injury site left cortex of injured animals by 38% at 30 min, 29% at 2.5 h, and 30% at 24 h after injury (p < 0.05). The level of norepinephrine was also reduced by similar to 20% in the cortex adjacent to the injury site in injured animals. The present results suggest that controlled cortical impact brain injury produces disorder in the neuronal oxidative and norepinephrine metabolism.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA	PRASAD, MR (corresponding author), UNIV KENTUCKY,MED CTR,DEPT SURG,DIV NEUROSURG,LEXINGTON,KY 40536, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31816, NS 29994] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS031816, R29NS029994, R01NS031816] Funding Source: NIH RePORTER		ADACHI N, 1991, J NEUROCHEM, V57, P61, DOI 10.1111/j.1471-4159.1991.tb02099.x; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; CVEJIC V, 1980, ACTA NEUROPATHOL, V51, P71, DOI 10.1007/BF00688852; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; GAUDET R, 1978, J NEUROCHEM, V30, P751, DOI 10.1111/j.1471-4159.1978.tb10781.x; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1992, BRAIN RES, V567, P1; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENNETT B, 1981, MANAGEMENT HEAD INJU, V20; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P146; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, J CEREB BLOOD FLO S1, V9, pS78; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MIYAZUKI M, 1988, BRAIN RES B, V22, P207; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1993, 11TH P ANN M SOC NEU; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	55	67	68	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	1994	63	3					1086	1094					9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	PC937	WOS:A1994PC93700033	8051549				2021-06-18	
J	OMMAYA, AK; HIRSCH, AE; FLAMM, ES; MAHONE, RH				OMMAYA, AK; HIRSCH, AE; FLAMM, ES; MAHONE, RH			CEREBRAL CONCUSSION IN MONKEY - AN EXPERIMENTAL MODEL	SCIENCE			English	Article																Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GURDJIAN ES, 1965, 7 STAPP CRASH C P; HOLBOURN AHS, 1943, LANCET, P438; OMMAYA AK, 1964, J NEUROSURG, V31, P249; OMMAYA AK, IN PRESS; SELLIER K, 1963, HEFTE UNFALLHEILKUND	6	67	69	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1966	153	3732					211	&		10.1126/science.153.3732.211			0	Multidisciplinary Sciences	Science & Technology - Other Topics	79346	WOS:A19667934600051	4957321				2021-06-18	
J	Kochanek, PM; Tasker, RC; Carney, N; Totten, AM; Adelson, PD; Selden, NR; Davis-O'Reilly, C; Hart, EL; Bell, MJ; Bratton, SL; Grant, GA; Kissoon, N; Reuter-Rice, KE; Vavilala, MS; Wainwright, MS				Kochanek, Patrick M.; Tasker, Robert C.; Carney, Nancy; Totten, Annette M.; Adelson, P. David; Selden, Nathan R.; Davis-O'Reilly, Cynthia; Hart, Erica L.; Bell, Michael J.; Bratton, Susan L.; Grant, Gerald A.; Kissoon, Niranjan; Reuter-Rice, Karin E.; Vavilala, Monica S.; Wainwright, Mark S.			Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						critical care; evidence-based medicine; guidelines; pediatrics; systematic review; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; EARLY DECOMPRESSIVE CRANIECTOMY; REFRACTORY INTRACRANIAL HYPERTENSION; COMMON DATA ELEMENTS; CEREBROSPINAL-FLUID DRAINAGE; SINGLE-CENTER EXPERIENCE; TIGHT GLYCEMIC CONTROL; LENGTH-OF-STAY; HYPERTONIC SALINE	This document was endorsed by the American Association of Neurological Surgeons/Congress of Neurological Surgeons. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, Stanford University, or the Brain Trauma Foundation. The information contained in the Guidelines for the Management of Pediatric Severe Traumatic Brain Injury reflects the current state of knowledge at the time of publication. The Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, and other collaborating organizations are not engaged in rendering professional medical services and assume no responsibility for patient outcomes resulting from application of these general recommendations in specific patient circumstances. Accordingly, the Brain Trauma Foundation, American Association of Neurological Surgeons, and Congress of Neurological Surgeons consider adherence to these clinical practice guidelines will not necessarily assure a successful medical outcome. The information contained in these guidelines reflects published scientific evidence at the time of completion of the guidelines and cannot anticipate subsequent findings and/or additional evidence, and therefore should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same result. Medical advice and decisions are appropriately made only by a competent and licensed physician who must make decisions in light of all the facts and circumstances in each individual and particular case and on the basis of availability of resources and expertise. Guidelines are not intended to supplant physician judgment with respect to particular patients or special clinical situations and are not a substitute for physician-patient consultation. Accordingly, the Brain Trauma Foundation, American Association of Neurological Surgeons, and Congress of Neurological Surgeons consider adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances.	[Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesiol Crit Care & Pain Med, Boston, MA 02115 USA; [Carney, Nancy; Totten, Annette M.; Davis-O'Reilly, Cynthia; Hart, Erica L.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Pacif Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosci, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, Pediat Neurosurg, Phoenix, AZ USA; [Adelson, P. David] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ USA; [Selden, Nathan R.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR USA; [Bell, Michael J.] Childrens Natl Med Ctr, Crit Care Med, Washington, DC 20010 USA; [Bratton, Susan L.] Univ Utah, Pediat, Salt Lake City, UT USA; [Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA; [Kissoon, Niranjan] Univ British Columbia, British Columbias Childrens Hosp, Dept Pediat, Child & Family Res Inst, Vancouver, BC, Canada; [Reuter-Rice, Karin E.] Duke Univ, Dept Pediat, Sch Med, Sch Nursing,Div Pediat Crit Care Med, Durham, NC 27706 USA; [Vavilala, Monica S.] Univ Washington, Strateg Affairs Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, HIPRC, Seattle, WA 98195 USA; [Wainwright, Mark S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Pediat Bioengn & Clin & Translat Sci, Pittsburgh, PA 15260 USA.; Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Childrens Hosp Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kissoon, Niranjan/AAC-6140-2021	Reuter-Rice, Karin/0000-0003-1501-8994; Kissoon, Niranjan/0000-0001-8847-9973			Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS53; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Adelson PD, 2012, J NEUROTRAUM, V29, P639, DOI 10.1089/neu.2011.1952; Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agus MSD, 2017, NEW ENGL J MED, V376, P729, DOI 10.1056/NEJMoa1612348; Agus MSD, 2012, NEW ENGL J MED, V367, P1208, DOI 10.1056/NEJMoa1206044; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Annane D, 2017, INTENS CARE MED, V43, P1751, DOI 10.1007/s00134-017-4919-5; ARJAMAA O, 1992, ACTA PHYSIOL SCAND, V144, P113, DOI 10.1111/j.1748-1716.1992.tb09275.x; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Bailey BM, 2012, J TRAUMA ACUTE CARE, V72, P263, DOI 10.1097/TA.0b013e31822a9512; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Bar-Joseph G, 2009, J NEUROSURG-PEDIATR, V4, P40, DOI 10.3171/2009.1.PEDS08319; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barthelemy EJ, 2016, WORLD NEUROSURG, V88, P411, DOI 10.1016/j.wneu.2015.12.044; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Bata SC, 2014, ANZ J SURG, V84, P438, DOI 10.1111/ans.12582; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; Bell MJ, 2017, CHILD NERV SYST, V33, P1663, DOI 10.1007/s00381-017-3530-y; Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bennett TD, 2017, JAMA PEDIATR, V171, P965, DOI 10.1001/jamapediatrics.2017.2127; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Bennett TD, 2012, CRIT CARE MED, V40, P208, DOI 10.1097/CCM.0b013e31822e9d31; Berger RP, 2012, J NEUROTRAUM, V29, P672, DOI 10.1089/neu.2011.1861; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Bramwell KJ, 2006, PEDIATR EMERG CARE, V22, P90, DOI 10.1097/01.pec.0000199563.64264.3a; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chin KH, 2015, PEDIATR CRIT CARE ME, V16, P352, DOI 10.1097/PCC.0000000000000344; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Chung MG, 2016, PEDIATR CRIT CARE ME, V17, P150, DOI 10.1097/PCC.0000000000000588; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cottenceau V, 2011, J NEUROTRAUM, V28, P2003, DOI 10.1089/neu.2011.1929; Crompton E, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002565; Crompton EM, 2017, CRIT CARE MED, V45, P575, DOI 10.1097/CCM.0000000000002205; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Csokay A, 2012, CHILD NERV SYST, V28, P441, DOI 10.1007/s00381-011-1661-0; Curry R, 2008, PEDIATR CRIT CARE ME, V9, P141, DOI 10.1097/PCC.0B013e318166870e; de Andrade AF, 2011, ARQ NEURO-PSIQUIAT, V69, P79, DOI 10.1590/S0004-282X2011000100016; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; DEBRAY JM, 1993, CHILD NERV SYST, V9, P220, DOI 10.1007/BF00303573; DeKosky ST, 2017, BRAIN INJURY, V31, P1177, DOI 10.1080/02699052.2017.1312528; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Desgranges FP, 2014, CHILD NERV SYST, V30, P1393, DOI 10.1007/s00381-014-2417-4; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Duhaime AC, 2012, J NEUROTRAUM, V29, P629, DOI 10.1089/neu.2011.1927; Edwards P, 2005, LANCET, V365, P1957; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; ESPARZA J, 1985, CHILD NERV SYST, V1, P109, DOI 10.1007/BF00706691; FANCONI S, 1988, INTENS CARE MED, V14, P163; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; Felmet K, 2003, PEDIATRICS, V112, P1002, DOI 10.1542/peds.112.4.1002; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Figaji AA, 2010, NEUROCRIT CARE, V12, P430, DOI 10.1007/s12028-010-9344-3; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fivez T, 2016, NEW ENGL J MED, V374, P1111, DOI 10.1056/NEJMoa1514762; Friess SH, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/361310; Garbutt JM, 2013, CLIN PEDIATR, V52, P1014, DOI 10.1177/0009922813504823; Gibbison B, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1659-4; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Guerra SD, 2010, J PEDIAT-BRAZIL, V86, P73, DOI [10.1590/S0021-75572010000100013, 10.2223/JPED.1960]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes GL, 2005, PEDIATR NEUROL, V33, P1, DOI 10.1016/j.pediatrneurol.2004.12.003; Honeybul S, 2018, CURR OPIN CRIT CARE, V24, P97, DOI 10.1097/MCC.0000000000000481; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hutchison JS, 2010, DEV NEUROSCI-BASEL, V32, P406, DOI 10.1159/000323260; Jacobi J, 2012, CRIT CARE MED, V40, P3251, DOI 10.1097/CCM.0b013e3182653269; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Jehan F, 2017, J TRAUMA ACUTE CARE, V83, P1148, DOI 10.1097/TA.0000000000001658; Jha RM, 2017, LANCET NEUROL, V16, P578, DOI 10.1016/S1474-4422(17)30225-9; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kapapa T, 2010, J CHILD NEUROL, V25, P274, DOI 10.1177/0883073809332699; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KASSELL NF, 1980, NEUROSURGERY, V7, P598, DOI 10.1227/00006123-198012000-00011; Kasselman LJ, 2007, J VASC RES, V44, P283, DOI 10.1159/000101450; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kerr ME, 1999, CRIT CARE MED, V27, P2776, DOI 10.1097/00003246-199912000-00028; Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2; Klein P, 2012, ARCH NEUROL-CHICAGO, V69, P1290, DOI 10.1001/archneurol.2012.445; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; Kochanek PM, 2019, PEDIATR CRIT CARE ME, V20, P269, DOI 10.1097/PCC.0000000000001737; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2015, SEMIN NEUROL, V35, P83, DOI 10.1055/s-0035-1544237; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655; Kurz JE, 2016, PEDIATR CRIT CARE ME, V17, P649, DOI 10.1097/PCC.0000000000000765; Kurzbuch AR, 2015, NEUROSURG REV, V38, P629, DOI 10.1007/s10143-015-0626-2; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI 10.1089/neu.2008-0828; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Macrae D, 2014, NEW ENGL J MED, V370, P107, DOI 10.1056/NEJMoa1302564; Malakouti A, 2012, PEDIATR CRIT CARE ME, V13, pE18, DOI 10.1097/PCC.0b013e31820aba1f; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Martinon C, 2011, PEDIATR CRIT CARE ME, V12, P65, DOI 10.1097/PCC.0b013e3181e2a244; MAXWELL RE, 1971, J NEUROSURG, V34, P477, DOI 10.3171/jns.1971.34.4.0477; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Mellion SA, 2013, PEDIATR CRIT CARE ME, V14, P239, DOI 10.1097/PCC.0b013e318271c3b2; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Mhanna MJ, 2015, J NEUROSURG PEDIAT, V16, P1; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Minardi C, 2012, CURR DRUG TARGETS, V13, P936, DOI 10.2174/138945012800675740; Morris KP, 2006, INTENS CARE MED, V32, P1606, DOI 10.1007/s00134-006-0285-4; Morton SC, 2018, AHRQ PUBLICATION; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nagai M, 2017, WORLD NEUROSURG, V100, P224, DOI 10.1016/j.wneu.2016.12.134; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449; PAPPIUS HM, 1969, ARCH NEUROL-CHICAGO, V20, P207, DOI 10.1001/archneur.1969.00480080107013; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Perez SE, 2011, J TRAUMA, V71, P133; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PFENNINGER J, 1983, INTENS CARE MED, V9, P13, DOI 10.1007/BF01693699; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; PIATT JH, 1984, NEUROSURGERY, V15, P427, DOI 10.1227/00006123-198409000-00023; Piper BJ, 2015, ANAESTH INTENS CARE, V43, P204, DOI 10.1177/0310057X1504300210; PITLICK WH, 1982, CLIN PHARMACOL THER, V31, P466, DOI 10.1038/clpt.1982.61; PITTMAN T, 1989, PEDIATR NEUROSCI, V15, P13, DOI 10.1159/000120433; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Prasad GL, 2015, CHILD NERV SYST, V31, P269, DOI 10.1007/s00381-014-2529-x; Prasad GL, 2015, BRAIN INJURY, V29, P1; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Ragan DK, 2012, PEDIATR RES, V71, P199, DOI 10.1038/pr.2011.31; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Roumeliotis N, 2016, CHILD NERV SYST, V32, P2363, DOI 10.1007/s00381-016-3231-y; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sakurai A, 2012, J NEUROTRAUM, V29, P313, DOI 10.1089/neu.2011.2152; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Schoon P, 2002, ACT NEUR S, V81, P285; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Shein SL, 2016, PEDIATR CRIT CARE ME, V17, P236, DOI 10.1097/PCC.0000000000000610; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Srinivasan Vijay, 2012, J Diabetes Sci Technol, V6, P37; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stippler M, 2012, J NEUROSURG-PEDIATR, V10, P383, DOI 10.3171/2012.8.PEDS12165; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Taha AA, 2011, J NEUROSCI NURS, V43, P291, DOI 10.1097/JNN.0b013e318234e9b2; Tapper Julius, 2017, Surg Neurol Int, V8, P141, DOI 10.4103/sni.sni_453_16; Tasker RC, 2017, CRIT CARE MED, V45, pE1091, DOI 10.1097/CCM.0000000000002526; Tasker RC, 2017, PEDIATR CRIT CARE ME, V18, P355, DOI 10.1097/PCC.0000000000001098; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P521, DOI [10.1089/neu.2000.17.521, DOI 10.1089/NEU.2000.17.521]; Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Tume LN, 2011, NURS CRIT CARE, V16, P77, DOI 10.1111/j.1478-5153.2010.00412.x; van Beek AHEA, 2008, J CEREBR BLOOD F MET, V28, P1071, DOI 10.1038/jcbfm.2008.13; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Webster DL, 2015, J CRIT CARE, V30, P1267, DOI 10.1016/j.jcrc.2015.07.022; Weed LH, 1919, AM J PHYSIOL, V48, P512; WEISS MH, 1970, J NEUROSURG, V32, P452, DOI 10.3171/jns.1970.32.4.0452; Welch TP, 2016, CRIT CARE MED, V44, P809, DOI 10.1097/CCM.0000000000001558; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; WISE B L, 1961, Surg Forum, V12, P398; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yue JK, 2017, J NEUROSURG SCI, DOI 10.23736/S0390-5616.17.04003-6; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	235	66	67	2	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2019	20	3		1			S1	S82		10.1097/PCC.0000000000001735			82	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	IQ4HT	WOS:000480712400001	30829890	Bronze	Y	N	2021-06-18	
J	Patel, NA; Moss, LD; Lee, JY; Tajiri, N; Acosta, S; Hudson, C; Parag, S; Cooper, DR; Borlongan, CV; Bickford, PC				Patel, Niketa A.; Moss, Lauren Daly; Lee, Jea-Young; Tajiri, Naoki; Acosta, Sandra; Hudson, Charles; Parag, Sajan; Cooper, Denise R.; Borlongan, Cesario V.; Bickford, Paula C.			Long noncoding RNA MALAT1 in exosomes drives regenerative function and modulates inflammation-linked networks following traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CELL-PROLIFERATION; STROMAL CELLS; NEUROVASCULAR PLASTICITY; COGNITIVE IMPAIRMENTS; SPLENIC MACROPHAGES; 17-BETA-ESTRADIOL; SNORNA; EXPRESSION; MIGRATION; BARRIER	Background: Neuroinflammation is a common therapeutic target for traumatic brain injury (TBI) due to its contribution to delayed secondary cell death and has the potential to occur for years after the initial insult. Exosomes from adipose-derived stem cells (hASCs) containing the long noncoding RNA MALAT1 are a novel, cellfree regenerative approach to long-term recovery after traumatic brain injury (TBI) that have the potential to modulate inflammation at the genomic level. The long noncoding RNA MALAT1 has been shown to be an important component of the secretome of hASCs. Methods: We isolated exosomes from hASC containing or depleted of MALAT1. The hASC-derived exosomes were then administered intravenously to rats following a mild controlled cortical impact (CCI). We followed the rats with behavior, in vivo imaging, histology, and RNA sequencing (RNA Seq). Results: Using in vivo imaging, we show that exosomes migrate into the spleen within 1 h following administration and enter the brain several hours later following TBI. Significant recovery of function on motor behavior as well as a reduction in cortical brain injury was observed after TBI in rats treated with exosomes. Treatment with either exosomes depleted of MALAT1 or conditioned media depleted of exosomes showed limited regenerative effects, demonstrating the importance of MALAT1 in exosome-mediated recovery. Analysis of the brain and spleen transcriptome using RNA Seq showed MALAT1-dependent modulation of inflammation-related pathways, cell cycle, cell death, and regenerative molecular pathways. Importantly, our data demonstrates that MALAT1 regulates expression of other noncoding RNAs including snoRNAs. Conclusion: We demonstrate that MALAT1 in hASC-derived exosomes modulates multiple therapeutic targets, including inflammation, and has tremendous therapeutic potential for treatment of TBI.	[Patel, Niketa A.; Hudson, Charles; Cooper, Denise R.; Bickford, Paula C.] James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA; [Patel, Niketa A.; Parag, Sajan; Cooper, Denise R.] Univ S Florida, Morsani Coll Med, Dept Mol Med, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA; [Moss, Lauren Daly; Lee, Jea-Young; Tajiri, Naoki; Acosta, Sandra; Borlongan, Cesario V.; Bickford, Paula C.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Tajiri, Naoki] Nagoya City Univ, Dept Neurophysiol & Brain Sci, Grad Sch Med Sci, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan; [Tajiri, Naoki] Nagoya City Univ, Sch Med, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan; [Borlongan, Cesario V.; Bickford, Paula C.] USF Hlth Ctr Excellence Aging & Brain Repair MDC, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA	Patel, NA; Bickford, PC (corresponding author), James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA.; Borlongan, CV; Bickford, PC (corresponding author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA.	Niketa.Patel@va.gov; pbickfor@health.usf.edu	Tajiri, Naoki/K-1230-2012; Bickford, Paula/J-5970-2012	Tajiri, Naoki/0000-0003-2189-662X; Patel, Niketa A./0000-0003-4811-8596; Bickford, Paula/0000-0001-9657-7725	USF; VAMR grant [I01BX003421, 821-MR-EN-20606]; Veterans AffairsUS Department of Veterans Affairs [I01BX003421, I01BX003836] Funding Source: NIH RePORTER	This work was supported by a grant from USF to PCB and CB and VAMR grant I01BX003421 to PCB and VAMR grant 821-MR-EN-20606 to NAP.	ACOSTA SA, 2013, PLOS ONE, V8; Aiello A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38414; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazeley PS, 2008, GENE, V408, P172, DOI 10.1016/j.gene.2007.10.037; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Chaudhry MA, 2014, CANCER BIOTHER RADIO, V29, P135, DOI 10.1089/cbr.2013.1574; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; de Turris V, 2004, J MOL BIOL, V344, P383, DOI 10.1016/j.jmb.2004.09.049; Du ZW, 2013, DEVELOPMENT, V140, P2611, DOI 10.1242/dev.092809; El Bassit G, 2017, ENDOCRINOLOGY, V158, P183, DOI 10.1210/en.2016-1819; Fang DF, 2015, BIOCHEM BIOPH RES CO, V457, P500, DOI 10.1016/j.bbrc.2014.12.114; Fendler A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080807; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Guo Y, 2012, ONCOL LETT, V4, P561, DOI 10.3892/ol.2012.775; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hildebrand F, 2006, J LEUKOCYTE BIOL, V79, P1173, DOI 10.1189/jlb.0106029; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kawasaki T, 2008, MOL IMMUNOL, V45, P376, DOI 10.1016/j.molimm.2007.06.148; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kishore S, 2006, COLD SPRING HARB SYM, V71, P329, DOI 10.1101/sqb.2006.71.024; Kishore S, 2010, HUM MOL GENET, V19, P1153, DOI 10.1093/hmg/ddp585; Konda N, 2017, HISTOCHEM CELL BIOL, V147, P317, DOI 10.1007/s00418-016-1494-8; Leo P., 2016, TRANSLATIONAL RES TR; Levin H, 2013, LANCET NEUROL, V12, P15, DOI 10.1016/S1474-4422(12)70300-9; Lewis A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173664; Li HP, 2013, CARCINOGENESIS, V34, P2443, DOI 10.1093/carcin/bgt206; Lund AH, 2010, CELL DEATH DIFFER, V17, P209, DOI 10.1038/cdd.2009.58; Magenta A, 2017, CIRC RES, V120, P1399, DOI 10.1161/CIRCRESAHA.116.310274; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Majer A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169081; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Mckee Ann C, 2015, Handb Clin Neurol, V127, P45, DOI 10.1016/B978-0-444-52892-6.00004-0; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Patel Rekha S, 2016, Stem Cell Investig, V3, P2, DOI 10.3978/j.issn.2306-9759.2016.01.02; Qin XY, 2014, INT J CLIN EXP PATHO, V7, P3065; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Schmidt LH, 2014, J THORAC ONCOL, V9, P1294, DOI 10.1097/JTO.0000000000000243; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Stewart IB, 2002, SPORTS MED, V32, P361, DOI 10.2165/00007256-200232060-00002; Suzuki T, 2007, AM J PHYSIOL-CELL PH, V293, pC978, DOI 10.1152/ajpcell.00092.2007; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tian Y, 2012, INT J ONCOL, V40, P1105, DOI 10.3892/ijo.2011.1306; Ting MJ, 2010, EXP HEMATOL, V38, P1087, DOI 10.1016/j.exphem.2010.07.007; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xu XM, 2012, ONCOL LETT, V4, P339, DOI 10.3892/ol.2012.714; Zeng Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep12098; Zhang XJ, 2017, J NEUROSCI, V37, P1797, DOI 10.1523/JNEUROSCI.3389-16.2017; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhao Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109782; Zhao ZY, 2014, BIOCHEM BIOPH RES CO, V445, P388, DOI 10.1016/j.bbrc.2014.02.006; Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3	64	66	71	1	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 12	2018	15								204	10.1186/s12974-018-1240-3			23	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GM9BC	WOS:000438535100001	30001722	DOAJ Gold, Green Published			2021-06-18	
J	Nordstrom, A; Nordstrom, P				Nordstrom, Anna; Nordstrom, Peter			Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study	PLOS MEDICINE			English	Article							ALZHEIMERS-DISEASE; HEAD-INJURY; OLDER-ADULTS; IMPAIRMENT; ONSET; AGE	Background Traumatic brain injury (TBI) has been associated with dementia. The questions of whether the risk of dementia decreases over time after TBI, whether it is similar for different TBI types, and whether it is influenced by familial aggregation are not well studied. Methods and findings The cohort considered for inclusion comprised all individuals in Sweden aged >= 50 years on December 31, 2005 (n = 3,329,360). Diagnoses of dementia and TBI were tracked through nationwide databases from 1964 until December 31, 2012. In a first cohort, individuals diagnosed with TBI (n = 164,334) were matched with up to two controls. A second cohort consisted of subjects diagnosed with dementia during follow-up (n = 136,233) matched with up to two controls. A third cohort consisted of 46,970 full sibling pairs with discordant TBI status. During a mean follow-up period of 15.3 (range, 0-49) years, 21,963 individuals in the first cohort (6.3% with TBI, 3.6% without TBI) were diagnosed with dementia (adjusted odds ratio [OR], 1.81; 95% confidence interval [CI], 1.75-1.86). The association was strongest in the first year after TBI (OR, 3.52; 95% CI, 3.23-3.84), but the risk remained significant > 30 years (OR, 1.25; 95% CI, 1.11-1.41). Single mild TBI showed a weaker association with dementia (OR, 1.63; 95% CI, 1.57-1.70) than did more severe TBI (OR, 2.06; 95% CI, 1.95-2.19) and multiple TBIs (OR, 2.81; 95% CI, 2.51-3.15). These results were in general confirmed in the nested case-control cohort. TBI was also associated with an increased risk of dementia diagnosis in sibling pairs with discordant TBI status (OR, 1.89; 95% CI, 1.62- 2.21). A main limitation of the present study is the observational design. Thus, no causal inferences can be made based on the associations found. Conclusions The risk of dementia diagnosis decreased over time after TBI, but it was still evident > 30 years after the trauma. The association was stronger for more severe TBI and multiple TBIs, and it persisted after adjustment for familial factors.	[Nordstrom, Anna] Umea Univ, Dept Publ Hlth & Clin Med, Environm Med, Umea, Sweden; [Nordstrom, Anna] UiT Arctic Univ Norway, Sch Sports Sci, Tromso, Norway; [Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden	Nordstrom, P (corresponding author), Umea Univ, Dept Community Med & Rehabil, Geriatr Med, Umea, Sweden.	peter.nordstrom@umu.se	Nordstrom, Anna/F-2238-2010; Nordstrom, Anna/O-2504-2018	Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2016-02584]	The present study was funded by the Swedish Research Council (https://www.vr.se, grant number 2016-02584). The funding body had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carroll LJ, 2004, J REHABIL MED, V84; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Li W, 2016, J NEUROL, V263, P1280, DOI 10.1007/s00415-016-8093-4; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Raj R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002316; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; van Doorn C, 2003, J AM GERIATR SOC, V51, P1213, DOI 10.1046/j.1532-5415.2003.51404.x; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	25	66	66	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JAN	2018	15	1							e1002496	10.1371/journal.pmed.1002496			13	Medicine, General & Internal	General & Internal Medicine	FU4JC	WOS:000423818400017	29381704	DOAJ Gold, Green Published			2021-06-18	
J	Liu, SF; Buch, S; Chen, YS; Choi, HS; Dai, YM; Habib, C; Hub, J; Jung, JY; Luo, Y; Utriainen, D; Wang, MY; Wu, DM; Xia, S; Haacke, EM				Liu, Saifeng; Buch, Sagar; Chen, Yongsheng; Choi, Hyun-Seok; Dai, Yongming; Habib, Charbel; Hub, Jiani; Jung, Joon-Yong; Luo, Yu; Utriainen, David; Wang, Meiyun; Wu, Dongmei; Xia, Shuang; Haacke, E. Mark			Susceptibility-weighted imaging: current status and future directions	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	susceptibility-weighted imaging; quantitative susceptibility mapping; phase imaging; multi-channel phase data combination; stroke; cerebral microbleeds	TRAUMATIC BRAIN-INJURY; INTERVERTEBRAL DISC DEGENERATION; CAROTID ATHEROSCLEROTIC PLAQUE; PROMINENT CORTICAL VEINS; ACUTE ISCHEMIC-STROKE; SPINAL-CORD-INJURY; MAGNETIC-RESONANCE; CEREBRAL MICROBLEEDS; MR VENOGRAPHY; HIGH-RESOLUTION	Susceptibility-weighted imaging (SWI) is a method that uses the intrinsic nature of local magnetic fields to enhance image contrast in order to improve the visibility of various susceptibility sources and to facilitate diagnostic interpretation. It is also the precursor to the concept of the use of phase for quantitative susceptibility mapping (QSM). Nowadays, SWI has become a widely used clinical tool to image deoxyhemoglobin in veins, iron deposition in the brain, hemorrhages, microbleeds and calcification. In this article, we review the basics of SWI, including data acquisition, data reconstruction and post-processing. In particular, the source of cusp artifacts in phase images is investigated in detail and an improved multi-channel phase data combination algorithm is provided. In addition, we show a few clinical applications of SWI for the imaging of stroke, traumatic brain injury, carotid vessel wall, siderotic nodules in cirrhotic liver, prostate cancer, prostatic calcification, spinal cord injury and intervertebral disc degeneration. As the clinical applications of SWI continue to expand both in and outside the brain, the improvement of SWI in conjunction with QSM is an important future direction of this technology. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Liu, Saifeng; Buch, Sagar; Haacke, E. Mark] MRI Inst Biomed Res, Waterloo, ON, Canada; [Chen, Yongsheng; Habib, Charbel; Hub, Jiani; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA; [Choi, Hyun-Seok; Jung, Joon-Yong] Catholic Univ Korea, St Marys Hosp, Dept Radiol, Seoul, South Korea; [Dai, Yongming; Utriainen, David; Haacke, E. Mark] MRI Inst Biomed Res, Detroit, MI USA; [Luo, Yu] Branch Shanghai First Hosp, Dept Radiol, Shanghai, Peoples R China; [Wang, Meiyun] Henan Prov Peoples Hosp, Dept Radiol, Zhengzhou, Henan, Peoples R China; [Wu, Dongmei; Haacke, E. Mark] East China Normal Univ, Shanghai Key Lab Magnet Resonance, Shanghai, Peoples R China; [Xia, Shuang] Tianjin First Cent Hosp, Dept Radiol, Tianjin, Peoples R China	Haacke, EM (corresponding author), MRI Concourse, 3990 John R St, Detroit, MI 48201 USA.	nmrimaging@aol.com	Buch, Sagar/H-3746-2017; Liu, Saifeng/I-1242-2019; Chen, Yongsheng/U-9800-2019; Jovicich, Jorge/D-2293-2010	Buch, Sagar/0000-0001-9483-269X; Chen, Yongsheng/0000-0001-7114-5731; Choi, Hyun Seok/0000-0003-4999-8513; Luo, Yu/0000-0003-4620-3869; Xia, Shuang/0000-0003-1626-6383; Liu, Saifeng/0000-0002-3642-8282	Canadian Institutes of Health Research/Heart and Stroke Foundation of Canada Synchrotron Medical Imaging Team [CIF 99472]; Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-10522]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21CA184682]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA184682] Funding Source: NIH RePORTER	This work was supported in part by the Canadian Institutes of Health Research/Heart and Stroke Foundation of Canada Synchrotron Medical Imaging Team Grant under award number CIF 99472, the Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC) under award number W81XWH-12-10522, and the National Cancer Institute, National Institutes of Health (NIH), through Grant Number R21CA184682. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The views, opinions and/or findings contained in this report are those of the author (s) and should not be construed as an official government position, policy or decision unless so designated by other documentation.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; ADAMS MA, 1986, J BONE JOINT SURG BR, V68, P36; Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c; Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; An H, 2003, MAGN RESON MED, V50, P708, DOI 10.1002/mrm.10576; An HY, 2015, STROKE, V46, P982, DOI 10.1161/STROKEAHA.114.008154; An HY, 2012, TRANSL STROKE RES, V3, P65, DOI 10.1007/s12975-011-0141-x; Antoniou J, 1996, J CLIN INVEST, V98, P996, DOI 10.1172/JCI118884; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; AVRAHAMI E, 1994, J NEUROL, V241, P381, DOI 10.1007/BF02033355; Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Bai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053237; Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148; Balassy C, 2014, RADIOLOGY, V270, P149, DOI 10.1148/radiol.13122440; Balla DZ, 2014, NEUROIMAGE, V100, P112, DOI 10.1016/j.neuroimage.2014.06.011; Barnes S, 2009, J MAGN RESON IMAGING, V29, P1465, DOI 10.1002/jmri.21791; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Bilgic B, 2016, NEUROIMAGE, V125, P1131, DOI 10.1016/j.neuroimage.2015.08.015; Bilgic B, 2015, MAGN RESON MED, V73, P2152, DOI 10.1002/mrm.25347; Bloch LO, 2014, J CARDIOVASC MAGN R, V16, DOI 10.1186/1532-429X-16-22; Buch S, 2015, MAGN RESON MED, V73, P2185, DOI 10.1002/mrm.25350; Butcher KS, 2005, STROKE, V36, P1153, DOI 10.1161/01.STR.0000166181.86928.8b; Bydder M, 2002, MAGNET RESON MED, V47, P539, DOI 10.1002/mrm.10092; Cai JM, 2002, CIRCULATION, V106, P1368, DOI 10.1161/01.CIR.0000028591.44554.F9; Cappendijk VC, 2005, RADIOLOGY, V234, P487, DOI 10.1148/radiol.2342032101; Chalian M, 2011, J NEURORADIOLOGY, V38, P187, DOI 10.1016/j.neurad.2010.12.006; Chang K, 2014, AM J NEURORADIOL, V35, P1091, DOI 10.3174/ajnr.A3818; Charidimou A, 2012, J NEUROL SCI, V322, P50, DOI 10.1016/j.jns.2012.05.052; Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065866; Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Dai Y, 2014, CLIN RADIOL, V69, pE392, DOI 10.1016/j.crad.2014.06.010; Dai YM, 2011, J MAGN RESON IMAGING, V34, P318, DOI 10.1002/jmri.22607; Dawber TR, 1951, AM J PUBLIC HEALTH N, V41, P279, DOI 10.2105/ajph.41.3.279; Deistung A, 2009, J MAGN RESON IMAGING, V29, P1478, DOI 10.1002/jmri.21673; Denk C, 2010, J MAGN RESON IMAGING, V31, P185, DOI 10.1002/jmri.21995; Dong JW, 2015, IEEE T MED IMAGING, V34, P531, DOI 10.1109/TMI.2014.2361764; Du YP, 2008, MAGN RESON MED, V59, P954, DOI 10.1002/mrm.21581; Du YPP, 2009, J MAGN RESON IMAGING, V30, P449, DOI 10.1002/jmri.21833; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Fatemi-Ardekani A, 2009, MED PHYS, V36, P5429, DOI 10.1118/1.3250860; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Feng W, 2013, MAGN RESON MED, V70, P117, DOI 10.1002/mrm.24457; Freilinger TM, 2012, JACC-CARDIOVASC IMAG, V5, P397, DOI 10.1016/j.jcmg.2012.01.012; Fujioka M, 2013, J STROKE CEREBROVASC, V22, P1428, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.009; Gaens ME, 2013, RADIOLOGY, V266, P271, DOI 10.1148/radiol.12120499; Ge YL, 2009, J MAGN RESON IMAGING, V29, P1190, DOI 10.1002/jmri.21758; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Gho SM, 2014, MAGN RESON MED, V72, P337, DOI 10.1002/mrm.24920; Gilbert G, 2012, MAGN RESON IMAGING, V30, P722, DOI 10.1016/j.mri.2012.02.008; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Grandin CB, 2002, RADIOLOGY, V223, P361, DOI 10.1148/radiol.2232010673; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregg NM, 2015, JAMA NEUROL, V72, P1021, DOI 10.1001/jamaneurol.2015.1359; Griffith JF, 2007, SPINE, V32, pE708, DOI 10.1097/BRS.0b013e31815a59a0; Griswold MA, 2002, MAGN RESON MED, V47, P1202, DOI 10.1002/mrm.10171; Guadagno JV, 2004, J CEREBR BLOOD F MET, V24, P1249, DOI 10.1097/01.WCB.0000141557.32867.6B; Guo LF, 2013, CLIN NEURORADIOL, V23, P121, DOI 10.1007/s00062-012-0185-7; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke E.M., 2011, SUSCEPTIBILITY WEIGH; Haacke E.M., 1999, MAGNETIC RESONANCE I; Haacke EM, 2007, J MAGN RESON IMAGING, V26, P256, DOI 10.1002/jmri.22987; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAACKE EM, 1991, PHYS MED BIOL, V36, P723, DOI 10.1088/0031-9155/36/6/002; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Hammond KE, 2008, NEUROIMAGE, V39, P1682, DOI 10.1016/j.neuroimage.2007.10.037; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Heiss WD, 2011, CEREBROVASC DIS, V32, P307, DOI 10.1159/000330462; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Hernando D, 2013, MAGN RESON MED, V70, P648, DOI 10.1002/mrm.24848; Hsu EW, 1999, MAGNET RESON MED, V41, P992, DOI 10.1002/(SICI)1522-2594(199905)41:5<992::AID-MRM19>3.0.CO;2-Y; Ingall Timothy, 2004, J Insur Med, V36, P143; Ishizaka K, 2010, J MAGN RESON IMAGING, V31, P32, DOI 10.1002/jmri.21989; Jin ZY, 2008, J MAGN RESON IMAGING, V28, P327, DOI 10.1002/jmri.21447; Kao HW, 2012, EUR RADIOL, V22, P1397, DOI 10.1007/s00330-012-2387-4; Kerwin WS, 2006, RADIOLOGY, V241, P459, DOI 10.1148/radiol.2412051336; Kerwin William S, 2009, Top Magn Reson Imaging, V20, P217, DOI 10.1097/RMR.0b013e3181ea2853; Kesavadas C, 2011, J NEUROL, V258, P932, DOI 10.1007/s00415-010-5843-6; Kim DH, 2014, MAGN RESON MED, V71, P1144, DOI 10.1002/mrm.24759; Kim WB, 2011, UROLOGY, V78, P447, DOI 10.1016/j.urology.2010.12.056; Krueger EC, 2007, AM J NEURORADIOL, V28, P1237, DOI 10.3174/ajnr.A0546; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Li NZ, 2015, J MAGN RESON IMAGING, V41, P1695, DOI 10.1002/jmri.24728; Li RK, 2012, J MAGN RESON IMAGING, V36, P900, DOI 10.1002/jmri.23734; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Lingegowda D, 2012, NEUROL INDIA, V60, P160, DOI 10.4103/0028-3886.96389; Linn J, 2015, CLIN NEURORADIOL, V25, P167, DOI 10.1007/s00062-015-0458-z; Liu CL, 2015, J MAGN RESON IMAGING, V42, P23, DOI [10.1002/jmri.24768, 10.3969/j.issn.1001-2400.2015.01.004]; Liu J, 2016, J NEUROTRAUM, V33, P10, DOI 10.1089/neu.2014.3856; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu S, 2015, P 23 ANN M ISMRM TOR, P3309; Liu SF, 2014, J MAGN RESON IMAGING, V40, P698, DOI 10.1002/jmri.24413; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lou M, 2014, AM J NEURORADIOL, V35, P2061, DOI 10.3174/ajnr.A4017; Luo S, 2015, J NEURORADIOLOGY, V42, P255, DOI DOI 10.1016/J.NEURAD.2014.07.002; Ma YJ, 2015, MED PHYS, V42, P637, DOI 10.1118/1.4905163; Majumdar S, 2006, NMR BIOMED, V19, P894, DOI 10.1002/nbm.1106; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Mathiesen EB, 2001, CIRCULATION, V103, P2171; Meoded A, 2014, J NEURORADIOLOGY, V41, P108, DOI 10.1016/j.neurad.2013.04.002; Mie MB, 2010, Z MED PHYS, V20, P143, DOI 10.1016/j.zemedi.2010.02.004; Miwa K, 2014, NEUROLOGY, V83, P646, DOI 10.1212/WNL.0000000000000692; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Moenninghoff C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122329; Nakarmi U, 2015, P 23 ANN M ISMRM TOR, P3329; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Neelavalli J, 2014, J MAGN RESON IMAGING, V40, P949, DOI 10.1002/jmri.24476; Neelavalli J, 2014, J MAGN RESON IMAGING, V39, P998, DOI 10.1002/jmri.24245; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Nerlich AG, 1997, SPINE, V22, P2781, DOI 10.1097/00007632-199712150-00001; Noguchi T, 2011, J AM COLL CARDIOL, V58, P416, DOI 10.1016/j.jacc.2011.01.056; Park MG, 2015, J STROKE CEREBROVASC, V24, P1229, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.021; Parker DL, 2014, MAGN RESON MED, V72, P563, DOI 10.1002/mrm.24932; Peterson CK, 2000, SPINE, V25, P218, DOI 10.1097/00007632-200001150-00013; Polak JF, 2011, NEW ENGL J MED, V365, P213, DOI 10.1056/NEJMoa1012592; Poser BA, 2010, NEUROIMAGE, V51, P261, DOI 10.1016/j.neuroimage.2010.01.108; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 2001, NMR BIOMED, V14, P453, DOI 10.1002/nbm.722; Reichenbach JR, 2001, NEURORADIOLOGY, V43, P364, DOI 10.1007/s002340000503; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Reichenbach JR, 1998, MAGN RESON MATER PHY, V6, P62, DOI 10.1016/S1352-8661(98)00011-8; Robertson CA, 2011, J CEREBR BLOOD F MET, V31, P1788, DOI 10.1038/jcbfm.2011.67; Robinson S, 2011, MAGN RESON MED, V65, P1638, DOI 10.1002/mrm.22753; ROEMER PB, 1990, MAGNET RESON MED, V16, P192, DOI 10.1002/mrm.1910160203; Ros C, 2009, IFMBE PROC, V22, P803; Santhosh K, 2009, CLIN RADIOL, V64, P74, DOI 10.1016/j.crad.2008.04.022; Santosh C, 2008, J CEREBR BLOOD F MET, V28, P1742, DOI 10.1038/jcbfm.2008.56; Sati P, 2014, MULT SCLER J, V20, P1464, DOI 10.1177/1352458514525868; SCHNEIDERMAN G, 1987, SPINE, V12, P276, DOI 10.1097/00007632-198704000-00016; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Schweser F, 2013, MAGN RESON MED, V69, P1581, DOI 10.1002/mrm.24405; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shams S, 2015, AM J NEURORADIOL, V36, P1089, DOI 10.3174/ajnr.A4248; Sharma SD, 2015, MAGN RESON MED, V74, P673, DOI 10.1002/mrm.25448; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Staub D, 2011, RADIOLOGY, V258, P618, DOI 10.1148/radiol.10101008; Sun HF, 2015, MAGN RESON MED, V73, P1932, DOI 10.1002/mrm.25316; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tempany C, 2008, J MAGN RESON IMAGING, V27, P356, DOI 10.1002/jmri.21259; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; TSUCHIYA K, 1993, NEURORADIOLOGY, V35, P341, DOI 10.1007/BF00588364; Tsui YK, 2009, J NEUROL SCI, V287, P7, DOI 10.1016/j.jns.2009.08.064; Uetani H, 2013, AM J NEURORADIOL, V34, P984, DOI 10.3174/ajnr.A3332; Verma RK, 2014, EUR J RADIOL, V83, P1448, DOI 10.1016/j.ejrad.2014.05.001; Walsh DO, 2000, MAGNET RESON MED, V43, P682, DOI 10.1002/(SICI)1522-2594(200005)43:5<682::AID-MRM10>3.0.CO;2-G; Wang DN, 2015, J STROKE CEREBROVASC, V24, P2728, DOI 10.1016/j.jstrokecerebrovasdis.2015.08.003; Wang MY, 2011, MAGN RESON IMAGING, V29, P365, DOI 10.1016/j.mri.2010.10.016; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Wei Chen, 2012, 2012 5th International Conference on BioMedical Engineering and Informatics (BMEI), P447, DOI 10.1109/BMEI.2012.6513159; Wu DM, 2016, MAGN RESON MED, V76, P478, DOI 10.1002/mrm.25878; Wu JL, 2011, J MAGN RESON IMAGING, V34, P791, DOI 10.1002/jmri.22687; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617; Xia S, 2014, MAGN RESON IMAGING, V32, P1272, DOI 10.1016/j.mri.2014.08.012; Xing W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057691; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Xu YB, 2008, MAGN RESON IMAGING, V26, P1406, DOI 10.1016/j.mri.2008.04.008; Yan L, 2014, RADIOL MED, V119, P175, DOI 10.1007/s11547-013-0328-1; Yang Q, 2009, J MAGN RESON IMAGING, V30, P357, DOI 10.1002/jmri.21859; Ye YQ, 2013, J MAGN RESON IMAGING, V38, P1539, DOI 10.1002/jmri.24128; YU S, 1989, RADIOLOGY, V170, P523, DOI 10.1148/radiology.170.2.2911680; Zhang JB, 2004, NMR BIOMED, V17, P459, DOI 10.1002/nbm.926; Zhaoyang Jin, 2012, 2012 5th International Conference on BioMedical Engineering and Informatics (BMEI), P22, DOI 10.1109/BMEI.2012.6512887; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064; Zhou ZY, 2013, RADIOLOGY, V268, P492, DOI 10.1148/radiol.13120874; Zwanenburg JJM, 2011, NEUROIMAGE, V56, P1902, DOI 10.1016/j.neuroimage.2011.03.046	181	66	69	3	41	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3552	10.1002/nbm.3552			22	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400003	27192086	Green Accepted			2021-06-18	
J	Parsons, TD; Carlew, AR; Magtoto, J; Stonecipher, K				Parsons, Thomas D.; Carlew, Anne R.; Magtoto, Jonlih; Stonecipher, Kiefer			The potential of function-led virtual environments for ecologically valid measures of executive function in experimental and clinical neuropsychology	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Virtual environments; Neuropsychological assessment; Ecological validity; Executive function	MULTIPLE ERRANDS TEST; CONTINUOUS PERFORMANCE-TEST; TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SIMULATOR DRIVING PERFORMANCE; ACTION PLANNING-SUPERMARKET; COGNITIVE IMPAIRMENTS; INITIAL VALIDATION; SIMPLIFIED VERSION; PEDESTRIAN SAFETY	The assessment of executive functions is an integral task of neuropsychological assessment. Traditional measures of executive function are often based on hypothetical constructs that may have little relevance to real-world behaviours. In fact, some traditional tests utilised today were not originally developed for clinical use. Recently, researchers have been arguing for a new generation of function-led neuropsychological assessments that are developed from directly observable everyday behaviours. Although virtual environments (VEs) have been presented as potential aides in enhancing ecological validity, many were modelled on construct-driven approaches found in traditional assessments. In the current paper, we review construct-driven and function-led VE-based neuropsychological assessments of executive functions. Overall, function-led VEs best represent the sorts of tasks needed for enhanced ecological validity and prediction of real-world functioning.	[Parsons, Thomas D.; Carlew, Anne R.; Magtoto, Jonlih; Stonecipher, Kiefer] Univ North Texas, Dept Psychol, Computat Neuropsychol & Simulat, Denton, TX USA	Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, CNS Lab, Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.; Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, CNS Lab, 1155 Union Circle 311280, Denton, TX 76203 USA.	Thomas.Parsons@unt.edu		Carlew, Anne/0000-0001-7980-3954; Parsons, Thomas/0000-0003-0331-5019			Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Allen AJ, 2009, ALCOHOL CLIN EXP RES, V33, P617, DOI 10.1111/j.1530-0277.2008.00876.x; Armstrong CM, 2013, J CLIN EXP NEUROPSYC, V35, P113, DOI 10.1080/13803395.2012.740002; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Attree E. A., 1996, ECDVRAT 1 EUR C DIS, V118; Avis KT, 2014, SLEEP, V37, P283, DOI 10.5665/sleep.3398; Bailey PE, 2010, Q J EXP PSYCHOL, V63, P646, DOI 10.1080/17470210903521797; Barkley RA, 2006, NEUROPSYCHOLOGY, V20, P77, DOI 10.1037/0894-4105.20.1.77; Barkley RA, 2005, J SAFETY RES, V36, P121, DOI 10.1016/j.jsr.2005.01.001; Barkley Russell A, 2007, J Atten Disord, V10, P306, DOI 10.1177/1087054706292122; Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Bedard M, 2010, AM J OCCUP THER, V64, P336, DOI 10.5014/ajot.64.2.336; Bioulac S, 2012, EUR J PAEDIATR NEURO, V16, P514, DOI 10.1016/j.ejpn.2012.01.006; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Buxbaum LJ, 2012, NEUROPSYCHOLOGY, V26, P430, DOI 10.1037/a0028674; Calhoun VD, 2012, NEUROIMAGE, V59, P25, DOI 10.1016/j.neuroimage.2011.06.037; Campbell Z, 2009, APPL NEUROPSYCHOL, V16, P295, DOI 10.1080/09084280903297891; Cao X, 2010, P 8 INT C DIS VIRT R, P71; Carelli L, 2008, 2008 VIRTUAL REHABILITATION, P99, DOI 10.1109/ICVR.2008.4625144; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cipresso P, 2013, EXP BRAIN RES, V229, P443, DOI 10.1007/s00221-013-3471-y; Clancy TA, 2006, J CLIN CHILD ADOLESC, V35, P203, DOI 10.1207/s15374424jccp3502_4; Cook LG, 2013, J INT NEUROPSYCH SOC, V19, P508, DOI 10.1017/S1355617712001452; Cox DJ, 2008, J CHILD ADOL PSYCHOP, V18, P1, DOI 10.1089/cap.2006.0141; Cuberos-Urbano G, 2013, J CLIN EXP NEUROPSYC, V35, P329, DOI 10.1080/13803395.2013.776011; Davis AL, 2013, J ADOLESCENT HEALTH, V53, P785, DOI 10.1016/j.jadohealth.2013.07.008; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Diaz-Orueta U, 2014, CHILD NEUROPSYCHOL, V20, P328, DOI 10.1080/09297049.2013.792332; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Fox J., 2009, J MEDIA PSYCHOL-GER, V21, P95, DOI [10.1027/1864-1105.21.3.95, DOI 10.1027/1864-1105.21.3.95]; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Goldstein G, 1996, ECOLOGICAL VALIDITY, P75; Henry M, 2012, J NEUROSCI METH, V210, P125, DOI 10.1016/j.jneumeth.2012.07.025; Iriarte Y, 2016, J ATTEN DISORD, V20, P542, DOI 10.1177/1087054712465335; Jansari AS, 2013, ADDICTION, V108, P977, DOI 10.1111/add.12082; Josman N, 2014, J STROKE CEREBROVASC, V23, P879, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.013; Josman N, 2009, SCHIZOPHR RES, V115, P270, DOI 10.1016/j.schres.2009.09.015; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P207, DOI 10.1080/09084282.2011.643956; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P171, DOI 10.1080/09084282.2011.643955; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Knouse Laura E, 2005, J Atten Disord, V8, P221, DOI 10.1177/1087054705280159; Lalonde G, 2013, J NEUROSCI METH, V219, P76, DOI 10.1016/j.jneumeth.2013.07.005; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; Law AS, 2013, Q J EXP PSYCHOL, V66, P1241, DOI 10.1080/17470218.2012.748813; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lee HC, 2003, ACCIDENT ANAL PREV, V35, P797, DOI 10.1016/S0001-4575(02)00083-0; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Logie RH, 2011, MEM COGNITION, V39, P1561, DOI 10.3758/s13421-011-0120-1; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Miller KJ, 2014, AGE AGEING, V43, P188, DOI 10.1093/ageing/aft194; Milleville-Pennel I, 2010, BRAIN INJURY, V24, P678, DOI 10.3109/02699051003692159; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Moffat SD, 2009, NEUROPSYCHOL REV, V19, P478, DOI 10.1007/s11065-009-9120-3; Montgomery C, 2011, HUM PSYCHOPHARM CLIN, V26, P208, DOI 10.1002/hup.1194; Morris R. G., 2002, INT C DIS VIRT REAL, V4, P101; Nagamatsu LS, 2011, PSYCHOL AGING, V26, P253, DOI 10.1037/a0022929; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; Parsey CM, 2013, CLIN NEUROPSYCHOL, V27, P1328, DOI 10.1080/13854046.2013.834971; Parsons TD, 2008, J BEHAV THER EXP PSY, V39, P250, DOI 10.1016/j.jbtep.2007.07.007; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons TD, 2013, 2013 1ST WORKSHOP ON VIRTUAL AND AUGMENTED ASSISTIVE TECHNOLOGY (VAAT), P27, DOI 10.1109/VAAT.2013.6786190; Parsons TD, 2014, J NEUROSCI METH, V222, P15, DOI 10.1016/j.jneumeth.2013.10.006; Parsons TD, 2013, J CLIN EXP NEUROPSYC, V35, P812, DOI 10.1080/13803395.2013.824556; Parsons TD, 2011, STUD COMPUT INTELL, V337, P271; Patil I, 2014, SOC NEUROSCI-UK, V9, P94, DOI 10.1080/17470919.2013.870091; Pedroli E., 2013, ANN REV CYBERTHERAPY, V191, P48; Pollak Y, 2010, CNS SPECTRUMS, V15, P125, DOI 10.1017/S109285290002736X; Pollak Y, 2009, J DEV BEHAV PEDIATR, V30, P2, DOI 10.1097/DBP.0b013e3181969b22; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Pugnetti L., 1998, CYBERPSYCHOL BEHAV, V1, P151; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Raspelli S, 2012, PRESENCE-TELEOP VIRT, V21, P31, DOI 10.1162/PRES_a_00077; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Rizzo AS, 2002, STUD NEUROPSYCHOL DE, P243; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Saidel-Goley IN, 2012, CYBERPSYCH BEH SOC N, V15, P112, DOI 10.1089/cyber.2011.0302; Sauzeon H, 2016, J NEUROPSYCHOL, V10, P33, DOI 10.1111/jnp.12055; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, V3rd ed., P367; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schultheis MT, 2007, ASSIST TECHNOL, V19, P1, DOI 10.1080/10400435.2007.10131860; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Simons J.S., 2005, EFFECTIVENESS REHABI, V211, DOI [10.1093/acprof:oso/9780198526544.003.0018, DOI 10.1093/ACPROF:OSO/9780198526544.001.0001]; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Toet A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00883; Wald J, 2001, ST HEAL T, V81, P564; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; Weigl E., 1948, J ABNORM SOC PSYCHOL, V36, P3; Werner P, 2009, DEMENT GERIATR COGN, V27, P301, DOI 10.1159/000204915; Wilson BA, 1996, BEHAV ASSESSMENT DYS	107	66	67	2	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	5			SI		777	807		10.1080/09602011.2015.1109524			31	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	EU3IT	WOS:000400923300010	26558491				2021-06-18	
J	Helmick, KM; Spells, CA; Malik, SZ; Davies, CA; Marion, DW; Hinds, SR				Helmick, Katherine M.; Spells, Cynthia A.; Malik, Saafan Z.; Davies, Cathleen A.; Marion, Donald W.; Hinds, Sidney R.			Traumatic brain injury in the US military: epidemiology and key clinical and research programs	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Military; Department of Defense; Concussion; Surveillance; Clinical recommendations	OPERATION IRAQI FREEDOM	Traumatic brain injury (TBI), and particularly concussion, is a major concern for the U.S. Military because of the associated short term disability, long term cognitive and pain symptoms suffered by some, and risk of prolonged or permanent neurologic injury if the Service member incurs a second TBI before full recovery from the first. Concussions were seen more often during the recent conflicts in Afghanistan and Iraq than in prior conflicts, such as the Vietnam War, because of the use of improvised explosive devices that typically caused non-penetrating closed head injury. Since 2000 more than 300,000 Service members were diagnosed with TBI, of which more than 80 % were concussions. Improved TBI screening tools also have identified a higher than expected incidence of concussions occurring in garrison. In this review we summarize current epidemiologic data for TBI in the Military, and describe contemporary Military procedures and strategies for TBI prevention, identification, evaluation, and acute and chronic care. Key TBI clinical research priorities and programs are described, and innovative organizational plans to address future TBI needs are summarized.	[Helmick, Katherine M.; Spells, Cynthia A.; Malik, Saafan Z.; Davies, Cathleen A.; Marion, Donald W.; Hinds, Sidney R.] DVBIC DCoE Headquarters, Silver Spring, MD 20910 USA	Helmick, KM (corresponding author), DVBIC DCoE Headquarters, 1335 East West Hwy,Suite 605, Silver Spring, MD 20910 USA.	Katherine.m.helmick.civ@mail.mil; donald.w.marion.ctr@mail.mil	Marion, Donald/AAR-5749-2021				Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; French L., 2008, J SPEC OPER MED, V8, P68; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003; Institute of Medicine (IOM) & National Research Council (NRC), 2013, SPORTS REL CONC YOUT; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Regasa LE, 2015, J HEAT TRAU IN PRESS; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	16	66	71	1	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					358	366		10.1007/s11682-015-9399-z			9	Neuroimaging	Neurosciences & Neurology	CR8LQ	WOS:000361604300002	25972118				2021-06-18	
J	Spielberg, JM; McGlinchey, RE; Milberg, WP; Salat, DH				Spielberg, Jeffrey M.; McGlinchey, Regina E.; Milberg, William P.; Salat, David H.			Brain Network Disturbance Related to Posttraumatic Stress and Traumatic Brain Injury in Veterans	BIOLOGICAL PSYCHIATRY			English	Article						Posttraumatic stress disorder; Traumatic brain injury; Brain network; Graph theory; Hippocampus; fMRI	DISORDER; PTSD; METAANALYSIS	BACKGROUND: Understanding the neural causes and consequences of posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) is a high research priority, given the high rates of associated disability and suicide. Despite remarkable progress in elucidating the brain mechanisms of PTSD and mTBI, a comprehensive understanding of these conditions at the level of brain networks has yet to be achieved. The present study sought to identify functional brain networks and topological properties (measures of network organization and function) related to current PTSD severity and mTBI. METHODS: Graph theoretic tools were used to analyze resting-state functional magnetic resonance imaging data from 208 veterans of Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn, all of whom had experienced a traumatic event qualifying for PTSD criterion A. Analyses identified brain networks and topological network properties linked to current PTSD symptom severity, mTBI, and the interaction between PTSD and mTBI. RESULTS: Two brain networks were identified in which weaker connectivity was linked to higher PTSD re-experiencing symptoms, one of which was present only in veterans with comorbid mTBI. Re-experiencing was also linked to worse functional segregation (necessary for specialized processing) and diminished influence of key regions on the network, including the hippocampus. CONCLUSIONS: Findings of this study demonstrate that PTSD re-experiencing symptoms are linked to weakened connectivity in a network involved in providing contextual information. A similar relationship was found in a separate network typically engaged in the gating of working memory, but only in veterans with mTBI.	[Spielberg, Jeffrey M.; Salat, David H.] Boston Univ, Sch Med, Neuroimaging Res Vet Ctr, Boston, MA 02215 USA; [McGlinchey, Regina E.; Milberg, William P.] Boston Univ, Sch Med, Geriatr Res Educ & Clin Ctr, Boston, MA 02115 USA; [McGlinchey, Regina E.; Milberg, William P.] Boston Univ, Sch Med, Translat Res Ctr TBI & Stress Disorders, Boston, MA 02115 USA; [Spielberg, Jeffrey M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [McGlinchey, Regina E.; Milberg, William P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Salat, David H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Spielberg, JM (corresponding author), VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, 150 South Huntington Ave 182 JP, Boston, MA 02130 USA.	jmsp@bu.edu	McGlinchey, Regina E/R-1971-2016; Spielberg, Jeffrey/D-1402-2014	Spielberg, Jeffrey/0000-0001-8348-7157	Translational Research Center for TBI and Stress Disorders; U.S. Department of Veterans Affairs Rehabilitation Research; Development Traumatic Brain Injury Center of Excellence [B9254-C]	This work was supported by the Translational Research Center for TBI and Stress Disorders, a U.S. Department of Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (Grant No. B9254-C).	Badre D, 2012, CEREB CORTEX, V22, P527, DOI 10.1093/cercor/bhr117; Banich MT, 2009, CURR DIR PSYCHOL SCI, V18, P89, DOI 10.1111/j.1467-8721.2009.01615.x; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brown AD, 2013, J BEHAV THER EXP PSY, V44, P129, DOI 10.1016/j.jbtep.2011.11.004; Castellanos FX, 2013, NEUROIMAGE, V80, P527, DOI 10.1016/j.neuroimage.2013.04.083; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; FRIEDMAN MJ, 1994, PSYCHIAT CLIN N AM, V17, P265; Garfinkel SN, 2009, PSYCHIAT ANN, V39, P370, DOI 10.3928/00485713-20090527-01; Gates MA, 2012, PSYCHOL SERV, V9, P361, DOI 10.1037/a0027649; Insel Thomas R, 2010, Sci Am, V302, P44; Kloppel S, 2012, NEUROIMAGE, V61, P457, DOI 10.1016/j.neuroimage.2011.11.002; Konkel A, 2009, FRONT NEUROSCI-SWITZ, V3, P166, DOI 10.3389/neuro.01.023.2009; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Morris Sarah E, 2012, Dialogues Clin Neurosci, V14, P29; Obama B, 2012, IMPROVING ACCESS MEN; Panagioti M, 2012, COMPR PSYCHIAT, V53, P915, DOI 10.1016/j.comppsych.2012.02.009; Rubinov M, 2013, TRENDS COGN SCI, V17, P641, DOI 10.1016/j.tics.2013.10.007; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Sadeh N, 2014, CLIN PSYCHOL SCI, V2, P748, DOI 10.1177/2167702614530113; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Suvak MK, 2011, J TRAUMA STRESS, V24, P3, DOI 10.1002/jts.20618; Turk-Browne NB, 2013, SCIENCE, V342, P580, DOI 10.1126/science.1238409; van den Heuvel MP, 2013, TRENDS COGN SCI, V17, P683, DOI 10.1016/j.tics.2013.09.012; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	29	66	67	1	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	AUG 1	2015	78	3					210	216		10.1016/j.biopsych.2015.02.013			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	CM2DC	WOS:000357489000011	25818631				2021-06-18	
J	Kourbeti, IS; Vakis, AF; Ziakas, P; Karabetsos, D; Potolidis, E; Christou, S; Samonis, G				Kourbeti, Irene S.; Vakis, Antonis F.; Ziakas, Panayiotis; Karabetsos, Dimitris; Potolidis, Evangelos; Christou, Silvana; Samonis, George			Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; meningitis; infection; ventilator-associated pneumonia; surgical site infections	VENTRICULOSTOMY-RELATED INFECTIONS; NEGATIVE BACILLARY MENINGITIS; NEUROSURGICAL SITE INFECTIONS; ACINETOBACTER-BAUMANNII; ANTIBIOTIC-PROPHYLAXIS; POSTOPERATIVE MENINGITIS; ELECTRODES; MANAGEMENT; SURGERY; ADULTS	OBJECT The authors performed a prospective study to define the prevalence and microbiological characteristics of infections in patients undergoing craniotomy and to clarify the risk factors for post-craniotomy meningitis. METHODS Patients older than 18 years who underwent nonstereotactic craniotomies between January 2006 and December 2008 were included. Demographic, clinical, laboratory, and microbiological data were systemically recorded. Patient characteristics, craniotomy type, and pre- and postoperative variables were evaluated as risk factors for meningitis RESULTS Three hundred thirty-four procedures were analyzed (65.6% involving male patients). Traumatic brain injury was the most common reason for craniotomy. Almost 40% of the patients developed at least 1 infection. Ventilator-associated pneumonia (VAP) was the most common infection recorded (22.5%) and Acinetobacter spp. were isolated in 44% of the cases. Meningitis was encountered in 16 procedures (4.8%), and CSF cultures were positive for microbial growth in 100% of these cases. Gram-negative pathogens (Acinetobacter spp., Klebsiella spp., Pseudomonas aeruginosa, Enterobacter cloaceae, Proteus mirabilis) represented 88% of the pathogens. Acinetobacter and Klebsiella spp. demonstrated a high percentage of resistance in several antibiotic classes. In multivariate analysis, the-risk for meningitis was independently associated with perioperative steroid use (OR 11.55, p = 0.005), CSF leak (OR 48.03, p < 0.001), and ventricular drainage (OR 70.52, p < 0.001). CONCLUSIONS Device-related postoperative communication between the CSF and the environment, CSF leak, and perioperative steroid use were defined as risk factors for meningitis in this study. Ventilator-associated pneumonia was the most common infection overall. The offending pathogens presented a high level of resistance to several antibiotics.	[Kourbeti, Irene S.] Gen Hosp Chalkida, Dept Internal Med, Chalkida, Greece; [Vakis, Antonis F.; Karabetsos, Dimitris] Univ Hosp Herakl, Dept Neurosurg, Iraklion, Greece; [Samonis, George] Univ Hosp Herakl, Dept Internal Med Infect Dis, Iraklion, Greece; [Potolidis, Evangelos] Gen Hosp Volos, Dept Internal Med, Volos, Greece; [Ziakas, Panayiotis] Brown Univ, Warren Alpert Med Sch, Dept Internal Med, Div Infect Dis, Providence, RI 02912 USA; [Christou, Silvana] Gen Hosp Nicosia, Dept Internal Med, Nicosia, Cyprus	Kourbeti, IS (corresponding author), Furness Gen Hosp, Dept Acute & Emergency Med, Dalton Ln, Barrow In Furness LA14 4LF, Cumbria, England.	irenekourbeti@hotmail.com	Karabetsos, Dimitris/AAA-2753-2021	Karabetsos, Dimitris/0000-0003-1960-945X; Ziakas, Panayiotis/0000-0002-5943-8635	PfizerPfizer; NovartisNovartis; GileadGilead Sciences; MSD	Dr. Samonis reports receiving non study related clinical or research support from Pfizer, Novartis, Gilead, and MSD.	Blomstedt G C, 1992, Neurosurg Clin N Am, V3, P375; Briggs S, 2004, SCAND J INFECT DIS, V36, P165, DOI 10.1080/00365540410027193; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Erdem I, 2008, NEUROL INDIA, V56, P433, DOI 10.4103/0028-3886.44629; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; Gulati S, 2001, NEUROL INDIA, V49, P134; Hersh EH, 2013, J NEUROSURG, V119, P48, DOI 10.3171/2013.3.JNS121489; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hsu Gwo-Jong, 1993, Journal of the Formosan Medical Association, V92, P317; Kim BN, 2009, LANCET INFECT DIS, V9, P245, DOI 10.1016/S1473-3099(09)70055-6; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; KORINEK AM, 1992, ANN FR ANESTH, V11, P711, DOI 10.1016/S0750-7658(05)80795-6; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2007, NEUROSURGERY, V60, P317, DOI 10.1227/01.NEU.0000249266.26322.25; Leib SL, 1999, CLIN INFECT DIS, V29, P69, DOI 10.1086/520184; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lu CH, 1999, SURG NEUROL, V52, P438, DOI 10.1016/S0090-3019(99)00129-9; MAHE V, 1995, ANN FR ANESTH, V14, P8, DOI 10.1016/S0750-7658(05)80144-3; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; McPhee IB, 1998, SPINE, V23, P726, DOI 10.1097/00007632-199803150-00015; Metan G, 2007, INT J ANTIMICROB AG, V29, P112, DOI 10.1016/j.ijantimicag.2006.08.035; MOLLMAN HD, 1986, J NEUROSURG, V64, P902, DOI 10.3171/jns.1986.64.6.0902; NAROTAM PK, 1994, NEUROSURGERY, V34, P409, DOI 10.1227/00006123-199403000-00004; NGUYEN MH, 1994, NEUROSURGERY, V35, P851, DOI 10.1227/00006123-199411000-00008; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Reichert MCF, 2002, AM J INFECT CONTROL, V30, P158, DOI 10.1067/mic.2002.119925; Rello J, 1999, CHEST, V115, P1226, DOI 10.1378/chest.115.5.1226; Shinoura N, 2004, BRIT J NEUROSURG, V18, P598, DOI 10.1080/02688690400022771; Srinivas D, 2011, NEUROL INDIA, V59, P195, DOI 10.4103/0028-3886.79136; Van Gompel JJ, 2008, NEUROSURGERY, V63, P498, DOI 10.1227/01.NEU.0000324996.37228.F8; Walcott BP, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12245; Wroblewska MM, 2004, J HOSP INFECT, V57, P300, DOI 10.1016/j.jhin.2004.04.009	34	66	75	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2015	122	5					1113	1119		10.3171/2014.8.JNS132557			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CG5XP	WOS:000353369500017	25343179	Bronze			2021-06-18	
J	Tian, Y; Salsbery, B; Wang, M; Yuan, HJ; Yang, J; Zhao, ZL; Wu, XP; Zhang, YJ; Konkle, BA; Thiagarajan, P; Li, M; Zhang, JN; Dong, JF				Tian, Ye; Salsbery, Breia; Wang, Min; Yuan, Hengjie; Yang, Jing; Zhao, Zilong; Wu, Xiaoping; Zhang, Yanjun; Konkle, Barbara A.; Thiagarajan, Perumal; Li, Min; Zhang, Jianning; Dong, Jing-fei			Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury	BLOOD			English	Article							NEURON-SPECIFIC ENOLASE; TISSUE-FACTOR; EARLY COAGULOPATHY; LIPID RAFTS; BLOOD; PLATELETS; ACTIVATION; EXPRESSION; SEROTONIN; HISTAMINE	Traumatic brain injury (TBI) is associated with coagulopathy, although it often lacks 2 key risk factors: severe bleeding and significant fluid resuscitation associated with hemorrhagic shock. The pathogenesis of TBI-associated coagulopathy remains poorly understood. We tested the hypothesis that brain-derived microparticles (BDMPs) released from an injured brain induce a hypercoagulable state that rapidly turns into consumptive coagulopathy. Here, we report that mice subjected to fluid percussion injury (1.9 +/- 0.1 atm) developed a BDMP-dependent hypercoagulable state, with peak levels of plasma glial cell and neuronal BDMPs reaching 17 496 +/- 4833/mu L and 18 388 +/- 3657/mu L 3 hours after TBI, respectively. Uninjured mice injected with BDMPs developed a dose-dependent hyper-turned hypocoagulable state measured by a progressively prolonged clotting time, fibrinogen depletion, and microvascular fibrin deposition in multiple organs. The BDMPs were 50 to 300 nm with intact membranes, expressing neuronal or glial cell markers and procoagulant phosphatidylserine and tissue factor. Their procoagulant activity was greater than platelet microparticles and was dose-dependently blocked by lactadherin. Microparticles were produced from injured hippocampal cells, transmigrated through the disrupted endothelial barrier in a platelet-dependent manner, and activated platelets. These data define a novel mechanism of TBI-associated coagulopathy in mice, identify early predictive markers, and provide alternative therapeutic targets.	[Tian, Ye; Yuan, Hengjie; Zhao, Zilong; Zhang, Yanjun; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Tian, Ye; Salsbery, Breia; Yuan, Hengjie; Yang, Jing; Wu, Xiaoping; Konkle, Barbara A.; Dong, Jing-fei] Puget Sound Blood Res Inst, Seattle, WA USA; [Wang, Min; Li, Min] Lanzhou Univ, Sch Basic Med Sci, Inst Pathol, Lanzhou 730000, Peoples R China; [Konkle, Barbara A.; Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Thiagarajan, Perumal] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA	Dong, JF (corresponding author), Puget Sound Blood Ctr, Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@psbc.org	zhang, yanjun/S-5114-2019; Zhao, Zilong/AAZ-2196-2020	Zhang, Yanjun/0000-0002-3123-1405	National Institutes of Health, National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL71895, R01HL085769]; National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81271359, 81372575]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895, R01HL085769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01HL71895 and R01HL085769 (to J.F.D.), National Natural Science Foundation of China State Key Program grant 81330029 (to J.N.Z.), and National Natural Science Foundation of China research grants 81271361, 81271359 (to J.N.Z.), and 81372575 (to M.L.).	ALKHAMIS TM, 1990, BLOOD, V75, P1568; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Biro E, 2005, J THROMB HAEMOST, V3, P2754, DOI 10.1111/j.1538-7836.2005.01646.x; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; BOTTARO D, 1986, J CELL PHYSIOL, V128, P189, DOI 10.1002/jcp.1041280208; Camera M, 2003, ARTERIOSCL THROM VAS, V23, P1690, DOI 10.1161/01.ATV.0000085629.23209.AA; Cloutier N, 2012, BLOOD, V120, P1334, DOI 10.1182/blood-2012-02-413047; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; DELZOPPO GJ, 1992, THROMB HAEMOSTASIS, V68, P642; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Duan SM, 2006, GLIA, V54, P738, DOI 10.1002/glia.20397; Exner T, 2003, BLOOD COAGUL FIBRIN, V14, P773, DOI 10.1097/00001721-200312000-00015; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geddings JE, 2013, BLOOD, V122, P1873, DOI 10.1182/blood-2013-04-460139; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Kunzelmann-Marche C, 2000, THROMB HAEMOSTASIS, V83, P282; Lee TH, 2014, J TRAUMA ACUTE CARE, V77, P67, DOI 10.1097/TA.0000000000000255; Lentz BR, 2003, PROG LIPID RES, V42, P423, DOI 10.1016/S0163-7827(03)00025-0; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; McNicol A, 1999, THROMB RES, V95, P1, DOI 10.1016/S0049-3848(99)00015-8; Michel CC, 1997, J PHYSIOL-LONDON, V501, P657, DOI 10.1111/j.1469-7793.1997.657bm.x; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Neto AC, 2014, NEUROCRIT CARE; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; PAUS E, 1989, TUMOR BIOL, V10, P23, DOI 10.1159/000217590; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; QUINTARELLI G, 1971, J HISTOCHEM CYTOCHEM, V19, P641, DOI 10.1177/19.11.641; Shah MD, 2008, PLATELETS, V19, P365, DOI 10.1080/09537100802054107; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tchaikovski SN, 2007, J THROMB HAEMOST, V5, P2079, DOI 10.1111/j.1538-7836.2007.02719.x; Thiagarajan P, 1997, CIRCULATION, V96, P2339; UiTei K, 1996, NEUROSCI LETT, V203, P191, DOI 10.1016/0304-3940(95)12292-3; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wallace PK, 2008, CYTOM PART A, V73A, P1019, DOI 10.1002/cyto.a.20619; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zhang YJ, 2013, THROMB HAEMOSTASIS, V110, P331, DOI 10.1160/TH12-11-0853; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399; ZWAAL RFA, 1977, NATURE, V268, P358, DOI 10.1038/268358a0	53	66	76	0	10	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	MAR 26	2015	125	13					2151	2159		10.1182/blood-2014-09-598805			9	Hematology	Hematology	CI3CX	WOS:000354626300022	25628471	Bronze, Green Published			2021-06-18	
J	Stanley, RM; Hoyle, JD; Dayan, PS; Atabaki, S; Lee, L; Lillis, K; Gorelick, MH; Holubkov, R; Miskin, M; Holmes, JF; Dean, JM; Kuppermann, N				Stanley, Rachel M.; Hoyle, John D., Jr.; Dayan, Peter S.; Atabaki, Shireen; Lee, Lois; Lillis, Kathy; Gorelick, Marc H.; Holubkov, Richard; Miskin, Michelle; Holmes, James F.; Dean, J. Michael; Kuppermann, Nathan		Pediat Emergency Care Appl Res	Emergency Department Practice Variation in Computed Tomography Use for Children with Minor Blunt Head Trauma	JOURNAL OF PEDIATRICS			English	Article							RADIATION-EXPOSURE; UNITED-STATES; PEDIATRIC CT; RISK; CANCER; SEDATION	Objective To describe factors associated with computed tomography (CT) use for children with minor blunt head trauma that are evaluated in emergency departments. Study design Planned secondary analysis of a prospective observational study of children <18 years with minor blunt head trauma between 2004 and 2006 at 25 emergency departments. CT scans were obtained at the discretion of treating clinicians. We risk-adjusted patients for clinically important traumatic brain injuries and performed multivariable regression analyses. Outcome measures were rates of CT use by hospital and by clinician training type. Results CT rates varied between 19.2% and 69.2% across hospitals. Risk adjustment had little effect on the differential rate of CT use. In low-and middle-risk patients, clinicians obtained CTs more frequently at suburban and nonfreestanding children's hospitals. Physicians with emergency medicine (EM) residency training obtained CTs at greater rates than physicians with pediatric residency or pediatric EM training. In multivariable analyses, compared with pediatric EM-trained physicians, theOR for CT use among EM-trained physicians in children <2 years was 1.24 (95% CI 1.04-1.46), and for children >2 years was 1.68 (95% CI 1.50-1.89). Physicians of all training backgrounds, however, overused CT scans in low-risk children. Conclusions Substantial variation exists in the use of CT for childrenwithminor blunt head trauma not explained by patient severityor rates of positive CT scans or clinically important traumaticbrain injuries.	[Stanley, Rachel M.] Univ Michigan, Dept Emergency Med & Pediat, Ann Arbor, MI 48109 USA; [Hoyle, John D., Jr.] Michigan State Univ, Coll Human Med, Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Atabaki, Shireen] George Washington Sch Med, Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC USA; [Lee, Lois] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Lillis, Kathy] SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA; [Lillis, Kathy] Womens & Childrens Hosp, Buffalo, NY USA; [Gorelick, Marc H.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Holubkov, Richard; Miskin, Michelle; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Holubkov, Richard; Miskin, Michelle; Dean, J. Michael] PECARN Data Coordinating Ctr, Salt Lake City, UT USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Dept Emergency Med, Davis, CA 95616 USA	Stanley, RM (corresponding author), Univ Michigan, Dept Emergency Med, 1500 E Med Ctr Dr,TC B1 354,SPC 5303, Ann Arbor, MI 48109 USA.	stanleyr@umich.edu		Tsung, James/0000-0002-4718-8325; Lee, Lois/0000-0002-3551-5050; Holubkov, Richard/0000-0003-0431-3381	Health Resources and Services Administration (HRSA)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Maternal and Child Health Bureau (MCHB) [R40MC02461]; Emergency Medical Services of Children (EMSC) Program through the PECARN; PECARN [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	Supported in part by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB; R40MC02461), the Emergency Medical Services of Children (EMSC) Program through the PECARN. PECARN is supported by the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. The authors declare no conflicts of interest.	Alpern ER, 2006, PEDIATR EMERG CARE, V22, P689, DOI 10.1097/01.pec.0000236830.39194.c0; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAULKNER K, 1987, ACTA RADIOL, V28, P483; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levine MB, 2013, AM J EMERG MED, V31, P1437, DOI 10.1016/j.ajem.2013.07.003; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Malviya S, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e42; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Sanborn PA, 2005, RADIOLOGY, V237, P288, DOI 10.1148/radiol.2371041415	20	66	66	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2014	165	6					1201	+		10.1016/j.jpeds.2014.08.008			8	Pediatrics	Pediatrics	AU3PS	WOS:000345526500027	25294604				2021-06-18	
J	Murugavel, M; Cubon, V; Putukian, M; Echemendia, R; Cabrera, J; Osherson, D; Dettwiler, A				Murugavel, Murali; Cubon, Valerie; Putukian, Margot; Echemendia, Ruben; Cabrera, Javier; Osherson, Daniel; Dettwiler, Annegret			A Longitudinal Diffusion Tensor Imaging Study Assessing White Matter Fiber Tracts after Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; longitudinal study; mTBI; radial diffusivity; sports-related concussion	TRAUMATIC BRAIN-INJURY; AXONAL INJURY; ACUTE MILD; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; CORPUS-CALLOSUM; ABNORMALITIES; DISABILITY; ANISOTROPY; PREDICTORS	The extent of structural injury in sports-related concussion (SRC) is central to the course of recovery, long-term effects, and the decision to return to play. In the present longitudinal study, we used diffusion tensor imaging (DTI) to assess white matter (WM) fiber tract integrity within 2 days, 2 weeks, and 2 months of concussive injury. Participants were right-handed male varsity contact-sport athletes (20.2 +/- 1.0 years of age) with a medically diagnosed SRC (no loss of consciousness). They were compared to right-handed male varsity non-contact-sport athletes serving as controls (19.9 +/- 1.7 years). We found significantly increased radial diffusivity (RD) in concussed athletes (n = 12; paired t-test, tract-based spatial statistics; p < 0.025) at 2 days, when compared to the 2-week postinjury time point. The increase was found in a cluster of right hemisphere voxels, spanning the posterior limb of the internal capsule (IC), the retrolenticular part of the IC, the inferior longitudinal fasciculus, the inferior fronto-occipital fasciculus (sagittal stratum), and the anterior thalamic radiation. Post-hoc, univariate, between-group (controls vs. concussed), mixed-effects analysis of the cluster showed significantly higher RD at 2 days (p = 0.002), as compared to the controls, with a trend in the same direction at 2 months (p = 0.11). Results for fractional anisotropy (FA) in the same cluster showed a similar, but inverted, pattern; FA was decreased at 2 days and at 2 months postinjury, when compared to healthy controls. At 2 weeks postinjury, no statistical differences between concussed and control athletes were found with regard to either RD or FA. These results support the hypothesis of increased RD and reduced FA within 72 h postinjury, followed by recovery that may extend beyond 2 weeks. RD appears to be a sensitive measure of concussive injury.	[Murugavel, Murali; Dettwiler, Annegret] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Cubon, Valerie] Kent State Univ, Dept Chem, Warren, OH USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Echemendia, Ruben] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Cabrera, Javier] Rutgers State Univ, Dept Stat, Piscataway, NJ USA; [Osherson, Daniel] Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; [Dettwiler, Annegret] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA	Dettwiler, A (corresponding author), Princeton Univ, Princeton Neurosci Inst, Washington Rd, Princeton, NJ 08544 USA.	adettwil@princeton.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	New Jersey Commission for Brain Injury Research [10-3217-BIR-E-0]; American Medical Society for Sports Medicine AMSSM Foundation [005548]; Goldstein Family Fund; Peter & Cynthia Kellogg Foundation	The authors acknowledge the athletic trainers of University Health Services for their assistance with subject recruitment and NP testing. This work was funded by the New Jersey Commission for Brain Injury Research (grant no.: 10-3217-BIR-E-0), the American Medical Society for Sports Medicine AMSSM Foundation (grant no.: 005548), the Goldstein Family Fund, and the Peter & Cynthia Kellogg Foundation.	Andersson J.L., 2007, TR07JA2 FMRIB U OXF; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Ding GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061241; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Horsfield MA, 1998, J NEUROL NEUROSUR PS, V64, pS80; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; JohansenBerg H, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P1; KIM J, 2010, CTS-CLIN TRANSL SCI, V3, pS45; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Langlois J. A., 2004, BIOL PSYCHIAT, V55, P21; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P., 2009, S AFR J SPORTS MED, V21; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S., 2007, INTRO DIFFUSION TENS; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pinheiro J., 2000, MIXED EFFECTS MODELS; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhu T., 2010, P 18 ANN M INT SOC M, P4482	89	66	66	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1860	1871		10.1089/neu.2014.3368			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400005	24786666	Green Published			2021-06-18	
J	Hillary, FG; Rajtmajer, SM; Roman, CA; Medaglia, JD; Slocomb-Dluzen, JE; Calhoun, VD; Good, DC; Wylie, GR				Hillary, Frank G.; Rajtmajer, Sarah M.; Roman, Cristina A.; Medaglia, John D.; Slocomb-Dluzen, Julia E.; Calhoun, Vincent D.; Good, David C.; Wylie, Glenn R.			The Rich Get Richer: Brain Injury Elicits Hyperconnectivity in Core Subnetworks	PLOS ONE			English	Article							INDEPENDENT COMPONENT ANALYSIS; WORKING-MEMORY DYSFUNCTION; GRAPH-THEORETICAL ANALYSIS; FUNCTIONAL MRI DATA; DEFAULT MODE; LOW-FREQUENCY; CONNECTIVITY; NETWORKS; DEFICITS; MILD	There remains much unknown about how large-scale neural networks accommodate neurological disruption, such as moderate and severe traumatic brain injury (TBI). A primary goal in this study was to examine the alterations in network topology occurring during the first year of recovery following TBI. To do so we examined 21 individuals with moderate and severe TBI at 3 and 6 months after resolution of posttraumatic amnesia and 15 age- and education-matched healthy adults using functional MRI and graph theoretical analyses. There were two central hypotheses in this study: 1) physical disruption results in increased functional connectivity, or hyperconnectivity, and 2) hyperconnectivity occurs in regions typically observed to be the most highly connected cortical hubs, or the "rich club". The current findings generally support the hyperconnectivity hypothesis showing that during the first year of recovery after TBI, neural networks show increased connectivity, and this change is disproportionately represented in brain regions belonging to the brain's core subnetworks. The selective increases in connectivity observed here are consistent with the preferential attachment model underlying scale-free network development. This study is the largest of its kind and provides the unique opportunity to examine how neural systems adapt to significant neurological disruption during the first year after injury.	[Hillary, Frank G.; Roman, Cristina A.; Medaglia, John D.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; [Rajtmajer, Sarah M.] Penn State Univ, Dept Math, University Pk, PA 16802 USA; [Slocomb-Dluzen, Julia E.; Good, David C.] Hershey Med Ctr, Dept Neurol, Hershey, PA USA; [Calhoun, Vincent D.] Mind Res Network, Albuquerque, NM USA; [Wylie, Glenn R.] Kessler Fdn Res Ctr, W Orange, NJ USA	Hillary, FG (corresponding author), Penn State Univ, Dept Psychol, University Pk, PA 16802 USA.	fhillary@psu.edu; gwylie@kesslerfoundation.org	Hillary, Frank/AAN-8622-2021		New Jersey Commission for Brain Injury Research [09.001.BIR1]; Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania	This work was funded in part by the New Jersey Commission for Brain Injury Research (09.001.BIR1) and the Social Sciences Research Institute at Pennsylvania State University in University Park, Pennsylvania. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Elseoud A, 2010, HUM BRAIN MAPP, V31, P1207, DOI 10.1002/hbm.20929; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Allen EA, 2012, NEUROIMAGE, V59, P4141, DOI 10.1016/j.neuroimage.2011.10.010; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Army Individual Test Battery, 1990, MAN DIR SCOR; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Caeyenberghs K, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00726; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Calhoun VD, 2001, HUM BRAIN MAPP, V13, P43, DOI 10.1002/hbm.1024; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 2012, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cayley A, 1875, BER DTSCH CHEM GES, V8, P1056; Cole MW, 2010, NEUROIMAGE, V49, P3132, DOI 10.1016/j.neuroimage.2009.11.001; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; Di Perri C, 2013, NEUROLOGY, V81, P1417, DOI 10.1212/WNL.0b013e3182a43b78; Du Y, 2014, P ORG HUM BRAIN MAPP; English SW, 2013, NEUROCRIT CARE, V18, P131, DOI 10.1007/s12028-012-9748-3; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; GAZZANIGA MS, 1984, BRAIN, V107, P145, DOI 10.1093/brain/107.1.145; GAZZANIGA MS, 1979, BRAIN, V102, P805, DOI 10.1093/brain/102.4.805; Harriger L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046497; Hilgetag CC, 2000, PHILOS T ROY SOC B, V355, P91, DOI 10.1098/rstb.2000.0551; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2014, NEUROPSYCHOLOGY; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2006, HUM BRAIN MAPP, V27, P837, DOI 10.1002/hbm.20226; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; JENSEN AR, 1966, ACTA PSYCHOL, V25, P36, DOI 10.1016/0001-6918(66)90004-7; Jimenez N, 2013, PEDIATRICS, V131, pE1850, DOI 10.1542/peds.2012-3354; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Kelly RE, 2010, J NEUROSCI METH, V189, P233, DOI 10.1016/j.jneumeth.2010.03.028; KIRCHNER WK, 1958, J EXP PSYCHOL, V55, P352, DOI 10.1037/h0043688; Kiviniemi V, 2009, HUM BRAIN MAPP, V30, P3865, DOI 10.1002/hbm.20813; Kouloulas EJ, 2013, INT J REHABIL RES, V36, P260, DOI 10.1097/MRR.0b013e32835fd99a; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Liang X, 2013, P NATL ACAD SCI USA, V110, P1929, DOI 10.1073/pnas.1214900110; Lin QH, 2010, HUM BRAIN MAPP, V31, P1076, DOI 10.1002/hbm.20919; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mantini D, 2011, J NEUROSCI, V31, P12954, DOI 10.1523/JNEUROSCI.2318-11.2011; Mazaika P K., 2009, HUMAN BRAIN MAPPING; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCauley SR, 2013, J NEUROTRAUM, V30, P1506, DOI 10.1089/neu.2013.2925; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Medaglia JD, 2012, HUM BRAIN MAPP, V33, P979, DOI 10.1002/hbm.21264; Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Palacios EM, 2013, JAMA NEUROL, P1; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pouratian Nader, 2003, Neurosurg Focus, V15, pE2; Radford K, 2013, BRAIN INJURY, V27, P507, DOI 10.3109/02699052.2013.766929; Reitan RM., 1985, HALSTEAD REITAN NEUR; Scott J., 2000, SOCIAL NETWORK ANAL; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Sidlauskaite J, 2014, NEUROIMAGE; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2004, NEUROSCI LETT, V355, P25, DOI 10.1016/j.neulet.2003.10.063; Stibick DL, 2001, J NEUROTRAUM, V18, P303, DOI 10.1089/08977150151070955; Strigel RM, 2005, AM J NEURORADIOL, V26, P578; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sylvester J, 1878, NATURE, V17, P284, DOI [10.1038/017284a0, DOI 10.1038/017284A0]; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; TEASDALE G, 1974, LANCET, V2, P81; Trenerry MR, 1989, PROFESSIONAL MANUAL; Turner GR, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00009; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; van den Heuvel MP, 2012, P NATL ACAD SCI USA, V109, P11372, DOI 10.1073/pnas.1203593109; Vul E, 2012, NEUROIMAGE, V62, P945, DOI 10.1016/j.neuroimage.2012.01.027; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wechsler D., 1997, ADM SCORING MANUAL; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xu JS, 2013, NEUROIMAGE, V79, P62, DOI 10.1016/j.neuroimage.2013.04.038; Ystad Martin A, 2009, BMC Med Imaging, V9, P17, DOI 10.1186/1471-2342-9-17; Yu QB, 2013, SCHIZOPHR RES, V143, P165, DOI 10.1016/j.schres.2012.11.001; Yu QB, 2012, FRONT SYST NEUROSCI, V5, DOI [10.3389/fnsys.2011.00103, 10.3389/fnsys.2011.00007]	97	66	66	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2014	9	8							e104021	10.1371/journal.pone.0104021			15	Multidisciplinary Sciences	Science & Technology - Other Topics	AO0QT	WOS:000341017000024	25121760	DOAJ Gold, Green Published			2021-06-18	
J	Almeida-Suhett, CP; Prager, EM; Pidoplichko, V; Figueiredo, TH; Marini, AM; Li, Z; Eiden, LE; Braga, MFM				Almeida-Suhett, Camila P.; Prager, Eric M.; Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.			Reduced GABAergic Inhibition in the Basolateral Amygdala and the Development of Anxiety-Like Behaviors after Mild Traumatic Brain Injury	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NICOTINIC ACETYLCHOLINE-RECEPTORS; CONTROLLED CORTICAL IMPACT; BENZODIAZEPINE-RECEPTOR; SYNAPTIC-TRANSMISSION; PREFRONTAL CORTEX; PANIC DISORDER; BINDING; SENSITIVITY; MICE	Traumatic brain injury (TBI) is a major public health concern affecting a large number of athletes and military personnel. Individuals suffering from a TBI risk developing anxiety disorders, yet the pathophysiological alterations that result in the development of anxiety disorders have not yet been identified. One region often damaged by a TBI is the basolateral amygdala (BLA); hyperactivity within the BLA is associated with increased expression of anxiety and fear, yet the functional alterations that lead to BLA hyperexcitability after TBI have not been identified. We assessed the functional alterations in inhibitory synaptic transmission in the BLA and one mechanism that modulates excitatory synaptic transmission, the alpha(7) containing nicotinic acetylcholine receptor (alpha(7)-nAChR), after mTBI, to shed light on the mechanisms that contribute to increased anxiety-like behaviors. Seven and 30 days after a mild controlled cortical impact (CCI) injury, animals displayed significantly greater anxiety-like behavior. This was associated with a significant loss of GABAergic interneurons and significant reductions in the frequency and amplitude of spontaneous and miniature GABA(A)-receptor mediated inhibitory postsynaptic currents (IPSCs). Decreases in the mIPSC amplitude were associated with reduced surface expression of alpha 1, beta 2, and gamma 2 GABA(A) receptor subunits. However, significant increases in the surface expression and current mediated by alpha(7)-nAChR, were observed, signifying increases in the excitability of principal neurons within the BLA. These results suggest that mTBI causes not only a significant reduction in inhibition in the BLA, but also an increase in neuronal excitability, which may contribute to hyperexcitability and the development of anxiety disorders.	[Almeida-Suhett, Camila P.; Prager, Eric M.; Marini, Ann M.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA; [Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Almeida-Suhett, Camila P.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Li, Zheng] NIMH, Sect Clin Studies, Intramural Res Program, NIH, Bethesda, MD 20892 USA; [Eiden, Lee E.] NIMH, Mol Neurosci Sect, Intramural Res Program, NIH, Bethesda, MD 20892 USA	Braga, MFM (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA.	maria.braga@usuhs.edu	Li, Zheng/I-8016-2014; Prager, Eric/O-1567-2015; Almeida-Suhett, Camila/I-8045-2016	Li, Zheng/0000-0002-2978-2531; Prager, Eric/0000-0002-3810-0985; Eiden, Lee/0000-0001-7524-944X; Almeida-Suhett, Camila/0000-0002-7588-9487	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1702Z]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002386] Funding Source: NIH RePORTER	The authors acknowledge the Department of Defense in the Center for Neuroscience and Regenerative Medicine for financially supporting the present work. Grant# G1702Z. URL of funder's website: http://www.usuhs.mil/cnrm/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; Aroniadou-Anderjaska V, 2012, NEUROSCIENCE, V221, P157, DOI 10.1016/j.neuroscience.2012.07.006; Bailey SJ, 2004, J NEUROSCI, V24, P6343, DOI 10.1523/JNEUROSCI.0563-04.2004; Barazangi N, 2001, J NEUROPHYSIOL, V86, P463; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bremner JD, 2000, AM J PSYCHIAT, V157, P1120, DOI 10.1176/appi.ajp.157.7.1120; Bremner JD, 2000, BIOL PSYCHIAT, V47, P96, DOI 10.1016/S0006-3223(99)00188-2; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Chen J, 2013, NEUROSCI LETT, V541, P275, DOI 10.1016/j.neulet.2013.02.005; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cowley DS, 1997, J CLIN PSYCHIAT, V58, P555, DOI 10.4088/JCP.v58n1208; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Faraday MM, 2001, PHARMACOL BIOCHEM BE, V70, P475, DOI 10.1016/S0091-3057(01)00642-6; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuerbach D, 2009, NEUROPHARMACOLOGY, V56, P254, DOI 10.1016/j.neuropharm.2008.08.025; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; GLUE P, 1991, LANCET, V337, P563, DOI 10.1016/0140-6736(91)91359-3; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holzschneider Kathrin, 2011, Dialogues Clin Neurosci, V13, P453; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jiang L, 2008, J NEUROPHYSIOL, V99, P1988, DOI 10.1152/jn.00933.2007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelso ML, 2012, CURR DRUG TARGETS, V13, P631, DOI 10.2174/138945012800398964; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Klein RC, 2006, J PHYSIOL-LONDON, V576, P865, DOI 10.1113/jphysiol.2006.118232; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Malizia AL, 1998, ARCH GEN PSYCHIAT, V55, P715, DOI 10.1001/archpsyc.55.8.715; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Pandya AA, 2013, BIOCHEM PHARMACOL, V86, P1054, DOI 10.1016/j.bcp.2013.05.018; Paxinos G., 2005, RAT BRAIN STEROTAXIC, Vfifth; Pidoplichko VI, 2005, J NEUROSCI METH, V142, P55, DOI 10.1016/j.jneumeth.2004.07.012; Pidoplichko VI, 2013, J NEUROPHYSIOL, V110, P2358, DOI 10.1152/jn.01030.2012; Prager EM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00038; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; RoyByrne P, 1996, AM J PSYCHIAT, V153, P1444; Sah P, 2003, ANN NY ACAD SCI, V985, P67; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Schmitz C, 2000, J CHEM NEUROANAT, V20, P93, DOI 10.1016/S0891-0618(00)00066-1; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Sibille E, 2000, J NEUROSCI, V20, P2758; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tiihonen J, 1997, MOL PSYCHIATR, V2, P463, DOI 10.1038/sj.mp.4000329; Truitt WA, 2009, NEUROSCIENCE, V160, P284, DOI 10.1016/j.neuroscience.2009.01.083; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; WOMBLE MD, 1993, J NEUROPHYSIOL, V70, P2056; Wood RL, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/HTR.0b013e31827eabba; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020	72	66	66	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102627	10.1371/journal.pone.0102627			13	Multidisciplinary Sciences	Science & Technology - Other Topics	AM0SW	WOS:000339558100054	25047645	DOAJ Gold, Green Published			2021-06-18	
J	Tollner, K; Brandt, C; Topfer, M; Brunhofer, G; Erker, T; Gabriel, M; Feit, PW; Lindfors, J; Kaila, K; Loscher, W				Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Brunhofer, Gerda; Erker, Thomas; Gabriel, Mario; Feit, Peter W.; Lindfors, Jenna; Kaila, Kai; Loescher, Wolfgang			A Novel Prodrug-Based Strategy to Increase Effects of Bumetanide in Epilepsy	ANNALS OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; CATION-CHLORIDE COTRANSPORTERS; RAT HIPPOCAMPUS; GABA UPTAKE; IN-VITRO; NKCC1; MODEL; TRANSPORTERS; DIURETICS; DRUGS	ObjectiveThere is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis. However, bumetanide is heavily bound to plasma proteins (approximate to 98%) and highly ionized at physiological pH, so that it only poorly penetrates into the brain, and chronic treatment with bumetanide is compromised by its potent diuretic effect. MethodsTo overcome these problems, we designed lipophilic and uncharged prodrugs of bumetanide that should penetrate the blood-brain barrier more easily than the parent drug and are converted into bumetanide in the brain. The feasibility of this strategy was evaluated in mice and rats. ResultsAnalysis of bumetanide levels in plasma and brain showed that administration of 2 ester prodrugs of bumetanide, the pivaloyloxymethyl (BUM1) and N,N-dimethylaminoethylester (BUM5), resulted in significantly higher brain levels of bumetanide than administration of the parent drug. BUM5, but not BUM1, was less diuretic than bumetanide, so that BUM5 was further evaluated in chronic models of epilepsy in mice and rats. In the pilocarpine model in mice, BUM5, but not bumetanide, counteracted the alteration in seizure threshold during the latent period. In the kindling model in rats, BUM5 was more efficacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital. InterpretationOur data demonstrate that the goal of designing bumetanide prodrugs that specifically target the brain is feasible and that such drugs may resolve the problems associated with using bumetanide for treatment of neurological disorders. ANN NEUROL 2014;75:550-562	[Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Feit, Peter W.; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Brunhofer, Gerda; Erker, Thomas; Gabriel, Mario] Univ Vienna, Dept Med Chem, Vienna, Austria; [Lindfors, Jenna; Kaila, Kai] Univ Helsinki, Dept Biosci, Helsinki, Finland; [Lindfors, Jenna; Kaila, Kai] Univ Helsinki, Ctr Neurosci, Helsinki, Finland	Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016; Kaila, Kai K/R-8528-2016	Loscher, Wolfgang/0000-0002-9648-8973; Kaila, Kai K/0000-0003-0668-5955	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/11]; Akademie fur Tiergesundheit (Bonn, Germany)	The study was supported by a grant (Lo 274/11; for WL) from the Deutsche Forschungsgemeinschaft (Bonn, Germany) and a scholarship (for M. T.) from the Akademie fur Tiergesundheit (Bonn, Germany). Leo Pharma (Ballerup, Denmark) provided a sample of the methyl ester of bumetanide, and Roquette-Pharma (Frankfurt, Germany) provided hydroxypropyl-beta-cyclodextrin.	Ben-Ari Y, 2012, EPILEPSIA, V53, P394, DOI 10.1111/j.1528-1167.2011.03378.x; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Cleary RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057148; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; COHEN MR, 1976, J PHARMACOL EXP THER, V197, P697; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; FEIT PW, 1971, J MED CHEM, V14, P432, DOI 10.1021/jm00287a014; FREY HH, 1980, NEUROPHARMACOLOGY, V19, P217, DOI 10.1016/0028-3908(80)90141-0; FREY HH, 1979, NEUROPHARMACOLOGY, V18, P581, DOI 10.1016/0028-3908(79)90108-4; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Hasannejad H, 2004, J PHARMACOL EXP THER, V308, P1021, DOI 10.1124/jpet.103.059139; Hochman D, 2009, AM EP SOC 63 ANN M D; Hochman DW, 2006, Methods and compositions for the treatment of neuropsychiatric disorders with bumetanide and furo-semide analogs, Patent No. [US20060089350A1, 20060089350]; Hochman DW, 2007, Methods and compositions using NKCC cotransporter inhibitors for the treatment of neuropsychiat-ric and addictive disorders, Patent No. [WO2007047698A2, 2007047698]; Huberfeld G, 2007, J NEUROSCI, V27, P9866, DOI 10.1523/JNEUROSCI.2761-07.2007; HUNTER R L, 1961, Ann Histochim, V6, P447; JAVAHERI S, 1993, J NEUROCHEM, V61, P1525, DOI 10.1111/j.1471-4159.1993.tb13648.x; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Kobayashi Y, 2005, EUR J PHARMACOL, V524, P44, DOI 10.1016/j.ejphar.2005.09.054; KOLIS SJ, 1976, DRUG METAB DISPOS, V4, P169; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Li XB, 2008, BRAIN RES, V1221, P141, DOI 10.1016/j.brainres.2008.04.047; Li YJ, 2011, J CHROMATOGR B, V879, P998, DOI 10.1016/j.jchromb.2011.02.018; Liu YQ, 2012, PEDIATR RES, V71, P559, DOI 10.1038/pr.2012.7; Loscher W, 2013, NEUROPHARMACOLOGY, V69, P62, DOI 10.1016/j.neuropharm.2012.05.045; LOSCHER W, 1983, J PHARMACOL EXP THER, V226, P839; LOSCHER W, 1986, EXP NEUROL, V93, P211, DOI 10.1016/0014-4886(86)90160-3; Loscher W, 1997, PROG NEUROBIOL, V53, P239, DOI 10.1016/S0301-0082(97)00035-X; LOSCHER W, 1985, EUR J PHARMACOL, V110, P103, DOI 10.1016/0014-2999(85)90034-2; Maa EH, 2011, EPILEPSIA, V52, P1559, DOI 10.1111/j.1528-1167.2011.03203.x; Mazarati A, 2009, EPILEPSIA, V50, P2117, DOI 10.1111/j.1528-1167.2009.02048.x; Munoz A, 2007, EPILEPSIA, V48, P663, DOI 10.1111/j.1528-1167.2007.00986.x; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177; Okabe A, 2002, NEUROSCI RES, V44, P225, DOI 10.1016/S0168-0102(02)00093-7; Okabe A, 2003, BRAIN RES, V990, P221, DOI 10.1016/S0006-8993(03)03528-5; OLSEN UB, 1977, ACTA PHARMACOL TOX, V41, P5; Palma E, 2006, P NATL ACAD SCI USA, V103, P8465, DOI 10.1073/pnas.0602979103; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Rattka M, 2012, EUR J NEUROSCI, V36, P2505, DOI 10.1111/j.1460-9568.2012.08143.x; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Rautio J, 2008, AAPS J, V10, P92, DOI 10.1208/s12248-008-9009-8; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Russell JM, 2000, PHYSIOL REV, V80, P211; Sipila ST, 2006, J PHYSIOL-LONDON, V573, P765, DOI 10.1113/jphysiol.2006.107086; Tollner K, 2011, EPILEPSIA, V52, P52; Tollner K, 2010, SOC NEUR ANN M NOV 1; Topfer M, 2011, AM EP SOC 65 ANN M D; Wanaski S, 2010, Preparation of bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and therapeutic compositions containing same for treating disorders involving the Na + K+Cl-cotransporter and GABAA receptors, Patent No. [WO2010085352A2, 2010085352]; Wanaski S, 2012, Arylsulfonamide derivatives as sodium-#potassium-chloride cotransporter inhibitors and their preparation, compositions, and methods of use, Patent No. [WO2012018635A2, 2012018635]; Weindlmayr-Goettel M, 2002, BRIT J ANAESTH, V88, P555, DOI 10.1093/bja/88.4.555	53	66	66	2	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2014	75	4					550	562		10.1002/ana.24124			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AG2GL	WOS:000335234200010	24615913				2021-06-18	
J	Acosta, SA; Tajiri, N; Shinozuka, K; Ishikawa, H; Sanberg, PR; Sanchez-Ramos, J; Song, SJ; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Sanchez-Ramos, Juan; Song, Shijie; Kaneko, Yuji; Borlongan, Cesar V.			Combination Therapy of Human Umbilical Cord Blood Cells and Granulocyte Colony Stimulating Factor Reduces Histopathological and Motor Impairments in an Experimental Model of Chronic Traumatic Brain Injury	PLOS ONE			English	Article							MARROW STROMAL CELLS; CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; FACTOR G-CSF; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTORS; COLLAGEN SCAFFOLDS; MILD HYPOTHERMIA; PROGENITOR CELLS	Traumatic brain injury (TBI) is associated with neuro-inflammation, debilitating sensory-motor deficits, and learning and memory impairments. Cell-based therapies are currently being investigated in treating neurotrauma due to their ability to secrete neurotrophic factors and anti-inflammatory cytokines that can regulate the hostile milieu associated with chronic neuroinflammation found in TBI. In tandem, the stimulation and mobilization of endogenous stem/progenitor cells from the bone marrow through granulocyte colony stimulating factor (G-CSF) poses as an attractive therapeutic intervention for chronic TBI. Here, we tested the potential of a combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI to counteract the progressive secondary effects of chronic TBI using the controlled cortical impact model. Four different groups of adult Sprague Dawley rats were treated with saline alone, G-CSF+saline, hUCB+saline or hUCB+G-CSF, 7-days post CCI moderate TBI. Eight weeks after TBI, brains were harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis by using immunohistochemical techniques. Results revealed that the rats exposed to TBI treated with saline exhibited widespread neuroinflammation, impaired endogenous neurogenesis in DG and SVZ, and severe hippocampal cell loss. hUCB monotherapy suppressed neuroinflammation, nearly normalized the neurogenesis, and reduced hippocampal cell loss compared to saline alone. G-CSF monotherapy produced partial and short-lived benefits characterized by low levels of neuroinflammation in striatum, DG, SVZ, and corpus callosum and fornix, a modest neurogenesis, and a moderate reduction of hippocampal cells loss. On the other hand, combined therapy of hUCB+G-CSF displayed synergistic effects that robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.	[Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] James Haley Vet Affairs Med Ctr, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL USA	Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012; Sanchez-Ramos, Juan/O-7870-2014; Sanchez-Ramos, Juan/A-1188-2009	Borlongan, Cesar/0000-0002-2966-9782; Sanchez-Ramos, Juan/0000-0002-3391-7857; Ishikawa, Hiroto/0000-0003-0760-7203; Shinozuka, Kazutaka/0000-0002-6435-4460	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida; Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS071956-01A1]; James and Esther King Biomedical Research Foundation [1KG01-33966]; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001407] Funding Source: NIH RePORTER	Financial support for this study was provided by the Department of Defense W81XWH-11-1-0634, the University of South Florida Signature Interdisciplinary Program in Neuroscience funds, the University of South Florida and Veterans Administration Reintegration Funds, and the University of South Florida Neuroscience Collaborative Program. CVB and PRS serve as consultant and founder, respectively, of Saneron CCEL Therapeutics, Inc. CVB is funded by the National Institutes of Health 1R01NS071956-01A1, James and Esther King Biomedical Research Foundation 1KG01-33966, SanBio Inc., KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bakhtiary Mehrdad, 2010, Iranian Biomedical Journal, V14, P142; Bath PMW, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005207.pub4; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Campbell K, 2013, BRAIN RES, V1502, P47, DOI 10.1016/j.brainres.2013.01.038; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cui LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064684; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guo XH, 2012, INT J NEUROSCI, V122, P723, DOI 10.3109/00207454.2012.716109; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Imamura K, 2005, ACTA NEUROPATHOL, V109, P141, DOI 10.1007/s00401-004-0919-y; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Joo YD, 2011, CYTOKINE, V54, P36, DOI 10.1016/j.cyto.2010.12.020; Jung KH, 2006, BRAIN RES, V1073, P190, DOI 10.1016/j.brainres.2005.12.037; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P265, DOI 10.1007/978-3-7091-0693-8_44; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Liu CY, 2008, NEUROSURGERY, V63, pN12, DOI 10.1227/01.NEU.0000339457.01711.3B; Lopes FRP, 2013, NEUROSCIENCE, V230, P184, DOI 10.1016/j.neuroscience.2012.10.025; Loving CL, 2013, BIOLOGICALS, V41, P368, DOI 10.1016/j.biologicals.2013.07.001; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lyman GH, 2013, ANN ONCOL, V24, P2475, DOI 10.1093/annonc/mdt226; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; Maurer MH, 2008, CURR MED CHEM, V15, P1407, DOI 10.2174/092986708784567671; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Morita Y, 2007, NEUROSCI RES, V58, P356, DOI 10.1016/j.neures.2007.04.006; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Prakash A, 2013, PHARMACOL BIOCHEM BE, V110, P46, DOI 10.1016/j.pbb.2013.05.015; Sakowitz OW, 2006, ACTA NEUROCHIR SUPPL, V96, P139; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sasaki A, 2008, BRAIN RES, V1214, P159, DOI 10.1016/j.brainres.2008.02.084; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stachura DL, 2013, BLOOD; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tajiri N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043779; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tsuji T, 1999, GROWTH FACTORS, V16, P225, DOI 10.3109/08977199909002132; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yang YN, 2013, PEDIATR NEONATOL, V54, P380, DOI 10.1016/j.pedneo.2013.04.011; Yasuda Y, 2007, BRAIN RES, V1138, P196, DOI 10.1016/j.brainres.2006.12.054; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2; Zhao LR, 2007, EXP NEUROL, V204, P569, DOI 10.1016/j.expneurol.2006.12.001	83	66	66	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e90953	10.1371/journal.pone.0090953			12	Multidisciplinary Sciences	Science & Technology - Other Topics	AC9HN	WOS:000332845300037	24621603	DOAJ Gold, Green Published			2021-06-18	
J	Crone, JS; Soddu, A; Holler, Y; Vanhaudenhuyse, A; Schurz, M; Bergmann, J; Schmid, E; Trinka, E; Laureys, S; Kronbichler, M				Crone, Julia Sophia; Soddu, Andrea; Hoeller, Yvonne; Vanhaudenhuyse, Audrey; Schurz, Matthias; Bergmann, Juergen; Schmid, Elisabeth; Trinka, Eugen; Laureys, Steven; Kronbichler, Martin			Altered network properties of the fronto-parietal network and the thalamus in impaired consciousness	NEUROIMAGE-CLINICAL			English	Article						Consciousness; Vegetative state; Network; Graph theory; Connectivity; Small world	DEFAULT MODE NETWORK; PERSISTENT VEGETATIVE STATE; FUNCTIONAL CONNECTIVITY MRI; TRAUMATIC BRAIN-INJURY; RESTING-STATE; FOCAL LESIONS; HEAD MOTION; DISORDERS; RECOVERY; IMPACT	Recovery of consciousness has been associated with connectivity in the frontal cortex and parietal regions modulated by the thalamus. To examine this model and to relate alterations to deficits in cognitive functioning and conscious processing, we investigated topological network properties in patients with chronic disorders of consciousness recovered from coma. Resting state fMRI data of 34 patients with unresponsive wakefulness syndrome and 25 in minimally conscious state were compared to 28 healthy controls. We investigated global and local network characteristics. Additionally, behavioral measures were correlated with the local metrics of 28 regions within the fronto-parietal network and the thalamus. In chronic disorders of consciousness, modularity at the global level was reduced suggesting a disturbance in the optimal balance between segregation and integration. Moreover, network properties were altered in several regions which are associated with conscious processing (particularly, in medial parietal, and frontal regions, as well as in the thalamus). Between minimally conscious and unconscious patients the local efficiency of medial parietal regions differed. Alterations in the thalamus were particularly evident in non-conscious patients. Most of the regions affected in patients with impaired consciousness belong to the so-called 'rich club' of highly interconnected central nodes. Disturbances in their topological characteristics have severe impact on information integration and are reflected in deficits in cognitive functioning probably leading to a total breakdown of consciousness. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.	[Crone, Julia Sophia; Bergmann, Juergen; Kronbichler, Martin] Paracelsus Med Univ, Inst Neurosci, A-5020 Salzburg, Austria; [Crone, Julia Sophia; Bergmann, Juergen; Kronbichler, Martin] Paracelsus Med Univ, Ctr Neurocognit Res, Christian Doppler Klin, A-5020 Salzburg, Austria; [Crone, Julia Sophia; Hoeller, Yvonne; Schurz, Matthias; Kronbichler, Martin] Salzburg Univ, Ctr Neurocognit Res, A-5020 Salzburg, Austria; [Crone, Julia Sophia; Hoeller, Yvonne; Schurz, Matthias; Kronbichler, Martin] Salzburg Univ, Dept Psychol, A-5020 Salzburg, Austria; [Crone, Julia Sophia; Hoeller, Yvonne; Schmid, Elisabeth; Trinka, Eugen] Paracelsus Med Univ, Dept Neurol, Christian Doppler Klin, Salzburg, Austria; [Soddu, Andrea; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Laureys, Steven] Univ Liege, CHU Sart Tilman Hosp, Dept Neurol, B-4000 Liege, Belgium; [Soddu, Andrea] Western Univ, Brain & Mind Inst, Dept Phys & Astron, London, ON, Canada	Crone, JS (corresponding author), Paracelsus Med Univ, Inst Neurosci, Ignaz Harrer Str 79, A-5020 Salzburg, Austria.	j.crone@neurocognition.org	Laureys, Steven/A-3349-2011; Kronbichler, Martin/A-5599-2008; Laureys, Steven/AAN-2097-2021; Holler, Yvonne/I-8928-2017; Soddu, Andrea/K-7087-2014; Vanhaudenhuyse, Audrey/AAP-2455-2020	Kronbichler, Martin/0000-0003-2240-2812; Laureys, Steven/0000-0002-3096-3807; Holler, Yvonne/0000-0002-1727-8557; Soddu, Andrea/0000-0001-6833-745X; Trinka, Eugen/0000-0002-5950-2692; Schurz, Matthias/0000-0002-6344-9943; Crone, Julia Sophia/0000-0002-0787-7003	Jubilaumsfonds of the National Bank of Austria [14201]; Scientific Funds of the Paracelsus Medical University [E-10/12/062-KRO]	This work was supported by the Jubilaumsfonds of the National Bank of Austria [grant number 14201]; and the Scientific Funds of the Paracelsus Medical University [grant number E-10/12/062-KRO].	Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Alexander-Bloch A, 2012, NEUROIMAGE, V59, P3889, DOI 10.1016/j.neuroimage.2011.11.035; Alexander-Bloch AF, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00147; Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; Andersen SM, 2010, NEUROIMAGE, V53, P78, DOI 10.1016/j.neuroimage.2010.06.003; ANSCOMBE FJ, 1953, J ROY STAT SOC B, V15, P1; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Braun U, 2012, NEUROIMAGE, V59, P1404, DOI 10.1016/j.neuroimage.2011.08.044; Bullmore ET, 2011, ANNU REV CLIN PSYCHO, V7, P113, DOI 10.1146/annurev-clinpsy-040510-143934; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Crinion J, 2007, NEUROIMAGE, V37, P866, DOI 10.1016/j.neuroimage.2007.04.065; Crone JS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00504; Crone JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026373; Edelman GM, 2003, P NATL ACAD SCI USA, V100, P5520, DOI 10.1073/pnas.0931349100; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-77; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guldenmund P, 2013, BRAIN CONNECT, V3, P273, DOI 10.1089/brain.2012.0117; He BJ, 2007, NEURON, V53, P905, DOI 10.1016/j.neuron.2007.02.013; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Horovitz SG, 2009, P NATL ACAD SCI USA, V106, P11376, DOI 10.1073/pnas.0901435106; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schiff ND, 2007, CURR OPIN NEUROL, V20, P638, DOI 10.1097/WCO.0b013e3282f1c6e4; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; Soddu A, 2011, FUNCT NEUROL, V26, P37; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Supekar K, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000100; Telesford QK, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00067; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wang JH, 2009, HUM BRAIN MAPP, V30, P1511, DOI 10.1002/hbm.20623; Ward LM, 2011, CONSCIOUS COGN, V20, P464, DOI 10.1016/j.concog.2011.01.007; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Weissenbacher A, 2009, NEUROIMAGE, V47, P1408, DOI 10.1016/j.neuroimage.2009.05.005; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Xie G, 2011, BRIT J ANAESTH, V106, P548, DOI 10.1093/bja/aeq415; Zalesky A, 2012, NEUROIMAGE, V60, P2096, DOI 10.1016/j.neuroimage.2012.02.001; Zhang JR, 2011, BIOL PSYCHIAT, V70, P334, DOI 10.1016/j.biopsych.2011.05.018; Zhou JS, 2011, CONSCIOUS COGN, V20, P257, DOI 10.1016/j.concog.2010.08.003	71	66	71	1	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2014	4						240	248		10.1016/j.nicl.2013.12.005			9	Neuroimaging	Neurosciences & Neurology	CB5LD	WOS:000349667600025	24455474	DOAJ Gold, Green Published			2021-06-18	
J	Covassin, T; Elbin, RJ; Bleecker, A; Lipchik, A; Kontos, AP				Covassin, Tracey; Elbin, R. J.; Bleecker, Alisha; Lipchik, Adam; Kontos, Anthony P.			Are There Differences in Neurocognitive Function and Symptoms Between Male and Female Soccer Players After Concussions?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sex difference; soccer; cognitive function; concussion	SEGMENT DYNAMIC STABILIZATION; INJURY SURVEILLANCE SYSTEM; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; SEX-DIFFERENCES; DESCRIPTIVE EPIDEMIOLOGY; INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; HEAD ACCELERATION; BASE-LINE	Background: Researchers have suggested that there are sex differences in outcomes after sport-related concussions. Factors such as sport type/rules, age, and body mass index (BMI) may influence these differences. Hypotheses/Purpose: The purposes of this study were (1) to examine neurocognitive performance after concussions between male and female soccer players and (2) to compare concussion symptoms between male and female soccer players. We hypothesized that female concussed soccer players would report more concussion symptoms and worse cognitive performance compared with male concussed soccer players. Study Design: Cohort study; Level of evidence, 2. Methods: A total of 39 male (mean BMI, 22.21 2.34 kg/m(2); mean age, 17.69 2.10 years) and 56 female (mean BMI, 23.47 +/- 2.66 kg/m(2); mean age, 17.78 +/- 2.30 years) concussed soccer players participated in this study. Participants were similar in age, history of concussion, sport, and time since injury. Participants completed computerized neurocognitive tests and symptom reports at baseline and 8 days after injury. Body mass index served as a covariate in all analyses. Results: After adjusting for BMI, results from a repeated-measures analysis of covariance (ANCOVA) revealed a group by time interaction for visual memory (F-1,F-82 = 5.50; P = .021). Specifically, female concussed soccer players (mean score, 68.7 +/- 15.2) performed worse at 8 days after a concussion compared with male concussed athletes (mean score, 77.2 +/- 8.9). Results of another ANCOVA for total concussion symptoms indicated an interaction for group by time (F-1,F-82 = 4.26; P = .04). Specifically, female concussed soccer players (mean score, 11.9 +/- 15.7) reported more total concussion symptoms at 8 days compared with male concussed athletes (mean score, 5.3 +/- 7.4). There were significant main effects for sex on verbal (F-1,F-82 = 5.98; P = .017) and visual (F-1,F-82 = 4.65; P = .034) memory, with female athletes reporting lower scores than male athletes. Female athletes also reported more symptoms on the migraine-cognitive-fatigue (F-1,F-82 = 10.8; P = .001) and sleep (F-1,F-82 = 9.2; P = .003) clusters than male athletes. Conclusion: In contrast to recent studies, after controlling for BMI, female athletes exhibited lower performance on visual memory composite scores and higher scores on total symptoms than male athletes after concussions.	[Covassin, Tracey; Elbin, R. J.; Bleecker, Alisha; Lipchik, Adam; Kontos, Anthony P.] Michigan State Univ, E Lansing, MI 48824 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 West Circle Dr,Room 105, E Lansing, MI 48824 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dick R, 2007, J ATHL TRAINING, V42, P278; Dick R, 2007, J ATHL TRAINING, V42, P194; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	25	66	66	0	34	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2890	2895		10.1177/0363546513509962			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	258QH	WOS:000327473300023	24197616				2021-06-18	
J	Kontos, AP; Elbin, RJ; Fazio-Sumrock, VC; Burkhart, S; Swindell, H; Maroon, J; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Fazio-Sumrock, Vanessa C.; Burkhart, Scott; Swindell, Hasani; Maroon, Joseph; Collins, Michael W.			Incidence of Sports-Related Concussion among Youth Football Players Aged 8-12 Years	JOURNAL OF PEDIATRICS			English	Article							STATES HIGH-SCHOOL; COLLEGIATE; EPIDEMIOLOGY; INJURY	Objective To determine the risk of concussion among youth football players (ages 8-12 years). Study design Participants included 468 male youth football players in western Pennsylvania during the 2011 youth football season. Incidence rates (IRs) and incidence density ratios (IDRs) of concussion were calculated for games and practices and for age groups. Results There was a total of 11 338 (8415 practice and 2923 game) athletic exposures (AEs) in the study period, during which 20 medically diagnosed concussions occurred. A majority of concussions were the result of head-to-head (45%) contact. The combined concussion IR for practices and games was 1.76 per 1000 AEs (95% CI 0.99-2.54). The concussion IR was 0.24 per 1000 AEs (95% CI 0.04-0.79) in practices and 6.16 per 1000 AEs (95% CI 3.76-9.54) in games. The IDR for concussions in games to practices was 25.91 (95% CI 6.01-111.70). The IDR of concussions for youth aged 11-12 years compared with youth aged 8-10 years was 2.72 (95% CI 0.66-4.78). Conclusions The overall IR for concussion in youth football players aged 8-12 years was comparable with that reported previously for high school and collegiate samples. However, participation in games was associated with an increase in risk of concussion compared with practices, which was higher than rates previously reported for high school and collegiate athletes. Younger players were slightly less likely to incur a concussion than were older players.	[Kontos, Anthony P.; Elbin, R. J.; Fazio-Sumrock, Vanessa C.; Burkhart, Scott; Collins, Michael W.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthopaed Surg,Concuss Program, Pittsburgh, PA USA; [Swindell, Hasani] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Maroon, Joseph] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA	Kontos, AP (corresponding author), UPMC, Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Football League Charities Medical Research grant	Funded by National Football League Charities Medical Research grant. The authors declare no conflicts of interest.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Centers for Disease Control and Prevention (CDC), HEADS CONC YOUTH SPO; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Pop Warner National Office, RUL CHANG REG PRACT; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; USA Football's Tackle Advisory Committee, US FOOTB HEADS TRACK	15	66	66	0	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	SEP	2013	163	3					717	720		10.1016/j.jpeds.2013.04.011			4	Pediatrics	Pediatrics	212LQ	WOS:000323985300024	23751761				2021-06-18	
J	Schatz, P; Ferris, CS				Schatz, Philip; Ferris, Charles S.			One-Month Test-Retest Reliability of the ImPACT Test Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ImPACT; Concussion; Neuropsychological testing; Mild head injury; Baseline screening	HIGH-SCHOOL; CLINICAL UTILITY; CONCUSSION	In order to better understand the test-retest reliability of the ImPACT test battery, 25 undergraduate students completed two ImPACT tests across a time frame of 4 weeks between assessments. Participants had not previously completed ImPACT and had no history of concussion. Pearson's correlation coefficients (r) and intraclass correlation coefficients (ICCs) were as follows: Verbal Memory = .66/.79 (r/ICC), Visual Memory = .43/.60, Visual Motor Speed = .78/.88, Reaction Time = .63/.77, and Total Symptoms = .75/.81. Dependent sample t-tests revealed significant improvement on only Visual Motor Speed composite scores. Reliable Change Indices showed a significant number of participants fell outside 80% and 95% confidence intervals for only Visual Motor Speed scores (but no other indices), whereas all scores were within 80% and 95% confidence intervals using regression-based measures. Results suggest that repeated exposure to the ImPACT test may result in significant improvements in the physical mechanics of how college students interact with the test (e. g., performance on Visual Motor Speed), but repeated exposure across 1 month does not result in practice effects in memory performance or reaction time.	[Schatz, Philip; Ferris, Charles S.] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 5600 City Ave,Post Hall 222, Philadelphia, PA 19131 USA.	pschatz@sju.edu					BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Chicchetti D. V., 1994, PSYCHOL ASSESSMENT, V6, P294, DOI DOI 10.1037//1040-3590.6.4.284; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; FLEISHMAN J, 1987, EDUC PSYCHOL MEAS, V47, P925, DOI 10.1177/0013164487474008; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2007, IMPACT VERSION 6 0 C; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; RODGERS JL, 1988, AM STAT, V42, P59, DOI 10.2307/2685263; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838	27	66	67	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					499	504		10.1093/arclin/act034			6	Psychology, Clinical; Psychology	Psychology	186CN	WOS:000322019600012	23702678	Bronze			2021-06-18	
J	O'Donnell, ML; Varker, T; Holmes, AC; Ellen, S; Wade, D; Creamer, M; Silove, D; McFarlane, A; Bryant, RA; Forbes, D				O'Donnell, Meaghan L.; Varker, Tracey; Holmes, Alexander C.; Ellen, Steven; Wade, Darryl; Creamer, Mark; Silove, Derrick; McFarlane, Alexander; Bryant, Richard A.; Forbes, David			Disability After Injury: The Cumulative Burden of Physical and Mental Health	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; CHRONIC PAIN; FUNCTIONAL OUTCOMES; HOSPITAL ANXIETY; DEPRESSION; PREVALENCE; SEVERITY; IMPACT; SCALE	Context: Injury is one of the leading contributors to the global burden of disease. The factors that drive long-term disability after injury are poorly understood. Objective: The main aim of the study was to model the direct and indirect pathways to long-term disability after injury. Specifically, the relationships between 3 groups of variables and long-term disability were examined over time. These included physical factors (including injury characteristics and premorbid disability), pain severity (including pain at 1 week and 12 months), and psychiatric symptoms (including psychiatric history and posttraumatic stress, depression, and anxiety symptoms at 1 week and 12 months). Design, Setting, and Participants: A multisite, longitudinal cohort study of 715 randomly selected injury patients (from April 2004 to February 2006). Participants were assessed just prior to discharge (mean = 7.0 days, SD = 7.8 days) and reassessed at 12 months postinjury. Injury patients who experienced moderate/severe traumatic brain injury and spinal cord injury were excluded from the study. Main Outcome Measure: The World Health Organization Disability Assessment Schedule 2.0 was used to assess disability at 12 months after injury. Results: Disability at 12 months was up to 4 times greater than community norms, across all age groups. The development and maintenance of long-term disability occurred through a complex interaction of physical factors, pain severity across time, and psychiatric symptoms across time. While both physical factors and pain severity contributed significantly to 12-month disability (pain at 1 week: total effect [TE] = 0.2, standard error [SE] < 0.1; pain at 12 months: TE = 0.3, SE < 0.1; injury characteristics: TE = 0.3, SE < 0.1), the total effects of psychiatric symptoms were substantial (psychiatric symptoms 1 week: TE = 0.30, SE < 0.1; psychiatric symptoms 12 months: TE = 0.71, SE < 0.1). Taken together, psychiatric symptoms accounted for the largest proportion of the variance in disability at 12 months. Conclusions: While the physical and pain consequences of injury contribute significantly to enduring disability after injury, psychiatric symptoms play a greater role. Early interventions targeting psychiatric symptoms may play an important role in improving functional outcomes after injury. (C) Copyright 2013 Physicians Postgraduate Press, Inc.	[O'Donnell, Meaghan L.; Varker, Tracey; Wade, Darryl; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3010, Australia; [O'Donnell, Meaghan L.; Varker, Tracey; Wade, Darryl; Forbes, David] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [Holmes, Alexander C.; Creamer, Mark] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Ellen, Steven] Alfred Hosp, Melbourne, Vic, Australia; [Ellen, Steven] Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia; [McFarlane, Alexander] Univ Adelaide, Ctr Traumat Stress, Adelaide, SA 5005, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	O'Donnell, ML (corresponding author), Level 1,340 Albert St, East Melbourne, Vic 3002, Australia.	mod@unimelb.edu.au	Varker, Tracey/T-5125-2019; Bryant, Richard/AAA-6479-2019	Varker, Tracey/0000-0002-7139-062X; Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022; Forbes, David/0000-0001-9145-1605; Wade, Darryl/0000-0002-8079-321X	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [568970]	This study was supported by a National Health and Medical Research Council of Australia program grant (568970).	Andrews G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008343; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bonne O, 2004, NEUROSCI BIOBEHAV R, V28, P65, DOI 10.1016/j.neubiorev.2003.12.001; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; chnurr PP, 2004, TRAUMA HLTH PHYS HLT, P3; Collip D, 2008, SCHIZOPHRENIA BULL, V34, P220, DOI 10.1093/schbul/sbm163; Fabian ES, 2007, REHABIL COUNS BULL, V50, P130, DOI 10.1177/00343552070500030101; Furlan JC, 2011, J NEUROTRAUM, V28, P1413, DOI 10.1089/neu.2009.1148; Gabbe BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025862; Geldman M, 2008, CLIN REHABIL, V22, P364, DOI 10.1177/0269215507081966; Hair J.F, 1998, MULTIVARIATE DATA AN; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kariuki M, 2011, DISABIL HEALTH J, V4, P91, DOI 10.1016/j.dhjo.2010.08.001; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Liedl A, 2010, PSYCHOL MED, V40, P1215, DOI 10.1017/S0033291709991310; Lopez AD, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-5; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; McFarlane AC, 2007, BEST PRACT RES CL RH, V21, P549, DOI 10.1016/j.berh.2007.03.008; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; O'Donnell ML, 2009, MED J AUSTRALIA, V190, pS71; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Perini SJ, 2006, J AFFECT DISORDERS, V90, P123, DOI 10.1016/j.jad.2005.10.011; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Richmond TS, 2003, AM J CRIT CARE, V12, P197, DOI 10.4037/ajcc2003.12.3.197; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Schnurr Paula P, 2004, Adv Mind Body Med, V20, P18; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; TEASDALE G, 1974, LANCET, V2, P81; Tunks ER, 2008, CAN J PSYCHIAT, V53, P224; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WHODAS Group, 2000, WHO DIS ASS SCHED 2; World Health Organisation, A29INFDOCI11976 WHO; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	47	66	66	0	21	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	FEB	2013	74	2					E137	E143		10.4088/JCP.12m08011			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AA4UN	WOS:000331091900004	23473359				2021-06-18	
J	Mahley, RW; Huang, YD				Mahley, Robert W.; Huang, Yadong			Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4-Associated Neuropathology	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							INCREASED TAU PHOSPHORYLATION; TRAUMATIC BRAIN-INJURY; E4 DOMAIN INTERACTION; E EPSILON 4; ALZHEIMERS-DISEASE; MUTANT P53; APOE GENOTYPE; PHARMACOLOGICAL CHAPERONE; IN-VITRO; DEPENDENT IMPAIRMENT	An attractive strategy to treat proteinopathies (diseases caused by malformed or misfolded proteins) is to restore protein function by inducing proper three-dimensional structure. We hypothesized that this approach would be effective in reversing the detrimental effects of apolipoprotein (apo) E4, the major allele that significantly increases the risk of developing Alzheimer's disease and other neurodegenerative disorders. ApoE4's detrimental effects result from its altered protein conformation ("domain interaction"), making it highly susceptible to proteolytic cleavage and the generation of neurotoxic fragments. Here, we review apoE structure and function and how apoE4 causes neurotoxicity, and describe the identification of potent;mall-molecule-based "structure correctors" that induce proper apoE4 folding. SAP. studies identified a series of small molecules that significantly reduced apoE4's neurotoxic effects in cultured neurons and a series that reduced apoE4 fragment levels in vivo, providing proof-of-concept for our approach. Structure-corrector-based therapies could prove to be highly effective for the treatment of many protein-misfolding diseases.	[Mahley, Robert W.; Huang, Yadong] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Mahley, Robert W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Huang, Yadong] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mahley, Robert W.; Huang, Yadong] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	Mahley, RW (corresponding author), Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	rmahley@gladstone.ucsf.edu	Du, Yan-Jun/K-1522-2019; Graaff, Reindert/G-8941-2011	Du, Yan-Jun/0000-0001-9533-8976; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG022074]; Alzheimer's Drug Discovery Foundation [20110501]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022074] Funding Source: NIH RePORTER	We thank Sylvia Richmond for manuscript preparation, Anna Lisa Lucido and Gary Howard for editorial assistance, and John C. W. Carroll for graphics. We are indebted to the staff of the Merck Research Laboratories (Boston, MA) for providing compounds from the Merck library and preparing specific chemical analogues. This work was supported, in part, by National Institutes of Health Grant P01 AG022074, Alzheimer's Drug Discovery Foundation Grant 20110501, a gift from the Stephen D. Bechtel, Jr. Foundation, and Merck Research Laboratories.	Accurso FJ, 2010, NEW ENGL J MED, V363, P1991, DOI 10.1056/NEJMoa0909825; Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; [Anonymous], 2009, MOL THER, V17, P1309; Balch WE, 2011, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A004499; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Benjamin ER, 2009, J INHERIT METAB DIS, V32, P424, DOI 10.1007/s10545-009-1077-0; Bien-Ly N, 2011, P NATL ACAD SCI USA, V108, P4236, DOI 10.1073/pnas.1018381108; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brodbeck J, 2008, P NATL ACAD SCI USA, V105, P1343, DOI 10.1073/pnas.0709906104; Brodbeck J, 2011, J BIOL CHEM, V286, P17217, DOI 10.1074/jbc.M110.217380; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105; Buttini M, 1999, J NEUROSCI, V19, P4867; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chen HK, 2012, J BIOL CHEM, V287, P5253, DOI 10.1074/jbc.M111.276162; Chen HK, 2011, J BIOL CHEM, V286, P5215, DOI 10.1074/jbc.M110.151084; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Enzinger C, 2003, ARCH NEUROL-CHICAGO, V60, P65, DOI 10.1001/archneur.60.1.65; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fan JQ, 2003, METHOD ENZYMOL, V363, P412; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Grainger DJ, 2004, J IMMUNOL, V173, P6366, DOI 10.4049/jimmunol.173.10.6366; Hagemans MLC, 2005, BRAIN, V128, P671, DOI 10.1093/brain/awh384; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Harris FM, 2004, J BIOL CHEM, V279, P44795, DOI 10.1074/jbc.M408127200; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200; Hirschhorn R., 2001, METABOLIC MOL BASES, P3389; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Huang YD, 2010, TRENDS MOL MED, V16, P287, DOI 10.1016/j.molmed.2010.04.004; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Hughes D, 2010, J INHERIT METAB DIS, V33, pS148; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalid O, 2010, J COMPUT AID MOL DES, V24, P971, DOI 10.1007/s10822-010-9390-0; Khanna R, 2010, MOL THER, V18, P23, DOI 10.1038/mt.2009.220; Kim J, 2011, J NEUROSCI, V31, P18007, DOI 10.1523/JNEUROSCI.3773-11.2011; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kornhaber GJ, 2008, CHEMBIOCHEM, V9, P2643, DOI 10.1002/cbic.200800249; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Lieberman RL, 2007, NAT CHEM BIOL, V3, P101, DOI 10.1038/nchembio850; Lieberman RL, 2009, BIOCHEMISTRY-US, V48, P4816, DOI 10.1021/bi9002265; Lindquist SL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004507; Liou B, 2006, J BIOL CHEM, V281, P4242, DOI 10.1074/jbc.M511110200; Lir H., 2004, BIOCHIM BIOPHYS ACTA, V1689, P219; Maegawa GHB, 2007, J BIOL CHEM, V282, P9150, DOI 10.1074/jbc.M609304200; Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martinez M, 2005, AM J MED GENET B, V136B, P72, DOI 10.1002/ajmg.b.30196; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nichols WC, 2009, NEUROLOGY, V72, P310, DOI 10.1212/01.wnl.0000327823.81237.d1; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Okumiya T, 2007, MOL GENET METAB, V90, P49, DOI 10.1016/j.ymgme.2006.09.010; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Parenti G, 2007, MOL THER, V15, P508, DOI 10.1038/sj.mt.6300074; Parsian A, 2002, GENOMICS, V79, P458, DOI 10.1006/geno.2002.6707; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pedemonte N, 2010, AM J PHYSIOL-CELL PH, V298, pC866, DOI 10.1152/ajpcell.00404.2009; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sawkar AR, 2006, CELL MOL LIFE SCI, V63, P1179, DOI 10.1007/s00018-005-5437-0; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Sloane PA, 2010, CURR OPIN PULM MED, V16, P591, DOI 10.1097/MCP.0b013e32833f1d00; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Steet RA, 2006, P NATL ACAD SCI USA, V103, P13813, DOI 10.1073/pnas.0605928103; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; VANGOOR F, 2009, WINE, V106, P18825, DOI DOI 10.1073/PNAS.0904709106; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Yam GHF, 2005, FASEB J, V19, P12, DOI 10.1096/fj.04-2375com; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102; Zarate YA, 2008, LANCET, V372, P1427, DOI 10.1016/S0140-6736(08)61589-5; Zhong N, 2008, ALZHEIMERS DEMENT, V4, P179, DOI 10.1016/j.jalz.2008.01.006; Zhong N, 2009, J BIOL CHEM, V284, P6027, DOI 10.1074/jbc.R800009200	114	66	68	0	24	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	NOV 8	2012	55	21					8997	9008		10.1021/jm3008618			12	Chemistry, Medicinal	Pharmacology & Pharmacy	033CE	WOS:000310769500003	23013167	Green Accepted			2021-06-18	
J	Catroppa, C; Godfrey, C; Rosenfeld, JV; Hearps, SSJC; Anderson, VA				Catroppa, Cathy; Godfrey, Celia; Rosenfeld, Jeffrey V.; Hearps, Stephen S. J. C.; Anderson, Vicki A.			Functional Recovery Ten Years after Pediatric Traumatic Brain Injury: Outcomes and Predictors	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain injury; children; functional	CLOSED-HEAD-INJURY; SHORT-TERM; PSYCHIATRIC-DISORDERS; BEHAVIOR PROBLEMS; CHILDREN; CHILDHOOD; ADOLESCENTS; SEVERITY; PERFORMANCE; SYMPTOMS	Functional impairments (adaptive, behavioral, educational) are common after preschool traumatic brain injury (TBI). In comparison with cognitive outcome, functional outcomes have received limited attention, with little evidence to determine whether these difficulties persist in the long term. The aim of this study was to examine functional outcomes at 10 years post-injury and identify predictors of outcome. The study compared children with a diagnosis of TBI (n = 40) to a healthy age-, gender-, and socioeconomic status (SES)-matched control group (n = 19) at 10 years post-injury. Outcomes and predictors of functional skills were investigated. Poorer adaptive skills were evident for those with more severe injury. Behavioral difficulties were present regardless of injury severity. Post-injury, arithmetic skills were the most compromised in the longer term. Pre-injury status, interventions accessed, and acute intellectual function were significant predictors of outcome. These results highlight the importance of monitoring functional skills in the long term, especially for those children presenting with risk factors.	[Catroppa, Cathy; Godfrey, Celia; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Catroppa, Cathy; Godfrey, Celia; Hearps, Stephen S. J. C.; Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Catroppa, C (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Hearps, Stephen/L-6853-2016; Rosenfeld, Jeffrey V/B-7249-2011		Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Royal Children's Hospital Research Foundation; Victorian Government's Operational Infrastructure Support Program	This research was supported by the Australian National Health and Medical Research Council, the Royal Children's Hospital Research Foundation, and the Victorian Government's Operational Infrastructure Support Program.	Alves W., 1992, PHYS MED REHABILITAT, V6, P21; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bayley N., 1969, BAYLEY SCALES INFANT; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Daniel A. E., 1983, POWER PRIVILEGE PRES; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Harrison P., 2003, ADAPTIVE BEHAV ASSES; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Lachar D, 1992, PERSONALITY INVENTOR; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Noller P, 1988, ICPS FAMILY FUNCTION; Rawlings JO, 1998, APPL REGRESSION ANAL; Reynolds C.R., 1992, BEHAV ASSESSMENT SYS; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Tabachnick B., 2001, USING MULTIVARIATE S; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; WECHSLER D, 1987, MANUAL PRESCHOOL PRI; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Woods DT, 2012, NEUROREHABILITATION, V30, P189, DOI 10.3233/NRE-2012-0744; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	63	66	66	2	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2539	2547		10.1089/neu.2012.2403			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900002	22846066				2021-06-18	
J	Fukuda, AM; Pop, V; Spagnoli, D; Ashwal, S; Obenaus, A; Badaut, J				Fukuda, A. M.; Pop, V.; Spagnoli, D.; Ashwal, S.; Obenaus, A.; Badaut, J.			DELAYED INCREASE OF ASTROCYTIC AQUAPORIN 4 AFTER JUVENILE TRAUMATIC BRAIN INJURY: POSSIBLE ROLE IN EDEMA RESOLUTION?	NEUROSCIENCE			English	Article						edema; astrocyte; aquaporin; juvenile traumatic brain injury	ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; AQP4 EXPRESSION; WATER CHANNELS; HEAD-INJURY; RAT-BRAIN; MICE; MODEL; PAIN; CHILDREN	Traumatic brain injury (TBI) is one of the leading causes of death and disability in children and adolescents. The neuropathological sequelae that result from TBI are a complex cascade of events including edema formation, which occurs more frequently in the pediatric than the adult population. This developmental difference in the response to injury may be related to higher water content in the young brain and also to molecular mechanisms regulating water homeostasis. Aquaporins (AQPs) provide a unique opportunity to examine the mechanisms underlying water mobility, which remain poorly understood in the juvenile post-traumatic edema process. We examined the spatiotemporal expression pattern of principal brain AQPs (AQP1, AQP4, and AQP9) after juvenile TBI (jTBI) related to edema formation and resolution observed using magnetic resonance imaging (MRI). Using a controlled cortical impact in postnatal 17 day-old rats as a model of jTBI, neuroimaging analysis showed a global decrease in water mobility (apparent diffusion coefficient, ADC) and an increase in edema (T2-values) at 1 day post-injury, which normalized by 3 days. Immunohistochemical analysis of AQP4 in perivascular astrocyte endfeet was increased in the lesion at 3 and 7 days postinjury as edema resolved. In contrast, AQP1 levels distant from the injury site were increased at 7, 30, and 60 days within septal neurons but did not correlate with changes in edema formation. Group differences were not observed AQP9. Overall, our observations confirm that astrocyticAQP4 plays a more central role than AQP1 or AQP9 during the edema process in the young brain. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Badaut, J.] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Fukuda, A. M.; Badaut, J.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Spagnoli, D.; Obenaus, A.] Loma Linda Univ, Dept Radiat Med, Loma Linda, CA 92354 USA; [Spagnoli, D.; Obenaus, A.] Loma Linda Univ, Dept Biophys & Engn, Loma Linda, CA 92354 USA; [Obenaus, A.] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu		Fukuda, Andrew/0000-0002-7927-6602	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01HD061946]; Loma Linda University Dept. of Pediatrics Research Fund; Swiss Science FoundationSwiss National Science Foundation (SNSF) [FN 31003A-122166, IZKOZ3-128973]; National Medical Test Bed; NASANational Aeronautics & Space Administration (NASA) [NCC9-149]; Department of Radiation Medicine at Loma Linda University; National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	The authors thank Beatrice Ternon for her help for part of the histology and tissue analysis and Arash Adami and David Ajao for TBI induction. This work was supported in part by NINDS Grant R01HD061946 (J.B.), the Loma Linda University Dept. of Pediatrics Research Fund, the Swiss Science Foundation (FN 31003A-122166 and IZKOZ3-128973, J.B.), National Medical Test Bed (A.O.) and a NASA Cooperative Agreement NCC9-149 to the Radiobiology Program, Department of Radiation Medicine at Loma Linda University. A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Sean M. Wilson) and the Loma Linda University School of Medicine.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 1998, ACT NEUR S, V71, P250; Ajao D, 2012, J NEUROTRAUMA; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Badaut J, 2010, NEUROSCIENCE, V168, P1047, DOI 10.1016/j.neuroscience.2009.10.030; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bertolizio G, 2011, PEDIATR ANESTH, V21, P1198, DOI 10.1111/j.1460-9592.2011.03695.x; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Borsani E, 2010, CURR NEUROPHARMACOL, V8, P122, DOI 10.2174/157015910791233187; Borsook D, 2012, BRAIN, V135, P320, DOI 10.1093/brain/awr271; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Dibaj P, 2007, J NEUROCHEM, V103, P2620, DOI 10.1111/j.1471-4159.2007.04979.x; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; DOBBING J, 1981, EARLY HUM DEV, V5, P227, DOI 10.1016/0378-3782(81)90030-X; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; GALLAGHER JP, 1995, PROG NEUROBIOL, V45, P373, DOI 10.1016/0301-0082(95)98600-A; Gomori E, 2006, INT J DEV NEUROSCI, V24, P295, DOI 10.1016/j.ijdevneu.2006.05.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hsu MS, 2011, NEUROSCIENCE, V178, P21, DOI 10.1016/j.neuroscience.2011.01.020; Igarashi H, 2011, NEUROL SCI, V32, P113, DOI 10.1007/s10072-010-0431-1; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lee DJ, 2012, EPILEPSY RES, V98, P264, DOI 10.1016/j.eplepsyres.2011.09.016; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nesic O, 2008, J NEUROCHEM, V105, P628, DOI 10.1111/j.1471-4159.2007.05177.x; Nesic O, 2010, NEUROSCIENCE, V168, P1019, DOI 10.1016/j.neuroscience.2010.01.037; Nicchia GP, 2005, FASEB J, V19, P1674, DOI 10.1096/fj.04-3281fje; Obenaus A, 2008, NEUROPHARMACOLOGY, V55, P271, DOI 10.1016/j.neuropharm.2008.06.010; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; Oshio K, 2006, BIOCHEM BIOPH RES CO, V341, P1022, DOI 10.1016/j.bbrc.2006.01.062; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Singewald GM, 2011, NEUROPSYCHOPHARMACOL, V36, P793, DOI 10.1038/npp.2010.213; Skucas VA, 2011, J NEUROSCI, V31, P6392, DOI 10.1523/JNEUROSCI.6249-10.2011; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070; Tran ND, 2010, J NEUROSURG, V112, P1095, DOI 10.3171/2009.8.JNS081704; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilcock DM, 2009, NEUROSCIENCE, V159, P1055, DOI 10.1016/j.neuroscience.2009.01.023; Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zheng GQ, 2010, NEUROCHEM INT, V56, P651, DOI 10.1016/j.neuint.2010.01.014	64	66	70	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	OCT 11	2012	222						366	378		10.1016/j.neuroscience.2012.06.033			13	Neurosciences	Neurosciences & Neurology	010HM	WOS:000309085500033	22728101	Green Accepted			2021-06-18	
J	Erdal, K				Erdal, Kristi			Neuropsychological Testing for Sports-related Concussion: How Athletes Can Sandbag their Baseline Testing Without Detection	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neuropsychological testing; Athletes; Baseline; Concussion	TEST-RETEST RELIABILITY; HEAD-INJURY; PERFORMANCE; IMPACT; SIMULATION; ABILITY	Neuropsychological baseline testing is commonplace in the assessment of concussion; however, claims of sandbagging the baseline have led neuropsychologists to ask to what extent athletes can perform intentionally poorly on baseline testing without reaching threshold on the test validity indicators. Seventy-five undergraduate athletes were re-administered the ImPACT neurocognitive battery, which they had previously taken to establish baseline functioning, but were instructed to perform more poorly than their baseline without reaching threshold on the test validity indicators. Eight participants were able to successfully fake significantly lower scores without detection by validity indicators. Concussion history was not related to performance. Successful fakers did not perform significantly worse on the Reaction Time Composite and Three Letters Total Letters Correct, questioning the utility of these measures for detecting sandbagging. Successful fakers reported using less purposeful faking strategies which naturally facilitated errors. The data suggest that sandbagging the baseline, even under conditions involving motivation, instruction, and experience with the test, is difficult to accomplish without being detected.	Colorado Coll, Dept Psychol, Colorado Springs, CO 80903 USA	Erdal, K (corresponding author), Colorado Coll, Dept Psychol, 14 E Cache La Poudre St, Colorado Springs, CO 80903 USA.	kerdal@coloradocollege.edu			Colorado College Psychology Department Sabine Funds	This work was supported by the Colorado College Psychology Department Sabine Funds.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; ImPACT, 2012, NORM BAS DAT; ImPACT Applications Inc, 2007, IMPACT 2007 6 0 CLIN; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Reicker LI, 2008, ARCH CLIN NEUROPSYCH, V23, P419, DOI 10.1016/j.acn.2008.02.003; Reilly R., 2011, TALK FOOTB ARCH PEYT; Rogers R., 2008, CLIN ASSESSMENT MALI; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005	23	66	66	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2012	27	5					473	479		10.1093/arclin/acs050			7	Psychology, Clinical; Psychology	Psychology	976UN	WOS:000306611300001	22684033	Bronze			2021-06-18	
J	Campbell, M; Hanrahan, F; Gobbo, OL; Kelly, ME; Kiang, AS; Humphries, MM; Nguyen, ATH; Ozaki, E; Keaney, J; Blau, CW; Kerskens, CM; Cahalan, SD; Callanan, JJ; Wallace, E; Grant, GA; Doherty, CP; Humphries, P				Campbell, Matthew; Hanrahan, Finnian; Gobbo, Oliviero L.; Kelly, Michael E.; Kiang, Anna-Sophia; Humphries, Marian M.; Nguyen, Anh T. H.; Ozaki, Ema; Keaney, James; Blau, Christoph W.; Kerskens, Christian M.; Cahalan, Stephen D.; Callanan, John J.; Wallace, Eugene; Grant, Gerald A.; Doherty, Colin P.; Humphries, Peter			Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury	NATURE COMMUNICATIONS			English	Article							DRUG-DELIVERY; BARRIER; ALTERNATION; MODEL	Traumatic brain injury is the leading cause of death in children and young adults globally. Malignant cerebral oedema has a major role in the pathophysiology that evolves after severe traumatic brain injury. Added to this is the significant morbidity and mortality from cerebral oedema associated with acute stroke, hypoxic ischemic coma, neurological cancers and brain infection. Therapeutic strategies to prevent cerebral oedema are limited and, if brain swelling persists, the risks of permanent brain damage or mortality are greatly exacerbated. Here we show that a temporary and size-selective modulation of the blood-brain barrier allows enhanced movement of water from the brain to the blood and significantly impacts on brain swelling. We also show cognitive improvement in mice with focal cerebral oedema following administration in these animals of short interfering RNA directed against claudin-5. These observations may have profound consequences for early intervention in cases of traumatic brain injury, or indeed any neurological condition where cerebral oedema is the hallmark pathology.	[Campbell, Matthew; Hanrahan, Finnian; Kiang, Anna-Sophia; Humphries, Marian M.; Nguyen, Anh T. H.; Ozaki, Ema; Keaney, James; Blau, Christoph W.; Humphries, Peter] Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland; [Gobbo, Oliviero L.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland; [Kelly, Michael E.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, FMRIB Ctr, Oxford OX3 9DU, England; [Kerskens, Christian M.] Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin 2, Ireland; [Cahalan, Stephen D.; Callanan, John J.] Univ Coll Dublin, UCD Sch Vet Med, Dublin 4, Ireland; [Cahalan, Stephen D.; Callanan, John J.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; [Wallace, Eugene; Doherty, Colin P.] St James Hosp, Hosp 5, Hlth Care Ctr, Dept Neurol, Dublin 8, Ireland; [Grant, Gerald A.] Duke Univ, Med Ctr, Dept Surg, Div Neurosurg, Durham, NC 27710 USA	Campbell, M (corresponding author), Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland.	matthew.campbell@tcd.ie	Kerskens, Christian Matthias/AAJ-6202-2020; Gobbo, Oliviero/S-2043-2019; Gobbo, Oliviero/R-1763-2016; Cahalan, Stephen/P-9149-2016	Gobbo, Oliviero/0000-0003-4629-9485; Gobbo, Oliviero/0000-0003-4629-9485; Kerskens, Christian Matthias/0000-0003-0823-4648; Doherty, Colin/0000-0002-8869-8567; Cahalan, Stephen/0000-0003-2287-1416; Callanan, John/0000-0003-4356-1783	US Department of Defense (US-DoD)United States Department of Defense; Telemedicine and Advanced Technology Research Center (TATRC); Enterprise Ireland (EI)	This work was supported by the US Department of Defense (US-DoD), Telemedicine and Advanced Technology Research Center (TATRC) and Enterprise Ireland (EI). Aspects of research involving neuronal barrier modulation are also supported by Science Foundation Ireland (SFI), the Health Research Board of Ireland (HRB) and Fighting Blindness-Ireland. We thank Prof. John Kelly and Dr Gemma Keegan for their assistance with the Zeta-sizer hardware. We also thank Dr Thomas Connor for assistance and advice relating to RT-PCR analyses and Rustam Rakhmatullin for technical assistance with MRI studies. We also thank Caroline Woods, Charles Murray, David Flynn, and Rebecca Robertson for animal husbandry, Brian Cloak for post-mortem technical assistance and photo-microscopy, and Joe Brady for processing brain samples.	Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Callans DJ, 2004, NEW ENGL J MED, V351, P632, DOI 10.1056/NEJMp048174; Campbell M, 2008, J GENE MED, V10, P930, DOI 10.1002/jgm.1211; Campbell M, 2011, EMBO MOL MED, V3, P235, DOI 10.1002/emmm.201100126; Campbell M, 2009, P NATL ACAD SCI USA, V106, P17817, DOI 10.1073/pnas.0908561106; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; Douglas R. J., 1975, HIPPOCAMPUS, V2, P327; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jinnouchi Y, 2007, BRAIN RES, V1167, P92, DOI 10.1016/j.brainres.2007.04.088; Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294; Kelly ME, 2009, PHYS MED BIOL, V54, P1235, DOI 10.1088/0031-9155/54/5/009; Kelly ME, 2010, J CEREBR BLOOD F MET, V30, P913, DOI 10.1038/jcbfm.2009.284; Klohs J, 2009, J NEUROSCI METH, V180, P126, DOI 10.1016/j.jneumeth.2009.03.002; Kroll RA, 1998, NEUROSURGERY, V43, P879, DOI 10.1097/00006123-199810000-00090; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MOULIN DE, 1985, STROKE, V16, P282, DOI 10.1161/01.STR.16.2.282; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Robbins M, 2007, MOL THER, V15, P1663, DOI 10.1038/sj.mt.6300240; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROBERTS WW, 1962, J COMP PHYSIOL PSYCH, V55, P695, DOI 10.1037/h0045168; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Shih RH, 2010, J NEUROTRAUM, V27, P1477, DOI 10.1089/neu.2009.1201; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Weiss C, 1998, NEUROSCI RES COMMUN, V23, P77, DOI 10.1002/(SICI)1520-6769(199809/10)23:2<77::AID-NRC2>3.0.CO;2-Y; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212	41	66	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	MAY	2012	3								849	10.1038/ncomms1852			12	Multidisciplinary Sciences	Science & Technology - Other Topics	949XP	WOS:000304611400044	22617289	DOAJ Gold			2021-06-18	
J	Zhao, SF; Fu, JD; Liu, XR; Wang, T; Zhang, JL; Zhao, YL				Zhao, Shangfeng; Fu, Jidi; Liu, Xiangrong; Wang, Tony; Zhang, Jialiang; Zhao, Yuanli			Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats	NEUROLOGICAL RESEARCH			English	Article						Akt; GSK-3beta; Beta-catenin; Traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3-BETA; CEREBRAL-ARTERY OCCLUSION; BETA-CATENIN; KINASE-B; APOPTOSIS; ISCHEMIA; CELL; AKT; DEATH; PHOSPHORYLATION	Objective: Apoptotic cell death is an important factor influencing the prognosis after traumatic brain injury (TBI). Akt/GSK-3beta/beta-catenin signaling plays a critical role in the apoptosis of neurons in several models of neurodegeneration. The goal of this study was to determine if the mechanism of cell survival mediated by the Akt/GSK-3beta/beta-catenin pathway is involved in a rat model of TBI. Methods: TBI was performed by a controlled cortical impact device. Expression of Akt, phospho-Akt, GSK-3beta, phospho-GSK-3beta, beta-catenin, phospho-beta-catenin were examined by immunohistochemistry and Western blot analysis. Double immunofluorenscent staining was used to observe the neuronal expression of the aforementioned subtrates. Terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling (TUNEL) staining was performed to identify apoptosis. Results: Western blot analysis showed that phospho-Akt significantly increased at 4 hours post-TBI, but decreased after 72 hours post-TBI. Phospho-GSK-3beta - phosphorylated by phospho-Akt - slightly increased at 4 hours post-TBI and peaked at 72 hours post-TBI. These changes in Phospho-GSK-3beta expression were accompanied by a marked increase in expression of phospho-beta-catenin at 4 hours post-TBI which was sustained until 7 days post-TBI. Double staining of phospho-Akt and NeuN revealed the colocalization of phospho-Akt positive cells and neuronal cells. In addition, double staining of phospho-Akt and TUNEL showed no colocalization of phospho-Akt cells and TUNEL-positive cells. Conclusion: Phosphorylation of Akt (Ser473) and GSK3beta (Ser9) was accelerated in the injured cortex, and involved in the neuronal survival after TBI. Moreover, neuroprotection of beta-catenin against ischemia was partly mediated by enhanced and persistent activation of the Akt/GSK3beta signaling pathway.	[Zhao, Yuanli] Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Zhao, Shangfeng; Fu, Jidi; Zhang, Jialiang] Capital Univ Med Sci, Beijing Tongren Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Liu, Xiangrong] Capital Univ Med Sci, Xuanwu Hosp, Key Lab Neurodegenerat Dis, Cerebrovasc Dis Res Inst,Minist Educ, Beijing 100050, Peoples R China; [Wang, Tony] Wayne State Univ, Detroit, MI USA	Zhao, YL (corresponding author), Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	zhaolang88@hotmail.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000504]	This project was supported by the Natural Science Foundation of China (Grant No. 81000504).	Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan PH, 2004, STROKE, V35, P2748, DOI 10.1161/01.STR.0000143325.25610.ac; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553; Geiger B, 1995, ACTA ANAT, V154, P46; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jin G, 2003, NEUROL RES, V25, P249, DOI 10.1179/016164103101201454; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Lei ZN, 2008, NEUROSCI LETT, V435, P108, DOI 10.1016/j.neulet.2008.02.031; Li Q, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.33; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Sanderson TH, 2009, NEUROL RES, V31, P947, DOI 10.1179/174313209X382449; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Wang SJ, 2002, NEUROL RES, V24, P719, DOI 10.1179/016164102101200645; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang HF, 2008, BRAIN RES, V1198, P182, DOI 10.1016/j.brainres.2008.01.007; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhu D, 2009, NEUROL RES, V31, P200, DOI 10.1179/174313209X393915	39	66	69	2	14	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAY	2012	34	4					400	407		10.1179/1743132812Y.0000000025			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	948XJ	WOS:000304536600012	22643085				2021-06-18	
J	Jinguji, TM; Bompadre, V; Harmon, KG; Satchell, EK; Gilbert, K; Wild, J; Eary, JF				Jinguji, Thomas M.; Bompadre, Viviana; Harmon, Kimberly G.; Satchell, Emma K.; Gilbert, Kaiulani; Wild, Jennifer; Eary, Janet F.			Sport Concussion Assessment Tool-2: Baseline Values for High School Athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; STATEMENT; SYMPTOMS; DEFICITS	Background Concussion head injuries are common in high school athletes. The Sport Concussion Assessment Tool - 2 (SCAT2) has been recommended and widely adopted as a standardised method of evaluating an injured athlete with a suspected concussion. Sideline return to play decisions can hinge on the results of a SCAT2 score. However, most athletes will not have had baseline testing performed for comparison if injury occurs. Therefore, establishing of age-, sex- and sport-matched normative data for the high school athlete population is critical. Purpose To determine baseline scores in all SCAT2 domains among high school athletes with no prior history of a concussion and to examine subgroup differences for girls and boys, age and sport to establish normative ranges. Materials and methods The SCAT2 was administered to 214 high school athletes (155 males and 59 females) who participated in football, women's soccer, men's basketball, gymnastics, baseball, softball and track with no prior history of concussion. There were 111 athletes in the 13-15-year-old cohort and 103 in the 16-19-yearold group with a mean age of 15.7 years of age. In all SCAT2 domains the mean and SD of the results were determined. The domains were analysed using age, sex and sport as covariates. Component parts of the cognitive (concentration) domain (digit sequencing and months of year in reverse order) were also analysed by age, sex and sport. The percentage of high school athletes able to perform each digit-sequencing test was calculated as was the percentage of participants who could recite the months of the year in reverse order. Results The average SCAT2 score for these high school athletes was 89 of a possible 100 with a SD of 6 units. Athletes reported two or three symptoms at baseline with older students reporting more symptoms than younger ones. The average balance score was 25.82 (of 30), and all athletes were able to complete the double-leg stance. Females scored significantly higher on the balance, immediate memory and concentration scores. Concentration scores in non-concussed high school athletes were low. Only 67% of high school athletes could recite the months of the year backward and only 41% could correctly sequence 5 digits backward. Only 55% of high school football players could correctly recite the months of the year backward and 32% could sequence 5 digits. Conclusions Non-concussed high school athletes scored near the total possible in most domains of the SCAT2 with the exception of concentration testing and balance testing. All athletes were able to complete the double-leg stance at baseline; however, there was significant variability of tandem and single-leg stance. Baseline testing is important when considering balance tests. Concentration testing in high school athletes is unreliable because of high baseline error and is likely to result in a high rate of false positives and false negatives. Return to play decisions should not rely on concentration testing without a baseline test for comparison.	[Jinguji, Thomas M.; Bompadre, Viviana; Satchell, Emma K.; Gilbert, Kaiulani; Eary, Janet F.] Seattle Childrens Hosp, Dept Orthopaed & Sports Med, Seattle, WA 98105 USA; [Harmon, Kimberly G.; Eary, Janet F.] Univ Washington, Dept Sports Med, Seattle, WA 98195 USA; [Wild, Jennifer] Univ Washington, Dept Pediat, Seattle, WA 98195 USA	Jinguji, TM (corresponding author), Seattle Childrens Hosp, Dept Orthopaed & Sports Med, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	thomas.jinguji@seattlechildrens.org			Seattle Children's Hospital	Academic Enrichment Fund - Seattle Children's Hospital.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Patel AV, 2007, J ATHL TRAINING, V42, P66; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	25	66	67	2	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2012	46	5					365	370		10.1136/bjsports-2011-090526			6	Sport Sciences	Sport Sciences	919QH	WOS:000302342800015	22228554				2021-06-18	
J	Saing, T; Dick, M; Nelson, PT; Kim, RC; Cribbs, DH; Head, E				Saing, Tommy; Dick, Malcolm; Nelson, Peter T.; Kim, Ronald C.; Cribbs, David H.; Head, Elizabeth			Frontal Cortex Neuropathology in Dementia Pugilistica	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid; C1q; chronic traumatic encephalopathy; tauopathy; TDP-43	FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; AMYLOID-BETA-PROTEIN; MOTOR-NEURON DISEASE; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; A-BETA; NEUROFIBRILLARY TANGLES; CASPASE ACTIVATION; NEURODEGENERATIVE DISEASES	Dementia pugilistica (DP) is associated with chronic traumatic brain injury (CTBI), and leads to a "punch drunk'' syndrome characterized by impairments in memory and executive function, behavioral changes, and motor signs. Microscopic features include the accumulation of neurofibrillary tangles (NFTs), beta-amyloid (A beta), and TAR DNA binding protein 43 (TDP-43) pathology. Here we describe detailed clinical and neuropathological data about a 55-year-old retired boxer (ApoE3/4), who presented with executive dysfunction and behavioral impairments. At autopsy, significant A beta pathology was seen, primarily in the form of diffuse plaques. Tau pathology was extensive and was determined to be of Braak and Braak stage VI. Frontal white matter showed evidence of glial tau inclusions (astrocytes and oligodendroglia). Cerebrovascular pathology was minimal with patchy amyloid angiopathy. Inflammation was another key feature, including microglial activation and significant C1q labeling of neurons, along with NFTs. TDP-43-positive pathology was also observed. Inflammation may be a key inciting as well as propagating feature of DP neuropathology.	[Nelson, Peter T.; Head, Elizabeth] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Saing, Tommy; Dick, Malcolm; Kim, Ronald C.; Cribbs, David H.; Head, Elizabeth] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA; [Kim, Ronald C.] Univ Calif Irvine, Dept Pathol, Irvine, CA USA; [Cribbs, David H.; Head, Elizabeth] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Head, Elizabeth] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA	Head, E (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 203 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	Elizabeth.head@uky.edu			University of California Irvine Alzheimer' Disease Research Center (National Institutes on Health/National Institutes on Aging) [P50 AG16573]; National Institutes on Health/National Institutes on Aging [AG21912, AG00538]; University of Kentucky Alzheimer's Disease Center [P30 AG028383]; National Institute of Child Health and Human Development Brain [N01-HD-4-3368, N01-HD-4-3383]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028383, P50AG016573, R01AG021912, P01AG000538] Funding Source: NIH RePORTER	Funding supported by the University of California Irvine Alzheimer' Disease Research Center (National Institutes on Health/National Institutes on Aging Grant #P50 AG16573), National Institutes on Health/National Institutes on Aging Grant #AG21912, and #AG00538. Additional support was received from the University of Kentucky Alzheimer's Disease Center Grant #P30 AG028383. A subset of human tissues was obtained from the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-4-3383. We are grateful to the family and to our patient with DP for their contributions to the study.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Aguzzi A, 2009, NEURON, V64, P783, DOI 10.1016/j.neuron.2009.12.016; ALLSOP D, 1990, AM J PATHOL, V136, P255; Angot E, 2010, LANCET NEUROL, V9, P1128, DOI 10.1016/S1474-4422(10)70213-1; Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Armstrong RA, 2010, J NEURAL TRANSM, V117, P227, DOI 10.1007/s00702-009-0350-6; Arnold SE, 2000, NEUROBIOL AGING, V21, P913, DOI 10.1016/S0197-4580(00)00173-1; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Belfor N, 2006, MECH AGEING DEV, V127, P203, DOI 10.1016/j.mad.2005.09.013; Brandmeir NJ, 2008, ACTA NEUROPATHOL, V115, P123, DOI 10.1007/s00401-007-0315-5; Brundin P, 2008, NAT REV NEUROSCI, V9, P741, DOI 10.1038/nrn2477; Cagnin A, 2004, ANN NEUROL, V56, P894, DOI 10.1002/ana.20332; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Fonseca MI, 2004, NEUROBIOL DIS, V15, P40, DOI 10.1016/j.nbd.2003.09.004; Forman MS, 2007, CURR OPIN NEUROBIOL, V17, P548, DOI 10.1016/j.conb.2007.08.005; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gitcho MA, 2008, ANN NEUROL, V63, P535, DOI 10.1002/ana.21344; Goedert M, 2010, TRENDS NEUROSCI, V33, P317, DOI 10.1016/j.tins.2010.04.003; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Head E, 2006, ACTA NEUROPATHOL, V112, P217, DOI 10.1007/s00401-006-0098-0; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hyman BT, 2011, NAT NEUROSCI, V14, P5, DOI 10.1038/nn0111-5; Ikeda K, 1998, NEUROBIOL AGING, V19, pS85, DOI 10.1016/S0197-4580(98)00034-7; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; JIANG HX, 1994, J IMMUNOL, V152, P5050; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Kordower JH, 2011, NEUROBIOL DIS, V43, P552, DOI 10.1016/j.nbd.2011.05.001; Kumar-Singh S, 2007, BRAIN PATHOL, V17, P104, DOI 10.1111/j.1750-3639.2007.00055.x; Kwong LK, 2007, ACTA NEUROPATHOL, V114, P63, DOI 10.1007/s00401-007-0226-5; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Langer F, 2011, J NEUROSCI, V31, P14488, DOI 10.1523/JNEUROSCI.3088-11.2011; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKenzie JE, 1996, NEURODEGENERATION, V5, P259, DOI 10.1006/neur.1996.0034; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Morales R, 2011, MOL PSYCHIAT; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Newman J, 2005, ACTA NEUROPATHOL, V110, P135, DOI 10.1007/s00401-005-1027-3; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Petrushina I, 2007, J NEUROSCI, V27, P12721, DOI 10.1523/JNEUROSCI.3201-07.2007; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1988, LANCET, V2, P1456; Rohn TT, 2008, REV NEUROSCIENCE, V19, P383; Schofield E, 2003, BRAIN, V126, P827, DOI 10.1093/brain/awg085; SPILLANE J D, 1962, Br Med J, V2, P1205; Spires-Jones TL, 2008, J NEUROSCI, V28, P862, DOI 10.1523/JNEUROSCI.3072-08.2008; SU JH, 1994, NEUROREPORT, V5, P2358, DOI 10.1097/00001756-199411000-00037; Thal DR, 2005, ACTA NEUROPATHOL, V110, P459, DOI 10.1007/s00401-005-1053-1; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uboga NV, 2000, NEUROBIOL AGING, V21, P1, DOI 10.1016/S0197-4580(00)00091-9; UHL GR, 1982, ANN NEUROL, V12, P99; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Volpicelli-Daley LA, 2011, NEURON, V72, P57, DOI 10.1016/j.neuron.2011.08.033; Webster S, 1997, J NEUROCHEM, V69, P388; Wilson AC, 2011, INT J CLIN EXP PATHO, V4, P147; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	94	66	66	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1054	1070		10.1089/neu.2011.1957			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100004	22017610	Green Published			2021-06-18	
J	Leventhal, JM; Martin, KD; Gaither, JR				Leventhal, John M.; Martin, Kimberly D.; Gaither, Julie R.			Using US Data to Estimate the Incidence of Serious Physical Abuse in Children	PEDIATRICS			English	Article						abuse; epidemiology-injury; injury severity	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; FRACTURES; VIOLENCE	BACKGROUND: There are limited data on the epidemiology of serious injuries due to physical abuse of children. METHODS: We used the 2006 Kids' Inpatient Database to estimate the incidence of hospitalizations due to serious physical abuse among children <18 years of age. Abuse was defined by using International Classification of Diseases, Ninth Revision, Clinical Modification codes for injuries (800-959) and for physical abuse (995.50, 995.54, 995.55, or 995.59), selected assault codes (E960-966, 968), or child battering (E967). We examined demographic characteristics, mean costs, and length of stay in 3 groups of hospitalized children: abusive injuries, nonabusive injuries, and all other reasons for hospitalization. Incidence was calculated using the weighted number of cases of physical abuse and the number of children at risk based on 2006 intercensal data. RESULTS: The weighted number of cases due to abuse was 4569; the incidence was 6.2 (95% confidence interval [CI]: 5.5-6.9) per 100 000 children <18 years of age. The incidence was highest in children <1 year of age (58.2 per 100 000; 95% CI: 51.0-65.3) and even higher in infants covered by Medicaid (133.1 per 100 000; 95% CI: 115.2-151.0 [or 1 in 752 infants]). Overall, there were 300 children who died in the hospital due to physical abuse. CONCLUSIONS: This is the first study to provide national US data on the occurrence of serious injuries due to physical abuse in hospitalized children. Data from the 2006 Kids' Inpatient Database on hospitalizations due to serious physical abuse can be used to track trends over time and the effects of prevention programs on serious physical abuse. Pediatrics 2012; 129:458-464	[Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Gaither, Julie R.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Martin, Kimberly D.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Martin, Kimberly D.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA	Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu			Yale University Department of Pediatrics	Supported by Child Abuse Funds in the Yale University Department of Pediatrics.	Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, OV KIDS INP DAT KID; [Anonymous], Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP); Berger LM, 2005, CHILD ABUSE NEGLECT, V29, P107, DOI 10.1016/j.chiabu.2004.02.006; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Gessner BD, 2004, CHILD ABUSE NEGLECT, V28, P9, DOI 10.1016/j.chiabu.2003.03.002; Hauck FR, 2008, PEDIATRICS, V122, P660, DOI 10.1542/peds.2007-0135; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Leventhal JM, 2007, CHILD ABUSE NEGLECT, V31, P311, DOI 10.1016/j.chiabu.2006.07.004; Lindberg DM, 2008, PEDIATRICS, V121, pE945, DOI 10.1542/peds.2007-2485; National Center for Health Statistics Centers for Medicare and Medicaid Services, 1999, INT CLASS DIS 9 REV; Sedlak A. J., 2010, 4 NATL INCIDENCE STU; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; United States Census Bureau, POP EST; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; *US BUR CENS, HLTH INS COV STAT TY; Wang C., 2007, TOTAL ESTIMATED COST; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	19	66	66	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2012	129	3					458	464		10.1542/peds.2011-1277			7	Pediatrics	Pediatrics	922IQ	WOS:000302541000042	22311999				2021-06-18	
J	Lin, KC; Niu, KC; Tsai, KJ; Kuo, JR; Wang, LC; Chio, CC; Chang, CP				Lin, Kao-Chang; Niu, Kuo-Chi; Tsai, Kuen-Jer; Kuo, Jinn-Rung; Wang, Liang-Chao; Chio, Chung-Ching; Chang, Ching-Ping			Attenuating inflammation but stimulating both angiogenesis and neurogenesis using hyperbaric oxygen in rats with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; hyperbaric oxygen; gliosis; inflammation; angiogenesis; neurogenesis	LATERAL FLUID-PERCUSSION; NEURAL STEM-CELLS; MYELOPEROXIDASE ACTIVITY; MITOCHONDRIAL-FUNCTION; CEREBRAL-ISCHEMIA; WATER-MAZE; MODEL; THERAPY; MECHANISMS; APOPTOSIS	BACKGROUND: Inflammation, angiogenesis, neurogenesis, and gliosis are involved in traumatic brain injury (TBI). Several studies provide evidence supporting the neuroprotective effect of hyperbaric oxygen (HBO2) therapy in TBI. The aim of this study was to ascertain whether inflammation, angiogenesis, neurogenesis, and gliosis during TBI are affected by HBO2 therapy. METHODS: Rats were randomly divided into three groups: TBI + NBA (normobaric air: 21% O-2 at 1 absolute atmospheres), TBI + HBO2, and Sham operation + NBA. TBI + HBO2 rats received 100% O-2 at 2.0 absolute atmospheres for 1 hr/d for three consecutive days. Behavioral tests and biochemical and histologic evaluations were done 4 days after TBI onset. RESULTS: TBI + NBA rats displayed: (1) motor and cognitive dysfunction; (2) cerebral infarction and apoptosis; (3) activated inflammation (evidenced by increased brain myeloperoxidase activity and higher serum levels of tumor necrosis factor-alpha); (4) neuronal loss (evidenced by fewer NeuN-positive cells); and (5) gliosis (evidenced by more glial fibrillary protein-positive cells). In TBI + HBO2 rats, HBO2 therapy significantly reduced TBI-induced motor and cognitive dysfunction, cerebral infarction and apoptosis, activated inflammation, neuronal loss, and gliosis. In addition, HBO2 therapy stimulated angiogenesis (evidenced by more bromodeoxyuridine-positive endothelial and vascular endothelial growth factor-positive cells), neurogenesis (evidenced by more bromodeoxyuridine-NeuN double-positive and glial cells-derived neurotrophic factor-positive cells), and overproduction of interleukin-10 (an anti-inflammatory cytokine). CONCLUSIONS: Collectively, these results suggest that HBO2 therapy may improve outcomes of TBI in rats by inhibiting activated inflammation and gliosis while stimulating both angiogenesis and neurogenesis in the early stage. (J Trauma. 2012; 72: 650-659. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Lin, Kao-Chang; Niu, Kuo-Chi; Kuo, Jinn-Rung; Chio, Chung-Ching] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Wang, Liang-Chao] Natl Cheng Kung Univ, Grad Inst Clin Med, Sch Med, Tainan 70101, Taiwan; [Wang, Liang-Chao] Natl Cheng Kung Univ Hosp, Dept Surg, Neurosurg Serv, Tainan, Taiwan; [Kuo, Jinn-Rung; Chang, Ching-Ping] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan	Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan.	liangcha@mail.ncku.edu.tw; mtlin@ym.edu.tw; jessica@mail.stut.edu.tw	Tsai, Kuen-Jer/B-9393-2009	Tsai, Kuen-Jer/0000-0002-2170-9735	Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, NSC98-2314-B-218-001-MY2]; Center of Excellence for Clinical Trial and Research in Neuroscience of the Taiwan Health Department [DOH99-TD-B-111-003]	Supported by the Taiwan National Science Council grant NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, and NSC98-2314-B-218-001-MY2 and the Center of Excellence for Clinical Trial and Research in Neuroscience grant DOH99-TD-B-111-003 of the Taiwan Health Department.	Akin ML, 2002, UNDERSEA HYPERBAR M, V29, P279; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feihl F, 2001, PHARMACOL THERAPEUT, V91, P179, DOI 10.1016/S0163-7258(01)00155-3; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kubes P, 2000, BRAIN PATHOL, V10, P127; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Nilsson OG, 1996, ACT NEUR S, V67, P45; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ren H, 2001, Chin J Traumatol, V4, P239; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tai PA, 2010, J NEUROTRAUM; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2000, ACT NEUR S, V76, P285; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang Y, 1997, J NEUROSCI, V17, P4341; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	56	66	77	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					650	659		10.1097/TA.0b013e31823c575f			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	906TR	WOS:000301371100030	22491549				2021-06-18	
J	Carlozzi, NE; Tulsky, DS; Kisala, PA				Carlozzi, Noelle E.; Tulsky, David S.; Kisala, Pamela A.			Traumatic Brain Injury Patient-Reported Outcome Measure: Identification of Health-Related Quality-of-Life Issues Relevant to Individuals With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Health-related quality of life; Outcome assessment (health care); Patient-reported outcomes; Quality of life; Rehabilitation; Traumatic brain injury	REHABILITATION STAKEHOLDERS; PARTICIPATION; SEVERITY; IMPACT	Carlozzi NE, Tulsky DS, Kisala PA. Traumatic brain injury patient-reported outcome measure: identification of health-related quality-of-life issues relevant to individuals with traumatic brain injury. Arch Phys Med Rehabil 2011;92 (10 Suppl 1):S52-60. This 2-part qualitative study explored health-related quality of life (HRQOL) in individuals with traumatic brain injury (TBI). A community-based participatory action research design was used, which emphasizes collaboration between researchers and individuals with disabilities to ensure that results are relevant for individuals with TBI. In study 1, community members (N=20) with TBI served as "experts" during 1-on-1 semistructured interviews, reviewing current HRQOL items and identifying HRQOL issues commonly experienced by individuals with TBI. Each participant identified at least 31 issues, with most generating more than 90 responses, highlighting the multifaceted nature of HRQOL in TBI. Study 2 consisted of 7 patient/consumer groups (33 individuals with TBI), 4 caregiver groups (17 caregivers), and 2 provider groups (15 providers). Qualitative analysis of patient focus groups indicated that 48% of focus group comments were related to emotional issues; 23%, to social functioning; 14%, to physical functioning; 11%, to cognition; and 7%, to personality changes (caregiver and provider focus group analysis indicated identical patterns of findings). In addition, both studies evaluated the applicability in TBI of generic items developed by the Patient-Reported Outcomes Measurement Information System and the Neurology Quality of Life Measurement initiative. Findings suggest that although there is some overlap between current generic measures of HRQOL and concepts reported by individuals with TBI, these generic measures do not capture the full complexity of HRQOL in TBI. TBI-targeted item banks are needed to ensure sensitive assessment of HRQOL in TBI.	[Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes & Assessment Res, Ann Arbor, MI 48109 USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes & Assessment Res, N Campus Res Complex,Bldg 520,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu		Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research [H133G070138]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133G070138).	Amtmann D, 2011, ARCH PHYS MED REHAB, V92, pS12, DOI 10.1016/j.apmr.2011.04.025; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cella D F, 1992, J Palliat Care, V8, P8; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CELLA DF, 1995, SEMIN ONCOL, V22, P73; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; *I MED, 2006, EV HRSA TRAUM BRAIN; KISALA P, 2010, APPL PSYCHO IN PRESS; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; MESSICK S, 1984, J EDUC MEAS, V21, P215, DOI 10.1111/j.1745-3984.1984.tb01030.x; Messick S, 1988, TEST VALIDITY, P33, DOI 10.4324/9780203056905-11; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Quatrano LA, 2011, ARCH PHYS MED REHAB, V92, pS7, DOI 10.1016/j.apmr.2010.08.032; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 2007, HDB REHABILITATION P, P49; Sherer M., 2005, FORENSIC NEUROPSYCHO, P237; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Soo C, 2007, COCHRANE DB SYST REV, V3; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss A., 1998, BASICS QUALITATIVE R; VANDERLINDEN WJ, 1997, HDB MODERN IRT; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; Whyte J, 2005, PHYS MED REHABILITAT, P1677; Whyte J, 2005, PHYS MED REHABILITAT	38	66	67	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2011	92	10		1			S52	S60		10.1016/j.apmr.2010.12.046			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	833DG	WOS:000295861400008	21958923				2021-06-18	
J	Cottenceau, V; Masson, F; Mahamid, E; Petit, L; Shik, V; Sztark, F; Zaaroor, M; Soustiel, JF				Cottenceau, Vincent; Masson, Francoise; Mahamid, Eugenia; Petit, Laurent; Shik, Venyamin; Sztark, Francois; Zaaroor, Menashe; Soustiel, Jean Francois			Comparison of Effects of Equiosmolar Doses of Mannitol and Hypertonic Saline on Cerebral Blood Flow and Metabolism in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CBF; cerebral metabolism; HTS; ICP; MTL; TBI	INCREASED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; 20-PERCENT MANNITOL; PERFUSION-PRESSURE; PRACTICAL SCALE; HYPERTENSION; ISCHEMIA; TOMOGRAPHY; HEMORRHAGE; MORTALITY	The potential superiority of hypertonic saline (HTS) over mannitol (MTL) for control of intracranial pressure (ICP) following traumatic brain injury (TBI) is still debated. Forty-seven severe TBI patients with increased ICP were prospectively recruited in two university hospitals and randomly treated with equiosmolar infusions of either MTL 20% (4mL/kg; n = 25 patients) or HTS 7.5% (2 mL/kg; n = 22 patients). Serum sodium, hematocrit, ICP, arterial blood pressure, cerebral perfusion pressure (CPP), shear rate, global indices of cerebral blood flow (CBF) and metabolism were measured before, and 30 and 120 min following each infusion during the course of illness. Outcome was assessed at 6 months. Both HTS and MTL effectively and equally reduced ICP levels with subsequent elevation of CPP and CBF, although this effect was significantly stronger and of longer duration after HTS and correlated with improved rheological blood properties induced by HTS. Further, effect of HTS on ICP appeared to be more robust in patients with diffuse brain injury. In contrast, oxygen and glucose metabolic rates were left equally unaffected by both solutions. Accordingly, there was no significant difference in neurological outcome between the two groups. In conclusion, MTL was as effective as HTS in decreasing ICP in TBI patients although both solutions failed to improved cerebral metabolism. HTS showed an additional and stronger effect on cerebral perfusion of potential benefit in the presence of cerebral ischemia. Treatment selection should therefore be individually based on sodium level and cerebral hemodynamics.	[Mahamid, Eugenia; Shik, Venyamin; Zaaroor, Menashe; Soustiel, Jean Francois] Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Neurosurg, IL-31096 Haifa, Israel; [Cottenceau, Vincent; Masson, Francoise; Petit, Laurent; Sztark, Francois] CHU Bordeaux, Hop Pellegrin, Serv Anesthesie Reanimat 1, Bordeaux, France	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		LAURENT, PETIT/0000-0003-1530-5678			Al-Rawi PG, 2010, STROKE, V41, P122, DOI 10.1161/STROKEAHA.109.560698; BARRY KG, 1961, NEW ENGL J MED, V264, P1085, DOI 10.1056/NEJM196105252642105; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker DP, 1972, INTRACRANIAL PRESSUR; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; Chieregato A, 2007, INTENS CARE MED, V33, P856, DOI 10.1007/s00134-007-0604-4; Chieregato A, 2009, NEUROSURGERY, V64, P705, DOI 10.1227/01.NEU.0000341872.17024.44; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JENNETT B, 1975, LANCET, V1, P480; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Soustiel JF, 2010, NEUROSURGERY, V67, P65, DOI 10.1227/01.NEU.0000370604.30037.F5; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; TEASDALE G, 1974, LANCET, V2, P81; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Zhao L, 2009, RESUSCITATION, V80, P253, DOI 10.1016/j.resuscitation.2008.10.014	41	66	69	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2003	2012		10.1089/neu.2011.1929			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500001	21787184				2021-06-18	
J	Wang, JY; Bakhadirov, K; Abdi, H; Devous, MD; de la Plata, CDM; Moore, C; Madden, CJ; Diaz-Arrastia, R				Wang, J. Y.; Bakhadirov, K.; Abdi, H.; Devous, M. D., Sr.; de la Plata, C. D. Marquez; Moore, C.; Madden, C. J.; Diaz-Arrastia, R.			Longitudinal changes of structural connectivity in traumatic axonal injury	NEUROLOGY			English	Article							DIFFUSION-TENSOR; BRAIN-INJURY; TRACTOGRAPHY; INTEGRITY; RECOVERY; ROBUST	Objectives: To identify structural connectivity change occurring during the first 6 months after traumatic brain injury and to evaluate the utility of diffusion tensor tractography for predicting long-term outcome. Methods: The participants were 28 patients with mild to severe traumatic axonal injury and 20 age-and sex-matched healthy control subjects. Neuroimaging was obtained 0-9 days postinjury for acute scans and 6-14 months postinjury for chronic scans. Long-term outcome was evaluated on the day of the chronic scan. Twenty-eight fiber regions of 9 major white matter structures were reconstructed, and reliable tractography measurements were determined and used. Results: Although most (23 of 28) patients had severe brain injury, their long-term outcome ranged from good recovery (16 patients) to moderately (5 patients) and severely disabled (7 patients). In concordance with the diverse outcome, the white matter change in patients was heterogeneous, ranging from improved structural connectivity, through no change, to deteriorated connectivity. At the group level, all 9 fiber tracts deteriorated significantly with 7 (corpus callosum, cingulum, angular bundle, cerebral peduncular fibers, uncinate fasciculus, and inferior longitudinal and fronto-occipital fasciculi) showing structural damage acutely and 2 (fornix body and left arcuate fasciculus) chronically. Importantly, the amount of change in tractography measurements correlated with patients' long-term outcome. Acute tractography measurements were able to predict patients' learning and memory performance; chronic measurements also determined performance on processing speed and executive function. Conclusions: Diffusion tensor tractography is a valuable tool for identifying structural connectivity changes occurring between the acute and chronic stages of traumatic brain injury and for predicting patients' long-term outcome. Neurology (R) 2011;77:818-826	[Wang, J. Y.; Bakhadirov, K.; Abdi, H.; Devous, M. D., Sr.] Univ Texas Dallas, Dept Cognit & Neurosci, Richardson, TX 75083 USA; [de la Plata, C. D. Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [Abdi, H.; Devous, M. D., Sr.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Moore, C.; Diaz-Arrastia, R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Madden, C. J.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA	Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA.	Ramon.Diaz-Arrastia@usuhs.mil	Abdi, Herve/G-6620-2011	Abdi, Herve/0000-0002-9522-1978; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD48179, U01-HD042652, K23-NS060827]; US Department of EducationUS Department of Education [H133 A020526]; Avid Radiopharmaceuticals, Inc.; NIH (NIA, NIDRR/US Dept. Ed.)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Alzheimer's AssociationAlzheimer's Association; UCBUCB Pharma SA; NIH/NIDRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	Study funding: Supported by the NIH (R01-HD48179 and U01-HD042652 to R. D.-A. and K23-NS060827 to C. D. M.) and the US Department of Education (H133 A020526 to R.D.-A.).; Dr. Wang, Dr. Bakhadirov, and Dr. Abdi report no disclosures. Dr. Devous serves on a scientific advisory board and as a consultant for Avid Radiopharmaceuticals, Inc.; served as an Associate Editor for the Journal of Experimental Biology; receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NIA, NIDRR/US Dept. Ed.), and the Alzheimer's Association; and holds stock/stock options in Avid Radiopharmaceuticals, Inc. Dr. Marquez de la Plata, C. Moore, and Dr. Madden report no disclosures. Dr. Diaz-Arrastia serves on the speakers' bureau for and has received funding for travel and speaker honoraria from UCB; serves on the editorial board of the Journal of Neurotrauma; and receives research support from the NIH/NIDRR and the Alzheimer's Association.	ABDI H, 2010, ENCY RES DESIGNS, P6556; ABDI H, 2007, ENCY MEASUREMENT STA, P2702; Abdi H, 2010, WIRES COMPUT STAT, V2, P97, DOI 10.1002/wics.51; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Concha L, 2005, AM J NEURORADIOL, V26, P2267; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Delis DC, 2000, CALIFORNIA VERBAL LE; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Huang H, 2004, MAGN RESON MED, V52, P559, DOI 10.1002/mrm.20147; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Spreen O., 1998, COMPENDIUM NEUROPSYC; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058	36	66	69	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG	2011	77	9					818	826		10.1212/WNL.0b013e31822c61d7			9	Clinical Neurology	Neurosciences & Neurology	815PH	WOS:000294537000009	21813787	Green Published			2021-06-18	
J	Ling, GSF; Ecklund, JM				Ling, Geoffrey S. F.; Ecklund, James M.			Traumatic brain injury in modern war	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						clinical practice guidelines; concussion; explosive blast; return to duty; traumatic brain injury	IRAQ	Purpose of review To review the emerging literature on traumatic brain injury (TBI) caused by explosive blast. Recent findings Efforts are underway to understand how explosive blast injures brain, what is the clinical presentation and how best to manage it. A major way blast injures brain is from detonation pressure waves coupling to a victim's head leading to brain deformation. The effect of other explosion-related elements is unknown. Because scientific insights take time to develop but injuries are occurring now, the military adopts existing civilian standard of care practices developed for similar diseases, such as the Guidelines for the Management of Severe Traumatic Brain Injury developed mainly for closed head TBI. When these do not exist, the military creates them, such as the Veterans Administration and Department of Defense Clinical Practice Guidelines for Concussion/Mild TBI. Another treatment advance is the creation of the first large system-wide approach to diagnosis and clinical management of TBI, which begins at the site of injury and extends through both the military and the Veterans' Administration medical care systems. Summary Explosive blast TBI is being addressed at all levels - basic research through clinical care. New clinical practice guidelines are being used in a standardized system-wide approach.	[Ling, Geoffrey S. F.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Ecklund, James M.] Dept Neurosurg, Falls Church, VA USA	Ling, GSF (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gling@usuhs.mil			Defense Military Research and Development Program; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	The authors report no conflicts of interests and no commercial sponsorships as they pertain to this topic. They gratefully acknowledge research grant funding from the Defense Military Research and Development Program and the Defense Advanced Research Projects Agency for work being done on explosive blast TBI and spinal cord injury.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; BELLAMY RF, 1995, OFFICE SURG GEN, P1; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Geocadin R., 2004, HDB NEURO CRITICAL C, P73; JAFFEE M, 2011, BRAINWAVES; JARRELL A, 2003, COMBAT MED BASIC CLI, P351; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Knuth T., 2005, GUIDELINES FIELD MAN; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling Geoffrey S F, 2010, Continuum (Minneap Minn), V16, P27, DOI 10.1212/01.CON.0000391451.30299.bc; Ling GSF, 2010, ANNU REV MED, V61, P457, DOI 10.1146/annurev.med.60.071207.140903; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; VADOD C, 2009, J REHABIL RES DEV, V46; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; 2001, J TRAUMA 1, V51, pS3	17	66	68	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					124	130		10.1097/ACO.0b013e32834458da			7	Anesthesiology	Anesthesiology	732AS	WOS:000288154100002	21301332				2021-06-18	
J	Griesbach, GS; Hovda, DA; Tio, DL; Taylor, AN				Griesbach, G. S.; Hovda, D. A.; Tio, D. L.; Taylor, A. N.			HEIGHTENING OF THE STRESS RESPONSE DURING THE FIRST WEEKS AFTER A MILD TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						corticosterone; fluid percussion injury; dexamethasone; adrenocorticotropic hormone; traumatic brain injury and stress	CORTICOTROPIN-RELEASING HORMONE; LATERAL FLUID PERCUSSION; PITUITARY-ADRENAL AXIS; NEUROTROPHIC FACTOR EXPRESSION; MAJOR DEPRESSIVE DISORDER; ADRENOCORTICAL-RESPONSE; GENE-EXPRESSION; DEVELOPING RAT; UP-REGULATION; ACUTE-PHASE	The effects of a mild traumatic brain injury range from white matter disruption to affective disorders. We set out to determine the response to restraint-induced stress after a mild fluid-percussion injury (FPI), an experimental model for brain injury. Hypothalamic-pituitary-adrenal (HPA) axis regulation of corticosterone (CORT) and adrenocorticotropic hormone (ACTH) was determined during the first post-injury weeks, which corresponds to the same time period when rehabilitative exercise has been shown to be ineffective after a mild FPI. Adult male rats underwent either an FPI or sham injury. Additional rats were only exposed to anesthesia. HPA regulation was evaluated by measuring the effects of dexamethasone (DEX) treatment on CORT and ACTH. Tail vein blood was collected following 30-min restraint stress, at post-injury days (PID) 1, 7 and 14, prior to (0 min) and at 30, 60, 90 and 120 min after stress onset. Results from these studies indicate that the stress response was significantly more pronounced after FPI in that CORT and ACTH restraint-induced increases were more pronounced and longer lasting compared to controls. DEX suppression of CORT and ACTH was observed in all groups, suggesting that stress hyper-responsiveness after mild FPI is not attributable to reduced sensitivity of CORT feedback regulation. The increased sensitivity to stressful events in the first two post-injury weeks after a mild FPI may have a negative impact on early rehabilitative therapies. (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Griesbach, G. S.; Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Tio, D. L.; Taylor, A. N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NINDS awardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS6190]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	This study was supported by NINDS award NS6190 (GSG) and the UCLA Brain Injury Research Center. We would also wish to thank David L. McArthur, PhD. for his statistical advice and David Garfinkel for his excellent technical help.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Ashman TA, 2006, MT SINAI J MED, V73, P999; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bornstein SR, 2008, TRENDS ENDOCRIN MET, V19, P175, DOI 10.1016/j.tem.2008.01.009; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; de Kloet ER, 2000, EUR J PHARMACOL, V405, P187, DOI 10.1016/S0014-2999(00)00552-5; DeKeyser FG, 2000, NEUROIMMUNOMODULAT, V7, P182, DOI 10.1159/000026437; Faul M., 2010, EMERGENCY DEP VISITS; Gold PW, 2002, MOL PSYCHIATR, V7, P254, DOI 10.1038/sj.mp.4001032; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hirasawa K, 2000, J NEUROSURG, V93, P581, DOI 10.3171/jns.2000.93.4.0581; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; Ising M, 2005, PROG NEURO-PSYCHOPH, V29, P1085, DOI 10.1016/j.pnpbp.2005.03.014; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Juruena Mario F., 2004, Revista Brasileira de Psiquiatria, V26; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Neigh GN, 2009, J CEREBR BLOOD F MET, V29, P1673, DOI 10.1038/jcbfm.2009.85; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Posener JA, 2000, ARCH GEN PSYCHIAT, V57, P755, DOI 10.1001/archpsyc.57.8.755; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; REIMOLD M, PSYCHOPHARM IN PRESS; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Santibanez M, 2006, J NEUROSCI RES, V84, P1270, DOI 10.1002/jnr.21023; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; SHENKIN HA, 1971, J NEUROSURG, V34, P657, DOI 10.3171/jns.1971.34.5.0657; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Strohle A, 2003, PHARMACOPSYCHIATRY, V36, pS207; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vreeburg SA, 2009, ARCH GEN PSYCHIAT, V66, P617, DOI 10.1001/archgenpsychiatry.2009.50; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Xu Miao, 2007, Chin J Traumatol, V10, P90; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Yuan ZH, 2010, CHIN J TRAUMATOL, V13, P42, DOI 10.3760/cma.j.issn.1008-1275.2010.01.008	70	66	69	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 31	2011	178						147	158		10.1016/j.neuroscience.2011.01.028			12	Neurosciences	Neurosciences & Neurology	736WK	WOS:000288525500015	21277947	Green Accepted			2021-06-18	
J	Alvarez, TL; Vicci, VR; Alkan, Y; Kim, EH; Gohel, S; Barrett, AM; Chiaravalloti, N; Biswal, BB				Alvarez, Tara L.; Vicci, Vincent R.; Alkan, Yelda; Kim, Eun H.; Gohel, Suril; Barrett, Anna M.; Chiaravalloti, Nancy; Biswal, Bharat B.			Vision Therapy in Adults with Convergence Insufficiency: Clinical and Functional Magnetic Resonance Imaging Measures	OPTOMETRY AND VISION SCIENCE			English	Article						convergence insufficiency; vision therapy; vergence; traumatic brain injury; prediction; frontal eye fields; supplementary eye field; dorsolateral prefrontal cortex; cerebellum; brain stem	VERGENCE EYE-MOVEMENTS; DISPARITY VERGENCE; PHORIA ADAPTATION; SYMPTOM SURVEY; CHILDREN; TRIAL; DYNAMICS; FREQUENCY; PRISM; MODEL	Purpose. This research quantified clinical measurements and functional neural changes associated with vision therapy in subjects with convergence insufficiency (CI). Methods. Convergence and divergence 4 degrees step responses were compared between 13 control adult subjects with normal binocular vision and four CI adult subjects. All CI subjects participated in 18 h of vision therapy. Clinical parameters quantified throughout the therapy included: nearpoint of convergence, recovery point of convergence, positive fusional vergence at near, near dissociated phoria, and eye movements that were quantified using peak velocity. Neural correlates of the CI subjects were quantified with functional magnetic resonance imaging scans comparing random vs. predictable vergence movements using a block design before and after vision therapy. Images were quantified by measuring the spatial extent of activation and the average correlation within five regions of interests (ROI). The ROIs were the dorsolateral prefrontal cortex, a portion of the frontal lobe, part of the parietal lobe, the cerebellum, and the brain stem. All measurements were repeated 4 months to 1 year post-therapy in three of the CI subjects. Results. Convergence average peak velocities to step stimuli were significantly slower (p = 0.016) in CI subjects compared with controls; however, significant differences in average peak velocities were not observed for divergence step responses (p = 0.30). The investigation of CI subjects participating in vision therapy showed that the nearpoint of convergence, recovery point of convergence, and near dissociated phoria significantly decreased. Furthermore, the positive fusional vergence, average peak velocity from 4 degrees convergence steps, and the amount of functional activity within the frontal areas, cerebellum, and brain stem significantly increased. Several clinical and cortical parameters were significantly correlated. Conclusions. Convergence peak velocity was significantly slower in CI subjects compared with controls, which may result in asthenopic complaints reported by the CI subjects. Vision therapy was associated with and may have evoked clinical and cortical activity changes. (Optom Vis Sci 2010;87:E985-E1002)	[Alvarez, Tara L.; Alkan, Yelda; Kim, Eun H.; Gohel, Suril] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Vicci, Vincent R.] Kessler Inst Rehabil, Dept Vis Rehabil, W Orange, NJ USA; [Gohel, Suril; Biswal, Bharat B.] Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA; [Barrett, Anna M.] Kessler Fdn, Stroke Res Lab, W Orange, NJ USA; [Chiaravalloti, Nancy] Kessler Fdn, Neuropsychol & Neurosci Lab, W Orange, NJ USA	Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu; bbiswal@gmail.com		Alvarez, Tara/0000-0002-8797-1613; Barrett, A.M./0000-0002-0789-2887	NSFNational Science Foundation (NSF) [BES-044713]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS049176, 5R01NS055808, 5K02NS047099-6]; Department of EducationUS Department of Education; NIDRR [H133P090009]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD062647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS047099, R01NS055808, R01NS049176] Funding Source: NIH RePORTER	This research was supported in part by NSF CAREER BES-044713 (to TLA), NIH 5R01NS049176 (to BBB), and NIH 5R01NS055808 and 5K02NS047099-6 (to AMB). The contents of this article were developed under a grant from the Department of Education, NIDRR Grant H133P090009 (to NC) but do not necessarily represent policy of the Department of Education.	Alvarez TL, 2007, COMPUT BIOL MED, V37, P903, DOI 10.1016/j.compbiomed.2006.03.009; Alvarez TL, 2010, VISION RES, V50, P2163, DOI 10.1016/j.visres.2010.08.018; Alvarez TL, 2005, J VISION, V5, P640, DOI 10.1167/5.7.4; Alvarez TL, 2002, CAH PSYCHOL COGN, V21, P243; Alvarez TL, 1999, ANN BIOMED ENG, V27, P380, DOI 10.1114/1.162; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; BAHILL AT, 1982, BIOL CYBERN, V45, P1, DOI 10.1007/BF00387207; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Berns G S, 1999, J Neurosci, V19, pRC17; Binder JR, 2004, NAT NEUROSCI, V7, P295, DOI 10.1038/nn1198; Birnbaum M H, 1999, J Am Optom Assoc, V70, P225; Borsting EJ, 2003, OPTOMETRY VISION SCI, V80, P832, DOI 10.1097/00006324-200312000-00014; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brautaset RL, 2005, OPHTHAL PHYSL OPT, V25, P215, DOI 10.1111/j.1475-1313.2005.00276.x; Brautaset RL, 2006, INVEST OPHTH VIS SCI, V47, P2876, DOI 10.1167/iovs.04-1372; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Chen YF, 2010, J MED BIOL ENG, V30, P1; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Cohen A H, 1984, J Am Optom Assoc, V55, P491; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 1999, NEUROIMAGE, V10, P6, DOI 10.1006/nimg.1999.0444; DAUM KM, 1984, AM J OPTOM PHYS OPT, V61, P16; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; Gavrilescu M, 2008, HUM BRAIN MAPP, V29, P1040, DOI 10.1002/hbm.20446; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Griffin J. R, 1988, BINOCULAR ANOMALIES; GRISHAM JD, 1988, AM J OPTOM PHYS OPT, V65, P448; Han SJ, 2010, OPHTHAL PHYSL OPT, V30, P95, DOI 10.1111/j.1475-1313.2009.00681.x; Hokoda S C, 1985, J Am Optom Assoc, V56, P560; Horng JL, 1998, IEEE T BIO-MED ENG, V45, P249, DOI 10.1109/10.661273; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; Kennedy DN, 1998, CEREB CORTEX, V8, P372, DOI 10.1093/cercor/8.4.372; Kim EH, 2010, INVEST OPHTH VIS SCI, V51, P4017, DOI 10.1167/iovs.09-4560; Lee YY, 2008, J VISION, V8, DOI 10.1167/8.12.5; Lee YY, 2009, VISION RES, V49, P2960, DOI 10.1016/j.visres.2009.09.013; Lewis JW, 2005, J NEUROSCI, V25, P5148, DOI 10.1523/JNEUROSCI.0419-05.2005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091; MILDER DG, 1983, ARCH NEUROL-CHICAGO, V40, P339, DOI 10.1001/archneur.1983.04050060039005; MORLEY JW, 1992, J NEUROPHYSIOL, V67, P1475; Nitta T, 2008, CEREB CORTEX, V18, P1042, DOI 10.1093/cercor/bhm143; Oakes TR, 2005, NEUROIMAGE, V28, P529, DOI 10.1016/j.neuroimage.2005.05.058; Patel SS, 1999, OPTOMETRY VISION SCI, V76, P656, DOI 10.1097/00006324-199909000-00024; PICKWELL LD, 1981, OPHTHAL PHYSL OPT, V1, P13, DOI 10.1111/j.1475-1313.1981.tb00143.x; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P1169, DOI 10.1097/OPX.0b013e3181baad13; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Rouse MW, 1999, OPTOMETRY VISION SCI, V76, P643, DOI 10.1097/00006324-199909000-00022; Rouse MW, 1998, OPTOMETRY VISION SCI, V75, P88, DOI 10.1097/00006324-199802000-00012; Sander T, 2009, BRAIN, V132, P103, DOI 10.1093/brain/awn306; Scheiman M, 2005, BRIT J OPHTHALMOL, V89, P1318, DOI 10.1136/bjo.2005.068197; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 1996, J Am Optom Assoc, V67, P193; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1336, DOI 10.1001/archopht.126.10.1336; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Scheiman M, 2010, OPTOMETRY VISION SCI, V87, P593, DOI 10.1097/OPX.0b013e3181e61bad; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P1096, DOI 10.1097/OPX.0b013e3181b6210f; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P420, DOI 10.1097/OPX.0b013e31819fa712; Schmid A, 2001, NEUROREPORT, V12, P1409, DOI 10.1097/00001756-200105250-00023; Sloan JA, 2005, J CLIN EPIDEMIOL, V58, P1217, DOI 10.1016/j.jclinepi.2005.07.009; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Takagi M, 2003, PROG BRAIN RES, V142, P19; Takagi M, 2001, INVEST OPHTH VIS SCI, V42, pS319; TALAIRACH J, 1988, COPLANNAR STEREOTAXI; Teitelbaum B, 2009, OPTOMETRY VISION SCI, V86, P153, DOI 10.1097/OPX.0b013e318194e985; Ungerleider L., 1982, ANAL VISUAL BEHAV, P549; van Leeuwen AF, 1999, VISION RES, V39, P3095, DOI 10.1016/S0042-6989(99)00066-8; Ward B., 2000, SIMULTANEOUS INFEREN; Weiss PH, 2000, BRAIN, V123, P2531, DOI 10.1093/brain/123.12.2531; Yuan WH, 2000, VISION RES, V40, P3089, DOI 10.1016/S0042-6989(00)00162-0; Yuan WH, 1999, IEEE T BIO-MED ENG, V46, P1191, DOI 10.1109/10.790495	77	66	67	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	DEC	2010	87	12					985	1002		10.1097/OPX.0b013e3181fef1aa			18	Ophthalmology	Ophthalmology	687CQ	WOS:000284752200010	21057347	Green Accepted			2021-06-18	
J	Schnuriger, B; Inaba, K; Abdelsayed, GA; Lustenberger, T; Eberle, BM; Barmparas, G; Talving, P; Demetriades, D				Schnuriger, Beat; Inaba, Kenji; Abdelsayed, George A.; Lustenberger, Thomas; Eberle, Barbara M.; Barmparas, Galinos; Talving, Peep; Demetriades, Demetrios			The Impact of Platelets on the Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Platelet; Traumatic brain injury; Intracranial; Hemorrhage; Progression; Blunt	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; COAGULOPATHY; CRITERIA; MODERATE	Background: The purpose of this study was to analyze the association of the initial platelet count with mortality and progression of intracranial hemorrhage (ICH) in blunt traumatic brain injured (TBI) patients. Methods: All blunt trauma patients with severe TBI admitted from January 2006 to December 2007 were retrospectively identified. Patients with a chest, abdomen, or extremity AIS score >3 were excluded to minimize the impact of concomitant injuries on the outcomes of the patients. All brain computed tomography scans were reviewed to analyze ICH progression. Discrete platelet cutoff values were entered into a multiple regression model to detect critical thresholds associated with ICH progression and mortality. Results: Of 626 TBI patients, 310 (49.5%) had a minimum of two brain computed tomography scans and were able to have ICH progression evaluated. Patients with platelets <175,000/mm(3) had a significantly increased risk for ICH progression (OR [95% CI]: 2.09 [1.07-4.37]; adjusted p = 0.043). ICH progression was associated with increased need for craniotomy (OR [95% CI]: 3.27 [1.28-8.33]; adjusted p = 0.013) and mortality (OR [95% CI]: 3.41 [1.11-10.53]; adjusted p = 0.033). A platelet count <100,000/m(3) was an independent predictor for mortality (OR [95% CI]: 9.5 [1.3-71.4]; adjusted p = 0.029). Conclusion: A platelet count <100,000/mm(3) is associated with a ninefold adjusted risk of death, and a platelet count <175,000/mm(3) is a significant predictor of ICH progression. The impact of early correction of the admission platelet count warrants further validation.	[Schnuriger, Beat; Inaba, Kenji; Abdelsayed, George A.; Lustenberger, Thomas; Eberle, Barbara M.; Barmparas, Galinos; Talving, Peep; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA	Schnuriger, B (corresponding author), 1200 N State St,Inpatient Tower C,5th Floor,Room, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu	Talving, Peep/G-8621-2015; Barmparas, Galinos/L-6530-2019; INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Akca S, 2002, CRIT CARE MED, V30, P753, DOI 10.1097/00003246-200204000-00005; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Gando S, 2006, CRIT CARE MED, V34, P625, DOI 10.1097/01.CCM.0000202209.42491.38; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; REILLY PL, 1975, LANCET, V2, P375; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Servadei F, 2000, NEUROSURGERY, V46, P70; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034	25	66	72	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					881	885		10.1097/TA.0b013e3181d3cc58			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	583GY	WOS:000276663100025	20386283				2021-06-18	
J	Jacobsson, LJ; Westerberg, M; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Lexell, J.			Health-related quality-of-life and life satisfaction 6-15 years after traumatic brain injuries in northern Sweden	BRAIN INJURY			English	Article						Long-term outcome; outcome assessment; traumatic brain injury; quality of life; questionnaires	COMMUNITY INTEGRATION; COPING STRATEGIES; SOCIAL SUPPORT; YOUNG-ADULTS; HEAD-INJURY; SCALE SWLS; SF-36; MODERATE; INDIVIDUALS; EMPLOYMENT	Objective: To describe health-related quality-of-life (HRQoL) and life satisfaction many years after a traumatic brain injury (TBI) and assess possible associations with variables related to the time of injury and follow-up and the individuals' self-appraisal of the impact of the TBI. Method: Sixty-seven individuals (18-65 years), on average 10 years post-injury, were interviewed. Data on HRQoL, using the SF-36 questionnaire, were compared with a Swedish age-and sex-matched reference sample, and life satisfaction, using the Satisfaction With Life Scale (SWLS), were compared with a nationwide Swedish sample of students. The participant's self-appraisal of the TBI was assessed with two supplementary questions. Data were analysed with hierarchical multiple regression analyses. Results: HRQoL as well as life satisfaction were lower compared with the reference samples. From the regression analyses, the individuals' own appraisal of the impact of the TBI and whether they were vocationally productive or not were strongly associated with their current physical health and life satisfaction. Conclusion: These results confirm the importance of TBI as a cause of long-term disability and the impact of the injury on the individuals' self-perceived values of health, quality-of-life and life satisfaction.	[Jacobsson, L. J.] Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden; [Jacobsson, L. J.; Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Westerberg, M.] Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden; [Lexell, J.] Skane Univ Hosp, Dept Rehabil Med, Lund, Sweden; [Lexell, J.] Lund Univ, Dept Clin Sci, Div Rehabil Med, Lund, Sweden	Jacobsson, LJ (corresponding author), Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden.	lars_j@glocalnet.net	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Lexell, Jan/0000-0001-5294-3332; Jacobsson, Lars/0000-0002-1127-1178	Norrbacka-Eugenia Foundation; Cancer and Traffic Injury Fund; Norrbotten County Council; Swedish Association of Brain Injured and their Families; Skane county council's research and development foundation	This study was supported by grants from the Norrbacka-Eugenia Foundation, the Cancer and Traffic Injury Fund, Norrbotten County Council, the Swedish Association of Brain Injured and their Families and Skane county council's research and development foundation.	Anaby D, 2010, SOC INDIC RES, V96, P267, DOI 10.1007/s11205-009-9476-z; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Antonovsky A., 1987, UNRAVELING MYSTERY H; Arrindell WA, 1999, PERS INDIV DIFFER, V26, P815, DOI 10.1016/S0191-8869(98)00180-9; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Charles ST, 2009, PSYCHOL AGING, V24, P645, DOI 10.1037/a0016673; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouveia VV, 2009, SOC INDIC RES, V90, P267, DOI 10.1007/s11205-008-9257-0; Hann M, 2008, QUAL LIFE RES, V17, P413, DOI 10.1007/s11136-008-9310-0; Hultell D, 2008, PERS INDIV DIFFER, V44, P1070, DOI 10.1016/j.paid.2007.10.030; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Riemsma R P, 2001, Health Technol Assess, V5, P1; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schopp LH, 2006, BRAIN INJURY, V20, P1155, DOI 10.1080/02699050600983735; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Slocum-Gori SL, 2009, SOC INDIC RES, V92, P489, DOI 10.1007/s11205-008-9303-y; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Sullivan MKJ, 2002, SVENSK MANUAL TOLKNI; Taft C, 2004, QUAL LIFE RES, V13, P251, DOI 10.1023/B:QURE.0000015290.76254.a5; Taft C, 2001, QUAL LIFE RES, V10, P395, DOI 10.1023/A:1012552211996; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	53	66	66	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	9					1075	1086		10.3109/02699052.2010.494590			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636RH	WOS:000280756700004	20597636				2021-06-18	
J	MacGregor, AJ; Shaffer, RA; Dougherty, AL; Galarneau, MR; Raman, R; Baker, DG; Lindsay, SR; Golomb, BA; Corson, KS				MacGregor, Andrew J.; Shaffer, Richard A.; Dougherty, Amber L.; Galarneau, Michael R.; Raman, Rema; Baker, Dewleen G.; Lindsay, Suzanne R.; Golomb, Beatrice A.; Corson, Karen S.			Prevalence and Psychological Correlates of Traumatic Brain Injury in Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						military; posttraumatic stress disorder; PTSD; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; HEAD-INJURY; SEVERITY SCORE; AMNESIA; PTSD; DEPRESSION; SYMPTOMS; CHILDREN; HISTORY	Objective: To describe the prevalence and psychological correlates of traumatic brain injury (TBI) among injured male combatants in the Iraq conflict. Participants: A total of 781 men injured during military combat between September 2004 and February 2005. Main Outcome Measures: Mental health diagnosis (ICD-9 290-319), particularly posttraumatic stress disorder and mood/anxiety disorders, assigned through November 2006. Results: 15.8% met criteria for TBI (13.4% mild, 2.4% moderate-severe TBI), 35.0% other head injury, and 49.2% non-head injury. Multivariate logistic regression suggested lower rates of posttraumatic stress disorder and mood/anxiety disorders among those with mild and moderate-severe TBI. Conclusions: These findings could reflect a problem with differential diagnosis or, conversely, a low rate of self-presentation for symptoms. Further research is needed to elucidate the psychological consequences, clinical implications, and overall impact of TBI among military combat veterans.	[MacGregor, Andrew J.; Shaffer, Richard A.; Galarneau, Michael R.; Corson, Karen S.] USN, Hlth Res Ctr, San Diego, CA 92106 USA; [Dougherty, Amber L.] Sci Applications Int Corp, San Diego, CA USA; [Raman, Rema; Baker, Dewleen G.; Golomb, Beatrice A.] Univ Calif San Diego, San Diego, CA 92103 USA; [Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA USA; [Lindsay, Suzanne R.] San Diego State Univ, San Diego, CA 92182 USA	Dougherty, AL (corresponding author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil	Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine and Surgery, Washington, DC	This work was supported by the US Navy Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60819. The views and opinions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2007.0004).	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; DOBSON JE, 1989, BRIT J ORAL MAX SURG, V27, P441, DOI 10.1016/S0266-4356(89)80001-4; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Friedman MJ, 2006, POSTTRAUMATIC ACUTE; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli T WE, ABBREVIATED INJURY S; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gunderson EKE, 2005, MIL MED, V170, P172; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KIM E, 2007, J NEUROPSYCHIATRY CL, V159, P1315; Klein E, 2003, CAN J PSYCHIAT, V48, P28; LINN S, 1993, INT J EPIDEMIOL, V22, P905, DOI 10.1093/ije/22.5.905; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Price K. P., 1994, DEF LAW J, V43, P113; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shalev AY, 2001, J CLIN PSYCHIAT, V62, P4; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; *US DEP DEF, 1984, 1340 DOD US MIL ENTR; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	53	66	67	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					1	8		10.1097/HTR.0b013e3181c2993d			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800001	20051901				2021-06-18	
J	McKinlay, A; Grace, RC; Horwood, LJ; Fergusson, DM; MacFarlane, MR				McKinlay, A.; Grace, R. C.; Horwood, L. J.; Fergusson, D. M.; MacFarlane, M. R.			Long-term behavioural outcomes of pre-school mild traumatic brain injury	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						children; cohort; longitudinal; mild traumatic brain injury; psychiatric disorders	HEAD-INJURY; NEUROPSYCHOLOGICAL FUNCTION; MENTAL-DISORDERS; CHILDREN; ADOLESCENTS; RECOVERY	Background Mild traumatic brain injury (MTBI) is a leading cause of injury for children during their pre-school years. However, there is little information regarding the long-term outcomes of these injuries. Method We used fully prospective data from an epidemiological study of a birth cohort to examine behavioural effects associated with MTBI during the pre-school years. Cases of confirmed MTBI were divided into two groups, those that had received outpatient medical attention, and those that had been admitted to hospital for a brief period of observation (inpatient cases). The remainder of the cohort served as a reference control group. Results Mother/teacher ratings for behaviours associated with attention deficit/hyperactivity disorder and oppositional defiant/conduct disorder, obtained yearly from age 7 to 13, revealed evidence of deficits after inpatient MTBI (n = 21), relative to more minor outpatient injury MTBI (n = 55) and the reference control group (n = 852). For the inpatient group there was evidence of increasing deficits over years 7-13. Conclusions More severe pre-school MTBI may be associated with persistent negative effects in terms of psychosocial development. The vulnerability of pre-school children to MTBI signals a pressing need to identify high-risk cases that may benefit from monitoring and early intervention.	[McKinlay, A.; Grace, R. C.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [MacFarlane, M. R.] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		McKinlay, Audrey/0000-0001-9846-8514; Fergusson, David/0000-0002-8117-017X; Horwood, L./0000-0003-4881-1956; Grace, Randolph/0000-0003-1115-6089	Health Research Council of New ZealandHealth Research Council of New Zealand; National Child Health Research Foundation; Canterbury Medical Research Foundation; New Zealand Lottery Grants Board; New Zealand Foundation for Research Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Todd Foundation; Neurological Foundation	The Christchurch Health and Development Study has been funded by grants from the Health Research Council of New Zealand, the National Child Health Research Foundation, the Canterbury Medical Research Foundation and the New Zealand Lottery Grants Board. Audrey McKinlay was sponsored by a scholarship from the New Zealand Foundation for Research Science and Technology, a Todd Foundation award for research excellence and a Neurological Foundation grant.	ACHENBACH TM, 1978, PSYCHOL BULL, V85, P1275, DOI 10.1037/0033-2909.85.6.1275; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bergman DA, 1999, PEDIATRICS, V104, P1407; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CASEY R, 1986, PEDIATRICS, V78, P497; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FERGUSSON DM, 1991, J CHILD PSYCHOL PSYC, V32, P257, DOI 10.1111/j.1469-7610.1991.tb00305.x; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Goodman SH, 1997, J ABNORM PSYCHOL, V106, P3, DOI 10.1037/0021-843X.106.1.3; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Horowitz I, 1983, Int Rehabil Med, V5, P32; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M	35	66	66	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1862	1365-2214		CHILD CARE HLTH DEV	Child Care Health Dev.	JAN	2010	36	1					22	30		10.1111/j.1365-2214.2009.00947.x			9	Psychology, Developmental; Pediatrics	Psychology; Pediatrics	536BF	WOS:000273016400003	19250251				2021-06-18	
J	Geyer, C; Ulrich, A; Grafe, G; Stach, B; Till, H				Geyer, Chrisrian; Ulrich, Anett; Graefe, Gerd; Stach, Barbara; Till, Holger			Diagnostic value of S100B and neuron-specific enolase in mild pediatric traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						S100B; neuron-specific enolase; biomarkers; traumatic brain injury	S-100 PROTEIN MEASUREMENTS; BIOCHEMICAL SERUM MARKERS; SEVERE HEAD-INJURY; CHILDREN; DAMAGE; BLOOD; PREDICTOR; BIOMARKERS; APOPTOSIS; PATHOLOGY	Object. During recent years, several biomarkers have been introduced for use in the diagnosis of traumatic brain injury (TBI). The primary objective of this investigation was to determine if S100B (or S100 calcium-binding protein B) and neuron-specific enolase (NSE) serum concentrations can effectively be used to discriminate between symptomatic and asymptomatic children with minor head trauma. Methods. The authors conducted a prospective clinical study that involved patients age 6 months to 15 years who had sustained minor head trauma. Children with concomitant extracranial injuries were excluded. Blood samples were obtained within 6 hours of injury to measure S100B and NSE levels in serum. The authors defined 2 diagnostic groups: a mild TBI group (patients with Glasgow Coma Scale [GCS] scores of 13-15) in whom there were clinical signs of concussion (short loss of consciousness, amnesia, nausea, vomiting, somnolence, headache, dizziness, or impaired vision) and a head contusion group (patients with a GCS score of 15) in whom symptoms were absent. Both S100B and NSE concentrations were compared between the 2 groups. Secondary end points were defined its follows: correlation of S100B/NSE and a) the presence of scalp lacerations, b) GCS score, c) age, and d) correlation between S100B and NSE. Results. One hundred forty-eight patients were enrolled (53 in the contusion group, 95 in the mild TBI group). After adjusting for differences in age and time of injury to blood sample withdrawal, there was no significant difference in S100B or NSE between patients in the 2 groups. Scalp lacerations and GCS score had no affect on posttraumatic S100B or NSE concentrations. The correlation between S100B and NSE was significant. Both markers showed a significant negative correlation with age. Conclusions. The authors demonstrated that S100B and NSE do not discriminate between symptomatic and asymptomatic children with minor head injury. There seem to be limitations in marker sensitivity when investigating pediatric patients with mild TBI. (DOI: 10.317112009.5.PEDS08481)	[Geyer, Chrisrian; Ulrich, Anett; Graefe, Gerd; Till, Holger] Univ Leipzig, Dept Pediat Surg, D-04103 Leipzig, Germany; [Stach, Barbara] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany	Geyer, C (corresponding author), Univ Leipzig, Dept Pediat Surg, Liebigstr 20A, D-04103 Leipzig, Germany.	christian.geyer@medizin.uni-leipzig.de					Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BERTHOLD F, 1991, In Vivo (Attiki), V5, P245; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Cotena S, 2006, J NEUROSURG, V104, P435, DOI 10.3171/ped.2006.104.6.435; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELDIK LJV, 1991, BRAIN RES, V542, P280; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Fulle S, 2000, EXP PHYSIOL, V85, P243; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Meyer S, 2006, KLIN PADIATR, V218, P49, DOI 10.1055/s-2005-836607; Park ES, 2004, BRAIN DEV-JPN, V26, P190, DOI 10.1016/S0387-7604(03)00126-8; Portela LVC, 2002, CLIN CHEM, V48, P950; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van Passel R, 2001, Eur J Paediatr Neurol, V5, P15, DOI 10.1053/ejpn.2001.0399; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	48	66	74	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2009	4	4					339	344		10.3171/2009.5.PEDS08481			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	503FS	WOS:000270519400010	19795965				2021-06-18	
J	Liu-DeRyke, X; Collingridge, DS; Orme, J; Roller, D; Zurasky, J; Rhoney, DH				Liu-DeRyke, Xi; Collingridge, Dave S.; Orme, James; Roller, Dean; Zurasky, John; Rhoney, Denise H.			Clinical Impact of Early Hyperglycemia During Acute Phase of Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Hyperglycemia; Glucose; Glucose control; Traumatic brain injury; Mortality	INTENSIVE INSULIN THERAPY; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; HEAD-INJURY; STROKE-ASSOCIATION; LACTATE LEVELS; GLUCOSE; MICRODIALYSIS; GUIDELINES; MANAGEMENT; COUNCIL	While tight glucose control has been widely adopted in the critical care setting, the optimal target glucose level following acute traumatic brain injury (TBI) remains debatable. This observational study was conducted to delineate the relationship between glucose levels and clinical outcomes during acute phase (first 5 days) of TBI. We retrospectively identified 429 TBI patients admitted to the intensive care unit (ICU) from January 2005 to December 2006. Of those, 380 patients were retained for final analysis. Collected data included demographics, admission Glasgow Coma Scale (GCS), and APACHE II, glucose on admission and during the first 5 days of admission, and insulin use. Clinical outcomes included mortality, ICU, and hospital length of stay. The overall hospital mortality was 13.2% (n = 50). Demographics were similar between survivor and nonsurvivor groups; however, nonsurvivors were older and had worse disease severity on admission. Nonsurvivors also had significantly higher glucose levels at admission and during the first 24 h of admission (P < 0.001). Based on the receiver operating characteristic (ROC) curve, admission and day-1 peak glucose were better predictors for mortality compared to hospital days 2-5 glucose levels, with day-1 peak glucose being the best predictor of mortality (AUC = 0.820). A Kaplan-Meier survival analysis also showed that patients with glucose < 160 mg/dl during the first day of ICU admission had a significantly better survival rate compared to those with glucose a parts per thousand yen160 mg/dl (P < 0.001). Two glucose bands, < 60 and a parts per thousand yen160 mg/dl, were identified to be associated with increased mortality irrespective of injury severity (OR = 1.130; 95% CI 1.034-1.235; P = 0.007; OR = 1.034; 95% CI 1.021-1.047, P < 0.001; respectively). Findings from our study suggest a glucose level a parts per thousand yen160 mg/dl within the first 24 h of admission following TBI is associated with poor outcomes irrespective of severity of injury, and this presents a timeframe for which active therapeutic interventions may improve clinical outcomes. Prospective efficacy trials are needed to corroborate these findings.	[Liu-DeRyke, Xi] Orlando Reg Med Ctr Inc, Orlando, FL 32806 USA; [Collingridge, Dave S.] LDS Hosp, Stat Data Ctr, Salt Lake City, UT 84146 USA; [Rhoney, Denise H.] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA	Liu-DeRyke, X (corresponding author), Orlando Reg Med Ctr Inc, 1414 Kuhl Ave,MP 180, Orlando, FL 32806 USA.	xi.liu@orlandohealth.com; David.collingridge@imail.org; James.orme@imail.org; Dean.roller@imail.org; John.zurasky@imail.or					Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Diringer MN, 2006, CRIT CARE MED, V34, P930, DOI 10.1097/01.CCM.0000202433.99341.D6; Godoy DA, 2008, NEUROCRIT CARE, V9, P217, DOI 10.1007/s12028-008-9063-1; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lee T H, 1991, J Formos Med Assoc, V90, P465; Levetan Claresa S, 2004, Endocr Pract, V10 Suppl 2, P34; MARGULIES DR, 1994, AM SURGEON, V60, P387; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; POUNGVARIN N, 1990, Journal of the Medical Association of Thailand, V73, P206; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4; 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209	27	66	75	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					151	157		10.1007/s12028-009-9228-6			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300004	19479209				2021-06-18	
J	Haider, AH; Crompton, JG; Oyetunji, T; Stevens, KA; Efron, DT; Kieninger, AN; Chang, DC; Cornwell, EE; Haut, ER				Haider, Adil H.; Crompton, Joseph G.; Oyetunji, Tolulope; Stevens, Kent A.; Efron, David T.; Kieninger, Alicia N.; Chang, David C.; Cornwell, Edward E., III; Haut, Elliott R.			Females have fewer complications and lower mortality following trauma than similarly injured males: A risk adjusted analysis of adults in the National Trauma Data Bank	SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the Society-of-University-Surgeons/4th Annual Academic Surgical Congress	FEB 03-06, 2009	Ft Myers, FL	Soc Univ Surg, Assoc Acad Surg			GENDER DIMORPHISM; SEXUAL-DIMORPHISM; HEMORRHAGIC-SHOCK; BRAIN-INJURY; OUTCOMES; MULTICENTER; SURVIVAL; AGE	Background. Studies of sexual dimorphism in trauma outcomes suggest that women have a survival advantage compared to equivalently injured. men. It is unknown if this gender disparity is mediated by potentially life-threatening complications. Objective. To determine (1) if there is a sex-based differences in the odds of developing inpatient complications after trauma, and (2) if are these complications associated with death among trauma patients. Methods. Review of adult trauma patients admitted to hospitals in the National Trauma Data Bank that report complications. Patient and injury severity covariates were adjusted using multiple logistic regression and the independent affect, of sex on developing complications and associated mortality was determined. Results. A total of 681, 730 adult patients met the inclusion criteria of hospital admission >= 3 days. Women demonstrated a 21% lower adjusted risk of death compared to males (OR 0.79, 95% CI 0.76-0.83). Females had decreased adjusted odds of developing life-threatening complications including pneumonia, acute respiratory distress syndrome, acute renal failure and pulmonary embolism. However, when compared to males with 1 fie-threatening complications, females with complications were found to be at greater risk of dying. Conclusion. This study demonstrates that women are less likely than men to develop inpatient complications, suggesting that the survival advantage among women after traumatic injury may involve a reduced susceptibility to developing life-threatening complications. (Surgery 2009;146:308-15.)	[Haider, Adil H.] Johns Hopkins Univ, Sch Med, Dept Surg, Trauma Outcomes Res Grp,Div Acute Care Surg, Baltimore, MD 21287 USA; [Oyetunji, Tolulope; Cornwell, Edward E., III] Howard Univ, Coll Med, Washington, DC USA	Haider, AH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Trauma Outcomes Res Grp,Div Acute Care Surg, 600 N Wolfe St,Halsted 610, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Oyetunji, Tolulope A/D-1447-2011; Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X; Oyetunji, Tolulope/0000-0003-3039-7195			*AM COLL SURG COMM, 2008, NTDB VERS 7 0; ANGELE MK, 1998, SURG FORUM, V49, P43; BAKER WA, 1976, INORG CHIM ACTA, V16, P5, DOI 10.1016/S0020-1693(00)91684-0; Berkowitz DM, 2007, CHEST, V132, P1725, DOI 10.1378/chest.07-2001; Bowles BJ, 2003, INJURY, V34, P27; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Croce MA, 2002, J TRAUMA, V53, P889, DOI 10.1097/00005373-200211000-00013; Deitch EA, 2007, ANN SURG, V246, P447, DOI 10.1097/SLA.0b013e318148566; Diodato MD, 2001, CYTOKINE, V14, P162, DOI 10.1006/cyto.2001.0861; Frink M, 2007, SHOCK, V27, P151, DOI 10.1097/01.shk.0000239767.64786.de; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, ARCH SURG-CHICAGO, V142, P875, DOI 10.1001/archsurg.142.9.875; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; Harbrecht BG, 2001, J TRAUMA, V51, P887, DOI 10.1097/00005373-200111000-00010; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; Magnotti LJ, 2008, J AM COLL SURGEONS, V206, P984, DOI 10.1016/j.jamcollsurg.2007.12.038; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P935, DOI 10.1001/archsurg.134.9.935; Rappold JF, 2002, J TRAUMA, V53, P436, DOI 10.1097/00005373-200209000-00007; Sperry JL, 2008, J LEUKOCYTE BIOL, V83, P499, DOI 10.1189/jlb.0607360; Sperry JL, 2008, CRIT CARE MED, V36, P1838, DOI 10.1097/CCM.0b013e3181760c14; Stallion A, 2007, J TRAUMA, V62, P1262; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	26	66	67	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2009	146	2					308	315		10.1016/j.surg.2009.05.006			8	Surgery	Surgery	483MY	WOS:000268972200025	19628090				2021-06-18	
J	Longhi, L; Perego, C; Ortolano, F; Zanier, ER; Bianchi, P; Stocchetti, N; McIntosh, TK; De Simoni, MG				Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Zanier, Elisa R.; Bianchi, Paolo; Stocchetti, Nino; McIntosh, Tracy K.; De Simoni, Maria Grazia			C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; inflammation; complement; neuroprotection	ISCHEMIA-REPERFUSION INJURY; MEMBRANE ATTACK COMPLEX; HEAD-INJURY; C1 INHIBITOR; C1-ESTERASE INHIBITOR; LEUKOCYTE ADHESION; GENE-EXPRESSION; NERVOUS-SYSTEM; MOTOR FUNCTION; FACTOR-B	Objective. The aim of the study was to evaluate the effects of C1-inhibitor (C1-INH), an endogenous inhibitor of complement and kinin systems, on neurobehavioral and histological outcome following controlled cortical impact brain injury. Design: Experimental prospective randomized study in mice. Setting. Experimental laboratory. Subjects: Male C5781/6 mice (n = 81). Interventions: Mice were subjected to controlled cortical impact brain injury followed by an intravenous bolus of either C1-INH (15 U either at 10 minutes or 1 hour postinjury) or saline (equal volume, 150 mu l at 10 minutes postinjury). Sham-operated mice received identical surgery and saline injection without brain injury. Neurological motor function was evaluated weekly for 4 weeks using the Composite Neuroscore. Cognitive function was evaluated at 4 weeks postinjury using the Morris Water Maze. Histological outcome was performed by measuring the contusion volume at 1 week and 4 weeks postinjury. Measurements and Main Results., Brain-injured mice receiving C1-INH at 10 minutes postinjury showed attenuated motor deficits, cognitive dysfunction and reduced contusion volume compared to brain-injured mice receiving saline. Mice receiving C1-INH at 1 hour postinjury showed reduced motor deficits compared to brain-injured mice receiving saline, but no significantly different cognitive and histological outcome. Immunohistochemical analysis showed that 20 minutes after infusion, C1-INH was localised on endothelial cells and in brain tissue surrounding brain capillaries of the injured hemisphere. Conclusion: Our results show that post-traumatic administration of C1-INH attenuates neuro-behavioral deficits and histological damage associated with traumatic brain injury. (Crit Care Med 2009; 37:659-665)	[Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Zanier, Elisa R.; De Simoni, Maria Grazia] Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, I-20157 Milan, Italy; [Longhi, Luca; Ortolano, Fabrizio; Zanier, Elisa R.; Bianchi, Paolo; Stocchetti, Nino] Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, Milan, Italy	De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.	desimoni@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; Longhi, Luca/AAF-9903-2021; Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020; Perego, Carlo/AAA-6513-2020	De Simoni, Maria Grazia/0000-0001-6695-5297; Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Perego, Carlo/0000-0002-0259-0003; Zanier, Elisa/0000-0002-3011-8718; Ortolano, Fabrizio/0000-0003-1996-948X			Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Cai SH, 2005, J IMMUNOL, V174, P6462, DOI 10.4049/jimmunol.174.10.6462; Cai SH, 2003, J IMMUNOL, V171, P4786, DOI 10.4049/jimmunol.171.9.4786; Caliezi C, 2000, PHARMACOL REV, V52, P91; Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003; De Simoni MG, 2004, AM J PATHOL, V164, P1857, DOI 10.1016/S0002-9440(10)63744-3; De Simoni MG, 2003, J CEREBR BLOOD F MET, V23, P232, DOI 10.1097/01.WCB.0000046146.31247.A1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hartman RE, 2002, J NEUROSCI, V22, P10083; Horstick G, 2002, IMMUNOBIOLOGY, V205, P552, DOI 10.1078/0171-2985-00154; Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609; Kerr FK, 2008, MOL IMMUNOL, V45, P670, DOI 10.1016/j.molimm.2007.07.008; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; STORINI C, 2007, SOC NEUR ANN M; Storini C, 2006, J PHARMACOL EXP THER, V318, P849, DOI 10.1124/jpet.106.105064; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Whalen MJ, 1998, ACT NEUR S, V71, P212; Xiong ZQ, 2003, J NEUROSCI, V23, P955; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	53	66	66	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2009	37	2					659	665		10.1097/CCM.0b013e318195998a			7	Critical Care Medicine	General & Internal Medicine	402LI	WOS:000263014800037	19114897				2021-06-18	
J	McLean, SA; Kirsch, NL; Tan-Schriner, CU; Sen, A; Frederiksen, S; Harris, RE; Maixner, W; Maio, RF				McLean, Samuel A.; Kirsch, Ned L.; Tan-Schriner, Cheribeth U.; Sen, Ananda; Frederiksen, Shirley; Harris, Richard E.; Maixner, William; Maio, Ronald F.			Health status, not head injury, predicts concussion symptoms after minor injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SICKNESS IMPACT PROFILE; BLOOD-PRESSURE; PAIN SENSITIVITY; SCALE; CARE; POLYMORPHISMS; QUESTIONNAIRE; INTENSITY	Objective: Postconcussion (PC) syndrome etiology remains poorly understood. We sought to examine predictors of persistent PC symptoms after minor injury. Methods: Health status, symptom, and injury information were obtained on a sample of patients presenting to the emergency department after minor injury. Postconcussion and cognitive symptoms were assessed at I, 3, and 12 months. Results: Among 507 patients enrolled, 339 had head injury. Repeated-measures logistic regression modeling of PC and cognitive symptom presence across time indicated that baseline mental health status and physical health status were most predictive of persistent symptoms. In contrast, head injury presence did not predict persistent PC syndrome. Discussion: Baseline mental health status and physical health status were associated with persistent PC syndrome after minor injury, but head injury status was not. Further studies of PC syndrome pathogenesis are needed. (C) 2009 Elsevier Inc. All rights reserved.	[McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA; [McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC 27599 USA; [Sen, Ananda] Univ Michigan, Med Ctr, Ctr Stat Consulting & Res, Ann Arbor, MI 48109 USA; [Maio, Ronald F.] Univ Michigan, Med Ctr, Injury Res Ctr, Ann Arbor, MI 48109 USA; [Tan-Schriner, Cheribeth U.] Michigan Publ Hlth Inst, Okemos, MI 48864 USA; [Maixner, William] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC 27599 USA	McLean, SA (corresponding author), Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA.	samclean@email.unc.edu		McLean, Samuel/0000-0001-9482-3582	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR523223-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 RR017607-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12RR017607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K23AR050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [P01DE007509] Funding Source: NIH RePORTER	This study was funded by the Centers for Disease Control (R49/CCR523223-01). Doctor McLean is supported by NIH K23 RR017607-01.	Al-Windi A, 2004, J PSYCHOSOM RES, V57, P307, DOI 10.1016/S0022-3999(03)00612-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bragdon EE, 1997, INT J BEHAV MED, V4, P17, DOI 10.1207/s15327558ijbm0401_2; Bruehl S, 2004, NEUROSCI BIOBEHAV R, V28, P395, DOI 10.1016/j.neubiorev.2004.06.004; *CDC, 2001, M SUMM NAT CTR UNPUB; *CDCP AG, 2001, MILD TRAUM INJ TOOL; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; DIATCHENKO L, 2006, AM J MOL GE IN PRESS; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015; Fillingim RB, 1998, INT J PSYCHOPHYSIOL, V30, P313, DOI 10.1016/S0167-8760(98)00024-5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; Girdler SS, 1998, PSYCHOSOM MED, V60, P736, DOI 10.1097/00006842-199811000-00016; KAY DWK, 1971, LANCET, V2, P1052; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Li C, 2005, MATURITAS, V52, P306, DOI 10.1016/j.maturitas.2005.05.005; Maixner W, 1997, PSYCHOSOM MED, V59, P503, DOI 10.1097/00006842-199709000-00007; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McBeth J, 2001, ARTHRITIS RHEUM, V44, P940, DOI 10.1002/1529-0131(200104)44:4<940::AID-ANR151>3.3.CO;2-J; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; *ORG WH, 1978, ICD 9 CLASS MENT BEH; Pfleeger M, 1997, INT J PSYCHOPHYSIOL, V27, P161, DOI 10.1016/S0167-8760(97)00058-5; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUTHERFORD WH, 1977, LANCET, V1, P1; Stein MB, 2005, NEUROPSYCHOPHARMACOL, V30, P2092, DOI 10.1038/sj.npp.1300787; SYMONDS C, 1962, LANCET, V1, P1; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wolfe F, 2003, J RHEUMATOL, V30, P369; Wolfe F, 2006, J RHEUMATOL, V33, P2291; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941	39	66	66	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	FEB	2009	27	2					182	190		10.1016/j.ajem.2008.01.054			9	Emergency Medicine	Emergency Medicine	416DN	WOS:000263985600009	19371526				2021-06-18	
J	Dejda, A; Jolivel, V; Bourgault, S; Seaborn, T; Fournier, A; Vaudry, H; Vaudry, D				Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Fournier, Alain; Vaudry, Hubert; Vaudry, David			Inhibitory Effect of PACAP on Caspase Activity in Neuronal Apoptosis: A Better Understanding Towards Therapeutic Applications in Neurodegenerative Diseases	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article; Proceedings Paper	8th International Symposium on VIP, PACAP and Related Peptides	SEP 03-08, 2007	Manchester, VT			Apoptosis; Caspase; PACAP; Neuroprotection	CYCLASE-ACTIVATING POLYPEPTIDE; CEREBELLAR GRANULE NEURONS; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; VASOACTIVE INTESTINAL POLYPEPTIDE; TRANSIENT CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; DIPEPTIDYL-PEPTIDASE-IV; SPINAL-CORD-INJURY	Programmed cell death, which is part of the normal development of the central nervous system, is also implicated in various neurodegenerative disorders. Cysteine-dependent aspartate-specific proteases (caspases) play a pivotal role in the cascade of events leading to apoptosis. Many factors that inhibit cell death have now been identified, but the underlying mechanisms are not fully understood. Pituitary adenylate cylase-activating polypeptide (PACAP) has been shown to exert neurotrophic activities during development and to prevent neuronal apoptosis induced by various insults such as ischemia. Most of the neuroprotective effects of PACAP are mediated through the PAC1 receptor. This receptor activates a transduction cascade of second messengers to stimulate Bcl-2 expression, which inhibits cytochrome c release and blocks the activation of caspases. The inhibitory effect of PACAP on the apoptotic cascade suggests that selective, stable, and potent PACAP derivatives could potentially be of therapeutic value for the treatment of post-traumatic and/or chronic neurodegenerative processes.	[Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Vaudry, Hubert; Vaudry, David] INSERM, Lab Cellular & Mol Neuroendocrinol, U413, Mont St Aignan, France; [Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Vaudry, Hubert; Vaudry, David] Univ Rouen, European Inst Peptide Res, IFRMP 23, F-76821 Mont St Aignan, France; [Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Fournier, Alain; Vaudry, Hubert; Vaudry, David] Int Associated Lab Samuel Champlain, Mont St Aignan, France; [Dejda, Agnieszka] Polish Acad Sci, Inst Med Biol, Lodz, Poland; [Jolivel, Valerie] QUIDD, F-76801 St Etienne, France; [Bourgault, Steve; Fournier, Alain] Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada	Vaudry, D (corresponding author), INSERM, Lab Cellular & Mol Neuroendocrinol, U413, Mont St Aignan, France.	hubert.vaudry@univ-rouen.fr; david.vaudry@univ-rouen.fr	VAUDRY, David/M-1454-2018; Seaborn, Tommy/J-1638-2012; Jolivel, Valerie/A-6810-2017	VAUDRY, David/0000-0003-3567-7452; Jolivel, Valerie/0000-0002-4114-4559			Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmad M, 1997, CANCER RES, V57, P615; Allais A, 2007, EUR J NEUROSCI, V25, P2604, DOI 10.1111/j.1460-9568.2007.05535.x; Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; AUBERT N, 2005, REGULATORY PEPTIDES, V130, P156; Aubert N, 2006, J NEUROCHEM, V99, P1237, DOI 10.1111/j.1471-4159.2006.04148.x; BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BASILLE M, 1994, DEV BRAIN RES, V82, P81, DOI 10.1016/0165-3806(94)90150-3; Beebe X, 2008, BIOORG MED CHEM LETT, V18, P2162, DOI 10.1016/j.bmcl.2008.01.052; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Birk S, 2007, REGUL PEPTIDES, V140, P185, DOI 10.1016/j.regpep.2006.12.010; BOURGAULT S, 2008, PEPTIDES IN PRESS, DOI DOI 10.1016/J.PEPTIDES.2008.01.022; Braun JS, 2007, EXP NEUROL, V206, P183, DOI 10.1016/j.expneurol.2007.03.032; Cameron DB, 2007, NEUROSCIENCE, V146, P697, DOI 10.1016/j.neuroscience.2007.02.025; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chang JY, 1996, NEUROSCI LETT, V206, P181, DOI 10.1016/S0304-3940(96)12468-X; Chauvier D, 2005, APOPTOSIS, V10, P1243, DOI 10.1007/s10495-005-1681-x; Chen J, 1998, J NEUROSCI, V18, P4914; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; David C, 2005, J MOL NEUROSCI, V27, P91, DOI 10.1385/JMN:27:01:91; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Dejda A, 2005, PHARMACOL REP, V57, P307; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Doberer D, 2007, EUR J CLIN INVEST, V37, P665, DOI 10.1111/j.1365-2362.2007.01832.x; Dohi K, 2002, REGUL PEPTIDES, V109, P83, DOI 10.1016/S0167-0115(02)00190-8; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Falluel-Morel A, 2004, J NEUROCHEM, V91, P1231, DOI 10.1111/j.1471-4159.2004.02810.x; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Gao Z, 2007, J BIOL CHEM, V282, P30718, DOI 10.1074/jbc.M705258200; Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3; Graf D, 2007, ARCH BIOCHEM BIOPHYS, V462, P162, DOI 10.1016/j.abb.2007.03.029; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han P, 2005, NEUROSCIENCE, V134, P745, DOI 10.1016/j.neuroscience.2005.05.007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Inoue H, 2003, EMBO J, V22, P6665, DOI 10.1093/emboj/cdg634; Journot L, 1998, ANN NY ACAD SCI, V865, P100, DOI 10.1111/j.1749-6632.1998.tb11168.x; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kang SJ, 2002, CELL DEATH DIFFER, V9, P1115, DOI 10.1038/sj.cdd.4401087; Katahira M., 2003, Regulatory Peptides, V115, P49; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li M, 2007, PEPTIDES, V28, P1891, DOI 10.1016/j.peptides.2007.05.002; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu HT, 2005, J BIOL CHEM, V280, P11578, DOI 10.1074/jbc.M414385200; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Malagelada C, 2005, NEUROBIOL DIS, V20, P27, DOI 10.1016/j.nbd.2005.01.028; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MASUO Y, 1994, NEUROSCI LETT, V170, P43, DOI 10.1016/0304-3940(94)90234-8; Matsui T, 2006, J NEUROPATH EXP NEUR, V65, P508, DOI 10.1097/01.jnen.0000229238.05748.12; Mei YA, 2004, EUR J NEUROSCI, V19, P1446, DOI 10.1111/j.1460-9568.2004.03227.x; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; NANDHA KA, 1991, J ENDOCRINOL, V129, P69, DOI 10.1677/joe.0.1290069; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; Niewiadomski P, 2002, POL J PHARMACOL, V54, P717; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Ohtaki H, 2005, REGUL PEPTIDES, V130, P149; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; Onoue S, 2002, FEBS LETT, V522, P65, DOI 10.1016/S0014-5793(02)02886-7; Onyuksel H, 2006, PEPTIDES, V27, P2271, DOI 10.1016/j.peptides.2006.03.003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Sakamaki K, 2002, CELL DEATH DIFFER, V9, P1196, DOI 10.1038/sj.cdd.4401090; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SAWANGJAROEN K, 1992, PEPTIDES, V13, P1029, DOI 10.1016/0196-9781(92)90068-E; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Sun CH, 2007, P NATL ACAD SCI USA, V104, P7875, DOI 10.1073/pnas.0611397104; SUZUKI H, 1995, LIFE SCI, V57, P1451, DOI 10.1016/0024-3205(95)02108-U; Tamas A, 2006, ANN NY ACAD SCI, V1070, P570, DOI 10.1196/annals.1317.083; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tokuda E, 2007, BRAIN RES, V1148, P234, DOI 10.1016/j.brainres.2007.02.087; Troy CM, 2000, J NEUROSCI, V20, P1386; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 2004, REGUL PEPTIDES, V123, P43, DOI 10.1016/j.regpep.2004.05.025; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Villalba M, 1997, J NEUROSCI, V17, P83; Wang G, 2005, FEBS LETT, V579, P4005, DOI 10.1016/j.febslet.2005.06.013; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2006, EMBO J, V25, P5896, DOI 10.1038/sj.emboj.7601445; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	150	66	66	1	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2008	36	1-3					26	37		10.1007/s12031-008-9087-1			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	376JP	WOS:000261180200005	18506634				2021-06-18	
J	Wade, SL; Walz, NC; Carey, JC; Williams, KM				Wade, Shari L.; Walz, Nicolay Chertkoff; Carey, JoAnne C.; Williams, Kendra M.			Preliminary Efficacy of a Web-Based Family Problem-Solving Treatment Program for Adolescents With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; online intervention; problem solving	PSYCHIATRIC-DISORDERS; SOCIAL COMPETENCE; CHILDREN; INTERVENTION; BEHAVIOR; SKILLS	Preliminary report of the efficacy of a Web-based treatment program to improve adolescent and family psychosocial functioning following traumatic brain injury (TBI). Participants: Families of 9 adolescents with TBI (2 severe and 7 moderate) injured less than 24 months ago participated in this study. Intervention: A Web-based family treatment program designed to enhance family problem solving and adjustment, as well as reduce adolescent behavioral and social problems that are common sequelae of moderate-to-severe TBI was used as intervention. The program consisted of 10 core sessions and up to 4 supplemental sessions, each consisting of self-guided Web exercises followed by a videoconference therapy session. Results: Significant improvements were found in parent-reported adolescent internalizing behaviors, self-reported adolescent depressive symptoms, parental depression, and parent-adolescent conflict. Effect sizes were in the medium-to-high range for these same contrasts. Exploratory analyses suggested that providing audio with the Web site may enhance some outcomes. Conclusions: This study provides preliminary evidence of the feasibility and efficacy of family-centered online intervention for improving adolescent and family adaptation following pediatric TBI.	[Wade, Shari L.] Univ Cincinnati, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Univ Cincinnati, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GLUECKAUF RL, 1992, REHABIL PSYCHOL, V37, P291, DOI 10.1037/0090-5550.37.4.291; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Norman S, 2006, J PSYCHIATR MENT HLT, V13, P771, DOI 10.1111/j.1365-2850.2006.01033.x; PATTERSON GR, 1988, STRESS COPING DEV CH, P235; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Puskar Kathryn, 2003, J Child Adolesc Psychiatr Nurs, V16, P71, DOI 10.1111/j.1744-6171.2003.tb00350.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; ROBIN AL, 1989, NEGOTIATING PARENT A; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCHWARTZ D, 2007, MONITOR PSYCHOL, V38, P54; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Spence SH, 2003, J CONSULT CLIN PSYCH, V71, P3, DOI 10.1037/0022-006X.71.1.3; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	33	66	66	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2008	23	6					369	377		10.1097/01.HTR.0000341432.67251.48			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	379WZ	WOS:000261428300002	19033829				2021-06-18	
J	Bivona, U; Ciurli, P; Barba, C; Onder, G; Azicnuda, E; Silvestro, D; Mangano, R; Rigon, J; Formisano, R				Bivona, Umberto; Ciurli, Paola; Barba, Carmen; Onder, Graziano; Azicnuda, Eva; Silvestro, Daniela; Mangano, Renata; Rigon, Jessica; Formisano, Rita			Executive function and metacognitive self-awareness after Severe Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						executive functions; metacognitive self-awareness; set shifting ability; perseverative responses; TBI rehabilitation	CLOSED-HEAD-INJURY; COMPETENCE RATING-SCALE; MULTIDIMENSIONAL APPROACH; BEHAVIORAL LIMITATIONS; PRACTICAL SCALE; REHABILITATION; DEFICITS; DYSFUNCTION; ADULTS; QUESTIONNAIRE	The objective of this Study is to identify the clinical, neuropsychological, neuropsychiatric, and functional variables that correlate with metacognitive self-awareness (SA) in severe traumatic brain injury (TBI) outpatients and to assess the influence of the same variables oil the sensory-motor, cognitive, and behavioral-affective indicators of SA. This cross-sectional observational study evaluated 37 outpatients from May 2006 to June 2007 in a neurorehabilitation hospital on the basis of the following inclusion criteria: (1) age >= 15 years; (2) diagnosis of severe TBI (Glasgow Coma Scale, GCS <= 8); (3) posttraumatic amnesia (PTA) resolution; (4) capacity to undergo formal psychometric evaluation despite cognitive and sensory-motor deficits; (5) absence of aphasia; (6) availability of informed consent. A neuropsychological battery was used to evaluate attention, memory, and executive functions. SA was assessed by the awareness questionnaire (AQ), administered to both patients and relatives. Decreased metacognitive self-awareness is significantly correlated with increased problems in some components of executive system, even when the AQ subscales were considered separately. The significant correlation found between some components of executive system and metacognitive self-awareness confirmed the importance of addressing this issue to treat SA contextually in the rehabilitation of executive functions.	[Bivona, Umberto; Ciurli, Paola; Azicnuda, Eva; Silvestro, Daniela; Mangano, Renata; Rigon, Jessica; Formisano, Rita] Fdn Santa Lucia, Unita Post Coma, I-00179 Rome, Italy; [Barba, Carmen] Childrens Hosp A Meyer, Pediat Neurol Unit, Florence, Italy; [Onder, Graziano] Catholic Univ, Dept Geriatr, Rome, Italy	Bivona, U (corresponding author), Fdn Santa Lucia, Unita Post Coma, Via Ardeatina 306, I-00179 Rome, Italy.	u.bivona@hsantalucia.it	Azicnuda, Eva/K-9010-2016; MANGANO, Giuseppa Renata/M-5292-2014	MANGANO, Giuseppa Renata/0000-0001-6552-4014; barba, carmen/0000-0001-5445-5842			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; APOLLONIO I, 2005, J NEUROL SCI, V26, P108; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Cicerone K. D., 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; CROSSON C, 1989, J HEAD TRAUMA REHAB, V4, P46; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Heaton R., 1993, WISCONSIN CARD SORTI; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIGHT LL, 1992, HDB AGING COGNITION; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Mukhopadhyay P, 2008, PROG BRAIN RES, V168, P95, DOI 10.1016/S0079-6123(07)68008-X; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Phillips LH, 1999, DEV NEUROPSYCHOL, V15, P249, DOI 10.1080/87565649909540748; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schwartz S, 2003, BRAIN LANG, V87, P400, DOI 10.1016/S0093-934X(03)00141-X; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRUDEL TM, 1998, REHABIL PSYCHOL, V43, P276; Unterrainer JM, 2006, J PHYSIOL-PARIS, V99, P308, DOI 10.1016/j.jphysparis.2006.03.014; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zimmerman P., 1992, TEST BATTERIE AUFMER	59	66	67	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					862	868		10.1017/S1355617708081125			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400016	18764981	Bronze			2021-06-18	
J	O'Phelan, K; McArthur, DL; Chang, CWJ; Green, D; Hovda, DA				O'Phelan, Kristine; McArthur, David L.; Chang, Cherylee W. J.; Green, Deborah; Hovda, David A.			The impact of substance abuse on mortality in patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; methamphetamine; alcohol; outcome	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; METHAMPHETAMINE USERS; ALCOHOL-ABUSE; HEAD-INJURY; METABOLISM; MARIJUANA; ABNORMALITIES; HYPERACTIVITY; PERFUSION	Background. Drug and alcohol use are common in neurotrauma patients. Despite growing methamphetamine use there are few studies of the impact of methamphetamine use on outcome after traumatic brain injury (TBI). Methods: We conducted a retrospective review of 5-years of data from a trauma database. Inclusion criteria included severe TBI and diagnosis codes indicating head injury. The entire database was analyzed and then a subset of patients with complete toxicology data were examined separately. Primary outcome was mortality. Results. Four hundred eighty-three patients were included. Toxicology re-suits were available for 52.6% of patients. Alcohol, amphetamines, and cannabis were the most commonly detected substances. Overall mortality was 50.9%. When the group with complete tox screen data were analyzed, a toxicology screen that was positive for alcohol or amphetamine was associated with decreased mortality with an odds ratio of 0.23 (CI: 0.10-0.56, p = 0.001) and 0.25 (CI: 0.08-0.79, p = 0.02), respectively. When the subset of patients for whom toxicology data were available was analyzed the amphetamine-positive group was more likely to use cannabis and less likely to use alcohol. Conclusions. We unexpectedly found alcohol and methamphetamine use to be associated with decreased mortality. Neurotoxic and possible neuroprotective mechanisms of these substances are discussed as well as possible interactions between cannabis and methamphetamine. The potential influence of psycho-social factors are also considered. Prospective studies are needed to further investigate the effects of drug and alcohol use on outcome after severe TBI.	[O'Phelan, Kristine; Chang, Cherylee W. J.; Green, Deborah] Queens Med Ctr, Inst Neurosci, Honolulu, HI 96813 USA; [O'Phelan, Kristine; Chang, Cherylee W. J.; Green, Deborah] Univ Hawaii, John A Burns Sch Med, Dept Med & Surg, Honolulu, HI 96822 USA; [McArthur, David L.; Hovda, David A.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA	O'Phelan, K (corresponding author), Queens Med Ctr, Inst Neurosci, 1301 Punchbowl St, Honolulu, HI 96813 USA.	kophelan@queens.org	McArthur, David/E-6442-2013; Chang, Cherylee/ABG-2080-2020; Chang, Cherylee/Y-8450-2019	McArthur, David/0000-0003-3385-1314; Green-LaRoche, MD, Deborah/0000-0001-8158-0788			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Chang L, 2002, PSYCHIAT RES-NEUROIM, V114, P65, DOI 10.1016/S0925-4927(02)00004-5; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; ERNST M, 1994, PSYCHOPHARMACOL BULL, V30, P219; Gonzalez R, 2004, DRUG ALCOHOL DEPEN, V76, P181, DOI 10.1016/j.drugalcdep.2004.04.014; Guilarte TR, 2003, NEUROSCIENCE, V122, P499, DOI 10.1016/S0306-4522(03)00476-7; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Mathew RJ, 2002, PSYCHIAT RES-NEUROIM, V116, P173, DOI 10.1016/S0925-4927(02)00069-0; MATOCHIK JA, 1993, NEUROPSYCHOPHARMACOL, V8, P377, DOI 10.1038/npp.1993.38; O'Leary DS, 2002, NEUROPSYCHOPHARMACOL, V26, P802, DOI 10.1016/S0893-133X(01)00425-0; R Development Core Team, 2007, R LANG ENV STAT COMP; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson PM, 2004, J NEUROSCI, V24, P6028, DOI 10.1523/JNEUROSCI.0713-04.2004; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; Tominaga GT, 2004, ARCH SURG-CHICAGO, V139, P844, DOI 10.1001/archsurg.139.8.844; Volkow ND, 2004, J NUCL MED, V45, p13N; Volkow ND, 1996, PSYCHIAT RES-NEUROIM, V67, P29, DOI 10.1016/0925-4927(96)02817-X; Voytek B, 2005, SYNAPSE, V57, P113, DOI 10.1002/syn.20155; Wang Y, 2001, STROKE, V32, P775, DOI 10.1161/01.STR.32.3.775; WILCOX RR, 2007, INTRO ROBUST ESTIMAT; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOLKIN A, 1987, PSYCHOPHARMACOLOGY, V92, P241; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	31	66	66	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2008	65	3					674	677		10.1097/TA.0b013e31817db0a5			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	350BC	WOS:000259326400034	18784583				2021-06-18	
J	DePompei, R; Gillette, Y; Goetz, E; Xenopoulos-Oddsson, A; Bryen, D; Dowds, M				DePompei, Roberta; Gillette, Yvonne; Goetz, Elaine; Xenopoulos-Oddsson, Annette; Bryen, Diane; Dowds, Murdo			Practical applications for use of PDAs and smartphones with children and adolescents who have traumatic brain injury	NEUROREHABILITATION			English	Article						Pediatric traumatic brain injury; PDAs; smartphones; memory and organizational; intervention plan	PORTABLE ELECTRONIC DEVICES; MEMORY AID; REHABILITATION; ADULTS	It is often recommended that individuals with memory and organizational problems after a traumatic brain injury (TBI) use some type of memory device such as a paper calendar. Recently the use of electronic devices has been suggested. This article outlines data obtained from in vivo trials using personal data assistants (PDAs) and follow up in depth studies with PDAs and smartphones. These trials were conduced with individuals who had memory and organizational problems as a result of cognitive disorders of traumatic brain injury (TBI) or intellectual disability (ID) Results indicate that the use of electronic devices can enhance independent behavior. Factors influencing success include: student motivation, audible beep of the device; support for programming and troubleshooting, alterations of functions; and selection of features to motivate. Based on the result of the studies, an intervention plan for use of PDAs was developed for use by clinicians.	[DePompei, Roberta; Gillette, Yvonne; Goetz, Elaine; Xenopoulos-Oddsson, Annette; Bryen, Diane; Dowds, Murdo] Univ Akron, Sch Speech Language Pathol & Audiol, Akron, OH 44325 USA	DePompei, R (corresponding author), Univ Akron, Sch Speech Language Pathol & Audiol, Polsky 188K, Akron, OH 44325 USA.	rdepom1@uakron.edu					Carey AC, 2005, MENT RETARD, V43, P322; Cihak D., 2006, FOCUS AUTISM DEV DIS, V21, P89, DOI [10.1177/10883576060210020601, DOI 10.1177/10883576060210020601]; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; DePompei R, 2004, LEARNING COGNITIVE C; EHLHARDT L, 2008, NEUROPSYCHOL REHABIL, V1, P1; Epstein J. N., 2001, Journal of Special Education Technology, V16, P19; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Friedman J, 2007, CRIT REV, V19, P1, DOI 10.1080/08913810701497506; FRIEDMAN M, 2005, WEB ACCESSIBILITY GU; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, 2003, ACHIEVING COMMUNICAT; GILLETTE Y, 2008, PSYCHOL SCH IN PRESS; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Inglis EA, 2004, NEUROPSYCHOL REHABIL, V14, P77, DOI 10.1080/09602010343000129; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Bryen DN, 2007, INTELLECT DEV DISAB, V45, P1, DOI 10.1352/1934-9556(2007)45[1:CPUBAW]2.0.CO;2; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Smith Myles B., 2007, FOCUS AUTISM DEV DIS, V22, P96, DOI [10.1177/10883576070220021001, DOI 10.1177/10883576070220021001]; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Taber T. A., 1999, FOCUS AUTISM OTHER D, V14, P159, DOI DOI 10.1177/108835769901400305; Taber-Doughty T, 2005, RES DEV DISABIL, V26, P411, DOI 10.1016/j.ridd.2004.07.006; THONEOTTO AIT, 2003, INT J PSYCHOL, V38, P1, DOI DOI 10.1080/00207590344000169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; WADE TK, 2001, BRAIN INJURY, V14, P455; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	33	66	66	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	6					487	499					13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200005	19127002				2021-06-18	
J	Muenchberger, H; Kendall, E; Neal, R				Muenchberger, Heidi; Kendall, Elizabeth; Neal, Ronita			Identity transition following traumatic brain injury: A dynamic process of contraction, expansion and tentative balance	BRAIN INJURY			English	Article						Traumatic brain injury; rehabilitation; identity; lived experience; disability	QUALITY-OF-LIFE; CHRONIC ILLNESS; SELF-CONCEPT; HEAD-INJURY; MULTIPLE-SCLEROSIS; PERSONAL IDENTITY; BIOGRAPHICAL WORK; CRITICAL INCIDENT; HEALTH-CARE; NARRATIVES	Primary objective: The study aimed to understand turning points and processes that define the experience of identity change for individuals with brain injury. Research design: The current study applied an interpretive qualitative research design using a phenomenological approach. Qualitative 'life-story' interviewing was undertaken to explore the natural course of identity following TBI and a critical incident technique was applied to systematically examine key milestones. Methods and procedures: A purposive sample of six individuals with brain injury who represented a successive range of post-injury time frames (1-2 years, 2-5 years, 5-10 years, 10-15 years, 15-20 years and 25+ years) participated in the interviews. Main outcomes and results: Qualitative analysis indicated that identity transition was characterized by a dynamic and convoluted process of contraction, expansion and tentative balance. Conclusions: The influence of subjective processes on the development of identity highlights the inadequacy of fragmented approaches when exploring the individual experience. Findings from this study have important implications for the delivery of person-focused rehabilitation and remind one to consider with caution the usual indicators of adjustment that are often applied to brain injury rehabilitation.	[Muenchberger, Heidi; Kendall, Elizabeth; Neal, Ronita] Griffith Univ, Res Ctr Clin & Community Practice Innovat, Brisbane, Qld 4111, Australia	Muenchberger, H (corresponding author), Res Ctr Clin & Community Practice Innovat, Univ Dr, Meadowbrook, Qld 4131, Australia.	h.muenchberger@griffith.edu.au	Muenchberger, Heidi/C-8425-2009; kendall, elizabeth/F-5065-2013	Kendall, Elizabeth/0000-0003-2399-1460			Atkinson M, 1997, AM J PSYCHIAT, V154, P99; Boeije HR, 2002, SOC SCI MED, V55, P881, DOI 10.1016/S0277-9536(01)00238-6; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Care W D, 1996, J Nurs Staff Dev, V12, P27; Charmaz K, 1987, RES SOCIOLOGY HLTH C, V6, P283, DOI DOI 10.1111/1467-9566.EP10491512; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Clapton J, 2002, DISABIL REHABIL, V24, P987, DOI 10.1080/09638280210152058; Cloute K, 2008, NEUROPSYCHOL REHABIL, V18, P651, DOI 10.1080/09602010701306989; Conneeley A. L., 2002, BRIT J OCCUPATIONAL, V65, P356; Cook-Sather A, 2006, INT J LEADERSH EDUC, V9, P345, DOI 10.1080/13603120600895437; Corbin J, 1987, RES SOCIOLOGY HLTH C, V6, P249, DOI DOI 10.1046/J.1365-2648.2001.01767.X; Coyle J, 1999, SOCIOL HEALTH ILL, V21, P95, DOI 10.1111/1467-9566.00144; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; Cutcliffe JR, 1999, J ADV NURS, V30, P374, DOI 10.1046/j.1365-2648.1999.01090.x; DEMO DH, 1992, ANNU REV SOCIOL, V18, P303; Dempsey OP, 2002, FAM PRACT, V19, P611, DOI 10.1093/fampra/19.6.611; Dowswell G, 2000, J CLIN NURS, V9, P507, DOI 10.1046/j.1365-2702.2000.00411.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Faircloth CA, 2004, SOCIOL HEALTH ILL, V26, P242, DOI 10.1111/j.1467-9566.2004.00388.x; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Forss A, 2004, SOCIOL HEALTH ILL, V26, P306, DOI 10.1111/j.1467-9566.2004.00392.x; Galvin RD, 2005, SOCIOL HEALTH ILL, V27, P393, DOI 10.1111/j.1467-9566.2005.00448.x; Gilbert N., 1993, ANAL TABULAR DATA LO; Grbich C., 1999, QUALITATIVE RES HLTH; Heidegger M., 1962, BEING TIME; Hitlin S, 2003, SOC PSYCHOL QUART, V66, P118, DOI 10.2307/1519843; Hoofinen D., 2003, BRAIN INJURY, V15, P189; JOHNSON CN, 1990, CHILD DEV, V61, P962, DOI 10.1111/j.1467-8624.1990.tb02834.x; Johnson M, 2000, NURS PHILOS, V1, P134, DOI DOI 10.1046/J.1466-769X.2000.00027.X; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kirkevold M, 2002, DISABIL REHABIL, V24, P887, DOI 10.1080/09638280210142239; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kralik D, 2002, J ADV NURS, V39, P146, DOI 10.1046/j.1365-2648.2000.02254.x; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEWINGTON P, 1996, WHAT IS MEANING RECO; Little M, 1998, SOC SCI MED, V47, P1485, DOI 10.1016/S0277-9536(98)00248-2; MATHIESON CM, 1995, SOCIOL HEALTH ILL, V17, P283, DOI 10.1111/1467-9566.ep10933316; MAYS N, 1995, BRIT MED J, V320, P50; MELIA KM, 1982, J ADV NURS, V7, P327, DOI 10.1111/j.1365-2648.1982.tb00248.x; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; Newsome R, 1996, AUSTR J REHABILITATI, V2, P71; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; NORMAN IJ, 1992, J ADV NURS, V17, P590, DOI 10.1111/j.1365-2648.1992.tb02837.x; Paterson B, 2001, J ADV NURS, V34, P574, DOI 10.1046/j.1365-2648.2001.01786.x; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; Patton MQ., 1990, QUALITATIVE EVALUATI; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Price B, 1996, J ADV NURS, V24, P275, DOI 10.1046/j.1365-2648.1996.02047.x; Purves Barbara, 2004, Can J Occup Ther, V71, P173; ROBINSON I, 1990, SOC SCI MED, V30, P1173, DOI 10.1016/0277-9536(90)90257-S; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Van Gennep Arnold, 1909, RITES PASSAGE; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Ville I, 2005, SOCIOL HEALTH ILL, V27, P324, DOI 10.1111/j.1467-9566.2005.00445.x; Woolsey L. K., 1986, CANADIAN J COUNSELLI, V20, P242, DOI DOI 10.1037/H0061470; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x	62	66	66	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					979	992	PII 905451178	10.1080/02699050802530532			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900009	19005890				2021-06-18	
J	Signoretti, S; Marmarou, A; Aygok, GA; Fatouros, PP; Portella, G; Bullock, RM				Signoretti, Stefano; Marmarou, Anthony; Aygok, Gunes A.; Fatouros, Panos P.; Portella, Gina; Bullock, Ross M.			Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy	JOURNAL OF NEUROSURGERY			English	Article						diffuse brain injury; focal brain injury; mitochondrial impairment; N-acetylaspartate; trauma	SEVERE HEAD-INJURY; N-ACETYL-ASPARTATE; AXONAL INJURY; CHROMATOGRAPHIC METHOD; WHITE-MATTER; IN-VIVO; H-1 MRS; ACETYLASPARTATE; DYSFUNCTION; METABOLISM	Object. The goal of this study was to demonstrate the posttraumatic neurochemical damage in normal-appearing brain and to assess mitochondrial dysfunction by measuring N-acetylaspartate (NAA) levels in patients with severe head injuries, using proton (H-1) magnetic resonance (MR) spectroscopy. Methods. Semiquantitative analysis of NAA relative to creatine-containing compounds (Cr) and choline (Cho) was carried out from proton spectra obtained by means of chemical shift (CS) imaging and single-voxel (SV) methods in 25 patients with severe traumatic brain injuries (TBIs) (Glasgow Coma Scale scores <= 8) using a 1.5-tesla MR unit. Proton MR spectroscopy was also performed in 5 healthy volunteers (controls). Results. The SV studies in patients with diffuse TBI showed partial reduction of NAA/Cho and NAA/Cr ratios within the first 10 days after injury (means +/- standard deviations 1.59 +/- 0.46 and 1.44 +/- 0.21, respectively, in the patients compared with 2.08 +/- 0.26 and 2.04 +/- 0.3 1, respectively, in the controls; nonsignificant difference). The ratios gradually declined in all patients as time from injury increased (mean minimum values NAA/Cho 1.05 +/- 0.44 and NAA/Cr 1.05 +/- 0.30, p < 0.03 and p < 0.02, respectively). This reduction was greater in patients with less favorable outcomes. In patients with focal injuries, the periphery of the lesions revealed identical trends of NAA/Cho and NAA/Cr decrease. These reductions correlated with outcome at 6 months (p < 0.01). Assessment with multivoxel methods (CS imaging) demonstrated that, in diffuse injury, NAA levels declined uniformly throughout the brain. At 40 days postinjury, initially low NAA/Cho levels had recovered to near baseline in patients who had good outcomes, whereas no recovery was evident in patients with poor outcomes (p < 0.01). Conclusions. Using H-1-MR spectroscopy, it is possible to detect the posttraumatic neurochemical damage of the injured brain when conventional neuroimaging techniques reveal no abnormality. Reduction of NAA levels is a dynamic process, evolving over time, decreasing and remaining low throughout the involved tissue in patients with poor outcomes. Recovery of NAA levels in patients with favorable outcomes suggests marginal mitochondrial impairment and possible resynthesis from vital neurons.	[Signoretti, Stefano; Marmarou, Anthony; Aygok, Gunes A.; Portella, Gina; Bullock, Ross M.] Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA 23298 USA; [Fatouros, Panos P.] Virginia Commonwealth Univ, Med Ctr, Dept Radiol, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, 1001 E Broad St,Suite 235,POB 980508, Richmond, VA 23298 USA.	amannaro@vcu.edu	Signoretti, stefano/AAL-5631-2020	Signoretti, stefano/0000-0002-8086-1622	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19235, NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS019235, R56NS019235] Funding Source: NIH RePORTER		Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; [Anonymous], 2000, J Head Trauma Rehabil, V15, P750; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/j.1749-6632.1987.tb32915.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ERNST T, 1991, MAGN RESON MED, V21, P82, DOI 10.1002/mrm.1910210111; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HU XP, 1988, MAGNET RESON MED, V8, P314, DOI 10.1002/mrm.1910080308; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushi H, 1999, ACT NEUR S, V75, P67; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marmarou A, 2005, ACT NEUR S, V95, P149; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; STACHNIAK J, 1994, J CLIN ANESTH, V6, P437, DOI 10.1016/S0952-8180(05)80020-0; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; TEDESCHI G, 1995, MAGNET RESON MED, V33, P127, DOI 10.1002/mrm.1910330120; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	58	66	68	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					42	52		10.3171/JNS/2008/108/01/0042			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300006	18173309				2021-06-18	
J	Simonsen, LL; Sonne-Holm, S; Krasheninnikoff, M; Engberg, AW				Simonsen, Louise Lau; Sonne-Holm, Stig; Krasheninnikoff, Michael; Engberg, Aase W.			Symptomatic heterotopic ossification after very severe traumatic brain injury in 114 patients: Incidence and risk factors	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						symptomatic heterotopic ossification; severe traumatic brain injuries; risk factors	ECTOPIC-BONE-FORMATION; SPINAL-CORD INJURY; HEAD-INJURIES; REHABILITATION; ADOLESCENTS; MANAGEMENT; HEMIPLEGIA; ANTIGENS; CHILDREN	The incidence of heterotopic ossification (HO) among patients with traumatic brain injury (TBI) varies in the literature from 11 to 73.3%. The aim of this study was to determine the incidence of HO among patients with very severe TBI treated in a new established intensive rehabilitation Brain Injury Unit and to list some of the risk-predicting features. The study comprised an approximately complete, consecutive series of 114 adult patients from a well-defined geographical area, and with a posttraurnatic amnesia period of at least 28 days, i.e. very severe TBI. Demographic and functional data as well as data about trauma severity and hospital stay of these patients have been registered prospectively in a database (Danish National Head Injury database) at the Brain Injury Unit where the sub acute rehabititation took place. The present study was based retrospectively on this database, combined with X-rays obtained for symptoms of HO and/or as fracture control. Clinically significant HO was found in 7.9% of the patients. Logistic regression showed an independent significant positive correlation between HO, the female gender and a high Injury Severity Score. The low incidence of HO might be explained by the application of early mobitisation and physiotherapy of the patients. The higher incidence of HO among women speaks for humoural and hormone factors initiating bone formation outside the bones. (c) 2007 Elsevier Ltd. All rights reserved.	Copenhagen Univ Hosp, Dept Orthopaed Surg, Hvidovre, Denmark; Copenhagen Univ Hosp, Dept Neurol Rehabil, Brain Injury Unit, Hvidovre, Denmark	Simonsen, LL (corresponding author), Valby Langgade 88 C,2 Tv, DK-2500 Valby, Denmark.	touiselau@dadtnet.dk					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; FURMAN R, 1970, J BONE JOINT SURG AM, VA 52, P1131, DOI 10.2106/00004623-197052060-00005; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Garland DE., 1995, TRAUMATIC BRAIN INJU, P119; Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604; GOLDBERG MA, 1977, ARCH INTERN MED, V137, P619, DOI 10.1001/archinte.137.5.619; Greenwood R, 1993, NEUROLOGICAL REHABIL, P206; HAJEK VE, 1987, ARCH PHYS MED REHAB, V68, P313; HARDY AG, 1963, J BONE JOINT SURG BR, V45, P76; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Jacobsen S, 1995, Ugeskr Laeger, V157, P5385; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LARSON JM, 1981, RHEUMATOL REHABIL, V20, P193, DOI 10.1093/rheumatology/20.4.193; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIBERSON M, 1953, JAMA-J AM MED ASSOC, V152, P1010, DOI 10.1001/jama.1953.03690110024008; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P214; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; NICHOLAS JJ, 1973, ARCH PHYS MED REHAB, V54, P354; ORZEL JA, 1985, J NUCL MED, V26, P125; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; ROSENTHAL M, 1999, REHABILITATION ADULT, P63; ROSIN AJ, 1975, ANN RHEUM DIS, V34, P499, DOI 10.1136/ard.34.6.499; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; Stover SL, 1986, MANAGEMENT SPINAL CO, P284; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; VARGHESE G, 1991, ARCH PHYS MED REHAB, V72, P1009; VENIER L H, 1971, Archives of Physical Medicine and Rehabilitation, V52, P475	34	66	77	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2007	38	10					1146	1150		10.1016/j.injury.2007.03.019			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	229GS	WOS:000250791900005	17572418				2021-06-18	
J	Scalea, TM; Bochicchio, GV; Habashi, N; McCunn, M; Shih, D; McQuillan, K; Aarabi, B				Scalea, Thomas M.; Bochicchio, Grant V.; Habashi, Nader; McCunn, Maureen; Shih, Diane; McQuillan, Karen; Aarabi, Bizhan			Increased intra-abdominal, intrathoracic, and intracranial pressure after severe brain injury: Mulitple compartment syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma		critical care; decompressive craniectomy; injury; morbidity; traumatic brain injury; trauma outcomes	CEREBRAL PERFUSION-PRESSURE; DECOMPRESSIVE CRANIECTOMY; ORGAN DYSFUNCTION; HYPERTENSION; MANAGEMENT	Objectives. Fluid therapy and/or acute lung injury may increase intra-abdominal pressure (IAP) and intrathoracic pressure, thereby increasing intracranial pressure (ICP) after traumatic brain injury (TBI). Further fluid administration to support cerebral perfusion or increasing ventilatory support to treat acute lung injury further increases ICP. This can create a cycle that ultimately produces multiple compartment syndrome (MCS). Both decompressive craniectomy (DC) and decompressive laparotomy (DL) decrease ICP. DL can also decrease IAP and ICP. We evaluated the serial application of DC and DL to treat MCS. Methods. Data were analyzed for 102 consecutive patients with severe TBI who underwent DC alone to decrease ICP or in combination with DL to treat MCS. Results: All 102 patients sustained blunt injury. Seventy percent were men with a mean age of 29.5 years, an Injury Severity Score of 34.4, and admission Glasgow Coma Scale score of 7.1. Fifty-one patients had diffuse brain injury and 51 had mass lesions. Seventy-eight patients (76%) underwent DC alone. Twenty-four (22%) had both therapies for MCS. Fifteen patients had DC before DL and nine had DL before DC. Mean time between DC and DL was 3.4 +/- 6 days. The mean IAP before DL was 28 +/- 5 turn Hg. Twenty-four-hour cumulative mean intrathoracic pressure decreased significantly after DL in the MCS group (p = 0.01). Mean ICP decreased significantly after both DC and DL (p < 0.05). Conclusion. Increased ICP may be from primary TBI or MCS. Patients with MCS have a higher Injury Severity Score, ICP, and fluid requirements, but no increase in mortality. Both DC and DL reduce ICP and can be used in sequence. MCS should be considered in multiply injured patients with increased ICP that does not respond to therapy.	Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, Baltimore, MD 21201 USA	Scalea, TM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	tscalea@umm.edu					ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BULLOCK R, 2000, MANAGEMENT PROGNOSIS; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Lacroix J, 2005, CRIT CARE MED, V33, P697, DOI 10.1097/01.CCM.0000155778.87402.56; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V203, P1778; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WILSON NW, 1991, AM J DIS CHILD, V145, P326, DOI 10.1001/archpedi.1991.02160030096029; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	23	66	70	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2007	62	3					647	656		10.1097/TA.0b013e31802ee542			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	145PP	WOS:000244877300020	17414342				2021-06-18	
J	Flaro, L; Green, P; Robertson, E				Flaro, Lloyd; Green, Paul; Robertson, Ellen			Word Memory Test failure 23 times higher in mild brain injury than in parents seeking custody: The power of external incentives	BRAIN INJURY			English	Article						brain injury; motivation; effort; symptom validity test; incentive	PERFORMANCE; ISSUES	Primary objective: Motivation has an important influence on neuropsychological test performances. This study examined effort on the Word Memory Test ( WMT) in groups with differing external incentives. Research design: 774 adults with Traumatic Brain Injury ( TBI), tested as part of a Workers' Compensation, disability or personal injury claim stood to gain financially by appearing impaired on testing. In contrast, parents ordered by the Court to undergo a parenting assessment were highly motivated to do their best on cognitive tests because their goal was to regain custody of their children. Outcomes and results: Consistent with these assumptions, 98.3% of 118 parents seeking child custody passed the WMT effort subtests but in cases of mild TBI the pass rate on the WMT was only 60%. The WMT failure rate in the mild TBI sample was 23 times higher than in the group of parents seeking custody. WMT failure was twice as frequent in the mild TBI group than in those with more severe TBI. WMT failure was also much higher in adults with mild TBI than in children with significant impairment from various clinical conditions. Conclusions: Such differences in failure rates on the WMT effort subtests cannot be explained by differences in cognitive skills but they are explainable by differences in external incentives. The findings support the recommendation that objective tests of effort should be used when evaluating cognitive impairment.		Flaro, L (corresponding author), Ed D Suite 210,17010 103 Ave, Edmonton, AB T5S 1K7, Canada.	drflaro@telus.net					ARDOLF BR, IN PRESS CLIN NEUROP; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DEFILIPPIS N, 2005, PAR STAFF CATEGORY T; Garcia, 1999, WECHSLER ABBREVIATED; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 2003, DETECTION RESPONSE B; Green P., 2003, MANUAL WORD MEMORY T; Green P., 1995, MANUAL ORAL WORD MEM; Harrison A.G., 2006, ADHD REPORT, V14, P1, DOI [DOI 10.1521/ADHD.2006.14.4.1, 10.1521/adhd.2006.14.4.1]; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Kuehnle K., 2000, FAMILY CONCILIATION, V38, P368, DOI DOI 10.1111/J. 174-1617. 2000. TB00580. X; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; Reitan RM., 1969, MANUAL ADM NEUROPSYC; SULLIVAN B, IN PRESS APPL NEUROP; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909	23	66	66	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	4					373	383		10.1080/02699050701311133			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600003	17487635				2021-06-18	
J	Thompson, SN; Gibson, TR; Thompson, BM; Deng, Y; Hall, ED				Thompson, Stephanie N.; Gibson, Tonya R.; Thompson, Brian M.; Deng, Ying; Hall, Edward D.			Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						GAP-43; synaptophysin; calpain; neuroplasticity; controlled cortical impact; de Olmos silver staining; neurodegeneration	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; COGNITIVE DEFICITS; FLUID PERCUSSION; ALPHA-SPECTRIN; REACTIVE SYNAPTOGENESIS; BEHAVIORAL RECOVERY; BREAKDOWN PRODUCTS; NEURONAL APOPTOSIS; STRUCTURAL EVENTS	The role of neuronal plasticity and repair on the final functional outcome following traumatic brain injury (TBI) remains poorly understood. Moreover, the relationship of the magnitude of post-traumatic secondary injury and neurodegeneration to the potential for neuronal repair has not been explored. To address these questions, we employed Western immunoblotting techniques to examine how injury severity affects the spatial and temporal expression of markers of axonal growth (growth-associated protein GAP-43) and synaptogenesis (pre-synaptic vesicular protein synaptophysin) following either moderate (0.5 mm, 3.5 M/s) or severe (1.0 mm, 3.5 M/s) lateral controlled cortical impact traumatic brain injury (CCI-TBI) in young adult male CF-1 mice. Moderate CCI increased GAP-43 levels at 24 and 48 h post-insult in the ipsilateral hippocampus relative to sham, non-injured animals. This increase in axonal plasticity occurred prior to maximal hippocampal neurodegeneration, as revealed by de Olmos silver staining, at 72 h. However, moderate CCI-TBI did not elevate GAP-43 expression in the ipsilateral cortex where neurodegeneration was extensive by 6 h post-TBI. In contrast to moderate injury, severe CCI-TBI failed to increase hippocampal GAP-43 levels and instead resulted in depressed GAP-43 expression in the ipsilateral hippocampus and cortex at 48 h post-insult. In regards to injury-induced changes in synaptogenesis, we found that moderate CCI-TBI elevated synaptophysin levels in the ipsilateral hippocampus at 24, 48, 72 h and 21 days, but this effect was not present after severe injury. Together, these data highlights the adult brain's ability for axonal and synaptic plasticity following a focal cortical injury, but that severe injuries may diminish these endogenous repair mechanisms. The differential effects of moderate versus severe TBI on the post-traumatic plasticity response may be related to the calpain-mediated proteolytic activity occurring after a severe injury preventing increased expression of proteins required for plasticity. Supporting this hypothesis is the fact that GAP-43 is a substrate for calpain along with our data demonstrating that calpain-mediated degradation of the cytoskeletal protein, alpha-spectrin, is approximately 10 times greater in ipsilateral hippocampal tissue following severe compared to moderate CCI-TBI. Thus, TBI severity has a differential effect on the injury-induced neurorestorative response with calpain activation being one putative factor contributing to neuroregenerative failure following severe CCI-TBI. If true, then calpain inhibition may lead to both neuroprotective effects and an enhancement of neuronal plasticity/repair mechanisms post-TBI. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, B383 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS046566] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566] Funding Source: NIH RePORTER		Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; Bergmann M, 1997, EXP BRAIN RES, V117, P80, DOI 10.1007/s002210050201; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BROCK TO, 1987, J NEUROSCI, V7, P931; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CABALKA LM, 1990, J COMP NEUROL, V295, P83, DOI 10.1002/cne.902950108; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DOSEMECI A, 1995, SYNAPSE, V20, P91, DOI 10.1002/syn.890200113; Emery DL, 2000, J COMP NEUROL, V424, P521; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1998, DRUG NEWS PERSPECT, V11, P215; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; KALIL K, 1986, J NEUROSCI, V6, P2563; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu YL, 1996, BRAIN RES, V732, P36, DOI 10.1016/0006-8993(96)00484-2; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OESTREICHER AB, 1986, BRAIN RES, V375, P267, DOI 10.1016/0006-8993(86)90747-X; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; RINK A, 1995, AM J PATHOL, V147, P1575; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAITO S, 1994, J NEUROSCI RES, V39, P57, DOI 10.1002/jnr.490390108; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; SCHAUWECKER PE, 1995, J NEUROSCI, V15, P2462; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; SIMAN R, 1987, J NEUROSCI, V7, P55; SINGH IN, 2006, J CEREB BLOOD FLOW M, P1; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Villa PG, 1998, J CELL SCI, V111, P713; Vinade L, 2001, SYNAPSE, V40, P302, DOI 10.1002/syn.1053; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zakharov IA, 2001, RUSS EDUC SOC, V43, P39; Zakharov VV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P897, DOI 10.1007/s10541-005-0200-6	86	66	71	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2006	201	1					253	265		10.1016/j.expneurol.2006.04.013			13	Neurosciences	Neurosciences & Neurology	079CC	WOS:000240152100027	16814284				2021-06-18	
J	Love, S; Siew, LK; Dawbarn, D; Wilcock, GK; Ben-Shlomo, Y; Allen, SJ				Love, Seth; Siew, L. Khai; Dawbarn, David; Wilcock, Gordon K.; Ben-Shlomo, Yoav; Allen, Shelley J.			Premorbid effects of APOE on synaptic proteins in human temporal neocortex	NEUROBIOLOGY OF AGING			English	Article						Alzheimer's disease; apolipoprotein E; normal brain; postsynaptic density-95; synapse; synaptophysin; syntaxin 1	APOLIPOPROTEIN-E EPSILON-4; CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; E ALLELE EPSILON-4; ALZHEIMERS-DISEASE; E GENOTYPE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; NEUROFIBRILLARY TANGLES; PARKINSONS-DISEASE	APOE affects the risk of Alzheimer's disease (AD) and course of several other neurologic diseases. Experimental studies suggest that APOE influences synaptogenesis. We measured the concentration of two presynaptic proteins, synaptophysin and syntaxin 1, and also postsynaptic density-95 (PSD95), in superior temporal cortex from 42 AD and 160 normal brains, and determined the APOE genotypes. The concentration of both presynaptic proteins was approximately two-thirds lower in AD than normal brains and that of PSD95 one-third lower. No effect of APOE on synaptic proteins was found in advanced AD. However, in normal brain, epsilon 4 was associated with lower concentrations of all three synaptic proteins and epsilon 2 with significantly elevated PSD95 (p = 0.03). A combined measure of synaptic proteins showed a significant linear decrease from epsilon 2 through epsilon 3 to epsilon 4 (p = 0.01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases. (c) 2005 Elsevier Inc. All rights reserved.	Univ Bristol, Dept Neuropathol, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England; Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England; Univ Bristol, Dept Care & Elderly, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	Love, S (corresponding author), Univ Bristol, Dept Neuropathol, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England.	seth.love@bris.ac.uk	Love, Seth/E-6545-2012	Love, Seth/0000-0001-8683-3625; Ben-Shlomo, Yoav/0000-0001-6648-3007; Allen, Shelley/0000-0001-7870-740X			Ahles TA, 2003, PSYCHO-ONCOL, V12, P612, DOI 10.1002/pon.742; Allen SJ, 1997, NEUROSCI LETT, V239, P33, DOI 10.1016/S0304-3940(97)00872-0; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bickeboller H, 1997, AM J HUM GENET, V60, P439; Blanche H, 2001, CR ACAD SCI III-VIE, V324, P129, DOI 10.1016/S0764-4469(00)01274-9; Bleich S, 2003, J NEURAL TRANSM, V110, P401, DOI 10.1007/s00702-002-0789-1; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; Callahan LM, 2002, J NEUROPATH EXP NEUR, V61, P384, DOI 10.1093/jnen/61.5.384; Chalmers K, 2003, NEUROPATH APPL NEURO, V29, P231, DOI 10.1046/j.1365-2990.2003.00457.x; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corey-Bloom J, 2000, NEUROLOGY, V54, P403, DOI 10.1212/WNL.54.2.403; De Stefano N, 2004, ARCH NEUROL-CHICAGO, V61, P536, DOI 10.1001/archneur.61.4.536; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; FARRER LA, 1995, EXP NEUROL, V136, P162, DOI 10.1006/exnr.1995.1093; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Hunt CA, 1996, J NEUROSCI, V16, P1380; Igbavboa U, 2002, J NEUROCHEM, V80, P255, DOI 10.1046/j.0022-3042.2001.00688.x; Kalman J, 2000, NEUROBIOL AGING, V21, P555, DOI 10.1016/S0197-4580(00)00150-0; Kirkwood B., 2003, ESSENTIAL MED STAT, V2nd; Landen M, 1996, J NEUROL NEUROSUR PS, V61, P352, DOI 10.1136/jnnp.61.4.352; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Love S, 2003, NEUROREPORT, V14, P1535, DOI 10.1097/00001756-200308060-00027; LOVE S, 2000, NEUROPATHOL APPL NEU, V26, P203; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1991, ACTA NEUROPATHOL, V81, P428, DOI 10.1007/BF00293464; MATSUMOTO S, 2003, NEUROLOGY, P60; Mattila PM, 1998, ACTA NEUROPATHOL, V96, P417, DOI 10.1007/s004010050913; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morris CM, 1995, NEUROSCI LETT, V201, P45, DOI 10.1016/0304-3940(94)12126-B; Muramatsu T, 1997, J NEURAL TRANSM, V104, P913, DOI 10.1007/BF01285559; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Pickering-Brown SM, 2000, EXP NEUROL, V163, P452, DOI 10.1006/exnr.2000.7387; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Poirier J, 1998, J NEURAL TRANSM-SUPP, P199; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng M, 2001, J CELL SCI, V114, P1251; Siew LK, 2004, J NEUROSCI METH, V139, P153, DOI 10.1016/j.jneumeth.2004.04.020; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Veinbergs I, 1999, NEUROSCI LETT, V265, P218, DOI 10.1016/S0304-3940(99)00243-8; Warzok RW, 1998, ALZ DIS ASSOC DIS, V12, P33, DOI 10.1097/00002093-199803000-00005; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Whitehead AS, 1996, J NEUROL NEUROSUR PS, V61, P347, DOI 10.1136/jnnp.61.4.347	62	66	66	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUN	2006	27	6					797	803		10.1016/j.neurobiolaging.2005.04.008			7	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	045WW	WOS:000237774400002	15979210				2021-06-18	
J	Fang, SH; Wei, EQ; Zhou, Y; Wang, ML; Zhang, WP; Yu, GL; Chu, LS; Chen, Z				Fang, S. H.; Wei, E. Q.; Zhou, Y.; Wang, M. L.; Zhang, W. P.; Yu, G. L.; Chu, L. S.; Chen, Z.			Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats	NEUROSCIENCE			English	Article						cysteinyl leukotriene receptor; cerebral ischemia; neuronal damage; astrogliosis; pranlukast; cysteinyl leukotriene receptor antagonist	FIBRILLARY ACIDIC PROTEIN; ARTERY OCCLUSION; ARACHIDONIC-ACID; CELL-DEATH; GLIAL SCAR; INJURY; EDEMA; ANTAGONIST; PROLIFERATION; REPERFUSION	Cysteinyl leukotrienes are potent pro-inflammatory mediators. Cysteinyl leukotriene receptor 1 is one of the two cysteinyl leukotriene receptors cloned. We recently reported that cysteinyl leukotriene receptor 1 antagonists protected against cerebral ischemic injury, and an inducible expression of cysteinyl leukotriene receptor 1 was found in neuron- and glial-appearing cells after traumatic injury in human brain. To determine the role of cysteinyl leukotriene receptor 1 in ischemic brain injury, we investigated the temporal and spatial profile of cysteinyl leukotriene receptor 1 expression in rat brain from 3 h to 14 days after 30 min of middle cerebral artery occlusion, and observed the effect of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, on the ischemic injury. We found that cysteinyl leukotriene receptor 1 mRNA expression was up-regulated in the ischemic core both 3-12 h and 7-14 days, and in the boundary zone 7-14 days after reperfusion. In the ischemic core, cysteinyl leukotriene receptor 1 was primarily localized in neurons 24 h, and in macrophage/microglia 14 days after reperfusion; while in the boundary zone it was localized in proliferated astrocytes 14 days after reperfusion. Pranlukast attenuated neurological deficits, reduced infarct volume and ameliorated neuron loss in the ischemic core 24 h after reperfusion; it reduced infarct volume, ameliorated neuron loss and inhibited astrocyte proliferation in the boundary zone 14 days after reperfusion. Thus, we conclude that cysteinyl leukotriene receptor 1 mediates acute neuronal damage and subacute/chronic astrogliosis after focal cerebral ischemia. (c) 2006 Published by Elsevier Ltd on behalf of IBRO.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China	Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 353 Yanan Rd, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com					BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; Ballerini P, 2005, INT J IMMUNOPATH PH, V18, P255, DOI 10.1177/039463200501800208; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; BAUD L, 1987, J IMMUNOL, V138, P1190; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Fagan SC, 2004, STROKE, V35, P2220, DOI 10.1161/01.STR.0000138023.60272.9e; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; LEIKAUF GD, 1990, AM J PHYSIOL, V259, pL255; LI Y, 1995, J NEUROL SCI, V128, P134, DOI 10.1016/0022-510X(94)00228-G; Lipton P, 1999, PHYSIOL REV, V79, P1431; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lynch KR, 1999, NATURE, V399, P789; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; Mazzetti L, 2003, BRIT J PHARMACOL, V138, P707, DOI 10.1038/sj.bjp.0705087; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249; PAPADOPOULOS SM, 1989, NEUROSURGERY, V25, P369, DOI 10.1227/00006123-198909000-00008; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Sarau HM, 1999, MOL PHARMACOL, V56, P657; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Yano T, 2003, ANESTHESIOLOGY, V98, P465, DOI 10.1097/00000542-200302000-00028; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; ZENG LH, 2001, ACTA PHARMACOL SINIC, V36, P148; Zhang RL, 2003, EXP NEUROL, V184, P746, DOI 10.1016/S0014-4886(03)00296-6; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	43	66	85	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	140	3					969	979		10.1016/j.neuroscience.2006.02.051			11	Neurosciences	Neurosciences & Neurology	052KG	WOS:000238232000020	16650938				2021-06-18	
J	Jagodic, HK; Jagodic, K; Podbregar, M				Jagodic, Helena Korosec; Jagodic, Klemen; Podbregar, Matej			Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma	CRITICAL CARE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; HEALTH-STATUS; SEPTIC SHOCK; SURVIVORS; RECOMMENDATIONS; POPULATION; EQ-5D	Introduction Our aim was to determine long-term survival and quality of life of patients admitted to a surgical intensive care unit (ICU) because of sepsis or trauma. Methods This was an observational study conducted in an 11-bed, closed surgical ICU at a 860-bed teaching general hospital over a 1-year period ( January 2003 to December 2003). Patients were divided into two groups according to admission diagnoses: group 1 included patients with sepsis; and group 2 included patients with trauma (polytrauma, multiple trauma, head injury, or spinal injury). Quality of life was assessed after 2 years following ICU admission using the EuroQol 5D questionnaire. Results A total of 164 patients ( 98 trauma patients and 66 patients with sepsis) were included in the study. Trauma patients were younger than patients with sepsis ( 53 +/- 21 years versus 64 +/- 13 years; P <= 0.001). There was no significant difference between groups in Acute Physiology and Chronic Health Evaluation II score or length of stay in the surgical SICU. Trauma patients stayed longer on the general ward ( 35 +/- 44 days versus 17 +/- 24 days; P < 001). Surgical ICU survival, in-hospital survival, and post-hospital and cumulative 2-year survival were lower in the sepsis group than in the trauma group ( surgical ICU survival: 60% versus 74%; in-hospital survival: 42% versus 62%; post-hospital survival: 78% versus 92%; cumulative 2-year survival: 33% versus 57%; P < 0.05). There was no significant difference in quality of life in all five dimensions of the EuroQol 5D between groups: 60% of patients had signs of depression, almost 60% had problems in usual activities and 56% had pain. Conclusion Patients with sepsis treated in a surgical ICU have higher short-term and long-term mortality than do trauma patients. However, quality of life is reduced to the same level in both groups.	Gen Hosp Celje, Dept Anesthesiol & Intens Therapy, Celje 3000, Slovenia; Gen Hosp Celje, Dept Urol, Celje 3000, Slovenia; Univ Med Ctr Ljubljana, Clin Dept Intens Internal Med, Ljubljana 1000, Slovenia	Jagodic, HK (corresponding author), Gen Hosp Celje, Dept Anesthesiol & Intens Therapy, Oblakova Ulica, Celje 3000, Slovenia.	helena.korosec-jagodic@guest.arnes.si					Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Badia X, 1998, QUAL LIFE RES, V7, P311, DOI 10.1023/A:1024933913698; Balk RA, 2000, CRIT CARE CLIN, V16, P179, DOI 10.1016/S0749-0704(05)70106-8; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Chang SY, 2005, CRIT CARE CLIN, V21, P43, DOI 10.1016/j.ccc.2004.07.003; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; Davidson TA, 1999, AM J RESP CRIT CARE, V160, P1838, DOI 10.1164/ajrccm.160.6.9903058; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Ferdinande P, 1997, INTENS CARE MED, V23, P226, DOI 10.1007/s001340050321; Fisher M, 1998, Ann Acad Med Singap, V27, P376; Grady KL, 2001, CRIT CARE MED, V29, P1844, DOI 10.1097/00003246-200109000-00036; Granja C, 2004, CRIT CARE, V8, pR91, DOI 10.1186/cc2818; Granja C, 2002, INTENS CARE MED, V28, P898, DOI 10.1007/s00134-002-1345-z; Haraldsen Pernille, 2003, Eur J Surg Suppl, P23; Herridge Margaret S, 2002, Curr Opin Crit Care, V8, P331, DOI 10.1097/00075198-200208000-00010; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Marshall JC, 2005, CRIT CARE MED, V33, P1708, DOI 10.1097/01.CCM.0000174478.70338.03; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Needham DM, 2005, INTENS CARE MED, V31, P1153, DOI 10.1007/s00134-005-2656-7; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Sznajder M, 2001, INTENS CARE MED, V27, P146, DOI 10.1007/s001340000760; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vincent JL, 2006, AM J RESP CRIT CARE, V173, P256, DOI 10.1164/rccm.200510-1604OE; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wright JC, 2003, ANAESTHESIA, V58, P637, DOI 10.1046/j.1365-2044.2003.03205.x	28	66	69	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2006	10	5							R134	10.1186/cc5047			7	Critical Care Medicine	General & Internal Medicine	185NS	WOS:000247718300010		DOAJ Gold, Green Published			2021-06-18	
J	Tomberg, T; Toomela, A; Pulver, A; Tikk, A				Tomberg, T; Toomela, A; Pulver, A; Tikk, A			Coping strategies, social support, life orientation and health-related quality of life following traumatic brain injury	BRAIN INJURY			English	Article						coping strategies; social support; optimism; health-related quality of life; traumatic brain injury	BREAST-CANCER; HEAD-INJURY; DEPRESSION; OPTIMISM; QUESTIONNAIRE; ADJUSTMENT; PSORIASIS; ARTHRITIS; SYMPTOMS; DISTRESS	Objective: To study coping strategies, social support and life orientation in patients following moderate and severe traumatic brain injury (TBI) in relation to health-related quality of life. Subjects: Eighty-five patients with moderate or severe TBI and 68 control persons. Methods: Estonian versions of the COPE-D test, the Brief Social Support Questionnaire, the Life Orientation Test and the RAND-36 questionnaire. Results: Persons with TBI reported using task-oriented and social/emotional support strategies less often and avoidance-oriented strategies more often than control persons (p < 0.05). The social support network, satisfaction with it and optimism as life orientation were lower in the patient group (p < 0.05). Task-oriented coping styles, satisfaction with social support and optimistic life orientation were associated with the majority of the domains of health-related quality of life and resuming work after TBI. Conclusions: To achieve effective rehabilitation and to enhance patients' well-being, it is important to improve the quality and amount of social support network, as well as to support patients' adequate coping efforts for promoting an active lifestyle.	Univ Tartu, Dept Neurol & Neurosurg, EE-51014 Tartu, Estonia; Univ Tartu, Dept Special Educ, Tartu, Estonia; Tallinn Pedag Univ, Dept Psychol, Tallinn, Estonia	Tomberg, T (corresponding author), Univ Tartu, Dept Neurol & Neurosurg, L Puusepa 2, EE-51014 Tartu, Estonia.	tiiu.tomberg@kliinikum.ee	Toomela, Aaro/H-6033-2018; Pulver, Aleksander/AAQ-6304-2020	Toomela, Aaro/0000-0002-8520-9676; Pulver, Aleksander/0000-0001-7642-4430			Andersen S, 1999, NEUROLOGY, V52, pS26; BARRERA M, 1990, J SOC PERS RELAT, V7, P541, DOI 10.1177/0265407590074010; CARVER CS, 1992, HOSTILITY, COPING & HEALTH, P167, DOI 10.1037/10105-012; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cook SW, 1997, EDUC PSYCHOL MEAS, V57, P906, DOI 10.1177/0013164497057006002; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Downe-Wamboldt BL, 1998, J ADV NURS, V27, P1109, DOI 10.1046/j.1365-2648.1998.00621.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finset A, 2000, BRAIN INJURY, V14, P887; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; HAYS RB, 1992, J CONSULT CLIN PSYCH, V60, P463, DOI 10.1037/0022-006X.60.3.463; Herodes M, 2001, EPILEPSIA, V42, P1061, DOI 10.1046/j.1528-1157.2001.0420081061.x; HOLAHAN CJ, 1995, HEALTH PSYCHOL, V14, P152, DOI 10.1037/0278-6133.14.2.152; JENNETT B, 1975, LANCET, V1, P480; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; KAPLAN RM, 1997, SOURCEBOOK SOCIAL SU, P279; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; *RAND HLTH SCI PRO, 1992, RAND 36 IT HLTH SURV; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SARASON IG, 1994, J SOC PERS RELAT, V11, P295, DOI 10.1177/0265407594112008; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Scharloo M, 1998, J PSYCHOSOM RES, V44, P573, DOI 10.1016/S0022-3999(97)00254-7; SCHEIER MF, 1986, J PERS SOC PSYCHOL, V51, P1257, DOI 10.1037/0022-3514.51.6.1257; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; Schnoll RA, 1998, PSYCHO-ONCOLOGY, V7, P69, DOI 10.1002/(SICI)1099-1611(199803/04)7:2<69::AID-PON286>3.0.CO;2-8; SVELNIKAS K, 1998, THESIS U TARTU TARTU; THOITS PA, 1995, J HLTH SOCIAL BEHAV, P53, DOI DOI 10.2307/2626957; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; TINA A, 1998, THESIS U TARTU TARTU; Toomela A, 2004, J REHABIL MED, V36, P63, DOI 10.1080/16501970310017414; Wahl A, 1999, QUAL LIFE RES, V8, P427, DOI 10.1023/A:1008944108101; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Welin C, 2000, J INTERN MED, V247, P629, DOI 10.1046/j.1365-2796.2000.00694.x; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; WORTMAN CB, 1984, CANCER-AM CANCER SOC, V53, P2339	44	66	66	0	17	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1181	1190		10.1080/02699050500150153			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200001	16286333				2021-06-18	
J	Mansell, J; Tierney, RT; Sitler, MR; Swanik, KA; Stearne, D				Mansell, J; Tierney, RT; Sitler, MR; Swanik, KA; Stearne, D			Resistance training and head-neck segment dynamic stabilization in male and female collegiate soccer players	JOURNAL OF ATHLETIC TRAINING			English	Article						cervical musculature; concussion; head acceleration	TRAUMATIC BRAIN-INJURY; IMPACT FORCES; ACCELERATION; PERFORMANCE; STRENGTH; PROPRIOCEPTION; GENDER; MOTION	Context: Cervical resistance training has been purported to aid in reducing the severity of brain injuries in athletes. Objective: To determine the effect of an 8-week resistance-training program on head-neck segment dynamic stabilization in male and female collegiate soccer players. Design: Pretest and posttest control group design. Setting: University research laboratory and fitness center. Patients or Other Participants: Thirty-six National Collegiate Athletic Association Division I collegiate soccer players (17 men, 19 women). Intervention(s): The resistance training group underwent an 8-week cervical resistance training program that consisted of 3 sets of 10 repetitions of neck flexion and extension at 55% to 70% of their 10-repetition maximum 2 times a week. Participants in the control group performed no cervical resistance exercises. Main Outcome Measure(s): Head-neck segment kinematics and stiffness, electromyographic activity of the upper trapezius and sternocleidomastoid muscles during force application to the head, and neck flexor and extensor isometric strength. Results: No kinematic, electromyographic, or stiffness training effects were seen. The posttest resistance training group isometric neck flexor strength was 15% greater than the pretest measurement. Isometric neck extensor strength in the female resistance training group was 22.5% greater at the posttest than at the pretest. Women's neck girth increased 3.4% over time regardless of training group level. Women exhibited 7% less head-neck segment length and 26% less head-neck segment mass than men. Conclusions: Despite increases in isometric strength and girth, the 8-week isotonic cervical resistance training did not enhance head-neck segment dynamic stabilization during force application in collegiate soccer players. Future researchers should examine the effect of head-neck segment training protocols that include traditional and neuromuscular activities (eg, plyometrics) with the focus of reducing head acceleration on force application.	Temple Univ, Philadelphia, PA 19122 USA; Lincoln Univ, Lincoln, PA USA	Tierney, RT (corresponding author), Temple Univ, 127 Pearson Hall, Philadelphia, PA 19122 USA.	rtierney@temple.edu					Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; BLAND JH, 1996, J MUSCULOSKEL MED, V13, P30; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Brooks G., 2000, EXERCISE PHYSL HUMAN, V3rd ed.; BRUNT D, 1990, ARCH PHYS MED REHAB, V71, P473; Chimera NJ, 2004, J ATHL TRAINING, V39, P24; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DICK RW, 1994, AM SOC TEST MATER, V1229, P13, DOI 10.1520/STP12799S; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GOODMAN R, 2000, PHYSIOTHER CAN, V52, P211; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; Heck RW, 1996, MED SCI SPORT EXER, V28, P877, DOI 10.1097/00005768-199607000-00015; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; Ito Y, 1997, EXP BRAIN RES, V117, P266, DOI 10.1007/s002210050221; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Kumar S, 2000, ACCIDENT ANAL PREV, V32, P233, DOI 10.1016/S0001-4575(99)00114-1; Maeda Akira, 1994, Annals of Physiological Anthropology, V13, P59; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McNair PJ, 2002, CLIN BIOMECH, V17, P536, DOI 10.1016/S0268-0033(02)00062-1; Morris CE, 1999, AVIAT SPACE ENVIR MD, V70, P851; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; POLLOCK ML, 1993, ARCH PHYS MED REHAB, V74, P1080, DOI 10.1016/0003-9993(93)90065-I; Portney L., 2015, FDN CLIN RES APPL PR, V3rd ed.; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; SCHOR RH, 1988, CONTROL HEAD MOVEMEN, P141; STUMP J, 1993, J MANIP PHYSIOL THER, V16, P155; Swanik CB, 1997, J SPORT REHABIL, V6, P182, DOI 10.1123/jsr.6.2.182; Swanik KA, 2002, J SHOULDER ELB SURG, V11, P579, DOI 10.1067/mse.2002.127303; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	40	66	66	0	34	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2005	40	4					310	319					10	Sport Sciences	Sport Sciences	996MO	WOS:000234178200010	16404453				2021-06-18	
J	Kim, HJ; Fillmore, HL; Reeves, TM; Phillips, LL				Kim, HJ; Fillmore, HL; Reeves, TM; Phillips, LL			Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis	EXPERIMENTAL NEUROLOGY			English	Article						MMP-3 expression; trauma; synaptogenesis	COMBINED FLUID PERCUSSION; MATRIX METALLOPROTEINASES; BRAIN-INJURY; DENTATE GYRUS; MESSENGER-RNA; WHITE-MATTER; ADULT-RATS; PLASMINOGEN-ACTIVATOR; MULTIPLE-SCLEROSIS; DENDRITIC SPINES	The matrix metalloproteinase (MMP) enzyme family contributes to the regulation of a variety of brain extracellular matrix molecules. In order to assess their role in synaptic plasticity following traumatic brain injury (TBI), we compared expression of stromelysin-1 (MMP-3) protein and mRNA in two rodent models of TBI exhibiting different levels of recovery: adaptive synaptic plasticity following central fluid percussion injury and maladaptive synaptic plasticity generated by combined TBI and bilateral entorhinal cortical lesion (TBI + BEC). We sampled the hippocampus at 7 days postinjury, targeting a selectively vulnerable brain region and a survival interval exhibiting rapid synaptogenesis. We report elevated expression of hippocampal MMP-3 mRNA and protein after TBI. MMP-3 immunohistochemical staining showed increased protein levels relative to sham-injured controls, primarily localized to cell bodies within the deafferented dendritic laminae. Injury-related differences in MMP-3 protein were also observed. TBI alone elevated MMP-3 immunobinding over the stratum lacunosum moleculare (SLM). inner molecular layer and hilus, while TBI + BEC generated more robust increases in MMP-3 reactivity within the deafferented SLM and dentate molecular layer (DML). Double labeling with GFAP confirmed the presence of MMP-3 within reactive astrocytes induced by each injury model. Semi-quantitative RT-PCR revealed that MMP-3 mRNA also increased after each injury, however, the combined insult induced a much greater elevation than fluid percussion alone: 1.9-fold vs. 79%, respectively. In the TBI + BEC model, MMP-3 up-regulation was spatio-temporally correlated with increased enzyme activity, an effect which was attenuated with the neuroprotective compound MK-801. These results show that distinct pathological conditions elicited by TBI can differentially affect MMP-3 expression during reactive synaptic plasticity. Notably, these effects are both transcriptional and translational and are correlated with functionally active enzyme. (C) 2004 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, Richmond, VA 23298 USA	Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Med Sci Bldg Room 736,1217 E Marshall St,POB 9807, Richmond, VA 23298 USA.	llphilli@vcu.edu		Fillmore, Helen/0000-0003-4131-579X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS44372] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS044372, R01NS044372] Funding Source: NIH RePORTER		Anan H, 1996, J ENDODONT, V22, P668, DOI 10.1016/S0099-2399(96)80061-6; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asahi M, 2001, J NEUROSCI, V21, P7724; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baldwin SA, 1996, GLIA, V16, P266; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; BEJARANO PA, 1988, BIOCHEM J, V256, P413, DOI 10.1042/bj2560413; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CROTTY P, 1994, HUM PATHOL, V25, P572, DOI 10.1016/0046-8177(94)90221-6; Cuzner ML, 1996, J NEUROPATH EXP NEUR, V55, P1194, DOI 10.1097/00005072-199612000-00002; D'Souza CA, 2002, J BIOL CHEM, V277, P13589, DOI 10.1074/jbc.M108817200; Davies SJA, 1997, NATURE, V390, P680; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; GARCIA DY, 1999, J NEUROCHEM, V73, P812; Giraudon P, 1997, MOL PSYCHIATR, V2, P107, DOI 10.1038/sj.mp.4000218; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; KALB RG, 1988, J NEUROSCI, V8, P2350; KIGASAWA K, 1995, JPN J OPHTHALMOL, V39, P35; Kim D, 1999, IEEE COMMUN LETT, V3, P9, DOI 10.1109/4234.740114; KIM HJ, 1997, J NEUROTRAUM, V14, P803; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; LEGENDRE DI, 1994, J NEUROTRAUM, V11, P333, DOI 10.1089/neu.1994.11.333; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NELSON RB, 1989, J NEUROSCI, V9, P381; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Oh LYS, 1999, J NEUROSCI, V19, P8464; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 2003, J NEUROSCI, V23, P10182; REEVES TM, 1986, EXP BRAIN RES, V65, P167; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SHEFFIELD JB, 1994, DEV DYNAM, V200, P79, DOI 10.1002/aja.1002000108; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1992, HIPPOCAMPUS, V2, P247, DOI 10.1002/hipo.450020305; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1990, J NEUROSCI, V10, P2373; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1983, J NEUROSCI, V3, P177; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; VanSaun M, 2000, J NEUROBIOL, V43, P140, DOI 10.1002/(SICI)1097-4695(200005)43:2<140::AID-NEU4>3.0.CO;2-K; Vansaun M, 2003, J NEUROCYTOL, V32, P1129, DOI 10.1023/B:NEUR.0000021907.68461.9c; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werle MJ, 2003, J NEUROCYTOL, V32, P905, DOI 10.1023/B:NEUR.0000020631.69804.f5; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zuo J, 1998, J NEUROSCI, V18, P5203; Zuo J, 1998, J NEUROBIOL, V34, P41, DOI 10.1002/(SICI)1097-4695(199801)34:1<41::AID-NEU4>3.3.CO;2-4	86	66	66	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					60	72		10.1016/j.expneurol.2004.10.014			13	Neurosciences	Neurosciences & Neurology	899LZ	WOS:000227147200007	15698619				2021-06-18	
J	Cato, MA; Delis, DC; Abildskov, TJ; Bigler, E				Cato, MA; Delis, DC; Abildskov, TJ; Bigler, E			Assessing the elusive cognitive deficits associated with ventromedial prefrontal damage: A case of a modern-day Phineas Gage	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ventromedial prefrontal cortex; executive functions; traumatic brain injury	FRONTAL-LOBE; DECISION-MAKING; WORKING-MEMORY; CORTEX; PATIENT; NETWORKS; EMOTION; BRAIN	Cognitive deficits following ventromedial prefrontal damage (VM-PFD) have been elusive, with most studies reporting primarily emotional and behavioral changes. The present case illustrates the utility of a process approach to assessing cognitive deficits following VM-PFD. At age 26, C.D. acquired bilateral VM-PFD, more so in the left frontal region, following a penetrating head injury. Despite exemplary premorbid academic and military performances, his subsequent history suggests dramatic occupational and social changes, reminiscent of Phineas Gage. In fact, lesion analysis revealed similar structural damage to that estimated of Gage. C.D.'s scores on the vast majority of neuropsychological measures were average to superior (e.g., Verbal IQ = 119). However, on several new process measures, particularly those that quantify error rates on multilevel executive function and memory tasks, C.D. exhibited marked impairments. From his pattern of deficits, C.D. appeared to sacrifice accuracy for speed and to adopt liberal response strategies, implicating problems with cognitive inflexibility, impulsivity, and disinhibition. The current findings suggest that VM-PFD may be associated with a wider spectrum of cognitive deficits than previously characterized.	VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Malcom Randall VA RR&D Brain Rehabil Res Ctr, Gainesville, FL USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Cato, MA (corresponding author), VA San Diego Healthcare Syst, 116B MIRECC,3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	acato@ucsd.edu					Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; BRICKNER RM, 1936, INTELLECTUAL FUNCTIO; Chao LL, 1998, J COGNITIVE NEUROSCI, V10, P167, DOI 10.1162/089892998562636; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Damasio A., 1994, DESCARTESERROR EMOTI; Damasio A. R., 1995, SOME FUNCTIONS HUMAN; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damasio H., 1989, LESION ANAL NEUROPSY; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DELIS DC, 2000, CALIFORNIA VERGAL LE; DELIS DC, 2000, NEUROPSYCHOLOGICAL T; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1080/13554799908411987; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FLEISCHMAN JOHN, 2002, PHINEAS GAGE GRUESOM; Fuster JM, 2000, BRAIN RES BULL, V52, P331, DOI 10.1016/S0361-9230(99)00258-0; Goldman-Rakic P. S., 2002, PRINCIPLES FRONTAL L, P85, DOI DOI 10.1093/ACPR0F:0S0/9780195134971.003.0005; GOLDSTEIN K, 1941, PSYCHOL MONOGR, V53, P151; Goldstein K, 1944, J PSYCHOL, V17, P187, DOI 10.1080/00223980.1944.9917192; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Heaton R., 1993, WISCONSIN CARD SORTI; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; Kaplan E, 1988, CLIN NEUROPSYCHOLOGY, P127, DOI DOI 10.1037/10063-004; Luria A R, 1969, Hyg Ment, V58, P1; LURIA AR, 1977, AM PSYCHOL, V32, P959, DOI 10.1037/0003-066X.32.11.959; MACMILLAN M, 2000, ODD KIND FAME STORIE; Milberg WP, 1996, NEUROPSYCHOLOGICAL A, P58; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; RASBAND W, 1996, IMAGE VERSION 1 60; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; Teuber H L, 1968, Neurology, V18, P287; Teuber HL, 1954, J PSYCHOL, V38, P177, DOI 10.1080/00223980.1954.9712928; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRANEL D, 2002, PRINCIPLES FRONTAL L, P338, DOI DOI 10.1093/ACPROF:OSO/9780195134971.001.0001; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; WHITE RF, 1997, CRIT ISS NE, P171; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME	46	66	66	0	37	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					453	465		10.1017/S1355617704103123			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500014	15147602				2021-06-18	
J	Popovich, PG; van Rooijen, N; Hickey, WF; Preidis, G; McGaughy, V				Popovich, PG; van Rooijen, N; Hickey, WF; Preidis, G; McGaughy, V			Hematogenous macrophages express CD8 and distribute to regions of lesion cavitation after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE PRODUCTION; MOTOR-NEURON INJURY; MONONUCLEAR PHAGOCYTES; MICROGLIAL CELLS; RAT-BRAIN; PERITONEAL-MACROPHAGES; INFLAMMATORY RESPONSE; TRAUMATIC INJURY	Historically, CD4 and CD8 antigens have been used to designate functionally distinct T-lymphocyte subsets. However, these antigens also have been described on macrophages in the normal and pathologic central nervous system (CNS). Signaling through CD4 or CD8 may impart unique functions in macrophage subsets that express these antigens. In the current study, the distribution and temporal patterns of expression of CD4 and CD8 were evaluated on various cell types within the traumatically injured spinal cord. The data reveal divergent patterns of CD4 and CD8 expression on unique macrophage populations. Specifically, we show sustained elevations of CD4 expression on microglia and macrophages throughout the lesion site and spared white matter. In contrast, CD8 is predominantly associated with hematogenous macrophages that are recruited from the blood during the first week postinjury. The distribution of CD8-positive cells is restricted to areas of necrotic cavitation. Differential signaling of resident and recruited macrophages through CD4 or CD8 may explain the apparent dichotomy of CNS-macrophage-mediated injury and repair. (C) 2003 Elsevier Science (USA). All rights reserved.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Vrije Univ Amsterdam, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; DHMC, Dartmouth Med Sch, Dept Pathol, Lebanon, NH 03756 USA	Popovich, PG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, 2078 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.		Van Rooijen, Nico/Z-1578-2019; Popovich, Phillip/C-9187-2009; Preidis, Geoffrey A./W-5538-2019	Popovich, Phillip/0000-0003-1329-7395; Preidis, Geoffrey A./0000-0002-2206-6452	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037846] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37846] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; AlberatiGiani D, 1996, J NEUROCHEM, V66, P996; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Boutin H, 2001, J NEUROSCI, V21, P5528; Buttini M, 1998, NAT MED, V4, P441, DOI 10.1038/nm0498-441; CROCKER PR, 1987, J EXP MED, V166, P613, DOI 10.1084/jem.166.2.613; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DeJong BA, 1997, NEUROCHEM RES, V22, P491, DOI 10.1023/A:1027372129989; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Giulian D, 1996, J NEUROSCI, V16, P3139; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HICKEY WF, 1983, J IMMUNOL, V131, P2805; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hirji N, 1997, J IMMUNOL, V158, P1833; Hirji N, 1998, J IMMUNOL, V160, P6004; Jander S, 1998, EUR J NEUROSCI, V10, P680, DOI 10.1046/j.1460-9568.1998.00078.x; Jander S, 2001, BRAIN PATHOL, V11, P27; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kim GM, 2001, J NEUROSCI, V21, P6617; Lin TJ, 2000, J IMMUNOL, V164, P1783, DOI 10.4049/jimmunol.164.4.1783; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MORIOKA T, 1992, ACTA NEUROPATHOL, V83, P590, DOI 10.1007/BF00299407; Mosley K, 1996, NEUROCHEM RES, V21, P481, DOI 10.1007/BF02527713; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P440; Soares HD, 1995, J NEUROSCI, V15, P8223; SROGA JM, 2001, J NEUROTRAUM, V18, P1155; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x	53	66	67	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	2003	182	2					275	287		10.1016/S0014-4886(03)00120-1			13	Neurosciences	Neurosciences & Neurology	707RY	WOS:000184524700003	12895439				2021-06-18	
J	Vink, R; O'Connor, CA; Nimmo, AJ; Heath, DL				Vink, R; O'Connor, CA; Nimmo, AJ; Heath, DL			Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; magnesium; neurotrauma; deficits	BLOOD; THERAPY; STRESS; ACIDS	Although a number of studies have demonstrated that magnesium improves acute motor and cognitive outcome after traumatic brain injury, others have failed to show positive effects on cognitive outcome and none have examined persistent functional deficits. The present study shows that severe impact-acceleration induced, diffuse traumatic brain injury in rats produced profound motor and cognitive deficits that persisted for at least 4 weeks after trauma. Intravenous administration of magnesium sulfate (250 [mumoles/kg) at 30 min after injury significantly improved rotarod (sensorimotor) and open field (stress/anxiety) performance, and led to a faster rate of recovery in the Barnes maze (learning). We conclude that posttraumatic magnesium administration attenuates long-term motor and cognitive deficits after traumatic brain injury, and that this improvement may include some reduction of post-traumatic stress and anxiety. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia	Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.	robert.vink@adelaide.edu.au	AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934			ALTURA BM, 1992, J APPL PHYSIOL, V72, P194; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; COX IM, 1991, LANCET, V337, P757, DOI 10.1016/0140-6736(91)91371-Z; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Galland L, 1991, Magnes Trace Elem, V10, P287; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Vallee M, 1997, J NEUROSCI, V17, P2626; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink	24	66	70	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 9	2003	336	1					41	44	PII S0304-3940(02)01244-2	10.1016/S0304-3940(02)01244-2			4	Neurosciences	Neurosciences & Neurology	636BD	WOS:000180433900011	12493598				2021-06-18	
J	Raivich, G; Liu, ZQ; Kloss, CUA; Labow, M; Bluethmann, H; Bohatschek, M				Raivich, G; Liu, ZQ; Kloss, CUA; Labow, M; Bluethmann, H; Bohatschek, M			Cytotoxic potential of proinflammatory cytokines: combined deletion of TNF receptors TNFR1 and TNFR2 prevents motoneuron cell death after facial axotomy in adult mouse	EXPERIMENTAL NEUROLOGY			English	Article						motoneuron; microglia; phagocytosis; cell death; alphaX beta2; CD11c/CD18 integrin; cytokine receptor	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; CENTRAL-NERVOUS-SYSTEM; MOTOR NUCLEUS; DEFICIENT MICE; INJURED BRAIN; FACTOR-ALPHA; LYMPHOCYTE RECRUITMENT; NEUROGLIAL ACTIVATION; MICROGLIAL ACTIVATION	Neural injury is known to trigger inflammatory changes, including the synthesis of proinflammatory cytokines such as interleukin-1-beta (IL1beta), tumor necrosis factor-alpha (TNFalpha), and interferon-gamma (IFNgamma) [G. Raivich, L. L. Jones, C. U. A. Kloss, A. Werner, H. Neumann, and G. W. Kreutzberg, 1998, J Neurosci, 18: 5804 -5816] that may play a pivotal role in mediating the cellular response in the affected brain tissue. Here we examined the effects of transgenic deletion of receptors for these cytokines on neuronal cell loss in the adult mouse facial motor nucleus after a peripheral, facial nerve cut. Homozygous deletion of IL1 receptor 1 (ILIRl), TNF receptor 1 or 2 (TNFR1 or TNFR2), or IFNgamma receptor 1 (IFNgammaR1) alone had no effect but combined deletion of TNFR1 and TNFR2 caused a striking absence of alphaX beta2 integrin/IBA1-double-labeled, phagocytic microglial nodules in the axotomized facial motor nucleus 14 days after nerve cut. Moreover, this combined deletion also led to an almost complete prevention of cell loss by Day 29. Additional neuronal cell counts at Day 60 revealed a second phase of motoneuron cell disappearance, which did not depend on the presence of TNF receptors. However, there was still the same 22% difference in the total number of motoneurons between the wild-type and TNFR1 & 2-deficient mice, underlining the role of TNF ligands and both TNF receptors in mediating the early phase of neuronal cell loss after traumatic injury. (C) 2002 Elsevier Science (USA).	UCL, Dept Anat, Dept Obstet & Gynaecol, Perinatal Brain Repair Grp, London WC1E 6HX, England; MPI Neurobiol, Dept Neuromorphol, D-82152 Martinsried, Germany; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Raivich, G (corresponding author), UCL, Dept Anat, Dept Obstet & Gynaecol, Perinatal Brain Repair Grp, 86-96 Chenies Mews, London WC1E 6HX, England.	g.raivich@ucl.ac.uk	Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Bernardes-Silva M, 2001, J CEREBR BLOOD F MET, V21, P1115, DOI 10.1097/00004647-200109000-00009; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bohatschek M., 1999, Society for Neuroscience Abstracts, V25, P1535; Bohatschek M, 2001, EXP NEUROL, V172, P137, DOI 10.1006/exnr.2001.7764; Bohatschek M, 2001, J NEUROSCI RES, V64, P508, DOI 10.1002/jnr.1103; Boutin H, 2001, J NEUROSCI, V21, P5528; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FERNANDES KJL, 2000, SOC NEUR ABS, V26; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Kalla R, 2001, J COMP NEUROL, V436, P182; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Krieglstein K, 2000, NAT NEUROSCI, V3, P1085, DOI 10.1038/80598; Labow M, 1997, J IMMUNOL, V159, P2452; Matsuda S, 1996, NEUROSCI LETT, V204, P109, DOI 10.1016/0304-3940(96)12340-5; MERRILL JE, 1992, P NATL ACAD SCI USA, V89, P574, DOI 10.1073/pnas.89.2.574; Moller JC, 1996, GLIA, V17, P121; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Raivich G, 1998, J NEUROSCI, V18, P5804; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Seilhean D, 1997, ACTA NEUROPATHOL, V93, P508, DOI 10.1007/s004010050646; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Terrado J, 2000, EUR J NEUROSCI, V12, P3443, DOI 10.1046/j.1460-9568.2000.00240.x; TORVIK A, 1971, ACTA NEUROPATHOL, V17, P265, DOI 10.1007/BF00685059; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002	48	66	68	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2002	178	2					186	193		10.1006/exnr.2002.8024			8	Neurosciences	Neurosciences & Neurology	628HX	WOS:000179988500004	12504878				2021-06-18	
J	Okada, Y; Akai, T; Okamoto, K; Iida, T; Takata, H; Iizuka, H				Okada, Y; Akai, T; Okamoto, K; Iida, T; Takata, H; Iizuka, H			A comparative study of the treatment of chronic subdural hematoma-burr hole: Drainage versus burr hole irrigation	SURGICAL NEUROLOGY			English	Article						chronic subdural hematoma; irrigation; drainage; recurrence	CLOSED-SYSTEM DRAINAGE; CRANIOSTOMY	BACKGROUND Several surgical procedures have been reported for the treatment of chronic subdural hematoma. Whether irrigation is required is not clear, We compared the results of treatment of chronic subdural hematoma obtained with burr hole drainage and burr hole irrigation retrospectively. METHODS Forty patients with chronic subdural hematoma underwent surgery at our institution in the last 3 years. The first 20 patients were treated by burr hole irrigation (irrigation group), while the last 20 patients underwent burr hole drainage (drainage group). The rates of recurrence changes in hematoma size, and number of days of postoperative hospitalization for the two groups were compared. No significant differences were found between the two groups in the presence of head injury, alcohol consumption, age, gender, or preoperative hematoma size. RESULTS Duration of postoperative hospitalization was 14.1 days in the drainage group and 25.5 days in the irrigation group. Recurrence was observed in 1 case (5%) in the drainage group, and in 5 cases (25%) in the irrigation group. In the drainage group, postoperative hematoma size was significantly decreased compared to preoperative hematoma size on the first postoperative day, after which change in hematoma size was minimal. On the other hand, in the irrigation group, hematoma size was decreased on the first postoperative day, but not to a significant extent, CONCLUSION For treatment of chronic subdural hematoma, postoperative hospitalization was shorter and the recurrence was less frequent with drainage than with irrigation. (C) 2002 by Elsevier Science Inc.	Kanazawa Med Univ, Dept Neurosurg, Kanazawa, Ishikawa 9200293, Japan	Akai, T (corresponding author), Kanazawa Med Univ, Dept Neurosurg, 1-1 Uchinada Machi, Kanazawa, Ishikawa 9200293, Japan.						Asano Y, 1992, No To Shinkei, V44, P827; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; IWATA T, 1980, NEUROTRAUMATOLOGY, V3, P202; KOTWICA Z, 1991, British Journal of Neurosurgery, V5, P461, DOI 10.3109/02688699108998474; KRUPP WF, 1995, BRIT J NEUROSURG, V9, P619, DOI 10.1080/02688699550040909; LUSINS J, 1978, J COMPUT ASSIST TOMO, V2, P460, DOI 10.1097/00004728-197809000-00016; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; RICHTER HP, 1984, ACTA NEUROCHIR, V71, P179, DOI 10.1007/BF01401313; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; Sato M, 1999, NEUROL SURG TOKYO, V27, P323; SHIMAZAKI M, 1998, NEUROTRAUMATOLOGY, V21, P161; Smely C, 1997, ACTA NEUROCHIR, V139, P818, DOI 10.1007/BF01411399; SUZUKI J, 1970, J NEUROSURG, V33, P548, DOI 10.3171/jns.1970.33.5.0548; Suzuki K, 1998, SURG NEUROL, V50, P231, DOI 10.1016/S0090-3019(97)00339-X; TABADDOR K, 1977, J NEUROSURG, V46, P220, DOI 10.3171/jns.1977.46.2.0220; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; WEIR BKA, 1983, CAN J NEUROL SCI, V10, P22, DOI 10.1017/S0317167100044516	20	66	75	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2002	57	6					405	410	PII S0090-3019(02)00720-6	10.1016/S0090-3019(02)00720-6			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	586DN	WOS:000177569500007	12176202				2021-06-18	
S	Flor, PJ; Battaglia, G; Nicoletti, F; Gasparini, F; Bruno, V		Alzheimer, C		Flor, PJ; Battaglia, G; Nicoletti, F; Gasparini, F; Bruno, V			Neuroprotective activity of metabotropic glutamate receptor ligands	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							GROWTH-FACTOR-BETA; EXCITOTOXIC NEURONAL DEATH; CEREBELLAR GRANULE CELLS; (+)-2-AMINOBICYCLO<3.1.0>HEXANE-2,6-DICARBOXYLIC ACID LY354740; CEREBROCORTICAL NERVE-TERMINALS; CULTURED CORTICAL-NEURONS; RAT HIPPOCAMPAL-NEURONS; GROUP-II; SYNAPTIC-TRANSMISSION; PHARMACOLOGICAL CHARACTERIZATION	Metabotropic glutamate receptors forma family of currently eight subtypes (mGluR1-8), subdivided into three groups (I-III). Activation of group-II (mGluR2 and -3) or group-Ill metabotropic glutamate receptors (mGluR4, -6, -7 and -8) has been established to be neuroprotective in vitro and in vivo. In contrast, group-I mGluRs (mGluR1 and -5) need to be antagonized in order to evoke protection. Initially, all neuroprotective mGluR ligands were analogues of L-glutamate. Those compounds were valuable to demonstrate protection in vitro, but showed limited applicability in animal models, particularly in chronic tests, due to low blood-brain-barrier penetration. Recently, systemically active and more potent and selective ligands. became available, e.g., the group-II mGluR agonists LY354740 and LY379268 or group-I antagonists like MPEP (mGluR5-selective) and BAY36-7620 (mGluR1-selective). This new generation of pharmacological agents allows a more stringent assessment of the role of individual mGluR-subtypes or groups of receptors in various nervous system disorders, including ischaemia-induced brain damage, traumatic brain injury, Huntington s and Parkinson s-like pathology or epilepsy. Moreover, the use of genetically modified animals (e.g., knock-out mice) is starting to shed light on specific functions of mGluR-subtypes in experimental neuropathologies.	Novartis Pharma AG, Nervous Syst Res, Basel, Switzerland; Ist Neurol Med Neuromed, Pozzilli, Italy; Univ Rome, Dept Human Physiol & Pharmacol, Rome, Italy	Flor, PJ (corresponding author), Novartis Pharma AG, Nervous Syst Res, Basel, Switzerland.		bruno, Valeria/F-3146-2012; Battaglia, Giuseppe/A-7709-2010; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016	bruno, Valeria/0000-0003-4231-0739; Battaglia, Giuseppe/0000-0001-7571-3417; NICOLETTI, Ferdinando/0000-0003-3366-7269			AbdulGhani AS, 1997, BRAIN RES, V755, P202, DOI 10.1016/S0006-8993(97)00098-X; Alagarsamy S, 1999, NAT NEUROSCI, V2, P234; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; AMBROSINI A, 1995, MOL PHARMACOL, V47, P1057; Ango F, 2000, J NEUROSCI, V20, P8710; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Awad H, 2000, J NEUROSCI, V20, P7871; Battaglia G, 1998, EUR J PHARMACOL, V356, P271, DOI 10.1016/S0014-2999(98)00551-2; BATTAGLIA G, 2001, IN PRESS MOL CELL NE; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Behrens MM, 1999, NEUROPHARMACOLOGY, V38, P1621, DOI 10.1016/S0028-3908(99)00098-2; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 1998, NEUROREPORT, V9, P1191, DOI 10.1097/00001756-199804200-00042; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bradley SR, 1999, J COMP NEUROL, V407, P33; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Bruno V, 2000, NEUROPHARMACOLOGY, V39, P2223, DOI 10.1016/S0028-3908(00)00079-4; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; Bruno V, 2001, EUR J NEUROSCI, V13, P1469, DOI 10.1046/j.0953-816x.2001.01541.x; Bruno V, 1996, EUR J PHARMACOL, V310, P61, DOI 10.1016/0014-2999(96)00358-5; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 1998, J NEUROSCI, V18, P9594; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; Bruno V, 1997, J NEUROSCI, V17, P1891; Buisson A, 1998, FASEB J, V12, P1683; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bushell TJ, 1999, NEUROPHARMACOLOGY, V38, P1553, DOI 10.1016/S0028-3908(99)00103-3; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Carroll FY, 2001, MOL PHARMACOL, V59, P965; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; Chapman AG, 1999, EUR J PHARMACOL, V383, P23, DOI 10.1016/S0014-2999(99)00615-9; Chuang SC, 2000, J NEUROPHYSIOL, V83, P2844; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Copani A, 1999, FASEB J, V13, P2225; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copani A, 1998, EUR J NEUROSCI, V10, P2173, DOI 10.1046/j.1460-9568.1998.00230.x; Corti C., 1997, Society for Neuroscience Abstracts, V23, P939; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Doherty AJ, 2000, BRIT J PHARMACOL, V131, P239, DOI 10.1038/sj.bjp.0703574; DONOFRIO M, 2001, IN PRESS J NEUROCHEM; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; FLOR PJ, 1995, EUR J NEUROSCI, V7, P622, DOI 10.1111/j.1460-9568.1995.tb00666.x; Flor PJ, 1996, J NEUROCHEM, V67, P58; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; FLOR PJ, 1995, NEUROPHARMACOLOGY, V34, P149, DOI 10.1016/0028-3908(94)00149-M; Gasparini F, 2000, BIOORG MED CHEM LETT, V10, P1241, DOI 10.1016/S0960-894X(00)00197-9; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; GEREAU RW, 1995, J NEUROSCI, V15, P6879; GOTTRON F, 1995, NEUROSCI LETT, V194, P1, DOI 10.1016/0304-3940(95)11698-V; GRAHAM ME, 1994, EUR J PHARM-MOLEC PH, V288, P115, DOI 10.1016/0922-4106(94)90016-7; Helton DR, 1997, NEUROPHARMACOLOGY, V36, P1511, DOI 10.1016/S0028-3908(97)00170-6; Helton DR, 1998, J PHARMACOL EXP THER, V284, P651; Henrich-Noack P, 1998, NEUROREPORT, V9, P985, DOI 10.1097/00001756-199804200-00006; Henrich-Noack P, 2000, NEUROPHARMACOLOGY, V39, P911, DOI 10.1016/S0028-3908(99)00256-7; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; Herrero I, 1998, J BIOL CHEM, V273, P1951, DOI 10.1074/jbc.273.4.1951; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IVERSEN L, 1994, J NEUROCHEM, V63, P625; Jia ZP, 1998, LEARN MEMORY, V5, P331; JOHANSEN PA, 1995, MOL PHARMACOL, V48, P140; JOLY C, 1995, J NEUROSCI, V15, P3970; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kingston AE, 1999, EUR J PHARMACOL, V377, P155, DOI 10.1016/S0014-2999(99)00397-0; Kingston AE, 1999, ANN NY ACAD SCI, V890, P438, DOI 10.1111/j.1749-6632.1999.tb08022.x; Klodzinska A, 2000, N-S ARCH PHARMACOL, V361, P283, DOI 10.1007/s002109900197; Klodzinska A, 1999, POL J PHARMACOL, V51, P543; Konieczny J, 1998, N-S ARCH PHARMACOL, V358, P500, DOI 10.1007/PL00005284; Kosinski CM, 1999, J COMP NEUROL, V415, P266; Lafon-Cazal M, 1999, EUR J NEUROSCI, V11, P663, DOI 10.1046/j.1460-9568.1999.00475.x; Lam AGM, 1998, NEUROSCI LETT, V254, P121, DOI 10.1016/S0304-3940(98)00651-X; Laurie DJ, 1996, EUR J PHARMACOL, V296, pR1, DOI 10.1016/0014-2999(95)00868-3; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Litschig S, 1999, MOL PHARMACOL, V55, P453; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; Maiese K, 2000, J NEUROSCI RES, V62, P257, DOI 10.1002/1097-4547(20001015)62:2<257::AID-JNR10>3.0.CO;2-H; Martin G, 1997, J NEUROPHYSIOL, V78, P3028; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; Meucci O, 1996, J NEUROSCI, V16, P4080; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; Mineff E, 1999, NEUROSCI LETT, V270, P95, DOI 10.1016/S0304-3940(99)00484-X; MIYAMOTO M, 1994, EUR J PHARMACOL, V260, P99, DOI 10.1016/0014-2999(94)90016-7; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; Morishita W, 1998, J NEUROSCI, V18, P4870; MULLER T, 2000, SOC NEUR ABSTR, V26, P1650; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Neugebauer V, 2000, J NEUROPHYSIOL, V84, P759; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; Orlando LR, 2001, EXP NEUROL, V167, P196, DOI 10.1006/exnr.2000.7542; PAQUET M, 2000, SOC NEUR ABS, V26, P13; Pekhletski R, 1996, J NEUROSCI, V16, P6364; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; Pizzi M, 2000, NEUROPHARMACOLOGY, V39, P903, DOI 10.1016/S0028-3908(99)00257-9; PIZZI M, 1993, J NEUROCHEM, V61, P683; Popik P, 2000, BRIT J PHARMACOL, V130, P1425, DOI 10.1038/sj.bjp.0703438; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Sabelhaus CF, 2000, BRIT J PHARMACOL, V131, P655, DOI 10.1038/sj.bjp.0703646; Salt TE, 2000, NEUROSCIENCE, V100, P375, DOI 10.1016/S0306-4522(00)00265-7; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Scorziello A, 1997, J NEUROSCI RES, V49, P600, DOI 10.1002/(SICI)1097-4547(19970901)49:5&lt;600::AID-JNR10&gt;3.0.CO;2-Z; Shekhar A, 2000, NEUROPHARMACOLOGY, V39, P1139, DOI 10.1016/S0028-3908(99)00215-4; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Sistiaga A, 1998, NEUROPHARMACOLOGY, V37, P1485, DOI 10.1016/S0028-3908(98)00129-4; Sistiaga A, 2000, J NEUROCHEM, V75, P1566, DOI 10.1046/j.1471-4159.2000.0751566.x; SPOOREN WPJ, 2001, IN PRESS TRENDS PHAR, V22; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tang E, 1997, EUR J PHARMACOL, V327, P109, DOI 10.1016/S0014-2999(97)89649-5; Thomsen C, 1999, J NEUROCHEM, V72, P835, DOI 10.1046/j.1471-4159.1999.0720835.x; Thomsen C, 1996, MOL PHARMACOL, V50, P6; Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Vandergriff J, 1999, NEUROPHARMACOLOGY, V38, P217, DOI 10.1016/S0028-3908(98)00196-8; Walker K, 2001, NEUROPHARMACOLOGY, V40, P1, DOI 10.1016/S0028-3908(00)00113-1; Wolfarth S, 2000, AMINO ACIDS, V19, P95, DOI 10.1007/s007260070038; Wood P L, 1998, Expert Opin Investig Drugs, V7, P1505, DOI 10.1517/13543784.7.9.1505; Wroblewska B, 1997, J NEUROCHEM, V69, P174	152	66	72	0	4	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						197	223					27	Medicine, Research & Experimental	Research & Experimental Medicine	BW92A	WOS:000183600500007	12575822				2021-06-18	
J	Rowles, DJ; McGrory, JE				Rowles, DJ; McGrory, JE			Percutaneous pinning of the proximal part of the humerus - An anatomic study	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							SURGICAL NECK; FRACTURES; FIXATION	Background: Closed reduction and percutaneous pinning of unstable proximal humeral fractures is a well-described technique with some theoretical advantages over open techniques. To our knowledge, the risk of injury to neurovascular structures from percutaneous pinning of the proximal part of the humerus has not been studied. We sought to quantify this risk using a cadaveric model. Methods: In ten fresh-frozen cadaveric shoulders, the intact proximal part of the humerus was pinned under fluoroscopic guidance with use of an identical published technique. A total of five 2.5-mm terminally threaded AO pins, including two lateral, one anterior, and two greater tuberosity pins, were used in each shoulder. The specimens were then dissected to determine the distance of each pin from adjacent neurovascular structures as well as key anatomic relationships. Results: The proximal lateral pins were located at a mean distance of 3 mm from the anterior branch of the axillary nerve. Four of the twenty lateral pins were noted to penetrate the articular cartilage of the humeral head. The anterior pins were located at a mean distance of 2 mm from the tendon of the long head of the biceps (perforating the tendon in three specimens) and of 11 mm from the cephalic vein (perforating the vein in one specimen). The proximal tuberosity pins were located at a mean distance of 6 and 7 mm from the axillary nerve and the posterior humeral circumflex artery (tenting the structures in two specimens with internal rotation), respectively. These pins moved away from the nerve with external rotation of the humerus. Conclusions: The technique used in this study may be associated with a risk of injury to important anatomic structures about the shoulder. Lateral pins should be distal enough to avoid injury to the anterior branch of the axillary nerve, and multiple fluoroscopic views should be obtained to avoid penetration of the humeral head cartilage. There may be a risk of injury to the cephalic vein, the biceps tendon, and the musculocutaneous nerve with use of anterior pins, and these pins should be employed with caution. Greater tuberosity pins should be placed with the arm in external rotation, should be aimed for a point greater than or equal to 20 mm from the inferior aspect of the humeral head, and should not overpenetrate the cortex.	USN, Med Ctr, Charette Hlth Care Ctr, Dept Orthopaed Surg, Portsmouth, VA 23708 USA	Rowles, DJ (corresponding author), 2144 Sunset Maple Lane, Chesapeake, VA 23323 USA.						Chen CY, 1998, J TRAUMA, V45, P1039, DOI 10.1097/00005373-199812000-00011; Ebraheim N, 1996, Am J Orthop (Belle Mead NJ), V25, P506; FLEISCHMANN W, 1993, ORTHOPEDICS, V16, P59; JABERG H, 1992, J BONE JOINT SURG AM, V74A, P508, DOI 10.2106/00004623-199274040-00006; JAKOB RP, 1991, J BONE JOINT SURG BR, V73, P295; KOCIALKOWSKI A, 1990, INJURY, V21, P209, DOI 10.1016/0020-1383(90)90003-D; Koval KJ, 1996, J TRAUMA, V40, P778, DOI 10.1097/00005373-199605000-00017; Maurer F, 1993, Aktuelle Traumatol, V23, P380; Naidu SH, 1997, ORTHOPEDICS, V20, P1073; NEER CS, 1963, SURG CLIN N AM, V43, P1581; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; OLMEDA A, 1989, Italian Journal of Orthopaedics and Traumatology, V15, P353; Povacz P, 1998, Ther Umsch, V55, P192	13	66	68	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	NOV	2001	83A	11					1695	1699		10.2106/00004623-200111000-00012			5	Orthopedics; Surgery	Orthopedics; Surgery	490YR	WOS:000172081700013	11701793				2021-06-18	
J	Bogner, JA; Corrigan, JD; Fugate, L; Mysiw, WJ; Clinchot, D				Bogner, JA; Corrigan, JD; Fugate, L; Mysiw, WJ; Clinchot, D			Role of agitation in prediction of outcomes after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							CLOSED-HEAD-INJURY; BEHAVIOR SCALE; GALVESTON ORIENTATION; PRACTICAL SCALE; AMNESIA TEST; RECOVERY; REHABILITATION; MANAGEMENT; COGNITION; PATIENT	Objective: To determine the role of agitation in the prediction of traumatic brain injury rehabilitation outcomes. Design: A longitudinal study of 340 consecutive patients admitted to an acute traumatic brain injury rehabilitation unit was conducted. Outcomes under study included rehabilitation length of stay, discharge destination, functional independence at discharge (FIM (TM) instrument), productivity at 1-yr follow-up, and life satisfaction at 1-yr follow-up (Satisfaction with Life Scale). Results: Univariate analyses suggested that the presence of agitation in rehabilitation is predictive of a longer length of stay and decreased functional independence in the cognitive realm at discharge. In addition, individuals who exhibit agitation at any time during rehabilitation are less likely to be discharged to a private residence. However, multivariate analyses indicated that cognitive functioning at admission to rehabilitation (FIM cognitive) mediates the relationship between the presence of agitation and length of rehabilitation, as well as between agitation and FIM cognitive at discharge. Similar results were found when discharge residence was the dependent variable; however, agitation also contributed some unique variance to the prediction. Lower cognitive functioning at admission to rehabilitation was associated with the occurrence of agitation during rehabilitation, longer length of stay, lower cognitive functioning at discharge, and a decreased likelihood that an individual would be discharged to a private residence. Conclusions: The results of the multivariate analyses support the contention that agitation and cognition are intimately related, with the long-term effects of the former being at least partially driven by the latter. These findings support the importance of systematically monitoring both agitation and cognition when applying interventions to reduce agitation.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Bogner, JA (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011; Bogner, Jennifer/E-2773-2011	Clinchot, Daniel/0000-0002-2810-7227			Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CANTINI E, 1992, Brain Injury, V6, P193, DOI 10.3109/02699059209029659; CASSIDY JW, 1994, J HEAD TRAUMA REHAB, V9, P43, DOI 10.1097/00001199-199409000-00005; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P262; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Dietz M A, 1991, J Stroke Cerebrovasc Dis, V1, P37, DOI 10.1016/S1052-3057(11)80018-2; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, STROKE, V21, P179; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HASHMI FH, 1998, ANN LONG TERM CARE, V6, P1; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KRAUS J, 1999, REHABILITATION ADULT; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Montgomery P, 1997, Rehabil Nurs, V22, P20; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; ROWLAND TR, 1992, ARCH PHYS MED REHAB, V73, P9653; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silver J M, 1993, NeuroRehabilitation, V3, P15, DOI 10.3233/NRE-1993-3204; *STAT U NEW YORK B, 1998, GUID UN DAT SET MED; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TEASDALE G, 1974, LANCET, V2, P81; TERI L, 1992, ALZ DIS ASSOC DIS, V6, P77, DOI 10.1097/00002093-199206020-00003; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zafonte RD, 1997, J HEAD TRAUMA REHAB, V12, P78, DOI 10.1097/00001199-199704000-00008	52	66	66	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP	2001	80	9					636	644		10.1097/00002060-200109000-00002			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	464ZW	WOS:000170564100002	11523965				2021-06-18	
J	McCrory, P; Johnston, KM; Mohtadi, NG; Meeuwisse, W				McCrory, P; Johnston, KM; Mohtadi, NG; Meeuwisse, W			Evidence-based review of sport-related concussion: Basic science	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; traumatic brain injury; sport	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; 2ND IMPACT SYNDROME; E-DEFICIENT MICE; DELAYED DETERIORATION; ALZHEIMERS-DISEASE; SOCCER INJURIES; NECK INJURIES; DAMAGE	The evidence base for sport-related concussive brain injury is reviewed in this paper. In the past, pathophysiological understanding of this common condition has been extrapolated from studies of severe brain trauma. More recent scientific study demonstrates that this approach is unsatisfactory, and the clinical features of concussion represent a predominantly functional brain injury rather than manifest by structural or neuropathological damage. Such understanding of this condition remains incomplete at this stage.	Univ Melbourne, Ctr Sports Med Res & Educ, Melbourne, Vic, Australia; Univ Melbourne, Brain Res Inst, Melbourne, Vic, Australia; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; Univ Calgary, Sport Med Ctr, Calgary, AB, Canada	McCrory, P (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3103, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				ADAMS J M, 1986, P1; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barth JT., 1989, MILD HEAD INJURY, P257; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BROWN WJ, 1972, AM J PATHOL, V67, P41; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; CANTU R, 1995, BOXING MED; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1982, ATHLETIC INJURIES HE, P93; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gilbert M M, 1968, Headache, V8, P57, DOI 10.1111/j.1526-4610.1968.hed0802057.x; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALL ED, 1993, CURRENT CONCEPTS UPJ, P1; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; JORDAN BD, 1993, MED ASPECTS BOXING; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MADDOCKS DL, 1995, THESIS U MELBOURNE M; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; NARAYANA R, 1996, NEUROTRAUMA; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1990, SPORTS NEUROLOGY; OPPENHEIMER D, 1968, J EXP NEUROL, V26, P77; PALMER AC, 1982, VET REC, V111, P575; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; PARKINSON D, 1988, NEUROSURGERY, V23, P682, DOI 10.1097/00006123-198811000-00029; PARKINSON D, 1988, SURG NEUROL, V30, P102, DOI 10.1016/0090-3019(88)90094-8; PARKINSON D, 1977, MAYO CLIN PROC, V52, P492; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; POVISHLOK J, 1983, J NEUROPATH EXP NEUR, V42, P225; RICE SG, 1995, SPORTS MED PRIM CARE, V1, P9; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shetter A G, 1979, Adv Neurol, V22, P5; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; SYMONDS C, 1962, LANCET, V1, P1; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; TAYLOR AR, 1966, HEAD INJURY, P235; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THORNDIEK A, 1952, NEW ENGL J MED, V246, P552; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WARD A, 1964, CLIN NEUROSURG, V12, P129; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	83	66	66	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					160	165		10.1097/00042752-200107000-00006			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900005	11495320				2021-06-18	
J	Hanten, G; Martin, RC				Hanten, G; Martin, RC			Contributions of phonological and semantic short-term memory to sentence processing: Evidence from two cases of closed head injury in children	JOURNAL OF MEMORY AND LANGUAGE			English	Article						short-term memory; sentence comprehension; sentence repetition; multiple components of STM; language development	WORKING-MEMORY; WORD-LENGTH; GRAMMATICALITY JUDGMENTS; ACOUSTIC SIMILARITY; SPOKEN LANGUAGE; COMPREHENSION; APHASIA; RECALL; SPAN; ACQUISITION	This paper reports the short-term memory and sentence processing performance of two head-injured children who were approximately 10 years of age at the time of test. The two children were found to have similarly reduced memory span on a variety of short-term memory tasks relative to age-matched control children, but differing patterns of performance. One child showed reduced (or absent) effects of phonological variables, and the other showed reduced effects of semantic variables. A dissociation in their performance on sentence processing tasks was also observed, with one child showing preserved comprehension but impaired repetition, and the other child showing the reverse. The results are consistent with previous findings from brain-damaged adults supporting a multiple-components model of short-term memory in which phonological and semantic components play different roles in sentence processing. Contrary to our initial hypothesis, the phonological component did not appear to play a more important role in sentence comprehension for children than for adults. (C) 2000 Acadcmic Press.	Rice Univ, Dept Psychol, Houston, TX 77251 USA	Martin, RC (corresponding author), Rice Univ, Dept Psychol, POB 1892, Houston, TX 77251 USA.	rmartin@rice.edu					Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; Baddeley A, 1993, Memory, V1, P65, DOI 10.1080/09658219308258225; Baddeley A. D., 1986, WORKING MEMORY; BOURASSA DC, 1994, PSYCHON B REV, V1, P122, DOI 10.3758/BF03200768; BUTTERWORTH B, 1986, Q J EXP PSYCHOL-A, V38, P705, DOI 10.1080/14640748608401622; Caplan D, 1999, BEHAV BRAIN SCI, V22, P77; CARAMAZZA A, 1981, BRAIN LANG, V14, P235, DOI 10.1016/0093-934X(81)90078-X; CARPENTER PA, 1981, J VERB LEARN VERB BE, V20, P137, DOI 10.1016/S0022-5371(81)90357-1; COWAN N, 1994, J MEM LANG, V33, P234, DOI 10.1006/jmla.1994.1012; COWAN N, 1991, J EXP CHILD PSYCHOL, V51, P30, DOI 10.1016/0022-0965(91)90076-5; DELL GS, 1990, LANG COGNITIVE PROC, V5, P313, DOI 10.1080/01690969008407066; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DUNN LM, 1980, PEABODY PICTURE VOCA; FREEDMAN M, IN PRESS COGNITIVE N; Gathercole S E, 1994, Memory, V2, P103, DOI 10.1080/09658219408258940; Gathercole SE, 1999, APPL COGNITIVE PSYCH, V13, P65, DOI 10.1002/(SICI)1099-0720(199902)13:1<65::AID-ACP548>3.0.CO;2-O; Gathercole SE, 1997, DEV PSYCHOL, V33, P966, DOI 10.1037/0012-1649.33.6.966; GATHERCOLE SE, 1990, BRIT J PSYCHOL, V81, P439, DOI 10.1111/j.2044-8295.1990.tb02371.x; GILHOOLY KJ, 1980, BEHAV RES METH INSTR, V12, P395, DOI 10.3758/BF03201693; HALL JF, 1954, AM J PSYCHOL, V67, P138, DOI 10.2307/1418080; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HENRY LA, 1991, Q J EXP PSYCHOL-A, V43, P35, DOI 10.1080/14640749108400998; HITCH GJ, 1989, MEM COGNITION, V17, P175, DOI 10.3758/BF03197067; HOLCOMB PJ, 1992, DEV NEUROPSYCHOL, V8, P203, DOI 10.1080/87565649209540525; HOLLAND BA, 1986, AM J NEURORADIOL, V7, P201; HULME C, 1989, J EXP CHILD PSYCHOL, V47, P72, DOI 10.1016/0022-0965(89)90063-5; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; HULME C, 1984, DEV PSYCHOL, V20, P650, DOI 10.1037/0012-1649.20.4.650; JESCHENIAK JD, 1994, J EXP PSYCHOL LEARN, V20, P824, DOI 10.1037/0278-7393.20.4.824; Kabrich M, 1996, AM J MENT RETARD, V100, P510; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Knott R, 1997, COGNITIVE NEUROPSYCH, V14, P1165, DOI 10.1080/026432997381303; Lenneberg Eric H., 1967, BIOL FDN LANGUAGE; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Liu H, 1997, APPL PSYCHOLINGUIST, V18, P157, DOI 10.1017/S0142716400009954; MANN VA, 1989, J LEARN DISABIL, V22, P76, DOI 10.1177/002221948902200202; MARSLENWILSON W, 1980, COGNITION, V8, P1, DOI 10.1016/0010-0277(80)90015-3; MARTIN N, 1992, BRAIN LANG, V43, P240, DOI 10.1016/0093-934X(92)90130-7; Martin N, 1997, COGNITIVE NEUROPSYCH, V14, P641; MARTIN N, 1990, BRAIN LANG, V39, P254, DOI 10.1016/0093-934X(90)90014-8; MARTIN R, 1995, PSYCH SOC M LOS ANG; Martin R.C., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; Martin R. C., 1996, MODELS SHORT TERM ME, P149; MARTIN RC, 1992, COGNITIVE NEUROPSYCH, V9, P509, DOI 10.1080/02643299208252070; MARTIN RC, 1994, J MEM LANG, V33, P83, DOI 10.1006/jmla.1994.1005; MARTIN RC, 1993, MEM COGNITION, V21, P176, DOI 10.3758/BF03202730; MARTIN RC, 1987, BRAIN LANG, V32, P159, DOI 10.1016/0093-934X(87)90122-2; Martin RC, 1999, J MEM LANG, V41, P3, DOI 10.1006/jmla.1999.2637; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; MONTGOMERY JW, 1995, J SPEECH HEAR RES, V38, P187, DOI 10.1044/jshr.3801.187; MORRISON CM, 1992, MEM COGNITION, V20, P705, DOI 10.3758/BF03202720; Nippold M. A., 1988, LATER LANGUAGE DEV; PAIVIO A, 1965, J VERB LEARN VERB BE, V4, P32, DOI 10.1016/S0022-5371(65)80064-0; PATTERSON K, 1994, J COGNITIVE NEUROSCI, V6, P57, DOI 10.1162/jocn.1994.6.1.57; Penney CG, 1999, J EXP PSYCHOL LEARN, V25, P284, DOI 10.1037/0278-7393.25.1.284; POTTER MC, 1990, J MEM LANG, V29, P633, DOI 10.1016/0749-596X(90)90042-X; QUINLAN PT, 1992, OXFORD PSYCHOLINGUIS; Romani C, 1999, J EXP PSYCHOL GEN, V128, P56, DOI 10.1037/0096-3445.128.1.56; Saffran E. M., 1990, NEUROPSYCHOLOGICAL I, P428; SAFFRAN EM, 1975, BRAIN LANG, V2, P420, DOI 10.1016/S0093-934X(75)80081-2; SAFFRAN EM, 1990, ADV COGNITIVE NEUROP, P137; Scott C. M., 1988, LATER LANGUAGE DEV A, P49; SHALLICE T, 1990, NEUROPSYCHOLOGICAL I, P131; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; TYLER LK, 1981, J VERB LEARN VERB BE, V20, P400, DOI 10.1016/S0022-5371(81)90524-7; VALLAR G, 1984, COGNITIVE NEUROPSYCH, V1, P21; WATERS G, 1991, COGNITIVE NEUROPSYCH, V8, P81, DOI 10.1080/02643299108253368; WULFECK B, 1991, BRAIN LANG, V41, P311, DOI 10.1016/0093-934X(91)90158-W; WULFECK BB, 1993, J SPEECH HEAR RES, V36, P1208, DOI 10.1044/jshr.3606.1208	70	66	67	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0749-596X	1096-0821		J MEM LANG	J. Mem. Lang.	AUG	2000	43	2					335	361		10.1006/jmla.2000.2731			27	Linguistics; Psychology; Psychology, Experimental	Linguistics; Psychology	340XE	WOS:000088561000009					2021-06-18	
J	Koshinaga, M; Katayama, Y; Fukushima, M; Oshima, H; Suma, T; Takahata, T				Koshinaga, M; Katayama, Y; Fukushima, M; Oshima, H; Suma, T; Takahata, T			Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices	JOURNAL OF NEUROTRAUMA			English	Article						brain slice; C3b complement receptor (CR3); controlled impact injury; microglial activation; OX42	COLONY-STIMULATING FACTORS; NITRIC-OXIDE; EXTRACELLULAR POTASSIUM; MONONUCLEAR PHAGOCYTES; SPREADING DEPRESSION; MACROPHAGES; INVITRO; ADULT; CELLS; EXPRESSION	In order to assess the role of circulating blood in early microglial activation after traumatic brain injury (TBI), controlled cortical impact injury was applied to adult rat brain slices (400 mu m in thickness) and the microglial response was examined. The complement receptor (CR3) expression and morphological transformation of the microglia were evaluated by OX42 immunohistochemistry. At 5 min following injury, activated microglia with intense CR3 expression appeared throughout the hemisphere on the injured side. In contrast, the morphology and CR3 expression of the microglia on the contralateral side were indistinguishable from those of the resident ramified microglia seen in normal brains, At 30 min following injury, microglial activation was more pronounced on the injured side, while the microglia on the contralateral side still retained a ramified morphology, These results are consistent with our previous observations made in in vivo experiments, which indicate that, as the brain slice paradigm excludes variables arising from the circulating blood, the rapid and widespread microglial activation observed following TBI can not be attributed exclusively to the infiltration of blood-borne macrophages or molecules. Rather this activation is most likely caused by intrinsic mechanisms within the brain tissue, such as traumatic depolarization.	Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan	Koshinaga, M (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, 30-1 Oyaguchi Kamimachi, Tokyo 1738610, Japan.						AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BANATI RB, 1994, J CEREBR BLOOD F MET, V14, P145, DOI 10.1038/jcbfm.1994.19; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Caggiano AO, 1996, J COMP NEUROL, V369, P93, DOI 10.1002/(SICI)1096-9861(19960520)369:1<93::AID-CNE7>3.0.CO;2-F; CHAO CC, 1992, J IMMUNOL, V149, P2736; COLTON CA, 1993, J NEUROSCI RES, V35, P297, DOI 10.1002/jnr.490350309; Del Rio-Hortega R., 1965, CYTOLOGY CELLULAR PA, P483; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elkabes S, 1996, J NEUROSCI, V16, P2508; FINSEN BR, 1993, J CHEM NEUROANAT, V6, P267, DOI 10.1016/0891-0618(93)90048-9; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; HADDAD GG, 1989, J NEUROPHYSIOL, V62, P1213; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; KREUTZBERG GW, 1989, METAB BRAIN DIS, V4, P81, DOI 10.1007/BF00999498; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LIGHTHALL JW, J NEUROTRAUMA, V5, P1; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; SHIMOHAMA S, 1989, MOL BRAIN RES, V5, P271, DOI 10.1016/0169-328X(89)90061-2; SHIPLEY MT, 1994, SOC NEUR ABSTR, V365, P4; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUZUMURA A, 1990, J NEUROIMMUNOL, V30, P111, DOI 10.1016/0165-5728(90)90094-4; SUZUMURA A, 1994, NEUROIMMUNOLOGY TOKY, V1, P122; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708	35	66	68	1	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2000	17	3					185	192		10.1089/neu.2000.17.185			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	297QY	WOS:000086095200002	10757324				2021-06-18	
J	Nakamura, M; Raghupathi, R; Merry, DE; Scherbel, U; Saatman, KE; McIntosh, TK				Nakamura, M; Raghupathi, R; Merry, DE; Scherbel, U; Saatman, KE; McIntosh, TK			Overexpression of Bcl-2 is neuroprotective after experimental brain injury in transgenic mice	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						apoptosis; cognitive function; hippocampus; Morris water maze; neuroprotection; protooncogene	CONTROLLED CORTICAL IMPACT; PROGRAMMED CELL-DEATH; PROTOONCOGENE BCL-2; COGNITIVE DEFICITS; NEURONAL APOPTOSIS; MEMORY IMPAIRMENT; SPATIAL MEMORY; NERVOUS-SYSTEM; CYTOCHROME-C; RATS	The cell death regulatory protein, Bcl-2, has been suggested to participate in the pathophysiology of various neurological disorders, including traumatic brain injury (TBI), The cognitive function and histopathologic sequelae after controlled cortical impact brain injury were evaluated in transgenic (TG) mice that overexpress human Bcl-2 protein (n = 13) and their wild type (WT) controls (n = 9). Although brain-injured Bcl-2 TG mice exhibited similar posttraumatic deficits in a Morris water maze (MWM) test of spatial memory as their WT counterparts at 1 week postinjury, the preinjury learning ability of Bcl-2 TG mice was impaired significantly compared with their WT littermates (P < 0.05). In contrast, histopathologic analysis revealed significantly attenuated tissue loss in the ipsilateral hemisphere (p < 0.01) and decreased tissue loss in ipsilateral hippocampal area CA3 (P < 0.001) and the dentate gyrus (P < 0.01) in brain-injured Bcl-2 TG mice compared with brain-injured WT mice. Immunohistochemical evaluation of glial fibrillary acidic protein also revealed a significant decrease in reactive astrocytosis in the ipsilateral dorsal thalamus (P < 0.05) and the ventral thalamus (P < 0.01) in brain-injured Bcl-2 TG mice. These results suggest that overexpression of Bcl-2 protein may play a protective role in neuropathologic sequelae after TBI. J. Comp. Neurol. 412:681-692, 1999. (C) 1999 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,102B Hayden Hall, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS036248, R55NS026818, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, R29-NS36248, P50-NS26818] Funding Source: Medline		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BECKER JT, 1980, BRAIN RES, V200, P307, DOI 10.1016/0006-8993(80)90922-1; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; Bonfanti L, 1996, J NEUROSCI, V16, P4186; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brown W.J., 1987, EPILEPSY, P300; BULLOCK R, 1994, J NEUROTRAUMA, V11, P214; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crawley JN, 1996, TRENDS NEUROSCI, V19, P181, DOI 10.1016/S0166-2236(96)20021-9; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FADEN AI, 1989, SCIENCE, V244, P789; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IIZUKA H, 1990, STROKE, V21, P7990; Isono M, 1997, BRAIN RES, V765, P319, DOI 10.1016/S0006-8993(97)00661-6; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRINO T, 1982, BRAIN RES, V239, P56; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LATHE R, 1994, NEUROPATH APPL NEURO, V20, P350, DOI 10.1111/j.1365-2990.1994.tb00980.x; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MERRY DE, 1994, DEVELOPMENT, V120, P301; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; OLTON DS, 1982, BRAIN RES, V233, P241, DOI 10.1016/0006-8993(82)91200-8; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Paxinos G., 1985, RAT NERVOUS SYSTEM; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shimizu S, 1996, ONCOGENE, V12, P2251; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; TSUJIMOTO Y, 1985, SCIENCE, V229, P1300; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VOLPE BT, 1988, BEHAV BRAIN RES, V27, P259, DOI 10.1016/0166-4328(88)90122-2; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	81	66	76	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	OCT 4	1999	412	4					681	692		10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F			12	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	230FL	WOS:000082241100009	10464363				2021-06-18	
J	Shohami, E; Gati, I; Beit-Yannai, E; Trembovler, V; Kohen, R				Shohami, E; Gati, I; Beit-Yannai, E; Trembovler, V; Kohen, R			Closed head injury in the rat induces whole body oxidative stress: Overall reducing antioxidant profile	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cyclic voltammetry; peripheral organs; total antioxidant power	CYCLIC VOLTAMMETRY; ENHANCED OSTEOGENESIS; MICROBIAL HEMOLYSINS; ALZHEIMERS-DISEASE; CATIONIC PROTEINS; BRAIN INJURY; URIC-ACID; OXIDANTS; CAPACITY; PLASMA	Traumatic injury to the brain triggers the accumulation of harmful mediators, including highly toxic reactive oxygen species (ROS). Endogenous defense mechanism against ROS is provided by low molecular weight antioxidants (LMWA), reflected in the reducing power of the tissue, which can be measured by cyclic voltammetry (CV). CV records biological peak potential (type of scavenger), and anodic current intensity (scavenger concentration). The effect of closed head injury (CHI) on the reducing power of various organs was studied. Water and lipid soluble extracts were prepared from the brain, heart, lung, kidney, intestine, skin, and liver of control and traumatized rats (1 and 24 h after injury) and total LMWA was determined. Ascorbic acid, uric acid, a-tocopherol, carotene and ubiquinol-10 were also identified by HPLC. The dynamic changes in LMWA levels indicate that the whole body responds to CHI. For example, transient reduction in LMWA (p < 0.01) in the heart, kidney, lung and liver at 1 h suggests their consumption, probably due to interaction with locally produced ROS. However, in some tissues (e.g., skin) there was an increase (p < 0.01), arguing for recruitment of higher than normal levels of LMWA to neutralize the ROS. alpha-tocopherol levels in the brain, liver, lung, skin, and kidney were significantly reduced (p < 0.01) even up to 24 h. We conclude that although the injury was delivered over the left cerebral hemisphere, the whole body appeared to be under oxidative stress, within 24 h after brain injury.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharm, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COHEN AM, 1984, FEBS LETT, V174, P147, DOI 10.1016/0014-5793(84)81094-7; COTEV S, 1990, INT CONGR SER, V885, P237; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; GINSBURG I, 1995, FREE RADICAL RES, V22, P489, DOI 10.3109/10715769509150323; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; HACKENBERRY LE, 1982, CRIT CARE MED, V10, P641; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Halliwell B, 1989, FREE RADICALS BIOL M; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; Kohen R, 1999, METHOD ENZYMOL, V300, P285; KOHEN R, 1988, P NATL ACAD SCI USA, V85, P3175, DOI 10.1073/pnas.85.9.3175; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 1993, INT S ANT DIS PREV I; LANG SA, 1989, AM J PHYSIOL, V256, pE345; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lyras L, 1997, J NEUROCHEM, V68, P2061; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; OGIHARA H, 1995, PEDIATR RES, V37, P219, DOI 10.1203/00006450-199502000-00016; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1071; REITER RJ, 1995, FASEB J, V9, P526; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROTEM M, 1988, NEUROSURGERY, V23, P89, DOI 10.1227/00006123-198807000-00015; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; YAMAMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V819, P29, DOI 10.1016/0005-2736(85)90192-0; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Yukido I, 1990, NEUROSURGERY, V27, P1	47	66	71	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					365	376		10.1089/neu.1999.16.365			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200003	10369557				2021-06-18	
S	Lee, SM; Wong, MD; Samii, A; Hovda, DA		Blass, JP; McDowell, FH		Lee, SM; Wong, MD; Samii, A; Hovda, DA			Evidence for energy failure following irreversible traumatic brain injury	OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Oxidative/Energy Metabolism in Neuridegenerative Disorders	MAR 19-22, 1999	NEW YORK, NEW YORK	New York Acad Sci, Winifred Masterson Burke Med Res Inst Inc, NIA, NIH, MitoKor, Amer Fed Aging Res, Warner Lambert Co, Parke Davis Pharmaceut Res			CEREBRAL GLUCOSE-UTILIZATION; RATS		Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Lee, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, 18-228 NPI, Los Angeles, CA 90095 USA.		Wong, Monica D/D-9016-2017	Wong, Monica D/0000-0001-7041-9518	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS37363, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308, R01NS037363] Funding Source: NIH RePORTER		BERGSNEIDER M, 1997, J NEUROSURG, V86, P247; Delaney SM, 1996, J NEUROSCI METH, V64, P151, DOI 10.1016/0165-0270(95)00119-0; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; REIGER D, 1997, ANAL BIOCHEM, V246, P67; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	7	66	66	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-209-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	893						337	340		10.1111/j.1749-6632.1999.tb07849.x			4	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Multidisciplinary Sciences; Neurosciences; Ornithology	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Science & Technology - Other Topics; Neurosciences & Neurology; Zoology	BP50E	WOS:000085330600038	10672261				2021-06-18	
J	Powell, JH; Beckers, K; Greenwood, RJ				Powell, JH; Beckers, K; Greenwood, RJ			Measuring progress and outcome in community rehabilitation after brain injury with a new assessment instrument - The BICRO-39 scales	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							INTEGRATION QUESTIONNAIRE; PERFORMANCE; DISABILITY	Objective: Construction and validation of a new instrument, the Brain Injury Community Rehabilitation Outcome scales, to assess problems experienced by brain-injured patients living in the community. Design: Seventy-six items describing aspects of personal and social functioning were generated. Two hundred thirty-five patients and/or their carers (separately) rated the items on 6-point scales, and patients retrospectively rated their functioning before injury. Seven scales were derived from factor analysis; one was included a priori. Thirty-nine items with high factor loadings were retained. Test-retest reliability, interrater reliability, and construct validity were examined in subsamples. Setting: Patients were recruited from four centers: two community-based teams, a day-patient clinic, and an outpatient clinic. Patients: Of the patients, 127 had traumatic brain injury, 72 had cerebrovascular accidents, 15 had multiple sclerosis, and 21 had acquired brain injury of other origins. Mean time since brain injury was 2.6 years; mean age was 43 years; 164 were men and 71 were women. Results: All scales showed good test-retest reliability, and agreement between patient and carer ratings was moderate to high. They showed predicted moderate correlations with other relevant scales. Postinjury scores differed significantly from preinjury scores, and 6 of the 8 scales showed change over a period of recovery/rehabilitation. Conclusions: The scales appear reliable and easy to complete. They may have utility as quantitative measures of outcome for clinical and treatment evaluations. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Homerton Hosp, Reg Neurol Rehabil Unit, London, England; Neurol Therapy Ctr, Dusseldorf, Germany	Powell, JH (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, New Cross, London SE14 6NW, England.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Glass CA, 1997, SPINAL CORD, V35, P320, DOI 10.1038/sj.sc.3100447; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1997, ARCH PHYS MED REHAB, V78, pS5, DOI 10.1016/S0003-9993(97)90149-0; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, P3; KLINE P, 1983, ADV BEHAV RES THER, V5, P141, DOI 10.1016/0146-6402(83)90017-6; MAHONEY F I, 1965, Md State Med J, V14, P61; PORT MWM, 1996, ARCH PHYS MED REHAB, V77, P440; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SEGAL ME, 1995, AM J PHYS MED REHABI, V74, P277; *STAT U NY BUFF, 1993, GUID UN DAT SYST MED; vanBennekom CAM, 1996, J CLIN EPIDEMIOL, V49, P39, DOI 10.1016/0895-4356(95)00559-5; Wade D T, 1985, Int Rehabil Med, V7, P176; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 1980, INT CLASS IMP DIS HA; Young NL, 1996, J CLIN EPIDEMIOL, V49, P1097, DOI 10.1016/0895-4356(96)00214-4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	25	66	69	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1998	79	10					1213	1225		10.1016/S0003-9993(98)90265-9			13	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	128CC	WOS:000076386800005	9779674				2021-06-18	
J	Prigatano, GP; Bruna, O; Mataro, M; Munoz, JM; Fernandez, S; Junque, C				Prigatano, GP; Bruna, O; Mataro, M; Munoz, JM; Fernandez, S; Junque, C			Initial disturbances of consciousness and resultant impaired awareness in Spanish patients with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; consciousness; Glasgow Coma Scale; neuropsychology; posttraumatic amnesia; traumatic brain injury	BEHAVIORAL LIMITATIONS; HEAD-INJURY; ANOSOGNOSIA; DYSFUNCTION; 1-YEAR; COMA	The purpose of this prospective, between-subjects study was to took at impaired awareness cross-culturally in patients with traumatic brain injury (TBI) and to relate impaired awareness after injury to the initial estimates of disturbed consciousness at time of injury. The study was conducted in community and inpatient and outpatient rehabilitation centers in Barcelona and;Madrid. Participants were 30 persons with primarily moderate to severe TBI who could complete a written questionnaire concerning their functioning and 28 age- and gender-matched controls. A Spanish translation of the Patient Competency Rating Scale (PCRS) was administered to each participant. Relatives or significant others also completed this scale on each participant using the relative's version (PCRS-R). Difference scores, Obtained by subtracting PCRS-R from PCRS-P (PCRS-P minus PCRS-R), were used as a marker of impaired awareness. Individuals with TBI were rated (by self and significant others) as being less competent than controls. Forty percent of Spanish patients with TBI who suffered severe injuries tended to overestimate their behavioral competencies. The PCRS-P minus the PCRS-R difference scores tended to correlate with admitting Glasgow Coma Scale (GCS) scores and retrospective estimates of posttraumatic amnesia (PTA). Initial disturbances of consciousness, one measure of severity of brain injury, appeared to relate to later measures of impaired self-awareness in Spanish patients with TBI. Non-brain-injured controls did not tend to report levels of competency that differed from their relatives' reports.	St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA; Univ Ramon Llull, Fac Psicol Blanquerna, Barcelona, Spain; Univ Barcelona, Fac Psicol, Barcelona, Spain; Univ Complutense Madrid, Fac Psicol, Madrid, Spain; Univ Jaen, Dept Psicol, Jaen, Spain	Prigatano, GP (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, 350 W Thomas Rd, Phoenix, AZ 85013 USA.		Junque, Carme/B-4400-2011; Bruna, Olga/ABG-7936-2020; Mataro, Maria/B-4524-2011	Junque, Carme/0000-0002-6381-3063; Bruna, Olga/0000-0002-7851-2909; Mataro, Maria/0000-0002-9946-2656			CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fleming J., 1995, BRIT J OCCUP THER, V58, P55, DOI DOI 10.1177/030802269505800204; GIANOTTI G, 1975, PSYCHIAT CLIN BASEL, V8, P99; Jennett B, 1981, MANAGEMENT HEAD INJU; KERTESZ A, 1993, CLIN NEUROPSYCHOLOGY; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P, 1988, BNI Q, V4, P40; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1995, MANUAL BNI SCREEN HI; PRIGATANO GP, 1987, BNI Q, V3, P10; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P27; PRIGATANO GP, 1991, AWRENESS DEFICIT BRA; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SHERER M, 1998, IN PRESS J INT NEURO; SQUIRE LR, 1988, J CLIN EXPT NEUROPSC, V10, P737; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; TEASDALE G, 1974, LANCET, V2, P81	26	66	67	0	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					29	38		10.1097/00001199-199810000-00005			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600005	9753533				2021-06-18	
J	Mesenge, C; Charriaut-Marlangue, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M				Mesenge, C; Charriaut-Marlangue, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M			Reduction of tyrosine nitration after N-omega-nitro-L-arginine-methylester treatment of mice with traumatic brain injury	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						traumatic brain injury; nitric oxide (NO); nitrotyrosine; peroxynitrite; mouse	EXPERIMENTAL HEAD-INJURY; OXYGEN RADICALS; OXIDE; PEROXYNITRITE; SUPEROXIDE	Oxygen free radicals and nitric oxide (NO) have been proposed to be involved in the cascade of injury elicited by traumatic brain injury. However, the mechanism(s) of injury remain to be explored. Since superoxide generation is triggered by traumatic brain injury, the cytotoxic peroxynitrite could be formed, but it is not known if this actually occurs. Dot blot and immunohistochemistry studies were performed to quantify tyrosine nitration and identify cell types in which such reactions occur in the brain of mice submitted to traumatic brain injury. Nitrotyrosine formation increased from 4 to 24 h after traumatic brain injury and was primarily observed in degenerating neurons, in areas corresponding to the sites of direct impact (frontal cortex) and diffuse impact (frontoparietal cortex and ventromedial hypothalamic nucleus). Furthermore, N-omega-nitro-L-arginine-methylester (L-NAME), a NO-synthase inhibitor which has previously been shown to promote neurological recovery in traumatic brain injury, reduced nitrotyrosine formation and the number of nitrotyrosine-positive neurons. These results indicate that traumatic brain injury induces peroxynitrite formation which may contribute to cell damage. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Paris 05, Pharmacol Lab, F-75270 Paris 06, France; INSERM, U29, F-75014 Paris, France	Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, 4 Ave Observ, F-75270 Paris 06, France.		, CHARRIAUT-MARLANGUE/H-3249-2019; MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Ayata C, 1997, J NEUROSCI, V17, P6908; BEAL M, 1997, ANN NEUROL, V42, P554; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, ADV NEUROL, V71, P339; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; COERELI L, 1998, IN PRESS J NEUROCHEM, V70; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Fukuyama N, 1998, J CEREBR BLOOD F MET, V18, P123, DOI 10.1097/00004647-199802000-00001; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MESENGE C, 1998, IN PRESS J PINEAL RE, V24; Smith MA, 1997, J NEUROSCI, V17, P2653; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILET AVD, 1994, FEBS LETT, V339, P89; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Ye YZ, 1996, METHOD ENZYMOL, V269, P201	27	66	66	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUL 17	1998	353	1					53	57		10.1016/S0014-2999(98)00432-4			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	105UK	WOS:000075091800007	9721039				2021-06-18	
J	Pleines, UE; Stover, JF; Kossmann, T; Trentz, O; Morganti-Kossmann, MC				Pleines, UE; Stover, JF; Kossmann, T; Trentz, O; Morganti-Kossmann, MC			Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adhesion molecules; blood-brain barrier; sICAM-1; traumatic brain injury	INTERCELLULAR-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID BARRIER; ENDOTHELIAL-CELLS; ARTERY OCCLUSION; MULTIPLE-SCLEROSIS; CIRCULATING ICAM-1; CORTICAL CONTUSION; RAT-BRAIN; EXPRESSION	The intercellular adhesion molecule-1 (ICAM-1) expressed by endothelial cells is crucial in promoting adhesion and transmigration of circulating leukocytes across the blood-brain barrier (BBB), Migrated immunocompetent cells, in turn, release mediators that stimulate glial and endothelial cells to express ICAM-1 and release cytokines, possibly sustaining cerebral damage. Following activation, proteolytic cleavage of membrane-anchored ICAM-1 results in measurable levels of a soluble form, sICAM-1, The aims of this study were to investigate the changes of sICAM-1 levels in ventricular CSF and serum and to elucidate the influence of structural brain damage as estimated by computerized tomography (CT) as well as the extent of BBB dysfunction as calculated by the CSF/serum albumin ratio (Q(A)) in patients with severe traumatic brain injury (TBI), All investigated parameters revealed two subgroups, Patients belonging to group A had sICAM-1 levels in CSF above normal range, presented marked cerebral damage and a disturbance of the BBB (range 0.6-24.7 ng/ml, n = 8), In contrast, patients belonging to group B had no elevation of sICAM-1 values in CSF (range 0.3-3.9 ng/ml, n = 5; p < 0.017) acid showed minor cerebral damage with an intact BBB in most cases. In addition, overall analysis showed that sICAM-1 in CSF correlated with the extent of BBB damage as indicated by the Q(A) (r = 10.76; P < 0.001), These results suggest that increased sICAM-1 levels in CSF might depict ongoing immunologic activation and that sICAM-1 correlates with the extent of tissue and BBB damage. The origin of soluble ICAM-1 in CSF and its pathophysiologic role after TBI remains to be clarified.	Univ Hosp Zuerich, Div Res, Zurich, Switzerland; Univ Hosp Zuerich, Dept Surg, Div Trauma Surg, Zurich, Switzerland	Morganti-Kossmann, MC (corresponding author), Univ Hosp Zuerich, Div Res, Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ALBELDA SM, 1994, FASEB J, V8, P504; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Budnik A, 1996, EXP HEMATOL, V24, P352; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; CARLOS TM, 1994, BLOOD, V84, P2068; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; CROSS AH, 1991, J NEUROIMMUNOL, V33, P237, DOI 10.1016/0165-5728(91)90111-J; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GEARING AJH, 1992, ANN NY ACAD SCI, V667, P324, DOI 10.1111/j.1749-6632.1992.tb51633.x; GREENWOOD J, 1991, NEURORADIOLOGY, V33, P95, DOI 10.1007/BF00588242; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; JANDER S, 1993, NEUROLOGY, V43, P1809, DOI 10.1212/WNL.43.9.1809; JENNETT B, 1975, LANCET, V1, P480; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; MANDI Y, 1995, RES EXP MED, V195, P297, DOI 10.1007/BF02576800; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MEYER DM, 1995, J IMMUNOL, V155, P3578; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; OHATA K, 1990, ACTA NEUROPATHOL, V81, P162, DOI 10.1007/BF00334505; OHATA K, 1992, J NEUROSURG, V77, P387, DOI 10.3171/jns.1992.77.3.0387; Onal C, 1997, ACTA NEUROCHIR, V139, P661, DOI 10.1007/BF01412002; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; RIECKMANN P, 1993, J NEUROIMMUNOL, V47, P133, DOI 10.1016/0165-5728(93)90023-R; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Rieckmann P, 1996, J NEUROIMMUNOL, V64, P193, DOI 10.1016/0165-5728(95)00176-X; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42; ROSSLER K, 1992, J NEUROSCI RES, V31, P365, DOI 10.1002/jnr.490310219; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SATOH J, 1991, J NEUROSCI RES, V29, P1, DOI 10.1002/jnr.490290102; SATOH JI, 1991, J NEUROPATH EXP NEUR, V50, P215, DOI 10.1097/00005072-199105000-00004; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Staub F, 1996, ACT NEUR S, V66, P56; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STOCKER R, 1995, INTEGRATED APPROACH, P197; TENGVAR C, 1982, ACTA NEUROPATHOL, V57, P233, DOI 10.1007/BF00685395; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958; Wakatsuki T, 1995, CELL ADHES COMMUN, V3, P283, DOI 10.3109/15419069509081014; WECKERLE H, 1993, BLOOD BRAIN BARRIER, P67; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	61	66	69	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					399	409		10.1089/neu.1998.15.399			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700002	9624625	Green Accepted			2021-06-18	
J	Semlyen, JK; Summers, SJ; Barnes, MP				Semlyen, JK; Summers, SJ; Barnes, MP			Traumatic brain injury: Efficacy of multidisciplinary rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; BLUNT HEAD-INJURY; RELATIVES	Objective: To establish efficacy of a coordinated multidisciplinary rehabilitation service for severe head injury, provided at Hunters Moor Regional Rehabilitation Centre. Design: A quasi-experimental design to compare treatment effects between two groups. The first group received a coordinated, multidisciplinary regional rehabilitation service; the other, a single discipline approach provided by local, district hospitals. Follow-up was for 2 years postinjury. Patients or Other Participants: Fifty-six consecutive severe head injury admissions, with an identified main caregiver, referred for rehabilitation within 4 weeks of their injury. Main Outcome Measures: The Barthel index, the Functional Independence Measure (FIM), and the Newcastle Independence Assessment Form (NIAF), a newly developed, real-life, comprehensive measure. In addition, caregivers completed the General Health Questionnaire. Results: The group that received coordinated multidisciplinary rehabilitation not only demonstrated significant gains throughout the study period but also maintained treatment effect after input ended. Furthermore, caregivers of this group had significantly reduced levels of distress. The comparison group, despite initial lower injury severity and shorter hospital stay, did not demonstrate equivalent gains or any posttreatment effect. Conclusions: The results show the efficacy of a comprehensive, specialist multidisciplinary regional service. There are significant implications for service provision for people with severe traumatic head injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Newcastle Upon Tyne, Acad Univ Neurol Rehabil, Hunters Moor Reg Rehabil Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Barnes, MP (corresponding author), Univ Newcastle Upon Tyne, Acad Univ Neurol Rehabil, Hunters Moor Reg Rehabil Ctr, Hunters Rd, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.			SEMLYEN, JOANNA/0000-0001-5372-1344			ANDERSON SI, 1992, BRAIN INJURY, V10, P115; ANDERSON SI, 1994, CLIN REHABIL, V8, P301; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BAUER D, 1989, FDN PHYSICAL REHABIL; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Bowers D, 1989, ARCH PHYS MED REHAB, V70, pA58; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Brooks N., 1984, CLOSED HEAD INJURY P; Chau N, 1994, Disabil Rehabil, V16, P63; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Cook T.D., 1979, QUASIEXPERIMENTATION; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; EAMES P, 1995, BRAIN INJURY, V10, P631; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Goldberg D., 1978, MANUAL GEN HLTH QUES; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JENNETT B, 1975, LANCET, V1, P480; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Johnstone B, 1996, BRAIN INJURY, V10, P627, DOI 10.1080/026990596124052; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, BMJ-BRIT MED J, V291, P919, DOI 10.1136/bmj.291.6500.919; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks JA, 1995, CLIN REHABIL, V9, P320; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCPHERSON K, 1993, CLIN REHABIL, V7, P105; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SANDEL ME, 1995, J NEUROL REHABIL, V9, P111; Semlyen JK, 1997, J NEUROL REHABIL, V11, P213; Semlyen JK, 1996, J NEUROL REHABIL, V10, P251; SEMLYENJK, 1998, BRAIN INJ, V12, P155; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Tennant A., 1996, CLIN REHABIL, V10, P301, DOI [10.1177/026921559601000407, DOI 10.1177/026921559601000407]	53	66	68	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					678	683		10.1016/S0003-9993(98)90044-2			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500014	9630149				2021-06-18	
J	Wahl, F; Renou, E; Mary, V; Stutzmann, JM				Wahl, F; Renou, E; Mary, V; Stutzmann, JM			Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury	BRAIN RESEARCH			English	Article						brain injury; head trauma; fluid percussion; neurological deficit; neuroprotection; riluzole	FOCAL CEREBRAL-ISCHEMIA; AMINO-ACID NEUROTRANSMISSION; SODIUM-CHANNEL BLOCKER; CLOSED-HEAD INJURY; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; ELIPRODIL SL-82.0715; POSSIBLE ANTAGONIST; MAGNETIC-RESONANCE; GLUTAMATE RELEASE; NMDA RECEPTORS	Riluzole (2-amino 6-trifluoromethoxy-benzothiazole) was studied in a rat model of traumatic brain injury (TBI) induced by a fluid percussion applied laterally to the right parietal cortex. Study I: vehicle or riluzole (4 or 8 mg/kg) was administered 15 min (i.v.), 6 h and 24 h (s.c.), after TBI. Brain lesions were quantified 1 week after insult. Riluzole significantly reduced the size of TBI-induced lesions by approximately 44% with either dose regime(P < 0.05). Study II: vehicle or riluzole (8 mg/kg) was administered 15 min (i.v.), 6 h (i.p.) and then twice daily (i.p.) for 6 days, after injury. One, 2 and 3 weeks after TBI, a neurological examination was performed. Control injured rats had a significant neurological deficit at 1, 2 and 3 weeks (P < 0.001). Riluzole treatment did not modify the neurological status evaluated for the first 2 weeks after TBI. However at 3 weeks, riluzole significant improved the neurological function of injured rats (P < 0.05). These results suggest that riluzole may be beneficial in the clinical treatment of TBI. The protective action of riluzole may result from (i) stabilization of the inactivated state of voltage-dependent sodium channels, (ii) indirect action on the glutamatergic pathway, and/or (iii) indirect neurotrophic effect.		Wahl, F (corresponding author), RHONE POULENC RORER, PHARMACEUT DISCOVERY, NEURODEGENERAT DIS DEPT, 13 QUAI JULES GUESDE, F-94403 VITRY SUR SEINE, FRANCE.						BARBEITO L, 1996, J NEUROTRAUM, V13, P629; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BITON B, 1994, EUR J PHARMACOL, V257, P297, DOI 10.1016/0014-2999(94)90142-2; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dargent B, 1996, NEUROSCIENCE, V73, P209, DOI 10.1016/0306-4522(95)00608-7; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; RENUKAPRASAD M, 1994, J NEUROCHEM, V63, P1086; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1993, NEURODEGENER DIS, P205; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; Urenjak J, 1996, PHARMACOL REV, V48, P21; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	61	66	68	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 9	1997	756	1-2					247	255		10.1016/S0006-8993(97)00144-3			9	Neurosciences	Neurosciences & Neurology	XA015	WOS:A1997XA01500032	9187339				2021-06-18	
J	Stella, N; Estelles, A; Siciliano, J; Tence, M; Desagher, S; Piomelli, D; Glowinski, J; Premont, J				Stella, N; Estelles, A; Siciliano, J; Tence, M; Desagher, S; Piomelli, D; Glowinski, J; Premont, J			Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes	JOURNAL OF NEUROSCIENCE			English	Article						purinoceptor; phospholipase; cytokine; inflammation; glutamate; neurotoxicity	CENTRAL-NERVOUS-SYSTEM; CEREBRAL CORTICAL ASTROCYTES; NECROSIS-FACTOR-ALPHA; PRIMARY CULTURES; GENE-EXPRESSION; CYTOSOLIC PHOSPHOLIPASE-A2; STRIATAL ASTROCYTES; PURINERGIC RECEPTOR; EXTRACELLULAR ATP; BRAIN ASTROCYTES	During neuropathological states associated with inflammation, the levels of cytokines such as interleukin-1 beta (IL-1 beta) are increased. Several studies have suggested that the neuronal damage observed in pathogenesis implicating IL-1 beta are caused by an alteration in the neurochemical interactions between neurons and astrocytes. We report here that treating striatal astrocytes in primary culture with IL-1 beta for 22-24 hr enhances the ATP-evoked release of arachidonic acid (AA) with no effect on the ATP-induced accumulation of inositol phosphates. The molecular mechanism responsible for this effect involves the expression of P-2Y2 receptors (a subtype of purinoceptor activated by ATP) and cytosolic phospholipase A2 (cPLA(2), an enzyme that mediates AA release). Indeed, P-2Y2 antisense oligonucleotides reduce the ATP-evoked release of AA only from IL-1 beta-treated astrocytes. Further, both the amount of cPLA2 (as assessed by Western blotting) and the release of AA resulting from direct activation of cPLA(2) increased fourfold in cells treated with IL-1 beta. We also report evidence indicating that the coupling of newly expressed P-2Y2 receptors to cPLA(2) is dependent on PKC activity. These results suggest that during inflammatory conditions, IL-1 beta reveals a functional P-2Y2 signaling pathway in astrocytes that results in a dramatic increase in the levels of free AA. This pathway may thus contribute to the neuronal loss associated with cerebral ischemia or traumatic brain injury.	COLL FRANCE,INSERM U114,NEUROPHARMACOL LAB,F-75231 PARIS 05,FRANCE	Stella, N (corresponding author), INST NEUROSCI,10640 JOHN J HOPKINS DR,SAN DIEGO,CA 92121, USA.						ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; AKBAR MGK, 1996, J BIOL CHEM, V271, P18363; BAN EM, 1993, NEUROSCIENCE, V52, P725, DOI 10.1016/0306-4522(93)90421-B; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNER G, 1990, J NEUROCHEM, V55, P1569, DOI 10.1111/j.1471-4159.1990.tb04940.x; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P812; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTJANSON LJ, 1993, GLIA, V7, P176, DOI 10.1002/glia.440070207; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DELUMEAU JC, 1991, EUR J NEUROSCI, V3, P539, DOI 10.1111/j.1460-9568.1991.tb00841.x; DINARELLO CA, 1994, FASEB J, V8, P1314; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ELETR M, 1989, J NEUROSCI, V9, P1473; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; GALLIGAN JJ, 1994, J NEUROSCI, V14, P7563; GEBICKEHAERTER PJ, 1988, N-S ARCH PHARMACOL, V338, P704, DOI 10.1007/BF00165638; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HERTIER E, 1988, J NEUROSCI RES, V21, P391; KASTRITSIS CHC, 1992, J NEUROCHEM, V58, P1277; KATCHMAN AN, 1994, NEUROSCI LETT, V168, P217, DOI 10.1016/0304-3940(94)90454-5; KATSUURA G, 1989, ENDOCRINOLOGY, V124, P3125, DOI 10.1210/endo-124-6-3125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Magistretti Pierre J., 1995, P657; MARIN P, 1993, MOL PHARMACOL, V44, P1176; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; NEARY JT, 1994, J NEUROCHEM, V63, P490; NEGRO A, 1992, GLIA, V6, P206, DOI 10.1002/glia.440060308; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; OKA S, 1991, J BIOL CHEM, V266, P9956; OKUDA S, 1994, NEUROSCIENCE, V63, P691, DOI 10.1016/0306-4522(94)90515-0; OZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P12, DOI 10.1006/bbrc.1994.2622; PEARCE B, 1989, J NEUROCHEM, V52, P971, DOI 10.1111/j.1471-4159.1989.tb02549.x; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; RICHARDSON PJ, 1987, J NEUROCHEM, V48, P622, DOI 10.1111/j.1471-4159.1987.tb04138.x; SALTER MW, 1994, J NEUROSCI, V14, P1563; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORG O, 1995, NEUROSCI LETT, V188, P109, DOI 10.1016/0304-3940(95)11410-X; STELLA N, 1994, J NEUROSCI, V14, P568; STELLA N, 1994, RENAL PHYSIOL BIOCH, V17, P153; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAMOTO K, 1988, BIOCHEM BIOPH RES CO, V156, P882, DOI 10.1016/S0006-291X(88)80926-4; YU ACH, 1986, J NEUROCHEM, V47, P1181; YU NC, 1995, MOL PHARMACOL, V48, P550; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	76	66	68	0	0	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	1997	17	9					2939	2946					8	Neurosciences	Neurosciences & Neurology	WU675	WOS:A1997WU67500003	9096130				2021-06-18	
J	Hollrigel, GS; Toth, K; Soltesz, I				Hollrigel, GS; Toth, K; Soltesz, I			Neuroprotection by propofol in acute mechanical injury: Role of GABAergic inhibition	JOURNAL OF NEUROPHYSIOLOGY			English	Article							RAT HIPPOCAMPAL-NEURONS; GYRUS GRANULE CELLS; GENERAL ANESTHETIC PROPOFOL; TRAUMATIC BRAIN INJURY; POSTSYNAPTIC CURRENTS; VOLATILE ANESTHETICS; GABA(A) RECEPTORS; GUNSHOT WOUNDS; PYRAMIDAL NEURONS; CALCIUM CURRENT	1. Whole cell patch-clamp and extracellular field recordings were obtained from granule cells of the dentate gyrus in 400-mu m-thick brain slices of the adult rat to determine the actions of the intravenous general anesthetic 2,6-diisopropylphenol (propofol) on acute neuronal survival and preservation of synaptic integrity after amputation of dendrites (dendrotomy), and to determine the role of gamma-aminobutyric acid-A (GABA(A))-receptor-mediated inhibition in the neuroprotective effects of propofol. The actions of propofol were compared with those exerted by another widely used intravenous general anesthetic, 5-ethyl-5-[1-methylbutyl]-2-thiobarbituric acid (thiopental). 2. Propofol (10 mu M) increased the frequency (control: 5.9 +/- 0.9 Hz, mean +/- SE; propofol: 10.5 +/- 1.3 Hz) and the single-exponential decay time constant (tau(D)) (control: 4.5 +/- 0.2 ms; propofol: 15.3 +/- 1.5 ms) of miniature inhibitory postsynaptic currents (mIPSCs) recorded in control neurons. Thiopental (25 mu M) also increased the tau(D) (14.3 +/- 0.9 ms) Of mISPCs, but had no effect on mIPSC frequency. Both anesthetics potentiated mIPSCs at low concentrations (propofol: 5 mu M; thiopental: 1 mu M) Propofol and thiopental did not change the peak amplitude and rise times of mIPSCs. 3. Propofol (10 mu M) was able to depress the excitability of control granule cells, as determined by the reduction in the amplitude of the orthodromic population spikes. This depression could be prevented by the GABA(A) receptor antagonist bicuculline (50 mu M), indicating that propofol reduces excitability via GABA(A) receptor functions. 4. Propofol and thiopental were neuroprotectant (assessed by antidromic population responses 2-5 h after injury) if present before and during the amputation of the granule cell dendrites. The protective actions were dose dependent, and at high doses (propofol: 200 mu M; thiopental: 400 mu M) the anesthetics were as neuroprotective against dendrotomy-induced cell death as 2-amino-5-phosphovaleric acid (APV) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). The protective effects of the anesthetics were completely blocked with the GABA(A) receptor antagonists picrotoxin or bicuculline, and were mimicked by the GABA(A) receptor agonist muscimol (100 mu M). 5. Propofol, in contrast to APV and CNQX, could not prevent the dendrotomy-induced Ca2+ dependent and long-lasting changes in mIPSC decay kinetics (appearance of a double-exponential, prolonged decay). 6. The protective effects of the anesthetics and those of APV and CNQX on neuronal survival were not significant when the drugs were applied after dendrotomy, indicating that dendrotomy carried out 150-200 mu m from the soma without neuroprotective agents rapidly induces irreversible acute degeneration in most injured neurons. The failure to rescue cells from dendrotomy-induced injury did not result from a decreased sensitivity of the GABA(A) receptors to the anesthetics, because the potentiating effects of the anesthetics on mIPSCs from control and dendrotomized neurons were not different. 7. These data indicate that propofol potentiates synaptic inhibition pre- and postsynaptically, and, when present during dendrotomy, it can protect neurons from acute mechanical-injury-induced cell death via potentiation of GABAA receptor functions. However, propofol fails to provide neuroprotection against dendrotomy-induced changes in synaptic physiology.	UNIV CALIF IRVINE, DEPT ANAT & NEUROBIOL, IRVINE, CA 92717 USA; HUNGARIAN ACAD SCI, INST EXPT MED, DEPT FUNCT NEUROANAT, H-1450 BUDAPEST, HUNGARY							ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; AMORIM P, 1995, ANESTHESIOLOGY, V83, P1254, DOI 10.1097/00000542-199512000-00016; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; BENDO AA, 1987, BRAIN RES, V403, P136, DOI 10.1016/0006-8993(87)90132-6; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Chong K. Y., 1994, Annals Academy of Medicine Singapore, V23, P145; COLLINS GGS, 1988, BRIT J PHARMACOL, V95, P939, DOI 10.1111/j.1476-5381.1988.tb11724.x; CONCAS A, 1992, ADV BIOCHEM PSYCHOPH, V47, P349; DRUMMOND JC, 1993, ANESTHESIOLOGY, V79, P877; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FFRENCHMULLEN JMH, 1993, J NEUROSCI, V13, P3211; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HANS P, 1994, J NEUROSURG ANESTH, V6, P249; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; HARRIS BD, 1995, MOL PHARMACOL, V47, P363; HARRY GJ, 1992, MOL NEUROBIOL, V6, P203; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; JENSEN AG, 1994, ANESTHESIOLOGY, V81, P1220, DOI 10.1097/00000542-199411000-00016; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339; KASS IS, 1992, NEUROSCIENCE, V49, P537, DOI 10.1016/0306-4522(92)90224-P; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KENDIG JJ, 1991, ANN NY ACAD SCI, V625, P37, DOI 10.1111/j.1749-6632.1991.tb33828.x; LEROUX PD, 1995, ANESTHETIC MANAGEMEN, P1; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; MACIVER MB, 1991, ANN NY ACAD SCI, V625, P91, DOI 10.1111/j.1749-6632.1991.tb33832.x; MIENVILLE JM, 1989, BRAIN RES, V489, P190, DOI 10.1016/0006-8993(89)90024-3; MODY I, 1991, BRAIN RES, V538, P319, DOI 10.1016/0006-8993(91)90447-4; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; OLCESE R, 1994, ANESTH ANALG, V78, P955; ORSER BA, 1994, J NEUROSCI, V14, P7747; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PRINCE RJ, 1992, BRAIN RES, V596, P238, DOI 10.1016/0006-8993(92)91553-Q; RAVUSSIN P, 1994, J NEUROSURG ANESTH, V6, P285; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROBERTSON B, 1989, BRIT J PHARMACOL, V98, P167, DOI 10.1111/j.1476-5381.1989.tb16878.x; RUTLEDGE LT, 1978, J COMP NEUROL, V178, P117, DOI 10.1002/cne.901780107; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; Salin P, 1995, J NEUROSCI, V15, P8234; SALZMAN SK, 1993, RES COMMUN CHEM PATH, V80, P59; SANNA E, 1995, MOL PHARMACOL, V47, P213; SANO T, 1993, ANESTH ANALG, V76, P990; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763; SOLTESZ I, 1994, J NEUROSCI, V14, P2365; STALEY KJ, 1991, SYNAPSE, V9, P219, DOI 10.1002/syn.890090308; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; STEWART L, 1994, ACTA NEUROCHIR, P544; SZTARK F, 1995, ANESTHESIOLOGY, V83, P1386, DOI 10.1097/00000542-199512000-00051; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; TEMPELHOFF R, 1995, ANN FR ANESTH, V14, P129, DOI 10.1016/S0750-7658(05)80161-3; VICINI S, 1987, J PHARMACOL EXP THER, V243, P1195; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014; YANG J, 1992, FASEB J, V6, P914; YEH JZ, 1991, ANN NY ACAD SCI, V625, P155, DOI 10.1111/j.1749-6632.1991.tb33839.x; ZIMMERMAN SA, 1994, J PHARMACOL EXP THER, V270, P987	73	66	68	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	OCT	1996	76	4					2412	2422					11	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	VN613	WOS:A1996VN61300025	8899614				2021-06-18	
J	HAYES, RL; YANG, K; RAGHUPATHI, R; MCINTOSH, TK				HAYES, RL; YANG, K; RAGHUPATHI, R; MCINTOSH, TK			CHANGES IN GENE-EXPRESSION FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article						BRAIN INJURY; GENE EXPRESSION; IMMEDIATE EARLY GENES; CYTOKINES	NERVE GROWTH-FACTOR; HEAT-SHOCK PROTEIN; C-FOS PROTEIN(S); CEREBELLAR GRANULE CELLS; FACTOR MESSENGER-RNA; CEREBRAL-ISCHEMIA; DIFFERENTIAL REGULATION; NEUROTROPHIC FACTOR; TRANSIENT ISCHEMIA; PRIMARY CULTURES	This paper reviews changes in gene expression produced by two rodent models of traumatic brain injury: cortical impact injury and fluid-percussion injury. Cortical impact injury produces transient increases in c-fos mRNA expression, which begin as early as 5 min after injury and subsides by 1 day after injury in the cerebral cortex ipsilateral to injury. In addition, AP-1 transcription factor binding is greatly increased in the injured cerebral cortex at 1, 3, and 5 h post-injury. AP-1 binding remains increased for at least I day after injury, while SP-1 transcription factor binding activity does not increase. Additional studies have confirmed increases in c-fos mRNA expression in the hippocampus at 30 min, 1 h, and 3 h after injury. These increases in c-fos mRNA in the hippocampus preceded increased levels of NGF mRNA that were detected at 1 and 3 h but not at 30 min following injury. Following fluid-percussion injury, increases in c-fos mRNA can be detected as early as 2 h following injury in the cortex ipsilateral to the site of injury as well as in the hippocampus. Heat-shock protein (hsp72) mRNA is also increased in the ipsilateral cortex and hippocampus following fluid percussion injury. By 24 h post-injury, both c-fos and hsp72 gene expression return to control levels. Severe but not moderate fluid percussion injury produces increased gene expression for glucose-regulated proteins (grp78, grp94) 12 h following injury. Fluid-percussion injury also produces significant increases in expression of both interleukin-1 beta and tumor necrosis factor-alpha in the injured cortex and ipsilateral hippocampus as early as 1 h post-injury, that remains elevated up to 6 h in the injured cortex and hippocampus.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV PENN,MED CTR,DEPT BIOCHEM,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19104	HAYES, RL (corresponding author), UNIV PENN,MED CTR,DEPT NEUROSURG,105 HAYDEN HALL,3220 SMITH WALK,PHILADELPHIA,PA 19104, USA.						AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHAN RKW, 1993, J NEUROSCI, V13, P5126; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DASH PK, 1995, J NEUROSCI, V15, P2030; Dekosky S. T., 1994, Society for Neuroscience Abstracts, V20, P193; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN L, 1994, J NEUROTRAUM, V11, P108; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL C, 1991, EPILEPSY RES S, V4, P225; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HASHIMOTO Y, 1992, NEUROSCI LETT, V139, P45, DOI 10.1016/0304-3940(92)90853-Y; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; JEHAN F, 1993, J NEUROCHEM, V60, P1843, DOI 10.1111/j.1471-4159.1993.tb13411.x; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAMINSKA B, 1993, NEUROSCI LETT, V153, P189, DOI 10.1016/0304-3940(93)90319-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRUUER W, 1985, P NATL ACAD SCI USA, V82, P7330; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, NEUR ABSTR, V15, P132; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGAN PF, 1991, NEUROREPORT, V2, P251, DOI 10.1097/00001756-199105000-00009; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PENG ZC, 1993, BRAIN RES, V632, P57, DOI 10.1016/0006-8993(93)91138-I; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PIERCE JES, 1995, IN PRESS J NEUROSCI; PRASAD MR, 1994, IN PRESS J NEUROCHEM; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, IN PRESS MOL BRAIN R; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; RUZDIJIC S, 1993, BRAIN RES, V69, P230; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHOZUHARA H, 1992, J NEUROCHEM, V59, P175, DOI 10.1111/j.1471-4159.1992.tb08888.x; SMEAL T, 1986, GENE DEV, V3, P2091; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOARES HD, 1995, IN PRESS J NEUROSCI; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1987, NEUROPHARMACOLOGY, V26, P1779, DOI 10.1016/0028-3908(87)90132-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TURNER R, 1989, SCIENCE, V243, P1659; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, UNPUB BRAIN RES; YANG K, 1993, P SOC NEUROSCI, V767, P1880; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	88	66	71	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					779	790		10.1089/neu.1995.12.779			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600003	8594207				2021-06-18	
J	RAGHUPATHI, R; WELSH, FA; LOWENSTEIN, DH; GENNARELLI, TA; MCINTOSH, TK				RAGHUPATHI, R; WELSH, FA; LOWENSTEIN, DH; GENNARELLI, TA; MCINTOSH, TK			REGIONAL INDUCTION OF C-FOS AND HEAT-SHOCK PROTEIN-72 MESSENGER-RNA FOLLOWING FLUID-PERCUSSION BRAIN INJURY IN THE RAT	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BRAIN INJURY; HEAT SHOCK PROTEINS; IMMEDIATE EARLY GENES; IN SITU HYBRIDIZATION	NERVE GROWTH-FACTOR; GLIAL-LIKE CELLS; TRANSCRIPTION FACTOR; ISCHEMIA; SIGNALS; GENE; IMMUNOREACTIVITY; ACTIVATION; EXPRESSION; BREAKDOWN	To evaluate the cellular response to traumatic brain injury, the expression of mRNA for c-fos and the 72-kDa heat shock protein (hsp72) was determined using in situ hybridization following lateral fluid-percussion in jury (2.2-2.4 atm) in rat brain. At 2 h after injury, induction of c-fos mRNA was observed throughout the cortex ipsilateral to the site of injury, while increased expression of hsp72 mRNA was restricted to regions of the cortex surrounding the contusion area. An increase in c-fos mRNA, but not hsp72 mRNA, was observed bilaterally in the CA, subfield of the hippocampus and the granule cells of the dentate gyrus and in the thalamus ipsilateral to the impact site. By 6 h, increased expression of c-fos mRNA was observed only in the corpus callosum on the impact side; hsp72 mRNA persisted in the deep cortical layers and upper layers of the subcortical white matter below the site of maximal injury. By 24 h, both c-fos and hsp72 mRNA had returned to control levels in all regions of the brain. These results demonstrate that lateral fluid-percussion brain injury triggers regionally and temporally specific expression of c-fos and hsp72 mRNA, which may be suggestive of differential neurochemical alterations in neurons and glia following experimental brain injury.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,EPILEPSY RES LAB,SAN FRANCISCO,CA 94143	RAGHUPATHI, R (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,RM 105,HAYDEN HALL,240 S 33 ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R55NS026818, R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ARENANDER A, 1992, PROG BRAIN RES, V94, P177; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRAN T, 1987, ONCOGENE, V2, P79; DRAGUNOW M, 1989, BRAIN RES, V501, P382, DOI 10.1016/0006-8993(89)90655-0; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MONSTEIN HJ, 1993, NEUROREPORT, V4, P195, DOI 10.1097/00001756-199302000-00020; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PHILIPS LL, 1993, J NEUROTRAUM, V9, P323; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	33	66	72	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1995	15	3					467	473		10.1038/jcbfm.1995.58			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	QT257	WOS:A1995QT25700015	7714005	Bronze			2021-06-18	
J	HALL, KM; JOHNSTON, MV				HALL, KM; JOHNSTON, MV			OUTCOMES EVALUATION IN TBI REHABILITATION .2. MEASUREMENT TOOLS FOR A NATIONWIDE DATA SYSTEM	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								In Part II we address tools for describing general functional levels of clients in acute care, in traumatic brain injury (TBI) rehabilitation programs, and in the community. Tools must be brief, have proven reliability, and measure characteristics common to moderately and severely brain-injured individuals. Possible components of a uniform dataset dedicated to TBI are described.	KESSLER INST REHABIL,E ORANGE,NJ; KESSLER INST REHABIL,W ORANGE,NJ	HALL, KM (corresponding author), SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128, USA.							0	66	66	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1994	75	12			SI		SC10	SC18					9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PY709	WOS:A1994PY70900003	7993177				2021-06-18	
J	CORRIGAN, JD; BOGNER, JA				CORRIGAN, JD; BOGNER, JA			FACTOR STRUCTURE OF THE AGITATED BEHAVIOR SCALE	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY	The Agitated Behavior Scale (ABS; Corrigan, 1989) is a 14-item scale developed to monitor agitation during the acute phase of recovery from acquired brain injury. While previous studies have supported the reliability, internal consistency, and concurrent validity of the ABS, the current study was designed to investigate its underlying factor structure, as well as to determine systematic effects of time-of-day on the occurrence of agitation. Subjects were 212 patients with traumatic or other recently acquired brain injury who exhibited agitation during their treatment on a specialized brain-injury unit of an acute rehabilitation hospital. Confirmatory factor analysis revealed that agitation is best represented by one general construct with three underlying factors: Aggression, Disinhibition, and Lability. Analysis of agitation by nursing shift in which ratings were made confirmed that overall level was lowest during the night shift; however, the relationship between time-of-day and underlying factors deviated from this pattern. Results are discussed in terms of the necessity for objective measurement, definition of the construct of agitation, and time-of-day issues in sampling agitated behavior.		CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,DIV REHABIL PSYCHOL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Herbel K, 1990, Rehabil Nurs, V15, P66; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Kelly G. A., 1955, PSYCHOL PERSONAL CON, VI; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MALKMUS D, 1980, REHABILITATION HEAD; MYSIW WJ, 1988, J PHYSICAL MED REHAB, V67, P29; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20	12	66	66	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					386	392		10.1080/01688639408402649			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400007	7929706				2021-06-18	
J	EVANS, RW				EVANS, RW			THE POSTCONCUSSION SYNDROME - 130 YEARS OF CONTROVERSY	SEMINARS IN NEUROLOGY			English	Article							MINOR HEAD-INJURY; POST-CONCUSSIONAL SYMPTOMS; MILD CONCUSSION; SEQUELAE; NEUROLOGY; LIGHT; SOUND; LONG	Controversial best describes the postconcussion syndrome. This controversy is expressed in the many terms proposed since the lectures of Erichsen in 1866 for the sequelae of usually mild head injury: spinal concussion, railway spine, railway brain, traumatic neurosis, nervous shock, traumatic hysteria, traumatic hysteroneurasthenia, spinal anemia, vasomotor symptom complex, litigation neurosis, compensation neurosis, accident neurosis, Erichsen's disease, Friedmann's disease, traumatic neurasthenia, the posttraumatic concussion state, the posttraumatic psychoneurotic state, traumatic encephalopathy, posttraumatic cerebral syndrome, posttraumatic syndrome, posttraumatic nervous instability, postconcussion syndrome, postconcussive syndrome, postconcussional syndrome, posttraumatic stress syndrome, and the persistent postconcussive syndrome. This article will selectively review definitions, historical aspects, causation, symptoms and signs, testing, prognosis, medicolegal aspects, and treatment. Other articles in this issue of Seminars review epidemiology, pathophysiology, neuropathology, posttraumatic headache, testing, and neuropsychologic testing. Areas of current controversy will be illustrated by some of the responses of neurologists in a recent nationwide survey we have conducted by mail, ''The Physician Survey on the Postconcussion and Whiplash Syndromes,'' of family physicians, neurologists, neurosurgeons, and orthopedists.1 Although the results may be biased because of a low response rate (21% of neurologists surveyed), the survey is the best information currently available on this topic. According to the survey results, neurologists see an average of five patients per month with postconcussion syndrome, and 7.1% of the neurology respondents had personally had a postconcussion syndrome with a mean duration of 1 month.	UNIV TEXAS,SCH MED,DEPT NEUROL,HOUSTON,TX 77025; BAYLOR COLL MED,HOUSTON,TX 77030; PK PLAZA HOSP,AMI,NEUROL SECT,HOUSTON,TX							Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; [Anonymous], 1989, Neurology, V39, P1100; Boake C., 1991, NEUROREHABILITATION, V1, P70; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CHILVERS CD, 1985, NEW ZEAL MED J, V98, P658; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Denker P., 1944, NY STATE J MED, V44, P379; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; ERICHSEN JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1992, NEUROL CLIN, V10, P815; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; EVANS RW, 1994, IN PRESS PHYSICIAN S; FEE CRA, 1988, ARCH EMERG MED, V5, P12; Friedmann M., 1892, ARCH PSYCHIAT, V23, P230; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gray LC, 1893, TREATISE NERVOUS MEN, P570; GRINKER RR, 1934, NEUROLOGY, P790; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; Hodges R. M., 1881, BOSTON MED SURG J, V104, P361, DOI [10.1056/NEJM188104211041601, DOI 10.1056/NEJM188104211041601]; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; KEANE JR, 1992, NEUROL CLIN, V10, P849; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MANDEL S, 1989, POSTGRAD MED, V85, P213; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; MERSKEY H, 1992, NEUROL CLIN, V10, P895; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Page Herbert, 1883, INJURIES SPINE SPINA; PRIGATANO GP, 1993, NEUROL CLIN, V11, P219; PUTNAM RJ, 1883, BOSTON MED SURG J, V109, P217; Rigler J, 1879, FOLGEN VERLETZUNGEN; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSON A, 1988, AUST NZ J PSYCHIAT, V22, P396, DOI 10.3109/00048678809161348; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; STEADMAN JH, 1969, P ROY SOC MED, V63, P23; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TRIMBLE MR, 1981, POST TRAUMATIC NEURO; UOMOTO JM, 1992, WESTERN J MED, V157, P665; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; 1881, LANCET, V1, P462; 1883, BOSTON MED SURG J, V109, P400	63	66	67	0	4	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0271-8235			SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					32	39		10.1055/s-2008-1041056			8	Clinical Neurology	Neurosciences & Neurology	NE151	WOS:A1994NE15100007	8029557				2021-06-18	
J	LEESHALEY, PR; DUNN, JT				LEESHALEY, PR; DUNN, JT			THE ABILITY OF NAIVE SUBJECTS TO REPORT SYMPTOMS OF MILD BRAIN INJURY, POSTTRAUMATIC-STRESS-DISORDER, MAJOR DEPRESSION, AND GENERALIZED ANXIETY DISORDER	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							HEAD-INJURY	Diagnoses of major depression, post-traumatic stress disorder, generalized anxiety disorder, and mild brain injury are based in substantial part on the self-reported symptoms of patients. This study found that 96.9% of untrained subjects were able to endorse symptoms on checklists to meet the DSM-III-R self-report criteria for major depression, 96.9% for generalized anxiety disorder, and 86% for PTSD. For the non-DSM-III-R diagnosis of mild brain injury, 63.3% of subjects were able to correctly identify 5 or more of 10 symptoms associated with this condition. Forensic examiners are advised to exercise special care in utilizing evaluation procedures that are of a leading nature, such as symptom checklists in which examinees may exhibit response biases.								American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CAVANAUGH JL, 1984, BEHAVIORAL SCI LAW, V2, P1; GOUVIER WD, 1988, NEUROPSYCHOLOGY, V3, P273; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRICE JR, 1992, MALINGERING MENTAL D; ROGERS R, 1988, CLIN ASSESSMENT MALI; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET           JAN, P1; SILVAN P, 1992, DEFENDING PTSD DEPRE; WEISSMAN HN, 1991, FORENSIC REPORTS, V4, P417; Weissman HN., 1990, BEHAV SCI LAW, V8, P67, DOI [10.1002/bsl.2370080108, DOI 10.1002/BSL.2370080108]	14	66	66	0	0	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAR	1994	50	2					252	256		10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T			5	Psychology, Clinical	Psychology	NE675	WOS:A1994NE67500016	8014250				2021-06-18	
J	CHEN, TY; WONG, CW; CHANG, CN; LUI, TN; CHENG, WC; TSAI, MD; LIN, TK; EPSTEIN, MH; HORWITZ, NH				CHEN, TY; WONG, CW; CHANG, CN; LUI, TN; CHENG, WC; TSAI, MD; LIN, TK; EPSTEIN, MH; HORWITZ, NH			THE EXPECTANT TREATMENT OF ASYMPTOMATIC SUPRATENTORIAL EPIDURAL HEMATOMAS	NEUROSURGERY			English	Article						COMPUTED TOMOGRAMS; EPIDURAL HEMATOMA; EXPECTANT TREATMENT; HEAD INJURY; HOSPITALIZATION; SUPRATENTORIAL EPIDURAL HEMATOMA	NON-SURGICAL MANAGEMENT; EXTRADURAL HEMATOMAS; SPONTANEOUS RESOLUTION; CHILDREN; SIZE	SEVENTY-FOUR PATIENTS WITH a traumatic epidural hematoma (EDH) and a Glasgow Coma Scale score of more than 12 received expectant treatment; 14 subsequently underwent surgical evacuation of the EDH. A patient with initial brain computed tomograms (CT) showing an EDH volume of more than 30 ml, a thickness of more than 15 mm, and a midline shift beyond 5 mm tended to require surgery within 3 days of the injury when the brain had exhausted its compensatory mechanism and yielded to the expanding EDH. After the 3-day period, in the absence of neurological symptoms, the presence of the EDH may not be an indication for surgical evacuation or hospitalization beyond 7 days. In our patients, the presence of a skull fracture in the temporal bone, the heterogeneous density of the EDH in the CT scan, or the 6-hour period between the CT study and the injury did not significantly increase the failure rate of nonsurgical treatment. Although a zero mortality was achieved in this series, these guidelines may not be applicable to the management of an infratentorial EDH.		CHEN, TY (corresponding author), CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,199 TUNG HWA N RD,TAIPEI 10591,TAIWAN.						ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; COOK RJ, 1988, ACTA NEUROCHIR, V95, P90, DOI 10.1007/BF01790766; GARZAMERCADO R, 1979, NEUROSURGERY, V5, P500, DOI 10.1227/00006123-197910000-00018; GURDJIAN F, 1947, AM J SURG, V73, P267; HANDA J, 1979, SURG NEUROL, V11, P217; ILLINGWORTH R, 1983, J NEUROL NEUROSUR PS, V46, P558, DOI 10.1136/jnnp.46.6.558; JENNETT B, 1975, LANCET, V1, P480; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P285; POZZATI E, 1987, J TRAUMA, V27, P579, DOI 10.1097/00005373-198705000-00024; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V1, P526; TOCHIO H, 1984, NEUROSURGERY, V15, P96, DOI 10.1227/00006123-198407000-00018; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; WONG C-W, 1991, Asian Journal of Surgery, V14, P64; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZUCCARELLO M, 1981, NEUROSURGERY, V8, P434, DOI 10.1227/00006123-198104000-00005	27	66	71	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1993	32	2					176	179		10.1227/00006123-199302000-00004			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KL520	WOS:A1993KL52000004	8437654				2021-06-18	
J	ANDREWS, BT; PITTS, LH				ANDREWS, BT; PITTS, LH			FUNCTIONAL RECOVERY AFTER TRAUMATIC TRANSTENTORIAL HERNIATION	NEUROSURGERY			English	Article						BURR HOLE; HEAD INJURY; SUBDURAL HEMATOMA; TRANSTENTORIAL HERNIATION	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; TENTORIAL HERNIATION; MANAGEMENT; PROGNOSIS; CHILDREN	To elucidate the factors associated with functional recovery after traumatic transtentorial herniation, we reviewed the records of 153 consecutive patients admitted with clinical signs of transtentorial herniation (altered level of consciousness, anisocoria or pupillary unresponsiveness, and abnormal motor findings). Overall, 28 patients (18%) had a functional outcome: 14 patients (9%) made a good recovery and 14 were moderately disabled. Sixteen patients (10.5%) were severly disabled or vegetative, and 104 (60%) died. Compared with patients who died or were left severely disabled or vegetative, patients who had a good recovery were younger (21 versus 38 years), were significantly more likely to be children (less-than-or-equal-to 17 years old) and have anisocoria and a deteriorating Glasgow Coma Score (GCS), and were significantly less likely to be flaccid or have bilaterally fixed pupils; moderately disabled patients also had a lower median age and a higher frequency of anisocoria. There was no difference in the incidence of significant intracranial hematomas between patients with a functional outcome and those with a nonfunctional outcome. Twenty-seven percent of the 95 patients with anisocoria had a good outcome or moderate disability, whereas only 3.5% of the 58 patients with bilaterally fixed and dilated pupils at admission had a functional recovery (P < 0.05). Age, level of consciousness, and the degree of residual upper brain stem function at admission appear to be the most important determinants of functional outcome after traumatic transtentorial herniation.	SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110	ANDREWS, BT (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,EDITORIAL OFF,DEPT NEUROL SURG,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94122, USA.						AMACHER AL, 1987, NEUROSURGERY, V20, P954; Andrews B T, 1988, Neurosurgery, V22, P614, DOI 10.1097/00006123-198803000-00035; ANDREWS BT, 1989, NEUROSURGERY, V24, P345, DOI 10.1227/00006123-198903000-00006; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; ANDREWS BT, 1987, SURG NEUROL, V28, P699; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; GROSSMAN RG, 1981, NEW ENGL J MED, V304, P1540, DOI 10.1056/NEJM198106183042510; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; HOFF JT, 1978, WESTERN J MED, V128, P112; HOWELL DA, 1959, BRAIN, V82, P525, DOI 10.1093/brain/82.4.525; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JAMIESON KG, 1972, J NEUROSURG, V37, P528, DOI 10.3171/jns.1972.37.5.0528; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETTB, 1981, MANAGEMENT HEAD INJU; KERNOHAN JW, 1929, LARCH NEUROOL PSYCHI, V21, P274; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MAHONEY DB, 1981, NEUROSURGERY, V8, P2551; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NEWFIELD P, 1980, NEUROSURGERY, V6, P596; OVERGAARD J, 1973, LANCET, V2, P631; PITTS LH, 1981, CLIN NEUROSURG, V29, P203; RICHARDS T, 1974, SURGERY, V75, P253; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROCKSWOLD GL, 1988, NEUROSURGERY, V22, P614; SACHS E, 1978, NEUROSURGERY, V3, P66, DOI 10.1227/00006123-197807000-00011; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140	39	66	67	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1991	29	2					227	231		10.1227/00006123-199108000-00010			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FX980	WOS:A1991FX98000010	1886660				2021-06-18	
J	LEZAK, MD				LEZAK, MD			RECOVERY OF MEMORY AND LEARNING FUNCTIONS FOLLOWING TRAUMATIC BRAIN INJURY	CORTEX			English	Article									UNIV OREGON,HLTH SCI CTR,PORTLAND,OR 97201	LEZAK, MD (corresponding author), VET ADM HOSP,PORTLAND,OR 97207, USA.						BLAKEMORE CB, 1967, J NEUROL NEUROSUR PS, V30, P364, DOI 10.1136/jnnp.30.4.364; Diller L., 1974, STUDIES COGNITION RE; FINNEY DJ, 1963, TABLES TESTING SIGNI; GRONWALL D, 1974, PSYCHOLOGICAL EFFECT; JENNETT B, 1975, 34 S OUTC SEV DAM CE; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MARSHALL JC, 1975, 34 S OUTC SEV DAM CT; Naquet R, 1970, Med Leg Dommage Corpor, V3, P32; NEWCOMBE F, 1975, J NEUROL SCI, V24, P127, DOI 10.1016/0022-510X(75)90013-1; Rey A., 1964, EXAMEN CLIN PSYCHOLO; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Russell W Ritchie, 1934, Edinb Med J, V41, P129; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SMITH A, 1964, J NEUROL NEUROSUR PS, V27, P511, DOI 10.1136/jnnp.27.6.511; SMITH A, 1960, J MENT SCI, V106, P767; SMITH E, 1974, J NEUROL NEUROSURG P, V37, P726; TEUBER HL, 1975, 34 S OUTC SEV DAM CT; VIGOUROUX RP, 1971, INT S HEAD INJURIES; WARRINGTON EK, 1966, BRAIN, V82, P53; WESCHSLER D, 1955, WECHSLER ADULT INTEL	22	66	67	0	8	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex		1979	15	1					63	72		10.1016/S0010-9452(79)80007-6			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	GU709	WOS:A1979GU70900006	446047				2021-06-18	
J	Hooker, DR				Hooker, DR			Physiological effects of air concussion	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article									Johns Hopkins Univ, Physiol Lab, Baltimore, MD USA							BURGE, 1918, AM J PHYSIOL, V45, P246; CANNON, 1918, JAMA-J AM MED ASSOC, V70, P611; CARVER, 1919, BRAIN, V42, P113; COMMANDER, 1916, REV GEN SCI     0415, P213; CRAMER, 1919, ARCH MAL COEUR, V11, P66; CRILE, OFFICIAL REPORT SURG; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; ERLANGER, 1919, AM J PHYSL, V49, P90; ERLANGER, 1919, AM J PHYSIOL, V49, P99; GATTI, 1918, RIFORMA MED, V34, P102; GITHENS, 1919, AM J PHYSIOL, V49, P120; HILL, 1912, CAISSON SICKNESS; HOOKER, 1918, AM J PHYSL, V46, P591; MAIRET, 1919, REV NEUROL, V26, P97; MAIRET, 1917, PRESSE MED      0816; MCKIBBEN, 1919, AM J PHYSIOL, V48, P331; MEEK, 1918, AM J PHYSIOL, V47, P302; MORISON, 1915, AM J PHYSIOL, V37, P86; MOTT, 1916, LANCET          0212; MOTT, 1916, LANCET, V1, P441; MOTT, 1917, BRIT MED J      0519; MOTT, 1917, J ROY ARMY MED CORPS, V29, P662; Mott FW, 1916, LANCET, V1, P331; Penfield WG, 1919, AM J PHYSIOL, V48, P121; PORTER, 1908, AM J PHYSIOL, V20, P500; PORTER, 1916, AM J PHYSIOL, V39, P236; PORTER, 1918, BOSTON MED SURG J, V179, P273; SEELIG, 1908, J AM MED ASS, V52, P45; VANSLYKE, 1917, J BIOL CHEM, V30, P347; WALLACE, 1917, LANCET, V2, P727; WIGGERS, 1918, AM J PHYSIOL, V45, P485	31	66	68	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	JAN	1924	67	2					219	274					56	Physiology	Physiology	V35SW	WOS:000202415000001					2021-06-18	
J	Degterev, A; Ofengeim, D; Yuan, JY				Degterev, Alexei; Ofengeim, Dimitry; Yuan, Junying			Targeting RIPK1 for the treatment of human diseases	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						RIPK1; necroptosis; apoptosis; inflammation; neurodegeneration	TNF-INDUCED-NECROPTOSIS; TUMOR-NECROSIS-FACTOR; NEURONAL CELL-DEATH; PROGRAMMED NECROSIS; KINASE-ACTIVITY; INFLAMMATORY CASPASES; ISCHEMIA; ACTIVATION; MICROGLIA; CONTRIBUTES	RIPK1 kinase has emerged as a promising therapeutic target for the treatment of a wide range of human neurodegenerative, autoimmune, and inflammatory diseases. This was supported by extensive studies which demonstrated that RIPK1 is a key mediator of apoptotic and necrotic cell death as well as inflammatory pathways. Furthermore, human genetic evidence has linked the dysregulation of RIPK1 to the pathogenesis of ALS as well as other inflammatory and neurodegenerative diseases. Importantly, unique allosteric small-molecule inhibitors of RIPK1 that offer high selectivity have been developed. These molecules can penetrate the blood-brain barrier, thus offering the possibility to target neuroinflammation and cell death which drive various neurologic conditions including Alzheimer's disease, ALS, and multiple sclerosis as well as acute neurological diseases such as stroke and traumatic brain injuries. We discuss the current understanding of RIPK1 regulatory mechanisms and emerging evidence for the pathological roles of RIPK1 in human diseases, especially in the context of the central nervous systems.	[Degterev, Alexei] Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Dev Mol & Chem Biol, Boston, MA 02445 USA; [Ofengeim, Dimitry] Sanofi US, Rare & Neurol Dis Res Therapeut Area, Framingham, MA 01701 USA; [Yuan, Junying] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA	Yuan, JY (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.	junying_yuan@hms.harvard.edu		Yuan, Junying/0000-0003-2405-6036	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AG047231, RF1AG055521, R21AG059073, 1R01CA190542, R21AI124049, 1R56AG058642]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA190542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI124049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG059073, R56AG058642, R01AG047231] Funding Source: NIH RePORTER	Studies in the authors' laboratories are supported by NIH Grants 1R01AG047231, RF1AG055521, and R21AG059073 (to J.Y.); and 1R01CA190542, R21AI124049, and 1R56AG058642 (to A.D.).	Amin P, 2018, P NATL ACAD SCI USA, V115, pE5944, DOI 10.1073/pnas.1806973115; Annibaldi A, 2018, MOL CELL, V69, P566, DOI 10.1016/j.molcel.2018.01.027; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Berger SB, 2014, J IMMUNOL, V192, P5476, DOI 10.4049/jimmunol.1400499; Caccamo A, 2017, NAT NEUROSCI, V20, P1236, DOI 10.1038/nn.4608; Callus BA, 2007, CELL DEATH DIFFER, V14, P73, DOI 10.1038/sj.cdd.4402034; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen YZ, 2018, NEUROSCIENCE, V371, P229, DOI 10.1016/j.neuroscience.2017.12.007; Chiu IM, 2009, P NATL ACAD SCI USA, V106, P20960, DOI 10.1073/pnas.0911405106; Christofferson DE, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.64; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Cirulli ET, 2015, SCIENCE, V347, P1436, DOI 10.1126/science.aaa3650; Collins JS, 2000, AM J MED GENET, V96, P823, DOI 10.1002/1096-8628(20001204)96:6<823::AID-AJMG26>3.0.CO;2-I; Cougnoux A, 2018, MOL GENET METAB, V125, P345, DOI 10.1016/j.ymgme.2018.10.009; Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641; Cullen V, 2011, ANN NEUROL, V69, P940, DOI 10.1002/ana.22400; Daniels BP, 2017, CELL, V169, P301, DOI 10.1016/j.cell.2017.03.011; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dillon CP, 2014, CELL, V157, P1189, DOI 10.1016/j.cell.2014.04.018; Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032; Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026; Duprez L, 2011, IMMUNITY, V35, P908, DOI 10.1016/j.immuni.2011.09.020; Dvoriantchikova G, 2014, EXP EYE RES, V123, P1, DOI 10.1016/j.exer.2014.04.009; Elliott PR, 2016, MOL CELL, V63, P990, DOI 10.1016/j.molcel.2016.08.001; Fan H, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0081-8; Fauster A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.130; Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418-018-0212-6; Freischmidt A, 2015, NAT NEUROSCI, V18, P631, DOI 10.1038/nn.4000; Garcia-Carbonell R, 2018, P NATL ACAD SCI USA, V115, pE9192, DOI 10.1073/pnas.1810584115; Geng JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00406-w; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Gregory AP, 2012, NATURE, V488, P508, DOI 10.1038/nature11307; Harris PA, 2017, J MED CHEM, V60, P1247, DOI 10.1021/acs.jmedchem.6b01751; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hong JM, 2016, TOXICOL APPL PHARM, V308, P1, DOI 10.1016/j.taap.2016.08.010; Iannielli A, 2018, CELL REP, V22, P2066, DOI 10.1016/j.celrep.2018.01.089; Ito Y, 2016, SCIENCE, V353, P603, DOI 10.1126/science.aaf6803; Kaiser WJ, 2014, P NATL ACAD SCI USA, V111, P7753, DOI 10.1073/pnas.1401857111; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Kang SH, 2013, NAT NEUROSCI, V16, P571, DOI 10.1038/nn.3357; Kang TB, 2018, CELL DEATH DIFFER, V25, P1107, DOI 10.1038/s41418-018-0104-9; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim CR, 2017, CURR EYE RES, V42, P771, DOI 10.1080/02713683.2016.1227449; Kim SJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.238; Kupka S, 2016, CELL REP, V16, P2271, DOI 10.1016/j.celrep.2016.07.086; Lafont E, 2018, NAT CELL BIOL, V20, P1389, DOI 10.1038/s41556-018-0229-6; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Li Y, 2019, P NATL ACAD SCI USA, V116, P970, DOI 10.1073/pnas.1813582116; Lin J, 2016, NATURE, V540, P124, DOI 10.1038/nature20558; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu SZ, 2017, P NATL ACAD SCI USA, V114, pE7450, DOI 10.1073/pnas.1707531114; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Liu YB, 2017, CELL DEATH DIFFER, V24, P1459, DOI 10.1038/cdd.2017.78; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Ma JM, 2011, J NEUROSCI RES, V89, P639, DOI 10.1002/jnr.22567; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071; Martens S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0245-7; McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576; Meng HY, 2018, P NATL ACAD SCI USA, V115, pE2001, DOI 10.1073/pnas.1722013115; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Najjar M, 2016, IMMUNITY, V45, P46, DOI 10.1016/j.immuni.2016.06.007; Najjar M, 2015, CELL REP, V10, P1850, DOI 10.1016/j.celrep.2015.02.052; Newton K, 2016, CELL DEATH DIFFER, V23, P1565, DOI 10.1038/cdd.2016.46; Newton K, 2016, MOL CELL; Ni Y, 2018, NEUROSCIENCE, V371, P60, DOI 10.1016/j.neuroscience.2017.10.038; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nuvolone M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171923; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ofengeim D, 2017, P NATL ACAD SCI USA, V114, pE8788, DOI 10.1073/pnas.1714175114; Ofengeim D, 2015, CELL REP, V10, P1836, DOI 10.1016/j.celrep.2015.02.051; Ofengeim D, 2013, NAT REV MOL CELL BIO, V14, P727, DOI 10.1038/nrm3683; Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818; Papassotiropoulos A, 2005, NEURODEGENER DIS, V2, P233, DOI 10.1159/000090362; Pegoretti V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00925; Peltzer N, 2016, TRENDS CELL BIOL, V26, P445, DOI 10.1016/j.tcb.2016.01.006; Petrie EJ, 2019, TRENDS BIOCHEM SCI, V44, P53, DOI 10.1016/j.tibs.2018.11.002; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Polykratis A, 2014, J IMMUNOL, V193, P1539, DOI 10.4049/jimmunol.1400590; Rehker J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185777; Rickard JA, 2014, CELL, V157, P1175, DOI 10.1016/j.cell.2014.04.019; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021; Safaiyan S, 2016, NAT NEUROSCI, V19, P995, DOI 10.1038/nn.4325; Said-Sadier Najwane, 2012, Biomed J, V35, P437, DOI 10.4103/2319-4170.104408; Saleh D, 2017, J IMMUNOL, V198, P4435, DOI 10.4049/jimmunol.1601717; Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115; Sarlus H, 2017, J CLIN INVEST, V127, P3240, DOI 10.1172/JCI90606; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Shi ZW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00721; Shutinoski B, 2016, CELL DEATH DIFFER, V23, P1628, DOI 10.1038/cdd.2016.51; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Streit WJ, 2018, GLIA, V66, P2550, DOI 10.1002/glia.23510; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Taraborrelli L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06155-8; Upton JW, 2012, CELL HOST MICROBE, V11, P290, DOI 10.1016/j.chom.2012.01.016; Vitner EB, 2014, NAT MED, V20, P204, DOI 10.1038/nm.3449; von Massenhausen A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0394-3; Wallach D, 2016, SCIENCE, V352, DOI 10.1126/science.aaf2154; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wang HB, 2017, P NATL ACAD SCI USA, V114, P11944, DOI 10.1073/pnas.1715742114; Wang W, 2018, CANCER CELL, V34, P757, DOI 10.1016/j.ccell.2018.10.006; Weisel K, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.365; Xie T, 2013, STRUCTURE, V21, P493, DOI 10.1016/j.str.2013.01.016; Yoshikawa M, 2018, J MED CHEM, V61, P2384, DOI 10.1021/acs.jmedchem.7b01647; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yuan JY, 2019, NAT REV NEUROSCI, V20, P19, DOI 10.1038/s41583-018-0093-1; Zhang Shehong, 2016, Medicines (Basel), V3, DOI 10.3390/medicines3030016; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhou W, 2014, SEMIN CELL DEV BIOL, V35, P14, DOI 10.1016/j.semcdb.2014.07.013; Zhu KZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0524-y; 2018, CELL, V174, P1477, DOI DOI 10.1016/J.CELL.2018.07.041; 2017, MOL CELL, V66, P698, DOI DOI 10.1016/J.MOLCEL.2017.05.003; 2018, NAT CELL BIOL, V20, P58, DOI DOI 10.1038/S41556-017-0003-1; 2016, J MED CHEM, V59, P2163, DOI DOI 10.1021/ACS.JMEDCHEM.5B01898	123	65	65	0	14	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 14	2019	116	20					9714	9722		10.1073/pnas.1901179116			9	Multidisciplinary Sciences	Science & Technology - Other Topics	HY0LS	WOS:000467804000010	31048504	Green Published, Other Gold			2021-06-18	
J	Ismael, S; Nasoohi, S; Ishrat, T				Ismael, Saifudeen; Nasoohi, Sanaz; Ishrat, Tauheed			MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain (NOD)-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						edema; inflammation; MCC950; neurological deficits; NLRP3-inflammasome inhibitor; traumatic brain injury	THIOREDOXIN-INTERACTING PROTEIN; NLRP3 INFLAMMASOME; ENDOTHELIAL-CELLS; CEREBRAL-CORTEX; HEAD-INJURY; MRC CRASH; KAPPA-B; ACTIVATION; NEUROPROTECTION; EDEMA	Nucleotide oligomerization domain (NOD)-like receptor protein-3 (NLRP3) inflammasome may intimately contribute to sustaining damage after traumatic brain injury (TBI). This study aims to examine whether specific modulation of NLPR3 inflammasome by MCC950, a novel selective NLRP3 inhibitor, confers protection after experimental TBI. Unilateral cortical impact injury was induced in young adult C57BL/6 mice. MCC950 (50 mg/kg, intraperitoneally) or saline was administration at 1 and 3 h post-TBI. Animals were tested for neurological function and then sacrificed at 24 or 72 h post-TBI. Immunoblotting and histological analysis were performed to identify markers of NLRP3 inflammasome and proapoptotic activity in pericontusional areas of the brains at 24 or 72h post-TBI. MCC950 treatment provided a significant improvement in neurological function and reduced cerebral edema in TBI animals. TBI upregulated NLRP3, apoptosis-associated speck-like adapter protein (ASC), cleaved caspase-1, and interlukein-1 beta (IL-1 beta) in the perilesional area. MCC950 efficiently repressed caspase-1 and IL-1 beta with a transient effect on ASC and NLRP3 post-TBI. MCC950 treatment also provided protection against proapoptotic activation of poly (ADP-ribose) polymerase and caspase-3 associated with TBI. A concurrent inhibition of inflammasome priming was also detectable at the nuclear factor kappa B/p65 and caspase-1 level. Our findings support the implication of NLRP3 inflammasome in the pathogenesis of TBI and further suggests the therapeutic potential of MCC950.	[Ismael, Saifudeen; Ishrat, Tauheed] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave,Wittenborg Bldg,Room 231, Memphis, TN 38163 USA; [Nasoohi, Sanaz] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Ishrat, Tauheed] Univ Tennessee, Hlth Sci Ctr, Neurosci Inst, Memphis, TN 38163 USA	Ishrat, T (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave,Wittenborg Bldg,Room 231, Memphis, TN 38163 USA.	tishrat@uthsc.edu	Ismael, Saifudeen/AAR-2031-2021; Ismael, Saifudeen/AAE-1679-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS097800]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097800] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R01-NS097800; to T.I.). The authors are thankful to Dr. Anton J. Reiner, for providing a CCI device (Impact One; Leica Biosystems, Buffalo Grove, IL) to induce TBI in mice.	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dempsey C, 2017, BRAIN BEHAV IMMUN, V61, P306, DOI 10.1016/j.bbi.2016.12.014; Edwards P, 2005, LANCET, V365, P1957; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hay N, 2011, BBA-MOL CELL RES, V1813, P1965, DOI 10.1016/j.bbamcr.2011.03.013; Henao-Mejia J, 2012, NAT IMMUNOL, V13, P321, DOI 10.1038/ni.2257; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ishrat T, 2018, CELLULAR MOL APPROAC, P427; Ishrat T, 2015, MOL NEUROBIOL, V51, P766, DOI 10.1007/s12035-014-8766-x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130; Karmakar M, 2015, J IMMUNOL, V194, P1763, DOI 10.4049/jimmunol.1401624; Kim GS, 2012, NEUROBIOL DIS, V46, P440, DOI 10.1016/j.nbd.2012.02.008; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kurokawa H, 2015, ATHEROSCLEROSIS, V239, P375, DOI 10.1016/j.atherosclerosis.2015.01.037; Li XN, 2009, BIOCHEM BIOPH RES CO, V381, P660, DOI 10.1016/j.bbrc.2009.02.132; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Malik S, 2015, EUR J PHARMACOL, V748, P54, DOI 10.1016/j.ejphar.2014.12.008; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mohamed IN, 2015, ANTIOXID REDOX SIGN, V22, P1188, DOI 10.1089/ars.2014.6126; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Perrone L, 2009, J CELL PHYSIOL, V221, P262, DOI 10.1002/jcp.21852; Primiano MJ, 2016, J IMMUNOL, V197, P2421, DOI 10.4049/jimmunol.1600035; Dinh QN, 2017, AGING-US, V9, P1595, DOI 10.18632/aging.101255; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Salla M, 2016, ACS MED CHEM LETT, V7, P1034, DOI 10.1021/acsmedchemlett.6b00198; Schumacher M, 2016, J STEROID BIOCHEM, V160, P53, DOI 10.1016/j.jsbmb.2015.11.010; Su N., 2016, MECH PROGRAMMED CELL; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247; Wali B, 2017, J NEUROTRAUM, V34, P2183, DOI 10.1089/neu.2016.4845; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang ZR, 2016, ASIAN PAC J TROP MED, V9, P269, DOI 10.1016/j.apjtm.2016.01.027; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao Q, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0878-6; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	58	65	69	2	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2018	35	11					1294	1303		10.1089/neu.2017.5344		APR 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GG7EW	WOS:000428870000002	29295651	Green Published, Bronze			2021-06-18	
J	Tucker, LB; Fu, AH; McCabe, JT				Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.			Performance of Male and Female C57BL/6J Mice on Motor and Cognitive Tasks Commonly Used in Pre-Clinical Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						learning and memory; motor; mouse; sex differences; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SEX-DIFFERENCES; BEHAVIORAL PERFORMANCE; MOUSE STRAINS; OPEN-FIELD; ENVIRONMENTAL ENRICHMENT; FUNCTIONAL RECOVERY; GENDER-DIFFERENCES; ANXIETY DISORDERS; REFERENCE MEMORY	To date, clinical trials have failed to find an effective therapy for victims of traumatic brain injury (TBI) who live with motor, cognitive, and psychiatric complaints. Pre-clinical investigators are now encouraged to include male and female subjects in all translational research, which is of particular interest in the field of neurotrauma given that circulating female hormones (progesterone and estrogen) have been demonstrated to exert neuroprotective effects. To determine whether behavior of male and female C57BL6/J mice is differentially impaired by TBI, male and cycling female mice were injured by controlled cortical impact and tested for several weeks with functional assessments commonly employed in pre-clinical research. We found that cognitive and motor impairments post-TBI, as measured by the Morris water maze (MWM) and rotarod, respectively, were largely equivalent in male and female animals. However, spatial working memory, assessed by the y-maze, was poorer in female mice. Female mice were generally more active, as evidenced by greater distance traveled in the first exposure to the open field, greater distance in the y-maze, and faster swimming speeds in the MWM. Statistical analysis showed that variability in all behavioral data was no greater in cycling female mice than it was in male mice. These data all suggest that with careful selection of tests, procedures, and measurements, both sexes can be included in translational TBI research without concern for effect of hormones on functional impairments or behavioral variability.	[Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Preclin Studies Core, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA	McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu		Tucker, Laura/0000-0002-5984-6399			ACKERLY DD, 1990, OECOLOGIA, V82, P474, DOI 10.1007/BF00319788; Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; Alstott J, 2009, BEHAV BRAIN RES, V196, P214, DOI 10.1016/j.bbr.2008.09.001; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; ARCHER J, 1975, BEHAV BIOL, V14, P451, DOI 10.1016/S0091-6773(75)90636-7; Avgustinovich D F, 2007, Neurosci Behav Physiol, V37, P731, DOI 10.1007/s11055-007-0075-7; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Bekker MHJ, 2007, GENDER MED, V4, pS178, DOI 10.1016/S1550-8579(07)80057-X; BERGERSWEENEY J, 1995, BEHAV NEUROSCI, V109, P859, DOI 10.1037/0735-7044.109.5.859; Bettis T, 2012, BEHAV BRAIN RES, V233, P288, DOI 10.1016/j.bbr.2012.04.028; Bhatnagar S, 2004, BEHAV BRAIN RES, V153, P527, DOI 10.1016/j.bbr.2004.01.018; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolivar VJ, 2000, BEHAV GENET, V30, P285, DOI 10.1023/A:1026545316455; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Collins TJ, 2007, BIOTECHNIQUES, V43, P25; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Dang MT, 2005, EXP NEUROL, V196, P452, DOI 10.1016/j.expneurol.2005.08.025; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davis MJ, 2012, BEHAV BRAIN RES, V229, P21, DOI 10.1016/j.bbr.2011.12.037; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Ennaceur A, 2014, PHYSIOL BEHAV, V135, P55, DOI 10.1016/j.physbeh.2014.05.032; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Frick KM, 2003, BEHAV NEUROSCI, V117, P1283, DOI 10.1037/0735-7044.117.6.1283; Frick KM, 2000, NEUROSCIENCE, V95, P293; Gresack JE, 2003, BRAIN RES, V982, P98, DOI 10.1016/S0006-8993(03)03000-2; Guzman CB, 2009, BEHAV BRAIN RES, V199, P355, DOI 10.1016/j.bbr.2009.01.005; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Hughes RN, 2007, BEHAV PHARMACOL, V18, P583, DOI 10.1097/FBP.0b013e3282eff0e8; Jonasson Z, 2005, NEUROSCI BIOBEHAV R, V28, P811, DOI 10.1016/j.neubiorev.2004.10.006; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Karl T, 2008, EUR J NEUROSCI, V28, P173, DOI 10.1111/j.1460-9568.2008.06306.x; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; Kokras N, 2014, BRIT J PHARMACOL, V171, P4595, DOI 10.1111/bph.12710; Kundakovic Marija, 2013, Front Psychiatry, V4, P78, DOI 10.3389/fpsyt.2013.00078; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; McCullough LD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293-014-0015-5; McIntosh TK, 1996, LAB INVEST, V74, P315; Meziane H, 2007, GENES BRAIN BEHAV, V6, P192, DOI 10.1111/j.1601-183X.2006.00249.x; Mogil JS, 2005, PAIN, V117, P1, DOI 10.1016/j.pain.2005.06.020; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nicolson TJ, 2010, TRENDS PHARMACOL SCI, V31, P108, DOI 10.1016/j.tips.2009.12.001; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; O'Leary TP, 2013, BEHAV GENET, V43, P34, DOI 10.1007/s10519-012-9572-8; O'Leary TP, 2012, J NEUROSCI METH, V203, P315, DOI 10.1016/j.jneumeth.2011.09.027; O'Leary TP, 2011, BEHAV BRAIN RES, V216, P531, DOI 10.1016/j.bbr.2010.08.030; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ramsey LCB, 2010, NEUROSCI LETT, V483, P148, DOI 10.1016/j.neulet.2010.07.082; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rial D, 2009, BRAIN RES BULL, V79, P177, DOI 10.1016/j.brainresbull.2009.02.003; Rizk A, 2005, BRAIN RES, V1034, P132, DOI 10.1016/j.brainres.2004.12.002; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandberg K, 2015, FASEB J, V29, P1646, DOI 10.1096/fj.14-269548; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Stein DG, 2007, PROG BRAIN RES, V161, P339, DOI 10.1016/S0079-6123(06)61024-8; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stevens LM, 2015, BEHAV BRAIN RES, V278, P496, DOI 10.1016/j.bbr.2014.10.033; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Typlt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081270; Van Swearingen AED, 2013, PSYCHOPHARMACOLOGY, V225, P707, DOI 10.1007/s00213-012-2860-4; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weil ZM, 2006, BRAIN RES BULL, V68, P425, DOI 10.1016/j.brainresbull.2005.09.016; Whitley HP, 2009, AM FAM PHYSICIAN, V80, P1254; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	105	65	65	1	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					880	894		10.1089/neu.2015.3977			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800010	25951234	Green Published			2021-06-18	
J	Fischer, TD; Hylin, MJ; Zhao, J; Moore, AN; Waxharni, MN; Dash, PK				Fischer, Tara D.; Hylin, Michael J.; Zhao, Jing; Moore, Anthony N.; Waxharni, M. Neal; Dash, Pramod K.			Altered Mitochondria! Dynamics and TBI Pathophysiology	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						Drp1; mitochondrial dynamics; neurodegeneration; neurogenesis; TBI	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; ADULT HIPPOCAMPAL NEUROGENESIS; DEPENDENT PROTEIN-KINASE; NEWBORN NEURONS; WORKING-MEMORY; CYCLOSPORINE-A; GRANULE CELLS; MOUSE MODEL; FISSION	Mitochondrial function is intimately linked to cellular survival, growth, and death. Mitochondria not only generate ATP from oxidative phosphorylation, but also mediate intracellular calcium buffering, generation of reactive oxygen species (ROS), and apoptosis. Electron leakage from the electron transport chain, especially from damaged or depolarized mitochondria, can generate excess free radicals that damage cellular proteins. DNA, and lipids. Furthermore, Mitochondrial damage releases pro-apoptotic factors to initiate cell death. Previous studies have reported that traumatic brain injury (TBI) reduces Mitochondrial respiration, enhances production of ROS, and triggers apoptotic cell death, suggesting a prominent role of mitochondria in TBI pathophysiology. Mitochondria maintain cellular energy homeostasis and health via balanced processes of fusion and fission, continuously dividing and fusing to form an interconnected network throughout the cell. An imbalance of these processes, particularly an excess of fission, can be detrimental to Mitochondrial function, causing decreased respiration, ROS production, and apoptosis. Mitochondrial fission is regulated by the cytosolic GTPase, dynamin-related protein 1 (Drp1), which translocates to the Mitochondrial outer membrane (MOM) to initiate fission. Aberrant Drp1 activity has been linked to excessive Mitochondrial fission and neurodegeneration. Measurement of Drp1 levels in purified hippocampal mitochondria showed an increase in TBI animals as compared to sham controls. Analysis of cryo-electron micrographs of these mitochondria also showed that TBI caused an initial increase in the length of hippocampal mitochondria at 24 h post-injury, followed by a significant decrease in length at 72 h. Post-TBI administration of Mitochondrial division inhibitor-1 (Mdivi-1), a pharmacological inhibitor of Drp1, prevented this decrease in mitochondria length. Mdivi-1 treatment also reduced the loss of newborn neurons in the hippocampus and improved novel object recognition (NOR) memory and context-specific fear memory. Taken together, our results show that TBI increases Mitochondrial fission and that inhibition of fission improves hippocampal-dependent learning and memory, suggesting that strategies to reduce fission may have translational value after injury.	[Fischer, Tara D.; Zhao, Jing; Moore, Anthony N.; Waxharni, M. Neal; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Hylin, Michael J.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; [Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, McGovern Pvled Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA	Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77030 USA.; Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Pvled Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.	p.dash@uth.tmc.edu	Fischer, Tara/ABA-1727-2020; Hylin, Michael/U-2878-2019	Fischer, Tara/0000-0002-6590-4401; Waxham, M. Neal/0000-0003-4801-1190	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS086301, NS087149]; William Wheless III professorship; Structural Biology Imaging Center at UTHSC-Houston; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016279]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS101686, R01NS086301, R01NS087149] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016279] Funding Source: NIH RePORTER	The authors would like to thank Kimberly Hood, John Redell for their assistance and suggestions. This work was supported by the Nina and Michael Zilkha endowment, grants from NIH (NS086301 and NS087149). MNW acknowledges the support of William Wheless III professorship. The Polara electron microscope was supported, in part, through the Structural Biology Imaging Center at UTHSC-Houston. The Gatan K2 Summit was funded by the National Institutes of Health-Award S10OD016279.	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Burte F, 2015, NAT REV NEUROL, V11, P11, DOI 10.1038/nrneurol.2014.228; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Costa V, 2010, EMBO MOL MED, V2, P490, DOI 10.1002/emmm.201000102; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Denny CA, 2012, HIPPOCAMPUS, V22, P1188, DOI 10.1002/hipo.20964; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drew MR, 2010, BEHAV NEUROSCI, V124, P446, DOI 10.1037/a0020081; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Jheng HF, 2012, MOL CELL BIOL, V32, P309, DOI 10.1128/MCB.05603-11; Kanamaru Yusuke, 2012, J Signal Transduct, V2012, P931215, DOI 10.1155/2012/931215; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Manczak M, 2012, HUM MOL GENET, V21, P2538, DOI 10.1093/hmg/dds072; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Otera H, 2013, BBA-MOL CELL RES, V1833, P1256, DOI 10.1016/j.bbamcr.2013.02.002; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rappold PM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6244; Reddy PH, 2011, BRAIN RES REV, V67, P103, DOI 10.1016/j.brainresrev.2010.11.004; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Santel A, 2008, IUBMB LIFE, V60, P448, DOI 10.1002/iub.71; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Suarez-Pereira I, 2015, HIPPOCAMPUS, V25, P51, DOI 10.1002/hipo.22349; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wang HX, 2011, J BIOL CHEM, V286, P11649, DOI 10.1074/jbc.M110.144238; Westermann B, 2012, BBA-BIOENERGETICS, V1817, P1833, DOI 10.1016/j.bbabio.2012.02.033; Wiltgen BJ, 2006, J NEUROSCI, V26, P5484, DOI 10.1523/JNEUROSCI.2685-05.2006; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao YX, 2014, CNS NEUROSCI THER, V20, P528, DOI 10.1111/cns.12266; Zhao YX, 2013, J NEUROCHEM, V127, P711, DOI 10.1111/jnc.12340	65	65	66	1	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	MAR 30	2016	10								20	10.3389/fnsys.2010.00020			12	Neurosciences	Neurosciences & Neurology	DH7IC	WOS:000372965600001	27065821	DOAJ Gold, Green Published			2021-06-18	
J	Korley, FK; Diaz-Arrastia, R; Wu, AHB; Yue, JK; Manley, GT; Sair, HI; Van Eyk, J; Everett, AD; Okonkwo, DO; Valadka, AB; Gordon, WA; Maas, AIR; Mukherjee, P; Yuh, EL; Lingsma, HF; Puccio, AM; Schnyer, DM				Korley, Frederick K.; Diaz-Arrastia, Ramon; Wu, Alan H. B.; Yue, John K.; Manley, Geoffrey T.; Sair, Haris I.; Van Eyk, Jennifer; Everett, Allen D.; Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Mukherjee, Pratik; Yuh, Esther L.; Lingsma, Hester F.; Puccio, Ava M.; Schnyer, David M.		TRACK-TBI Investigators	Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; brain-derived neurotrophic factor; glial fibrillary acidic protein; traumatic brain injury; ubiquitin C-terminal hydrolase-L1	FIBRILLARY ACIDIC PROTEIN; COMMON DATA ELEMENTS; C-TERMINAL HYDROLASE; RAT-BRAIN; HUMAN PLATELETS; BDNF LEVELS; TRANSFORMING RESEARCH; EMERGENCY-DEPARTMENT; CLINICAL KNOWLEDGE; FACTOR EXPRESSION	Brain-derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration. We investigated the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI). We examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments (EDs) of the Johns Hopkins Hospital (JHH; n=76) and San Francisco General Hospital (SFGH, n=80), and a control group of JHH ED patients without TBI (n=150). Findings were subsequently validated in the prospective, multi-center Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Pilot study (n=159). We investigated the association between BDNF, glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) and recovery from TBI at 6 months in the TRACK-TBI Pilot cohort. Incomplete recovery was defined as having either post-concussive syndrome or a Glasgow Outcome Scale Extended score <8 at 6 months. Median day-of-injury BDNF concentrations (ng/mL) were lower among TBI cases (JHH TBI, 17.5 and SFGH TBI, 13.8) than in JHH controls (60.3; p=0.0001). Among TRACK-TBI Pilot subjects, median BDNF concentrations (ng/mL) were higher in mild (8.3) than in moderate (4.3) or severe TBI (4.0; p=0.004. In the TRACK-TBI cohort, the 75 (71.4%) subjects with very low BDNF values (i.e., <the 1st percentile for non-TBI controls, <14.2ng/mL) had higher odds of incomplete recovery than those who did not have very low values (odds ratio, 4.0; 95% confidence interval [CI]: 1.5-11.0). The area under the receiver operator curve for discriminating complete and incomplete recovery was 0.65 (95% CI: 0.52-0.78) for BDNF, 0.61 (95% CI: 0.49-0.73) for GFAP, and 0.55 (95% CI: 0.43-0.66) for UCH-L1. The addition of GFAP/UCH-L1 to BDNF did not improve outcome prediction significantly. Day-of-injury serum BDNF is associated with TBI diagnosis and also provides 6-month prognostic information regarding recovery from TBI. Thus, day-of-injury BDNF values may aid in TBI risk stratification.	[Korley, Frederick K.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA; [Sair, Haris I.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21209 USA; [Everett, Allen D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21209 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Wu, Alan H. B.] San Francisco Gen Hosp, Clin Chem Lab, San Francisco, CA 94110 USA; [Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Mukherjee, Pratik; Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Van Eyk, Jennifer] Cedars Sinai Med Ctr, Dept Med, Adv Clin Biosyst Res Inst, Los Angeles, CA 90048 USA; [Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Mukherjee, Pratik; Yuh, Esther L.; Lingsma, Hester F.; Puccio, Ava M.; Schnyer, David M.] Transforming Res & Clin Knowledge TBI TRACK Inves, New York, NY USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lingsma, Hester F.] Erasmas Med Ctr, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Korley, FK (corresponding author), Johns Hopkins Univ, Sch Med, Davis Bldg,Suite 3220,5801 Smith Ave, Baltimore, MD 21209 USA.	fkorley1@jhmi.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Mukherjee, Pratik/0000-0001-7473-7409; Schnyer, David/0000-0002-7472-2853; Diaz-Arrastia, Ramon/0000-0001-6051-3594	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, RC2NS069409] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [HHSN268201000032C] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, U01NS086090] Funding Source: NIH RePORTER		Alonso M, 2002, HIPPOCAMPUS, V12, P551, DOI 10.1002/hipo.10035; Apple FS, 2003, CLIN CHEM, V49, P1331, DOI 10.1373/49.8.1331; Apple FS, 2005, CLIN CHEM, V51, P2198, DOI 10.1373/clinchem.2005.052886; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Fidalgo TM, 2014, J ECT, V30, P47, DOI 10.1097/YCT.0b013e31828b34d8; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Golden E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010099; Green MJ, 2011, MOL PSYCHIATR, V16, P960, DOI 10.1038/mp.2010.88; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gutierrez S., 2014, CRIT CARE MED, V42, pA1488, DOI [10.1097/01.ccm.0000458030.91776.65, DOI 10.1097/01.CCM.0000458030.91776.65]; Helan M, 2014, J MOL CELL CARDIOL, V68, P89, DOI 10.1016/j.yjmcc.2014.01.006; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karege F, 2002, NEUROSCI LETT, V328, P261, DOI 10.1016/S0304-3940(02)00529-3; Kim DH, 2005, NEUROCRIT CARE, V3, P71, DOI 10.1385/NCC:3:1:071; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Korley FK, 2014, ACAD EMERG MED, V21, P728, DOI 10.1111/acem.12417; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nieto R, 2013, Front Psychiatry, V4, P45, DOI 10.3389/fpsyt.2013.00045; O'Neil M.E., 2013, VA EVIDENCE BASED SY; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; Suliman S, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00055; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Yamada K, 2003, J PHARMACOL SCI, V91, P267; YAMAMOTO H, 1990, J NEUROSCI, V10, P3469; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	68	65	65	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					215	225		10.1089/neu.2015.3949			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800007	26159676	Green Published, Green Accepted			2021-06-18	
J	Wu, Q; Xia, SX; Li, QQ; Gao, Y; Shen, X; Ma, L; Zhang, MY; Wang, T; Li, YS; Wang, ZF; Luo, CL; Tao, LY				Wu, Qiong; Xia, Shui-Xiu; Li, Qian-Qian; Gao, Yuan; Shen, Xi; Ma, Lu; Zhang, Ming-Yang; Wang, Tao; Li, Yong-Sheng; Wang, Zu-Feng; Luo, Cheng-Liang; Tao, Lu-Yang			Mitochondrial division inhibitor 1 (Mdivi-1) offers neuroprotection through diminishing cell death and improving functional outcome in a mouse model of traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Mitochondrial fusion; Dynamin-related protein 1; Apoptosis	CONTROLLED CORTICAL IMPACT; DYNAMIN-RELATED PROTEIN-1; INTRACEREBRAL HEMORRHAGE; PLASMALEMMA PERMEABILITY; APOPTOTIC PATHWAY; BARRIER DAMAGE; CYTOCHROME-C; MICE; FISSION; AUTOPHAGY	Mitochondria dysfunction, an enormous potential crisis, has attracted increasing attention. Disturbed regulation of mitochondrial dynamics, the balance of mitochondrial fusion and fission, has been implicated in neurodegenerative diseases, such as Parkinson's disease and cerebral ischemia/reperfusion. However the role of mitochondrial dynamics in traumatic brain injury (TBI) has not been illuminated. The aim of the present study was to investigate the role of Mdivi-1, a small molecule inhibitor of a key mitochondrial fission protein dynamin-related protein 1 (Drp1), in TBI-induced cell death and functional outcome deficits. Protein expression of Drp1 was first investigated. Outcome parameters consist of motor test, Morris water maze, brain edema and lesion volume. Cell death was detected by propidium iodide (PI) labeling, and mitochondrial morphology was assessed using transmission electron microscopy. In addition, the expression of apoptosis-related proteins cytochrome c (cyt-c) and caspase-3 was investigated. Our findings showed that up-regulation of Drp1 expression started at 1 h post-TBI and peaked at 24 h, but inhibition of Drp1 by Mdivi-1 significantly alleviated TBI-induced behavioral deficits and brain edema, reduced morphological change of mitochondria, and decreased TBI-induced cell death together with lesion volume. Moreover, treatment with Mdivi-1 remarkably inhibited TBI-induced the release of cyt-c from mitochondria to cytoplasm, and activation of caspase-3 at 24 h after TBI. Taken together, these data imply that inhibition of Drp1 may help attenuate TBI-induced functional outcome and cell death through maintaining normal mitochondrial morphology and inhibiting activation of apoptosis. (C) 2015 Elsevier B.V. All rights reserved.	[Wu, Qiong; Xia, Shui-Xiu; Gao, Yuan; Shen, Xi; Ma, Lu; Zhang, Ming-Yang; Wang, Tao; Wang, Zu-Feng; Luo, Cheng-Liang; Tao, Lu-Yang] Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China; [Li, Qian-Qian] Wannan Med Coll, Dept Forens Med, Wuhu 241002, Peoples R China; [Li, Yong-Sheng] Suzhou Publ Secur Bur, Wuzhong Branch, Suzhou 215128, Peoples R China	Wang, ZF (corresponding author), Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China.	zufengwang@suda.edu.cn; clluo@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Shen, Xi/0000-0001-7568-7335	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400999, 81172911, 81373251, 81530062]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M551660]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (Nos. 81400999, 81172911, 81373251, and 81530062), China Postdoctoral Science Foundation (No. 2014M551660), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Babbitt SE, 2015, TRENDS BIOCHEM SCI, V40, P446, DOI 10.1016/j.tibs.2015.05.006; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Boland K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.250; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cui T, 2015, CELL BIOCHEM BIOPHYS, V71, P595, DOI 10.1007/s12013-014-0239-3; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lackner LL, 2009, BBA-MOL BASIS DIS, V1792, P1138, DOI 10.1016/j.bbadis.2008.11.011; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Purnell PR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-86; Qi X, 2013, J CELL SCI, V126, P789, DOI 10.1242/jcs.114439; Santopietro John, 2015, N C Med J, V76, P96; Sharp Willard W, 2015, Crit Care Med, V43, pe38, DOI 10.1097/CCM.0000000000000817; Wall DM, 2014, CELL MICROBIOL, V16, P1746, DOI 10.1111/cmi.12368; Wang DB, 2013, J NEUROSCI, V33, P1357, DOI 10.1523/JNEUROSCI.3365-12.2013; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wang T, 2013, BEHAV BRAIN RES, V247, P132, DOI 10.1016/j.bbr.2013.03.023; Wang X, 2011, J NEUROSCI, V31, P14496, DOI 10.1523/JNEUROSCI.3059-11.2011; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Watson William D, 2013, Front Neuroenergetics, V5, P12, DOI 10.3389/fnene.2013.00012; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xu XW, 2008, CELL MOL NEUROBIOL, V28, P875, DOI 10.1007/s10571-008-9265-2; Yuan H, 2007, CELL DEATH DIFFER, V14, P462, DOI 10.1038/sj.cdd.4402046; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang N, 2013, NEUROSCI LETT, V535, P104, DOI 10.1016/j.neulet.2012.12.049; Zhu XX, 2012, STROKE, V43, P524, DOI 10.1161/STROKEAHA.111.635672; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	39	65	66	2	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						134	143		10.1016/j.brainres.2015.11.016			10	Neurosciences	Neurosciences & Neurology	CZ4YU	WOS:000367109900014	26596858				2021-06-18	
J	Rangarajan, P; Karthikeyan, A; Lu, J; Ling, EA; Dheen, ST				Rangarajan, P.; Karthikeyan, A.; Lu, J.; Ling, E. -A.; Dheen, S. T.			SIRTUIN 3 REGULATES Foxo3a-MEDIATED ANTIOXIDANT PATHWAY IN MICROGLIA	NEUROSCIENCE			English	Article						microglia; Sirt3; Foxo3a; ROS; antioxidant; brain injury	OXIDATIVE STRESS; BRAIN-INJURY; MITOCHONDRIA; ACTIVATION; SUPPRESSION	Microglia are the prime cellular sources of reactive oxygen species (ROS) in the central nervous system (CNS). Chronic activation of microglia has been linked to aging-associated neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) since they produce excessive amounts of ROS for a prolonged duration leading to oxidative stress. The present study was aimed at investigating the expression and role of Sirtuin 3 (Sirt3), a protein deacetylase which is implicated in regulating cellular ROS levels. It has been shown that Sirt3 reduces cellular ROS levels by deacetylating forkhead box O 3a (Foxo3a), a transcription factor which transactivates antioxidant genes, catalase (Cat) and manganese superoxide dismutase (mnSod). In the present study, Sirt3 immunoreactivity was localized in the ameboid microglial cells distributed in the corpus callosum (CC) of the early postnatal rat brain and diminished in the ramified microglial cells in the CC of the adult rat brain. A marked induction of Sirt3 expression was seen in lipopolysaccharide (LPS)-activated microglia in vivo and in vitro as well as in adult rat brains subjected to traumatic brain injury (TBI). Knock-down of Sirt3 in microglia led to an increase in the cellular and mitochondrial ROS and decrease in the expression of antioxidant, mnSod which is indicative of the function of Sirt3 in ROS regulation in microglia. Conversely, Sirt3 overexpression led to increase in the expression of antioxidants Cat and mnSod. Further, increase in the expression and nuclear translocation of Foxo3a was observed following Sirt3 overexpression, suggesting that Sirt3 regulates ROS by inducing the expression of antioxidants via activation of Foxo3a. The above results point to an antioxidant defense mechanism presented by Sirt3 through the activation of Foxo3a, in microglia. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Rangarajan, P.; Karthikeyan, A.; Lu, J.; Ling, E. -A.; Dheen, S. T.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Lu, J.] Def Med & Environm Res Inst, DSO Natl Labs, Singapore, Singapore	Dheen, ST (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Block MD10,4 Med Dr, Singapore 117597, Singapore.	thameem_dheen@nuhs.edu.sg	Dheen, S. Thameem/AAU-8627-2020	Dheen, S. Thameem/0000-0001-9600-6789	NUHS Seed Fund for Basic Science Research Grant, Singapore [R-181-000-166-112]; National University of Singapore, University Strategic Research [DPRT/944/09/14]; NUS Yong Loo Lin School of Medicine Aspiration Fund, Singapore [R-185-000-271-720]	This research was supported by the NUHS Seed Fund for Basic Science Research Grant, Singapore (R-181-000-166-112) and supported by the National University of Singapore, University Strategic Research (DPRT/944/09/14) and NUS Yong Loo Lin School of Medicine Aspiration Fund (R-185-000-271-720), Singapore. We also thank Dr. Li Yali for providing technical assistance.	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Bao JJ, 2010, FREE RADICAL BIO MED, V49, P1230, DOI 10.1016/j.freeradbiomed.2010.07.009; Bao JJ, 2010, J CELL BIOCHEM, V110, P238, DOI 10.1002/jcb.22531; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Hristova M, 2010, GLIA, V58, P11, DOI 10.1002/glia.20896; Huo YQ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-49; Jacobs KM, 2008, INT J BIOL SCI, V4, P291; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Keller JN, 1998, J NEUROSCI, V18, P687; Kim SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014731; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marques CP, 2008, J NEUROVIROL, V14, P229, DOI 10.1080/13550280802093927; Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001; Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; Sidorova-Darmos E, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00333; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Wilkinson BL, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-30	26	65	72	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 17	2015	311						398	414		10.1016/j.neuroscience.2015.10.048			17	Neurosciences	Neurosciences & Neurology	CY1CJ	WOS:000366144000034	26523980				2021-06-18	
J	Villapol, S; Balarezo, MG; Affram, K; Saavedra, JM; Symes, AJ				Villapol, Sonia; Balarezo, Maria G.; Affram, Kwame; Saavedra, Juan M.; Symes, Aviva J.			Neurorestoration after traumatic brain injury through angiotensin II receptor blockage	BRAIN			English	Article						candesartan; telmisartan; inflammation; apoptosis; recovery	SPONTANEOUSLY HYPERTENSIVE-RATS; PPAR-GAMMA ACTIVATION; AT(1) RECEPTOR; OXIDATIVE STRESS; FUNCTIONAL RECOVERY; STROKE-RESISTANT; ISCHEMIC-STROKE; MEMORY FUNCTION; CANDESARTAN; TELMISARTAN	Traumatic brain injury frequently leads to long-term cognitive problems and physical disability yet remains without effective therapeutics. Traumatic brain injury results in neuronal injury and death, acute and prolonged inflammation and decreased blood flow. Drugs that block angiotensin II type 1 receptors (AT1R, encoded by AGTR1) (ARBs or sartans) are strongly neuroprotective, neurorestorative and anti-inflammatory. To test whether these drugs may be effective in treating traumatic brain injury, we selected two sartans, candesartan and telmisartan, of proven therapeutic efficacy in animal models of brain inflammation, neurodegenerative disorders and stroke. Using a validated mouse model of controlled cortical impact injury, we determined effective doses for candesartan and telmisartan, their therapeutic window, mechanisms of action and effect on cognition and motor performance. Both candesartan and telmisartan ameliorated controlled cortical impact-induced injury with a therapeutic window up to 6 h at doses that did not affect blood pressure. Both drugs decreased lesion volume, neuronal injury and apoptosis, astrogliosis, microglial activation, pro-inflammatory signalling, and protected cerebral blood flow, when determined 1 to 3 days post-injury. Controlled cortical impact-induced cognitive impairment was ameliorated 30 days after injury only by candesartan. The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARg, encoded by PPARG) antagonist T0070907, showing the importance of PPARg activation for the neurorestorative effect of these sartans. AT1R knockout mice were less vulnerable to controlled cortical impactinduced injury suggesting that the sartan's blockade of the AT1R also contributes to their efficacy. This study strongly suggests that sartans with dual AT1R blocking and PPARg activating properties have therapeutic potential for traumatic brain injury.	[Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Villapol, Sonia; Balarezo, Maria G.; Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Saavedra, Juan M.] Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, Washington, DC 20057 USA	Villapol, S (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,WG20,3970 Reservoir Rd NW, Washington, DC 20057 USA.	sonia.villapol@georgetown.edu	Villapol, Sonia/D-1949-2014; Saavedra, Juan/AAO-7149-2020; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM); CNRM postdoctoral fellowship; Intramural Research Program at the National Institute of Mental Health, NIH [MH 002762-16]	This work was supported by a Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM) grant to A.J.S. S.V. was supported by a CNRM postdoctoral fellowship. J.M.S. was supported by the Intramural Research Program at the National Institute of Mental Health, NIH (MH 002762-16).	Alhusban A, 2013, J PHARMACOL EXP THER, V344, P348, DOI 10.1124/jpet.112.197483; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Armando I, 2002, NEUROENDOCRINOLOGY, V76, P137, DOI 10.1159/000064525; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Bennai F, 1999, J AM SOC NEPHROL, V10, pS104; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Cabaleiro T, 2013, DRUG METAB DISPOS, V41, P224, DOI 10.1124/dmd.112.046292; Cernes R, 2011, VASC HEALTH RISK MAN, V7, P749, DOI 10.2147/VHRM.S22591; Deppe S, 2010, EXPERT OPIN DRUG MET, V6, P863, DOI 10.1517/17425255.2010.494597; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2003, J HUM HYPERTENS, V17, P781, DOI 10.1038/sj.jhh.1001613; Fukui Y, 2014, J STROKE CEREBROVASC, V23, P1545, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.052; Garrido-Gil P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-38; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Gleiter CH, 2002, CLIN PHARMACOKINET, V41, P7, DOI 10.2165/00003088-200241010-00002; Guan WH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024551; Hajar I, 2013, J AM GERIATR SOC, V61, P194, DOI 10.1111/jgs.12100; Hajjar I, 2012, ARCH NEUROL-CHICAGO, V69, P1632, DOI 10.1001/archneurol.2012.1010; Hamai M, 2006, NEUROPHARMACOLOGY, V51, P822, DOI 10.1016/j.neuropharm.2006.05.029; Hsu CY, 2013, CIRC J, V77, P405, DOI 10.1253/circj.CJ-12-0658; Ishrat T, 2015, MOL NEUROBIOL, V51, P1542, DOI 10.1007/s12035-014-8830-6; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104; Joseph JP, 2014, NEUROPHARMACOLOGY, V81, P134, DOI 10.1016/j.neuropharm.2014.01.044; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Justin A, 2014, PHARMACOL BIOCHEM BE, V122, P61, DOI 10.1016/j.pbb.2014.03.009; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Kozak A, 2009, STROKE, V40, P1870, DOI 10.1161/STROKEAHA.108.537225; Kozak W, 2008, J PHARMACOL EXP THER, V326, P773, DOI 10.1124/jpet.108.139618; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li JJ, 2009, NEUROSCIENCE, V158, P1488, DOI 10.1016/j.neuroscience.2008.11.046; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu H, 2008, J HYPERTENS, V26, P1435, DOI 10.1097/HJH.0b013e3283013b6e; Lu GC, 2009, STROKE, V40, P3876, DOI 10.1161/STROKEAHA.109.559989; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Meredith PA, 2004, J RENIN-ANGIO-ALDO S, V5, P59, DOI 10.3317/jraas.2004.011; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Mitchell K, 2014, J NEUROCHEM, V129, P155, DOI 10.1111/jnc.12612; Mogi M, 2008, BIOCHEM BIOPH RES CO, V375, P446, DOI 10.1016/j.bbrc.2008.08.032; Nishimura Y, 2000, BRAIN RES, V871, P29, DOI 10.1016/S0006-8993(00)02377-5; Noda A, 2012, NUCL MED BIOL, V39, P1232, DOI 10.1016/j.nucmedbio.2012.06.012; Ohshima K, 2013, CURR HYPERTENS REV, V9, P99, DOI 10.2174/15734021113099990004; Omura-Matsuoka E, 2009, HYPERTENS RES, V32, P548, DOI 10.1038/hr.2009.69; Ozacmak VH, 2007, NEUROCHEM RES, V32, P1314, DOI 10.1007/s11064-007-9305-1; Pelisch N, 2013, CURR HYPERTENS REV, V9, P93, DOI 10.2174/15734021113099990003; Rodriguez-Perez AI, 2015, GLIA, V63, P466, DOI 10.1002/glia.22765; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2006, J HYPERTENS, V24, pS131, DOI 10.1097/01.hjh.0000220418.09021.ee; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65; Soliman S, 2014, J PHARMACOL EXP THER, V349, P444, DOI 10.1124/jpet.113.212613; Stangier J, 2000, J CLIN PHARMACOL, V40, P1355; Steckelings UM, 2012, EXPERT OPIN INV DRUG, V21, P763, DOI 10.1517/13543784.2012.681046; Sumners C, 2013, CLIN EXP PHARMACOL P, V40, P580, DOI 10.1111/1440-1681.12137; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Thone-Reineke C, 2006, J HYPERTENS, V24, pS115; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Tota S, 2009, BEHAV BRAIN RES, V199, P235, DOI 10.1016/j.bbr.2008.11.044; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Umschweif G, 2014, NEUROTHERAPEUTICS, V11, P665, DOI 10.1007/s13311-014-0286-x; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Villapol S, 2009, AM J PATHOL, V175, P2111, DOI 10.2353/ajpath.2009.090257; Villela D, 2015, CLIN SCI, V128, P227, DOI 10.1042/CS20130515; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright JW, 2011, PROG NEUROBIOL, V95, P49, DOI 10.1016/j.pneurobio.2011.07.001; WRIGHT JW, 1994, NEUROSCI BIOBEHAV R, V18, P21, DOI 10.1016/0149-7634(94)90034-5; Wu CY, 2013, MOL CELL BIOCHEM, V382, P47, DOI 10.1007/s11010-013-1717-4; Yamashita T, 2014, J STROKE CEREBROVASC, V23, P2240, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.010; Zanchetti A, 2006, BLOOD PRESSURE, V15, P71, DOI 10.1080/08037050600771583; Zhang M, 2010, NEUROSCIENCE, V171, P852, DOI 10.1016/j.neuroscience.2010.09.029; Zhou J, 2006, STROKE, V37, P1271, DOI 10.1161/01.STR.0000217404.64352.d7; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062	80	65	67	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV 1	2015	138		11							10.1093/brain/awv172			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CW6VF	WOS:000365135700025	26115674	Green Published, Bronze			2021-06-18	
J	Talbott, JF; Whetstone, WD; Readdy, WJ; Ferguson, AR; Bresnahan, JC; Saigal, R; Hawryluk, GWJ; Beattie, MS; Mabray, MC; Pan, JZ; Manley, GT; Dhall, SS				Talbott, Jason F.; Whetstone, William D.; Readdy, William J.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Mabray, Marc C.; Pan, Jonathan Z.; Manley, Geoffrey T.; Dhall, Sanjay S.			The Brain and Spinal Injury Center score: a novel, simple, and reproducible method for assessing the severity of acute cervical spinal cord injury with axial T2-weighted MRI findings	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal cord injury; MRI; T2; ASIA; contusion; BASIC; trauma	OF-THE-ART; MAGNETIC-RESONANCE; PATHOLOGICAL CORRELATIONS; MOUSE MODEL; TRAUMA; RECOVERY; DEMOGRAPHICS; DAMAGE	OBJECT Previous studies that have evaluated the prognostic value of abnormal changes in signals on T2-weighted MRI scans of an injured spinal cord have focused on the longitudinal extent of this signal abnormality in the sagittal plane. Although the transverse extent of injury and the degree of spared spinal cord white matter have been shown to be important for predicting outcomes in preclinical animal models of spinal cord injury (SCI), surprisingly little is known about the prognostic value of altered T2 relaxivity in humans in the axial plane. METHODS The authors undertook a retrospective chart review of 60 patients who met the inclusion criteria of this study and presented to the authors' Level I trauma center with an acute blunt traumatic cervical SCI. Within 48 hours of admission, all patients underwent MRI examination, which included axial and sagittal T2 images. Neurological symptoms, evaluated with the grades according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS), at the time of admission and at hospital discharge were correlated with MRI findings. Five distinct patterns of intramedullary spinal cord T2 signal abnormality were defined in the axial plane at the injury epicenter. These patterns were assigned ordinal values ranging from 0 to 4, referred to as the Brain and Spinal Injury Center (BASIC) scores, which encompassed the spectrum of SCI severity. RESULTS The BASIC score strongly correlated with neurological symptoms at the time of both hospital admission and discharge. It also distinguished patients initially presenting with complete injury who improved by at least one AIS grade by the time of discharge from those whose injury did not improve. The authors' proposed score was rapid to apply and showed excellent interrater reliability. CONCLUSIONS The authors describe a novel 5-point ordinal MRI score for classifying acute SCIs on the basis of axial T2-weighted imaging. The proposed BASIC score stratifies the SCIs according to the extent of transverse T2 signal abnormality during the acute phase of the injury. The new score improves on current MRI-based prognostic descriptions for SCI by reflecting functionally and anatomically significant patterns of intramedullary T2 signal abnormality in the axial plane.	[Talbott, Jason F.; Mabray, Marc C.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Readdy, William J.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Manley, Geoffrey T.; Dhall, Sanjay S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pan, Jonathan Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Whetstone, William D.] San Francisco Gen Hosp, Dept Emergency Med, San Francisco, CA 94110 USA; [Ferguson, Adam R.; Bresnahan, Jacqueline C.; Saigal, Rajiv; Hawryluk, Gregory W. J.; Beattie, Michael S.; Pan, Jonathan Z.; Manley, Geoffrey T.; Dhall, Sanjay S.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA	Dhall, SS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,Rm M-779, San Francisco, CA 94143 USA.	sanjay.dhall@ucsf.edu	Mabray, Marc/AAI-6660-2020	Mabray, Marc/0000-0001-7355-6833; Ferguson, Adam/0000-0001-7102-1608	Department of Defense Congressionally Directed Medical Research Programs award [SC140137]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067092] Funding Source: NIH RePORTER	Partial support for this study was provided by a Department of Defense Congressionally Directed Medical Research Programs award (SC140137) to Drs. Beattie, Manley, Bresnahan, Whetstone, and Ferguson. Dr. Dhall has received speaker honoraria from DePuy and Globus.	Andreoli Chiara, 2005, Radiol Med, V110, P636; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BONDURANT FJ, 1990, SPINE, V15, P161, DOI 10.1097/00007632-199003000-00002; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Burke DA, 2001, SPINAL CORD, V39, P274, DOI 10.1038/sj.sc.3101158; CHAKERES DW, 1987, AM J NEURORADIOL, V8, P5; Collignon FD, 2002, J NEUROSURG, V96, P29, DOI 10.3171/spi.2002.96.1.0029; Cotler H B, 1988, J Orthop Trauma, V2, P1, DOI 10.1097/00005131-198802000-00001; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; GOLDBERG AL, 1988, SKELETAL RADIOL, V17, P89, DOI 10.1007/BF00365133; Gomori J M, 1988, Radiographics, V8, P427; HAYASHI K, 1995, PARAPLEGIA, V33, P212, DOI 10.1038/sc.1995.47; Kelley BJ, 2014, J NEUROTRAUM, V31, P1362, DOI 10.1089/neu.2013.3238; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Kulkarni M V, 1988, Radiographics, V8, P1059; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Machino M, 2011, SPINE, V36, pE1568, DOI 10.1097/BRS.0b013e31821273c0; MARCIELLO MA, 1993, ARCH PHYS MED REHAB, V74, P940; MARTIN D, 1992, NEURORADIOLOGY, V34, P262, DOI 10.1007/BF00588177; Mihai G, 2008, J NEUROTRAUM, V25, P1, DOI 10.1089/neu.2007.0338; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Nout YS, 2009, CRIT CARE MED, V37, P2160, DOI 10.1097/CCM.0b013e3181a05d41; Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720; Pouw MH, 2012, SPINAL CORD, V50, P426, DOI 10.1038/sc.2011.168; QUENCER RM, 1992, NEURORADIOLOGY, V34, P85, DOI 10.1007/BF00588148; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; SCHAEFER DM, 1989, SPINE, V14, P1090, DOI 10.1097/00007632-198910000-00011; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shimada K, 1999, SPINAL CORD, V37, P410, DOI 10.1038/sj.sc.3100858; Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107; Stroman PW, 2014, NEUROIMAGE, V84, P1070, DOI 10.1016/j.neuroimage.2013.04.124; Sun LQ, 2014, SPINAL CORD, V52, P541, DOI 10.1038/sc.2014.60; Thompson C, 2015, J SPINAL CORD MED, V38, P214, DOI 10.1179/2045772314Y.0000000233; Wang MY, 2011, MAGN RESON IMAGING, V29, P365, DOI 10.1016/j.mri.2010.10.016; Wheeler-Kingshott CA, 2014, NEUROIMAGE, V84, P1082, DOI 10.1016/j.neuroimage.2013.07.014; Wilson JR, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.AOSPINE1245	42	65	65	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	OCT	2015	23	4					495	504		10.3171/2015.1.SPINE141033			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CS1YF	WOS:000361864100016	26161519	Bronze			2021-06-18	
J	Al Nimer, F; Thelin, E; Nystrom, H; Dring, AM; Svenningsson, A; Piehl, F; Nelson, DW; Bellander, BM				Al Nimer, Faiez; Thelin, Eric; Nystrom, Harriet; Dring, Ann M.; Svenningsson, Anders; Piehl, Fredrik; Nelson, David W.; Bellander, Bo-Michael			Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light	PLOS ONE			English	Article							NEURON-SPECIFIC ENOLASE; AMYOTROPHIC-LATERAL-SCLEROSIS; GLASGOW COMA SCALE; HEAD-INJURY; PREDICTIVE-VALUE; BARRIER CHANGES; SEVERITY SCORE; AXONAL INJURY; S100B LEVELS; BLOOD	Traumatic brain injury (TBI) is a common cause of death and disability, worldwide. Early determination of injury severity is essential to improve care. Neurofilament light (NF-L) has been introduced as a marker of neuroaxonal injury in neuroinflammatory/-degenerative diseases. In this study we determined the predictive power of serum (s-) and cerebrospinal fluid (CSF-) NF-L levels towards outcome, and explored their potential correlation to diffuse axonal injury (DAI). A total of 182 patients suffering from TBI admitted to the neurointensive care unit at a level 1 trauma center were included. S-NF-L levels were acquired, together with S100B and neuron-specific enolase (NSE). CSF-NF-L was measured in a subcohort (n = 84) with ventriculostomies. Clinical and neuro-radiological parameters, including computerized tomography (CT) and magnetic resonance imaging, were included in the analyses. Outcome was assessed 6 to 12 months after injury using the Glasgow Outcome Score (1-5). In univariate proportional odds analyses mean s-NF-L, -S100B and -NSE levels presented a pseudo-R-2 Nagelkerke of 0.062, 0.214 and 0.074 in correlation to outcome, respectively. In a multivariate analysis, in addition to a model including core parameters (pseudo-R-2 0.33 towards outcome; Age, Glasgow Coma Scale, pupil response, Stockholm CT score, abbreviated injury severity score, S100B), S-NF-L yielded an extra 0.023 pseudo-R-2 and a significantly better model (p = 0.006) No correlation between DAI or CT assessed-intracranial damage and NF-L was found. Our study thus demonstrates that SNF-L correlates to TBI outcome, even if used in models with S100B, indicating an independent contribution to the prediction, perhaps by reflecting different pathophysiological processes, not possible to monitor using conventional neuroradiology. Although we did not find a predictive value of NF-L for DAI, this cannot be completely excluded. We suggest further	[Al Nimer, Faiez; Piehl, Fredrik] Karolinska Inst, Dept Clin Neurosci, Neuroimmunol Unit, Stockholm, Sweden; [Thelin, Eric; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden; [Nystrom, Harriet] Karolinska Inst, Dept Clin Neurosci, Neuroradiol Sect, Stockholm, Sweden; [Dring, Ann M.; Svenningsson, Anders] Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden; [Nelson, David W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden	Thelin, E (corresponding author), Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012; Nimer, Faiez Al/ABB-9465-2020	Thelin, Eric Peter/0000-0002-2338-4364; Svenningsson, Anders/0000-0003-0663-2220; Al Nimer, Faiez/0000-0003-0937-5995	Roche Diagnostics	The authors have read the journal's policy and have the following competing interests: BM and ET received funds from Roche Diagnostics as compensation for lectures concerning other procedures/products in the past. However, the authors certify that this did not in any way influence their objectivity in the current study. Concerning the funding, authors ET and BM wish to declare that this did not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Barry DM, 2007, EXP CELL RES, V313, P2110, DOI 10.1016/j.yexcr.2007.03.011; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bergman AS, 2009, VERIFICATIO IN PRESS; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Disanto G, 2016, J NEUROL NEUROSUR PS, V87, P126, DOI 10.1136/jnnp-2014-309690; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JENNETT B, 1975, LANCET, V1, P480; Khademi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063172; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2013, MULT SCLER J, V19, P1597, DOI 10.1177/1352458513482374; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Raj R, 2014, J NEUROTRAUM, V31, P1721, DOI 10.1089/neu.2014.3361; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schmidt FM, 2015, WORLD J BIOL PSYCHIA, V16, P106, DOI 10.3109/15622975.2014.952776; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; SMITH ME, 1984, NEUROCHEM RES, V9, P1493, DOI 10.1007/BF00964675; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Thelin EP, 2012, S100B IS IMPORTANT O; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vajtr D, 2012, Soud Lek, V57, P7; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wolf H, 2015, J NEUROTRAUM, V32, P23, DOI 10.1089/neu.2013.3202; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	70	65	65	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2015	10	7							e0132177	10.1371/journal.pone.0132177			19	Multidisciplinary Sciences	Science & Technology - Other Topics	CN1CS	WOS:000358154400103	26136237	DOAJ Gold, Green Published			2021-06-18	
J	Samadani, U; Ritlop, R; Reyes, M; Nehrbass, E; Li, M; Lamm, E; Schneider, J; Shimunov, D; Sava, M; Kolecki, R; Burris, P; Altomare, L; Mehmood, T; Smith, T; Huang, JH; McStay, C; Todd, SR; Qian, M; Kondziolka, D; Wall, S; Huang, P				Samadani, Uzma; Ritlop, Robert; Reyes, Marleen; Nehrbass, Elena; Li, Meng; Lamm, Elizabeth; Schneider, Julia; Shimunov, David; Sava, Maria; Kolecki, Radek; Burris, Paige; Altomare, Lindsey; Mehmood, Talha; Smith, Theodore; Huang, Jason H.; McStay, Christopher; Todd, S. Rob; Qian, Meng; Kondziolka, Douglas; Wall, Stephen; Huang, Paul			Eye Tracking Detects Disconjugate Eye Movements Associated with Structural Traumatic Brain Injury and Concussion	JOURNAL OF NEUROTRAUMA			English	Article						disconjugate; eye movement tracking; cranial nerve palsy; ocular motility; concussion	MINOR HEAD-INJURY; NULL DISTRIBUTION; POST-CONCUSSION; RULE	Disconjugate eye movements have been associated with traumatic brain injury since ancient times. Ocular motility dysfunction may be present in up to 90% of patients with concussion or blast injury. We developed an algorithm for eye tracking in which the Cartesian coordinates of the right and left pupils are tracked over 200 sec and compared to each other as a subject watches a short film clip moving inside an aperture on a computer screen. We prospectively eye tracked 64 normal healthy noninjured control subjects and compared findings to 75 trauma subjects with either a positive head computed tomography (CT) scan (n=13), negative head CT (n=39), or nonhead injury (n=23) to determine whether eye tracking would reveal the disconjugate gaze associated with both structural brain injury and concussion. Tracking metrics were then correlated to the clinical concussion measure Sport Concussion Assessment Tool 3 (SCAT3) in trauma patients. Five out of five measures of horizontal disconjugacy were increased in positive and negative head CT patients relative to noninjured control subjects. Only one of five vertical disconjugacy measures was significantly increased in brain-injured patients relative to controls. Linear regression analysis of all 75 trauma patients demonstrated that three metrics for horizontal disconjugacy negatively correlated with SCAT3 symptom severity score and positively correlated with total Standardized Assessment of Concussion score. Abnormal eye-tracking metrics improved over time toward baseline in brain-injured subjects observed in follow-up. Eye tracking may help quantify the severity of ocular motility disruption associated with concussion and structural brain injury.	[Samadani, Uzma; Li, Meng; Qian, Meng] New York Univ Sch Med, Steven & Alexandra Cohen Vet Ctr Posttraumat Stre, NYU Langone Med Ctr, New York, NY USA; [Samadani, Uzma; Ritlop, Robert; Reyes, Marleen; Nehrbass, Elena; Lamm, Elizabeth; Schneider, Julia; Shimunov, David; Sava, Maria; Kolecki, Radek; Burris, Paige; Altomare, Lindsey; Mehmood, Talha; Kondziolka, Douglas; Huang, Paul] New York Univ Sch Med, Dept Neurosurg, New York, NY USA; [Smith, Theodore] New York Univ Sch Med, Dept Ophthalmol, New York, NY USA; [McStay, Christopher; Wall, Stephen] New York Univ Sch Med, Dept Emergency Med, New York, NY USA; [Todd, S. Rob] New York Univ Sch Med, Dept Trauma Surg, New York, NY USA; [Samadani, Uzma; Reyes, Marleen; Nehrbass, Elena] New York Harbor Hlth Care Syst, Dept Neurosurg, New York, NY USA; [Huang, Jason H.] Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX USA	Samadani, U (corresponding author), New York Univ Sch Med, Dept Neurosurg, 423 East 23rd St,MC 112, New York, NY 10012 USA.	uzma.samadani@nyumc.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168; smith, theodore/0000-0002-1693-943X; Huang, Paul/0000-0003-0563-921X; Wall, Stephen/0000-0003-3965-5074	Steven and Alexandra Cohen Center for Veteran Post-Traumatic Stress and Traumatic Brain Injury; NYU Applied Research Support Fund; Veterans AffairsUS Department of Veterans Affairs [I01RX000319] Funding Source: NIH RePORTER	This work was supported by the Steven and Alexandra Cohen Center for Veteran Post-Traumatic Stress and Traumatic Brain Injury and the NYU Applied Research Support Fund. The funding sources had no role in the collection, analysis, and interpretation of data, the writing of the report, and the decision to submit the manuscript for publication.	Cavezian C, 2010, RES DEV DISABIL, V31, P1102, DOI 10.1016/j.ridd.2010.03.006; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Dickmann A, 2012, OPHTHAL EPIDEMIOL, V19, P302, DOI 10.3109/09286586.2012.694553; Ganz JC, 2014, J NEUROSURG, V120, P1238, DOI 10.3171/2013.12.JNS131520; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Maruta J, 2014, MIL MED, V179, P619, DOI 10.7205/MILMED-D-13-00420; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Murray NG, 2014, BRAIN INJURY, V28, P496, DOI 10.3109/02699052.2014.887144; Pagnacco Guido, 2012, Biomed Sci Instrum, V48, P332; Pollard KS, 2004, J STAT PLAN INFER, V125, P85, DOI 10.1016/j.jspi.2003.07.019; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Samadani U., 2014, J NEUROSURG, P1; Samadani U., 2013, Methods and kits for assessing central nervous system integrity, Patent No. [PCT/US 13/33672, 1333672]; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schotter ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035608; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; van der Laan MJ, 2006, STAT APPL GENET MOL, V5	23	65	65	0	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					548	556		10.1089/neu.2014.3687			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900004	25582436	Green Published			2021-06-18	
J	Westover, MB; Shafi, MM; Bianchi, MT; Moura, LMVR; O'Rourke, D; Rosenthal, ES; Chu, CJ; Donovan, S; Hoch, DB; Kilbride, RD; Cole, AJ; Cash, SS				Westover, M. Brandon; Shafi, Mouhsin M.; Bianchi, Matt T.; Moura, Lidia M. V. R.; O'Rourke, Deirdre; Rosenthal, Eric S.; Chu, Catherine J.; Donovan, Samantha; Hoch, Daniel B.; Kilbride, Ronan D.; Cole, Andrew J.; Cash, Sydney S.			The probability of seizures during EEG monitoring in critically ill adults	CLINICAL NEUROPHYSIOLOGY			English	Article						Continuous electroencephalography; ICU EEG monitoring; Nonconvulsive seizures	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; INTRACEREBRAL HEMORRHAGE; ELECTROGRAPHIC SEIZURES; DISCHARGES; FREQUENCY; IMPACT	Objective: To characterize the risk for seizures over time in relation to EEG findings in hospitalized adults undergoing continuous EEG monitoring (cEEG). Methods: Retrospective analysis of cEEG data and medical records from 625 consecutive adult inpatients monitored at a tertiary medical center. Using survival analysis methods, we estimated the time-dependent probability that a seizure will occur within the next 72-h, if no seizure has occurred yet, as a function of EEG abnormalities detected so far. Results: Seizures occurred in 27% (168/625). The first seizure occurred early (< 30 min of monitoring) in 58% (98/168). In 527 patients without early seizures, 159 (30%) had early epileptiform abnormalities, versus 368 (70%) without. Seizures were eventually detected in 25% of patients with early epileptiform discharges, versus 8% without early discharges. The 72-h risk of seizures declined below 5% if no epileptiform abnormalities were present in the first two hours, whereas 16 h of monitoring were required when epileptiform discharges were present. 20% (74/388) of patients without early epileptiform abnormalities later developed them; 23% (17/74) of these ultimately had seizures. Only 4% (12/294) experienced a seizure without preceding epileptiform abnormalities. Conclusions: Seizure risk in acute neurological illness decays rapidly, at a rate dependent on abnormalities detected early during monitoring. This study demonstrates that substantial risk stratification is possible based on early EEG abnormalities. Significance: These findings have implications for patient-specific determination of the required duration of cEEG monitoring in hospitalized patients. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Westover, M. Brandon; Shafi, Mouhsin M.; Bianchi, Matt T.; Moura, Lidia M. V. R.; O'Rourke, Deirdre; Rosenthal, Eric S.; Chu, Catherine J.; Donovan, Samantha; Hoch, Daniel B.; Kilbride, Ronan D.; Cole, Andrew J.; Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, Boston, MA 02114 USA; [Shafi, Mouhsin M.] Beth Israel Deaconess Med Ctr, Epilepsy Serv, Dept Neurol, Boston, MA 02214 USA	Westover, MB (corresponding author), Massachusetts Gen Hosp, Wang 7 Neurol,55 Fruit St, Boston, MA 02114 USA.	mwestover@mgh.harvard.edu; mshafi@bidmc.harvard.edu; mtbianchi@mgh.harvard.edu; lmoura@mgh.harvard.edu; daorourke@mgh.harvard.edu; erosenthal@mgh.harvard.edu; cchu3@mgh.harvard.edu; dbhoch@mgh.harvard.edu; rkilbride@mgh.harvard.edu; acole1@mgh.harvard.edu; scash@mgh.harvard.edu	Rosenthal, Eric Scott/A-2085-2017	Rosenthal, Eric Scott/0000-0003-3900-356X; Hoch, Daniel/0000-0002-4294-024X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12 NS066225, K23 NS092923] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12NS066225] Funding Source: NIH RePORTER		Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; COLLETT D, 2003, MODELLING SURVIVAL D; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; FOY PM, 1981, ACTA NEUROCHIR, V55, P253, DOI 10.1007/BF01808441; HASAN D, 1993, ANN NEUROL, V33, P286; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jordan K, 1992, NEUROLOGY, V42, P180; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kaplan PW, 1999, J CLIN NEUROPHYSIOL, V16, P341, DOI 10.1097/00004691-199907000-00006; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; KVAM DA, 1983, NEUROSURGERY, V12, P14, DOI 10.1227/00006123-198301000-00003; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; MATTHEW E, 1980, CAN J NEUROL SCI, V7, P285, DOI 10.1017/S0317167100022757; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Murthy JMK, 2003, NEUROL INDIA, V51, P453; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rausand M, 2003, SYSTEM RELIABILITY T, V2nd; Shafi MM, 2012, NEUROLOGY, V79, P1796, DOI 10.1212/WNL.0b013e3182703fbc; SUNDARAM MBM, 1986, CAN J NEUROL SCI, V13, P229, DOI 10.1017/S0317167100036325; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Wright WL, 2006, SEMIN NEUROL, V26, P396, DOI 10.1055/s-2006-948320; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117	40	65	67	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2015	126	3					463	471		10.1016/j.clinph.2014.05.037			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CB4RX	WOS:000349616700008	25082090	Green Accepted, Green Published			2021-06-18	
J	El-Etr, M; Rame, M; Boucher, C; Ghoumari, AM; Kumar, N; Liere, P; Pianos, A; Schumacher, M; Sitruk-Ware, R				El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Kumar, Narender; Liere, Philippe; Pianos, Antoine; Schumacher, Michael; Sitruk-Ware, Regine			Progesterone and Nestorone Promote Myelin Regeneration in Chronic Demyelinating Lesions of Corpus Callosum and Cerebral Cortex	GLIA			English	Article						remyelination; oligodendrocytes; progestogens; cuprizone; progesterone receptor	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; SPINAL-CORD; NEURODEGENERATIVE DISORDERS; TRANSCRIPTION FACTORS; CNS REMYELINATION; AXONAL DAMAGE; IN-VITRO	Multiple Sclerosis affects mainly women and consists in intermittent or chronic damages to the myelin sheaths, focal inflammation, and axonal degeneration. Current therapies are limited to immunomodulators and antiinflammatory drugs, but there is no efficient treatment for stimulating the endogenous capacity of myelin repair. Progesterone and synthetic progestins have been shown in animal models of demyelination to attenuate myelin loss, reduce clinical symptoms severity, modulate inflammatory responses and partially reverse the age-dependent decline in remyelination. Moreover, progesterone has been demonstrated to promote myelin formation in organotypic cultures of cerebellar slices. In the present study, we show that progesterone and the synthetic 19-nor-progesterone derivative Nestorone (R) promote the repair of severe chronic demyelinating lesions induced by feeding cuprizone to female mice for up to 12 weeks. Progesterone and Nestorone increase the density of NG2(+) oligodendrocyte progenitor cells and CA II+ mature oligodendrocytes and enhance the formation of myelin basic protein (MBP)- and proteolipid protein (PLP)-immunoreactive myelin. However, while demyelination in response to cuprizone was less marked in corpus callosum than in cerebral cortex, remyelination appeared earlier in the former. The remyelinating effect of progesterone was progesterone receptor (PR)-dependent, as it was absent in PR-knockout mice. Progesterone and Nestorone also decreased (but did not suppress) neuroinflammatory responses, specifically astrocyte and microglial cell activation. Therefore, some progestogens are promising therapeutic candidates for promoting the regeneration of myelin. GLIA 2015;63:104-117 Main Points <list id="glia22736-list-0001" list-type="bulleted"> <list-item id="glia22736-li-0001">Progesterone and the specific analog Nestorone arrest neuroinflammation and facilitate remyelination when administered to female mice as a treatment after a chronic demyelination. <list-item id="glia22736-li-0056">This effect requires intracellular progesterone receptors.	[El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Liere, Philippe; Pianos, Antoine; Schumacher, Michael] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Liere, Philippe; Pianos, Antoine; Schumacher, Michael] Univ Paris Sud, F-94276 Le Kremlin Bicetre, France; [Kumar, Narender; Sitruk-Ware, Regine] Populat Council, New York, NY 10021 USA; [Kumar, Narender; Sitruk-Ware, Regine] Rockefeller Univ, New York, NY 10021 USA	El-Etr, M (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	martine.el-etr@inserm.fr	Schumacher, Michael/G-3581-2013	Schumacher, Michael/0000-0001-6117-5371	NICHD U54 [5U54HD9990]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD029990] Funding Source: NIH RePORTER	Grant sponsor: NICHD U54; Grant number: # 5U54HD9990.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Bastida CM, 2002, BIOCHEM BIOPH RES CO, V293, P106, DOI 10.1016/S0006-291X(02)00191-2; BLAUSTEIN JD, 1989, BRAIN RES, V495, P75, DOI 10.1016/0006-8993(89)91219-5; Calabrese M, 2012, BRAIN, V135, P2952, DOI 10.1093/brain/aws246; Calabrese M, 2010, NAT REV NEUROL, V6, P438, DOI 10.1038/nrneurol.2010.93; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Fraser IS, 2007, CONTRACEPTION, V76, P432, DOI 10.1016/j.contraception.2007.08.006; Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Geldenhuys WJ, 2013, EXPERT OPIN DRUG DIS, V8, P115, DOI 10.1517/17460441.2013.744746; Geurts JJG, 2012, LANCET NEUROL, V11, P1082, DOI 10.1016/S1474-4422(12)70230-2; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hussain R, 2013, BRAIN, V136, P132, DOI 10.1093/brain/aws284; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; JUNGTESTAS I, 1991, EXP CELL RES, V193, P12, DOI 10.1016/0014-4827(91)90532-Y; Khalaj AJ, 2013, P NATL ACAD SCI USA, V110, P19125, DOI [10.1073/pnas.311763110, 10.1073/pnas.1311763110]; Kieseier BC, 2011, NAT REV NEUROL, V7, P255, DOI 10.1038/nrneurol.2011.41; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lindner M, 2009, NEUROSCI LETT, V453, P120, DOI 10.1016/j.neulet.2009.02.004; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2010, ENDOCRINOLOGY, V151, P5782, DOI 10.1210/en.2010-0005; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; Martino G, 2010, NAT REV NEUROL, V6, P247, DOI 10.1038/nrneurol.2010.35; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; PARSONS B, 1982, J NEUROSCI, V2, P1446; Polanczyk M, 2003, AM J PATHOL, V163, P1599, DOI 10.1016/S0002-9440(10)63516-X; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Sakamoto H, 2001, J NEUROSCI, V21, P6221; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sitruk-Ware R, 2010, CONTRACEPTION, V82, P410, DOI 10.1016/j.contraception.2010.04.004; Skripuletz T, 2008, AM J PATHOL, V172, P1053, DOI 10.2353/ajpath.2008.070850; Skripuletz T, 2010, NEUROCHEM RES, V35, P1422, DOI 10.1007/s11064-010-0202-7; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Taylor LC, 2010, J NEUROSCI RES, V88, P391, DOI 10.1002/jnr.22215; van der Star BJ, 2012, CNS NEUROL DISORD-DR, V11, P570, DOI 10.2174/187152712801661284; Wang C, 2009, IMMUNOLOGY, V126, P329, DOI 10.1111/j.1365-2567.2008.03051.x; WAREMBOURG M, 1989, BRAIN RES, V480, P1, DOI 10.1016/0006-8993(89)91561-8; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Wood GA, 2007, REPRODUCTION, V133, P1035, DOI 10.1530/REP-06-0302; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079	70	65	65	0	27	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2015	63	1					104	117		10.1002/glia.22736			14	Neurosciences	Neurosciences & Neurology	AU0XC	WOS:000345344500008	25092805	Green Accepted			2021-06-18	
J	Putukian, M; Echemendia, R; Dettwiler-Danspeckgruber, A; Duliba, T; Bruce, J; Furtado, JL; Murugavel, M				Putukian, Margot; Echemendia, Ruben; Dettwiler-Danspeckgruber, Annegret; Duliba, Tawny; Bruce, Jared; Furtado, John L.; Murugavel, Murali			Prospective Clinical Assessment Using Sideline Concussion Assessment Tool-2 Testing in the Evaluation of Sport-Related Concussion in College Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; SCAT-2; SCAT-3; sideline assessment; college athlete; sport-related concussion	NEUROPSYCHOLOGICAL TEST PROTOCOL; TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; SOCCER PLAYERS; MANAGEMENT; SYMPTOMS	Objective: To evaluate the utility of the Sideline Concussion Assessment Tool (SCAT)-2 in collegiate athletes with sport-related concussion. Design: Prospective cross-sectional study with baseline testing and serial repeat testing after concussion in contact sport athletes and non-concussed control athletes. Setting: Division I University. Participants: Male and female club rugby and varsity athletes. Interventions: Baseline measures of concussion symptoms, cognitive function, and balance were obtained using the SCAT-2. Serial postinjury testing was conducted as clinically indicated. Main Outcome Measures: The SCAT-2 total and subset scores were calculated and evaluated at baseline and after injury. Results: The total SCAT-2 score and the composite scores of symptoms, symptom severity, and balance were significantly different in concussed groups after injury when compared with baseline. When comparing performance in concussed versus control athletes, all subcomponents of the SCAT-2 were significantly different. No differences in baseline SCAT-2 scores were seen based on self-reported history of concussion. At baseline, anxiety and depression screening scores were associated with higher symptom scores. When compared with baseline, a 3.5-point drop in SCAT-2 score had 96% sensitivity and 81% specificity in detecting concussion. When examined to exclude baseline scores, a cutoff value of 74.5 was associated with 83% sensitivity and 91% specificity in predicting concussion versus control status. Conclusions: The SCAT-2 total composite score and each sub-component are useful in the assessment of concussion. As SCAT-3 is similar to SCAT-2, it is expected that it too will be a useful tool.	[Putukian, Margot; Furtado, John L.] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Princeton, NJ USA; [Echemendia, Ruben; Bruce, Jared] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Echemendia, Ruben] Univ Orthoped Comprehens Concuss Care Clin, State Coll, PA USA; [Dettwiler-Danspeckgruber, Annegret; Duliba, Tawny; Murugavel, Murali] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA	Putukian, M (corresponding author), Princeton Univ, Univ Hlth Serv, Washington Rd, Princeton, NJ 08544 USA.	putukian@princeton.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	American Medical Society for Sports Medicine Foundation; New Jersey Commission on Brain Injury Research; Princeton UniversityPrinceton University; National Hockey League; Major League Soccer; Archives of Clinical Neuropsychology	Supported by the American Medical Society for Sports Medicine Foundation and the New Jersey Commission on Brain Injury Research.; All authors participated in the design, implementation, and/or review of the manuscript. M. Putukian reports nonfinancial support from National Football League Head Neck and Spine Committee, US Lacrosse Sports Science Safety Committee, and National Collegiate Athletics Association during the conduct of the study. R. Echemendia reports personal fees from Princeton University and personal fees and nonfinancial support from National Hockey League and Major League Soccer during the conduct of the study. J. Bruce reports personal fees from Princeton University, National Hockey League, and Archives of Clinical Neuropsychology during the conduct of the study. The remaining authors report no conflicts of interest.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Runkle D., NCAA REQUIRED CONCUS; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	42	65	65	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2015	25	1					36	42		10.1097/JSM.0000000000000102			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AX7BX	WOS:000347072800011	24915173				2021-06-18	
J	Gavvala, J; Abend, N; LaRoche, S; Hahn, C; Herman, ST; Claassen, J; Macken, M; Schuele, S; Gerard, E				Gavvala, Jay; Abend, Nicholas; LaRoche, Suzette; Hahn, Cecil; Herman, Susan T.; Claassen, Jan; Macken, Micheal; Schuele, Stephan; Gerard, Elizabeth		Critical Care EEG Monitoring Res	Continuous EEG monitoring: A survey of neurophysiologists and neurointensivists	EPILEPSIA			English	Article						Continuous video-EEG monitoring; Nonconvulsive seizures; Quantitative EEG	NONCONVULSIVE STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; QUANTITATIVE EEG; CONTINUOUS ELECTROENCEPHALOGRAPHY; ELECTROGRAPHIC SEIZURES; ICU; IDENTIFICATION; HEMORRHAGE	ObjectiveContinuous EEG monitoring (cEEG) of critically ill adults is being used with increasing frequency, and practice guidelines on indications for cEEG monitoring have recently been published. However, data describing the current practice of cEEG in critically ill adults is limited. We aimed to describe the current practice of cEEG monitoring in adults in the United States. MethodsA survey assessing cEEG indications and procedures was sent to one intensivist and one neurophysiologist responsible for intensive care unit (ICU) cEEG at 151 institutions in the United States. At some institutions only one physician could be identified. ResultsOne hundred thirty-seven physicians from 97 institutions completed the survey. Continuous EEG is utilized by nearly all respondents to detect nonconvulsive seizures (NCS) in patients with altered mental status following clinical seizures, intra cerebral hemorrhage (ICH), traumatic brain injury, and cardiac arrest, as well as to characterize abnormal movements suspected to be seizures. The majority of physicians monitor comatose patients for 24-48h. In an ideal situation with unlimited resources, 18% of respondents would increase cEEG duration. Eighty-six percent of institutions have an on-call EEG technologist available 24/7 for new patient hookups, but only 26% have technologists available 24/7 in-house. There is substantial variability in who reviews EEG and how frequently it is reviewed as well as use of quantitative EEG. SignificanceAlthough there is general agreement regarding the indications for ICU cEEG, there is substantial interinstitutional variability in how the procedure is performed.	[Gavvala, Jay; Macken, Micheal; Schuele, Stephan; Gerard, Elizabeth] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Abend, Nicholas] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Abend, Nicholas] Univ Penn, Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Abend, Nicholas] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [LaRoche, Suzette] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Hahn, Cecil] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [Hahn, Cecil] Univ Toronto, Toronto, ON, Canada; [Herman, Susan T.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Claassen, Jan] Columbia Univ Coll Phys & Surg, Dept Neurol, Neurol Inst, New York, NY 10032 USA	Gerard, E (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, 710 North Lake Shore Dr 1114, Chicago, IL 60611 USA.	e-gerard@northwestern.edu	Hahn, Cecil/J-3372-2016; Hahn, Cecil D./F-6218-2011; Claassen, Jan/AAA-5451-2020	Hahn, Cecil/0000-0002-0887-8761; Hahn, Cecil D./0000-0002-0887-8761; Gavvala, Jay/0000-0002-9392-6608; gerard, elizabeth/0000-0003-3062-8360	UCB PharmaUCB Pharma SA; Lundbeck, IncLundbeck Corporation; National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Fidelity Biosciences Research Initiative; Epilepsy Therapy Development Project	Dr. Schuele is on the speakers' bureau for GlaxoSmithKline and Lundbeck. Dr. Herman is on the advisory board for Eisai, Inc., consults for Biotie, Inc., and provides research support for UCB Pharma, Lundbeck, Inc, National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS), Fidelity Biosciences Research Initiative, and Epilepsy Therapy Development Project. Dr. Macken is a consultant and on the speakers bureau for Cyberonics, Lundbeck, and UCB Pharma. None of the other authors have any conflicts of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Akman CI, 2011, EPILEPSY RES, V93, P66, DOI 10.1016/j.eplepsyres.2010.10.018; Baruch Y, 1999, HUM RELAT, V52, P421, DOI 10.1023/A:1016905407491; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Diedler J, 2009, NEUROCRIT CARE, V11, P210, DOI 10.1007/s12028-009-9236-6; Finnigan S, 2013, CLIN NEUROPHYSIOL, V124, P10, DOI 10.1016/j.clinph.2012.07.003; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Huang ZC, 2002, CLIN NEUROPHYSIOL, V113, P446, DOI 10.1016/S1388-2457(02)00012-3; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; Kennedy JD, 2012, CURR NEUROL NEUROSCI, V12, P419, DOI 10.1007/s11910-012-0289-0; Kurtz P, 2014, INTENS CARE MED, V40, P228, DOI 10.1007/s00134-013-3149-8; Kurtz P, 2009, CURR OPIN CRIT CARE, V15, P99, DOI 10.1097/MCC.0b013e3283294947; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Newey CR, 2013, NEUROCRIT CARE, V18, P261, DOI 10.1007/s12028-011-9650-4; Ney JP, 2013, NEUROLOGY, V81, P2002, DOI 10.1212/01.wnl.0000436948.93399.2a; Nulty DD, 2008, ASSESS EVAL HIGH EDU, V33, P301, DOI 10.1080/02602930701293231; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pensirikul AD, 2013, J CLIN NEUROPHYSIOL, V30, P371, DOI 10.1097/WNP.0b013e31829de01c; Rathakrishnan R, 2011, NEUROCRIT CARE, V14, P152, DOI 10.1007/s12028-010-9495-2; Richardson J.T.E., 2005, ASSESS EVAL HIGH EDU, V30, P387, DOI DOI 10.1080/02602930500099193; Riviello JJ, 2013, NEUROCRIT CARE, V18, P193, DOI 10.1007/s12028-012-9790-1; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Stewart CP, 2010, NEUROLOGY, V75, P1501, DOI 10.1212/WNL.0b013e3181f9619e; Tichauer KM, 2009, J APPL PHYSIOL, V106, P1506, DOI 10.1152/japplphysiol.91156.2008; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; U. S. News Best Hospitals: Neurology & Neurosurgery, US NEWS WORLD REP 20; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; WINER JW, 1991, NEUROSURGERY, V29, P739, DOI 10.1227/00006123-199111000-00016; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	40	65	66	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2014	55	11					1864	1871		10.1111/epi.12809			8	Clinical Neurology	Neurosciences & Neurology	AT9DE	WOS:000345227400029	25266728				2021-06-18	
J	Ding, K; Wang, HD; Xu, JG; Lu, XY; Zhang, L; Zhu, L				Ding, Ke; Wang, Handong; Xu, Jianguo; Lu, Xinyu; Zhang, Li; Zhu, Lin			Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Melatonin; Microglia activation; Inflammation; Mammalian target of rapamycin	CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; MAMMALIAN TARGET; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; UP-REGULATION; KAPPA-B; RAPAMYCIN; CELLS; MODEL	This study was designed to detect the modulation manner of melatonin on microglial activation and explore herein possible involvement of mammalian target of rapamycin (mTOR) pathway following traumatic brain injury (TBI). ICR mice were divided into four groups: sham group, TBI group, TBI + sal group and TBI + Melatonin group. A weight-drop model was employed to cause TBI. Neurological severity score (NSS) tests were performed to measure behavioral outcomes. Nissl staining was conducted to observe the neuronal degeneration and wet-to-dry weight ratio indicated brain water content. Immunofluorescence was designed to investigate microglial activation. Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate proinflammatory cytokine levels (interleukin-beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha)). Western blotting was engaged to analyze the protein content of mammalian target of rapamycin (mTOR), p70 ribosomal S6 kinase (p70S6K) and S6 ribosomal protein (S6RP). Melatonin administration was associated with markedly restrained microglial activation, decreased release of proinflammatory cytokines and increased the number of surviving neurons at the site of pen-contusion. Meanwhile, melatonin administration resulted in dephosphorylated mTOR pathway. In conclusion, this study presents a new insight into the mechanisms responsible for the anti-neuroinflammation of melatonin, with possible involvement of mTOR pathway. (C) 2014 Elsevier Ltd. All rights reserved.	[Ding, Ke; Wang, Handong; Xu, Jianguo; Lu, Xinyu; Zhang, Li; Zhu, Lin] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China	Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81271377, 81371357]; Research Project of Jinling Hospital [2014040]	This work was supported by Grants from the Natural Science Fund of China (Nos. 81271377 and 81371357) and the Research Project of Jinling Hospital (No. 2014040).	Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dan HC, 2008, J IMMUNOL, V180, P7582, DOI 10.4049/jimmunol.180.11.7582; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dello Russo C, 2009, BIOCHEM PHARMACOL, V78, P1242, DOI 10.1016/j.bcp.2009.06.097; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hara A, 2000, STROKE, V31, P236, DOI 10.1161/01.STR.31.1.231-e; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee DF, 2007, CELL CYCLE, V6, P3011, DOI 10.4161/cc.6.24.5085; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Lee SH, 2006, J PINEAL RES, V40, P79, DOI 10.1111/j.1600-079X.2005.00283.x; Lieberthal W, 2009, J AM SOC NEPHROL, V20, P2493, DOI 10.1681/ASN.2008111186; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Min KJ, 2003, BIOCHEM BIOPH RES CO, V312, P969, DOI 10.1016/j.bbrc.2003.11.010; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078-0432.CCR-04-1393; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Tarantino G, 2013, ANN MED, V45, P348, DOI 10.3109/07853890.2013.770333; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Wang Z, 2013, PHARMACOL RES, V76, P84, DOI 10.1016/j.phrs.2013.07.008; Welp A, 2010, J IMMUNOL METHODS, V358, P1, DOI 10.1016/j.jim.2010.03.018; Wong Michael, 2013, Biomed J, V36, P40, DOI 10.4103/2319-4170.110365; Wu UI, 2011, J PINEAL RES, V50, P159, DOI 10.1111/j.1600-079X.2010.00825.x; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	68	65	65	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	OCT	2014	76						23	31		10.1016/j.neuint.2014.06.015			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AQ0MO	WOS:000342477600003	24995391				2021-06-18	
J	Klinger, DR; Madden, C; Beshay, J; White, J; Gambrell, K; Rickert, K				Klinger, Daniel R.; Madden, Christoper; Beshay, Joseph; White, Jonathan; Gambrell, Kenneth; Rickert, Kim			Autologous and Acrylic Cranioplasty: A Review of 10 Years and 258 Cases	WORLD NEUROSURGERY			English	Article						Cranioplasty; Craniotomy/craniectomy; Hemorrhage; Infection; Traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; SURGERY; COMPLICATIONS; MULTICENTER; INFARCTION; INFECTION; HEAD	INTRODUCTION: Cranioplasty is a well-accepted neurosurgical procedure that has application to a wide range of pathologies. Given the varied need for both autologous and synthetic cranial grafts, it is important to establish rates of procedural complication. METHODS: A retrospective review identified 282 patients undergoing cranioplasty at our institution over a 10-year period, of which 249 patients underwent 258 cranioplasties with either autologous or acrylic flaps. A database including patient age, gender, presenting diagnosis, hospital of surgery, presence of a drain, and surgical complications was created in order to analyze the autologous and acrylic cranioplasty data. RESULTS: A total of 28 complications were noted, yielding a rate of 10.9% (28/ 258). There was no statistically significant difference in infection rate between autologous and acrylic cranioplasty (7.2% vs. 5.8%, P = 0.80). Male patients (P = 0.007), tumor patients (P = 0.02), and patients undergoing surgery at the county hospital (P = 0.06) sustained a statistically higher rate of infection. Among traumatic brain injury patients, complex injuries and surgical involvement of the frontal sinus carried a significantly higher infection rate of 17% and 38.5%, respectively (P = 0.03, P = 0.001). Postoperative epidural hematoma requiring reoperation occurred in 3.5% (9/258) with no difference in hematoma rate with placement of a drain (P = 1). CONCLUSIONS: Cranioplasty carries a significant risk of infection and postoperative hematoma. In this large series comparing autologous and acrylic flaps, male patients, tumor patients, and those undergoing surgery at the county hospital were at increased risk of postoperative infection. Among traumatic brain injury cases, complex injuries and cases with surgical involvement of the frontal sinus may portend a higher risk.	[Klinger, Daniel R.; Madden, Christoper; Beshay, Joseph; White, Jonathan; Rickert, Kim] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Gambrell, Kenneth] Univ Texas SW Med Ctr Dallas, Dept Oral & Maxillofacial Surg, Dallas, TX 75390 USA	Klinger, DR (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.	danielrklinger@gmail.com					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AZIZ T Z, 1990, British Journal of Neurosurgery, V4, P417, DOI 10.3109/02688699008992764; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; OSAWA M, 1990, ACTA NEUROCHIR, V102, P38, DOI 10.1007/BF01402184; Penel N, 2001, HEAD NECK-J SCI SPEC, V23, P447, DOI 10.1002/hed.1058; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, J NEUROSURG, V110, P1242, DOI 10.3171/2008.8.JNS08314; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	24	65	65	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	SEP-OCT	2014	82	3-4					E525	E530		10.1016/j.wneu.2013.08.005			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AQ6HV	WOS:000342912300029	24036124				2021-06-18	
J	Schneider, EB; Sur, S; Raymont, V; Duckworth, J; Kowalski, RG; Efron, DT; Hui, X; Selvarajah, S; Hambridge, HL; Stevens, RD				Schneider, Eric B.; Sur, Sandeepa; Raymont, Vanessa; Duckworth, Josh; Kowalski, Robert G.; Efron, David T.; Hui, Xuan; Selvarajah, Shalini; Hambridge, Hali L.; Stevens, Robert D.			Functional recovery after moderate/severe traumatic brain injury A role for cognitive reserve?	NEUROLOGY			English	Article							EDUCATION; CONNECTIVITY; NETWORK	Objective:To evaluate the hypothesis that educational attainment, a marker of cognitive reserve, is a predictor of disability-free recovery (DFR) after moderate to severe traumatic brain injury (TBI).Methods:Retrospective study of the TBI Model Systems Database, a prospective multicenter cohort funded by the National Institute on Disability and Rehabilitation Research. Patients were included if they were admitted for rehabilitation after moderate to severe TBI, were aged 23 years or older, and had at least 1 year of follow-up. The main outcome measure was DFR 1 year postinjury, defined as a Disability Rating Scale score of zero.Results:Of 769 patients included, 214 (27.8%) achieved DFR at 1 year. In total, 185 patients (24.1%) had <12 years of education, while 390 (50.7%) and 194 patients (25.2%) had 12 to 15 years and 16 years of education, respectively. DFR was achieved by 18 patients (9.7%) with <12 years, 120 (30.8%) with 12 to 15 years, and 76 (39.2%) with 16 years of education (p < 0.001). In a logistic regression model controlling for age, sex, and injury- and rehabilitation-specific factors, duration of education of 12 years was independently associated with DFR (odds ratio 4.74, 95% confidence interval 2.70-8.32 for 12-15 years; odds ratio 7.24, 95% confidence interval 3.96-13.23 for 16 years).Conclusion:Educational attainment was a robust independent predictor of 1-year DFR even when adjusting for other prognostic factors. A dose-response relationship was noted, with longer educational exposure associated with increased odds of DFR. This suggests that cognitive reserve could be a factor driving neural adaptation during recovery from TBI.	[Schneider, Eric B.; Efron, David T.; Hui, Xuan; Selvarajah, Shalini; Hambridge, Hali L.] Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21205 USA; [Kowalski, Robert G.; Stevens, Robert D.] Johns Hopkins Sch Med, Div Neurosci Crit Care, Dept Anesthesiol, Baltimore, MD USA; [Kowalski, Robert G.; Stevens, Robert D.] Johns Hopkins Sch Med, Dept Crit Care Med, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Sur, Sandeepa] Tulane Univ, Sch Med, Tulane Ctr Aging, New Orleans, LA 70112 USA; [Raymont, Vanessa; Duckworth, Josh; Stevens, Robert D.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Raymont, Vanessa] Imperial Coll London, Dept Med, Ctr Mental Hlth, London, England	Schneider, EB (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21205 USA.	eschnei1@jhmi.edu			National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education	No external funding was provided for this study. The collection of the original data was supported by the National Institute on Disability and Rehabilitation Research and the U.S. Department of Education.	Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Cader S, 2006, BRAIN, V129, P527, DOI 10.1093/brain/awh670; Chang L, 2004, ANN NEUROL, V56, P259, DOI 10.1002/ana.20190; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Fuentes A, 2010, BRAIN INJURY, V24, P995, DOI 10.3109/02699052.2010.489791; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kemppainen NM, 2008, ANN NEUROL, V63, P112, DOI 10.1002/ana.21212; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Murray AD, 2011, BRAIN, V134, P3684, DOI 10.1093/brain/awr259; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rentz DM, 2010, ANN NEUROL, V67, P353, DOI 10.1002/ana.21904; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stern Y, 2008, CEREB CORTEX, V18, P959, DOI 10.1093/cercor/bhm134; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307	21	65	67	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 6	2014	82	18					1636	1642		10.1212/WNL.0000000000000379			7	Clinical Neurology	Neurosciences & Neurology	AH9XB	WOS:000336497400013	24759845	Green Published			2021-06-18	
J	Castellino, FJ; Chapman, MP; Donahue, DL; Thomas, S; Moore, EE; Wohlauer, MV; Fritz, B; Yount, R; Ploplis, V; Davis, P; Evans, E; Walsh, M				Castellino, Francis J.; Chapman, Michael P.; Donahue, Deborah L.; Thomas, Scott; Moore, Ernest E.; Wohlauer, Max V.; Fritz, Braxton; Yount, Robert; Ploplis, Victoria; Davis, Patrick; Evans, Edward; Walsh, Mark			Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; coagulopathy; platelet; thrombelastography; ADP receptor	ACUTE COAGULOPATHY; DYSFUNCTION; ACTIVATION; THROMBELASTOGRAPHY; HYPOPERFUSION; REPLACE; TISSUE	BACKGROUND: Coagulopathy in traumatic brain injury (CTBI) is a well established phenomenon, but its mechanism is poorly understood. Various studies implicate protein C activation related to the global insult of hemorrhagic shock or brain tissue factor release with resultant platelet dysfunction and depletion of coagulation factors. We hypothesized that the platelet dysfunction of CTBI is a distinct phenomenon from the coagulopathy following hemorrhagic shock. METHODS: We used thrombelastography with platelet mapping as a measure of platelet function, assessing the degree of inhibition of the adenosine diphosphate (ADP) and arachidonic acid (AA) receptor pathways. First, we studied the early effect of TBI on platelet inhibition by performing thrombelastography with platelet mapping on rats. We then conducted an analysis of admission blood samples from trauma patients with isolated head injury (n = 70). Patients in shock or on clopidogrel or aspirin were excluded. RESULTS: In rats, ADP receptor inhibition at 15 minutes after injury was 77.6% +/- 6.7% versus 39.0% +/- 5.3% for controls (p < 0.0001). Humans with severe TBI (Glasgow Coma Scale [GCS] score <= 8) showed an increase in ADP receptor inhibition at 93.1% (interquartile range [IQR], 44.8-98.3%; n = 29) compared with 56.5% (IQR, 35-79.1%; n = 41) in milder TBI and 15.5% (IQR, 13.2-29.1%) in controls (p = 0.0014 and p < 0.0001, respectively). No patient had significant hypotension or acidosis. Parallel trends were noted in AA receptor inhibition. CONCLUSION: Platelet ADP and AA receptor inhibition is a prominent early feature of CTBI in humans and rats and is linked to the severity of brain injury in patients with isolated head trauma. This phenomenon is observed in the absence of hemorrhagic shock or multisystem injury. Thus, TBI alone is shown to be sufficient to induce a profound platelet dysfunction. (J Trauma Acute Care Surg. 2014; 76: 1169-1176. Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Castellino, Francis J.; Donahue, Deborah L.; Ploplis, Victoria; Davis, Patrick; Walsh, Mark] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Thomas, Scott; Yount, Robert; Evans, Edward; Walsh, Mark] Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA; [Fritz, Braxton; Davis, Patrick; Walsh, Mark] Indiana Univ Sch Med, South Bend, IN USA; [Chapman, Michael P.; Moore, Ernest E.; Wohlauer, Max V.] Univ Colorado, Dept Surg, Boulder, CO 80309 USA; [Chapman, Michael P.; Moore, Ernest E.; Wohlauer, Max V.] Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; [Chapman, Michael P.] Georgia Hlth Sci Univ, Dept Surg, Augusta, GA USA	Chapman, MP (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St, Denver, CO 80204 USA.	michael.chapman@ucdenver.edu; ernest.moore@dhha.org		Walsh, Mark/0000-0002-5795-1144	Haemonetics Corporation, Niles, Illinois; NIH(NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL019982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL019982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008315, P50GM049222] Funding Source: NIH RePORTER	This study received research support from the Haemonetics Corporation, Niles, Illinois. The animal portion of this study was funded in part by NIH(NHLBI) grant #HL019982.	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Eachempati Soumitra R, 2003, Surg Infect (Larchmt), V4, P193, DOI 10.1089/109629603766956988; FitzSullivan E, 2005, AM J SURG, V190, P941, DOI 10.1016/j.amjusrg.2005.08.024; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Hoffman M, 2009, STROKE, V40, P2882, DOI 10.1161/STROKEAHA.109.555433; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Kutcher ME, 2013, J TRAUMA, V73, P13; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maeda T, 1997, ACT NEUR S, V70, P102; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Schrieber M, 2007, J TRAUMA, V63, P1261; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein SC, 2012, NEUROSURGERY, V70, P1345; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	28	65	72	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2014	76	5					1169	1175		10.1097/TA.0000000000000216			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AG6YA	WOS:000335563800001	24747445	Green Accepted			2021-06-18	
J	Schonfeld, D; Bressan, S; Da Dalt, L; Henien, MN; Winnett, JA; Nigrovic, LE				Schonfeld, Deborah; Bressan, Silvia; Da Dalt, Liviana; Henien, Mira N.; Winnett, Jill A.; Nigrovic, Lise E.			Pediatric Emergency Care Applied Research Network head injury clinical prediction rules are reliable in practice	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; SKELETAL SURVEYS; CHILDREN; MANAGEMENT; CHILDHOOD; SCANS; RISK	Objective The Pediatric Emergency Care Applied Research Network (PECARN) traumatic brain injury (TBI) age-based clinical prediction rules identify children at very low risk of a significant head injury who can safely avoid CT. Our goal was to independently validate these prediction rules. Design Cross-sectional study. Setting Two paediatric emergency departments located in USA and in Italy. Patients All children presenting within 24 h of a head injury with a Glasgow Coma Score of >= 14. Intervention Assessment of PECARN TBI clinical predictors. Main outcome measure Clinically important TBI defined as head injury resulting in death, intubation for >24 h, neurosurgery or two or more nights of hospitalisation for the management of head trauma. Results During the study period, we included 2439 children (91% of eligible patients), of which 959 (39%) were <2 years of age and 1439 (59%) were male. Of the study patients, 373 (15%) had a CT performed, 69 (3%) had traumatic findings on their CT and 19 (0.8%) had a clinically important TBI. None of the children with a clinically important TBI were classified as very low risk by the PECARN TBI prediction rules (overall sensitivity 100%; 95% CI 83.2% to 100%, specificity 55%, 95% CI 52.5% to 56.6%, and negative predictive value 100%, 95% CI 99.6% to 100%). Conclusions In our external validation, the age-based PECARN TBI prediction rules accurately identified children at very low risk for a clinically significant TBI and can be used to assist CT decision making for children with minor blunt head trauma.	[Schonfeld, Deborah; Henien, Mira N.; Winnett, Jill A.; Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Schonfeld, Deborah] Hosp Sick Children, Div Emergency Med, Toronto, ON M5G 1X8, Canada; [Bressan, Silvia; Da Dalt, Liviana] Univ Padua, Dept Womans & Childs Hlth, Padua, Italy	Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	Lise.nigrovic@childrens.harvard.edu	Li, Jun/A-5088-2009; Tan, Weihong/A-5412-2008	Tan, Weihong/0000-0002-8066-1524; Nigrovic, Lise/0000-0002-6369-3997	Hood Childhood Research Grant, Boston Children's Hospital House-officers Grant	Hood Childhood Research Grant, Boston Children's Hospital House-officers Grant.	[Anonymous], 2012, PASW STAT 21; Boutis K, 2013, PEDIATRICS, V132, P305, DOI 10.1542/peds.2013-0378; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Forsyth R, 2013, ARCH DIS CHILD; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Karpas A, 2013, PEDIATR EMERG CARE, V29, P30, DOI 10.1097/PEC.0b013e31827b5090; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2013, ANN EMERG MED, V62, P327, DOI 10.1016/j.annemergmed.2013.02.027; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	22	65	66	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	MAY	2014	99	5					427	431		10.1136/archdischild-2013-305004			5	Pediatrics	Pediatrics	AF0IH	WOS:000334397000007	24431418				2021-06-18	
J	Dettwiler, A; Murugavel, M; Putukian, M; Cubon, V; Furtado, J; Osherson, D				Dettwiler, Annegret; Murugavel, Murali; Putukian, Margot; Cubon, Valerie; Furtado, John; Osherson, Daniel			Persistent Differences in Patterns of Brain Activation after Sports-Related Concussion: A Longitudinal Functional Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						concussion; DLPFC; fMRI; n-back task; working memory	COMPENSATORY CORTICAL ACTIVATION; WORKING-MEMORY; MULTIPLE-SCLEROSIS; PREFRONTAL CORTEX; INJURY; FMRI; REORGANIZATION; PERFORMANCE; RECOVERY; ABNORMALITIES	Avoiding recurrent injury in sports-related concussion (SRC) requires understanding the neural mechanisms involved during the time of recovery after injury. The decision for return-to-play is one of the most difficult responsibilities facing the physician, and so far this decision has been based primarily on neurological examination, symptom checklists, and neuropsychological (NP) testing. Functional magnetic resonance imaging (fMRI) may be an additional, more objective tool to assess the severity and recovery of function after concussion. The purpose of this study was to define neural correlates of SRC during the 2 months after injury in varsity contact sport athletes who suffered a SRC. All athletes were scanned as they performed an n-back task, for n=1, 2, 3. Subjects were scanned within 72 hours (session one), at 2 weeks (session two), and 2 months (session three) post-injury. Compared with age and sex matched normal controls, concussed subjects demonstrated persistent, significantly increased activation for the 2 minus 1 n-back contrast in bilateral dorsolateral prefrontal cortex (DLPFC) in all three sessions and in the inferior parietal lobe in session one and two (0.01 corrected). Measures of task performance revealed no significant differences between concussed versus control groups at any of the three time points with respect to any of the three n-back tasks. These findings suggest that functional brain activation differences persist at 2 months after injury in concussed athletes, despite the fact that their performance on a standard working memory task is comparable to normal controls and normalization of clinical and NP test results. These results might indicate a delay between neural and behaviorally assessed recovery after SRC.	[Dettwiler, Annegret; Murugavel, Murali] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08540 USA; [Furtado, John] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08540 USA; [Cubon, Valerie] Kent State Univ, Dept Chem, Warren, OH USA; [Osherson, Daniel] Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA	Dettwiler, A (corresponding author), Princeton Univ, Princeton Neurosci Inst, Green Hall, Princeton, NJ 08540 USA.	adettwil@princeton.edu			New Jersey Commission for Brain Injury Research [10-3217-BIR-E-0]; AMSSM Foundation [005548]; Goldstein Family Fund; Peter & Cynthia Kellogg Foundation	We would like to acknowledge the athletic trainers of University Health Services for their assistance with subject recruitment and NP testing. This work was funded by the New Jersey Commission for Brain Injury Research grant No. 10-3217-BIR-E-0, AMSSM Foundation grant No. 005548, the Goldstein Family Fund, and the Peter & Cynthia Kellogg Foundation.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hockey A, 2004, INTELLIGENCE, V32, P591, DOI 10.1016/j.intell.2004.07.009; Hoptman MJ, 2010, SCHIZOPHR RES, V117, P13, DOI 10.1016/j.schres.2009.09.030; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jezzard P., 2003, FUNCTIONAL MRI INTRO; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; KARNI A, 1995, NATURE, V377, P155; Kiviniemi V, 2000, MAGN RESON MED, V44, P373, DOI 10.1002/1522-2594(200009)44:3<373::AID-MRM5>3.3.CO;2-G; Kleiner M, 2007, WHATS NEW PSYCHTOOLB; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Landau SM, 2004, NEUROIMAGE, V22, P211, DOI 10.1016/j.neuroimage.2004.01.003; Langlois J, 2005, TRAUMATIC BRAIN INJU; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mainero C, 2006, J NEUROL SCI, V245, P93, DOI 10.1016/j.jns.2005.08.024; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Matthews PM, 2004, J NEUROL NEUROSUR PS, V75, P6; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pantano P, 2006, J NEUROIMAGING, V16, P104, DOI 10.1111/j.1552-6569.2006.00029.x; Partington J. E., 1949, PSYCHOL SERVICE CTR, V1, P9; Pauling L, 1936, P NATL ACAD SCI USA, V22, P210, DOI 10.1073/pnas.22.4.210; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Williams M., 1991, COGNITIVE BEHAV RATI; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	69	65	67	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					180	188		10.1089/neu.2013.2983			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600004	23914845	Green Published			2021-06-18	
J	West, TA; Marion, DW				West, Therese A.; Marion, Donald W.			Current Recommendations for the Diagnosis and Treatment of Concussion in Sport: A Comparison of Three New Guidelines	JOURNAL OF NEUROTRAUMA			English	Article						concussion; guidelines; mild traumatic brain injury; post-concussion syndrome; return to play	STATEMENT	Currently, there is considerable debate within the sports medicine community about the role of concussion and the risk of chronic neurological sequelae. This concern has led to significant confusion among primary care providers and athletic trainers about how to best identify those athletes at risk and how to treat those with concussion. During the first quarter of 2013, several new or updated clinical practice guidelines and position statements were published on the diagnosis, treatment, and management of mild traumatic brain injury/concussion in sports. Three of these guidelines were produced by the American Medical Society for Sports Medicine, The American Academy of Neurology, and the Zurich Consensus working group. The goal of each group was to clearly define current best practices for the definition, diagnosis, and acute and post-acute management of sports-related concussion, including specific recommendations for return to play. In this article, we compare the recommendations of each of the three groups, and highlight those topics for which there is consensus regarding the definition of concussion, diagnosis, and acute care of athletes suspected of having a concussion, as well as return-to-play recommendations.	[West, Therese A.; Marion, Donald W.] DVBIC, Silver Spring, MD 20910 USA	West, TA (corresponding author), DVBIC, 1335 East West Highway,Suite 605, Silver Spring, MD 20910 USA.	therese.a.west.ctr@mail.mil	Marion, Donald/AAR-5749-2021		CCSi; Henry Jackson Foundation	Defense and Veterans Brain Injury Center is a component center of The Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury; CCSi and Henry Jackson Foundation contracting support.	Centers for Disease Control and Prevention, 2013, INJ PREV CONTR; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Institutes of Health, 2013, NIH CONS DEV PROGR	7	65	67	1	42	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					159	168		10.1089/neu.2013.3031			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600002	23879529	Green Published			2021-06-18	
J	Dougan, BK; Horswill, MS; Geffen, GM				Dougan, Brooke K.; Horswill, Mark S.; Geffen, Gina M.			Athletes' Age, Sex, and Years of Education Moderate the Acute Neuropsychological Impact of Sports-Related Concussion: A Meta-analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article							TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; POSTURAL STABILITY; CEREBRAL CONCUSSION; SYMPTOMS; RECOVERY; COLLEGIATE		[Dougan, Brooke K.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia	Dougan, BK (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	brooke.dougan@uqconnect.edu.au	Horswill, Mark/J-9029-2019	Horswill, Mark/0000-0002-0286-6292	Australian Postgraduate AwardAustralian Government	This research forms part of the doctoral thesis of the first author, submitted to the University of Queensland, and was supported by an Australian Postgraduate Award. This research received no specific grant from any other funding agency, commercial or not-for-profit sectors. We confirm that the information in this manuscript and the manuscript itself has never been published either electronically or in print and that none of the authors has any financial or other conflict of interest affecting this manuscript. We acknowledge the help of John Guimelli in checking the data for accuracy.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Borenstein M., 2005, COMPREHENSIVE METAAN; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bruce JM, 2004, NEUROLOGY, V63, P1516; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hedges L.V., 1985, STAT METHODS META AN; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kaplan RF, 2009, J CLIN EXP NEUROPSYC, V31, P868, DOI 10.1080/13803390802635174; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lipsey M.W., 2001, PRACTICAL META ANAL; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nassiri JD, 2002, MIL MED, V167, P873; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	125	65	65	1	31	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2014	20	1					64	80		10.1017/S1355617712001464			17	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AC2VC	WOS:000332373400009	23375058				2021-06-18	
J	Selassie, AW; Wilson, DA; Pickelsimer, EE; Voronca, DC; Williams, NR; Edwards, JC				Selassie, Anbesaw W.; Wilson, Dulaney A.; Pickelsimer, E. Elisabeth; Voronca, Delia C.; Williams, Nolan R.; Edwards, Jonathan C.			Incidence of sport-related traumatic brain injury and risk factors of severity: a population-based epidemiologic study	ANNALS OF EPIDEMIOLOGY			English	Article						Sport-related TBI; Severity; Concussion; Mechanism of injury; Repetitive TBI	HIGH-SCHOOL; UNITED-STATES; CONCUSSION INCIDENCE; FOOTBALL; COLLEGIATE; HEAD; HOSPITALIZATION; TRENDS; IMPACT; US	Purpose: Few studies of sport-related traumatic brain injury (TBI) are population-based or rely on directly observed data on cause, demographic characteristics, and severity. This study addresses the epidemiology of sport-related TBI in a large population. Methods: Data on all South Carolina hospital and emergency department encounters for TBI, 1998-2011, were analyzed. Annual incidence rate of sport-related TBI was calculated, and rates were compared across demographic groups. Sport-related TBI severity was modeled as a function of demographic and TBI characteristics using logistic regression. Results: A total of 16,642 individuals with sport-related TBI yielded an average annual incidence rate of 31.5/100,000 population with a steady increase from 19.7 in 1998 to 45.6 in 2011. The most common mechanisms of sport-related TBI were kicked in football (38.1%), followed by fall injuries in sports (20.3%). Incidence rate was greatest in adolescents ages 12-18 (120.6/100,000/persons). Severe sport-related TBI was strongly associated with off-road vehicular sport (odds ratio [OR], 4.73; 95% confidence interval [95% Cl], 2.92-7.67); repeated head trauma (OR, 4.36; 95% CI, 3.69-5.15); equestrian sport (OR, 2.73; 95% CI, 1.64-4.51); and falls during sport activities (OR, 2.72; 95% Cl, 1.67-4.46). Conclusions: The high incidence of sport-related TBI in youth, potential for repetitive mild TBI, and its long-term consequences on learning warrants coordinated surveillance-activities and population-based outcome studies. (C) 2013 Elsevier Inc. All rights reserved.	[Selassie, Anbesaw W.; Wilson, Dulaney A.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Dept Publ Hlth Sci, Div Epidemiol, Charleston, SC 29425 USA; [Voronca, Delia C.] Med Univ S Carolina, Dept Publ Hlth Sci, Div Biostatistist, Charleston, SC 29425 USA; [Williams, Nolan R.; Edwards, Jonathan C.] Med Univ S Carolina, Dept Neurosci, Div Neurol, Charleston, SC 29425 USA	Selassie, AW (corresponding author), 135 Cannon St,Suite 302M, Charleston, SC 29425 USA.	selassie@musc.edu		Williams, Nolan/0000-0003-4368-3203; Wilson, Dulaney/0000-0003-4726-7848	National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU421926]; South Carolina Department Disabilities and Special Needs, Head and Spinal Cord Division; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R25DA020537] Funding Source: NIH RePORTER	This study was partially supported by a grant from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, grant number U17/CCU421926 (PI: Anbesaw Selassie, DrPH). The study is also supported by the South Carolina Department Disabilities and Special Needs, Head and Spinal Cord Division. The contents do not necessarily represent the opinion of the funding agencies, and should not be assumed as endorsement by the Federal and State Government.	ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; American Medical Association, 2009, INT CLASS DIS; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowman SM, 2009, INJURY PREV, V15, P3, DOI 10.1136/ip.2008.019372; Butler JA, 2000, CENTRAL NERVOUS SYST; Center for Injury Research and Policy The Johns Hopkins University School of Public Health, 1997, ICDMAP 90 SOFTW; Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), 2012, BRIDG RAC POP EST US; Centers for Disease Control and Prevention (CDC) NCHS, 2010, DROWN DEATHS SC MULT; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Darlington GA, 1998, ENCY BIOSTATISTICS, P788; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dempsey RL, 2005, INJURY PREV, V11, P91, DOI 10.1136/ip.2004.006205; Denning GM, 2013, ACCIDENT ANAL PREV, V52, P64, DOI 10.1016/j.aap.2012.12.015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Gelman A, 2013, BRIT J MATH STAT PSY, V66, P8, DOI 10.1111/j.2044-8317.2011.02037.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hosmer DW, 2000, MULTINOMINAL LOGISTI; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Kushner DS, 2001, AM FAM PHYSICIAN, V64, P1007; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lustenberger T, 2010, J TRAUMA, V69, P924, DOI 10.1097/TA.0b013e3181b9a05a; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Mattei TA, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11176; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Micheli LJ, 2000, CLIN SPORT MED, V19, P821, DOI 10.1016/S0278-5919(05)70239-8; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; O'Day J, 2001, CLIN EXP OPHTHALMOL, V29, P207, DOI 10.1046/j.1442-9071.2001.00415.x; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SAS Institute, 2011, STAT AN SOFTW VERS 9; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Selassie A, 2004, S CAROLINA TRAUMATIC; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Shoko T, 2010, J AM COLL SURGEONS, V211, P338, DOI 10.1016/j.jamcollsurg.2010.04.010; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; South Carolina Athletic Administrators Association, 2012, POP SPORTS POLL; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	64	65	69	1	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1047-2797	1873-2585		ANN EPIDEMIOL	Ann. Epidemiol.	DEC	2013	23	12					750	756		10.1016/j.annepidem.2013.07.022			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	265CA	WOS:000327926100002	24060276	Green Accepted			2021-06-18	
J	Rojas, JC; Gonzalez-Lima, F				Rojas, Julio C.; Gonzalez-Lima, F.			Neurological and psychological applications of transcranial lasers and LEDs	BIOCHEMICAL PHARMACOLOGY			English	Article						Cognitive enhancement; Cytochrome oxidase; Low-level light therapy; Methylene blue; Neuroprotection; Photobiomodulation	NEAR-INFRARED LIGHT; TRAUMATIC BRAIN-INJURY; MIDBRAIN DOPAMINERGIC CELLS; METHYLENE-BLUE; COGNITIVE DEFICITS; CYTOCHROME-OXIDASE; ALZHEIMERS-DISEASE; EMBOLIC STROKES; THERAPY; IRRADIATION	Transcranial brain stimulation with low-level light/laser therapy (LLLT) is the use of directional low-power and high-fluency monochromatic or quasimonochromatic light from lasers or LEDs in the red-to-near-infrared wavelengths to modulate a neurobiological function or induce a neurotherapeutic effect in a nondestructive and non-thermal manner. The mechanism of action of LLLT is based on photon energy absorption by cytochrome oxidase, the terminal enzyme in the mitochondrial respiratory chain. Cytochrome oxidase has a key role in neuronal physiology, as it serves as an interface between oxidative energy metabolism and cell survival signaling pathways. Cytochrome oxidase is an ideal target for cognitive enhancement, as its expression reflects the changes in metabolic capacity underlying higher-order brain functions. This review provides an update on new findings on the neurotherapeutic applications of LLLT. The photochemical mechanisms supporting its cognitive-enhancing and brain-stimulatory effects in animal models and humans are discussed. LLLT is a potential non-invasive treatment for cognitive impairment and other deficits associated with chronic neurological conditions, such as large vessel and lacunar hypoperfusion or neurodegeneration. Brain photobiomodulation with LLLT is paralleled by pharmacological effects of low-dose USP methylene blue, a non-photic electron donor with the ability to stimulate cytochrome oxidase activity, redox and free radical processes. Both interventions provide neuroprotection and cognitive enhancement by facilitating mitochondrial respiration, with hormetic dose-response effects and brain region activational specificity. This evidence supports enhancement of mitochondrial respiratory function as a generalizable therapeutic principle relevant to highly adaptable systems that are exquisitely sensitive to energy availability such as the nervous system. (C) 2013 Elsevier Inc. All rights reserved.	[Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Pharmacol, Austin, TX 78712 USA; [Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Toxicol, Austin, TX 78712 USA; [Rojas, Julio C.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75235 USA	Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Rojas, Julio/AAL-7973-2020	Gonzalez-Lima, Francisco/0000-0001-9856-0775			Ahmed NAEH, 2008, PHOTOMED LASER SURG, V26, P479, DOI 10.1089/pho.2007.2190; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arntzen KA, 2012, CEREBROVASC DIS, V33, P159, DOI 10.1159/000334182; Bangen KJ, 2012, J ALZHEIMERS DIS, V31, pS59, DOI 10.3233/JAD-2012-120292; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Bashkatov AN, 2006, P SOC PHOTO-OPT INS, V6163, P61630; Bruchey Aleksandra K, 2008, Am J Pharmacol Toxicol, V3, P72; Byrnes KR, 2005, LASER SURG MED, V37, P161, DOI 10.1002/lsm.20202; Calabrese EJ, 2008, AM J PHARM TOXICOL, V3, P59, DOI DOI 10.3844/AJPTSP.2008.59.71; Callaway NL, 2002, NEUROSCI LETT, V332, P83, DOI 10.1016/S0304-3940(02)00827-3; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; de la Torre Jack C, 2012, Cardiovasc Psychiatry Neurol, V2012, P367516, DOI 10.1155/2012/367516; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Deiana S, 2009, PSYCHOPHARMACOLOGY, V202, P53, DOI 10.1007/s00213-008-1394-2; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Drummond SPA, 2005, SLEEP, V28, P1059; Furian AF, 2007, NEUROCHEM INT, V50, P164, DOI 10.1016/j.neuint.2006.07.012; Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Jang H, 2012, PHOTOMED LASER SURG, V30, P405, DOI 10.1089/pho.2012.3240; Jenkins PA, 2011, PHOTOMED LASER SURG, V29, P785, DOI 10.1089/pho.2011.9895; Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 1996, LASER SURG MED, V18, P171, DOI 10.1002/(SICI)1096-9101(1996)18:2<171::AID-LSM7>3.0.CO;2-P; Karu TI, 2001, LASER SURG MED, V28, P227, DOI 10.1002/lsm.1043; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lee RB, 2002, ARTHRITIS RHEUM, V46, P3190, DOI 10.1002/art.10686; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Mak HKF, 2012, J ALZHEIMERS DIS, V31, P33, DOI 10.3233/JAD-2012-111877; Medina DX, 2011, BRAIN PATHOL, V21, P140, DOI 10.1111/j.1750-3639.2010.00430.x; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; National Institute of Aging, 2012, ALZH DIS PROGR REP I; National Institute of Neurological Disorders and Stroke, 2004, STROK HOP RES; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; O'Leary JC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-45; Ohlow MJ, 2011, DRUG DISCOV TODAY, V16, P119, DOI 10.1016/j.drudis.2011.01.001; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Leal ECP, 2010, J ORTHOP SPORT PHYS, V40, P524, DOI 10.2519/jospt.2010.3294; Poyton RO, 2011, DISCOV MED, V11, P154; Poyton RO, 2009, ANN NY ACAD SCI, V1177, P48, DOI 10.1111/j.1749-6632.2009.05046.x; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Riha PD, 2011, NEUROIMAGE, V54, P2623, DOI 10.1016/j.neuroimage.2010.11.023; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Rojas JC, 2009, NEUROTOX RES, V15, P260, DOI 10.1007/s12640-009-9027-z; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Schirmer RH, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.12.012; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Sokoloff L, 1989, CIRCULATION ENERGY M; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001; Wong-Riley MTT, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P1; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; Yip KK, 2011, NEUROSCIENCE, V190, P301, DOI 10.1016/j.neuroscience.2011.06.022; Zhang XA, 2006, NEUROTOX RES, V9, P47, DOI 10.1007/BF03033307; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	75	65	66	2	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	AUG 15	2013	86	4					447	457		10.1016/j.bcp.2013.06.012			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	203MK	WOS:000323297100001	23806754				2021-06-18	
J	Roth, RM; Lance, CE; Isquith, PK; Fischer, AS; Giancola, PR				Roth, Robert M.; Lance, Charles E.; Isquith, Peter K.; Fischer, Adina S.; Giancola, Peter R.			Confirmatory Factor Analysis of the Behavior Rating Inventory of Executive Function-Adult Version in Healthy Adults and Application to Attention-Deficit/Hyperactivity Disorder	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Executive function; Factor analysis; Psychometrics; Self-regulation; Neuropsychology; ADHD	COVARIANCE STRUCTURE-ANALYSIS; TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; FRONTAL LOBES; FIT INDEXES; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR; TEST STATISTICS; DAILY-LIFE; CHILDREN	The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a questionnaire measure designed to assess executive functioning in everyday life. Analysis of data from the BRIEF-A standardization sample yielded a two-factor solution (labeled Behavioral Regulation and Metacognition). The present investigation employed confirmatory factor analysis (CFA) to evaluate four alternative models of the factor structure of the BRIEF-A self-report form in a sample of 524 healthy young adults. Results indicated that a three-factor model best fits the data: a Metacognition factor, a Behavioral Regulation factor consisting of the Inhibit and Self-Monitor scales, and an Emotional Regulation factor composed of the Emotional Control and Shift scales. The three factors contributed 14%, 19%, and 24% of unique variance to the model, respectively, and a second-order general factor accounted for 41% of variance overall. This three-factor solution is consistent with recent CFAs of the Parent report form of the BRIEF. Furthermore, although the Behavioral Regulation factor score in the two-factor model did not differ between adults with attention-deficit/hyperactivity disorder and a matched healthy comparison group, greater impairment on the Behavioral Regulation factor but not the Emotional Regulation factor was found using the three-factor model. Together, these findings support the multidimensional nature of executive function and the clinical relevance of a three-factor model of the BRIEF-A.	[Roth, Robert M.; Isquith, Peter K.; Fischer, Adina S.] Dartmouth DHMC, Geisel Sch Med, Dept Psychiat, Lebanon, NH 03756 USA; [Lance, Charles E.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA; [Giancola, Peter R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA	Roth, RM (corresponding author), Dartmouth DHMC, Geisel Sch Med, Dept Psychiat, Neuropsychol Program, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	robert.m.roth@dartmouth.edu	Isquith, Peter/AAY-4851-2020		National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01-AA-11691]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA011691] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (R01-AA-11691 to PRG) and the National Center for Research Resources to PRG.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Baird AA, 2010, SOC NEUROSCI-UK, V5, P519, DOI 10.1080/17470911003747386; Barkley R. A., 1997, ADHD NATURE SELF CON; Barkley R. A., 2011, EXECUTIVE FUNCTIONIN; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Biederman J, 2011, EUR NEUROPSYCHOPHARM, V21, P508, DOI 10.1016/j.euroneuro.2010.11.005; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; BROWNE MW, 1984, BRIT J MATH STAT PSY, V37, P62, DOI 10.1111/j.2044-8317.1984.tb00789.x; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Chang WP, 2009, J PSYCHOPHYSIOL, V23, P113, DOI 10.1027/0269-8803.23.3.113; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; CHOU CP, 1991, BRIT J MATH STAT PSY, V44, P347, DOI 10.1111/j.2044-8317.1991.tb00966.x; Christ SE, 2010, NEUROPSYCHOLOGY, V24, P590, DOI 10.1037/a0019176; Cortina JM, 2001, ORGAN RES METHODS, V4, P324, DOI 10.1177/109442810144002; Dawson EL, 2012, J CLIN EXP NEUROPSYC, V34, P297, DOI 10.1080/13803395.2011.639297; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Giancola PR, 2012, PSYCHOL ADDICT BEHAV, V26, P201, DOI 10.1037/a0025207; Gioia G., 2002, J INT NEUROPSYCH SOC, V8, P229; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2001, PSYCHOLOGICAL AND DEVELOPMENTAL ASSESSMENT, P317; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Godefroy O, 1999, CORTEX, V35, P1, DOI 10.1016/S0010-9452(08)70782-2; Handler J., 1994, HANDB NEUR, P125; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037/0033-2909.112.2.351; Joreskog K. G., 2004, LISREL 8 80; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kompus K, 2009, NEUROSCI LETT, V467, P76, DOI 10.1016/j.neulet.2009.10.005; Koven NS, 2010, PERS INDIV DIFFER, V49, P24, DOI 10.1016/j.paid.2010.02.034; Kumbhani SR, 2010, J NEUROPSYCH CLIN N, V22, P304, DOI 10.1176/appi.neuropsych.22.3.304; Latzman RD, 2010, ASSESSMENT, V17, P172, DOI 10.1177/1073191109356254; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mohanty A, 2007, PSYCHOPHYSIOLOGY, V44, P343, DOI 10.1111/j.1469-8986.2007.00515.x; Mur M, 2007, J CLIN PSYCHIAT, V68, P1078, DOI 10.4088/JCP.v68n0715; Nigg JT, 2005, J ABNORM PSYCHOL, V114, P706, DOI 10.1037/0021-843X.114.3.706; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Rabin LA, 2011, J CLIN EXP NEUROPSYC, V33, P344, DOI 10.1080/13803395.2010.518597; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Roth R.M., 2005, BEHAV RATING INVENTO; Roth RM, 2006, FOCUS ON NEUROPSYCHOLOGY RESEARCH, P1; Schroeder VM, 2008, FAM RELAT, V57, P404, DOI 10.1111/j.1741-3729.2008.00509.x; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; Turken U, 2008, NEUROSCI LETT, V441, P7, DOI 10.1016/j.neulet.2008.05.115; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Zelazo P. D., 2002, BLACKWELL HDB CHILDH, P445, DOI DOI 10.1002/9780470996652.CH20	63	65	67	1	52	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					425	434		10.1093/arclin/act031			10	Psychology, Clinical; Psychology	Psychology	186CN	WOS:000322019600005	23676185	Bronze, Green Published			2021-06-18	
J	Burke, JF; Stulc, JL; Skolarus, LE; Sears, ED; Zahuranec, DB; Morgenstern, LB				Burke, James F.; Stulc, Jessica L.; Skolarus, Lesli E.; Sears, Erika D.; Zahuranec, Darin B.; Morgenstern, Lewis B.			Traumatic brain injury may be an independent risk factor for stroke	NEUROLOGY			English	Article							ISCHEMIC-STROKE; SPONTANEOUS DISSECTION; ADMINISTRATIVE DATA; UNITED-STATES; YOUNG-ADULTS; ALGORITHMS; ACCURACY; EPILEPSY; CHILDREN; ARTERIES	Objective: To explore whether traumatic brain injury (TBI) may be a risk factor for subsequent ischemic stroke. Methods: Patients with any emergency department visit or hospitalization for TBI (exposed group) or non-TBI trauma (control) based on statewide emergency department and inpatient databases in California from 2005 to 2009 were included in a retrospective cohort. TBI was defined using the Centers for Disease Control definition. Our primary outcome was subsequent hospitalization for acute ischemic stroke. The association between TBI and stroke was estimated using Cox proportional hazards modeling adjusting for demographics, vascular risk factors, comorbidities, trauma severity, and trauma mechanism. Results: The cohort included a total of 1,173,353 trauma subjects, 436,630 (37%) with TBI. The patients with TBI were slightly younger than the controls (mean age 49.2 vs 50.3 years), less likely to be female (46.8% vs 49.3%), and had a higher mean injury severity score (4.6 vs 4.1). Subsequent stroke was identified in 1.1% of the TBI group and 0.9% of the control group over a median follow-up period of 28 months (interquartile range 14-44). After adjustment, TBI was independently associated with subsequent ischemic stroke (hazard ratio 1.31, 95% confidence interval 1.25-1.36). Conclusions: In this large cohort, TBI is associated with ischemic stroke, independent of other major predictors.	[Burke, James F.] Univ Michigan, Dept Vet Affairs, VA Ctr Clin Management & Res, Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA; [Stulc, Jessica L.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Burke, James F.; Skolarus, Lesli E.; Zahuranec, Darin B.; Morgenstern, Lewis B.] Univ Michigan, Stroke Program, Ann Arbor, MI 48109 USA; [Sears, Erika D.] Univ Michigan, Dept Surg, Sect Plast Surg, Ann Arbor, MI 48109 USA; [Morgenstern, Lewis B.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	Burke, JF (corresponding author), Univ Michigan, Dept Vet Affairs, VA Ctr Clin Management & Res, Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA.	jamesbur@umich.edu			VA Advanced Fellowship; NIH from the National Institute of Neurological Diseases and Stroke [K23NS073685]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG038731]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS38916, R01NS062675, U01NS056975, U01NS062835, R18HS017690, R01NS073595, R01HL098065]; St. Jude MedicalSt. Jude Medical; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS073685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG038731] Funding Source: NIH RePORTER	J. Burke is supported by a VA Advanced Fellowship. J. Stulc reports no disclosures relevant to the manuscript. L. Skolarus is supported by NIH K23NS073685 from the National Institute of Neurological Diseases and Stroke. E. Sears reports no disclosures relevant to the manuscript. D. Zahuranec is supported by grant K23AG038731 from the National Institute on Aging. L. Morgenstern receives NIH funding (significant) from grants R01NS38916, R01NS062675, U01NS056975, U01NS062835, R18HS017690, R01NS073595, and R01HL098065. He receives significant research support from St. Jude Medical. Go to Neurology.org for full disclosures.	Agency for Healthcare Research and Quality (AHRQ), 2012, HCUP CLINICAL CLASSI; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Association for the Advancement of Automotive Medicine, THE ABBREVIATED INJU; Baracchini C, 2010, NEUROLOGY, V75, P1864, DOI 10.1212/WNL.0b013e3181feae5e; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Brown DL, 2006, NEUROLOGY, V67, P1390, DOI 10.1212/01.wnl.0000237024.16438.20; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; CAPLAN LR, 1985, STROKE, V16, P1030, DOI 10.1161/01.STR.16.6.1030; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.2307/2335362; DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA, 2006, INCIDENCE AND ECONOM; FISHER CM, 1978, CAN J NEUROL SCI, V5, P9, DOI 10.1017/S0317167100024690; Fullerton HJ, 2001, NEUROLOGY, V57, P1155, DOI 10.1212/WNL.57.7.1155; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Goldstein LB, 1998, STROKE, V29, P1602, DOI 10.1161/01.STR.29.8.1602; Haas B, 2012, CAN J SURG, V55, P21, DOI 10.1503/cjs.017510; Hand PJ, 2006, STROKE, V37, P769, DOI 10.1161/01.STR.0000204041.13466.4c; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Ji RJ, 2013, JAMA NEUROL, V70, P51, DOI 10.1001/jamaneurol.2013.575; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; National Center for Injury Prevention, 2003, REPORT TO CON GRESS; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rector TS, 2004, HEALTH SERV RES, V39, P1839, DOI 10.1111/j.1475-6773.2004.00321.x; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sniezek JE, 1995, GUIDELINES FOR SURVE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Touze E, 2003, NEUROLOGY, V61, P1347, DOI 10.1212/01.WNL.0000094325.95097.86; Williams LS, 1997, NEUROLOGY, V49, P1541, DOI 10.1212/WNL.49.6.1541	36	65	65	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 2	2013	81	1					33	39		10.1212/WNL.0b013e318297eecf			7	Clinical Neurology	Neurosciences & Neurology	304JC	WOS:000330741900010	23803315	Green Published			2021-06-18	
J	Dennis, M; Simic, N; Bigler, ED; Abildskov, T; Agostino, A; Taylor, HG; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Dennis, Maureen; Simic, Nevena; Bigler, Erin D.; Abildskov, Tracy; Agostino, Alba; Taylor, H. Gerry; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Cognitive, affective, and conative theory of mind (ToM) in children with traumatic brain injury	DEVELOPMENTAL COGNITIVE NEUROSCIENCE			English	Article						Childhood traumatic brain injury; Social cognition; Theory of mind; Emotion; Empathy; MRI	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILDHOOD HEAD-INJURY; MIRROR-NEURON SYSTEM; 1ST 6 MONTHS; SOCIAL COGNITION; INHIBITORY CONTROL; DEFAULT-MODE; BEHAVIORAL-REGULATION; SPECTRUM DISORDERS; SPEECH ACTS	We studied three forms of dyadic communication involving theory of mind (ToM) in 82 children with traumatic brain injury (TBI) and 61 children with orthopedic injury (OI): Cognitive (concerned with false belief), Affective (concerned with expressing socially deceptive facial expressions), and Conative (concerned with influencing another's thoughts or feelings). We analyzed the pattern of brain lesions in the TBI group and conducted voxel-based morphometry for all participants in five large-scale functional brain networks, and related lesion and volumetric data to ToM outcomes. Children with TBI exhibited difficulty with Cognitive, Affective, and Conative ToM. The perturbation threshold for Cognitive ToM is higher than that for Affective and Conative ToM, in that Severe TBI disturbs Cognitive ToM but even Mild Moderate TBI disrupt Affective and Conative ToM. Childhood TBI was associated with damage to all five large-scale brain networks. Lesions in the Mirror Neuron Empathy network predicted lower Conative ToM involving ironic criticism and empathic praise. Conative ToM was significantly and positively related to the package of Default Mode, Central Executive, and Mirror Neuron Empathy networks and, more specifically, to two hubs of the Default Mode Network, the posterior cingulate/retrosplenial cortex and the hippocampal formation, including entorhinal cortex and parahippocampal cortex. (C) 2012 Elsevier Ltd. All rights reserved.	[Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Bigler, Erin D.; Abildskov, Tracy] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Agostino, Alba] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Univ Hosp Cleveland, Case Med Ctr, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA	Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020; Gerhardt, Cynthia/E-3109-2011; Vannatta, Kathryn/E-4237-2011; Rubin, Kenneth H/M-5276-2018	Rubin, Kenneth H/0000-0002-2608-2484; Yeates, Keith/0000-0001-7680-2892; Agostino, Alexandra/0000-0001-8739-0061	National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 HD 04946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Preparation of this paper was supported by National Institute of Neurological Diseases and Stroke Grant 1 RO1 HD 04946, "Social Outcomes in Pediatric Traumatic Brain Injury."	Adams RB, 2006, MOTIV EMOTION, V30, P179, DOI 10.1007/s11031-006-9020-2; Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bickart KC, 2011, NAT NEUROSCI, V14, P163, DOI 10.1038/nn.2724; Bigler E.D., HETEROGENEITY BRAIN; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Dawes CT, 2012, P NATL ACAD SCI USA, V109, P6479, DOI 10.1073/pnas.1118653109; Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, BRAIN COGNITION, V47, P197; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dunbar RIM, 2012, TRENDS COGN SCI, V16, P101, DOI 10.1016/j.tics.2011.11.013; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Green MJ, 2003, COGNITION EMOTION, V17, P779, DOI 10.1080/02699930302282; Greenbaum RL, 2009, ALCOHOL CLIN EXP RES, V33, P1656, DOI 10.1111/j.1530-0277.2009.01003.x; Gu XS, 2013, CEREB CORTEX, V23, P20, DOI 10.1093/cercor/bhr367; Hadjikhani N, 2006, CEREB CORTEX, V16, P1276, DOI 10.1093/cercor/bh069; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; HILGARD ER, 1980, J HIST BEHAV SCI, V16, P107, DOI 10.1002/1520-6696(198004)16:2<107::AID-JHBS2300160202>3.0.CO;2-Y; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Howard I, 2005, ETHNIC DIS, V15, pS51; Huang L, 2011, SOC PSYCHOL PERS SCI, V2, P351, DOI 10.1177/1948550610391677; Jakobson Roman, 1960, STYLE LANGUAGE, P350; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; Kamawar D, 2011, J EXP CHILD PSYCHOL, V108, P734, DOI 10.1016/j.jecp.2010.10.005; Kamawar D, 2009, J COGN DEV, V10, P285, DOI 10.1080/15248370903389499; Kober H, 2008, NEUROIMAGE, V42, P998, DOI 10.1016/j.neuroimage.2008.03.059; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; Max J. E., 2005, J AM ACAD CHILD ADOL, V44, P435; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Militello L.G., 2006, COLL TECHN SYST CTS; Molenberghs P, 2012, NEUROSCI BIOBEHAV R, V36, P341, DOI 10.1016/j.neubiorev.2011.07.004; Newsome MR, 2012, INT J DEV NEUROSCI, V30, P255, DOI 10.1016/j.ijdevneu.2011.10.008; Nummenmaa L, 2012, P NATL ACAD SCI USA, V109, P9599, DOI 10.1073/pnas.1206095109; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; PERNER J, 1998, LANGUAGE THOUGHT INT, P270; Perner J., 2000, UNDERSTANDING OTHER, P150; Qin SZ, 2012, P NATL ACAD SCI USA, V109, P7941, DOI 10.1073/pnas.1120408109; Rameson LT, 2012, J COGNITIVE NEUROSCI, V24, P235, DOI 10.1162/jocn_a_00130; Rameson LT, 2009, SOC PERSONAL PSYCHOL, V3, P94, DOI 10.1111/j.1751-9004.2008.00154.x; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 2010, NAT REV NEUROSCI, V11, P264, DOI 10.1038/nrn2805; Russell J, 1997, AUTISM EXECUTIVE DIS, P256, DOI DOI 10.1093/MED:PSYCH/9780198523499.003.0008; Schilbach L, 2008, CONSCIOUS COGN, V17, P457, DOI 10.1016/j.concog.2008.03.013; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Senju A, 2012, NEUROSCIENTIST, V18, P108, DOI 10.1177/1073858410397208; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Sinopoli KJ, 2011, J CLIN EXP NEUROPSYC, V33, P805, DOI 10.1080/13803395.2011.562864; Sommer M, 2010, BRAIN RES, V1354, P123, DOI 10.1016/j.brainres.2010.07.057; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stano J, 1999, WECHSLER ABBREVIATED; Stiller J, 2007, SOC NETWORKS, V29, P93, DOI 10.1016/j.socnet.2006.04.001; TEASDALE G, 1974, LANCET, V2, P81; Uddin LQ, 2011, J NEUROSCI, V31, P18578, DOI 10.1523/JNEUROSCI.4465-11.2011; Uekermann J, 2010, NEUROSCI BIOBEHAV R, V34, P734, DOI 10.1016/j.neubiorev.2009.10.009; Vogel AC, 2010, NEUROPSYCHOL REV, V20, P362, DOI 10.1007/s11065-010-9145-7; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Ybarra O, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00075; Yeates K.O., J INT NEURO IN PRESS; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zaitchik D, 2010, NEUROPSYCHOLOGIA, V48, P2528, DOI 10.1016/j.neuropsychologia.2010.04.031	100	65	67	1	42	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1878-9293	1878-9307		DEV COGN NEUROS-NETH	Dev. Cogn. Neurosci.	JUL	2013	5						25	39		10.1016/j.dcn.2012.11.006			15	Psychology, Developmental; Neurosciences	Psychology; Neurosciences & Neurology	168WZ	WOS:000320739900003	23291312	Green Published, Green Accepted			2021-06-18	
J	Schatz, P; Glatts, C				Schatz, Philip; Glatts, Colette			Sandbagging Baseline Test Performance on ImPACT, Without Detection, Is More Difficult than It Appears	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Coached versus nave malingering; ImPACT	SPORTS-RELATED CONCUSSION; HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; BRAIN-INJURY; HIGH-SCHOOL; VALIDITY; DIAGNOSIS; SPECIFICITY; RELIABILITY; SYMPTOMS	Participants coached to display poor effort on neuropsychological tests have successfully evaded detection. Recent research has documented that 89 college athletes instructed to perform poorly on a follow-up baseline ImPACT (Immediate Post-concussion Assessment and Cognitive Testing) test were unable to bypass detection, but otherwise, sandbagging on baseline testing has not been directly studied. In an analog study intended to measure participants ability to successfully sandbag, we compared baseline test performance in three groups of individuals, instructed: (a) to perform their best, (b) to malinger without guidance (e.g., nave), and (c) how to malinger (e.g., coached), using ImPACT, the Medical Symptom Validity Test (MSVT), and the Balance Error Scoring System. The MSVT identified more participants in the nave (80) and coached (90) groups than those automatically flagged by ImPACT (60 and 75, respectively). Inclusion of additional indicators within ImPACT increased identification to 95 of nave and 100 of coached malingerers. These results suggest that intentional sandbagging on baseline neurocognitive testing can be readily detected.	[Schatz, Philip; Glatts, Colette] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	Dr. Schatz has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation and the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications, Inc., in the context of analyzing normative data and establishing age-and gender-based norms. However, ImPACT Applications, Inc. had no role in the conceptualization of the study, the collection or analysis of data, the writing of the article, or the decision to submit it for publication. Ms. Glatts has no Conflict of Interest to declare.	ALVES WM, 1987, CLIN SPORT MED, V6, P211; [Anonymous], 2012, SPORTING NEWS; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT, 1989, MILD HEAD INJURY; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Elbin R. J., 2011, AMERICAN JOURNAL OF; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2004, MEDICAL SYMPTOM VALI; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2007, IMPACT VERSION 6 0 C; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Marvez A., 2012, PLAYERS MAY TRY TO B; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Reilly R., 2011, TALKING FOOTBALL WIT; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P., 2012, AMERICAN JOURNAL OF; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Weinborn M, 2012, CLIN NEUROPSYCHOL, V26, P832, DOI 10.1080/13854046.2012.686630	39	65	65	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2013	28	3					236	244		10.1093/arclin/act009			9	Psychology, Clinical; Psychology	Psychology	138YK	WOS:000318547600004	23403552	Bronze			2021-06-18	
J	Tanaka, Y; Matsuwaki, T; Yamanouchi, K; Nishihara, M				Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.			EXACERBATED INFLAMMATORY RESPONSES RELATED TO ACTIVATED MICROGLIA AFTER TRAUMATIC BRAIN INJURY IN PROGRANULIN-DEFICIENT MICE	NEUROSCIENCE			English	Article						progranulin; traumatic brain injury; neuroinflammation; microglia; CD68; TGF beta 1	AMYOTROPHIC-LATERAL-SCLEROSIS; GRANULIN-EPITHELIN PRECURSOR; GROWTH-FACTOR-BETA; FRONTOTEMPORAL LOBAR DEGENERATION; OLIGOMERIC MATRIX PROTEIN; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASE; GENETIC-VARIABILITY; SURFACE EXPRESSION	Progranulin (PGRN), a multifunctional growth factor, appears to play a role in neurodegenerative diseases accompanied by neuroinflammation. In this study, we investigated the role of PGRN in neuroinflammation, especially in the activation of microglia, by means of experimental traumatic brain injury (TBI) in the cerebral cortex of mice. The expression of GRN mRNA was increased in association with neuroinflammation after TBI. Double-immunohistochemical study showed that PGRN-immunoreactive (-IR) cells were mainly overlapped with CD68-IR cells, suggesting that the main source of PGRN was CD68-positive activated microglia. To investigate the role of PGRN in inflammatory responses related to activated microglia, we compared the immunoreactivity and expression of ionized calcium-binding adaptor molecule 1 (Iba1), CD68, and CD11b as markers for activated microglia between wild-type (WT) and GRN-deficient (KO) mice. The number of Iba1- and CD11b-IR cells and gene expression of Iba1 and CD11b were not significantly different between WT and KO mice, while the number of CD68-IR cells and CD68 expression in KO mice were significantly greater than those in WT mice. Double-immunohistochemical study showed that CD68-IR microglia were also IR for TGF beta 1, and TGF beta 1 expression and Smad3 phosphorylation in KO mice were elevated compared to WT mice. Moreover, double-immunostaining between phospho-Smad3 and glial fibrillary acidic protein suggested increased TGF beta 1-Smad3 signal mainly by astrocytes. The levels of protein carbonyl groups, which reflect protein oxidation, and laminin immunoreactivity, which is associated with angiogenesis, were also significantly increased in KO mice compared to WT mice. These results suggest that PGRN is produced in CD68-positive microglia and suppresses excessive inflammatory responses related to activated microglia after TBI in mice. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo 1138657, Japan	Nishihara, M (corresponding author), Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004, 24-7548]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004, 12J07548] Funding Source: KAKEN	This work was supported in part by JSPS KAKENHI Grant Number 23228004 to MN and 24-7548 to YT.	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Asakura R, 2011, NEUROREPORT, V22, P881, DOI 10.1097/WNR.0b013e32834bf4ca; BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Carecchio M, 2009, J NEUROL SCI, V287, P291, DOI 10.1016/j.jns.2009.07.011; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Cortini F, 2008, EUR J NEUROL, V15, P1111, DOI 10.1111/j.1468-1331.2008.02266.x; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; de Beer MC, 2003, J LIPID RES, V44, P674, DOI 10.1194/jlr.M200444-JLR200; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Feng JAQ, 2010, FASEB J, V24, P1879, DOI 10.1096/fj.09-144659; Fenger C, 2006, GLIA, V54, P591, DOI 10.1002/glia.20405; Ghoshal N, 2012, NEUROBIOL DIS, V45, P395, DOI 10.1016/j.nbd.2011.08.029; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Guo FJ, 2010, ARTHRITIS RHEUM-US, V62, P2023, DOI 10.1002/art.27491; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Jantaratnotai N, 2010, CURR ALZHEIMER RES, V7, P625, DOI 10.2174/156720510793499039; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kao AW, 2011, P NATL ACAD SCI USA, V108, P4441, DOI 10.1073/pnas.1100650108; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Ling L, 2009, J CEREBR BLOOD F MET, V29, P1538, DOI 10.1038/jcbfm.2009.76; Liu CJ, 2009, NAT CLIN PRACT RHEUM, V5, P38, DOI 10.1038/ncprheum0961; Llaverias G, 2004, BIOCHEM BIOPH RES CO, V318, P265, DOI 10.1016/j.bbrc.2004.04.021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Louboutin JP, 2010, EXP NEUROL, V221, P231, DOI 10.1016/j.expneurol.2009.11.004; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43; Naphade SB, 2010, ACTA NEUROPATHOL, V119, P123, DOI 10.1007/s00401-009-0616-y; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Robinson CE, 1999, ANAL BIOCHEM, V266, P48, DOI 10.1006/abio.1998.2932; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Smith ME, 2000, J NEUROIMMUNOL, V102, P154, DOI 10.1016/S0165-5728(99)00218-0; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Wappler EA, 2011, MICROVASC RES, V81, P153, DOI 10.1016/j.mvr.2010.12.005; Welser JV, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-89; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Xu K, 2007, J BIOL CHEM, V282, P11347, DOI 10.1074/jbc.M608744200; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	68	65	66	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	FEB 12	2013	231						49	60		10.1016/j.neuroscience.2012.11.032			12	Neurosciences	Neurosciences & Neurology	087EN	WOS:000314744200005	23201826				2021-06-18	
J	Brenner, M; Stein, DM; Hu, PF; Aarabi, B; Sheth, K; Scalea, TM				Brenner, Megan; Stein, Deborah M.; Hu, Peter F.; Aarabi, Bizhan; Sheth, Kevin; Scalea, Thomas M.			Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Continuous vital signs; outcomes; secondary brain injury; hypotension	HEAD-INJURY; VARIABLES	BACKGROUND: Vital signs, particularly blood pressure, are often manipulated to maximize perfusion and optimize recovery from severe traumatic brain injury (sTBI). We investigated the utility of automated continuously recorded vital signs to predict outcomes after sTBI. METHODS: Sixty patients with head Abbreviated Injury Scale score >= 3, age >14 years, "isolated" TBI, and need for intracranial pressure monitoring were prospectively enrolled at a single, large urban tertiary care facility. Outcome was measured by mortality and extended Glasgow Outcome Scale (GOSE) at 12 months. Continuous, automated, digital data were collected every 6 seconds for 72 hours after admission, and 5-minute means of systolic blood pressure (SBP) were recorded. We calculated SBP as pressure x time dose (PTD) to describe the cumulative amplitude and duration of episodes above and below clinical thresholds. The extent and duration of the insults were calculated as percent time (%time), PTD, and PTD per day (PTD/D) of defined thresholds (SBP: <90 mm Hg, <100 mm Hg, <110 mm Hg, and <120 mm Hg; mean arterial pressure: <60 mm Hg and <70 mm Hg; heart rate: >100 bpm and >120 bpm; and SpO(2) : <88% and <92%) for the first 12 hours, 24 hours, and 48 hours of intensive care unit admission. We analyzed their ability to predict mortality and GOSE by receiver operator characteristics. RESULTS: Mean age was 33.9 (range, 16-83) years, mean admission Glasgow Coma Scale score 6.4 +/- 3, and mean head Abbreviated Injury Scale score 4.2 +/- 0.72. The 30-day mortality rate was 13.3%. Of the 45 patients in whom GOSE at 12 months was available, 28 (62%) had good neurologic outcomes (GOSE score >4). Traditional markers of poor outcome (admission SBP, admission Glasgow Coma Scale, and Marshall score) were not different between groups with good or poor outcome. PTD, PTD/D, and %time SBP <110 mm Hg and SBP <120 mm Hg predicted mortality at 12 hours, 24 hours, and 48 hours (p < 0.04). Percent time SBP <110 mm Hg in the first 24 hours was predictive of 12-month GOSE (p = 0.02). PTD/D SBP < 120 mm Hg in the first 24 hours and PTD and PTD/D in the first 48 hours were also predictive of 12-month GOSE (p < 0.05). CONCLUSIONS: Within the first 48 hours of intensive care unit admission, hypotension was found to be predictive of mortality and functional outcomes at higher thresholds than traditionally defined. Systemic blood pressure targets closer to 120 mm Hg may be more efficacious in minimizing secondary insults and particularly useful in settings without invasive intracranial monitoring capabilities. (J Trauma. 2012; 72: 1135-1139. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Brenner, Megan] Univ Maryland, Med Ctr, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr,Sc, Baltimore, MD 21201 USA; [Stein, Deborah M.; Hu, Peter F.; Scalea, Thomas M.] Univ Maryland, Shock Trauma & Anesthesiol Res Organized Res Ctr, Sch Med, Baltimore, MD 21201 USA	Brenner, M (corresponding author), Univ Maryland, Med Ctr, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr,Sc, 22 S Greene St, Baltimore, MD 21201 USA.	mbrenner@umm.edu		Stein, Deborah/0000-0003-3683-3963	Haemonetics; Golden Helix; Expression Analysis; Illumina; Lineagan	Ernest E. Moore, MD, Editor, received research support from Haemonetics. David B. Hoyt, MD, Associate Editor/CME Editor, Ronald Maier, MD, Associate Editor, and Steven Shackford, MD, Associate Editor have nothing to disclose. Jennifer Crebs, Managing Editor, received consulting fees from Golden Helix, Expression Analysis, Illumina, and Lineagan. Jo Fields, Editorial Assistant, and Angela Sauaia, MD, Biostatistician, have nothing to disclose.	Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Berry C, 2011, INJURY          0920; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care AANS/CNS, 2007, J NEUROTRAUMA S, V24, pS1, DOI DOI 10.1089/NEU.2007.9976; Bratton S. L., 2007, J NEUROTRAUMA S1, V24, pS37; Chestnut RM, 1987, J TRAUMA, V27, P1007; Chiara O, 2008, MINERVA ANESTESIOL, V74, P303; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x	12	65	65	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1135	1139		10.1097/TA.0b013e31824af90b			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	944JD	WOS:000304195100002	22673237				2021-06-18	
J	Barr, WB; Prichep, LS; Chabot, R; Powell, MR; Mccrea, M				Barr, William B.; Prichep, Leslie S.; Chabot, Robert; Powell, Matthew R.; Mccrea, Michael			Measuring brain electrical activity to track recovery from sport-related concussion	BRAIN INJURY			English	Article						Electroencephalography; traumatic brain injury; concussion; athletes	INJURY; EEG; FOOTBALL	Primary objective: To follow recovery from concussion in a sample of athletes using an electroencephalographic (EEG) index of quantitative brain activity developed previously on an independent Emergency Department (ED) sample of head-injured subjects with traumatic brain injury. Methods and procedures: EEG recordings from five frontal electrode sites were obtained on 59 injured athletes and 31 controls at the time of injury and at 8 and 45 days afterward. All subjects also completed standardized clinical assessment of post-concussion symptoms, postural stability and cognitive functioning at injury and 8 and 45 days post-injury. Results: Abnormalities in clinical assessment measures were observed in injured subjects only at time of injury. Statistical analysis of brain electrical activity measures with the ED-based algorithm revealed significant differences between injured athletes vs controls at the time of injury and at day 8. Measures from the two groups did not differ on day 45. Conclusions: This study demonstrated that an algorithm of brain electrical activity developed on an independent sample of ED subjects with head injury is sensitive to the effects of sport-related concussion. Using this algorithm, abnormal features of brain electrical activity were detected in athletes with concussion at the time of injury and persisted beyond the point of recovery on clinical measures.	[Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Prichep, Leslie S.; Chabot, Robert] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY USA; [Prichep, Leslie S.] Nathan S Kline Inst Psychiat Res, New York State Dept Mental Hlth, Orangeburg, NY 10962 USA; [Powell, Matthew R.] Minocqua Ctr, Marshfield Clin, Neuropsychol Serv, Minoqua, WI USA; [Mccrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Mccrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	Barr, WB (corresponding author), NYU, Comprehens Epilepsy Ctr, 223 E 34th St, New York, NY 10016 USA.	william.barr@nyumc.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc.	This research was supported by a clinical research grant from BrainScope, Inc. as an investigator-initiated study, with Dr Barr and Dr McCrea as principal investigators. The investigators thank the certified athletic trainers and student athletes from those high schools and colleges that participated. We also acknowledge the insights of E. Roy John, PhD, in the concept and design of this study. Dr McCrea and Dr Barr had full access to all of the clinical data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; Dr Prichep holds the same responsibility for the integrity and accuracy of the electrophysiological data.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; ONEIL B, 2011, ANN EMERG MED, V58, pS228; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	35	65	65	1	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					58	66		10.3109/02699052.2011.608216			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900006	22107157				2021-06-18	
J	Blume, HK; Vavilala, MS; Jaffe, KM; Koepsell, TD; Wang, J; Temkin, N; Durbin, D; Dorsch, A; Rivara, FP				Blume, Heidi K.; Vavilala, Monica S.; Jaffe, Kenneth M.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Durbin, Dennis; Dorsch, Andrea; Rivara, Frederick P.			Headache After Pediatric Traumatic Brain Injury: A Cohort Study	PEDIATRICS			English	Article						traumatic brain injury; headache; child; epidemiology; posttraumatic headache; adolescents	SEX-DIFFERENCES; POSTTRAUMATIC HEADACHE; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; UNITED-STATES; CONCUSSION; PREVALENCE; RECOVERY; MIGRAINE; CHILDREN	OBJECTIVE: To determine the prevalence of headache 3 and 12 months after pediatric traumatic brain injury (TBI). METHODS: This is a prospective cohort study of children ages 5 to 17 years in which we analyzed the prevalence of headache 3 and 12 months after mild TBI (mTBI; n = 402) and moderate/severe TBI (n = 60) compared with controls with arm injury (AI; n = 122). RESULTS: The prevalence of headache 3 months after injury was significantly higher after mTBI than after AI overall (43% vs 26%, relative risk [RR]: 1.7 [95% confidence interval (CI): 1.2-2.3]), in adolescents (13-17 years; 46% vs 25%, RR: 1.8 [95% CI: 1.1-3.1]), and in girls (59% vs 24%, RR: 2.4 [95% CI: 1.4-4.2]). The prevalence of headache at 3 months was also higher after moderate/severe TBI than AI in younger children (5-12 years; 60% vs 27%; RR: 2.0 [95% CI: 1.2-3.4]). Twelve months after injury, TBI was not associated with a significantly increased frequency of headache. However, girls with mTBI reported serious headache (>= 5 of 10 pain scale rating) more often than controls (27% vs 10%, RR: 2.2 [95% CI: 0.9-5.6]). CONCLUSIONS: Pediatric TBI is associated with headache. A substantial number of children suffer from headaches months after their head injury. The prevalence of headache during the year after injury is related to injury severity, time after injury, age, and gender. Girls and adolescents appear to be at highest risk of headache in the months after TBI. Pediatrics 2012; 129: e31-e39	[Blume, Heidi K.] Univ Washington, Div Pediat Neurol, Seattle, WA 98105 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98105 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98105 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98105 USA; [Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98105 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98105 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98105 USA; [Vavilala, Monica S.; Jaffe, Kenneth M.; Koepsell, Thomas D.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98105 USA; [Blume, Heidi K.] Seattle Childrens Res Inst, Seattle, WA USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Dorsch, Andrea] Mary Bridge Childrens Hosp, Div Pediat Psychol, Tacoma, WA USA	Blume, HK (corresponding author), Univ Washington, Seattle Childrens Hosp & Res Inst, Div Pediat Neurol, 4800 Sandpoint Way,Mailstop B-5552, Seattle, WA 98105 USA.	heidi.blume@seattlechildrens.org					Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Hershey Andrew D, 2005, Curr Pain Headache Rep, V9, P341, DOI 10.1007/s11916-005-0010-y; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Kirk C, 2008, DEV MED CHILD NEUROL, V50, P422, DOI 10.1111/j.1469-8749.2008.02063.x; LANZI G, 1985, CEPHALALGIA, V5, P211, DOI 10.1046/j.1468-2982.1985.0504211.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lucas S, 2011, NATURAL HIST HEADACH; Marr AL., 2004, CENTRAL NERVOUS SYST; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Powers SW, 2003, PEDIATRICS, V112, pE1, DOI 10.1542/peds.112.1.e1; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Wong D. L., 2001, WONGS ESSENTIALS PED; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	32	65	65	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					E31	E39		10.1542/peds.2011-1742			9	Pediatrics	Pediatrics	870BT	WOS:000298644800005	22144708				2021-06-18	
J	Luchetti, S; Bossers, K; Van de Bilt, S; Agrapart, V; Morales, RR; Frajese, GV; Swaab, DF				Luchetti, Sabina; Bossers, Koen; Van de Bilt, Saskia; Agrapart, Vincent; Morales, Rafael Ramirez; Frajese, Giovanni Vanni; Swaab, Dick F.			Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease	NEUROBIOLOGY OF AGING			English	Article						Neurosteroids; GABA-A receptors; Alzheimer's disease; Postmortem; Prefrontal cortex; Aromatase; Gene expression	TRAUMATIC BRAIN-INJURY; DIAZEPAM-BINDING INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; OF-THE-ART; GABA(A) RECEPTORS; PROGESTERONE METABOLITES; NEUROACTIVE STEROIDS; NERVOUS-SYSTEM; SPINAL-CORD	Expression of the genes for enzymes involved in neurosteroid biosynthesis was studied in human prefrontal cortex (PFC) in the course of Alzheimer's disease (AD) (n = 49). Quantitative RT-PCR (qPCR) revealed that mRNA levels of diazepam binding inhibitor (DBI), which is involved in the first step of steroidogenesis and in GABAergic transmission, were increased, as were mRNA levels for several neurosteroid biosynthetic enzymes. Aromatase, 17 beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and aldo-keto reductase 1C2 (AKR1C2), were all increased in the late stages of AD. Several GABA-A subunits were significantly reduced in AD. Increased expression of aromatase in the PFC was confirmed by immunohistochemistry and was found to be localized predominantly in astrocytes. These data suggest a role for estrogens and allopregnanolone produced by astrocytes in the PFC in AD, possibly as part of a rescue program. The reduced gene expression of some synaptic and extra-synaptic GABA-A subunits may indicate a deficit of modulation of GABA-A receptors by neuro active steroids, which may contribute to the neuropsychiatric characteristics of this disease. (C) 2009 Elsevier Inc. All rights reserved.	[Luchetti, Sabina; Bossers, Koen; Van de Bilt, Saskia; Swaab, Dick F.] NIN, NL-1105 BA Amsterdam, Netherlands; [Luchetti, Sabina] Santa Lucia Fdn Sci Inst, Ist Dermopat Immacolata IDI IRCCS, Rome, Italy; [Agrapart, Vincent; Morales, Rafael Ramirez; Frajese, Giovanni Vanni] Univ Roma Tor Vergata, Endocrinol Lab, Dept Internal Med, Rome, Italy; [Frajese, Giovanni Vanni] Univ Cassino, Fac Motor Sci, I-03043 Cassino, Italy	Luchetti, S (corresponding author), Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	s.luchetti@nin.knaw.nl	Bossers, Koen/I-4002-2013; Kruisbrink, Jenneke/D-8060-2013; Ramirez Morales, Rafael/C-9444-2013	Ramirez Morales, Rafael/0000-0001-8261-8450; Swaab, Dick/0000-0002-9665-7845; Bossers, Koen/0000-0002-0272-4518	Istituto Der-mopatico Immacolata (IDI-IRCCS); Santa Lucia Foundation (Santa Lucia-IRCCS), Rome, Italy; Netherlands Institute for Neuroscience	Authors would like to thank, R. Balesar, B. Fisser, A. Sluiter, U. Unmehopa, J.J. Van Heerikhuize for technical assistance, Dr. M. Hofman for statistical advises, Dr. M.R.J. Mason and Dr. W. Kamphuis for critical comments of the paper. S.L. was supported by funds from the Istituto Der-mopatico Immacolata (IDI-IRCCS to Prof. G. Frajese) and the Santa Lucia Foundation (Santa Lucia-IRCCS to Prof G. Bernardi), Rome, Italy. Experimental materials were funded by the Netherlands Institute for Neuroscience to D.F.S. We thank the Netherlands Brain Bank for providing the human material.	Bancher C, 1996, EUR ARCH PSY CLIN N, V246, P137, DOI 10.1007/BF02189115; BARBACCIA ML, 1986, ARCH GEN PSYCHIAT, V43, P1143; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; Bialek M, 2004, POL J PHARMACOL, V56, P509; Biggio F, 2006, PHARMACOL BIOCHEM BE, V84, P545, DOI 10.1016/j.pbb.2006.07.002; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Bossers K, 2009, BRAIN PATHOL, V19, P91, DOI 10.1111/j.1750-3639.2008.00171.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Cherrier MM, 2005, NEUROLOGY, V64, P2063, DOI 10.1212/01.WNL.0000165995.98986.F1; Cholerton B, 2002, DRUG AGING, V19, P405, DOI 10.2165/00002512-200219060-00002; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; COSTA E, 1994, ANN NY ACAD SCI, V746, P223; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DOREGO JL, 2009, FRONT NEUROENDOCRINO; Dubrovsky BO, 2005, PROG NEURO-PSYCHOPH, V29, P169, DOI 10.1016/j.pnpbp.2004.11.001; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; FERRARESE C, 1990, NEUROLOGY, V40, P632, DOI 10.1212/WNL.40.4.632; FERRERO P, 1988, J NEUROL SCI, V87, P327, DOI 10.1016/0022-510X(88)90257-2; Follesa P, 2005, J NEUROCHEM, V94, P659, DOI 10.1111/j.1471-4159.2005.03303.x; Francis PT, 2003, INT J GERIATR PSYCH, V18, pS15, DOI 10.1002/gps.934; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 2008, J NEUROENDOCRINOL, V20, P705, DOI 10.1111/j.1365-2826.2008.01713.x; Genazzani AR, 2007, HUM REPROD UPDATE, V13, P175, DOI 10.1093/humupd/dml042; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; He XY, 2005, MOL CELL ENDOCRINOL, V229, P111, DOI 10.1016/j.mce.2004.08.011; Herd MB, 2007, PHARMACOL THERAPEUT, V116, P20, DOI 10.1016/j.pharmthera.2007.03.007; Hogervorst Eef, 2008, Evid Based Med, V13, P71, DOI 10.1136/ebm.13.3.71; Kask K, 2008, PSYCHOPHARMACOLOGY, V199, P161, DOI 10.1007/s00213-008-1150-7; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Lanctot KL, 2007, INT PSYCHOGERIATR, V19, P151, DOI 10.1017/S1041610206003899; Leichtnam ML, 2006, PHARM RES-DORDR, V23, P1117, DOI 10.1007/s11095-006-0072-5; Lethaby A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003122.pub2; Li R, 2000, J NEUROCHEM, V75, P1447, DOI 10.1046/j.1471-4159.2000.0751447.x; Lin HK, 2004, STEROIDS, V69, P795, DOI 10.1016/j.steroids.2004.09.014; Liu XA, 2008, NEUROCHEM RES, V33, P1811, DOI 10.1007/s11064-008-9638-4; LOWE SL, 1988, BRAIN, V111, P785, DOI 10.1093/brain/111.4.785; Lu PH, 2006, ARCH NEUROL-CHICAGO, V63, P177, DOI 10.1001/archneur.63.2.nct50002; Manly JJ, 2000, NEUROLOGY, V54, P833, DOI 10.1212/WNL.54.4.833; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; MOUNTJOY CQ, 1984, BRAIN, V107, P507, DOI 10.1093/brain/107.2.507; Mulnard RA, 2005, ANN NY ACAD SCI, V1052, P173, DOI 10.1196/annals.1347.014; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Penning TM, 2003, J STEROID BIOCHEM, V85, P247, DOI 10.1016/S0960-0760(03)00236-X; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pike CJ, 2006, ENDOCRINE, V29, P233, DOI 10.1385/ENDO:29:2:233; Pluchino N, 2006, J STEROID BIOCHEM, V102, P205, DOI 10.1016/j.jsbmb.2006.09.023; REINIKAINEN KJ, 1988, J NEUROL SCI, V84, P101, DOI 10.1016/0022-510X(88)90179-7; Rosario ER, 2006, J NEUROSCI, V26, P13384, DOI 10.1523/JNEUROSCI.2514-06.2006; Rosario ER, 2004, JAMA-J AM MED ASSOC, V292, P1431, DOI 10.1001/jama.292.12.1431-b; ROSARIO ER, 2009, NEUROBIOL AGING; ROSSOR MN, 1982, BRAIN, V105, P313, DOI 10.1093/brain/105.2.313; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; THIGPEN AE, 1993, J CLIN INVEST, V92, P903, DOI 10.1172/JCI116665; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; van Wingen G, 2007, J NEUROSCI, V27, P11416, DOI 10.1523/JNEUROSCI.1715-07.2007; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054	85	65	67	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	NOV	2011	32	11					1964	1976		10.1016/j.neurobiolaging.2009.12.014			13	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	824RV	WOS:000295220700005	20045216				2021-06-18	
J	Chen, YH; Kang, JH; Lin, HC				Chen, Yi-Hua; Kang, Jiunn-Horng; Lin, Herng-Ching			Patients With Traumatic Brain Injury Population-Based Study Suggests Increased Risk of Stroke	STROKE			English	Article						Traumatic brain injury; stroke; epidemiology	ISCHEMIC-STROKE; REHABILITATION; EPIDEMIOLOGY; ADULTS	Background and Purpose-Previous studies have identified an array of morbidities following traumatic brain injury (TBI), including certain neurological disorders. However, no direct evidence has been reported on the link between TBI and stroke. This population-based study was designed to estimate the risk of stroke during a period of 5 years following a TBI, compared with individuals who did not suffer TBI during the same period. Methods-Data were obtained from the Longitudinal Health Insurance Database 2000 (LHID 2000). A total of 23 199 patients receiving ambulatory or hospitalization care with a diagnosis of TBI were included, together with 69 597 non-TBI patients as our comparison group, matched by sex, age, and year of index use of health care. Each individual was followed for 5 years to identify subsequent occurrence of stroke. Cox proportional hazard regressions were performed for analysis. Results-During the 3-month follow-up period, 675 strokes (2.91%) occurred in TBI patients and in 207 patients (0.30%) in the non-TBI comparison cohort. A diagnosis of TBI was independently associated with a 10.21 (95% CI, 8.71-11.96), 4.61 (95% CI, 4.16-5.11), and 2.32 (95% CI, 2.17-2.47) times greater risk of stroke during 3-month, 1-year, and 5-year follow-up, respectively, after adjusting for sociodemographic characteristics and selected comorbidities. The risk of intracerebral hemorrhage was more noticeable among patients with TBI compared with those without a TBI. Conclusions-This is the first report showing an increased risk of stroke among individuals who have sustained a TBI. We suggest a need for more intensive medical monitoring and health education following TBI, especially during the first few months and years. (Stroke. 2011; 42: 2733-2739.)	[Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei 110, Taiwan; [Chen, Yi-Hua] Taipei Med Univ, Sch Publ Hlth, Taipei 110, Taiwan; Taipei Med Univ, Coll Med, Sch Med, Dept Phys Med & Rehabil, Taipei 110, Taiwan; Taipei Med Univ Hosp, Neurosci Res Ctr, Taipei, Taiwan	Lin, HC (corresponding author), Taipei Med Univ, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.	henry11111@tmu.edu.tw					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1016/S0003-9993(00)90137-0; Borsheim E, 2007, ARCH PHYS MED REHAB, V88, P234, DOI 10.1016/j.apmr.2006.11.003; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chen YC, 2011, SCIENTOMETRICS, V86, P365, DOI 10.1007/s11192-010-0289-2; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gill SS, 2005, BMJ-BRIT MED J, V330, P445, DOI 10.1136/bmj.38330.470486.8F; Glenn MB, 2010, J HEAD TRAUMA REHAB, V25, P68, DOI 10.1097/HTR.0b013e3181be1eab; Graham DI, 2000, HEAD INJURY; GURURAJ G, 2004, NEUROTRAUMA REGISTRY; Herrmann N, 2004, AM J PSYCHIAT, V161, P1113, DOI 10.1176/appi.ajp.161.6.1113; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kang JH, 2011, STROKE, V42, P336, DOI 10.1161/STROKEAHA.110.595538; Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2; KRAUS J, 2004, NEUROEPIDEMIOLOGY PR; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeonCarrion J, 2006, STUD NEUROPSYCH DEV, P1; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; Romero Jose Rafael, 2008, Ther Adv Cardiovasc Dis, V2, P287, DOI 10.1177/1753944708093847; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan Teng-Yeow, 2002, Chang Gung Med J, V25, P458; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; TORNER J, 1999, TRAUMATIC BRAIN INJU; VITAL M, 2002, NIH PUBLICATION; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yasseen B, 2008, BRAIN INJURY, V22, P752, DOI 10.1080/02699050802320132	38	65	65	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2011	42	10					2733	2739		10.1161/STROKEAHA.111.620112			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	824QM	WOS:000295217100021	21799162	Bronze			2021-06-18	
J	Tran, HT; Sanchez, L; Esparza, TJ; Brody, DL				Tran, Hien T.; Sanchez, Laura; Esparza, Thomas J.; Brody, David L.			Distinct Temporal and Anatomical Distributions of Amyloid-beta and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; INTRANEURONAL A-BETA-42 ACCUMULATION; ALZHEIMERS-DISEASE; A-BETA; PRECURSOR-PROTEIN; HEAD-INJURY; PLAQUE-FORMATION; GAMMA-SECRETASE; DOWN-SYNDROME; MOUSE MODEL	Traumatic brain injury TBI is a major environmental risk factor for Alzheimer's disease. Intracellular accumulations of amyloid-beta and tau proteins have been observed within hours following severe TBI in humans. Similar abnormalities have been recapitulated in young 3xTg-AD mice subjected to the controlled cortical impact model (CCI) of TBI and sacrificed at 24 h and 7 days post injury. This study investigated the temporal and anatomical distributions of amyloid-beta and tau abnormalities from 1 h to 24 h post injury in the same model. Intra-axonal amyloid-beta accumulation in the fimbria was detected as early as 1 hour and increased monotonically over 24 hours following injury. Tau immunoreactivity in the fimbria and amygdala had a biphasic time course with peaks at 1 hour and 24 hours, while tau immunoreactivity in the contralateral CA1 rose in a delayed fashion starting at 12 hours after Injury Furthermore, rapid intra-axonal amyloid-beta accumulation was similarly observed post controlled cortical injury in APP/PS1 mice, another transgenic Alzheimer's disease mouse model. Acute increases in total and phospho-tau imunoreactivity were also evident in single transgenic Tau(p301L) mice subjected to controlled cortical injury. These data provide further evidence for the causal effects of moderately severe contusional TBI on acceleration of acute Alzheimer-related abnormalities and the independent la on hip between a amyloid-beta and tau in this setting.	[Tran, Hien T.; Sanchez, Laura; Esparza, Thomas J.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63130 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO USA	Tran, HT (corresponding author), Washington Univ, Dept Neurol, St Louis, MO 63130 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069 (Brody), K08 NS049237 (Brody)]; Burroughs Wellcome Career AwardBurroughs Wellcome Fund; Biomedical Sciences (Brody); Thrasher Research Fund (Brody); Washington University Office of Undergraduate Research Award (Sanchez); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R01NS065069] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS065069 (Brody), NIH K08 NS049237 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (Brody), the Thrasher Research Fund (Brody), and a Washington University Office of Undergraduate Research Award (Sanchez). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chui DH, 1999, NAT MED, V5, P560; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mastrangelo MA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-81; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Osawa S, 2008, J BIOL CHEM, V283, P19283, DOI 10.1074/jbc.M705954200; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Winton MJ, 2011, J NEUROSCI, V31, P7691, DOI 10.1523/JNEUROSCI.6637-10.2011; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	46	65	67	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2011	6	9							e25475	10.1371/journal.pone.0025475			8	Multidisciplinary Sciences	Science & Technology - Other Topics	834DM	WOS:000295939600028	21980472	DOAJ Gold, Green Published			2021-06-18	
J	Cloots, RJH; van Dommelen, JAW; Nyberg, T; Kleiven, S; Geers, MGD				Cloots, R. J. H.; van Dommelen, J. A. W.; Nyberg, T.; Kleiven, S.; Geers, M. G. D.			Micromechanics of diffuse axonal injury: influence of axonal orientation and anisotropy	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury (TBI); Diffuse axonal injury (DAI); Brain tissue; Finite element model; Cellular mechanics; Axons; Neurons	PREFRONTAL CORTEX; PYRAMIDAL NEURONS; SIMPLE ELONGATION; LARGE-DEFORMATION; WHITE-MATTER; BRAIN-INJURY; HEAD-INJURY; SOMAL SIZE; MODEL; SCHIZOPHRENIA	Multiple length scales are involved in the development of traumatic brain injury, where the global mechanics of the head level are responsible for local physiological impairment of brain cells. In this study, a relation between the mechanical state at the tissue level and the cellular level is established. A model has been developed that is based on pathological observations of local axonal injury. The model contains axons surrounding an obstacle (e.g., a blood vessel or a brain soma). The axons, which are described by an anisotropic fiber-reinforced material model, have several physically different orientations. The results of the simulations reveal axonal strains being higher than the applied maximum principal tissue strain. For anisotropic brain tissue with a relatively stiff inclusion, the relative logarithmic strain increase is above 60%. Furthermore, it is concluded that individual axons oriented away from the main axonal direction at a specific site can be subjected to even higher axonal strains in a stress-driven process, e.g., invoked by inertial forces in the brain. These axons can have a logarithmic strain of about 2.5 times the maximum logarithmic strain of the axons in the main axonal direction over the complete range of loading directions. The results indicate that cellular level heterogeneities have an important influence on the axonal strain, leading to an orientation and location-dependent sensitivity of the tissue to mechanical loads. Therefore, these effects should be accounted for in injury assessments relying on finite element head models.	[Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands; [Nyberg, T.; Kleiven, S.] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, S-14152 Huddinge, Sweden	van Dommelen, JAW (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	j.a.w.v.dommelen@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351	Dutch Technology Foundation STW, applied science division of NWOTechnologiestichting STWNetherlands Organization for Scientific Research (NWO); Ministry of Economic Affairs	This work has been supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs.	Abolfathi N, 2009, COMPUT METHOD BIOMEC, V12, P249, DOI [10.1080/10255840802430587, 10.1080/10255840903097871]; Alberts B, 1994, MOL BIOL CELL; ALBSHARAT AS, 1999, STAPP CAR CRASH C P, V43; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Braitenberg V., 1998, CORTEX STAT GEOMETRY; BRANDS DWA, 2002, STAPP CAR CRASH C P, V46; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; ETOH A, 1994, JPN J APPL PHYS 1, V33, P2874, DOI 10.1143/JJAP.33.2874; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDMAN DE, 1956, J ACOUST SOC AM, V28, P35, DOI 10.1121/1.1908216; Highley JR, 2003, BRIT J PSYCHIAT, V183, P414, DOI 10.1192/bjp.183.5.414; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hutsler JJ, 2003, BRAIN LANG, V86, P226, DOI 10.1016/S0093-934X(02)00531-X; Karami G, 2009, J MECH BEHAV BIOMED, V2, P243, DOI 10.1016/j.jmbbm.2008.08.003; Khoshgoftar Mehdi, 2007, American Journal of Applied Sciences, V4, P918, DOI 10.3844/ajassp.2007.918.924; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; Lauret C, 2009, MED ENG PHYS, V31, P392, DOI 10.1016/j.medengphy.2008.05.004; LIN S, 1997, P CTR DIS CONTR WAYN, P27; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Marieb E. N., 1998, HUMAN ANATOMY PHYSL; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; NOLTE J, 2002, HUMAN BRAIN INTRO IT; Pierri JN, 2001, ARCH GEN PSYCHIAT, V58, P466, DOI 10.1001/archpsyc.58.5.466; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2000, STAPP CAR CRASH C P, V44; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Roberts VL, 1976, HDB HUMAN TOLERANCE; *SIM, 2008, AB 6 8 MAN; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAKHOUNTS EG, 2003, STAPP CAR CRASH C P, V47; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; VERSACE J, 1971, STAPP CAR CRASH C P, V15	47	65	68	1	23	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959			BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JUN	2011	10	3					413	422		10.1007/s10237-010-0243-5			10	Biophysics; Engineering, Biomedical	Biophysics; Engineering	762NP	WOS:000290486600011	20635116	Other Gold			2021-06-18	
J	Leblanc, E; Trensz, F; Haroun, S; Drouin, G; Bergeron, E; Penton, CM; Montanaro, F; Roux, S; Faucheux, N; Grenier, G				Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Bergeron, Eric; Penton, Christopher M.; Montanaro, Federica; Roux, Sophie; Faucheux, Nathalie; Grenier, Guillaume			BMP-9-Induced Muscle Heterotopic Ossification Requires Changes to the Skeletal Muscle Microenvironment	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						MUSCLE RESIDENT STROMAL CELLS; SCA1; MUSCLE DAMAGE; mu CT SCAN; ALK1	SPINAL-CORD-INJURY; ENDOTHELIAL-CELLS; SATELLITE CELLS; BONE; DIFFERENTIATION; PROGRESSIVA; IDENTIFICATION; INDOMETHACIN; PREVENTION; EXPRESSION	Heterotopic ossification (HO) is defined as the formation of bone inside soft tissue. Symptoms include joint stiffness, swelling, and pain. Apart from the inherited form, the common traumatic form generally occurs at sites of injury in damaged muscles and is often associated with brain injury. We investigated bone morphogenetic protein 9 (BMP-9), which possesses a strong osteoinductive capacity, for its involvement in muscle HO physiopathology. We found that BMP-9 had an osteoinductive influence on mouse muscle resident stromal cells by increasing their alkaline phosphatase activity and bone-specific marker expression. Interestingly, BMP-9 induced HO only in damaged muscle, whereas BMP-2 promoted HO in skeletal muscle regardless of its state. The addition of the soluble form of the ALK1 protein (the BMP-9 receptor) significantly inhibited the osteoinductive potential of BMP-9 in cells and HO in damaged muscles. BMP-9 thus should be considered a candidate for involvement in HO physiopathology, with its activity depending on the skeletal muscle microenvironment. (C) 2011 American Society for Bone and Mineral Research.	[Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Grenier, Guillaume] Univ Sherbrooke, Fac Med, Dept Orthoped Surg, Sherbrooke, PQ J1H 5N4, Canada; [Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Grenier, Guillaume] Res Ctr Ageing, Sherbrooke, PQ, Canada; [Roux, Sophie; Faucheux, Nathalie; Grenier, Guillaume] Etienne Lebel Clin Res Ctr, Sherbrooke, PQ, Canada; [Bergeron, Eric; Faucheux, Nathalie] Univ Sherbrooke, Fac Engn, Dept Chem & Biotechnol Engn, Sherbrooke, PQ J1H 5N4, Canada; [Penton, Christopher M.; Montanaro, Federica] Nationwide Childrens Hosp, Res Inst, Ctr Gene Therapy, Columbus, OH USA; [Montanaro, Federica] Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Montanaro, Federica] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Roux, Sophie] Univ Sherbrooke, Fac Med, Dept Med, Sherbrooke, PQ J1H 5N4, Canada	Grenier, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Orthoped Surg, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	guillaume.grenier@usherbrooke.ca	Bergeron, Eric/G-6544-2011; Montanaro, Federica/E-3691-2011	Montanaro, Federica/0000-0002-3338-0498	Fondation pour la Recherche et l'Enseignement en Orthopedie de Sherbrooke (FREOS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec; National Science and Engineering Research of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI)Canada Foundation for Innovation; Cell and Tissue Therapy Network of FRSQ	We are grateful to Dr Anthony Scime for his critical reading of the manuscript. We thank Paul Oleynick for technical assistance with the MoFloCytometer as well as Nancy Charland at the Anatomopathology Service. EL received scholarships from the Fondation pour la Recherche et l'Enseignement en Orthopedie de Sherbrooke (FREOS) and the Canadian Institutes of Health Research (CIHR). GG received a New Investigator Award from Fonds de la Recherche en Sante du Quebec (FRSQ). This work was supported by grants from the CIHR, the National Science and Engineering Research of Canada (NSERC), the Canada Foundation for Innovation (CFI), and the Cell and Tissue Therapy Network of FRSQ.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Banovac K, 2001, SPINAL CORD, V39, P370, DOI 10.1038/sj.sc.3101166; Beiner JM, 2002, CLIN ORTHOP RELAT R, pS110, DOI 10.1097/01.blo.0000037969.69509.2c; Bergeron E, 2007, J MATER SCI-MATER M, V18, P255, DOI 10.1007/s10856-006-0687-4; Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Caron AZ, 2009, J APPL PHYSIOL, V106, P2049, DOI 10.1152/japplphysiol.91505.2008; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36; CHANTRAINE A, 1981, SCAND J REHABIL MED, V13, P31; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133; Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06-08-0693; CRAVEN PL, 1971, CLIN ORTHOP RELAT R, P231; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Depew Michael J., 2008, V461, P37, DOI 10.1007/978-1-60327-483-8_5; Egermann M, 2006, HUM GENE THER, V17, P507, DOI 10.1089/hum.2006.17.507; Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Grenier G, 2007, STEM CELLS, V25, P3101, DOI 10.1634/stemcells.2006-0795; Hosoyama T, 2009, DIFFERENTIATION, V77, P350, DOI 10.1016/j.diff.2008.11.001; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Kablar B, 1997, DEVELOPMENT, V124, P4729; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774-008-0879-8; Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437; King JB, 1998, BRIT J SPORT MED, V32, P287, DOI 10.1136/bjsm.32.4.287; KITISIN K, 2007, SCI STKE, V399; Kozlowski Piotr, 2004, Chir Narzadow Ruchu Ortop Pol, V69, P241; Lopez-Coviella I, 2006, BRAIN RES, V1088, P49, DOI 10.1016/j.brainres.2006.02.073; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; MOLLAN RAB, 1979, J BONE JOINT SURG BR, V61, P432; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Reddi AH, 2003, J BONE JOINT SURG AM, V85A, P3, DOI 10.2106/00004623-200300003-00002; Romano CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883-5403(03)00279-1; ROTHWELL AG, 1982, CLIN ORTHOP RELAT R, P97; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Scime A, 2010, MECH AGEING DEV, V131, P9, DOI 10.1016/j.mad.2009.11.001; Senta H, 2009, CYTOKINE GROWTH F R, V20, P213, DOI 10.1016/j.cytogfr.2009.05.006; Shehab D, 2002, J NUCL MED, V43, P346; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Teasell RW, 2010, SPINAL CORD, V48, P512, DOI 10.1038/sc.2009.175; Trensz F, 2010, AM J PHYSIOL-CELL PH, V299, pC939, DOI 10.1152/ajpcell.00253.2010; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; Walker MR, 2009, J PATHOL, V217, P169, DOI 10.1002/path.2474; WALTON M, 1983, CLIN ORTHOP RELAT R, P273; Wick L, 2005, EUR RADIOL, V15, P1867, DOI 10.1007/s00330-005-2769-y; Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917	55	65	69	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0884-0431			J BONE MINER RES	J. Bone Miner. Res.	JUN	2011	26	6					1166	1177		10.1002/jbmr.311			12	Endocrinology & Metabolism	Endocrinology & Metabolism	770SP	WOS:000291109100003	21611960				2021-06-18	
J	DuBose, JJ; Barmparas, G; Inaba, K; Stein, DM; Scalea, T; Cancio, LC; Cole, J; Eastridge, B; Blackbourne, L				DuBose, Joseph J.; Barmparas, Gallinos; Inaba, Kenji; Stein, Deborah M.; Scalea, Tom; Cancio, Leopoldo C.; Cole, John; Eastridge, Brian; Blackbourne, Lorne			Isolated Severe Traumatic Brain Injuries Sustained During Combat Operations: Demographics, Mortality Outcomes, and Lessons to be Learned From Contrasts to Civilian Counterparts	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Severe traumatic brain injury; Combat; Civilian; Outcomes	RECEIVING MASSIVE TRANSFUSIONS; CENTER DESIGNATION; PLASMA; GUIDELINES; MANAGEMENT; SURVIVAL; MODERATE; RATIO	Background: Severe traumatic brain injuries occurring in the context of modern military conflict are entities about which little has been reported. We reviewed the epidemiology of these injuries from the Joint Trauma Theater Registry (JTTR), contrasting these results with civilian counterparts from the National Trauma Databank (NTDB). Methods: Isolated severe brain injuries (defined as head abbreviated injury scale [AIS] >= 3 and no other body region AIS >2) were queried from the JTTR over a period from 2003 to 2007. The demographics and outcomes of these injuries were reviewed. These results were then contrasted to findings of similar patients, age 18 years to 55 years, over the same period from the NTDB using propensity score matching derived from age, gender, systolic blood pressure, Glasgow Coma Scale, and AIS. Results: JTTR review identified 604 patients meeting study criteria, with a mean age of 25.7 years. Glasgow Coma Scale was <8 in 27.8%, and 98.0% were men. Hypotension at presentation was noted in 5.5%. Blast (61.9%) and gunshot wound (19.5%) mechanisms accounted for the majority of combat injuries. Intracranial pressure monitoring was used in 15.2%, and 27.0% underwent some form of operative cranial decompression, lobectomy, or debridement. When compared with matched civilian NTDB counterparts, JTTR patients were significantly more likely to undergo intracranial pressure monitoring (13.8% vs. 1.7%; p < 0.001) and operative neurosurgical intervention (21.5% vs. 7.2%; p < 0.001). Mortality was also significantly better among military casualties overall (7.7% vs. 21.0%; p < 0.001; odds ratio, 0.32 [0.16-0.61]) and particularly after penetrating mechanisms of injury (5.6% vs. 47.9%; p < 0.001; odds ratio, 0.07 [0.02-0.20]) compared with propensity score-matched NTDB counterparts. Conclusion: Patients sustaining severe traumatic brain injury during military operations represent a unique population. Comparison with civilian counterparts has inherent limitations but reveals higher rates of neurosurgical intervention performed after penetrating injuries and a corresponding improvement in survival. Many factors likely contribute to these findings, which highlight the need for additional research on the optimal management of penetrating brain injury.	[DuBose, Joseph J.; Stein, Deborah M.; Scalea, Tom] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Barmparas, Gallinos; Inaba, Kenji] Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma Surg & Surg Crit Care, Los Angeles, CA 90033 USA; [Cancio, Leopoldo C.; Cole, John; Eastridge, Brian; Blackbourne, Lorne] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA	DuBose, JJ (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, 22 S Greene St,Room T5R46, Baltimore, MD 21201 USA.	jdubose@umm.edu	INABA, KENJI/AAC-8532-2020	Stein, Deborah/0000-0003-3683-3963			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; BRIDGES E, 2010, AACN ADV CRIT CARE, V21, P278; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Brown JB, 2010, J TRAUMA, V69, P263, DOI 10.1097/TA.0b013e3181e5d72e; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Johannigman JA, 2008, CRIT CARE MED, V36, pS377, DOI 10.1097/CCM.0b013e31817e31e1; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	23	65	67	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2011	70	1					11	18		10.1097/TA.0b013e318207c563			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	707WD	WOS:000286320300006	21217475				2021-06-18	
J	Peiniger, S; Nienaber, U; Lefering, R; Braun, M; Wafaisade, A; Wutzler, S; Borgmann, M; Spinella, PC; Maegele, M				Peiniger, Sigune; Nienaber, Ulrike; Lefering, Rolf; Braun, Maximilian; Wafaisade, Arasch; Wutzler, Sebastian; Borgmann, Matthew; Spinella, Philip C.; Maegele, Marc		TR-DGU	Balanced massive transfusion ratios in multiple injury patients with traumatic brain injury	CRITICAL CARE			English	Article							FRESH-FROZEN PLASMA; RED-BLOOD-CELL; MORTALITY; COAGULOPATHY; SURVIVAL; REGISTRY; IMPACT; SCORE	Introduction: Retrospective studies have demonstrated a potential survival benefit from transfusion strategies using an early and more balanced ratio between fresh frozen plasma (FFP) concentration and packed red blood cell (pRBC) transfusions in patients with acute traumatic coagulopathy requiring massive transfusions. These results have mostly been derived from non-head-injured patients. The aim of the present study was to analyze whether a regime using a high FFP: pRBC transfusion ratio (FFP: pRBC ratio > 1:2) would be associated with a similar survival benefit in severely injured patients with traumatic brain injury (TBI) (Abbreviated Injury Scale (AIS) score, head >= 3) as demonstrated for patients without TBI requiring massive transfusion (>= 10 U of pRBCs). Methods: A retrospective analysis of severely injured patients from the Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie (TR-DGU) was conducted. Inclusion criteria were primary admission, age >= 16 years, severe injury (Injury Severity Score (ISS) >= 16) and massive transfusion (>= 10 U of pRBCs) from emergency room to intensive care unit (ICU). Patients were subdivided into patients with TBI (AIS score, head >= 3) and patients without TBI (AIS score, head < 3), as well as according to the transfusion ratio they had received: high FFP: pRBC ratio (FFP: pRBC ratio > 1:2) and low FFP: pRBC ratio (FFP: pRBC ratio <= 1:2). In addition, morbidity and mortality between the two groups were compared. Results: A total of 1,250 data sets of severely injured patients from the TR-DGU between 2002 and 2008 were analyzed. The mean patient age was 42 years, the majority of patients were male (72.3%), the mean ISS was 41.7 points (+/- 15.4 SD) and the principal mechanism of injury was blunt force trauma (90%). Mortality was statistically lower in the high FFP:pRBC ratio groups versus the low FFP: pRBC ratio groups, regardless of the presence or absence of TBI and across all time points studied (P < 0.001). The frequency of sepsis and multiple organ failure did not differ among groups, except for sepsis in patients with TBI who received a high FFP: pRBC ratio transfusion. Other secondary end points such as ventilator-free days, length of stay in the ICU and overall in-hospital length of stay differed significantly between the two study groups, but not when only data for survivors were analyzed. Conclusions: These results add more detailed knowledge to the concept of a high FFP:pRBC ratio during early aggressive resuscitation, including massive transfusion, to decrease mortality in severely injured patients both with and without accompanying TBI. Future research should be conducted with a larger number of patients to prove these results in a prospective study.	[Peiniger, Sigune; Braun, Maximilian; Wafaisade, Arasch; Wutzler, Sebastian; Maegele, Marc] Univ Witten Herdecke, CMMC, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Peiniger, Sigune; Nienaber, Ulrike; Lefering, Rolf; Braun, Maximilian; Wafaisade, Arasch; Maegele, Marc] Univ Witten Herdecke, CMMC, Inst Res Operat Med IFOM, D-51109 Cologne, Germany; [Borgmann, Matthew] San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA; [Spinella, Philip C.] CCMC, Dept Surg, Dept Pediat, Hartford, CT 06106 USA	Maegele, M (corresponding author), Univ Witten Herdecke, CMMC, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de	Borgman, Matthew A/L-9477-2015	Borgman, Matthew A/0000-0002-2008-7380			BJORKLIND A, 1977, ACTA PATH MICRO IM B, V85, P277; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; BORGMAN MA, VOX SANG IN PRESS; Borgman M, 2009, CRIT CARE MED, V37, pA264; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cotton BA, 2010, J TRAUMA, V69, pS33, DOI 10.1097/TA.0b013e3181e42411; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2010, BIOLOGICALS, V38, P72, DOI 10.1016/j.biologicals.2009.10.007; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Lefering R, 2009, EUR J TRAUMA EMERG S, V35, P437, DOI 10.1007/s00068-009-9122-0; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; MAUERSBERGER W, 1979, NEUROCHIRURGIA, V22, P68; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Nascimento B, 2010, CRIT CARE, V14, DOI 10.1186/cc8205; Pathak A, 2005, Neurol India, V53, P178; Perkins JG, 2008, CRIT CARE MED, V36, pS325, DOI 10.1097/CCM.0b013e31817e2ec5; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Popovsky MA, 2006, TRANSFUS APHER SCI, V34, P243, DOI 10.1016/j.transci.2006.01.005; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Stainsby D, 2006, TRANSFUS MED REV, V20, P273, DOI 10.1016/j.tmrv.2006.05.002; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Zehtabchi S, 2009, ACAD EMERG MED, V16, P371, DOI 10.1111/j.1553-2712.2009.00386.x	33	65	72	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2011	15	1							R68	10.1186/cc10048			9	Critical Care Medicine	General & Internal Medicine	742RJ	WOS:000288961900068	21342499	DOAJ Gold, Green Published			2021-06-18	
J	Hu, SL; Luo, HS; Li, JT; Xia, YZ; Li, L; Zhang, LJ; Meng, H; Cui, GY; Chen, Z; Wu, N; Lin, JK; Zhu, G; Feng, H				Hu, Sheng-Li; Luo, Hai-Shui; Li, Jiang-Tao; Xia, Yong-Zhi; Li, Lan; Zhang, Li-Jun; Meng, Hui; Cui, Gao-Yu; Chen, Zhi; Wu, Nan; Lin, Jiang-Kai; Zhu, Gang; Feng, Hua			Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells	CRITICAL CARE MEDICINE			English	Article						functional recovery; mesenchymal stem cells; spinal cord injury; transplantation; umbilical cord	IN-VITRO; STROMAL CELL; PROGENITOR CELLS; FEEDER LAYER; RODENT MODEL; DIFFERENTIATION; NEURONS; REGENERATION; EXPRESSION; THERAPY	Objective: Spinal cord injury results in loss of neurons, degeneration of axons, formation of glial scar, and severe functional impairment. Human umbilical cord mesenchymal stem cells can be induced to form neural cells in vitro. Thus, these cells have a potential therapeutic role for treating spinal cord injury. Design and Setting: Rats were randomly divided into three groups: sham operation group, control group, and human umbilical cord mesenchymal stem cell group. All groups were subjected to spinal cord injury by weight drop device except for sham group. Subjects: Thirty-six female Sprague-Dawley rats. Interventions: The control group received Dulbecco's modified essential media/nutrient mixture F-12 injections, whereas the human umbilical cord mesenchymal stem cell group undertook cells transplantation at the dorsal spinal cord 2 mm rostrally and 2 mm caudally to the injury site at 24 hrs after spinal cord injury. Measurements: Rats from each group were examined for neurologic function and contents of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and neurotrophin-3. Survival, migration, and differentiation of human umbilical cord mesenchymal stem cells, regeneration of axons, and formation of glial scar were also explored by using immunohistochemistry and immunofluorescence. Main Results: Recovery of hindlimb locomotor function was significantly enhanced in the human umbilical cord mesenchymal stem cells grafted animals at 5 wks after transplantation. This recovery was accompanied by increased length of neurofilament-positive fibers and increased numbers of growth cone-like structures around the lesion site. Transplanted human umbilical cord-mesenchymal stem cells survived, migrated over short distances, and produced large amounts of glial cell line-derived neurotrophic factor and neurotrophin-3 in the host spinal cord. There were fewer reactive astrocytes in both the rostral and caudal stumps of the spinal cord in the human umbilical cord-mesenchymal stem cell group than in the control group. Conclusions: Treatment with human umbilical cord mesenchymal stem cells can facilitate functional recovery after traumatic spinal cord injury and may prove to be a useful therapeutic strategy to repair the injured spinal cord. (Crit Care Med 2010; 38: 2181-2189)	[Hu, Sheng-Li; Luo, Hai-Shui; Li, Jiang-Tao; Xia, Yong-Zhi; Li, Lan; Zhang, Li-Jun; Meng, Hui; Cui, Gao-Yu; Chen, Zhi; Wu, Nan; Lin, Jiang-Kai; Zhu, Gang; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China	Hu, SL (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	fenghua8888@yahoo.com.cn		Chen, Zhi/0000-0002-8404-4937	National Natural Science Foundation of China, Peking, ChinaNational Natural Science Foundation of China (NSFC) [0330220, 30572167, 30872735]; Natural Science Foundation of Chong-Qing, Chong-Qing, ChinaNatural Science Foundation of Chongqing [2008BA5002]	This work was supported, in part, by grants from the National Natural Science Foundation of China, Peking, China (0330220, 30572167, 30872735), and from the Natural Science Foundation of Chong-Qing, Chong-Qing, China (2008BA5002).	Bailey MM, 2007, TISSUE ENG, V13, P2003, DOI 10.1089/ten.2006.0150; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Chang SA, 2008, STEM CELLS, V26, P1901, DOI 10.1634/stemcells.2007-0708; Civin CI, 2002, STEM CELLS, V20, P482, DOI 10.1634/stemcells.20-6-482; Conconi MT, 2006, INT J MOL MED, V18, P1089; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; FOKSEANG J, 1995, BRAIN RES, V689, P207, DOI 10.1016/0006-8993(95)00575-B; Freed CR, 2002, P NATL ACAD SCI USA, V99, P1755, DOI 10.1073/pnas.062039699; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678; Fu-Jiang C, 2009, CHINESE MED J-PEKING, V122, P225, DOI 10.3760/cma.j.issn.0366-6999.2009.02.021; Gao L, 2006, BLOOD CELL MOL DIS, V36, P322, DOI 10.1016/j.bcmd.2005.12.036; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hu SL, 2009, J CELL BIOCHEM, V108, P529, DOI 10.1002/jcb.22283; Jang YK, 2006, ANN HEMATOL, V85, P212, DOI 10.1007/s00277-005-0047-3; Jomura S, 2007, STEM CELLS, V25, P98, DOI 10.1634/stemcells.2006-0055; Kadner A, 2004, EUR J CARDIO-THORAC, V25, P635, DOI 10.1016/j.ejcts.2003.12.038; Kaltz N, 2008, STEM CELLS, V26, P2419, DOI 10.1634/stemcells.2008-0304; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277-004-0918-z; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Lim PAC, 2007, ANN ACAD MED SINGAP, V36, P49; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308; Ma L, 2005, CHINESE MED J-PEKING, V118, P1987; Marcus AJ, 2008, DIFFERENTIATION, V76, P130, DOI 10.1111/j.1432-0436.2007.00194.x; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004-0024; Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Rooney GE, 2009, TISSUE ENG PT A, V15, P3049, DOI [10.1089/ten.tea.2009.0045, 10.1089/ten.TEA.2009.0045]; Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004-0166; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Tuszynski MH, 2003, EXP NEUROL, V181, P47, DOI 10.1016/S0014-4886(02)00055-9; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007-1028; Willerth SM, 2008, ADV DRUG DELIVER REV, V60, P263, DOI 10.1016/j.addr.2007.08.028; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang ZY, 2009, STEM CELLS, V27, P126, DOI 10.1634/stemcells.2008-0456	56	65	81	0	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2010	38	11					2181	2189		10.1097/CCM.0b013e3181f17c0e			9	Critical Care Medicine	General & Internal Medicine	667YW	WOS:000283235400014	20711072				2021-06-18	
J	Lustenberger, T; Talving, P; Kobayashi, L; Inaba, K; Lam, L; Plurad, D; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Inaba, Kenji; Lam, Lydia; Plurad, David; Demetriades, Demetrios			Time course of coagulopathy in isolated severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Severe traumatic brain injury; Head injury severity; Coagulopathy; Time course	SEVERE HEAD-INJURY	Background: Time aspects of coagulopathy following severe traumatic brain injury (sTBI) are ill defined throughout the literature. Thus, the aim of this study was to evaluate the time course of coagulopathy following isolated sTBI and its relationship to in-hospital outcomes. Methods: Retrospective analysis of patients sustaining isolated sTBI (head AIS >= 3, extracranial injuries AIS < 3). TBI coagulopathy was defined as thrombocytopenia and/or elevated international normalised ratio (INR) and/or prolonged activated partial thromboplastin time (aPTT). Incidence, onset and duration of sTBI-coagulopathy and its impact on morbidity and mortality were analysed. Results: Overall, 45.7% (n = 127) of the 278 patients included developed coagulopathy. Coagulopathy occurred 23.1 +/- 2.2 h [range: 0.1-108.2 h (0-4.5 days)] post-admission with a mean duration of 68.0 +/- 7.4 h [range: 2.6-531.4 h (0.1-22.1 days)]. The time interval to onset of coagulopathy decreased significantly with increasing head injury severity (p = 0.015). Early coagulation abnormalities occurring within 12 h of admission along with markers of devastating head injury including head AIS 5, penetrating injury mechanism, subdural hematoma, and a low GCS on admission proved to be independent risk factors for mortality. Conclusions: The sTBI-associated coagulopathy may ensue as late as 5 days after injury with a prolonged duration (>72 h) in 30% of patients. Early coagulopathy occurring within 12 h after injury is a marker of increased morbidity and poor outcomes. Pertinent prolonged screening of this sequela is warranted. (C) 2010 Elsevier Ltd. All rights reserved.	[Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Inaba, Kenji; Lam, Lydia; Plurad, David; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, LAC USC Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Dept Surg,Los Angeles Cty Gen Hosp,LAC USC, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013; Talving, Peep/G-8621-2015	Talving, Peep/0000-0002-9741-2073			Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Lever A, 2007, BMJ-BRIT MED J, V335, P879, DOI 10.1136/bmj.39346.495880.AE; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	12	65	75	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2010	41	9					924	928		10.1016/j.injury.2010.04.019			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	634SL	WOS:000280605500009	20471013				2021-06-18	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Taymans, T; Vander Linden, C; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Geurts, Monique; Taymans, Tom; Vander Linden, Catharine; Smits-Engelsman, Bouwien C. M.; Sunaert, Stefan; Swinnen, Stephan P.			Brain-Behavior Relationships in Young Traumatic Brain Injury Patients: DTI Metrics are Highly Correlated with Postural Control	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; DTI; balance; children; neuroplasticity	DIFFUSION TENSOR IMAGES; WHITE-MATTER; HEAD-INJURY; CEREBELLAR ATROPHY; CORPUS-CALLOSUM; MILD; CHILDREN; BALANCE; MODERATE; ATLAS	Traumatic brain injury (TBI) is a major cause of impairment and functional disability in children and adolescents, including deterioration in fine as well as gross motor skills. The aim of this study was to assess deficits in sensory organization and postural ability in a young group of TBI patients versus controls by using quantitative force-platform recordings, and to test whether balance deficits are related to variation in structural properties of the motor and sensory white matter pathways. Twelve patients with TBI and 14 controls (aged 8-20 years) performed the Sensory Organisation Test (SOT) protocol of the EquiTest(R) (Neurocom). All participants were scanned using Diffusion Tensor Imaging (DTI) along with standard anatomical scans. Quantitative comparisons of DTI parameters (fractional anisotropy, axial and radial diffusivity) between TBI patients and controls were performed. Correlations between DTI parameters and SOT balance scores were determined. Findings revealed that the TBI group scored generally lower than the control group on the SOT, indicative of deficits in postural control. In the TBI group, reductions in fractional anisotropy were noted in the cerebellum, posterior thalamic radiation, and corticospinal tract. Degree of white matter deterioration was highly correlated with balance deficits. This study supports the view that DTI is a valuable tool for assessing the integrity of white matter structures and for selectively predicting functional motor deficits in TBI patients. Hum Brain Mapp 31:992-1002, 2010. (C) 2009 Wiley-Liss, Inc.	[Swinnen, Stephan P.] Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, B-3001 Heverlee, Belgium; [Leemans, Alexander] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff, S Glam, Wales; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Dept Radiol, Utrecht, Netherlands; [Vander Linden, Catharine] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Smits-Engelsman, Bouwien C. M.] Univ Profess, Breda, Netherlands; [Sunaert, Stefan] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium	Swinnen, SP (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, Tervuursevest 101, B-3001 Heverlee, Belgium.	stephan.swinnen@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Sunaert, Stefan/E-8031-2011	Leemans, Alexander/0000-0002-9306-6126; Sunaert, Stefan/0000-0002-1177-4680; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation - Flanders (FWO)FWO [7.0004.05]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	Support for this study was provided through a grant from the Research Programme of the Research Foundation - Flanders (FWO) (Levenslijn # 7.0004.05), as well as Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a PhD fellowship of the Research Foundation - Flanders (FWO).	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Arfanakis K, 2002, MAGNET RESON MED, V47, P354, DOI 10.1002/mrm.10046; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Boska MD, 2007, NEUROBIOL DIS, V26, P590, DOI 10.1016/j.nbd.2007.02.010; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Henderson S. E., 1992, MOVEMENT ASSESSMENT; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Hoon AH, 2002, NEUROLOGY, V59, P752, DOI 10.1212/WNL.59.5.752; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Kamali A, 2009, EUR RADIOL, V19, P1480, DOI 10.1007/s00330-009-1305-x; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, 17 ANN M INT SOC MAG, P3537; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SCHAECHTER JD, 2009, MICROSTRUCT IN PRESS; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sosin DM, 1996, BRAIN INJURY, V10, P47; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	65	65	65	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUL	2010	31	7					992	1002		10.1002/hbm.20911			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	622TT	WOS:000279689400005	19998364	Green Published			2021-06-18	
J	Syam, SS; Cote, MJ				Syam, Siddhartha S.; Cote, Murray J.			A location-allocation model for service providers with application to not-for-profit health care organizations	OMEGA-INTERNATIONAL JOURNAL OF MANAGEMENT SCIENCE			English	Article						Health care; Integer programming; Location-allocation; Simulated annealing	FACILITY LOCATION	In this paper, we develop and solve a model for the location and allocation of specialized health care services such as traumatic brain injury (TBI) treatment. The model is based on and applied to one of the Department of Veterans Affairs' integrated service networks. A cost minimization model with service proportion requirements is solved using simulated annealing. Large instances of the model with 100 candidate medical center locations and 15 open treatment units are solved in about 1000s. In order to test the real-world applicability of our model, an extensive managerial experiment is conducted using data derived from our health care setting. In this experiment, the effects of three critical factors: (1) degree of centralization of services, (2) the role of patient retention as a function of distance to a treatment unit, and (3) the geographic density of the patient population are investigated with respect to the important trade-off between the cost of providing service and the need to provide such service. Our analysis shows that all three factors of the experiment are both relevant and useful to decision-makers when selecting locations for their services. (C) 2009 Elsevier Ltd. All rights reserved.	[Syam, Siddhartha S.] Marquette Univ, Dept Management, Milwaukee, WI 53201 USA; [Cote, Murray J.] Univ Colorado Denver, Dept Med, Div Hlth Care Policy & Res, Aurora, CO 80045 USA	Syam, SS (corresponding author), Marquette Univ, Dept Management, Milwaukee, WI 53201 USA.	syams@mu.edu; murray.cote@ucdenver.edu			Department of Veterans Affairs (VA) Rehabilitation Research and Development (RR&D) Service through the VA RR&D Rehabilitation Outcomes Research Center at the Malcolm Randall VA Medical Center in Gainesville, FloridaUS Department of Veterans Affairs [B2610R]	This work was funded by the Department of Veterans Affairs (VA) Rehabilitation Research and Development (RR&D) Service through the VA RR&D Rehabilitation Outcomes Research Center at the Malcolm Randall VA Medical Center in Gainesville, Florida (Project #B2610R, W. Bruce Vogel, Principal Investigator).	Branas CC, 2000, HEALTH SERV RES, V35, P489; Cornuejols G., 1990, DISCRETE LOCATION TH; CRAINIC TG, 1993, TRANSPORT SCI, V27, P90, DOI 10.1287/trsc.27.2.90; DASKIN M, 2004, OPERATIONS RES HLTH; ERLENKOTTER D, 1978, OPER RES, V26, P992, DOI 10.1287/opre.26.6.992; FISHER ML, 1985, INTERFACES, V15, P10, DOI 10.1287/inte.15.2.10; Garey M.R., 1979, COMPUTERS INTRACTABI; Geoffrion M., 1974, LAGRANGEAN RELAXATIO, P82, DOI DOI 10.1007/BFB0120690; Harper PR, 2005, OMEGA-INT J MANAGE S, V33, P141, DOI 10.1016/j.omega.2004.03.011; KIRPATRICK S, 1983, SCIENCE, V220, P671; Knuth D. E, 1997, ART COMPUTER PROGRAM, V3; Mehrez A, 1996, J OPER RES SOC, V47, P612, DOI 10.2307/3010013; Muppani VR, 2008, OMEGA-INT J MANAGE S, V36, P609, DOI 10.1016/j.omega.2007.01.006; Olson D.L., 1996, DECISION AIDS SELECT; PIERSKALLA WP, 1989, REV OPERATIONS RES I; PRICE WL, 1986, INTERFACES, V16, P17, DOI 10.1287/inte.16.5.17; Schrage LE., 1997, OPTIMIZATION MODELIN; SCHWEIKHART SB, 1993, SOCIO ECON PLAN SCI, V27, P289, DOI 10.1016/0038-0121(93)90021-A; Scniederjans M.J., 1995, GOAL PROGRAMMING MET; SMITHDANIELS VL, 1988, DECISION SCI, V19, P889, DOI 10.1111/j.1540-5915.1988.tb00310.x; Stahl JE, 2005, MED DECIS MAKING, V25, P35, DOI 10.1177/0272989X04273137; Syam SS, 2002, COMPUT OPER RES, V29, P1173, DOI 10.1016/S0305-0548(01)00023-5; Wesolowsky GO., 1988, FACILITIES LOCATION	23	65	65	1	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0305-0483			OMEGA-INT J MANAGE S	Omega-Int. J. Manage. Sci.	JUN-AUG	2010	38	3-4					157	166		10.1016/j.omega.2009.08.001			10	Management; Operations Research & Management Science	Business & Economics; Operations Research & Management Science	539GH	WOS:000273241400005					2021-06-18	
J	Bigler, ED; Abildskov, TJ; Wilde, EA; McCauley, SR; Li, XQ; Merkley, TL; Fearing, MA; Newsome, MR; Scheibel, RS; Hunter, JV; Chu, ZL; Levin, HS				Bigler, Erin D.; Abildskov, Tracy J.; Wilde, Elisabeth A.; McCauley, Stephen R.; Li, Xiaoqi; Merkley, Tricia L.; Fearing, Michael A.; Newsome, Mary R.; Scheibel, Randall S.; Hunter, Jill V.; Chu, Zili; Levin, Harvey S.			Diffuse damage in pediatric traumatic brain injury: A comparison of automated versus operator-controlled quantification methods	NEUROIMAGE			English	Article							HUMAN CEREBRAL-CORTEX; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; MRI FINDINGS; SEGMENTATION; MODERATE; HIPPOCAMPAL; CHILDREN; ATROPHY; VOLUME	This investigation had two main objectives: 1) to assess the comparability Of volumes determined by operator-controlled image quantification with automated image analysis in evaluating atrophic brain changes related to traumatic brain injury (TBI) in children, and 2) to assess the extent of diffuse structural changes throughout the brain as determined by reduced volume of a brain Structure or region of interest (ROI). Operator-control led methods used ANALYZE (R) software for segmentation and tracing routines of pre-defined brain structures and Rots. For automated image analyses, the open-access FreeSurfer program was used. Sixteen children with moderate-to-severe TBI were compared to individually matched, typically developing control children and the Volumes of 18 brain structures and/or ROIs were compared between the two methods. Both methods detected atrophic changes but differed in the magnitude of the atrophic effect with the best agreement in subcortical Structures. The volumes of all brain structures/ROIs were smaller in the TBI group regardless of method used; overall effect size differences were minimal for caudate and putamen but moderate to large for all other measures. This is reflective of the diffuse nature of TBI and its widespread impact on structural brain integrity, indicating that both FreeSurfer and operator-control led methods can reliably assess cross-sectional volumetric changes in pediatric TBI. (C) 2010 Elsevier Inc. All rights reserved.	[Bigler, Erin D.; Abildskov, Tracy J.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Li, Xiaoqi; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Fearing, Michael A.] Hebrew SeniorLife, Dept Med Neuropyschol, Boston, MA USA; [Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin-bigler@byu.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; TIRR Foundation. Erin D. Bigler [1 R01 HD048946-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant NS-21889 awarded to Harvey S. Levin by the National Institutes of Health. We also acknowledge the generous Support of Mission Connect of the TIRR Foundation. Erin D. Bigler was partially supported by grant 1 R01 HD048946-01A.Z. We acknowledge the contribution of Stacey K. Martin and Jo Ann Petrie for assistance in manuscript preparation. We would also like to thank Paul Swank, PhD, for his helpful advice regarding statistical methodology. Finally, we thank the participants and their farnilies for their interest and involvement in this study.	Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bozzali M, 2008, MAGN RESON IMAGING, V26, P1065, DOI 10.1016/j.mri.2008.01.044; Cherbuin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005265; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; FILIPEK PA, 1995, CURR OPIN NEUROL, V8, P134, DOI 10.1097/00019052-199504000-00009; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Hasan KM, 2009, NEUROIMAGE, V48, P497, DOI 10.1016/j.neuroimage.2009.05.004; Hasan KM, 2009, NEURORADIOLOGY, V51, P201, DOI 10.1007/s00234-008-0492-5; JACK CR, 1995, MAGN RESON IMAGING, V13, P1057, DOI 10.1016/0730-725X(95)02013-J; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; Khan AR, 2008, NEUROIMAGE, V41, P735, DOI 10.1016/j.neuroimage.2008.03.024; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; LEHMANN M, 2009, NEUROIMAGE, DOI DOI 10.1016/J.NEUROIMAGE.200910.056; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Makris N, 2003, J COGNITIVE NEUROSCI, V15, P584, DOI 10.1162/089892903321662967; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MOREY RA, 2009, NEUROIMAGE, DOI DOI 10.1016/J.NEUROIMAGE.07.013; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; ROBB R, 1995, ANAL 3 DIMENSIONAL B; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shen L, 2009, HIPPOCAMPUS, V19, P588, DOI 10.1002/hipo.20613; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	56	65	65	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 15	2010	50	3					1017	1026		10.1016/j.neuroimage.2010.01.003			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	566YA	WOS:000275408200016	20060915				2021-06-18	
J	Staal, JA; Dickson, TC; Gasperini, R; Liu, Y; Foa, L; Vickers, JC				Staal, Jerome A.; Dickson, Tracey C.; Gasperini, Robert; Liu, Yao; Foa, Lisa; Vickers, James C.			Initial calcium release from intracellular stores followed by calcium dysregulation is linked to secondary axotomy following transient axonal stretch injury	JOURNAL OF NEUROCHEMISTRY			English	Article						calcineurin; diffuse axonal injury; intracellular calcium disruption; neuronal stretch injury; secondary axotomy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; IN-VITRO; CORTICAL-NEURONS; NEURITE OUTGROWTH; SODIUM-CHANNELS; GROWTH CONES; INFLUX; FK506; REORGANIZATION; TETRODOTOXIN	P>Acute axonal shear and stretch in the brain induces an evolving form of axonopathy and is a major cause of ongoing motor, cognitive and emotional dysfunction. We have utilized an in vitro model of mild axon bundle stretch injury, in cultured primary cortical neurons, to determine potential early critical cellular alterations leading to secondary axonal degeneration. We determined that transient axonal stretch injury induced an initial acute increase in intracellular calcium, principally derived from intracellular stores, which was followed by a delayed increase in calcium over 48 h post-injury (PI). This progressive and persistent increase in intracellular calcium was also associated with increased frequency of spontaneous calcium fluxes as well as cytoskeletal abnormalities. Additionally, at 48 h post-injury, stretch-injured axon bundles demonstrated filopodia-like sprout formation that preceded secondary axotomy and degeneration. Pharmacological inhibition of the calcium-activated phosphatase, calcineurin, resulted in reduced secondary axotomy (p < 0.05) and increased filopodial sprout length. In summary, these results demonstrate that stretch injury of axons induced an initial substantial release of calcium from intracellular stores with elevated intracellular calcium persisting over 2 days. These long-lasting calcium alterations may provide new insight into the earliest neuronal abnormalities that follow traumatic brain injury as well as the key cellular changes that lead to the development of diffuse axonal injury and secondary degeneration.	[Staal, Jerome A.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; Univ Tasmania, Menzies Res Inst, Wicking Dementia Res & Educ Ctr, Hobart, Tas 7001, Australia	Staal, JA (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Bag 29, Hobart, Tas 7001, Australia.	jerome.staal@utas.edu.au	Foa, Lisa/J-7781-2014; Gasperini, Rob/J-7804-2014; Vickers, James C/J-7464-2014	Foa, Lisa/0000-0003-4131-8341; Vickers, James C/0000-0001-5671-4879; Dickson, Tracey/0000-0002-9196-1661; Gasperini, Rob/0000-0001-6859-1247	Tasmanian Masonic Centenary Medical Research Foundation	The Tasmanian Masonic Centenary Medical Research Foundation supports Dr. Jerome Staal.	Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Blizzard CA, 2007, EUR J NEUROSCI, V26, P1100, DOI 10.1111/j.1460-9568.2007.05750.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; Dent EW, 2004, J NEUROSCI, V24, P3002, DOI 10.1523/JNEUROSCI.4963-03.2004; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; Dickson TC, 2007, NEUROREPORT, V18, P283, DOI 10.1097/WNR.0b013e3280143cdb; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Erez H, 2008, J COMP NEUROL, V507, P1019, DOI 10.1002/cne.21522; Gallo G, 1998, J NEUROSCI, V18, P5403; Hutchins BI, 2008, J NEUROSCI, V28, P143, DOI 10.1523/JNEUROSCI.4548-07.2008; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kamber D, 2009, EXP NEUROL, V219, P112, DOI 10.1016/j.expneurol.2009.05.004; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; Meaney DF, 2001, J NEUROSURG, V95, P1108; Prince D A, 1999, Adv Neurol, V79, P665; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Tang FJ, 2005, J NEUROSCI, V25, P6702, DOI 10.1523/JNEUROSCI.0871-05.2005; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Ziv NE, 1997, J NEUROSCI, V17, P3568	39	65	68	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2010	112	5					1147	1155		10.1111/j.1471-4159.2009.06531.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	551VZ	WOS:000274241900005	19968758	Bronze			2021-06-18	
J	Liu, Y; Figley, S; Spratt, SK; Lee, G; Ando, D; Surosky, R; Fehlings, MG				Liu, Yang; Figley, Sarah; Spratt, S. Kaye; Lee, Gary; Ando, Dale; Surosky, Richard; Fehlings, Michael G.			An engineered transcription factor which activates VEGF-A enhances recovery after spinal cord injury	NEUROBIOLOGY OF DISEASE			English	Article						SCI; ZFP-VEGF; Angiogenesis; Neuroprotection; Molecular therapy	ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; THERAPEUTIC ANGIOGENESIS; HINDLIMB ISCHEMIA; GENE-TRANSFER; NEUROLOGICAL FUNCTION; NERVOUS-SYSTEM; BLOOD-FLOW; EXPRESSION; RAT	Spinal cord injury (SCI) leads to local vascular disruption and progressive ischemia, which contribute to secondary degeneration. Enhancing angiogenesis through the induction of vascular endothelial growth factor (VEGF)-A expression therefore constitutes an attractive therapeutic approach. Moreover. emerging evidence suggests that VEGF-A may also exhibit neurotrophic, neuroprotective, and neuroproliferative effects. Building on this previous work, we seek to examine the potential therapeutic benefits of an engineered zinc finger protein (ZFP) transcription factor designed to activate expression of all isoforms of endogenous VEGF-A (ZFP-VEGF). Administration of ZFP-VEGF resulted in increased VEGF-A mRNA and protein levels, an attenuation of axonal degradation, a significant increase in vascularity and decreased levels of apoptosis. Furthermore, ZFP-VEGF treated animals showed significant improvements in tissue preservation and neurobehavioural outcomes. These data suggest that activation of VEGF-A via the administration of an engineered ZFP transcription factor holds promise as a therapy for SCI and potentially other forms of neurotrauma. (c) 2009 Elsevier Inc. All rights reserved.	[Liu, Yang; Figley, Sarah; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Res Inst, Dept Genet & Dev, Toronto, ON, Canada; [Liu, Yang; Figley, Sarah; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Spinal Program, Toronto, ON, Canada; [Spratt, S. Kaye; Lee, Gary; Ando, Dale; Surosky, Richard] Sangamo BioSci, Dept Therapeut Dev, Richmond, CA USA; [Fehlings, Michael G.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Figley, Sarah; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	Fehlings, MG (corresponding author), Univ Toronto, Univ Hlth Network, Div Neurosurg, 399 Bathurst St,4WW 449, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364	Sangamo BioSciences; Krembil Chair in Neural Repair and Regeneration	The authors would like to thank Wendy Zhang for assistance with the histochemistry experiments, Jian Wang and Behzad Azad for their help with behavioural testing, Julio Furlan for assistance with data analysis and Allyson Tighe for her editorial reviews. This study was supported by Sangamo BioSciences and the Krembil Chair in Neural Repair and Regeneration (held by Dr. Michael G. Fehlings). The authors thank Philip Gregory and Edward Rebar of Sangamo BioSciences for scientific review.	Adris S, 2005, CELL MOL NEUROBIOL, V25, P1035, DOI 10.1007/s10571-005-8472-3; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Choi BH, 2007, J NEUROSURG-SPINE, V7, P54, DOI 10.3171/SPI-07/07/054; Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Larrivee B, 2000, INT J MOL MED, V5, P447; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YJ, 2007, DIABETES, V56, P656, DOI 10.2337/db06-0999; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Marti HH, 2002, ADV EXP MED BIOL, V513, P375; McMahon SS, 2009, J ANAT, V215, P267, DOI 10.1111/j.1469-7580.2009.01107.x; Price SA, 2006, DIABETES, V55, P1847, DOI 10.2337/db05-1060; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060; Xie DH, 2006, J VASC SURG, V44, P166, DOI 10.1016/j.jvs.2006.03.024; Yu J, 2006, FASEB J, V20, P479, DOI 10.1096/fj.04-3670fje; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	42	65	72	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2010	37	2			SI		384	393		10.1016/j.nbd.2009.10.018			10	Neurosciences	Neurosciences & Neurology	551QP	WOS:000274224400018	19879362				2021-06-18	
J	Smits, M; Dippel, DWJ; Nederkoorn, PJ; Dekker, HM; Vos, PE; Kool, DR; van Rijssel, DA; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Hunink, MGM				Smits, Marion; Dippel, Diederik W. J.; Nederkoorn, Paul J.; Dekker, Helena M.; Vos, Pieter E.; Kool, Digna R.; van Rijssel, Daphne A.; Hofman, Paul A. M.; Twijnstra, Albert; Tanghe, Herve L. J.; Hunink, M. G. Myriam			Minor Head Injury: CT-based Strategies for Management - A Cost-effectiveness Analysis	RADIOLOGY			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; EXTRADURAL HEMATOMA; RULE; RECOMMENDATIONS; SCALE; VALIDATION; ADMISSION	Purpose: To compare the cost-effectiveness of using selective computed tomographic (CT) strategies with that of performing CT in all patients with minor head injury (MHI). Materials and methods: The internal review board approved the study; written informed consent was obtained from all interviewed patients. Five strategies were evaluated, with CT performed in all patients with MHI; selectively according to the New Orleans criteria (NOC), Canadian CT head rule (CCHR), or CT in head injury patients ( CHIP) rule; or in no patients. A decision tree was used to analyze short-term costs and effectiveness, and a Markov model was used to analyze long-term costs and effectiveness. n-Way and probabilistic sensitivity analyses and value-of-information (VOI) analysis were performed. Data from the multicenter CHIP Study involving 3181 patients with MHI were used. Outcome measures were first-year and lifetime costs, quality-adjusted life-years, and incremental cost-effectiveness ratios. Results: Study results showed that performing CT selectively according to the CCHR or the CHIP rule could lead to substantial U. S. cost savings ($120 million and $71 million, respectively), and the CCHR was the most cost-effective at reference-case analysis. When the prediction rule had lower than 97% sensitivity for the identification of patients who required neurosurgery, performing CT in all patients was cost-effective. The CHIP rule was most likely to be cost-effective. At VOI analysis, the expected value of perfect information was $7 billion, mainly because of uncertainty about long-term functional outcomes. Conclusion: Selecting patients with MHI for CT renders cost savings and may be cost-effective, provided the sensitivity for the identification of patients who require neurosurgery is extremely high. Uncertainty regarding long-term functional outcomes after MHI justifies the routine use of CT in all patients with these injuries.	[Smits, Marion; van Rijssel, Daphne A.; Tanghe, Herve L. J.; Hunink, M. G. Myriam] Erasmus MC, Univ Med Ctr Rotterdam, Dept Radiol, NL-3000 CA Rotterdam, Netherlands; [Dippel, Diederik W. J.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [van Rijssel, Daphne A.; Hunink, M. G. Myriam] Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; [Nederkoorn, Paul J.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Dekker, Helena M.; Kool, Digna R.] Univ Med Ctr Nijmegen St Radboud, Dept Radiol, Nijmegen, Netherlands; [Vos, Pieter E.] Univ Med Ctr Nijmegen St Radboud, Dept Neurol, Nijmegen, Netherlands; [Hofman, Paul A. M.] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; [Twijnstra, Albert] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Hunink, MGM (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Radiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.hunink@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Vos, Pieter/A-6043-2012; Smits, Marion/E-4795-2011; Smits, Marion/AAB-3985-2019; Dekker, H.M./L-4262-2015	Dippel, Diederik/0000-0002-9234-3515; Smits, Marion/0000-0001-5563-2871; 	ZonMW (ZonMW DO)Netherlands Organization for Health Research and Development [945-06-309]; College voorZorgverzekeringen (CVZ) [VAZ 01-104]; Radiologisch onderzoek Nederland (RADION)	From the Departments of Radiology ( M. S., D. A. v. R., H.L.J.T., M. G. M. H.), Neurology (D.W.J.D.), and Epide miology & Biostatistics ( M. G. M. H., D. A. v. R.), Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Rotterdam, the Netherlands; Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands (P.J.N.); Departments of Radiology ( H. M. D., D. R. K.) and Neurology ( P. E. V.), University Medical Center Nijmegen St. Radboud, Nijmegen, the Netherlands; Departments of Radiology ( P. A. M. H.) and Neurology ( A. T.), University Hospital Maastricht, Maastricht, the Netherlands; and Department of Health Policy & Management, Harvard School of Public Health, Boston, Mass ( M. G. M. H.). Received September 18, 2008; revision requested December 12; revision received May 5, 2009; accepted May 27; final version accepted August 10. Supported by grants from ZonMW (ZonMW DO: 945-06-309) and by College voorZorgverzekeringen (CVZ: VAZ 01-104) and Radiologisch onderzoek Nederland (RADION). Address correspondence to M. G. M. H. (e-mail: m.hunink@erasmusmc.nl).	Ades AE, 2004, MED DECIS MAKING, V24, P207, DOI 10.1177/0272989X04263162; af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; AFGEIJERSTAM JL, 2003, ACTA NEUROCHIR WIEN, V145, P850; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *CENTR BUR STAT, STATLINE DAT; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; *COLL ZORGV, 2006, GUID PHARM EC RES; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; DEANDRADE AF, 2006, SURG NERUOL S1, V65; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; JENNETT B, 1975, LANCET, V1, P480; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; Miller J D, 1988, Brain Inj, V2, P83, DOI 10.3109/02699058809150934; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; *OAND, FXHISTORY HIST CURR; Ouwendijk R, 2005, RADIOLOGY, V236, P1094, DOI 10.1148/radiol.2363041140; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, J TRAUMA, V62, P1314, DOI 10.1097/TA.0b013e3180342959; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253	50	65	68	0	6	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2010	254	2					532	540		10.1148/radiol.2541081672			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	546QF	WOS:000273824600025	20093524	Bronze			2021-06-18	
J	Garden, N; Sullivan, KA				Garden, Natalie; Sullivan, Karen A.			An Examination of the Base Rates of Post-Concussion Symptoms: The Influence of Demographics and Depression	APPLIED NEUROPSYCHOLOGY			English	Article						base rates; depression; mild traumatic brain injury; neuropsychology; post-concussion syndrome	TRAUMATIC-BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; CHRONIC PAIN; STRESS; ADULTS	Post-concussion syndrome (PCS) is a controversial constellation of cognitive, emotional, and physical symptoms that some patients experience following a mild traumatic brain injury or concussion. PCS-like symptoms are commonly found in individuals with depression, pain, and stress, as well as healthy individuals. This study investigated the base rate of PCS symptoms in a healthy sample of 96 participants and examined the relationship between these symptoms, depression, and sample demographics. PCS symptoms were assessed using the British-Columbia Post-Concussion Symptom Inventory. Depression was measured using the Beck Depression Inventory II. Results demonstrated that: The base rate of PCS was very high; there was a strong positive relationship between depression and PCS; and demographic characteristics were not related to PCS in this sample. These findings are broadly consistent with literature suggesting a significant role for non-neurological factors in the expression of PCS symptomatology. This study adds to the growing body of literature that calls for caution in the clinical interpretation of results from PCS symptom inventories.	[Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Garden, Natalie] Queensland Univ Technol, Sch Psychol & Counseling, Clin Neuropsychol Res Grp, Brisbane, Qld 4001, Australia	Sullivan, KA (corresponding author), Queensland Univ Technol, Sch Psychol & Counseling, Clin Neuropsychol Res Grp, O Block B Wing Room 523,Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	karen.sullivan@qut.edu.au			School of Psychology and Counseling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (approval no. 0700000965) approved all research documented in this report. The authors wish to acknowledge the generous assistance of Dr. Patricia Obst, statistics consultant, School of Psychology and Counseling, Queensland University of Technology, and Dr. Rael T. Lange who contributed to early discussions about this manuscript. Funding for this project was provided by the School of Psychology and Counseling, Queensland University of Technology.	Anderson T, 2006, PRACT NEUROL, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Draguns JG, 2003, BEHAV RES THER, V41, P755, DOI 10.1016/S0005-7967(02)00190-0; GFELLER J, 1996, ASSESSMENT, V3, P393; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stonnington CM, 2001, BRAIN INJURY, V15, P561, DOI 10.1080/02699050110034316; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Sullivan K. A., J HEAD TRAU IN PRESS; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	36	65	65	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	1					1	7	PII 919154553	10.1080/09084280903297495			7	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	554JY	WOS:000274432500001	20146116				2021-06-18	
J	Kennedy, JE; Leal, FO; Lewis, JD; Cullen, MA; Amador, RR				Kennedy, Jan E.; Leal, Felix O.; Lewis, Jeffrey D.; Cullen, Maren A.; Amador, Ricardo R.			Posttraumatic stress symptoms in OIF/OEF service members with blast-related and non-blast-related mild TBI	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast injury; PTSD	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; US MILITARY; HEAD-INJURY; IRAQ WAR; DISORDER; AFGHANISTAN; SOLDIERS	Purpose: To examine the proportion and severity of stress-related symptoms in U. S. service members with mild traumatic brain injuries (mTBI) received during deployment to Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF). Stress-related symptoms reported by service members with mTBI from explosive munitions are compared to symptoms reported by those with mTBI received from other mechanisms (i.e. falls, motor vehicle accidents). Methods: Posttraumatic stress, as measured by scores on the Posttraumatic Stress Disorder Checklist (PCL-C), for a sample of 586 OIF/OEF service members with blast-related mTBI was compared to a sample of 138 OIF/OEF service members with non-blast mTBI selected from retrospective review of research records. Results: Re-experiencing symptoms such as flashbacks and nightmares were higher for the blast mTBI group than for the non-blast mTBI group. Symptoms on other PTSD clusters and total score did not significantly differ between groups. Equivalent proportions of the blast and non-blast groups endorsed severe PTSD symptoms, with total PCL-C scores greater than or equal to 50. Conclusions: Consistent with prior reports, high levels of posttraumatic stress symptoms occur in a substantial proportion of service members who experienced deployment-related blast and non-blast mTBI. Results suggest that the psychological rehabilitation of OIF/OEF service members with mTBI from explosive blast should include particular attention to addressing re-experiencing symptoms.	[Kennedy, Jan E.; Leal, Felix O.; Lewis, Jeffrey D.; Cullen, Maren A.; Amador, Ricardo R.] San Antonio Mil Med Ctr S, Def & Vet Brain Injury Ctr, Lackland AFB, TX 78236 USA	Kennedy, JE (corresponding author), San Antonio Mil Med Ctr S, Def & Vet Brain Injury Ctr, 59 MDOS SGO5N DVBIC,2200 Berquist Dr Suite 1, Lackland AFB, TX 78236 USA.	jan.kennedy@lackland.af.mil					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BREWIN CR, 2005, NEUROPSYCHOLOGY PTSD; Cahill S., 2007, HDB PTSD SCI PRACTIC; Centers for Disease C Prevention, 2006, MMWR-MORBID MORTAL W, V55, P201; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P1262, DOI 10.1038/jcbfm.2010.37; *DVBIC, 2008, DEF VET BRAIN INJ FA; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nixon RDV, 2005, J ANXIETY DISORD, V19, P587, DOI 10.1016/j.janxdis.2004.05.001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schell TL, 2004, J ABNORM PSYCHOL, V113, P189, DOI 10.1037/0021-843X.113.2.189; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; TANIELIAN T, 2008, RAND CORPORATION, P276; Vermetten E, 2002, DEPRESS ANXIETY, V16, P14, DOI 10.1002/da.10017; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEATHERS FW, 1993, PTSD CHECKLIST PCL D; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	38	65	65	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					223	231		10.3233/NRE-2010-0558			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300006	20448312				2021-06-18	
J	Maxwell, WL; MacKinnon, MA; Stewart, JE; Graham, DI				Maxwell, William L.; MacKinnon, Mary-Anne; Stewart, Janice E.; Graham, David I.			Stereology of cerebral cortex after traumatic brain injury matched to the Glasgow Outcome Score	BRAIN			English	Article						cortical neurons; head injury; stereology	WHITE-MATTER; DIFFUSION-TENSOR; HEAD-INJURY; LONGITUDINAL CHANGES; PROGRESSIVE ATROPHY; CORTICAL THICKNESS; CORPUS-CALLOSUM; THALAMIC NUCLEI; AXONAL INJURY; MODERATE	Magnetic resonance imaging provides evidence for loss of both white and grey matter, in terms of tissue volume, from the cerebral hemispheres after traumatic brain injury. However, quantitative histopathological data are lacking. From the archive of the Department of Neuropathology at Glasgow, the cerebral cortex of 48 patients was investigated using stereology. Patients had survived 3 months after traumatic brain injury and were classified using the Glasgow Outcome Scale as follows: moderately disabled (n = 13), severely disabled (n = 12) and vegetative state (n = 12); and controls. Some patients from the archive were diagnosed with diffuse axonal injury post-mortem. Comparisons of changes in cortical neuron population across Glasgow Outcome Scale groups between diffuse axonal injury and non-diffuse axonal injury patients were undertaken using effect size analyses. The hypotheses tested were that (i) thinning of the cerebral cortex occurred after traumatic brain injury; (ii) changes in thickness of cortical layers in Brodmann areas 11, 10, 24a and 4 differed; and (iii) different changes occurred for neuronal number, their size and nearest neighbour index across Glasgow Outcome Scale groups. There was a greater loss of large pyramidal and large non-pyramidal neurons with a more severe score on the Glasgow Outcome Scale from all four cortical regions, with the greatest loss of neurons from the prefrontal cortex of patients with diffuse axonal injury. There were differences in the changes of number of medium and small pyramidal and non-pyramidal neurons between different cortical regions, and between patients with and without diffuse axonal injury. Generally, a decrease in the somatic diameter of pyramidal and non-pyramidal neurons was associated with a more severe clinical outcome. However, in the motor cortex a more severe Glasgow Outcome Scale was associated with an increased diameter of medium pyramidal neurons and small non-pyramidal cells. Pyramidal and non-pyramidal neurons did not follow a Poisson distribution within the neuropil of control patients. Pyramidal neurons were usually scattered while medium and small non-pyramidal neurons were clustered. An increased spacing between remaining neurons usually occurred across Glasgow Outcome Scale groups. It is concluded that loss of neurons resulted in reduced executive and integrative capability in patients after traumatic head injury.	[Maxwell, William L.] Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [MacKinnon, Mary-Anne; Stewart, Janice E.; Graham, David I.] Univ Glasgow, Acad Unit Neuropathol, So Gen Hosp, Inst Neurol Sci, Glasgow G53 4TF, Lanark, Scotland	Maxwell, WL (corresponding author), Inst Biomed & Life Sci, Thomson Bldg,Gilmorehill, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk					*ABS, 2008, SURV DIS AG CAR DEF; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blinkov S. M., 1968, HUMAN BRAIN FIGURES; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Buxhoeveden DP, 2002, BRAIN, V125, P935, DOI 10.1093/brain/awf110; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; COE R, 2002, EFFECT SIZE CALCULAT; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Cossa FM, 1999, ITAL J NEUROL SCI, V20, P145, DOI 10.1007/s100720050024; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Diggle P, 1983, STAT ANAL SPATIAL PO, V1st; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; FARAONE SV, 2008, UNDERSTANDING EFFECT; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harrison PJ, 1995, NEUROSCI LETT, V200, P151, DOI 10.1016/0304-3940(95)12102-A; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; HOWARD CV, 1998, UNBIASED STEREOLOGY; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lewis DA, 2004, AM J PSYCHIAT, V161, P1366, DOI 10.1176/appi.ajp.161.8.1366; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408; MOUTON PR, 2002, PRINCIPLES PRACTICES; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; ONG WY, 1991, J ANAT, V175, P79; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Preul C, 2006, J MAGN RESON IMAGING, V24, P513, DOI 10.1002/jmri.20665; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; REILLY PL, 1975, LANCET, V2, P375; Rivara CB, 2003, ANAT REC PART A, V270A, P137, DOI 10.1002/ar.a.10015; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sasaki S, 2001, J ANAT, V199, P699, DOI 10.1046/j.1469-7580.2001.19960699.x; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCHLAUG G, 1995, J COMP NEUROL, V351, P441, DOI 10.1002/cne.903510310; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmitz C, 2002, CEREB CORTEX, V12, P954, DOI 10.1093/cercor/12.9.954; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Thomson AM, 2003, CEREB CORTEX, V13, P5, DOI 10.1093/cercor/13.1.5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; Woods TM, 2000, J NEUROSCI, V20, P3884; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	85	65	72	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2010	133		1				139	160		10.1093/brain/awp264			22	Clinical Neurology; Neurosciences	Neurosciences & Neurology	542KT	WOS:000273492800013	19897544	Bronze			2021-06-18	
J	Norrie, J; Heitger, M; Leathem, J; Anderson, T; Jones, R; Flett, R				Norrie, Joan; Heitger, Marcus; Leathem, Janet; Anderson, Tim; Jones, Richard; Flett, Ross			Mild traumatic brain injury and fatigue: A prospective longitudinal study	BRAIN INJURY			English	Article						Fatigue; mild traumatic brain injury; concussion; depression; anxiety; FSS; FAS; RPSQ; HADS; SF-36v2	POST-CONCUSSION SYMPTOMS; FORM HEALTH SURVEY; DEPRESSION SCALE; HOSPITAL ANXIETY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; MISERABLE MINORITY; SEVERITY SCALE; SURVEY SF-36; FOLLOW-UP	Primary objective: To examine fatigue prevalence, severity, predictors and co-variates over 6 months post-mild traumatic brain injury (MTBI). Research design: Longitudinal prospective study including 263 adults with MTBI. Procedures: Participants completed the Fatigue Severity Scale (FSS), Rivermead Post-concussion Symptoms Questionnaire (RPSQ), Hospital Anxiety and Depression Scale (HADS) and the Short Form 36 Health Survey-Version 2 (SF-36v2). Complete data were available for 159 participants. Key measures; prevalence-RPSQ Item 6: severity-FSS. The effect of time on fatigue prevalence and severity was examined using ANOVA. Multiple regression analysis identified statistically significant covariates. Main outcomes and results: Post-MTBI fatigue prevalence was 68%, 38% and 34% at 1 week, 3 and 6 months, respectively. There was a strong effect for time over the first 3 months and moderate-to-high correlations between fatigue prevalence and severity. Early fatigue strongly predicted later fatigue; depression, but not anxiety was a predictor. Fatigue was seen as laziness by family or friends in 30% of cases. Conclusions: Post-MTBI fatigue is a persistent post-concussion symptom, exacerbated by depression but not anxiety. It diminishes in the first 3 months and then becomes relatively stable, suggesting the optimum intervention placement is at 3 months or more post-MTBI.	[Norrie, Joan; Flett, Ross] Massey Univ, Dept Psychol, Palmerston North 4442, New Zealand; [Heitger, Marcus; Anderson, Tim; Jones, Richard] Univ Otago, Dept Med, Christchurch, New Zealand; [Heitger, Marcus; Anderson, Tim; Jones, Richard] Van der Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; [Leathem, Janet] Massey Univ, Dept Psychol, Wellington, New Zealand	Norrie, J (corresponding author), Massey Univ, Dept Psychol, PB 11222, Palmerston North 4442, New Zealand.	j.m.norrie@massey.ac.nz		Flett, Ross/0000-0002-3638-710X; Jones, Richard/0000-0003-2287-3358	Canterbury Medical Research Foundation (CMRF) [05/02]	The study was hosted by the Canterbury District Health Board and the University of Otago-Christchurch, New Zealand. Funding for participants' travel costs was provided by the Canterbury Medical Research Foundation (CMRF project number 05/02). We wish to thank these institutions for their support of this research.	Addington AM, 2001, PSYCHOL MED, V31, P1037, DOI 10.1017/S0033291701004214; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CAVALLO MM, 2005, TXB TRAUMATIC BRAIN, P533; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FUHRER R, 1995, PSYCHOL MED, V25, P895, DOI 10.1017/S0033291700037387; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; HEITGER MH, 2005, MILD HEAD INJURY USE; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hillier SL, 1997, BRAIN INJURY, V11, P661; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jason L A, 1999, J Health Psychol, V4, P9, DOI 10.1177/135910539900400103; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnear P., 2008, SPSS 15 MADE SIMPLE; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Krupp L.B., 2003, FATIGUE, V1st; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Martin CR, 2005, CURR PSYCHIATRY REV, V1, P69, DOI 10.2174/1573400052953510; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; *NZ GUID GROUP, 2006, ACC2404 NZ GUID GROU; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Rao V, 2005, TXB TRAUMATIC BRAIN, P369; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Russo J, 1998, MED CARE, V36, P752, DOI 10.1097/00005650-199805000-00015; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SCHONBERGER M, 2010, PSYCHIAT RE IN PRESS; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Stewart AL, 1992, MEASURING FUNCTIONIN; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang WR, 2006, QUAL LIFE RES, V15, P1525, DOI 10.1007/s11136-006-0012-1; Ware JE., 2000, SCORE VERSION 2 SF 3; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 INT STAT CLAS; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CM, 2005, QUAL LIFE RES, V14, P1357, DOI 10.1007/s11136-004-5680-0; ZASLER ND, 2005, BRAIN INJURY MED PRI; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	73	65	66	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1528	1538		10.3109/02699052.2010.531687			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800002	21058899				2021-06-18	
J	Singh, M; Jeong, J; Hwang, D; Sungkarat, W; Gruen, P				Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya; Gruen, Peter			Novel diffusion tensor imaging methodology to detect and quantify injured regions and affected brain pathways in traumatic brain injury	MAGNETIC RESONANCE IMAGING			English	Article						Diffusion tensor imaging; Tractography; Normalization; Traumatic brain injury	WHITE-MATTER INJURY; AXONAL INJURY; SPATIAL NORMALIZATION; HEAD TRAUMA; FIBER TRACKING; DTI-TRACTOGRAPHY; MRI; ABNORMALITIES; STRATEGIES; TRACTS	Purpose: To develop and apply diffusion tensor imaging (DTI)-based normalization methodology for the detection and quantification of sites of traumatic brain injury (TBI) and the impact of injury along specific brain pathways in (a) individual TBI subjects and (b) a TBI group. Materials and Methods: Normalized DTI tractography was conducted in the native space of 12 TBI and 10 age-matched control subjects using the same number of seeds in each subject, distributed at anatomically equivalent locations. Whole-brain tracts from the control group were mapped onto the head of each TBI subject. Differences in the fractional anisotropy (FA) maps between each TBI subject and the control group were computed in a common space using a t test, transformed back to the individual TBI subject's head space, and thresholded to form regions of interest (ROIs) that were used to sort tracts from the control group and the individual TBI subject. Tract counts for a given ROI in each TBI subject were compared to group mean for the same ROI to quantify the impact of injury along affected pathways. The same procedure was used to compare the TBI group to the control group in a common space. Results: Sites of injury within individual TBI subjects and affected pathways included hippocampal/fomix, inferior fronto-occipital, inferior longitudinal fasciculus, corpus callosum (genu and splenium), cortico-spinal tracts and the uncinate fasciculus. Most of these regions were also detected in the group study. Conclusions: The DTI normalization methodology presented here enables automatic delineation of ROIs within the heads of individual subjects (or in a group). These ROIs not only localize and quantify the extent of injury, but also quantify the impact of injury on affected pathways in an individual or in a group of TBI subjects. (C) 2010 Elsevier Inc. All rights reserved.	[Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya] Univ So Calif, Dept Radiol, Los Angeles, CA 90089 USA; [Singh, Manbir; Jeong, Jeongwon; Hwang, Darryl; Sungkarat, Witaya] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA; [Gruen, Peter] Univ So Calif, Dept Neurol Surg, Los Angeles, CA 90033 USA	Singh, M (corresponding author), Univ So Calif, Dept Radiol, Los Angeles, CA 90089 USA.	msingh@usc.edu	Hwang, Darryl/M-7221-2019	Hwang, Darryl/0000-0002-1111-9176	USA Medical Research and Material Command [W81XWH-07-1-0015]; TATRC; NIA-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG05142]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005142] Funding Source: NIH RePORTER	This research was supported by Contract No. W81XWH-07-1-0015 awarded by USA Medical Research and Material Command, TATRC, and partially supported by grant NIA-NIH P50 AG05142.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, HUM BRAIN MAPP, V9, P212, DOI 10.1002/(SICI)1097-0193(200004)9:4<212::AID-HBM3>3.0.CO;2-#; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CLAYDEN J, 2005, P ESMRMB 22 ANN M EU, P508; Clayden JD, 2006, NEUROIMAGE, V33, P482, DOI 10.1016/j.neuroimage.2006.07.016; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Dauguet J, 2007, NEUROIMAGE, V37, P530, DOI 10.1016/j.neuroimage.2007.04.067; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2002, NEUROIMAGE, V17, P592, DOI 10.1006/nimg.2002.1148; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2001, MAGN RESON MED, V46, P18, DOI 10.1002/mrm.1155; Mori S, 2000, ANN NEUROL, V47, P412, DOI 10.1002/1531-8249(200003)47:3<412::AID-ANA28>3.3.CO;2-8; Muller HP, 2007, PHYS MED BIOL, V52, pN99, DOI 10.1088/0031-9155/52/6/N01; Nair G, 2005, NEUROIMAGE, V28, P165, DOI 10.1016/j.neuroimage.2005.05.049; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2005, P SOC PHOTO-OPT INS, V5746, P138, DOI 10.1117/12.594721; SINGH M, 2008, P INT SOC MAG RESON, V16, P2269; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1961, LANCET, V2, P443; Tyszka JM, 2006, NEUROIMAGE, V29, P1058, DOI 10.1016/j.neuroimage.2005.08.037; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu DR, 2003, MAGN RESON MED, V50, P175, DOI 10.1002/mrm.10489; Zhang RL, 2003, NEUROSCIENCE, V116, P373, DOI 10.1016/S0306-4522(02)00696-6; Zhang T, 2008, 2008 IEEE INTERNATIONAL CONFERENCE ON VEHICULAR ELECTRONICS AND SAFETY, P1, DOI 10.1109/ISEE.2008.4562845	53	65	68	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	JAN	2010	28	1					22	40		10.1016/j.mri.2009.05.049			19	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	583BX	WOS:000276648600004	19608369	Green Accepted			2021-06-18	
J	Bell, JD; Park, E; Ai, J; Baker, AJ				Bell, J. D.; Park, E.; Ai, J.; Baker, A. J.			PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma	CELL DEATH AND DIFFERENTIATION			English	Article						AMPA; PICK1; trauma; GluR2; stretch; PKC alpha	PROTEIN-KINASE-C; GLUTAMATE-RECEPTOR SUBUNIT-2; AMPA RECEPTORS; BRAIN-INJURY; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELLS; PHOSPHORYLATION; POTENTIATION	Constitutive and activity-dependent regulation of the AMPA receptor GluR2 content is recognized as an important mediator of both neuronal plasticity and vulnerability to excitotoxic neuron death. In the latter case, inclusion of GluR2 protects against glutamate excitotoxicity in CNS disease by lowering receptor single-channel conductance and preventing deleterious calcium influx. We investigated the hypothesis that aberrations in GluR2 trafficking after in vitro and in vivo cerebral trauma contribute to excitotoxicity and associated calcium-dependent cell death processes. First, in an in vitro model of traumatic brain injury (TBI), we observed PICK1 and N-methyl-D-aspartic acid (NMDA) receptor-dependent phosphorylation and internalization of GluR2. The contributing cell signaling mechanisms involved enhanced binding between PKC alpha (the kinase that phosphorylates GluR2) and PICK1 (its PDZ-binding partner), and a novel protein interaction between PKC alpha and the NMDA receptor scaffolding protein PSD-95. Functionally, these phenomena enhanced single cell AMPAR mEPSCs and protracted calcium extrusion. In vivo TBI similarly promoted GluR2 phosphorylation and internalization, with enhanced expression of calcium-permeable AMPARs in the injured hippocampus. Peptide-mediated perturbation of the PKC alpha/PICK1 protein interaction after trauma preserved surface GluR2 expression, attenuated AMPAR-mediated toxicity, and occluded the sensitivity of neuronal physiology to calcium-permeable AMPAR antagonists. These findings suggest that experimental TBI promotes the expression of injurious GluR2-lacking AMPARs, thereby enhancing cellular vulnerability to secondary excitotoxicity. Cell Death and Differentiation (2009) 16, 1665-1680; doi: 10.1038/cdd.2009.106; published online 31 July 2009	[Baker, A. J.] St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; [Baker, A. J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Park, E.; Baker, A. J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Park, E.; Baker, A. J.] St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Baker, A. J.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5S 1A1, Canada; [Ai, J.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada	Baker, AJ (corresponding author), St Michaels Hosp, Dept Crit Care, 30 Bond St,7th Floor Bond Wing,Rm 088, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca			Ontario Neurotrauma Foundation; Heart and Stroke Foundation of OntarioHeart & Stroke Foundation of Ontario	We thank Elaine Liu for technical assistance with intravenous drug injections and Kevin Park for help with mathematical integration of calcium curves. We also thank Matthew Common for technical assistance. This work was supported by funding to AJB and JDB from the Ontario Neurotrauma Foundation and the Heart and Stroke Foundation of Ontario.	Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Borges K, 1998, PROG BRAIN RES, V116, P153, DOI 10.1016/S0079-6123(08)60436-7; Chung HJ, 2000, J NEUROSCI, V20, P7258; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Knapp LT, 2002, J NEUROSCI RES, V70, P1, DOI 10.1002/jnr.10371; Knapp LT, 2002, J NEUROSCI, V22, P674, DOI 10.1523/JNEUROSCI.22-03-00674.2002; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Leitges M, 2004, NEURON, V44, P585, DOI 10.1016/j.neuron.2004.10.024; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Lu YM, 1996, J NEUROSCI, V16, P5457; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noh KM, 2005, P NATL ACAD SCI USA, V102, P12230, DOI 10.1073/pnas.0505408102; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Perez JL, 2001, J NEUROSCI, V21, P5417; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rakhade SN, 2008, J NEUROSCI, V28, P7979, DOI 10.1523/JNEUROSCI.1734-08.2008; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Saglietti L, 2007, NEURON, V54, P461, DOI 10.1016/j.neuron.2007.04.012; Santos AE, 2006, CELL DEATH DIFFER, V13, P652, DOI 10.1038/sj.cdd.4401785; Seidenman KJ, 2003, J NEUROSCI, V23, P9220; Serulle Y, 2007, NEURON, V56, P670, DOI 10.1016/j.neuron.2007.09.016; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Terashima A, 2004, J NEUROSCI, V24, P5381, DOI 10.1523/JNEUROSCI.4378-03.2004; Terashima A, 2008, NEURON, V57, P872, DOI 10.1016/j.neuron.2008.01.028; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	37	65	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	DEC	2009	16	12					1665	1680		10.1038/cdd.2009.106			16	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	519QY	WOS:000271783600011	19644508	Bronze			2021-06-18	
J	Figaji, AA; Zwane, E; Thompson, C; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Thompson, Crispin; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			Brain tissue oxygen tension monitoring in pediatric severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Brain tissue oxygen tension; Outcome; Hypoxia; Children; Traumatic; Brain injury	SEVERE HEAD-INJURY; CEREBRAL OXYGENATION; COMPUTERIZED-TOMOGRAPHY; INTENSIVE-CARE; DELIVERY; SATURATION; PRESSURE; ISCHEMIA; THERAPY; DAMAGE	Introduction Intracranial pressure (ICP) monitoring and cerebral perfusion pressure (CPP) management are the current standards to guide care of severe traumatic brain injury (TBI). However, brain hypoxia and secondary brain injury can occur despite optimal ICP and CPP. In this study, we used brain tissue oxygen tension (PbtO(2)) monitoring to examine the association between multiple patient factors, including PbtO(2), and outcome in pediatric severe TBI. Materials and methods In this prospective observational study, 52 children (less than 15 years) with severe TBI were managed with continuous PbtO(2) and ICP monitoring. The relationships between outcome [Glasgow Outcome Score (GOS) and Pediatric Cerebral Performance Category Scale] and clinical, radiologic, treatment, and physiological variables, including PbtO(2), were examined using multiple logistic regression analysis. Results Outcome was favorable in 40 patients (77%) and unfavorable (mortality, 9.6%; n = 5) in 12 (23%). In univariate analysis, the following variables had a significant association with unfavorable outcome: initial GCS, computed tomography classification, ICP(peak), mICP(24), mICP, CPP(low), CPP(< 40), pupil reactivity, PbtO(2low), PbtO(2) < 5 mmHg, PbtO(2) < 10 mmHg, mPbtO(224), and time-severity product. PbtO(2) parameters had the strongest independent association with poor outcome in multiple regression analysis. In particular, when PbtO(2) was < 5 mmHg for > 1 h, the adjusted OR for poor outcome was 27.4 (95% confidence interval, 1.9-391). No variables apart from PbtO(2) were independently associated with mortality when controlled for PbtO(2). Conclusion Reduced PbtO(2) is shown to be an independent factor associated with poor outcome in pediatric severe TBI in the largest study to date. It appears to have a stronger association with outcome than conventionally evaluated measures.	[Figaji, Anthony A.; Thompson, Crispin; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Div Neurosurg, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Infect Dis Epidemiol Unit Biostat, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA	Figaji, AA (corresponding author), Univ Cape Town, Div Neurosurg, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Fieggen, Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; JENNETT B, 1975, LANCET, V1, P480; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; MALONEYWILENSKY E, 2009, CRIT CARE M IN PRESS; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P199; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SIMPSON D, 1982, LANCET, V2, P450; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZAUNER A, 1997, NEUROSURGERY, V41, P1091; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	45	65	67	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2009	25	10					1325	1333		10.1007/s00381-009-0822-x			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	494TE	WOS:000269838900021	19214532				2021-06-18	
J	Tan, G; Fink, B; Dao, TK; Hebert, R; Farmer, LS; Sanders, A; Pastorek, N; Gevirtz, R				Tan, Gabriel; Fink, Brandi; Dao, Tam K.; Hebert, Russell; Farmer, Lorie S.; Sanders, April; Pastorek, Nicholas; Gevirtz, Richard			Associations among Pain, PTSD, mTBI, and Heart Rate Variability in Veterans of Operation Enduring and Iraqi Freedom: A Pilot Study	PAIN MEDICINE			English	Article						Pain; PTSD; mTBI; Heart Rate Variability; Polytrauma	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; PSYCHOPHYSIOLOGICAL ASSESSMENT; CLINICAL-IMPLICATIONS; HEALTH; DYSAUTONOMIA; BIOFEEDBACK; PREDICTOR; DEATH	Objective. The objective of the study was to determine if there is dysregulated autonomic nervous system activity as manifested by depressed heart rate variability (HRV) among veterans of Operations Enduring and Iraqi Freedom (OEF/OIF). Participants and Setting. The study used a convenience sample of OEF/OIF veterans (n = 28) seen at a Level II Polytrauma Network Site at the Michael E. DeBakey VA Medical Center. Participants were similar to other OEF/OIF veterans who received care at this site. Design. Cross sectional study. Measures. Time domain analysis (standard deviation of beat-to-beat intervals [SDNN]) of HRV, diagnoses of mild traumatic brain injury and post-traumatic stress disorder (PTSD), and pain ratings from medical records. Results. As a group, the sample evidenced markedly depressed HRV (as reflected by SDNN) as compared with available age and gender corrected normative data. Pain (71%), PTSD (57%), and mild traumatic brain injury (mTBI) (64%) were prevalent. Thirty-six percent had all three measures (P3). Pain and P3 were significantly and negatively associated with SDNN (r = -0.460, P = 0.014; r = -0.373, P = 0.05, respectively). Conclusions. These preliminary findings support the high prevalence of depressed HRV and P3 among veterans seen in a level II Polytrauma Center. The findings also suggest a possible synergistic effect of pain, PTSD, and mTBI on depressed HRV. The nature and implications of these relationships require additional research to elucidate.	[Tan, Gabriel; Fink, Brandi; Dao, Tam K.; Hebert, Russell; Farmer, Lorie S.; Sanders, April; Pastorek, Nicholas] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Tan, Gabriel; Dao, Tam K.; Farmer, Lorie S.; Pastorek, Nicholas] Baylor Coll Med, Houston, TX 77030 USA; [Gevirtz, Richard] Alliant Int Univ, CSPP, San Diego, CA USA	Tan, G (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe 145, Houston, TX 77030 USA.	tan.gabriel@va.gov					Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; BENGE JF, 2009, 37 ANN M INT NEUR SO; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BLECHERT J, 1998, BIOL PSYCHIAT, V44, P1054; Bornstein MH, 2000, CHILD DEV, V71, P273, DOI 10.1111/1467-8624.00143; Carney RM, 2000, PSYCHOSOM MED, V62, P639, DOI 10.1097/00006842-200009000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CLARK ME, 2009, NAT VA PAIN MAN C E; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cohen H, 1997, BIOL PSYCHIAT, V41, P627, DOI 10.1016/S0006-3223(96)00525-2; COHEN JA, 2002, TRAUMA VIOLENCE ABUS, V3, P91, DOI DOI 10.1177/15248380020032001; GALER BS, 1995, J PAIN SYMPTOM MANAG, V10, P385, DOI 10.1016/0885-3924(95)00061-3; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; GIRONDA RJ, REHAB PSYCH IN PRESS; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Hassett AL, 2007, APPL PSYCHOPHYS BIOF, V32, P1, DOI 10.1007/s10484-006-9028-0; Helmer DA, 2007, J OCCUP ENVIRON MED, V49, P475, DOI 10.1097/JOM.0b013e318042d682; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hopper JW, 2006, J PSYCHOSOM RES, V60, P83, DOI 10.1016/j.jpsychores.2005.06.002; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; Karavidas M.K., 2008, BIOFEEDBACK, V36, P18; Lehrer PM, 2004, CHEST, V126, P352, DOI 10.1378/chest.126.2.352; McCraty R, 2001, BIOL PSYCHOL, V56, P131, DOI 10.1016/S0301-0511(01)00074-6; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; Orr SP, 2000, J AFFECT DISORDERS, V61, P225, DOI 10.1016/S0165-0327(00)00340-2; OTIS JD, 2008, COMPREHENSIVE HDB CL, P349; PITMAN RK, 1987, ARCH GEN PSYCHIAT, V44, P970; Porges SW, 1996, DEV PSYCHOBIOL, V29, P697, DOI 10.1002/(SICI)1098-2302(199612)29:8<697::AID-DEV5>3.0.CO;2-O; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RECHLIN T, 1994, J AFFECT DISORDERS, V32, P271, DOI 10.1016/0165-0327(94)90091-4; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Sahar T, 2001, BIOL PSYCHIAT, V49, P637, DOI 10.1016/S0006-3223(00)01045-3; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Umetani K, 1998, J AM COLL CARDIOL, V31, P593, DOI 10.1016/S0735-1097(97)00554-8; Van der Kolk BA, 2006, ANN NY ACAD SCI, V1071, P277, DOI 10.1196/annals.1364.022; Veterans Health Administration, 2005, VHA HDB; Weathers F., 1994, PTSD RES Q, V5, P2, DOI DOI 10.1037/E572192010-003; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010	53	65	66	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	OCT	2009	10	7					1237	1245		10.1111/j.1526-4637.2009.00712.x			9	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	504BT	WOS:000270589100009	19818034	Bronze			2021-06-18	
J	Doig, E; Fleming, J; Cornwell, PL; Kuipers, P				Doig, Emmah; Fleming, Jennifer; Cornwell, Petrea L.; Kuipers, Pim			Qualitative Exploration of a Client-Centered, Goal-Directed Approach to Community-Based Occupational Therapy for Adults With Traumatic Brain Injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						brain injuries; community health services; goals; patient participation; rehabilitation	SELF-IDENTIFIED GOALS; REHABILITATION PROCESS; AWARENESS; PEOPLE; STROKE; ACHIEVEMENT; DEFICITS; COMA	OBJECTIVES. We explored the clinical application of goal-directed therapy in community-based rehabilitation from the perspective of clients with traumatic brain injury (TBI), their significant others, and their treating occupational therapists. METHOD. Twelve people with TBI and their significant others completed an outpatient, goal-directed, 12-week occupational therapy program. Semistructured interviews with 12 participants, 10 significant others, and 3 occupational therapists involved in delivering the therapy programs explored their experiences of goal-directed therapy. RESULTS. Participants, their significant others, and therapists described goal-directed therapy positively, expressing satisfaction with progress made. CONCLUSION. Goals provide structure, which facilitates participation in rehabilitation despite the presence of barriers, including reduced motivation and impaired self-awareness. A therapist-facilitated, structured, goal-setting process in which the client, therapist, and significant others work in partnership can enhance the process of goal setting and goal-directed rehabilitation in a community rehabilitation context.	[Doig, Emmah] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4062, Australia	Doig, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4062, Australia.	emmah.doig@optusnet.com.au	Cornwell, Petrea/AAE-5547-2019; Doig, Emmah/AAG-6674-2021; Fleming, Jennifer M/B-4436-2011	Doig, Emmah/0000-0002-7020-053X; Kuipers, Pim/0000-0003-0340-2286			Barnes M, 2000, TXB REHABILITATION M; Bodiam C., 1999, BR J OCCUP THER, V62, P123, DOI DOI 10.1177/030802269906200310; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Doig EJ, 2008, BR J OCCUP THER, V71, P360, DOI DOI 10.1177/030802260807100902; EAMES J, 1999, BRIT J OCCUPATIONAL, V62, P257; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gagne DE, 2003, AM J OCCUP THER, V57, P215, DOI 10.5014/ajot.57.2.215; GAUGGEL S, 2004, HDB MOTIVATIONAL COU, P421; Jenkinson N, 2007, BRAIN INJURY, V21, P1283, DOI 10.1080/02699050701739531; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Kielhofner G, 1998, AM J OCCUP THER, V52, P345, DOI 10.5014/ajot.52.5.345; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kuipers P., 2004, BRAIN IMPAIR, V5, P30, DOI DOI 10.1375/BRIM.5.1.30.35404; Lannin Natasha, 2003, Occup Ther Health Care, V17, P43, DOI 10.1080/J003v17n01_04; Law M, 1991, CANADIAN OCCUPATIONA; Lawler J, 1999, J ADV NURS, V30, P401, DOI 10.1046/j.1365-2648.1999.01086.x; LEACH E, DISABILITY IN PRESS; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; MacLeod GM, 1996, SPINAL CORD, V34, P525, DOI 10.1038/sc.1996.95; MALEC JF, 1999, NEUROPSYCHOL REHABIL, V314, P253; Mason J., 2002, QUALITATIVE RES; McAndrew E., 1999, PHYS OCCUP THER GERI, V17, P55; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Patton M.Q., 2002, QUALITATIVE RES EVAL; Pedretti L. W., 1996, OCCUPATIONAL THERAPY, P3; Phipps S, 2007, AM J OCCUP THER, V61, P328, DOI 10.5014/ajot.61.3.328; Playford ED, 2000, CLIN REHABIL, V14, P491, DOI 10.1191/0269215500cr343oa; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reed KL., 1980, CONCEPTS OCCUPATIONA; Ritchie J, 2003, QUALITATIVE RES PRAC, P219, DOI DOI 10.4135/9781452230108; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; SCHUT HA, 1994, DISABIL REHABIL, V16, P223, DOI 10.3109/09638289409166616; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Spencer L., 2003, QUALITATIVE RES PRAC, P199; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Sumison T, 2004, BRIT J OCCUPATIONAL, V67, P2; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Wilson BA, 2002, J HEAD TRAUMA REHAB, V17, P542, DOI 10.1097/00001199-200212000-00006; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 1999, DISABIL REHABIL, V21, P80, DOI 10.1080/096382899298016	51	65	65	0	16	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5			SI		559	568		10.5014/ajot.63.5.559			10	Rehabilitation	Rehabilitation	493SG	WOS:000269757700006	19785255	Green Published, Bronze			2021-06-18	
J	Bjork, JM; Grant, SJ				Bjork, James M.; Grant, Steven J.			Does Traumatic Brain Injury Increase Risk for Substance Abuse?	JOURNAL OF NEUROTRAUMA			English	Article						addiction; closed-head injury; cognition; drug abuse; drug dependence; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; DECISION-MAKING; DRUG-USE; EMERGENCY-ROOM; IMPULSE CONTROL; COCAINE USERS; PRIMARY-CARE; ALCOHOL; DEFICITS	Wars in Afghanistan and Iraq have resulted in thousands of military personnel suffering traumatic brain injury (TBI), including closed-head injuries. Of interest is whether these individuals and other TBI survivors are at increased risk for substance use disorder (SUD). While it has been well established that drug or alcohol intoxication itself increases probability of suffering a TBI in accidents or acts of violence, little is known about whether the brain insult itself increases the likelihood that a previously non-drug-abusing individual would develop SUD. Might TBI survivors be unusually vulnerable to addiction to opiate analgesics compared to other pain patients? Similarly, it is not known if TBI increases the likelihood of relapse among persons with SUD in remission. We highlight challenges in answering these questions, and review neurochemical and behavioral evidence that supports a causal relationship between TBI and SUD. In this review, we conclude that little is known regarding the directionality of TBI increasing drug abuse, and that collaborative research in this area is critically needed.	[Bjork, James M.; Grant, Steven J.] Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, NIH, Bethesda, MD 20892 USA	Bjork, JM (corresponding author), Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, NIH, 6001 Execut Blvd,Room 3151, Bethesda, MD 20892 USA.	jbjork@mail.nih.gov	Bjork, James/Q-5108-2019	Bjork, James/0000-0003-0593-3291			Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cherpitel CJ, 2008, DRUG ALCOHOL DEPEN, V97, P226, DOI 10.1016/j.drugalcdep.2008.03.033; Cherpitel CJ, 2008, AM J DRUG ALCOHOL AB, V34, P576, DOI 10.1080/00952990802308189; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI 10.1016/j.coph.2006.11.003; Dixon MR, 2005, BEHAV INTERVENT, V20, P101, DOI 10.1002/bin.173; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Franulic A, 2000, BRAIN INJURY, V14, P431; Hester R, 2007, NEUROPSYCHOPHARMACOL, V32, P1974, DOI 10.1038/sj.npp.1301326; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kaufman JN, 2003, J NEUROSCI, V23, P7839; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Reynolds B, 2006, BEHAV PHARMACOL, V17, P651, DOI 10.1097/FBP.0b013e3280115f99; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schultz W, 2007, TRENDS NEUROSCI, V30, P203, DOI 10.1016/j.tins.2007.03.007; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Taylor SF, 2007, NEUROSCIENTIST, V13, P160, DOI 10.1177/1073858406298184; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vitale S, 2006, DRUG ALCOHOL DEPEN, V82, P1, DOI 10.1016/j.drugalcdep.2005.08.017; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087	50	65	65	0	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1077	1082		10.1089/neu.2008.0849			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500013	19203230	Green Published			2021-06-18	
J	Echegoyen, J; Armstrong, C; Morgan, RJ; Soltesz, I				Echegoyen, Julio; Armstrong, Caren; Morgan, Robert J.; Soltesz, Ivan			Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Epilepsy; Rimonabant; CB1	TEMPORAL-LOBE EPILEPSY; BRAIN-INJURY; RISK-FACTORS; EPILEPTOGENESIS; HIPPOCAMPUS; RIMONABANT; OVERWEIGHT; SEIZURES; DISEASE	Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have yielded no long-term antiepileptogenic effects. We report that a single, rapid post-traumatic application of the proconvulsant cannabinoid type-1 (CB1) receptor antagonist SR141716A (Rimonabant-Acomplia (R)) abolishes the long-term increase in seizure susceptibility caused by head injury in rats. These results indicate that, paradoxically, a seizure-enhancing drug may disrupt the epileptogenic process if applied within a short therapeutic time window. (C) 2009 Elsevier B.V. All rights reserved.	[Echegoyen, Julio; Armstrong, Caren; Morgan, Robert J.; Soltesz, Ivan] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Armstrong, C (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	cmarmstr@uci.edu	Armstrong, Caren/AAM-2033-2021	Armstrong, Caren/0000-0001-8010-0850	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS35915]; UCI Medical Scientist Training Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS035915, R29NS035915, R01NS035915] Funding Source: NIH RePORTER	We thank R. Zhu and E. Kim for technical assistance. Supported by the US National Institutes of Health grant NS35915 and the UCI Medical Scientist Training Program.	Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Katona I, 2008, NAT MED, V14, P923, DOI 10.1038/nm.f.1869; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lutz B, 2008, NAT MED, V14, P721, DOI 10.1038/nm0708-721; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920	19	65	66	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUL	2009	85	1					123	127		10.1016/j.eplepsyres.2009.02.019			5	Clinical Neurology	Neurosciences & Neurology	470VV	WOS:000268011100014	19369036	Green Accepted			2021-06-18	
J	Svetlov, SI; Larner, SF; Kirk, DR; Atkinson, J; Hayes, RL; Wang, KKW				Svetlov, Stanislav I.; Larner, Stephen F.; Kirk, Daniel R.; Atkinson, Joseph; Hayes, Ronald L.; Wang, Kevin K. W.			Biomarkers of Blast-Induced Neurotrauma: Profiling Molecular and Cellular Mechanisms of Blast Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blast; brain injury; molecular pathways; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SPECTRIN BREAKDOWN PRODUCTS; NEUROTROPHIC PROTEIN S100B; NITRIC-OXIDE SYNTHASE; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID; NEUROPROTECTIVE ROLE; OXIDATIVE STRESS; SERUM S-100B; TAU CLEAVAGE	The nature of warfare in the 21st century has led to a significant increase in primary blast or over-pressurization injuries to the whole body and head, which manifest as a complex of neuro-somatic damage, including traumatic brain injury (TBI). Identifying relevant pathogenic pathways in reproducible experimental models of primary blast wave exposure is therefore vital to the development of biomarkers for diagnostics of blast brain injury. Comparative analysis of mechanisms and putative biomarkers of blast brain injury is complicated by a deficiency of experimental studies. In this article, we present an overview of current TBI biomarkers, as well as outline experimental strategies to investigate molecular signatures of blast neurotrauma and to develop a pathway network map for novel biomarker discovery. These biomarkers will be effective for triaging and managing both combat and civilian causalities.	[Svetlov, Stanislav I.; Larner, Stephen F.; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Kirk, Daniel R.; Atkinson, Joseph] Florida Inst Technol, Dept Mech & Aerosp Engn, Melbourne, FL 32901 USA; [Svetlov, Stanislav I.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA	Svetlov, SI (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	ssvetlov@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [N14-06-1-1029, W81XWH-8-1-0376, X81XWH-07-01-0701]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER	The authors wish to thank Ms. Qiushi Tang for her excellent technical assistance. This work was supported by grants N14-06-1-1029, W81XWH-8-1-0376 and X81XWH-07-01-0701 from Department of Defense.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 1991, Vojnosanit Pregl, V48, P515; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1991, Vojnosanit Pregl, V48, P507; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cernak Ibolja, 1995, Magnesium Research, V8, P249; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; Elsayed NM, 1996, EXP LUNG RES, V22, P179, DOI 10.3109/01902149609050846; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; Gorbunov NV, 1996, BIOCHEM BIOPH RES CO, V219, P835, DOI 10.1006/bbrc.1996.0319; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320; Guy R J, 2000, J R Nav Med Serv, V86, P125; Guy R J, 2000, J R Nav Med Serv, V86, P27; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; Januszkiewicz AJ, 1997, TOXICOLOGY, V121, P51, DOI 10.1016/S0300-483X(97)03655-X; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lescuyer P, 2007, J PROTEOME RES, V6, P3371, DOI 10.1021/pr0702060; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Michetti F, 2002, CLIN CHEM, V48, P2097; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Nath R, 1998, J NEUROCHEM, V71, P186; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Park SY, 2007, NEUROSCIENCE, V144, P119, DOI 10.1016/j.neuroscience.2006.09.012; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Savic J, 1991, Vojnosanit Pregl, V48, P499; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	89	65	68	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					913	921		10.1089/neu.2008.0609			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600009	19422293	Green Published			2021-06-18	
J	Theeler, BJ; Erickson, JC				Theeler, Brett J.; Erickson, Jay C.			Mild Head Trauma and Chronic Headaches in Returning US Soldiers	HEADACHE			English	Article						headache; Iraq; traumatic brain injury; post-traumatic headache	BRAIN-INJURY; POSTTRAUMATIC HEADACHES; NECK; MIGRAINE; AFGHANISTAN; PREVALENCE; IRAQ	To determine the incidence and types of head or neck trauma and headache characteristics among US Army soldiers evaluated for chronic headaches at a military neurology clinic following a combat tour in Iraq. Head or neck trauma and headaches are common in US soldiers deployed to Iraq. The temporal association between mild head trauma and headaches, as well as the clinical characteristics of headaches associated with mild head trauma, has not been systematically studied in US soldiers returning from Iraq. A retrospective cohort study was conducted with 81 US Army soldiers from the same brigade who were evaluated at a single military neurology clinic for recurrent headaches after a 1-year combat tour in Iraq. All subjects underwent a standardized interview and evaluation to determine the occurrence of head or neck trauma during deployment, mechanism and type of trauma, headache type, and headache characteristics. In total, 33 of 81 (41%) soldiers evaluated for headaches reported a history of head or neck trauma while deployed to Iraq. A total of 18 (22%) subjects had concussion without loss of consciousness and 15 (19%) had concussion with loss of consciousness. Ten subjects also had an accompanying traumatic neck injury. No subjects had moderate or severe traumatic brain injury. Exposure to blasts was the most common cause of trauma, accounting for 67% of head and neck injuries. Headaches began within one week after trauma in 12 of 33 (36%) soldiers with head or neck injury. Another 12 (36%) reported worsening of pre-existing headaches after trauma. Headaches were classified as migraine type in 78% of soldiers with head or neck trauma. Headache types, frequency, severity, duration, and disability were similar for soldiers with and without a history of head or neck trauma. A history of mild head trauma, usually caused by exposure to blasts, is found in almost half of returning US combat troops who receive specialized care for headaches. In many cases, head trauma was temporally associated with either the onset of headaches or the worsening of pre-existing headaches, implicating trauma as a precipitating or exacerbating factor, respectively. Headaches in head trauma-exposed soldiers are usually migraine type and are similar to nontraumatic headaches encountered at a military specialty clinic.	[Theeler, Brett J.] Madigan Army Med Ctr, Neurol Serv, Dept Neurol, Tacoma, WA 98431 USA	Theeler, BJ (corresponding author), Madigan Army Med Ctr, Neurol Serv, Dept Neurol, 9040A Fitzsimmons Dr, Tacoma, WA 98431 USA.						Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Solomon S, 2005, HEADACHE, V45, P53, DOI 10.1111/j.1526-4610.2005.05011.x; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	21	65	66	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	APR	2009	49	4					529	534		10.1111/j.1526-4610.2009.01345.x			6	Clinical Neurology	Neurosciences & Neurology	424JZ	WOS:000264564300004	19220499	Bronze			2021-06-18	
J	Hoskison, MM; Moore, AN; Hu, B; Orsi, S; Koboric, N; Dash, PK				Hoskison, M. M.; Moore, A. N.; Hu, B.; Orsi, S.; Koboric, N.; Dash, P. K.			PERSISTENT WORKING MEMORY DYSFUNCTION FOLLOWING TRAUMATIC BRAIN INJURY: EVIDENCE FOR A TIME-DEPENDENT MECHANISM	NEUROSCIENCE			English	Article						Golgi staining; neuronal morphology; prelimbic cortex; delayed alternation T-maze; delay match-to-place; GAD	MEDIAL PREFRONTAL CORTEX; ALTERS DENDRITIC MORPHOLOGY; CONTROLLED CORTICAL IMPACT; PYRAMIDAL NEURONS; DEFICITS; MODEL; RATS; HISTOPATHOLOGY; EXPRESSION; REVERSAL	The prefrontal cortex is highly vulnerable to traumatic brain injury (TBI) resulting in the dysfunction of many high-level cognitive and executive functions such as planning, information processing speed, language, memory, attention, and perception. All of these processes require some degree of working memory. Interestingly, in many cases, post-injury working memory deficits can arise in the absence of overt damage to the prefrontal cortex. Recently, excess GABA-mediated inhibition of prefrontal neuronal activity has been identified as a contributor to working memory dysfunction within the first month following cortical impact injury of rats. However, it has not been examined if these working memory deficits persist, and if so, whether they remain amenable to treatment by GABA antagonism. Our findings show that working memory dysfunction, assessed using both the delay match-to-place and delayed alternation T-maze tasks, following lateral cortical impact injury persists for at least 16 weeks post-injury. These deficits were found to be no longer the direct result of excess GABA-mediated inhibition of medial prefrontal cortex neuronal activity. Golgi staining of prelimbic pyramidal neurons revealed that TBI causes a significant shortening of layers V/VI basal dendrite arbors by 4 months post-injury, as well as an increase in the density of both basal and apical spines in these neurons. These changes were not observed in animals 14 days post-injury, a time point at which administration of GABA receptor antagonists improves working memory function. Taken together, the present findings, along with previously published reports, suggest that temporal considerations must be taken into account when designing mechanism-based therapies to improve working memory function in TBI patients. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Moore, A. N.; Orsi, S.; Dash, P. K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hoskison, M. M.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77225 USA; [Hu, B.; Koboric, N.; Dash, P. K.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160] Funding Source: NIH RePORTER	The authors would like to thank Tim Graham and Melanie Moody for technical assistance. The work performed in the authors' laboratories was made possible by grants from NIH.	Amat J, 2005, NAT NEUROSCI, V8, P365, DOI 10.1038/nn1399; Arnsten AFT, 1997, J PSYCHOPHARMACOL, V11, P151, DOI 10.1177/026988119701100208; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Blum S, 2006, NEUROREPORT, V17, P341, DOI 10.1097/01.wnr.0000201509.53750.bc; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brown SM, 2005, CEREB CORTEX, V15, P1714, DOI 10.1093/cercor/bhi048; Cerqueira JJ, 2007, J NEUROSCI, V27, P2781, DOI 10.1523/JNEUROSCI.4372-06.2007; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cook SC, 2004, J NEUROBIOL, V60, P236, DOI 10.1002/neu.20025; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Dash PK, 2007, LEARN MEMORY, V14, P554, DOI 10.1101/lm.558707; DESCARRIES L, 1987, NEUROSCIENCE, V21, P807, DOI 10.1016/0306-4522(87)90038-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EMSON PC, 1978, BRAIN RES, V142, P249, DOI 10.1016/0006-8993(78)90634-0; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Finley JW, 2005, J NUTR, V135, P1236; Flores G, 2005, NEUROSCIENCE, V133, P463, DOI 10.1016/j.neuroscience.2005.02.021; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Jo YS, 2007, J NEUROSCI, V27, P13567, DOI 10.1523/JNEUROSCI.3589-07.2007; Kalus P, 2000, NEUROREPORT, V11, P3621, DOI 10.1097/00001756-200011090-00044; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; KRAUS J, 2005, NEUROPSYCHIATRY TRAU; Locchi F, 2007, NEUROSCI LETT, V422, P213, DOI 10.1016/j.neulet.2007.06.023; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Papadeas ST, 2008, J COMP NEUROL, V511, P271, DOI 10.1002/cne.21835; Rajkowska G, 2000, PROG BRAIN RES, V126, P397; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Runyan JD, 2005, LEARN MEMORY, V12, P103, DOI 10.1101/lm.89405; SHOLL DA, 1956, PROG NEUROBIOL, V2, P324; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wang HD, 2008, NEUROPSYCHOPHARMACOL, V33, P1276, DOI 10.1038/sj.npp.1301521	42	65	72	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 17	2009	159	2					483	491		10.1016/j.neuroscience.2008.12.050			9	Neurosciences	Neurosciences & Neurology	418QC	WOS:000264162300005	19167462	Green Accepted			2021-06-18	
J	McIntosh, AS; McCrory, P; Finch, CF; Best, JP; Chalmers, DJ; Wolfe, R				McIntosh, Andrew S.; McCrory, Paul; Finch, Caroline F.; Best, John P.; Chalmers, David J.; Wolfe, Rory			Does Padded Headgear Prevent Head Injury in Rugby Union Football?	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						FOOTBALL; HEAD INJURY; CONCUSSION; HELMETS; SPORTS INJURY PREVENTION; RANDOMIZED CONTROLLED TRIAL	PROTECTIVE EQUIPMENT; PROFESSIONAL FOOTBALL; PERFORMANCE; EPIDEMIOLOGY; PLAYERS; CONCUSSION; IMPACTS; SPORT	MCINTOSH, A. S., P. MCCRORY, C. F. FINCH, J. P. BEST, D. J. CHALMERS. and R. WOLFE. Does Padded Headgear Prevent Head Injury in Rugby Union Football? Med. Sci. Sports Exerc. Vol. 41, No. 2, pp. 306-313, 2009. Background: Concussion is a serious problem in many contact sports, including rugby union football. The study's primary aim was to measure the efficacy of padded headgear in reducing the rates of head injury or Concussion. Methods: A cluster randomized controlled trial with three arms was conducted with rugby union football teams as the unit of randomization. Teams consisted of males participating in under 13-, 15- 1 8- and 20-yr age group competitions. The interventions were "standard" and "modified" padded headgear. Headgear wearing and injury were measured for each study team at each game over two seasons. Results: Eighty-two teams participated in year I and 87 in year 2. A total of 1493 participants (10,040 player hours) were in the control group. 1128 participants (8170 player hours) were assigned to the standard headgear group, and 1474 participants (10,650 player hours) were assigned to the modified headgear group. The compliance rates were low in all groups, but 46% of participants wore standard headgear. An intention-to-treat analysis showed no differences in the rates of head injury or concussion between controls and headgear arms. Incidence rate ratios for standard headgear wearers referenced to controls were 0.95 and 1.02 for game and missed game injuries. Analyses of injury rates based on observed wearing patterns also showed no significant differences. Incidence rate ratios for standard headgear wearers referenced to nonweaters were 1.11 and 1.10 for game and missed game injuries. Conclusions: Padded headgear does not reduce the rate of head injury or concussion. The low compliance rates are a limitation. Although individuals may choose to wear padded headgear, the routine or mandatory use of protective headgear cannot be recommended.	[McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia; [Finch, Caroline F.] Univ Ballarat, Ballarat, Vic 3353, Australia; [Best, John P.] Orthosports Grp, Sydney, NSW, Australia; [Chalmers, David J.] Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand; [Wolfe, Rory] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	McIntosh, AS (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568; Wolfe, Rory/0000-0002-2126-1045			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Braham RA, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2002.004002; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; CANTU RC, 1992, CLIN J SPORT MED, V2, P180; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; GARRAWAY M, 1995, LANCET, V345, P1485; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Liu B., 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004333.pub2, DOI 10.1002/14651858.CD004333.PUB2]; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MURRAY DM, 1998, DESIGN ANAL GROUP RA, P99; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Sparks J P, 1981, Br J Sports Med, V15, P30; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2	30	65	65	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2009	41	2					306	313		10.1249/MSS.0b013e3181864bee			8	Sport Sciences	Sport Sciences	396OO	WOS:000262601200007	19127196				2021-06-18	
J	Neumann, M; Wang, YG; Kim, S; Hong, SM; Jeng, L; Bilgen, M; Liu, JL				Neumann, Melanie; Wang, Yonggang; Kim, Sharon; Hong, Shwuhey M.; Jeng, Lareine; Bilgen, Mehmet; Liu, Jialing			Assessing gait impairment following experimental traumatic brain injury in mice	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Controlled cortical impact; Catwalk; Motor function; Corticospinal tract; Neuroplasticity	ACUTE PREDICTORS; LOCOMOTION; ADULT; SPEED; RATS; DEFICITS; RELIABILITY; MOVEMENT; STRAIN; RETURN	Although gait disturbance is frequently documented among patients with traumatic brain injury (TBI), gait data from animal models of TBI are lacking. To determine the effect of TBI on gait function in adult mice, we assessed gait changes following unilateral controlled cortical impact (CCI) using a computer-assisted automated gait analysis system. Three days after CCI, intensity, area or width of paw contact were significantly decreased in forepaw(s) while the relative paw placement between the fore and hindpaws altered, suggesting that TBI affected sensorimotor status and reduced interlimb coordination. Similar to TBI patients, CCI decreased gait velocity and stride length, and prolonged stance and swing phase in mice. Following CCI, step pattern was also changed with increasing use in the ipsilateral-diagonal limb sequence. Our results indicate that gait analysis provides great insight into both spatial and temporal aspects of limb function changes during overground locomotion in quadruped species with head injury that are valuable for the purpose of treatment and rehabilitation. Our study also provides additional functional validation for the established mouse CCI model that is relevant to human head injury. Published by Elsevier B.V.	[Liu, Jialing] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Neurol Surg, San Francisco, CA 94121 USA; [Neumann, Melanie; Wang, Yonggang; Kim, Sharon; Hong, Shwuhey M.; Jeng, Lareine; Liu, Jialing] San Francisco & SFVAMC, San Francisco, CA 94121 USA; [Neumann, Melanie] Univ Klinikum Hamburg Eppendorf, D-20246 Hamburg, Germany; [Wang, Yonggang] Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurol Surg, Beijing 100050, Peoples R China; [Jeng, Lareine] Watchung Hills Reg High Sch, Warren, NJ 07059 USA; [Bilgen, Mehmet] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA	Liu, JL (corresponding author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Neurol Surg, 112C,4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	VAUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; Northern California Institute for Research and Education; Department of Defense collaborative in Neuroscience Center of ExcellenceUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS051576, R01NS040469, R01NS071050] Funding Source: NIH RePORTER	The authors are grateful for the technical assistance and overall expertise on experimental TBI model provided by Drs. Linda J. Noble-Haeusslein and Kyoko Tsuru. This work was supported by a VA Merit award (JL), Department of Defense (JL) and infrastructural fund by Northern California Institute for Research and Education and the Department of Defense collaborative in Neuroscience Center of Excellence.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Chen G, 2005, GAIT POSTURE, V22, P51, DOI 10.1016/j.gaitpost.2004.06.009; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELLON ES, 1991, PLAST RECONSTR SURG, V88, P686, DOI 10.1097/00006534-199110000-00020; Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Gillis GB, 2001, J EXP BIOL, V204, P2717; Gorska T, 1998, ACTA NEUROBIOL EXP, V58, P227; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Ng SS, 2005, ARCH PHYS MED REHAB, V86, P1641, DOI 10.1016/j.apmr.2005.01.011; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Vlamings R, 2007, NEUROSCIENCE, V148, P815, DOI 10.1016/j.neuroscience.2007.06.043; Vogelaar CF, 2004, BRAIN RES, V1027, P67, DOI 10.1016/j.brainres.2004.08.036; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zverev Y, 2002, East Afr Med J, V79, P420	35	65	68	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2009	176	1					34	44		10.1016/j.jneumeth.2008.08.026			11	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	375MK	WOS:000261117800004	18805438	Green Accepted			2021-06-18	
J	Lange, RT; Iverson, GL; Franzen, MD				Lange, Rael T.; Iverson, Grant L.; Franzen, Michael D.			Neuropsychological functioning following complicated vs. uncomplicated mild traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	27th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 14-17, 2007	Scottsdale, AZ	Natl Acad Neuropsychol		Mild traumatic brain injury; complicated; outcome; neurocognitive	WORD-ASSOCIATION TEST; HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT; MODERATE; TRAIL; ABNORMALITIES; PERFORMANCE; TIME	Objective: It would be logical to assume that patients with intracranial abnormalities (i.e. complicated MTBIs) would have worse outcome than patients without these abnormalities (i.e. uncomplicated MTBIs). However, the literature is limited and somewhat mixed regarding outcome in patients with complicated mild TBIs. The purpose of this study is to employ a carefully controlled research design to compare the acute neuropsychological functioning of patients following complicated and uncomplicated MTBI. Method: Participants were 20 patients with complicated MTBI and 20 patients with uncomplicated MTBI selected from an archival database of 465 patients. Patients were carefully matched on age, education, gender, ethnicity, days assessed post-injury and mechanism of injury. Patients were assessed an average of 3.5 days (SD = 1.9) post-injury with 13 common cognitive variables. Results: There were significant group differences on only three of the 13 cognitive measures (complicated mild TBI worse than uncomplicated mild TBI). There were no significant differences in the proportion of impaired scores between groups on all measures, with the exception of Hopkins Verbal Learning Test Delayed Recall. Conclusion: Patients with complicated MTBIs performed more poorly only on a small number of tests during the acute recovery period.	[Franzen, Michael D.] Allegheny Gen Hosp, Pittsburgh, PA USA; [Lange, Rael T.] BC Mental Hlth & Addict Serv, PHSA Res & Networks, Vancouver, BC V5Z 4C2, Canada; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Franzen, Michael D.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Lange, RT (corresponding author), BC Mental Hlth & Addict Serv, PHSA Res & Networks, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BENTON AL, 1994, MANUAL INSTRUCTIONS; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FRENCH BN, 1977, SURG NEUROL, V7, P171; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton RK, 2004, REVISED COMPREHENSIV; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PRIFITERA CA, 1992, NORMATIVE DELA UNPUB; Reitan R. M., 1992, TRAIL MAKING TEST MA; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tellier A, 1999, BRAIN INJURY, V13, P463; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wechsler D., 1987, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	44	65	65	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					83	91	PII 908454607	10.1080/02699050802635281			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200002	19191087				2021-06-18	
J	Zeitzer, JM; Friedman, L; O'Hara, R				Zeitzer, Jamie M.; Friedman, Leah; O'Hara, Ruth			Insomnia in the context of traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive behavioral therapy; comorbidity; insomnia; pharmacotherapy; rehabilitation; sleep; sleep disorder; sleep disruption; traumatic brain injury; veterans	COGNITIVE-BEHAVIOR THERAPY; SLEEP DISORDERS; ACTIGRAPHIC MEASUREMENT; STIMULUS-CONTROL; HEAD-INJURY; PLACEBO; PAIN; METHYLPHENIDATE; DISTURBANCES; NEUROBIOLOGY	Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality in the United States. One of the most common comorbidities of TBI is the disruption of normal sleep. While often viewed as a nuisance symptom, sleep disruption can delay TBI recovery and negatively affect many of the psychological (e.g., anxiety, depression) and neuromuscular (e.g., pain) sequelae of TBI, decreasing quality of life. Treatment of sleep disruption in the context of TBI is complicated by issues of an altered neuronal milieu, polypharmacy, and the complex relationship between the various comorbidities often found in patients with TBI. Given the growing number of veterans returning from combat with TBI and the elevated risk of comorbid disrupted sleep, both caused by and independent of TBI, a comprehensive review of sleep disruption and its treatment is of great relevance to the Department of Veterans Affairs.	Dept Vet Affairs Palo Alto Hlth Care Syst, Psychiat Serv, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Zeitzer, JM (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA.	jzeitzer@stanford.edu	Zeitzer, Jamie M/A-1168-2007; Zeitzer, Jamie/AAO-2103-2020	Zeitzer, Jamie M/0000-0001-6174-5282; Zeitzer, Jamie/0000-0001-6174-5282	VA Mental Illness Research, Education, and Clinical Center	This material was based on work supported by the VA Mental Illness Research, Education, and Clinical Center.	ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; [Anonymous], 2005, SLEEP, V28, P1049; [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Broomfield NM, 2003, BEHAV COGN PSYCHOTH, V31, P313, DOI 10.1017/S1352465803003060; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Currie SR, 2004, ADDICTION, V99, P1121, DOI 10.1111/j.1360-0443.2004.00835.x; Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI 10.1016/J.CPR.2005.04.003; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Espana RA, 2004, SLEEP, V27, P811; ESPIE CA, 1989, BEHAV RES THER, V27, P79, DOI 10.1016/0005-7967(89)90123-X; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Fichten CS, 2001, COGNITIVE THER RES, V25, P665, DOI 10.1023/A:1012963121729; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; FRIEDMAN L, 1991, J GERONTOL, V46, pP1, DOI 10.1093/geronj/46.1.P1; Friedman L, 2000, J GERIATR PSYCH NEUR, V13, P17, DOI 10.1177/089198870001300103; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; Hauri P. J., 1991, CASE STUDIES INSOMNI, P65, DOI DOI 10.1007/978-1-4757-9586-8_5; Hoch CC, 2001, J GERONTOL B-PSYCHOL, V56, pP52, DOI 10.1093/geronb/56.1.P52; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Krystal AD, 2008, SLEEP, V31, P79, DOI 10.1093/sleep/31.1.79; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lichstein KL, 2001, J CONSULT CLIN PSYCH, V69, P227, DOI 10.1037/0022-006X.69.2.227; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manber R, 2005, CLIN PSYCHOL REV, V25, P535, DOI 10.1016/J.CPR.2005.04.002; Mimeault V, 1999, J CONSULT CLIN PSYCH, V67, P511, DOI 10.1037/0022-006X.67.4.511; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; MORIN CM, 1987, J CONSULT CLIN PSYCH, V55, P260, DOI 10.1037/0022-006X.55.2.260; MORIN CM, 1988, J CONSULT CLIN PSYCH, V56, P748, DOI 10.1037/0022-006X.56.5.748; Morin CM, 2004, AM J PSYCHIAT, V161, P332, DOI 10.1176/appi.ajp.161.2.332; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Onen SH, 2001, J SLEEP RES, V10, P35, DOI 10.1046/j.1365-2869.2001.00240.x; Perlis ML, 2004, SLEEP, V27, P715, DOI 10.1093/sleep/27.4.715; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Riedel BW, 1998, BEHAV MODIF, V22, P3, DOI 10.1177/01454455980221001; Riemann D, 2007, SLEEP MED, V8, pS15, DOI 10.1016/S1389-9457(08)70004-2; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Roth T, 2004, SLEEP MED, V5, pS23, DOI 10.1016/S1389-9457(04)90004-4; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Sharafkhaneh A, 2004, SLEEP MED, V5, P345, DOI 10.1016/j.sleep.2004.01.019; Stepanski EJ, 2003, SLEEP MED REV, V7, P215, DOI 10.1053/smrv.2001.0246; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wicklow A, 2000, BEHAV RES THER, V38, P679, DOI 10.1016/S0005-7967(99)00136-9; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2006, TRENDS PHARMACOL SCI, V27, P368, DOI 10.1016/j.tips.2006.05.006	61	65	65	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					827	835		10.1682/JRRD.2008.08.0099			9	Rehabilitation	Rehabilitation	531BQ	WOS:000272638100014	20104406	Bronze			2021-06-18	
J	Taylor, HG; Swartwout, MD; Yeates, KO; Walz, NC; Stancin, T; Wade, SL				Taylor, H. Gerry; Swartwout, Maegan D.; Yeates, Keith Owen; Walz, Nicolay Chertkoff; Stancin, Terry; Wade, Shari L.			Traumatic brain injury in young children: Postacute effects on cognitive and school readiness skills	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						child; preschool; brain injuries; neurobehavior manifestations; outcome. moderator variables	CLOSED-HEAD-INJURY; GLASGOW COMA SCALE; EARLY-CHILDHOOD; EXECUTIVE FUNCTIONS; PRESCHOOL-CHILDREN; SEVERITY SCORE; SHORT-TERM; RECOVERY; MILD; OUTCOMES	Previous studies have documented weaknesses in cognitive ability and early academic readiness in young children with traumatic brain injury (TBI). However, few of these studies have rigorously controlled for demographic characteristics, examined the effects of TBI severity on a wide range of skills, or explored moderating influences of environmental factors on outcomes. To meet these objectives. each of three groups of children with TBI (20 with severe, 64 with moderate, and 15 with mild) were compared with a group of 117 children with orthopedic injuries (01 group). The children were hospitalized for their injuries between 3 and 6 years of age and were assessed an average of 11/2 months post injury. Analysis revealed generalized weaknesses in cognitive and school readiness skills in the severe TBI group and less pervasive effects of moderate TBI. Indices of TBI severity predicted outcomes within the TBI sample and environmental factors moderated the effects of TBI on some measures. The findings document adverse effects of TBI in early childhood on postacute cognitive and school readiness skills and indicate that these effects are related to both injury severity and the family environment.	[Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediatr Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Swartwout, Maegan D.] Univ Houston, Dept Psychol, Houston, TX USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Div Psychol, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Ctr Med, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH USA; [Walz, Nicolay Chertkoff] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Rehabil, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Taylor, HG (corresponding author), Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediatr Psychol, DO Walker Bldg,Suite 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Sady, Maegan/0000-0002-1438-4477	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; USPHS NIHUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	Supported by grant R01 HD42729 to Dr. Wade from NICHD, in part by USPHS NIH Grant no. M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services. The authors wish to acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. We also thank Nori Minich for her assistance in data analysis. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Bracken BA, 1998, BRACKEN BASIC CONCEP; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; Carrow-Woolfolk E, 2000, COMPREHENSIVE ASSESS; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Donders J, 2005, J INT NEUROPSYCH SOC, V11, P386, DOI 10.1017/S1355617705050435; Donders J, 2001, CHILD NEUROPSYCHOL, V7, P99, DOI 10.1076/chin.7.2.99.3126; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; GOTSCHALL CS, 1993, PEDIAT TRAUMA PREVEN, P16; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Jaccard J, 2002, J CLIN CHILD ADOLESC, V31, P130, DOI 10.1207/153744202753441747; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kirkwood M. W., CLIN NEUROP IN PRESS; Kochanska G, 2000, DEV PSYCHOL, V36, P220, DOI 10.1037//0012-1649.36.2.220; Korkman M, 1998, NEPSY DEV NEUROPSYCH; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MCDERMOTT PA, 1995, J SCHOOL PSYCHOL, V33, P75, DOI 10.1016/0022-4405(94)00025-4; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Moos R, 1994, LIFE STRESSORS SOCIA; Morse S, 1999, Pediatr Rehabil, V3, P139; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Tabachnick B.G., 1989, USING MULTIVARIATE S; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON T, 2003, J LEARNING DISABILIT, V7, P345, DOI DOI 10.1177/1469004703074003; Verger K, 2000, BRAIN INJURY, V14, P495; WETHERINGTON CE, 2006, EXCEPTIONALITY, V12, P155; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	82	65	65	1	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					734	745		10.1017/S1355617708081150			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400004	18764969	Green Accepted, Bronze			2021-06-18	
J	Dietz, RM; Weiss, JH; Shuttleworth, CW				Dietz, Robert M.; Weiss, John H.; Shuttleworth, Claude W.			Zn2+ influx is critical for some forms of spreading depression in brain slices	JOURNAL OF NEUROSCIENCE			English	Article						hippocampal slice; mitochondria; spreading depression; calcium channels; zinc; ouabain	HIPPOCAMPAL CA1 NEURONS; PERIINFARCT DEPOLARIZATIONS; CEREBRAL-ISCHEMIA; NEUROTRANSMITTER RELEASE; CORTICAL-NEURONS; IN-VITRO; ZINC; CALCIUM; MITOCHONDRIAL; MECHANISMS	Spreading depression ( SD) is wave of profound depolarization that propagates throughout brain tissue and can contribute to the spread of injury after stroke or traumatic insults. The contribution of Ca2+ influx to SD differs depending on the stimulus, and we show here that Zn2+ can play a critical complementary role in murine hippocampal slices. In initial studies, we used the Na+/K+ ATPase inhibitor ouabain and found conditions in which SD was always prevented by L- type Ca2+ channel blockers; however, Ca2+ influx was not responsible for L- type effects. Cytosolic Ca2+ increases were not detectable in CA1 neurons before SD, and removal of extracellular Ca2+ did not prevent ouabain- SD. In contrast, cytosolic Zn2+ increases were observed in CA1 neurons before ouabain- SD, and L- type channel block prevented the intracellular Zn2+ rises. A slow mitochondrial depolarization observed before ouabain- SD was abolished by L- type channel block, and Zn2+ accumulation contributed substantially to initial mitochondrial depolarizations. Selective chelation of Zn2+ with N, N, N', N'- tetrakis(2-pyridylmethyl) ethylenediamine ( TPEN) abolished SD, implying that Zn2+ entry can play a critical role in the generation of ouabain- SD. TPEN was most effective when synaptic activity was reduced by adenosine A1 receptor activation, and a combination of Ca2+ and Zn2+ removal was required to prevent ouabain- SD when A1 receptors were blocked. Similarly, Zn2+ chelation could prevent SD triggered by oxygen/ glucose deprivation but Zn2+ accumulation did not contribute to SD triggered by localized high K+ exposures. These results identify Zn2+ as a new target for the block of spreading depolarizations after brain injury.	[Dietz, Robert M.; Shuttleworth, Claude W.] Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA; [Weiss, John H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; [Weiss, John H.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Shuttleworth, CW (corresponding author), Univ New Mexico, Sch Med, Dept Neurosci, MSC08 4740,1 Univ New Mexico, Albuquerque, NM 87131 USA.	bshuttleworth@salud.unm.edu	weiss, john/B-4283-2008	weiss, john/0000-0001-9323-7813	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051288, R01NS036548] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS051288-03, R01 NS051288, NS36548, R01 NS036548, NS051288] Funding Source: Medline		ADLER EM, 1991, J NEUROSCI, V11, P1496; Aitken PG, 1998, J NEUROPHYSIOL, V80, P1514; Ayata C, 2000, NEUROSCIENCE, V95, P639; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; BALESTRINO M, 1986, BRAIN RES, V385, P219, DOI 10.1016/0006-8993(86)91067-X; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Basarsky TA, 1999, J NEUROSCI, V19, P6439; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; BURESOVA O, 1969, Journal of Neurobiology, V1, P135, DOI 10.1002/neu.480010202; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Devinney MJ, 2005, CELL CALCIUM, V37, P225, DOI 10.1016/j.ceca.2004.10.003; DIETZ RM, 2007, SOC NEUR ABSTR, V33; Dietz RM, 2007, HIPPOCAMPUS, V17, P1049, DOI 10.1002/hipo.20336; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Duchen MR, 2003, METHOD ENZYMOL, V361, P353; Footitt DR, 1998, BRAIN RES, V781, P339, DOI 10.1016/S0006-8993(97)01359-0; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Gerich FJ, 2006, J NEUROPHYSIOL, V96, P492, DOI 10.1152/jn.01015.2005; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hashimoto M, 2000, BRAIN RES, V872, P294, DOI 10.1016/S0006-8993(00)02509-9; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kay AR, 2003, J NEUROSCI, V23, P6847; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kunkler PE, 2004, HIPPOCAMPUS, V14, P356, DOI 10.1002/hipo.10181; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x; Marchi B, 2000, CELL CALCIUM, V28, P225, DOI 10.1054/ceca.2000.0155; Masino SA, 1999, J NEUROSCI, V19, P1932; Menna G, 2000, J NEUROPHYSIOL, V83, P1338; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Peters O, 2003, J NEUROSCI, V23, P9888; Qian J, 2005, J PHYSIOL-LONDON, V566, P747, DOI 10.1113/jphysiol.2005.089276; RADER RK, 1989, NEUROSCI LETT, V99, P125, DOI 10.1016/0304-3940(89)90276-0; RAMOS JG, 1975, ACTA PHYSIOL LAT AM, V25, P112; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Sensi SL, 2000, EUR J NEUROSCI, V12, P3813, DOI 10.1046/j.1460-9568.2000.00277.x; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; YOUNG JN, 1992, BRAIN RES, V573, P70, DOI 10.1016/0006-8993(92)90114-O	59	65	69	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 6	2008	28	32					8014	8024		10.1523/JNEUROSCI.0765-08.2008			11	Neurosciences	Neurosciences & Neurology	334RE	WOS:000258238100010	18685026	Green Published, Bronze, Green Accepted			2021-06-18	
J	McCabe, A; Bliss, L; Barra, G; Bennett, M				McCabe, Allyssa; Bliss, Lynn; Barra, Gabriela; Bennett, MariBeth			Comparison of personal versus fictional narratives of children with language impairment	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						children; language disorders; assessment; narrative	TRAUMATIC BRAIN INJURY; STORY STRUCTURE; POOR READERS; DISCOURSE; PERFORMANCE; GENERATION; ABILITIES; LITERACY; COHESION; EVENT	Purpose: Personal narratives are common in children's conversations, recommended as the appropriate genre for early writing by educators, and part of many high-stakes tests, possibly because they tend to be better formed than fictional narratives. However, current practice in the field of speech-language pathology employs fictional narratives in assessment, intervention, and study of children with impaired language development. This article explored performance on personal versus fictional narratives by children with language. impairment (LI), hypothesizing that performance on the former would be better and a minimal relationship between performances in the 2 genres. Method: Twenty-seven children age 7;0-9;9 (years;months) with LI orally produced personal and fictional narratives (responses to a wordless picture book). Narratives were analyzed by raters blind to experimental hypotheses using high-point analysis and an analysis derived from scoring of a high-stakes composition for 4th grade. Results: High-point ratings of personal significantly exceeded those of fictional narratives. Disproportionate fictional stories did not meet minimal narrative criteria. However, more personal narratives than would be expected by chance did. The analyses were significantly correlated. Quality of a child's performance of personal was minimally related to that of fictional narratives. Conclusions: Clinicians may want to consider functional aspects of personal narratives.	[McCabe, Allyssa; Barra, Gabriela; Bennett, MariBeth] Univ Massachusetts, Lowell, MA USA; [Bliss, Lynn] Univ Houston, Houston, TX USA	McCabe, A (corresponding author), Univ Massachusetts Lowell, Dept Psychol, 870 Broadway St,Suite 1, Lowell, MA 01854 USA.	allyssa-mccabe@uml.edu					ALLEN MS, 1994, APPL PSYCHOLINGUIST, V15, P149, DOI 10.1017/S0142716400005300; ALTMAN D, 1990, PRACTICAL STAT MEDIC; Bamberg M, 2002, J CHILD LANG, V29, P449, DOI 10.1017/S0305000902215342; Bamberg M., 1994, RELATING EVENTS NARR, P189; BAMBERG M, IN PRESS FESTSCHRIFT; Berman R., 1994, RELATING EVENTS NARR; BERMAN RA, 1995, J NARRAT LIFE HIST, V5, P285, DOI 10.1075/jnlh.5.4.01nar; Bernays A., 1995, WHAT WRITING EXERCIS; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Boland AM, 2003, J COGN DEV, V4, P39, DOI 10.1207/S15327647JCD4,1-02; Bourg T., 1997, DEV SPANS EVENT COMP, P385; BROWN L, 1977, TEST NONVERBAL INTEL; CALKINS L. M, 1994, ART TEACHING WRITING; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Catts HW, 2003, J LEARN DISABIL-US, V36, P151, DOI 10.1177/002221940303600208; CHAPMAN R, 1992, CHILDTALK PROCESS LA; Dickinson, 2001, HDB EARLY LITERACY R, V1, P97; Duke N.K., 2009, J ED, V189, P107, DOI [10.1177/0022057409189001-208, DOI 10.1177/0022057409189001-208]; Dunn L., 1981, PEABODY PICTURE VOCA; Fey M. E., 1986, LANGUAGE INTERVENTIO; FINESTACK LH, 2006, SHARING BOOKS STORIE, P319; Fivush R, 2006, CHILD DEV, V77, P1568, DOI 10.1111/j.1467-8624.2006.00960.x; FORDHAM AE, 1989, CHILDRENS LIT COUNCI, V2, P20; GARCIAMARQUEZ G, 1982, SOLITUDE LATIN AM; GARDINER M, 2000, EXPRESSIVE ONE WORD; GHEZZI PM, 1987, PSYCHOL REC, V37, P109, DOI 10.1007/BF03395877; GILLAM R, 1995, LANGUAGE INTERVENTIO, P145; Gillam RB, 2002, TOP LANG DISORD, V22, P30, DOI 10.1097/00011363-200205000-00005; GRAYBEAL CM, 1981, APPL PSYCHOLINGUIST, V2, P269, DOI 10.1017/S014271640000655X; Griffin P., 1998, PREVENTING READING D; GRIFFITH PL, 1986, J PSYCHOLINGUIST RES, V15, P539, DOI 10.1007/BF01067635; Hadley PA, 1998, LANG SPEECH HEAR SER, V29, P132, DOI 10.1044/0161-1461.2903.132; HANSEN CL, 1978, LEARN DISABILITY Q, V1, P62, DOI 10.2307/1510938; Hay E, 2005, AM J SPEECH-LANG PAT, V14, P324, DOI 10.1044/1058-0360(2005/031); Hayward D., 2000, CHILD LANG TEACH THE, V16, P255, DOI DOI 10.1191/026565900680410215; Hedberg N. L., 1993, ANAL STORYTELLING SK; HEWITT LE, 1995, TOP LANG DISORD, V15, P1, DOI 10.1097/00011363-199508000-00003; Hoffman P. R, 1990, LANG SPEECH HEAR SER, V21, P102; Hudson J. A., 1991, DEV NARRATIVE STRUCT, P89; Hughes D., 1997, GUIDE NARRATIVE LANG; Janes H, 2001, J ADOLESC ADULT LIT, V44, P458; JOHN VP, 1968, DISADVANTAGED CHILD, V2, P259; Johnston J. R., 1982, LANG SPEECH HEAR SER, V13, P144; JOHNSTON JR, 2006, TALKING CHILD LANGUA; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Justice LM, 2006, AM J SPEECH-LANG PAT, V15, P177, DOI 10.1044/1058-0360(2006/017); Kaderavek JN, 2000, J SPEECH LANG HEAR R, V43, P34, DOI 10.1044/jslhr.4301.34; Kamhi A., 1988, LANG SPEECH HEAR SER, V19, P304; King S., 2000, WRITING MEMOIR CRAFT; Klecan-Aker J., 1997, CONT ISSUES COMMUNIC, V24, P23; Labov William., 1972, LANGUAGE INNER CITY; Lahey M., 1988, LANGUAGE DISORDERS L; LANDIS JR, 1977, BIOMETRICS, V33, P174; Losh M, 2003, J AUTISM DEV DISORD, V33, P239, DOI 10.1023/A:1024446215446; *MASS DEP ED, 2006, MASS COMPR ASS SYST; Mayer M., 1967, BOY FROG DOG; MAYER M, 1969, FROG WHERE ARE YOU; McCabe A., 2005, IMAGINATION COGNITIO, V24, P331, DOI DOI 10.2190/CJQ8-8C9G-051G-0C2M; McCabe A., 1994, AM J SPEECH-LANG PAT, V3, P45, DOI [10.1044/1058-0360.0301.45, DOI 10.1044/1058-0360.0301.45, 10. 1044/10580360.0301.45.]; McCabe A., 2003, PATTERNS NARRATIVE D; McCardle P., 2001, LEARN DISABIL RES PR, V16, P230, DOI [DOI 10.1111/0938-8982.00023, 10.1111/0938-8982.00023, https://doi.org/10.1111/0938-8982.00023]; MCCONAUGHY SH, 1985, READ RES QUART, V20, P219, DOI 10.2307/747757; MENIGPETERSON CL, 1975, CHILD DEV, V46, P1015; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; MERRITT DD, 1989, J SPEECH HEAR DISORD, V54, P438, DOI 10.1044/jshd.5403.438; Miller L., 2001, DYNAMIC ASSESSMENT I; Miranda AE, 1998, APPL PSYCHOLINGUIST, V19, P647, DOI 10.1017/S0142716400010407; OWENS RE, 2004, LANGUAGE DISORDERS; Paul R., 2006, LANGUAGE DISORDERS I; Pearson N.A., 2004, TEST NARRATIVE LANGU; Perry T., 1998, REAL EBONICS DEBATE; Peterson C, 1999, J CHILD LANG, V26, P49, DOI 10.1017/S0305000998003651; PETERSON C, 1983, DEV NARRATIVE STRUCT; PREECE A, 1987, J CHILD LANG, V14, P273; RIPICH DN, 1988, J LEARN DISABIL, V21, P165, DOI 10.1177/002221948802100309; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; SCOTT CM, 1999, LANGUAGE READING DIS, P224; Semel E. M., 1995, CLIN EVALUATION LANG; Shiro M, 2003, J CHILD LANG, V30, P165, DOI 10.1017/S0305000902005500; Snyder LE, 2002, TOP LANG DISORD, V22, P1, DOI 10.1097/00011363-200205000-00003; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; Strong C. J., 1998, STRONG NARRATIVE ASS; Swanson LA, 2005, AM J SPEECH-LANG PAT, V14, P131, DOI 10.1044/1058-0360(2005/014); Tabors P. O., 2001, BEGINNING LITERACY L, P313; WEAVER PA, 1982, DISCOURSE PROCESS, V5, P225, DOI 10.1080/01638538209544544; WESTBY CE, 1999, LANGUAGE READING DIS, P154; Wolf D, 2004, FIRST LANG, V24, P123, DOI [10.1177/0142723704042369, DOI 10.1177/0142723704042369]	87	65	66	0	13	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2008	17	2					194	206		10.1044/1058-0360(2008/019)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	295OZ	WOS:000255485100009	18448606				2021-06-18	
J	Freeman, SS; Udomphom, Y; Armstead, WM; Fisk, DM; Vavilala, MS				Freeman, Serena S.; Udomphom, Yuthana; Armstead, William M.; Fisk, Dana M.; Vavilala, Monica S.			Young age as a risk factor for impaired cerebral autoregulation after moderate to severe pediatric traumatic brain injury	ANESTHESIOLOGY			English	Article							BLOOD-FLOW VELOCITY; TRANSCRANIAL DOPPLER; CHANNEL FUNCTION; CHILDREN; HEMODYNAMICS; METABOLISM; INFANTS; RESPONSES; IMMATURE; TIME	Background: Little is known about age and cerebral autoregulation in children with traumatic brain injury (TBI). The authors compared cerebral autoregulation between young (aged <4 yr) and older (aged >= 4 yr) children with TBI. Methods. After University of Washington's institutional review board approval, a retrospective analysis of prospectively collected data (May 2002 and June 2007) was performed. Eligibility criteria included age 16 yr or younger, moderate to severe (admission Glasgow Coma Scale score <13) TBI, TBI on computed tomography scan, and tracheal intubation. Cerebral antoregulation testing was performed within 72 h after TBI, and antoregulation was quantified using the autoregulatory index. An antoregulatory index less than 0.4 represents impaired cerebral autoregulation. The 12-month Glasgow outcome score was measured. Data arc presented as mean +/- SD or range. Results: Thirty-seven children (8.9 +/- 5.1 yr; 0.8-16 yr) were enrolled. Children younger than 4 yr had a higher incidence of impaired cerebral autoregulation (8 of 10 vs. 7 of 27; P = 0.006) and worse 12-month outcome (Glasgow outcome score 3.0 +/- 1.0 vs. 4.0 +/- 1.0; P = 0.02) than older children. Age less than 4 yr (adjusted odds ratio, 12.2; 95% confidence interval, 1.5-98-5) and low Glasgow Coma Scale score (adjusted odds ratio for higher Glasgow Coma Scale, 0.53; 95% confidence interval, 0.30-0.96) were independently associated with impaired cerebral autoregulation. Conclusions: Age less than 4 yr was a risk factor for impaired cerebral autoregulation, independent of TBI severity. Age-related factors may play a role in the mechanisms maintaining or worsening cerebral autoregulation in children after TBI.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Fisk, Dana M.; Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; [Vavilala, Monica S.] Childrens Hosp & Reg Med Ctr, Seattle, WA USA; [Freeman, Serena S.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA; [Armstead, William M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35-HD007446, K23-HD044632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35HD007446] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bode H, 1988, APPL PEDIAT TRANSCRA, P114; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; GERMARELLI TA, 1994, J NEUROTRAUM, V11, P357; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Karsli C, 2002, CAN J ANAESTH, V49, P830, DOI 10.1007/BF03017417; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SEVERINGHAUS JW, 1967, CIRC RES, V20, P272, DOI 10.1161/01.RES.20.2.272; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F	34	65	66	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2008	108	4					588	595		10.1097/ALN.0b013e31816725d7			8	Anesthesiology	Anesthesiology	281AE	WOS:000254467500008	18362589	Bronze			2021-06-18	
J	Slobounov, S; Cao, C; Sebastianelli, W; Slobounov, E; Newell, K				Slobounov, Semyon; Cao, Cheng; Sebastianelli, Wayne; Slobounov, Elena; Newell, Karl			Residual deficits from concussion as revealed by virtual time-to-contact measures of postural stability	CLINICAL NEUROPHYSIOLOGY			English	Article						VTC; mild traumatic brain injury (MTBI); postural control	CEREBRAL CONCUSSION; BRAIN-INJURY; RECOVERY; BOUNDARIES; SUPPORT; SWAY	Objective: Traumatic brain injury (TBI), including mild traumatic brain injury (MTBI), commonly known as a "concussion", is still one of the most puzzling neurological disorders and least understood injuries facing sport medicine and the scientific community Cantu R. Concussion assessment Ongoing controversy. In: Slobounov S, Sebastianelli W, editors. Foundations of sport-related brain injuries. New York: Springer Press; 2006. p. 87-111.]. It was our primary objective to assess the dynamic properties of postural control in subjects prior to and after sport-related MTBI using the traditional center of pressure (COP) and virtual time-to-contact (VTC) measures. Methods: We assessed 12 student-athletes prior to and 30 days after they suffered sport-related MTBI on a number of standing still and dynamic postural tasks. All subjects were clinically asymptomatic at day 30 of testing and were cleared for full sport participation based upon neurological and neuropsychological assessments, as well as clinical symptoms resolution. Results: The findings showed: (1) no significant differences for any of the standard COP-based measures of postural control (i.e., 90% ellipse COP area, COP velocity and Stability Index) as a function of testing day (prior to and 30 days post-injury, p >.05); (2) no differences in terms of VTC shape, distribution and nominal values before and after concussion during standing still postural tasks regardless of vision conditions, p >.05; and (3) there were significant alterations in VTC in terms of absolute values, range of VTC at the deflection points and mode at the day 30 post-injury. Conclusions: The deficits in VTC control are indicative of residual postural abnormality in subjects suffering from mild traumatic brain injuries and provide further evidence that VTC is used to regulate dynamic postural movement. Significance: The results show that residual postural abnormalities in concussed individuals may be undetected using conventional research methods and the implications of this for clinical practice are discussed. (c) 2007 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Cao, Cheng; Newell, Karl] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Sebastianelli, Wayne] Penn State Univ, Athlet Med Clin, University Pk, PA 16802 USA; [Slobounov, Elena] Penn State Univ, Informat Technol Serv, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu					BARIN K, 1992, IEEE ENG MED BIOL, V11, P52, DOI 10.1109/51.256960; Barth JT, 2001, J ATHL TRAINING, V36, P253; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; CARELLO C, 1985, BEHAV BRAIN SCI, V8, P151, DOI 10.1017/S0140525X00020021; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz KM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P65, DOI 10.1007/0-387-32565-4_4; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Haddad JM, 2006, J APPL BIOMECH, V22, P155, DOI 10.1123/jab.22.2.155; Haibach PS, 2007, EXP BRAIN RES, V177, P471, DOI 10.1007/s00221-006-0703-4; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hertel J, 2006, J APPL BIOMECH, V22, P67, DOI 10.1123/jab.22.1.67; HERTEL J, 2007, GAIT POSTURE, V40, P69; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Kahneman D., 1973, ATTENTION EFFORT; Krishnamoorthy V, 2005, J PHYSIOL-LONDON, V565, P675, DOI 10.1113/jphysiol.2005.084772; Kugler P. N., 1987, INFORM NATURAL LAW S; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; RICCIO GE, 1993, VARIABILITY AND MOTOR CONTROL, P317; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S., 1994, GAIT POSTURE, V2, P85, DOI [10.1016/0966-6362(94)90097-3, DOI 10.1016/0966-6362(94)90097-3]; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov SM, 1997, J MOTOR BEHAV, V29, P263, DOI 10.1080/00222899709600841; Slobounov SM, 1998, J GERONTOL A-BIOL, V53, pB71, DOI 10.1093/gerona/53A.1.B71; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Valovich TC, 2003, J ATHL TRAINING, V38, P51; van Wegen EEH, 2002, HUM MOVEMENT SCI, V21, P61, DOI 10.1016/S0167-9457(02)00077-5; van Wegen EEH, 2001, MOTOR CONTROL, V5, P254, DOI 10.1123/mcj.5.3.254; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	44	65	65	0	24	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2008	119	2					281	289		10.1016/j.clinph.2007.10.006			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	260SB	WOS:000253029600005	18068428				2021-06-18	
J	Gregory, NG; Lee, CJ; Widdicombe, JP				Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.			Depth of concussion in cattle shot by penetrating captive bolt	MEAT SCIENCE			English	Article						captive bolt; gun; stunning; cattle; slaughter; concussion; abattoir; nystagmus; corneal reflex; tongue	SLAUGHTER; SUICIDE	The prevalence of shallow depth of concussion following captive bolt shooting was assessed in 1608 cattle at an abattoir. Depth of concussion was determined in each animal from physical collapse, presence or absence of corneal reflex, normal rhythmic breathing, eyeball rotation, and whether the animal was re-shot. The presence of nystagmus and the absence of tongue protrusion were also monitored as potential indicators of a shallow depth of concussion, and simultaneous noise measurements assessed whether loudness of gun discharge was linked to concussion depth. The prevalence of a shallow depth of concussion was 8% for all cattle and 15%, for young bulls. Nystagmus was associated with other indicators of a shallow depth of concussion. Absence of tongue protrusion was not associated with depth of concussion, but could serve as a useful indicator of jaw relaxation and insensibility following exsanguination. Soft-sounding shots (<= 111 dB) when using 4.5 gr cartridges were associated with shallow depth of concussion, (C) 2007 Elsevier Ltd. All rights reserved.	[Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.] BBSRC, Hatfield AL9 7TA, Herts, England; [Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.] Univ London Royal Vet Coll, Hatfield AL9 7TA, Herts, England	Gregory, NG (corresponding author), BBSRC, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.	ngregory@rve.ac.uk					BLACKMORE DK, 1988, VET CONTINUING ED PU, V118; Gnjidic Z, 2002, ACTA NEUROCHIR, V144, P1271, DOI 10.1007/s00701-002-1018-2; Grandin T, 2002, J AM VET MED ASSOC, V221, P1258, DOI 10.2460/javma.2002.221.1258; Gregory N., 2000, Journal of Applied Animal Welfare Science, V3, P215, DOI 10.1207/S15327604JAWS0303_3; Gregory NG, 2006, MEAT SCI, V74, P655, DOI 10.1016/j.meatsci.2006.05.021; Gregory NG, 1998, ANIMAL WELFARE MEAT, P298; Gregory NG, 2007, ANIMAL WELFARE MEAT, P299; MENDELOW AD, 1990, HDB CLIN NEUROLOGY, V57, P123; TOGLIA JU, 1976, HDB CLIN NEUROLOGY, V24, P119; Viola L, 2004, J FORENSIC SCI, V49, P595	10	65	69	1	41	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0309-1740			MEAT SCI	Meat Sci.	DEC	2007	77	4					499	503		10.1016/j.meatsci.2007.04.026			5	Food Science & Technology	Food Science & Technology	241DO	WOS:000251637300008	22061934				2021-06-18	
J	Wong, DY; Hollister, SJ; Krebsbach, PH; Nosrat, C				Wong, Darice Y.; Hollister, Scott J.; Krebsbach, Paul H.; Nosrat, Christopher			Poly(epsilon-caprolactone) and poly (L-lactic-co-glycolic acid) degradable polymer sponges attenuate astrocyte response and lesion growth in acute traumatic brain injury	TISSUE ENGINEERING			English	Article							RAT; BIOCOMPATIBILITY; CELLS; MICROGLIA; TIME; CNS; IDENTIFICATION; DISEASES; TISSUE	This study evaluated the response of rat brain to 2 degradable polymers (poly (L-lactic-co-glycolic acid) (PLGA), and poly(epsilon-caprolactone) (PCL)), two common materials in tissue engineering. PLGA has been extensively studied in the brain for controlled drug release as injectable microspheres and is generally accepted as biocompatible in that capacity. Biocompatibility in other forms and for different functions in the brain has not been widely studied. PCL was chosen as an alternative to PLGA for its slower degradation and less-acidic pH upon degradation. Porous scaffolds were made from both polymers and implanted into rat cerebral cortex for 1 and 4 weeks. Morphology, defect size, activation of microglia (OX-42) and astrocytes ( glial fibrillary acidic protein (GFAP)), infiltration of activated macrophages ( major histocompatibility complex ( MHC)-II), and ingrowth of neurons (b-tubulin type III (Tuj-1)) and progenitor cells ( nestin) were analyzed using hematoxylin and eosin staining and immunofluorescence. PCL induced a lower inflammatory response than PLGA, as demonstrated by lower MHC-II and GFAP expression and greater ingrowth. Both polymers alleviated astrocytic activation and prevented enlargement of the defect. Tuj-1-, nestin-, and GFAP-positive cells were observed growing on both polymers at the peripheries of the sponge implants, demonstrating their permissiveness to neural ingrowth. These findings suggest that both polymers attenuate secondary death and scarring and that PCL might have advantages over PLGA.	Univ Tennessee, Coll Dent, Hlth Sci Ctr, Canc Res Bldg, Memphis, TN USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA	Wong, DY (corresponding author), Univ Tennessee, Coll Dent, Hlth Sci Ctr, Canc Res Bldg, Memphis, TN USA.	dywong@umich.edu	Krebsbach, Paul H./AAC-4765-2021	Hollister, Scott/0000-0001-7625-892X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE007057] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Dehay C, 2001, J NEUROSCI, V21, P201, DOI 10.1523/JNEUROSCI.21-01-00201.2001; Fournier E, 2003, BIOMATERIALS, V24, P3311, DOI 10.1016/S0142-9612(03)00161-3; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Johann V, 2007, EXP BRAIN RES, V177, P458, DOI 10.1007/s00221-006-0689-y; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; Kerwin BA, 2002, PROTEIN SCI, V11, P1825, DOI 10.1110/ps.0208102; Kou JH, 1997, J CONTROL RELEASE, V43, P123, DOI 10.1016/S0168-3659(96)01477-0; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; MENEI P, 1994, J BIOMED MATER RES, V28, P1079, DOI 10.1002/jbm.820280913; Mozzetti S, 2005, CLIN CANCER RES, V11, P298; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Popovic N, 2006, INT J PHARMACEUT, V314, P120, DOI 10.1016/j.ijpharm.2005.09.040; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Stidworthy MF, 2004, BRAIN, V127, P1928, DOI 10.1093/brain/awh217; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun HF, 2006, BIOMATERIALS, V27, P1735, DOI 10.1016/j.biomaterials.2005.09.019; Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066; Tang ZG, 2004, BIOMATERIALS, V25, P4741, DOI 10.1016/j.biomaterials.2003.12.003; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; TAYLOR MS, 1994, J APPL BIOMATER, V5, P151, DOI 10.1002/jab.770050208; Thompson TP, 1999, NEUROSURGERY, V45, P741, DOI 10.1097/00006123-199910000-00001; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; WHITELAND JL, 1995, J HISTOCHEM CYTOCHEM, V43, P313, DOI 10.1177/43.3.7868861; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang YW, 2006, STEM CELLS DEV, V15, P943, DOI 10.1089/scd.2006.15.943; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	35	65	67	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1076-3279			TISSUE ENG	Tissue Eng.	OCT	2007	13	10					2515	2523		10.1089/ten.2006.0440			9	Cell & Tissue Engineering	Cell Biology	220NE	WOS:000250162600014	17655492				2021-06-18	
J	Ellemberg, D; Leclerc, S; Couture, S; Daigle, C				Ellemberg, Dave; Leclerc, Suzanne; Couture, Sandra; Daigle, Chantal			Prolonged neuropsychological impairments following a first concussion in female university soccer athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; women; soccer; neuropsychology; sports	TRAUMATIC BRAIN-INJURY; CONCUSSION HISTORY; SEX-DIFFERENCES; HEAD	Objective: Although research is accumulating on the cognitive sequelae from sports-related concussions in men, little to nothing is known about the prolonged cognitive outcome after a concussion 'm women. This point is important because recent evidence suggests th at female athletes are at greater risk of sustaining a concussion. Design: We assessed cognitive functioning after a first concussion n female soccer players, 6 to 8 months after their injury. The first-time concussed athletes were compared with a group of age-matched teammates who had never experienced a concussion. Setting and Participants: A total of 22 female university-level soccer players participated in the study. Main Outcome Measurements: Paper-and-pencil and computcrized tasks were used to assess different neuropsycliological functions. Results: Short- and long-term verbal memory, attention, and simrle reaction time were non-nal. In contrast, compared with the contiol group, the concussed athletes were significantly slower on tasks ttat required decision making (complex reaction time), inhibition and flexibility (Stroop), and planning (Tour of London task). Conclusions: The results of this study suggest that cognitive functions related to cognitive processing speed are most vulnerable to a sports-related concussion and are still impaired for a half year afcr injury in university-level female soccer players.	Univ Montreal, Dept Kinesiol, Montreal, PQ H3T 1J4, Canada; Ctr Rech En Neuropsychol Et Cognition, Montreal, PQ, Canada	Ellemberg, D (corresponding author), Univ Montreal, Dept Kinesiol, 2100 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	dave.ellemberg@umontreal.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Covassin T, 2003, J ATHL TRAINING, V38, P238; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; CULBERTSON WC, 2001, TOWER LONDON; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MASTER EJ, 1999, JAMA-J AM MED ASSOC, V282, P971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; *NAT COLL ATHL ASS, 2000, INJ SURV SYST AC YEA; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; Smith A., 1982, SYMBOL DIGIT MODALIT; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; THALHEIMER W, HOW CALCULATE EFFECT; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P204; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	47	65	65	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2007	17	5					369	374		10.1097/JSM.0b013e31814c3e3e			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	208GP	WOS:000249308100006	17873549				2021-06-18	
J	Jorge, RE; Acion, L; Starkstein, SE; Magnotta, V				Jorge, Ricardo E.; Acion, Laura; Starkstein, Sergio E.; Magnotta, Vincent			Hippocampal volume and mood disorders after traumatic brain injury	BIOLOGICAL PSYCHIATRY			English	Article						glial loss; hippocampal; mood disorder; TBI	STRUCTURED CLINICAL INTERVIEW; HUMAN HEAD-INJURY; MAJOR DEPRESSION; GERIATRIC DEPRESSION; ACUTE PREDICTORS; TIME-COURSE; ATROPHY; MRI; MEMORY; RAT	Background: Recent evidence from clinical studies and animal models of traumatic brain injury (TBI) suggest that neuronal and glial loss might progress after the initial insult in selectively vulnerable regions of the brain such as the hippocampus. There is also evidence that hippocampal dysfunction plays a role in the pathogenesis of mood disorders. We examined the relationship between hippocampal damage and mood disorders after TBI and the effect of hippocampal atrophy on the outcome of TBI patients. Methods: The study group consisted of 37 patients with closed head injury who were evaluated at baseline and at 3,6, and 12 months after trauma. Psychiatric diagnosis was made with a structured clinical interview and DSM-IV criteria. Quantitative magnetic resonance imaging scans were obtained at 3-months follow-up. Results: Patients with moderate to severe head injury had significantly lower hippocampal volumes than patients with mild TBI. Patients who developed mood disorders had significantly lower hippocampal volumes than patients without mood disturbance. Furthermore, there was a significant interaction between mood disorders diagnosis and severity of TBI, by which patients with moderate to severe TBI who developed mood disorders had significantly smaller hippocampal volumes than patients with equivalent severe TBI who did not develop mood disturbance. Finally, reduced hippocampal volumes were associated with poor vocational outcome at 1-year follow-up. Conclusions: Our findings are consistent with a "double-hit" mechanism by which neural and glial elements already affected by trauma are further compromised by the functional changes associated with mood disorders (e.g., the neurotoxic effects of increased levels of cortisol or excitotoxic damage resulting from overactivation of glutaminergic pathways). Finally, patients with greater hippocampal damage were less likely to return to a productive life 1 year after trauma.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Western Australia, Dept Psychiat, Perth, WA 6009, Australia	Jorge, RE (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, Psychiat Res 2-202 MEB, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu		Acion, Laura/0000-0001-5213-6012; Magnotta, Vincent/0000-0001-8639-5354	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH52879, MH40355, MH53592] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH052879, R01MH040355] Funding Source: NIH RePORTER		ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; AXELSON DA, 1993, PSYCHIAT RES, V47, P163, DOI 10.1016/0165-1781(93)90046-J; Bell-McGinty S, 2002, AM J PSYCHIAT, V159, P1424, DOI 10.1176/appi.ajp.159.8.1424; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brown ES, 1999, NEUROPSYCHOPHARMACOL, V21, P474, DOI 10.1016/S0893-133X(99)00054-8; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ENTON AL, 1994, MULTILINGUAL APHASIA; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frodl T, 2004, ARCH GEN PSYCHIAT, V61, P177, DOI 10.1001/archpsyc.61.2.177; Frodl T, 2002, AM J PSYCHIAT, V159, P1112, DOI 10.1176/appi.ajp.159.7.1112; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gold JJ, 2005, HIPPOCAMPUS, V15, P79, DOI 10.1002/hipo.20032; Golden C., 1978, STROOP COLOR WORD TE; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hajek T, 2005, BIPOLAR DISORD, V7, P393, DOI 10.1111/j.1399-5618.2005.00238.x; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Heaton R., 1993, WISCONSIN CARD SORTI; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Koura SS, 1998, ACT NEUR S, V71, P244; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Magnotta VA, 1999, CEREB CORTEX, V9, P151, DOI 10.1093/cercor/9.2.151; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; McEwen BS, 2000, NEUROPSYCHOPHARMACOL, V22, P108, DOI 10.1016/S0893-133X(99)00129-3; Mervaala E, 2000, PSYCHOL MED, V30, P117, DOI 10.1017/S0033291799001567; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Pantel J, 2000, HIPPOCAMPUS, V10, P752, DOI 10.1002/1098-1063(2000)10:6<752::AID-HIPO1012>3.0.CO;2-Y; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1999, J NEUROSCI, V19, P5034; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Starr L B, 1982, Soc Work Res Abstr, V18, P28; Steffens DC, 2000, BIOL PSYCHIAT, V48, P301, DOI 10.1016/S0006-3223(00)00829-5; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Vythilingam M, 2002, AM J PSYCHIAT, V159, P2072, DOI 10.1176/appi.ajp.159.12.2072; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	92	65	65	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	AUG 15	2007	62	4					332	338		10.1016/j.biopsych.2006.07.024			7	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	198WL	WOS:000248658100009	17123480				2021-06-18	
J	Wagner, AK; Kline, AE; Ren, DX; Willard, LA; Wenger, MK; Zafonte, RD; Dixon, CE				Wagner, Amy K.; Kline, Anthony E.; Ren, Dianxu; Willard, Lauren A.; Wenger, Michael K.; Zafonte, Ross D.; Dixon, C. Edward			Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						traumatic brain injury; gender; methylphenidate; spatial learning; behavioral performance	WATER MAZE PERFORMANCE; DOPAMINE TRANSPORTER; ENVIRONMENTAL ENRICHMENT; STRIATAL DOPAMINE; FRONTAL-CORTEX; AMPHETAMINE; RAT; RECOVERY; IMPACT; PROGESTERONE	Evidence suggests that dopamine (DA) agonists improve cognition after traumatic brain injury (TBI). Methylphenidate (MPH) is a DA agonist that blocks the dopamine transporter (DAT). Moreover, female sex hormones modulate DAT expression. Therefore, the purpose of this study was to evaluate how MPH affects behavioral performance in male and female rats. Under anesthesia, rats underwent either controlled cortical impact (CCI) or sham injury operations. Beginning post-operative day 1, rats received daily intraperitoneal injections of MPH (5 mg/kg) or saline. Beam balance (BB) and beam-walking (BW) were assessed on post-operative days 1-5. Exploratory behavior was assessed using an open field free choice novelty (FCN) task on day 13. Spatial memory was assessed with a Morris water maze (MWM) task on days 14-20. Multivariate analyses showed TBI females performed better than TBI males on both motor tasks (P < 0.05 both comparisons), and MPH improved BB performance for both male and female injury groups (P = 0.05) compared to their respective vehicle treated injury groups. Multivariate analysis showed that MPH enhanced MWM performance (spatial learning and retention) after TBI. Significant improvements were noted only in injured males treated with MPH compared to their vehicle control (P < 0.05) with respect to improvements in memory acquisition and retention. Further, injured females treated with MPH had faster swimming speeds than all other groups (P < 0.05 all comparisons), and MPH increased activity in TBI females but not males in the FCN task (P < 0.05). These results sug gest that MPH is beneficial after TBI. However there are gender specific drug differences in 9 behavioral performance and sensitivity to treatment with MPH that may have implications for treatment efficacy and dosing clinically after TBI. (c) 2007 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neruosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD041399, K08HD040833] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833, R03 HD041399-02, K08 HD040833, K08 HD040833-03, R03 HD041399, K08 HD040833-05, K08 HD040833-01, K08 HD040833-02, K08 HD040833-04, R03 HD041399-01, R03HD41399] Funding Source: Medline		Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P53, DOI 10.1016/S0091-3057(99)00091-X; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KUHN CM, 1978, J PHARMACOL EXP THER, V207, P544; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; PERIS J, 1991, BRAIN RES, V566, P255, DOI 10.1016/0006-8993(91)91706-7; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; REBEC GV, 1984, NEUROSCI BIOBEHAV R, V8, P153, DOI 10.1016/0149-7634(84)90030-7; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SHARP PE, 1998, LABORATORY; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	44	65	67	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	AUG 6	2007	181	2					200	209		10.1016/j.bbr.2007.04.006			10	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	185MS	WOS:000247715700004	17517440	Green Accepted			2021-06-18	
J	Alexander, S; Kerr, ME; Kim, Y; Kamboh, MI; Beers, SR; Conley, YP				Alexander, Sheila; Kerr, Mary E.; Kim, Yookyung; Kamboh, M. Ilyas; Beers, Sue R.; Conley, Yvette P.			Apolipoprotein E4 allele presence and functional outcome after severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; genotype; outcome; traumatic brain injury	TRANSGENIC MICE; APOE GENOTYPE; HEAD-INJURY; E EPSILON-4; E4; E3; POLYMORPHISM; CHOLESTEROL; LIPOPROTEIN; PROTEIN	Presence of the apolipoprotein E (APOE) 4 allele has been associated with increased incidence and faster progression of neurodegenerative diseases, poorer recovery from neurologic insult, and decreased cognitive function in the well-elderly. The specific association between APOE genotype and recovery from severe traumatic brain injury (TBI) is conflicting with many groups finding the APOE 4 allele to be associated with poorer outcome while others have found no association. The purpose of this study was to investigate the association between APOE 4 allele presence and recovery during the two years after injury from severe TBI in light of other potential covariates, such as age, race, gender, hypotension or hypoxia before hospital admission and severity of injury. APOE genotype was determined for 123 subjects with severe TBI. Glasgow outcome score (GOS) and mortality were collected at 3, 6, 12, and 24 months after injury. Results showed individuals improved over the two year period following injury and those with the 4 allele had a slower recovery rate than those without the APOE 4 allele over the two year period. We did not however find significant differences in GOS at individual time points when controlling for other covariates. Our findings suggest that APOE 4 allele presence influences recovery rate from severe TBI independent of other covariates. The findings of this study are unique in that they address not only the relationship between APOE 4 allele presence and outcome from severe TBI, but also describe differences in trajectory of recovery by APOE 4 allele presence.	Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; NINR, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15261 USA	Conley, YP (corresponding author), Univ Pittsburgh, Dept Human Genet, 440 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	yconley@pitt.edu		Kamboh, M. Ilyas/0000-0002-3453-1438	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004801] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [NR04801] Funding Source: Medline		Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Hayashi H, 2002, NEUROREPORT, V13, P383, DOI 10.1097/00001756-200203250-00004; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KAMBOH MI, 1995, ATHEROSCLEROSIS, V112, P145, DOI 10.1016/0021-9150(94)05409-C; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Muller W, 1998, BRAIN PATHOL, V8, P641; Nathan BP, 2002, BRAIN RES, V928, P96, DOI 10.1016/S0006-8993(01)03367-4; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; PEPE MG, 1986, J IMMUNOL, V136, P3716; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sun YL, 1998, J NEUROSCI, V18, P3261; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	37	65	68	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					790	797		10.1089/neu.2006.0133			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300004	17518534				2021-06-18	
J	Dick, R; Lincoln, AE; Agel, J; Carter, EA; Marshall, SW; Hinton, RY				Dick, Randall; Lincoln, Andrew E.; Agel, Julie; Carter, Elizabeth A.; Marshall, Stephen W.; Hinton, Richard Y.			Descriptive epidemiology of collegiate women's lacrosse injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussions; lower extremity injuries; knee injuries; facial injuries	ANKLE SPRAINS; PROSPECTIVE INTERVENTION; PROFESSIONAL FOOTBALL; PREVENTION PROGRAM; TEAM HANDBALL; NECK INJURIES; EYE INJURIES; ICE HOCKEY; PLAYERS; HEAD	Objective: To review 16 years of National Collegiate Athletic Association injury surveillance data for women's lacrosse and identify potential areas for injury prevention initiatives. Background: Women's lacrosse is a fast-paced, primarily noncontact sport. Participation in collegiate women's lacrosse almost doubled between the 1688-1989 and 2003-2004 seasons. Lacrosse equipment consists of sticks made of wood or a synthetic material and a hard rubber ball. Until recently, mouth guards were the only required protective equipment. Main Results: Collegiate women's lacrosse game injury rates increased over the 16-year study period. More than 60% of all severe game injuries were lower extremity sprains and strains and knee internal derangements, most frequently the result of noncontact incidents. The most common injury scenarios by injury mechanism and player activity were no contact while ball handling (16.4%) and contact from a stick while ball handling (10.5%). Contact from a stick or a ball accounted for 5.6% and 5.2% of injuries sustained during shooting activities, respectively. Approximately 22% of all game and 12% of all practice injuries involved the head and neck. Contact from a stick accounted for the majority (56.0%) of above-the-neck injuries in games; contact from the ball accounted for 20.0% of these injuries. Participants had 5 times the risk of sustaining a concussion in a game as in a practice (0.70 versus 0.15 injuries per 1000 athletic-exposures, rate ratio = 4.7, 95% confidence interval = 3.8, 6.5). Recommendations: To reduce the lower extremity injuries that comprise the greatest injury burden in women's lacrosse, future researchers should evaluate proprioceptive, plyometric, and balance training interventions designed specifically for female players. Other research areas of great interest involve determining whether protective eyewear (mandated in 2004) reduces injuries to the eye, orbit, and nasal area and identifying any unintended consequences of the mandate, such as increased risk of injuries to other areas of the face or more aggressive play.	MedStar Res Inst, Hyattsville, MD 20783 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Union Mem Hosp, Baltimore, MD USA	Lincoln, AE (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	andrew.e.lincoln@medstar.net		Marshall, Stephen/0000-0002-2664-9233			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P172, DOI 10.1111/j.1600-0838.1997.tb00135.x; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Dick R, 2007, J ATHL TRAINING, V42, P255; Dick R, 2007, J ATHL TRAINING, V42, P173; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Grandstrand SL, 2006, J STRENGTH COND RES, V20, P331; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Livingston LA, 2006, J SCI MED SPORT, V9, P299, DOI 10.1016/j.jsams.2006.05.022; Matz SO, 2004, AM J SPORT MED, V32, P608, DOI 10.1177/0363546503262172; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; *NAT COLL ASS, 2006, 1981 82 2004 05 NCAA; Pfeiffer RP, 2006, J BONE JOINT SURG AM, V88A, P1769, DOI 10.2106/JBJS.E.00616; Stoner LJ, 1993, SAFETY ICE HOCKEY, V2, P183; Thacker SB, 1999, AM J SPORT MED, V27, P753, DOI 10.1177/03635465990270061201; Verhagen E, 2004, AM J SPORT MED, V32, P1385, DOI 10.1177/0363546503262177; Waicus KM, 2002, CLIN J SPORT MED, V12, P24, DOI 10.1097/00042752-200201000-00008; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41; Wester JU, 1996, J ORTHOP SPORT PHYS, V23, P332, DOI 10.2519/jospt.1996.23.5.332	24	65	65	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					262	269					8	Sport Sciences	Sport Sciences	180RC	WOS:000247382300013	17710175				2021-06-18	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Chopp, Michael			Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats	NEUROSURGERY			English	Article							GROWTH-FACTOR; FUNCTIONAL RECOVERY; NERVOUS-SYSTEM; HEAD-INJURY; ADULT RATS; TRANSPLANTATION; NEUROTROPHINS; NEURONS; DIFFERENTIATE; GENERATION	OBJECTIVE: This study investigated the effects of a combination therapy of marrow stromal cells (MSCs) and statins (atorvastatin) after traumatic brain injury in rats. METHODS: Thirty-two female Wistar rats were injured by controlled cortical impact and divided into four groups. Group I was injected with MSCs (1 x 10(6)) intravenously 24 hrs after traumatic brain injury. Group II was administered atorvastatin (0.5 mg/kg) orally for 14 days starting 24 hours after traumatic brain injury. Group III received MSCs (1 x 10(6)) combined with atorvastatin (0.5 mg/kg). Group IV (control) was injected with saline. MSCs were harvested from the bone marrow of male rats to identify male donor cells within female recipient animals by localization of Y chromosomes. Functional analysis was performed using modified neurological severity scores and the Morris water maze test. Animals were sacrificed 35 days after injury and brain sections stained with RESULTS: No functional improvement was seen in animals treated with MSCs or atorvastatin alone (Groups I and II). However, functional improvement was seen with both testing modalities (modified neurological severity scores and Morris water maze) in animals receiving combination therapy (Group III1). Microscopic analysis showed that significantly more MSCs were present in animals receiving combination therapy than in those receiving MSCs alone. Also, significantly more endogenous cellular proliferation was seen in the hippocampus and injury boundary zone of the combination therapy group than in the monotherapy or control groups. CONCLUSION: When administered in combination with MSCs, atorvastatin increases MSC access and/or survival within the injured brain and enhances functional recovery compared with monotherapy.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA	Mahmood, A (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Alder J, 1999, NAT NEUROSCI, V2, P535; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; DEGROOT CJA, 1992, GLIA, V6, P301, DOI 10.1002/glia.440060408; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Pujol BF, 2001, EUR J CELL BIOL, V80, P99, DOI 10.1078/0171-9335-00136; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011	34	65	73	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2007	60	3					546	553		10.1227/01.NEU.0000255346.25959.99			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	144LH	WOS:000244797000028	17327800				2021-06-18	
J	Horn, EM; Feiz-Erfan, I; Lekovic, GP; Dickman, CA; Sonntag, VKH; Theodore, N				Horn, Eric M.; Feiz-Erfan, Iman; Lekovic, Gregory P.; Dickman, Curtis A.; Sonntag, Volker K. H.; Theodore, Nicholas			Survivors of occipitoatlantal dislocation injuries: imaging and clinical correlates	JOURNAL OF NEUROSURGERY-SPINE			English	Article						occipitoatlantal dislocation; spinal cord injury; atlantoaxial distraction; occipitoatlantal joint; craniocervical junction	TRAUMATIC ATLANTOOCCIPITAL DISLOCATION; ATLANTO-OCCIPITAL DISLOCATION; CERVICAL-SPINE; CRUCIATE PARALYSIS; FRACTURE-DISLOCATION; CHILDREN; DIAGNOSIS; JUNCTION; PSEUDOMENINGOCELE; DISSOCIATION	Object. Although rare, traumatic occipitoatlantal dislocation (OAD) injuries are associated with a high mortality rate. The authors evaluated the imaging and clinical factors that determined treatment and were predictive of outcomes, respectively, in survivors of this injury. Methods. The medical records and imaging studies obtained in 33 patients with OAD were reviewed retrospectively. Clinical factors that predicted outcomes, especially neurological injury at presentation and imaging findings, were evaluated. The most sensitive method for the diagnosis of OAD was the measurement of basion axial-basion dens interval on computed tomography (CT) scanning. Five patients with severe traumatic brain injuries (TBIs) were not treated and subsequently died. Of the 28 patients in whom treatment was performed, 23 underwent fusion and five were fitted with an external orthosis. Abnormal findings of the occipitoatlantal ligaments on magnetic resonance (MR) imaging, associated with no or questionable abnormalities on CT scanning, provided the rationale for nonoperative treatment. Of the 28 patients treated for their injuries, perioperative death occur-red in five, three of whom had presented with severe neurological injuries. The mortality rate was highest in patients with a TBI at presentation. The mortality rate was lower in patients presenting with a spinal cord injury, but in this group there was a higher rate of persistent neurological deficits. Conclusions. The spines in patients with CT-documented OAD are most likely unstable and need surgical fixation. In patients for whom CT findings are normal and MR imaging findings suggest marginal abnormalities, nonoperative treatment should be considered. The best predictors of outcome were severe brain or upper cervical injuries at initial presentation.	St Josephs Hosp, Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, Phoenix, AZ 85013 USA	Theodore, N (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	neuropub@chw.edu		Theodore, Nicholas/0000-0001-5355-2683			ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; Apostolides PJ, 1996, SPINE, V21, P1630, DOI 10.1097/00007632-199607150-00004; Bani Alan, 2003, Spine (Phila Pa 1976), V28, pE95; Bellabarba C, 2006, J NEUROSURG-SPINE, V4, P429, DOI 10.3171/spi.2006.4.6.429; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOHLMAN HH, 1979, J BONE JOINT SURG AM, V61, P1119, DOI 10.2106/00004623-197961080-00001; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BULAS DI, 1993, RADIOLOGY, V188, P155, DOI 10.1148/radiology.188.1.8511290; BUNDSCHUH CV, 1992, SPINE, V17, P245, DOI 10.1097/00007632-199202000-00024; Chaljub G, 2001, NEURORADIOLOGY, V43, P41, DOI 10.1007/s002340000483; Deliganis AV, 2000, RADIOGRAPHICS, V20, pS237, DOI 10.1148/radiographics.20.suppl_1.g00oc23s237; DEOLIVEIRA E, 1985, SURG NEUROL, V24, P293, DOI 10.1016/0090-3019(85)90042-4; DICKMAN CA, 1993, J SPINAL DISORD, V6, P300, DOI 10.1097/00002517-199306040-00004; DICKMAN CA, 1990, J NEUROSURG, V73, P850, DOI 10.3171/jns.1990.73.6.0850; DONAHUE DJ, 1994, PEDIATR NEUROSURG, V21, P105, DOI 10.1159/000120822; Dziurzynski K, 2005, SPINE, V30, P1427, DOI 10.1097/01.brs.0000166524.88394.b3; FARTHING J W, 1948, N C Med J, V9, P34; Feiz-Erfan I, 2005, J NEUROSURG-SPINE, V2, P381, DOI 10.3171/spi.2005.2.3.0381; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; FUJIMURA Y, 1995, PARAPLEGIA, V33, P195, DOI 10.1038/sc.1995.44; Gonzalez LF, 2005, J NEUROSURG-SPINE, V3, P318, DOI 10.3171/spi.2005.3.4.0318; Gonzalez LF, 2004, J NEUROSURG-SPINE, V1, P273, DOI 10.3171/spi.2004.1.3.0273; Govender S, 2003, J BONE JOINT SURG BR, V85B, P875, DOI 10.1302/0301-620X.85B6.14092; Grabb BC, 1999, PEDIATR RADIOL, V29, P275, DOI 10.1007/s002470050588; Guigui P, 1995, Eur Spine J, V4, P242, DOI 10.1007/BF00303419; Hadley MN, 2002, NEUROSURGERY, V50, pS105; HARRIS JH, 1994, AM J ROENTGENOL, V162, P887, DOI 10.2214/ajr.162.4.8141013; Horn EM, 2004, J NEUROSURG-SPINE, V1, P39, DOI 10.3171/spi.2004.1.1.0039; Hosalkar HS, 2005, J BONE JOINT SURG AM, V87A, P2480, DOI 10.2106/JBJS.D.01897; Houle P, 2001, PEDIATR NEUROSURG, V34, P193, DOI 10.1159/000056019; Kenter K, 2001, J PEDIATR ORTHOPED, V21, P585, DOI 10.1097/00004694-200109000-00006; Labbe JL, 2001, J PEDIATR ORTHOP B, V10, P319, DOI 10.1097/00009957-200110000-00010; Labler L, 2004, EUR SPINE J, V13, P172, DOI 10.1007/s00586-003-0653-5; LADOUCEUR D, 1991, SPINE, V16, P1383, DOI 10.1097/00007632-199112000-00010; Naso WB, 1997, NEUROSURGERY, V40, P1288, DOI 10.1097/00006123-199706000-00033; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; PAPPAS CTE, 1991, J NEUROSURG, V75, P935, DOI 10.3171/jns.1991.75.6.0935; Park JB, 2001, EUR SPINE J, V10, P524, DOI 10.1007/s005860100334; Przybylski GJ, 1996, SPINE, V21, P1761, DOI 10.1097/00007632-199608010-00009; Rahimi Scott Y, 2003, Neurosurg Focus, V15, pECP1; Reed CM, 2005, SPINE, V30, pE128, DOI 10.1097/01.brs.0000154654.37815.01; Rhoton  Jr AL, 1998, SURG CRANIOVERTEBRAL, P13; Saeheng S, 2001, SURG NEUROL, V55, P35, DOI 10.1016/S0090-3019(00)00350-5; Seibert PS, 2005, ACTA NEUROCHIR, V147, P435, DOI 10.1007/s00701-004-0461-7; Steinmetz Michael P, 2003, Neurosurg Focus, V14, pecp1; Sun PP, 2000, J NEUROSURG, V93, P28, DOI 10.3171/spi.2000.93.1.0028; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; van de Pol GJ, 2005, SPINE, V30, pE424, DOI 10.1097/01.brs.0000170595.83169.94; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WILLIAMS MJ, 1995, J CLIN ANESTH, V7, P156, DOI 10.1016/0952-8180(94)00031-X; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21	52	65	68	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	FEB	2007	6	2					113	120		10.3171/spi.2007.6.2.113			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	132ZQ	WOS:000243981800004	17330577				2021-06-18	
J	Piolino, P; Desgranges, B; Manning, L; North, P; Jokic, C; Eustache, F				Piolino, Pascale; Desgranges, Beatrice; Manning, Liliane; North, Pierre; Jokic, Corinne; Eustache, Francis			Autobiographical memory, the sense of recollection and executive functions after severe traumatic brain injury	CORTEX			English	Article						autobiographical memory; autonoetic consciousness; remembering; self-perspective; executive functions	FOCAL RETROGRADE-AMNESIA; CLOSED-HEAD INJURY; EPISODIC MEMORY; REMOTE MEMORY; AUTONOETIC CONSCIOUSNESS; CONTEXT MEMORY; TEMPORAL-LOBE; OLD MEMORIES; MILD; AGE	Residual disorders of autobiographical memory long after trauma resulting from head injury are rarely assessed, even though they may affect social adjustment and the resumption of daily life. We conducted a thorough study of autobiographical memory in severe traumatic brain injury (TBI) patients, examined at least one year post-trauma. Twenty-five patients were submitted to a novel and controlled autobiographical procedure specially designed to measure episodic memories (i.e., unique, specific in time and space, and detailed) from their entire life span with two kinds of self-remembering experience. The ability to mentally travel back through time and re-experience the source of acquisition, i.e. autonoetic consciousness, was assessed via the "Remember/Know" paradigm and a checking procedure of sense of remembering. Self-perspective in visual imagery, which is also critically involved in episodic recollection, was assessed by the "Field/Observer perspective" paradigm. In addition, the patients underwent a battery of standardized neuropsychological, tests to assess episodic and semantic memory, orientation and executive functions. The results showed that the patients, compared with healthy controls, were significantly impaired in recalling episodic autobiographical memories. This impairment was not related to the life period tested or the patients' ages nor the intellectual impairment. Deficits involved disturbances in sense of remembering, visual imagery self-perspective and recollection of spatiotemporal details. Stepwise-regression analyses carried out in the TBI patients revealed a significant relationship between an abnormal sense of remembering and executive dysfunction covering both anterograde and retrograde components. The novel assessment used in this study provides the first detailed evidence of a more fine-grained deficit of autobiographical memory in TBI patients. Indeed, the results suggest that these patients, long after trauma, present autonoetic consciousness and self-perspective disorders, which include sense of identity (the self) as a continuous entity across time, probably related to frontal dysfunction.	Univ Caen, EPHE, Neuropsychol Lab, CHU Cote Nacre,INSERM E0218, F-14033 Caen, France; Univ Paris 05, Ecole Prat Hautes Etud, CNRS, UMR 8581, Paris, France; Univ Strasbourg, CNRS, Lab Behav & Cognit Neurosci, UMR 7521, Strasbourg, France; Hosp Mulhouse, Dept Funct Rehabil, Mulhouse, France	Eustache, F (corresponding author), Univ Caen, EPHE, Neuropsychol Lab, CHU Cote Nacre,INSERM E0218, EO218, F-14033 Caen, France.	neuropsycho@chu-caen.fr	DESGRANGES, BEATRICE/AAK-4756-2021; Desgranges, Beatrice/L-7739-2015; Piolino, pascale/F-8075-2014; Eustache, Francis/J-9465-2015	DESGRANGES, BEATRICE/0000-0002-3657-9996; Piolino, pascale/0000-0002-7787-924X; Eustache, Francis/0000-0003-4460-8686; Manning, Liliann/0000-0001-5027-8551			Baddeley A, 2001, PHILOS T R SOC B, V356, P1345, DOI 10.1098/rstb.2001.0957; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; BREWER W, 1996, THEORETICAL PERSPECT; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Clarys D, 2002, ACTA PSYCHOL, V109, P315, DOI 10.1016/S0001-6918(01)00064-6; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Conway MA, 1999, MEMORY, V7, P679, DOI 10.1080/096582199387805; Conway MA, 2003, CORTEX, V39, P667, DOI 10.1016/S0010-9452(08)70859-1; Conway MA, 2001, PHILOS T R SOC B, V356, P1375, DOI 10.1098/rstb.2001.0940; CONWAY MA, 2000, HDB NEUROPSYCHOLOGY, V2; CONWAY MA, 1996, REMEMBERING OUR PAST; CROVITZ HF, 1986, AUTOBIOGRAPHICAL MEM; DELLASALA S, 1993, NEUROPSYCHOLOGIA, V31, P823; DELOCHE G, 1997, TEST DENOMIATION ORA; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; Fink GR, 1996, J NEUROSCI, V16, P4275; FITZGERLD JM, 1996, REMEMBERGING PAST ST; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; Gardiner JM, 2001, PHILOS T R SOC B, V356, P1351, DOI 10.1098/rstb.2001.0955; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; HOLLAND CA, 1990, Q J EXP PSYCHOL-A, V42, P441, DOI 10.1080/14640749008401232; Howell D., 1998, METHODES STAT SCI HU; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; KENAN JP, 2003, SELF NEUROSCIENCE PS; KNOWLTON BJ, 1995, J EXP PSYCHOL LEARN, V21, P699, DOI 10.1037/0278-7393.21.3.699; Knowlton BJ, 1998, ACTA PSYCHOL, V98, P253, DOI 10.1016/S0001-6918(97)00045-0; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; Kopelman MD, 2003, HIPPOCAMPUS, V13, P879, DOI 10.1002/hipo.10140; KOPELMAN MD, 1991, BRAIN, V114, P117; Kopelman MD, 2002, BRAIN, V125, P2152, DOI 10.1093/brain/awf229; Kopelman MD, 1997, NEUROPSYCHOLOGIA, V35, P1533, DOI 10.1016/S0028-3932(97)00076-6; KOPELMAN MD, 1989, NEUROPSYCHOLOGIA, V27, P437, DOI 10.1016/0028-3932(89)90050-X; Kopelman MD, 2001, PHILOS T R SOC B, V356, P1409, DOI 10.1098/rstb.2001.0942; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; KOPELMAN MD, 2000, HDB NEUROPSYCHOLOGY; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maguire EA, 2001, PHILOS T R SOC B, V356, P1441, DOI 10.1098/rstb.2001.0944; Mangels JA, 1996, NEUROPSYCHOLOGY, V10, P32, DOI 10.1037/0894-4105.10.1.32; MANTYLA T, 1993, MEM COGNITION, V21, P379, DOI 10.3758/BF03208271; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCARTHY RA, 1992, NEUROPSYCHOLOGIA, V30, P633, DOI 10.1016/0028-3932(92)90068-W; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M, 1999, MEMORY CONSCIOUSNESS; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NIGRO G, 1983, COGNITIVE PSYCHOL, V15, P467, DOI 10.1016/0010-0285(83)90016-6; PETRIDES M, 2000, HDB NEUROPSYCHOLOGY, V2; Piolino P, 2005, COGN NEUROPSYCHOL, V22, P1005, DOI 10.1080/02643290442000428; Piolino P, 2004, NEUROIMAGE, V22, P1371, DOI 10.1016/j.neuroimage.2004.02.025; Piolino P, 2003, BRAIN, V126, P2203, DOI 10.1093/brain/awg222; Piolino P, 2003, COGN NEUROPSYCHOL, V20, P619, DOI 10.1080/02643290242000899; Piolino P, 2002, MEMORY, V10, P239, DOI 10.1080/09658210143000353; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ribot T-A., 1881, MALADIES MEMOIRE; Robinson J A, 1993, Memory, V1, P169; Ross SM, 2000, CORTEX, V36, P521, DOI 10.1016/S0010-9452(08)70536-7; Rubin DC, 1998, MEM COGNITION, V26, P3, DOI 10.3758/BF03211366; SCHACTER DL, 1996, SEARCHING MEMORY BRA; SHIMAMURA AP, 1991, PSYCHOBIOLOGY, V19, P1; SHIMAMURA AP, 1986, BEHAV NEUROSCI, V100, P165, DOI 10.1037/0735-7044.100.2.165; Sirigu A, 1996, CORTEX, V32, P83, DOI 10.1016/S0010-9452(96)80018-9; SQUIRE LR, 1975, J EXP PSYCHOL-HUM L, V104, P50; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; WECHSLER D, 1985, ECHELLE INTELLIGENCE; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; Wheeler MA, 2003, CORTEX, V39, P827, DOI 10.1016/S0010-9452(08)70866-9; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177	88	65	65	0	16	ELSEVIER MASSON, CORP OFF	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2007	43	2					176	195		10.1016/S0010-9452(08)70474-X			20	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	155JZ	WOS:000245575000003	17405665				2021-06-18	
J	Gemma, C; Bickford, PC				Gemma, Carmelina; Bickford, Paula C.			Interleukin-1 beta and caspase-1: Players in the regulation of age-related cognitive dysfunction	REVIEWS IN THE NEUROSCIENCES			English	Article						interleukin-1 beta; caspase-1; inflammation; apoptosis; microglia; aging; learning; memory	LONG-TERM POTENTIATION; TUMOR-NECROSIS-FACTOR; NEURONAL SIGNAL-TRANSDUCTION; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN INJURY; RAT DENTATE GYRUS; GENE-EXPRESSION; RECEPTOR ANTAGONIST; FISCHER-344 RATS; AGING BRAIN	Scientific research on the unprecedented and growing number of older adults in the United States and other industrialized countries has focused much attention on the health consequences of aging. Over the last few decades, inflammation in the brain and its implication in the progression of aging and age-related cognitive dysfunction has been an area of increasing importance to neuroscientists and is now considered as one of the most interesting and promising topics for aging research. One of the critical aspects of inflammatory processes is that the activation of one upstream inflammatory molecule initiates a cascade of self-sustaining inflammatory events which leads to the activation of a number of different downstream functions. Recently, a great deal of attention has been given to the interplay between inflammatory and apoptotic processes and the regulation of these processes by the caspases. The caspase family of proteases can be divided into proapoptotic and pro-inflammatory members. The present review summarizes recent observations of the interactions between the inflammatory cytokine interleukin-1 (IL-1) beta and the inflammatory/apoptotic caspase-1 and their involvement in age-related impairments in cognition. A comprehensive understanding of these mechanisms could potentially lead to the development of preventive or protective therapies that reduce or inhibit the cognitive decline associated with aging and age-related neurodegenerative disease.	Univ S Florida, Ctr Excellence Aging & Brain Repair, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, Tampa, FL 33612 USA; James A Haley Vet Adm Med Ctr, Tampa, FL USA	Bickford, PC (corresponding author), Univ S Florida, Ctr Excellence Aging & Brain Repair, Coll Med, Dept Neurosurg, 12901 Bruce B Downs Blvd,MDC-78, Tampa, FL 33612 USA.	pbickfor@health.usf.edu	Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725; Gemma, Carmelina/0000-0002-4480-0056			Ali A, 1999, J HEMATOTH STEM CELL, V8, P343, DOI 10.1089/152581699320108; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Anisman H, 1999, ADV EXP MED BIOL, V461, P199; Balschun D, 2003, ANN NY ACAD SCI, V992, P1, DOI 10.1111/j.1749-6632.2003.tb03132.x; Barrientos RM, 2002, BEHAV BRAIN RES, V134, P291, DOI 10.1016/S0166-4328(02)00043-8; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BENVENISTE EN, 1992, AM J PHYSIOL, V263, P16; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cartford MC, 2002, J NEUROSCI, V22, P5813; Cavallaro S, 2002, P NATL ACAD SCI USA, V99, P16279, DOI 10.1073/pnas.242597199; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Coleman GJ, 1999, BRAIN RES, V832, P188, DOI 10.1016/S0006-8993(99)01498-5; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; CRESTANI F, 1991, BRAIN RES, V542, P330, DOI 10.1016/0006-8993(91)91587-Q; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; David JP, 1997, NEUROSCI LETT, V235, P53, DOI 10.1016/S0304-3940(97)00708-8; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; FARRAR WL, 1987, J IMMUNOL, V139, P459; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 2000, ARCH NEUROL-CHICAGO, V57, P1273, DOI 10.1001/archneur.57.9.1273; Gahtan E, 1999, NEUROSCI BIOBEHAV R, V23, P615, DOI 10.1016/S0149-7634(98)00058-X; Gemma C, 2005, EUR J NEUROSCI, V22, P1751, DOI 10.1111/j.1460-9568.2005.04334.x; Gemma C, 2002, J NEUROSCI, V22, P6114; Granholm AC, 1997, EXP BRAIN RES, V116, P29, DOI 10.1007/PL00005741; Hirsch E, 1996, P NATL ACAD SCI USA, V93, P11008, DOI 10.1073/pnas.93.20.11008; Hwang DY, 2002, FASEB J, V16, DOI 10.1096/fj.01-0732com; Joseph JA, 1999, J NEUROSCI, V19, P8114; Joseph JA, 1998, J NEUROSCI, V18, P8047; Joshi VD, 2003, FEBS LETT, V555, P180, DOI 10.1016/S0014-5793(03)01271-7; Joshi VD, 2002, INFECT IMMUN, V70, P6896, DOI 10.1128/IAI.70.12.6896-6903.2002; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kotloski R, 2002, PROG BRAIN RES, V135, P95; Krueger JM, 1998, ANN NY ACAD SCI, V856, P148, DOI 10.1111/j.1749-6632.1998.tb08323.x; Lynch MA, 2002, VITAM HORM, V64, P185, DOI 10.1016/S0083-6729(02)64006-3; Lynch MA, 1998, REV NEUROSCIENCE, V9, P169; MAIER SF, 1995, BRAIN RES, V695, P279, DOI 10.1016/0006-8993(95)00930-O; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Mesches MH, 2004, NEUROBIOL AGING, V25, P315, DOI 10.1016/S0197-4580(03)00116-7; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; OPP MR, 1994, AM J PHYSIOL, V266, pR688; PETERSON PK, 1994, CLIN INFECT DIS, V19, P1158, DOI 10.1093/clinids/19.6.1158; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Pugh CR, 1999, BEHAV BRAIN RES, V106, P109, DOI 10.1016/S0166-4328(99)00098-4; Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524; Randle JCR, 2001, EXPERT OPIN INV DRUG, V10, P1207, DOI 10.1517/13543784.10.7.1207; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Sakao Y, 1999, INT IMMUNOL, V11, P471, DOI 10.1093/intimm/11.3.471; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; SMITH A, 1988, PSYCHOPHARMACOLOGY, V96, P414, DOI 10.1007/BF00216072; SPADARO F, 1990, BRAIN BEHAV IMMUN, V4, P308, DOI 10.1016/0889-1591(90)90034-N; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sue W, 2006, AM J CLIN NUTR, V83, p470S; Sugaya K, 2001, Nihon Yakurigaku Zasshi, V118, P251; Taglialatela G, 1996, NEUROREPORT, V7, P977, DOI 10.1097/00001756-199604100-00004; Taishi P, 1997, J NEUROIMMUNOL, V75, P69, DOI 10.1016/S0165-5728(97)00002-7; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; Terao A, 2002, J NEUROIMMUNOL, V132, P99, DOI 10.1016/S0165-5728(02)00317-X; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Warner HR, 1999, ANN NY ACAD SCI, V887, P1; Weindruch R, 2002, ARCH NEUROL-CHICAGO, V59, P1712, DOI 10.1001/archneur.59.11.1712; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072; YIRMIYA R, 1995, BRAIN BEHAV IMMUN, V9, P220, DOI 10.1006/brbi.1995.1021; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	89	65	66	0	2	FREUND & PETTMAN PUBLISHERS	EAST YORKSHIRE	ENHOLMES HALL, PATRINGTON, EAST YORKSHIRE HU12 OPR, ENGLAND	0334-1763			REV NEUROSCIENCE	Rev. Neurosci.		2007	18	2					137	148					12	Neurosciences	Neurosciences & Neurology	177AL	WOS:000247125900003	17593876				2021-06-18	
J	Lammertse, D; Dungan, D; Dreisbach, J; Falci, S; Flanders, A; Marino, R; Schwartz, E				Lammertse, Daniel; Dungan, David; Dreisbach, James; Falci, Scott; Flanders, Adam; Marino, Ralph; Schwartz, Eric			From the 2006 NIDRR SCI measures FTI - Neuroimaging in traumatic spinal an evidence-based meeting cord injury: An evidence-based review for clinical practice and research	JOURNAL OF SPINAL CORD MEDICINE			English	Article; Proceedings Paper	American-Spinal-Injury-Association/45th Annual Meeting of the International-Spinal-Cord-Society	JUN 27, 2006	Boston, MA	Amer Spinal Injury Assoc, Int Spinal Cord Soc		spinal cord injuries; evidence-based medicine; neuroimaging; spinal sonography; magnetic resonance imaging; MRI-diffusion weighted imaging; functional MRI; positron emission tomography; computerized tomography; national institute on disability and rehabilitation research	APPARENT DIFFUSION-COEFFICIENTS; RESONANCE-IMAGING FINDINGS; OPTIMAL RADIOLOGIC METHOD; MOTOR CORTEX; IN-VIVO; NEUROLOGIC RECOVERY; INTRAOPERATIVE SONOGRAPHY; CORTICAL REPRESENTATION; CANAL COMPROMISE; MR	Objective: To perform an evidence-based review of the literature on neuroimaging techniques utilized in spinal cord injury clinical practice and research. Methods: A search of the medical literature for articles on specific neuroimaging techniques used in SCI resulted in 2,302 published reports. Review at the abstract and full report level yielded 99 clinical and preclinical articles that were evaluated in detail. Sixty nine were clinical research studies subjected to quality of evidence grading. Twenty-three articles were drawn from the pre-clinical animal model literature and used for supportive evidence. Seven review articles were included to add an element of previous syntheses of current thinking on neuroimaging topics to the committee process (the review articles were not graded for quality of evidence). A list of clinical and research questions that might be answered on a variety of neuroimaging topics was created for use in article review. Recommendations on the use of neuroimaging in spinal cord injury treatment and research were made based on the quality of evidence. Results: Of the 69 original clinical research articles covering a range of neuroimaging questions, only one was judged to provide Class I evidence, 22 provided Class 11 evidence, 17 Class III evidence, and 29 Class IV evidence. Recommendations: MRI should be used as the imaging modality of choice for evaluation of the spinal cord after injury. CT and plain radiography should be used to assess the bony anatomy of the spine in patients with SCI. MRI may be used to identify the location of spinal cord injury. MRI may be used to demonstrate the degree of spinal cord compression after SCI. MRI findings of parenchymal hemorrhage/contusion, edema, and spinal cord disruption in acute and subacute SCI may contribute to the understanding of severity of injury and prognosis for neurological improvement. MRI-Diffusion Weighted Imaging may be useful in quantifying the extent of axonal loss after spinal cord injury. Functional MRI may be useful in measuring the anatomic functional/metabolic correlates of sensory-motor activities in persons with SCI. MR Spectroscopy may be used to measure the biochemical characteristics of the brain and spinal cord following SCI. Intraoperative Spinal Sonography may be used to identify spinal and spinal cord anatomy and gross pathology during surgical procedures. Further research in these areas is warranted to improve the strength of evidence supporting the use of neuroimaging modalities. Positron Emission Tomography may be used to assess metabolic activity of CNS tissue (brain and spinal cord) in patients with SCI.	CNS, Craig Hosp, Rocky Mt Regional Spinal Injury Syst, Englewood, CO 80110 USA; Univ Colorado, Denver Hlth Sci Ctr, Dept Phys Med & Rehabil, Denver, CO USA; Hosp Rocky Mt Reg Spinal Injury Syst, Englewood, CO USA; Swedish Med Ctr, Dept Radiol, Englewood, CO 80110 USA; Thomas Jefferson Univ, Dept Radiol, Philadelphia, PA USA; Reg Spinal Cord Injury Syst, Philadelphia, PA USA; Thomas Jefferson Univ, Dept Phys Med & Rehabil, Philadelphia, PA USA; Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA USA	Lammertse, D (corresponding author), CNS, Craig Hosp, Rocky Mt Regional Spinal Injury Syst, 3425s Clarkson St, Englewood, CO 80110 USA.	dlammertse@craighospital.org		Lammertse, Daniel/0000-0003-4590-2481; Marino, Ralph/0000-0003-2670-4113; Falci, Scott/0000-0003-4209-0959			Bammer R, 2000, AM J NEURORADIOL, V21, P587; Bammer Roland, 2003, Top Magn Reson Imaging, V14, P461, DOI 10.1097/00002142-200312000-00004; BECERRA JL, 1995, AM J NEURORADIOL, V16, P125; Berens SA, 2005, AM J NEURORADIOL, V26, P1612; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; BONDURANT FJ, 1990, SPINE, V15, P161, DOI 10.1097/00007632-199003000-00002; Bruehlmeier M, 1998, EUR J NEUROSCI, V10, P3918, DOI 10.1046/j.1460-9568.1998.00454.x; Clifton GL, 1996, SPINAL CORD, V34, P193, DOI 10.1038/sc.1996.38; Collignon FD, 2002, J NEUROSURG, V96, P29, DOI 10.3171/spi.2002.96.1.0029; Corbetta M, 2002, P NATL ACAD SCI USA, V99, P17066, DOI 10.1073/pnas.262669099; Cramer SC, 2005, BRAIN, V128, P2941, DOI 10.1093/brain/awh648; Curt A, 2002, J NEUROTRAUM, V19, P43, DOI 10.1089/089771502753460222; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Dai Liyang, 2001, Chinese Medical Sciences Journal, V16, P107; Demir A, 2003, RADIOLOGY, V229, P37, DOI 10.1148/radiol.2291020658; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Dohrmann GJ, 1997, NEUROL RES, V19, P317, DOI 10.1080/01616412.1997.11740819; DUNN EA, 2005, MOLE IMAGING, V4, P58; Dunning MD, 2004, J NEUROSCI, V24, P9799, DOI 10.1523/JNEUROSCI.3126-04.2004; Edlund W, 2004, AM ACAD NEUROLOGY CL; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; Falci S P, 1999, J Spinal Cord Med, V22, P173; Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Finnerup NB, 2003, NEUROLOGY, V61, P1569, DOI 10.1212/01.WNL.0000096016.29134.FA; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; Fukuoka M, 1998, SPINE, V23, P1540, DOI 10.1097/00007632-199807150-00008; HACKNEY DB, 1994, NEUROSURGERY, V35, P1104, DOI 10.1227/00006123-199412000-00013; Ishida Y, 2002, SPINE, V27, P1652, DOI 10.1097/00007632-200208010-00011; ITOH D, 2005, J AM VET MED ASSOC, V227, P1454; Krzyzak AT, 2005, ACTA NEUROBIOL EXP, V65, P255; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; Liao CC, 2005, J NEUROSURG, V103, P17, DOI 10.3171/ped.2005.103.1.0017; Lotze M, 1999, RESTOR NEUROL NEUROS, V14, P183; Madi S, 2001, AM J NEURORADIOL, V22, P1768; MARCIELLO MA, 1993, ARCH PHYS MED REHAB, V74, P940; Mikulis DJ, 2002, NEUROLOGY, V58, P794, DOI 10.1212/WNL.58.5.794; MIRVIS SE, 1990, AM J NEURORADIOL, V11, P755; MONTALVO BM, 1984, RADIOLOGY, V153, P125, DOI 10.1148/radiology.153.1.6473773; Moore CI, 2000, P NATL ACAD SCI USA, V97, P14703, DOI 10.1073/pnas.250348997; Morio Y, 2001, SPINE, V26, P1238, DOI 10.1097/00007632-200106010-00012; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; OHSHIO I, 1993, SPINE, V18, P1140, DOI 10.1097/00007632-199307000-00005; Ohta K, 1999, SPINAL CORD, V37, P580, DOI 10.1038/sj.sc.3100881; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Peyron R, 2004, NEUROLOGY, V63, P1838, DOI 10.1212/01.WNL.0000144177.61125.85; Puri BK, 1998, J NEUROL NEUROSUR PS, V65, P748, DOI 10.1136/jnnp.65.5.748; QUENCER RM, 1984, AM J ROENTGENOL, V143, P1301, DOI 10.2214/ajr.143.6.1301; QUENCER RM, 1992, NEURORADIOLOGY, V34, P85, DOI 10.1007/BF00588148; Quencer RM, 1996, SPINE, V21, P2064, DOI 10.1097/00007632-199609150-00002; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; Rao SC, 1999, SPINE, V24, P598, DOI 10.1097/00007632-199903150-00022; Roelcke U, 1997, J NEUROL NEUROSUR PS, V62, P61, DOI 10.1136/jnnp.62.1.61; RUBIN JM, 1985, RADIOLOGY, V155, P197, DOI 10.1148/radiology.155.1.3883416; Sabbah P, 2002, J NEUROTRAUM, V19, P53, DOI 10.1089/089771502753460231; Sagiuchi T, 2002, J COMPUT ASSIST TOMO, V26, P654, DOI 10.1097/00004728-200207000-00032; SATO T, 1994, PARAPLEGIA, V32, P81, DOI 10.1038/sc.1994.14; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; SCHAEFER DM, 1989, SPINE, V14, P1090, DOI 10.1097/00007632-198910000-00011; Schwartz ED, 2005, J NEUROTRAUM, V22, P1388, DOI 10.1089/neu.2005.22.1388; Schwartz ED, 2005, AM J NEURORADIOL, V26, P390; Schwartz ED, 2005, AM J NEURORADIOL, V26, P7; Schwartz ED, 2005, NEUROREPORT, V16, P73, DOI 10.1097/00001756-200501190-00017; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Schwartz ED, 2003, EXP NEUROL, V182, P49, DOI 10.1016/S0014-4886(03)00036-0; Schwartz ED, 1999, AM J NEURORADIOL, V20, P1422; Selden NR, 1999, NEUROSURGERY, V44, P785, DOI 10.1097/00006123-199904000-00057; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Shimada K, 1999, SPINAL CORD, V37, P410, DOI 10.1038/sj.sc.3100858; Shin JC, 2005, YONSEI MED J, V46, P379, DOI 10.3349/ymj.2005.46.3.379; Shoham S, 2001, NATURE, V413, P793, DOI 10.1038/35101651; SILBERSTEIN M, 1992, AM J NEURORADIOL, V13, P1597; Stroman PW, 2002, NEUROIMAGE, V17, P1854, DOI 10.1006/nimg.2002.1305; Stroman PW, 2004, SPINAL CORD, V42, P59, DOI 10.1038/sj.sc.3101559; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; Takahashi M, 1993, Radiat Med, V11, P127; Takahashi M, 2002, J Orthop Surg (Hong Kong), V10, P129; Takahashi T, 1996, SPINE, V21, P166, DOI 10.1097/00007632-199601150-00002; Tewari MK, 2005, SURG NEUROL, V63, P204, DOI 10.1016/j.surneu.2004.05.042; Turner JA, 2001, IEEE T NEUR SYS REH, V9, P154, DOI 10.1109/7333.928575; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Uchida K, 2004, J NEUROSURG-SPINE, V1, P72, DOI 10.3171/spi.2004.1.1.0072; Wasenko JJ, 1997, CLIN IMAG, V21, P246, DOI 10.1016/S0899-7071(96)00041-1; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; Whipple B, 2002, J SEX MARITAL THER, V28, P79, DOI 10.1080/009262302317251043; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; WIRTH ED, 1992, J NEUROSURG, V76, P261, DOI 10.3171/jns.1992.76.2.0261; Wirth ED, 2001, J NEUROTRAUM, V18, P911, DOI 10.1089/089771501750451839; Yamazaki T, 2005, SURG NEUROL, V63, P95, DOI 10.1016/j.surneu.2004.03.020	91	65	67	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.		2007	30	3					205	214		10.1080/10790268.2007.11753928			10	Clinical Neurology	Neurosciences & Neurology	187ZT	WOS:000247888700002	17684886	Green Published			2021-06-18	
J	VanLandingham, JW; Cutler, SM; Virmani, S; Hoffman, SW; Covey, DF; Krishnan, K; Hammes, SR; Jamnongjit, M; Stein, DG				VanLandingham, Jacob W.; Cutler, Sarah M.; Virmani, Sharad; Hoffman, Stuart W.; Covey, Douglas F.; Krishnan, Kathiresan; Hammes, Stephen R.; Jamnongjit, Michelle; Stein, Donald G.			The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury	NEUROPHARMACOLOGY			English	Article						progesterone; enantiomer; allopregnanolone; traumatic brain injury; neuroprotection; progesterone receptor	HIPPOCAMPAL-NEURONS; LIPID-PEROXIDATION; CEREBRAL EDEMA; CELL-DEATH; RATS; ALLOPREGNANOLONE; STEROIDS; RECEPTOR; EXCITOTOXICITY; ANTIOXIDANT	Previous work shows that neurosteroid enantiomers activate specific molecular receptors that relay neuroprotection. However, the actions of the enantiomer of progesterone (ent-PROG) at the PROG receptor (PR) are unknown. PR binding and transcriptional assays were performed to determine the actions of ent-PROG at the classical PR. Additionally, the neuroprotective effects of ent-PROG in traumatic brain injury (TBI) were investigated and compared to the actions of PROG and its metabolite allopregnanolone (ALLO), both of which have been shown to have neuroprotective properties when given after TBI. Binding studies performed in COS cells over-expressing the PR showed that ent-PROG inhibited PROG binding to the PR. In contrast, ent-PROG did not activate PR-mediated transcription. Rats received bilateral medial frontal cortex injury followed by treatments at 1, 6, 24 and 48 h with PROG, ALLO or ent-PROG. Brains were processed for edema, protein and enzyme activity. ent-PROG treatment in vivo decreased cerebral edema, cell death mediators, inflammatory cytokines, and reactive gliosis, and increased antioxidant activity. These findings suggest that the progestin-mediated pro-survival response seen with TBI is regulated either independently of the classical PR or via nongenomic PR-regulated actions. (c) 2006 Elsevier Ltd. All rights reserved.	Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA; Washington Univ, Dept Mol Biol & Pharmacol, Sch Med, St Louis, MO USA; Texas SW Med Ctr, Dept Pharmacol, Dallas, TX USA	VanLandingham, JW (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	jvanlan@emory.edu	Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P01GM047969] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5P01GM47969] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N538664, 1R01N540825] Funding Source: Medline		Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; Auchus RJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P134, DOI 10.1016/S0003-9861(02)00491-5; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Cassidy RA, 2003, SHOCK, V20, P85, DOI 10.1097/01.shk.0000070740.34700.cd; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Green PS, 2001, ENDOCRINOLOGY, V142, P400, DOI 10.1210/en.142.1.400; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Kirsch M, 2001, FASEB J, V15, P1569, DOI 10.1096/fj.00-0823hyp; Kuebler JF, 2003, CRIT CARE MED, V31, P1786, DOI 10.1097/01.CCM.0000063441.41446.23; LANGLOIS JA, 2004, TRUMATIC BRAIN INJUR; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pearson D, 1999, CHILD CARE HLTH DEV, V25, P3, DOI 10.1046/j.1365-2214.1999.00086.x; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Telci A, 2002, GYNECOL OBSTET INVES, V54, P88, DOI 10.1159/000067718; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wittmer LL, 1996, MOL PHARMACOL, V50, P1581; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xia S, 2002, NEUROBIOL DIS, V9, P282, DOI 10.1006/nbdi.2002.0478; Zorumski CF, 1998, SYNAPSE, V29, P162, DOI 10.1002/(SICI)1098-2396(199806)29:2<162::AID-SYN7>3.0.CO;2-5; Zucchini N, 2005, BBA-MOL CELL RES, V1745, P48, DOI 10.1016/j.bbamcr.2005.02.005	48	65	67	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	NOV	2006	51	6					1078	1085		10.1016/j.neuropharm.2006.07.015			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	112WS	WOS:000242559200007	16926035				2021-06-18	
J	McCrimmon, S; Oddy, M				McCrimmon, Sarah; Oddy, Michael			Return to work following moderate-to-severe traumatic brain injury	BRAIN INJURY			English	Article						return to work; traumatic brain injury; fatigue; cognitive functioning; mood; self-report measures	SEVERE HEAD-INJURY; VOCATIONAL-REHABILITATION; ACUTE PREDICTORS; EMPLOYMENT; OUTCOMES; INDICATORS; IMPAIRMENT; EXPERIENCE; DISABILITY; FATIGUE	Primary objective: To investigate the role of cognitive functioning, fatigue, mood and behaviour in return to work (RTW) following moderate-to-severe traumatic brain injury. Design and methods: Between-groups comparisons were conducted with 20 participants who had RTW and 13 who had not. Participants were well matched for age, pre-morbid intellectual functioning, years of education, injury severity and time since injury. Outcomes and results: The unemployed group reported significantly higher levels of fatigue and depression and significantly more problems on self-report questionnaires. A significantly higher proportion of this group was seeking compensation. No significant differences were obtained on neuropsychological measures of cognitive functioning. Conclusions: Mood, fatigue and behavioural problems may impede a person's ability to RTW. Subjective measures may be more superior to objective measures in predicting RTW. The litigation process may affect people's motivation to RTW.	Sevenoaks Hosp, W Kent Neurorehabil Unit, Sevenoaks TN13 3PG, Kent, England; Brain Injury Rehabil Trust, Burgess Hill, W Sussex, England	McCrimmon, S (corresponding author), Sevenoaks Hosp, W Kent Neurorehabil Unit, Darent House,Hosp Rd, Sevenoaks TN13 3PG, Kent, England.	smccrimmon@ukonline.co.uk					Baddeley A.D., 1992, SPEED CAPACITY LANGU; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; COUGHLIN AK, 1985, ADULT MEMORY INFORM; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CRISP R, 1992, J REHABIL, V58, P27; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DERNAALT J, 1999, J NEUROL NEUROSUR PS, V66, P207; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hillier SL, 1997, BRAIN INJURY, V11, P661; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KOSCIULEK JF, 1991, VOCATIONAL EVALUATIO, V24, P137; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; NAJENSON T, 1995, INT J REHABILITATION, V2, P17; Nybo T, 1999, BRAIN INJURY, V13, P759; Power PW, 2003, BRAIN INJURY, V17, P1021, DOI 10.1080/0269905031000110526; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; SERIO CD, 1993, NEUROREHABILITATION, V4, P53; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Voogt RD, 1998, NEUROREHABILITATION, V11, P107, DOI 10.1016/S1053-8135(98)00015-8; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; West M, 1990, Int J Rehabil Res, V13, P291, DOI 10.1097/00004356-199012000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	65	67	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1037	1046		10.1080/02699050600909656			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100005	17060136				2021-06-18	
J	Drysdale, AJ; Ryan, D; Pertwee, RG; Platt, B				Drysdale, AJ; Ryan, D; Pertwee, RG; Platt, B			Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells	NEUROPHARMACOLOGY			English	Article						cannabidiol; calcium; CB1; vanilloid; voltage-gated calcium channels; intracellular calcium stores; IP3 receptors; ryanodine receptor	CANNABINOID RECEPTOR AGONISTS; CLOSED-HEAD INJURY; CALCIUM-CHANNELS; SYNAPTIC-TRANSMISSION; RAT; MECHANISMS; ANANDAMIDE; INHIBITION; ENDOCANNABINOIDS; SYNAPSES	The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45% of basal Ca2+ levels in both glia (77% responders) and neurones (51% responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50%) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100%) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland	Platt, B (corresponding author), Univ Aberdeen, Sch Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.	b.platt@abdn.ac.uk	Pertwee, Roger Guy/E-1312-2011	Platt, Bettina/0000-0002-7852-0749; Pertwee, Roger/0000-0003-3227-2783			Begg M, 2003, J BIOL CHEM, V278, P46188, DOI 10.1074/jbc.M307258200; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Breivogel CS, 2001, MOL PHARMACOL, V60, P155; Brenowitz SD, 2003, J NEUROSCI, V23, P6373; Brown SP, 2004, J NEUROSCI, V24, P5623, DOI 10.1523/JNEUROSCI.0918-04.2004; CAULFIELD MP, 1992, BRIT J PHARMACOL, V106, P231, DOI 10.1111/j.1476-5381.1992.tb14321.x; Chou KJ, 2001, LIFE SCI, V69, P1541, DOI 10.1016/S0024-3205(01)01242-5; Clodfelter GV, 2002, EUR J PHARMACOL, V447, P189, DOI 10.1016/S0014-2999(02)01843-5; CONSROE P, 1981, J CLIN PHARMACOL, V21, pS428, DOI 10.1002/j.1552-4604.1981.tb02623.x; Costa B, 2004, BRIT J PHARMACOL, V143, P247, DOI 10.1038/sj.bjp.0705920; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Dib B, 1996, INT J TISSUE REACT, V18, P27; Docherty RJ, 1997, BRIT J PHARMACOL, V121, P1461, DOI 10.1038/sj.bjp.0701272; Drysdale AJ, 2003, CURR MED CHEM, V10, P2719, DOI 10.2174/0929867033456387; DRYSDALE AJ, 2005, SOC NEUR ABSTR; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huang CC, 2001, J PHYSIOL-LONDON, V532, P731, DOI 10.1111/j.1469-7793.2001.0731e.x; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; Lorton D, 2000, NEUROIMMUNOMODULAT, V7, P115, DOI 10.1159/000026429; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Mukhopadhyay S, 2002, CHEM PHYS LIPIDS, V121, P91, DOI 10.1016/S0009-3084(02)00153-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Netzeband JG, 1999, J NEUROSCI, V19, P8765, DOI 10.1523/JNEUROSCI.19-20-08765.1999; Nogueron MI, 2001, J NEUROCHEM, V79, P371, DOI 10.1046/j.1471-4159.2001.00567.x; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pertwee RG, 2005, NEUROPHARMACOLOGY, V48, P1139, DOI 10.1016/j.neuropharm.2005.01.010; Pertwee RG, 2004, NEUROSCI INTELL UNIT, P32; Pertwee RG, 2002, EUR J PHARMACOL, V456, P99, DOI 10.1016/S0014-2999(02)02624-9; Pertwee RG, 1996, EUR J PHARMACOL, V315, P195, DOI 10.1016/S0014-2999(96)00631-0; Platt B., 2004, Current Neuropharmacology, V2, P103, DOI 10.2174/1570159043476972; Power JM, 2005, J PHYSIOL-LONDON, V562, P439, DOI 10.1113/jphysiol.2004.076711; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Rubovitch V, 2004, MOL BRAIN RES, V120, P138, DOI 10.1016/j.molbrainres.2003.10.012; Rubovitch V, 2002, MOL BRAIN RES, V101, P93, DOI 10.1016/S0169-328X(02)00174-2; Shen MX, 1998, MOL PHARMACOL, V54, P459; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43; van der Stelt M, 2005, EMBO J, V24, P3026, DOI 10.1038/sj.emboj.7600784; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Verkhratsky A, 2003, J CELL MOL MED, V7, P351, DOI 10.1111/j.1582-4934.2003.tb00238.x; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Walter L, 2003, J NEUROSCI, V23, P1398; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Whittle B. A., 2001, Journal of Cannabis Therapeutics, V1, P183, DOI 10.1300/J175v01n03_12; Xiong H, 2004, NEUROBIOL AGING, V25, P349, DOI 10.1016/S0197-4580(03)00123-4; Zygmunt PM, 1999, NATURE, V400, P452	56	65	65	2	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2006	50	5					621	631		10.1016/j.neuropharm.2005.11.008			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	034FL	WOS:000236914300012	16386766				2021-06-18	
J	Hicdonmez, T; Kanter, M; Tiryaki, M; Parsak, T; Cobanoglu, S				Hicdonmez, Tufan; Kanter, Mehmet; Tiryaki, Mehmet; Parsak, Turgay; Cobanoglu, Sebahattin			Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats	NEUROCHEMICAL RESEARCH			English	Article						trauma; brain tissue; MDA; antioxidant enzyme activity; N-acetylcysteine; caspase-3; rat	CONTROLLED CORTICAL IMPACT; BRAIN-INJURY; LIPID-PEROXIDATION; ACETYL-CYSTEINE; OXIDATIVE STRESS; APOPTOSIS; ISCHEMIA; ANTIOXIDANTS; SUPEROXIDE; ACTIVATION	N-acetylcysteine (NAC) is a precursor of glutathione, a potent antioxidant, and a free radical scavenger. The beneficial effect of NAC on nervous system ischemia and ischemia/reperfusion models has been well documented. However, the effect of NAC on nervous system trauma remains less understood. Therefore, we aimed to investigate the therapeutic efficacy of NAC with an experimental closed head trauma model in rats. Thirty-six adult male Sprague-Dawley rats were randomly divided into three groups of 12 rats each: Group I (control), Group II (trauma-alone), and Group III (trauma+NAC treatment). In Groups II and III, a cranial impact was delivered to the skull from a height of 7 cm at a point just in front of the coronal suture and over the right hemisphere. Rats were sacrificed at 2 h (Subgroups I-A, II-A, and III-A) and 12 h (Subgroups I-B, II-B, and III-B) after the onset of injury. Brain tissues were removed for biochemical and histopathological investigation. The closed head trauma significantly increased tissue malondialdehyde (MDA) levels (P < 0.05), and significantly decreased tissue superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities (P < 0.05), but not tissue catalase (CAT) activity, when compared with controls. The administration of a single dose of NAC (150 mg/kg) 15 min after the trauma has shown protective effect via decreasing significantly the elevated MDA levels (P < 0.05) and also significantly (P < 0.05) increasing the reduced antioxidant enzyme (SOD and GPx) activities, except CAT activity. In the trauma-alone group, the neurons became extensively dark and degenerated into picnotic nuclei. The morphology of neurons in the NAC treatment group was well protected. The number of neurons in the trauma-alone group was significantly less than that of both the control and trauma+NAC treatment groups. In conclusion, the NAC treatment might be beneficial in preventing trauma-induced oxidative brain tissue damage, thus showing potential for clinical implications.	Trakya Univ, Dept Histol & Embryol, Fac Med, Edirne, Turkey; Trakya Univ, Dept Neurosurg, Fac Med, Edirne, Turkey	Kanter, M (corresponding author), Trakya Univ, Dept Histol & Embryol, Fac Med, Edirne, Turkey.	mkanter65@yahoo.com					AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Cakir O, 2003, CARDIOVASC SURG, V11, P375, DOI 10.1016/S0967-2109(03)00077-2; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Charriaut-Marlangue C., 1999, Annales Pharmaceutiques Francaises, V57, P309; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Conti AC, 1998, J NEUROSCI, V18, P5663; Cuzzocrea S, 2000, CARDIOVASC RES, V47, P537, DOI 10.1016/S0008-6363(00)00018-3; Demir S, 1998, CLIN CHIM ACTA, V275, P127, DOI 10.1016/S0009-8981(98)00078-3; Dickey DT, 2004, HEARING RES, V193, P25, DOI 10.1016/j.heares.2004.02.007; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hashimoto K, 2004, NEUROPSYCHOPHARMACOL, V29, P2018, DOI 10.1038/sj.npp.1300512; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jayalakshmi K, 2005, BRAIN RES, V1046, P97, DOI 10.1016/j.brainres.2005.03.054; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kaynar MY, 1998, NEUROSURG REV, V21, P260, DOI 10.1007/BF01105782; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Krasowska A, 2004, BRAIN RES, V997, P176, DOI 10.1016/j.brainres.2003.09.080; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Michel PP, 1999, CLIN NEUROPHARMACOL, V22, P137; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Nehru B, 2004, BIOL TRACE ELEM RES, V101, P257, DOI 10.1385/BTER:101:3:257; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicoletti VG, 2005, NEUROCHEM RES, V30, P737, DOI 10.1007/s11064-005-6867-7; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OZBEN T, 1989, FREE RADICALS OXIDAT, P163; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RINK A, 1995, AM J PATHOL, V147, P1575; Santangelo F, 2003, CURR MED CHEM, V10, P2599, DOI 10.2174/0929867033456567; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shen WH, 2003, ACTA PHARMACOL SIN, V24, P1125; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sochman J, 2002, J AM COLL CARDIOL, V39, P1422, DOI 10.1016/S0735-1097(02)01797-7; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P381, DOI 10.1016/S0025-6196(12)64861-7; SUN Y, 1988, CLIN CHEM, V34, P497; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; Tripathi Y, 1999, Indian J Physiol Pharmacol, V43, P518; Unterberg AW, 1997, ACT NEUR S, V70, P106; Ustun ME, 2001, J TRAUMA, V51, P22, DOI 10.1097/00005373-200107000-00004; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055	64	65	68	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2006	31	4					473	481		10.1007/s11064-006-9040-z			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	051CS	WOS:000238138800004	16758355				2021-06-18	
J	Henry, JD; Phillips, LH; Crawford, JR; Theodorou, G; Summers, F				Henry, JD; Phillips, LH; Crawford, JR; Theodorou, G; Summers, F			Cognitive and psychosocial correlates of alexithymia following traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						emotional change; 'Organic' alexithymia; executive dysfunction	VERBAL FLUENCY PERFORMANCE; QUALITY-OF-LIFE; TORONTO-ALEXITHYMIA; FRONTAL-LOBE; EMOTION RECOGNITION; FACTORIAL VALIDITY; HEAD-INJURY; DEPRESSION; SCALE; ANXIETY	Changes in emotional and social behaviour are considered to be amongst the most common and debilitating consequences of traumatic brain injury (TBI). Little is known of the effects of TBI on alexithymia, which refers to impairment in aspects of understanding emotions. In the current study TBI patients (N = 28) were compared with demographically matched healthy controls (N = 31) on the Toronto Alexithymia Scale-20 (TAS-20), a measure that taps three distinct characteristics of the alexithymia concept; difficulty in identifying emotions, difficulty in describing emotions and externally oriented thinking. Patients and controls also completed measures of anxiety, depression, quality of life, and measures of fluency to assess executive function. Patients showed greater levels of alexithymia, in terms of difficulty identifying emotions and reduced introspection. Difficulty in identifying emotions was associated with poorer quality of life, even when depression and anxiety were controlled. Difficulty in identifying emotions was also uniquely associated with executive function deficits. Thus, although studies typically focus on aspects of cognitive change following head injury, these results lend support to Becerra et al.'s (Becerra, R., Amos, A., & Jongenelis, S. (2002). Organic alexithymia: a study of acquired emotional blindness. Brain Injury, 16, 633-645.) notion of an 'organic alexithymia', and suggest that more attention should be focused upon assessment of emotional change post-head injury. (c) 2005 Elsevier Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; Univ Aberdeen, Sch Psychol, Aberdeen, Scotland; Univ Aberdeen, Dept Neurosurg, Aberdeen, Scotland	Henry, JD (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	julie.henry@unsw.edu.au	Crawford, John R/A-4165-2008; Phillips, Louise H/A-7952-2008	Crawford, John R/0000-0003-3403-3428; Phillips, Louise H/0000-0003-1005-8567; Phillips, Louise/0000-0002-0988-3028; Henry, Julie/0000-0002-2081-3717			Allerdings MD, 2001, BRAIN COGNITION, V47, P304; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; De Leo D, 1998, BEHAV MED, V24, P17, DOI 10.1080/08964289809596377; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Eizaguirre AE, 2004, PERS INDIV DIFFER, V36, P321, DOI 10.1016/S0191-8869(03)00099-0; Gundel H, 2004, PSYCHOSOM MED, V66, P132, DOI 10.1097/01.PSY.0000097348.45087.96; Gunzelmann T, 2002, COMPR PSYCHIAT, V43, P74, DOI 10.1053/comp.2002.29855; Henry JD, 2005, J CLIN EXP NEUROPSYC, V27, P78, DOI 10.1080/138033990513654; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; HENRY JD, IN PRESS AGING NEURO; HENRY JD, 2005, UNPUB NEW CONCEPTUAL; Hintikka J, 2001, COMPR PSYCHIAT, V42, P234, DOI 10.1053/comp.2001.23147; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kano M, 2003, BRAIN, V126, P1474, DOI 10.1093/brain/awg131; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; LANE RD, 1990, J PERS ASSESS, V55, P124, DOI 10.1207/s15327752jpa5501&2_12; Lane RD, 2000, PSYCHOSOM MED, V62, P492, DOI 10.1097/00006842-200007000-00007; Larsen JK, 2003, J PSYCHOSOM RES, V54, P533, DOI 10.1016/S0022-3999(02)00466-X; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lipsanen T, 2004, PSYCHOPATHOLOGY, V37, P200, DOI 10.1159/000080132; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Lumley MA, 1996, J PSYCHOSOM RES, V41, P519, DOI 10.1016/S0022-3999(96)00227-9; Lundh LG, 2001, J PERS, V69, P483, DOI 10.1111/1467-6494.00153; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monsen J T, 1996, J Psychother Pract Res, V5, P238; Muller J, 2003, PSYCHOPATHOLOGY, V36, P71, DOI 10.1159/000070361; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phillips LH, 1997, Methodology of frontal " and executive function, P191; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; SCMITZ M, 2000, DISS ABSTR INT B, V60, P5790; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spalletta G, 2001, PSYCHOSOM MED, V63, P944, DOI 10.1097/00006842-200111000-00013; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Taylor G. J., 1997, DISORDERS AFFECT REG; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Taylor GJ, 2000, CAN J PSYCHIAT, V45, P134, DOI 10.1177/070674370004500203; Waldstein SR, 2002, PSYCHOL HEALTH, V17, P597, DOI 10.1080/08870440290025803; Waller E, 2004, J PSYCHOSOM RES, V57, P239, DOI 10.1016/S0022-3999(03)00613-5; Welsh MC, 1999, BRAIN COGNITION, V41, P231, DOI 10.1006/brcg.1999.1123; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	62	65	67	4	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	1					62	72		10.1016/j.neuropsychologia.2005.04.011			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	004FJ	WOS:000234737100005	15896816				2021-06-18	
J	Ahmad, I; Lope-Piedrafita, S; Bi, XN; Hicks, C; Yao, YQ; Yu, C; Chaitkin, E; Howison, CM; Weberg, L; Trouard, TP; Erickson, RP				Ahmad, I; Lope-Piedrafita, S; Bi, XN; Hicks, C; Yao, YQ; Yu, C; Chaitkin, E; Howison, CM; Weberg, L; Trouard, TP; Erickson, RP			Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurodegeneration; neurosteroids; mouse models; magnetic resonance imaging; Niemann-Pick C	ORGANOTYPIC SLICE CULTURES; TRAUMATIC BRAIN-INJURY; RAT PREFRONTAL CORTEX; DISEASE TYPE-C; CHOLESTEROL ACCUMULATION; GENE-EXPRESSION; MURINE MODEL; MOUSE MODEL; CELL-DEATH; PROTEIN	Niemann-Pick C disease (NPC) is an irreversible neurodegenerative disorder without current treatment. It is thought to result from deficient intracellular cholesterol and/or ganglioside trafficking. We have investigated the effects of allopregnanolone treatments on survival, weight loss, motor function, magnetic resonance imaging (MRI), and neuropathology in the mouse model of NPC (Npc1(-/-) mice). We confirmed previous results showing that a single injection of 250 mu g of allopregnanolone on postnatal day 7 significantly extended the life span of Npc1(-/-) mice. This caused a marked difference in the weight curves of the treated mice but no statistical difference in the Rota-Rod performance. T2-weighted MRI and diffusion tensor imaging (DTI) of treated mice showed values of signal intensity and fractional anisotropy closer to those of wildtype mice than those of untreated Npc1(-/-) mice. Neuropathology showed that day-7 treatment markedly suppressed astrocyte reaction and significantly reduced microglial activation. Furthermore, the steroid treatment also increased myelination in brains of Npc1(-/-) mice. Similar effects of allopregnanolone treatment were observed in Npc1(-/-), mdr1a(-/-) double-mutant mice, which have a deficient blood-brain barrier, resulting in increased steroid uptake. The effects on survival and weight loss of a single injection on day 7 followed by injections every 2 weeks were also evaluated in Npc1(-/-) mice, and the beneficial effects were found to be greater than with the single injection at day 7. We conclude that allopregnanolone treatment significantly ameliorates several symptoms of NPC in Npc1(-/-) mice, presumably by effects on myelination or neuronal connectivity. (c) 2005 Wiley-Liss, Inc.	Univ Arizona, Dept Pediat 4341 B, Tucson, AZ 85724 USA; Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA; Univ Arizona, Ctr Opt Sci, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Biomed Engn Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Interdept Program Genet, Tucson, AZ 85724 USA	Erickson, RP (corresponding author), Univ Arizona, Dept Pediat 4341 B, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	erickson@peds.arizona.edu	Lope-Piedrafita, Silvia/I-4808-2012	Lope-Piedrafita, Silvia/0000-0002-8127-6425	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000343] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00343] Funding Source: Medline		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baudry M, 2003, EXP NEUROL, V184, P887, DOI 10.1016/S0014-4886(03)00345-5; Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Erickson RP, 2000, J INHERIT METAB DIS, V23, P54, DOI 10.1023/A:1005650930330; Erickson RP, 2002, MOL REPROD DEV, V62, P167, DOI 10.1002/mrd.10093; Erickson RP, 2002, J NEUROSCI RES, V68, P738, DOI 10.1002/jnr.10257; Garver WS, 2002, J LIPID RES, V43, P579; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Gizerian SS, 2004, BRAIN RES, V1012, P66, DOI 10.1016/j.brainres.2004.03.049; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2003, J NEUROSCI, V23, P1832; Hasan KM, 2001, J MAGN RESON, V152, P41, DOI 10.1006/jmre.2001.2400; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Lamba V, 2004, TOXICOL APPL PHARM, V199, P251, DOI 10.1016/j.taap.2003.12.027; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leventhal AR, 2004, J BIOL CHEM, V279, P8084, DOI 10.1074/jbc.M310672200; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 2002, HUM MOL GENET, V11, P3107, DOI 10.1093/hmg/11.24.3107; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Mascia MP, 2002, J PHARMACOL EXP THER, V303, P1014, DOI 10.1124/jpet.102.040063; Meijer OC, 1998, ENDOCRINOLOGY, V139, P1789, DOI 10.1210/en.139.4.1789; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Passeggio J, 2005, J BIOL CHEM, V280, P10333, DOI 10.1074/jbc.M413657200; Patterson M.C., 2001, METABOLIC MOL BASES, VIII, P3611; PATTERSON MC, 1993, NEUROLOGY, V43, P61, DOI 10.1212/WNL.43.1_Part_1.61; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; ROFF CF, 1993, ENDOCRINOLOGY, V133, P2913, DOI 10.1210/en.133.6.2913; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Sooksawate T, 2001, BRIT J PHARMACOL, V134, P1303, DOI 10.1038/sj.bjp.0704360; Swanson L.W., 1992, BRAIN MAPS STRUCTURE; Trouard TP, 1999, MAGNET RESON MED, V42, P11, DOI 10.1002/(SICI)1522-2594(199907)42:1<11::AID-MRM3>3.0.CO;2-J; Vincent I, 2003, CURR OPIN NEUROL, V16, P155, DOI 10.1097/00019052-200304000-00006; Wu YP, 2005, MOL GENET METAB, V84, P9, DOI 10.1016/j.ymgme.2004.08.017; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7	49	65	66	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2005	82	6					811	821		10.1002/jnr.20685			11	Neurosciences	Neurosciences & Neurology	993GV	WOS:000233943500009	16273542				2021-06-18	
J	Bakshi, A; Keck, CA; Koshkin, VS; LeBold, DG; Siman, R; Snyder, EY; McIntosh, TK				Bakshi, A; Keck, CA; Koshkin, VS; LeBold, DG; Siman, R; Snyder, EY; McIntosh, TK			Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain	BRAIN RESEARCH			English	Article						traumatic brain injury; neural progenitor cell; transplantation; graft cell death mechanism	SITU DNA FRAGMENTATION; NITRIC-OXIDE; STEM-CELLS; DOPAMINERGIC-NEURONS; TIME-COURSE; 3-NITROPROPIONIC ACID; MESENCEPHALIC TISSUE; WHITE-MATTER; CROSS-TALK; CALPAIN-I	Neural progenitor cells (NPCs) have been shown to be a promising therapy for cell replacement and gene transfer in neurological diseases including traumatic brain injury (TBI). However, NPCs often survive poorly after transplantation despite immunosuppression, and the mechanisms of graft cell death are unknown. In this study, we evaluated caspase- and calpain-mediated mechanisms of cell death of neonatal mouse C17.2 progenitor cells, transplanted at 24 It following lateral fluid percussion brain injury (FP) in rats. Adult Male Sprague-Dawley rats (n = 30) were subjected to lateral FP injury (n = 18) or sham surgery (n = 12). C 17.2 cells labeled with green fluorescent dye (CMFDA) were engrafted in the perilesional deep cortex, and animals were sacrificed at 24 h, 72 h and I week post-transplantation. Pro-apoptotic caspase-mediated cleavage products (Ab246) and calpain-mediated cleavage products (Ab38) were detected in the engrafted cells using immunohistochemistry. Only 2 to 4.5% of grafted NPCs were found to survive at 24 h post-transplantation, regardless of injury status of the host brain, although brain-injured animals had significantly fewer graft cells than sham-injured animals. Limited caspase and calpain-mediated graft cell death was observed in both sham- and brain-injured animals, and caspase-mediated graft cell death was significantly greater than calpain-mediated graft cell death in all animals. Brain-injured animals had significantly increased caspase-mediated graft cell death compared to sham-injured animals. These results suggest that both the caspase and calpain family of proteases are involved in graft cell death, and that caspase-mediated apoptotic graft cell death predominates in the acute post-traumatic period following TBI. (C) 2005 Elsevier B.V. All rights reserved.	Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Burnham Inst, Program Dev & Regenerat Cell Biol, La Jolla, CA 92037 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Bakshi, A (corresponding author), Univ Penn, 105,Hayden Hall,3320,Smith Walk, Philadelphia, PA 19144 USA.	ashabakshi@gmail.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40978] Funding Source: Medline		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Akerud P, 2001, J NEUROSCI, V21, P8108; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Baker GR, 1997, AM J HEMATOL, V56, P17; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Berardi P, 2004, CELL MOL LIFE SCI, V61, P2173, DOI 10.1007/s00018-004-4179-8; Bizat N, 2003, J BIOL CHEM, V278, P43245, DOI 10.1074/jbc.M305057200; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Branton RL, 1999, EXP NEUROL, V160, P88, DOI 10.1006/exnr.1999.7207; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Cambray N, 2002, DEVELOPMENT, V129, P4855; Ceccatelli S, 2004, TOXICOL LETT, V149, P59, DOI 10.1016/j.toxlet.2003.12.060; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cicchetti F, 2002, EXP NEUROL, V177, P376, DOI 10.1006/exnr.2002.8007; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Davenne M, 2005, CHEM SENSES, V30, pI115, DOI 10.1093/chemse/bjh141; DUAN WM, 1995, NEUROSCIENCE, V64, P629, DOI 10.1016/0306-4522(94)00416-3; Emgard M, 1999, EXP NEUROL, V160, P279, DOI 10.1006/exnr.1999.7198; Emgard M, 2003, J NEUROCHEM, V86, P1223, DOI 10.1046/j.1471-4159.2003.01931.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gahm C, 2000, NEUROSURGERY, V46, P169; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; Hansson O, 2000, EXP NEUROL, V164, P102, DOI 10.1006/exnr.2000.7406; Helt CE, 2001, EXP NEUROL, V170, P258, DOI 10.1006/exnr.2001.7709; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim DE, 2004, STROKE, V35, P952, DOI 10.1161/01.STR.0000120308.21946.5D; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; Marchionini DM, 2004, CELL TRANSPLANT, V13, P273, DOI 10.3727/000000004783983972; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nadarajah B, 2002, NAT NEUROSCI, V5, P218, DOI 10.1038/nn813; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NIKKHAH G, 1994, NEUROSCIENCE, V63, P57, DOI 10.1016/0306-4522(94)90007-8; Oo TF, 2002, EXP NEUROL, V175, P1, DOI 10.1006/exnr.2002.7881; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosario CM, 1997, DEVELOPMENT, V124, P4213; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Rosenblad C, 1999, NEUROREPORT, V10, P1783, DOI 10.1097/00001756-199906030-00029; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Slagsvold HH, 2003, BRAIN RES, V984, P111, DOI 10.1016/S0006-8993(03)03119-6; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Soares HD, 1995, J NEUROSCI, V15, P8223; Sortwell CE, 2000, EXP NEUROL, V165, P268, DOI 10.1006/exnr.2000.7476; Sortwell CE, 2003, FRONT BIOSCI, V8, pS522, DOI 10.2741/1096; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Tamm C, 2004, EUR J NEUROSCI, V19, P2613, DOI 10.1111/j.0953-816X.2004.03391.x; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wennberg L, 2001, TRANSPLANTATION, V71, P1797, DOI 10.1097/00007890-200106270-00016; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILLIAMS S, UNPUB J NEUROTRAUMA; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091; Zaman V, 2002, NEUROSCIENCE, V109, P537, DOI 10.1016/S0306-4522(01)00478-X; Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zietlow R, 2002, CELL TRANSPLANT, V11, P637, DOI 10.3727/000000002783985396	91	65	75	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 14	2005	1065	1-2					8	19		10.1016/j.brainres.2005.09.059			12	Neurosciences	Neurosciences & Neurology	997FA	WOS:000234229200002	16309635				2021-06-18	
J	Acquarolo, A; Urli, T; Perone, G; Giannotti, C; Candiani, A; Latronico, N				Acquarolo, A; Urli, T; Perone, G; Giannotti, C; Candiani, A; Latronico, N			Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study	INTENSIVE CARE MEDICINE			English	Article						pneumonia; antibiotic prophylaxis; coma; brain injury	VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; RISK-FACTORS; TRAUMA PATIENTS; HEAD TRAUMA; COLONIZATION; INFECTIONS; INJURY; MORTALITY	Objective: To evaluate if a 3-day ampicillin-sulbactam prophylaxis can reduce the occurrence of early-onset pneumonia (EOP) in comatose mechanically-ventilated patients. Design: This was a single-centre, prospective, randomised, open study. Setting: A 10-bed general-neurological ICU in a 2,000-bed university hospital. Patients and participants: Comatose mechanically-ventilated patients with traumatic, surgical or medical brain injury. Interventions: Patients were randomized to either ampicillin-sulbactam prophylaxis (3 g every 6 h for 3 days) plus standard treatment or standard treatment alone. Measurements and results: Main outcome was the occurrence of EOP. Secondary outcome measures were occurrence of late-onset pneumonia, percentage of non-pulmonary infections and of emerging multiresistant bacteria, duration of mechanical ventilation and of ICU stay and ICU mortality. Interim analysis at 1 year demonstrated a statistically significant reduction of EOP in the ampicillin-sulbactam group, and the study was interrupted. Overall, 39.5% of the patients developed EOP, 57.9% in the standard treatment group and 21.0% in the ampicillin-sulbactam group (chi-square 5.3971; P = 0.022). Relative risk reduction of EOP in patients receiving ampicillin-sulbactam prophylaxis was 64%; the number of patients to be treated to avoid one episode of EOP was three. No differences in other outcome parameters were found; however, the small sample size precluded a definite analysis. Conclusions: Antibiotic prophylaxis with ampicillin-sulbactam significantly reduced the occurrence of EOP in critically ill comatose mechanically ventilated patients. This result should encourage a large multicenter trial to demonstrate whether ampicillin-sulbactam prophylaxis reduces patient mortality, and whether antibiotic resistance is increased in patients receiving prophylaxis.	Univ Brescia Spedali Civili, Inst Anesthesiol Intens Care, I-25125 Brescia, Italy	Acquarolo, A (corresponding author), Univ Brescia Spedali Civili, Inst Anesthesiol Intens Care, Piazzale Osped Civili 1, I-25125 Brescia, Italy.	a.acquarolo@tiscali.it	Latronico, Nicola/F-1557-2010	Latronico, Nicola/0000-0002-2521-5871			Abraham E, 2004, INTENS CARE MED, V30, P1017, DOI 10.1007/s00134-004-2321-6; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fridkin SK, 1999, CLIN CHEST MED, V20, P303, DOI 10.1016/S0272-5231(05)70143-X; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65; JENNETT B, 1977, LANCET, V1, P878; LANGER M, 1987, INTENS CARE MED, V13, P342; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Plum F, 1972, Contemp Neurol Ser, V10, P1; POCOCK SJ, 1982, BIOMETRICS, V38, P153, DOI 10.2307/2530298; Rello J, 2003, CRIT CARE MED, V31, P2544, DOI 10.1097/01.CCM.0000089928.84326.D2; RELLO J, 1992, EUR RESPIR J, V5, P1249; Robert R, 2003, INTENS CARE MED, V29, P1062, DOI 10.1007/s00134-003-1729-8; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Urli T, 2002, J HOSP INFECT, V52, P130, DOI 10.1053/jhin.2002.1271; VALCKE YJ, 1990, ANTIMICROB AGENTS CH, V34, P958, DOI 10.1128/AAC.34.6.958	25	65	67	1	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2005	31	4					510	516		10.1007/s00134-005-2585-5			7	Critical Care Medicine	General & Internal Medicine	910WR	WOS:000227963400006	15754197				2021-06-18	
J	Levine, B; Black, SE; Cheung, G; Campbell, A; O'Toole, C; Schwartz, ML				Levine, B; Black, SE; Cheung, G; Campbell, A; O'Toole, C; Schwartz, ML			Gambling task performance in traumatic brain injury - Relationships to injury severity, atrophy, lesion location, and cognitive and psychosocial outcome	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						prefrontal cortex; self-regulation; magnetic resonance imaging; neuropsychological assessment; psychosocial outcome	VENTROMEDIAL PREFRONTAL CORTEX; NEUROBEHAVIORAL RATING-SCALE; CLOSED-HEAD-INJURY; DECISION-MAKING; FRONTAL-LOBE; STRATEGY APPLICATION; EPISODIC MEMORY; WORKING-MEMORY; DAMAGE; DEFICITS	Objective: To determine the sensitivity of the Gambling Test (GT) to the neurocognitive effects of traumatic brain injury (TBI) and to examine the cognitive, neural, and psychosocial correlates of impaired GT performance in patients with TBI. Background: The GT is sensitive to behavioral deficits in patients with prefrontal brain damage, especially in ventral regions. Patients with TBI and behavioral deficits often have focal ventral prefrontal damage as well as diffuse damage. Analysis of the correlates of the GT in this population has implications for interpretation of the GT in other groups. Method: Seventy-one TBI patients were administered the GT, neuropsychological tests, and psychosocial outcome questionnaires. Patients also had high-resolution structural magnetic resonance imaging analyzed for both lesion location and tissue compartment volumes. Results: The GT was sensitive to TBI in general, but not to TBI severity or quantified chronic phase atrophy. Marked impairment was observed in (but not limited to) patients with large frontal lesions. There were modest correlations between the GT and tests of working memory and executive functioning as well as between self- and other-rated real-life memory, executive, and emotional problems. Conclusions: The GT can be a useful adjunct to assessment of patients with TBI. Interpretation of GT performance in patients with complex neuropsychological deficits such as TBI should consider the influence of domain-general resources in addition to specific ventral prefrontal function.	Univ Toronto, Baycrest Ctr Geriatr Care, Rotman Res Inst, Dept Psychol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Med Imaging, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Surg, Toronto, ON M6A 2E1, Canada	Levine, B (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Rotman Res Inst, Dept Psychol, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.utoronto.ca	Levine, Brian/O-2725-2019; Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; Craik FIM, 1982, AGING COGNITIVE PROC, P191, DOI DOI 10.1007/978-1-4684-4178-9_11; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Denburg NL, 2001, BRAIN COGNITION, V47, P156; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Ernst M, 2002, NEUROPSYCHOPHARMACOL, V26, P682, DOI 10.1016/S0893-133X(01)00414-6; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1994, NEUROPSYCHOLOGIA, V32, P729, DOI 10.1016/0028-3932(94)90032-9; FUSTER JM, 1997, PREFRONTAL CORTEX AN; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P, 1996, WORD MEMORY TEST; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JonesGotman M, 1997, BRAIN, V120, P1845, DOI 10.1093/brain/120.10.1845; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B., 2002, PRINCIPLES FRONTAL L, P448; LEWIN ICF, 1992, COST DISORDERS BRAIN; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; MOSCOVITCH M, 1992, NEUROPSYCHOLOGY MEMO, P5; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Pandya D. N., 1987, FRONTAL LOBES REVISI, P41; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stout JC, 2001, J INT NEUROPSYCH SOC, V7, P92, DOI 10.1017/S1355617701711095; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; *WAR DEP ADJ GEN O, 1944, ARM IND TEST BATT; Wilson B.A., 1997, METHODOLOGY FRONTAL, P239; Winocur G, 1992, HDB AGING COGNITION, P315; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8	88	65	70	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	MAR	2005	18	1					45	54		10.1097/01.wnn.0000152227.13001.c3			10	Behavioral Sciences; Clinical Neurology	Behavioral Sciences; Neurosciences & Neurology	927YF	WOS:000229236600006	15761276				2021-06-18	
J	Soustiel, JF; Palzur, E; Nevo, O; Thaler, I; Vlodavsky, E				Soustiel, JF; Palzur, E; Nevo, O; Thaler, I; Vlodavsky, E			Neuroprotective anti-apoptosis effect of estrogens in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; estrogens; head injury; neuroprotection	MICE OVEREXPRESSING BCL-2; HEAD-INJURY; MESSENGER-RNA; EXPERIMENTAL STROKE; ESTRADIOL PROTECTS; FOREBRAIN ISCHEMIA; COGNITIVE RECOVERY; NEURONAL DAMAGE; CLINICAL-TRIALS; FOCAL ISCHEMIA	Traumatic brain injury (TBI) is a leading cause of death and functional disability in western countries, affecting mostly young patients. Despite intense and sustained efforts deployed for the development of new therapeutic strategies, no clinical benefit has been shown by any of the investigated compounds. Increasing attention has been drawn during the past two decades to the neuroprotective effects of estrogens, although most of the available data relate to ischemic brain injury. The purpose of the present study was to investigate the potential neuroprotective value of estrogens in TBI as a therapeutic modality. For this purpose, a contusion was created in the parietal cortex by dynamic cortical deformation in two groups of 10 Sprague-Dawley male rats. Following the injury, treated animals received conjugated estrogens for 3 days, using a subcutaneously implanted osmotic pump. Animals were then sacrificed, and TUNEL, anti-active Caspase 3, bcl-2, and bax labeling were performed in paraffin-embedded brain sections, allowing for comparative and quantitative analysis. In estrogen-treated animals, there was a marked and significant reduction of apoptosis in comparison with non-treated animals. The reduction in TUNEL and active Caspase 3 staining was similar and close to 50%. Optical analysis of histological slides prepared by bcl-2 labeling showed a significant increase in bcl-2 expression in estrogen-treated animals compared to non-treated animals. On the contrary, bax expression was not influenced by hormonal treatment, and no difference could be noticed between the two groups. These results support the potential therapeutic value of estrogens in TBI and further clarify their mode of action.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Phys, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Obstet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Phys, Acute Brain Injury Res Lab, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 1998, FASEB J, V12, pA954; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Geary GG, 2000, AM J PHYSIOL-HEART C, V279, pH511; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Holm KH, 2001, NEUROSCIENCE, V104, P397, DOI 10.1016/S0306-4522(01)00098-7; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kauser K, 1997, J VASC RES, V34, P229, DOI 10.1159/000159227; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Li KW, 1996, STROKE, V27, P498, DOI 10.1161/01.STR.27.3.498; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Sato S, 1998, BRAIN RES, V808, P56, DOI 10.1016/S0006-8993(98)00784-7; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shi J, 1997, EXP BRAIN RES, V117, P200, DOI 10.1007/s002210050216; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Tang MY, 1996, BBA-LIPID LIPID MET, V1299, P155, DOI 10.1016/0005-2760(95)00227-8; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Yang LC, 1998, J NEUROSCI, V18, P8145; Zaulyanov LL, 1999, CELL MOL NEUROBIOL, V19, P705, DOI 10.1023/A:1006948921855	51	65	68	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					345	352		10.1089/neu.2005.22.345			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500002	15785230				2021-06-18	
J	de Boussard, CN; Lundin, A; Karlstedt, D; Edman, G; Bartfai, A; Borg, J				de Boussard, CN; Lundin, A; Karlstedt, D; Edman, G; Bartfai, A; Borg, J			S100 and cognitive impairment after mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						MTBI; biochemical markers; S100B; S100A1B; neuropsychology; cognition	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; PROTEIN; SERUM; S-100B; DYSFUNCTION; MARKERS; ADULTS; DAMAGE	Objective: The aim of this study was to explore the relationship between the proteins S100B and S100A1B and symptoms and signs of cognitive impairment for 3 months after mild traumatic brain injury (MTBI). Methods: Serum concentrations of S100A1B and S100B were examined in a prospective cohort study of patients with MTBI and a Glasgow Coma Scale score of 14 or 15. Cognitive performance was assessed by repeated computerized neuropsychological testing and an extended neuropsychological test. Symptoms were assessed using the Rivermead Post-Concussion Symptoms Questionnaire. Results: Concentrations of S100B and S100A1B were above cut-off in 31% and 48% respectively. Eight percent of the patients had signs of cognitive impairment according to the computerized neuropsychological tests and 30% according to the extended test. Symptoms of cognitive impairment were reported by 44% of the patients on the first day post-injury and by 26% at 3 months. No significant associations between S100B or S100A1B concentrations and symptoms or signs of cognitive impairment were found. Conclusion: Abnormal S100 serum concentrations and symptoms or signs of cognitive impairment were not significantly associated in patients with MTBI and a Glasgow Coma Scale score of 14 or 15.	Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden; Danderyd Hosp, Karolinska Inst, R&D Unit, SE-18288 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Rehabil Med, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden	de Boussard, CN (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden.	catharina.nygren@reh.ds.sll.se		Borg, Jorgen/0000-0002-2372-7478; Bartfai, Aniko/0000-0002-0815-2485			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2002, EUR J MED RES, V7, P164; Bland JM, 1996, BRIT MED J, V313, P744; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GRONWALL D, 1974, LANCET, V2, P605; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVANDER S, 1987, NORD PSYKIATR TIDSKR, V41, P417; LEZAK MD, 1991, NEUROPSYCHOLOGICAL A; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Teasdale TW, 1997, BRIT MED J, V315, P569; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler, 1981, WAIS R MANUAL; Winer B.J., 1962, STAT PRINCIPLES EXPT; Winocur G, 2001, NEUROBIOL LEARN MEM, V75, P230, DOI 10.1006/nlme.2000.3961	33	65	67	1	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2005	37	1					53	57		10.1080/16501970410015587			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	893NL	WOS:000226726400009	15788333	DOAJ Gold			2021-06-18	
J	Powell, KB; Voeller, KKS				Powell, KB; Voeller, KKS			Prefrontal executive function syndromes in children	JOURNAL OF CHILD NEUROLOGY			English	Article							SPATIAL WORKING-MEMORY; FRONTAL-LOBE FUNCTIONS; CARD SORTING TEST; HUMAN INFANTS; CORTEX; CEREBELLAR; BRAIN; CONSEQUENCES; PERFORMANCE; DAMAGE	"Executive function" is a term describing the processes required for conscious control of thought, emotion, and action that are central to the management of one's day-to-day life. Executive function is subserved by the prefrontal cortex and related subcortical structures. Disorders affecting the prefrontal cortex-subcortical system are numerous and heterogeneous, but contemporary research has begun to elucidate the mechanisms and consequences of dysfunction in various subsystems with increasing specificity. Prefrontal executive dysfunction results in impaired regulation of cognition, attention, behaviors, arousal, and emotion, all of which have serious and pervasive consequences for functioning across the life span. These executive function deficits are typically difficult to treat, ameliorate, or remediate and require sensitive handling by caretakers. Executive dysfunction can arise as a consequence of many different factors (metabolic, genetic, certain types of epilepsy, cerebral dysgenesis, prematurity, traumatic brain injury, hypoxia, and toxic exposure). The present review delineates the features of prefrontal executive function deficits in children and proposes a roadmap for their diagnosis, treatment, and management. (J Child Neurol 2004; 19:785-797).	Western Inst Neurdev Studies & Intervent, Boulder, CO 80302 USA	Powell, KB (corresponding author), Western Inst Neurdev Studies & Intervent, 2501 Walnut St,Suite 104, Boulder, CO 80302 USA.	kbpow@attglobal.net					Aarsen FK, 2004, NEUROLOGY, V62, P1311, DOI 10.1212/01.WNL.0000120549.77188.36; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1974, RECENT ADV LEARNING, V8, P47, DOI DOI 10.1016/S0079-7421(08)60452-1; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BENSON DF, 1990, SCHIZOPHRENIA BULL, V16, P403, DOI 10.1093/schbul/16.3.403; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; Blair RJR, 2001, J ABNORM CHILD PSYCH, V29, P499, DOI 10.1023/A:1012277125119; BOONE KB, 1988, NEUROLOGY, V38, P583, DOI 10.1212/WNL.38.4.583; Bradshaw J.L., 2001, DEV DISORDERS FRONTO; BRADSHAW JL, 1997, HUMAN EVOLUTION NEUR; Cato MA, 2004, J INT NEUROPSYCH SOC, V10, P453, DOI 10.1017/S1355617704103123; Chang BS, 2003, ANN NEUROL, V53, P596, DOI 10.1002/ana.10520; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Culhane-Shelburne K, 2002, J INT NEUROPSYCH SOC, V8, P623, DOI 10.1017/S1355617702801308; Damasio A., 1994, DESCARTESERROR EMOTI; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; DERIX MMA, 1997, DEPRESSION NEUROBIOL, P109; DESPOSITO M, 2002, PRINCIPLES FRONTAL L, P168, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0011; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.1111/j.1467-8624.1985.tb00160.x; Diamond A, 2000, CHILD DEV, V71, P44, DOI 10.1111/1467-8624.00117; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; DIAMOND A, 1989, DEV PSYCHOBIOL, V22, P271, DOI 10.1002/dev.420220307; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1080/13554799908411987; Dum RP, 2003, J NEUROPHYSIOL, V89, P634, DOI 10.1152/jn.00626.2002; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Floel A, 2004, CEREB CORTEX, V14, P404, DOI 10.1093/cercor/bhh002; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331; Gioia G.A., 2000, BEHAV RATING INVENTO; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; GOLDMAN PS, 1972, BRAIN RES, V43, P53, DOI 10.1016/0006-8993(72)90274-0; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; Heaton R., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1991, EPILEPSIA, V32, pS41; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Karatekin C, 2000, PEDIATR NEUROL, V22, P106, DOI 10.1016/S0887-8994(99)00128-9; Kerr A, 2004, BRAIN COGNITION, V55, P148, DOI 10.1016/s0278-2626(03)00275-6; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Krasnegor N. A., 1997, DEV PREFRONTAL CORTE; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Lichter DC, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P260; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Matsuoka T, 2000, IPAP CONFERENCE SER, V1, P11; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; Middleton FA, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P44; Middleton FA, 1997, INT REV NEUROBIOL, V41, P61, DOI 10.1016/S0074-7742(08)60347-5; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moll J, 2003, NEUROREPORT, V14, P299, DOI 10.1097/01.wnr.0000057866.05120.28; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; Moore C., 2001, SELF TIME DEV PERSPE; Nagahama Y, 1996, BRAIN, V119, P1667, DOI 10.1093/brain/119.5.1667; Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422; OSTERGAARD AL, 1987, NEUROPSYCHOLOGIA, V25, P341, DOI 10.1016/0028-3932(87)90023-6; PENNINGTION BF, 1994, WORKING MEMORY FUNCT; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Pizzagalli DA, 2002, BIOL PSYCHIAT, V52, P73, DOI 10.1016/S0006-3223(02)01313-6; PODELL K, 2001, FRONTAL LOBES NEUROP, P83; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Riva D, 2000, BRAIN, V123, P1051, DOI 10.1093/brain/123.5.1051; Rogers MA, 1998, BRAIN RES BULL, V47, P297, DOI 10.1016/S0361-9230(98)00126-9; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; Saxena S, 1998, BRIT J PSYCHIAT, V173, P26; Schmahmann JD, 1998, TRENDS COGN SCI, V2, P362, DOI 10.1016/S1364-6613(98)01218-2; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Sinclair DB, 2004, PEDIATR NEUROL, V30, P169, DOI 10.1016/j.pediatrneurol.2003.08.005; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Tatcher R.W, 1997, DEV PREFRONTAL CORTE, P85; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; WEINBERGER DR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P275; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; ZALD DH, 2001, FRONTAL LOBES NEUROP, P83; Zarahn E, 1999, COGNITIVE BRAIN RES, V7, P255, DOI 10.1016/S0926-6410(98)00029-9	92	65	70	2	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	OCT	2004	19	10					785	797		10.1177/08830738040190100801			13	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	920PT	WOS:000228703300008	15559894				2021-06-18	
J	Tateno, A; Jorge, RE; Robinson, RG				Tateno, A; Jorge, RE; Robinson, RG			Pathological laughing and crying following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; COMPUTERIZED-TOMOGRAPHY; MULTIPLE-SCLEROSIS; STROKE PATIENTS; HEAD-INJURY; LAUGHTER; SCALE; DEPRESSION; EMOTIONALISM; PREVALENCE	The authors examined the prevalence and clinical correlates of pathological laughing and crying (PLC) using the Pathological Laughter and Crying Scale (PLAC) in 92 consecutive patients with acute symptoms 3, 6, and 12 months after traumatic brain injury (TBI). The prevalence of PLC during the first year after TBI was 10.9%. Compared to patients without PLC, patients with PLC had significantly more depressive, anxious, and aggressive behaviors and had poorer social functioning. Additionally, PLC was associated with the presence of anxiety disorder, and focal frontal lobe lesions, especially in the lateral aspect of the left frontal lobe. Findings revealed that prefrontal regulation of limbic circuits may be involved in the pathophysiology of this disturbed emotional expression.	Univ Iowa, Coll Med, Dept Psychiat, MEB Psychiat Res, Iowa City, IA 52242 USA; Nippon Med Coll, Dept Neuropsychiat, Tokyo 113, Japan	Jorge, RE (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, MEB Psychiat Res, 500 Newton Rd, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu	Robinson, Robert/AAF-6191-2021		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355, R01MH052879, R01MH053592] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-40355, MH-52879, MH-53592] Funding Source: Medline		ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; CURTIS G, 1993, WISCONSIN CARD SORT; Damasio H., 1989, LESION ANAL NEUROPSY; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCullagh S, 1999, J NEUROL SCI, V169, P43, DOI 10.1016/S0022-510X(99)00214-2; Mendez MF, 1999, J NEUROPSYCH CLIN N, V11, P253; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Mukand J, 1996, ARCH PHYS MED REHAB, V77, P1309, DOI 10.1016/S0003-9993(96)90198-7; Padberg F, 2001, J NEUROPSYCH CLIN N, V13, P206, DOI 10.1176/appi.neuropsych.13.2.206; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; Sartorius N, 1974, MEASUREMENT CLASSIFI; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Spitzer RL, 1990, STRUCTURED CLIN INTE; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; WILSON SAK, 1923, J NEUROL PSYCHOPATH, V4, P299; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006	39	65	66	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2004	16	4					426	434		10.1176/appi.neuropsych.16.4.426			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	881VN	WOS:000225897600004	15616168				2021-06-18	
J	Davis, DP; Dunford, JV; Ochs, M; Park, K; Hoyt, DB				Davis, DP; Dunford, JV; Ochs, M; Park, K; Hoyt, DB			The use of quantitative end-tidal capnometry to avoid inadvertent severe hyperventilation in patients with head injury after paramedic rapid sequence intubation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						rapid sequence intubating; paramedic; traumatic brain injury; capnometry; hyperventilation	CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; INTRAHOSPITAL TRANSPORT; HEMORRHAGIC-SHOCK; OXYGENATION; VOLUME; GASES	Background. This study aimed to determine whether field end-tidal carbon dioxide CO2 (ETCO2) monitoring decreases inadvertent severe hyperventilation after paramedic rapid sequence intubation. Methods. Data were collected prospectively as part of the San Diego Paramedic Rapid Sequence Intubation Trial, which enrolled adults with severe head injuries (Glasgow Coma Score, 3-8) that could not be intubated without neuromuscular blockade. After preoxygenation, the patients underwent rapid sequence intubation using midazolam and succinylcholine. A maximum of three intubation attempts were allowed before Combitube insertion was mandated. Tube confirmation was accomplished by physical examination, qualitative capnometry, pulse oximetry, and syringe aspiration. Standard ventilation parameters (tidal volume, 800 mL; 12 breaths/minute) were taught. One agency used portable ETCO2 monitors, with ventilation modified to target ETCO2 values of 30 to 35 rum Hg. Trial patients transported by aeromedical crews also underwent ETCO2 monitoring. The primary outcome measure was the incidence of inadvertent severe hyperventilation, defined as arterial blood gas partial pressure of CO2 (PCO2) of less than 25 mm Hg at arrival, for patients with and those without ETCO2 monitoring. These groups also were compared in terms of age, gender, clinical presentation, Abbreviated Injury Score, Injury Severity Score, arrival arterial blood gas data, and survival. Results: The study enrolled 426 patients and administered neuromuscular blocking agents to 418 patients. Endotracheal intubation was successful for 355 of these patients (85.2%). Another 58 patients (13.6%) underwent Combitube insertion. For 291 successfully intubated patients, arrival pCO(2) values were documented, with continuous ETCO2 monitoring performed for 144 of these patients (49.4%). Patients with ETCO2 monitoring had a lower incidence of inadvertent severe hyperventilation than those without ETCO2 monitoring (5.6% vs. 13.4%; odds ratio, 2.64; 95% confidence interval, 1.12-6.20; p = 0.035). There were no significant differences in terms of age, gender, clinical presentation, Abbreviated Injury Score, Injury Severity Score, arrival partial pressure of oxygen (pO(2)) and pH, or survival. The patients in both groups with severe hyperventilation had a significantly higher mortality rate than the patients without hyperventilation (56 vs. 30%; odds ratio, 2.9; 95% confidence interval, 1.3-6.6; p = 0.016), which could not be explained solely on the basis of their injuries. Conclusions. The use of ETCO2 monitoring is associated with a decrease in inadvertent severe hyperventilation.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA USA; San Diego Cty Emergency Med Serv, San Diego, CA USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Trauma, Dept Surg, San Diego, CA USA	Davis, DP (corresponding author), 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Benallal H, 2002, MED SCI SPORT EXER, V34, P622, DOI 10.1097/00005768-200204000-00010; Bhende M, 1999, PEDIATR EMERG CARE, V15, P64, DOI 10.1097/00006565-199902000-00019; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Fletcher R, 2000, EUR J ANAESTH, V17, P306, DOI 10.1046/j.1365-2346.2000.00660.x; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; FORTUNE JB, 1995, J TRAUMA, V39, P463; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GRAHAM DI, 1971, LANCET, V1, P265; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Prause G, 1997, RESUSCITATION, V35, P145, DOI 10.1016/S0300-9572(97)00043-9; RELLER MD, 1985, PEDIATR RES, V19, P337, DOI 10.1203/00006450-198519040-00003; RUTA TS, 1993, ANESTHESIOLOGY, V78, P134, DOI 10.1097/00000542-199301000-00019; SANTHI PB, 1994, SOLVENT EXTR ION EXC, V12, P633, DOI 10.1080/07366299408918229; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; TUOR UI, 1984, AM J PHYSIOL, V247, pH40; VALENTINE C, 2002, PREHOSP EMERG CARE, V6, P144; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; WEI EP, 1980, AM J PHYSIOL, V238, pH697, DOI 10.1152/ajpheart.1980.238.5.H697; Williams JS, 1997, J APPL PHYSIOL, V83, P312	31	65	65	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2004	56	4					808	814		10.1097/01.TA.0000100217.05066.87			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	818TZ	WOS:000221268700020	15187747				2021-06-18	
J	Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Yu, CL; Hovda, DA; Phelps, ME; Bergsneider, M				Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Yu, CL; Hovda, DA; Phelps, ME; Bergsneider, M			Selective metabolic reduction in gray matter acutely following human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						2-deoxy-2-[F-18]fluoro-D-glucose; glucose; lumped constant; metabolism; positron emission tomography; traumatic brain injury	CEREBRAL BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; FDG LUMPED CONSTANT; HEAD-INJURY; GLUCOSE-UTILIZATION; PARAMETRIC IMAGES; PRACTICAL SCALE; PET; ISCHEMIA; RAT	The aim of this study was to determine whether the apparent loss of overall gray-white matter contrast (GNMM) seen on FDG-PET imaging reflects the differential changes of glucose metabolic rate (CMRglc) in cortical gray mater (GM) and subcortical white mater (WM) following TBI. The clinical significance of the CMRglc GM-to-WM ratio was also evaluated. Nineteen normal volunteers and 14 TBI patients were studied. Each subject had a quantitative FDG-PET, a quantitative (H2O)-O-15- PET and a MR scan acutely following TBI. Stabilities of the global and regional FDG lumped constants (LC) were studied. Parametric images (pixel unit: mg/min/100g) of FDG uptake rate (CURFDG) and CMRglc were generated. The changes of CMRglc in whole brain, GM and WM were studied separately by using a MRI-segmentation-based technique. The GM-to-WM ratios of both CURFDG and CMRglc images were significantly (p < 0.001) decreased (>31%) in TBI patients. The global LC value reduced significantly (p < 0.01) in TBI patients. The CMRglc decreased significantly (p < 0.001) in GM but not in WM (p > 0.1). Kinetic analysis revealed significant (P < 0.001) decrease of GM hexokinase activity in TBI patients. The GM-to-WM ratios of CMRgl, correlated (r = 0.64) with the initial Glasgow Coma Score (GCS) of TBI patients. The patients with higher CMRglc GM-to-WM ratios (>1.54) showed good recovery 12 months after TBI. There was a selective CMRglc reduction in cortical GM following TBI. The pathophysiological basis for the reduction in GM-to-WM CMRglc ratio seen on FDG-PET imaging following TBI remains to be determined.	Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA	Wu, HM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA.	cwu@mednet.ucla.edu	Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012	Glenn, Thomas/0000-0003-4273-3408	NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE-FC03-02ER63420, DE FC0387-ER60615] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [Z01DE000387] Funding Source: NIH RePORTER		Alavi A, 1997, J NUCL MED, V38, P1717; Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brix G, 1997, J NUCL MED, V38, P1614; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; CHOI Y, 1991, J NUCL MED, V32, P733; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GJEDDE A, 1982, BRAIN RES REV, V4, P237, DOI 10.1016/0165-0173(82)90018-2; Graham MM, 2002, J NUCL MED, V43, P1157; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; HAWKINS RA, 1986, J CEREBR BLOOD F MET, V6, P170, DOI 10.1038/jcbfm.1986.30; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOFFMAN EJ, 1979, J COMPUT ASSIST TOMO, V3, P299, DOI 10.1097/00004728-197906000-00001; HUANG SC, 1982, J CEREBR BLOOD F MET, V2, P99, DOI 10.1038/jcbfm.1982.11; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KUWABARA H, 1990, J CEREBR BLOOD F MET, V10, P180, DOI 10.1038/jcbfm.1990.33; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NAKAI H, 1987, J CEREBR BLOOD F MET, V7, P640, DOI 10.1038/jcbfm.1987.117; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1983, J CEREB BLOOD FLO S1, V3, pS13; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; STEWART L, 1994, ACTA NEUROCHIR, P544; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; VANNUCCI RC, 1989, PEDIATR RES, V26, P208, DOI 10.1203/00006450-198909000-00011; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WU HM, 2003, MOL IMAGING BIOL, V4, P1; WU HM, 2002, BRAIN IMAGING USING, P147; Yang J, 1996, IEEE T NUCL SCI, V43, P3322, DOI 10.1109/23.552745; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	47	65	65	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					149	161		10.1089/089771504322778613			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200003	15000756				2021-06-18	
J	Bao, F; Liu, D				Bao, F; Liu, D			Hydroxyl radicals generated in the rat spinal cord at the level produced by impact injury induce cell death by necrosis and apoptosis: Protection by a metalloporphyrin	NEUROSCIENCE			English	Article						reactive oxygen species; hydrogen peroxide; secondary cell death; spinal cord injury; Fenton reaction; Mn (III) tetrakis (4-benzoic acid) porphyrin	MANGANESE SUPEROXIDE-DISMUTASE; MODEL COMBINING MICRODIALYSIS; EXPERIMENTAL HEAD-INJURY; ISCHEMIC BRAIN-INJURY; NITRIC-OXIDE; OXIDATIVE STRESS; IN-VIVO; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; PEROXYNITRITE	We previously measured the time courses of hydrogen peroxide (H2O2), hydroxyl radical ((OH)-O-.), and catalytic iron increases following traumatic spinal cord injury (SCI). This study determines whether the SCI-elevated level of (OH)-O-. causes cell death. OH was generated by administering H2O2 and Fe2+ at the concentrations attained following SCI, each through a separate microdialysis fiber inserted laterally into the gray matter of the cord. The duration of (OH)-O-. generation mimics the duration of its elevation after SCI. The death of neurons and astrocytes was characterized at 24 h post-(OH)-O-. exposure and quantitated by counting surviving cells along the fiber track in sections stained with Cresyl Violet, or immunohistochemically stained with anti-neuron-specific enolase (anti-NSE) and anti-glial fibrillary acidic protein (antiGFAP). DNA fragmentation in neurons was characterized by double staining with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling JUNEL) and anti-NSE. Using a one way ANOVA followed by the Tukey test, we demonstrated that (OH)-O-. generated in the cord induced significant losses of neurons in both Cresyl Violet (P<0.001) and anti-NSE-stained sections (P<0.001), and of astrocytes in GFAP-stained sections (P=0.001). (OH)-O-. generated in the cord increased numbers of TUNEL-positive neurons compared with Ringer's solution administered as a control (P=0.001). Mn (111) tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic and a broad spectrum reactive species scavenger, significantly reduced (OH)-O-.-induced death of neurons (P<0.001 in anti-NSE stained sections and P=0.002 in the Cresyl Violet-stained sections) and astrocytes (P=0.03). It also reduced the numbers of TUNEL-positive neurons (P=0.01). Electron microscopy confirmed that generated (OH)-O-. induced neuronal and glial death with characteristic features of both necrosis and apoptosis. We conclude that 1) SCI-elevated (OH)-O-. is sufficient to induce both necrosis and apoptosis, criteria for identifying an endogenous secondary damaging agent; 2) MnTBAP reduces (OH)-O-.-induced cell death, perhaps by removing H2O2 administered in the tissue, thereby blocking formation of (OH)-O-., and also by scavenging downstream reactive species. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	Liu, D (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035119, R01NS044324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS44324, NS35119] Funding Source: Medline		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Balentine JD, 1985, CENTRAL NERVOUS SYST, P455; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; Carriedo SG, 1998, J NEUROSCI, V18, P7727; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; IKEDA Y, 1989, Neurological Research, V11, P213; Keller JN, 1998, J NEUROSCI, V18, P687; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; LING X, 2001, J NEUROTRAUM, V18, P1169; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; LIU D, 2004, IN PRESS J NEUROTRAU; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOKANATHA V, 2002, J NEUROTRAUM, V19, P1297; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Oury TD, 2001, AM J RESP CELL MOL, V25, P164, DOI 10.1165/ajrcmb.25.2.4235; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	54	65	65	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	126	2					285	295		10.1016/j.neuroscience.2004.03.054			11	Neurosciences	Neurosciences & Neurology	829SJ	WOS:000222069700005	15207346				2021-06-18	
J	Hooper, SR; Alexander, J; Moore, D; Sasser, HC; Laurent, S; King, J; Bartel, S; Callahan, B				Hooper, SR; Alexander, J; Moore, D; Sasser, HC; Laurent, S; King, J; Bartel, S; Callahan, B			Caregiver reports of common symptoms in children following a traumatic brain injury	NEUROREHABILITATION			English	Article						pediatric traumatic brain injury; TBI symptoms; symptom complaints; TBI follow-up	POSTTRAUMATIC-STRESS-DISORDER; FAMILY-MEMBERS; HEAD-TRAUMA; MILD; PREVALENCE; DEPRESSION; SYMPTOMATOLOGY; ADOLESCENTS; CONCORDANCE; DYSFUNCTION	This study describes the common symptoms in children and adolescents following a traumatic brain injury (TBI) as reported by their primary caregivers. Utilizing data from a large-scale state demonstration project, 681 children who had sustained a TBI were ascertained from both Hospital Emergency Departments (n = 409) and Pediatric Inpatient settings (n = 272). The sample ranged in age from infancy to 18 years, was largely male (59.7%), and had equal numbers of Caucasian and minority patients. Most of the participants experienced a mild TBI (83%), with about 5.1% being moderate and 12% severe. Caregivers described the presence of current symptoms (neurological, neurocognitive, behavioral, school problems) using a series of dichotomous questions regarding their child via a structured telephone interview at 1, 4, and 10 months post-injury. Inpatient children were described as manifesting more symptoms at each of the follow-up time points than their ED counterparts. At 1 month inpatients were described as having more symptoms across all 4 domains. At 4 and 10 months, the inpatients were described as having more neurocognitive symptoms and as not returning to school on a full-time basis, with behavior problems approaching significance at the 10-month point. A large number of individuals from both groups also reported persistent symptoms 10 months post-injury including headaches, attention and memory problems, low frustration tolerance, sleep problems, personality changes, and new school problems. Practical implications of these findings for the ongoing management of these children are discussed.	Univ N Carolina, Sch Med, Clin Ctr Study Dev & Learning, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Chapel Hill, NC USA; E Carolina Univ, Brody Sch Med, Dept Phys Med & Rehabil, Greenville, NC USA; Carolinas HealthCare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC USA; Carolinas Med Ctr, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; N Carolina State Div Dev Disabil, Mental Hlth Serv, Raleigh, NC USA; N Carolina State Div Dev Disabil, Subst Abuse Serv, Raleigh, NC USA	Hooper, SR (corresponding author), Univ N Carolina, Sch Med, Ctr Dev & Learning, CB 7255, Chapel Hill, NC 27599 USA.	Stephen.hooper@cdl.unc.edu	Hooper, Stephen/X-8171-2019				Alexander J, 2001, N C Med J, V62, P344; Alexander J, 2001, N C Med J, V62, P359; Annoni J M, 1992, Disabil Rehabil, V14, P23; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; *CDCP, 2001, TRAUM BRAIN INJ; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Childers MK, 1998, BRAIN INJURY, V12, P613; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; DISCALA C, 2003, BRAIN INJURY SOU SPR, P8; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; HACKL JM, 1986, ANAESTHESIST, V35, P171; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HARVEY AG, 1993, J INT NEUROPSYCH SOC, V9, P663; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hellawell DJ, 2001, DISABIL REHABIL, V23, P300, DOI 10.1080/769979114; Hooper S R, 2001, N C Med J, V62, P350; HOOPER SR, 2003, BRAIN INJURY SOU SPR, P28; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lash M, 2003, BRAIN INJURY SOU SPR, P20; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Masson F, 1996, ARCH PEDIATRIE, V3, P651, DOI 10.1016/0929-693X(96)87085-0; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McMahon MA, 2001, J HEAD TRAUMA REHAB, V16, P587, DOI 10.1097/00001199-200112000-00006; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Roberts MA, 1996, BRAIN INJURY, V10, P739, DOI 10.1080/026990596124007; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Smith C G, 2001, N C Med J, V62, P328; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; Thurman DJ., 1995, GUIDELINES SURVEILLA; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026	66	65	65	1	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					175	189					15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000002	15502252				2021-06-18	
J	Ergh, TC; Hanks, RA; Rapport, LJ; Coleman, RD				Ergh, TC; Hanks, RA; Rapport, LJ; Coleman, RD			Social support moderates caregiver life satisfaction following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							REHABILITATION; DISABILITY; RELATIVES; PREDICTORS; VALIDITY; MEDIATOR; SCALE	Social support is an important determinant of adjustment following traumatic brain injury (TBI) sustained by a family member. The present study examined the extent to which social support moderates the influence of characteristics of the person with injury on caregiver subjective well-being. Sixty pairs of individuals who had sustained a moderate to severe TBI and their caregivers (N = 120) participated. Years postinjury ranged from 0.3 to 9.9 (M = 4.8, SD = 2.6). Cognitive, functional, and neurobehavioral functioning of participants with TBI were assessed using neuropsychological tests and rating scales. Caregiver life satisfaction and perceived social support were assessed using self-report questionnaires. Results indicated that time since injury was unrelated to life satisfaction. Neurobehavioral disturbances showed an inverse relation with life satisfaction. Social support emerged as an important moderator of fife satisfaction. Only among caregivers with low social support was cognitive dysfunction adversely related to life satisfaction. Similarly, a trend suggested that patient unawareness of deficit was associated with caregiver life dissatisfaction only among caregivers with low social support. In contrast, these characteristics were unrelated to life satisfaction among caregivers with adequate social support.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Inst Rehabil, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA	Ergh, TC (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	tergh@sun.science.wayne.edu					ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BLAIS MR, 1989, CAN J BEHAV SCI, V21, P210, DOI 10.1037/h0079854; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cantor N., 1996, PSYCHOL ACTION LINKI, P338; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; Cummins RA, 2001, J INTELLECT DEV DIS, V26, P83, DOI 10.1080/13668250020032787; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; DELIA LF, 1996, COLOR TRIALS TEST; DIENER E, 1995, J PERS SOC PSYCHOL, V68, P653, DOI 10.1037/0022-3514.68.4.653; Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2002, PERS SOC PSYCHOL B, V28, P437, DOI 10.1177/0146167202287002; Diener E., 2002, HDB POSITIVE PSYCHOL, P63, DOI DOI 10.1093/OXFORDHB/9780195187243.013.0017; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FENGLER AP, 1979, GERONTOLOGIST, V19, P175, DOI 10.1093/geront/19.2.175; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GEORGE JM, 1991, J APPL SOC PSYCHOL, V21, P296, DOI 10.1111/j.1559-1816.1991.tb00522.x; GERVASOI AH, 1997, J MARITAL FAMILY THE, V15, P65; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Harlow RE, 1996, J PERS SOC PSYCHOL, V71, P1235, DOI 10.1037/0022-3514.71.6.1235; JUDGE T, 1990, THESIS U ILLINOIS; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; MOHIDE EA, 1993, DEPRESSION SOCIAL EN, P289; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OMODEI MM, 1990, J PERS SOC PSYCHOL, V59, P762, DOI 10.1037/0022-3514.59.4.762; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; SANDER A, 1999, REHABILITATION ADULT, P199; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Schwarz N., 1999, WELL BEING FOUND HED, P61; Singer GHS, 1989, SUPPORT CAREGIVING F, P3; Smead V. S., 1991, ANN CONV AM ASS APPL; Suh E, 1998, J PERS SOC PSYCHOL, V74, P482, DOI 10.1037/0022-3514.74.2.482; Tabachnick BG, 2013, USING MULTIVARIATE S; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76	50	65	66	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2003	25	8					1090	1101		10.1076/jcen.25.8.1090.16735			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	744LK	WOS:000186631900006	14566583				2021-06-18	
J	Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Yam, A; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC				Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Yam, A; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC			Cerebral vasomotor reactivity testing in head injury: the link between pressure and flow	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; TRANSCRANIAL DOPPLER; PERFUSION-PRESSURE; HEALTHY-VOLUNTEERS; AUTOREGULATION; VELOCITY; VASOSPASM; THRESHOLDS; VALIDATION	Background: It has been suggested that a moving correlation index between mean arterial blood pressure and intracranial pressure, called PRx, can be used to monitor and quantify cerebral vasomotor reactivity in patients with head injury. Objectives: To validate this index and study its relation with cerebral blood flow velocity and cerebral autoregulation; and to identify variables associated with impairment or preservation of cerebral vasomotor reactivity. Methods: The PRx was validated in a prospective study of 40 head injured patients. A PRx value of less than 0.3 indicates intact cerebral vasomotor reactivity, and a value of more than 0.3, impaired reactivity. Arterial blood pressure, intracranial pressure, mean cerebral perfusion pressure, and cerebral blood flow velocity, measured bilaterally with transcranial Doppler ultrasound, were recorded. Dynamic cerebrovascular autoregulation was measured using a moving correlation coefficient between arterial blood pressure and cerebral blood flow velocity, the Mx, for each cerebral hemisphere. All variables were compared in patients with intact and impaired cerebral vasomotor reactivity. Results: No correlation between arterial blood pressure or cerebral perfusion pressure and cerebral blood flow velocity was seen in 19 patients with intact cerebral vasomotor reactivity. In contrast, the correlation between these variables was significant in 21 patients with impaired cerebral vasomotor reactivity, whose cerebral autoregulation was reduced. There was no correlation with intracranial pressure, arterial blood pressure, cerebral perfusion pressure, or interhemispheric cerebral autoregulation differences, but the values for these indices were largely within normal limits. Conclusions: The PRx is valid for monitoring and quantifying cerebral vasomotor reactivity in patients with head injury. This intracranial pressure based index reflects changes in cerebral blood flow and cerebral autoregulatory capacity, suggesting a close link between blood flow and intracranial pressure in head injured patients. This explains why increases in arterial blood pressure and cerebral perfusion pressure may be useful for reducing intracranial pressure in selected head injured patients ( those with intact cerebral vasomotor reactivity).	Univ Sydney, Dept Neurosurg, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Dept Neurol, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Dept Intens Care, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Kiel, Dept Neurosurg, Kiel, Germany	Lang, EW (corresponding author), Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.		Mehdorn, Maximilian/D-2495-2010				BULLOCK R, 1996, GUIDELINES MANAGEMEN; Carey BJ, 2000, STROKE, V31, P2895, DOI 10.1161/01.STR.31.12.2895; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DAFFERTSHOFER M, 1991, J NEUROL SCI, V104, P32, DOI 10.1016/0022-510X(91)90212-P; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LANG EW, IN PRESS J CLIN NEUR; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; RINGELSTEIN RB, 1989, NONINVASIVE IMAGING, P75; Rosner Michael J., 1993, P57; Schmidt EA, 2002, ACT NEUR S, V81, P133; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 2002, CRIT CARE MED, V30, P1969, DOI 10.1097/00003246-200209000-00004; TAKEUCHI H, 1991, NEUROSURGERY, V28, P41, DOI 10.1227/00006123-199101000-00007; Vavilala MS, 2002, ACTA ANAESTH SCAND, V46, P393, DOI 10.1034/j.1399-6576.2002.460411.x; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287; Yundt KD, 1998, J CEREBR BLOOD F MET, V18, P419, DOI 10.1097/00004647-199804000-00010	32	65	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2003	74	8					1053	1059		10.1136/jnnp.74.8.1053			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	703MJ	WOS:000184283100012	12876233	Bronze, Green Published			2021-06-18	
J	Varma, S; Janesko, KL; Wisniewski, SR; Bayir, H; Adelson, PD; Thomas, NJ; Kochanek, PM				Varma, S; Janesko, KL; Wisniewski, SR; Bayir, H; Adelson, PD; Thomas, NJ; Kochanek, PM			F-2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; free radical; head injury; inflicted childhood trauma; oxidative stress; pediatric	FOCAL CEREBRAL-ISCHEMIA; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; GENDER-DIFFERENCES; RELEASE; ACID; ESTROGEN; EFFICACY; CSF	It has been hypothesized that oxidative stress plays an important role in mediating secondary damage after traumatic brain injury (TBI). To study the relationship between lipid peroxidation, clinical variables, and neuronal damage in pediatric TBI, we measured levels of F-2-isoprostane, a marker of lipid peroxidation, and neuron-specific enolase (NSE), a marker of neuronal damage, in serial cerebrospinal fluid (CSF) samples from 23 infants and children with severe TBI (Glasgow Coma Scale score < 8). These were compared to CSF samples from 10 uninjured pediatric controls. On d1 after injury, F2-isoprostane was increased 6-fold vs. control (36.59 +/- 8.96 pg/ml vs. 5.64 +/- 8.08 pg/ml, p = 0.0035) and NSE was increased 10-fold (100.62 +/- 17.34 ng/ml vs. 8.63 +/- 2.76 ng/ml, p = 0.0002). Multivariate analysis of F-2-isoprostane levels and selected clinical variables showed a trend toward an inverse association with time after injury (p = 0.0708). Multivariate analysis of NSE levels and selected variables showed a positive association between d1 NSE and F-2-isoprostane (P = 0.0426). CSF F-2-isoprostane increases early after TBI in infants and children and is correlated with NSE, supporting a role for oxidative stress in the evolution of secondary damage early after severe TBI in infants and children.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; Penn State Childrens Hosp, Dept Pediat, Div Pediat Crit Care Med, Hershey, PA USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Thomas, Neal/0000-0002-7991-7510			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2001, CRIT CARE MED, V29, pA5; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CHADWICK DL, 1992, PEDIATR ANN, V21, P477, DOI 10.3928/0090-4481-19920801-07; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Fujimura M, 1999, J NEUROSCI, V19, P3414; Hall ED, 1996, ACT NEUR S, V66, P107; Ikeda Y, 1990, Adv Neurol, V52, P441; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marin JG, 2000, NEUROREPORT, V11, P1357, DOI 10.1097/00001756-200004270-00041; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORRIS HC, 1992, THEOR PSYCHOL, V2, P89, DOI 10.1177/0959354392021005; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pratico D, 1998, FASEB J, V12, P1777; Proteggente AR, 2002, FREE RADICAL RES, V36, P157, DOI 10.1080/10715760290006475; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907	38	65	70	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					781	786		10.1089/089771503767870005			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000008	12965056				2021-06-18	
J	Krassioukov, AV; Furlan, JC; Fehlings, MG				Krassioukov, AV; Furlan, JC; Fehlings, MG			Medical co-morbidities, secondary complications, and mortality in elderly with acute spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						elderly; medical co-morbidity; mortality; neurotrauma; secondary complication; spinal cord injury	AGE; EPIDEMIOLOGY; COSTS; POPULATION; OUTCOMES; OLDER	Despite an increasing incidence of spinal cord injury (SCI) in the elderly and evidence that age appears to influence outcome after neurotrauma, surprisingly little is known regarding clinical outcomes and secondary complications in elderly with an acute SCI. This study was undertaken to evaluate the effect of age on clinical outcomes after acute traumatic SCI managed in an acute care unit by a multidisciplinary team. A retrospective chart review of all patients with acute SCI admitted to an acute care unit at a university hospital between 1998 and 2000 was performed. Data on clinical outcomes and secondary complications in younger individuals (group 1: age < 60 years) were compared to elderly subjects (group 2: age : 60 years). There were 28 elderly (age 60-89 years) and 30 younger (age 17-56 years) individuals. The severity and level of SCI were similar in both groups (p = 0.11; p = 0.93). Co-morbidities were more frequent in the elderly (p < 0.01). There was a trend, which did not achieve significance, for an increased incidence of secondary complications in the elderly (57.1% versus 33.3%; p = 0.11). The most common secondary complications in both groups were infections, psychiatric disorders, pressure sores, and cardiovascular complications. Mortality rates in elderly and younger individuals with acute SCI (p = 0.41) were not significantly different. Our data suggest that rigorous attention to principles of acute SCI care can minimize previously reported higher susceptibility for secondary complications in the elderly. A multidisciplinary team approach to the management of the elderly with acute SCI is essential to minimize or prevent secondary complications.	Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON, Canada; Univ Hlth Network, Krembil Neurosci Ctr, Spinal Program, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Dept Surg,, Div Neurosurg, McLaughlin Pavil,Room 12-407,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca	Krassioukov, Andrei V/K-3131-2017; Furlan, Julio/Q-8290-2018	Furlan, Julio/0000-0002-2038-0018; Fehlings, Michael/0000-0002-5722-6364			ALANDER DH, 1994, SPINE, V19, P2299, DOI 10.1097/00007632-199410150-00008; BENEDICT RC, 1981, J REHABIL, V47, P10; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; *CAN I HLTH INF, 2001, 5432 CAN I HLTH INF; CHARLES ED, 1978, PARAPLEGIA, V15, P302, DOI 10.1038/sc.1977.46; CHEN CF, 1985, PARAPLEGIA, V23, P364, DOI 10.1038/sc.1985.58; Chen HY, 1997, NEUROEPIDEMIOLOGY, V16, P241, DOI 10.1159/000109693; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; Dai LY, 2001, INJURY, V32, P195, DOI 10.1016/S0020-1383(00)00176-5; DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026; EISENBERG MG, 1985, PARAPLEGIA, V23, P335, DOI 10.1038/sc.1985.53; GERHART KA, 1994, ANN EMERG MED, V23, P807, DOI 10.1016/S0196-0644(94)70318-3; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; HARVEY C, 1992, PARAPLEGIA, V30, P834, DOI 10.1038/sc.1992.160; HESSE KA, 1984, J AM GERIATR SOC, V32, P747, DOI 10.1111/j.1532-5415.1984.tb04174.x; Ide M, 2001, SPINAL CORD, V39, P387, DOI 10.1038/sj.sc.3101171; Imai K, 1996, J CLIN EPIDEMIOL, V49, P505, DOI 10.1016/0895-4356(95)00576-5; KARAMEHMETOGLU SS, 1995, PARAPLEGIA, V33, P469, DOI 10.1038/sc.1995.102; Karlsson AK, 1999, SPINAL CORD, V37, P383, DOI 10.1038/sj.sc.3100867; Liang HW, 2001, SPINAL CORD, V39, P375, DOI 10.1038/sj.sc.3101169; Mathias CF, 1992, AUTONOMIC FAILURE TX, P839; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MEYERS AR, 1985, ARCH PHYS MED REHAB, V66, P704; MILLER RA, 1998, PRINCIPLES GERIATRIC, P3; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; Mylotte JM, 2000, CLIN INFECT DIS, V30, P425, DOI 10.1086/313708; Noreau L, 2000, AM J PHYS MED REHAB, V79, P526, DOI 10.1097/00002060-200011000-00009; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; Seel R T, 2001, J Spinal Cord Med, V24, P241; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; STEINBERG FU, 1984, ARCH PHYS MED REHAB, V65, P8; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Subbarao J V, 1987, J Am Paraplegia Soc, V10, P30; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; *U AL, 2002, NAT SPIN CORD INJ DA; van Asbeck FWA, 2000, SPINAL CORD, V38, P420, DOI 10.1038/sj.sc.3101003; Villanueva N E, 2000, Crit Care Nurs Clin North Am, V12, P509; Watson N, 1976, Paraplegia, V14, P36; WILLIAMS ME, 1998, PRINCIPLES GERIATRIC, P249; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	43	65	71	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					391	399		10.1089/089771503765172345			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900008	12866818				2021-06-18	
J	Chodobski, A; Chung, I; Kozniewska, E; Ivanenko, T; Chang, W; Harrington, JF; Duncan, JA; Szmydynger-Chodobska, J				Chodobski, A; Chung, I; Kozniewska, E; Ivanenko, T; Chang, W; Harrington, JF; Duncan, JA; Szmydynger-Chodobska, J			Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury	NEUROSCIENCE			English	Article						subarachnoid space; choroid plexus; astrocytes; heparan sulfate proteoglycans; extracellular matrix; rat	NECROSIS-FACTOR-ALPHA; HEPARAN-SULFATE PROTEOGLYCAN; MIDDLE CEREBRAL-ARTERY; BLOOD-RETINAL BARRIER; FACTOR VEGF; DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; NEURONAL EXPRESSION; FACTOR FAMILY; UP-REGULATION	The formation of edema after traumatic brain injury (TBI) is in part associated with the disruption of the blood-brain barrier. However, the molecular and cellular mechanisms underlying these phenomena have not been fully understood. One possible factor involved in edema formation is vascular endothelial growth factor (VEGF). This growth factor has previously been demonstrated to increase the blood-brain barrier permeability to the low molecular weight markers and macromolecules. In this study, we analyzed the temporal changes in VEGF expression after TBI in rats. In the intact brain, VEGF was expressed at relatively low levels and was found in the cells located close to the cerebrospinal fluid space. These were the astrocytes located under the ependyma and the pia-glial lining, as well as the epithelial cells of the choroid plexus. In addition, several groups of neurons, including those located in the frontoparietal cortex and in all hippocampal regions, were VEGF-positive. The pattern of VEGF-immunopositive staining of neurons and choroidal epithelium suggested that in these cells, VEGF binds to the cell membrane-associated heparan sulfate proteoglycans. Following TBI, there was an early (within 4 h post-injury) increase in VEGF expression in the traumatized parenchyma associated with neutrophilic invasion. The ipsilateral choroid plexus appeared to play a role in facilitating the migration of neutrophils from blood into the cerebrospinal fluid space, from where many of these cells infiltrated the brain parenchyma. VEGF-immunopositive staining of neutrophils resembled haloes and was found ipsilaterally within the frontoparietal cortex and around the velum interpositum, a part of the subarachnoid space. These haloes likely represent the deposition of neutrophil-derived VEGF within the extracellular matrix, from where this growth factor may be gradually released during an early post-traumatic period. The maximum number of VEGF-secreting neutrophils was observed between 8 h and 1 day after TBI. In addition, from 4 h post-TBI, there was a progressive increase in the number of VEGF-immunoreactive astrocytes in the ipsilateral frontoparietal cortex. The maximum number of astrocytes expressing VEGF was observed 4 days after TBI, and then the levels of astroglial VEGF expression declined gradually. Early invasion of brain parenchyma by VEGF-secreting neutrophils together with a delayed increase in astrocytic synthesis of this growth factor correlate with the biphasic opening of the blood-brain barrier and formation of edema previously observed after TBI. Therefore, these findings suggest that VEGF plays an important role in promoting the formation of post-traumatic brain edema. (C) 2003 IBRO. Published by Elsevier Ltd. All rights reserved.	Brown Univ, Sch Med, Dept Clin Neurosci, Providence, RI 02903 USA; Med Res Ctr Polish Acad Sci, Lab Nucl Med, PL-02106 Warsaw, Poland	Chodobski, A (corresponding author), Brown Univ, Sch Med, Dept Clin Neurosci, Aldrich Bldg,Room 405,593 Eddy St, Providence, RI 02903 USA.	adam_chodobski@brown.edu		Kozniewska, Ewa/0000-0003-0675-1238	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039921] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-39921] Funding Source: Medline		ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung I, 2003, NEUROSCIENCE, V116, P349, DOI 10.1016/S0306-4522(02)00720-0; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Esser S, 1998, J CELL SCI, V111, P1853; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Iseki K, 2002, GLIA, V39, P1, DOI 10.1002/glia.10078; Issa R, 1999, LAB INVEST, V79, P417; Kaneider NC, 2001, BIOCHEM BIOPH RES CO, V287, P42, DOI 10.1006/bbrc.2001.5534; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Murata T, 1996, LAB INVEST, V74, P819; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; PARK JE, 1993, MOL BIOL CELL, V4, P1317; Pichiule P, 1999, MOL BRAIN RES, V74, P83, DOI 10.1016/S0169-328X(99)00261-2; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Robinson CJ, 2001, J CELL SCI, V114, P853; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Scapini P, 1999, J IMMUNOL METHODS, V232, P121, DOI 10.1016/S0022-1759(99)00170-2; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; STRUGAR JG, 1995, J NEUROSURG, V83, P682, DOI 10.3171/jns.1995.83.4.0682; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434; Webb NJA, 1998, CYTOKINE, V10, P254, DOI 10.1006/cyto.1997.0297; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Zhang H, 2001, J LEUKOCYTE BIOL, V70, P225	61	65	67	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2003	122	4					853	867		10.1016/j.neuroscience.2003.08.055			15	Neurosciences	Neurosciences & Neurology	751PD	WOS:000187075400001	14643756				2021-06-18	
J	Lew, HL; Dikmen, S; Slimp, J; Temkin, N; Lee, EH; Newell, D; Robinson, LR				Lew, HL; Dikmen, S; Slimp, J; Temkin, N; Lee, EH; Newell, D; Robinson, LR			Use of somatosensory-evoked potentials and cognitive event-related potentials in predicting outcomes of patients with severe traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	MAR 01-03, 2001	Hilton Head Isl, SC	Assoc Acad Phsyiatrists		traumatic brain injury; event-related potentials; N100; P300; somatosensory-evoked potential; Glasgow Coma Scale; Glasgow Outcome Scale-Extended; functional outcome	GLASGOW COMA SCALE; HEAD-INJURY; P300; RECOVERY; LATENCY	Objective: This study was performed to evaluate the usefulness of somatosensory-evoked potentials (SEPs) and cognitive event-related potentials (ERPs) in predicting functional outcomes of severe traumatic brain injury patients. Design: Prospective study of 22 patients with severe traumatic brain injury. Demographic information, Glasgow Coma Scale, and electrophysiologic measurements were recorded. Functional outcomes, as quantified by the Glasgow Outcome Scale-Extended, were obtained. Results: Bilateral absence of median nerve SEP was strongly predictive of the worst functional outcome. The specificity and positive predictive value of absent SEP for predicting death or persistent vegetative state at 6 mo after traumatic brain injury were as high as 100%. If the definition of unfavorable outcome was ex-expanded to include Glasgow Outcome Scale-Extended 1-4, absence of ERP was equivalent to the absence of SEP in specificity and positive predictive value. On the other hand, normal ERPs showed higher sensitivity and negative predictive value for prognosticating the best outcomes compared with normal SEPs. If the definition of favorable outcome was expanded to include Glasgow Outcome Scale-Extended 5-8, ERP was still superior to SEP for prognosticating good outcome. Interestingly, the highest sensitivity and negative predictive value for favorable outcomes were associated with the presence of any discernible waveform. Conclusions: Although median nerve SEP continues to make reliable prediction of ominous outcome in severe traumatic brain injury, the addition of the speech-evoked ERPs may be helpful in predicting favorable outcomes. The strength of the latter test seems to complement the weakness of the former.	Stanford Univ, Comprehens Rehabil Ctr, Phys Med & Rehabil Serv, VAPAHCS,Sch Med, Palo Alto, CA 94304 USA; Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Dept Neurosurg, Seattle, WA 98195 USA	Lew, HL (corresponding author), Stanford Univ, Comprehens Rehabil Ctr, Phys Med & Rehabil Serv, VAPAHCS,Sch Med, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.		Robinson, Lawrence/D-8455-2013		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD01097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Ashley MJ, 1997, BRAIN INJURY, V11, P677; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; FIORETTO M, 1995, J MED ENG TECHNOL, V19, P80, DOI 10.3109/03091909509030280; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lew H, 1997, J Am Acad Audiol, V8, P104; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	32	65	73	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2003	82	1					53	61		10.1097/00002060-200301000-00009			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	632AA	WOS:000180199700009	12510186				2021-06-18	
J	Schoenberg, MR; Scott, JG; Duff, K; Adams, RL				Schoenberg, MR; Scott, JG; Duff, K; Adams, RL			Estimation of WAIS-III intelligence from combined performance and demographic variables: Development of the OPIE-3	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; PREMORBID INTELLIGENCE; INDEX; AGE; VALIDATION; ACCURACY; SCORES; SCALE; IQ	Data from the WAIS-III standardization sample (The Psychological Corporation, 1997) was used to generate several FSIQ estimation formulas that used demographic variables and current WAIS-III subtest performance. The standardization sample (N = 2,450) was randomly divided into two groups, the first was used to develop the formulas and the second group was used to validate the prediction equations. Age, education, ethnicity, gender, region of the country as well as Vocabulary, Information, Matrix Reasoning, and Picture Completion subtests raw scores were used as predictor variables. Regression formulas were generated using four subtest, two subtest, single verbal, two performance subtest, and single performance algorithms. The four-subtest model combined Information, Vocabulary, Matrix Reasoning, and,Picture Completion raw scores with demographic variables. The two-subtest algorithm used Vocabulary and Matrix Reasoning raw scores with demographic variables. Formulas to estimate FSIQ using only verbal or performance subtests were developed for use with lateralized populations. The formulas for estimating premorbid FSIQ were highly significant and accurate in predicting FSIQ scores of participants in the WAIS-III normative sample.	Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA	Schoenberg, MR (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, POB 26901, Oklahoma City, OK 73190 USA.		Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			ALEKOUMBIDES A, 1987, INT J CLIN NEUROPSYC, V9, P11; Axelrod BN, 1999, ARCH CLIN NEUROPSYCH, V14, P341, DOI 10.1016/S0887-6177(98)00028-6; BAADE LE, 2000, 20 ANN NAT ASS NEUR; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P793, DOI 10.1016/0191-8869(89)90126-8; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; Kaufman A. S., 1990, ASSESSING ADOLESCENT; KAUFMAN AS, 1989, INTELLIGENCE, V13, P235, DOI 10.1016/0160-2896(89)90020-2; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson HE, 1982, NATL ADULT READING T; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Psychological Corporation, 2001, MAN WECHSL TEST AD R; Ryan J. J., 1990, PSYCHOL ASSESSMENT J, V2, P404; SCHINKA JA, 2000, CLIN GUIDE NEUROPSYC; Schopp LH, 2001, REHABIL PSYCHOL, V46, P279, DOI 10.1037/0090-5550.46.3.279; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; Tabachnick BG, 2013, USING MULTIVARIATE S; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Vanderploeg RD, 1996, PSYCHOL ASSESSMENT, V8, P404, DOI 10.1037/1040-3590.8.4.404; Vanderploeg RD, 1998, PSYCHOL ASSESSMENT, V10, P277, DOI 10.1037/1040-3590.10.3.277; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 2008, WECHSLER ADULT INTEL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	37	65	67	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2002	16	4					426	438		10.1076/clin.16.4.426.13913			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	681AY	WOS:000183015300002	12822052				2021-06-18	
